<SEC-DOCUMENT>0001104659-23-052043.txt : 20230428
<SEC-HEADER>0001104659-23-052043.hdr.sgml : 20230428
<ACCEPTANCE-DATETIME>20230428070116
ACCESSION NUMBER:		0001104659-23-052043
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230428
DATE AS OF CHANGE:		20230428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39997
		FILM NUMBER:		23860078

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>adag-20221231x20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 4/28/2023 10:19:17 AM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: 74c4296c-6c70-4aca-99ff-2ce046380e4c -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:adag="http://www.adagene.com/20221231"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" xs:nil="true" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_gDsuqX0SREaLUckfrpidUA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" xs:nil="true" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Vh7sy4pjdUyIhle5YQXnBQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_1ECxitTWhE-HpyA0a6D4Gg">15950698</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_TGXO-tvayEmVbbOXVwm15w">50032009</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_1xSUIEfuCE-FTf5Pm-Ozaw">54135084</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_51Bi1WeiWUGX73SptRbRfg">2.67</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_0kOo5P5xz0yt2vmjurC3Gw">1.46</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_EpgFPY8zJkq1AhHJZ6OD6Q">1.48</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_rP_ZtM9G8EmayLsfIZ8I3w">54595667</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_sRbjWAccFkeLc4ATnl88EQ">54065709</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityCentralIndexKey" id="Tc_9K7cV1YfHU-8QZKA6FCK4w_3_1">0001818838</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentFiscalPeriodFocus" id="Tc_sOGEf9SyNkKgDCDpnoZlzA_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentFiscalYearFocus" id="Tc_LG0WloTBDE6809hH9klFmQ_5_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:AmendmentFlag" id="Tc_k9ajP9SXf0G3lgt5ZDmjZQ_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:EntityAddressAddressLine1" id="Tc_C2CSsuf1v06ggA8VQ0aqUA_7_1">10179 Huennekens Street Suite 103</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:EntityAddressCityOrTown" id="Tc_1WVtGXqTSU2vawPyz9oHnQ_8_1">San Diego</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:EntityAddressStateOrProvince" id="Hidden_rZAIXyRXfEaKYXOQHkHLpg">CA</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw" name="dei:NoTradingSymbolFlag" id="Hidden_GqZ4e-5sDUeUrCQEYrvXig">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_TMpIxqHNTkuI5ZxoBGbcRg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_YJ-Y0N5DlEGk0tP_BHb2Lg">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="adag-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_PpX3jqVYjUKGSc4PUVCqbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_FfVHeu36qEOc41XZB5QsSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_H1fu9nxkjU2h3rSJ7njn8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_OffjEdDiwUq_QKSdjqfmkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_Z9mphkrR0kmVJfMEZDudGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_c6cCpTT3-UCFa3iydypLlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_GF6f3RbJt0mSKdc-gIpyMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yBEmNnp9JkKRwrCjjyfHqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_sQqB69UJ9UC_sksuTF-VLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_V8r0Nfbtg0etm8S7eTVjcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_8Qw98XWW1UumdeUdUM175Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_AEEEQVw_NU6BvaZkgLzS0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_k-Tj_Iz31EmvHKgzizS4_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_g02U-ugGTkWtKxibVH1wIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_-lU6hnUg1USHN9tNgX6z5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_LM0cYbNYBkuxPFEH3zcWdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_CtbvulJUiUmHT0BVyHHTeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_WRYTAw9fyUK5wNbAtUEgzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_L7regPgk0U6wE3_qz1Zy6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_WRGc8jvai0S64dQK-czIGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_o9la4OH3f0S73pFAL_jdvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_LetG2TvOqky7qj1cVnqr1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_m7mB-vO98k6ssn4DOuHCmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_VrdzSlGiIU21zpTy5Vhp1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_29_2022_To_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_ALi5xN2v_Ui4UIlZQtgALA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2021_To_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_skBGvFvBgEm6UOz4-CGzgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-07</xbrli:startDate><xbrli:endDate>2021-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_EzSDNbQB5EWZPn-NGBx2SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_kmEX4yG-ZEuDCtdXxBARXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_B7KydVxEvkqzOuPCW8zKlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_kqrGAtT1eEGm0zzWRDQUBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Fsp_-okReEKrd3koR5i-HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pizwZd0AoUe6Rr73Pf4YZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_2hVJvj7Zgk2flnbUuLCHEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_5kY-i-Zg3k-S2BENf9UwDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TTeXW30sp0OT1Sxf3PgmKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_x6getxpL9EmAJ2xaJGImaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_VElBgd6POkGwMjlKJdoNAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DcS5Ka-g5Uuv_EvSXAJk_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E1yBXnv1JEqkFifQJ0DCkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r4Z52hagwUK01HtKpXLekA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_ancTWgsA3EaZqftsGC9BMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Za0p7Lfn0SI4LJAXHWLYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8CaGtWv9QUicSDrtUt3MzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Q0akVaGa0UGbNziyt_b1ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KG8su_uOu0a0KunRTlLxoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_OPji8N90TES4hj8qFG2_Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pNeBwXPMFUiQuaK_5XpBZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UKTQnfrtqE-IQhyGVhZXZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J78E05vN20erGsltKQSaYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ZAIqUZ6DnEaGRXvod8zuFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-fGWKFY2rEOZsvz04ykZLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pIuFXCNeoUy7CaDSOhk2xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_MvdjFPDEXkW0jwwbZh-cTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_QTNt0bXsx0a3cvqcs-sJBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_zXGYISRRU0mn6bkSMKyVSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_vrEMPt5leE2LUHWCygtNag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_vua2vlRLFESfuxZbRFuRuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WBu5OJOR70SEMOJWhuD6rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_25mz8MzMZU6-TK20uJ2UWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YPqb6m0diEulW2HtfQSfmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_PEIXHzXukUSrP_zBNlrOtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-07</xbrli:startDate><xbrli:endDate>2022-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Cc4l6GLQ9UWIXpyBn68CYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-07</xbrli:startDate><xbrli:endDate>2022-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_mYqtV1u_dUOeGU09TxPkwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qodzJmIask-OtNzB-p7X4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__xADkSqTO0S-DY3ZQNH76A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-09</xbrli:startDate><xbrli:endDate>2020-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_DQ9yn7uS2EGDv6fQLKvPeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-09</xbrli:startDate><xbrli:endDate>2020-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_4_30_2023_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jbskMAiPskm8ahOT8fG0aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_EMWaJe9pw0yONDIyRxQ1EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_QB4Okja9ZEGLGUBdgEeHpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_o7k1J95q30-im7Wsqr0zgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-08</xbrli:startDate><xbrli:endDate>2022-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_7_2022_To_12_27_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_lXgW5nkfeUOQyYVN7MFj6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-07</xbrli:startDate><xbrli:endDate>2022-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2022_To_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember__79tbn2a-EGdvybT6uk1ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-07</xbrli:startDate><xbrli:endDate>2022-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_cp16D7zq-k6IluFfoJ6iCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_1eP-WkT9Skmw68n0YD2iXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_fLrvwshp_kef4yuIOIUV5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_sTKKUtyqS0eFI2J-zEunNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_HX6qRchl3UOJYp2kC_kivw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_JHoh1u6SlUWt5wpfBqAllA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_Q157HUAGCUiQ3O7w3B8ZAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_EJ0fi0sr6k2AD6FT92wY0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ymf1E7tmdEWfCfZo72BFWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-15</xbrli:startDate><xbrli:endDate>2020-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wZ9cdC31zEC6F4Aji6T7Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_VsC-jPAYAUqbiloJ81rslQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctMaterialTransferAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_3qRSyDBk-U6_JWTPepBfbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_ydcSvQ_MrUWX4ODW9D_Low"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TIiFTeaXkUeerjdaxd6jwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_0q1bEcQFREGMTjD4ZvPvnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ZBzOSEd9-keWfT5F8GU35g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_hlw_TK4DbU6yZTcHfKFcyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_yuDqrjY2ZES39bMfzJzDpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_hHC55XuXUE2hmp5hAZXI4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_3nKdmvhHQ0e0MXKzpN6qwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vDDRVJHJWEiIRkoC0j_pHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_1rOMO6-cAU-GIBzCBWWxnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_jTkNK83fPE6etG2zBbgm_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_53NbnrlZsUSgSYUOMp8aRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_mtdgNiOXz0Od9s3DiXLFWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_XfcO1vA5gES98UF8hk_gOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Xo3frStwAkqUZlLqb4wjJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_r4lFa-Ww0kCU3jAskRrUVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_fmpyuXJQ_EqCRbO-JtqTjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_lU_OCdJ2sUCF8wkKIvaYFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_jQzQ-Qs4jUWen2BvHNx06Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_f5vXDOcWdkSV-l04XmsJrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Itm1UFewfkK9c21wwIKhCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_MJlpRPr5HkyPVxy3B1RlaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_pvNixmkY0UODGpGvN2b_aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_U14hTTfIw0aauKmk513MSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_V0FQCFIXf0qnsEhwdlQOIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xRsWSZSyjEauMH-_N844Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2h413p21UkmzRBTslwlxxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KrbO3xolp0mWoDpH-tUPDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_-m_klozaH0y8y3effakxHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_E2F3cjJxskiJsRXhTacDag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_Ed31KlzZbUezDqBMeti4vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_HEZrgDuwzU2I-5vwCDZhrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DNi18GaWDEuLxJST1LKg5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_rn5z_oGtm0i4zKXJtLEPBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_sW55u4h2J0OcuFvypf5muw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_ITtG4X4HskK8vTiFNbmV8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MipZoRX4l0apHBHgnqY4mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_-deeomKWdka8knVPbfU3GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-htfaRs6hE-PttrYcJWsUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_O5OcHRqnw0Wo-gX84ILHew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EML4beDnNUeNnibb9wySxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WtkVxDqueEGxL4XHYvRZcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_8PMoYsniJEKQ59jVt_gtxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_BH3baoGYjECWp2ep1hunvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iYVX4_oPbUSXBpxQ0gDPag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZgaIiUt-UEqjj7jLhIpMZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GClxeG8xvEeEJiRr287NPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_US_9sDKIIcAC0O2whabXRhATQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_SG_aoUeaWEODUuRBoaCnL4L8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_HK_Otsf7MqCgkyOm-luahjSsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CN_pERkzB2zbEuJoXns9cPQzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CH_u8WhTZKTgk6uGwI8YPJBBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AU_iIjaBK7jEEatSAUYG4p5Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TiCAjHF8_U-6H2PHnG8Zpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJZYhVw9NU-SOXmev5aACA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IvlyyVsaP0qH00DZs-cOzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_pEeZWdw_fkSZYD0_eWIssg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_G1AQfi6p4E24BfwphzFniA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdagenePte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneProjectC1Pte.Ltd.Member_umWeTmICo062uH3oJz8eNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneProjectC1Pte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneIncorporatedMember_BR7xdhRIAki49kFwg0OQzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_LuGkr2nW5UuEFN70Vzi-Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_HRsrjutOV0G30qtLf1pIow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAgMember_Pnv6Ik0j60COLF1wUWv5dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_Kyvt-xNRBUiAu-DLngZgGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_tHkOGLmG7kWYIeDJOJTVtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_qYhrznmDM0a0FqD3lA6Fbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_ymVbWklhkUCmOkHyKVKxVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_zUL5X-s5MEOb_qYJhHPkHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_v_9yYOSrf0y4xth99sJ-dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_BtH_9qawAU6ZHHYCSElW5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vOz3vIv740GU9REG4Z_wcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_CaP4Z8PlL0OapP5FtNaLKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_7v2coKKIyUmDdlmU0Olo6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_stpr_CA_J0BfSQ8UxU6Mwv9l4cdG6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_FibIWHTvR0OvdHAkZv3YsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_X7h_82d2c0KzwUudQtykwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_9BXgsqEAak6neZEeIkuLdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2008-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_0M5cOB2hoEaTbUgHkdCREw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_IGFUJEto00G2d7K3PSE_Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_t_0MJ4wuNkyxIV4bgXJFmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_R1F5ndSVPkCgXKmwyzbScg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_7-okYR-WZkiKB1VW-JL4qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaConstructionBankCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_Cvjhq1dzz0iJpxmkLeqhQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfJiangsuCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_1aTpF0ph_0-mY4m38ylZKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_qhmYvReawUyRvQAZITHLMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_M1R5q493x0epZjiLXZubXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_m85-xLE3m0awlOkyhyozPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_mUP8HKs3QE-VA88oUIhohw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_UzX_9ytflk6kC_qnriMQxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_o0zaN5JGjUuNPtedN9XKFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_GObFgSRwTUiB_WsA8h6l6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaConstructionBankCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfJiangsuCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_1YpVsNTuokSIfl2TMrVz6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SbWl9Shq4E6nlxFVgDBgpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_AXlFqdkG3UW_uqmcSDFkCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_qXLooUnAXE2ppSJQSdpERw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XFO8ZN7Etk2rs2waJjZ9vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_hl4SM9JGdEip0cnxdAqRJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_Kp5I1u1AQkCMEJ0paDZCvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_ZkAGkZRbN0SrE5hh7uf0cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_Ony51QAJ_02DctV0aevFAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember__YdfUW6IYUmfXgc9SfOrnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_8B7AeaXkck6JwjDBIkApxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_IfdRhB-Ii0Onl99aJ0jfJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xEF_4pgz1k6DXF8uNNBIvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_x3zBUisNukS5eVvI4gf_kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_n1ed7fGyz0KAIk8k73AxhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KuH9w-ji8E6oP8LOHD8eoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DQhBNix_zU24lt2mhsh67Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XApzz6RZb0COodakWjZlyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kkEXFXNRGUij0o1EOEbICA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ER1dY2hYkkebuGSCOwJV8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9u6PsJmRs0uWqcLpDwttXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_CH2MGlfLkEa-Mm5SY3caCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_E-IfTqEmFkC8P1gI378n2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CN_4etyAVb-kUilTpUBQYyO4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CH_otva1hRmgEGFbXAakLJRqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AU_c4N8MZWDzESe5gDU2Tk-5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_ee_5WiU0cUurw-SNNKSXuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_gn5TOqPkiEmr84V7LuQlbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Y81m7zrxYE2aoB4C9ZGt2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_eIoK0LUqmECLHEJOC58yjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_wh21KqXIxUieE_LnSC8fWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_wIkgvAtqC0W5o3H3Cfgn_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_YUb_RBfSLEO6_Ii2KjdzgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_xlZey60WBUuy5XYgHHijLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_wbQEbLCaH0CT2Hi48HK61Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_aTNTT8uQeEK_xzzYuJc0jQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_p76MqEtu0ESUlhT30hlMQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-16</xbrli:startDate><xbrli:endDate>2021-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-09</xbrli:startDate><xbrli:endDate>2020-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_FuMVl1AODUSWgqaccUaZLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_avqczjeiakGTBo6mGn9tGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-16</xbrli:startDate><xbrli:endDate>2021-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_mXd1utWD0Uy80tRoBoh-xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_MoK8o28CCE-5S19pyoHFfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LdAvTZA4DkCZZqMFxvFSkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZBLOK46STEKlz-d2OVI5uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_aR_5qQM_PUCejdDJoX8SrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SanofiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_lP6oVbKR6UmaFzbif9o9lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AVPy-5gte0WCo8vAl_mD9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Hp2hcBhCBUKfwPXhVKSC_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_b2-6zipvrUqdvncotPk1BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2008-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_VXRQnsAoMkSLLvY_DjFWlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_MSt1DxwXfUKQtc262Vnbaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SanofiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_zebDcdEQ3kW1LZbwJkj0Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SanofiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_jfKRlHoZrkOzsx-d3nM1UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_rvKTnfEkyUSop_lAg3fNuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_WFeE0wneck-MydNDO4uWyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctMaterialTransferAndOptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ay_6hRJo4U6yLXVvpTOGEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_3KyS7h9LmU6xtV1jimeGaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_DZY2VoRVfUyY29viuxBhrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_a1oYWpJoW026Q5lt5DP2dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_Y1LEBiLCsUiXix5-VE8rGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA"><xbrli:measure>adag:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:12.65pt;"><a id="_b9ca7aec_6b98_47ec_925e_a03382be1478"></a><a id="_Hlk132246385"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:13pt;">UNITED STATES</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">Washington, D.C. 20549</p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentType" id="Narr_J0jbBEHJ6EqWaoZtt0U8Ng"><b style="font-weight:bold;">20-F</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentRegistrationStatement" id="Narr_Awpc6V3Knku2O0H6YRgV9w"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentAnnualReport" id="Narr_JKtm9RujfEK3w4PZW1DRzA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 4pt 36pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentPeriodEndDate" id="Narr_JgteUCE9xUm3SEXE5Q1gog"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:CurrentFiscalYearEndDate" id="Narr_Bb8iFzyDA0CuPJoO2qtLLA"><b style="font-size:9pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, 2022</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentTransitionReport" id="Narr_DG8SYxGyMU-6HKWDsaFuFg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentShellCompanyReport" id="Narr_mNXdCXjRckykO17xfjplRA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 4pt 36pt;"><b style="font-weight:bold;">Date of event requiring this shell company report ___________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Commission file number: </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityFileNumber" id="Narr_j0olXLsmLkC56Z6Z9Rav4w"><span style="font-size:9pt;">001-39997</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityRegistrantName" id="Narr_ezM64_6ZiUSSlFVjVprlzw"><b style="font-weight:bold;">Adagene Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Exact name of Registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Translation of Registrant&#8217;s name into English)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityIncorporationStateCountryCode" id="Narr_gvZjuv4wW0ajIUsn4f-ZYg"><b style="font-weight:bold;">Cayman Islands</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Jurisdiction of incorporation or organization)</p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityAddressAddressLine1" id="Narr_pRWgxVsZwE-hFxSx0eQVqA"><b style="font-weight:bold;">4F, Building C14, No. 218</b></ix:nonNumeric></p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityAddressAddressLine2" id="Narr_p8IUyPZFVE-Vdp2C3AUbFA"><b style="font-weight:bold;">Xinghu Street, Suzhou Industrial Park</b></ix:nonNumeric></p><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:0pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityAddressCityOrTown" id="Narr_OEvsn-H--kmO-svT02VGVw"><b style="font-weight:bold;">Suzhou</b></ix:nonNumeric><b style="font-weight:bold;">, Jiangsu Province, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityAddressPostalZipCode" id="Narr_JpNS1_lbiUmO-SOa3yQfNQ"><b style="font-weight:bold;">215123</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">People&#8217;s Republic of </b><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityAddressCountry" id="Narr_bGZwwp2KX0KPz5xOVUYZxA"><b style="font-weight:bold;">China</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:ContactPersonnelName" id="Narr_2rDQJtB7jEy_2FQbaj3oEw"><b style="font-size:10pt;font-weight:bold;">Peter Luo</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">+</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:CountryRegion" id="Narr_Yv2fFE7KREqmKDUSz7748g"><b style="font-size:10pt;font-weight:bold;">86</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:CityAreaCode" id="Narr_ymB8yrFkKkKtGqiZWaIJbw"><b style="font-size:10pt;font-weight:bold;">512</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:LocalPhoneNumber" id="Narr_D8_MTmvhTkyv6mW-d-B32g"><b style="font-size:10pt;font-weight:bold;">87773616</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">Email:</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw" name="dei:ContactPersonnelEmailAddress" id="Narr_zFnQoxFvokiu9lKbnF7cmg"><b style="font-size:10pt;font-weight:bold;">peter_luo@adagene.com</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">At the address of the Company set forth above</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Securities registered or to be registered pursuant to Section 12(b) of the Act:</p><a id="_69843d0e_c6dc_40f2_835a_8c0dc6b0110f"></a><div style="margin-left:0pt;"><a id="Tc_zyuTReRK6UO6FdPWj3rong_1_0"></a><a id="Tc_h14sz0xf5kOofADCpmUyjw_1_2"></a><a id="Tc_AjW_BmTixESBqJIuwDiqgw_1_4"></a><a id="Tc_OUzDifqoK0OUIMot3P8VJw_2_0"></a><a id="Tc_wTcGh3dZ50Gq4Int_b_CNg_3_0"></a><a id="Tc_OZyKg1ognk2d_pS-Y4CBZQ_3_4"></a><a id="Tc_ecqpjvpLeE2_ysvUqzEv-w_4_0"></a><a id="Tc_o5mpS7WDVUaErrFadG2z_g_5_0"></a><a id="Tc_sAhHg26t202pvqasLFkF0w_6_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g" name="dei:Security12bTitle" id="Narr_23833KN79ESPKaMvy2ehXA"><span style="font-size:9pt;">American depositary shares</span></ix:nonNumeric><span style="font-size:9pt;">, each ADS representing one</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g" name="dei:TradingSymbol" id="Tc_QcIC-eFT2UKlTgTHA9QfFg_2_2"><span style="font-size:9pt;">ADAG</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g" name="dei:SecurityExchangeName" id="Tc_2lwHM13jcE2OzJWKWxj1IA_2_4"><span style="font-size:9pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">and one quarter</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">(The Nasdaq Global Market)</p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">ordinary shares, par value US$0.0001 per share</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw" name="dei:Security12bTitle" id="Narr_ZpTA33FTYUKpSs3ADwBszg"><span style="font-size:9pt;">Ordinary shares, par value US$0.0001 per share</span></ix:nonNumeric><span style="font-size:9pt;">*</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_GqZ4e-5sDUeUrCQEYrvXig;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">N/A</span></span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw" name="dei:SecurityExchangeName" id="Tc_REz6X-oq2E6bvkBmO6I8lQ_5_4"><span style="font-size:9pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">(The Nasdaq Global Market)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">*</span></span>Not for trading, but only in connection with the listing on the Nasdaq Global Market of American depositary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered or to be registered pursuant to Section 12(g) of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Title of Class)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Title of Class)</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_czG0_YkXMUSo7thK4dEpcg">54,065,709</ix:nonFraction> ordinary shares, par value US$0.0001 per share, as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_jdT4se-gOE-wCD83e17MJQ"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityVoluntaryFilers" id="Narr_u_5E_u8Zy0aFiBpuImpdvg"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityCurrentReportingStatus" id="Narr_5wtuXgdG3Uux8q2qFfXSRA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:EntityInteractiveDataCurrent" id="Narr_iIrWrqBgN0KyhI6v2uNxHA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. Check one:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Large Accelerated Filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span> </p></td><td style="vertical-align:top;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="Narr_Vd154OiwQUKlMHbKmXvc7Q"><span style="font-size:10pt;">Accelerated Filer</span></ix:nonNumeric><span style="font-size:10pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9746;</span></p></td><td style="vertical-align:bottom;width:27.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Non-accelerated Filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="Narr_GCeyWOK6u0u76CVTKc-8pw"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards &#8224; provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="Narr_7_NyEsuR_0GxoxPcMftBSA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountant firm that prepared or issued its audit report. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" id="Narr_64ZbDr8go0iH2IVNpaDpnw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 18pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:DocumentAccountingStandard" id="Narr_pVHx7Nof4EuM6y6Kybf-8Q"><span style="font-size:9pt;">U.S. GAAP</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;&#160;&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 18pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span><span style="font-family:'Segoe UI Symbol';"> </span>International Financial Reporting Standards as issued by the International Accounting Standards Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 18pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span><span style="font-family:'Segoe UI Symbol';"> </span>Other</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span> Item 17&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span> Item 18</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Yes </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="Narr_WzZx6NyVZEaVoYbSj2qKIw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">Yes <span style="font-family:'Segoe UI Symbol';">&#9744;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;No <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><span style="font-size:7pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_deed5700_6f64_4e24_bac8_40d161d3a6d2"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.19%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:90.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Page</p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#INTRODUCTION_914373"><span style="font-style:normal;font-weight:normal;">INTRODUCTION</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">1</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#FORWARDLOOKINGINFORMATION_280297"><span style="font-style:normal;font-weight:normal;">Forward-Looking Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTI_224417"><span style="font-style:normal;font-weight:normal;">PART I</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">5</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM1IDENTITY_297271"><span style="font-style:normal;font-weight:normal;">Item 1. Identity of Directors, Senior Management and Advisors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">5</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM2OFFERSTATISTICS_443951"><span style="font-style:normal;font-weight:normal;">Item 2. Offer Statistics and Expected Timetable</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">5</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM3KEYINFORMATION_236761"><span style="font-style:normal;font-weight:normal;">Item 3. Key Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">5</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM4INFORMATIONONTHECOMPANY_682720"><span style="font-style:normal;font-weight:normal;">Item 4. Information of the Company</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">82</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM4AUNRESOLVEDSTAFFCOMMENTS_814425"><span style="font-style:normal;font-weight:normal;">Item 4A. Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">154</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM5OPERATINGANDFINANCIALREVIEWANDPROSP"><span style="font-style:normal;font-weight:normal;">Item 5. Operating and Financial Review and Prospects</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">155</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM6DIRECTORSSENIORMANAGEMENTANDEMPLOYE"><span style="font-style:normal;font-weight:normal;">Item 6. Directors, Senior Management and Employees</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">172</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item7MajorShareholdersandRelatedPartyTra"><span style="font-style:normal;font-weight:normal;">Item 7. Major Shareholders and Related Party Transactions</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">190</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item8FinancialInformation_179985"><span style="font-style:normal;font-weight:normal;">Item 8. Financial Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">191</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item9TheOfferandListing_756002"><span style="font-style:normal;font-weight:normal;">Item 9. The Offer and Listing</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">192</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item10AdditionalInformation_357630"><span style="font-style:normal;font-weight:normal;">Item 10. Additional Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">192</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">Item 11. Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">203</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM12DESCRIPTIONOFSECURITIESOTHERTHANEQ"><span style="font-style:normal;font-weight:normal;">Item 12. Description of Securities Other Than Equity Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">204</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTII_838708"><span style="font-style:normal;font-weight:normal;">PART II</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">207</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM13ITEMDEFAULTSDIVIDENDARREARAGESANDD"><span style="font-style:normal;font-weight:normal;">Item 13. Defaults, Dividend Arrearages and Delinquencies</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">207</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM14MATERIALMODIFICATIONSTOTHERIGHTSOF"><span style="font-style:normal;font-weight:normal;">Item 14. Material Modifications to the Rights of Securities Holders and Use of Proceeds.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">207</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM15CONTROLSANDPROCEDURES_210978"><span style="font-style:normal;font-weight:normal;">Item 15. Control and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">207</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item16AAuditCommitteeFinancialExpert_659"><span style="font-style:normal;font-weight:normal;">Item 16.A. Audit Committee Financial Expert</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">208</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="font-size:10pt;" href="#Item16BCodeofEthics_352573"><span style="font-style:normal;font-weight:normal;">Item 16.B. Code of Ethics</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">208</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="font-size:10pt;" href="#Item16CPrincipalAccountantFeesandService"><span style="font-style:normal;font-weight:normal;">Item 16.C. Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a href="#a16DExemptionsfromtheListingStandardsfor"><span style="font-style:normal;font-weight:normal;">Item </span><span style="font-size:10pt;font-style:normal;font-weight:normal;">16.D. Exemptions from the Listing Standards for Audit Committees</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a href="#a16EPurchasesofEquitySecuritiesbytheIssu"><span style="font-style:normal;font-weight:normal;">Item </span><span style="font-size:10pt;font-style:normal;font-weight:normal;">16.E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a href="#a16FChangeinRegistrantsCertifyingAccount"><span style="font-style:normal;font-weight:normal;">Item </span><span style="font-size:10pt;font-style:normal;font-weight:normal;">16.F. Change in Registrant&#8217;s Certifying Accountant</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">210</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a href="#a16GCorporateGovernance_85646"><span style="font-style:normal;font-weight:normal;">Item </span><span style="font-size:10pt;font-style:normal;font-weight:normal;">16.G. Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">211</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a href="#a16HMineSafetyDisclosure_791076"><span style="font-style:normal;font-weight:normal;">Item </span><span style="font-size:10pt;font-style:normal;font-weight:normal;">16.H. Mine Safety Disclosure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">211</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a href="#a16IDisclosureRegardingForeignJurisdicti"><span style="font-style:normal;font-weight:normal;">Item </span><span style="font-size:10pt;font-style:normal;font-weight:normal;">16.I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">212</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIII_403713"><span style="font-style:normal;font-weight:normal;">PART III</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">213</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM17FINANCIALSTATEMENTS_534522"><span style="font-style:normal;font-weight:normal;">Item 17. Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">213</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM18FINANCIALSTATEMENTS_506735"><span style="font-style:normal;font-weight:normal;">Item 18. Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">213</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM19EXHIBITS_246848"><span style="font-style:normal;font-weight:normal;">Item 19. Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">213</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cda0a3f6_a39a_4ada_8ff1_b4031b2d3413"></a><a id="INTRODUCTION_914373"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">INTRODUCTION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Except where the context otherwise indicates and for the purpose of this annual report only:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Adagene Suzhou&#8221; refers to Adagene (Suzhou) Limited, our subsidiary in the PRC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Adagene Incorporated&#8221; reference to Adagene Incorporated, our subsidiary in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;ADSs&#8221; refers to the American depositary shares, each representing one and one quarter (1.25) of our ordinary shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Antibody binding interface&#8221; or &#8220;antibody binding sites&#8221; refers to the antibody binding surface spots in contact with its recognition antigen;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;China&#8221; or &#8220;PRC&#8221; refers to the People&#8217;s Republic of China; and only in the context of describing PRC rules, laws, regulations, regulatory authority, and any PRC entities or citizens under such rules, laws and regulations and other legal or tax matters in this annual report, excludes Taiwan, Hong Kong, and Macau;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;conformational diversity&#8221; or &#8220;dynamic diversity&#8221; refers to the existence of more than one conformation or structure due to dynamic fluctuation of the structures for a given protein sequence, independent of any conformational changes caused by external binding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;epitopes&#8221; or &#8220;epitope of an antigen&#8221; refers to the specific binding spots of an antigen in contact with its antibody binding surface;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Greater China,&#8221; for the purpose of this annual report, refers to the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;multi-specificity&#8221; refers to a protein exerting a similar function (such as binding) on distinctly different ligands, perhaps while using different active site residues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;NEObody&#8221; refers to antibody designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOA, using our NEObody technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;POWERbody&#8221; refers to antibody that utilizes our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or antibodies, which are designed to reach beyond the therapeutic potency of traditional monospecific antibodies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;RMB&#8221; or &#8220;Renminbi&#8221; refers to the legal currency of the People&#8217;s Republic of China;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;SAFEbody&#8221; refers to antibody engineered with its binding sites masked, which are designed to be selectively activated in the TME, potentially limiting on-target off-tumor toxicity in normal tissues; SAFEbody&#174; is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;species cross-reactivity&#8221; refers to reactivity of the same protein that recognizes and binds to similar epitopes of a given class of targets in different species;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;US$,&#8221; &#8220;dollars&#8221; or &#8220;U.S. dollars&#8221; refers to the legal currency of the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company,&#8221; and &#8220;our,&#8221; refer to Adagene Inc., a Cayman Islands exempted company and its subsidiaries.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;NEObodies&#8221; refer to antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOAs, using our NEObody technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;ordinary shares&#8221; or &#8220;shares&#8221; refers to our ordinary shares of par value US$0.0001 per share;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;POWERbodies&#8221; refer to antibodies that utilize our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or antibodies, which are designed to reach beyond the therapeutic potency of traditional monospecific antibodies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;SAFEbodies&#8221; refer to antibodies engineered with their binding sites masked, which are designed to be selectively activated in the tumor microenvironment, potentially limiting on-target off-tumor toxicity in normal tissues.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a96b1b5b_5a97_4840_bcf0_65256dd89663"></a><a id="FORWARDLOOKINGINFORMATION_280297"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This annual report contains forward-looking statements that reflect our current expectations and views of future events. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements are made under the &#8220;safe harbor&#8221; provision under Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and as defined in the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, including but not limited to Adagene&#8217;s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene&#8217;s drug candidates; Adagene&#8217;s ability to achieve commercial success for its drug candidates, if approved; Adagene&#8217;s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene&#8217;s reliance on third parties to conduct drug development, manufacturing and other services; Adagene&#8217;s limited operating history and Adagene&#8217;s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene&#8217;s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene&#8217;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#8220;Risk Factors&#8221; section in Adagene&#8217;s filings with the SEC. Such known and unknown risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In some cases, you can identify these forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;is/are likely to,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our goals and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our future business development, results of operations and financial condition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our discovery programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to utilize our proprietary Dynamic Precision Library platform, or DPL, to design, construct and develop next-generation antibodies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance product candidates into, and successfully complete, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of regulatory filings and approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercializing of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future strategic arrangements and/or collaborations and the potential benefits of such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our anticipated use of our existing resources and the proceeds from our initial public offering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model, strategic plans for our business and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights, such as our proprietary DPL, which includes NEObody platform, SAFEbody platform and POWERbody platform, product candidates and discovery programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential to enter into new collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pricing, coverage and reimbursement of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry, including competing product candidates and therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the direct and indirect impact of the COVID-19 pandemic on our business and operations and on development of our clinical and preclinical programs, and the duration and impact of COVID-19 or any of its variants that may affect, precipitate or exacerbate one or more of any of the risks and uncertainties mentioned in this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relevant government policies and regulations relating to our business and industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic and business condition in the markets we have businesses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumptions underlying or related to any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We would like to caution you not to place undue reliance on these forward-looking statements and you should read these statements in conjunction with the risk factors disclosed in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; of this annual report and other risks outlined in our other filings with the Securities and Exchange Commission, or the SEC. Those risks are not exhaustive. We operate in an evolving environment. New risks emerge from time to time and it is impossible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should not rely upon forward-looking statements as predictions of future events. We do not undertake any obligation to update or revise the forward-looking statements except as required under applicable law. You should read this annual report and the documents that we reference in this annual report completely and with the understanding that our actual future results may be materially different from what we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f2c4709c_7676_4af5_9418_82a67d6b7cc4"></a><a id="PARTI_224417"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="ITEM1IDENTITY_297271"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 1.&#160;IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_fc47ce1d_c3d0_4f58_937f_dc6896ee73a5"></a><a id="ITEM2OFFERSTATISTICS_443951"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 2.&#160;OFFER STATISTICS AND EXPECTED TIMETABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_809864a6_f781_45dc_a193_220155fd82b9"></a><a id="ITEM3KEYINFORMATION_236761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 3.&#160;KEY INFORMATION</p><a id="_3fe8cebd_fa69_4675_ad68_0d638da82ab0"></a><a id="a3AReserved_450679"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.A. [Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_8c955cec_163a_4eb4_9ca9_5e1b830583f1"></a><a id="a3BCapitalizationandIndebtedness"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3.B. Capitalization and Indebtedness</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_ed8b697e_f0eb_465d_ae3b_78c23e9aec8a"></a><a id="a3CReasonfortheOfferandUseofProceeds_915"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3.C. Reason for the Offer and Use of Proceeds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_5b8e3eea_b063_4ee2_9b53_5ac612304b66"></a><a id="a3DRiskFactors_683481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3.D. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Investors in Adagene Inc.&#8217;s equity securities are investing equity securities of a Cayman Islands holding company rather than equity securities of our subsidiaries that have substantive business operations in China or in the United States. Adagene Inc. is a Cayman Islands holding company that conducts a substantial portion of its operations in China through its PRC subsidiary, Adagene (Suzhou) Limited. In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. Our corporate group does not include any variable interest entities. Such structure involves unique risks to investors in the ADSs and ordinary shares. You should carefully consider all of the information in this annual report before making an investment in our ADSs. In particular, as we are a holding company with substantial business operations in China, you should pay special attention to subsections headed &#8220;Item 4.A.&#8211;&#8211; 4.A. History and Development of the Company Recent&#8211;&#8211;Regulatory Developments,&#8221; &#8220;Item 3.D. Risk Factors&#8211;&#8211;Risks Related to Doing Business in the PRC,&#8221; including but not limited to risk factor such as &#8220;uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us.&#8221; The PRC government has significant authority to exert influence on the ability of a company with substantive operations in China, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy, as well as the lack of PCAOB inspection on our auditor. Such risks could result in a material change in our operations and/or the value of our ADSs or could significantly limit or completely hinder our ability to offer or continue to offer ADSs and/or other securities to investors and cause the value of such securities to significantly decline or be worthless.  The PRC government also has significant oversight and discretion over the conduct of our business and as such may influence our operations at any time, which could result in a material adverse effect on our operations. The PRC government has recently published new policies and made statements, such as those related to regulatory approvals of offshore offerings and data security or anti-monopoly concerns, that although did not target on our company specifically, nevertheless have significantly affected certain industries and other PRC-based issuers as a whole, and we cannot rule out the possibility that it will in the future release regulations or policies regarding the industry where we operate, which could adversely affect our business, financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. These risks could result in a material change in our operations and the value of our ordinary shares or the ADSs, or could significantly limit or completely hinder our ability to conduct our business, accept foreign investments, or maintain listing on Nasdaq or list on other foreign exchange, and offer or continue to offer securities to investors, and cause the value of such securities to significantly decline or become worthless.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should carefully consider all of the information in this annual report before making an investment in the ordinary shares or ADSs. Below please find a summary of the principal risks and uncertainties we face, organized under relevant headings. In particular, as we are a company incorporated in the Cayman Islands with substantive business operations in China, you should pay special attention to subsections headed &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8221; and &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8212;Risks Related to the ADSs.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below please find a summary of the principal risks we face, organized under relevant headings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Doing Business in the PRC </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to doing business in China include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us. For details, see page 9 of this annual report; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations. For details, see page 9 of this annual report; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The PCAOB had historically been unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections of our auditor in the past has deprived our investors with the benefits of such inspections. For details, see page 10 of this annual report.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The delisting of the ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. For details, see page 10 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The enactment of the Accelerating Holding Foreign Companies Accountable Act decreases the number of non-inspection years from three years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted. For details, see page 11 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Your investments in our ADSs and/or ordinary shares are investments in equity securities of a Cayman Islands holding company rather than equity securities of our subsidiaries that have substantive business operations in China. As a result, you may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management based on foreign laws. For details, see page 14 of this annual report; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be required to obtain approval or complete filing or other requirements of the CSRC or other PRC government authorities in connection with our issuances of securities overseas, and, if required, we cannot predict whether we will be able to obtain such approval or complete such governmental procedure. For details, see page 16 of this annual report; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations. For details, see page 19 of this annual report.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Prospects and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to our financial prospectus and need for additional capital include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance. For details, see page 26 of this annual report;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred net losses historically and we may continue to incur net losses in the near future. For details, see page 26 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all. For details, see page 27 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict our operations or require us to relinquish rights to our technologies or product candidates. For details, see page 28 of this annual report; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have certain shareholders who have board representation rights and their individual interests may differ from yours. For details, see page 29 of this annual report.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Clinical Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to clinical development of our product candidates include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success. For details, see page 29 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates. For details, see page 30 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our business and financial condition. For details, see page 30 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates, for which we intend to seek approval as biologic products, may face competition sooner than anticipated. For details, see page 30 of this annual report; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend substantially on the success of our product candidates, particularly our anti-CTLA-4 franchise, including ADG116 and ADG126, and our two anti-CD137 antibodies, ADG106 and ADG206, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. For details, see page&#160;31 of this annual report.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Risks Related to Obtaining Regulatory Approval of Our Drug Candidates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to obtaining regulatory approval of our drug candidates include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed. For details, see page 36 of this annual report.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business. For details, see page 38 of this annual report.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. For details, see page 38 of this annual report.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials. For details, see page 39</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval. For details, see page 39 of this annual report.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to our intellectual property include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world. For details, see page 64 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. For details, see page 67 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and licensing deals. For details, see page 68 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our product candidates. For details, see page 69 of this annual report; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our commercial success depends significantly on our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties. For details, see page 69 of this annual report.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risks Related to the ADSs </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to the ADSs include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine, including particularly how countries like the United States and China choose to respond to this war. As a result, the value of our ADSs may significantly decline. For details, see page 74 of this annual report.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may be subject to limitations on transfer of your ADSs. For details, see page 74 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The trading price of the ADSs is likely to be volatile, which could result in substantial losses to investors. For details, see page 74 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements. For details, see page 75 of this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If securities or industry analysts cease to publish research or reports about our business, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline. For details, see page 75 of this annual report; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the ADSs could adversely affect their market price. For details, see page 75 of this annual report;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We were likely a passive foreign investment company, or PFIC, for 2022, and there is a significant risk that we will be a PFIC for 2023 and possibly subsequent taxable years, in which case U.S. investors will generally be subject to adverse U.S. federal income tax consequences; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If a U.S. person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences. For details, see page 81 of this annual report. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Doing Business in the PRC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations in China are governed by the PRC laws and regulations. The PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. In addition, any new PRC laws or changes in PRC laws and regulations related to, among other things, foreign investment and manufacturing in China could have a material adverse effect on our business and our ability to operate our business in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory provisions and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy, than in more developed legal systems. These uncertainties may impede our ability to enforce contracts in China and could materially and adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, or at all, and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime after the violation. Such unpredictability towards our contractual, property and procedural rights could adversely affect our business, and impede our ability to continue our operations and proceed with our future business plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PRC government has significant oversight over the conduct of our business and may intervene or influence our operations at any time, which may potentially result in a material adverse effect on our operations. PRC government has also recently indicated an intent to exert more oversight over offerings that are conducted overseas and foreign investment in China-based issuers, which could impact our ability to raise additional capital in international capital markets. In addition, the PRC government has recently published new policies that significantly affected certain industries such as the education and internet industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Any such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, as there are still regulatory uncertainties in this regard, we cannot assure you that we will be able to comply with new laws and regulations in all respects, and we may be ordered to rectify, suspend or terminate any actions or services that are deemed illegal by the regulatory authorities and become subject to material penalties, which may materially harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The PCAOB had historically been unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections of our auditor in the past has deprived our investors with the benefits of such inspections.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. The auditor is located in mainland China, a jurisdiction where the PCAOB was historically unable to conduct inspections and investigations completely before 2022. As a result, we and investors in the ADSs were deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in mainland China in the past has made it more difficult to evaluate the effectiveness of our independent registered public accounting firm&#8217;s audit procedures or quality control procedures as compared to auditors outside of mainland China that are subject to the PCAOB inspections. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. However, if the PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in mainland China and Hong Kong, and we use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the Securities and Exchange Commission, we and investors in our ADSs would be deprived of the benefits of such PCAOB inspections again, which could cause investors and potential investors in the ADSs to lose confidence in our audit procedures and reported financial information and the quality of our financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The delisting of the ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the HFCAA, if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspections by the PCAOB for two consecutive years, the SEC will prohibit our shares or ADSs from being traded on a national securities exchange or in the over-the-counter trading market in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On December 16, 2021, the PCAOB issued a report to notify the SEC of its determination that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong and our auditor was subject to that determination. In May 2022, the SEC conclusively listed us as a Commission-Identified Issuer under the HFCAA following the filing of our annual report on Form 20-F for the fiscal year ended December 31, 2021.  On December 15, 2022, the PCAOB removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. For this reason, we do not expect to be identified as a Commission-Identified Issuer under the HFCAA after we file this annual report on Form 20-F for the fiscal year ended December 31, 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Each year, the PCAOB will determine whether it can inspect and investigate completely audit firms in mainland China and Hong Kong, among other jurisdictions. If the PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in mainland China and Hong Kong and we use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the Securities and Exchange Commission, we would be identified as a Commission-Identified Issuer following the filing of the annual report on Form 20-F for the relevant fiscal year. In accordance with the HFCAA, our securities would be prohibited from being traded on a national securities exchange or in the over-the-counter trading market in the United States if we are identified as a Commission-Identified Issuer for two consecutive years in the future.  If our shares and ADSs are prohibited from trading in the United States, there is no certainty that we will be able to list on a non-U.S. exchange or that a market for our shares will develop outside of the United States. A prohibition of being able to trade in the United States would substantially impair your ability to sell or purchase our ADSs when you wish to do so, and the risk and uncertainty associated with delisting would have a negative impact on the price of our ADSs. Also, such a prohibition would significantly affect our ability to raise capital on terms acceptable to us, or at all, which would have a material adverse impact on our business, financial condition, and prospects.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The enactment of the Accelerating Holding Foreign Companies Accountable Act decreases the number of non-inspection years from three years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2021, the U.S. Senate passed a bill, also known as the Accelerating Holding Foreign Companies Accountable Act, to amend Section 104(i) of the Sarbanes-Oxley Act of 2002 (15 U.S.C. 7214(i)) to prohibit securities of any registrant from being listed on any of the U.S. securities exchanges or traded over-the-counter if the auditor of the registrant&#8217;s financial statements is not subject to PCAOB inspection for two consecutive years, instead of three consecutive years as initially required under the HFCA Act, after the law becomes effective. On February 4, 2022, the U.S. House of Representatives passed the America COMPETES Act of 2022, which includes the exact same amendments as the bill passed by the Senate. On December 29, 2022, the Accelerating Holding Foreign Companies Accountable Act was signed into law as part of the recently passed fiscal year 2023 omnibus spending legislation. It requires the SEC to prohibit an issuer&#8217;s securities from trading on U.S. markets if the SEC identifies such issuer to be a Commission-Identified Issuer for two consecutive years. Accordingly, it will reduce the time period before our ADSs will be prohibited from trading on the Nasdaq or over-the-counter or be delisted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be restricted from transferring our scientific data abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#8220;state secret&#8221; is not clearly defined, there is no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our preclinical studies or clinical trials conducted within China) abroad, or to our foreign partners in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the Cyberspace Administration of China, or the CAC, issued the Measures on Security Assessment of the Cross-border Transfer of Personal Information (Draft for Comment) in June 2019, pursuant to which, any cross-border transfer of information that may endanger national security, damage public interest, or fail to offer effective protection of personal information security, as assessed by relevant regulatory bodies, will be prohibited. In July 2022, CAC issued the Measures on Security Assessment of the Cross-border Data Transfer, which regulates the thresholds for triggering mandatory security assessments not only in the cross-border transfers of personal information, but also in the cross-border transfers of &#8220;important data&#8221; collected and generated in China under certain circumstance. The term &#8220;important data&#8221; means any data, the tampering, damage, leakage, or illegal acquisition or use of which, if it happens, may endanger national security, the operation of the economy, social stability, public health and security, etc. Given that the government body will have full discretion in the assessment, it is unclear if and the extent to which our clinical data will be considered as an endangerment to national or personal information security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cross-border data transfer from other jurisdictions may also be limited if we fail to comply with relevant requirements, such as obtaining authorization from patients regarding the use, transfer and retrieval of their personal information or data and adopting measures to ensure the safety of personal information or data in the transfer. Also, cross-border transfer of personal data by its nature is subject to general data privacy regulations in various jurisdictions, and thus any failure to comply with data privacy protection may lead to a restriction of transferring our data across different jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of product candidates may be hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the requirements under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information and important data worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented and are considering a number of legislative and regulatory proposals concerning data protection. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China&#8217;s Cybersecurity Law, which became effective in June 2017, established China&#8217;s first national-level data protection for &#8220;network operators,&#8221; which may include all organizations in China that connect to or provide services over the internet or other information network. The Cybersecurity Law requires network operators to perform certain functions related to cybersecurity protection. In addition, the Cybersecurity Law imposes certain requirements on network operators of critical information infrastructure, or the CIIOs. For example, the CIIOs generally shall, during their operations in the PRC, store the personal information and important data collected and produced within the territory of PRC, and shall perform certain security obligations as required under the Cybersecurity Law, including that the CIIOs shall pass the national security review when purchasing network product or service which may affect national security. In addition, China&#8217;s Data Security Law, which was promulgated by the Standing Committee of PRC National People&#8217;s Congress, or the SCNPC, on June 10, 2021 and came into effect on September 1, 2021, outlines the main system framework of data security protection. For example, the Data Security Law introduces a data classification and hierarchical protection system based on the importance of data in economic and social development, as well as the degree of harm it will cause to national security, public interests, or legitimate rights and interests of individuals or organizations when such data is tampered with, destroyed, leaked, or illegally acquired or used. Processors of &#8220;important data&#8221; are further required to conduct periodic risk assessment and submit assessment report to relevant regulatory authorities. In addition, the Data Security Law provides a national security review procedure for those data activities which may affect national security. Furthermore, Regulations on the Security Protection of Critical Information Infrastructure, which was promulgated by the State Council of PRC on July 30, 2021 and came into effect on September 1, 2021, or the CII Protection Regulations, stipulates the obligations and liabilities of the regulators, society and CIIOs in protecting the security of critical information infrastructure, or the CII. According to the CII Protection Regulations, regulators supervising specific industries shall formulate detailed guidance to recognize the CII in the respective sectors, and CIIOs shall take the responsibility to protect the CII&#8217;s security by performing certain prescribed obligations. For example, CIIOs are required to conduct network security test and risk assessment, report the assessment results to relevant regulatory authorities, and timely rectify the issues identified at least once a year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law, which were issued by the General Committee and State Council on July 6, 2021, require the speed-up of the revision of the provisions on strengthening the confidentiality and archives coordination between regulators related to overseas issuance and listing of securities, and improvement to the laws and regulations related to data security, cross-border data flow, and management of confidential information. Numerous regulations, guidelines and other measures have been or are expected to be adopted under the umbrella of, or in addition to the Cybersecurity Law and Data Security Law , including the Cybersecurity Review Measures published by Cyberspace Administration of China, or the CAC, and other 12 relevant PRC government authorities in December 2021, which provides that, among others, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office, and that the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2022, CAC issued the Measures on Security Assessment of the Cross-border Data Transfer, or the Security Assessment Measures, which provide that data processors shall make self-assessment of the risks before transferring data cross-border, and shall apply for security assessment for cross-border data transfer in any of the following circumstances: (i) outbound transfer of important data by a data processor; (ii) outbound transfer of personal information by CIIO Operators or a personal information processor who has processed the personal information of more than 1,000,000 people; (iii) outbound transfer of personal information by a personal information processor who has made outbound transfers of the personal information of 100,000 people cumulatively or the sensitive personal information of 10,000 people cumulatively since 1 January of the previous year; or (iv) other circumstances where an application for the security assessment of an outbound data transfer is required as prescribed by the national cyberspace administration authority. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the CAC published the Regulations for the Administration of Cyber Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments in November 2021, which reiterate that a data processor who processes personal information of more than one million individuals must complete the cybersecurity review if it intends to be listed in a foreign country, and if a data processor conducts any data processing activities that affect or may affect national security, an application for cybersecurity review shall also be made by such a processor. The Draft Data Security Regulations also require that data processors who process important data or whose securities are listed outside of China shall carry out annual data security assessment by itself or through a third party data security service provider and submit the assessment report to local agency of the CAC. Also see &#8220;Item 4. Information on the Company&#8212;4.B. Business Overview&#8212;Regulation&#8212;Other PRC Government Regulations&#8212;Regulations on Information Security and Data Protection&#8221; for detailed discussion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report, the exact scope of CIIOs and important data under the current laws, regulations and regulatory regime remains unclear, and the authorities may have wide discretion in the interpretation and enforcement of the related laws and regulations. If we are deemed as a CIIO, or as an operator who collects, uses and processes important data according to the Cybersecurity Law, Data Security Law and other relevant laws and regulations, we may need to perform or be subject to certain prescribed obligations, and if we were found to be in violation of these applicable laws and regulations, we may be subject to administrative penalties, including fines and service suspension. We also cannot rule out the possibility that certain of our customers may be deemed as CIIOs, or as operators processing important data, in which case our products or services or data processing activities, if being deemed as related to national security, will need to be submitted for cybersecurity review before we can enter into agreements with such customers, and before the conclusion of such procedure, the customers will not be allowed to use our products or services. If the reviewing authority considers that the use of our services by certain of our customers involves risk of disruption, is vulnerable to external attacks, or may negatively affect, compromise, or weaken the protection of national security, we may not be able to provide our products or services to such customers, which could have a material adverse effect on our results of operations and business prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of the date of this annual report, we have not been involved in any investigations on cybersecurity review initiated by the Cyberspace Administration of China, and we have not received any inquiry, notice, warning, sanctions in such respect or any regulatory objections to our listing status on the Nasdaq. As there are still uncertainties regarding the further enaction of new laws and regulations as well as the revision, interpretation and implementation of those existing laws and regulations, however, we cannot assure you that we will be able to comply with such regulations in all respects, and we may be ordered to rectify, suspend or terminate any actions or services that are deemed illegal or incompliance by the regulatory authorities and become subject to fines and/or other penalties. If we are unable to address such issue in a timely manner or at all, we may be required to suspend or terminate our related businesses or face other penalties, our business, financial condition, results of operations, and prospects could be materially harmed.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, certain PRC regulatory authorities recently issued the Opinions on Strictly Cracking Down on Illegal Securities Activities. These opinions call for strengthened regulation over illegal securities activities and supervision of overseas listings by China-based companies and propose to take effective measures. As of the date of this annual report, no official guidance or related implementation rules have been issued and taken into effect in relation to such opinions and as a result, the interpretation and implementation of these opinions remain unclear at this stage. We cannot assure you that we will not be required to obtain the pre-approval of the CSRC and potentially other regulatory authorities to pursue an offering of securities overseas or to maintain the listing status of our ADSs on the Nasdaq. See also &#8220;&#8211;&#8211;We may be required to obtain approval or complete filing or other requirements of the CSRC or other PRC government authorities in connection with our issuances of securities overseas, and, if required, we cannot predict whether we will be able to obtain such approval or complete such governmental procedure.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State Council promulgated Regulations on the Administration of Human Genetic Resources (effective in July 2019), which require approval from or filings with the Science and Technology Administration Department of the State Council where human genetic resources, or HGR, are involved in any international collaborative project and additional approval for any export or cross-border transfer of the HGR samples or human genetic resource information. In addition, the Ministry of Science and Technology of the PRC published the Implementing Rules of the Administrative Regulations on Human Genetic Resources (Draft for Comment), which refined the requirements related to the ethical review required in the collection, conservation, utilization, and external provision of HGR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in confiscation of HGR samples and human genetic resource information and administrative fines or in worst cases, criminal penalties. In addition, the interpretation and application of data and personal information protection laws in China and elsewhere are often uncertain and in flux.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Dividends we receive from our subsidiaries located in the PRC may be taxed at a higher rate, which could materially and adversely affect the amount of dividends, if any, we may pay our shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Double Tax Avoidance Arrangement between Hong Kong and China, or the Double Tax Avoidance Treaty, and the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties, or the Notice on Tax Treaties, issued on February 20, 2009 by the State Administration of Taxation of the PRC, or the SAT, if a Hong Kong resident enterprise owns more than 25% of the equity interest of a PRC company at all times during the twelve-month period immediately prior to obtaining a dividend from such company, the 10% withholding tax on such dividend is reduced to 5%, provided that certain other conditions and requirements under the Double Tax Avoidance Treaty and other applicable PRC laws are satisfied at the discretion of the relevant PRC tax authority. However, based on the Notice on Tax Treaties, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, the PRC tax authorities may adjust the preferential tax treatment. Based on the Notice on Issues concerning Beneficial Owner in Tax Treaties, or Circular 9, issued on February 3, 2018 by the SAT and effective on April 1, 2018, when determining the applicant&#8217;s status as a &#8220;beneficial owner&#8221; for purpose of tax treatments in connection with dividends, interests or royalties in the tax treaties, several factors will be taken into account, and it will be analyzed according to the actual circumstances of the specific cases. If our Hong Kong subsidiary is determined by PRC government authorities as receiving benefits from reduced income tax rates due to a structure or arrangement that is primarily tax-driven, the dividends paid by our PRC subsidiaries to our Hong Kong subsidiary will be taxed at a higher rate, which will have an adverse effect on our financial and operational conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Your investments in our ADSs and/or ordinary shares are investments in equity securities of a Cayman Islands holding company rather than equity securities of our subsidiaries that have substantive business operations in China for instance. As a result, you may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management based on foreign laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adagene Inc. is a holding company incorporated under the laws of the Cayman Islands with no operations of its own. It conducts a substantial portion of its operations in China primarily through its subsidiary in China, Adagene (Suzhou) Limited. In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. As such, investors in the ADSs or ordinary shares are not purchasing equity securities of our subsidiaries that have substantive business operations in China or in the U.S. but instead are purchasing equity securities of a Cayman Islands holding company. In addition, some of our senior executive officers and directors reside within China for a significant portion of the time and some are PRC nationals. As a result, it may be difficult for our shareholders or investors to effect service of process upon us or those persons inside China. In addition, China does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the Cayman Islands and many other countries and regions. Therefore, recognition and enforcement in China of judgments of a court in any of these non-PRC jurisdictions in relation to any matter not subject to a binding arbitration provision may be difficult or impossible.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shareholder claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the local authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to Article 177 of the PRC Securities Law which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators and relevant authorities, no organization or individual may provide the documents and materials relating to securities business activities to overseas parties. See also &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks Related to the ADSs&#8212;You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Recent litigation and negative publicity surrounding China-based companies listed in the United States may result in increased regulatory scrutiny of us and negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the United States have negatively impacted stock prices for these companies. Various equity-based research organizations have published reports on China-based companies after examining their corporate governance practices, related party transactions, sales practices and financial statements, and these reports have led to special investigations and listing suspensions on U.S. national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have an adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. and international trade policies, particularly with regard to China, may adversely impact our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although cross-border business may not be an area of our focus, if we plan to expand our business internationally in the future, any unfavorable government policies on international trade, such as capital controls or tariffs, may affect the demand for our products and services, impact our competitive position, or prevent us from being able to conduct business in certain countries. If any new tariffs, legislation, or regulations are implemented, or if existing trade agreements are renegotiated, such changes could adversely affect our business, financial condition, and results of operations. Recently, there have been heightened tensions in international economic relations, such as the one between the United States and China. The U.S. government has recently imposed, and has recently proposed to impose additional, new, or higher tariffs on certain products imported from China to penalize China for what it characterizes as unfair trade practices. China has responded by imposing, and proposing to impose additional, new, or higher tariffs on certain products imported from the United States. Following mutual retaliatory actions for months, on January 15, 2020, the United States and China entered into the Economic and Trade Agreement Between the United States of America and the People&#8217;s Republic of China as a phase one trade deal, effective on February 14, 2020. It remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to international trade, tax policy related to international commerce, or other trade matters. The situation is further complicated by the political tensions between the United States and China that escalated during the COVID-19 pandemic and in the wake of the PRC National People&#8217;s Congress&#8217; decision on Hong Kong national security legislation, sanctions imposed by the U.S. Department of Treasury on certain officials of the Hong Kong Special Administrative Region and the central government of the PRC and the executive orders issued by U.S. President in August 2020 that prohibit certain transactions with certain China-based companies and their respective subsidiaries. Rising trade and political tensions could reduce levels of trade, investments, technological exchanges and other economic activities between China and other countries, which would have an adverse effect on global economic conditions, the stability of global financial markets, and international trade policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Although the direct impact of the current international trade and political tension, and any escalation of such tension, on the biopharmaceutical companies in China is uncertain, the negative impact on general, economic, political and social conditions may adversely impact our business, financial condition and results of operations.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be required to obtain approval or complete filing or other requirements of the CSRC or other PRC government authorities in connection with our issuances of securities overseas, and, if required, we cannot predict whether we will be able to obtain such approval or complete such governmental procedure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The M&amp;A Rules requires an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle&#8217;s securities on an overseas stock exchange. However, the application of the M&amp;A Rules remains unclear. If CSRC approval is required for any of our future offerings of securities overseas or to maintain the listing status of the ADSs, it is uncertain whether it would be possible for us to obtain the approval, and any failure to obtain or delay in obtaining such approval would subject us to sanctions imposed by the CSRC and other PRC government authorities.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the &#8220;Opinions on Severely Cracking Down on Illegal Securities Activities According to Law&#8221; (&#8220;Opinions&#8221;) which were made available to the public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies. These Opinions proposed to take effective measures, such as promoting the construction of relevant regulatory systems, to deal with the risks and incidents facing China-based overseas-listed companies and the demand for cybersecurity and data privacy protection. The policies described above and any related implementation rules to be enacted may subject us to additional compliance requirement in the future. As the Opinions only provide general guidance, the interpretation and implementation of the Opinions remain unclear in several respects at this time. Therefore, we cannot assure you that we will remain fully compliant with all new regulatory requirements of the Opinions or any future implementation rules on a timely basis, or at all. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 24, 2021, the CSRC issued the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments) and the Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), collectively the Draft Overseas Listing Regulations, for public comment until January 23, 2022. Following issuance of the Draft Overseas Listing Regulations, on February 17, 2023, the CSRC issued the Notice on Filing Arrangements for Overseas Securities Offering and Listing by Domestic Companies (the &#8220;CSRC Filing Notice&#8221;), stating that the CSRC has published the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;) and five supporting guidelines (the &#8220;Listing Guidelines&#8221;), collectively the Trial Measures and Listing Guidelines, which came into effect on March 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Trial Measures provide that an overseas listing or offering securities (which, for the purposes of the Trial Measures, are defined thereunder as equity shares, depository receipts, corporate bonds convertible to equity shares, and other equity securities that are offered and listed overseas, either directly or indirectly, by PRC domestic companies) is explicitly prohibited under any of the following circumstances: (i) such securities offering and listing is explicitly prohibited by provisions in laws, administrative regulations and relevant state rules of the PRC; (ii) the intended securities offering and listing may endanger national security as reviewed and determined by competent authorities under the State Council in accordance with law; (iii) the domestic company, its controlling shareholder(s) or the actual controller have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three years; (iv) the domestic company is currently under investigations for suspicion of criminal offenses or major violations of laws and regulations, and no conclusion has yet been made thereof; or (v) there are material ownership disputes over equity held by the domestic company&#8217;s controlling shareholder(s) or by other shareholder(s) that are controlled by the controlling shareholder(s) and/or actual controller. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A filing-based regulatory regime is adopted to regulate both direct and indirect overseas securities offering and listing by the domestic companies undert the Trial Measures. Direct overseas offering and listing by domestic companies refers to such overseas offering and listing by a joint-stock company incorporated domestically, while the indirect overseas offering and listing by domestic companies refers to the offering and listing by a company in the name of an overseas incorporated entity which major business operations are located domestically and such offering and listing is based on the underlying equity, assets, earnings or other similar rights of a domestic company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Trial Measures stipulate that an overseas listing will be determined as &#8220;indirect&#8221; if the issuer meets both of the following conditions: (1) 50% or more of any of the issuer&#8217;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most recent accounting year are accounted for by PRC domestic companies (&#8220;Condition I&#8221;), and (2) the main parts of the issuer&#8217;s business activities are conducted in the PRC, or its main places of business are located in the PRC, or the senior managers in charge of its business operations and management are mostly Chinese citizens or domiciled in the PRC (&#8220;Condition II&#8221;); whether Chinese citizens from Taiwan, Hong Kong, and Macau are included in the foregoing specification is not specified. The determination as to whether or not an overseas offering and listing by PRC domestic companies is indirect shall be made on a &#8220;substance over form&#8221; basis; the Listing Guidelines further stipulate that if an issuer not satisfying Condition I submits an application for issuance and listing in overseas markets in accordance with relevant non-PRC issuance regulations requiring such issuer to disclose risk factors mainly related to the PRC, the securities firm(s) and the issuer&#8217;s PRC counsel should follow the principle of &#8220;substance over form&#8221; in order to identify and argue whether the issuer should complete a filing under the Trial Measures. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Subsequent securities offerings of an issuer in (i) the same overseas market where it has previously offered and listed securities, and (ii) an overseas market other than one where the issuer has previously offered and listed securities shall be filed with the CSRC within three working days after offerings are completed.  Additionally, the Trial Measures stipulate that after an issuer has offered and listed securities in an overseas market, the issuer shall submit a report to the CSRC within three working days after the occurrence and public disclosure of (i) a change of control thereof, (ii) investigations of or sanctions imposed on the issuer by overseas securities regulators or relevant competent authorities, (iii) changes of listing status or transfers of listing segment, and (iv) a voluntary or mandatory delisting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CSRC Filing Notice states that, beginning from March 31, 2023, PRC domestic enterprises which have already issued and listed securities overseas and fall within the scope of filing under the Trial Measures shall be considered &#8220;existing enterprises&#8221; (&#8220;Existing Listed Enterprises&#8221;). Existing Listed Enterprises are not required to complete filings immediately; rather, Existing Listed Enterprises should complete filings if they are subsequently involved in matters require filings, such as follow-on financing activities, in accordance with the Trial Measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, in the event that the issuer does not meet either Condition I or Condition II, the filing requirements under the Trial Measures will not apply. However, we cannot assure you that our relevant indicators listed in Condition I and Condition II will not change in the future nor that the CSRC will agree with our determination. To the extent we are deemed as a PRC domestic company that is subject to the CSRC filing, we may be further deemed as an Existing Listed Enterprise as defined under the CSRC Filing Notice, and that future offerings of listed securities or listings outside China by us or voluntary delisting may be subject to CSRC filing requirements in accordance with the Trial Measures. Given that the Trial Measures and Listing Guidelines have been introduced recently, and that there remain substantial uncertainties surrounding the enforcement thereof, we cannot assure you that, if required, we would be able to complete the filings and fully comply with the relevant new rules on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Measures for Cybersecurity Review, which took effect on February 15, 2022, requires, among others, prior cybersecurity review for online platform operators holding over one million users&#8217; personal information before any public listing in a foreign country. The Measures on Security Assessment of Cross-border Data Transfer, effective on September 1, 2022, specify that data controllers and/or critical information infrastructure operators will be subject to security assessment. There remain uncertainties as to whether such measures are applicable to our business. See also &#8220;&#8212;&#8212;Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 24, 2023, the CSRC and other PRC governmental authorities jointly issued the Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Confidentiality Provisions&#8221;), which will come into effect on March 31, 2023. According to the Confidentiality Provisions, PRC domestic companies that directly or indirectly conduct overseas offerings and listings shall strictly abide by the laws and regulations on confidentiality when providing or publicly disclosing, whether directly or through their overseas listed entities, materials to securities services providers. In the event such materials contain state secrets or working secrets of government agencies, PRC domestic companies shall first obtain approval from authorities, and file with the secrecy administrative department at the same level with the approving authority; in the event that such materials, if divulged, will jeopardize national security or public interest, PRC domestic companies shall comply with procedures stipulated by national regulations. PRC domestic companies shall also provide a written statement of the specific sensitive information provided when providing materials to securities service providers, and such written statements shall be retained for inspection. As the Confidentiality Provisions were recently promulgated and are yet to take effect, their interpretation and implementation remain substantially uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If (i) we mistakenly conclude that certain regulatory filings, permissions and approvals are not required or (ii) applicable laws, regulations, or interpretations change and (iii) we are required to obtain such filings, permissions or approvals in the future, we may be unable to obtain them in a timely manner, or at all, and such filings, permissions or approvals may be denied or rescinded even if obtained. We may face adverse actions or sanctions by the CSRC or other PRC regulatory agencies if we are unable to comply with such requirements, which may result in fines and penalties, restrictions on our operations, having to delist from a stock exchange outside of China, the halting of securities offerings to foreign investors and other actions that could materially and adversely affect our operations and the interest of our investors and cause a significant depreciation in the price of our ordinary shares and ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside of the PRC with a &#8220;de facto management body&#8221; within the PRC is considered a &#8220;resident enterprise&#8221; and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term &#8220;de facto management body&#8221; as the body that exercises full and substantial control over and overall management of the business, productions, personnel, accounts and properties of an enterprise. In 2009, SAT issued a circular, known as SAT Circular 82, which provides certain specific criteria for determining whether the &#8220;de facto management body&#8221; of a PRC-controlled enterprise that is incorporated offshore is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#8217;s general position on how the &#8220;de facto management body&#8221; test should be applied in determining the tax resident status of all offshore enterprises. According to SAT Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#8220;de facto management body&#8221; in China and will be subject to PRC enterprise income tax on its global income only if all of the following conditions are met: (i) the primary location of the day-to-day operational management and the places where they perform their duties are in the PRC; (ii) decisions relating to the enterprise&#8217;s financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC; (iii) the enterprise&#8217;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv) at least 50% of voting board members or senior executives habitually reside in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that we are not a PRC resident enterprise for PRC tax purposes. See &#8220;Item 10 Additional Information&#8212;Taxation&#8212; Material PRC Income Tax Considerations.&#8221; However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; If the PRC tax authorities determine that we or any of our non-PRC subsidiaries are a PRC resident enterprise for enterprise income tax purposes, we or the subsidiary will be subject to PRC tax at a rate of 25%. In addition, we may be required to withhold taxes from dividends, and non-PRC shareholders (including ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC, as described below under &#8220;Item 3.D.Risk Factors&#8212;Risks Related to the ADS&#8212;You may be subject to PRC income tax on dividends from us or any gain realized on the transfer of our ADSs.&#8221; </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may be subject to PRC income tax on dividends from us or on any gain realized on the transfer of our ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Enterprise Income Tax Law of the PRC, or the EIT Law, and its implementation rules, PRC withholding tax at the rate of 10% is generally applicable to dividends from PRC sources paid to investors that are resident enterprises outside of China and that do not have an establishment or place of business in China, or that have an establishment or place of business in China but the relevant income is not effectively connected with the establishment or place of business. Any gain realized on the transfer of shares by such investors is subject to 10% PRC income tax if this gain is regarded as income derived from sources within China. Under the PRC Individual Income Tax Law and its implementation rules, dividends from sources within China paid to foreign individual investors who are not PRC residents are generally subject to a PRC withholding tax at a rate of 20% and gains from PRC sources realized by these investors on the transfer of shares are generally subject to 20% PRC income tax. Any such PRC tax liability may be reduced by the provisions of an applicable tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have substantial business operations in China, it is unclear whether the dividends we pay with respect to our shares or ADSs, or the gains realized from the transfer of our shares or ADSs, would be treated as income derived from sources within China and as a result be subject to PRC income tax if we were considered a PRC resident enterprise. If PRC income tax is imposed on gains realized through the transfer of our ADSs or on dividends paid to our non-resident investors, the value of your investment in our ADSs may be adversely affected. Furthermore, our shareholders whose jurisdictions of residence have tax treaties or arrangements with China may not qualify for, or able to obtain in practice, the benefits under these tax treaties or arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The biopharmaceutical industry in China is highly regulated and such regulations are subject to changes which may affect approval and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Part of our research and development operations are in China, which we believe confers clinical, commercial and regulatory advantages. The biopharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new product candidates. See &#8220;Item 4 Information on the Company&#8212;Regulation&#8221; for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the biopharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our product candidates in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the biopharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities fines, warnings, administrative or criminal penalties in China. We believe our strategy and approach are aligned with the PRC government&#8217;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 15, 2019, the PRC National People&#8217;s Congress approved the Foreign Investment Law, which came into effect on January 1, 2020 and replaces the trio of existing laws regulating foreign investment in the PRC, namely, the Sino-Foreign Equity Joint Venture Enterprise Law, the Sino-Foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-Invested Enterprise Law, together with their implementation rules and ancillary regulations and become the legal foundation for foreign investment in the PRC. Meanwhile, the <i style="font-style:italic;">Implementation Regulation of the Foreign Investment Law and the Measures for Reporting of Information on Foreign Investment</i> came into effect as of January 1, 2020, which clarified and elaborated the relevant provisions of the <i style="font-style:italic;">Foreign Investment Law</i>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Foreign Investment Law sets out the basic regulatory framework for foreign investments and proposes to implement a system of pre-entry national treatment with a negative list for foreign investments, pursuant to which (i) foreign entities and individuals are prohibited from investing in the areas that are not open to foreign investments, (ii) foreign investments in the restricted industries must satisfy certain requirements under the law, and (iii) foreign investments in business sectors outside of the negative list will be treated equally with domestic investments. The Foreign Investment Law also sets forth necessary mechanisms to facilitate, protect and manage foreign investments and proposes to establish a foreign investment information reporting system, through which foreign investors or foreign-invested enterprises are required to submit initial report, report of changes, report of deregistration and annual report relating to their investments to the Ministry of Commerce, or MOFCOM, or its local branches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our business may be negatively affected by the potential obligations to make additional social insurance and housing fund contributions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required by PRC labor laws and regulations, such as the Social Insurance Law, Administrative Regulations on the Housing Provident Fund and other related rules, to pay various statutory employee benefits, including pensions insurance, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and housing fund, to designated government agencies for the benefit of our employees. The relevant government agencies may examine whether an employer has made adequate and timely payments of the requisite statutory employee benefits, and employers who fail to make adequate and timely payments may be subject to supplemental contributions, late payment fees, fines compulsory enforcement and/or other penalties. If the relevant PRC authorities determine that we shall make supplemental social insurance and housing fund contributions or that we are subject to fines and legal sanctions in relation to our failure to make social insurance and housing fund contributions in full for our employees, our business, financial condition and results of operations may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The lease agreements of our leased properties have not been registered with the relevant PRC government authorities as required by PRC law, which may expose us to potential fines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under PRC law, lease agreements of commodity housing tenancy are required to be registered with the local construction (real estate) departments. Although failure to do so does not in itself invalidate the leases, the parties of the lease agreements may be exposed to potential fines if they fail to rectify such non-compliance within the prescribed time frame after receiving notice from the relevant PRC government authorities. The penalty ranges from RMB1,000 to RMB10,000 for each unregistered lease, at the discretion of the relevant authority. As of the date of this annual report, the lease agreements for our leased properties in China have not been registered with the relevant PRC government authorities. As of the date of this annual report, we are not aware of any regulatory or governmental actions, claims or investigations being contemplated or any challenges by third parties to our use of our leased properties that the lease agreements of which have not been registered with the government authorities. However, we cannot assure you that the government authorities will not impose fines on us due to our failure to register any of our lease agreements, which may negatively impact our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly Listed Company, replacing earlier rules promulgated in 2007. Pursuant to these rules, PRC citizens and non-PRC citizens who reside in China for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be the PRC subsidiary of such overseas-listed company, and complete certain other procedures. In addition, an overseas-entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or who reside in the PRC for a continuous period of not less than one year and who have been granted options will be subject to these regulations. Failure to complete the SAFE registrations may subject them to fines and legal sanctions, there may be additional restrictions on the ability of them to exercise their stock options or remit proceeds gained from the sale of their stock into the PRC. We also face regulatory uncertainties that could restrict our ability to adopt incentive plans for our directors, executive officers and employees under PRC law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Announcement of the State Administration of Taxation on Several Issues concerning Enterprise Income Tax on the Indirect Transfers of Property by Non-Resident Enterprises, issued by the SAT in 2015, where a non-resident enterprise indirectly transfers equities and other property of a Chinese resident enterprise to evade its obligation of paying enterprise income tax by implementing arrangements that are not for bona fide commercial purpose, such indirect transfer shall, in accordance with the provisions of Article 47 of the Enterprise Income Tax Law, be re-identified and recognized as a direct transfer of equities and other property of the Chinese resident enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 3, 2015, the SAT issued the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises, or SAT Bulletin 7. SAT Bulletin 7 supersedes the rules with respect to the Indirect Transfer under SAT Circular 698. SAT Bulletin 7 has introduced a new tax regime that is significantly different from the previous one under SAT Circular 698. SAT Bulletin 7 extends the PRC&#8217;s tax jurisdiction to not only Indirect Transfers set forth under SAT Circular 698 but also transactions involving a transfer of other taxable assets through an offshore transfer of a foreign intermediate holding company. In addition, SAT Bulletin 7 provides clearer criteria than SAT Circular 698 for assessment of reasonable commercial purposes and has introduced safe harbors for internal group restructurings and the purchase and sale of equity through a public securities market. SAT Bulletin 7 also brings challenges to both foreign transferor and transferee (or another person who is obligated to pay for the transfer) of taxable assets. Where a non-resident enterprise transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an Indirect Transfer, the non-resident enterprise, being the transferor, or the transferee, or the PRC entity that directly owns the taxable assets, may report such Indirect Transfer to the relevant tax authority. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding or deferring PRC tax. As a result, gains derived from such Indirect Transfer may be subject to PRC enterprise income tax, and the transferee or another person who is obligated to pay for the transfer is obligated to withhold the applicable taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Matters Concerning Withholding of Income Tax of Non-resident Enterprises at Source, or SAT Bulletin 37, which, among others, repealed the SAT Circular 698 on December 1, 2017. SAT Bulletin 37 further details and clarifies the tax withholding methods in respect of income of non-resident enterprises under SAT Circular 698. In addition, certain rules stipulated in SAT Bulletin 7 are replaced by SAT Bulletin 37. Where the non-resident enterprise fails to declare the tax payable pursuant to Article 39 of the PRC Enterprise Income Tax Law, the tax authority may order it to pay the tax due within required time limits, and the non-resident enterprise shall declare and pay the tax payable within such time limits specified by the tax authority; however, if the non-resident enterprise voluntarily declares and pays the tax payable before the tax authority orders it to do so within required time limits, it shall be deemed that such enterprise has paid the tax in time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face uncertainties as to the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring, sale of the shares in our offshore subsidiaries and investments. Our company may be subject to filing obligations or taxed if our company is a transferor in such transactions, and may be subject to withholding obligations if our company is a transferee in such transactions, under SAT Bulletin 7 and SAT Bulletin 37. For transfer of shares in our company by investors who are non-PRC resident enterprises, our PRC subsidiary may be requested to assist in the filing under SAT Bulletin 7 and SAT Bulletin 37. As a result, we may be required to expend valuable resources to comply with SAT Bulletin 7 and SAT Bulletin 37 or to request the relevant transferors from whom we purchase taxable assets to comply with these circulars, or to establish that our company should not be taxed under these circulars, which may have a material adverse effect on our financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If our preferential tax treatments are revoked, become unavailable or if the calculation of our tax liability is challenged by the PRC tax authorities, we may be required to pay tax, interest and penalties in excess of our tax provisions, and our results of operations could be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Chinese government has provided various tax incentives to our subsidiaries in China. These incentives include reduced enterprise income tax rates. For example, under the Enterprise Income Tax Law and its implementation rules, the statutory enterprise income tax rate is 25%. However, the income tax of an enterprise that has been determined to be a technologically advanced service enterprise can be reduced to a preferential rate of 15%. Any increase in the enterprise income tax rate applicable to our PRC subsidiary, or any discontinuation or retroactive or future reduction of any of the preferential tax treatments currently enjoyed by our PRC subsidiary, could adversely affect our business, financial condition and results of operations. In addition, in the ordinary course of our business, we are subject to complex income tax and other tax regulations and significant judgment is required in the determination of a provision for income taxes. Although we believe our tax provisions are reasonable, if the PRC tax authorities successfully challenge our position and we are required to pay tax, interest and penalties in excess of our tax provisions, our financial condition and results of operations would be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Among other things, the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, the MOFCOM be notified in advance or its approval be obtained in certain situations, such as any change-of-control transaction in which a foreign investor acquires control of a PRC domestic enterprise of Undertakings, issued by the State Council in 2008 and amended in 2018, were triggered. Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of the PRC National People&#8217;s Congress, or NPC, which was lastesd revised in June 2022 and came into effect in August 2022, requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by the State Council&#8217;s anti-monopoly law enforcement authority before they can be completed. In addition, PRC national security review rules which became effective in September 2011 require acquisitions by foreign investors of PRC companies engaged in military-related or certain other industries that are crucial to national security be subject to security review before consummation of any such acquisition. We may pursue potential strategic acquisitions that are complementary to our business and operations. Complying with the requirements of these regulations to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval or clearance from the State Council&#8217;s anti-monopoly law enforcement authority, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries&#8217; ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. SAFE Circular 37 is applicable to our shareholders who are PRC residents and may be applicable to any offshore acquisitions that we make in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under SAFE Circular 37, PRC residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is a direct or indirect shareholder of an SPV, is required to update its filed registration with the local branch of SAFE with respect to that SPV, to reflect any material change, including, among other things, any major change of a PRC resident shareholder, name or term of operation of the SPVs, or any increase or reduction of the SPVs&#8217; registered capital, share transfer or swap, merger or division. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident shareholders to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional capital contributions into its subsidiary in China. On February 13, 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE or its branches. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our existing shareholders, each of whom owns our ordinary shares, including but not limited to as a result of exercising share options, are PRC residents under SAFE Circular 37. However, we cannot provide any assurance that these PRC residents comply with our request to make or obtain any applicable registrations or change registration or comply with all of the requirements under SAFE Circular 37 or other related rules. Furthermore, we may not be informed of the identities of all the PRC residents holding direct or indirect interest in our company. The failure or inability of our PRC resident shareholders to comply with the registration procedures set forth in these regulations may subject us to fines and legal sanctions, restrict our cross-border investment activities, limit the ability of our wholly foreign-owned subsidiary in China to distribute dividends and the proceeds from any reduction in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into the subsidiary. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits to you could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the interpretation and implementation of these foreign exchange regulations has been constantly evolving, it is unclear how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant government authorities. For example, we may be subject to a more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, we cannot assure you that we or the owners of such company, as the case may be, will be able to obtain the necessary approvals or complete the necessary filings and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and could adversely affect our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be materially adversely affected if our shareholders and beneficial owners who are PRC entities fail to comply with the relevant PRC overseas investment regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 26, 2017, the NDRC promulgated the Administrative Measures on Overseas Investments, or NDRC Order No. 11, which took effect as of March 1, 2018. According to NDRC Order No. 11, non-sensitive overseas investment projects are subject to record-filing requirements with the local branch of the NDRC. On September 6, 2014, MOFCOM promulgated the <i style="font-style:italic;">Administrative Measures on Overseas Investments</i>, which took effect as of October 6, 2014. According to this regulation, overseas investments of PRC enterprises that involve non-sensitive countries and regions and non-sensitive industries are subject to record-filing requirements with a local MOFCOM branch. According to the <i style="font-style:italic;">Circular of the State Administration of Foreign Exchange on Issuing the Regulations on Foreign Exchange Administration of the Overseas Direct Investment of Domestic Institutions</i>, which was promulgated by SAFE on July 13, 2009 and took effect on August 1, 2009, PRC enterprises must register for overseas direct investment with a local SAFE branch.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be fully informed of the identities of all our shareholders or beneficial owners who are PRC entities, and we cannot provide any assurance that all of our shareholders and beneficial owners who are PRC entities has or will comply with our request to complete the overseas direct investment procedures under the aforementioned regulations or other related rules in a timely manner, or at all. If they fail to complete the filings or registrations required by the overseas direct investment regulations, the relevant authorities may order them to suspend or cease the implementation of such investment impose warnings and sanctions and make corrections within a specified time, or limit our ability to distribute dividends and proceeds to our PRC subsidiary, which may adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 8pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We are an offshore holding company conducting our operations in China through our PRC subsidiary. We also hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. We may in the future make loans or provide guarantee to our PRC subsidiary subject to the approval or registration from governmental authorities and limitation of amount, or we may make additional capital contributions to our wholly foreign-owned subsidiary in China. Any loans to our wholly foreign-owned subsidiary in China, which are treated as foreign-invested enterprises under PRC law, are subject to foreign exchange loan registrations. In addition, a foreign-invested enterprise, or FIE, shall use its capital pursuant to the principle of authenticity and self-use within its business scope. The capital of an FIE shall not be used for the following purposes: (i) directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii) directly or indirectly used for investment in securities or investments other than banks&#8217; principal-secured products unless otherwise provided by relevant laws and regulations; (iii) the granting of loans to non-affiliated enterprises, except where it is expressly permitted in the business license; and (iv) paying the expenses related to the purchase of real estate that is not for self-use (except for the foreign-invested real estate enterprises).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans by us to our PRC subsidiary or with respect to future capital contributions by us to our PRC subsidiary. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds from our initial public offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 10pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material and adverse effect on our ability to conduct our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are a Cayman Islands holding company and we currently rely principally on equity financing for our cash requirements, including the funds necessary to pay cash considerations for services we may incur. In the future, when and after we become profitable and generate cash flows from operating activities, we may rely principally on dividends and other distributions on equity from our PRC and U.S. subsidiaries for our cash requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders for services of any debt we may incur. If our PRC subsidiary incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiary, which is a wholly foreign-owned enterprise, may pay dividends only out of its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A portion of our revenue was generated by our PRC subsidiary in Renminbi, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiary to use its Renminbi revenues to pay dividends to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiary to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises are incorporated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions in China and by China&#8217;s foreign exchange policies. On July 21, 2005, the PRC government changed its policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. Since October 1, 2016, Renminbi has joined the International Monetary Fund&#8217;s basket of currencies that make up the Special Drawing Right, or SDR, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter of 2016, the Renminbi has depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. With the development of the foreign exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system, and we cannot assure you that the Renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we received from our equity financings into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or the ADSs or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert Renminbi into foreign currency.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Governmental control of currency conversion may limit our ability to utilize our cash balance effectively and affect the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China. We did not receive any of our revenues in Renminbi in cash in the years ended Decemebr 31, 2020, 2021 and 2022. Under our current corporate structure, our Cayman Islands holding company primarily relies on proceeds from previous equity financing activities to fund any cash and financing requirements we may have. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval of SAFE by complying with applicable laws and regulations, as well as certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval of SAFE, cash generated from the operations of our PRC subsidiary may be used to pay dividends to our company. However, approval from or registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we need to obtain SAFE approval to use the cash generated from the operations of our PRC subsidiary to pay off their respective debt in a currency other than Renminbi owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including holders of the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Prospects and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biotechnology company with a limited operating history. Since our inception in 2011, we have focused substantially all of our efforts and financial resources on the discovery and development of antibody therapeutics for the treatment of cancer. We have no products approved for commercial sale and therefore we have not generated any revenue from product sales. We have not obtained regulatory approvals for any of our product candidates and there is no assurance that we will obtain approvals in the future. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and may continue to have an adverse effect on our working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations to date have focused on developing our product candidates, building our intellectual property portfolio, conducting preclinical testing and clinical trials, and raising capital. These operations provide a limited basis for you to assess our ability to successfully market and commercialize our product candidates. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to shift our focus to late stage development and commercial activities. If we do not address these risks and difficulties successfully, we may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have incurred net losses historically and we may continue to incur net losses in the near future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2011, we have devoted our resources to the development of innovative antibodies in the therapeutic area. While we have generated revenues from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we have had significant operating losses since our inception. For the years ended December 31, 2020, 2021 and 2022, we incurred net losses of US$42.4 million, US$73.2 million and US$80.0 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs. To date, we have financed our operations principally through proceeds from our prior equity financing activities. Our product candidates and programs are in preclinical development or early stage clinical development, and we have not received marketing approval for any of our product candidates. Our product candidates will require substantial investments and significant marketing efforts before we generate any revenues from product sales, if ever. We expect our net losses will increase as more product candidates enter into clinical trial stage. Our ability to generate product revenue and achieve profitability depends on, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing research and development of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiating, enrolling patients in and completing clinical trials of product candidates on a timely basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approvals and marketing authorizations for any product candidates for which we complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and maintaining adequate manufacturing capabilities either by ourselves or in connection with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing any product candidates for which we obtain regulatory approvals and marketing authorizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing a sales, marketing and commercialization team for any future products for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking to identify additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with the development, delivery and commercialization of complex innovative antibody therapeutic, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase and profitability could be further delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become or remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business or continue our operations. Failure to become and remain profitable may adversely affect the market price of the ADSs and our ability to raise capital and continue operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of biopharmaceutical product candidates is capital-intensive. We have used substantial funds to advance our discovery programs and develop our technology and product candidates, and will require significant funds to conduct further research and development, preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, that are approved for commercial sales. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory and manufacturing capabilities. We also expect to incur significant costs associated with operating as a public company.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To date, we have funded our operations primarily through capital contributions from our shareholders via private placements and proceeds from our initial public offering. Our operations have consumed substantial amounts of cash since inception. As of December 31, 2022, we had US$143.8 million in cash and cash equivalents. The net cash used in our operating activities was US$28.5 million, US$43.4 million and US$48.6 million for the years ended December 31, 2020, 2021 and 2022, respectively. Our future funding requirements and the period for which we expect increasing capital need may be different from what we plan. Our monthly spending levels vary based on new and ongoing research and development activities. Because of the numerous risks and uncertainties associated with our product development, we are unable to accurately predict the timing and amount of our operating expenditures, which will depend largely on:</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress, costs and results of discovery, preclinical development, laboratory testing and clinical development activities of our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number, scope, progress and results of preclinical and clinical programs we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and research and development agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our current licenses, research and development programs, and to establish new collaboration arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain competitive advantage over other AI-powered technology platforms at generating highly differentiated product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcome of regulatory review of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Any additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek additional funding through a combination of equity and debt financings and collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the beneficial ownership interest of existing holders of our shares and/or ADSs will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing holders of our shares and/or ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in certain additional restrictive covenants, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through partnerships, collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have certain shareholders who have board representation rights and their individual interests may differ from yours.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2014, we completed private placements of our Series&#160;A-1 and A-2 preferred shares, in which we raised gross proceeds of approximately US$8.5 million. In 2016, we completed a private placement of our Series&#160;B preferred shares, in which we raised gross proceeds of approximately US$28.0 million. In 2018, we completed a private placement of our Series&#160;C-1 preferred shares, in which we raised gross proceeds of approximately US$50.0 million. In 2019, we completed private placements of our Series&#160;C-2 and C-3 preferred shares, in which we raised gross proceeds of approximately US$69.0 million in aggregate. As a result of these private placements, a significant portion of our outstanding equity is currently held by multiple separate institutional investors through several separate funds and our founders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These institutional investors will continue have a significant level of influence because of their level of ownership, including a greater ability than you and our other shareholders to influence the election of directors and the potential outcome of matters submitted to a vote of our shareholders, such as mergers, the sale of substantially all of our assets and other extraordinary corporate matters. These investors and our founder, Peter Luo, also have certain rights, such as board representation right and registration right that our other shareholders do not have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For instance, our current effective memorandum and articles of association provides that JSR Limited shall have the right to designate, appoint, remove and replace and reappoint one director so long it holds at least five percent of the shares outstanding on a fully-diluted basis and an as-converted basis, although JSR Limited currently does not have representation at our board; as long as Wuxi Pharmatech Healthcare Fund I L.P., which is controlled by the ultimate controlling party of our sole supplier, holds at least five percent of the shares outstanding on a fully-diluted basis, it shall have the right to nominate one independent non-executive director and such one director shall be appointed and agreed by the board; as long as Peter Luo holds or beneficially owns any shares or is employed by us or any of our subsidiaries, he will serve as one of our directors and the Chairman of the Board of Directors; in addition, during the period commencing upon February&#160;2021 and ending on the earlier of (i)&#160;the date upon which Peter Luo beneficially owns less than five percent of the shares outstanding on a fully diluted basis, (ii)&#160;the death or legal determination of Peter Luo&#8217;s incapacity or (iii)&#160;the termination of Peter Luo as an executive officer or principal scientific advisor to us or any of our subsidiaries or for cause (as determined under his related employment or consulting arrangements and subject to all related cure provisions), Peter Luo shall have the right to designate, appoint, remove and replace and reappoint one additional director; and as long as General Atlantic Singapore AI Pte. Ltd. and its affiliates hold at least five percent of the shares outstanding on a fully-diluted basis, they shall have the right to designate, appoint, remove and replace and reappoint one director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interests of these investors could conflict with the interests of our other shareholders, including you, and any future transfer by these investors of their shares of preferred or ordinary share to other investors who have different business objectives could have a material adverse effect on our business, results of operations, financial condition and the market value of our ordinary shares or ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Clinical Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we will focus our efforts on continued preclinical and clinical developments, regulatory approval process and commercialization with respect to our existing product candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to obtain marketing approval; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be effective in treating their targeted diseases.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific targets. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later may be proved to have greater commercial potential or a greater likelihood of success. On the other hand, if we do not prioritize the allocation of our resources and conduct research programs that cover a broad range of targets or engage clinical programs that are overly expansive, we may be subject to significant risk of loss as a large part of the research and clinical programs fail. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, there can be no assurance that we will ever be able to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A key element of our strategy is to leverage our technology platform to expand our pipeline of antibody product candidates and in order to do so, we will continue to invest in our platform and development capabilities. Although our research and development efforts to date have resulted in a pipeline of product candidates, these product candidates may not be safe and effective. In addition, although we expect that our platform will allow us to develop a diverse pipeline of novel and differentiated product candidates, we may not prove to be successful at doing so. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects, efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance. Even after approval, if we cannot successfully develop or commercialize our products, or if serious adverse events are discovered after commercialization, we will not be able to generate any product revenue, which would adversely affect business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates are created with, and dependent upon, our proprietary antibody discovery platforms, such as our proprietary Dynamic Precision Library platform, which includes our NEObody platform, SAFEbody platform and POWERbody platform. These proprietary technology platforms are also the basis of our collaborations with certain other partners. To date, no products based on any of these technologies have been approved for commercial sale in any jurisdiction. Any failures or setbacks with respect to our proprietary technologies, including adverse effects resulting from the use of product candidates derived from these technologies in human clinical trials and/or the imposition of clinical holds on trials of any product candidates using our proprietary technologies, could have a detrimental impact on our clinical pipeline, as well as our ability to maintain and enter into new corporate collaborations regarding our technologies or otherwise, which would negatively affect our business and financial conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates, for which we intend to seek approval as biologic products, may face competition sooner than anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we are successful in achieving a final regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar or other biologic products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the Biologics License Application (BLA) pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. A product may also make modifications and seek approval as a BLA. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for interchangeable or generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are not fully understood.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the European Union has had an established regulatory pathway for biosimilars since 2005.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if our clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s)&#160;or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We depend substantially on the success of our product candidates, particularly our anti-CTLA-4 franchise, including ADG116 and ADG126, and our two anti-CD137 antibodies, ADG106 and ADG206, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business and the ability to generate revenue related to product sales, if ever, will depend on the successful development, regulatory approval and commercialization of our antibody product candidates for the treatment of patients with cancer, particularly ADG116, ADG126, ADG106 and ADG206, which are still in clinical stage. Other than our wholly-owned product candidates (ADG116, ADG126, ADG106 and ADG206) and our outlicensed product candidates, ADG104 and ADG125, our current product candidates are in relatively early stages of development. We have invested a significant portion of our efforts and financial resources in the development of our existing product candidates and all of our product candidates will require significant further development and financial resources. The success of our product candidates, including ADG116, ADG126, ADG106 and ADG206, will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in, and completion of, preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of regulatory approvals from the FDA, NMPA and other comparable regulatory authorities for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities, either by building facilities ourselves or making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relying on third parties to conduct our clinical trials safely and efficiently;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting our rights in our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ensuring we do not infringe, misappropriate or otherwise violate the patent, trade secret or other intellectual property rights of third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of our product candidates, if and when approved;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition with other product candidates and drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued acceptable safety profile for our product candidates following final regulatory approval, if and when received.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, we may not successfully develop any of our product candidates, or we or our partners may choose to discontinue the development of product candidates for a variety of reasons. Our failure to effectively advance our development programs could have a material adverse effect on our business, financial condition, results of operations and future growth prospects, and cause the market price of our ADSs to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are expensive, time consuming and difficult to design and implement and may fail to demonstrate adequate safety and efficacy of our product candidates. The results of our current and previous preclinical studies or clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities or provide the basis for regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical studies and extensive clinical trials to demonstrate their safety and efficacy in humans. Clinical testing is expensive and difficult to design and implement. Clinical testing can take many years to complete, and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe, pure, and effiective for use in a diverse patient population before we can seek final regulatory approvals for their commercial sale. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional and expansive preclinical or clinical testings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The results are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, the NMPA and comparable foreign regulatory authorities, despite having progressed through preclinical studies or initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials or registration clinical trials. For example, a number of companies in the biopharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in later staged clinical trials, even after obtaining promising results in earlier clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A failure of a clinical trial to meet its predetermined primary endpoints may cause us to abandon a pipeline product or an indication and may delay development of any other pipeline products. Any delay in, or termination of, our clinical trials will delay the submission for regulatory approval and application, and, ultimately, our ability to commercialize any of our pipeline products and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, principal investigators for our clinical trials may serve and have served as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our pipeline products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may experience delays in our ongoing clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to obtain regulatory authorization to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to obtain institutional review board, or IRB, approval at each site;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in recruiting clinical trial investigators of appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in establishing the appropriate dosage levels in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to recruit and enroll suitable patients to participate in a trial, particularly considering study inclusion and exclusion criteria and patients&#8217; prior lines of therapy and treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower than anticipated retention rates of patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to have patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays adding new investigators or clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety or tolerability concerns could cause us or our collaborators or governmental authorities, as applicable, to suspend or terminate a trial if it is found that the participants are being exposed to unacceptable health risks, undesirable side effects or other unfavorable characteristics of the product candidate, or if such undesirable effects or risks are found to be caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements, policies and guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to comply with the applicable regulatory requirements through the clinical process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">he quality or stability of a product candidate falling below acceptable standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the treatment landscape for our target indications that may make our product candidates no longer relevant; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party actions claiming infringement by our product candidates in clinical trials outside the United States and obtaining injunctions interfering with our progress.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, while we plan to submit additional investigational new drug applications, or INDs, for other product candidates, we may not be able to file such INDs on the timeline we expect. For example, we may experience manufacturing delays or other delays with IND-enabling preclinical studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other studies with respect to any of our product candidates beyond those that we initially contemplated, if we are unable to successfully complete our clinical trials or other studies or if the results of these studies are not positive or are only modestly positive, we may be delayed in obtaining regulatory approval for that product candidate, we may not be able to obtain regulatory approval at all or we may obtain approval for indications that are not as broad as intended. Our drug development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process. Significant clinical trial delays could allow our competitors to bring drugs to market before we do and impair our ability to commercialize our drugs, if and when approved. If any of this occurs, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations and guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial or to perform obligations in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, clinical trials must be conducted with supplies of our product candidates produced under current good manufacturing practices, or cGMP, requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study in accordance with GCP or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Our clinical trials may be subject to delays for a variety of reasons, including as a result of enrollment taking longer than anticipated, subject withdrawal or adverse events. These types of developments could cause us to delay the trial or halt further development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we believe our differentiated product candidates address highly unmet medical needs that will facilitate our patient enrollment, clinical trials may compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for cancer therapies is challenging, as cancer patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care antibody therapy (and thus do not enroll in clinical trials) are believed to have tumor types that would have responded well to our product candidates. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved product candidates. However, these prior treatment regimens may render our therapies less effective in clinical trials. Additionally, patients who have failed with prior approved therapies will typically have more advanced cancer and a poorer long-term prognosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of our pipeline products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our resources to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">th</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patients&#8217; consent; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose preliminary or topline or data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Obtaining Regulatory Approval of Our Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, marketing approval of biologics requires the submission of a BLA to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the BLA for that product candidate. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a BLA to the FDA or similar regulatory approval filings to the NMPA or other comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process, and as a company we have no experience with the preparation of a BLA submission or any other application for marketing approval. In addition, the FDA has the authority to require a risk evaluation and mitigation strategies, or REMS, plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FDA approval is not guaranteed, and the time required to obtain approval by the FDA, NMPA and other comparable regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical trials and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, due to external issues such as pandemics or other public health emergencies, FDA, NMPA and other comparable regulatory authorities may be delayed in their review of product applications. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may discover, in-license or acquire and seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive regulatory approval from the FDA, NMPA or a comparable regulatory authority for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to demonstrate that a product candidate is safe and effective or safe, pure, and potent for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of clinical trial results to meet the level of statistical significance required for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement with our interpretation of data from preclinical trials or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a BLA or other submission or to obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, NMPA or comparable regulatory authority&#8217;s finding of deficiencies related to the manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our product candidates to ensure compliance with Good Manufacturing Practice, or cGMP, following inspections during the regulatory review process or across the production cycle of our product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in approval policies, guidances or regulations that render our preclinical and clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of and opinions on our preclinical and clinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA, NMPA or a comparable regulatory authority may require more information, including additional preclinical or clinical data, to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, may approve a product candidate with a label that is not desirable for the successful commercialization of that product candidate, or may be difficult to meet manufacturing requirements. In addition, if our product candidate produces undesirable side effects or safety issues, the FDA may require the establishment of Risk Evaluation Mitigation Strategies, or REMS, or the NMPA or a comparable regulatory authority may require the establishment of a similar strategy, that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us. Any of the foregoing scenarios could materially harm the commercial prospects of our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, in response to the COVID-19 pandemic, on March&#160;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. On February 2, 2022, the FDA announced it would be resuming domestic surveillance inspections across all product types, beginning on February 7, 2022, in light of declining COVID-19 rates. Regulatory authorities outside the United States may adopt or lift similar restrictions or other policy measures in response to the COVID-19 pandemic. While President Biden has now stated that he will lift all restrictions relating to the COVID-19 (and the declaration of a Public Health Emergency) on May 11, 2022, there are backlogs of filings and other issues that may arise that delay the United States review of applications. For example, there may be a prolonged government shutdown, or if other global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other countries. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in various jurisdictions could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States, including in Australia, Europe or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Otherwise, for studies that are conducted at sites outside of the United States and not subject to an IND and which are intended to support a marketing application (but which are not intended to serve as the sole basis for marketing approval), the FDA requires the clinical trial to have been conducted in accordance with good clinical practice, or GCP, requirements and the FDA must be able to validate the data from the clinical trial through an on site inspection if it deems such inspection necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations, statistical powering, and specific documentation requirements must be met. Many foreign regulatory bodies, such as NMPA, have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, NMPA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, NMPA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Undesirable adverse events caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA or other comparable regulatory authority. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events. In such an event, our trials could be suspended or terminated and the FDA, NMPA or other comparable regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Drug-related adverse events could affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in potential product liability claims. Moreover, such events may require us to amend our trials, including reducing the dosage in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For instance, in September 2019, the FDA placed a clinical hold on our Phase 1 trial of ADG116 (ADG116-1001) in the United States after we reported to the FDA the death of the only patient dosed in the trial. We revised the study protocol to mitigate the risk of drug-induced liver toxicity, lower the starting dose of ADG116, and tighten the inclusion and exclusion criteria. The FDA removed the clinical hold on this protocol on December 5, 2019. In parallel, we initiated a new Phase 1 clinical trial of ADG116 (ADG116-1003) in Australia and completed multiple levels of dose escalation without serious adverse events. In March 2021, we submitted this new protocol for ADG116 (ADG116-1003) to FDA with safety data from Australia. Upon receiving clearance from FDA to open sites in the United States for ADG116-1003, we terminated the prior Phase 1 trial (ADG116-1001) in the United States for business reasons. Overall, we have evaluated ADG116 monotherapy in approximately 50 patients up to 10 mg/kg with repeat dosing and the majority of reported TRAEs were Grade 1/2 (56%), with one DLT event (Grade 4 hyperglycemia) at the 10 mg/kg dose level.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot provide any assurance that there will not be treatment-related severe adverse events with our product candidates, that the trials for our product candidates will not be suspended in the future, or that patient recruitment for trials with our product candidates will not be adversely impacted by the ADG116 related adverse events, any of which could materially and adversely affect our business and prospects. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. In the event that any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may suspend marketing of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw or limit approvals of such products or require us to take an approved product off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan to ensure that the benefits of the product outweigh its risks or to develop a similar strategy as required by a comparable regulatory authority, that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to conduct post-market studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to limitations on how we may promote or manufacture the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of the product may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to subjects or patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, combination therapy involves unique adverse events that could be exacerbated compared to adverse events from monotherapies. These types of adverse events could be caused by our product candidates and could also cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA or other comparable regulatory authority. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may seek Orphan Drug Designation for some of our product candidates, and we may be unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a disease with a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, if a drug with an Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication during the period of exclusivity. The applicable period is seven years in the United States. Orphan Drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain Orphan Drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition and the same drugs can be approved for a different condition but used off-label for any orphan indication we may obtain. Even after an orphan drug is approved, the FDA may subsequently approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post- approval confirmatory studies to verity and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to seeking accelerated approval for any of our product candidates, we intend to obtain a meeting and meet with the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approvals for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory reviews, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, import, export, adverse event reporting, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, NMPA and comparable regulatory authority requirements, including, in the United States, ensuring that quality control and manufacturing procedures conform to current cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, NMPA, or a comparable regulatory authority approves our product candidates, we will have to comply with requirements including, for example, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and Good Clinical Practices, or cGCPs, for any clinical trials that we conduct post approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and NMPA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our drugs, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, untitled or warning letters, or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA, NMPA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA, NMPA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA, NMPA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We intend to focus our activities in the major markets such as the United States and China. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like ours that plans to operate in these regions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals and compliance with appropriate laws and regulations require substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial suspension of production or distribution; injunctions; fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Future strategic partnerships may be important to us. We will face significant competition in seeking new strategic partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not yet have any capability for manufacturing, sales, marketing or distribution. For some of our product candidates, we may in the future determine to collaborate with pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. The competition for strategic partners is intense. Our ability to reach a definitive agreement for collaboration will depend, among other things, upon our assessment of the strategic partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed strategic partner&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The strategic partner may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such collaboration could be more attractive than the one with us for our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Strategic partnerships are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future strategic partners. Even if we are successful in entering into collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements with other potential collaborators.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to reach agreements with suitable strategic partners on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into strategic partnerships and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platform and our business may be materially and adversely affected. Any collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the partner terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, and increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations, and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to enter into additional collaboration agreements beyond our existing clinical trial collaboration with Roche, technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics, our outlicensing agreements with Guilin Sanjin and Dragon Boat, or Discovery Agreements such as those with NIH, Tanabe, Celgene, GSK, Hengrui and others. If we are unable to maintain existing and future strategic partnerships or collaborations, or if these strategic partnerships or collaborations are not successful, our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our existing strategic partnerships, collaborations and any future strategic partnerships we enter into may pose a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to enter into critical strategic partnerships or enter into them on favorable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators have significant discretion in determining the effort and resources that they will apply to such a partnership, and they may not perform their obligations as agreed, expected, or in compliance with applicable legal requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the partners&#8217; strategic focus or available funding, or external factors, such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the strategic partners or collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our strategic partners or collaborators as competitive with their own product candidates or products, which may cause strategic partners or collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a strategic partner or collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with strategic partners or collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may claim for a substantial compensation for our failure of development of the product candidates specified under the relevant out-licensing agreements that solely arose out of problems of our previous R&amp;D basis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partnerships or collaborations may be terminated for the convenience of the partner or the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any partnerships or collaboration we enter into do not result in the successful development of our product candidates or if one of our partners or collaborator terminates the agreement with us, our continued development of our product candidates could be delayed and our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, we had 248 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to enter into additional relationships with collaborators or partners, suppliers and other organizations and establish a sales and marketing team in preparation for commercialization activities. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Disruptions in the financial markets and economic conditions could affect our ability to raise capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Global economies could suffer dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well as a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. In the past, governments have taken unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If these actions are not successful, the return of adverse economic conditions may cause a significant impact on our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world&#8217;s leading economies, including the United States and China. There have been concerns over unrest and terrorist threats in the Middle East, Europe and Africa and over the conflicts involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian countries, which may result in or intensify potential conflicts in relation to territorial disputes or the trade related disputes between the United States and China. In addition, the U.K. held a referendum on June 23, 2016 on its membership in the EU, in which voters approved an exit from the EU, commonly referred to as &#8220;Brexit&#8217;&#8217;; the U.K. formally left the EU on January 31, 2020. The EU and the U.K have entered into the post-Brexit Trade and Cooperation Agreement, an agreement purporting to create a broad economic partnership between the EU and the U.K., which was approved by the European Parliament in April 2021 and went into force fully on May 1, 2021. Nonetheless, Brexit could still adversely affect European and worldwide economic and market conditions and could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic conditions in the long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we face allegations of non-compliance with laws and encounter sanctions, our reputation, revenues and liquidity may suffer, and our product candidates and approved products, if any, could be subject to restrictions or withdrawal from the market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to obtain approvals commercialize and generate revenues from our drugs. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from our product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our reputation is important to our success. Negative publicity may adversely affect our reputation and business prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any negative publicity concerning us, our affiliates or any entity that shares the &#8220;Adagene&#8217;&#8217; name, even if untrue, could adversely affect our reputation and business prospects. There can be no assurance that negative publicity about us or any of our affiliates or any entity that shares the &#8220;Adagene&#8217;&#8217; name would not damage our brand image or have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Potential future acquisitions or strategic collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic collaboration may entail numerous risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and/or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current or future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners, or vendors violate these laws, we could face substantial penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current or future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal civil and criminal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims laws, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Effective January&#160;1, 2022, the U.S. federal physician transparency reporting requirements will extend to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse practitioners;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require the registration of pharmaceutical sales representatives; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities. For detailed discussion on material applicable PRC regulation, see &#8220;Item 4 Information on the Company&#8212;PRC Regulation&#8221; Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and many other countries, rising healthcare costs have been a concern for governments, patients and the health insurance sector, which resulted a number of changes to laws and regulations, and may result in further legislative and regulatory action regarding the healthcare and health insurance systems that could affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted in the United States in March&#160;2010 with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare, and includes measures to change health care delivery, increase the number of individuals with insurance, ensure access to certain basic health care services, and contain the rising cost of care. Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently facing legal and constitutional challenges in the Fifth Circuit Court of Appeals and the United States Supreme Court. Additionally, the current administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, other federal health reform measures have been proposed and adopted in the United States. For example, as a result of the Budget Control Act of 2011, providers are subject to Medicare payment reductions of 2% per fiscal year through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. Payment adjustments for the Medicare quality payment program began in 2019. At this time, it is unclear how the introduction of the quality payment program will impact overall physician reimbursement under the Medicare program. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since January&#160;2017, there has been legislation considered in Congress to restrict the pricing of drug products to a governmental negotiated rate or to other similar rates that would reduce the costs to government, commercial payers and individuals. In July&#160;2020, President Trump signed four Executive Orders directing the Department of Health and Human Services and other agencies to take specific actions to reduce prescription drug prices. The first order directs federally qualified health centers to pass along significant discounts on insulin and epinephrine from drug companies to low-income individuals. The second order would allow the important of prescription drugs from Canada into the United States where the prices are deemed to be lower. The third order would eliminate safe harbor protections under the federal Anti-Kickback Statute that currently covers rebates paid by manufacturers to Medicare Part&#160;D plans and Medicaid managed care organizations, either directly or through pharmacy benefit managers under contract with such plans or organizations, so long as such actions are not projected to increase federal spending, Medicare beneficiary premiums or patients&#8217; total out-of-pocket cases. The fourth order will reduce the payment for Medicare part B drugs to be paid at the same rate as other developed nations, thereby reducing the reimbursement. All of these Executive Orders require rulemaking prior to implementation and could be stalled by Congress or the next election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combination of healthcare cost containment measures, increased health insurance costs, reduction of the number of people with health insurance coverage, as well as future legislation and regulations focused on reducing healthcare costs by reducing the cost of or reimbursement and access to pharmaceutical products, may limit or delay our ability to generate revenue, attain profitability, or commercialize our pipeline products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We face intense competitions and rapid technological changes, as well as the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our ability to successfully commercialize our product candidates and our financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies and development candidates that may compete with our wholly owned clinical candidates as they engage similar targets, such as agents targeting CD137 and CTLA-4, and bispecifics targeting both. We have competitors in the United States, China and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development, marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have no experience in launching and marketing product candidates. We may not be able to effectively build and manage our sales network, or benefit from third-party collaborators&#8217; sales network.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have no manufacturing, sales, marketing or commercial product distribution capabilities and have no experience in marketing drugs. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given that marketing generally requires extensive training and oversight, and if we are unable or decide not to establish internal sales, marketing and commercial distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our product candidates, if approved. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We will also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will be able to develop in-house sales, marketing and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product candidate, if approved, and as a result, we may not be able to generate product sales revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize any approved product candidates, coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, and we may be subject to unfavorable pricing regulations, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact our revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the global healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Our ability to commercialize any drugs successfully also will depend in part on the extent to which coverage and reimbursement for these drugs and related treatments will be available on adequate terms, or at all, from government health administration authorities, private health insurers and other organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, no uniform policy of coverage and reimbursement for biopharmaceutical products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a drug from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our drugs on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given drug, the resulting reimbursement rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of our genetically modified drugs. Patients are unlikely to use our drugs and any approved product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of the drug. Because some of our product candidates have a higher cost of goods than conventional therapies, may require long-term follow up evaluations, and will likely be administered under the supervision of a physician, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining reimbursement for approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or other comparable regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for our drugs and any new product candidates that we develop could have a material adverse effect on our business, our operating results, and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In China, the Ministry of Human Resources and Social Security of China or provincial or local human resources and social security authorities, together with other government authorities, review the inclusion or removal of drugs from China&#8217;s National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List, or the NRDL, or provincial or local medical insurance catalogues for the National Medical Insurance Program regularly, and the tier under which a drug will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those drugs. There can be no assurance that our drugs and any approved product candidates will be included in the NRDL or provincial reimbursements lists. Products included in the NRDL have been typically generic and essential drugs. Innovative drugs similar to our product candidates have historically been more limited on their inclusion in the NRDL due to the affordability of the government&#8217;s Basic Medical Insurance, although this has been changing in recent years. According to currently effective PRC laws and regulations, the prices of approved drugs are determined by market competition. The government regulate prices mainly by establishing a consolidated procurement mechanism, revising the NRDL and strengthening regulation of medical and pricing practices. We cannot predict the extent to which our business may be affected by potential future legislative or regulatory developments. Changes in pricing regulation could restrict the amount that we are able to charge for our future approved drugs, which would adversely affect our revenue, profitability and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to seek approval to market our product candidates in the United States, China and in other jurisdictions. In some non-U.S. countries, the pricing of drugs and biologics is subject to governmental control, which can take considerable time even after obtaining regulatory approval. Market acceptance and sales of our drugs will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for drugs and may be affected by existing and future health care reform measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">As we engage in collaboration worldwide, we may be exposed to specific risks of conducting our business and operations in international markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biotechnology company with global footprints. We are currently building our clinical and technology infrastructures to support our future global operations and prepare to serve global markets. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets, or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and distribution efforts may increase our expenses or divert our management&#8217;s attention from the acquisition or development of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements for drug approvals and marketing internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty of effective enforcement of contractual provisions in local jurisdictions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potentially reduced protection for intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation or political instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of applicable tax structures and potentially adverse tax consequences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty and labor unrest and failure to comply with the applicable laws and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulations in relation to management of the employment of foreigners within the PRC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules&#160;and regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules&#160;and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geo-political actions, including war and terrorism, or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Building our commercialization capabilities will require significant investment of time and money. There would be no assurance that we will successfully set up our commercialization capabilities in any of the proposed jurisdictions or at all, or that we will successfully commercialize any of our product candidates in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently in the early stages of building and expanding our commercial capabilities to allow us to market our own products, if approved, in the future. We will need to set up full commercialization capabilities in the jurisdictions, including China and the United States, which would require substantial investment of time and money and will divert significant management focus and resources. We also face competition with multinational and local pharmaceutical and biotechnology companies with established commercialization capabilities in terms of marketing and attracting talents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Therefore, there can be no assurance that our efforts to set up commercialization capabilities will be successful in any of the proposed jurisdictions or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if ADG116, ADG126, ADG106, ADG206 or one of our other proprietary product candidates obtains regulatory approval, we may determine that commercializing such product candidate ourselves would not be the most effective way to create value for our shareholders or holders of ADSs. In addition, if we choose to commercialize any of our product candidates, our marketing efforts may be unsuccessful as a result of unfavorable pricing or reimbursement limitations, delays, competition or other factors. Failure to successfully market one or more of our approved products, or delays in our commercialization efforts, may diminish the commercial prospects for such products and may result in financial losses or damage to our reputation, each of which may have a negative impact on the market price of our ADSs and our financial condition, results of operations and future growth prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may continue to pursue collaborations or licensing arrangements, joint ventures, strategic alliances, partnerships or other strategic investment or arrangements, which may fail to produce anticipated benefits and adversely affect our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may continue to pursue opportunities for collaboration, out-license, joint ventures, acquisitions of products, assets or technology, strategic alliances, or partnerships that we believe would advance our development. We may consider pursuing growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities. Proposing, negotiating and implementing these opportunities may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not be able to identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited experience with respect to these business development activities. Management and integration of a licensing arrangement, collaboration, joint venture or other strategic arrangement may disrupt our current operations, decrease our profitability, result in significant expenses, or divert management resources that otherwise would be available for our existing business. We may not realize the anticipated benefits of any such transaction or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, partners, collaborators, or other parties to such transactions or arrangements may fail to fully perform their obligations or meet our expectations or cooperate with us satisfactorily for various reasons and subject us to potential risks, including the followings:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties have significant discretion in determining the efforts and resources that they will apply to a transaction or arrangement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties could independently develop, or develop with third parties, services and products that compete directly or indirectly with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may stop, delay or discontinue clinical trials as well as repeat clinical trials or conduct new clinical trials by using our intellectual property or proprietary information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between us and partners, collaborators, or other parties that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable services and products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may own or co-own intellectual properties covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual properties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any such transactions or arrangements may also require actions, consents, approval, waiver, participation or involvement of various degrees from third parties, such as regulators, government authorities, creditors, licensors or licensees, related individuals, suppliers, distributors, shareholders or other stakeholders or interested parties. There is no assurance that such third parties will be cooperative as we desire, or at all, in which case we may be unable to carry out the relevant transactions or arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to support, conduct and monitor our preclinical studies and clinical trials. Therefore, we may not be able to directly control the timing, process, expense and quality of our clinical trials and we cannot assure these third parties can duly perform their obligations as agreed and expected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat or suspend clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We currently rely on a third-party manufacturer to produce our product candidates. Any failure by the third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently rely on a third-party manufacturer and expect to continue to rely for some time on third parties to manufacture our product candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards, and may do so for the commercial manufacture of some of our product candidates, if approved. To date, we have obtained bulk drug substance for ADG116, ADG126, ADG106 and ADG206 from a single-source third-party contract manufacturer. Any reduction or halt in supply of the drug substance from such contract manufacturer could severely constrain our ability to develop our product candidates until a replacement contract manufacturer is found and qualified. If we are unable to arrange for and maintain such third-party manufacturing sources that are capable of meeting regulatory standards, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of product candidate or we may be delayed in doing so. If we were to experience an unexpected loss of supply of our product candidates, for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Such failure or substantial delay or loss of supply could materially harm our business. We are continuously evaluating multiple vendors both in China and abroad to ensure that we have a continuous supply of products for global trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may have little to no control regarding the occurrence of third-party manufacturer incidents. Any failure by our third-party manufacturer to comply with good manufacturing practices, or GMPs, or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, would lead to a delay in, or failure to seek or obtain, regulatory approval of any of our product candidates. Furthermore, any change in manufacturer of our product candidates or approved products, if any, would require new regulatory approvals, which could delay completion of clinical trials or disrupt commercial supply of approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer, we may have difficulty transferring such skills or technology to another third party and a feasible alternative many not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If our current research collaborators or scientific advisors and employees terminate their relationships with us or develop relationships with our competitors, our ability to discover antibodies and to conduct research and development could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The responsibility of overseeing research and development of our product candidates is concentrated among a number of key research collaborators and/or scientific advisors. There can be no assurance that there will not be a detrimental impact on us if one or more of these key research collaborators and/or scientific advisors were to cease relationship or employment with us, potentially as a result of lateral recruitment by existing or new competitors. As a result, this may adversely affect our ability to conduct research and development on antibody product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our ability to continue to conduct and expand operations depends on our ability to attract and retain a large and growing number of personnel. The ability to meet our expertise needs, including the ability to find qualified personnel to fill positions that become vacant at our research and development department or to collaborate with us in research and development efforts, while controlling our costs, is generally subject to numerous external factors, including the availability of a sufficient number of qualified persons in the biopharmaceutical industry, the unemployment levels within those markets, prevailing wage rates, changing demographics, health and other insurance costs and adoption of new or revised employment and labor laws and regulations. If we are unable to locate, to attract or to retain qualified personnel, the quality of services and products provided to customers may decrease and our financial performance may be adversely affected. In addition, if costs of labor or related costs to maintain relationships with research collaborators increase for other reasons or if new or revised labor laws, rules&#160;or regulations or healthcare laws are adopted or implemented that further increase labor costs, our business, financial condition and results of operations could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to attract and retain key senior management members or research and development personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future success depends upon the continuing services of members of our senior management team and key research and development personnel and consultants. Although we typically require our key personnel to enter into non-compete and confidentiality agreements with us, we cannot prevent them from joining our competitors after the non-compete period. The loss of their services could adversely impact our ability to achieve our business objectives. If one or more of our senior management or key clinical and scientific personnel are unable or unwilling to continue in their present positions or joins a competitor or forms a competing company, we may not be able to replace them in a timely manner or at all, which will have a material and adverse effect on our business, financial condition and results of operations. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the continued growth of our business depends on our ability to hire additional qualified personnel with expertise in molecular biology, chemistry, biological information processing, computational biology, software, engineering, sales, marketing, and technical support. We compete for qualified management and scientific personnel with other life science and technology companies, universities, and research institutions in China and overseas. Competition for these individuals is intense, and the turnover rate can be high. Failure to attract and retain management and scientific and engineering personnel could prevent us from pursuing collaborations or developing our product candidates or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We face risks related to health epidemics, severe weather conditions and other outbreaks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">China has in the past experienced significant natural disasters, including earthquakes, extreme weather conditions, as well as health scares related to epidemic diseases, and any similar event could materially impact our business in the future. If a disaster or other disruption were to occur in the future that affects the regions where we operate our business, our operations could be materially and adversely affected due to loss of personnel and damage to property. Even if we are not directly affected, such a disaster or disruption could affect the operations or financial conditions of our customers, which could harm our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our business could be affected by public health epidemics and pandemics, such as the outbreak of avian influenza, severe acute respiratory syndrome, or SARS, Zika virus, Ebola virus or other diseases. In December 2019, a respiratory illness caused by a novel strain of coronavirus, SARS-CoV2, causing the Coronavirus Disease 2019, also known as COVID-19 or coronavirus, emerged. As COVID-19 has evolved into a worldwide health crisis, it has resulted in adverse effects in the global economy and financial markets, such as significant declines in the global stock markets. If the COVID-19 outbreak is not effectively controlled globally, our business and results of operations could be adversely affected to the extent the COVID-19 outbreak harms the Chinese or world economy generally. The extent to which the COVID-19 outbreak impacts our financial condition and results of operations for the full year of 2023 cannot be reasonably estimated at this time and will depend on future developments that currently cannot be predicted, including the development of a COVID-19 vaccine and the actions taken to contain the COVID-19 outbreak, among others. Any future outbreak of public health epidemics may restrict economic activities in affected regions, disrupt our business operations and adversely affect our results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic could adversely impact our business, including our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The spread of the COVID-19 coronavirus in many countries continues to adversely impact global economic activity and has contributed to significant volatility and negative pressure in financial markets and supply chains. The pandemic has had, and could have a significantly greater, material adverse effect on the global economy. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. The pandemic has also resulted, and may continue to result for an extended period, in significant disruption of global financial markets, which may reduce our ability to access capital in the future, which could negatively affect our liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has adversely affected the clinical development of our product candidates. Our clinical development program timelines could continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition, and results of operations. Further, due to &#8220;shelter in place&#8221; orders and other public health guidance measures, we have been required to implement a work-from-home policy from time to time for certain staff members in our Suzhou site excluding those necessary to maintain minimum basic operations. In such an instance, our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic may impact our workforce, supply chains or distribution networks or otherwise impact our ability to restock our medical device and supply inventories and depending upon the severity of the COVID-19 pandemic&#8217;s continued spread in the United States and other countries, we may experience disruptions that could severely impact our business and clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitation of company operations, including work from home policies and office closures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one or more key officers and/or employees could contract COVID-19 or otherwise be adversely affected by the virus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in receiving deliveries of critical experimental materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation or expansion, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations, or CROs, and vendors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA or other regulatory authorities to accept data from clinical trials in affected geographies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in obtaining inspections at foreign manufacturing sites that could delay approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on our business, including the conduct of our clinical trials, such as because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in China, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have limited insurance coverage, and any claims beyond our insurance coverage may result in us incurring substantial costs and a diversion of resources.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our assessment of our operational needs and industry practice. We also maintain liability insurance covering our clinical trials as well as maintain key-man insurance policy. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances, such as business interruption insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any uninsured risks may result in substantial costs and the diversion of resources, which could adversely affect our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have adopted a share incentive plan and will continue to grant share-based awards in the future, which may increase expenses associated with share-based compensation. Exercise of the awards granted will increase the number of our outstanding ordinary shares, which may adversely affect the market price of our ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We adopted the Second Amended and Restated Share Incentive Plan in December 2019 and the 2021 Performance Incentive Plan in January 2021, which we refer to as the 2019 Plan and the 2021 Plan, respectively, in this annual report, to enhance our ability to attract and retain exceptionally qualified individuals and to encourage them to acquire a proprietary interest in the growth and performance of us. We have terminated the authority to grant additional awards under the 2019 Plan and all future awards will be granted under the 2021 Plan. Therefore, the effective maximum number of shares issuable under the 2019 Plan is 10,125,726. A total of 2,994,000 of our ordinary shares was authorized for issuance with respect to awards granted under the 2021 Plan. As of March 31, 2023, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan was 2,714,814. As of March 31, 2023, we have granted 3,979,160 shares awards under the 2021 Plan, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. See &#8220;Item 6 Directors, Senior Management and Employees&#8212;Share Incentive Plan.&#8221; We believe the granting of share-based awards is of significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses associated with share-based compensation may increase, which may have an adverse effect on our results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our employees, third-party suppliers, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, and insider trading.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, third-party suppliers, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the NMPA and overseas regulators that have jurisdictions over us, comply with healthcare fraud and abuse laws and regulations in China and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law and curtailment or restructuring of our operations, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to liability lawsuits arising from our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various exclusions, and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials. Even a successful defense would require significant financial and management resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regardless of the merits or eventual outcome, liability claims may result in significant negative consequences to our business and prospects, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates or any resulting products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of other clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of our management&#8217;s time and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in the market price of our ADSs.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of noncompliance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to rules&#160;and regulations by various governing bodies, including, for example, the FDA, the NMPA, the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and the various regulatory authorities in China, the United States, the EU, the Cayman Islands, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalties and our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and Chinese anti-corruption laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to anti-bribery laws in China that generally prohibit companies and their intermediaries from making payments to government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, although currently our primary operating business is in China, we are subject to the Foreign Corrupt Practices Act, or the FCPA. The FCPA generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We are also subject to the anti-bribery laws of other jurisdictions, particularly China. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures and controls to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Any failure to comply with applicable regulations and industry standards or obtain various licenses and permits could harm our reputation, business, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A number of governmental agencies or industry regulatory bodies in China, the United States and other applicable jurisdictions impose strict rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs&#8217; failure to comply with such regulations could result in the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business, reputation, prospects for future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the Association for Assessment and Accreditation of Laboratory Animal Care, it could revoke any such accreditation and the accuracy of our animal research data could be questioned.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we or our third-party research collaborators or other contractors or consultants fail to comply with environmental, fire protection, drainage or health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and third parties, such as our CROs, are subject to numerous environmental, fire protection, drainage or health and safety laws and regulations, including but not limited to those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes discharge of stationary pollution sources. The cost of compliance with health and safety regulations is substantial. Our business activities involve the controlled use of hazardous materials. Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations. We cannot guarantee that the safety procedures utilized by our partners and by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we could be held liable for any resulting damages, and such liability could exceed our resources. In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations which are complex, change frequently and have tended to become more stringent. We do not currently carry biological or hazardous waste insurance coverage. In the event of an accident or environmental discharge, we may be held liable for any consequential damage and any resulting claims for damages, which may exceed our financial resources and may materially adversely affect our business, financial condition, results of operations and future growth prospects, and the value of our ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store preclinical trial data and clinical trial data which could be sensitive, including research and development information, health-related information, personally identifiable information, intellectual property, and proprietary business information owned or controlled by ourselves or other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based application systems. We utilize external security and infrastructure vendors to manage parts of our data centers. We also communicate sensitive data with third parties. We face a number of risks relative to protecting this critical information, including material system failure or security breach, loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit, and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data and third-party collaborators who share with us sensitive data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance, or other malicious or inadvertent disruptions that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive, and/ or proprietary data, including health-related and other personal information, and could subject us to significant liabilities and regulatory and enforcement actions, and reputational damage. The COVID-19 pandemic is generally increasing the attack surface available to criminals, as more companies and individuals work online and work remotely, and as such, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#8220;hackers&#8221; hoping to use the COVID-19 pandemic to their advantage. In addition, while we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss, or dissemination could also result in delays of our product development and regulatory approval efforts as well as damage our reputation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in any regulatory approval or clearance efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize the product. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of health-related or other personal information, we may have to notify consumers, partners, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on our third-party research institution collaborators and other third parties to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our insurance policies may not be adequate to compensate us for the potential losses arising from such disruptions, failure, or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are subject to existing or future foreign laws and regulations related to privacy or data security, which could lead to government enforcement actions, including civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, we and our partners may be subject to state and federal laws and regulations that govern data privacy, protection and security. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and regulations implemented thereunder (collectively, &#8220;HIPAA&#8217;&#8217;). Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even when HIPAA does not apply, according to the Federal Trade Commission, or the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain state and non-U.S. laws, such as the European Union General Data Protection Regulation, or the GDPR, govern the privacy and security of health information and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California enacted legislation, the California Consumer Privacy Act, or CCPA, which went into effect January&#160;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. In Europe, the GDPR went into effect in May&#160;2018 and introduces strict requirements for processing the personal data of individuals within the EU, and the European Economic Area, or the EEA. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws, and recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For example, on July&#160;16, 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-US Privacy Shield Framework, or Privacy Shield, under which personal data could be transferred from the EU and the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to A20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Additionally, following Brexit, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the U.K. and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or courts in their interpretation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical partners and other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach affecting personal information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue, increase our costs and expenses, and have adverse effect on our financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations and third parties with which we have collaborations could be subjected to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. In addition, we partially rely on our CROs for conducting research and development, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we maintain incident management and disaster response plans, in the event of a major disruption caused by a natural disaster or man-made problem, such as power disruptions, computer viruses, data security breaches or terrorism, we may be unable to continue our operations and may endure system interruptions, reputational harm, delays in our development activities, lengthy interruptions in service, breaches of data security and loss of critical data, any of which could adversely affect our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately or timely report our results of operations or prevent fraud, and investors&#8217; confidence and the market price of our ADSs may be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC, as required by Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, adopted rules requiring most public companies to include a management report on such company&#8217;s internal control over financial reporting in its annual report, which contains the management&#8217;s assessment of the effectiveness of the company&#8217;s internal control over financial reporting. In addition, when a company meets the SEC&#8217;s criteria, an independent registered public accounting firm must report on the effectiveness of the company&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a public company in the United States subject to the Sarbanes-Oxley Act of 2002. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting and concluded that our internal control over financial reporting was effective as of December 31, 2022. For details, see &#8220;Item 15. Controls and Procedures&#8212;Remediation of Previously Reported Material Weaknesses in Internal Control over Financial Reporting.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, we cannot assure you that in the future our management or, if applicable, our independent registered public accounting firm will not identify material weaknesses during the Section 404 of the Sarbanes-Oxley Act audit process. In addition, because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of the ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. Furthermore, we have incurred and expect to continue to incur considerable costs and to use significant management time and the other resources in an effort to comply with Section 404 and other requirements of the Sarbanes-Oxley Act, which can significantly divert our management&#8217;s attention from operating our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the Nasdaq, regulatory investigations and civil or criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend, in part, on our ability to obtain, maintain and defend patent and other intellectual property protection (including trademarks and trade secrets) with respect to our product candidates. We cannot be certain that patents will be issued or granted with respect to our patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid and/or unenforceable, be interpreted in a manner that does not adequately protect our product candidates, or otherwise provide us with any competitive advantage. Additionally, the patent applications in respect of patents licensed under our in-license arrangements may not be issued or granted, and as a result, we may not be able to have adequate protection with respect to such patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies is generally uncertain because it involves complex legal and factual considerations. Patent applications we have filed may not be granted or issued as valid enforceable patents. Moreover, some of our patents and patent applications may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owned interest in such patents or patent applications, such co-owners may be able to license or transfer their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. As such, we do not know the degree of future protection that we will have on our product candidates and technology, if any, and a failure to obtain adequate intellectual property protection with respect to our product candidates could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Composition-of-matter patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our products for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of use patents, the practice is common and such infringement is difficult to prevent or prosecute. We endeavor to seek composition-of-matter patent protection for all of our product candidates. Where appropriate, we also seek method-of-use patents and patents protecting other aspects of our product candidates, including processes for discovery and manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the PRC and abroad. For example, we may become involved in opposition, interference, derivation, inter partes review or other similar proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or in-licensed patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the measures we can take to increase our likelihood of obtaining patent and other intellectual property protections with respect to our product candidates, there can be no assurance that the existence, validity, enforceability, or scope of our intellectual property rights will not be challenged by a third party, or that we can obtain sufficient scope of claim in those patents to prevent a third party from competing against our product candidates. For example, in an infringement proceeding, a court may hold that patent rights or other intellectual property rights owned by us are invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the ground that our patent rights or other intellectual property rights do not cover the technology in question. An adverse result in any litigation proceedings could put our patent, as well as any patents that may issue in the future from our pending patent applications, at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the National Intellectual Property Administration of China, or NIPA, or the applicable foreign counterpart, or made a misleading statement, during prosecution. Although we believe that we have conducted our patent prosecution in accordance with all applicable duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third parties may also raise similar claims before administrative bodies in the PRC or abroad, even outside the context of litigation. Such mechanisms include ex parte re-examination, inter partes review, post-grant review, derivation and equivalent proceedings, such as opposition proceedings. Such legal proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability can be unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose part or all of the patent protection on our product candidates. Any loss of patent protection could have a material adverse impact on one or more of our product candidates and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know-how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially viable terms, then we may not be able to launch our product. Although we require our employees to assign their inventions to us, and require our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of different countries do not protect proprietary rights to the same extent or in the same manner as the laws of the PRC. We may encounter significant problems in protecting and defending our intellectual property both in the PRC and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors or use such information to compete with us. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be adversely affected and this would have a material adverse effect on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries do not favor the enforcement or protection of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in certain countries could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We and our contractors and partners operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct or indirect intrusion by private parties or international actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect or enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biotechnology and biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in various countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, patent reform legislation in the United States includes provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents via post-grant proceedings. The Leahy-Smith Act and any continuing changes in patent laws and regulations in various patent jurisdictions could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our or our collaboration partners&#8217; patent applications and the enforcement or defense of our or our collaboration partners&#8217; issued patents, all of which could harm our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain due to changes in law and courts&#8217; interpretation of the law. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Other courts in the United States, for example, have heightened the bar for broadly claiming antibodies. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Additionally, there are periodic proposals for changes to the patent laws of China, United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similarly in China, intellectual property laws are constantly evolving, with efforts being made to improve intellectual property protection in China. For example, according to the Patent Law of the PRC which was latest amended in June 2021, in order to make up the time taken up by review and approval for marketing of new drugs, the patent administrative department under the State Council shall, at the request of the relevant patentee, make up the patent right duration for invention patents pertaining to new drugs that obtain the marketing authorization in China. The make-up duration shall not exceed five years, and the total valid duration of a patent right shall not exceed 14 years after a new drug is approved for marketing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and licensing deals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patents and other rights to third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to transfer or assign the license; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patent rights or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us, alleging that we infringed their patents. In addition, in a patent infringement proceeding, there is a risk that a court will decide that our asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the others from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the others from using the invention at issue on the grounds that our patents do not cover the alleged infringing activity or product. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties and other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects, and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that our asserted marks are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of our trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In any litigation involving our intellectual property, the award of monetary damages we receive may not be commercially valuable or even sufficient to cover our cost of bringing such action. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ADSs. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends significantly on our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The life sciences industry is subject to rapid technological change and substantial litigation regarding patent and other intellectual property rights. Our potential competitors in both the PRC and abroad, may have substantially greater resources than us and are likely to make substantial investments in patent portfolios and competing technologies, and may apply for or obtain patents that could prevent, limit or otherwise interfere with our ability to make, use and sell our products. Numerous third-party patents exist in fields relating to our products and technologies, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our products and technologies. Moreover, because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that will cover our products and technologies if they issue as patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from using our technology. Our failure to obtain or maintain a license from third parties to any technology that we require may materially harm our business, financial condition and results of operations. Furthermore, we would be exposed to a threat of litigation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party intellectual property right holders may also actively bring infringement or other intellectual property-related claims against us, even if we have received patent protection for our technologies, products, and services. Regardless of the merit of third parties claims against us for infringement, misappropriation or violations of their intellectual property rights, such third parties may seek and obtain injunctive or other equitable relief, which could effectively block our ability to perform clinical trials or develop, manufacture or sell our products. Further, if a patent infringement suit were brought against us, we could be forced to temporarily or permanently stop or delay our development or regulatory approval process or other activities that are the subject of such suit. Defense of these claims, even if such claims are resolved in our favor, could cause us to incur substantial expenses and be a substantial diversion of our employee resources even if we are ultimately successful. Any adverse ruling or perception of an adverse ruling in defending ourselves could have a material adverse impact on our cash position and stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ADSs. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depend on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent authorities, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NIPA, and various foreign governmental patent agencies including the USPTO, JPO, and EPO require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application and prosecution process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid to the NIPA and various other governmental patent agencies outside of China in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official communications within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not enter into invention assignment and confidentiality agreements with all of our employees and third parties and such agreements may not prevent ownership disputes or unauthorized disclosure of trade secrets and other proprietary information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely in part upon unpatented or unpatentable trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by entering into agreements, including confidentiality agreements and non-disclosure agreements, with parties that have a need for access to them, such as certain of our employees, consultants, academic institutions, corporate partners and, other third-party service providers. Nevertheless, there can be no guarantee that an employee or a third party will not make an unauthorized use or disclosure of our proprietary confidential information. This might happen intentionally or inadvertently. It is possible that a competitor will gain access to such information and make use of such information, and that our competitive position will be compromised, in spite of any legal action we might take against persons making such unauthorized disclosures. In addition, to the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors or business partners might intentionally or inadvertently disclose our trade secret information to competitors or our trade secrets may otherwise be misappropriated. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We sometimes engage individuals or research institutions to conduct research relevant to our business. The ability of these individuals or research institutions to publish or otherwise publicly disclose data and other information generated during the course of their research is subject to certain contractual limitations. These contractual provisions may be insufficient or inadequate to protect our confidential information. If we do not apply for patent protection prior to such publication, or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized, which could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also seek to enter agreements with our employees and consultants that obligate them to assign any inventions created during their work for us to us. However, we may not obtain these agreements in all circumstances and the assignment of intellectual property under such agreements may not be self-executing. And it is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets and inventions through such breaches or violations. Any of the foregoing could have a material and adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our employees and consultants were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and our specific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Also, former employees may become employed by competitors who develop similar technology, and could assist the competitor in designing around our patents. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily protect us from all potential threats to our competitive advantages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to independently develop similar or alternative technologies or designs that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or may in the future exclusively license, which could result in the patent applications not issuing or being invalidated after issuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to file patent applications covering certain of our inventions, which could result in the patent applications not issuing or being invalidated after issuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive services and products for commercialization in our major markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may fail to develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business, for example by preventing us from commercializing one or more of our product candidates for one or more indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may not be sufficient to effectively protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In most countries in which we plan to file applications for patents, the term of an issued patent is generally 20 years from the earliest claimed filing date of the priority application to which a non-provisional patent application in the applicable country claims priority. Although various extensions may be available in various countries, the life of a patent and the protection it affords are limited. Even if patents covering our product candidates are obtained, we may be open to competition from other companies once our patent rights expire. Accordingly, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Excluding any patent term adjustment and patent term extension, our currently issued patents are expected to expire from 2033 to 2038. As a result, our patent portfolio may not provide us with sufficient rights over a sufficient length of time to exclude others from commercializing products similar or identical to ours.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Uncertainty of the length of patent term extensions and data and market exclusivities for our pharmaceutical products could increase the risk of generic competition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Federal Food, Drug, and Cosmetic Act, as amended by the law generally referred to as the &#8220;Hatch-Waxman Amendments,&#8221; provides the opportunity for patent-term restoration of up to five years to reflect patent term lost during certain portions of product development and the FDA regulatory review process. The Hatch-Waxman Amendments also have a process for patent linkage, pursuant to which FDA will stay approval of certain follow-on applications during the pendency of litigation between the follow-on applicant and the patent holder or licensee, generally for a period of 30 months. Finally, the Hatch-Waxman Amendments provide for statutory exclusivities that can prevent submission or approval of certain follow-on marketing applications. For example, federal law provides a five-year period of exclusivity within the United States to the first applicant to obtain approval of a new chemical entity (as defined) and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where FDA designates the product candidate as an orphan drug and the drug is approved for the designated orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after FDA grants marketing approval for the innovative product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In China, however, there is no currently effective law or regulation providing patent term extension, patent linkage, or data exclusivity (referred to as regulatory data protection). Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for integrating patent linkage and data exclusivity into the Chinese regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, the NMPA has issued several draft implementing regulations in this regard for public comment but no regulations have been formally issued. These factors result in weaker protection for us against generic competition in China than could be available to us in the United States until the relevant implementing regulations for extension, patent linkage, or data exclusivity are put into effect officially in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. We may also encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the jurisdictions of the registration of our intellectual properties. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect and enforce our trademarks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently hold issued trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the registration or maintenance of the same. If we are unsuccessful in obtaining trademark protection for our primary brands, we may be required to change our brand names, which could materially adversely affect our business. Moreover, as our products mature, our reliance on our trademarks to differentiate us from our competitors will increase, and as a result, if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, or engaging in conduct that constitutes unfair competition, defamation or other violation of our rights, our business could be materially adversely affected. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to the ADSs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine, including particularly how countries like the United States and China choose to respond to this war. As a result, the value of our ADSs may significantly decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;">Our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine. We do not conduct business in either Russia or Ukraine. However, our global operations expose us to geopolitical risks, including particularly here, how the United States and China choose to respond to the war between Ukraine and Russia. If this war continues, increases, or expands, or leads to continued political or economic instability, terrorist activity, or gives rise to further government actions such as sanctions or increased economic or political tensions between the United States and China, our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely impacted and the value of our ADSs may significantly decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may be subject to limitations on transfer of your ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The trading price of the ADSs is likely to be volatile, which could result in substantial losses to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading price of our ADSs ranged from US$0.90 to US$29.99 per ADS since the listing of ADSs on Nasdaq. The trading price of the ADSs is likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, including the performance and fluctuation of the market prices of other companies with business operations located mainly in China that have listed their securities in the United States. In addition to market and industry factors, the price and trading volume for the ADSs may be highly volatile for factors specific to our own operations, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our net revenues, earnings and cash flow;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new investments, acquisitions, strategic partnerships, or joint ventures by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new products and services and expansions by us or our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in operating metrics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure on our part to realize monetization opportunities as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in revenues generated from our significant business partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">release of lock-up or other transfer restrictions on our outstanding equity securities or sales of additional equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">detrimental negative publicity about us, our management, our competitors or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments affecting us or our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential litigation or regulatory investigations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these factors may result in large and sudden changes in the trading volume and price of the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount of our management&#8217;s attention and other resources from our business and operations and require us to incur significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we may take advantage of certain exemptions from requirements applicable to other public companies that are not emerging growth companies including, most significantly, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 for so long as we remain an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to certain information they may deem important.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts cease to publish research or reports about our business, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for the ADSs will be influenced by research or reports that industry or securities analysts publish about our business. If one or more analysts who cover us downgrade the ADSs, the market price for the ADSs would likely decline. If one or more of these analysts cease to cover us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for the ADSs to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the ADSs could adversely affect their market price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of substantial amounts of the ADSs in the public market, or the perception that these sales could occur, could adversely affect the market price of the ADSs and could materially impair our ability to raise capital through equity offerings in the future. The ADSs sold in our initial public offering are freely tradable by persons other than our &#8220;affiliates&#8221; without restriction or further registration under the Securities Act, and shares held by our existing shareholders may also be sold in the public market in the future subject to the restrictions in Rule&#160;144 and Rule&#160;701 under the Securities Act and the applicable lock-up agreements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our memorandum and articles of association contain anti-takeover provisions that could have a material adverse effect on the rights of holders of our ordinary shares and the ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have adopted amended and restated memorandum and articles of association. Our new memorandum and articles of association contain provisions to limit the ability of others to acquire control of our company or cause us to engage in change-of-control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, including ordinary shares represented by ADSs. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of the ADSs may fall and the voting and other rights of the holders of our ordinary shares and the ADSs may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You must rely on the judgment of our management as to the use of the net proceeds from our equity financing activities, and such use may not produce income or increase our ADS price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management will have considerable discretion in the application of the net proceeds received by us. You will not have the opportunity, as part of your investment decision, to assess whether proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not improve our efforts to achieve or maintain profitability or increase our ADS price. The net proceeds from our initial public offering and other equity financing activities may be placed in investments that do not produce income or that lose value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior consent of the ADS holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us. Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship with the depositary. In the event that the terms of an amendment are disadvantageous to ADS holders, ADS holders will only receive 30 days&#8217; advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement. Furthermore, we may decide to terminate the ADS facility at any time for any reason. For example, terminations may occur when we decide to list our shares on a non-U.S. securities exchange and determine not to continue to sponsor an ADS facility or when we become the subject of a takeover or a going-private transaction. If the ADS facility is going to terminate, ADS holders will receive at least 90 days&#8217; prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but will have no right to any compensation whatsoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s)&#160;in any such action.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s)&#160;in any such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules&#160;and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise your right to direct the voting of the underlying ordinary shares represented by your ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of ADSs do not have the same rights as our registered shareholders. As a holder of ADSs, you will not have any direct right to attend general meetings of our shareholders or to cast any votes at such meetings. You will only be able to exercise the voting rights attached to the ordinary shares underlying your ADSs indirectly by giving voting instructions to the depositary in accordance with the provisions of the deposit agreement. Where any matter is to be put to a vote at a general meeting, then upon receipt of your voting instructions, the depositary will try, as far as is practicable, to vote the underlying ordinary shares represented by your ADSs in accordance with your instructions. You will not be able to directly exercise your right to vote with respect to the underlying ordinary shares unless you cancel and withdraw the shares and become the registered holder of such shares prior to the record date for the general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When a general meeting is convened, you may not receive sufficient advance notice of the meeting to withdraw the ordinary shares represented by your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our post-offering memorandum and articles of association, for the purposes of determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the setting of such a record date may prevent you from withdrawing the underlying ordinary shares represented by your ADSs and from becoming the registered holder of such shares prior to the record date, so that you would not be able to attend the general meeting or to vote directly. Where any matter is to be put to a vote at a general meeting, upon our instruction the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct how the underlying ordinary shares represented by your ADSs are voted and you may have no legal remedy if the underlying ordinary shares represented by your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#8217; meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the deposit agreement, if you do not vote, the depositary may give us a discretionary proxy to vote the ordinary shares underlying the ADSs at shareholders&#8217; meetings if we have timely provided the depositary with notice of meeting and related voting materials and (i)&#160;we have instructed the depositary that we wish a discretionary proxy to be given, (ii)&#160;we have informed the depositary that there is no substantial opposition as to a matter to be voted on at the meeting, and (iii)&#160;a matter to be voted on at the meeting would not have a material adverse impact on shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The effect of this discretionary proxy is that you cannot prevent the underlying ordinary shares represented by the ADSs from being voted, except under the circumstances described above. This may make it more difficult for ADS holders to influence the management of the company. Holders of ordinary shares are not subject to this discretionary proxy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of the ADSs for return on your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently intend to retain most, if not all, of our available funds and any future earnings to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in the ADSs as a source for any future dividend income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has complete discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit, retained earnings, or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiary, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in the ADSs will likely depend entirely upon any future price appreciation of the ADSs. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in the ADSs and you may even lose your entire investment in the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depositary has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act of 1933 but that are not properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not feasible to distribute certain property through the mail. Additionally, the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may experience dilution of your holdings due to the inability to participate in rights offerings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may, from time to time, distribute rights to our shareholders, including rights to acquire securities. Under the deposit agreement, the depositary will not distribute rights to holders of ADSs unless the distribution and sale of rights and the securities to which these rights relate are either exempt from registration under the Securities Act with respect to all holders of ADSs, or are registered under the provisions of the Securities Act. The depositary may, but is not required to, attempt to sell these undistributed rights to third parties, and may allow the rights to lapse. We may be unable to establish an exemption from registration under the Securities Act, and we are under no obligation to file a registration statement with respect to these rights or underlying securities or to endeavor to have a registration statement declared effective. Accordingly, holders of ADSs may be unable to participate in our rights offerings and may experience dilution of their holdings as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We will incur increased costs as a result of being a public company, particularly after we cease to qualify as an &#8220;emerging growth company.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a public company and expect to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules&#160;subsequently implemented by the Securities and Exchange Commission, or the SEC, and the Nasdaq Global Market, impose various requirements on the corporate governance practices of public companies. As a company with less than US$1.07 billion in revenues for our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, in the assessment of the emerging growth company&#8217;s internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect these rules&#160;and regulations to increase our legal and financial compliance costs and to make some corporate activities more time-consuming and costly. After we are no longer an &#8220;emerging growth company,&#8221; we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 and the other rules&#160;and regulations of the SEC. For example, as a result of becoming a public company, we will need to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules&#160;and regulations, and we cannot predict or estimate with any degree of certainty the number of additional costs we may incur or the timing of such costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act (as amended) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have the standing to initiate a shareholder derivative action in a federal court of the United States.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of lists of shareholders of these companies. Our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of all of the above, our public shareholders may have more difficulties in protecting their interests in the face of actions taken by management, members of our board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Certain judgments obtained against us by our shareholders may not be enforceable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a Cayman Islands exempted company and substantially all of our assets are located outside of the United States. Our current operations are primarily conducted in China. In addition, some of our current directors and officers are nationals and residents of countries other than the United States. Substantially all of the assets of these persons are located outside the United States. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of China may render you unable to enforce a judgment against our assets or the assets of our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq listing standards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Cayman Islands exempted company listed on the Nasdaq Global Market, we are subject to the Nasdaq listing standards. However, Nasdaq rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq listing standards. We have relied on and plan to rely on home country practice with respect to our corporate governance. For example, we do not have a majority of independent directors serving on our board of directors, and each of our nominating committee and compensation committee is not composed entirely of independent directors. In addition, we do not plan to seek shareholder approval in connection with certain transactions effecting securities issuance. We also do not plan to hold annual meeting of shareholders no later than one year after the end of fiscal year-end. For details, please refer to &#8220;Item 6. Directors, Senior Management and Employees&#8212;6.C. Board Practices&#8212;Board of Directors&#8221; and &#8220;Item 16G&#8212;Corporate Governance.&#8221; As a result, our shareholders may be afforded less protection than they would otherwise enjoy under the Nasdaq listing standards applicable to U.S. domestic issuers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are a foreign private issuer within the meaning of the rules&#160;under the Exchange Act, and as such we are exempt from certain provisions applicable to U.S. domestic public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules&#160;and regulations in the United States that are applicable to U.S. domestic issuers, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rules&#160;under the Exchange Act requiring the filing with the SEC of quarterly reports on Form&#160;10-Q or current reports on Form&#160;8-K;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the selective disclosure rules&#160;by issuers of material nonpublic information under Regulation FD.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will be required to file an annual report on Form&#160;20-F within four months of the end of each fiscal year. In addition, we have published and intend to continue to publish a summary of our financial results on a semi-annually basis as press releases, distributed pursuant to the rules&#160;and regulations of the Nasdaq Global Market. Press releases relating to financial results and material events will also be furnished to the SEC on Form&#160;6-K. However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We were likely a passive foreign investment company, or PFIC, for 2022, and there is a significant risk that we will be a PFIC for 2023 and possibly subsequent taxable years, in which case U.S. investors will generally be subject to adverse U.S. federal income tax consequences. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, a non-U.S. corporation will be a PFIC for any taxable year in which (i) 75% or more of its gross income consists of passive income, or the income test, or (ii) 50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the ordinary shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill is an active asset under the PFIC rules to the extent attributable to activities that produce active income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. The value of our goodwill for any taxable year may be determined in large part by reference to the average of our market capitalization for that year. Because our market capitalization has generally declined substantially since our initial public offering (including in 2022 and recent months), if the value of our goodwill is determined by reference to the average of our quarterly market capitalization, then it is our belief that we were likely a PFIC for our 2022 taxable year. Due to our declining market capitalization, there is a significant risk that we will also be a PFIC for 2023 and possibly future taxable years. In addition, the extent to which our goodwill should be characterized as a non-passive asset is not entirely clear. We have not obtained any valuation of our assets (including goodwill). U.S. Holders of our ADSs or ordinary shares should consult their tax advisors regarding the value and characterization of our assets for purposes of the PFIC rules, which are subject to some uncertainties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are a PFIC for any taxable year during which a U.S. investor owns our ADSs or ordinary shares, the U.S. taxpayer generally will be subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and &#8220;excess distributions,&#8221; and additional reporting requirements. This will generally continue to be the case even if we ceased to be a PFIC in a later taxable year, unless certain elections are made. See &#8220;Item 10 Additional Information&#8212;Taxation&#8212;Material U.S. Federal Income Tax Consequences&#8212;Passive Foreign Investment Company Rules.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If a U.S. person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a U.S. person is treated as owning (directly, indirectly or constructively) 10% or more of our stock (including our ADSs and ordinary shares) by value or voting power, such person generally will be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation,&#8221; or CFC, in our group. A CFC is a non-U.S. corporation more than 50% of the stock (by voting power or value) of which is owned (directly, indirectly or constructively) by &#8220;United States shareholders.&#8221; We have not determined whether we are a CFC. However, even if we are not a CFC, under certain ownership attribution rules our non-U.S. subsidiaries would be treated as owned by our U.S. subsidiary and thus may be treated as CFCs. A United States shareholder of a CFC may be subject to additional U.S. federal income tax liabilities and reporting requirements. We do not intend to furnish to any information that may be necessary for United States shareholders, if any, to comply with the CFC rules. U.S. investors that may be treated for purposes of the CFC rules as owning 10% of our stock by voting power or value should consult their tax advisors regarding the potential application of these rules in their particular circumstances.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ad62f36d_6a56_42c6_99ba_53b4acb4edc5"></a><a id="ITEM4INFORMATIONONTHECOMPANY_682720"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 4. INFORMATION ON THE COMPANY</p><a id="_53378893_c8c8_4cf2_8369_77c3ef569bbc"></a><a id="a4AHistoryandDevelopmentoftheCompany_695"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">4.A. History and Development of the Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February&#160;2011, Adagene Inc. was incorporated under the laws of the Cayman Islands as our offshore holding company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December&#160;2011, we established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as our intermediary holding company. In February&#160;2012, Adagene Hong Kong incorporated Adagene (Suzhou) Limited, or Adagene Suzhou, in China, through which we commenced our research and development activities in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In September&#160;2017, we established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct our research and development activities in the United States to facilitate the discovery and development of product candidates and expand our global presence, we have further incorporated several subsidiaries overseas, such as Australia, Singapore and Switzerland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a holding company and do not directly conduct any substantive business operations in the PRC. In addition to our R&amp;D activities in the United States, Australia and Singapore, we currently focus our business operations within the PRC through Adagene Suzhou. We (Adagene Inc.), however, hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. See &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in the PRC.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, we completed an initial public offering in which we offered and sold an aggregate of 10,571,375 ordinary shares in the form of ADSs. Upon the initial public offering, all of our then issued and outstanding preferred shares were automatically converted into ordinary shares on a one-for-one basis. On February&#160;9, 2021, the ADSs began trading on the Nasdaq under the symbol &#8220;ADAG.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters is located at 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. Our San Diego office address is 10179 Huennekens Street Suite 103, San Diego, CA 92121. Our registered office is located at Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands. Our telephone number is +86-512-8777-3632. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. Our corporate website is www.adagene.com. The information contained on or that can be accessed through our website is not incorporated by reference into this annual report, and you should not consider information on our website to be part of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC maintains an internet site at <i style="font-style:italic;">www.sec.gov</i> that contains reports, information statements, and other information regarding issuers that file electronically with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recent Regulatory Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Implication of the Holding Foreign Companies Accountable Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Holding Foreign Companies Accountable Act (the &#8220;HFCA Act&#8221;), was enacted on December 18, 2020. Trading in our ADSs on the Nasdaq or over-the-counter will be prohibited, and as a result, our ADSs will be delisted under the HFCA Act, if the PCAOB has determined that it has been unable to inspect registered public accounting firms headquartered in mainland China and Hong Kong for two consecutive years. The enactment of the Accelerating Holding Foreign Companies Accountable Act (&#8220;AHFCA Act&#8221;) decreases the number of non-inspection years from three years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted. For the details of the risks associated with the enactment of the AHFCA Act, see &#8220;Item 3. Key Information&#8211;&#8211;3.D. Risk Factors&#8211;&#8211; The enactment of the Accelerating Holding Foreign Companies Accountable Act decreases the number of non-inspection years from three years to two, thus reducing the time period before our ADSs may be prohibited from trading on the Nasdaq Stock Market or in the over-the-counter market or delisted.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 16, 2021, PCAOB issued the HFCA Act Determination Report, according to which our auditor was subject to the determinations that the PCAOB is unable to inspect or investigate completely (the &#8220;2021 Determinaitons&#8221;). In March 2022, the SEC issued its first &#8220;Conclusive list of issuers identified under the HFCAA&#8221; indicating that those companies are now formally subject to the delisting provisions if they remain on the list for two consecutive years. We were conclusively identified on May 26, 2022. See https:// www.sec.gov/hfcaa. Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Since our auditor is located in China, a jurisdiction where the PCAOB had been unable to conduct inspections without the approval of the PRC authorities, our auditor was not inspected by the PCAOB. Final rules implementing the submission and disclosure requirements in the HFCA Act were adopted by the SEC on December 2, 2021 and became effective on January 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On August 26, 2022, the PCAOB signed a Statement of Protocol with China Securities Regulatory Commission and the Ministry of Finance of the People&#8217;s Republic of China, taking the first step toward opening access for the PCAOB to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong. On December 15, 2022, the PCAOB announced that it was able, in 2022, to inspect and investigate completely issuer audit engagements of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong and that it had vacated its 2021 Determinaitons accordingly. As a result, we do not expect to be identified as a Commission-Identified Issuer under the HFCA Act for the fiscal year ended December 31, 2022 after we file our annual report on Form 20-F for such fiscal year. However, whether the PCAOB will continue to conduct inspections and investigations completely to its satisfaction of PCAOB-registered public accounting firms headquartered in mainland China and Hong Kong is subject to uncertainty and depends on a number of factors out of our, and our auditor&#8217;s, control, including positions taken by authorities of the PRC. The PCAOB is expected to continue to demand complete access to inspections and investigations against accounting firms headquartered in mainland China and Hong Kong in the future and states that it has already made plans to resume regular inspections in early 2023 and beyond. The PCAOB is required under the HFCA Act to make its determination on an annual basis with regards to its ability to inspect and investigate completely accounting firms based in the mainland China and Hong Kong. The possibility of being a &#8220;Commission-Identified Issuer&#8221; and risk of delisting could continue to adversely affect the trading price of our securities. If the PCAOB determines in the future that it no longer has full access to inspect and investigate accounting firms headquartered in mainland China and Hong Kong and we continue to use such accounting firm to conduct audit work, we would be identified as a &#8220;Commission-Identified Issuer&#8221; under the HFCA Act following the filing of the annual report for the relevant fiscal year, and if we were so identified for two consecutive years, trading in our securities on U.S. markets would be prohibited. For the details of the risks associated with the enactment of the HFCA Act, see &#8220;Item 3. Key Information&#8211;&#8211;3.D. Risk Factors&#8211;&#8211;Risks Related to Doing Business in the PRC&#8211;&#8211;Our ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The delisting of the ADSs, or the threat of them being delisted, may materially and adversely affect the value of your investment.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:11pt;margin:0pt 0pt 10pt 0pt;">Cybersecurity Review Measures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On December 28, 2021, the Cyberspace Administration of China, or the CAC, and 12 other relevant PRC government authorities published the amended Cybersecurity Review Measures, or the Cybersecurity Review Measures, which went on February 15, 2022 and supersede and replace the current Cybersecurity Review Measures previously promulgated on April 13, 2020. The Cybersecurity Review Measures provide that the purchase of network products and services by a &#8220;critical information infrastructure operator&#8221; and the data processing activities of a &#8220;network platform operator&#8221; that affect or may affect national security shall be subject to the cybersecurity review. Furthermore, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office. In addition, the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On November 14, 2021, the CAC released the Regulations for the Administration of Network Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments. The Draft Data Security Regulations provide that (i) a data processor who processes personal information of more than one million individuals must complete a cybersecurity review if it intends to be listed in a foreign country, and (ii) a data processor who carries out other data processing activities which affect or may affect national security should also complete the cybersecurity review. The Draft Data Security Regulations provide a broad definition of &#8220;data processing activities,&#8221; including collection, storage, usage, processing, transfer, provision, publication, deletion and other activities, which covers the entire life cycle of data processing. The Draft Data Security Regulations also provide a broad definition of &#8220;data processors&#8221; as individuals and entities that may autonomously determine the purpose and method of data processing activities. In addition, the Draft Data Security Regulations require data processors who process important data or whose securities are listed outside of China to carry out annual data security assessment either by itself or through a third party data security service provider and submit the assessment report to a local agency of the CAC. See &#8220;Item 4. Information of the Company&#8212;4.B. Business Overview&#8212;Regulation&#8212;Other PRC Government Regulations&#8212; Regulations on Information Security and Data Protection&#8221; for detailed discussion. As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, the Draft Data Security Regulations were released for public comment only with the deadline of submitting public comments or opinions by December 13, 2021, and its provisions and anticipated adoption or effective date are subject to changes and thus its interpretation and implementation remain substantially uncertain. We cannot predict the impact of the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, given the nature of our business, since we do not possess or process personal information of more than one million users/individuals, and we do not believe we are a &#8220;critical information infrastructure operator,&#8221; &#8220;network platform operator&#8221; or a data processor whose purchase of network products and services or data processing activities affect or may affect national security, the listing of our ADSs on the Nasdaq and future potential offering of our ADSs will not be subject to the cybersecurity review process under the Cybersecurity Review Measures, although we cannot guarantee that the relevant PRC regulatory authority will agree with our interpretation. Currently, the Cybersecurity Review Measures and the Draft Data Security Regulations have not materially affected our business and operations, but in anticipation of the strengthened implementation of cybersecurity laws and regulations and the continued expansion of our business, we face potential risks if we are deemed as a critical information infrastructure operator, a network platform operator or data processing operator under the PRC cybersecurity laws and regulations. In such case, we must fulfill certain obligations as required under the PRC cybersecurity laws and regulations, including, among others, storing personal information and other important data collected and produced within the PRC territory as we advance our drug discovery pipelines as part of our future operations in China, and we may be subject to lengthy cybersecurity review, annual data security assessment and other enhanced regulatory requirements when purchasing network products and services or conducting other data processing activities. We may face challenges in addressing such enhanced regulatory requirements and be required to make necessary changes to our internal policies and practices in data privacy and cybersecurity matters. As advised by our PRC legal counsel, Jingtian &amp; Gongcheng, as of the date of this annual report, no detailed rules or implementation of the Cybersecurity Review Measures have been issued by the CAC and the Draft Data Security Regulations were only released for public comments, and the PRC governmental authorities have broad discretion in the interpretation and enforcement of these laws and regulations. It also remains uncertain whether the future regulatory changes will impose additional restrictions on companies like us. We cannot predict the impact of the Cybersecurity Review Measures and/or the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. If the future enacted laws and regulations, including the enacted version of the data security regulations mandate clearance of cybersecurity review and other specific actions to be completed by companies like us before we are able to complete this offering, we will face uncertainties as to whether such clearance and/or other specific actions can be timely obtained or completed, or at all. If we are not able to comply with the cybersecurity and data privacy requirements in a timely manner, or at all, we may be subject to government enforcement actions and investigations, fines, penalties, or suspension of our non-compliant operations, among other sanctions, which could materially and adversely affect our business and results of operations. Any failure to complete the required cybersecurity review may result in administrative penalties, including fines, a shut-down of our business, revocation of requisite licenses, as well as reputational damage or legal proceedings or actions against us, which may have material adverse effects on our business, financial condition and results of operations. As of the date of this annual report, we have not been involved in any investigation on cybersecurity review made by the CAC on such basis, and we have not received any inquiry, notice, warning, or sanction in such respect, and we have not been subject to any material fines or other material penalties due to non-compliance with cybersecurity or data privacy laws or regulations. Our PRC legal counsel does not expect that, as of the date of this annual report, we are required to file an application for the cybersecurity review by CAC in connection with our previous issuance of securities to foreign investors or maintaining our listing status on Nasdaq. We have been making continuous efforts to comply with the relevant cybersecurity and data protection laws and regulations of the PRC, and will endeavor to comply with any updated applicable laws, regulations or guidelines as issued by any relevant regulatory authority in the PRC. See &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, investigation or sanction by regulatory authorities, private litigation, other liabilities, and/or adverse publicity.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Material Licenses and Approvals </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our PRC subsidiary has obtained all material licenses and approvals required for our operations in China. For details of our material licenses and approvals, see &#8220;Item 4. Information of the Company&#8212;4.B. Business Overview&#8212;Material Licenses and Approvals.&#8221; For risks relating to licenses and approvals required for our operations in China, see &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8212;Risks Related to Doing Business in the PRC,&#8221; &#8220;&#8212;Risks Related to Clinical Development of Our Product Candidates,&#8221; and &#8220;&#8212;Risks Related to Obtaining Regulatory Approval of Our Drug Candidates.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, in connection with our historical issuance of securities to foreign investors, under currently effective PRC laws, regulations and regulatory rules, as of the date of this annual report, we are not currently required to obtain permissions from the China Securities Regulatory Commission (the &#8220;CSRC&#8221;), and we have not received any formal notice from any PRC authority indicating that we should apply for or are otherwise subject to cybersecurity review or security assessment. In addition, we have not been asked to obtain such permissions by any PRC authority or received any denial to do so. However, the PRC government has recently indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers. For example, the CSRC published the Trial Measures and Listing Guidelines on February 17, 2023, designed to regulate overseas securities offerings by PRC domestic companies. Given the recent nature of the introduction of the Trial Measures and Listing Guidelines, there remains significant uncertainty as to the enactment, interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If (i) we mistakenly conclude that certain regulatory filings, permissions and approvals are not required or (ii) applicable laws, regulations, or interpretations change and (iii) we are required to obtain such filings, permissions or approvals in the future, but fail to receive or maintain such filings, permissions or approvals, we may face sanctions by the CSRC, the Cyberspace Administration of China (the &#8220;CAC&#8221;) or other PRC regulatory agencies. In addition, rules and regulations in China can change quickly with little advance notice. These regulatory agencies may impose fines and penalties on our operations in China, limit our operations in China, limit our ability to pay dividends outside of China, limit our ability to list on stock exchanges outside of China or offer our securities to foreign investors or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our securities. Our non-consolidated joint venture faces the same risks as well. See also &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;We may be required to obtain approval or complete filing or other requirements of the CSRC or other PRC government authorities in connection with our issuances of securities overseas, and, if required, we cannot predict whether we will be able to obtain such approval or complete such governmental procedure.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Transfer of Funds and Other Assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under relevant PRC laws and regulations, we are permitted to remit funds to Adagene Suzhou through loans, capital contributions or as payment of considerations for the services rendered. In 2020, 2021 and 2022, Adagene Inc. made payments of US$15.5 million, US$30.0 million and US$24.5 million, respectively, in cash to Adagene Suzhou as consideration for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. There were no intercompany loans provided by Adagene Inc. to Adagene Suzhou during the years ended and as of December 31, 2020, 2021 and 2022. In addition, as advised by our PRC legal counsel, Jingtian &amp; Gongcheng, Adagene Suzhou is able to mark up and charge to Adagene Inc., its ultimate parent, for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. and Adagene Inc. is able to make cash payments to Adagene Suzhou for considerations of such services. In the future, cash proceeds raised from overseas financing activities, including this offering, may be transferred by Adagene Inc., the Cayman holding company, (i) through Adagene (Hong Kong) Limited, our Hong Kong subsidiary, to Adagene Suzhou, our PRC subsidiary, and (ii) to Adagene Incorporated, our U.S. subsidiary, via capital contribution, shareholder loans or consideration for the services rendered, as the case may be. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than the above disclosed transfer of funds, we did not transfer any type of assets between Adagene Suzhou and other Adagene subsidiaries in 2020, 2021 and 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Restrictions on Foreign Exchange and the Ability to Transfer Cash between Entities, Across Borders and to U.S. Investors  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we become profitable, Adagene Inc.&#8217;s ability to pay dividends, if any, to the shareholders and ADS investors and to service any debt it may incur will depend upon dividends paid by our PRC and U.S. subsidiaries. Under the PRC laws and regulations, our PRC subsidiary is subject to certain restrictions with respect to paying dividends or otherwise transferring any of their net assets offshore to Adagene Inc. In particular, under the current effective PRC laws and regulations, dividends may be paid only out of distributable profits. Distributable profits are the net profit as determined under PRC GAAP, less any recovery of accumulated losses and appropriations to statutory and other reserves required to be made. Our PRC subsidiary shall appropriate 10% of the net profits as reported in its respective statutory financial statements (after offsetting any prior year&#8217;s losses) to the statutory surplus reserves until such reserves have reached 50% of its respective registered capital. In addition, the EIT Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises are incorporated. See &#8220;Item 3.D.Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material and adverse effect on our ability to conduct our business.&#8221; Further, if any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may also restrict its ability to pay dividends ultimately to Adagene Inc. As a result, our PRC subsidiary may not have sufficient, or any, distributable profits to pay dividends to us in the near future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Furthermore, if certain procedural requirements are satisfied, the payment of current account items, including profit distributions and trade and service related foreign exchange transactions, can be made in foreign currencies without prior approval from State Administration of Foreign Exchange (&#8220;SAFE&#8221;) or its local branches. However, where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses, such as the repayment of loans denominated in foreign currencies, approval from or registration with competent government authorities or its authorized banks is required. The PRC government may take measures at its discretion from time to time to restrict access to foreign currencies for current account or capital account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our offshore intermediary holding companies or ultimate parent company, and therefore, our shareholders or investors in our ADSs. Further, we cannot assure you that new regulations or policies will not be promulgated in the future, which may further restrict the remittance of RMB into or out of the PRC. We cannot assure you, in light of the restrictions in place, or any amendment to be made from time to time, that our current or future PRC subsidiaries will be able to satisfy their respective payment obligations that are denominated in foreign currencies, including the remittance of dividends outside of the PRC. See &#8220;Item 4 Information on the Company&#8212;PRC Regulation &#8212;Regulations on Foreign Exchange and Dividend Distribution&#8221; for detailed discussion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For PRC and United States federal income tax consideration of an investment in the ADSs, see &#8220;Item 10. Additional Information&#8212;10.E. Taxation.&#8221;</p><a id="_62f524e8_584f_4262_8e73_c97b3862eaeb"></a><a id="a4BBusinessOverview_294009"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4.B. Business Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OVERVIEW</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. We are combining computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by our proprietary Dynamic Precision Library (DPL) platform, which fuels our NEObody&#8482;, SAFEbody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and POWERbody&#8482; technologies, we are developing a highly differentiated pipeline of novel immunotherapies. We have forged strategic collaborations with reputable global partners that leverage our technology in multiple approaches at the vanguard of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. We have pioneered a dynamic antibody technology interface to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Additionally, we have a proprietary precision masking technology and specialized antibody engineering capabilities which enable us to design therapeutics with unique features.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Dynamic Precision Library (DPL) fuels our three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The NEObody technology platform is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic antibody technologies through its innovative designs and precise constructions. NEObody technology enables the generation of antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes, triggering a novel MOA. The species cross-reactive antibodies generated by NEObody technology not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune system intact animal models, resulting in high fidelity translation from preclinical to clinical studies. We refer to antibodies generated by our NEObody technology as NEObodies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The SAFEbody technology platform is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its target in healthy tissues, minimizing on target, off tumor toxicities. The masking motif is designed to activate, or unmask, the antibody to allow binding in the tumor microenvironment, or TME, where certain activation conditions such as a protease is upregulated as compared to healthy tissues, allowing the antibody to bind to its target for tumor killing. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while remaining largely in an inactive state in healthy tissues. Our SAFEbody technology can be applied to mask the binding sites of any antibodies including but not limited to NEObodies. We refer to such masked antibodies as SAFEbodies. Notably, SAFEbody technology can be applied to our NEObodies, such as what we did with ADG116 to potentially achieve an increased therapeutic index with ADG126. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The POWERbody technology platform enables the creation of new versions of antibodies, which may be bispecific T-cell engagers, or TCEs, or Fc-engineered antibodies, antibody-drug conjugates, or ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies. Our POWERbody candidates incorporate SAFEbody precision masking technology and are designed to improve antitumor activity while maintaining the enhanced safety profile. As an example, we have developed bispecific TCEs with either a CD3 or a CD28 arm and demonstrated the ability to combine them together for potentially safe and durable immunotherapies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our AI-powered technology allows us to engineer and select species cross-reactive antibodies designed to dynamically adapt to unique and evolutionally conserved epitopes. We believe that comprehensive <i style="font-style:italic;">in vivo</i> preclinical evaluations using these species cross-reactive antibodies are the key to assess the efficacy and safety potential of tailor-made antibody candidates before progressing them into lengthy and costly clinical trials. Our NEObody, SAFEbody and POWERbody technology platforms are all designed to facilitate favorable druggability, manageable CMC attributes, and reduced immunogenicity. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:245.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The figure below shows how our NEObody, SAFEbody, and POWERbody technologies are inter-connected with our DPL and utilized for the building of our product pipeline of mono- and combination immunotherapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f002.jpg" alt="Graphic" style="display:inline-block;height:245.22pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:241.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our DPL Platform fuels three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates. Antibodies generated by NEObody technology are designed with dynamic binding sites that adapt kinetically to unique epitopes, thereby triggering a novel MOA. SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the TME, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues. POWERbody candidates are designed to unleash the efficacy of a therapeutic through Fc-engineering, drug conjugation, or T-cell engagement, while securing safety by precision masking with SAFEbody technology. Thus, POWERbody candidates also incorporate SAFEbody precision masking technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Our Robust, Transformative Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated and wholly-owned clinical-stage pipeline consists of two anti-CTLA-4 antibodies, ADG116 (NEObody) and ADG126 (SAFEbody), which are both in Phase 1b/2 clinical evaluation in single agent and/or combination clinical trials designed to evaluate safety and preliminary efficacy, and two anti-CD137 antibodies, ADG106 (NEObody) and ADG206 (POWERbody). We also have several programs in IND-enabling studies, including an IND-ready masked, IgG1 anti-CD47 SAFEbody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we have out-licensed the Greater China rights of ADG104, an anti-PD-L1 mAb currently in Phase 2 clinical development, to Sanjin, and the Greater China rights of ADG125, a novel anti-CSF-1R mAb in Phase 1 development, to Dragon Boat Biopharmaceuticals. We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 and ADG125 in the rest of the world, where we retain a majority of the economic benefits. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:240.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following chart provides an overview of the status of each of our wholly-owned clinical and pre-clinical programs for which we have global rights: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;">A Robust, Transformative Pipeline of Wholly-Owned Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f003.jpg" alt="Graphic" style="display:inline-block;height:240.22pt;width:510.58pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have deployed our NEObody and SAFEbody technology platforms to develop our wholly-owned clinical candidates, ADG116, ADG126, ADG106 and ADG206, which are in ongoing clinical evaluation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG116 is a fully human anti-CTLA-4 NEObody, which binds to a novel epitope of CTLA-4 different from ipilimumab, the only CTLA-4 mAb approved globally in both monotherapy and in combination with anti-PD-1. The dynamic interface of ADG116 enables not only its species cross-reactivity with human, cynomolgus monkey, and mouse CTLA-4 for preclinical studies, but also its dynamic engagement on a unique epitope of CTLA-4 to trigger a novel MOA distinct from ipilimumab by partial ligand blocking and stronger regulatory T-cell depletion via strong antibody-dependent cellular cytotoxicity (ADCC). ADG116 is designed to overcome the safety challenges of existing CTLA-4 therapeutics, with enhanced Treg depletion, and improved safety and efficacy profiles, with confirmed clinical responses both as monotherapy and in combination with anti-PD-1. ADG116 is currently in phase 1b/2 evaluation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG126 is a fully human anti-CTLA-4 SAFEbody, which applies SAFEbody precision masking technology to ADG116 to further enhance safety and efficacy profiles by masking the antibody binding site which is then conditionally activated in the TME to limit on target, off tumor toxicity. ADG126 is designed to further increase the therapeutic window of ADG116, and optimize efficacy by achieving higher doses and constant target engagement with repeat dosing of anti-CTLA-4 that may unlock the full potential of CTLA-4 as a proven target for strong ADCC-mediated Treg depletion in the TME. ADG126 has consistently shown best-in-class safety and differentiated efficacy profiles in clinic, which is consistent with and enabled by the broad species cross-reactivity of ADG126 for extensive preclinical evaluation from mouse, rats and monkeys, including GLP toxicology data. In clinic, no dose-limiting toxicities have been observed up to 20 mg/kg. ADG126 is currently in phase 1b/2 evaluation.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG106 is a fully human ligand-blocking agonistic anti-CD137 NEObody, which targets a unique epitope of CD137 that is different from other anti-CD137 antibodies currently under clinical development. Preclinical and clinical studies show that ADG106 is capable of binding to CD137 in a fashion similar to its natural ligand, CD137L. ADG106 is designed to balance safety and efficacy to overcome the known safety challenges of anti-CD137 targeted therapy, particularly when used in combination with anti-PD-1 or anti-CTLA-4 therapies. In clinic, ADG106 has shown a well-tolerated safety profile and evidence of single-agent efficacy, while combination therapy development is supported by the combined findings of our phase 1 monotherapy trials, data from extensive preclinical studies, as well as PD marker-based modelling from prior and ongoing trials. Phase 1b/2 investigator-initiated trials in combination settings are ongoing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG206 is a masked, Fc engineered anti-CD137 agonistic POWERbody. ADG206 incorporates SAFEbody&#174; precision masking technology and is designed to achieve improved safety and efficacy. ADG206 has demonstrated enhanced crosslinking by FcgRIIb in vitro upon activation and antitumor activity in vivo, while the SAFEbody masking technology limits on-target off-tumor toxicities by preferential activation in the TME. ADG206 is currently in Phase 1 evaluation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Additionally, we have multiple preclinical programs that are currently in IND-enabling studies as candidates for future clinical development as resources allow. See &#8220;</span><i style="font-weight:normal;">&#8212;IND-ready Candidates and Preclinical Pipeline</i><span style="font-style:normal;font-weight:normal;">&#8221;.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Our Global Partnerships and Collaborations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a successful track record of collaborations and partnerships with global biopharmaceutical companies and academic institutions. So far, we have established multiple collaborations and we continue to seek partnership opportunities where we can leverage our proprietary technology platform to develop novel antibodies to address unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We enter into collaborations with biotechnology and pharmaceutical companies to leverage the power of our technology platforms, creating a network of potential future revenue streams that complement future long-term value from our wholly-owned pipeline. These collaborations include both technology licensing agreements and outlicensing of product candidates, both of which allow us to retain significant future participation in product sales through royalties paid on net sales. In the future, we may also enter into strategic collaborations which may involve joint development for our preclinical and/or clinical assets to both accelerate the path to clinic and drive global commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics to develop antibody-based therapeutics against tumor targets using our SAFEbody technology. We have also out-licensed the Greater China rights for two antibody candidates to Sanjin and its affiliates. Additionally, we have leveraged our DPL technology platform and antibody discovery and engineering capabilities in discovery collaborations with the U.S. National Institutes of Health (NIH), Mitsubishi Tanabe, Celgene (now BMS), GSK and Hengrui. To further advance our pipeline, we have also put in place various clinical collaborations, including an agreement with Roche who is sponsoring and conducting a randomized combination trial with ADG126, clinical collaborations and supply agreements with Merck who will provide pembrolizumab for certain of our combination clinical trials, and an agreement with research organizations in Singapore for investigator-initiated trials of our ADG106 clinical candidate in combination settings. See &#8220;<i style="font-style:italic;">&#8212;Clinical Collaboration Agreements</i>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our collaborations empower our growth by generating cash flow and revenues that partially offset expenditures on our internal research and development programs, expand our knowledge base regarding antibody technology across multiple targets and antibodies provided by our partners, and provide us with future joint development opportunities.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OUR CLINICAL PIPELINE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our wholly owned, highly differentiated pipeline consists of two anti-CTLA-4 clinical candidates, ADG116 NEObody, ADG126 SAFEbody (with masking), and two anti-CD137 candidates, ADG106 NEObody and ADG206 POWERbody (with masking). We also have multiple IND-ready preclinical candidates and a discovery pipeline in various stages of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, we have out-licensed the Greater China rights of ADG104, an anti-PD-L1 mAb in Phase 2 development, to our partner Sanjin, and the Greater China rights of ADG125, a novel anti-CSF-1R mAb in Phase 1 development, to Dragon Boat Biopharmaceuticals. We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 and ADG125 in the rest of the world, where we retain a majority of the economic benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Together, our wholly-owned internal candidates and partnered programs provide multiple product development and future commercial opportunities, either alone or with partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of immune checkpoint inhibitors has revolutionized cancer immunotherapy in the past decade. In fact, recent trials have shown that immunotherapy can induce durable and extensive tumor regression, potentially converting previously fatal diseases into chronic, manageable diseases for certain patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Anti-CTLA-4 therapy is one of the first immune checkpoint inhibitor treatments to demonstrate definite clinical benefit through direct T-cell activation. Ipilimumab (Yervoy&#174;) was the first approved immune checkpoint inhibitor by the FDA in 2011 for the treatment of advanced melanoma. This was followed by FDA approval in 2022 of tremelimumab (Imjudo&#174;) in combination with anti-PD-L1 for treatment of unresectable hepatocellular carcinoma (HCC) and metastatic non-small cell lung cancer (NSCLC) after more than ten years, while more than ten anti-PD-1/PD-L1 therapies and their combinations were approved globally with comparable safety and efficacy profiles, highlighting the unique challenge to unleashing the full therapeutic potential for anti-CTLA-4 therapies. Indeed, anti-CTLA-4 therapies approved or in clinical development show a strong dose- dependent toxicity and efficacy, both alone and in combination with anti-PD-1/L1, limiting their acceptance in clinical practice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart demonstrates the dose-dependent toxicities with ipilimumab monotherapy treatment in melanoma, limiting its dosing and therefore efficacy:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f004.jpg" alt="Graphic" style="display:inline-block;height:176.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:405.69pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">* Reference: Ascierto PA, et al. J Immunother Cancer 2020;8:e000391. doi:10.1136/jitc-2019-000391</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:140.23pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart shows that ipilimumab has a strong dose-dependent toxicity and efficacy in the combination setting with anti-PD-1, as shown for second-line HCC:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><b style="color:#0070c0;font-weight:bold;">Ipilimumab: Combination Data in HCC Highlight</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;">Dose Dependent Challenge of Anti-CTLA-4 Therapy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f005.jpg" alt="Graphic" style="display:inline-block;height:140.23pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:370.45pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For HCC, approved dose level is Nivo 1mg/kg+ Ipi 3mg/kg; Nivo + 4 doses of Ipi; patient population is previously treated with sorafenib (2L); dosing regimens Q3W for 4 doses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Indeed, ipilimumab is still being debated for its function in blocking CTLA-4 via its binding arms or in depleting CTLA-4 expressing Treg cells intratumorally for anti-CTLA-4 therapies. Thus, development of next generation anti-CTLA-4 therapies with an improved safety profile and antitumor efficacy through enhanced CTLA-4 blockage and/or Treg depletion (via its Fc-mediated ADCC effect) are urgently needed to improve upon existing anti-CTLA-4 therapies, as well as open the new doors to treat cold tumors such as MSS-CRC. Additionally, addressing the dose-dependent toxicities of anti-CTLA-4 therapy may enable more front-line combinations, fully unlocking the potential of anti-CTLA-4 as a cornerstone of cancer care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">ADG116 NEObody: A Unique Entry Point for Anti-CTLA-4 Therapy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG116 is a fully human anti-CTLA-4 antibody generated using our NEObody technology, designed to target a unique epitope of CTLA-4, to enhance the efficacy profile and to address both the toxicity and efficacy concerns associated with existing CTLA-4 therapeutics. It is currently under Phase 1b/2 clinical evaluation in multiple trials in the U.S., China and Asia Pacific (APAC), both as monotherapy and in combination with other therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development rationale for ADG116 focuses on its softer CTLA-4 ligand blocking and stronger ADCC for depleting regulatory T-cells than ipilimumab. In a head-to-head <i style="font-style:italic;">in vivo </i>efficacy study, ADG116 was observed to have a five-fold greater anti-tumor activity in comparison with ipilimumab. In addition, ADG116 was observed to induce antitumor responses concomitant with reduced immunosuppressive regulatory T-cell and enhanced cytotoxic T lymphocyte (CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T-cells) activities in the TME.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our clinical program is designed to demonstrate the differentiated safety and efficacy profile of ADG116 and to support our evaluation of our anti-CTLA-4 SAFEbody ADG126, for which ADG116 is the parental antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We initiated a monotherapy trial of ADG116 in Australia (ADG116-1003) designed to evaluate safety and determine a recommended Phase 2 dose, or RP2D, in patients with advance metastatic tumors. A secondary objective of the trial is to evaluate preliminary efficacy based upon anti-tumor activity both as monotherapy and in combination regimens. Since 2021, we have expanded the trial (ADG116- 1003) to sites in the U.S. after receiving clearance from the FDA. Upon the receipt of such clearance from the FDA, we terminated a prior Phase 1 trial (ADG116-1001) in the U.S. for business reasons. In addition, we obtained approval to initiate cohorts in other countries, including Singapore and South Korea. For detailed discussion on our terminated ADG116-1001 clinical trial in U.S., see &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks relating to obtaining regulatory approval of our drug candidates&#8212;Our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:158.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In 2022, we completed dose escalation of ADG116 monotherapy up to 15 mg/kg with repeat dosing and initiated dose escalation in combination with anti-PD-1 under the same protocol. In November 2021, we also received clearance from the FDA to initiate a trial of ADG116 in combination with pembrolizumab (ADG116-P001 / KEYNOTE-C97). Data from both of these phase 1b/2 studies were presented in November 2022 at the  annual meeting of the Society for Immunotherapy of Cancer (SITC).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Clinical Studies &amp; Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we reported comprehensive safety and interim efficacy data from our ongoing phase 1b/2 monotherapy and combination clinical studies of ADG116 in two poster presentations at SITC 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Results from monotherapy evaluation in patients with advanced/metastatic solid tumors (N=50) showed ADG116 is well tolerated across dose levels with repeat dosing. Grade 1/2 and Grade 3/4 treatment-related adverse events (TRAEs) were reported in 28 (56%) and 3 (6%) patients, respectively. With repeat dosing and tracking for late-onset toxicities in the same 10mg/kg cohort, the overall rate of Grade 3 or higher TRAEs was 13%. There were no Grade 3 or higher TRAEs reported at the 15 mg/kg dose level for ADG116 monotherapy. For reference, the reported rate of TRAEs Grade 3 and higher for the currently approved anti-CTLA-4 therapy, ipilimumab, is approximately 36% at 10 mg/kg in first-line monotherapy in melanoma patients (<i style="font-style:italic;">Ascierto PA, et al. J Immunother Cancer 2020;8:e000391. Doi:10.1136/jitc-2019-000391</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart demonstrates the incidence of treatment emergent adverse events with ADG116 by grade and dose level, showing the vast majority of TRAEs were Grade 1 or 2:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;">ADG116 Monotherapy: TRAEs Show Compelling Safety Profile up to 15 mg/kg with Repeat Dosing*</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><img src="adag-20221231x20f006.jpg" alt="Graphic" style="display:inline-block;height:158.24pt;width:216pt;" /></p></td><td style="vertical-align:middle;width:50.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><img src="adag-20221231x20f007.jpg" alt="Graphic" style="display:inline-block;height:83.51pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:252pt;" /></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">* Results as of the 2022 SITC Data Cut-off Date </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At SITC 2022, we also reported preliminary efficacy data from the ongoing monotherapy trial in these heavily pre-treated patients with difficult-to-treat tumors. <span style="color:#333333;">The overall disease control rate (DCR) was 33% across all monotherapy dose levels, with additional tumor reduction observed in patients with both warm and cold tumors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Among 36 efficacy evaluable patients as of the SITC data cut-off date, an initial partial response was observed after two cycles of treatment in a Kaposi&#8217;s sarcoma patient, who was one of three treated with ADG116 monotherapy at 15 mg/kg. An additional partial response was observed as of&#160;</span>November 2, 2022<span style="color:#333333;">&#160;in a patient with renal cell carcinoma who progressed after two prior lines of therapy, including an anti-PD-L1 inhibitor. The patient received four cycles of ADG116 monotherapy at 10 mg/kg with no Grade 3 or higher TRAEs reported.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Further, in&#160;</span>February 2023<span style="color:#333333;">, a third partial response with monotherapy was reported in a patient with MSI-H endometrial cancer. The patient had received five cycles of ADG116 at 10 mg/kg with only Grade 1 TRAEs reported.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to monotherapy evaluation in the ADG116-1003 trial, we received NMPA approval to initiate another monotherapy trial, ADG116-1002 in China, to provide additional clinical data regarding safety and activity of ADG116 in Chinese patients, including the combination of ADG116 and other immunotherapies. Data from the trial are expected to enable China to join our global clinical program. As of this annual report, dose escalation cohorts in the trial are ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In parallel to the ongoing monotherapy evaluation, we initiated dose escalation cohorts for ADG116 in combination with two anti-PD-1 therapies in the ADG116-1003 (toripalimab) and ADG116-P001 (pembrolizumab) trials. At SITC 2022, we provided an interim update on these trials, which demonstrated the manageable safety profile and early efficacy in 15 heavily pre-treated patients with difficult-to-treat tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">ADG116 was dosed every three weeks at 3 mg/kg or 6 mg/kg in combination with 240 mg of toripalimab (N=9). Although ADG116 with toripalimab at 6 mg/kg did not meet the target toxicity level (TTL) (i.e., lower rate of Grade 3 or higher TRAEs than those approved for anti-CTLA-4 and anti-PD-1 combination therapies), 3 mg/kg of ADG116 every three weeks with toripalimab was both manageable within the TTL and demonstrated impressive efficacy profile in difficult-to-treat tumors. Further dose optimization is planned, including ongoing evaluation of late-onset toxicities associated with </span><span style="color:#333333;">ADG116 plus toripalimab with repeat dosing to meet the desired TTL.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Among seven efficacy evaluable patients who received ADG116 in combination with toripalimab, one confirmed complete response was observed in a patient with platinum-refractory recurrent head and neck squamous cell carcinoma (HNSCC). The patient received 3 mg/kg of ADG116 in combination (n=5; Objective response rate = 20%; DCR = 100%). Lesions completely disappeared after two cycles of therapy, and the durable response was maintained far beyond six cycles as of the SITC Data Cut-off Date. The patient remains on therapy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">A second combination trial, ADG116-P001, evaluated ADG116 in combination with pembrolizumab in pre-treated patients (N=6) primarily with cold tumors. The findings were presented at SITC and further support the differentiated safety profile of ADG116 dosed at 3 mg/kg every three weeks, as well as its efficacy potential when combined with pembrolizumab at a flat dose of 200 mg. No TRAEs higher than Grade 3 were reported and no DLT was observed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">In the combination trial with pembrolizumab, significant changes were observed in a tumor-related biomarker in two patients with metastatic microsatellite-stable (MSS)&#160;colorectal cancer (CRC), who experienced a 43% and 27% reduction in carcinoembryonic antigen (CEA) levels, respectively. Both patients had either liver or lung metastases. These data support continued evaluation of ADG116 plus pembrolizumab as a combination of anti-CTLA-4 and anti-PD-1 therapies that may improve outcomes in certain patients with difficult-to-treat tumor types such as MSS-CRC observed here.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Clinical Development Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Our clinical development of ADG116 is focused on expanding its safety and efficacy profiles </span>in combination with anti-PD-1 therapy. <span style="color:#333333;">Combination dose expansion cohorts for ADG116 with anti-PD-1 therapy are ongoing for dose optimization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;white-space:pre-wrap;">ADG116 Background:  Mechanism of Action &amp; Preclinical Profile</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have previously conducted extensive preclinical analysis and modeling to establish the safety and efficacy potentials of ADG116, which is also the parental antibody for our masked, anti-CTLA-4 SAFEbody candidate, ADG126.  We have persistently and pursued and implements seamless translational studies using the epitope across different species for both programs, observing a good correlation between preclinical and clinical results both as single agents and in combination with anti-PD-1. Taken together, these preclinical studies (summarized below) have demonstrated that ADG116 has at least a five-fold greater potency profile than ipilimumab, a commercially-available anti-CTLA-4 therapy, and superior activity in various tumor specific models, while its safety profile is at least three-fold better based on GLP monkey data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:322.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG116 is designed to target a unique conserved epitope of CTLA-4. In preclinical studies, ADG116 was observed to have partial CTLA-4 ligand blocking and stronger ADCC for regulatory T-cell depletion than ipilimumab, even with the same Fc isotype. ADG116 has been observed in preclinical animal studies to mediate effector functions to eliminate CTLA-4 highly expressed cells, particularly regulatory T-cells in TME through strong ADCC effect. These actions of ADG116 could lead to enhanced activation and proliferation of tumor infiltrating T-effector cells and reduced T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including an enhanced antitumor immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We extensively evaluated ADG116 in both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> preclinical studies. Our <i style="font-style:italic;">in vivo</i> efficacy studies were conducted in mice, and safety evaluations were conducted in both cynomolgus monkeys and rats. ADG116 was observed to show robust <i style="font-style:italic;">in vivo</i> anti-tumor activity in multiple syngeneic mouse tumor models. Ipilimumab was included as a benchmark and was compared with ADG116 in a series of our preclinical studies. In these preclinical studies, we observed that ADG116 had a potential advantage over ipilimumab in potentiating T-cell activation. While ADG116 has partial CTLA-4 ligand blocking, it was observed to have superior ability in eliminating CTLA-4 positive regulatory T-cells via ADCC in tumors resulting in enhanced antitumor responses. ADG116 was well tolerated in rats and cynomolgus monkeys at doses up to 30 mg/kg in GLP-compliant four-week repeat-dose toxicology studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Pharmacology:</i> We evaluated ADG116 as a monotherapy <i style="font-style:italic;">in vivo</i> in an H22 liver cancer syngeneic mouse model. As shown in the figure below, ADG116 was observed to induce an encouraging antitumor response at low doses in a dose-dependent manner (see figure below on the left). Additionally, ADG116 was observed to inhibit tumor growth of large tumors in the same model (see figure below on the right).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f008.jpg" alt="Graphic" style="display:inline-block;height:322pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:462.1pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.26pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As illustrated in the below figure, in a liver cancer tumor rechallenge study, ADG116 was observed to induce significant antitumor response. Fifty-nine days after the initial tumor inoculation and more than 30 days after the last ADG116 treatment, mice were then rechallenged with the same tumor. We observed that mice that responded to the initial ADG116 treatment remained tumor-free even without additional ADG116 treatment while na&#239;ve mice developed tumors, indicating the development of antitumor memory response elicited by ADG116.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f009.jpg" alt="Graphic" style="display:inline-block;height:219.26pt;width:413.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since ADG116 was observed to exhibit strong ADCC activity <i style="font-style:italic;">in vitro</i>, we evaluated the ability of ADG116 to deplete regulatory T-cells <i style="font-style:italic;">in vivo</i> in a CT26 mouse colon cancer syngeneic model. ADG116 treatment was observed to specifically deplete regulatory T-cells in the tumor, but not in peripheral blood mononuclear cells, or PBMCs, or lymph nodes. The following figure shows significant regulatory T-cell depletion (left figure) and inhibition of CTLA-4 expression (right figure) in tumors by ADG116.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f010.jpg" alt="Graphic" style="display:inline-block;height:159.73pt;width:392.09pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In a series of preclinical studies, we compared the effect of ADG116 to ipilimumab. We believe that these studies suggest that ADG116 has a unique MOA compared to ipilimumab and has a potential advantage over ipilimumab in eliciting antitumor responses. These preclinical trial results support the further clinical evaluation of ADG116 as a monotherapy and in combination with other therapies for a wide range of tumor types.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:276.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the CTLA-4 blockade bioassay illustrated in the figure below on the left, ADG116 was observed to exhibit weaker blocking than ipilimumab of CTLA-4&#8217;s ability to inhibit CD80- and CD86-induced IL-2 production. This result supports our belief that ADG116 can function as a CTLA-4 checkpoint inhibitor with weaker activity than ipilimumab, which may result in less systemic autoimmune side effects on normal tissues. On the other hand, ADG116 was observed to exhibit notably stronger ADCC activity than ipilimumab in the <i style="font-style:italic;">in vitro</i> assay shown in the figure below on the right. Since CTLA-4 is expressed on regulatory T-cells, we believe that ADG116 offers a potential advantage over ipilimumab in depleting regulatory T-cells by means of ADCC. We subsequently investigated this <i style="font-style:italic;">in vivo</i> in a syngeneic mouse tumor model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f011.jpg" alt="Graphic" style="display:inline-block;height:160.35pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:432.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To compare ADG116&#8217;s <i style="font-style:italic;">in vivo</i> antitumor activity to ipilimumab, we utilized a subcutaneous MC38 mouse syngeneic colon cancer model in hCTLA-4, knock-in, or KI, C57BL/6 mice. We selected the hCTLA-4 KI mice as ipilimumab does not cross-react with mouse CTLA-4. As shown in the figure below, ADG116 was observed in this study to exhibit stronger antitumor activity than ipilimumab (ADG116 at 0.2 mg/kg induced equivalent antitumor response as 1 mg/kg of ipilimumab).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f012.jpg" alt="Graphic" style="display:inline-block;height:276.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:320.62pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:246.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the figure below, we measured tumor infiltrating regulatory T-cells in the subcutaneous hCTLA-4 KI MC38 mouse colon cancer model after ADG116 or ipilimumab treatment. Among the TILs, the percentage of regulatory T-cells was observed to be significantly reduced after ADG116 treatment while the regulatory T-cell reduction after ipilimumab treatment was not significant. Notably, we observed that regulatory T-cell depletion by ADG116 occurred only in the TME, and not in PBMCs or the spleen. We believe that these results provide a mechanistic rationale for the enhanced <i style="font-style:italic;">in vivo</i> antitumor activity of ADG116 compared to ipilimumab. ADG116 may reduce the immunosuppressive regulatory T-cell activity specifically in the TME to enhance antitumor immune responses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As illustrated below, in addition to evaluating the efficacy of ADG116 as a monotherapy, we also evaluated ADG116 in combination therapies. ADG116 was observed to have an antitumor effect with an anti-PD-1 treatment in a Lewis lung cancer syngeneic mouse model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also examined the effects of ADG116 in combination with our CD137 agonistic antibody, ADG106, in a B16F10 melanoma syngeneic mouse model. As shown below, we observed that the combination of ADG116 with ADG106 enhanced the antitumor activity compared with ADG116 or ADG106 alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><img src="adag-20221231x20f013.jpg" alt="Graphic" style="display:inline-block;height:246.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:317.62pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Toxicology:</i> We performed preclinical toxicology studies in cynomolgus monkeys and rats to evaluate the toxicity of ADG116. There were no abnormal findings in the single-dose toxicology studies. We observed that ADG116 was well tolerated in both cynomolgus monkeys and rats at up to 200 mg/kg. In a GLP-compliant, four-week repeat-dose toxicology study, ADG116 was tolerated at doses up to 30 mg/kg/dose (five doses per week). In this study, ADG116 related hematology parameter changes, serum chemistry changes, mononuclear infiltration of predominantly lymphocytes with fewer macrophages into the parenchyma of numerous organs were the primary test article-related effects evaluated. These changes were reversible at &#8804; 30 mg/kg/dose, and consistent with the biological role of CTLA-4 in regulating and maintaining peripheral immune tolerance. The NOAEL was considered to be 30 mg/kg/dose in both rats and cynomolgus monkeys.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ADG126 SAFEbody: A Best-in-Class Anti-CTLA-4 Therapy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our most advanced SAFEbody program, ADG126, is a masked fully-human anti-CTLA-4 mAb engineered to address the safety concerns associated with existing CTLA-4 therapeutics, while maintaining potency when locally activated in the TME. It is currently under Phase 1b/2 clinical evaluation in multiple trials in the U.S., China and APAC, both as monotherapy and in combination with anti-PD-1 therapy.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG126 is designed to address the toxicity issues of the approved CTLA-4 immuno-oncology therapy and achieve enhance anti-tumor efficacy to expand the potential of CTLA-4 as a target for the treatment of cancer. It applies our proprietary SAFEbody technology to a parental antibody, ADG116, enabling ADG126 to be activated primarily in tumor tissues rather than healthy tissues, minimizing the risk of on-target, off-tumor toxicities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2022, we presented the first clinical results from our monotherapy evaluation in a poster presentation at the European Society of Medical Oncology (ESMO) annual congress. The data showed a best-in-class safety profile for ADG126 with repeat dosing and anti-tumor activity observed in cold tumors with steady accumulation of activated ADG126. During 2022, we also continued to advance global dose escalation trials of ADG126 in combination with anti-PD-1 therapies. In January 2023, we announced interim findings from these trials showing the combination safety profile and confirmed clinical responses with ADG126 up to 10 mg/kg with repeat cycles in combination with anti-PD-1 from the dose escalation portion of our ongoing phase 1b/2 studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 5pt 0pt;">Detailed dose escalation results from these trials of ADG126 in combination with either toripalimab or pembrolizumab were later presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2023, along with updated findings from our ongoing monotherapy evaluation. In totality, the data support best-in-class safety and differentiated efficacy profiles for ADG126 both as monotherapy and in combination with anti-PD-1, with potential to overcome the safety challenges of anti-CTLA-4 therapy and become a cornerstone of cancer care by its T cell priming and strong Treg depletion in the TME. As our clinical program advances, we expect the best-in-class safety profile of ADG126 to translate into enhanced clinical benefit by dosing ADG126 at higher levels more frequently in combination with anti-PD-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Clinical Studies &amp; Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2021, we initiated a Phase 1 trial of ADG126 (ADG126-1001) as monotherapy to evaluate safety and determine a RP2D in patients with advance metastatic tumors, using a traditional &#8220;3+3&#8221; dose escalation design. A secondary objective of the trial is to evaluate preliminary efficacy based upon anti-tumor activity both as monotherapy and in combination regimens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we initiated a second monotherapy trial of ADG126 following NMPA approval to start an ADG126 Phase 1 trial in China (ADG126-1002), designed to further support our global clinical development program and pave the way for combination studies of ADG126 in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2022, we completed monotherapy dose escalation of ADG126 up to 20 mg/kg in both trials, and we initiated monotherapy dose expansion cohorts at 10 mg/kg in the ADG126-1001 trial. Patients received continuous dosing, and we observed favorable pharmacokinetic activity compared to our unmasked anti-CTLA-4 antibody, ADG116. ADG126 has shown a best-in-class safety profile in clinic, consistent with preclinical evaluation enabled by the broad species cross-reactivity of ADG126, including GLP toxicology data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">In September 2022 and April 2023, we presented these clinical results from our ADG126 monotherapy evaluation at the ESMO and AACR annual meetings, respectively. The presentation at AACR included a larger number of patients (N=30) and further reinforced the compelling, best-in-class safety profile at dosing levels up to 20 mg/kg in a heavily pretreated patient population (majority received &#8805;3 prior lines of therapy) once every three weeks</span><span style="color:#333333;"> with repeat dosing. No Grade 3 or higher TRAEs were reported. </span>The following chart summarizes the most common TRAEs and their incidence <span style="color:#333333;">across dose levels:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="color:#0070c0;font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:163.56pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;">ADG126 Monotherapy: Best-in-class Safety Profile up to 20 mg/kg with Repeat Dosing*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#333333;font-weight:bold;"><img src="adag-20221231x20f014.jpg" alt="Graphic" style="display:inline-block;height:163.56pt;width:313.77pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">* Results as of the 2023 AACR Data Cut-off Date </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Monotherapy data also showed the disease control rate was 37% among 27 evaluable patients across dose levels. Prolonged stable disease was observed in five patients, including an ovarian cancer patient treated at 1 mg/kg with and tumor shrinkage (22% reduction in sum of target lesions) and stable disease observed after 22 cycles. Previously, this patient had surgery and five prior lines of systemic therapies. Additionally, tumor shrinkage (12% reduction in sum of target lesions) was observed in a non-small cell lung cancer patient (NSCLC) who received 14 cycles of ADG126 at 20 mg/kg. Previously, this patient was treated with pembrolizumab and docetaxel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Our monotherapy evaluation of ADG126 has also increased our understanding of its MOA and our masking technology in clinic. For example, at ESMO 2022, we reported that ADG126 plasma pharmacokinetics (PK) were approximately linear and activated ADG126 accumulated steadily during repeat dosing across different dose levels. This analysis suggests prolonged exposures of activated ADG126 in the tumor microenvironment (TME), with cleaved ADG126 on average accumulating &#8805;3-fold during repeat dosing, associated with the longer half-life of total ADG126 compared with its parental antibody.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#333333;">Further, analysis of a clinical sample from a hepatocellular carcinoma (HCC) patient previously treated with atezolizumab and bevacizumab and then followed by lenvatinib demonstrated about nine-fold Teff/Treg improved ratio after dosing relative to before dosing due to reduction in Treg and improvement in T effect cells. These data support the mechanism of action for ADG126 as shown below in data presented at AACR 2023:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;">ADG126 Monotherapy Tumor Biopsy: Case Study Shows Increased Teff / Treg with Treg Depletion in TME of an HCC Patient who Progressed on Atezolizumab + Bevacizumab*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;"><img src="adag-20221231x20f015.jpg" alt="Graphic" style="display:inline-block;height:144.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:370.39pt;" /></b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:175.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">* Data from paired tumor biopsies were collected before and after treatment. Multiplex immunofluorescence analysis was performed by Dr. Joe Yeong&#8217;s lab at IMCB, A*STAR. Images were analyzed using HALO. Tregs were defined as Foxp3+ CD8- cells. Teff cells were defined as CD8+ T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2022, we also advanced our phase 1b/2 combination trials for ADG126 with anti-PD-1. In March 2022, we received clearance from the FDA to initiate a new Phase 1b/2 trial to evaluate ADG126 in combination with pembrolizumab (ADG126-P001/KEYNOTE-C98). We are conducting the trial at multiple sites in the U.S. and APAC. In parallel, as part of the ongoing ADG126-1001 trial, a combination dose escalation was initiated to evaluate ADG126 with toripalimab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2023, we presented data from the dose escalation portion of these studies of ADG126 in combination with anti-PD-1 treatments at AACR. The results reinforced the best-in-class safety profile of ADG126 at doses from 6 mg/kg up to 10 mg/kg. The combination was well tolerated with no dose-limiting toxicities observed with repeat cycles, including in patients who received four or more cycles in the combination cohort with toripalimab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Across 31 patients in combination dose escalation cohorts of ADG126, a total of seven (22.6%) Grade 3 TRAEs were reported, suggesting a safety profile comparable to anti-PD-1 monotherapy and a best-in-class safety profile in combination with anti-PD-1, even at much higher doses. This has been achieved without aggressive safety management for immune-mediated diarrhea/colitis, such as infliximab infusion<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following charts summarize the safety profile from our studies of ADG126 with two different anti-PD-1 therapies, toripalimab and pembrolizumab, as presented in posters at AACR 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#0070c0;font-weight:bold;">Combination Safety: TRAEs for ADG126 with Toripalimab (N=20)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f016.jpg" alt="Graphic" style="display:inline-block;height:140.19pt;width:293.04pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="color:#0070c0;font-weight:bold;">Combination Safety: TRAEs for ADG126 with Pembrolizumab (N=11)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="adag-20221231x20f017.jpg" alt="Graphic" style="display:inline-block;height:174.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:241.2pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The early efficacy profile of ADG126 was also demonstrated in these heavily pre-treated patient groups, with clinical responses and tumor shrinkage observed during combination dose escalation. Data presented at AACR summarize patient case studies demonstrating clinical benefit, including three confirmed partial responses and multiple cases of prolonged stable disease with tumor shrinkage in patients who received ADG126 plus anti-PD-1 therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of note, two cases of significant tumor shrinkage (20% reduction and higher in target lesions) were observed in MSS CRC patients with liver metastasis who received ADG126 plus toripalimab. This aligns with anti-tumor activity in MSS CRC shown with ADG116 NEObody in combination with anti-PD-1 therapy showing reductions in CEA levels. Overall, the results further support our ongoing combination dose expansion cohorts evaluating ADG126 in combination with anti-PD-1 in this indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At AACR, partial responses were reported in two patients with anal and penile squamous cell carcinoma who received ADG126 plus toripalimab; the patients experienced 36% and 72% reductions in sum of target lesions, respectively. A third partial response was reported in a patient with metastatic endometrial cancer (MSI-H) who received ADG126 plus pembrolizumab and experienced a 37% reduction in target lesions. All three patients were treated at the 10 mg/kg dose administered every three weeks (Q3W).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2023, after the AACR Data Cut-off, an additional (initial) partial response was reported in an IO-experienced cervical cancer patient who was previously treated with two lines of therapy and had progressed after nine cycles of pembrolizumab (CPS = 1; TMB =24).The patient experienced no Grade 3 or higher TRAEs and showed a 30% reduction in target lesions at the end of eight cycles of treatment with ADG126 (10 mg/kg Q3W) and pembrolizumab (200 mg Q3W), following earlier observation of 13% tumor shrinkage as reported at AACR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The robust safety of masked anti-CTLA-4 enables continuous dosing with anti-CTLA-4 or ADG126 therapy in combination with anti-PD-1 to drive the efficacy in patients in PD-L1 low expression and PD-1 resistant anti-CTLA-4 therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our clinical development of ADG126 is focused on expanding its safety and efficacy profile in combination with anti-PD-1 therapy. Combination dose expansion cohorts for ADG116 with anti-PD-1 therapies are ongoing, including in MSS CRC to establish proof-of-concept. Additionally, our clinical collaboration with Roche is enabling a randomized, phase 1b/2 clinical trial to evaluate ADG126 in a triple combination in first-line HCC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">ADG126 Background: Mechanism of Action &amp; Preclinical Profile</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG126 is a fully human anti-CTLA-4 mAb. The masking moiety in ADG126 functions to block the interaction between ADG126 and its target CTLA-4 protein. Once ADG126 enters the TME, proteases overexpressed in the TME cleave off the masking moiety, and the antibody is then activated, binding to CTLA-4 and inhibiting its function. ADG126 is locally activated specifically in the TME, rather than systemically, to stimulate antitumor immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In preclinical studies, we observed that ADG126 had an enhanced therapeutic window and improved safety features. Furthermore, in PD studies of ADG126, it was observed that while the CTLA-4 binding affinity was masked in an intact ADG126 antibody, once the masking peptide was cleaved off of ADG126, its high binding affinity to CTLA-4 was restored. In preclinical studies, ADG126 was tolerated at doses of up to 200 mg/kg in nonhuman primate models. We believe the encouraging preclinical tolerability of ADG126 suggests its potential in combination with other immunotherapies such as an anti-PD-1/PD-L1 antibody or an anti-CD137 antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that activated ADG126 potentiates T-cell immune response by blocking the inhibitory effect of CTLA-4. ADG126/ADG116 is designed to target CTLA-4 conserved epitope with species cross-reactivity for translational fidelity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:277.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="adag-20221231x20f018.jpg" alt="Graphic" style="display:inline-block;height:147.61pt;width:166.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, ADG126 has been observed in preclinical animal studies to mediate effector functions to eliminate highly upregulated CTLA-4 expressing cells, particularly regulatory T-cells in the TME, primarily through its strong ADCC. These actions of ADG126 could lead to enhanced activation and proliferation of tumor infiltrating T-effector cells and reduced T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including an enhanced antitumor immune response. The below diagram illustrates the MOA of activated ADG126.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="adag-20221231x20f019.jpg" alt="Graphic" style="display:inline-block;height:277.25pt;left:0%;padding-bottom:0.25pt;position:relative;top:0pt;width:467.11pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;ADCP&#8221; refers to antibody-dependent cell-mediated phagocytosis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;MHC&#8221; refers to major histocompatibility complex;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8220;TCR&#8217;&#8217; refers to T-cell receptor;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-style:italic;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Pharmacology</i><b style="font-weight:bold;">: </b>We observed in PD studies that ADG126, in its intact SAFEbody form, bound weakly to CTLA-4. However, once the proteases cleaved off the masking peptide, ADG126 was activated and bound at a high affinity to human, cynomolgus monkey and mouse CTLA-4, as shown in the figures below. Activated ADG126 was observed to lead to the release of CD80/CD86 ligands from CTLA-4 sequestration, and stimulation of CD28 signaling to boost T-cell activity. It also targets regulatory T-cells for depletion within the TME by means of ADCC, to mediate antitumor T-cell immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f020.jpg" alt="Graphic" style="display:inline-block;height:280.35pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:462.1pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We evaluated the <i style="font-style:italic;">in vivo </i>antitumor efficacy of ADG126 in syngeneic mouse tumor models. As shown in the figures below, in these studies, ADG126 was observed to inhibit tumor growth in different mouse tumor models as a monotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f021.jpg" alt="Graphic" style="display:inline-block;height:179.26pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:400.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As shown in the figure below, ADG126 synergized with an anti-PD-1 antibody to elicit a stronger anti-tumor response than ADG126 or the anti-PD-1 antibody alone in a Lewis lung cancer model.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:161.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f022.jpg" alt="Graphic" style="display:inline-block;height:161.2pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:351.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG126 treatment was observed to specifically deplete regulatory T-cells in the tumor, but not in peripheral tissues. The following figures illustrate the reduction of CTLA-4 expression in infiltrating lymphocytes, or TILs (see figure below on the left) and regulatory T-cell depletion (see figure below on the right) by ADG126 in CT26 tumor model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f023.jpg" alt="Graphic" style="display:inline-block;height:150.93pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:408.9pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Note: &quot;Treg&quot; refers to regulatory T-cells</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Toxicology: </i>We performed preclinical toxicology studies designed to assess the toxicity features of ADG126. We selected cynomolgus monkeys and mice as toxicology species for animal toxicity evaluation. No abnormal findings attributable to ADG126 were observed. We utilized a nonobese diabetic mouse model to determine percentage of survival with AD126 treatment. All mice survived after six treatments of ADG126 at 50 mg/kg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In a four-week GLP repeat-dose toxicology studies, intravenous infusion of ADG126 to cynomolgus monkeys at 5, 30, or 200 mg/kg/dose once weekly for five doses followed by a 28-day recovery period was well-tolerated. Adverse, but reversible, microscopic findings of minimal to moderate mixed perivascular infiltrates were observed at 200 mg/kg in both sexes in the kidney, liver, pancreas, epididymis, skin, and were observed in the ovaries in females, and the connective tissue associated with the mesenteric lymph node and thyroid gland. The NOAEL was considered to be 30 mg/kg/dose and the highest non-severely toxic dose was considered to be 200 mg/kg/dose.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:195.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">About CD137 </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CD137 stimulates the immune system to attack cancer cells and is a key driver for T-cell and natural killer cell, or NK cell, proliferation. ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like binding and cross-linking by Fcy receptors. The broad species cross-reactivity of ADG106 observed in preclinical studies has enabled us to explore robust translational studies concerning the biology of CD137 in mouse, rat, nonhuman primate, and human, especially for anti-CD137 as a single agent and in combination therapies in immuno-competent syngeneic tumor models. CD137 is a member of the tumor necrosis factor, or TNF, receptor superfamily. The binding of an antibody to this receptor induces a co-stimulatory signal on activated enhanced cytotoxic T lymphocyte, or CD8+ T-cells, and natural killer, or NK cells, resulting in proliferation, and increased pro-inflammatory cytokine secretion and cytolytic function. CD137 co-stimulation is a clinically validated pathway for T-cell activation and its antitumor response is highlighted by the approval of a CD137-targeting CAR-T therapy by the FDA. Because most tumors are killed by cytotoxic T-cells in an antigen specific manner, we believe agents that mediate CD8+ T-cell activation can impart strong cytolytic activity. Therefore, we believe that CD137 agonists are promising candidates with potential to enhance and mediate long lasting antitumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">CD137: Our Solution</i><span style="display:inline-block;width:3.33pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our two anti-CD137 antibody candidates target a unique epitope of CD137 to balance the safety and efficacy of anti-CD137 therapies (see figure below). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like binding. ADG106 has not been observed to bind to unstimulated naive T-cells, which have no detectable level of CD137 expression. ADG106 is also designed to bind to activated NK cells to boost their cytotoxic and ADCC functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 can also mediate cross-linking via Fc receptors, which are critical for its activity. Our next generation anti-CD137, ADG206 IgG1 POWERbody features Fc-engineering to enhance the cross-linking. With further addition of our SAFEbody precision masking technology, ADG206 is poised to power the efficacy of anti-CD137 therapies (4-fold higher preclinical potency than urelumab analog), while ensuring the safety via conditional activation by pushing the boundaries of prior anti-CD137 agonistic approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="color:#0070c0;font-weight:bold;">ADG 106/206 target a unique epitope of CD137/4-1BB pathway validated by CAR-T</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="adag-20221231x20f024.jpg" alt="Graphic" style="display:inline-block;height:195.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:207.79pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">ADG106 NEObody: A Novel Agonistic Anti-CD137</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106, is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb generated using our NEObody technology to target a unique conserved epitope of CD137. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We previously completed two Phase 1 clinical trials, ADG106-1001 and ADG106-1002, in the U.S. and China, respectively, evaluating ADG106 as monotherapy in a total of 98 patients with advanced or metastatic solid tumors and/or NHL. Our results demonstrated that ADG106 had a well-tolerated safety profile and evidence of single-agent efficacy profile. In preclinical studies, we also observed that ADG106 had encouraging antitumor activity and was well tolerated as a monotherapy and had additive or synergistic effects in combination with the existing standard-of-care, or SOC, and other immuno-oncology therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As monotherapy, ADG106 was well-tolerated at doses of 3 and 5 mg/kg, and at 300 mg and 400 mg flat doses. We also observed tumor shrinkage in some patients, including one patient with nasopharyngeal cancer (NPC) who previously failed multiple therapies and showed a partial response to ADG106 treatment with a 40% tumor size reduction. In addition, two NHL patients showed more than a 30% tumor size reduction. Overall, we observed a significant disease control rate of 56% (45 among 81 patients) for anti-CD137 monotherapy with robust safety profiles, including tumor size reductions in the multiple patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Importantly, across all dose cohorts in both trials, we observed three patients with &#8805; Grade 3 liver enzyme increase; among them, two patients with &#8805;Grade 3 AST increase enrolled in ADG106-1001 (treated at 10 mg/kg and 300 mg fixed dose levels), including one patient who had abnormal baseline liver enzyme exhibited Grade 3 AST increase, and one patient enrolled in ADG106-1002 with abnormal liver enzyme baseline showed a Grade 3 AST and ALT liver enzyme increase (treated at 5 mg/kg). These liver enzyme increases were not observed to be dose-dependent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Clinical Summary: Focus on Investigator-Initiated Trials in Combination Settings</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 is now being evaluated in combination settings in two investigator-initiated trials. The studies are supported by the combined findings of our phase 1 monotherapy trials, data from our extensive preclinical studies, as well as PD marker-based modelling from our prior and ongoing trials. These clinical results indicate that targeting the unique and highly conserved epitope of CD137 by ADG106/ ADG206 has the potential to balance safety and efficacy, thereby addressing the limitations of other existing anti-CD137 agonists that target very different epitopes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Previously, we evaluated clinical safety and efficacy profiles of ADG106 in combination with anti-PD-1 therapy in patients with advanced solid tumors and relapsed or refractory NHL. Results from the Phase 1b/2 trial in China (ADG106-1008) showed one observed partial response in an NPC patient out of 20 patients enrolled. In August 2022, we announced plans to wind down the ADG106-1008 trial, given prioritization of our anti-CTLA-4 programs and potential of our next generation anti-CD137 therapy, ADG206.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also observed dose dependent sCD137 changes in blood samples of patients treated by ADG106 in combination with anti-PD-1, further supporting its potential in combination and consistent with observation by other clinical studies. The semi-quantitative analysis and studies conducted suggest the increase of plasma sCD137 or its induction ratio of induced sCD137 over the baseline value is associated with the clinical benefits of NPC patients from stable disease to partial response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2021, we announced an investigator-initiated trial with the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in collaboration with the Singapore Translational Cancer Consortium to evaluate ADG106 with another anti-PD-1, nivolumab, in patients with advanced non-small cell lung cancer (NSCLC). The Phase 1b/2 open label trial (ADG106-T6001) is designed to evaluate safety, tolerability, and anti-tumor activity of the combination in up to 53 patients with advanced NSCLC who have progressed after prior treatment. In January 2022, we reported that the trial had enrolled and dosed the first patients. The trial is currently ongoing as of the date of this annual report with plans to present interim results at an upcoming medical conference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in August 2022, we announced a second investigator-initiated trial with the Singapore research consortium. The Phase 1b/2 clinical trial (ADG106-T6002) is evaluating ADG106 in combination with neoadjuvant chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel) in up to 66 patients with early-stage, HER2 negative breast cancer. The trial is currently ongoing as of the date of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">ADG206 POWERbody: A Masked, IgG1 FC-engineered Next Generation Anti-CD137 Therapy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG206 is designed to solve the safety and efficacy challenges of anti-CD137 therapy, leveraging the same novel epitope as ADG106 and learnings from development of urelumab (another company&#8217;s anti-CD137 targeting antibody), which showed single agent clinical efficacy and dose-dependent liver toxicity in clinic.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April 2022, we announced preclinical data showing how this, Fc-engineered anti-CD137 agonistic POWERbody incorporates SAFEbody&#174; precision masking technology for conditional activation and is designed to achieve improved safety and efficacy. We reported data from preclinical studies demonstrating that the FcgR-mediated crosslinking of ADG206 in IgG1 format enhances T-cell responses and antitumor activity, while the SAFEbody masking technology secures its activation in the TME to limit on-target off-tumor toxicities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical data demonstrated that ADG206 was well tolerated, with normal pharmacokinetic properties and minimal activation in circulation. It also had robust anti-tumor activity as a single agent in multiple tumor models, with 4-fold stronger anti-CD137 agonistic activity of its activated form than a benchmark antibody (analog of urelumab), which is one of the most potent anti-CD137 agonists in development for T-cell co-activation that has demonstrated clinical activity as a single agent but has also shown dose-dependent liver toxicity. ADG206 demonstrated enhanced anti-tumor activity as a single agent and in combination with other checkpoint inhibitors, including anti-PD-1 or anti-CTLA-4 therapy. We believe that the safety and efficacy profiles of ADG206 strongly supports its potential as a combination agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2022, following completion of IND enabling studies, we submitted a Human Research Ethics Committee (HREC) regulatory filing in Australia to advance this anti-CD137 POWERbody&#8482;, ADG206, into a phase 1 clinical trial in patients with advanced metastatic solid tumors. We have subsequently initiated dosing of the first patient in a phase 1 trial evaluating safety, efficacy and tolerability profiles for ADG206 POWERbody in patients with advanced/metastatic tumors. This next generation anti-CD137 candidate is the first POWERbody candidate to advance into clinic, combining precision masking, Fc-engineering and targeting of a unique epitope to solve the safety and efficacy challenges of anti-CD137 therapies. The phase 1 trial is currently ongoing; pending monotherapy dose escalation results, evaluation in combination settings is planned. For example, it is biologically compelling to combine clinically safe and potent anti-CD137 and anti-CTLA-4 therapies for their synergistic anti-tumor efficacy, but also to ameliorate the toxicity of each monotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">IND-READY CANDIDATES &amp; PRECLINICAL PIPELINE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our clinical-stage product candidates, we have several IND-ready preclinical candidates and have built a deep, broad and differentiated preclinical pipeline with potential first and best-in-class programs. These programs are in various stages of drug discovery and preclinical evaluation utilizing our three DPL platform technologies NEObody, SAFEbody, and POWERbody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have multiple differentiated programs undergoing IND-enabling studies, each with robust CMC profiles and compelling preclinical safety and efficacy data. In December 2021, we disclosed the first two of these candidates, ADG152 and ADG153, and reported preclinical data at the American Society of Hematology (ASH) annual meeting. <span style="background:#ffffff;">In March 2022, we introduced two additional programs, ADG206 (later advanced into clinical stage) and ADG138, and reported data demonstrating their first and best-in-class potential in conjunction with the American Association for Cancer Research (AACR) annual meeting. </span>Additionally, at AACR 2022, we introduced a new capability for our<span style="background:#ffffff;"> proprietary bispecific T-cell engagers (TCEs)&#160;targeting CD28, which we believe offers a new paradigm and novel approach to overcome the challenges of this target by combining a unique, highly conserved epitope, with our precision masking technology and a tumor antigen targeted TCE for local activation. At AACR 2022, we also presented data for these preclinical candidates to be used as monotherapies or in combination with our CD3 TCEs to achieve</span><i style="font-style:italic;background:#ffffff;"> </i><span style="color:#333333;">safe, powerful and durable immunotherapy</span><i style="font-style:italic;background:#ffffff;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Additionally, at AACR in April 2023, we presented an additional poster on ADG153, with more comprehensive data showing the candidate&#8217;s anti-tumor activity in solid tumor models, as well as target engagement in the tumor microenvironment.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary of our pipeline of preclinical programs follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG153:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This masked anti-CD47 IgG1 SAFEbody is differentiated by the novel epitope it recognizes, its strong antibody-dependent cellular cytot</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">oxicity (ADCC)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> antibody-dependent cellular phagocytosis (ADCP) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activity, and precision masking for conditional activation. It is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">designed to realize the full potential of anti-CD47 therapy for both hematologic and solid tumor indications. ADG153 targets a unique epitope with reduced hemagglutination activities in comparison with two benchmark antibodies. It incorporates SAFEbody masking technology to limit on-target off-tumor toxicities and overcome the known safety liabilities of anti-CD47 therapies. The safety mask prevents its rapid clearance by CD47 directed antigen sink effect. </span><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical data demonstrated that ADG153 IgG1 was well tolerated, did not induce human hemagglutination and significantly reduced anemia-related and antigen sink liabilities. In particular, ADG153 IgG1 at a 10 mg/kg dose demonstrated only an 8 percent decrease in red blood cell counts, compared to a 49 percent decrease with a benchmark antibody which is in IgG4 format (analog of magrolimab). </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After a single intravenous dose, ADG153 IgG1 demonstrated an approximately 8-fold longer apparent half-life and 5-fold higher area under the curve (AUC) at 10mg/kg than the benchmark. </span><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results also showed that ADG153 IgG1 demonstrated greater anti-tumor activity than the benchmark</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">We believe it is the first anti-CD47 antibody in IgG1 isotype that shows strong ADCC and ADCP effects for tumor killing without serious safety liabilities.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG153 is currently in the IND-enabling phase.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG138</i><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: This novel HER2xCD3 POWERbody is masked on both arms with an impressively high therapeutic index relative to its parental non-masked TCE in both HER2 high and low expressing solid tumors including HER2 high resistant/refractory tumors relative to a benchmark antibody (DS-8201, a HER2 targeting antibody drug conjugate commercially available in specific indications). ADG138 preclinical data support its development for HER2-expressing solid tumors as a single agent and in combination with other immune modulating agents. Preclinical data demonstrated the excellent safety profile of ADG138, including 100-fold greater reduction in cytokine release compared to its parental TCE. Results showed that ADG138 has potent anti-tumor activity in HER2 high and low expressing tumors, as well as resistant/refractory tumors. ADG138 also had synergistic anti-tumor activity in HER2 positive tumors when combined with anti-CD137 or anti-PD-1 therapy, or tumor targeted CD28 bispecific antibody. ADG138 is currently in the IND-enabling phase.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG152: </i><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This CD20xCD3 POWERbody integrates the company&#8217;s proprietary bispecific TCE platform with SAFEbody precision masking technology to minimize cytokine release syndrome (CRS) and on-target off-tumor toxicities for an increased therapeutic index. The anti-CD20 arm of ADG152 has enhanced the binding to CD20, while its anti-CD3 arm has tailor made affinity for CD3 using SAFEbody technology. In comparison with a benchmarked antibody in clinical development (analog of plamotumab), ADG152 showed improved safety with cytokine release control even at a 100-fold higher dose than the benchmarked antibody analog and 2- to 3-fold prolonged half-life than the benchmarked antibody analog in exploratory preclinical monkey studies. In preclinical mouse xenograft tumor models, ADG152 demonstrated strong and sustained anti-tumor activity, with almost complete tumor growth inhibition when dosed at 1.5 mg/kg. ADG152 is currently in the IND-enabling phase.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">CD28 T-cell engagers: </i><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are developing anti-CD28 bispecific POWERbody TCEs that exhibit enormous potential to fulfill the promises of safe and durable T-cell mediated synergistic immunotherapies when combined with CD3 bispecific POWERbody TCEs and/or checkpoint inhibitors. Enabled by our suite of antibody platform technologies, preclinical data demonstrated the potential to mitigate the serious safety concerns of CD28 activation and make custom designed antibodies targeting a highly conserved epitope with broad species reactivity. We currently have multiple tumor associated antigen (TAA)xCD28&#160;POWERbodies in preclinical development, such as B7-H3xCD28 and HER2xCD28, which can also be combined with our CD3 TCEs to achieve safe, powerful and durable immunotherapy for solid tumors through combination of the fundamental mechanisms and pathways across the cancer immunity cycle.&#160;&#160;For the avoidance of doubt, as of the date of this annual report, the CD28 T-cell engagers have not entered into </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IND-enabling stage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OUR PLATFORM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our proprietary DPL platform is built upon our insights into precise and dynamic antibody-antigen interaction. As such, our DPL platform has been designed to enable the discovery of antibodies with better developability properties. By addressing the challenges in traditional antibody design and engineering, we believe that our DPL platform will enable us to improve the efficacy and safety profile of antibody therapeutics. Our DPL platform is empowered by our computational platform, artificial intelligence and three innovative technologies: NEObody, SAFEbody, and POWERbody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Life is motion</i>: <i style="font-style:italic;">Harnessing the Dynamic Power of Antibodies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The motion of proteins and their dynamic interactions trigger a cascade of complex biological and pharmacological effects. Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino acid sequence can adopt multiple structures and functions. Our approach recognizes that a protein&#8217;s native state is not accurately represented by a single static structure but rather by a variety of structures in dynamic equilibrium, resulting in a high level of functional diversity, in contrast to the conventional static antibody drug discovery paradigm of &#8220;one sequence, one structure and one function.&#8221; We have developed our proprietary AI-Powered DPL platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of antibody sequences in particular, as a new paradigm for antibody drug discovery. Our DPL platform combines artificial intelligence, or AI, algorithms and ever-increasing big data in antibody sequence, structure, binding epitope and affinity from public and our own proprietary databases to design, construct and screen high-quality proprietary antibody libraries with well-defined sequence, scaffold and biophysical attributes for antibody drug discovery. Powered by computational physics in combination with AI and big data, our DPL platform samples a potentially infinite number of dynamic binding interface structures arising from the conformational diversity of a finite number of antibody amino acid sequences, allowing us to exponentially expand the universe of candidate antibody binding sites far beyond conventional natural or synthetic antibody repertoires. By exploiting conformational diversity, we have designed and precisely constructed approximately one trillion (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an antibody) coverage and robust chemistry, manufacturing, and control, or CMC, attributes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe our AI-powered antibody discovery and engineering DPL platform significantly increase R&amp;D productivity for antibody drug discovery, as illustrated by our clinical and preclinical pipeline. For example, DPL library screening against CTLA-4 or CD137 antigens has yielded a large number of high affinity primary hits. The abundant discovery hits with diversified binding epitopes show the power of our AI-powered DPL platform not only in creating novel antibodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across different species of a given antigen with broad species cross-reactivity from human, monkey to mouse, which enables us to study their efficacy and safety in extensive immuno-competent or syngeneic animal models, to explore their pharmacodynamics and predictive biomarkers in responding vs nonresponding tumor models in vivo, and to understand their deep target biology and novel MOA before testing them in human clinical trials to look for their clinical signals consistent with their MOA. Our DPL platform empowers us to engage the dynamic epitope of the conformationally dynamic target which might be challenging using conventional antibody discovery approaches. We believe that the high-affinity and cross-reactive primary hits from our AI-Powered DPL library screening save time and cost from discovery to early clinical proof of concept. The broad species cross-reactivity of the primary hits also streamlines lead identification and potentially enables high fidelity translation from preclinical to clinical studies. Furthermore, we believe our AI-powered dynamic precision library expands the diversity at the start of discovery to maximize the chance that suitable leads are found on the first pass.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Translational fidelity from preclinical modeling to informed clinical development is one of the top challenges to developing cancer immunotherapies. Most traditionally developed antibodies do not cross react between their human and murine targets due to their limited species cross-reactivity, making it very difficult to reliably evaluate the same antibody in both the preclinical and clinical settings. Some of the most contentious issues related to preclinical and clinical studies of the targets of our clinical-stage product candidates, immunotherapies are traceable to the differences between the antibodies used for preclinical and clinical studies. For example, we believe our clinical stage anti-CTLA-4 and anti-CD137 candidates bind to different epitopes and exhibit dramatic differences in their respective clinical safety and efficacy results, underscoring the importance of finding suitable species cross-reactive antibodies like those we have utilized for comprehensive preclinical evaluation before entering clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that it is essential to model the interactions between tumors and an intact host immune system <i style="font-style:italic;">in vivo </i>to evaluate the therapeutic potential of antibodies in preclinical studies. The flexibility of antibody binding interface is fundamental to the NEObody technology of our DPL Platform and allows us to generate species cross-reactive antibodies to assess the safety and efficacy potential of mono- and combination therapy candidates in syngeneic animal models before launching clinical trials. We use syngenic animal models which are known for their intact <i style="font-style:italic;">in vivo </i>immune systems to provide the original proof of concept for cancer immunotherapies by blocking immune check points with monoclonal antibodies, or mAbs. We believe that the use of species cross-reactive antibodies, rather than surrogate antibodies used in traditional syngeneic mouse models, should facilitate the translational relevance and clinical utility of these well-established preclinical models for determining optimal dose, schedule, sequencing, combination synergy, risk and benefit features. The results from the assessment of new species cross-reactive antibodies in rigorous preclinical models may allow us to control the scope and cost of clinical trials, enable the identification of potential clinical biomarkers useful to monitor clinical pharmacological and safety signals, and help preselect patients for precision mono- and combination therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">AI-Powered Antibody Discovery</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that efficient drug discovery requires significant commitment to resolve three key challenges: 1) the selection of targets with preclinical and/or clinical validation; 2) the availability of abundant hits at discovery stage for the identification of Pre-Clinical Candidates, or PCC, that usually takes a highly iterative process from target-to-hits, lead identification and lead optimization; and 3) deep understanding of target biology and MOA from detailed molecular, cellular, <i style="font-style:italic;">in vivo </i>preclinical and human disease models. To address these challenges and to improve antibody R&amp;D productivity, we have designed and built our AI-powered DPL platform to provide sufficient discovery capacity, capable of generating abundant high quality hits against targets, and then selecting the right leads for extensive preclinical testing in order to understand their MOAs, their efficacy and safety potential before going for clinical proof of concept testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that it is critical to pair the right PCC with the specific epitope of a chosen target. The affinity and precise orientation by which the specific epitope of a given target is engaged by the PCC can have a profound impact on the pharmacology and toxicity of drug candidate. Therefore, we believe precision design and engineering of antibody-based drugs make a fundamental difference on the success of a drug discovery program. As demonstrated by extensive preclinical and early clinical data for our three clinical programs targeting a conserved epitope, across humans, monkeys and mice can give rise to novel biological and pharmacological activities. The broad species cross-reactivity of our candidates can facilitate seamless translational studies from different immune-competent syngeneic tumor models to monkeys, and then subsequent clinical trials in humans. The novel MOA and biology concerning targets such as CTLA-4 and CD137 include their regulation in peripheral and tumor microenvironments, the involvement of different immune cells upon target engagement such as T-regulatory cells by anti-CTLA-4 specific antibodies ADG116 and ADG126 and NK cells by anti-CD137 ADG106. We believe these examples provide strong support for our proposal to search for &#8220;The Right PCC&#8221; that is paired with the specific epitope of a given target in order to unlock the biology of such target and its pathway and to facilitate a deep understanding of its MOA in triggering a cascade of biological and pharmacological events leading to disease control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to search for &#8220;The Right PCC,&#8221; our proprietary DPL platform uses a deep learning approach to explore the conformational diversity of antibody binding sites. Our DPL platform combines AI algorithms and ever-increasing big data in antibody sequence, structure, and binding epitope and affinity from public and our own proprietary databases to design, construct and screen high-quality proprietary antibody libraries with well-defined sequence, scaffold and biophysical attributes for antibody drug discovery. Our computational engine combines software, AI and visualization tools to mine, organize, compute, and interactively explore these immense multidimensional big data sets. We iteratively inform wetlab experimentation with <i style="font-style:italic;">in silico </i>computation, and vice versa. By exploiting conformational diversity through the combination of our proprietary computational algorithms with AI, we have designed and precisely constructed approximately one trillion (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an antibody) coverage and robust CMC attributes. The antibodies discovered can be further engineered into NEObody, SAFEbody and POWERbody antibodies depending on the targeted product profile of a given therapeutic target.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our three clinical programs illustrate how our AI-powered DPL platform has improved our R&amp;D productivity. Our DPL library is a large physical phage library (~10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) that contain our AI-powered synthetic designer antibodies with flexible antibody binding interface. The combination of binding interface flexibility with the variation of amino acid sequences in the antigen binding interface exponentially increases the conformational diversity of our AI-powered DPL libraries, far beyond conventional natural or synthetic antibody libraries. Our AI-Powered DPL library screening against target antigens have yielded a large number of high affinity primary hits. For example, the anti-CTLA-4 antibody ADG116, was identified from 74 high affinity primary hits with a wide range of epitope diversity in terms of their species cross-reactivities: 19 clones are human, monkey, canine and mouse cross-reactive; 12 clones are human and monkey cross reactive but weak mouse cross-reactive; 32 clones are human and monkey cross-reactive; 11 clones only recognize human CTLA-4. The abundant discovery hits with diversified binding epitopes for varying degree of species cross-reactivity show the power of our AI-powered DPL platform not only in creating novel NEObodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across different species of a given antigen to enable translational studies from immune-competent animal tumor models to human patients due to their broad species cross-reactivities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the high affinity and species cross-reactive primary hits from our DPL library screening saves time and cost from primary hits to straight PCC. The broad species cross-reactivity of the primary hits also streamlines lead identification through simple syngeneic tumor models for safety and efficacy testing. The robust CMC attributes of our DPL library are designed to also eliminate the requirement to optimize antibody sequences before starting CMC process for IND enabling and formulation studies. Furthermore, we believe our AI-powered dynamic precision library of approximately one trillion (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) antibody sequences expands the diversity at the start of discovery to maximize the chance that suitable leads are found on the first pass. In conclusion, we believe our AI-powered antibody discovery and engineering DPL platform significantly increases R&amp;D productivity for antibody drug discovery. It has enabled us to generate highly differentiated PCC molecules that we believe can target the conserved epitope across different species for novel MOAs and also facilitate seamless translational studies from animals to human via their broad species cross-reactivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Briefly, our AI-powered antibody discovery engine includes six steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">First principle of antibody folding and dynamics. We fold the antibody primary amino acid sequence into three-dimensional structures based on machine learning or homology modeling in combination with the Molecular Dynamic Simulation in the presence and absence of dynamic interaction with their antigen targets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered deep learning of antibody sequence and structure and binding epitopes. AI algorithm and machine learning have been widely used to map protein sequence and structure variation and connectivity. Deep learning has been used to map the antibody and antigen epitope in order to learn the landscape of the epitope space and their correlation with antibody binding interface.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibody design that combines the conformational diversity with primary amino acid sequence variation. We have designed antibody libraries that contain dynamic binding units and their combination in the context of different CDRs and framework scaffold to capture their conformational diversity of antibody binding interface in combination with variation in primary amino acid sequences far beyond conventional natural or synthetic antibody libraries.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Synthetic dynamic precision library by AI-powered computational design. The amino acid sequence library is converted into synthetic DNAs that can be assembled and constructed for phage and yeast library screening.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Directed evolution by phage and yeast libraries. The synthetic phage and yeast libraries can be screened semi-automatically for more than 100 antigens to yield high affinity primary hits.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PCC identification by targeting conserved epitope with broad species cross-reactivity to unlock the deep biology of target and its MOA upon target engagement by the PCC. PCC is designed and selected to target the conserved epitope of a given target across different species. Traditionally, affinity of primary hits from synthetic antibody libraries have to be improved before subjecting them to extensive in vitro and in vivo assays for lead identification and optimization through an iterative process between functional assays and antibody engineering. Our DPL platform can yield high affinity primary hits, which can then become product candidate leads subject to functional characterization without intensive iterative lead optimization process.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:232.56pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following diagram illustrates how AI algorithms and big data empower rapid antibody discovery with improved productivity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f025.jpg" alt="Graphic" style="display:inline-block;height:232.56pt;width:442.89pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">NEObody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NEObody technology is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic antibody technologies through its innovative designs and precise constructions. Our designs are based on critical insights gained from extensive studies of antibody structural variability made possible by our proprietary in-house developed computational tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovative antibody library design: </b>We believe that diversity of an antibody library should be defined at the quaternary structural level, instead of the traditional primary amino acid sequence level. Comparison of structural and sequence diversity revealed that variability as assessed by structural alignments was generally lower than the variability observed with sequence alignments. Based on our deep understanding of chemical principles governing antibody folding and extensive analysis of a vast number of antibody structural variability, through novel statistical tools developed in-house, we have redefined the antibody hyper-variable regions, or HVRs, that are critical for antigen recognition. These HVRs, as defined based on structural variability, are distinct from but complementary with complementarity-determining regions that are traditionally defined based on amino acid sequence variability. In addition, we have defined and designed dynamic motifs which adopt multiple conformations and incorporated them into our DPL antibody library design to enable the coverage of a wide range of structural diversity with a limited number of amino acid sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Broad epitope coverage, particularly of evolutionarily conserved epitopes: </b>NEObody technology enables us to discover antibodies targeting numerous epitopes against a broad range of antigens. In particular, we focus on the antibodies targeting the conserved epitopes of divergent antigens. These species cross-reactive antibodies not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical to clinical studies. Our NEObody technology has been evaluated in preclinical studies with numerous antigens, including some difficult antigens such as membrane or oligomeric proteins. The success criteria in our preclinical assays include high affinity of primary hits with diverse antibody sequences, broad epitope coverage, as well as favorable CMC development properties. For example, ADG106 was discovered using our NEObody technology to target a conserved epitope of CD137 that mostly overlaps with its ligand binding site, which we believe enables ADG106 to activate CD137 in its natural ligand-like fashion, with complete blocking of CD137L, which may differentiate it from two other investigational leading CD137 agonistic antibodies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:151.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Enhanced developability profiles: </b>NEObody technology is designed to preemptively eliminate the chemically unstable sites, or combinations of &#8220;problematic&#8221; sites that may pose risk for downstream manufacturing processes. This precision design strategy coupled with precision oligonucleotides and library construction have resulted in our high-quality antibody discovery libraries. The primary hits from these libraries generally lack severe &#8220;problematic&#8221; and spurious amino acid sites, and therefore, may offer promising characteristics for further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">SAFEbody</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SAFEbody is our proprietary differentiated precision antibody masking technology designed to enable an antibody to bind its target specifically only after conditional activation of the antibody in target tissues. By engineering our antibody therapeutic candidates to selectively activate in the TME, our SAFEbody technology is designed to improve safety and tolerability of antibody therapeutics while simultaneously maintaining clinical activity. Through this technology, we believe we can provide a solution to on-target off-tumor toxicity, one of the long-lasting challenges with many approved antibody therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><img src="adag-20221231x20f026.jpg" alt="Graphic" style="display:inline-block;height:151.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:416.35pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Activation in the TME: </b>SAFEbody technology is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its target in healthy tissues. The masking motif is designed to activate or unmask the antibody binding in the TME where certain activation conditions such as a protease is upregulated as compared to healthy tissues, allowing the antibody to bind to and attack the tumor. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while remaining largely in an inactive state in healthy tissues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovative masking moiety library design: </b>Leveraging computational biology, we have designed multiple masking libraries with structured scaffolds and balanced chemistry of amino acids with favorable attributes for masking, easier manufacturing processes, and lower immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Precision masking without self-inhibition: </b>To differentiate from other masking technologies, our antibody masking moieties have been designed and discovered in the right context in an effort to provide greater expression and specificity with no self-inhibition upon activation. We employ sophisticated screening processes for rapid discovery of highly masked SAFEbody product candidates subject to systematic tuning of the masking efficiency to match the target biology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Improved pharmacology and safety features: </b>We believe our SAFEbody technology has the potential to also reduce the dose-limiting toxicities observed in combination therapies and thus potentially enable new combinations with other cancer therapies that were previously difficult to use. Our SAFEbody technology may also provide favorable for PK and PD profiles for antibodies and ADCs to reduce the drug clearance from circulation in healthy tissues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our SAFEbody technology has been applied to multiple target antibodies that have been either discovered with NEObody technology or supplied by our partners. Our ADG126 was discovered by combining SAFEbody technology with its parental antibody discovered through our NEObody technology.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">POWERbody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In recent years, multiple modalities have been developed to enhance the potency of traditional antibody drugs. These include Fc engineering for enhanced ADCC or cross-linking efficiency, ADCs and TCEs. Some of them, such as TCEs, can be so potent that only micrograms of the active ingredient are needed for a single dose, in contrast to regular antibody where hundreds of milligrams or even grams are required for a single dose. NEObodies can be converted into SAFEbodies which can be further reformatted into SAFEbody ADCs, bispecific TCEs, and Fc engineered antibodies. We refer to these to as POWERbodies to indicate their potentially enhanced potency and safety profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe SAFEbodies can be applied to these modalities. Since an unmasked ADC, TCE, or Fc engineered antibody can be so potent, there is the risk that it will cause severe toxicity due to damage to healthy tissues or fast lysis of tumor cells, resulting in a narrow therapeutic window, as is frequently observed with some ADC drugs or TCEs that have been FDA approved or are in clinical development. We believe our POWERbodies enabled by our SAFEbody technology with ADC, TCE,&#160;etc., due to their inactivity in circulation and specific local activation in TME, could significantly reduce toxicity and at the same time retain efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">POWERbody technology aims to boost the efficacy of antibody candidates with safety profiles enhanced by our SAFEbody technology. We believe our POWERbody technology will unleash the full power of antibody-based therapeutics to kill cancer cells with enhanced safety, achieving full potential in antibody-based therapies such as bispecific TCEs and ADCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CLINICAL COLLABORATION AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To further advancement of our pipeline, we have put in place various clinical collaborations with pharmaceutical companies and academic or research organizations. We completed several such agreements to support the clinical evaluation of our wholly-owned pipeline candidates. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">In December 2022, we announced a clinical trial collaboration agreement with Roche to evaluate the triple combination of our ADG126 with Roche&#8217;s atezolizumab and bevacizumab in first-line treatment of advanced hepatocellular carcinoma (HCC). The collaboration will utilize Roche&#8217;s MORPHEUS-LIVER platform for rapid and efficient combination development. Under the collaboration, Roche will sponsor and conduct a randomized phase 1b/2 multi-national trial to evaluate the efficacy, safety and pharmacokinetics of ADG126 in combination with bevacizumab and atezolizumab, versus atezolizumab and bevacizumab alone, initially in 60 patients. Each company is supplying its respective anti-cancer agent(s) to support the trial. We will retain global development and commercialization rights to ADG126. We believe this trial reflects Roche&#8217;s leadership and commitment to HCC, where they pioneered the established standard-of-care doublet combination.  We also believe it validates Adagene&#8217;s differentiated ADG126 anti-CTLA-4 clinical program.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In August 2022 and October 2021, we announced agreements with research organizations in Singapore for an investigator-initiated trials of our ADG106 clinical candidate with neoadjuvant chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel) in early-stage, HER2 negative breast cancer and in combination with anti-PD-1 therapy in patients with advanced non-small cell lung cancer (NSCLC), respectively. Both of these ongoing phase 1b/2 clinical trials (ADG106-T6001 and ADG106-T6002) are being conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in collaboration with the Singapore Translational Cancer Consortium.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July 2021, we entered into two clinical collaborations with Merck, a leader in immuno-oncology. The clinical collaboration and supply agreements include two open-label, dose escalation and expansion clinical studies to evaluate our anti-CTLA-4 mAb product candidates, ADG116 and ADG126, in combination with pembrolizumab for patients with advanced/metastatic solid tumors, respectively. Under terms of the agreement, Merck provides pembrolizumab and input on our clinical trials evaluating pembrolizumab in combination with ADG116 and ADG126, respectively.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">TECHNOLOGY COLLABORATIONS WITH BIOPHARMACEUTICAL COMPANIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We enter into collaborations with biotechnology and pharmaceutical companies to leverage the power of our technology platforms, creating a network of potential future revenue streams that complements future long-term value from our wholly-owned pipeline. These collaborations include both technology licensing agreements and outlicensing of product candidates, which allow us to retain significant future participation in product sales through royalties paid on net sales. In the future, we may also enter into strategic collaborations for our preclinical and clinical assets to both accelerate the path to clinic and drive global commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Previously, we have entered into technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics to develop antibody-based therapeutics against tumor targets using our SAFEbody technology. We have also out-licensed the Greater China rights for two antibody candidates to Dragon Boat Pharmaceuticals and its affiliates. Additionally, we have leveraged our DPL technology platform and antibody discovery and engineering capabilities in discovery efforts with the NIH, and Mitsubishi Tanabe, Celgene (now BMS) and GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our technology collaborations enable growth by generating cash flow and revenues that partially offset expenditures on our internal research and development programs, expanding our knowledge base regarding our antibody technologies across multiple targets and antibodies provided by our partners, and providing us with future joint development opportunities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are the highlights of those collaborations with our business partners:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Sanofi Collaboration and Technology License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, we entered into a collaboration and license agreement (the &#8220;Sanofi Agreement&#8221;) with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (&#8220;Sanofi&#8221;), pursuant to which we agreed to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi with our SAFEbody technology. Under the terms of the agreement,&#160;Adagene&#160;will be responsible for early-stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene&#8217;s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanofi Agreement, we granted Sanofi an exclusive, worldwide, sublicensable license to research, develop, use, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to certain exclusivity provisions limiting our right to pursue, engage in, on our own or in collaboration with one or more third parties, directly or indirectly, non-clinical (including pre-clinical research) or clinical development of, commercialization of or manufacture for clinical or commercial use, of any research, develop, make, and commercialize any other antibodies directed to the selected targets for a period of five years, subject to exceptions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to use commercially reasonable efforts to generate masked antibodies in accordance the program plan for each target at our cost. Sanofi is required to use commercially reasonable efforts to further develop, obtain regulatory approval and commercialize the antibodies at its costs.<span style="color:#4472c4;text-decoration-line:line-through;text-decoration-style:solid;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Sanofi Agreement, we received a US$17.5 million upfront payment for Sanofi to advance two initial Sanofi antibody candidates in the collaboration, followed by options to intiate for two additional candidates. To exercise an option, Sanofi is obligated to pay an additional fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we will be eligible to receive total potential development, regulatory and commercial milestone payments of up to $2.5 billion for advancement of the candidates, or US$625 million per program. All four potential candidates in the collaboration will be exclusively developed and commercialized by Sanofi. In addition, we are entitled to receive low to mid-single-digit tiered royalties on global net sales on products developed under the Sanofi Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis until the latest of (i) the tenth anniversary of the first commercial sale of such product in such country, (ii) the expiration of the last-to-expire of certain specified patents that cover such product&#39;s composition of matter or method of use as sold in such country or (iii) the expiration of regulatory exclusivity for such product in such country.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sanofi Agreement will expire upon the termination of all royalty obligations. Sanofi will own the inventions relating to the compounds arising in connection with the Sanofi Agreement and we will own the inventions relating to our platform. Sanofi may terminate the Sanofi Agreement without cause, in its entirety or on a target-by-target basis or on country-by-country basis, upon a specified notice period, and may terminate for safety reasons on a target-by-target basis upon a specified notice period. Either party has the right to terminate the Sanofi Agreement for cause upon the other party&#8217;s uncured material breach or insolvency. Upon termination of the Sanofi Agreement for any reason, the license granted to Sanofi will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Exelixis Collaboration and Technology License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2021, we entered into a collaboration and license agreement (the &#8220;Exelixis Agreement&#8221;) with Exelixis, Inc., pursuant to which we agreed to generate masked antibodies with our SAFEbody technology against two targets selected by Exelixis. Pursuant to the Exelixis Agreement, we granted Exelixis an exclusive, worldwide, sublicensable license to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by us with respect to both targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2021, we achieved a key milestone in the collaboration for successful nomination of SAFEbody candidates, which triggered a US$3.0 million milestone payment received by Adagene in January 2022. As of the date of this annual report, we have received US$15.1 million in aggregate payments, including an upfront fee of US$11.0 million received in 2021, the milestone fee of US$3 million and an upfront fee of US$1.1 million for an expanded collaboration in SAFEbody discovery received in 2022 under the Exelixis Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are subject to certain exclusivity provisions limiting our right to research, develop, make, and commercialize any other antibodies directed to the selected targets during the term of the Exelixis Agreement, subject to exceptions for antibodies with sequence identities that differ by a specified amount. Exelixis is subject to certain exclusivity provisions limiting its rights to research, develop, make, and commercialize any other masked antibodies directed to the selected targets during the term of the Exelixis Agreement, subject to exceptions for antibodies with sequence identities that differ by a specified amount or use different masking technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are required to use commercially reasonable efforts to generate masked antibodies in accordance the program plan for each target at our cost. Exelixis is required to use commercially reasonable efforts to further develop, obtain regulatory approval and commercialize a product for each target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the upfront payment of US$11.0 million received in 2021, in the aggregate, we could be eligible to receive up to US$55,000,000 in development milestone payments, among which we have received US$3.0 million in 2022, US$200,000,000 in regulatory milestone payments, and up to US$525,000,000 in sales milestone payments for both targets under the Exelixis Agreement. In addition, we are entitled to receive mid-single-digit percentage net sales-based royalties on products developed under the Exelixis Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the latest of (i) the tenth anniversary of the first commercial sale of such product in such country, (ii) the expiration of the last-to-expire of certain specified patents that cover such product&#8217;s composition of matter or method of use as sold in such country or (iii) the expiration of regulatory or data exclusivity for such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Exelixis Agreement will expire upon the termination of all royalty obligations. Exelixis will own the inventions relating to the compounds arising in connection with the Exelixis Agreement and we will own the inventions relating to our platform. Exelixis may terminate the Exelixis Agreement without cause, in its entirety or on a target-by-target basis, upon a specified notice period, and may terminate for safety reasons on a target-by-target basis immediately upon notice. Either party has the right to terminate the Exelixis Agreement for cause upon the other party&#8217;s uncured material breach or insolvency, provided that, upon our material uncured breach, Exelixis may elect to instead continue the Exelixis Agreement, and any subsequent milestones or royalty amounts payable to us after such time will be reduced by a specified percentage. Upon termination of the Exelixis Agreement for any reason, the license granted to Exelixis will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">ADC Therapeutics Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2019, we entered into a material transfer and collaboration agreement (the &#8220;ADCT Collaboration Agreement&#8221;) and a license agreement (the &#8220;ADCT License Agreement&#8221;) with ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of targeted ADCs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">ADCT Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADCT Collaboration Agreement, we agreed to generate masked antibodies with our SAFEbody technology that could be combined with the pyrrolobenzodiazepine-based cytotoxic payload used in ADC Therapeutics&#8217; ADCs to create novel ADCs. ADC Therapeutics entered into the ADCT Collaboration Agreement with us to evaluate the use of our SAFEbody technology with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license our SAFEbody technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of the date of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both parties are required to use commercially reasonable efforts to perform certain development obligations under the ADCT Collaboration Agreement. Additionally, we are subject to exclusivity obligations to ADC Therapeutics under the ADCT Collaboration Agreement with respect to (i)&#160;the targets for which ADC Therapeutics has a license or an option to license and (ii)&#160;the use or licensing of our intellectual property that is necessary or useful to the development plan under the ADCT Collaboration Agreement or that would preclude us from granting to ADC Therapeutics the licenses under the ADCT License Agreement. ADC Therapeutics owns intellectual property that are specific to the SAFEbodies that we develop under the ADCT Collaboration Agreement with respect to the two elected targets, and we will own all intellectual property developed under the ADCT Collaboration Agreement that relates generally to our SAFEbody platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT Collaboration Agreement, we are eligible to receive up to US$1,600,000 in consideration for our exclusivity obligations, upon achievement of certain development milestones and upon ADC Therapeutics&#8217; election to proceed with development for the two elected targets. As of the date of this annual report, we have received US$550,000 in aggregate payments under the ADCT Collaboration Agreement. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days&#8217; prior written notice to us. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#8217;s uncured material breach of the agreement or the other party&#8217;s insolvency-related events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">ADCT License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the exercise of the options contained in the ADCT Collaboration Agreement, we have granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by us under these programs. Subject to certain conditions, including the exercise by ADC Therapeutics of its first option to license our SAFEbody technology, ADC Therapeutics will grant us the option to negotiate a license to develop, manufacture and commercialize ADCs containing our SAFEbody technology in Greater China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, we could be eligible to receive up to US$166,090,000 in aggregate milestone payments, in addition to mid-single-digit percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable. In addition to the contingent milestone and royalty payments, if ADC Therapeutics exercises both of its options granted under the ADCT Collaboration Agreement, we are also entitled to a mid-six-figure dollar amount annual maintenance fee. ADC Therapeutics has not yet exercised the options contained in the ADCT Collaboration Agreement as of the date of this annual report. Therefore, we have not received any payment under the ADCT License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon thirty days&#8217; written notice to us, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#8217;s uncured material breach or insolvency.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Sanjin Collaboration/ Out-Licensing Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">2018 Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, we entered into (i)&#160;a collaboration agreement (the &#8220;Sanjin Greater China Agreement&#8221;) that covers Greater China with Guilin Sanjin Pharmaceutical Co.,&#160;Ltd. (&#8220;Sanjin&#8221;) and certain of its subsidiaries (collectively, &#8220;Sanjin Parties&#8221;) and (ii)&#160;a collaboration agreement (the &#8220;Sanjin ROW Agreement,&#8221; together with the Sanjin Greater China Agreement, the &#8220;2018 Sanjin Agreements&#8221;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, we transferred the Chinese intellectual property directly related to a monoclonal antibody molecule that binds to the PD-L1 target (the &#8220;PD-L1 Project&#8221;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#8217; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. We also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission,&#160;etc. Sanjin Parties will pay us (i)&#160;within the validity period of the patent of PD-L1 molecule, single-digit percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. We also received a low-seven figure dollar upfront fee upon the effectiveness of the agreement from Sanjin Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanjin ROW Agreement, we granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that we controlled before we entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between us and Sanjin&#8217;s affiliates in connection with the collaboration will be jointly owned. We have the right to apply for the patents derived from our core and key technologies pertaining to the PD-L1 molecule in the rest of the world and we retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case we intend to transfer to a third party our share of economic interests in any country outside of Greater China, we must notify Sanjin and Sanjin will receive a right of first refusal if it pays us a deposit equal to a low double-digit percentage of the consideration that we expect to receive from such third party. If Sanjin waives the right of first refusal, we can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Sanjin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2018 Sanjin Agreements, we agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent us from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and probody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#8217;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to us all the intellectual property transferred by us to the Sanjin Parties as well as documents and data provided by us under the 2018 Sanjin Agreements. The 2018 Sanjin Agreements are governed by PRC law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2021, Sanjin advanced this anti-PDL-1 monoclonal antibody (ADG104) into Phase 2 development, following completion of a Phase 1 program that, according to Sanjin, showed an ORR in NPC of over 30%. Clinical development of this candidate is ongoing.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">2019 Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, we entered into (i)&#160;a collaboration agreement that covers Greater China (the &#8220;Dragon Boat Greater China Agreement&#8221;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#8220;Dragon Boat ROW Agreement,&#8221; together with the Dragon Boat Greater China Agreement, the &#8220;2019 Dragon Boat Agreements&#8221;), with Dragon Boat Biopharmaceutical (Shanghai) Limited. (&#8220;Dragon Boat&#8221;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, we will transfer the Chinese intellectual property directly related to a certain monoclonal antibody molecule (the &#8220;Specified Molecule&#8221;) that binds to a specified target (the &#8220;Specified Project&#8221;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#8217;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. We also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission,&#160;etc. and will pay us (i)&#160;RMB6,000,000 (equivalent to approximately US$0.9 million) milestone payments and (ii)&#160;a single-digit percentage of net sales of the products that within the validity period of the patent of the Specified Molecule use the licensed antibody after such products enter the market. Dragon Boat also paid us a mid-six figure dollar upfront fee upon the signing of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dragon Boat ROW Agreement, we granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that we controlled before we entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between us and Dragon Boat in connection with the collaboration will be jointly owned. We have the right to apply for the patents derived from our core and key technologies pertaining to the Specified Molecule in the rest of the world and we retain a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case we intend to transfer to a third party our share of economic interests in any country outside of Greater China, we must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays us a deposit equal to a low double-digit percentage of the consideration that we expect to receive from such third party. If Dragon Boat waives the right of first refusal, we can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2019 Dragon Boat Agreements, we agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent us from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and probody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#8217;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to us all the intellectual property transferred by us to Dragon Boat as well as documents and data provided by us under the 2019 Dragon Boat Agreements. The 2019 Dragon Boat Agreements are governed by PRC law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2021, Dragon Boat advanced this candidate, an anti-CSF-1R monoclonal antibody (ADG125/BC006) into phase 1 development. Clinical development of this candidate is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of the date of this annual report, we have received approximately US$1.5 million and US$1.2 million in aggregate payments under the 2018 Sanjin Agreements and the 2019 Dragon Boat Agreements, respectively.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">Additional Discovery AGREEMENTs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition to our SAFEbody technology licensing collaborations and out-licensing collaborations, from time to time, we further enhance our discovery efforts to leverage our DPL platform and antibody engineering capabilities with other biotechnology and pharmaceutical companies. These activities further validate our technologies and establish foundations to expand our relationships with various organizations and global biopharmaceutical companies with whom we may partner in the future.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">Examples of such prior agreements include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We collaborated with Dr. Richard Childs, Chief of the Laboratory of Transplantation Immunotherapy at National Heart Lung and Blood Institute, part of the National Institutes of Health, or NIH, NHLBI, who has used antibodies discovered by us to develop a CAR-T cell therapy candidate targeting a human endogenous retrovirus expressed in the majority of clear cell kidney tumors. In January 2021, we announced the successful completion of our component of the collaboration. The NIH now leads and is responsible for the manufacturing and clinical development of the CAR-T cell therapy candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under a material transfer agreement, we developed SAFEbody drug conjugates candidates against a tumor target selected by Tanabe Research Laboratories, Inc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We had worked with Celgene (now Bristol-Myers Squibb) to discover antibodies targeting novel antigens using our proprietary DPL platform.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We collaborated with GlaxoSmithKline (China), or GSK China, where we were engaged to generate high affinity antibodies against multiple epitopes of multi-transmembrane targets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We worked with Jiangsu Hengrui Medicine Company Limited, or Jiangsu Hengrui, where we were able to discover cross-reactive agonistic antibody for immuno-oncology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">INTELLECTUAL PROPERTY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Protection of our intellectual property is fundamental to the long-term success of our business. Specifically, our success is dependent on our ability to obtain and maintain protection for our technology and the know-how related to our business, defend and enforce our intellectual property rights, and operate our business without infringing, misappropriating, or otherwise violating valid and enforceable intellectual property rights of others. Our patent strategy is focused on seeking coverage for our core technologies and products, such as the DPL platform, ADG116, ADG126, ADG106 and ADG206. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product candidates, and continuing innovation to develop, strengthen, and maintain our proprietary position in our technology, platforms and product candidates. We expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023, we owned three issued patents and nine pending patent applications in China and we also owned two issued patents and ten pending applications in Europe filed with the European Patent Office, five issued patents, 16 pending patent applications and four pending provisional applications in the United States, as well as 11 pending international PCT applications, three issued patents and 90 pending patent applications in other jurisdictions. Our patents and patent applications cover our key technologies and product candidates, including the DPL platform, our clinical candidates, ADG116, ADG126, ADG106, ADG206 and our preclinical candidates including ADG153, ADG138 and ADG152. Excluding any patent term adjustment and patent term extension, our currently issued patents are expected to expire from 2033 to 2038. If any patents issue from our pending patent applications, excluding any patent term adjustments and patent term extension, such patents will be expected to expire from 2033 to 2043. If any patents issue from our pending patent applications, excluding any patent term adjustments and patent term extension, such patents will be expected to expire from 2033 to 2042. The following table summarizes material pending patent applications in the United States, China, Europe and under Patent Cooperation Treaty, or PCT, covering our product candidates, including ADG116, ADG126, ADG106 and ADG104 and ADG125.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Product Candidates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;Patent&#160;Application</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type&#160;of&#160;Patent&#160;Applications</b><b style="font-family:'Times New Roman Bold';font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:24.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">ADG116</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CTLA4 antibodies and methods of making and using the same</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America, China and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">ADG126</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CTLA4 antibodies and methods of making and using the same</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America, China and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">ADG106</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CD137 molecules and uses thereof Combination therapy comprising anti-CD137 antibodies</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making method of treatment/ method of use</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America China and European Patent Office </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">ADG206</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CD137 antibodies and methods of making and using the same</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/method of use/method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent Cooperation Treaty<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">ADG104</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-PD-L1 antibodies and use thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;">ADG125</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CSF1R molecules and use thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/method of use/method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You should read the Risk Factors included elsewhere in this annual report for important information about risks posed by the loss of patent protection, in particular the risks described under &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent Application of ADG125 has not yet entered into national phase of Patent Cooperation Treaty.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes material issued patents in Europe and China covering our proprietary technologies and product candidates.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:20.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Application No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;Patent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type&#160;of&#160;Patent</b><b style="font-family:'Times New Roman Bold';font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:20.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">13877452.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">An Integrated System for Library Construction, Affinity Binder Screening and Expression Thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">201380074656.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">An Integrated System for Library Construction, Affinity Binder Screening and Expression Thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">14908246.3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Methods and Systems for Autoinduction of Protein Expression</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">201410789857.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Filter Vector System And Its Applications</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">16108018</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CD137 Molecules and Use Thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15536939</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Methods and Systems for Autoinduction of Protein Expression</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">201480084652.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Methods and Systems for Autoinduction of Protein Expression</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">16640673</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dynamic Human Antibody Light Chain Libraries</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Library</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">16640679</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Dynamic Human Heavy Chain Antibody Libraries</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Library</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">16265946</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CTLA4 Antibodies And Methods of Making and Using the Same</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You should read the Risk Factors included elsewhere in this annual report for important information about risks posed by the loss of patent protection, in particular the risks described under &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We continually assess and refine our intellectual property strategy as we develop new platform technologies and product candidates. To that end, we are prepared to file additional patent applications relating to the new technologies that we develop if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities. In addition to filing and prosecuting patent applications in China and the United States, we may elect to file counterpart patent applications in additional countries and regions where we believe such foreign filing is likely to be beneficial.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As with other biotechnology and biopharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our platform technologies and product candidates will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned pending patent applications, and any patent applications that we may in the future file or license from third parties may not result in the issuance of patents. In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed or intend to file in the future, including the United States, the patent term is 20 years from the earliest filing date of a nonprovisional patent application. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. The life of a patent, and the protection it affords, is therefore limited and once the patent life of our issued patents has expired, we may face competition, including from other competing technologies. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We seek to ensure that investments made into the development of our technology are protected by relying on a combination of patents, trademarks, copyrights, trade secrets and contractual rights, including license agreements. In addition to our patent portfolio described above, as of March 31, 2023, our PRC subsidiary owned 62 registered trademarks relating to various aspects of our operations, and two registered domain names in China. To protect our rights, we seek to enter into confidentiality agreements, nondisclosure agreements and employee disclosure and invention assignment agreements with our employees, contractors and other third parties who may have or need access to our confidential information. We have also employed internal policies, encryptions and data security measures to protect our proprietary rights. However, there can be no assurance that our efforts will be successful. If our employees, contractors or other third parties violate these agreements or otherwise infringe upon, misappropriate or otherwise violate our intellectual property rights, we may seek to enforce our rights against such parties. In addition, from time to time, third parties may initiate litigation against us alleging infringement, misappropriation or other violation of their proprietary rights or declaring their noninfringement of our intellectual property rights. An adverse result in any such proceeding could enjoin the commercialization of our technology platform and product candidates, result in significant damages, and have a material adverse effect on our business. Even if we are successful in any such litigation, we may be required to incur significant costs and dedicate significant personnel time in defending such litigation. For more information on these and other risks related to intellectual property, see &#8220;Item 3 Key Information&#8212;3.D. Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">MANUFACTURING AND SUPPLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adagene currently outsources the GMP manufacturing, QC testing and QA release of clinical trial materials to WuXi Biologics. We have entered into a framework agreement with Wuxi Biologics, under which it provides services to us on a project-by-project basis. Adagene is also working with other qualified manufacturers to diversify manufacturing outsourcing for the clinical supply production. Adagene has assembled a seasoned internal team with rich experience to oversee the clinical manufacturing to comply with cGMP guidelines and other applicable regulations required by agencies. Currently, Wuxi Biologics as our main CDMO is responsible for obtaining raw materials from multiple suppliers that we believe have sufficient capacity to meet our demands. We expect to continue our relationships with WuXi Biologics while Adagene is continuously evaluating multiple global vendors to ensure continuous supply of Adagene pipeline products for on-going and planned clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">COMPETITION </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are highly competitive and characterized by continuing technological advancement, significant competition and an emphasis on intellectual property. While we believe that our management&#8217;s research, development and commercialization experience provide us with competitive advantages, we face potential competition from many different sources, including global biopharmaceutical companies, major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of cancer immunotherapies. Any product candidates that we successfully develop and commercialize will compete with new immunotherapies and other drug products that may become available in the future. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer and more effective, have fewer or less severe side effects or are more convenient than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we do.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop cancer treatments. There are many other companies that have commercialized and/or are developing immuno-oncology treatments for cancer, including large pharmaceutical and biotechnology companies. Many of our competitors have significantly greater financial, technical and human resources than we have, and mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunities could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future product candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our clinical stage products include ADG116 and ADG126, which are investigational fully human anti-CTLA-4 mAbs generated through our NEObody and SAFEbody technologies, respectively. We expect our primary competition for these two candidates to be within the anti-CTLA-4 antibody market. As of March 31, 2023, Yervoy (ipilimumab) from BMS and Imjudo (tremelimumab) from AstraZeneca are the two marketed anti-CTLA-4 therapies approved by FDA for various cancer indications. Iplilimumab is approved both as a monotherapy and a combination therapy in six indications, while tremelimumab is approved as a combination therapy for two indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the marketed anti-CTLA-4 therapies, there are multiple &#8220;next generation&#8221; anti-CTLA-4 antibodies in clinical development globally. Examples of these programs include: Agenus (Zalifrelimab/AGEN1181), Bristol-Myers Squibb Company (BMS-986249, BMS-986288), Merck (quavonlimab/MA-1308), Onco-C4, Inc. (ONC-392) and Xilio (XTX101). Yervoy was also approved in China in 2021, where additional CTLA-4 antibodies are in clinical development. These anti-CTLA-4 therapies in development in China include HBM4003 from Harbour BioMed and CD1002 from CStone Pharmaceuticals (Suzhou) Co., Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Major limitations of anti-CTLA-4 mAbs include toxicity. According to our internal market analysis, nivolumab and ipilimumab combination therapy has shown relatively higher toxicity in clinical studies even at lower dosages, which was observed from the published clinical data. We believe that the continued expansion of indications, and the launch of innovative novel anti-CTLA-4 antibodies with potential for higher safety and better efficacy may increase the market for CTLA-4 antibodies significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also developing the anti-CD137 targeting antibodies ADG106 and ADG206. We expect our primary competition for this candidate to be with other clinical-stage CD137 agonist product candidates. As of the date of this annual report, there are no marketed CD137 agonist drugs. The two leading molecules in clinical trials are utomilumab (PF-05082566) from Pfizer and urelumab (BMS-663513) from BMS. Other anti-CD137 candidates in earlier stages of development include ATOR-1017 from Alligator Bioscience, CTX-471 from Compass, and AGEN2373 from Agenus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">INSURANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We provide social security insurance including pension insurance, unemployment insurance, work-related injury insurance and medical insurance for our employees. We maintain property insurance, general liability insurance, products/completed operations insurance, auto and international auto liability insurance, workers compensation insurance, key-men insurance, international workers compensation insurance, accident and health insurance and director and officer liabilities insurance. We consider our insurance coverage sufficient and in line with market practice for our business operations in the industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. As of the date of this annual report, we are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MATERIAL LICENSES AND APPROVALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a list of material licenses and approvals, subject to further renewal, that our PRC subsidiary is required to obtain to carry out our operations in China.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">License</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Entity&#160;Holding&#160;the&#160;License</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Regulatory&#160;Authority</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Business License</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">SAMR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG104*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">* Note: We have out-licensed the Greater China rights of ADG104 to our partner Sanjin.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">REGULATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">United States Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates biologic products under the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act and the implementing regulations and other laws, including, in the case of biologics, the Public Health Service Act. Our product candidates are subject to regulation by the FDA as biologics. Biologics require the submission of a BLA and licensure, which constitutes approval, by the FDA before being marketed in the United States. None of our product candidates has been approved by the FDA for marketing in the United States, and we currently have no BLAs pending. Failure to comply with applicable FDA or other requirements at any time during product development, clinical testing, the approval process or after approval may result in administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, suspension or revocation of approved applications, warning letters, product recalls, product seizures, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s GLP regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety and effectiveness of the proposed biologic product candidate for its intended indications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a BLA when adequate data are obtained from pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of a BLA to accept the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP regulations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND application to the FDA. An IND application is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND application is on the general investigational plan and the protocol(s)&#160;for clinical trials. The IND application also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. If the IND sponsor is not able to address FDA&#8217;s concerns satisfactorily within the 30-day time frame, the IND may be placed on clinical hold. The IND sponsor and the FDA must resolve any outstanding concerns or questions before the IND is cleared by the FDA and the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Generally, a separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB, which provides recommendation on whether or not a study should move forward at designated check points based on access to certain data from the study. The DSMB may recommend halting of the clinical trial if it determines that there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase I&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. For investigational products developed for oncology indications, the Phase I trials are normally conducted in patients with serious or life-threatening diseases without other treatment alternatives.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase II&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase II clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase III clinical trials. For certain indications in patients with serious or life-threatening diseases and with no available therapies, it may be possible to obtain BLA approval based on data from Phase II trials if a positive benefit risk profile is demonstrated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase III&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an original BLA has been submitted, FDA has 60 days to determine whether the application can be filed. If FDA determines that an application to be deficient, on its face, in a way that precludes a complete review, FDA may not accept the application for review and may issue a refuse-to-file letter to the sponsor. If FDA determines the application is filable, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facilities in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the commercial product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, in which case the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase I and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well- controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, FDA established a new regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act, which was signed into law in December&#160;2016. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1)&#160;it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#160;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&#160;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like fast track and breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical trials, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Biosimilars and Reference Product Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product be biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered to a patient more than once, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the competing product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, FDA has stated that products deemed &#8220;interchangeable&#8221; can be readily substituted by pharmacies, depending on state pharmacy laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes which prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and which, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, also imposes certain requirements on HIPAA covered entities and their business associates relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments or other transfers of value made to physicians, as defined by such law, certain other health care providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">United States state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts, including laws governing the privacy and security of personal data, such as the GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU and EEA (including with regard to health data).</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payers, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payers. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. As there is no uniform policy of coverage and reimbursement for drug products among third-party payers in the United States, coverage and reimbursement policies for drug products can differ significantly from payer to payer. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payers will decide with respect to coverage and reimbursement for our drug products. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payers are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payer not to cover a product could reduce physician usage and patient demand for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the 2020 federal spending package permanently eliminates, effective January&#160;1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. In addition, the Tax Act was enacted, which, among other things, removes penalties for not complying with ACA&#8217;s individual mandate to carry health insurance. On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal or replace the ACA will impact the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, unless additional Congressional action is taken. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 includes a US$135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Further, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out- of-pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May&#160;2019, the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, issued a final rule&#160;to allow Medicare Advantage plans the option to use step therapy for Part&#160;B drugs beginning January&#160;1, 2020. This final rule&#160;codified CMS&#8217;s policy change that was effective January&#160;1, 2019. Most recently, in July&#160;2020, President Trump also signed a number of executive orders that attempt to implement several of the Administration&#8217;s proposals. While some of measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">PRC Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to a variety of PRC laws, rules&#160;and regulations affecting many aspects of our business. This section sets out a summary of the major relevant laws, regulations, rules&#160;and policies which may have material impact on our business and operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Company Establishment and Foreign Investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The establishment, operation and management of corporate entities in China are governed by the Company Law of PRC, or the PRC Company Law, which was promulgated by the Standing Committee of the National People&#8217;s Congress, or the Standing Committee of the NPC, in December&#160;1993 and further amended in December&#160;1999, August&#160;2004, October&#160;2005, December&#160;2013 and October&#160;2018, respectively. According to the PRC Company Law, companies are generally classified into two categories: limited liability companies and companies limited by shares. The PRC Company Law also applies to foreign-invested limited liability companies. According to the PRC Company Law, where laws on foreign investment have other stipulations, such stipulations shall prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Investment activities in the PRC by foreign investors are governed by the Catalog of Encouraged Industries for Foreign Investment (2022 Edition), which was promulgated by the National Development and Reform Commission, or the NDRC, and Ministry of Commerce of the PRC, or the MOFCOM,  in October 2022 and came into effect in January 2023, and the Special Administrative Measures for the Access of Foreign Investment (Negative List), or the Negative List, which was promulgated by the MOFCOM and the NDRC in December 2021 and came into effect in January 2022. The Negative List sets out the restrictive measures in a unified manner, such as the requirements on shareholding percentages and management, for the access of foreign investments, and the industries that are prohibited from receiving foreign investment. The Negative List covers 12 industries, and any field not falling under the Negative List shall be administered under the principle of equal treatment to domestic and foreign investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign Investment Law of the PRC, or the Foreign Investment Law, was promulgated by the National People&#8217;s Congress, or the NPC in March&#160;2019 and came into effect in January&#160;2020. When the Foreign Investment Law came into effect, the Law on Wholly Foreign-owned Enterprises of the PRC, the Law on Sino-foreign Equity Joint Ventures of the PRC and the Law on Sino-foreign Cooperative Joint Ventures of the PRC were repealed simultaneously. The investment activities of foreign natural persons, enterprises or other organizations (collectively, the &#8220;foreign investors&#8221;) directly or indirectly within the territory of China shall comply with and be governed by the Foreign Investment Law. Such activities include: 1) establishing by foreign investors of foreign-invested enterprises in China alone or jointly with other investors; 2) acquiring by foreign investors of shares, equity, property shares, or other similar interests of Chinese domestic enterprises; 3) investing by foreign investors in new projects in China alone or jointly with other investors; and 4) other forms of investment prescribed by laws, administrative regulations or the State Council.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the State Council promulgated the Regulations on Implementing the Foreign Investment Law of the PRC, which came into effect in January&#160;2020. When the Regulations on Implementing the Foreign Investment Law of the PRC came into effect, the Regulation on Implementing the Sino-Foreign Equity Joint Venture Enterprise Law of the PRC, Provisional Regulations on the Duration of Sino-Foreign Equity Joint Venture Enterprise, the Regulations on Implementing the Wholly Foreign-Invested Enterprise Law of the PRC and the Regulations on Implementing the Sino-Foreign Cooperative Joint Venture Enterprise Law of the PRC were repealed simultaneously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the MOFCOM and the State Administration for Market Regulation, or the SAMR promulgated the Measures on Reporting of Foreign Investment Information, which came into effect in January&#160;2020. When the Measures on Reporting of Foreign Investment Information came into effect, the Interim Measures for the Administration of Filing for Establishment and Changes in Foreign Investment Enterprises were repealed simultaneously. Since January&#160;1, 2020, for foreign investors carrying out investment activities directly or indirectly in China, the foreign investors or foreign-invested enterprises shall submit investment information to the relevant commerce administrative authorities according to the Measure on Reporting of Foreign Investment Information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulation on Pharmaceutical Product Development, Approval and Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Regulatory Regime</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Drug Administration Law of the PRC, or the Drug Administration Law, was promulgated by the Standing Committee of the NPC, in September&#160;1984. The two latest amendments to the Drug Administration Law were the amendment promulgated in April&#160;2015 and in August&#160;2019. The Regulations for the Implementation of the Drug Administration Law was promulgated by the State Council in August&#160;2002, and was last amended in March&#160;2019. The Drug Administration Law and the Regulations for the Implementation of the Drug Administration Law have jointly established the legal framework for the administration of pharmaceutical products in China, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products. It regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and medicinal preparations of medical institutions, and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. The Regulations for the Implementation of the Drug Administration Law, at the same time, provide the detailed implementation regulations for the Drug Administration Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the drug regulatory system entered a new and significant period of reform. The General Office of the State Council and the General Committee of China Communist Party jointly issued Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, or the Innovation Opinions. The expedited programs, the record-filing system, the prioritized review mechanism, the acceptance of foreign clinical data under the Innovation Opinions and other recent reforms encourage drug manufacturers to seek marketing approval in China first for the development of drugs in highly prioritized therapeutic areas, such as oncology or rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To implement the regulatory reform introduced by Innovation Opinions, the Standing Committee of the NPC, the National Medical Products Administration, or the NMPA, a newly formed government authority as well as other authorities, are currently responsible for revising the laws, regulations and rules&#160;governing the pharmaceutical products and the industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2019, the Standing Committee of the NPC promulgated the new Drug Administration Law, or the 2019 Amendment, which came into effect in December&#160;2019. The 2019 Amendment contains many of the major reform initiatives implemented by the Chinese government since 2015, including but not limited to the Marketing Authorization Holder, or the MAH, system, conditional approvals of drugs, traceability system of drugs, and the cancellation of relevant certification according to the Good Manufacturing Practice, or the GMP, and the Good Supply Practice, or the GSP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulatory Authorities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical products in China are monitored and supervised on a national scale by the NMPA. The local provincial medical products administrative authorities are responsible for supervision and administration of drugs within their respective administrative regions. The NMPA was newly formed under the SAMR. The NMPA&#8217;s predecessor, the State Drug Administration, or the SDA, was replaced by the State Food and Drug Administration, or the SFDA, which was later reorganized into the China Food and Drug Administration, or the CFDA, as part of the institutional reforms implemented by the State Council.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary responsibilities of the NMPA include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring and supervising the administration of pharmaceutical products, medical appliances and equipment as well as cosmetics in the PRC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating administrative rules&#160;and policies concerning the supervision and administration of pharmaceutical, medical devices, and cosmetics industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating, registering and approving new drugs, generic drugs, imported drugs and traditional Chinese medicine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving and issuing permits for the manufacture and export/import of pharmaceutical products, medical appliances and equipment;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving the establishment of enterprises to be engaged in the manufacture and distribution of pharmaceutical products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">examining and evaluating the safety of pharmaceutical products, medical devices, and cosmetics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing significant accidents involving pharmaceutical products, medical devices and cosmetics.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2013, the Ministry of Health, or the MOH, and the National Population and Family Planning Commission were integrated into the National Health and Family Planning Commission of the PRC, or the NHFPC. In March&#160;2018, the First Session of the Thirteenth NPC approved the State Council Institutional Reform Proposal, according to which, NHFPC and certain other governmental authorities were consolidated into the National Health Commission, or the NHC. The responsibilities of the NHC include coordinating the formulation of national drug policies, the national essential medicine system and the National Essential Medicines List and drafting the administrative rules&#160;for the procurement, distribution and use of national essential medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Decision of the CFDA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs, which was promulgated by the CFDA in March&#160;2017 and came into effect in May&#160;2017, the Investigational New Drug Application, or the IND, approval should be issued by the Center for Drug Evaluation, or the CDE, on behalf of the CFDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Clinical Trials and Registration of Drugs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Administrative Measures for Drug Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2007, the SFDA promulgated the amended version of the Administrative Measures for Drug Registration, or the Registration Measures, which became effective in October&#160;2007. The Registration Measures mainly cover: (1)&#160;definitions of drug registration applications and regulatory responsibilities of drug administration; (2)&#160;general requirements for drug registration, including application for registration of new drugs, generic drugs, imported drugs and supplemental application, as well as application for re-registration; (3)&#160;clinical trials; (4)&#160;application, examination and approval of new drugs, generic drugs and imported drugs; (5)&#160;supplemental applications and re-registrations of drugs; (6)&#160;inspections; (7)&#160;registration standards and specifications; (8)&#160;time limit; (9)&#160;re-examination; and (10)&#160;liabilities and other supplementary provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, drug registration applications are divided into three different types, namely Domestic New Drug Application, Domestic Generic Drug Application and Imported Drug Application. Drugs which fall into one of three general types are divided according to the drug&#8217;s working mechanism, namely whether the drug is classified as a chemical medicine, a biological product, a traditional Chinese medicine or a natural medicine. New Drug Application, or NDA, refers to an application for registration of a drug that has not yet been marketed for sale in China. In addition, the registration of drugs that change the dosage form of the marketed drugs, change the route of administration and increase the new indications shall be reported in accordance with the application procedures for new drugs. Under the Registration Measures, a Category 1 drug refers to a new drug that has never been marketed in any country, and such drug is eligible for special review or fast track approval by the NMPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2020, the SAMR released the amended Administrative Measures for Drug Registration, or the Amended Registration Measures, which came into effect in July&#160;2020. The Amended Registration Measures provide detailed procedural and substantive requirements for the key regulatory concepts established by the Drug Administration Law, and confirms a number of reform actions that have been taken in the past years, including but not limited to: (i)&#160;the full implementation of the MAH system and implied approval of the commencement of clinical trial; (ii)&#160;the implementation of associated review of drugs, excipients and packaging materials; and (iii)&#160;the introduction of four procedures for expedited registration of drugs, which are procedures for ground-breaking therapeutic drugs, procedures for conditional approval, procedures for prioritized reviews and approval, and procedures for special examination and approval. Detailed implementation rules&#160;for drug classification and requirements for corresponding application materials will be promulgated by the NMPA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2016, the CFDA issued the Reform Plan for Registration Category of Chemical Medicine, which outlined the reclassifications of drug applications under the Registration Measures. According to the Reform Plan for Registration Category of Chemical Medicine, Category 1 drugs refer to innovative new drugs that have not been marketed anywhere in the world. Improved new drugs that are not marketed anywhere in the world fall into Category 2 drugs. Generic drugs, that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed abroad but not yet in China, can be classified as Category 3 drugs. Generic drugs, that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed in China, fall into Category 4 drugs. Category 5 drugs are drugs which have already been marketed abroad, but are not yet approved in China. Category 1 drugs and Category 5 drugs can be registered through the Domestic New Drug Application and the Imported Drug Application Procedures under the Registration Measures, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SFDA promulgated the Administrative Provisions on Special Examination and Approval of Registration of New Drugs in January&#160;2009, according to which, the SFDA conducts special examination and approval for new drug registration applications when: (1)&#160;the effective constituent of drug extracted from plants, animals, minerals,&#160;etc., as well as the preparations thereof have never been marketed in China, and the material medicines and the preparations thereof are newly discovered; (2)&#160;the chemical raw material medicines as well as the preparations thereof and the biological product have not been approved for marketing at home and abroad; (3)&#160;the new drugs have obvious clinical treatment advantages for such diseases as AIDS, malignant tumors and orphan diseases,&#160;etc. or (4)&#160;the new drugs treat diseases currently with no effective methods of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the clinical trial application stage if the product candidate falls within items (1)&#160;or (2). The provisions provide that for product candidates that fall within items (3)&#160;or (4), the application for special examination and approval cannot be made until filing for production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Accelerated Approval for Clinical Trial and Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Innovation Opinions established a framework for reforming the evaluation and approval system for drugs, medical devices and equipment. The Innovation Opinions enhanced the standard of approval for drug registration and accelerated the evaluation and approval process for innovative drugs as well as drug clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CFDA released the Circular Concerning Several Policies on Drug Registration Review and Approval in November&#160;2015, which further clarified the measures and policies for simplifying and accelerating the approval process of clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a one-time umbrella approval procedure allowing the overall approval of all phases of a new drug&#8217;s clinical trials, replacing the current phase-by-phase application and approval procedure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fast track drug registration or clinical trial approval pathway for the following applications: (1)&#160;registration of innovative new drugs for treating HIV, cancer, serious infectious diseases and orphan diseases,&#160;etc.; (2)&#160;registration of pediatric drugs; (3)&#160;registration of geriatric drugs and drugs treating PRC-prevalent diseases in elders; (4)&#160;registration of drugs listed in national major science and technology projects or national key research and development plan; (5)&#160;registration of clinical urgently needed drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (6)&#160;registration of foreign innovative drugs to be manufactured locally in China; (7)&#160;concurrent applications for new drug clinical trials which are already approved in the United States or EU or concurrent drug registration applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#8217; onsite inspections in the United States or EU and are manufactured using the same production line in China; and (8)&#160;clinical trial applications for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one year.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NMPA released the Circular on Adjusting Evaluation and Approval procedures for Clinical Trials for Drugs in July&#160;2018, according to which, within 60 days after the acceptance of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE. Such approval process has been further enacted into the 2019 Amendment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Trial Exemptions and Acceptance of Foreign Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data in July&#160;2018, as one of the implementing rules&#160;for the Innovation Opinions, which provides that overseas clinical data can be submitted for the drug registration applications in China. Such applications can be in the form of waivers to China-based clinical trials, bridging trials and direct NDAs. According to the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data, sponsors may use the data of foreign clinical trials to support drug registration in China, provided that sponsors must ensure the authenticity, completeness, accuracy and traceability of foreign clinical trial data and such data must be obtained consistent with the relevant requirements under the Good Clinical Trial Practice of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, or the ICH. Sponsors must also comply with other relevant sections of the Registration Measures when applying for drug registrations in China using foreign clinical trial data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NMPA now officially permits, and its predecessor agencies have permitted on a case-by-case basis in the past, drugs approved outside of China to be approved in China on a conditional basis without pre-approval clinical trials being conducted in China. Specifically, the NMPA and the NHC released the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs in October&#160;2018, permitting drugs that have been approved within the last ten years in the United States, the EU or Japan and that prevent or treat orphan diseases, or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China, or for which the foreign-approved drug would have clear clinical advantages. Applicants will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trial Process and Good Clinical Practices</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, a clinical trial consists of Phases I,&#160;II,&#160;III and IV. Phase I refers to the initial clinical pharmacology and safety evaluation studies in humans. Phase II refers to the preliminary evaluation of a product candidate&#8217;s therapeutic effectiveness and safety for particular indications in patients, to provide evidence and support for the design of Phase III clinical trials and to settle the administrative dose regimen. Phase III refers clinical trials undertaken to confirm the therapeutic effectiveness and safety on patients with target indications, to evaluate the overall benefit-risk relationships of the drug, and ultimately to provide sufficient evidence for the review of drug registration application. Phase IV refers to a new drug&#8217;s post-marketing study to assess therapeutic effectiveness and adverse reactions when the drug is widely used, to evaluate the overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To improve the quality of clinical trials, the SFDA promulgated the Good Clinical Trial Practice for Drugs in August&#160;2003, or the GCP Rules, which was replaced by the revised Good Clinical Trial Practice for Drugs, the Revised GCP Rules, promulgated by the NMPA and the NHC in April&#160;2020 and coming into effect in July&#160;2020. According to the Administration of Quality of Drug Clinical Practice, clinical trial means systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug. The Revised GCP Rules&#160;provide comprehensive and substantive requirements on the design and conduct of clinical trials in China. In particular, the Revised GCP Rules&#160;enhance the protection for study subjects and tighten the control over bio-samples collected under clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Revised GCP Rules&#160;also set out the qualifications and requirements for the investigators and centers participating in clinical trial, who must: (i)&#160;have professional certification at a clinical trial center, professional knowledge, training experience and capability of clinical trial, and be able to provide the latest resume and relevant qualification documents per request; (ii)&#160;be familiar with the trial protocol, investigator&#8217;s brochure and relevant information of the trial drug provided by the applicant; (iii)&#160;be familiar with and comply with the Revised GCP Rules&#160;and relevant laws and regulations relating to clinical trials; (iv)&#160;keep a copy of the authorization form on work allocation signed by investigators; (v)&#160;accept supervision and inspection organized by the applicant and inspection by the drug regulatory authorities; and (vi)&#160;in the case of investigators and clinical trial centers authorizing other individual or institution to undertake certain responsibilities and functions relating to clinical trial, they shall ensure such individual or institution are qualified and establish complete procedures to ensure the responsibilities and functions are fully performed and generate reliable data.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Communication with the CDE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, where the application for clinical trial of new investigational drug has been approved, upon the completion of Phases I and II clinical trials and prior to Phase III clinical trial, the applicant shall submit the application for Communication Session to the CDE to discuss the key technical questions including the design of Phase III clinical trial protocol. Within 60 days after the acceptance of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The NMPA promulgated the Administrative Measures for Communication on the Research, Development and Technical Evaluation of Drugs in December 2020, according to which, during the research and development periods and in the registration applications of traditional Chinese medicines, chemical drugs and biological products, the applicants may propose to conduct communication meetings with the CDE on key technologies and other issues not covered in the existing guidelines for drug research, development and evaluation during the process of technical evaluation of drug research, development and registration. The communication meetings can be classified into three types. Type I meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the research and development of breakthrough therapeutic drugs. Type II meetings are held during the key research and development periods of drugs, mainly including meetings before the IND application, meetings upon the completion of Phase II trials and before the commencement of Phase III trials, meetings before submitting a marketing application for a new drug, and meetings for risk evaluation and control. Type III meetings refer to meetings not classified as Type I or Type II.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Clinical Trial Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, upon obtaining the approval of its IND applications and before conducting a clinical trial, an applicant shall file a registration form with the SFDA containing various details, including the clinical trial protocol, the name of the principal researcher of the leading institution, the names of participating institutions and researchers, an approval letter from the ethics committee, and a sample of the informed consent form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. The CFDA released the Announcement on Drug Clinical Trial Information Platform in September&#160;2013, according to which, instead of the aforementioned registration field with the CFDA, all clinical trials approved by the CFDA and conducted in China shall complete a clinical trial registration and publish trial information through the Drug Clinical Trial Information Platform. The applicant shall complete the trial pre-registration within one month after obtaining the approval of the clinical trial approval in order to obtain the trial&#8217;s unique registration number and complete registration of certain follow-up information before the first subject&#8217;s enrollment in the trial. If the registration is not completed within one year after the approval of the IND applications, the applicant shall submit an explanation, and if the first submission is not completed within three years, the approval of the IND applications shall automatically expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">New Drug Application</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, drug registration applications include domestic NDA, domestic generic drug application and imported drug application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases I,&#160;II and III clinical trials have been completed, the applicant may apply to the SFDA for approval of the NDA. The SFDA then determines whether to approve the application according to the comprehensive evaluation opinion provided by the CDE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Pilot Plan for the MAH System</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Innovation Opinions provide a pilot plan for the MAH system.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the authorization of the Standing Committee of the NPC, the General Office of the State Council issued the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in May&#160;2016, which provides a detailed pilot plan for the MAH system in 10 Chinese provinces. Under the MAH system, domestic drug research and development institutions and individuals in the pilot regions are eligible to be holders of drug registrations without having to become drug manufacturers. The marketing authorization holders may engage contract manufacturers for manufacturing, provided that the contract manufacturers are licensed and located within the pilot regions. Drugs that qualify for the MAH system are: (1)&#160;new drugs (including but not limited to drugs under category I to category IV of chemical drugs, and targeted preparation, sustained release preparation, controlled release preparation under category V of chemical drugs, biological products approved as category I and VII drugs and biosimilars under the Registration Measures) approved after the implementation of the MAH system; (2)&#160;generic drugs approved as category III or IV drugs under the Reform Plan for Registration Category of Chemical Medicine; (3)&#160;previously approved generics that have passed equivalence assessments against original drugs; and (4)&#160;previously approved drugs whose licenses were held by drug manufacturers originally located within the pilot regions, but which have moved out of the pilot regions due to corporate mergers or other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CFDA promulgated the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System in August&#160;2017. It clarified the legal liability of the MAH, who is responsible for managing the whole manufacturing and marketing chain and the whole life cycle of drugs and legally liable for preclinical drug study, clinical trials, manufacturing, marketing, distribution and adverse drug reaction monitoring. According to the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System, the MAH shall submit a report of drug manufacturing, marketing, prescription, techniques, pharmacovigilance, quality control measures and other situations to the CFDA within 20 working days after the end of each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Pilot Plan for the Drug Marketing Authorization Holder Mechanism, the pilot plan was originally set for a three-year period and was scheduled to expire in November&#160;2018. The Standing Committee of the NPC promulgated the Decision of Extending the Pilot Period of Authorizing the State Council to Carry Out the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in Certain Places in October&#160;2018, which extended the term of the MAH system to November&#160;4, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the 2019 Amendment, which came into effect on December&#160;1, 2019, the MAH system will be applicable throughout the country and the legal representative and the key person-in-charge of a drug MAH shall be fully responsible for the quality of drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">International Multi-Center Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The International Multi-Center Clinical Trial Guidelines (Trial), or the Multi-Center Clinical Trial Guidelines, which was promulgated by the CFDA in January&#160;2015 and came into effect in March&#160;2015, provided guidance on the implementation of Multi-Regional Clinical Trials, or the MRCT, in China. According to the Multi-Center Clinical Trial Guidelines, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to implement the international multi-center clinical trials in the PRC, the applicants shall comply with relevant laws and regulations, such as the Drug Administration Law, the Implementing Regulations of the Drug Administration Law and the Registration Measures, execute the GCP Rules, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations of the countries involved in the international multi-center clinical trials. Where the applicants plan to use the data derived from the international multi-center clinical trials for approval of a drug registration in the PRC, it shall involve at least two countries, including China, and shall satisfy the requirements for clinical trials set forth in the Multi-Center Clinical Trial Guidelines, Registration Measures and other related laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the NMPA and the NHC promulgated the Revised GCP Rules, which came into effect in July&#160;2020. The Revised GCP Rules&#160;summarize the requirements for initiating an MRCT, that is, before initiating an MRCT: (i)&#160;the applicant shall ensure that all the centers participating in the clinical trial comply with the trial protocol; (ii)&#160;the applicant shall provide each center with the same trial protocol, and each center shall comply with the same unified evaluation criterion for clinical trial and laboratory data and the same guidance for case report form; (iii)&#160;each center shall use the same case report form to record the data of each human subject obtained during the trial; (iv)&#160;before initiating a clinical trial, a written document is required to specify the responsibilities of the investigators of each center; and (v)&#160;the applicant shall ensure the communication among the investigators of each center.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data derived from international multi-center clinical trials can be used for the new drug applications with the NMPA. When using international multi-center clinical trial data to support new drug applications in China, applicants shall submit the completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in accordance with the content and format requirements under the International Conference on Harmonization-Common Technical Document; subgroup research results summary and comparative analysis shall also be conducted concurrently. Leveraging the clinical trial data derived from international multi-center clinical trials conducted by our partners, we may avoid unnecessarily repetitive clinical trials and thus further accelerate the NDA process in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CFDA released the Decision on Adjusting Items concerning the Administration of Imported Drug Registration in October&#160;2017, which includes the following key points:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the International Multicenter Clinical Trial, or the IMCCT, of a drug is conducted in China, Phase I clinical trial of the drug is allowed simultaneously. The IMCCT drug does not need to be approved or to enter into either a Phase II or III clinical trial in a foreign country, except for preventive biological products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the IMCCT is conducted in China, the application for drug marketing authorization can be submitted directly after the completion of the IMCCT. The Registration Measures and relevant laws and regulations shall be complied with for registration application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to applications for clinical trial and marketing of the imported innovative chemical drugs and therapeutic biological products, the marketing authorization in the country or region where the foreign drug manufacturer is located will not be required; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to drug applications that have been accepted before the release of this Decision, if relevant requirements are met, importation permission can be granted if such applications request exemption of clinical trials for the imported drugs based on the data generated from the IMCCT.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Approval of Human Genetic Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Interim Administrative Measures on Human Genetic Resources, promulgated by the Ministry of Science and Technology and the MOH in June&#160;1998, aimed at protecting and fairly utilizing human genetic resources in the PRC. The Ministry of Science and Technology promulgated the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC in July&#160;2015, according to which, the sampling, collection or research activities of human genetic resources by a foreign-invested sponsor fall within the scope of international cooperation, and the cooperating Chinese organization shall apply for approval of the China Human Genetic Resources Management Office through an online system. The Ministry of Science and Technology further promulgated the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources in October&#160;2017 and October&#160;2020, which became effective in December&#160;2017 and October&#160;2020, respectively and simplified the approval of sampling and collecting human genetic resources for listing a drug in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Regulations of the PRC on the Administration of Human Genetic Resources, which was promulgated by the State Council in May 2019 and came into effect in July 2019, further stipulates that, in order to obtain marketing authorization for relevant drugs and medical devices in China, no approval is required in international clinical trial cooperation using China&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials. However, the type, quantity and usage of the human genetic resource to be used shall be filed with the administrative department of science and technology under the State Council before clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Bio-security Law of the PRC promulgated by the Standing Committee of the NPC in October 2020, and took effect in April 2021, provides that the state shall have sovereignty over the human genetic resources and biological resources of the PRC. The Bio-security Law of the PRC further stipulates that the department of science and technology under the State Council shall be the competent authority for the approval or filing of using China&#8217;s human genetic resources.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Drug Manufacturing and Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Drug Administration Law and the Implementing Regulations of the Drug Administration Law, a drug manufacturing enterprise is required to obtain a drug manufacturing license from the relevant provincial drug administration authority of the PRC. The grant of such license is subject to an inspection of the manufacturing facilities, and an inspection to determine whether the sanitary condition, quality assurance systems, management structure and equipment meet the required standards. According to the Implementing Regulations of the Drug Administration Law and the Measures on the Supervision and Administration of the Manufacture of Drugs, which was promulgated in August&#160;2004, amended in November&#160;2017 and January&#160;2020 and came into effect in July&#160;2020, the drug manufacturing license is valid for five years and shall be renewed at least six months prior to its expiration date upon a re-examination by the relevant authority. In addition, the name, legal representative, registered address and type of the enterprise specified in the drug manufacturing certificate shall be identical to that set forth in the business license as approved and issued by the industrial and commercial administrative department. To the extent the MAH does not manufacture the drug internally but through a contract manufacturing organization, the MAH shall apply for drug manufacturing license with the provincial counterpart of the NMPA, subject itself to inspections and other regulatory oversight by the agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Good Manufacturing Practice for Drugs was promulgated in March&#160;1988 and was amended in December&#160;1992 and June&#160;1999 and January&#160;2011. The latest amendment was in June&#160;2020 and came into effect in October&#160;2020. The Good Manufacturing Practice for Drugs comprises a set of detailed standard guidelines governing the manufacture of drugs, which include institution and staff qualifications, production premises and facilities, equipment, hygiene conditions, production management, quality controls, product operation, raw material management, maintenance of sales records, management of customer complaints and adverse event reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Drug Administration Law, its implementing regulations and the Measures for the Supervision and Administration of Circulation of Pharmaceuticals, which was approved by the SFDA in December&#160;2006 and came into effect in May&#160;2007, pharmaceutical enterprises shall be responsible for the quality of the pharmaceuticals that they manufacture, operate, use, purchase, sell, transport, or store.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Measures for the Administration of Pharmaceutical Operation Certificate, which was promulgated in February&#160;2004 and amended in November&#160;2017 by the CFDA, a Medicine Operation Certificate is valid for five years. Each holder of the Medicine Operation Certificate must apply for an extension of its permit six months prior to expiration. The establishment of a wholesale pharmaceutical distribution company requires the approval of provincial medicine administrative authorities. Upon approval, the authority will grant a Medicine Operation Certificate in respect of the wholesale pharmaceutical product distribution company. The establishment of a retail pharmacy store requires the approval of the local medicine administrative authorities at or above the county level. Upon approval, the authority will grant a Medicine Operation Certificate in respect of the retail pharmacy store.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Other PRC Government Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Intellectual Property Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In terms of international conventions, China has entered into (including but not limited to) the Agreement on Trade-Related Aspects of Intellectual Property Rights, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the International Registration of Marks and the Patent Cooperation Treaty.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Patent Law of the PRC, which was promulgated by the Standing Committee of the NPC in March 1984, amended in September 1992, August 2000, December 2008 and October 2020, and came into effect in June 2021, and the Implementation Rules of the Patent Law of the PRC, which was promulgated by the State Council in June 2001 and amended in December 2002 and January 2010, there are three types of patents in the PRC: invention patents, utility model patents and design patents. The protection period is 20 years for an invention patent and 10 years for a utility model patent and 15 years for a design patent, commencing from their respective application dates. For the purpose of compensating for the time taken to evaluate and approve a new drug to be put on market, the patent administrative department under the State Council shall grant compensation for duration of patent rights for invention of a new drug approved to be put on market in the PRC upon request of the patentee. The compensation period shall not exceed five years, and the total validity period of patent rights for a new drug approved to be put on market shall not exceed 14 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the process of evaluation and approval of marketing of a drug, where a dispute arises over the patent rights relating to the drug for which registration is applied between a drug marketing authorization applicant and a relevant patentee or interested party, the relevant party may file a lawsuit with a people&#39;s court, requesting a ruling on whether the relevant technical solution of the drug for which registration is applied falls within the scope of protection of others&#39; drug patent rights. The drug regulatory department under the State Council may, within the stipulated period, make a decision on whether to suspend the approval of marketing of the drug concerned based on the effective judgment made by the people&#39;s court. A drug marketing authorization applicant and a relevant patentee or interested party may also request an administrative ruling from the patent administrative department under the State Council in respect of a dispute over patent rights relating to the drug for which registration is applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any individual or entity that utilizes a patent or conducts any other activities that infringe a patent without prior authorization of the patent holder shall pay compensation to the patent holder and is subject to a fine imposed by relevant administrative authorities and, if constituting a crime, shall be held criminally liable in accordance with the law. According to the Patent Law of the PRC, any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in China is required to report to the NIPA for confidentiality examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Anti-Unfair Competition Law, which was promulgated by the Standing Committee of the NPC in September&#160;1993 and amended in November&#160;2017 and April&#160;2019, respectively, the term &#8220;trade secrets&#8221; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#8217; trade secrets by: (1)&#160;obtaining the trade secrets from the legal owners or holders by any unfair methods such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2)&#160;disclosing, using or permitting others to use the trade secrets obtained illegally under item (1)&#160;above; (3)&#160;disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence; or (4)&#160;instigating, inducing or assisting others to violate a confidentiality obligation or to violate a rights holder&#8217;s requirements on keeping confidentiality of trade secrets, disclosing, using or permitting others to use the trade secrets of the rights holder. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#8217; trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may stop any illegal activities and fine infringing parties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC in August&#160;1982, and amended in February&#160;1993, October&#160;2001, August&#160;2013 and April&#160;2019, respectively, the period of validity for a registered trademark is ten years, commencing on the date of registration. The registrant shall go through the formalities for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing on the day immediately after the expiry of the preceding period of validity for the trademark. In the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior that infringes the exclusive right under a registered trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><i style="font-weight:normal;">Domain Names</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Domain names are protected under the Administrative Measures on the Internet Domain Names, which was promulgated by the Ministry of Industry and Information Technology in August&#160;2017, and the Implementing Rules&#160;on Registration of National Top-level Domain Names, which was promulgated by China Internet Network Information Center in and came into effect in June&#160;2019. The Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Regulations on Information Security and Data Protection </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Scientific data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2018, the General Office of the State Council of the PRC promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. Pursuant to the Scientific Data Measures, the scientific data involving state secrets, national security, social or public interests, trade secrets and individual privacy shall be kept confidential; where it is necessary to disclose such data, the purposes of utilization, qualifications of users and confidentiality conditions, among others shall be examined, and the scope of those with access thereto shall be strictly controlled. Enterprises in the PRC must seek governmental approval before any scientific data involving a state secret is provided during foreign contacts and cooperation. Upon approval by the competent departments, corporate entities shall undergo the relevant formalities as required, and sign confidentiality agreements with users. Furthermore, any researcher conducting research funded in part or in whole by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before that data may be published in any foreign academic journal. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Personal data </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Civil Code of the PRC, the personal information of an individual shall be protected by the law. Any organization or individual that needs to obtain personal information of others shall obtain such information legally and ensure the safety of such information, and shall not illegally collect, use, process or transmit personal information of others, or illegally purchase or sell, provide or publish personal information of others. In addition, the processing of personal information shall follow the principles of lawfulness, appropriateness and necessity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Personal Information Protection Law of the PRC promulgated by the Standing Committee of the NPC and took into effect in November 2021. The Personal Information Protection Law of the PRC shall apply to the processing of the personal information of natural persons within the territory of the PRC under any of the following circumstances: (i) where the purpose is to provide domestic natural persons with products or services; (ii) where the activities of domestic natural persons are analyzed and evaluated; and (iii) other circumstances as prescribed by laws and administrative regulations. The processing of personal information shall follow the principles of lawfulness, legitimacy, necessity and good faith, and it is not allowed to process personal information by misleading, fraud, coercion or otherwise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Information security and review </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 7, 2016, the Standing Committee of NPC promulgated the Cybersecurity Law of the PRC, which became effective on June 1, 2017, pursuant to which, network operators shall fulfill their obligations to safeguard security of the network when conducting business and providing services. Those who provide services through networks shall take technical measures and other necessary measures pursuant to laws, regulations and compulsory national requirements to safeguard the safe and stable operation of the networks, respond to network security incidents effectively, prevent illegal and criminal activities, and maintain the integrity, confidentiality and usability of network data. Network operator shall not collect the personal information irrelevant to the services it provides or collect or use the personal information in violation of the provisions of laws or agreements concluded with its users, and network operators of key information infrastructure shall store within the PRC all the personal information and important data collected and produced within the PRC. The purchase of network products and services that may affect national security shall be subject to national cybersecurity review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 10, 2021, the Standing Committee of NPC promulgated the Data Security Law of the PRC, or the Data Security Law, which came into effect on September 1, 2021. The Data Security Law sets forth the regulatory framework and the responsibilities of the relevant governmental authorities in regulating data security. It provides that the central government shall establish a central data security work liaison system, which shall coordinate the relevant authorities covering different industries to formulate the catalogs of key data, and the special measures that shall be taken to protect the security of the key data. In addition, the Data Security Law provides that important data processors shall appoint a data security officer and a management department to take charge of data security, and such processors shall evaluate the risk of their data activities periodically and file assessment reports with the relevant regulatory authorities. Violation of Data Security Law may subject the relevant entities or individuals to warning, fines, business suspension, revocation of permits or business licenses, or even criminal liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 28, 2021, the Cybersecurity Review Measures was promulgated by Cyberspace Administration of China, State Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Public Security, Ministry of State Security, Ministry of Finance, Ministry of Commerce, People&#8217;s Bank of China, SAMR, National Radio and Television Administration, CSRC, National Administration of State Secrets Protection and State Cryptography Administration and came into effect in February 2022. According to the Cybersecurity Review Measures, (i) the purchase of network products and services by a &#8220;critical information infrastructure operator&#8221; and the data processing activities of a &#8220;network platform operator&#8221; that affect or may affect national security shall be subject to the cybersecurity review; (ii) if a network platform operator who possesses personal information of more than 1 million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office; and (iii) the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services or data processing activities affect or may affect national security. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, in July 2022, CAC issued the Measures on Security Assessment of the Cross-border Data Transfer, or the Security Assessment Measures, which provide that data processors shall make self-assessment of the risks before transferring data cross-border, and shall apply for security assessment for cross-border data transfer in any of the following circumstances: (i) outbound transfer of important data by a data processor; (ii) outbound transfer of personal information by CIIO Operators or a personal information processor who has processed the personal information of more than 1,000,000 people; (iii) outbound transfer of personal information by a personal information processor who has made outbound transfers of the personal information of 100,000 people cumulatively or the sensitive personal information of 10,000 people cumulatively since 1 January of the previous year; or (iv) other circumstances where an application for the security assessment of an outbound data transfer is required as prescribed by the national cyberspace administration authority.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 14, 2021, the CAC published the Regulations for the Administration of Cyber Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comment by December 13, 2021. The Draft Data Security Regulations reiterate that a data processor who processes personal information of more than one million individuals must complete the cybersecurity review if it intends to be listed in a foreign country, and further stipulate that a data processor shall also apply for the cybersecurity review if it carries out data processing activities that affect or may affect national security. The Draft Data Security Regulations provide a broad definition of &#8220;data processing activities,&#8221; including collection, storage, usage, processing, transfer, provision, publication, deletion and other activities, which covers the entire life cycle of data processing. The Draft Data Security Regulations also provide a broad definition of &#8220;data processor&#8221; as individuals and entities that may autonomously determine the purpose and method of data processing activities. In addition, the Draft Data Security Regulations require data processors which process important data or whose securities are listed outside of China to carry out data security assessment annually either by itself or through a third party data security service provider and submit the assessment report to a local agency of the CAC. The Draft Data Security Regulations remain silent on what constitutes a situation that &#8220;affects or may affect national security&#8221; and are subject to public comments and further changes before being formally adopted and entering into effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Product Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the strict new drug approval process, certain PRC laws have been promulgated to protect the rights of consumers and to strengthen the control of medical products in the PRC. Under current PRC laws, manufacturers and vendors of defective products in the PRC may incur liability for loss and injury caused by such products. According to the General Principles of the Civil Law of the PRC promulgated in April 1986 and amended in August 2009 and General Rules of the Civil Law of the People&#8217;s Republic of China promulgated in March 2017 and took effect in October 2017, the manufacturer or vendor of a defective product which causes property damage or physical injury to any person may be subject to civil liability for such damage or injury. In January 2021, the PRC Civil Code came into effect, the General Principles of the Civil Law of the PRC and General Rules of the Civil Law of the PRC were repealed simultaneously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February 1993, the Product Quality Law of the PRC, or the Product Quality Law, was promulgated aiming to protect the legitimate rights and interests of the end-users and consumers and to strengthen the supervision and control of the quality of products. The Product Quality Law was last revised in December 2018. According to the revised Product Quality Law, manufacturers who produce defective products may be subject to civil or criminal liability and have their business licenses revoked.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Law of the PRC on the Protection of the Rights and Interests of Consumers was promulgated in October 1993 and amended in October 2013 to protect consumer rights when they purchase or use goods and services. According to which, all business operators must comply with this law when they manufacture or sell goods and/or provide services to customers. Under the latest amendment, all business operators shall protect the customers&#8217; privacy and keep any consumer information they obtain during the business operation strictly confidential. In addition, in extreme situations, pharmaceutical product manufacturers and operators may be subject to criminal liability if their goods or services lead to the death or injuries of customers or other third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Tort</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Civil Code, if damages to other persons are caused by defective products due to the fault of third parties, such as the parties providing transportation or warehousing, the producers and the sellers of the products have the right to recover their respective losses from such third parties. If defective products are identified after they have been put into circulation, the producers or the sellers shall take remedial measures such as issuance of a warning, recall of products, etc., in a timely manner. The producers or the sellers shall be liable under tort if they fail to take remedial measures in a timely manner or have not made efforts to take remedial measures, thus causing damages. If the products are produced or sold with known defects, causing deaths or severe adverse health issues, the infringed party has the right to claim punitive damages in addition to compensatory damages.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Environment Protection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Environmental Protection Law of the PRC promulgated by the Standing Committee of the NPC, in December&#160;1989, amended in April&#160;2014 and effective in January&#160;2015, any entity which discharges or will discharge pollutants during its course of operations or other activities must implement effective environmental protection safeguards and procedures to control and properly treat waste gas, waste water, waste residue, dust, malodorous gases, radioactive substances, noise vibrations, electromagnetic radiation and other hazards produced during such activities. According to the provisions of the Environmental Protection Law, in addition to other relevant laws and regulations of the PRC, the Ministry of Environmental Protection and its local counterparts take charge of administering and supervising said environmental protection matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Environmental Protection Law, the environmental impact statement on any construction project must assess the pollution that the project is likely to produce and its impact on the environment, and stipulate preventive and curative measures; the statement shall be submitted to competent administrative department of environmental protection for approval. Installations for the prevention and control of pollution in construction projects must be designed, built and commissioned together with the principal part of the project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Law of the People&#8217;s Republic of China on Environment Impact Assessment, which was promulgated in October&#160;2002 and most recently amended in December&#160;2018, the State implements a classification-based management on the environmental impact assessment of construction projects according to the impact of the construction projects on the environment. Construction units shall prepare an Environmental Impact Report or an Environmental Impact Statement, or fill out the Environmental Impact Registration Form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Regulations on Urban Drainage and Sewage Disposal, which was promulgated in October 2013 and came into effect in January 2014, and the Measures for the Administration of Permits for the Discharge of Urban Sewage into the Drainage Network, which was promulgated in December 2022 and came into effect in February 2023, drainage entities covered by urban drainage facilities shall discharge sewage into urban drainage facilities in accordance with the relevant provisions of the state. Where a drainage entity needs to discharge sewage into urban drainage facilities, it shall apply for a drainage license in accordance with the provisions of these Measures. The drainage entity that has not obtained the drainage license shall not discharge sewage into urban drainage facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Fire Protection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Fire Prevention Law of the PRC, or the Fire Prevention Law, was adopted in April&#160;1998 and last amended in April&#160;2021. The Fire Prevention Law provides that fire control design and construction of a construction project shall comply with the State&#8217;s fire control technical standards. Developers, designers, builders and project supervisors shall be responsible for the quality of the fire control design and construction of the construction project pursuant to the law. Development project fire safety design examinations and acceptance systems shall be implemented for development projects which are required to have fire safety design in accordance with the national fire protection technical standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Eight Measures for the Public Security Fire Department to Deepen Reform and Serve Economic and Social Development promulgated by the Ministry of Public Security of the PRC in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">August&#160;2015, the fire protection design and completion acceptance fire protection record of construction projects with an investment of less than RMB300,000 or a building area of less than 300 square meters (or below the limit set by the housing and urban construction department of the provincial people&#8217;s government) was no longer required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Regulations on Overseas Securities Offering and Listing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2021, the CSRC promulgated the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or the Draft CSRC Administration Provisions, and the Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or the Draft CSRC Filing Measures, to regulate overseas offerings by domestic companies of equity shares, depository receipts, convertible corporate bonds, or other equity-like securities, and overseas listing of the securities for trading. Both direct and indirect overseas securities offering and listing by domestic companies would be regulated, of which the former refers to securities offering and listing in an overseas market made by a joint-stock company incorporated domestically, and the latter refers to securities offering and listing in an overseas market made in the name of an offshore entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following issuance of the Draft CSRC Filing Measures, on February 17, 2023, the CSRC issued the Notice on Filing Arrangements for Overseas Securities Offering and Listing by Domestic Companies (the &#8220;CSRC Filing Notice&#8221;), stating that the CSRC has published the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Trial Measures&#8221;) and five supporting guidelines (the &#8220;Listing Guidelines&#8221;), collectively the Trial Measures and Listing Guidelines, which came into effect on March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Trial Measures provide that an overseas listing or offering securities (which, for the purposes of the Trial Measures, are defined thereunder as equity shares, depository receipts, corporate bonds convertible to equity shares, and other equity securities that are offered and listed overseas, either directly or indirectly, by PRC domestic companies) is explicitly prohibited under any of the following circumstances: (i) such securities offering and listing is explicitly prohibited by provisions in laws, administrative regulations and relevant state rules of the PRC; (ii) the intended securities offering and listing may endanger national security as reviewed and determined by competent authorities under the State Council in accordance with law; (iii) the domestic company, its controlling shareholder(s) or the actual controller have committed relevant crimes such as corruption, bribery, embezzlement, misappropriation of property or undermining the order of the socialist market economy during the latest three years; (iv) the domestic company is currently under investigations for suspicion of criminal offenses or major violations of laws and regulations, and no conclusion has yet been made thereof; or (v) there are material ownership disputes over equity held by the domestic company&#8217;s controlling shareholder(s) or by other shareholder(s) that are controlled by the controlling shareholder(s) and/or actual controller.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A filing-based regulatory regime is adopted to regulate both direct and indirect overseas securities offering and listing by the domestic companies undert the Trial Measures. Direct overseas offering and listing by domestic companies refers to such overseas offering and listing by a joint-stock company incorporated domestically, while the indirect overseas offering and listing by domestic companies refers to the offering and listing by a company in the name of an overseas incorporated entity which major business operations are located domestically and such offering and listing is based on the underlying equity, assets, earnings or other similar rights of a domestic company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Trial Measures stipulate that an overseas listing will be determined as &#8220;indirect&#8221; if the issuer meets both of the following conditions: (1) 50% or more of any of the issuer&#8217;s operating revenue, total profit, total assets or net assets as documented in its audited consolidated financial statements for the most recent accounting year are accounted for by PRC domestic companies (&#8220;Condition I&#8221;), and (2) the main parts of the issuer&#8217;s business activities are conducted in the PRC, or its main places of business are located in the PRC, or the senior managers in charge of its business operations and management are mostly Chinese citizens or domiciled in the PRC (&#8220;Condition II&#8221;); whether Chinese citizens from Taiwan, Hong Kong, and Macau are included in the foregoing specification is not specified. The determination as to whether or not an overseas offering and listing by PRC domestic companies is indirect shall be made on a &#8220;substance over form&#8221; basis; the Listing Guidelines further stipulate that if an issuer not satisfying Condition I submits an application for issuance and listing in overseas markets in accordance with relevant non-PRC issuance regulations requiring such issuer to disclose risk factors mainly related to the PRC, the securities firm(s) and the issuer&#8217;s PRC counsel should follow the principle of &#8220;substance over form&#8221; in order to identify and argue whether the issuer should complete a filing under the Trial Measures.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Subsequent securities offerings of an issuer in (i) the same overseas market where it has previously offered and listed securities, and (ii) an overseas market other than one where the issuer has previously offered and listed securities shall be filed with the CSRC within three working days after offerings are completed.  Additionally, the Trial Measures stipulate that after an issuer has offered and listed securities in an overseas market, the issuer shall submit a report to the CSRC within three working days after the occurrence and public disclosure of (i) a change of control thereof, (ii) investigations of or </span>sanctions imposed on the issuer by overseas securities regulators or relevant competent authorities, (iii) changes of listing status or transfers of listing segment, and (iv) a voluntary or mandatory delisting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CSRC Filing Notice states that, beginning from March 31, 2023, PRC domestic enterprises which have already issued and listed securities overseas and fall within the scope of filing under the Trial Measures shall be considered &#8220;existing enterprises&#8221; (&#8220;Existing Listed Enterprises&#8221;). Existing Listed Enterprises are not required to complete filings immediately; rather, Existing Listed Enterprises should complete filings if they are subsequently involved in matters require filings, such as follow-on financing activities, in accordance with the Trial Measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Foreign Exchange and Dividend Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Foreign Exchange Control</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Regulation for the Foreign Exchange promulgated by the State Council in January&#160;1996, which was amended in January&#160;1997 and August&#160;2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment promulgated by the People&#8217;s Bank of China in June&#160;1996, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular of the State Administration of Foreign Exchange, or the SAFE, on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment and its appendix promulgated in November&#160;2012 and amended in May&#160;2015, October&#160;2018 and December&#160;2019 by the SAFE, (1)&#160;the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject to approval by the SAFE; (2)&#160;reinvestment with legal income of foreign investors in China is no longer subject to approval by SAFE; (3)&#160;the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified; (4)&#160;purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5)&#160;domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6)&#160;the administration over the conversion of foreign exchange capital of foreign-invested enterprises is improved. Later, the SAFE promulgated the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment in February&#160;2015, which was further amended in December&#160;2019 and prescribed that the bank instead of the SAFE can directly handle the foreign exchange registration and approval under foreign direct investment while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which were promulgated by the SAFE in May&#160;2013 and amended in October&#160;2018 and December&#160;2019, regulate and clarify the administration over foreign exchange administration in foreign direct investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises promulgated by the SAFE in Mach 2015 and amended in December&#160;2019, and the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects promulgated by the SAFE in June&#160;2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for their own operational purposes within the business scope of the foreign invested enterprises and follow the principles of authenticity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Dividend Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAFE promulgated the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control in January&#160;2017, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including the following: (1)&#160;under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (2)&#160;domestic entities shall hold income to account for previous years&#8217; losses before remitting the profits. Moreover, domestic entities shall make detailed explanations of sources of capital and utilization arrangements, and provide board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Foreign Exchange Registration of Offshore Investment by PRC Residents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAFE promulgated the SAFE Circular 37 in July&#160;2014. The SAFE Circular 37 requires PRC residents (including PRC institutions and individuals) to register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or the SPV, directly established or indirectly controlled by PRC residents for offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC residents are also required to amend their registrations with the SAFE when there is a change to the basic information of the SPV, such as changes of a PRC resident individual shareholder, the name or operating period of the SPV, or when there is a significant change to the SPV, such as changes of the PRC individual resident&#8217;s increase or decrease of its capital contribution in the SPV, or any share transfer or exchange, merger, division of the SPV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which was promulgated in February&#160;2015 and effective in June&#160;2015 and further amended in December&#160;2019, provides that PRC residents may register with qualified banks instead of the SAFE in connection with their establishment or control of an offshore entity established for the purpose of overseas direct investment. The SAFE and its branches shall implement indirect supervision over foreign exchange registration of direct investment via the banks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the registration procedures set forth in the SAFE Circular 37 may result in restrictions on the foreign exchange activities of the relevant onshore company, including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange capital, and may also subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Labor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Labor Law and Labor Contract Law</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Labor Law, which was promulgated by the Standing Committee of the NPC in July&#160;1994 and amended in August&#160;2009 and December&#160;2018, respectively, the PRC Labor Contract Law, which was promulgated by the Standing Committee of the NPC in June&#160;2007 and amended in December&#160;2012 and came into effect July&#160;2013, and the Implementing Regulations of the Employment Contracts Law of the PRC, which was promulgated by the State Council in September&#160;2008, labor contracts in written form shall be executed to establish labor relationships between employers and employees. In addition, wages cannot be lower than the local minimum wage. The employers must establish a system for labor safety and sanitation, strictly abide by State rules&#160;and standards, provide education regarding labor safety and sanitation to its employees, provide employees with labor safety and sanitation conditions and necessary protection materials in compliance with State rules, and carry out regular health examinations for employees engaged in work involving occupational hazards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Social Insurance and Housing Provident Funds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Social Insurance Law of PRC, which was promulgated by the Standing Committee of the NPC in October&#160;2010 and came into effect in July&#160;2011, and further amended in December&#160;2018, and the Interim Regulations on the Collection and Payment of Social Security Funds, which was promulgated by the State Council in January&#160;1999 and amended in March&#160;2019, and the Regulations on the Administration of Housing Provident Funds, which was promulgated by the State</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Council in April&#160;1999 and amended in March&#160;2002 and March&#160;2019, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to contribute may be fined and ordered to make good the deficit within a stipulated time limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Enterprise Income Tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Enterprise Income Tax Law promulgated by the Standing Committee of the NPC in March&#160;2007 and amended in February&#160;2017 and December&#160;2018, and the Implementation Rules&#160;of the Enterprise Income Tax Law of the PRC promulgated by the State Council in December&#160;2007 and amended in April&#160;2019, other than a few exceptions, the income tax rate for both domestic enterprises and foreign-invested enterprises is 25%. Enterprises are classified as either &#8220;resident enterprises&#8221; or &#8220;non-resident enterprises.&#8221; Besides enterprises established within the PRC, enterprises established outside China whose &#8220;de facto management bodies&#8221; are located in China are considered &#8220;resident enterprises&#8221; and subject to the uniform 25% enterprise income tax rate for their global income. A non-resident enterprise refers to an entity established under foreign law whose &#8220;de facto management bodies&#8221; are not within the PRC but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the PRC but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources within the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Notice on Promoting the Implementation of Corporate Income Tax Policies for Advanced Technology Service Enterprises Nationwide, or the Notice, since January&#160;2017, an enterprise which is recognized as an &#8220;Advanced Technology Service Enterprises&#8221; under the Notice enjoys a reduced enterprise income tax rate of 15%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Arrangement Between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with Respect to Taxes on Income, or the Double Tax Avoidance Arrangement, which was promulgated and came into effect in August&#160;2006, and other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5%. However, based on the Circular on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties which was promulgated by the State Administration of Taxation, the STA, in February&#160;2009, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. Based on the Announcement on Certain Issues with Respect to the &#8220;Beneficial Owner&#8221; in Tax Treaties, which was promulgated by the STA in February&#160;2018 and came into effect in April&#160;2018, if an applicant&#8217;s business activities do not constitute substantive business activities, it could result in the negative determination of the applicant&#8217;s status as a &#8220;beneficial owner,&#8221; and consequently, the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Value Added Tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Provisional Regulations of the PRC on Value-Added Tax, effective in January&#160;1994 and further amended in November&#160;2008, February&#160;2016, and November&#160;2017, and its implementation rules&#160;effected in January&#160;1994 and amended in December&#160;2008 and October&#160;2011, except stipulated otherwise, taxpayers who sell goods, labor services or tangible personal property leasing services or import goods shall be subject to a 17% tax rate; taxpayers who sell transport services, postal services, basic telecommunications services, construction services, or real property leasing services, sell real property, transfer the land use right shall be subject to an 11% tax rate, and taxpayers who sell services or intangible assets shall be subject to a 6% tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular of the Ministry of Finance and the State Administration of Taxation on Adjusting Value-added Tax Rates adopted in April&#160;2018, as of May&#160;2018, where a taxpayer engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 17% and 11% rates are adjusted to 16% and 10%.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Announcement on Relevant Policies for Deepening Value-Added Tax Reform, effective in April&#160;2019, the 16% VAT tax rate, which applies to the sales or imported goods of a VAT general taxpayer, will be lowered to 13%; and the 10% VAT tax rate will be lowered to 9%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Measures for the Exemption of Value-Added Tax from Cross-Border Taxable Activities in the Collection of Value-Added Tax in Lieu of Business Tax (for Trial Implementation) revised in June&#160;2018, if domestic enterprises provide cross-border taxable activities such as professional technical services, technology transfer, software services, the above-mentioned cross-border taxable activities are exempt from VAT.</p><a id="_4d041369_e2c4_4305_ab17_b7fef7d9b847"></a><a id="a4COrganizationalStructure_866231"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4.C. Organizational Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following diagram illustrates our corporate structure as of the date of this annual report, including our material subsidiaries directly or indirectly owned by us through equity ownership (our group structure does not include any variable interest entities):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20221231x20f029.jpg" alt="Graphic" style="display:inline-block;height:224.63pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:480.6pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e93d9ccd_d41b_486e_9139_6c906847ba80"></a><a id="a4DPropertyPlantsandEquipment_662127"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4.D. Property, Plants and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our headquarter is based in Suzhou, China, which are approximately 2,946 square meters in size. The expiration dates of the lease agreements for this facility range from March 31, 2023 to September 15, 2024. We also have a 1,081 square feet facility in San Diego, California for laboratory, research and development functions, the lease for which expires on August 31, 2023. We do not expect difficulties in renewing lease agreements for our facilities.</p><a id="_e71b83a5_9ebe_43ae_acae_43e626f5bfb1"></a><a id="ITEM4AUNRESOLVEDSTAFFCOMMENTS_814425"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 4A. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_37cef03b_92cb_4cbf_93ad_50ea71d1ddf1"></a><a id="ITEM5OPERATINGANDFINANCIALREVIEWANDPROSP"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the section entitled &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements and the related notes included elsewhere in this annual report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those we describe under &#8220;Item 3.D. Risk Factors&#8221; and elsewhere in this annual report.</p><a id="_dec69990_6e80_4032_91ae_6950b25d298d"></a><a id="a5AOperatingResults_653990"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.A. Operating Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. We are combining computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by our proprietary Dynamic Precision Library (DPL) platform, which fuels our NEObody&#8482;, SAFEbody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and POWERbody&#8482; technologies, we are developing a highly differentiated pipeline of novel immunotherapies. We have forged strategic collaborations with reputable global partners that leverage our technology in multiple approaches at the vanguard of science. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. We have pioneered a dynamic antibody technology interface to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Additionally, we have a proprietary precision masking technology and specialized antibody engineering capabilities which enable us to design therapeutics with unique features.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Dynamic Precision Library fuels our three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates. By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated and wholly-owned clinical-stage pipeline consists of two anti-CTLA-4 antibodies ADG116 (NEObody) and ADG126 (SAFEbody), and two anti-CD137 antibodies ADG106 (NEObody) and ADG206 (POWERbody). ADG116, ADG126 and ADG106 are in Phase 1b/2 clinical evaluation in single agent and/or combination clinical trials designed to evaluate safety and preliminary efficacy, while ADG206 is in Phase 1 single agent clinical trial. We also have a robust preclinical pipeline of four programs in IND-enabling studies, including a masked anti-CD47 SAFEbody, as well as over 50 programs in various stages of discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2011, our operations have focused on organizing and staffing our company, conducting preclinical studies and clinical trials, business planning, establishing our intellectual property portfolio and raising capital. We do not have any product candidates approved for sale and have not generated any revenue from product sales. We have financed operations mainly through the private placements of our preferred shares before our initial public offering completed in February 2021 and through proceeds received from the initial public offering. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. Our net losses were US$42.4, US$73.2 million and US$80.0 million for the years ended December 31, 2020, 2021 and 2022, respectively. As of December 31, 2022, we had accumulated deficit of US$258.8 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue advancement of and investment in our proprietary DPL platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance the development of ADG116, ADG126, ADG106, ADG206 and other preclinical drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our ongoing and planned research and development of other lead product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discover and develop additional antibody product candidates and further expand our preclinical and clinical product pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our collaborations with contract manufacturing organizations and contract research organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales and marketing teams and distribution network to commercialize any product candidate for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire and retain additional clinical, scientific, management and administrative personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operations globally; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beginning in January&#160;2020, the emergence and wide spread of COVID-19 has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in the United States and China and elsewhere. Substantially all of our operating and workforce are based in the United States and China. Since late July 2021, the delta variant of COVID-19 has resurged in several provinces across China and the Omicron variant of COVID-19 has been detected in most states and territories of the United States and is rapidly increasing the proportion of COVID-19 cases it is causing. Consequently, the COVID-19 outbreak and its resurgences caused by the new variants could potentially delay a patient&#8217;s access to hospital and the progress of our clinical trials, including patient enrollment, which may adversely affect our business operations, financial condition and operating results for 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The extent of the impact of the COVID-19 pandemic on our business, operations and regulatory and commercialization timelines will depend on certain developments, including the duration and spread of the outbreak and its impact on clinical trials, regulatory authorities and our key scientific and management personnel as well as its impact on our partners, laboratory sites, and other third parties with whom we collaborate, and the extent of future resurgences of the disease and its variants, vaccine distribution and other actions in response to the virus or to contain its impact, and we are closely monitoring its impact on us. See &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks relating to obtaining regulatory approval of our drug candidates&#8212;The COVID-19 pandemic could adversely impact our business, including our clinical trials.&#8221; We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter our business operations, including those that may be required by government authorities, or that we determine are in the best interests of our employees, partners and shareholders. At this point, the extent to which the COVID-19 pandemic may impact our business, operations and regulatory and commercialization timelines remains uncertain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Key Components of Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licensing and collaboration revenue.</i> Our licensing and collaboration revenue is currently comprised of upfront and/or milestone payments associated with out-licensing arrangements. Our licensing and collaboration revenue for the years ended December 31, 2020, 2021 and 2022 was primarily derived from granting licenses to use and otherwise exploit certain of our intellectual properties. To date, we have not generated any revenue from the sale of products and do not expect to generate any revenue from product sales in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses. </i>Our research and development expenses consist principally of (1)&#160;payroll and other related costs of personnel engaged in research and development activities, (2)&#160;costs related to pre-clinical testing of our technologies under development and clinical trials such as payments to contract research organizations, or CRO, and contract manufacturing organization, or CMO, investigators and clinical trial sites that conduct the clinical studies, (3)&#160;costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4)&#160;other research and development expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2020, 2021 and 2022, our research and development expenses were US$33.5 million, US$68.1 million and US$81.3 million, respectively. The increase was primarily due to increased research and development activities for our clinical programs and preclinical testing for candidates in the IND-enabling phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses may vary substantially from period to period according to the status of our research and development activities. The timing of expenses is impacted by the commencement of clinical trials and enrollment of patients in clinical trials. Research and development expenses are expected to increase as we advance the clinical development of ADG116, ADG126, ADG106 and ADG206, and further advance the research and development of our other product candidates. The successful development of our product candidates is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses for our clinical-stage product candidates, preclinical product candidates and research pipeline for the years ended December 31, 2020, 2021 and 2022, respectively.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">ADG126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,091</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,543</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,229</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">ADG116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,156</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,236</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,271</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">ADG106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,504</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,798</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,604</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Preclinical product candidates, research pipeline and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,787</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 38,522</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 42,236</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 33,538</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 68,099</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 81,340</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical supplies, and establishing commercial supplies, of any product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of establishing sales, marketing and distribution capabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaboration, licensing or other arrangements that we may establish, including any required milestone and royalty payments thereunder.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of our product candidates or any other current or future product candidates could mean a significant change in the costs and timing associated with the development of such product candidate. For example, if we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated or if we experience significant delays in enrollment in any clinical trials, we could incur significant additional costs and the clinical development timeline for our product candidates may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Administrative expenses</i> <i style="font-style:italic;">. </i>. Our administrative expenses consist primarily of wages, salaries and benefits for personnel other than research and development staff. Our administrative expenses, excluding share-based compensation expenses, may decrease in absolute amount in the year ended December 31, 2023 as we implement different cost control measures.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Other income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income primarily includes government subsidies that Adagene Suzhou received from local government in the PRC. The receipt of such government subsidies is not dependent on our performance of any obligations. In addition, the subsidiary in Australia received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Taxation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Cayman Islands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, we are not subject to income, corporation or capital gains tax in the Cayman Islands. In addition, our payment of dividends, if any, is not subject to withholding tax in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our wholly-owned subsidiary in Hong Kong, Adagene (Hong Kong) Limited, is subject to Hong Kong profits tax on the taxable income as reported in its statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. Under Hong Kong tax law, our subsidiary in Hong Kong is exempted from income tax on their foreign-derived income and there is no withholding tax in Hong Kong on remittance of dividends. No provision for Hong Kong profits tax was made as there were no assessable profits derived from or earnings in Hong Kong for the years ended December 31, 2020, 2021 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:10.8pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our subsidiary in the U.S., Adagene Incorporated, is incorporated in the U.S. and subject to U.S. federal corporate income tax at a rate of 21%. It is also subject to state income tax in California of 8.84%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to 30% withholding tax, unless the respective non-U.S. resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">PRC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our subsidiary in China is incorporated under PRC law and, as such, is subject to PRC enterprise income tax on their taxable income in accordance with the relevant PRC income tax laws. Pursuant to the PRC Enterprise Income Tax Law, or EIT Law, which became effective on January 1, 2008, a uniform 25% enterprise income tax rate is generally applicable to both foreign-invested enterprises and domestic enterprises, except where a special preferential rate applies. In accordance with the implementation rules of EIT Law, a qualified Technology Advanced Service Enterprises, or TASE, is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every year. Adagene Suzhou was first recognized as a qualified TASE in March 2015 and renewed in December 2018 and December 2021. Adagene Suzhou can enjoy the preferential tax rate of 15% from 2015 to at least 2023. In addition, the research and development expenses of Adagene Suzhou are subject to a 75% super-deduction for the income tax, which increased to 100% from October 2022 to December 2022. The enterprise income tax is calculated based on the entity&#8217;s global income as determined under PRC tax laws and accounting standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to VAT at a rate of 3%, 6%, or 13% on the services we provide and related surcharges. We are also subject to surcharges on VAT payments in accordance with PRC law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Cayman Islands holding company, we may receive dividends from Adagene Suzhou. The PRC EIT Law and its implementing rules&#160;provide that dividends paid by a PRC entity to a nonresident enterprise for income tax purposes is subject to PRC withholding tax at a rate of 10%, subject to reduction by an applicable tax treaty with China. Pursuant to the Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, the withholding tax rate in respect to the payment of dividends by a PRC enterprise to a Hong Kong enterprise may be reduced to 5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least 25% of the PRC enterprise. Pursuant to the Notice of the State Administration of Taxation on the Issues concerning the Application of the Dividend Clauses of Tax Agreements, or SAT Circular 81, a Hong Kong resident enterprise must meet the following conditions, among others, in order to apply the reduced withholding tax rate: (i)&#160;it must be a company; (ii)&#160;it must directly own the required percentage of equity interests and voting rights in the PRC resident enterprise; and (iii)&#160;it must have directly owned such required percentage in the PRC resident enterprise throughout the 12 months prior to receiving the dividends. In August&#160;2015, the State Administration of Taxation promulgated the Administrative Measures for Nonresident Taxpayers to Enjoy Treatment under Tax Treaties, or SAT Circular 35, which later became effective on January&#160;1, 2020. SAT Circular 35 provides that non-resident enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced withholding tax. Instead, nonresident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, and file necessary forms and supporting documents when performing tax filings, which will be subject to post-tax filing examinations by the relevant tax authorities. Accordingly, Adagene (Hong Kong) Limited may be able to benefit from the 5% withholding tax rate for the dividends it receives from its PRC subsidiary, if it satisfies the conditions prescribed under SAT Circular 81 and other relevant tax rules&#160;and regulations. However, according to SAT Circular 81 and SAT Circular 35, if the relevant tax authorities consider the transactions or arrangements we have are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable withholding tax in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a &#8220;resident enterprise&#8221; under the PRC EIT Law, it would be subject to enterprise income tax on its worldwide income at a rate of 25%. See &#8220;Item 3 Key Information&#8212; Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Judgments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements include the financial statements of Adagene Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in our consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The functional currency of Adagene Inc., Adagene (Hong Kong) Limited, Adagene Incorporated, Adagene PTE. Ltd. and Adagene Project C1 PTE. Ltd. is the U.S. dollar, or US$. The functional currency of our PRC subsidiary is Renminbi, or RMB. The functional currency of our Australia subsidiary is Australian dollar, or AU$.The functional currency of our Swiss subsidiary is Swiss Franc, or CHF. The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification, or ASC, 830, <i style="font-style:italic;">Foreign Currency Matters</i>. We use US$ as our reporting currency. The financial statements of our PRC subsidiary, Australia subsidiary and Swiss subsidiary are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are re-measured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China, or the PBOC, prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangement, we analyze the arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i>, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>, or ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the criteria of ASC 606, we recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. We adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. We review the contract to determine which performance are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property</i>: Upfront non-refundable payments for licensing our intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. For licenses determined not to be distinct, we account for the promise to grant a license and those other promised goods or services together as a single performance obligation when recognizing revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i>: The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized over time as delivery of such services occurs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments</i>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract assets and contract liabilities</i>: When a customer pays consideration before we transfer products or services, we record our obligation as a contract liability; when we satisfy our performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, we recognize our rights to consideration as a contract asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We apply ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>, or ASC 820. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, short-term investments, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not transfer any assets or liabilities in or out of Level 3 during the year ended December 31, 2021 or 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December 31, 2021 and 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of our technologies under development and clinical trials such as payments to contract research organizations, or CRO, and contract manufacturing organizations, or CMO, investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, (4) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses. As of December 31, 2022, we have several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at our option. We did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2021 or 2022 as we did not have any plan to cancel the existing CRO or CMO contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We follow the liability method of accounting for income taxes in accordance with ASC 740,&#160;<i style="font-style:italic;">Income Taxes</i>, or ASC 740. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. We record a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We evaluate our uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognize in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is our policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have incurred net accumulated operating losses for income tax purposes since our inception. We believe that it is more likely than not that these net accumulated operating losses will not be utilized in the near future. Therefore, we have provided full valuation allowances for the deferred tax assets for subsidiaries other than the U.S. subsidiary as of December 31, 2021 and for all subsidiaries as of December 31, 2022. There was no income tax expense for the years ended December 31, 2020, as our subsidiaries did not have any taxable profits. For the year ended December 31, 2021 and 2022, income tax expense was US$1.7 and US$0.5 million due to taxable profits generated by the U.S. subsidiary, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We grant restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the company concludes that it is probable that the performance conditions will be achieved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, we recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, we have made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. Our management is ultimately responsible for the determination of the estimated fair value of its ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions used to estimate the fair value of the share options granted are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the year eneded December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.68% - 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.11% - 1.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.92% - 4.25 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">72.3% - 73.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">73.1% - 75.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">74.2% - 74.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A list of recent relevant accounting pronouncements is included in Note 2 &#8220;Summary of Significant Accounting Policies&#8221; to our consolidated financial statements included elsewhere in this annual report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our consolidated results of operations for the periods presented. This information should be read together with our consolidated financial statements and related notes included elsewhere in this annual report. The operating results in any period are not necessarily indicative of the results that may be expected for any future period.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except per share information)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Licensing and collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 701</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9,293</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,538)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68,099)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (81,340)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10,315)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14,440)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (11,874)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,853)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (82,539)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (93,214)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,152)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,364)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (83,921)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 629</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 378</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (202)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (364)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (693)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 972</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,779</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,168</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain (loss), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (645)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (603)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,555</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,397)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (71,476)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,513)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,702)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (459)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,397)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,178)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,972)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustments, net of nil tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 257</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (755)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,403)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,921)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (80,727)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,397)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,178)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,972)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (248)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,645)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,206)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,972)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of ordinary shares used in per share calculation:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,951</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54,135</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,951</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54,135</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.67)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.48)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.67)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.48)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Year Ended December&#160;31, 2022 Compared to Year Ended December&#160;31, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Licensing and collaboration revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our licensing and collaboration revenue was US$9.3 million for the year ended December 31, 2022, compared to US$10.2 million for the year ended December 31, 2021. Our licensing and collaboration revenue in 2022 was recognized due to fulfillment of performance obligations over time associated with the collaboration and technology licensing agreement with Sanofi to develop antibody-based therapies. Such revenue was also recognized from the material transfer and option agreement with ADCT as performance obligation was satisfied at a point in time in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our total research and development expenses for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and development expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Payroll and other related costs of personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 41.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,093</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Costs related to clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,278</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29,384</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 36.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Costs related to clinical trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,371</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,277</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">CMC and toxicology costs associated with the clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,907</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,107</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Costs related to preclinical testing of non-clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,795</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 20,697</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 25.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Costs required to develop the product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,103</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,216</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,950</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 68,099</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 81,340</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses increased by 19.4% from US$68.1 million for the year ended December 31, 2021 to US$81.3 million for the year ended December 31, 2022, primarily attributable to increased research and development activities for our clinical programs and preclinical testing for candidates in the IND-enabling phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our administrative expenses decreased by 17.4% from US$14.4 million for the year ended December 31, 2021 to US$11.9 million for the year ended December 31, 2022, primarily attributable to a decrease in personnel expenses of US$2.1 million, and a decrease in professional fees and office-related expenses of US$0.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Loss from operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, our loss from operations increased by 15.9% from approximately US$72.4 million in the year ended December 31, 2021 to approximately US$83.9 million in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Interest income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our interest income was US$0.4 million for the year ended December 31, 2022, as compared to US$0.1 million for the year ended December 31, 2021. This increase was primarily attributable to an increase in interest rate and increase in the amount of term deposits placed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Other income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our other income increased from US$1.8 million for the year ended December 31, 2021 to US$2.2 million for the year ended December 31, 2022, primarily attributable to (i) an increase in government subsidies received by Adagene Suzhou to support our ongoing operations in Jiangsu Province during the year ended December 31, 2022, and (ii) a research and development tax incentive from the Australian Taxation Office received by Adagene Australia Pty Ltd, our wholly-owned subsidiary in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Foreign exchange loss, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recorded foreign exchange loss of US$0.6 million for the year ended December 31, 2021 and foreign exchange gain of US$2.6 million for the year ended December 31, 2022. This gain of foreign exchange was primarily attributable to the appreciation of U.S. dollars against Renminbi which positively impacted our U.S. dollar denominated accounts receivable of Adagene Suzhou.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Income tax expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our income tax expense was US$1.7 million for the year ended December 31, 2021 as compared to US$0.5 million for the year ended December 31, 2022. The income tax expense for the year ended December 31, 2022 was primarily attributable to the current tax expenses on income reported by Adagene Incorporated, our wholly owned subsidiary in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Net loss attributable to Adagene Inc.&#39;s shareholders</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our net loss for the period increased by 9.3% from US$73.2 million for the year ended December 31, 2021 to US$80.0 million for the year ended December 31, 2022. The 2022 net loss was higher largely due to increases in costs associated with clinical, pre-clinical and CMC activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Year Ended December 31, 2021 Compared to Year Ended December 31, 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 5. Operating and Financial Review and Prospects &#8211; 5.A Operating Results &#8212;Year Ended December 31, 2021 Compared to Year Ended December 31, 2020&#8221; beginning on page 166 of our annual report on <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1818838/000110465922050329/adag-20211231x20f.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission on April 26, 2021</span></a> incorporated by reference into this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Non-GAAP Financial Measures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-GAAP net loss, which is defined as net loss attributable to ordinary shareholders for the period after excluding (i) share-based compensation expenses and (ii) accretion of convertible redeemable preferred shares to redemption value, as applicable. The Non-GAAP net loss was US$69.5 million for the year ended December 31, 2022, compared to US$54.5 million for the same period in 2021. Non-GAAP net loss per ordinary share for the year ended December 31, 2022 on both basic and diluted basis was US$1.28. Non-GAAP net loss per ordinary share for the year ended December 31, 2021 on both basic and diluted basis was US$1.09.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use non-GAAP net loss and non-GAAP net loss per ordinary share for the year, which are non-GAAP financial measures, in evaluating our operating results and for financial and operational decision-making purposes. We believe that non-GAAP net loss and non-GAAP net loss per ordinary share for the year help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in our loss for the year. We believe that non-GAAP net loss and non-GAAP net loss per ordinary share for the year provide useful information about our results of operations, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by its management in our financial and operational decision-making.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-GAAP net loss and non-GAAP net loss per ordinary share for the year should not be considered in isolation or construed as an alternative to operating profit, loss for the year or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-GAAP net loss and non-GAAP net loss per ordinary share for the year and the reconciliation to their most directly comparable GAAP measures. Non-GAAP net loss and non-GAAP net loss per ordinary share for the year here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encoruage investors and others to review our financial information in its entirety and not rely on a single financial measure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-GAAP net loss and non-GAAP net loss per ordinary share for the year represent net loss attributable to ordinary shareholders for the year excluding (i) share-based compensation expenses, and (ii) accretion of convertible redeemable preferred shares to redemption value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please see the &#8220;Reconciliation of GAAP and Non-GAAP Results&#8221; below for a full reconciliation of GAAP net loss attributable to ordinary shareholders for the year to non-GAAP net loss attributable to ordinary shareholders and non-GAAP net loss per ordinary share for the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Reconciliation of GAAP and Non-GAAP Results</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">GAAP net loss attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,645,392)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,206,488)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,971,847)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Add back:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,129,541</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,679,658</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,520,282</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 248,113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,553</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-GAAP net loss attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (32,267,738)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (54,498,277)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (69,451,565)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of ordinary shares used in per share calculation:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,950,698</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032,009</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54,135,084</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,950,698</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032,009</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 54,135,084</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-GAAP net loss per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.02)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.09)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.28)</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.02)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.09)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.28)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_7ec1bf1b_8fc8_4393_94d4_b889bbb63a06"></a><a id="a5BLiquidityandCapitalResources_247343"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.B. Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the inception, we have incurred net losses and negative cash flow from our operations. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval and subsequently commercialize one of our current or future drug candidates. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to expand our research and development capabilities, invest in preclinical tests and clinical trials and increase our efforts in obtaining regulatory approvals. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Moreover, we expect to incur additional costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal source of liquidity has been cash generated from the proceeds received from the issuance and sale of our shares. In February 2021, we completed our initial public offering in which we issued and sold an aggregate of 8,457,100 ADSs, representing 10,571,375 ordinary shares, resulting in net proceeds to us of approximately US$145.9 million, net of the underwriting discounts and commissions and other fees paid or payable by us in connection with the offering. As of December 31, 2022, we had US$143.8 million in cash and cash equivalents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to finance our future working capital requirements and capital expenditures primarily from funds raised from financing activities, including the net proceeds received from our initial public offering, future public and private offerings of our securities, proceeds from our collaborations, and/or proceeds from borrowings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on our current operating plan, we believe that our current cash and cash equivalents will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for at least the next 12 months.The assumptions on which our estimates are based may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amount of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In utilizing the proceeds that we received from our initial public offering, we may make capital contributions to our subsidiaries in the PRC, the United States, Australia, Hong Kong, Singapore and Switzerland, acquire or establish new subsidiaries, or grant loans to our subsidiaries. However, uses of the proceeds by our PRC subsidiary are subject to PRC regulations. See &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.&#8221; We have operations in China and many of the related transactions are settled in Renminbi. Our financial statements are presented in U.S. dollars. Under existing PRC foreign exchange regulations, Renminbi may be converted into foreign currencies for current account items, including profit distributions, interest payments and trade- and service-related foreign exchange transactions, without prior SAFE approval as long as certain routine procedural requirements are fulfilled. Our PRC subsidiary is allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from or registration with competent government authorities is required where the Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents our selected consolidated cash flow data for the years ended December 31, 2020, 2021 and 2022.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28,530)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43,415)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (48,612)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net cash (used in) generated from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,073</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,510)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (686)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net cash generated from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,439</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 145,357</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,823</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (364)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (192)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 843</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,382)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 99,240</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (30,632)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 92,533</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 75,151</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 174,391</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 75,151</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 174,391</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 143,759</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Operating activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was US$48.6 million in 2022. The difference between our net loss of US$80.0 million and the net cash used in operating activities was mainly due to (i) an increase in prepayments and other current assets of US$0.9 million, (ii) a decrease in accruals and other current liabilities of US$0.8 million, (iii) a decrease in income tax payable of US$1.7 million as income tax was paid, and (iv) a decrease in lease liabilities of US$0.3 million given adoption of ASC 842, offset by (i) non-cash share-based compensation expenses of US$10.5 million, (ii) a decrease of accounts receivable of US$3.0 million given receipt of milestone payment from Exelixis, Inc., (iii) a decrease in amounts due from related parties of US$3.9 million, (iv) an increase of accounts payable of US$0.3 million, (v) an increase in contract liabilities of US$9.6 million given receipt of upfront fee from Sanofi, (vi) an increase in amount due to related parties of US$8.9 million, (vii) depreciation and amortization of US$1.1 million, and (viii) amortization of right-of use assets and interest of lease liabilities of US$0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was US$43.4 million in 2021. The difference between our net loss of US$73.2 million and the net cash used in operating activities was mainly due to (i) an increase of accounts receivable of US$3.0 million due to milestone payment from Exelixis, Inc. which was received in January 2022, (ii) an increase in prepayments and other current assets of US$0.2 million due to our prepaid service fees to our vendors, and (iii) an increase in amount due from related parties of US$4.4 million due to prepayments made to our related parties, offset by (i) non-cash share-based compensation expenses of US$18.7 million, (ii) an increase in accounts payable of US$1.5 million, (iii) an increase in contract liabilities of US$4.8 million, (iv) an increase in amount due to related parties of US$7.9 million, (v) an increase in accruals and other current liabilities of US$1.1 million, (vi) an increase in income tax payable of US$1.7 million, and (vii) depreciation and amortization of US$1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was US$28.5 million in 2020. The difference between our net loss of US$42.4 million and the net cash used in operating activities was mainly due to (i)&#160;an increase in prepayments and other current assets of US$2.3 million due to our prepaid service fees to our vendor, (ii)&#160;a decrease in contract liabilities of US$0.3 million, offset by (i)&#160;non-cash share-based compensation expenses of US$10.1 million, (ii)&#160;an increase in accounts payable of US$1.1 million (iii)&#160;a decrease in accounts receivable of US$0.5 million, (iv)&#160;a decrease in amount due from related parties of US$1.3 million, (v)&#160;an increase in accruals and other current liabilities of US$1.2 million, and (vi)&#160;depreciation and amortization of US$0.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Investing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was US$0.7 million in 2022, which was primarily attributable to the purchase of property, equipment and software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was US$2.5 million in 2021, which was attributable to the purchase of property, equipment and software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from investing activities was US$7.1 million in 2020, which was primarily attributable to withdrawal of short-term investments of US$8.0 million, partially offset by purchase of property, equipment and software of US$0.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Financing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from financing activities was US$17.8 million in 2022, which was mainly attributable to proceeds from borrowings of US$25.8 million, offset by (i) repayment of borrowings of US$4.4 million, and (ii) purchase of treasury shares under stock repurchase program of US$4.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from financing activities was US$145.4 million in 2021, which was mainly attributable to (i) proceeds from initial public offering net of underwriting commissions of $149.4 million, and (ii) proceeds from borrowings of US$4.4 million, offset by (i) repayment of borrowings of US$5.1 million, (ii) payment of initial public offering costs of US$1.6 million, and (iii) purchase of treasury shares under stock repurchase program of US$2.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from financing activities was US$4.4 million in 2020, which was mainly attributable to proceeds from borrowings of US$6.1 million, partially offset by repayment of borrowings of US$1.1 million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Capital Expenditures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our capital expenditures are incurred primarily in connection with research and development equipment. Our capital expenditures were US$0.9 million, US$2.5 million and US$0.7 million, in 2020, 2021 and 2022, respectively. We intend to fund our future capital expenditures with our existing cash balance. We will continue to incur capital expenditures to meet the expected growth of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Holding Company Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adagene Inc. is a holding company with no material operations of its own. Adagene Inc. holds certain intellectual properties and outsources certain research and development activities related to these intellectual properties to its subsidiaries. We conduct our operations primarily through our subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by our subsidiaries. If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our subsidiary in China is permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with the Accounting Standards for Business Enterprise as promulgated by the Ministry of Finance of the PRC, or PRC GAAP. Pursuant to the law applicable to China&#8217;s foreign investment enterprise, our subsidiary that is foreign investment enterprise in the PRC has to make appropriation from its after-tax profit, as determined under PRC GAAP, to reserve funds including (i)&#160;general reserve fund, (ii)&#160;enterprise expansion fund and (iii)&#160;staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the reserve fund has reached 50% of the registered capital of our subsidiary. Appropriation to the other two reserve funds are at our subsidiary&#8217;s discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an offshore holding company, we are permitted under PRC laws and regulations to provide funding from the proceeds of our offshore fund-raising activities to our PRC subsidiary through loans or capital contribution, subject to the satisfaction of the applicable government registration and approval requirements. See &#8220;Item 3 Key Information&#8212; Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.&#8221; As a result, there is uncertainty with respect to our ability to provide prompt financial support to our PRC subsidiary when needed.</p><a id="_11612545_0f96_4de6_a95d_0ca2b190ebc9"></a><a id="a5CResearchandDevelopmentPatentsandLicen"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.C. Research and Development, Patents and Licenses, Etc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 4 Information on the Company&#8212;4.C. Business Overview &#8212; Our Platform&#8221; and &#8220;&#8212;Intellectual Property.&#8221;</p><a id="_4f0af32e_dbb6_499a_a4e0_b6554ed5092e"></a><a id="a5DTrendInformation_715692"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.D. Trend Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the year ended December 31, 2022 that are reasonably likely to have a material and adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results of operations or financial condition. </p><a id="_1444a214_6b78_44b4_8ac6_be93da4090a0"></a><a id="a5ECriticalAccountingEstimates_321468"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.E. Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of these estimates are considered critical as they involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our consolidated financial statements. Our critical accounting estimates are summarized below. See Note 2 to our consolidated financial statements included elsewhere in this annual report for a description of our significant accounting policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We adopted ASC 606 for all periods presented. Consistent with the criteria of ASC 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price based on contractual price and other factors for each performance obligation identified in the contract. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method based on the nature and preconditions of the development milestones. There are uncertainties in terms of the judgement over the probability of achieving such development milestones and any related constraint. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in assumptions or estimates can materially affect the revenue recognized. The assessment and conclusion reached for revenue recognition are disclosed in note 10 to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical trial costs are a significant component of our research and development expenses. We have a history of contracting with third parties that perform various preclinical and clinical trial activities on behalf of us during the ongoing research and development process. Expenses related to preclinical and clinical trials are accrued based on our estimates of the actual services performed by the third parties for the respective period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of estimating our research and development expenses involves reviewing open contracts and purchase orders, communicating with our research and development personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share based compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the we conclude that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including expected volatility, the exercise multiple, the risk free rate and the dividend yield and making assumptions about them. The cost related to share based compensation is sensitive to the aforementioned inputs. These inputs are evaluated periodically considering historical actuals and management judgement. For the measurement of the fair value of share options at the grant date, we use a binomial option valuation model. Changes in assumptions or estimates can materially affect the fair value of the share-based compensation awards. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 9 to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred tax assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i>, we recognize in our financial statements the benefit of a tax position if the tax position is more likely than not to prevail based on the facts and technical merits of the position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Judgement is required to determine whether deferred tax assets are recognized in the statement of financial position. Deferred tax assets arise because of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as from net operating losses. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. However, the ultimate realization of our deferred tax assets is subject to a number of variables, including our future profitability within relevant tax jurisdictions. The actual benefits ultimately realized may differ from our estimates. The assessment of the deferred tax assets as well as related valuation allowance is disclosed in note 11 to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_b640d172_5697_4ef7_8a51_b7242440d58a"></a><a id="ITEM6DIRECTORSSENIORMANAGEMENTANDEMPLOYE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</p><a id="_06c84e73_44a8_46f2_853f_6208d9ce514d"></a><a id="a6ADirectorsandSeniorManagement_393694"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.A. Directors and Senior Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding our executive officers, key employees and directors as of the date of this annual report.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position/Title</b></p></td></tr><tr><td style="vertical-align:top;width:49.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Peter Luo, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Co-Founder, Chief Executive Officer and Chairman of the Board</p></td></tr><tr><td style="vertical-align:top;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Fangyong (Felix) Du, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Technology Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:49.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">JC Xu, M.D., Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Scientific Officer</p></td></tr><tr><td style="vertical-align:top;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Qinghai Zhao, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Manufacturing Officer</p></td></tr><tr><td style="vertical-align:top;width:49.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Man Kin (Raymond) Tam, M.B.A., B. Eng.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Financial Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Chunfang (Vicky) Gu M.B.A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Director of Finance</p></td></tr><tr><td style="vertical-align:top;width:49.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Executive Director of Human Resources</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Key Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position/Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yan Li, M.B.A.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Vice President, Bioinformatics and Information Technology</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Xiaohong (Kristine) She</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Vice President, Head of Clinical Operations</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Guizhong Liu, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Head of Biology and Pharmacology</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Alexander Goergen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President, Head of Business Development</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Songmao Zheng, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President, Head of Clinical and Quantitative Pharmacology</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Jiping Zha</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Executive Vice President of Clinical Development</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Wenlin Zeng</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President of Early Stage CMC</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Ami Knoefler</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President of Investor Relations and Corporate Communications</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Dana Hu-Lowe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President of Global Product Team Leadership</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Ai Li</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President, Head of Biometrics</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position/Title</b></p></td></tr><tr><td style="vertical-align:top;width:49.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yumeng Wang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Andy (Yiu Leung) Cheung</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr><tr><td style="vertical-align:top;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Min Li</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yuwen Liu*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr><tr><td style="vertical-align:top;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Cuong Do</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr><tr><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Mervyn Turner, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="white-space:pre-wrap;">*  The expiry of initial term of our independent director Yuwen Liu has been extended from February 2023 to April 2023. Upon the filing of our annual report for the year ended Decemebr 31, 2022, the extended initial term of Ms. Liu&#8217;s directorship will expire and Ms. Liu will depart from the Board and audit committee of the Board. Ms. Liu has confirmed that she has no disagreement with the Board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Executive Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Peter Luo, Ph.D. </span>is our Co-Founder and has served as our Chief Executive Officer since November&#160;2011 and Chairman of the Board of the Directors since February&#160;2018. Dr.&#160;Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor (Nasdaq: XNCR) from July&#160;1998 to August&#160;2000. In September&#160;2000, Dr.&#160;Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May&#160;2006, Dr.&#160;Luo led the acquisition of Abmaxis Inc. by Merck&#160;&amp; Co. (NYSE: MRK), after which Dr.&#160;Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck&#160;&amp; Co. Throughout his career, Dr.&#160;Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr.&#160;Luo received his bachelor&#8217;s degree in applied chemistry in technical physics from Peking University in 1986, master&#8217;s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr.&#160;Luo also completed his postdoctoral research in protein folding at Stanford University in 1998. Dr.&#160;Luo&#8217;s spouse is Xiaohong (Kristine) She who is our Senior Vice President, Head of Clinical Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fangyong (Felix) Du, Ph.D. </span>joined us as Vice President of Technology Development in January&#160;2012 and has served as our Chief Technology Officer since May&#160;2019 and our director since April 2023. Dr.&#160;Du has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. Dr.&#160;Du worked at Affomix from October&#160;2009 to July&#160;2010 and Illumina (Nasdaq: ILMN) from July&#160;2010 to January&#160;2012, and then joined the Company in January&#160;2012 as the Vice President of Technology Development. Dr.&#160;Du received his bachelor&#8217;s degree and master&#8217;s degree in physiology and biophysics in 1991 and 1994, respectively, from Peking University, and his Ph.D. degree in biology from the California Institute of Technology in 2001. Dr.&#160;Du also completed his postdoctoral research from Yale University in 2007.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">JC Xu, M.D., Ph.D. </span>has served as our Chief Scientific Officer since August&#160;2020. Dr.&#160;Xu has more than 20 years of experience in oncology drug discovery and development, and more than four years of experience in business development, strategy, and operations in the biopharmaceutical industry in the United States. Prior to joining Adagene, Dr.&#160;Xu was head of R&amp;ED China Strategy at Celgene now BMS from 2017 to 2020. Prior to that, Dr.&#160;Xu was Director of Strategy&#160;&amp; Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals from 2012 to 2017. Prior to Quanticel, Dr.&#160;Xu worked in leadership roles at a number of biopharmaceutical companies, including Pfizer, Amgen, and Corixa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Xu received her M.D. degree from Beijing Medical University (now Peking University Health Science Center) in 1987 and her Ph.D. degree in Immunology from University of Alabama at Birmingham in 1993. She completed her post-doctoral training at DNAX Research Institute (now Merck Palo Alto) in 1996. She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Qinghai Zhao, Ph.D. </span>has served as our Chief Manufacturing Officer since October&#160;2020. Dr.&#160;Zhao has more than 25 years of experience in protein therapeutics development and defining product development strategy from early stage IND through commercial filing. Prior to joining Adagene, Dr.&#160;Zhao was Vice President of Technical Development and Manufacturing at Forty Seven Inc. (NASDAQ:FTSV) from 2017 to October&#160;2020. Prior to that, Dr.&#160;Zhao was vice president of CMC/ Manufacturing at AnaptysBio (NASDAQ:ANAB) from 2016 to 2017. Prior to AnaptysBio, Dr.&#160;Zhao worked as an Executive Director and the Head of CMC at NGM Biopharmaceuticals from 2014 to 2016. Dr.&#160;Zhao also held various positions at Human Genome Sciences,&#160;Inc., Cogenesys and Teva Biopharmaceuticals USA from 2001 to 2014. Dr.&#160;Zhao received his bachelor&#8217;s degree from Shanghai Chemical Engineering Institute (now East China University of Sciences and Technology) in 1982, master&#8217;s degree from Shanghai Medical University (now merged with Fudan University) in 1986 and Ph.D. degree from University of Uppsala in 1998.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Man Kin (Raymond) Tam </span>has served as our Chief Financial Officer since September&#160;2019 and our director since February&#160;2021. Mr.&#160;Tam has over 20 years of management experience in finance and banking across the Asia-Pacific region. Mr.&#160;Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr.&#160;Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited from April&#160;2010 to October&#160;2015. From October&#160;2015 to August&#160;2019, Mr.&#160;Tam consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited (HKEx: 8158), Beijing Gas Blue Sky Holdings Limited (HKEx: 6828), and AgenTus Therapeutics,&#160;Inc. Mr.&#160;Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder. He received his bachelor&#8217;s degree in civil&#160;&amp; resources engineering from the University of Auckland in 1997, master&#8217;s degree in practising accounting from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chunfang (Vicky) Gu, M.B.A.</span><span style="font-size:11pt;"> </span>joined Adagene in September 2017 and serves as Senior Director of Finance. Reporting to the Chief Financial Officer, Vicky manages Adagene Inc.&#8217;s finance team, plays a key role in Adagene Inc.&#8217;s capital markets and fund-raising transactions and assisted to establish the employee incentive plans of Adagene Inc. Vicky has over 17 years of experience in financial management with exposure to audit firms and multinational corporations including Sulzer Pumps, Bluescope Steel and Mercury Marine. Vicky has rich experience on financial reporting, budgeting and cost analysis, internal control and related compliance, taxation, as well as project management. Vicky received her Master of Business Administration degree from Xiamen University in 2016 and bachelor&#8217;s degree in accounting from Tianjin University of Commerce in 2003. Vicky is a member of the American Institute of Certified Management Accountant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ling (Jolin) Zhou&#160;</span>has served as our Executive Director of Human Resources since October 2019. Before joining Adagene, Ms. Zhou served as the HR director of Asia Pacific at Tekni-Plex, where she was responsible for strategic HR initiatives and business support from May 2010 to August 2019. Between October 2004 and May 2010, Ms. Zhou served as the HR supervisor at Suzhou Capsugel Ltd., a division of Pfizer, where she was responsible for all HR functions and personnel training. Ms. Zhou received her bachelor&#8217;s degree in law from South-Central University for Nationalities in 2003. She is a DDI Certified Trainer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Key Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Yan Li, M.B.A. </span>has served as our Senior Vice President of Bioinformatics and Information Technology since November&#160;2011. Ms.&#160;Li has over 25 years of experience in software development, with about 20 years focusing on the development of informatics software tools for antibody library design and analysis. Ms.&#160;Li served as the senior software engineer and applications scientist at Abmaxis from November&#160;2001 to May&#160;2006. Following the acquisition of Abmaxis by Merck&#160;&amp; Co, Ms.&#160;Li worked at Merck&#160;&amp; Co from May&#160;2006 to December&#160;2010. She received the Merck Award for Excellence in &#8220;Innovative Technologies&#8221; with the team and a Special Award for her contribution. Ms.&#160;Li received her bachelor&#8217;s degree in information science from East China University of Science and Technology in 1995 and a Master of Business Administration degree in 2010 from Santa Clara University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Xiaohong (Kristine) She </span>has served as our Senior Vice President, Head of Clinical Operations since November&#160;2011. Ms.&#160;She has over 20 years of laboratory and laboratory management experience in the renowned laboratories in the United States and has completed multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran&#8217;s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. Ms.&#160;She received her bachelor&#8217;s degree in microbiology from Wuhan University in 1986 and master&#8217;s degree in biochemistry and microbiology from the Institute of Microbiology of the Chinese Academy of Sciences in 1989. Ms.&#160;She&#8217;s spouse is Peter Luo, Ph.D., our Co-Founder, Chief Executive Officer and Chairman of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Guizhong Liu, Ph.D. </span>has served as our Head of Biology and Pharmacology since October&#160;2015. Dr.&#160;Liu has over 15 years of experience in drug discovery and development, both in small molecule kinase inhibitors and large molecule antibodies in oncology and immunology field. He has published over 40 peer-reviewed papers in high-profile journals involving key signalling pathways and targets in cancer biology. From July&#160;2007 to August&#160;2011, Dr.&#160;Liu served as an assistant professor of the department of oncological science at Mount Sinai School of Medicine. Prior to joining us, Dr.&#160;Liu served as head of molecular cancer biology in CrownBio from October&#160;2011 to September&#160;2015. Dr.&#160;Liu received his bachelor&#8217;s degree in biology in 1992 and master&#8217;s degree in cell biology in 1995 from Beijing Normal University and Ph.D. degree in cell biology from Peking Union Medical College in 1998. He also completed his postdoctoral training in cancer biology at Mount Sinai School of Medicine in 2004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alexander Goergen </span>has served as our Head of Business Development since October&#160;2017 when he joined the Company. Mr.&#160;Goergen has worked in various roles at the Covance, TRC and International AIDS Vaccine Initiative from October&#160;2008 to October&#160;2012. Prior to joining us, Alexander worked in business development for Catalent Pharma Solutions Biologics Division since October&#160;2012. Mr.&#160;Goergen completed many licensing, manufacturing, and cell line development programs both domestically and internationally during his previous employment. Mr.&#160;Goergen received his bachelor&#8217;s degree in Chemistry from Lafayette College in 2008 and master&#8217;s degree in Biotechnology from the University of Wisconsin-Madison in 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Songmao Zheng, Ph.D.</span> is currently our Vice President, Head of Clinical and Quantitative Pharmacology, and leads quantitative model-informed drug discovery and development in both preclinical and clinical space. Prior to joining us, Dr.&#160;Zheng had served as Scientific Director/Group Leader, leading numerous biologics programs at Janssen BioTherapeutics, Janssen R&amp;D since 2013. Dr.&#160;Zheng received his bachelor&#8217;s degree in biological sciences from Sichuan University in 2007 and Ph.D. degree in pharmaceutical sciences from University of Washington in 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jiping Zha, Ph.D.</span> has served as our Executive Vice President of Clinical Development since September 2021. Dr. Zha is responsible for clinical development, clinical operation and drug safety group. He is a physician scientist with over 20 years of formative experience in both academia and biotech industry. Dr. Zha has served as executive director of translational sciences at NGM Biopharmaceuticals from April 2017 to September 2021, and held various leadership positions at MedImmune, Crown Bioscience, Genentech from November 2003 to March 2017. Dr. Zha has over forty publications in high-impact scientific journals, such as Cell, Science and Nature, and authored multiple patents. Dr. Zha received his M.D. degree in basic medicine from Shanghai Medical University in 1987 and Ph.D. degree in Microbiology and Immunology from University of Tennessee in 1993, and was Board-Certified in Anatomic Pathology by American Board of Pathology in 1999.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Wenlin Zeng, Ph.D.</span><span style="white-space:pre-wrap;"> has served as our Vice President of Early Stage CMC since June 2021.  Dr. Zeng brings more than 20 years of experience in drug discovery and drug development in the biopharmaceutical industry. Prior to joining us, Dr. Zeng was the senior director of upstream process development responsible for both early and late stage programs at Gilead Sciences, Inc from July 2020 to June 2021</span><i style="font-style:italic;">.</i> Prior to that, she was the senior director of cell line and upstream process development at Forty-Seven Inc. from April 2018 to June 2020, where she was responsible for cell line, upstream process development and manufacturing for a number of programs, including magrolimab. Prior to Forty-Seven, Dr. Zeng held leadership positions at multiple biopharmaceutical companies, including NGM Bio, GSK, MedImmune, and Abgenix. Dr. Zeng began her career in biopharmaceutical industry from June 1997 to April 2018 after completing her post-doctoral training at Stanford University. Dr. Zeng received her bachelor&#39;s degree in cell biology from Wuhan University in 1983 and Ph.D. degree in biochemistry from the Universy of Iowa in 1990.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ami C. Knoefler</span> has served as our Vice President of Investor Relations and Corporate Communications since July 2021. Ms. Knoefler has more than 25 years of global experience in pharmaceutical, biotech and medical technology communications. She most recently served as consultant and Senior Director at Ascendis Pharma from June 2015 to August 2021, and previously held multiple leadership positions at Jazz Pharmaceuticals, PDL BioPharma, Abgenix and Bristol-Myers Squibb from May 2007 to March 2013. She received her bachelor&#8217;s degree in mass communication/public relations from Boston University in 1992.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dana Hu-Lowe, Ph.D.</span> is currently our Vice President of Global Product Team Leadership. Dr. Hu-Lowe has more than 20 years of industry experience in oncology and R&amp;D including years of experience in project and strategic alliance management, and leadership for both preclinical and clinical product programs. Before joining Adagene, she served as an Executive Director and Global Product Team Leader at Turning Point Therapeutics from April 2019 to October 2021. She was the Senior Director of Strategic Alliance and Program management at Wellspring Biosciences Inc. from March 2013 to March 2019, where she managed both internal discovery and IND-enabling programs and strategic alliance with Janssen Pharmaceuticals. Dr. Hu-Lowe had over 12 years of career at Pfizer Oncology November 1999 to December 2011, where she led cross-functional teams advancing programs from preclinical into clinical development. Dr. Hu-Lowe received her bachelor&#8217;s dgreee in chemistry from Beijing Normal University in 1984 and Ph.D. degree in biochemistry from the University of Mississippi in 1992 and completed her Post-doctoral training at Scripps Research Institute and the Burnham Cancer Center (now the Sanford Burnham Prebys Medical Discovery Institute).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ai Li, Ph.D</span>. has served as our Vice President, Head of Biometrics since March 2022. Dr. Li has over 14 years of experience as a biostatistician and lead of biometrics. Dr. Li has extensive experience in both early and late phase studies over various oncology indications. He has worked on small molecule and biologics drugs, T-cell therapy, and an oncolytic virus. He previously worked at QED Therapeutics (&#8220;QED&#8221;) FROM July 20220 to March 2022, leading the biometrics team for the filing of a targeted cancer therapy, which has been approved in the U.S., Canada, and Australia. Before QED, he worked for Novartis, Amgen, Puma Biotechnology and Atara Biotherapeutics, and was the key member of two successful NDA/BLA filings, including the first oncolytic virus approved for use in the U.S. and European Union. Dr. Li has more than 30 publications and received more than 3000 citations. Dr. Li received his bachelor&#8217;s degree in technical physics in 2000 and master&#8217;s degree in statistics in 2003 from Peking University. Dr. Li received his Ph.D. in Biostatistics from University of California, Los Angeles in 2007.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 7.2pt;">Non-Employee Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Yumeng Wang</span> has served as our director since April 2023 designated by General Atlantic Singapore AI Pte. Ltd. pursuant to our current effective shareholders agreement. Ms. Yumeng Wang is currently a vice president at General Atlantic, primarily responsible for investments in healthcare and life sciences sectors. Prior to joining General Atlantic, Ms. Wang served as an equity research analyst at The Hongkong and Shanghai Banking Corporation, mainly focusing on the healthcare sector. Ms. Wang also serves as a non-executive director of Ocumension Therapeutics (1477.HK) and Biotheus Inc. Ms. Wang received her bachelor&#8217;s degree in business administration in June 2013 and her master degree in biotechnology in 2021 from The Hong Kong University of Science and Technology.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Andy (Yiu Leung) Cheung </span>has served as our independent director since February 2021. Mr. Cheung has many years of auditing and accounting professional experience. Mr. Cheung was deputy area managing partner of Ernst &amp; Young (&#8220;EY&#8221;) in Asia Pacific overseeing the business operations, finance, information technology and risk management functions from July 2018 to June 2020. Mr. Cheung was the assurance leader for EY in Greater China from July 2013 to June 2018. Mr. Cheung has served as an independent non-executive director of JW (Cayman) Therapeutics Co. Ltd (HKEX:2126) since October 2020 and an independent non-executive director of Hua Medicine (HKEX:2552) since January 2023. Mr. Cheung received his bachelor&#8217;s degree in accounting and finance from the University of Lancaster in the United Kingdom in July 1982. He obtained a master&#8217;s degree in accounting and finance from London School of Economics and Political Science in the United Kingdom in August 1983. Mr. Cheung is a member of Hong Kong Institute of Certified Public Accountants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Min Li, Ph.D. </span>has served as our independent director since February&#160;2021. Dr.&#160;Min Li is the founder, CEO and director of SciNeuro Pharmaceuticals, a biotechnology company headquartered in Shanghai focused on developing innovative therapeutics for CNS diseases. Dr.&#160;Li was formerly Senior Vice President, Global Head of Neuroscience R&amp;D at GSK from 2013 to 2019. During his employment with GSK, he also served as General Manager of GSK R&amp;D China, the highest-ranking officer at the country level. Before moving into industry, Dr.&#160;Li had served as a tenured Professor of Neuroscience at Johns Hopkins University School of Medicine for over 20 years. Dr.&#160;Li served on scientific advisory boards, non-profit and corporate boards that include multinational corporations (Corning, Pfizer and Merck), disease foundations (RYR-foundation, AHA) and biotech companies (Xencor, Affymax, Datavant,&#160;Icagen, and Coda Biotechnologies). He is also an Adjunct Professor of Neuroscience at Johns Hopkins School of Medicine. Dr.&#160;Li received his B.S. degree in biochemistry from Wuhan University in 1984 and his Ph.D. in molecular immunology from Johns Hopkins University in 1990. As a Helen Hay Whitney Fellow, he performed postdoctoral research at University of California San Francisco. With a Sloan Award, in 1994 he returned to Johns Hopkins to join the faculty as an Esther A&#160;&amp; Joseph Klingenstein Neuroscience Fellow. Dr.&#160;Li has published more than 120 scientific articles and holds patents in biotechnologies. His research and scholarship were recognized internationally with awards including being a fellow of American Association for Advancement of Science and an established fellow of American Heart Association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Yuwen Liu</span> has served as our independent director since February 2022. Ms. Liu is a leading advocate for the biotechnology, biopharmaceutical and medical technology industries, with over 20 years as an entrepreneur, advisor and investor. From 2010 to 2014, Ms. Liu was Chair and CEO, followed by executive director, of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY), building it into one of the fastest growing biotech clusters serving over 400 start-ups, including BrightGene, Innovent, and Qiagen (Suzhou), where she also served on the boards of directors. Prior to that, Ms. Liu served various positions at BioBay since 2005. As a strong supporter of innovation, she was also a founding partner of BOHE Angel Fund, one of the first angel funds in China focusing on healthcare start-ups, which invests in biologics, drug discovery and diagnostics. Ms. Liu was also a founding Chair of BioVENTURE Fund Investment committee. Ms. Liu previously served as the first Chief Representative to set up the China operation of Perrigo. Earlier in her career, she had various positions in quality and business development at Capsugel, a division of Warner-Lambert later acquired by Pfizer. Ms. Liu graduated from China Pharmaceutical University with a master&#8217;s degree in pharmaceutics in 1997 and Master of Management at Fudan University and Norwegian Management School BI in 2004. She is a licensed pharmacist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cuong Do</span> has served as our independent director since November 2022. Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimer&#8217;s Disease, Parkinson&#8217;s disease and refractory Ascites. Prior to BioVie, Mr. Do was President of Samsung&#8217;s Global Strategy Group where he helped to set the strategic direction for Samsung Group&#8217;s diverse business portfolio, including the growth of its biologics businesses. He was previously the Chief Strategy Officer for Merck, a leading global pharmaceuticals company, where he played a key role in defining the company&#8217;s strategy, including the focus on oncology and creating its leading position with the anti-PD-1 therapy, pembrolizumab (KEYTRUDA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>). Mr. Do was also a senior partner at McKinsey &amp; Company, where he spent 17 years helping to build the healthcare, high technology, and corporate finance practices. He holds a BA from Dartmouth College and an MBA from the Tuck School of Business at Dartmouth.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Mervyn Turner, Ph.D.</span>, has served as our independent director since April 2023. Dr. Turner accumulated over 25 years of experience at Merck Research Laboratories in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years, he was head of world-wide licensing and external research at Merck, during a period of rapid expansion in Merck&#8217;s partnering activities. He became Merck&#8217;s first Chief Strategy Officer and a member of the senior executive team in 2008, before retiring from the company in 2011. Dr. Turner received his BS and Ph.D. in Chemistry from the University of Sheffield in 1970. He also completed his postdoctoral research in biochemistry of histocompatibility at Havard University in 1974.</p><a id="_47f4bd82_7670_4bf2_832b_5293959f4c7d"></a><a id="a6BCompensation_267993"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.B. Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year ended December 31, 2022, we paid an aggregate of US$3.7 million in cash to our executive officers and an aggregate of US$0.2 million in cash to our independent directors. For the fiscal year ended December 31, 2022, we did not pay any cash compensation to non-executive directors who are not independent directors. For the fiscal year ended December 31, 2022, we did not set aside or accrue expenses related to pension, retirement or other similar benefits to our executive officers and directors. Our PRC subsidiary is required by law to make contributions equal to certain percentages of each employee&#8217;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund. For share incentive grants to our directors and executive officers, see &#8220;Item 6 Directors, Senior Management and Employees&#8212;Share Incentive Plan.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into employment agreements with each of our executive officers. Each of our executive officers is employed for a period of twelve months, which will be renewed automatically and extended automatically for a period of twelve months unless the executive or we give prior written notice. We may terminate an executive officer&#8217;s employment for cause at any time without advance notice in certain events. We may terminate an executive officer&#8217;s employment by giving a prior written notice or by paying certain compensation. In such case of termination by us, we will provide severance payments to the executive officer as expressly required by applicable law of the jurisdiction where the executive officer is based. An executive officer may terminate his or her employment at any time by giving a prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each executive officer has agreed to hold, unless expressly consented to by us, at all times during and after the termination of his or her employment agreement, in strict confidence and not to use, any of our confidential information or the confidential information of our customers and suppliers. In addition, each executive officer has agreed to be bound by certain non-competition and non-solicitation restrictions during the term of his or her employment and for a maximum of two years following the last date of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Adagene Inc. Second Amended and Restated Share Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In November&#160;2015, we adopted Adagene Inc. Share Incentive Plan, or the 2015 Plan, which was later superseded and replaced by Adagene Inc. Amended and Restated Share Incentive Plan, or the 2017 Plan, in September&#160;2017. In December&#160;2019, we adopted the Second Amended and Restated Share Incentive Plan, or the 2019 Plan, to supersede and replace the 2017 Plan. The terms of the 2015 Plan, the 2017 Plan and the 2019 Plan are substantially the same other than the maximum aggregate number of shares we may issue under the respective plan.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2019 Plan is to attract, motivate, retain and reward certain officers, employees, directors and other eligible persons and to further link the interests of award recipients with those of our shareholders generally. The 2019 Plan provides for the issuance of up to an aggregate of 11,391,131 of our ordinary shares. We have terminated the authority to grant additional awards under the 2019 Plan and all future awards will be granted under the 2021 Plan. Therefore, the effective maximum number of shares issuable under the 2019 Plan is 10,125,726. As of March 31, 2023, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan is 2,714,814, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. The term of the awards will expire not more than ten years after the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following paragraphs summarize the principal terms of the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Types of Awards. </span>The 2019 Plan permits the awards of options, share appreciation rights, ordinary shares or restricted shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Plan Administration. </span>The 2019 Plan shall be administrated by our board of directors or one or more committees appointed by the board of directors or another committee (within its delegated authority), the Plan Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Notes. </span>The promissory notes with respect to the 2019 Plan, or the 2019 Promissory Notes are full recourse, repayable within a period of time determined by the Plan Administrator, which should not exceed five years (subject to certain early repayment events), and bear interest at the interest rate determined by the Plan Administrator but not less than the interest rate necessary to avoid the imputation of interest under United States Internal Revenue Code of 1986, as amended or other applicable tax law. Certain plan participants previously purchased our shares with such promissory notes. The largest aggregate amount outstanding since the first issuance of the promissory notes was US$7.0 million. All amounts outstanding under the promissory notes have been settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Repayment of the Promissory Notes. </span>The terms, repayment provisions, and collateral release provisions of the note and the pledge securing the note shall conform with all applicable rules&#160;and regulations, including those of the Federal Reserve Board of the United States and any applicable law, as then in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility. </span>The plan administrators may decide that an award under the 2019 Plan be granted to any employee, officer or director of the Company or its affiliates, or that it be granted to any consultant or advisor who provides services to the Company or its affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Award Agreements. </span>Each award under the 2019 Plan shall be evidenced by an award agreement in the form approved by the plan administrators. The terms of the award agreements will be determined by the plan administrators and consistent with the terms of the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions of Award. </span>The plan administrators shall determine the participants, types of awards, numbers of shares to be covered by awards, terms and conditions of each award, including, but not limited to, the price and number of securities to be offered or awarded, the installments (if applicable) in which such awards will become exercisable or will vest, performance targets (if applicable), the events of termination or reversion of such awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer Restrictions. </span>With a few exceptions, no right of interest of a participant in any award may be subject in any manner to sale, transfer, anticipation, alienation, assignment, pledge, encumbrance or charge. This restriction does not apply to (i)&#160;transfers to our company, (ii)&#160;transfers by gift or domestic relations order to one or more family members, (iii)&#160;the designation of a beneficiary to receive benefits if a participant dies or transfers by will, (iv)&#160;permitted transfers or exercises on behalf of a participant by the participant&#8217;s duly authorized legal representative if the participant has suffered a disability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reduction or Clawback of Awards. </span>The awards granted under the 2019 Plan are subject to the terms of our recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of awards or any ordinary shares or other cash or property received with respect to the awards (including any value received from a disposition of the shares acquired upon payment of the Awards).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination of the 2019 Plan. </span>The board of directors may, at any time, terminate or, from time to time, amend, modify or suspend the 2019 Plan, in whole or in part. No awards may be granted during any period that the board of directors suspends the 2019 Plan. To the extent then required by applicable law or listing agency, any amendment to the 2019 Plan may be subject to shareholder approval. Unless earlier terminated by the board of directors, the 2019 Plan will terminate at the close of business on the day before the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the date the board of directors approved the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 7.2pt;"><span style="font-style:italic;font-weight:bold;">Adagene Inc. 2021 Performance Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, our board of directors adopted, and our shareholders approved, the 2021 Performance Incentive Plan, or the 2021 Plan, to provide an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The terms of the 2021 Plan are summarized below. Employees, officers, directors and consultants that provide services to us or one of our subsidiaries may be selected to receive awards under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors or a committee appointed by the board administers the 2021 Plan. The plan administrator has broad authority to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">select participants and determine the types of awards that they are to receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the number of shares that are to be subject to awards and the terms and conditions of awards, including the price (if any) to be paid for the shares or the award and establish the vesting conditions (if applicable) of such shares or awards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cancel, modify or waive our rights with respect to, or modify, discontinue, suspend or terminate any or all outstanding awards, subject to any required consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">construe and interpret the terms of the 2021 Plan and any agreements relating to the plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerate or extend the vesting or exercisability or extend the term of any or all outstanding awards subject to any required consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to the other provisions of the 2021 Plan, make certain adjustments to one or more outstanding awards (including a repricing of the exercise or base price of any outstanding option or share appreciation right without shareholder approval) and authorize the termination, conversion, substitution or succession of awards; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the purchase price of an award or our ordinary shares to be paid in the form of cash, check or electronic funds transfer, by the delivery of previously-owned ordinary shares or by a reduction of the number of shares deliverable pursuant to the award, by services rendered by the recipient of the award, by notice and third party payment or cashless exercise on such terms as the plan administrator may authorize or any other form permitted by law.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A total of 2,994,000 of our ordinary shares was authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1) 5% of the total number of our outstanding ordinary shares on December 31 of the prior year, or (2) such lesser number as determined by our board of directors. Any shares subject to awards granted under the 2021 Plan or our Second Amended and Restated Share Incentive Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan. On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of 2,060,308 share options granted to certain employees were modified. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) 25% of the total number of share options of each grantee (&#8220;Annual Cap&#8221;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#8220;Credited Shares&#8221;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. As of March 31, 2023, we had granted equity awards representing 3,979,160 ordinary shares under the 2021 Plan, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. As of March 31, 2023, 4,324,177 ordinary shares authorized under the 2021 Plan is available for award purposes. Such number includes an annual automatic increase in an amount equal to 5% of the total number of outstanding ordinary shares on December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards under the 2021 Plan may be in the form of incentive or nonqualified stock options, share appreciation rights, share bonuses, restricted shares, share units, restricted share units and other forms of awards including cash awards. Awards under the plan generally will not be transferable other than by will or the laws of descent and distribution, except that the plan administrator may authorize certain transfers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options and share appreciation rights may not be granted under the 2021 Plan at exercise prices below the fair market value of the underlying ordinary shares on the date of grant, except that the plan administrator may grant such awards with exercise prices below the fair market value of the underlying shares to service-providers who are not subject to U.S. taxes. The maximum term of options and share appreciation rights granted under the plan is ten years. Incentive stock options granted to any 10% owner of our ordinary shares must have an exercise price that is at least 110% of the fair market value of our ordinary shares on the grant date and a maximum term of five years. These and other awards may also be issued solely or in part for services. Awards are generally paid in cash or our ordinary shares. The plan administrator may provide for the deferred payment of awards and may determine the terms applicable to deferrals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is customary in incentive plans of this nature, the number and type of shares available under the 2021 Plan and any outstanding awards, as well as the exercise or purchase prices of awards, will be subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, share splits, share dividends or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, and subject to limited exceptions set forth in the 2021 Plan, if we dissolve or undergo certain corporate transactions such as a merger, business combination or other reorganization, or a sale of all or substantially all of our assets, all awards then-outstanding under the 2021 Plan will become fully vested or paid, as applicable, and will terminate or be terminated in such circumstances, unless the plan administrator provides for the assumption, substitution or other continuation of the award. The plan administrator also has the discretion to establish other change in control provisions with respect to awards granted under the 2021 Plan. For example, the administrator could provide for the acceleration of vesting or payment of an award in connection with a corporate event that is not described above and provide that any such acceleration shall be automatic upon the occurrence of any such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may amend or terminate the 2021 Plan at any time, but no such action will affect any outstanding award in any manner materially adverse to a participant without the consent of the participant. Plan amendments will be submitted to shareholders for their approval as required by applicable law or deemed necessary or advisable by the board. The 2021 Plan is not exclusive; our board of directors and compensation committee may grant shares and performance incentives or other compensation, in shares or cash, under other plans or authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan will terminate on January&#160;16, 2031. However, the plan administrator will retain its authority until all outstanding awards are exercised or terminated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes, as of March&#160;31, 2023, the number of ordinary shares under outstanding awards that we granted to our directors and executive officers under the 2019 Plan, which replaced the 2015 Plan, and under the 2021 Plan, excluding awards that were exercised, forfeited or canceled after the relevant grant dates.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ordinary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$/Share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date of Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date of Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 287,415</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 372,819</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 202,973</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 111,744</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 150,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 152,452</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">JC Xu, M.D., Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">JC Xu, M.D., Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  December 2032</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  December 2032</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam, M.B.A., B. Eng.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam, M.B.A., B. Eng.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam, M.B.A., B. Eng.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">  December 2032</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2029</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.06</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yumeng Wang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Andy (Yiu Leung) Cheung</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Min Li</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yuwen Liu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Cuong Do</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Mervyn Turner</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">November 2028</p></td></tr><tr><td style="vertical-align:bottom;width:52.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">All directors and executive officers as a group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,508,641</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Various dates from November 2018 to December 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Various dates from November 2028 to December 2032</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">Note:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">*&#160;&#160;&#160;&#160;The shares held by each of these directors and executive officers represent less than 1% of our total outstanding shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023, our award holders other than our directors and executive officers as a group held outstanding awards to purchase 3,185,333 ordinary shares. For discussions of our accounting policies and estimates for awards granted pursuant to the 2019 Plan and 2021 Plan, see &#8220;Item 5 Operating and Financial Review and Prospects&#8212;Share-based compensation.&#8221;</p><a id="_33a876ea_cbc1_42eb_96ee_7e6206e74e1d"></a><a id="a6CBoardPractices_80216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.C. Board Practices</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors currently consists of nine directors, including five independent directors, namely Andy (Yiu Leung) Cheung, Min Li, Yuwen Liu, Cuong Do and Mervyn Turner. Yuwen Liu will depart from our board and applicable committee upon the filing of this annual report on Form 20-F. A director is not required to hold any shares in our company to qualify to serve as a director. The Corporate Governance Rules of the Nasdaq generally require that a majority of an issuer&#8217;s board of directors must consist of independent directors. However, the Corporate Governance Rules of the Nasdaq permit foreign private issuers like us to follow &#8220;home country practice&#8221; in certain corporate governance matters. We rely on this &#8220;home country practice&#8221; exception and do not have a majority of independent directors serving on our board of directors , our compensation committee and our nominating and corporate governance committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with our company is required to declare the nature of his or her interest at a meeting of our directors. A general notice given to the directors by any director to the effect that he or she is a member, shareholder, director, partner, officer or employee of any specified company or firm and is to be regarded as interested in any contract or transaction with that company or firm shall be deemed a sufficient declaration of interest for the purposes of voting on a resolution in respect to a contract or transaction in which he/she has an interest, and after such general notice it shall not be necessary to give special notice relating to any particular transaction.<span style="font-size:11pt;"> </span>Subject to our memorandum and articles of association, as amended n restated from time to time, our company may by ordinary resolution appoint any person to be a director and the board may, by affirmative vote of a simple majority of the remaining directors present and voting at a board meeting, appoint any person as a director to fill a casual vacancy or as an addition to the existing board. A director may vote in respect of any contract or proposed contract or arrangement notwithstanding that he/she may be interested therein and if he/ she does so, his/her vote shall be counted and he/she may be counted in the quorum at any meeting of the directors at which any such contract or proposed contract or arrangement is considered, subject to any separate requirement for Audit Committee approval under applicable law or the Listing Rules&#160;of the Nasdaq. Our board of directors may exercise all of the powers of our company to borrow money, to mortgage or charge its undertaking, property and uncalled capital, or any part thereof, and to issue debentures, debenture stock or other securities whenever money is borrowed or as security for any debt, liability or obligation of our company or of any third party. None of our directors has a service contract with us that provides for benefits upon termination of service as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Committees of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have established an audit committee, a compensation committee and a nominating and corporate governance committee under our board of directors. We have also adopted a charter for each of the three committees. Each committee&#8217;s members and functions are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee. </span>Our audit committee consists of Andy (Yiu Leung) Cheung, Min Li, Yuwen Liu and Cuong Do, and is chaired by Andy (Yiu Leung) Cheung. We have determined that each of Andy (Yiu Leung) Cheung, Min Li, Yuwen Liu and Cuong Do satisfies the requirements of Rule 5605(a)(2) of the Listing Rules of the Nasdaq and meets the independence standards under Rule 10A-3 under the Securities Exchange Act of 1934, as amended. Yuwen Liu will depart from our board and audit committee upon the filing of this annual report on Form 20-F. We have determined that Andy (Yiu Leung) Cheung qualifies as an &#8220;audit committee financial expert.&#8221; The audit committee oversees our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and recommending to our board for approval, the appointment, re-appointment or removal of the independent auditor, after considering its annual performance evaluation of the independent auditor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving the remuneration and terms of engagement of the independent auditor and pre-approving all auditing and non-auditing services permitted to be performed by our independent auditors at least annually;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining a written report from our independent auditor describing matters relating to its independence and quality control procedures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with the independent registered public accounting firm any audit problems or difficulties and management&#8217;s response;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing with our independent auditor, among other things, the audits of the financial statements, including whether any material information should be disclosed, issues regarding accounting and auditing principles and practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the Securities Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and recommending the semi-annually financial data the annual financial statements to our board for inclusion in our semi-annually earnings releases and annual reports, respectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing the annual audited financial statements with management and the independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any special steps taken to monitor and control major financial risk exposures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and reassessing the adequacy of the committee charter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving annual audit plans, and undertaking an annual performance evaluation of the internal audit function;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and overseeing procedures for the handling of complaints and whistleblowing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting separately and periodically with management and the independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting regularly to the board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee.</span> Our compensation committee consists of Peter Luo, Andy (Yiu Leung) Cheung and Min Li and is chaired by Peter Luo. We have determined that each of Andy (Yiu Leung) Cheung and Min Li satisfies the &#8220;independence&#8221; requirements of Rule 5605(a)(2) of the Listing Rules of the Nasdaq. The compensation committee assists the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our Chief Executive Officer may not be present at any committee meeting during which their compensation is deliberated upon. The compensation committee is responsible for, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing the development and implementation of compensation programs in consultation with our management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and approving, or recommending to the board for its approval, the compensation for our executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and recommending to the board for determination with respect to the compensation of our non-executive directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing periodically and approving any incentive compensation or equity plans, programs or other similar arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing executive officer and director indemnification and insurance matters;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing our regulatory compliance with respect to compensation matters, including our policies on restrictions on compensation plans and loans to directors and executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and reassessing the adequacy of the committee charter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selecting compensation consultant, legal counsel or other advisor only after taking into consideration all factors relevant to that person&#8217;s independence from management; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting regularly to the board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee. </span>Our nominating and corporate governance committee consists of Peter Luo, Andy (Yiu Leung) Cheung and Min Li, and is chaired by Peter Luo. We have determined that each of Andy (Yiu Leung) Cheung and Min Li satisfies the &#8220;independence&#8221; requirements of Rule 5605(a)(2) of the Listing Rules of the Nasdaq. The nominating and corporate governance committee assists the board in selecting individuals qualified to become our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommending nominees to the board for election or re-election to the board, or for appointment to fill any vacancy on the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing annually with the board the current composition of the board with regards to characteristics such as independence, knowledge, skills, experience, expertise, diversity and availability of service to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and recommending to our board such policies and procedures with respect to nomination or appointment of members of our board and chairs and members of its committees or other corporate governance matters as may be required pursuant to any SEC or Nasdaq rules, or otherwise considered desirable and appropriate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selecting and recommending to the board the names of directors to serve as members of the audit committee and the compensation committee, as well as of the nominating and corporate governance committee itself;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and reassessing the adequacy of the committee charter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and reviewing at least annually the corporate governance principles adopted by the board and advising the board with respect to significant developments in the law and practice of corporate governance and our compliance with such laws and practices; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the performance and effectiveness of the board as a whole.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Duties and Functions of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors also owe to our company a duty to exercise the skill they actually possess and such care and diligence that a reasonable prudent person would exercise in comparable circumstances. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended and restated from time to time. Our company has the right to seek damages if a duty owed by our directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in our name if a duty owed by our directors is breached. The functions and powers of our board of directors include, among others, (i)&#160;convening shareholders&#8217; annual general meetings and reporting its work to shareholders at such meetings, (ii)&#160;declaring dividends, (iii)&#160;appointing officers and determining their terms of offices and responsibilities, (iv)&#160;exercising the borrowing powers of our company, and (v)&#160;approving the transfer of shares of our company, including the registering of such shares in our share register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Terms of Directors and Officers </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our officers are elected by and serve at the discretion of the board of directors. Other than Andy (Yiu Leung) Cheung, Min Li, Yuwen Liu, Man Kin (Raymond) Tam, Felix Du, Cuong Do and Mervyn Turner, each director is not subject to a term of office and holds office until such time as his successor takes office or until the earlier of his death, resignation or removal from office pursuant to the applicable provisions of our memorandum and articles of association. The current term of our independent directors, namely Andy (Yiu Leung) Cheung, Min Li and Mervyn Turner, is one-year from the date of filing of this annual report on Form 20-F. The initial term of our independent director Cuong Do is two-year from the effectiveness of the appointment. Each of Andy (Yiu Leung) Cheung, Min Li and Yuwen Liu&#8217;s initial term has been extended to April 2023 and will expire upon the filing of this annual report on Form 20-F. The Board has decided to renew Andy (Yiu Leung) Cheung, Min Li and Man Kin (Raymond) Tam&#8217;s term of director position for one year. The term of director position for each of Andy (Yiu Leung) Cheung, Man Kin (Raymond) Tam, Felix Du, Min Li, Cuong Do and Mervyn Turner is subject to re-appointment by the board of directors. A director will be removed from office automatically if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) dies or is found by our company to be of unsound mind; (iii) resigns by notice in writing to our company; (iv) without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his office be vacated; (v) is prohibited by law or the Listing Rules of the Nasdaq Global Market from being a director; or (vi) is removed from office pursuant to any other provisions of our post-offering amended and restated memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Board Diversity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The board diversity matrix is set out below.<span style="font-size:11pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board Diversity Matrix (As of the Date of This Annual Report)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Country of Principal Executive Offices</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China</p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign Private Issuer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yes</p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Disclosure Prohibited under Home Country Law</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">No</p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Did Not Disclose</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Female</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Male</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Binary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Gender</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Part I: Gender Identity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Part II: Demographic Background</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Underrepresented Individual in Home Country Jurisdiction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">LGBTQ+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Did Not Disclose Demographic Background</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Note: *Yumen Liu, a female director, will depart from our board upon filing of this annual report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Interested Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A director may, subject to any separate requirement for audit and risk committee approval under applicable law or applicable Nasdaq listing rules, vote in respect of any contract or transaction in which he or she is interested, provided that the nature of the interest of any directors in such contract or transaction is disclosed by him or her at or prior to its consideration and any vote in that matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_e43bea1c_0383_41b3_85ed_0915db831e28"></a><a id="a6DEmployees_447015"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.D. Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had a total of 198, 259 and 248 employees as of December 31, 2020, 2021 and 2022, respectively. The following table sets forth the numbers of our employees categorized by function as of December 31, 2022. We also engage consultants and part-time staff as and when appropriate.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Function</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Employees</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">196</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Computational Biology and Informatics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Technology Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Drug Discovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Clinical Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">CMC Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">General Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">49</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">HR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Finance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">IT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Business Development and Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">248</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends on our ability to attract, motivate, train and retain qualified personnel. We believe we offer our employees competitive compensation packages and an environment that encourages self-development. We regularly recruit new talents through campus events and colleague referral to build and develop our own talent pool. Through employee succession planning, we help employees understand their career path within Adagene, motivate them to remain in the organization and to achieve their personal career goals. Other initiatives for talent retention include executive coaching, employee surveys or engagement, training and development, compensation and rewards. As a result of these efforts, we have generally been able to attract and retain qualified personnel and maintain a stable core management team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As required by regulations in China, we participate in various employee social security plans that are organized by municipal and provincial governments, including pension insurance, unemployment insurance, maternity insurance, work-related injury insurance, medical insurance and housing funds. We are required under PRC law to make contributions to employee benefit plans at specified percentages of the salaries, bonuses and certain allowances of our employees, up to a maximum amount specified by the local government from time to time. We have granted, and plan to continue to grant, share-based incentive awards to our employees in the future to incentivize their contributions to our growth and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that we maintain a good working relationship with our employees, and we have not experienced any material labor disputes. None of our employees is requested by labor unions.</p><a id="_04caf600_928b_45b2_aa53_55cdc906c2e4"></a><a id="a6EShareOwnership_384399"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.E. Share Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information concerning the beneficial ownership of our ordinary shares, as of March&#160;31, 2023, by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our directors and executive officers; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person known to us to beneficially own more than 5% of our ordinary shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculations in the table below are based on 54,715,839 ordinary shares issued and outstanding as of March 31, 2023, excluding the 832,500 ordinary shares, issued but deemed to be not outstanding as of March 31, 2023, held by Great Han Fortune LP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant, or other right or the conversion of any other security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These shares, however, are not included in the computation of the percentage ownership of any other person.<i style="font-style:italic;"> </i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ordinary Shares Beneficially Owned as of March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Directors and Executive Officers:&#8224;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,799,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,303,938</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"> <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">JC Xu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yumeng Wang</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Andy (Yiu Leung) Cheung (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Min Li (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yuwen Liu (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Cuong Do (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Mervyn Turner (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> **</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> **</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All directors and executive officers as a group</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 13,014,227</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 23.8</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">%</b><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal Shareholders:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo act-in-concert group(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,799,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 23.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">JSR Limited(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,340,742</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Asia Ventures II L.P.(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,826,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">F-Prime Capital Partners Healthcare Fund III LP(6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,632,237</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Wuxi Pharmatech Healthcare Fund I L.P.(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,282,120</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">General Atlantic Singapore AI Pte. Ltd.(8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,782,441</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt;">Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;For each person and group included in this table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of (i) 54,715,839 being the number of ordinary shares as of March 31, 2023 and (ii) the number of ordinary shares underlying share options held by such person or group that are exercisable within 60 days after March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">**&#160;&#160;&#160;Represents beneficial ownership of less than one percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;The business address of our directors and executive officers, except for Cuong Do, Yumeng Wang, Yuwen Liu and Mervyn Turner, is 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. The business address of Yumeng Wang is Suite 5704-5706, 57F, Two IFC, 8 Finance Street, Central, Hong Kong; the business address of Yuwen Liu is 3 Fl, Building No. 10, Dongshahu Equity Investment Center, East Suhong Road, Suzhou Industrial Park; the business address of Cuong Do is 660 Destacada Ave, Miami, United States FL 33156-8000; and the business address of Mervyn Turner is MJ Turner Consulting LLC, Westfield, NJ, USA.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 12,799,269 ordinary shares held by Peter Luo act-in-concert group, as set forth in note (3) below.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents (i) 785,944 ordinary shares held by Ping Ren, who is the spouse of Fangyong (Felix) Du, (ii) 397,500 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren, (iii) 5,000 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren that are vested or will be vested within 60 days of March 31, 2023, (iv) 115,494 ordinary shares underlying 115,494 share options granted to Ping Ren that that are vested or will be vested within 60 days of March 31, 2023. Great Han Fortune LP is controlled by Peter Luo and is formed to hold ordinary shares in connection with the share awards issued under the 2019 Plan.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents (i) 8,035,316 ordinary shares held by Peter Luo; (ii) 337,415 ordinary shares underlying share options granted to Peter Luo that are vested or will be vested within 60 days of March 31, 2023, (iii) 766,667 ordinary shares held by Great Han Fortune LP for the benefit of Peter Luo and (iv) 33,333 ordinary shares held by Great Han Fortune LP for the benefit of Peter Luo that will be vested within 60 days of March 31, 2023; (v) 0 ordinary shares held by HAN 2020 GRAT, for which Peter Luo is a Trustee; (vi) 52,198 ordinary shares held by Xiaohong She, who is the spouse of Peter Luo; (vii) 48,230 ordinary shares underlying share options granted to Xiaohong She that are vested or will be vested within 60 days of March 31, 2023, (viii) 192,083 ordinary shares held by Great Han Fortune LP for the benefit of Xiaohong She, (ix) 4,167 ordinary shares held by Great Han Fortune LP for the benefit of Xiaohong She that will be vested within 60 days of March 31, 2023; (x) 785,944 ordinary shares held by Ping Ren, who is the spouse of Fangyong (Felix) Du, (xi) 397,500 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren, (xii) 5,000 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren that are vested or will be vested within 60 days of March 31, 2023, (xiii) 115,494 ordinary shares underlying 115,494 share options granted to Ping Ren that that are vested or will be vested within 60 days of March 31, 2023, (xiv) total of 1,312,357 ordinary shares held by Raymond Tam, JC Xu, Qinghai Zhao and several key employees of the Company, and (xv) total of 713,565 share options granted to Raymond Tam, JC Xu, Qinghai Zhao and several key employees that are vested or will be vested within 60 days of March 31, 2023. On December 14, 2020, Peter Luo, Fangyong (Felix) Du, Ping Ren, Hua Gong, JC Xu, Qinghai Zhao, Man Kin (Raymond) Tam, Xiaohong (Kristine) She, Yu (Albert) Ren, Yan Li, Guizhong Liu and Alexander Goergen entered into a concert party agreement, pursuant to which the parties agree to (i) always be acting in concert in respect of their respective direct or indirect voting rights at our shareholders&#8217; general meetings, (ii) recognize the controlling position of Peter Luo; and (iii) act in concert in accordance with Peter Luo&#8217;s opinions in respect of the daily operations and management and the major decision-making of us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 5,340,742 ordinary shares, consisting of (i) 4,828,242 ordinary shares and (ii) 512,500 ordinary shares in the form of ADSs, are held of record by JSR Limited, a British Virgin Islands company. JSR Limited is controlled by GP Healthcare Capital Co., Ltd. The registered address of JSR Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands. Information set forth above is based upon JSR Limited&#39;s Schedule 13G/A filing with the SEC on February 6, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 4,826,037 ordinary shares held by Asia Ventures II L.P., a limited partnership incorporated in the Bermuda. The general partner of Asia Ventures II L.P. is Asia Partners II L.P. a Bermuda exempt limited partnership. The general partner of Asia Partners II L.P. is Eight Roads GP, who is ultimately controlled by Eight Roads Holdings Limited. The registered address of Asia Ventures II L.P. is Pembroke Hall, 42 Crow Lane, Pembroke, Bermuda HM 19. Information set forth above is based upon FIL Ltd&#39;s Schedule 13G filing with the SEC on February 19, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 4,632,237 ordinary shares held by F-Prime Capital Partners Healthcare Fund III LP. F-Prime Capital Partners Healthcare Advisors Fund III LP is the general partner of F-Prime Capital Partners Healthcare Fund III LP. F-Prime Capital Partners Healthcare Advisors Fund III LP is solely managed by Impresa Management LLC, its general partner and investment manager. Each of the entities listed above expressly disclaims beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. The address of these entities is 245 Summer Street, Boston, MA 02210. Information set forth above is based upon FMR LLC&#39;s Schedule 13G/A filing with the SEC on February 9, 2023.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 5,282,120 ordinary shares in the form of ADSs that were held of record by WuXi PharmaTech Healthcare Fund I L.P., a limited partnership incorporated in the Cayman Islands. WuXi Pharmatech Healthcare Fund I L.P. is an indirect wholly owned subsidiary of WuXi AppTec Co., Ltd (SSE: 603259; SEHK: 2359). WuXi AppTec Co., Ltd. is a listed company on the Shanghai Stock Exchange and the Main Board of the Hong Kong Stock Exchange. The registered address of WuXi Pharmatech Healthcare Fund I L.P. is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Information set forth above is based upon WuXi PharmaTech Healthcare Fund I L.P&#39;s Schedule 13G filing with the SEC on January 26, 2022.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Represents 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares held by General Atlantic Singapore AI Pte. Ltd. (&#8220;GA AI&#8221;), a company incorporated under the laws of Singapore. GA AI is wholly-owned by General Atlantic Singapore Fund Pte. Ltd. (&#8220;GASF&#8221;), which is controlled by General Atlantic Singapore Interholdco Ltd. (&#8220;GAS Interholdco&#8221;) The members of GAS Interholdco that share beneficial ownership of the ordinary shares and ADSs held of record by GA AI are the GA Funds. The general partner of General Atlantic Partners (Lux) SCSp (&#8220;GAP Lux&#8221;) is General Atlantic GenPar, (Lux) SCSp (&#8220;GA GenPar Lux&#8221;) and the general partner of GA GenPar Lux is General Atlantic (Lux) S.&#224;. r.l. (&#8220;GA Lux&#8221;). The general partner of General Atlantic Partners (Bermuda) EU, L.P. (&#8220;GAP Bermuda EU&#8221;) and General Atlantic Partners (Bermuda) IV, L.P. (&#8220;GAP Bermuda IV&#8221;) and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P. (&#8220;GenPar Bermuda&#8221;).  GAP (Bermuda) L.P., which is controlled by the Management Committee of GASC MGP, LLC (the &#8220;GA Management Committee&#8221;), is the general partner of GenPar Bermuda.  General Atlantic, L.P. (&#8220;GA LP&#8221;), which is also controlled by the GA Management Committee, is the managing member of GAP Coinvestments III, LLC (&#8220;GAPCO III&#8221;), GAP Coinvestments IV, LLC (&#8220;GAPCO IV&#8221;) and GAP Coinvestments V, LLC (&#8220;GAPCO V&#8221;) and the general partner of GAP Coinvestments CDA, L.P. (&#8220;GAPCO CDA&#8221;). GAP Bermuda IV, GAP Bermuda EU, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA are collectively referred to as the &#8220;GA Funds.&#8221; There are nine members of the GA Management Committee as of the date hereof. Each of the members of the GA Management Committee disclaims ownership of the ordinary shares, the ADSs and the underlying ordinary shares except to the extent that he has a pecuniary interest therein. The registered address of General Atlantic Singapore AI Pte. Ltd. is 80 Robinson Road, #02-00 Singapore 068898. Information set forth above is based upon General Atlantic, L.P.&#8217;s Schedule 13G filing with the SEC on February 11, 2022.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023, a total of 25,831,040 ordinary shares, representing 47.2% of our outstanding ordinary shares, including ordinary shares issued in advance but deemed not outstanding to facilitiate conversation of ordinary shares to ADSs for the employee share incentive plans, are held by one record holder in the United States. The holder is the depositary of our ADS program. In addition, 26.0% of our outstanding ordinary shares were held by record holders in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal shareholders do not have different voting rights. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</p><a id="_7bcab170_3f50_4277_9bed_40b5aa4d6a24"></a><a id="a6FDisclosureofaRegistrantsActiontoRecov"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.F. Disclosure of a Registrant&#39;s Action to Recover Erroneously Awarded Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_8a524dc4_6162_4851_850b_521d68756d08"></a><a id="Item7MajorShareholdersandRelatedPartyTra"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 7. Major Shareholders and Related Party Transactions</p><a id="_03d5ba37_bdf9_4b24_94c8_323cc95e342b"></a><a id="a7AMAJORSHAREHOLDERS_545494"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">7.A. Major Shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to &#8220;Item 6. Directors, Senior Management and Employees &#8212; E. Share Ownership.&#8221;</p><a id="_9a2c09b7_9eed_425d_8802_fce70930aecc"></a><a id="a7BRELATEDPARTYTRANSACTIONS_165301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">7.B. Related Party Transactions <span style="font-style:italic;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of transactions since January&#160;1, 2022 to which we have been a participant in which any of our then directors, executive officers or holders of more than 10% of any class of our voting securities at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 6 Directors, Senior Management and Employees&#8212;6.B. Compensation&#8212;Employment Agreements and Indemnification Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share Incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 6 Directors, Senior Management and Employees&#8212;6.B. Compensation&#8212;Share Incentive Plan.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Other Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Transactions with WuXi AppTec Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We received research and development services from WuXi AppTec Group, the parent company of one of our principal shareholders. The amounts for the purchase of the services were US$7.4 million in 2022. As of December 31, 2022, the amounts due to WuXi AppTec Group were US$1.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Transactions with WuXi Biologics (Cayman) Inc. or WuXi Biologics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We received research and development services, including provision of manufacturing and quality control testing services, from WuXi Biologics, an entity controlled by the ultimate controlling party of one of our principal shareholders. The amounts for the purchase of the services were US$27.8 million in 2022. As of December 31, 2022, the amounts due to WuXi Biologics were US$17.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_71198302_6eef_47bb_923f_30da75e701be"></a><a id="a7CInterestsofExpertsandCounsel_412934"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">7.C.&#160;Interests of Experts and Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_2b663bf7_37d7_438f_a7bc_667e70ede46e"></a><a id="Item8FinancialInformation_179985"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 8.&#160;Financial Information</p><a id="_18c95262_a0bd_4a09_b7b2_530175c2c4dc"></a><a id="a8AConsolidatedStatementsandOther"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8.A.&#160;Consolidated Statements and Other Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have appended consolidated financial statements filed as part of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Legal and Administrative Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report, we are not a party to any material legal or administrative proceedings. We may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business. Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in a substantial cost and diversion to our resources, including our management&#8217;s time and attention. For risks relating to legal and administrative proceedings against us, please see &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Relating to Our Operations&#8212;Allegations or lawsuits against us or our management may harm our reputation and business.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our shares or the ADSs representing our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a holding company incorporated in the Cayman Islands. In the future, we may rely on dividends from our subsidiaries, including our PRC and U.S. subsidiaries, for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiary to pay dividends to us. See &#8220;Item 4 Information of the Company&#8212;B. Business Overview&#8212;Regulation&#8212;Regulations relating to Dividend Distribution.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to the provisions of our post-offering articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit, retained earnings or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect of the ordinary shares underlying the ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to the ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See &#8220;Item 12 Description of Securities Other Than Equity Securities&#8212;D. American Depositary Shares.&#8221;</p><a id="_d28ced12_ce27_4efb_9cb7_3922b27d5f67"></a><a id="a8BSignificantChanges_30259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8.B. Significant Changes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise disclosed in this report, we have not experienced any significant changes since the date of the annual financial statements included herein.</p><a id="_979c41a4_163d_4963_ad96_beef28b3a0bd"></a><a id="Item9TheOfferandListing_756002"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 9. The Offer and Listing</p><a id="_59ec15aa_2e2f_4c3e_8bb5_930fc787ebf2"></a><a id="a9AOfferingandListingDetails_144386"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.A. Offering and Listing Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ADSs have been listed on the Nasdaq Global Market since February&#160;9, 2021 under the symbol &#8220;ADAG.&#8221; Each ADS represents one and one quarter ordinary shares, par value US$0.0001 per share.</p><a id="_6ad36cef_d5fe_4633_a58f_5043248cba0c"></a><a id="a9BPlanofDistribution_978914"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.B. Plan of Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_871b2ebb_47d2_4a18_878c_2d16c00466f9"></a><a id="a9CMarkets_923664"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.C. Markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ADSs have been listed on the Nasdaq Global Market since February&#160;9, 2021 under the symbol &#8220;ADAG.&#8221;</p><a id="_9927e59a_0e1a_4792_b32e_c0e071b01071"></a><a id="a9DSellingShareholders"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.D. Selling Shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_04f4e7b1_8300_4359_a321_2ada57514c6d"></a><a id="a9EDilution_990429"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.E. Dilution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_fb935857_7cd5_4983_aa33_23b484ac2503"></a><a id="a9FExpensesoftheIssue_581594"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.F. Expenses of the Issue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_32d685aa_973f_4c2e_83b8_1b9a7f6a8e73"></a><a id="Item10AdditionalInformation_357630"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 10. Additional Information</p><a id="_b3b20972_6a69_4347_84bc_a0387c77b1b2"></a><a id="a10AShareCapital_984479"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.A. Share Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f347a69f_8661_4ce4_9da7_827b0a24b920"></a><a id="a10BMemorandumandArticlesofAssociation_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.B. Memorandum and Articles of Association</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a Cayman Islands exempted company and our affairs are governed by our memorandum and articles of association, as amended and restated from time to time, and Companies Act of the Cayman Islands, and the common law of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We incorporate by reference into this annual report our amended and restated memorandum and articles of association, the form of which was filed as <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000233/a2242824zex-3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit&#160;3.2 to our registration statement on Form&#160;F-1 (File Number 333-252210), as amended, filed with the Securities and Exchange Commission on February&#160;1, 2021</span></a>. Our members adopted our amended and restated memorandum and articles of association by a special resolution on January&#160;19, 2021, which became effective immediately prior to completion of our initial public offering of ADSs representing our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following are summaries of material provisions of our Seventh Amended and Restated Memorandum and Articles of Association and the Companies Act insofar as they relate to the material terms of our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Registered Office and Objects</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our registered office in the Cayman Islands is at the offices of Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands or at such other location as the Directors may from time to time determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to Clause 3 of our Seventh Amended and Restated Memorandum of Association, the objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by any law as provided by Section&#160;7(4)&#160;of the Companies Act (as amended) of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 6 Directors, Senior Management and Employees.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Ordinary shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General. </span>Our authorized share capital is US$80,000 divided into 800,000,000 shares comprising (i)&#160;640,000,000 ordinary shares of a par value of US$0.0001 each, and (ii)&#160;160,000,000 shares of a par value of US$0.0001 each of such class or classes (however designated) as our board of directors may determine in accordance with our amended and restated memorandum and articles of association. Holders of ordinary shares have the same rights. All of our issued and outstanding ordinary shares are fully paid and non-assessable. Certificates representing the ordinary shares are issued in registered form. We may not issue share to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold, transfer and vote their ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends. </span>The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors subject to our post-offering memorandum and articles of association and the Companies Act. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Our post-offering memorandum and articles of association provide that dividends may be declared and paid out of our profits, realized or unrealized, or from any reserve set aside from profits which our board of directors determine is no longer needed. Dividends may also be declared and paid out of the share premium account or any other fund or account which can be authorized for this purpose in accordance with the Companies Act. No dividend may be declared and paid unless our directors determine that, immediately after the payment, we will be able to pay our debts as they become due in the ordinary course of business and we have funds lawfully available for such purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting Rights. </span>In respect of all matters subject to a shareholders&#8217; vote, holder of an Ordinary Share is entitled to one vote for each Ordinary Share registered in his or her name on our register of members. Voting at any meeting of shareholders is by way of a poll unless a show of hands is permitted. A poll may be demanded by the chairman of such meeting or any one shareholder.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A quorum required for a meeting of shareholders consists of two or more shareholders holding not less than one-half of the votes attaching to the issued and outstanding shares entitled to vote at general meetings present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders&#8217; annual general meetings. Our post-offering memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place as may be determined by our board of directors. We, however, will hold an annual shareholders&#8217; meeting during each fiscal year, as required by the Listing Rules&#160;of the Nasdaq Global Market. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting. Shareholders&#8217; annual general meetings and any other general meetings of our shareholders may be called by a majority of our board of directors or our chairman or upon a requisition of shareholders holding at the date of deposit of the requisition not less than 20% of the votes attaching to the issued and outstanding shares entitled to vote at general meetings, in which case the directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our post-offering memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders. Advance notice of at least seven (7)&#160;days is required for the convening of our annual general meeting and other general meetings in accordance with our post-offering memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution also requires the affirmative vote of no less than two-thirds of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting. A special resolution will be required for important matters such as a change of name or making changes to our post-offering memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer of Ordinary Shares. </span>Subject to the restrictions in our post-offering memorandum and articles of association as set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may, in its absolute discretion, decline to register any transfer of any Ordinary Share. Our board of directors may also decline to register any transfer of any Ordinary Share unless:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the instrument of transfer is in respect of only one class of shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the instrument of transfer is properly stamped, if required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a transfer to joint holders, the number of joint holders to whom the Ordinary Share is to be transferred does not exceed four;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the shares are free from any lien in favor of us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our directors refuse to register a transfer, they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration of transfers may, after compliance with any notice requirement of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the registration of transfers shall not be suspended nor the register closed for more than 30 days in any year as our board may determine.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation. </span>On a return of capital on winding up or otherwise (other than on conversion, redemption or purchase of ordinary shares), if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them. Any distribution of assets or capital to a holder of ordinary shares will be the same in any liquidation event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Calls on Ordinary Shares and Forfeiture of Ordinary Shares. </span>Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The ordinary shares that have been called upon and remain unpaid are subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption, Repurchase and Surrender of Ordinary Shares. </span>We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders thereof, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by an ordinary resolution of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by an ordinary resolution of our shareholders, or are otherwise authorized by our post-offering memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company&#8217;s profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the Company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)&#160;unless it is fully paid up, (b)&#160;if such redemption or repurchase would result in there being no shares outstanding, or (c)&#160;if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Variations of Rights of Shares. </span>If at any time our share capital is divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided by the terms of issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of holders of not less than a majority of the issued shares of that class or series or with the sanction of a special resolution at a separate meeting of the holders of the shares of the class or series. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking <i style="font-style:italic;">pari passu </i>with such existing class of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inspection of Books and Records. </span>Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we will provide our shareholders with annual audited financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of Additional Shares. </span>Our post-offering memorandum and articles of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our post-offering memorandum and articles of association also authorizes our board of directors to establish from time to time one or more series of preferred shares and to determine, with respect to any series of preferred shares, the terms and rights of that series, including:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">the designation of the series;</span></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of shares of the series;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the dividend rights, dividend rates, conversion rights, voting rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights and terms of redemption and liquidation preferences.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may issue preferred shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of holders of ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-Takeover Provisions. </span>Some provisions of our post-offering memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Changes in Capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may from time to time by ordinary resolution:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sub-divide our existing shares, or any of them into shares of a smaller amount; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so canceled.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exempted Company. </span>We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">does not have to file an annual return of its shareholders with the Registrar of Companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is not required to open its register of members for inspection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">does not have to hold an annual general meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may issue shares with no par value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30 years in the first instance);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may register as a limited duration company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may register as a segregated portfolio company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Limited liability&#8221; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder&#8217;s shares of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Register of Members.</span> Under the Companies Act, we must keep a register of members and there should be entered therein:</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the names and addresses of our members, and a statement of the shares held by each member, which shall include: (i) the amount paid or agreed to be considered as paid on the shares of each member, (ii) the number and category of shares held by each member, and (iii) whether each relevant category of shares held by a member carries voting rights under the post-offering memorandum and articles of association, and if so, whether such voting rights are conditional;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which the name of any person was entered on the register as a member; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which any person ceased to be a member.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Act, the register of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as a matter of the Companies Act to have legal title to the shares as set against its name in the register of members. Upon completion of this offering, we will perform the procedure necessary to immediately update the register of members to record and give effect to the issuance of shares by us to the Depositary (or its nominee) as the depositary. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If the name of any person is incorrectly entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any person having ceased to be a member of our company, the person or member aggrieved (or any member of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_ec0bc5a7_d2d8_4640_87f4_3b50b87006d8"></a><a id="a10CMaterialContracts_95807"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.C. Material Contracts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not entered into any material contracts other than in the ordinary course of business and other than those described in this annual report.</p><a id="_cef3f19a_2ae7_4aae_a2a9_4bd2aa3f6da2"></a><a id="a10DExchangeControls_660603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.D. Exchange Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cayman Islands currently has no exchange control regulations or currency restrictions. For exchange control regulations or currency restrictions in China, see &#8220;Item 4 Information of the Company&#8212;B. Business Overview&#8212;Regulation&#8212;Regulations Relating to Foreign Exchange.&#8221;</p><a id="_1dc1c64c_dbc3_42d5_9475_7f7b17fd8bb2"></a><a id="a10ETaxation_830656"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.E. Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion of Cayman Islands, PRC and U.S. federal income tax consequences of the ownershihp and disposition of the ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are subject to change. This discussion does not deal with all possible tax consequences relating to the ownership and disposition of the ADSs or ordinary shares, such as the tax consequences under state, local and other tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cayman Islands Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to Walkers (Hong Kong), our Cayman Islands counsel, the Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation, and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us or holders of our ADSs or ordinary shares levied by the government of the Cayman Islands, except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments of dividends and capital in respect of the ADSs or ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the ADSs or ordinary shares, nor will gains derived from the disposal of the ADSs or ordinary shares be subject to Cayman Islands income or corporation tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Material PRC Income Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the PRC EIT Law, which became effective on January&#160;1, 2008 and was amended on December&#160;29, 2018, an enterprise established outside the PRC with &#8220;de facto management bodies&#8221; within the PRC is considered a &#8220;resident enterprise&#8221; for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. Under the implementation rules&#160;to the PRC EIT Law, a &#8220;de facto management body&#8221; is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and properties of an enterprise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the SAT Circular 82 issued by the SAT in April&#160;2009 specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be classified as PRC resident enterprises if the following are located or resident in the PRC: (a)&#160;senior management personnel and departments that are responsible for daily production, operation and management; (b)&#160;financial and personnel decision-making bodies; (c)&#160;key properties, accounting books, company seal, minutes of board meetings and shareholders&#8217; meetings; and (d)&#160;half or more of the senior management or directors having voting rights. Further to SAT Circular 82, the SAT issued the SAT Bulletin 45, which took effect in September&#160;2011, to provide more guidance on the implementation of SAT Circular 82. SAT Bulletin 45 provides for procedures and administration details of determination on resident status and administration on post-determination matters. Our company is a company incorporated outside the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside the PRC. As such, we do not believe that our company meets all of the conditions above or is a PRC resident enterprise for PRC tax purposes. For similar reasons, we believe our other entities outside China are not PRC resident enterprises either. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; There can be no assurance that the PRC government will ultimately take a view that is consistent with us. If the PRC tax authorities determine that our Cayman Islands holding company is a PRC resident enterprise for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences could follow. For example, a 10% withholding tax would be imposed on dividends we pay to our non-PRC enterprise shareholders (including our ADS holders). In addition, nonresident enterprise shareholders (including our ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC. Furthermore, if we are deemed a PRC resident enterprise, dividends paid to our non-PRC individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% (which, in the case of dividends, may be withheld at source by us). These rates may be reduced by an applicable tax treaty, but it is unclear whether in practice non-PRC shareholders of our company would be able to obtain the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. See &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Material U.S. Federal Income Tax Considerations <span style="font-style:italic;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion describes U.S. federal income tax consequences to the U.S. Holders described below of the ownership and disposition of the ADSs or ordinary shares. This discussion is not a comprehensive description of all of the tax considerations that may be relevant to your decision to hold the ADSs or ordinary shares. This discussion applies to you only if you are a U.S. Holder that holds the ADSs or underlying ordinary shares as capital assets for U.S. federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of your particular circumstances, including the alternative minimum tax, the Medicare contribution tax on net investment income, and tax consequences applicable to you if you are subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one of certain financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a dealer or trader in securities that uses a mark-to-market method of tax accounting;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person holding ADSs or ordinary shares as part of a straddle, conversion transaction, integrated transaction or similar transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an entity classified as a partnership for U.S. federal income tax purposes (and investors therein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a tax-exempt entity, &#8220;individual retirement account&#8221; or &#8220;Roth IRA&#8217;&#8217;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person who acquired our ADSs or ordinary shares pursuant to the exercise of an employee stock option or otherwise as compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person that owns or is deemed to own 10% or more of our stock by vote or value; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person holding ADSs or ordinary shares in connection with a trade or business conducted outside the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a partnership for U.S. federal income tax purposes, the U.S. federal income tax consequences to your partners will generally depend on their status and your activities. Partnerships holding ADSs or ordinary shares and their partners should consult their tax advisors as to the particular U.S. federal income tax consequences of acquiring, owning or disposing of the ADSs or ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, and the income tax treaty between the United States and the PRC, or the Treaty, all as of the date hereof, any of which is subject to change, possibly with retroactive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, you are a &#8220;U.S. Holder&#8221; if you are eligible for the benefits of the Treaty and are, for U.S. federal income tax purposes, a beneficial owner of ADSs or ordinary shares and:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a citizen or individual resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Treasury regulations that apply to taxable years beginning on or after December 28, 2021 (the &#8220;Foreign Tax Credit Regulations&#8221;) may in some circumstances prohibit a U.S. person from claiming a foreign tax credit with respect to certain non-U.S. taxes that are not creditable under applicable income tax treaties. Accordingly, U.S. investors that are not eligible for Treaty benefits should consult their tax advisors regarding the creditability or deductibility of any PRC taxes imposed on dividends on, or dispositions of, the ADSs or ordinary shares. This discussion does not apply to investors in this special situation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, if you own ADSs you will be treated as the owner of the underlying ordinary shares represented by those ADSs for U.S. federal income tax purposes. Accordingly, no gain or loss will be recognized if you exchange ADSs for the underlying ordinary shares represented by those ADSs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Passive Foreign Investment Company Rules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, a non-U.S. corporation will be a passive foreign investment company, or a PFIC, for any taxable year in which (i)&#160;75% or more of its gross income consists of passive income, or the income test, or (ii)&#160;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the ordinary shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill is an active asset under the PFIC rules&#160;to the extent attributable to activities that produce active income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The value of our goodwill for any taxable year may be determined in large part by reference to the average of our market capitalization for that year. Because our market capitalization has generally declined substantially since our initial public offering (including in 2022 and recent months), if the value of our goodwill is determined by reference to the average of our quarterly market capitalization then it is our belief that we were likely a PFIC for our 2022 taxable year. Due to our declining market capitalization, there is a significant risk that we will also be a PFIC for 2023 and possibly future taxable years. In addition, the extent to which our goodwill should be characterized as a non-passive asset is not entirely clear. We have not obtained any valuation of our assets (including goodwill). U.S. Holders of our ADSs or ordinary shares should consult their tax advisors regarding the value and characterization of our assets for purposes of the PFIC rules, which are subject to some uncertainties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are a PFIC for any taxable year and any of our subsidiaries is also a PFIC (any such entity, a &#8220;Lower-tier PFIC&#8221;), U.S. Holders will be deemed to own a proportionate amount (by value) of the shares of each Lower-tier PFIC and will be subject to U.S. federal income tax according to the rules described in the subsequent paragraph on (i) certain distributions by a Lower-tier PFIC and (ii) dispositions of shares of Lower-tier PFICs, in each case as if the U.S. Holders held such shares directly, even though the U.S. Holders will not receive the proceeds of those distributions or dispositions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, if we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs or ordinary shares, gain recognized by such U.S. Holder on a sale or other disposition (including certain pledges) of its ADSs or ordinary shares will be allocated ratably over that U.S. Holder&#8217;s holding period. The amounts allocated to the taxable year of the sale or disposition and to any year before we became a PFIC will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge will be imposed on the resulting tax liability for each such year. Furthermore, to the extent that distributions received by a U.S. Holder in any taxable year on its ADSs or ordinary shares exceed 125% of the average of the annual distributions on the ADSs or ordinary shares received during the preceding three taxable years or the U.S. Holder&#8217;s holding period, whichever is shorter, the excess distributions will be subject to taxation in the same manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under a rule commonly referred to as the &#8220;once a PFIC, always a PFIC&#8221; rule, if we are a PFIC for any taxable year during which a U.S. Holder owns ADSs or ordinary shares, we will generally continue to be treated as a PFIC with respect to the U.S. Holder for all succeeding taxable years during which the U.S. Holder owns the ADSs or ordinary shares, even if we cease to meet the threshold requirements for PFIC status. If we are a PFIC for any taxable year but cease to be PFIC for subsequent years, U.S. Holders should consult their tax advisors regarding the advisability of making a &#8220;deemed sale&#8221; election that will allow them to eliminate the continuing PFIC status under certain circumstances, but may require them to recognize gain taxed under the general PFIC rules described in the preceding paragraph. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alternatively, if we are a PFIC and if the ADSs are &#8220;regularly traded&#8221; on a &#8220;qualified exchange,&#8221; a U.S. Holder of ADSs may make a mark-to-market election that will result in tax treatment different from the general tax treatment for PFICs described above. The ADSs will be treated as &#8220;regularly traded&#8221; for any calendar year in which more than a <i style="font-style:italic;">de minimis</i> quantity of the ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter. The Nasdaq Global Market, where the ADSs are listed, is a qualified exchange for this purpose, but there is no assurance that our ADSs will be treated as regularly traded for any relevant period. If a U.S. Holder makes the mark-to-market election, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in the ADSs will be adjusted to reflect the income or loss amounts recognized. Any gain recognized on the sale or other disposition of ADSs in a taxable year in which we are a PFIC will be treated as ordinary income, and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election, with any excess treated as capital loss). If a U.S. Holder makes the mark-to-market election, distributions paid on ADSs will be treated as discussed under &#8220;&#8212;Taxation of Distributions&#8221; below (but subject to the discussion in the immediately subsequent paragraph). If we are a PFIC for any taxable year, U.S. Holders should consult their tax advisors regarding the availability and advisability of making a mark-to-market election in their particular circumstances. In particular, U.S. Holders should consider carefully the impact of a mark-to-market election with respect to their ADSs because we may have Lower-tier PFICs for which a mark-to-market election likely cannot be made. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The favorable tax rates for dividends paid to certain non-corporate U.S. Holders of ADSs, which are discussed below, do not apply to dividends from a corporation that is a PFIC in the year the dividend is paid or the preceding year. We do not intend to provide information necessary for U.S. Holders to make a &#8220;qualified electing fund election,&#8221; which, if available, would result in tax treatment different from the tax treatment for PFICs described above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are a PFIC for any taxable year during which a U.S. Holder owns any ADSs or ordinary shares, the U.S. Holder will generally be required to file annual reports with the Internal Revenue Service (the &#8220;IRS&#8221;). U.S. Holders should consult their tax advisors regarding the PFIC rules and their application. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Taxation of Distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is subject to the discussion under <i style="font-style:italic;">&#8220;&#8212;Passive Foreign Investment Company Rules&#8221;</i> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Distributions paid on ADSs or ordinary shares, other than certain pro rata distributions of ordinary shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that any distributions will be reported to you as dividends. Dividends will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Subject to applicable limitations, dividends paid by &#8220;qualified foreign corporations&#8221; to certain non-corporate U.S. Holders are taxable at the favorable rates applicable to long-term capital gains. A non-U.S. corporation is generally treated as a qualified foreign corporation with respect to dividends paid on stock that is readily tradable on a securities market in the United States, such as the Nasdaq Global Market, where the ADSs are listed, or where the non-U.S. corporation is eligible for benefits of a comprehensive income tax treaty with the United States. Therefore such favorable rates may apply for so long as our ADSs are listed on the Nasdaq Global Market or if in the future we are eligible for benefits under the Treaty. However, as discussed above, the favorable rates do not apply if we are (or are treated with respect to a U.S. Holder as) a PFIC for the taxable year in which the dividend is paid or the preceding taxable year. Non-corporate U.S. Holders should consult their tax advisors to determine whether the favorable rate will apply to dividends they receive and whether they are subject to any special rules that limit their ability to be taxed at this favorable rate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends will be treated as foreign-source income for foreign tax credit purposes. As described in &#8220;&#8212;Material PRC Income Tax Considerations,&#8221; dividends paid by us may be subject to PRC withholding tax. For U.S. federal income tax purposes, the amount of the dividend income will include any amounts withheld in respect of PRC withholding tax. Subject to applicable limitations, which vary depending upon your circumstances, PRC taxes withheld from dividend payments (at a rate not exceeding the applicable rate provided in the Treaty) generally will be creditable against your U.S. federal income tax liability. In lieu of claiming a credit, you may elect to deduct creditable PRC taxes in computing your taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits must apply to all creditable foreign taxes paid or accrued in the taxable year. The rules governing foreign tax credits are complex, and you should consult your tax advisors regarding the creditability of foreign tax credits in your particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Sale or Other Disposition of ADSs or Ordinary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is subject to the discussion under <i style="font-style:italic;">&#8220;&#8212;Passive Foreign Investment Company Rules&#8221;</i> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Gain or loss realized on the sale or other taxable disposition of ADSs or ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if you held the ADSs or ordinary shares for more than one year. The amount of the gain or loss will equal the difference between your tax basis in the ADSs or ordinary shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As described in &#8220;&#8212;Material PRC Income Tax Considerations&#8221; above, gains on the sale of ADSs or ordinary shares may be subject to PRC taxes. Under the Code, capital gains of U.S. persons are generally treated as U.S.-source income. However, you may be able to elect to treat the gain as foreign-source income under the Treaty and claim foreign tax credit in respect of any PRC tax on dispositions. The Foreign Tax Credit Regulations generally preclude you from claiming a foreign tax credit with respect to PRC income taxes on gains from dispositions of ADSs or ordinary shares if you do not elect to apply the benefits of the Treaty. However, in that case it is possible that any PRC taxes on disposition gains may either be deductible or reduce the amount realized on the disposition.  The rules governing foreign tax credits and deductibility of foreign taxes are complex. You should consult your tax advisor regarding the consequences of the imposition of any PRC tax on disposition gains, including the Treaty&#8217;s resourcing rule, any reporting requirements with respect to a Treaty-based return position and the creditability or deductibility of the PRC tax on disposition gains in your particular circumstances (including any applicable limitations).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments of dividends and sales proceeds from the sale or exchange of our ADSs or ordinary shares that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;you are a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, you provide a correct taxpayer identification number and certify that you are not subject to backup withholding. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to you will be allowed as a credit against your U.S. federal income tax liability and may entitle you to a refund, provided that the required information is timely furnished to the IRS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain U.S. Holders who are individuals (and certain specified entities) may be required to report information relating to their ownership of ordinary shares, or non-U.S. accounts through which ADSs or ordinary shares are held. You should consult your tax advisor regarding your reporting obligations with respect to the ADSs or ordinary shares.</p><a id="_d42924ae_2eff_4ef1_82d6_125e386ab6e9"></a><a id="a10FDividendsandPayingAgents_24522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.F. Dividends and Paying Agents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_f6700246_74f4_433e_8862_b3be1e05a454"></a><a id="a10GStatementbyExperts_487266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.G. Statement by Experts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b1267181_3052_4459_b993_b765a772b21d"></a><a id="a10HDocumentsonDisplay_386080"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.H. Documents on Display</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We previously filed with the SEC registration statement on Form&#160;F-1 (File Number 333-252210), as amended, including annual report contained therein, to register our ordinary shares in relation to our initial public offering. We also filed with the SEC related registration statement on Form&#160;F-6&#160;(File Number&#160;333-252543)&#160;to register the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form&#160;20-F&#160;within four months after the end of each fiscal year. Copies of reports and other information, when so filed with the SEC, can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You can request copies of these documents, upon payment of a duplicating fee, by writing to the SEC. The public may obtain information regarding the Washington, D.C. Public Reference Room by calling the Commission at&#160;1-800-SEC-0330.&#160;The SEC also maintains a web site at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules&#160;of the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will furnish JPMorgan Chase Bank, N.A., the depositary of our ADSs, with our annual reports, which will include a review of operations and annual audited consolidated financial statements, and all notices of shareholders&#8217; meetings and other reports and communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, upon our request, will mail to all record holders of ADSs the information contained in any notice of a shareholders&#8217; meeting received by the depositary from us.</p><a id="_e53aeff3_df77_4163_a009_f9212760c174"></a><a id="a10ISubsidiaryInformation_103259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.I. Subsidiary Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_db7d9517_da9a_4b64_b64b_92115932492c"></a><a id="a10JAnnualReporttoSecurityHolders_93877"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">10.J. Annual Report to Security Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><a id="_da718e9d_a4d6_4863_b132_82f22d204fe8"></a><a id="ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Interest rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits. We have not used any derivative financial instruments to manage our interest risk exposure. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed, nor do we anticipate being exposed, to material risks due to changes in interest rates. However, our future interest income may be lower than expected due to changes in market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Foreign exchange risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a global business enterprise with part of our operations based in the PRC. A part of our transactions were settled in Renminbi, and our financial statements are presented in U.S. dollars. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in the ADSs will be affected by the exchange rate between U.S. dollar and Renminbi because a portion of value of our business is effectively denominated in Renminbi, while the ADSs representing our ordinary shares will be traded in U.S. dollars.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The value of the Renminbi against the U.S. dollar and other currencies is affected by changes in China&#8217;s political and economic conditions and by China&#8217;s foreign exchange policies, among other things. In July&#160;2005, the PRC government changed its decades-old policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July&#160;2008 and June&#160;2010, this appreciation subsided and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June&#160;2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. While appreciating approximately by 7% against the U.S. dollar in 2017, the Renminbi in 2018 depreciated approximately by 5% against the U.S. dollar. Since October&#160;1, 2016, the Renminbihas joined the International Monetary Fund (IMF)&#8217;s basket of currencies that make up the Special Drawing Right (SDR), along with the U.S. dollar, the Euro, the Japanese yen and the British pound. With the development of the foreign exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system and there is no guarantee that the RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that we need to convert U.S. dollars into Renminbi for our operations, appreciation of Renminbi against the U.S. dollar would reduce the Renminbi amount we receive from the conversion. Conversely, if we decide to convert Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs, servicing our outstanding debt, or for other business purposes, appreciation of the U.S. dollar against the Renminbi would reduce the U.S. dollar amounts available to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Inflation risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception, inflation in China has not materially impacted our results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for December 2020, 2021 and 2022 were increases of 2.4%, 0.9% and 2.0%, respectively. Although we have not in the past been materially affected by inflation since our inception, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China.</p><a id="_dc95bdfb_e612_4bfa_8cce_47619c537002"></a><a id="ITEM12DESCRIPTIONOFSECURITIESOTHERTHANEQ"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</p><a id="_684b19f8_30ad_4038_ab7a_61d9a0934b1a"></a><a id="a12ADebtSecurities_373051"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.A. Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_6f828253_66ee_4765_aba8_8175507376bc"></a><a id="a12BWarrantsandRights_197872"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.B. Warrants and Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_311e2638_e2f8_489f_ae66_5c44f2eaac38"></a><a id="a12COtherSecurities_121938"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.C. Other Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_f8215fa0_ea24_4282_8ffd_a234fb3ff42b"></a><a id="a12DAmericanDepositaryShares_154963"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.D. American Depositary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fees and Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of shares, issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities, and each person surrendering ADSs for withdrawal of deposited securities or whose ADRs are cancelled or reduced for any other reason, $5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, or upon which a share distribution or elective distribution is made or offered, as the case may be. The depositary may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distribution prior to such deposit to pay such charge.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following additional charges shall also be incurred by the ADR holders, the beneficial owners, by any party depositing or withdrawing shares or by any party surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee of U.S.$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee of U.S.$0.05 or less per ADS held for any cash distribution made, or for any elective cash/ stock dividend offered, pursuant to the deposit agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an aggregate fee of U.S.$0.05 or less per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding provision);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without limitation, the custodian and expenses incurred on behalf of ADR holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the shares or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in connection with the depositary&#8217;s or its custodian&#8217;s compliance with applicable law, rule&#160;or regulation (which fees and charges shall be assessed on a proportionate basis against ADR holders as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such ADR holders or by deducting such charge from one or more cash dividends or other cash distributions);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were shares) but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those ADR holders entitled thereto;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock transfer or other taxes and other governmental charges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of shares, ADRs or deposited securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfer or registration fees for the registration of transfer of deposited securities on any applicable register in connection with the deposit or withdrawal of deposited securities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions and other corporate actions, the depositary may engage the foreign exchange desk within JPMorgan Chase Bank, N.A. (the &#8220;Bank&#8221;) and/or its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars. For certain currencies, foreign exchange transactions are entered into with the Bank or an affiliate, as the case may be, acting in a principal capacity. For other currencies, foreign exchange transactions are routed directly to and managed by an unaffiliated local custodian (or other third party local liquidity provider), and neither the Bank nor any of its affiliates is a party to such foreign exchange transactions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foreign exchange rate applied to a foreign exchange transaction will be either (a)&#160;a published benchmark rate, or (b)&#160;a rate determined by a third party local liquidity provider, in each case plus or minus a spread, as applicable. The depositary will disclose which foreign exchange rate and spread, if any, apply to such currency on the &#8220;Disclosures&#8221; page&#160;(or successor page) of ADR.com. Such applicable foreign exchange rate and spread may (and neither the depositary, the Bank nor any of their affiliates is under any obligation to ensure that such rate does not) differ from rates and spreads at which comparable transactions are entered into with other customers or the range of foreign exchange rates and spreads at which the Bank or any of its affiliates enters into foreign exchange transactions in the relevant currency pair on the date of the foreign exchange transaction. Additionally, the timing of execution of a foreign exchange transaction varies according to local market dynamics, which may include regulatory requirements, market hours and liquidity in the foreign exchange market or other factors. Furthermore, the Bank and its affiliates may manage the associated risks of their position in the market in a manner they deem appropriate without regard to the impact of such activities on the depositary, us, holders or beneficial owners. <i style="font-style:italic;">The spread applied does not reflect any gains or losses that may be earned or incurred by the Bank and its affiliates as a result of risk management or other hedging related activity.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, to the extent we provide U.S. dollars to the depositary, neither the Bank nor any of its affiliates will execute a foreign exchange transaction as set forth herein. In such case, the depositary will distribute the U.S. dollars received from us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Further details relating to the applicable foreign exchange rate, the applicable spread and the execution of foreign exchange transactions will be provided by the depositary on ADR.com. Each holder and beneficial owner by holding or owning an ADR or ADS or an interest therein, and we, each acknowledge and agree that the terms applicable to foreign exchange transactions disclosed from time to time on ADR.com will apply to any foreign exchange transaction executed pursuant to the deposit agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from time to time between us and the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The right of the depositary to receive payment of fees, charges and expenses survives the termination of the deposit agreement, and shall extend for those fees, charges and expenses incurred prior to the effectiveness of any resignation or removal of the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fees and charges described above may be amended from time to time by agreement between us and the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services to ADR holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Payments by Depositary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our depositary anticipates to reimburse us for certain expenses we incur in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Depositary agrees with us from time to time. As of the date of this annual report, we have not received such reimbursement from the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_234784a7_0056_469f_ac9d_122f3522362c"></a><a id="PARTII_838708"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="ITEM13ITEMDEFAULTSDIVIDENDARREARAGESANDD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_68a49cde_678e_4557_abd2_b189edcd4aac"></a><a id="ITEM14MATERIALMODIFICATIONSTOTHERIGHTSOF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</p><a id="_401397c6_faf5_4e9e_98ec_9c249ba112f4"></a><a id="a14A14DMaterialModificationstotheRightso"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">14.A. &#8212; 14.D. Material Modifications to the Rights of Security Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 10 Additional Information&#8221; for a description of the rights of shareholders, which remain unchanged.</p><a id="_dd62be93_2870_4b5e_89e2_6d60de2d138e"></a><a id="a14EUseofProceeds_380361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">14.E. Use of Proceeds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following &#8220;Use of Proceeds&#8221; information relates to the registration statement on Form&#160;F-1, as amended (File No.&#160;333- 252210) in relation to our initial public offering, which was declared effective by the SEC on February&#160;8, 2021. In February&#160;2021, we completed our initial public offering in which we issued and sold an aggregate of 8,457,100 ADSs, representing 10,571,375 ordinary shares, resulting in net proceeds to us of approximately US$145.9 million, net of the underwriting discounts and commissions and other fees paid or payable by us in connection with the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The&#160;F-1&#160;Registration Statement was declared effective by the SEC on February 8, 2021. The total expenses incurred for our company&#8217;s account in connection with our initial public offering was approximately US$15.1&#160;million, which included US$11.2&#160;million in underwriting discounts and commissions for the initial public offering and approximately US$3.6&#160;million in other costs and expenses for our initial public offering. We received net proceeds of approximately US$145.9&#160;million from our initial public offering. None of the transaction expenses included payments to directors or officers of our company or their associates, persons owning more than 10% or more of our equity securities or our affiliates. None of the net proceeds from the initial public offering were paid, directly or indirectly, to our directors or officers and persons owning 10% or more of our equity securities or our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the period from the effective date of the registration statement on Form F-1 to December 31, 2022, we used US$64 million of the net proceeds received from our initial public offering primarily for research and development of our product candidates. We still intend to use the remainder of the proceeds from our initial public offering as disclosed in our registration statements on Form&#160;F-1.</p><a id="_b969592f_df5c_4c2a_a94d_876020d23f51"></a><a id="ITEM15CONTROLSANDPROCEDURES_210978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 15. CONTROLS AND PROCEDURES </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;under the Exchange Act) as of the end of the period covered by this report, as required by Rule&#160;13a-15(b)&#160;under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon that evaluation, our management has concluded that, as of December&#160;31, 2022, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act was recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms, and that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. As required by Rule 13a-15(c) of the Exchange Act, our management conducted an evaluation of our company&#8217;s internal control over financial reporting as of December 31, 2022 based on the framework in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Attestation Report of the Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This annual report on Form&#160;20-F does not include an attestation report of our registered public accounting firm due to a transition period established by rules&#160;of the SEC for newly public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) during the period covered by this annual report on Form&#160;20-F that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_a83d4f71_c952_43bf_a78b_c8656d83b05e"></a><a id="Item16AAuditCommitteeFinancialExpert_659"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 16.A. Audit Committee Financial Expert</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors has determined that Mr.&#160;Andy (Yiu Leung) Cheung, an independent director and the chairperson of our audit committee, qualifies as an &#8220;audit committee financial expert&#8221; within the meaning of the SEC rules&#160;and in accordance with applicable Nasdaq Global Market standards. Mr.&#160;Andy (Yiu Leung) Cheung satisfies the &#8220;independence&#8221; requirements of Rule&#160;10A-3 under the Securities Exchange Act of 1934, as amended, and the applicable Nasdaq Global Market standards.</p><a id="_10c949f2_73b7_4233_b605_e4836453a0e7"></a><a id="Item16BCodeofEthics_352573"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 16.B. Code of Ethics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors has adopted a code of business conduct and ethics that applies to all of our directors, officers, employees, including certain provisions that specifically apply to our principal executive officer, principal financial officer, principal accounting officer or controller and any other persons who perform similar functions for us. We have filed our code of business conduct and ethics as Exhibit&#160;99.1 of our registration statement on Form&#160;F-1 (File No.&#160;333- 252210), as amended, filed with the SEC on January&#160;19, 2021 and posted a copy of our code of business conduct and ethics on our website at<i style="font-style:italic;"> http://investor.adagene.com</i>. We hereby undertake to provide to any person without charge, a copy of our code of business conduct and ethics within ten working days after we receive such person&#8217;s written request.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_9362ea95_1a94_4c0d_ad74_c2d05f2994d7"></a><a id="Item16CPrincipalAccountantFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 16.C. Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Auditor Fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered by PricewaterhouseCoopers Zhong Tian LLP, our independent registered public accounting firm, for the periods indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RMB</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RMB</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Services</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Audit Fees(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,800</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Audit-Related Fees(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Tax Fees(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other Fees(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,800</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Audit Fees</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Audit fees mean the aggregate fees billed in each of the fiscal periods listed for professional services rendered by our principal auditors for the audit of our annual consolidated financial statements and assistance with and review of documents filed with the SEC.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Audit-related Fees.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Audit-related fees mean the aggregate fees billed for professional services rendered by our principal auditors for the assurance and related services, which were not included under Audit Fees above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Tax Fees</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Tax fees mean fees incurred from professional services related to tax compliance.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Fees</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Other fees mean fees incurred from professional services related to training, advisory and assurance for corporate and social responsibility reporting and professional services related to tax advice.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The policy of our audit committee is to pre-approve all audit and non-audit services provided by PricewaterhouseCoopers Zhong Tian LLP, our independent registered public accounting firm, including audit services and audit-related services as described above, other than those for <i style="font-style:italic;">de minimis</i> services which are approved by the audit committee prior to the completion of the audit.</p><a id="_59c26862_b70d_477d_8b2b_5c7d5ca401b5"></a><a id="a16DExemptionsfromtheListingStandardsfor"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.D. Exemptions from the Listing Standards for Audit Committees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_e8e1ff4d_dc90_4f14_8ea8_2c1270a2d54b"></a><a id="a16EPurchasesofEquitySecuritiesbytheIssu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 7, 2021, our board of directors authorized a share repurchase program whereby our company was authorized a share repurchase program under which the Company may repurchase up to US$20.0 million of its ordinary shares in the form of American depositary shares during a period of up to 12 months commencing on July 20, 2021 (the &#8220;2021 Share Repurchase Program&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s share repurchases may be made from time to time on the open market at prevailing market prices, in open-market transactions, privately negotiated transactions or block trades, and/or through other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of the share repurchases will be subject to various factors including the requirements under Rule 10b-18 and Rule 10b5-1 of the Exchange Act. Our board of directors will review the share repurchase program periodically and may authorize adjustments to its terms and size or suspend or discontinue the program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the details of the repurchases made in accordance with the 2021 Share Repurchase Program from April 1, 2022 to July 19, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Approximate&#160;Dollar&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Number&#160;of&#160;ADSs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;ADSs&#160;that&#160;May&#160;Yet&#160;Be</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchased&#160;as&#160;Part&#160;of&#160;the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchased&#160;Under&#160;the&#160;Plan</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ADSs&#160;Purchased</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid&#160;Per&#160;ADS</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Publicly&#160;Announced&#160;Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$in&#160;thousand)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">April 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 195,788</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 730,595</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,259</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">May 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 102,689</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 833,284</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,936</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">June 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 190,083</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,023,367</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,513</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">July 1 - 19, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 383,218</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,406,585</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,731</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 871,778</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2.6</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,406,585</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 13,731</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(1)</span></span>Each ADS representing one and one quarter ordinary shares. Average price paid per ADS is calculated using the execution price for each repurchase excluding commissions paid to the broker.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 29, 2022, our board of directors authorized a share repurchase program whereby our company was authorized a share repurchase program under which the Company may repurchase up to US$10.0 million of its ordinary shares in the form of American depositary shares during a period of up to 12 months commencing on July 20, 2022 (the &#8220;2022 Share Repurchase Program&#8221;). The 2022 Share Repurchase Program was subsequently terminated in July 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s share repurchases may be made from time to time on the open market at prevailing market prices, in open-market transactions, privately negotiated transactions or block trades, and/or through other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of the share repurchases will be subject to various factors including the requirements under Rule 10b-18 and Rule 10b5-1 of the Exchange Act. Our board of directors will review the share repurchase program periodically and may authorize adjustments to its terms and size or suspend or discontinue the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table summarizes the details of the repurchases made in accordance with the 2022 Share Repurchase Program from July 20, 2022 to July 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Approximate&#160;Dollar&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Number&#160;of&#160;ADSs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;ADSs&#160;that&#160;May&#160;Yet&#160;Be</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchased&#160;as&#160;Part&#160;of&#160;the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchased&#160;Under&#160;the&#160;Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ADSs&#160;Purchased</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid&#160;Per&#160;ADS</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Publicly&#160;Announced&#160;Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$ in&#160;thousand)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">July 20 &#8211; 31, 2022 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 39,900</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;">1.8</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 39,900</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 9,928</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;">Each ADS representing one and one quarter ordinary shares. Average price paid per ADS is calculated using the execution price for each repurchase excluding commissions paid to the broker.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_bbfebf2b_0b76_48c6_a764_6b68c841b1ff"></a><a id="a16FChangeinRegistrantsCertifyingAccount"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.F. Change in Registrant&#8217;s Certifying Accountant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_290a7382_263a_4621_829b_f0a92bb61586"></a><a id="a16GCorporateGovernance_85646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.G. Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Cayman Islands exempted company listed on Nasdaq Stock Market, we are subject to the Nasdaq corporate governance listing standards. However, Rule 5615 of the Nasdaq Rules permits a foreign private issuer like our company to follow home country practice in lieu of certain corporate governance matters as required under Rule 5600 Series, Rule 5250(b)(3) and Rule 5250(d) of the Nasdaq Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq corporate governance listing standards. We elect to rely on home country practice exemption in lieu of the requirements of the Rule 5600 Series of the Nasdaq Rules, except the following: compliance with the Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640), the Diverse Board Representation Rule (Rule 5605(f)), the Board Diversity Disclosure Rule (Rule 5606), having an audit committee that satisfies Rule 5605(c)(3), and ensuring that such audit committee&#39;s members meet the independence requirement in Rule 5605(c)(2)(A)(ii).  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular, we relied on home country practice exemption with respect to Rule 5620(a) of the Nasdaq Rules, which requires a Nasdaq-listed company to hold an annual meeting of Shareholders no later than one year after the end of the company&#39;s fiscal year-end and we did not hold an annual shareholders meeting in 2021. We may, however, hold annual shareholder meetings in the future if there are significant issues that require shareholders&#8217; approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We elected to follow home country practice exemption and be exempt from the requirements to obtain shareholder approval for (1) certain acquisitions of the stock or assets of another company under Rule 5635(a) of the Nasdaq Rules, (2) the issuance of securities when the issuance or potential issuance will result in a change of control of the Company under Rule 5635(b) of the Nasdaq Rules, (3) the issuance of securities when a stock option or purchase plan is to be established or materially amended or other equity compensation arrangement made or materially amended under Rule 5635(c) of the Nasdaq Rules, and (4) the issuance of 20% or more of its outstanding ordinary shares under Rule 5635(d) of the Nasdaq Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We relied on our home country practice exemption with respect to Rule 5605(d)(2) of the Nasdaq Rules, which requires a Nasdaq-listed company to establish a compensation committee comprised entirely of independent directors and two out of three members of our compensation committee are independent directors. We relied on our home country practice exemption with respect to Rule 5605(e)(1) of the Nasdaq Rules, which requires a Nasdaq-listed company to nominate director nominees either by a majority independent board or by a nominations committee comprised solely of independent directors and we do not have a majority independent board or a nominations committee comprised solely of independent directors. We relied on our home country practice exemption with respect to Rule 5250(b)(3) of the Nasdaq Rules, which requires a Nasdaq-listed company to disclose third party director and nominee compensation no later than when the companies files its next Form 20-F and we did not disclose such information in the form of 20-F for the year of 2020,2021 and 2022. We may also opt to rely on additional home country practice exemptions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Walkers (Hong Kong), our Cayman Islands counsel, has provided a letter to the Nasdaq Stock Market certifying that under Cayman Islands law, we are not required to comply with abovementioned requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our shareholders may be afforded less protection than they otherwise would under the Nasdaq Global Market corporate governance listing standards applicable to U.S. domestic issuers. See &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Related to the ADSs&#8212;As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq listing standards.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_2136ea6e_cca1_42ba_997d_a2b0ed1246e9"></a><a id="a16HMineSafetyDisclosure_791076"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.H. Mine Safety Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_547089b4_cf4a_49be_8ce6_7a0168e6fea4"></a><a id="a16IDisclosureRegardingForeignJurisdicti"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">16.I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;">(a) We have electronically submitted to the SEC on a supplemental basis documentation that establishes that Adagene Inc. is not owned or controlled by a governmental entity in the foreign jurisdiction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;">(b) For the immediately preceding annual financial statement period, our auditor, which was a registered public accounting firm that the PCAOB was unable to inspect or investigate completely because of a position taken by the PRC government, issued our audit report that was included in our Form 20-F for the fiscal year of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report and to our best knowledge:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">none of our shares are owned by governmental entities in the jurisdiction in which we are incorporated or otherwise organized;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">none of the governmental entities in the applicable foreign jurisdiction with respect to our registered public accounting firm have a controlling financial interest in us;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;">none of the members of our board of directors or the board of directors of our operating entity is an official of the Chinese Communist Party; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;">our amended and restated memorandum and articles of association does not contain any charter of the Chinese Communist Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="_7771c936_b867_49a9_8390_b234143b90f0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">16.J. Insider Trading Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;">(a) We have adopted insider trading policies and procedures governing the purchase, sale, and other dispositions of our securities by directors, senior management, and employees that are reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;">(b) [Not applicable.]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f41a488f_5858_4f89_9f0f_f4b5658ab6b3"></a><a id="PARTIII_403713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="ITEM17FINANCIALSTATEMENTS_534522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 17. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have elected to provide financial statements pursuant to Item 18.</p><a id="_0802a2fa_27d6_48fa_a9cd_e875a80ea95b"></a><a id="ITEM18FINANCIALSTATEMENTS_506735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 18. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are included at the end of this annual report.</p><a id="_90673c7f_90e9_485c_8e2b_14ed396ffc04"></a><a id="ITEM19EXHIBITS_246848"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 19. EXHIBITS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Seventh Amended and Restated Memorandum and Articles of Association of the Registrant, as currently effective (incorporated by reference to Exhibit&#160;3.2 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Registrant&#8217;s Specimen American Depositary Receipt ((incorporated by reference to Exhibit&#160;4.3 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021))</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.2</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registrant&#8217;s Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit&#160;4.2 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.3</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Deposit Agreement between the Registrant, the depositary and holders of the American Depositary Shares (incorporated by reference to Exhibit&#160;4.3 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.4</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amended and Restated Shareholders Agreement by and among Adagene Inc. and shareholders of Adagene Inc. named therein dated December&#160;19, 2019 (incorporated by reference to Exhibit&#160;4.4 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.5*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex2d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amended and Restated Right of First Refusal and Co-Sale Agreement by and between Adagene Inc., non-investor shareholders and investors named therein dated December&#160;19, 2019 (incorporated by reference to Exhibit&#160;4.5 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Adagene Inc. Second Amended and Restated Share Incentive Plan (incorporated by reference to Exhibit&#160;10.1 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit&#160;10.2 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Employment Agreement between the Registrant and an executive officer of the Registrant (incorporated by reference to Exhibit&#160;10.3 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Adagene Inc. 2021 Performance Incentive Plan (incorporated by reference to Exhibit&#160;10.13 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000233/a2242824zex-10_14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement between Exelixis,&#160;Inc. and Adagene Incorporated dated February&#160;1, 2021 (incorporated by reference to Exhibit&#160;10.14 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.7 &#8224; #</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000110465922050329/adag-20211231xex4d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Collaboration and License Agreement between Adagene Incorporated and Genzyme Corporation dated February 25, 2022  (incorporated by reference to Exhibit 4.16 from our annual report for the year of 2021, filed with the SEC on April 26, 2022)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8.1*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="adag-20221231xex8d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of subsidiaries of the Registrant</span></a> </p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Code of Business Conduct and Ethics of the Registrant (incorporated by reference to Exhibit&#160;99.1 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12.1*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex12d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12.2*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex12d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Accounting Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">13.1**</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex13d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">13.2**</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex13d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Accounting Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.1*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex15d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Jingtian &amp; Gongcheng</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.2*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex15d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Walkers (Hong Kong)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.3*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex15d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Gr</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">eenberg </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Tr</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">aurig</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.4*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex15d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of PricewaterhouseCoopers Zhong Tian LLP,&#160;Independent Registered Public Accounting Firm</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.5*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20221231xex15d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Submission under Item 16I(a) of Form 20-F in relation to the Holding Foreign Companies Accountable Act</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.INS*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.SCH*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.CAL*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.DEF*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.LAB*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.PRE*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">104*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;Filed herewith</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">**&#160;&#160;&#160;Furnished herewith</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">#&#160;&#160;&#160;&#160;&#160;Certain of the appendices, annexes, exhibits and/or schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_952c2157_2248_4bc3_9677_8982d33a196b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The registrant hereby certifies that it meets all of the requirements for filing its annual report on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: April 28, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:55.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;Adagene&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;width:55.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;width:55.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ PETER LUO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-style:italic;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-style:italic;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6813d694_8142_41c0_a9e3_1ce8801ddccf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ADAGENE INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.29%;"><tr><td style="vertical-align:bottom;width:91.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements as of and for the Years Ended December 31, 2020, 2021 and 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">PAGES</b></p></td></tr><tr><td style="vertical-align:bottom;width:91.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;"> (PCAOB ID: </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:AuditorFirmId" id="Narr_FveG66kJh0Cy7mjHFIPc7Q"><span style="font-size:10pt;">1424</span></ix:nonNumeric><span style="font-size:10pt;">)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDBALANCESHEETS_305472"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2021 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOS"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2020, 2021 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHO"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit) for the Years Ended December 31, 2020, 2021 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_933280"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2020, 2021 and 2022</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#NOTESTOTHECONSOLIDATEDFINANCIALSTATEMENT"><span style="font-style:normal;font-weight:normal;">Notes to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c94785ad_4ef4_49bd_a0dd_1fea6e57e2a4"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">To the Board of Directors and Shareholders of Adagene Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Adagene Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, and the related consolidated statements of comprehensive loss, of changes in shareholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December&#160;31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022 in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Change in Accounting Principle</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">/s/ </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:AuditorName" id="Narr_7mHoRbRjckKtQjIZ3sANnw"><span style="font-size:10pt;">PricewaterhouseCoopers Zhong Tian&#160;LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="dei:AuditorLocation" id="Narr_X78HSeahnk6xEqTK-SdNnQ"><span style="font-size:10pt;">Shanghai, the People&#8217;s Republic of China</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">April 28, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a536c477_be04_4ccc_bcd2_78779d598ffb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE INC.</p><a id="CONSOLIDATEDBALANCESHEETS_305472"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">AS OF DECEMBER 31, 2021 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_18c1d574_9f07_43eb_833f_a93411c728a2"></a><a id="Tc_86V4MA_5-Ey6WZuUYPCvDw_1_4"></a><a id="Tc_l_Nwqe_PwkCmTNNG0G95yQ_2_2"></a><a id="Tc_g8WZ-bWGfk-uQLAVYHj74Q_2_4"></a><a id="Tc_LGUgHWMWnkG10w1gCpugjw_2_6"></a><a id="Tc_WwhTFQWViUChoea3_stCvA_3_4"></a><a id="Tc_mXfI9pIhIU27MEe89WEgRA_3_6"></a><a id="Tc_UCOfZFRLz0KIZcmiXAWqeQ_4_0"></a><a id="Tc_4NNPMjf7WE-us0HMDgGnqA_5_0"></a><a id="Tc_4NIZNevT1EeAFXSEEZv_wQ_6_0"></a><a id="Tc_qB4DT8BCGkOB_Mkdz4xBzg_7_0"></a><a id="Tc_OjLLI_lnKESPbIRYBsFtIg_7_2"></a><a id="Tc_QJyqV_CxDU-HdhvsGRZnxw_7_6"></a><a id="Tc_Ve57lXdlike4GQnNwUpdgw_8_0"></a><a id="Tc_A-LYkRsA0Um9gCGrW-JSTQ_8_2"></a><a id="Tc_Tb9PiEidH0atVmpQ65amdg_9_0"></a><a id="Tc_bkr7pNdKYka4JtA6P_phUw_9_2"></a><a id="Tc_d6X65bdIR0ysxRpAF_DrDQ_10_0"></a><a id="Tc_6tXcqfqFKEOuCJ-LCCZ-1g_11_0"></a><a id="Tc_VLiT7t053kui4PiVGd3wFQ_11_2"></a><a id="Tc_c6IvhPP6GEmhADiBk4OF3A_12_0"></a><a id="Tc_pKzPQVxohEOQqR-othJZow_12_2"></a><a id="Tc_WhZkiEUlxUe8K-jK5G9LuQ_12_4"></a><a id="Tc_L_ILNSke10G9Fbgp_-RRSA_13_0"></a><a id="Tc_UYnEPiVu1kay_7Jw5AxIRA_14_0"></a><a id="Tc_MCRmMBeakU6BCgJxXHAd8w_15_0"></a><a id="Tc_DxxfwOCXhUiKgZe08yq1Kg_16_0"></a><a id="Tc_0lc9u-yPOU2jWSVokAKuig_17_0"></a><a id="Tc_FOzPNIlGUkSECWlATfFJcw_18_0"></a><a id="Tc_RHcgNOneQEmmdlt_vc2oXw_19_0"></a><a id="Tc_e68_tkpcbESCS5CFT9T8zw_19_2"></a><a id="Tc_RXlTH8dve0aFMSoKCSchHA_20_0"></a><a id="Tc_fEr0x-z6aUOa1pStIf0jBQ_20_2"></a><a id="Tc_hfZSD9-_zUeaEpW3Ye0iww_21_0"></a><a id="Tc_OzUO0PlXekC65XnRwfg1nw_21_2"></a><a id="Tc_Z7CAUzMI0kuPpY064BxMcQ_21_6"></a><a id="Tc_wg3pILOEu0CZe4_lLaMOxA_22_0"></a><a id="Tc_Z1xQpeDABkCeb0ScdCfBjg_22_2"></a><a id="Tc_9P-1O0aTb0itbFZJIYxdXg_23_0"></a><a id="Tc_ynZ22MIvL02ghfz8oLVTTg_23_2"></a><a id="Tc_ba70qtlVCEmGxPsLWuoFCA_24_0"></a><a id="Tc_iVLSupjRREqLe19Wtd5IQg_24_2"></a><a id="Tc_M0Oi6Xay4E6sZosFx1nXAA_24_4"></a><a id="Tc_XRkGl-Y_KkSpcsJFUkaPqg_25_0"></a><a id="Tc_xPDKKy8ayUuOv9mNIF1dvQ_26_0"></a><a id="Tc_wXQ3-_oU_0mM1cnC6_jd_A_26_2"></a><a id="Tc_HZKZym9mhUe1ETeCi-U1uQ_27_0"></a><a id="Tc_xmQu1beHlki-zWDROmCPbQ_27_2"></a><a id="Tc_ZW-nvykAX0WBEHxTFu73sg_27_4"></a><a id="Tc_AjIPtD-rM0SCJERPjZom_Q_28_0"></a><a id="Tc_fjSzu1VcUU-0wh2BISxUzg_28_2"></a><a id="Tc_RyXyLIzoP0CCpd3iQGSdjw_28_6"></a><a id="Tc_nE88if9BVEqce9TJaNUbOg_29_0"></a><a id="Tc_HqjtwFEQxE2OFJIBhr0xhw_30_0"></a><a id="Tc_sytBUCjRZUex7sJDGH2WiQ_31_0"></a><a id="Tc_7EHNefZK7kadfqx9q2_nKw_31_2"></a><a id="Tc_OoJxWZw-mE-cW2HnSFa3Nw_32_0"></a><a id="Tc_zhPr9nJ500Galx7bjh6StQ_33_0"></a><a id="Tc_SaYEYdo6PEmY4lkHmk6frA_34_0"></a><a id="Tc_VdkSKPWvoka4_7EAP3gKsw_34_2"></a><a id="Tc_0Z44t5JYkUCJR6admZmZzA_35_0"></a><a id="Tc_bfXiHH8RvkyR1NbnYZ0_tA_36_0"></a><a id="Tc_0EaygWX2fEaTNfS9R-ya1w_37_0"></a><a id="Tc_CWgXiJocIEG8d-waCTrn3g_38_0"></a><a id="Tc_kp9exiNzPEmiGKur3Hjghw_39_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_otGRtl_iDUGEqm2Jildqcw_6_4">174,391,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_X5FxQlK0t0mCcZn-cP6I6g_6_6">143,758,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3,10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_p05vVqV47EmU0QigpFggeg_7_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Amounts due from related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_LZ3d8L1V3kmoywsbSCVs5A_8_4">4,506,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_xLnCkwtOq02t0AHWaAP_5Q_8_6">619,432</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Prepayments and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_VnQaBJXHYkeDaB68gJMZ6Q_9_4">4,055,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_9iQwttJN1kq4FHqvN9A4cw_9_6">4,937,323</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_FhUUISS5_k2Y_bdaq6Ps7g_10_4">185,953,834</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_kkvbL0GueUy9_hHHq2yxVQ_10_6">149,315,433</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Property, equipment and software, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_5EDpeIAIzke5BCYTOMnqNw_11_4">3,487,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_bZUDiCxJxEO7mxKaiBYgtA_11_6">2,782,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_jZAftmJX3EevdkcMCX7l2w_12_6">191,877</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_135X03FOX0eUlJcH7BE4lw_13_4">69,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_ZOT7uc80hUibAdmbfiqWvw_13_6">109,572</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_G891cCHygUqTpligB_60Hg_14_4">189,510,726</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_fcNh3lB_MkKc98Y5yV74yg_14_6">152,399,845</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_LJU7qfSUKEGysJ6R38f6wg_17_4">3,321,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_p-5_yCCT60a2WSVDvPOBtw_17_6">3,666,124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_Ji1eVDzovEaTMnWhaqNZ3g_18_4">5,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_v3awmWNNWkOJTIFbe1Yf7A_18_6">15,107,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Amounts due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc__cmryureJ0GeB-oLC_aCqQ_19_4">10,466,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_8RgI9f3CHkOqFA7A4QIoAQ_19_6">19,323,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accruals and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_TX1jtQkksU-PUznbCO_brw_20_4">4,379,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_CClrUBRSqUWVTs8JNRTk-g_20_6">3,212,809</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" id="Tc_UG5OsuTnd0SHed3gBdMnyQ_21_4">1,657,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Short-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_rDA6uJmlIE2HYZs-LVAqMg_22_4">3,121,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_leClezLNxE-3vCW1Gub2TA_22_6">10,768,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_xPaPy9uxCEKGf2IiWGFfMw_23_4">1,376,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_V5uySfpTvE6OG83YJD95HQ_23_6">2,850,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_rXcCiiHgSUe1tMb9VYewew_24_6">151,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_b5XMu3gcekSBk_ui8kGG1w_25_4">29,821,914</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_vZnJqjsRw0Gfw1jKKo30pg_25_6">55,080,402</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_9UFFxymeZE6yqhRBtCcNPQ_26_4">2,991,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_8QQs_FfSYEutASPS7YywMQ_26_6">14,146,541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_mPcHnrIEL0OFi5X-B7WLzg_27_6">53,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="Tc_VWUeDOSukUin8Kgw-neGMQ_28_4">44,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="Tc_q51H4n5T90WPaa5rzgT0hA_29_4">94,107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="Tc_1wxQMsOZ2EmOkgQCm-VgzQ_29_6">28,718</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_jQXA9oAdGUKvMfNaX9yWgw_30_4">32,952,013</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_6riIwNAawk-Gr-qag4McCw_30_6">69,309,495</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and contingencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Ordinary shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_B7mbxkC3m02IVBVZ2d_6Eg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_hmUInQMH5UGhsSf2BIaauw">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Yz55Cu8ENk-Dyvyvx8ci-w">640,000,000</ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_Bn0Uh1CwzEetpv3SHNeecA">54,595,667</ix:nonFraction></span><span style="font-size:8pt;"> shares issued and </span><span style="-sec-ix-hidden:Hidden_rP_ZtM9G8EmayLsfIZ8I3w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of December 31, 2021; and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_6wFWtTrryk6dKMsqOmIywQ">640,000,000</ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_-Vy9EetzzESqCn3ocVWaQA">54,065,709</ix:nonFraction></span><span style="font-size:8pt;"> shares issued and </span><span style="-sec-ix-hidden:Hidden_sRbjWAccFkeLc4ATnl88EQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of December 31, 2022)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_jTcFqC2Us0Cqx5vUiWUnLg_33_4">5,627</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_iX_IAaTIKEqCm5qxAzay8Q_33_6">5,497</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Treasury shares, at cost (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Narr_FVzABJNctEa0nnUsvgJjmg">94,074</ix:nonFraction> shares as of December 31, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Narr_JUzhoovy0kGlyjaYOBPFHg">1</ix:nonFraction> share as of as of December 31, 2022)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonValue" scale="0" id="Tc_L_R9tO1TRE-KFwavDfdZwA_34_4">619,605</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonValue" scale="0" id="Tc_bjMUlz-2Yku0OxhKieWjMA_34_6">4</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_Dbd_ygPIS0255KSLHfOy1Q_35_4">336,099,931</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_ASffXZXcEkCguOc-9sE8ag_35_6">342,739,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_n4d6lDU6akadfUvjOlUj7A_36_4">93,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_sZWoxyg8W0CJJGswWyZKbA_36_6">849,305</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_MqtWgbLI-0yb1meJyGVliw_37_4">178,833,259</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_Y3L1t1a7SESf8K3blCRXLQ_37_6">258,805,106</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ZKACWStI8UaMA85xquPmNA_38_4">156,558,713</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gqScXx-YXku82-QxXiFtsw_38_6">83,090,350</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_V5GFwXl7EUm6mYSTbHbnnw_39_4">189,510,726</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_zaw12crZp0OYIEDKzW4gfQ_39_6">152,399,845</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f77d0ef_2980_40f7_a32c_1ac0c69486f8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">ADAGENE&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2020, 2021 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c1ab1226_56e8_472f_8ef9_1582b5222bf5"></a><a id="Tc_JDiqtaiXDUuIes9W4_oTZw_1_4"></a><a id="Tc_59gLrU_oikm3_9LMLbYrLw_2_4"></a><a id="Tc_a1WGf1J6j0umTUP5EA66eg_3_2"></a><a id="Tc_Kbq-3EwzJUOPBJJL7VTaoQ_3_4"></a><a id="Tc_31lyJqFZOUKCfoZG3kQSlQ_3_6"></a><a id="Tc_tf_5PbGWo0KGF0__6vNruA_3_8"></a><a id="Tc_zThFHDTYjE2cxIn4RI1XXQ_4_4"></a><a id="Tc_mbguP3dZMk-mH3GTnSfxiw_4_6"></a><a id="Tc_3okSmmWoUUyDrZ3-RbO5rQ_4_8"></a><a id="Tc_xFfh9uuCHEOAQieZXKCamQ_5_0"></a><a id="Tc_34tGbdfquEO5u1_4MuMoQg_6_0"></a><a id="Tc_KBwkLCyu9kaJ6jVv4r36aA_6_2"></a><a id="Tc_u5cwIlKvkkq4hFTHbB-Q9A_7_0"></a><a id="Tc_uw2DD7y35kaSrOocVbGSkQ_8_0"></a><a id="Tc_rqTU6dOMuUq0Fso1lpcE6Q_9_0"></a><a id="Tc_f07FZ8w63Uu6H5Z6MgUPww_10_0"></a><a id="Tc_VqX4U0r_H0CSZh4N21IVCg_11_0"></a><a id="Tc_CItdt31x7Ui1bTssAs8y7A_12_0"></a><a id="Tc_XH_QCzia90erwVrXHGgRqA_13_0"></a><a id="Tc_7Nr4DGpXDEueQ0FOqcdjsw_14_0"></a><a id="Tc_ngnBt__fK0aaeolpeJLW2w_15_0"></a><a id="Tc_lk2wy3dVVEuKfa22kl6Zng_16_0"></a><a id="Tc_2-vRb8DlOkuc-ZJLWwq-Xg_17_0"></a><a id="Tc_a-_WTXW4lkmVb1GNTIoxrA_18_0"></a><a id="Tc_qx5wwJH4WkWID_PrsSgpVw_18_2"></a><a id="Tc__NJQPhm1R0WQEBft9UBrOQ_18_4"></a><a id="Tc_H1aeF9YWxUyyjfxh91eiOA_19_0"></a><a id="Tc_n73dhu_-QEGTYN0hWMh-Wg_20_0"></a><a id="Tc_p3cjDnojI06GckwYs-vFWQ_21_0"></a><a id="Tc_ed715jlQ_k-yISaVgveFOg_22_0"></a><a id="Tc_fp-xYC3ryEWZRrn2yniNKA_23_0"></a><a id="Tc_J23gb1EHf0O1jH1A-Ep1ng_24_0"></a><a id="Tc_gtdJV7mX0UKWHlnF1av2nA_24_2"></a><a id="Tc_stI-NleDzk-Z40XWm6BfvA_24_8"></a><a id="Tc_GIz7aXmdm06GpeuuZ9hj4A_25_0"></a><a id="Tc_qlvFPn6QV06of_g7bWB6eQ_26_0"></a><a id="Tc_MQVOj4mNa0in-zakK7Dheg_27_0"></a><a id="Tc_c6lLui6MbkmmfKumhqIkbg_27_2"></a><a id="Tc_wqu_Y5tEikSFAdIPC-VPeg_28_0"></a><a id="Tc_Dh3JKhLP5UWwrClJ4BpEdQ_28_2"></a><a id="Tc_ts501_vtw0ScYlJS41BX8A_29_0"></a><a id="Tc_Xig90dereUCashX9165YNA_30_0"></a><a id="Tc_S68Lf-sABUO5TlKR2J4Hhg_30_2"></a><a id="Tc_89ah5_otiUW9ShRfdy9yDA_31_0"></a><a id="Tc_ogFqJ8wha0KR1qbT0L6JzA_31_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Licensing and collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_cWSph83BskeBPg1le1UOAw_6_4">700,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_gHDbFRNcME25N0-u3NmpnQ_6_6">10,175,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_G9X8uYMlSUGSvuU7feoo6w_6_8">9,292,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_VlT5XcMSjkC8w3Ur1mNECA_8_4">33,538,035</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_QInRhcFLMUaRf4ZKRUCm8Q_8_6">68,099,385</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_a2g0VyHfLE-GYzEJnv4JrA_8_8">81,339,540</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Third parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="adag:ResearchAndDevelopmentExpenseThirdParties" scale="0" id="Tc_paaCQ31HLEarMqs2phvSAg_9_4">23,645,740</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:ResearchAndDevelopmentExpenseThirdParties" scale="0" id="Tc_ysKxNPBuwUOJncTqX5Geag_9_6">55,020,367</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:ResearchAndDevelopmentExpenseThirdParties" scale="0" id="Tc_z8KMWcDYmk6wZy-gOD5h1A_9_8">46,212,077</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" scale="0" id="Tc_U5BZkWuzZ0efBDj2eLQK9Q_10_4">9,892,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" scale="0" id="Tc_MG0ylQ7fpkCXMiXD_R07gg_10_6">13,079,018</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" scale="0" id="Tc_OOpb41L7kk6jfhtlGW6L2A_10_8">35,127,463</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_VPciAjgmaUqekEAJqvxOEg_11_4">10,314,536</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_SwNs-ofv3kuHRNu4VaGNrA_11_6">14,439,962</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_rF4iH4ku0k2UiLywkqe-wg_11_8">11,873,867</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_wIYGieTEg0SRoROMaH2THw_12_4">43,151,658</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_UeJZunLapUeTAORbhXVRKQ_12_6">72,364,089</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_TXDOD9Dw_USVp4UnUbhPpA_12_8">83,920,683</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="0" id="Tc_xQr8rIcMT0GwgY5OcykUrg_13_4">629,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="0" id="Tc_o4AzmV8ifU6WewD-X8_B-A_13_6">76,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="0" id="Tc_PRYGDukkGUyvWHRp4FT8sg_13_8">377,501</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_bbio_aQaNEWOIvHkqa5FgA_14_4">202,165</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_OVCIs9YVQkGi1S3q-QgSoA_14_6">363,762</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_gFDGsJ-4qEe8Z-EqXTlvRQ_14_8">693,323</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_zL9OAErI6UCYrNL1hx62BQ_15_4">971,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_JNg8W316QUG4EYiCdVYnNg_15_6">1,778,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_O_jfrbujzUqXJIUOVNTnXA_15_8">2,168,388</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Foreign exchange gain (loss), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_cdvN78HAoEqJ8BQ22XlE-Q_16_4">644,693</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_WK55f_NHpku29mNlRnn_ng_16_6">603,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_XOrC_i444E6FNExWoAKVEA_16_8">2,555,325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_kggjuTRiE0ew0qB6Y8QCVA_17_4">42,397,279</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_sM0X6ChnPEeO7XbulkmvrQ_17_6">71,476,322</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_CxHLFX6y20CXGXe6irEPPA_17_8">79,512,792</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_G3R4JUftbUqYlYYRVOTXSg_18_6">1,701,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_7kLNOIYQcE6qZIYB7UjmfQ_18_8">459,055</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_25pcWkGHM0eyTUQLMlT-9A_19_4">42,397,279</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_cmTt25v8QECS2nS5mlz1UA_19_6">73,177,935</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LRnEaEmhUE6X5P3lgjXbpQ_19_8">79,971,847</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Foreign currency translation adjustments, net of <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="0" id="Narr_-O6MMF-QeUGJqAwfJdN2bQ"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="0" id="Narr_8Cr4c9W88UC-FNmRgke3hA"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="0" id="Narr__nxZEdUAWES5JbB1JFQUhQ">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_pVjOzs1wG0WGcIRVxzTurg_21_4">6,087</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_SmKphJ_uv0qmHi8zZye4Yg_21_6">257,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_zizRTqkEdk2e-pi5fVsXjQ_21_8">755,324</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_mE9ff2ckjEWxiVCmfOvrwA_22_4">42,403,366</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_GLDVx7e5X02DcqY3EDZYCg_22_6">72,920,935</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_Fkq_VnrTT0yJEhvYha2Lrw_22_8">80,727,171</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_b83FmH3H90ONJwW85MoSkA_23_4">42,397,279</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_UPPro85Of0-sFPUSPp0X1g_23_6">73,177,935</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_CKHYSW62Ek24KgubUYXw2Q_23_8">79,971,847</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_boxHExmfoEq2ISprMPM42Q_24_4">248,113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_cs7qHknTzEGY6mWyJc8XZw_24_6">28,553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_klrWIfoiz0ylrlD4RHXJtQ_25_4">42,645,392</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_wJkrLzg5SUiydBGoSWfWaA_25_6">73,206,488</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_6-aL7eVwj06K8PpxTdw_sQ_25_8">79,971,847</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of ordinary shares used in per share calculation:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_ocqf5Kz8tkygnTYWncETLA_27_4">15,950,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JtEQJoPNxUSoGb4eWQuoSg_27_6">50,032,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Kc91rSv4cE-Qlg6zxEBSdw_27_8">54,135,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_jGqBrTXQe0GcAHho_TDuIA_28_4">15,950,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_tBynbnKsP0WnC3wNd6EeUQ_28_6">50,032,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_g1GfbDhwXkCjBDEkggVrFg_28_8">54,135,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_yOA_0anJAE2caTuzN947Sw_30_4">2.67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Jv9heSOXP0CxO6tSGNJryA_30_6">1.46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_c5EAaavd0EWiaiufmqNAeQ_30_8">1.48</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_HJtyKtA29km6dMqv9q0jXQ_31_4">2.67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_0guKDFQ6FkG_AjHgW7GO0g_31_6">1.46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_J6owIEqUFEeYJ9QrgmW4Tg_31_8">1.48</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cb62e308_5101_46a3_ba34_d49e25744f2f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2020, 2021 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_839f1bb5_5cfd_461b_af1e_b42aa4f0e8e8"></a><a id="Tc_3AZtEPrtHkW7O5-U45SaBg_1_10"></a><a id="Tc_GHWoToLx0EiwTBX4iLixtQ_1_14"></a><a id="Tc_9aq5M0fEQkuZaEkhOspAWQ_2_2"></a><a id="Tc_bDJ5TxRahUqDgccIvyyiPg_2_6"></a><a id="Tc_Ie-WOkap30CDCdrdLKVYtg_2_10"></a><a id="Tc_xFonmECKHUuJ0vSeFhJROQ_2_12"></a><a id="Tc_ljg5fVx45U6-ao5Aatx1IQ_2_14"></a><a id="Tc_RE4wYQvMRU6wFbN-1TTw6w_2_18"></a><a id="Tc_hFC0XPdVtESbfUHWIVNLxg_3_2"></a><a id="Tc_HMAUCiljW0ayoTFScLva5g_3_6"></a><a id="Tc_lrV50vtqik6XZitsHqXaiA_3_10"></a><a id="Tc_3heiWDiUFkaa7el9sNIvug_3_12"></a><a id="Tc_BZVUoU2RnEe5Ufo6QUYjUw_3_14"></a><a id="Tc_TCvu20MTPUGRedXx00FOkA_3_16"></a><a id="Tc_PzwJSlQorkeAroSXNUY1Ww_3_18"></a><a id="Tc_S4Q9JzSbaEihHcFMfnl4aQ_4_2"></a><a id="Tc_OmOe10FTsU2c6eiYm2n5ig_4_4"></a><a id="Tc_Ax_eydiZ8U2hqHcgcNx0Rg_4_6"></a><a id="Tc_56ef1BoXkkyLMyHHcctpVw_4_8"></a><a id="Tc_6Eyv88L8rEu4FaX87dLpEw_4_10"></a><a id="Tc_aXNEGjpObU-VGLV0PpWLZw_4_12"></a><a id="Tc_RbK-lEeiJEaCjJRsGchzcA_4_14"></a><a id="Tc_yUQkqiD0AE-wfiIzL_ZpJw_4_16"></a><a id="Tc_ZYWroPHyeUiaAseg2BBV_Q_4_18"></a><a id="Tc_yBb6k7VevUiIM3G7jwSGTw_5_4"></a><a id="Tc_PdSlcI4nxkKdSqUF0GD5Ww_5_8"></a><a id="Tc_qvSNfbEyNUaECY0p1hDpWw_5_10"></a><a id="Tc_3KfOgZjZJUSSMnWXdzxhhQ_5_12"></a><a id="Tc_Bon9PmikOUGbUyBUlGcn0g_5_14"></a><a id="Tc_9FNccLSalUO9ksluv1h-xQ_5_16"></a><a id="Tc_qoo5y5E8ikeZSN8DAEXeiQ_5_18"></a><a id="Tc__sZ7nnhC-ky1ewQFq5xcjw_6_0"></a><a id="Tc_zv2B2MaT5ECfN96kTsgAYg_6_6"></a><a id="Tc_f4j3FxGTHEWwzG0ic52Zlg_6_8"></a><a id="Tc_DmD1fG_82EmHIs9HHI50Og_7_0"></a><a id="Tc_T_eiKgQJNkCrYrHDTk1bDg_7_2"></a><a id="Tc_h7xNBU9m60eCcGltgeqMrQ_7_4"></a><a id="Tc_WQz-UUJ0306QRdR4EWCJvw_7_6"></a><a id="Tc_F8kZjUhfNUaPNmliCCj5lA_7_8"></a><a id="Tc_3nxhxyYzSUSwScAc9Eo-XQ_7_10"></a><a id="Tc_oUGytuBHNUi6P2Cta1Ks_Q_7_12"></a><a id="Tc_kJArmFx4rES4LbrdeebwIw_7_14"></a><a id="Tc_enEapXoyS0KaislFqGXjmA_8_0"></a><a id="Tc_GgD04wnkEEiYdTBYyDeDEQ_8_2"></a><a id="Tc_Bc5N8SVdTECOEPRV6GS5wQ_8_4"></a><a id="Tc_Gz_0B8A6jU2xsouPWgoiVA_8_6"></a><a id="Tc_66qB2M7moUCv0lHCXW0lWA_8_8"></a><a id="Tc_vdc2aZZz8ESZ0D1NKfehlA_8_10"></a><a id="Tc_Uru_hMZ2dE6GKOJ01_I4Aw_8_12"></a><a id="Tc_wvtlokQTYU2SJysyOG4GLA_8_16"></a><a id="Tc_tC2SdN-4AkW2eEClibqliA_9_0"></a><a id="Tc_YqbHLvFoK0CZ2bVeyg306w_9_6"></a><a id="Tc_MCdz0T5660GxXANdTqS80w_9_8"></a><a id="Tc_aoWxAxJuMkqtFX5kH8882w_9_14"></a><a id="Tc_NPJ39TPNOUOxDv88rwHY2Q_9_16"></a><a id="Tc_Qyl6jM0DeEicKH5wA8qCTg_10_0"></a><a id="Tc_r1IJYeV90ECQwK6efqMsPw_10_2"></a><a id="Tc_SLH9heeQyk2OccTMRwWpuA_10_4"></a><a id="Tc_zUzWVUZYzU25PWYWdXsTWQ_10_6"></a><a id="Tc_gWLZ7scxcUyqb6VpmzDN-w_10_8"></a><a id="Tc_E-KHnaJDO0aPLJ4j3mO8lA_10_10"></a><a id="Tc_romQO3H4vEST58YdTfFFQg_10_14"></a><a id="Tc_FqA1BpVwm0-N-ahAj_SSxw_10_16"></a><a id="Tc_B2x1dLsU4EWkrCGe7YVX-A_11_0"></a><a id="Tc_QpBm_sfdAkelPjFhwNJKNw_11_2"></a><a id="Tc_l_CT2MZ3wEOB5WIllxNiMA_11_4"></a><a id="Tc_SBo5l57I5UCYObz9w9ATgQ_11_6"></a><a id="Tc_ndU6yvPDdU6G6AOKsqoB0w_11_8"></a><a id="Tc_nhUecWRkV0GKl8l1oayJsg_11_10"></a><a id="Tc_9kl4xygqS0K_pMDSaqihMg_11_14"></a><a id="Tc_OormBnuORkSJ40p-XhKifg_11_16"></a><a id="Tc_ib-j9dq-iUisTbBif5E2kg_12_0"></a><a id="Tc_2sw1bj_Tc0WGav4tl-A1iw_12_6"></a><a id="Tc_xzXFF5lSIUSvvZn96tFV3w_12_8"></a><a id="Tc_wvGrmMx64kaasEq04elFEw_13_0"></a><a id="Tc_3BiBSlCKA0Wj3kLspJZpOQ_13_2"></a><a id="Tc_uZhK6oqUsUWL1Uu23Rpzdg_13_4"></a><a id="Tc_OEcSHGUUhEmqVlxJxQf68g_13_6"></a><a id="Tc_bmueSc2h1EGpRg5jE5bmfA_13_8"></a><a id="Tc_iIAPJt3Pu0euMbdTK3vP3g_13_10"></a><a id="Tc_noXWl8tTckKDCYiy-dGReg_13_12"></a><a id="Tc___Jtu7tMmU22GRTW4c84fw_13_14"></a><a id="Tc_qIYCVKxJjEiYRYH4o6SR7A_14_0"></a><a id="Tc__rLv9k4LOUSZu3RPDW8P1Q_14_2"></a><a id="Tc_A6H3KE3X6EyDtIGmYV_MKw_14_4"></a><a id="Tc_oMAV48ERgUuvoUzmNFc2LA_14_6"></a><a id="Tc_Vnnk3JTo10unum9OhgHK3A_14_8"></a><a id="Tc_Fvw1CvlKXkK0Gby8PESVfg_14_10"></a><a id="Tc_SndnIv4uQEeHpWML5Wq9ew_14_12"></a><a id="Tc_Zny7Ky70UE2rAqrqODSe6Q_14_16"></a><a id="Tc_VjfYKIovPES6PXg7et8n_Q_15_0"></a><a id="Tc_XnThbgmzEEyRJJJ1Oc9RQA_15_6"></a><a id="Tc_pxFu0J_nR06VARzf6KGUyA_15_8"></a><a id="Tc_wxVHJb9wbUG9-Lo7EjXiqw_15_10"></a><a id="Tc_N3rp-FsPj0-0CWufLYm58w_15_14"></a><a id="Tc_Vf867CeiJk-Qj0zRrIaP6Q_15_16"></a><a id="Tc_goK-6zUhd0yR_XcP5Y0XxQ_16_0"></a><a id="Tc_Yin1O34G30WULyL5gERhiQ_16_6"></a><a id="Tc_2Vh3XgUnXUS4LxGTgzAk8A_16_8"></a><a id="Tc_QVw2Mo2pHk-S-oxuOXfLUw_16_10"></a><a id="Tc_aTeG6XM4zU6HlNA7Pi_N1g_16_14"></a><a id="Tc_3YdRhWJIqkCjjSFt6bDoiA_16_16"></a><a id="Tc_MHHuQmrWSE2Bv6jqu3oFPQ_17_0"></a><a id="Tc_qbXMnCUb7EqWBKR1B4TQsQ_17_2"></a><a id="Tc_BBAs24quAEy1wJxeuxaBNg_17_4"></a><a id="Tc_d8ygHF-9IkGo_POTlPDHRw_17_6"></a><a id="Tc_INmNAcn8D0S1_wn5KJ70iw_17_8"></a><a id="Tc_kTxD__ysNE2e5Tyt0T89TA_17_12"></a><a id="Tc_GQzrdBB4Y0yePvvKATwdpA_17_14"></a><a id="Tc_Ra-hYGTV4UKH-2p2ohRFZg_17_16"></a><a id="Tc_ziB9CNxWdkC8Uc9iXMSDbA_18_0"></a><a id="Tc_1uTKrGy9Lk2qhYsWH4g6xg_18_2"></a><a id="Tc_d-JrvFzdj0uvYM7F8cfipQ_18_4"></a><a id="Tc_lWkJW_yFK0-U_Uat-pJkug_18_6"></a><a id="Tc_g1WsbeicZEGuKFWZfLJKjA_18_8"></a><a id="Tc_dvA2_U-UVUW-tKmWgtzjPg_18_10"></a><a id="Tc_NpwDl1C_eEu16FIDQhlYAg_18_14"></a><a id="Tc_1dglKrAcpkaXZbnYFZ9t9w_18_16"></a><a id="Tc__aDKQCoz3kqtWhZyMyp5ow_19_0"></a><a id="Tc_hDvBnaPxFUmZ30XhL1Mq9A_19_2"></a><a id="Tc_O-LqsfDVpUu9xF35Kpe5wA_19_4"></a><a id="Tc_lcN6L3I9y0iD2w2Tkl-c_w_19_6"></a><a id="Tc_ORhIrJMBJken2RYn6HtqNg_19_8"></a><a id="Tc_jTfvxeHjIUWxct4LdP1-bw_19_10"></a><a id="Tc_ishNQrYx9EqoiG3dAeEz4A_19_14"></a><a id="Tc_Aa_mZqUjMkGFxcJgY4WojA_19_16"></a><a id="Tc_jux8fy2RjkS2s_hLbXP5gg_20_0"></a><a id="Tc_9CvMtJ6mM0-8MP_LqoSsuw_20_6"></a><a id="Tc_m4cSulLHKkWdJOJKSBe7YQ_20_8"></a><a id="Tc_-IHYLGqqEUKHX5-PFpP5zg_20_10"></a><a id="Tc_xTyNR6V7WkOkun2Z-Ibf_A_20_14"></a><a id="Tc_JMGpxeX5Tkqe_74t5YKIZg_20_16"></a><a id="Tc_8CrKU5tk5keAmBsSiBhyGQ_21_0"></a><a id="Tc_t5RmeH9ZhEiT4mRgcKzXzw_21_6"></a><a id="Tc_94I8DGAfPEG4tVb5Y3MZ5A_21_8"></a><a id="Tc_ECOQkc9bNU2fjmfoePciKQ_21_10"></a><a id="Tc_j-k29ceQEEKtFzpj7HzW5Q_21_14"></a><a id="Tc_r8c6Kqg0P06WL93zIQT1nw_21_16"></a><a id="Tc_jcqHlZU2_0aBmhmdDEQWLw_22_0"></a><a id="Tc_7dWuGT4ERUWnidnmBNqMRg_22_2"></a><a id="Tc_RvZj7kF09kKIBJSpirMQPw_22_4"></a><a id="Tc_ScFXCFmJckqOMyM6OQJwIw_22_10"></a><a id="Tc_p3ZRuy3xGEGvza-NHtSzpA_22_12"></a><a id="Tc_cmksSuMkW02-G9ndZvMs1w_22_14"></a><a id="Tc_Gk6EXrnSgkWzn5UGAJwSaA_22_16"></a><a id="Tc_NkmLTEwEokKrHIzV31eqKg_23_0"></a><a id="Tc_1eYZorxpEka_Xmz5q89fJg_23_10"></a><a id="Tc_ePx4ITzOYEyaUHxjPDdbDw_23_14"></a><a id="Tc_zrvJZ4RZI0i3ZHoXzY8IJw_23_16"></a><a id="Tc_LFRUwxc9-U6O-WGASN8Puw_24_0"></a><a id="Tc_8z9aHfi6kkuqZkwhcMjztQ_24_6"></a><a id="Tc_9P-5b6sD9kakHgWgeX7q_Q_24_8"></a><a id="Tc_6Z3Ax6oLAE2AAdycKPShXQ_24_14"></a><a id="Tc_aa4KYZlii0urOK_rBloeBA_24_16"></a><a id="Tc_iEoNPA8mSEmlZQvAZxSl4g_25_0"></a><a id="Tc_rrUGRtZBtEqWj3sy7-tbUg_25_10"></a><a id="Tc_B2KHaCa84kS356pyShbl6Q_26_0"></a><a id="Tc_-_UkbeZbNk-oVsg53ltJaQ_26_2"></a><a id="Tc_-boIxwlSk062Ivf5iFeXlg_26_4"></a><a id="Tc_Ny_090CDMkKlWznLp_ukww_26_6"></a><a id="Tc_6YLR-AOM50O2-2-J88PnXg_26_8"></a><a id="Tc_Pe1KJKjHg0-v-8Od4HlpBA_26_10"></a><a id="Tc_8X8nOgoZGUyTBHk22r9yHQ_26_12"></a><a id="Tc_WXMb6mk820eRKMqnk8vDTg_26_14"></a><a id="Tc_29e82B8J5ka-kGRP7vhqEw_27_0"></a><a id="Tc_2L8l3p8YJUqXTQvRkHC4lQ_27_2"></a><a id="Tc_pQkJjJh9j02uVBQk-dD6BA_27_4"></a><a id="Tc_ljlq0v2oXEmPbX9MR6wenQ_27_6"></a><a id="Tc_-wIAVD_opkSAoT58Y7BZjQ_27_8"></a><a id="Tc_fLY1rCx7-EakkcWoM5i6pQ_27_10"></a><a id="Tc_S-06nInBVEeaJMLHewleHw_27_12"></a><a id="Tc_NedNkPc0f0W32J-6BW6JCw_27_16"></a><a id="Tc_dNZZPF7Cf0KHk3onUSewmg_28_0"></a><a id="Tc_zmI8vAFeZUm9minHAaAG7g_28_6"></a><a id="Tc_Lx_5K9vqI0GhnT9I_-otPQ_28_8"></a><a id="Tc_Vx7CB2MlEEyWDVeJ0rwf0Q_28_10"></a><a id="Tc_ZSUif7xc1E6wtmoi6bpUqw_28_14"></a><a id="Tc_BpBhk2pD1EqEcJaA7DESkw_28_16"></a><a id="Tc_SSRVKVvYLUOuu1f2xQl8Yw_29_0"></a><a id="Tc_CVZTmmiud0WBbZ8h_mk4ew_29_6"></a><a id="Tc__gTaLPjhTkqhSI5TycGBAw_29_8"></a><a id="Tc_n-k-CDhyYkm5iugnuzrkNA_29_10"></a><a id="Tc_EZ66Nqry4UOvzAru-I6TcQ_29_14"></a><a id="Tc_J7JvEj3yJk-H5pDW32R7RQ_29_16"></a><a id="Tc_v2mVE61nG0SAOSVCIHx47A_30_0"></a><a id="Tc_90Es9j2AC06WMsqI_5mltg_30_2"></a><a id="Tc_XVZxToknC0W3Z6Fj69PXrQ_30_4"></a><a id="Tc_3_FXibVk5UiYEXRlkbrDsw_30_6"></a><a id="Tc_oH8qHsSKsE6TDSoSm3M_ZA_30_8"></a><a id="Tc_6uYghWnwgkCBuBzJ4UtnsA_30_10"></a><a id="Tc_claIvoowgEmskb5rk-DSJg_30_14"></a><a id="Tc_opoi-ttQtEqkIAvCev0EmA_30_16"></a><a id="Tc_9ywN8J9_VkuAao3QHIDdzA_31_0"></a><a id="Tc_s2oeDLUfR0uLj8ujhegwXg_31_2"></a><a id="Tc_97NFMa-NQEaygb036JQEqw_31_4"></a><a id="Tc_cyPAUsoyfEqRRVs6fVwYwA_31_10"></a><a id="Tc_DD2_qef310ekiCWyFB8jyQ_31_12"></a><a id="Tc_tAbviOoA_0SzFu2LUwodJQ_31_14"></a><a id="Tc_ZFx7b0RS80eLq__Lg-_n4A_31_16"></a><a id="Tc_0zpJf9dNFkeXcXcsNBSQHg_32_0"></a><a id="Tc_FWwwUgRJP06Q-DcPAIYdVA_32_10"></a><a id="Tc_fJHHmOzilU2GsJa-QsXRIg_32_14"></a><a id="Tc_imt3b8QirU6NlM47TlzY0Q_32_16"></a><a id="Tc_oT9hr9BFCkmTDxD2AQYZ8Q_32_18"></a><a id="Tc_eAxIVU2kwkCQd6GrH66bxw_33_0"></a><a id="Tc_lb2v7Tb3X0OtMGcAWp4rNQ_33_10"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Subscriptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Ordinary&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Treasury shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">paid</b><b style="font-size:6.5pt;font-weight:bold;">&#8209;</b><b style="font-size:6.5pt;font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shareholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">equity (deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of January 1, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_eeLjBK3bNE6uqS6GX-yqig_6_2">15,193,136</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_8JU-nLujLEmdxlqbRRlLKQ_6_4">1,519</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ZAIqUZ6DnEaGRXvod8zuFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_pC34tqrHtkq_pB69qmVhEA_6_10">197,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-fGWKFY2rEOZsvz04ykZLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_2QKxF9Xs-EW09BzHwdimOg_6_12">6,789,542</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pIuFXCNeoUy7CaDSOhk2xQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Fk0cHSCsj0GHIqHBExZAjw_6_14">344,894</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J78E05vN20erGsltKQSaYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_qP71QPanZ0O5NP9j-YhGwQ_6_16">63,258,045</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_1sAq8L8SPk-nZCF6FXbbLQ_6_18">57,008,946</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IvlyyVsaP0qH00DZs-cOzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_VqKZCjoEkUWozwQHa3-QyQ_7_16">42,397,279</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_4ZJm1UztLEKg2W8DSSuVYw_7_18">42,397,279</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Other comprehensive income (loss)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GClxeG8xvEeEJiRr287NPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_4PAG-YW9QUOIOMBTe12C_w_8_14">6,087</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_RYjOLXatNUevIgh-aBJRjg_8_18">6,087</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Exercise of share options (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TTeXW30sp0OT1Sxf3PgmKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_S8EmWOVh6UClmfZLRZXHvw_9_2">3,694,934</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TTeXW30sp0OT1Sxf3PgmKg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_ASHW5MG0RUmwhhmI5QUlmw_9_4">370</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_B7KydVxEvkqzOuPCW8zKlg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_1TrjROnzAkW_8dBy8q62eg_9_10">6,975,124</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_JavwC_Nuh0e0V41z0vw28A_9_12">7,115,682</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_cQ_tk7Eu00OD7klz2Lojkg_9_18">140,928</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_vzkvYtBRvUK8IEndv5N9hg_10_12">10,129,541</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_cq0_iXhcfkWyJdEjbk69ug_10_18">10,129,541</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_U0N_buSCv0q5Ovu2LpjwFw_11_12">248,113</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_Slxw7FBBy0qmmOAhnrN5OQ_11_18">248,113</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YPqb6m0diEulW2HtfQSfmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_12R6OSS4tEmnvVi5Uo2QRA_12_2">18,888,070</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YPqb6m0diEulW2HtfQSfmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_MkzVrUWWZk6LtKTumbk4SQ_12_4">1,889</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_OPji8N90TES4hj8qFG2_Ug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_F60iGJ4jSkmBOQUyeVDyfw_12_10">7,172,192</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pNeBwXPMFUiQuaK_5XpBZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_vKhG99Ikf0OndUmqgPjg4g_12_12">23,786,652</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UKTQnfrtqE-IQhyGVhZXZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_qvVoPj45Bk-NekfTVEkqVg_12_14">350,981</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KG8su_uOu0a0KunRTlLxoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_VYRi63G1_E2M8XJGB3G-aA_12_16">105,655,324</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_WQoqxeotjUKfcEvc_eGaug_12_18">89,389,956</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJZYhVw9NU-SOXmev5aACA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_DkPphyiTJkCv_-JzLsftNg_13_16">73,177,935</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_pe-_z9QAEkewYqIlba-Wbw_13_18">73,177,935</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Other comprehensive income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZgaIiUt-UEqjj7jLhIpMZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_hKDFM-7BnUiq_5z1mPt1sg_14_14">257,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_4aDSf256l0Wda1kra_7Wlw_14_18">257,000</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Exercise of share options (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_j-UujZnfhk-U6gPi0IAFMg_15_2">233,957</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_A94Is4-1mEuIT5q1VlJ2Ng_15_4">23</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_VHf6QePCYUKcjCiLotiVvw_15_12">226,758</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_ScAcRfNBmku8EMFJIVusoQ_15_18">226,781</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Issuance of ordinary shares under performance incentive plan (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_rhpCnCUj6ku5xsB-BlJd8A_16_2">23,734</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_yjFhjhO1XUGqlcdlRpbaVw_16_4">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_lkczTdzQl0mh_9pge1IcfQ_16_12">416,749</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_UvuErkevF0m5b2B6wROFRw_16_18">416,751</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Subscription from shareholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_VXRQnsAoMkSLLvY_DjFWlA" decimals="0" format="ixt:numdotdecimal" name="adag:CommonStockSubscriptionsValue" scale="0" id="Tc_4ivjtRz0wUeIZTYYHhPFUQ_17_10">381,282</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:CommonStockSubscriptionsValue" scale="0" id="Tc_kL8cCo83pEuxzrzXE_d9iA_17_18">381,282</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_i7rQtGVo-kW0Iz0JMhDVDg_18_12">18,679,658</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_2JHylzS0jU-eDVKaeI-spg_18_18">18,679,658</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_433n4PZx2EiXC_Gshu_hUQ_19_12">28,553</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_g8PmP6BkFk21z44q9IJKPw_19_18">28,553</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering (&#8220;IPO&#8221;)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_jtusZggYKE6nU86GU3YnTg_20_2">27,249,824</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_l5HyIxmyeU2-9X88yhvBcw_20_4">2,725</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_IR63wEwyUEiHGO69smGECw_20_12">154,475,235</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_XhsaCZgg40KchIZvmiugwA_20_18">154,477,960</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Issuance of ordinary shares upon IPO, net of issuance cost</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_Iwv20QfVNUOTsCEcjZprgQ_21_2">10,571,375</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_VaMpIOWEA0WBoDGRcQfCpA_21_4">1,057</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_g7IgLCYfkU-Qn0aNwgJrLQ_21_12">147,094,280</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_i27PqkWjLkiziKNLEZFGkw_21_18">147,095,337</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Purchase of treasury shares under share repurchase program (Note 17)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Tc_yzlsZtYzsU2tsON83gd17g_22_6">295,174</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Tc_ZPWYb5RQXE6x_VDeC5Imeg_22_8">2,361,576</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Tc_45Ve-0Gv4EKiD_WFxY8EpQ_22_18">2,361,576</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Retirement of treasury shares (Note 17)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" sign="-" scale="0" id="Tc_Ijf5xj_PckyyYGEjeaoRPA_23_2">201,100</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_X1T3tBV00U6w1yRXAZYn-Q_23_4">20</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Tc_HKYgfdIL9kqUo4pte8jcEQ_23_6">201,100</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" sign="-" scale="0" id="Tc_ECK0HrhdK0qq0oeVIVSo4Q_23_8">1,741,971</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_iDpnkbVCfE2rVvU23Qlw9A_23_12">1,750,041</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_72csQG6SB0-ExDw5W-jM-A_23_18">8,090</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Surrender of ordinary shares for repayment of promissory notes (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="INF" format="ixt:numdotdecimal" name="adag:SharesSurrenderedSharesForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_fpzb3XPV1kS_7mMzynOeaQ_24_2">491,119</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_tWNIOLt2sEiG5RopTGhJQg_24_4">49</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_VXRQnsAoMkSLLvY_DjFWlA" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" scale="0" id="Tc_VC30ftt7m0mtGoJ5rcKC4A_24_10">6,790,910</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_THbLNonyKUiI5-X9bqCRHQ_24_12">6,800,807</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_ejAICKVmbkyssHTGD5rFhA_24_18">9,946</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_25mz8MzMZU6-TK20uJ2UWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc__hlTisnAbE6C9731TeUyiw_25_2">56,274,741</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_25mz8MzMZU6-TK20uJ2UWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_5p62u1Q8iUy60hSwLj9elQ_25_4">5,627</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_ancTWgsA3EaZqftsGC9BMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Tc_UD3q8LEEfEm7AdllP0nZkg_25_6">94,074</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_ancTWgsA3EaZqftsGC9BMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_4urnMTY-BUG6IvDGtdT0VQ_25_8">619,605</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8CaGtWv9QUicSDrtUt3MzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_MhyBeWRRc0KGS6JsiLpdoA_25_12">336,099,931</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Q0akVaGa0UGbNziyt_b1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc__nqDt4OQn0ON83t_882XLA_25_14">93,981</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Za0p7Lfn0SI4LJAXHWLYA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_PjyLQpJlGEGI19cEaGr35Q_25_16">178,833,259</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_FPfd_kQGUEq-JBB1C1rClQ_25_18">156,558,713</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TiCAjHF8_U-6H2PHnG8Zpg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_orOjso31RUWjM5HUUBodDA_26_16">79,971,847</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_t0793F4PXUOn1AwBkHZAtQ_26_18">79,971,847</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Other comprehensive income (loss)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iYVX4_oPbUSXBpxQ0gDPag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_-9aC5PGRu0GGd9UKvnjIRw_27_14">755,324</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_y_89qmgwZ06Od5Th6N4JyQ_27_18">755,324</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Exercise of share options (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ERSaFCIXd0ySdZdYwcs1Cg_28_2">197,975</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_2xfECp0ffU2zq_30UFAmpw_28_4">20</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_smhY5XHuPEKVomWH4kYElQ_28_12">323,192</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_TK3hWVWhCUWNDe356z-p-Q_28_18">323,212</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Issuance of ordinary shares under performance incentive plan (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_P4ButmeZ8E-1eiW7slXJyA_29_2">99,999</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_d1NcWp-wtESpoa_TTGfaFA_29_4">10</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_qSZn0_r9ZkOfaKIRlPMu3w_29_12">391,985</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc__PnSMKtirUOZDIRBJ7kQcw_29_18">391,995</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_35SLsOTAKkeD2BwOviq4yw_30_12">10,520,282</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc__AVo_RsktUyrN6YJDDnnkA_30_18">10,520,282</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Purchase of treasury shares under share repurchase program (Note 17)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Tc_B7IQYcslcUm8aMWaUk-suw_31_6">1,512,932</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Tc_azteZO1qq0SLxeQgr4RagA_31_8">3,976,681</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Tc_UN4wZHF9_UGBcDdtFSelWQ_31_18">3,976,681</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Retirement of treasury shares (Note 17)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" sign="-" scale="0" id="Tc_0mN-uxDutkSszkDUxQrNvg_32_2">1,607,005</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_A7HfSDQh20aYa6htDwEqjQ_32_4">160</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Tc_kL54arQo4kivvLHCkUN1ww_32_6">1,607,005</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" sign="-" scale="0" id="Tc_fp-CdTP-BUq8PM6v9f7ouQ_32_8">4,596,282</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_8ZzwmhCBz0i5Z3RA0nY2bQ_32_12">4,596,122</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WBu5OJOR70SEMOJWhuD6rA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_siYtY1u9Ck-5IAiPiFgilQ_33_2">54,965,710</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WBu5OJOR70SEMOJWhuD6rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_-0q55o8jZE2fU0zmV28RHA_33_4">5,497</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_VElBgd6POkGwMjlKJdoNAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Tc_pdQccY9330SfW13OZQRuFg_33_6">1</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_VElBgd6POkGwMjlKJdoNAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_1x4uH_FWIkOW-kK6eVg-Bw_33_8">4</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E1yBXnv1JEqkFifQJ0DCkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_qxXdfXyBOU2cNUkOVelChQ_33_12">342,739,268</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r4Z52hagwUK01HtKpXLekA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_nwA2wO2Puk6tDmU22kJZNQ_33_14">849,305</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DcS5Ka-g5Uuv_EvSXAJk_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_TFxyY9XQ80qI4l8uyxuPSA_33_16">258,805,106</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_X5n3Zriwrky755ON--yk0A_33_18">83,090,350</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:90.91%;border:0;margin:30pt 4.55% 30pt 4.55%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a6892079_7043_4991_8fb9_56c53d863f91"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_933280"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2020, 2021 AND 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8d7a301d_930c_42e9_ab93_7caa01beeaef"></a><a id="Tc_Q0u6RkF6MEGPZ6OJ2Em-qA_1_2"></a><a id="Tc_nFcU3PpPdECsSptjimSeMw_2_2"></a><a id="Tc_zIoCDjRIkk6AjRq7SffzzA_3_2"></a><a id="Tc_cnAUB3Z1dkqXChkwNelTpA_3_4"></a><a id="Tc_7Rcwwtm4B0i-CkFqZHP5xQ_3_6"></a><a id="Tc_L28FHQV11E2-S6yV3g0e3g_4_2"></a><a id="Tc_lKjyNm5IwkCvctDr3Z4gjA_4_4"></a><a id="Tc_UOv7JcKX-EWtNyFEkgPO8w_4_6"></a><a id="Tc_NAqt5GR3lkadVT5hsykpCA_5_0"></a><a id="Tc_Of_d-rLROUWsF59JVihH4w_6_0"></a><a id="Tc_Rbv7a0AfHUOvR3j1-zz8Ow_7_0"></a><a id="Tc_jKRKjuc1M0ypWnTLrM4WzQ_8_0"></a><a id="Tc_qc5ZcPxbgUWPIksBnyg5Bg_9_0"></a><a id="Tc_40Y7rKF_DEKi8WvjpGSBSw_10_0"></a><a id="Tc_gu-2Cgr19EKz_TFGvoZWdQ_11_0"></a><a id="Tc_jYHEGwvzNke7nV1CJIIxag_11_2"></a><a id="Tc_DJUCa2ug90yk94390VI7LA_11_6"></a><a id="Tc_XmuIioAnHEG39IDhZHleig_12_0"></a><a id="Tc_0VbecLYSf0OVb72noQzzKw_12_2"></a><a id="Tc_6hVHh-GNWEuSxEDrZlf9JA_12_4"></a><a id="Tc_uJ9_lH3nIEa6ns5jaVxnBw_13_0"></a><a id="Tc_0G9Jd7x-YE-ULXTR9sMYvQ_14_0"></a><a id="Tc_a3EbB0eNlkeAl1iFJXPqWw_15_0"></a><a id="Tc_17qqClZyVE-LdCyeKNp6IQ_16_0"></a><a id="Tc_xzzaxgK09kK4oFNlIh3O9g_17_0"></a><a id="Tc_yrTI9xY7fUynefkNvIXIqQ_18_0"></a><a id="Tc_Rv-a2z2Tgk6kIk6HYahkKA_19_0"></a><a id="Tc_IIX_r557Tk-M4hykZBKCLQ_20_0"></a><a id="Tc_lBPVZsJdHUKSTXK1k_bwjg_21_0"></a><a id="Tc_16PbsIJwR06n7lY-sGMhaA_22_0"></a><a id="Tc_LMowN308L0WOn7LT1BDPPQ_23_0"></a><a id="Tc_vkwsQjCKnESTnADGwhzpHA_23_2"></a><a id="Tc_NK-F2xQaV028L4oD-y6V_g_23_4"></a><a id="Tc_0P2vbo1sfEmCqFMAx_DzIw_24_0"></a><a id="Tc_hFOKrBIc6ESyJ9do8Jesrw_24_2"></a><a id="Tc_-O2wNP5r10Kzp9X5tQ3sfw_25_0"></a><a id="Tc_RPVpLqptUEOLGVM124lY_Q_25_2"></a><a id="Tc_hcaBk5MS9EqHIXkj8TU5LQ_26_0"></a><a id="Tc_vh1vEoqnqEyj8DvrUwAz1g_26_4"></a><a id="Tc_RFb_7AC9fkmLRODjMy3CaA_27_0"></a><a id="Tc_P4foVvR4NUyO0yr15MNdpQ_28_0"></a><a id="Tc_h2_WW1K2EEWez4dc1B3MOw_29_0"></a><a id="Tc_uhcNTTYCW0uWME-7P-p7Kw_29_4"></a><a id="Tc_YM2GQ1FHqEucuuLe0BO8LA_29_6"></a><a id="Tc_F7aHebu4JU-Y4wzwcMmimw_30_0"></a><a id="Tc_ul2f0zDYjUqG9aHxO8zVYA_30_4"></a><a id="Tc_gMz6JqLclkWH1RpEiMBuUQ_31_0"></a><a id="Tc_VGrQ6-qmtkuoSJoVAjd5cw_32_0"></a><a id="Tc_fasL15YAeUuh0vwaDzrmFA_33_0"></a><a id="Tc_-kcYQYdIN0-wmix-Zg6OKA_34_0"></a><a id="Tc_95GWrLipPk2-Y3XEm6yF6Q_35_0"></a><a id="Tc_BZov2Htm1Uuy7fgKAhcDlg_35_2"></a><a id="Tc_x-Gni_Vw606g24Ma9A3YEw_35_6"></a><a id="Tc_hspp446IYE2T4ZxjPMSxdQ_36_0"></a><a id="Tc_Gtt_tfo49k6WpjVsC8Ml9Q_37_0"></a><a id="Tc_zw-KQLq1ykas_ETUeTML4Q_37_2"></a><a id="Tc__Ea0JYnMJ0uJvZEZ3mP4qw_37_6"></a><a id="Tc_iU6KWytzREC3IIn_QtJYKw_38_0"></a><a id="Tc_IcXGE1uGX02mxH7ahRx7Kg_39_0"></a><a id="Tc_bExacyqxdU2yo6FxU0ghFA_39_6"></a><a id="Tc_1PySZrvwqkm3rTnHcBPewg_40_0"></a><a id="Tc_0QqT7j56wEeZvOSr5HyS5Q_40_2"></a><a id="Tc_HQA00Ihd40mHQHPCUCg5zg_41_0"></a><a id="Tc_LNcy1_-xYUuUCAcqndu_Ig_41_2"></a><a id="Tc_hOgEQPd1iE-rar0spo9_wQ_41_6"></a><a id="Tc_gQ7RXu8_zkiUi5-FS89UHQ_42_0"></a><a id="Tc_SGVE3TO1JEK6QGuQRPdpzg_43_0"></a><a id="Tc_cuacs4OQDUeF2cXXPwEy6A_44_0"></a><a id="Tc_hxT4O05zBkOrUCtdqXKq4Q_45_0"></a><a id="Tc_OwqWEHjFI0qsLCqYZK4hnw_46_0"></a><a id="Tc_7Fje9R3fUku28ppwK9iFiw_47_0"></a><a id="Tc_w5baACRiqke07L_B0nLsgw_48_0"></a><a id="Tc_TQ_H3OZwHkilJjkoTNzhZw_49_0"></a><a id="Tc_VQzhYdErC0WaeXvRx51UEw_49_2"></a><a id="Tc_RFE_r1dgVUivo7gv4JRJMA_49_4"></a><a id="Tc_4uWp45FLWUO9JiHB5moTPw_50_0"></a><a id="Tc_9cYwsHnvUkSJHS0jlAj3QQ_50_2"></a><a id="Tc_ovFVjcmTCkufrG21_tGmWQ_50_4"></a><a id="Tc_-wMMRGO5HkCxAXPLQI3Bkw_51_0"></a><a id="Tc_sRV_CpSIiUm1yaGbu6Tfcg_51_2"></a><a id="Tc_pc-BUT4lYE6XGn6NvkfgPA_51_4"></a><a id="Tc_zSP4f3d7cEOxiKtB87YHyQ_52_0"></a><a id="Tc_5M0oOhJA6kaXpK4Wh0zb1Q_53_0"></a><a id="Tc_kM9T48LAfEC-MPKwMdnEKQ_53_6"></a><a id="Tc_FG3AlsEz80KWG4f3-nkKhA_54_0"></a><a id="Tc_JSdjubwxRESdB2skXc18kA_54_2"></a><a id="Tc_YcujvLOzUkW1a_WZJuYqjg_54_6"></a><a id="Tc_791Dex14ZkmvPSpTgmmVlg_55_0"></a><a id="Tc_I6WYJBo_rEKvHCYpI7Zo5w_55_4"></a><a id="Tc_qlevIHlGQEG2mKfSfhNONA_55_6"></a><a id="Tc_KJ--HThzDkSZgWvAAI6jIA_56_0"></a><a id="Tc_HswWYUfY6kOxLz-LCaAPcw_56_2"></a><a id="Tc_wCYWXKJMiUWdPEykgUnofw_57_0"></a><a id="Tc_u5M-uUtL3kSPF8c0vYlQSg_57_2"></a><a id="Tc_JI9i3SC5Ik62_0ekqCnRoQ_57_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_VWDKGGuj10C8KJZdB4aw6g_6_2">42,397,279</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_1TwQ3wl4vEuNyyrVqWD1og_6_4">73,177,935</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_oZ59jc1aekukF2h2JcKQEQ_6_6">79,971,847</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Depreciation and amortization</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_-_9ClzmHl02vK9xpjf3o-g_8_2">858,408</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_F7PICqvRAUyiAmJwB9jnKg_8_4">1,125,032</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_-kkCHaz5CUiTmUSI8ICs5w_8_6">1,145,995</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Net loss on disposal of property, equipment, software and operating lease right-of-use asset</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" scale="0" id="Tc_XNTF7yc6QUipOxsO49B-yQ_9_2">327</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" scale="0" id="Tc_Wmw_kiN_rk-47iRuy5cepA_9_4">18,973</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" scale="0" id="Tc_VG-NEqc59UaXo_Q-pL1ruA_9_6">6,811</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_ITlq5-NRuESNAZMkCcLqwg_10_2">10,129,541</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_cgx5b9lV10CwX_n3LJ5kGw_10_4">18,679,658</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_n2WCOX4XYk-GHL_eBy0CWg_10_6">10,520,282</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Interest income on promissory notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:InterestIncomeExpenseOnPromissoryNotes" scale="0" id="Tc_xMRUHKYTTU61iTpvkK26zA_11_4">9,946</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Amortization of right-of use assets and interest of lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" scale="0" id="Tc_D1-YUGKGG0SLGSE2n0qLVQ_12_6">303,535</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Foreign exchange loss (gain), net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_qLg87hOmk063OIQSed2udw_13_2">644,693</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_vA0laYK_uEqHCf3qBZtOXA_13_4">603,459</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_U29t_RItdkmgbsYWRWhWLQ_13_6">2,555,325</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Changes in operating assets and liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Accounts receivable, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="0" id="Tc_XIfhCMMae0Os4hpquzW9HA_15_2">480,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_ZmHWyuMseUGxV1YlA4QUpw_15_4">3,000,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="0" id="Tc_z7R2tLnOA0u14aa003_SSA_15_6">3,000,000</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Prepayments and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_deh8iHDt6ke9Gj_QY8U5Ew_16_2">2,337,011</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_qNg7CRj6WEm-8iAjWSGafA_16_4">231,287</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_ImHjBI8D802zzYWp2KzGuA_16_6">881,402</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Amount due from related parties</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" sign="-" scale="0" id="Tc_t6owjbDjmE2XDk3ZZJ3BRg_17_2">1,300,790</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" id="Tc_IH5NyybvlkeT4CDPa4vR0g_17_4">4,374,274</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" sign="-" scale="0" id="Tc_XJcnHkSBIk25kOSkXlOIaQ_17_6">3,887,238</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Other non-current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_uENx1kXsN0-HjqpUrCvHuw_18_2">13,292</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_ic_GFvLB6EeL7lPTubGuJA_18_4">24,210</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_eXxv0BSMFkiRl2xzzkEnFg_18_6">40,297</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_RmgUj26CMkyfWdKSrCLeEw_19_2">1,097,261</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_R9vtN9neTE-LGOhPbnwyzA_19_4">1,511,640</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_ghA07XXR80KdaR_2eAtz7Q_19_6">344,509</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Contract liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="0" id="Tc_ILkHtVLi9EKbYYzFArORYg_20_2">267,842</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="Tc_bFGwNhA5X0mYBFaqDZxEcA_20_4">4,774,464</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="Tc_Mg8IMHmjGUyBs_NEjS4oFQ_20_6">9,607,276</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Amount due to related parties</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="Tc_3_fLfBD2TkCd4o5rJphfnA_21_2">639,579</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="Tc_4ESRWkQqyk-lDrJZ9Y6Utw_21_4">7,930,703</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="Tc_AfEr0Wz7IECUzGsKqZnImw_21_6">8,857,276</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Accruals and other current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" id="Tc_6F8v6NmHLk-yPaZnawGiBA_22_2">1,243,150</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" id="Tc_v_WQulDCHUqB8kC8KnBuYQ_22_4">1,057,491</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" sign="-" scale="0" id="Tc_NHYZciKMmk-Dt7qqR9L5_w_22_6">823,928</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="0" id="Tc_qJ37veS2ZUi1D5LxHF_5gw_23_6">280,465</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Income tax payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" id="Tc_HmhVPZf4rkSpXNZji3KF0g_24_4">1,657,450</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" sign="-" scale="0" id="Tc_-BIYmeExhEOxTCiQF-qCzw_24_6">1,657,450</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" sign="-" scale="0" id="Tc_3Qqky96OeUKOkSme60m78w_25_4">44,163</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="0" id="Tc_nRZbFIw9cUqRTNi_GGquog_25_6">44,163</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Other non-current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="Tc_AaIwKMCIDki6T-E1XzvlJw_26_2">91,955</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="0" id="Tc_jvsmubriKUGQwT-81gIlmQ_26_6">29,732</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_TkqYyrp1QEupvM1RaoMe4w_27_2">28,529,720</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_xe3xnTnuHUWXsV001O0lNA_27_4">43,414,619</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_7DU6LUih9EGUcf8GNi-ZcA_27_6">48,611,687</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Withdrawal of short-term investments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc__u0DzD70I0uJJyULCnrhzg_29_2">8,000,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from disposal of property, equipment and software</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" id="Tc_ca1mkeTLXk6hOmPJ7bJsIA_30_2">7,930</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" id="Tc_W2a3x6UeaEyyLRhdZR6OKA_30_6">4,892</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Purchase of property, equipment and software</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" id="Tc_RfUxfmpEH0G6lLhl8j53DA_31_2">935,199</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" id="Tc_reknxDswCEqnAAqv3bsiWg_31_4">2,509,926</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" id="Tc_UwupB3CVGEOBWMuo9HJiIQ_31_6">690,938</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net cash generated from (used in) investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_y_Z93hJCEUChV874Pr7VCg_32_2">7,072,731</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_CX6rTnXuFESLkp9sjJ_cSQ_32_4">2,509,926</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_hx56_sAj-UCfD0TWd0fbOw_32_6">686,046</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from borrowings</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_eYkAgqeAAEqS-ITW4beqvA_34_2">6,083,650</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_LhPPDEzX50OxC1HOrrEdCQ_34_4">4,386,860</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_LsOCftJKAEue_PPwyLFg0w_34_6">25,830,030</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from share subscriptions</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" id="Tc_3yONXQdIEk6isS3ZpjsxbQ_35_4">381,282</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from exercise of share options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_UZviajpPMkW7_BFXAQ60Aw_36_2">140,928</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_FHmLEl_UckSxKaNhT7XA6w_36_4">231,521</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_sSektnXC9kqI6ahf4GSc0Q_36_6">323,212</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from initial public offering, net of underwriting commissions</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc_kp7ZgRVQckyOdDfBtv-l1g_37_4">149,411,950</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Repayment of borrowings</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_DsHloF9mzE-oCJDzrrajMg_38_2">1,063,670</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_fzmaV1Yo3E24rdNbCYcwHw_38_4">5,089,717</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_sVbyE6pUkUm5Q0hLcX_LHw_38_6">4,353,588</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Payment of initial public offering costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_8l77VfKNXEi8em6hY79IYQ_39_2">721,532</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_owgepjfavUCgMdIzzbb5cQ_39_4">1,595,088</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Purchase of treasury shares under stock repurchase program</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="Tc_X9zClO9R6Eqd2B2hEPnNtA_40_4">2,361,576</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="Tc_UJwaM-1Kt02rDgRyuZr-hQ_40_6">3,976,681</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Costs for retirement of treasury shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:RetirementOfTreasuryShares" scale="0" id="Tc_clHJFch1S0qEnJSYsPlE4Q_41_4">8,090</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net cash generated from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_wAvovPLCTk-hH3gC3mA5Og_42_2">4,439,376</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_3MiQz4vHikGRuYvsgOa2og_42_4">145,357,142</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_qPxEnIvkJkyWcNdLga9HcQ_42_6">17,822,973</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Effect of exchange rate on cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_K-G4Lj2_SkyjNeUjLTpVlQ_43_2">364,177</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_vdck2qVxMEWmwFrgyv_Nww_43_4">192,352</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_JO-7pEZcMkGBUwSVGOrR9A_43_6">842,195</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net increase (decrease) in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_X4TOWEJRp06f5Au6nVbI0g_44_2">17,381,790</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_7oJuEVPAc0KoTLh-HmspAA_44_4">99,240,245</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_CZwvi7GZC0ihHvOemXruaw_44_6">30,632,565</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Cash and cash equivalents at the beginning of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_26Zc6s--80mcBNGkJpVOIA_45_2">92,532,788</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_dHAL3xvHjUG_0-z0GBa0mg_45_4">75,150,998</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_wWNy6W287E6sgIzwrznx7g_45_6">174,391,243</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash and cash equivalents at the end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_giz2c9oHP06TXKFogGAfEw_46_2">75,150,998</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_BxTkvFOEoUekqJDZxMH1mw_46_4">174,391,243</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_5eUpzUHA0kWP06pB6WP-8A_46_6">143,758,678</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Supplemental cash flow disclosures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Interest paid</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_V2y4FIqfgU6RfsbblvdSJw_48_2">202,165</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_dJG8jbEdlEqIYPtNkdeuyA_48_4">359,569</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_gCiuzyQmO06VtvZ_mkL2MA_48_6">603,680</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Income tax paid</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="Tc_91DiWBvyqk6BUCLoigNx4Q_49_6">2,433,241</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Tc_VaUzelfNLUiU3daRs1ITWQ_50_6">313,929</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Right-of-use assets obtained in exchange for operating lease obligations</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="Tc_otOcVNZANEqF05TTVVaBUg_51_6">217,227</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><b style="font-size:7.5pt;font-weight:bold;">Non-cash activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_ZnqE8HQEjkeSyDqUTyUNEg_53_2">248,113</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_hV-XPZ9T6U-TM1gXYpfI5w_53_4">28,553</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Conversion of preferred shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="Tc__bTg5AV2dk-ls12GhLCJvA_54_4">154,477,960</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Payables for deferred initial public offering cost</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="adag:PayablesForDeferredInitialPublicOfferingCost" scale="0" id="Tc_698CHEJKV0WvJxkQemLeVg_55_2">2,276,183</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Retirement of treasury shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:NonCashActivitiesRetirementOfTreasuryShares" scale="0" id="Tc_5oaBv_F04UG79-xRu0XrOw_56_4">1,741,971</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:NonCashActivitiesRetirementOfTreasuryShares" scale="0" id="Tc_OsvZGUKTAUWuKqc4DzRWcA_56_6">4,596,282</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Surrender of ordinary shares for repayment of promissory notes </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" scale="0" id="Tc_jZn2V1P6R0-7H54k_yla5g_57_4">6,800,856</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7724592a_b10a_40db_8920_10fe060ad95a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE INC.</p><a id="NOTESTOTHECONSOLIDATEDFINANCIALSTATEMENT"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">DECEMBER 31, 2020, 2021 AND 2022</p><a id="Tc_Oc89XwgGWkytnr1MwpnYZQ_1_6"></a><a id="Tc_tOb6sDvEl0Cev9-YdnF77A_2_2"></a><a id="Tc_Y-bkTlBIAk-ZipJ35uJ4ig_2_4"></a><a id="Tc_-dpROxcKa0SG--5MLIyk7w_2_6"></a><a id="Tc_za-7Oh-urUS-WQ4wLUaiFA_3_0"></a><a id="Tc_SH3oDrXOdkepEotvqOkPOg_3_2"></a><a id="Tc_34AX6PJCtE-PxQQJvhO91A_3_4"></a><a id="Tc_ieonet8vRkCZDocQKR1X7w_3_6"></a><a id="Tc_aCYk3mDrzEOK_ZwzNCowAg_3_8"></a><a id="Tc_O7K3_PcMnkysdnKWGGGmDA_4_0"></a><a id="Tc_sRZQ9actH0StoPKKtVkr6Q_4_2"></a><a id="Tc_wapS1pjdqUyVfXVV-1AV0g_4_4"></a><a id="Tc_QRGnfJa1R02KKFcFahmmUQ_4_7"></a><a id="Tc_xTgEmg5RpkydKiAQkPXTHQ_4_8"></a><a id="Tc_vG5-o32LwkeGit9GsHGPmg_5_0"></a><a id="Tc_vaLqrnt0s0Sa4QSAfW0nLw_5_2"></a><a id="Tc_EURB0FkIbkG5FTYRNL_s9w_5_4"></a><a id="Tc_75Jhcz0ztkaiXXAqvjAzEA_5_7"></a><a id="Tc_fMdj2Wg-s0umDFaB49cUYw_5_8"></a><a id="Tc_sGfinanrnU2zXqHY1lqTYw_6_0"></a><a id="Tc_1W-iGjV-yEGBJADy1b4bTQ_6_2"></a><a id="Tc_RBTwGXyEUUWWdyRzcoHFVg_6_4"></a><a id="Tc_gbvlLGdu90OPjmkLptbckw_6_7"></a><a id="Tc_LCzDS-AuHESUIkj77V4sBQ_6_8"></a><a id="Tc_bDdhL5RDekmWgki0wJPVoQ_7_0"></a><a id="Tc_41m3ukD0mEu5D3ia0Iw9Og_7_2"></a><a id="Tc_wDRBRbQ4n0Wj9YPkJy2eAg_7_4"></a><a id="Tc_xOMw23IDu0aURqMgeisXoA_7_7"></a><a id="Tc_WohChtj_lEq0lUu0zz7vAQ_7_8"></a><a id="Tc_CMknrIwsZUuuD9G2TRkZUA_8_0"></a><a id="Tc_8A3rt-KUIkuGLxIMA3pmYQ_8_2"></a><a id="Tc_oHlT476ts0eT2tTmgQ0rqg_8_4"></a><a id="Tc_iBLrqTfMbE-rcR2SWz1-Lg_8_7"></a><a id="Tc_ihN7yl-rxka6aa3j4DeruQ_8_8"></a><a id="Tc_-i7VrMSRVkiF_KHqZUklPA_9_0"></a><a id="Tc_g_rFKs6PyU62qAjoweGLVw_9_2"></a><a id="Tc_8JQkl1toVU6hnxIAwU5nqA_9_4"></a><a id="Tc_rxqClu_MEkyV1ih2vTYWWw_9_7"></a><a id="Tc_jMTjmBNsB0-U4d2NzLXG_w_9_8"></a><a id="Tc_WX8H70T07ka0_4fm9y0npg_10_0"></a><a id="Tc_JFAMOXzBhEy_BpnPwyUNQg_10_2"></a><a id="Tc_hiOBl-c3TEKas_cNDusRhQ_10_4"></a><a id="Tc_XnbWk8R9wESPGHkA7dh4hg_10_7"></a><a id="Tc_mfhScVBSsEWNBcBIlMBlTw_10_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_6JdgnMnXhU2qGDI73l021w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">1. ORGANIZATION AND BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. (the &#8220;Company&#8221;) is a limited liability company incorporated in the Cayman Islands on February&#160;25, 2011. The Company, together with its subsidiaries (collectively, the &#8220;Group&#8221;), are principally engaged in research, development and production of monoclonal antibody drugs for cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 8, 2021, the Company&#8217;s registration statement relating to its initial public offering (&#8220;IPO&#8221;) of its American Depositary Shares (&#8220;ADSs&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) and the shares of its ADSs began trading on the NASDAQ Global Market on February 9, 2021. The public offering price of the ADSs sold in the IPO was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Zlj0nScBWU-c4g2DG5w44A">19.00</ix:nonFraction> per ADS. The IPO closed on February 11, 2021, pursuant to which the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_8PMoYsniJEKQ59jVt_gtxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_gvAEAetTG0meUqlloOMRdA">8,457,100</ix:nonFraction> ADSs, including the exercise in full of the underwriters&#8217; option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_x6getxpL9EmAJ2xaJGImaw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_2JSkUBs7UEWQje2rf7dNMg">1,103,100</ix:nonFraction> additional ADSs from the Company. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_8PMoYsniJEKQ59jVt_gtxQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_cE7zs8IeiEeaDVZTEMFpeA">145.9</ix:nonFraction> million, after underwriting discounts, commissions and estimated offering expenses. Each ADS represents one and one quarter (<ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw" decimals="2" format="ixt:numdotdecimal" name="dei:EntityListingDepositoryReceiptRatio" scale="0" id="Narr_b2tvTAPqvkeXwBsfNc276w">1.25</ix:nonFraction>) ordinary shares of the Company. Upon the completion of the IPO, all outstanding shares of the convertible redeemable preferred shares were converted into ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company&#8217;s principal subsidiaries are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:SummaryOfPrincipalSubsidiariesTableTextBlock" id="Tb_pdT3yzQYV0a8xpqHL9vShg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;legal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Place&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">by&#160;the&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal&#160;activities</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 12, 2011</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Hong Kong</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_LuGkr2nW5UuEFN70Vzi-Qg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_eO7oNSZBuUyiEGilf9q5Jw_4_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment holding</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Incorporated</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September 20, 2017</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The United States of America</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneIncorporatedMember_BR7xdhRIAki49kFwg0OQzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_6zktEILzd0SejX0k6g-okQ_5_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 28, 2012</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;)</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_pEeZWdw_fkSZYD0_eWIssg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_Y8uS8pdX1kiwjon4YhDYVw_6_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Australia PTY Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 30, 2018</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Australia</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_HRsrjutOV0G30qtLf1pIow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_hwIVHJxJ0UyMx8k09SLDFg_7_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2020</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_G1AQfi6p4E24BfwphzFniA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_KPyeJ1_M30aXl0D09U6YPA_8_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene AG</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 31, 2020</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Switzerland</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAgMember_Pnv6Ik0j60COLF1wUWv5dg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_lAa2zufa_U--HLHASz01QQ_9_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Project C1 PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneProjectC1Pte.Ltd.Member_umWeTmICo062uH3oJz8eNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_x3IKNbwDS0CXvRu_mTdvxA_10_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_qlAUkrP4eE2wdGN_eHTVzQ" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_A1qFhi9mkEicutDEMuBPcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). References to specific U.S. GAAP principles throughout these notes to the accompanying financial statements are to the Accounting Standards Codification (&#8220;ASC&#8221;), as published by the U.S. Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_kF8NOqhY0Uuk3QGFGAup4A" continuedAt="Tb_kF8NOqhY0Uuk3QGFGAup4A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont1" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont2"><ix:continuation id="Tb_kF8NOqhY0Uuk3QGFGAup4A_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:UseOfEstimates" id="Tb_AzUt4jkjsE6koFTm0VvesQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_J7bUbe7ul0-38zpx-zO-1A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated, Adagene PTE. Ltd. and Adagene Project C1 PTE. Ltd. is the United States dollar (&#8220;US$&#8221;). The functional currency of the Company&#8217;s PRC subsidiary is Renminbi (&#8220;RMB&#8221;). The functional currency of the Company&#8217;s Australian subsidiary is Australian dollar (&#8220;AU$&#8221;). The functional currency of the Company&#8217;s Swiss subsidiary is Swiss Franc (&#8220;CHF&#8221;). The determination of the respective functional currency is based on the criteria stated in ASC 830, <i style="font-style:italic;">Foreign Currency Matters</i>. The Company uses US$ as its reporting currency. The financial statements of the Company&#8217;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China (the &#8220;PBOC&#8221;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_uHVFkIWhWkCbzbqOJPkMnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" id="Tb_A6_2Q2B3VkOJoAq2eGQ1Pg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Accounts receivable and allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#8217;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_yWXtcNbKvU6Dd0OJeacxDg" continuedAt="Tb_yWXtcNbKvU6Dd0OJeacxDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group applies ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_UuwptcMVIE2a4g0jHnClOQ_1_0"></a><a id="Tc_q7XQVGTvtE2A6cVX6KeeJg_1_2"></a><a id="Tc_XE12-ZZ9sU2tDSkwKIbfNQ_2_0"></a><a id="Tc_uQhPMB8-KECz4rdZ8cTZfg_3_0"></a><a id="Tc_G4Af_RNsTUOBflpBOxjp2A_4_0"></a><a id="Tc_bDlnXP8T5kaECCbAGxQbGg_4_2"></a><a id="Tc_V9FvGXr88EqIERWObhV27g_5_0"></a><a id="Tc_9E8cqIZOZEWSysOT30kXPw_6_0"></a><a id="Tc_X30TafeJQkmLV7c-Rr6Hxw_6_2"></a><a id="Tc_Q4AkXWoz-0KR1gzN9Wb96A_7_0"></a><a id="Tc_AlGpNSFOrUubKAk7qh7f5w_7_2"></a><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont2" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont3"><ix:continuation id="Tb_yWXtcNbKvU6Dd0OJeacxDg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2021 or 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group had <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Hp2hcBhCBUKfwPXhVKSC_w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="Narr_vfRrcHTwO0iYdeiFxyA_WA"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="Narr_PT2qB1PrXkGZwCcJcVeYng"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Hp2hcBhCBUKfwPXhVKSC_w" decimals="0" format="ixt-sec:numwordsen" name="adag:FinancialAssetsFairValueDisclosure" scale="0" id="Narr_gX8g6SakFUWoi8s5CH0SCA"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg" decimals="0" format="ixt-sec:numwordsen" name="adag:FinancialAssetsFairValueDisclosure" scale="0" id="Narr_ss1gURjfGEaFDTv5V6zVyA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2021 and 2022.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_KSWmmDDc306P2XUV2GWKZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property, equipment and software</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="Tb_4ZB1WLCj4ESjJgqYsqwXlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KrbO3xolp0mWoDpH-tUPDg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_ULDzVv0P9U26VbNwq5VA3w_2_2"><span style="font-size:10pt;">5 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2h413p21UkmzRBTslwlxxQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_syB7WbvC90qx9qgiPlsWiQ_3_2"><span style="font-size:10pt;">4 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_U14hTTfIw0aauKmk513MSQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_pWJhk8g2a0OG1LFLJlnZQw"><span style="font-size:10pt;">3</span></ix:nonNumeric><span style="font-size:10pt;"> - </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xRsWSZSyjEauMH-_N844Nw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_c0dK0TgTcUKKLI9dN6hwtg"><span style="font-size:10pt;">5 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_-m_klozaH0y8y3effakxHA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_LMcdJ0vJu0OU8N04AKS49A_5_2"><span style="font-size:10pt;">3 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_pvNixmkY0UODGpGvN2b_aA" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_TkTSgyJLUUWIpgBKOaiqhg"><span style="font-size:10pt;">3</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_V0FQCFIXf0qnsEhwdlQOIA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_p0UjiZW7V0yYR6J5KwgWmg"><span style="font-size:10pt;">5 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_edL_oDUsjkC-CL8z_y4BDg" continuedAt="Tb_edL_oDUsjkC-CL8z_y4BDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#8217; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_isDTYBAoI0GOk6c9ZCp1Mg"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_NcLHq80Nb0u_QzgOlw640A"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_SvT_k85RbEaWZE488hFn5Q">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment loss was recorded for the&#160;years ended December&#160;31, 2020, 2021 and 2022. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont3" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont4"><ix:continuation id="Tb_edL_oDUsjkC-CL8z_y4BDg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_vuFlB-xj0UCRGKZLfo6Iag" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Segment reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 280, </span><i style="font-weight:normal;">Segment Reporting</i><span style="font-style:normal;font-weight:normal;">, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief Executive Officer. The Group&#8217;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#8217;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_IqWuhsuYLk-mb5XH3mwRiw" continuedAt="Tb_IqWuhsuYLk-mb5XH3mwRiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> Upfront non-refundable payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. For licenses determined not to be distinct, the Group accounts for the promise to grant a license and those other promised goods or services together as a single performance obligation when recognizing revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i><span style="white-space:pre-wrap;">:  The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont4" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont5"><ix:continuation id="Tb_IqWuhsuYLk-mb5XH3mwRiw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contract assets and contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_S0a5CS6IAEOmeC5IGQnHow" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;) and contract manufacturing organizations (&#8220;CMO&#8221;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2021 and 2022, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#8217;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2021 or 2022 as the Group did not have any plan to cancel the existing CRO or CMO contracts.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:GovernmentSubsidiesPolicyTextBlock" id="Tb_RNMPOOypbk2l-YvcVZ8pZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Government subsidies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#8217;s PRC based subsidiary received government subsidies from certain local government. The Group&#8217;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. In addition, the Group&#8217;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies of US</span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="-5" format="ixt:numdotdecimal" name="adag:GovernmentSubsidiesReceived" scale="6" id="Narr_6vC4CRWwm0uNS2bO1nkTAw">0.8</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million, US</span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="-5" format="ixt:numdotdecimal" name="adag:GovernmentSubsidiesReceived" scale="6" id="Narr_SCGf8ENIIUCuo12f3nYYIw">1.4</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million and US</span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="-5" format="ixt:numdotdecimal" name="adag:GovernmentSubsidiesReceived" scale="6" id="Narr_w4AVGft190i_9gTmUA_Iug">2.1</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million were received and recognized as other income during the years ended December 31, 2020, 2021 and 2022, respectively.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_D7yeO-mp5kS4JcSZd1LAkQ" continuedAt="Tb_D7yeO-mp5kS4JcSZd1LAkQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the adoption of ASC 842, <i style="font-style:italic;">Leases</i> (&quot;ASC 842&quot;) on January 1, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases, mainly leases of office spaces where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon and hereafter the adoption of ASC 842 on January 1, 2022:</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont5" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont6"><ix:continuation id="Tb_D7yeO-mp5kS4JcSZd1LAkQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determines if an arrangement is or contains a lease at inception. For arrangements that meet the definition of a lease, the Group determines the classification of the lease based on the relevant factors present and records a right-of-use (&quot;ROU&quot;) asset and lease liability at the lease commencement date. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. As the rate implicit in the Group&#8217;s leases is not typically readily available, the Group uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Group could borrow the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Group will exercise that option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use assets and lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) elect for each lease not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component; (ii) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii) the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January 1, 2022 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the adoption of ASC 842 on January 1, 2022, the Group recorded an impact of approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_oy690xxky0O7vM2NEm7ocQ">0.6</ix:nonFraction> million and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_jzVPSRMxa02oPKNM1XHE8w">0.6</ix:nonFraction> million for the recognition of operating lease right-of-use-assets and operating lease liabilities, respectively, on its consolidated balance sheet, which are primarily related to the lease of the Group&#8217;s offices. The adoption of ASC 842 did not have a material impact on the Group&#8217;s consolidated statements of comprehensive loss and cash flows.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_jjSdptbvSU6TVFwceui9Wg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_dG1hfLckBkqTSpplj2Awtw" continuedAt="Tb_dG1hfLckBkqTSpplj2Awtw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC&#160;740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont6" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont7"><ix:continuation id="Tb_dG1hfLckBkqTSpplj2Awtw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:DebtPolicyTextBlock" id="Tb_Elyr8z5J8U6QqBqevA8YoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_OvFr4MAzlk29qqYFmc6uUQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation-Stock Compensation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; (b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or (c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_cfqZNG-nEESC9iuOpRkFlw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 260, </span><i style="font-weight:normal;">Earnings Per Share</i><span style="font-style:normal;font-weight:normal;">, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:EmployeeDefinedContributionPlanPolicyTextBlock" id="Tb_AwKgeMC-RkSwljK4CmDhqQ" continuedAt="Tb_AwKgeMC-RkSwljK4CmDhqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employee defined contribution plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#8217; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#8217;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_AYHWSzrwM0eLqiW00fAPmQ">622,377</ix:nonFraction> , US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_FuDFetTnaEKjgCN3ykxcGQ">2,223,493</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_RqBR9jUnSkWL2qXBQsxhwA">2,984,251</ix:nonFraction> for the&#160;years ended December&#160;31, 2020 , 2021 and 2022, respectively.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont7" continuedAt="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont8"><ix:continuation id="Tb_AwKgeMC-RkSwljK4CmDhqQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_0Z11wV4gvkagLyMd8PXYCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2022, the amount of cash and cash equivalents of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_8B7AeaXkck6JwjDBIkApxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_dMbp6dzwI02E8MlPWpDEsw">3,650,474</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_Ony51QAJ_02DctV0aevFAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_hdEQPKInIUa15kST6JmVKg">8,617,157</ix:nonFraction> respectively, were held at major financial institutions located in Mainland China, and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember__YdfUW6IYUmfXgc9SfOrnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_G5C8pXJfFE-S-t8iz-Hx_g">170,740,769</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_ZkAGkZRbN0SrE5hh7uf0cQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr__y37xiSslEGqDXpURnI-Vw">135,141,521</ix:nonFraction>,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s research and development services were purchased from <ix:nonFraction unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LdAvTZA4DkCZZqMFxvFSkQ" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfMajorSupplier" scale="0" id="Narr_r6prjLR9uUWiBXI8wXlFBg"><ix:nonFraction unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_MoK8o28CCE-5S19pyoHFfQ" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfMajorSupplier" scale="0" id="Narr_0kYqk-jSO0aaIxrv9JVmWw"><ix:nonFraction unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_mXd1utWD0Uy80tRoBoh-xA" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfMajorSupplier" scale="0" id="Narr_1Ao81w4hVE623ePpt_q9TQ">one</ix:nonFraction></ix:nonFraction></ix:nonFraction> supplier group, who collectively accounted for <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XFO8ZN7Etk2rs2waJjZ9vA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_S4m-vsT4fkavF-wtmBq1ng">21.5</ix:nonFraction>%,<ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_qXLooUnAXE2ppSJQSdpERw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_Upi3Ciay30Oa05tOr50eyA">18.5</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_AXlFqdkG3UW_uqmcSDFkCQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_VNq5WPOG7kO8OVvBG_aVug">34.1</ix:nonFraction>%of the Group&#8217;s total research and development services purchases for the&#160;years ended December&#160;31, 2020, 2021 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#8217;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#8217;s ability to attract employees necessary to support its growth. The Group&#8217;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#8217; invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="4" format="ixt:numdotdecimal" name="adag:PercentageOfDepreciationOfForeignCurrency" scale="-2" id="Narr_aGhNH7jbQE-T7t3UWrVGUA">2.29</ix:nonFraction>% in the year ended December 31,2021 and appreciation of approximately <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="4" format="ixt:numdotdecimal" name="adag:PercentageOfDepreciationOfForeignCurrency" scale="-2" id="Narr_qNdU47UY2UugPEjsqispdw">9.24</ix:nonFraction>% in the&#160;year ended December&#160;31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#8217;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_jr5G1eI5HkGIo9yAV-W-Uw" continuedAt="Tb_jr5G1eI5HkGIo9yAV-W-Uw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is an emerging growth company (&#8220;EGC&#8221;) as defined by the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_qlAUkrP4eE2wdGN_eHTVzQ_cont8"><ix:continuation id="Tb_jr5G1eI5HkGIo9yAV-W-Uw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU No. 2016-02 (&#8220;ASU 2016-02&#8221;), <i style="font-style:italic;">Leases</i> (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-10 (&#8220;ASU 2018-10&#8221;), <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#8220;ASU 2018-11&#8221;), <i style="font-style:italic;">Leases (Topic 842): Targeted Improvements</i>, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current U.S. GAAP (Topic 840, <i style="font-style:italic;">Leases</i>). Further, the FASB issued ASU No. 2020-05 (&#8220;ASU 2020-05&#8221;), <i style="font-style:italic;">Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities,</i> which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted.<span style="font-size:11pt;"> </span>The Group adopted the new guidance on January 1, 2022, using the alternative transition approach. For additional information, see Note 14, <i style="font-style:italic;">Leases</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and does not expect the adoption of ASU 2016-13 to have a material impact on the financial statements including the notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. This update simplifies the accounting for income taxes as part of the FASB&#8217;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, <i style="font-style:italic;">Income Taxes</i>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2021. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted ASU 2019-12 in 2022 and the adoption of ASU 2019-12 did not have a material impact on the financial statements including the notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</i>, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Group is currently evaluating the impact of this accounting standard update on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In March 2022, the FASB issued ASU 2022-02, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings (&#8220;TDR&#8221;) and Vintage Disclosures</i> (&#8220;ASU 2022-02&#8221;). ASU 2022-02 eliminates the TDR recognition and measurement guidance, enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. For entities that have not yet adopted ASU 2016-13, the ASU is effective upon adoption of the amendments in ASU 2016-13. Early adoption is not permitted before an entity&#39;s adoption of ASU 2016-13. The Group has not adopted ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="Tc_rNheTO1pp02tC-U64Ab2gA_1_2"></a><a id="Tc_98TrjCJIDU6HhdmaVmuarw_2_2"></a><a id="Tc_iaKIApHE6EyR6mPE0SF2RQ_2_4"></a><a id="Tc_IVAunD96OEOKcSs7C9nxxQ_3_2"></a><a id="Tc_Mp1sMm0pbU6-FWSx3pn0uQ_3_4"></a><a id="Tc_RreL40Maqk2e7tX62ZbWgg_4_0"></a><a id="Tc_LimQZ8QlbUe73cHy6MlxTw_4_4"></a><a id="Tc_DuwF6aibPE-7L3MhnccBSQ_5_0"></a><a id="Tc_-PsjagfCnk6kxoNGeun1tw_5_2"></a><a id="Tc_zrrOf4NEb0uYGV4TliBRMA_5_4"></a><a id="Tc_0ir7qwHT80WGb8TctDFE5A_6_4"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_dDF9wb-wTEuPsr3eaEe_jw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3. ACCOUNTS RECEIVABLE, NET</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="Tb_Exg80oELbUK0TrE3LemoOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGross" scale="0" id="Tc_CEQODxnys0-PXlXuV7R7rQ_4_2">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="0" id="Tc_XWz7Vj_OH0-2fR0W2597Jw_6_2">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9a2b8f55_f70b_4335_afde_759ab42b291b"></a><a id="Tc_IYMd_xiYuUWifl8lp6Epyg_1_2"></a><a id="Tc_oG0Rx_Cy0kyKiULbg-_Utw_2_2"></a><a id="Tc_f5maofGZjkqVXXZTObefyw_2_4"></a><a id="Tc_5CJ5x9BOxUW82V8omwvQ9Q_3_2"></a><a id="Tc_kHS1AxvfsEy8vrdJXFi_0g_3_4"></a><a id="Tc_JTnlJhQ5ZUOyqYcyFnvsow_4_0"></a><a id="Tc_rrWLuF9hXEGl4TUCCAmYsQ_5_0"></a><a id="Tc_f2TFr0frNk-TBpoegoMlYA_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="Tb_5EsVINau-keawlUg2lCiWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4. PREPAYMENTS AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepayments and other current assets consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_QRCjj2FYn06TGdYn_zpyEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_1Q5UYZP_kk-tX8zp4Cm-eA_4_2">1,562,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_Z-9bgQoiyU6DLTJ-_YSpbg_4_4">1,161,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deposits (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsCurrent" scale="0" id="Tc_pkrb3Au55EuO-cfLt88Qew_5_2">1,873,843</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsCurrent" scale="0" id="Tc_hYUSDSI8-E6RL-r8NjvWRQ_5_4">2,970,421</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="Tc_F3fNjr9cREqT8PFRkmExzg_6_2">619,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="Tc_ve9mzQx78k-eM1UFhP495g_6_4">804,992</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_hYa6H5kTO0uarzESDcLSpQ_7_2">4,055,921</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_MWxlk47lwkOkNDvYE-Yh3w_7_4">4,937,323</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="font-weight:normal;">Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_6i8WB2ET10KEEXHknFCOdQ_1_2"></a><a id="Tc_J8JYcu_eFEqc04ytz0DgDA_2_2"></a><a id="Tc_vhX6QIk2NUSLa-t1F3ldPg_2_4"></a><a id="Tc_FsVKFCPkWkWYrSwlo52vSw_3_2"></a><a id="Tc_E5d48Cy1f0CxqhGep1kmJw_3_4"></a><a id="Tc_yDreX7MCKUuDaPYDJN5Eog_4_0"></a><a id="Tc_8l5BaHLZLUaAqAfni_bQaw_5_0"></a><a id="Tc_ZUry9sDKVkea6Jqm42-Vcw_6_0"></a><a id="Tc_rlL-XQXJAEWtFBWNxzekfw_7_0"></a><a id="Tc_beq17BMHG0m7zc-VP-xwow_8_0"></a><a id="Tc_2e9bt-6BH0ioo3fYnJq8aQ_9_0"></a><a id="Tc_zb_BsAVHJkOfFwcWKMU8pQ_10_0"></a><a id="Tc_VeMOZ-g3m0Gzv6c1UpVoUw_11_0"></a><a id="Tc_F_rVc7zGlEig77oTqeuK8g_12_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_yD5dSVaSE0KcXXUemWYWiw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5. PROPERTY, EQUIPMENT AND SOFTWARE, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment and software consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_WbohXBQ-EEKNWKG03T31xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_-deeomKWdka8knVPbfU3GQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_T2KE8isYpEWf7n4Cd9D8PQ_4_2">5,252,399</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_HEZrgDuwzU2I-5vwCDZhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_3FxB0pnlnEq9fQqc3F_AtA_4_4">5,293,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-htfaRs6hE-PttrYcJWsUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_zzuFDu-yY0SCNA0g6AP1zg_5_2">1,152,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DNi18GaWDEuLxJST1LKg5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_nQRHpTOfIkeyQB3NjsilyA_5_4">1,055,271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EML4beDnNUeNnibb9wySxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_nbZaaVeOVke6X4mdvqRKnw_6_2">1,863,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_sW55u4h2J0OcuFvypf5muw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_SYSuVoKkMUScTY973NGb0g_6_4">1,863,963</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_O5OcHRqnw0Wo-gX84ILHew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_UxkA7wWnZ0a4HYiKB0vI2Q_7_2">81,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_rn5z_oGtm0i4zKXJtLEPBw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_a7FQdsq1XEyg-QsvF0BT1g_7_4">29,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_ITtG4X4HskK8vTiFNbmV8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_SBF3eeY2zUCBh9csHILMyA_8_2">87,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_E2F3cjJxskiJsRXhTacDag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_BWhrAZMuwkqaULN4VFPz5g_8_4">80,266</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MipZoRX4l0apHBHgnqY4mA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_C9A7lgxKXke9ZHDbR0EvEA_9_2">371,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_Ed31KlzZbUezDqBMeti4vA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_IBdOgoKdg0qotDXqql3Buw_9_4">369,698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_bvz92vUUQESelLcccdCrZg_10_2">8,809,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_fm5HyhODf02_QeynWBayAw_10_4">8,692,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_HdrPW95NZUC1xuoji0GitA_11_2">5,322,264</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_Yh0AaYsep0OORTWGmPMIzg_11_4">5,909,305</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_SNqsLWet5UKyZLgJsrY_Uw_12_2">3,487,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc__8E78h90TEWCXrJKwLA1Pw_12_4">2,782,963</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Depreciation and amortization expenses recognized for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_lE-Bi9dgV06SYBUx5alNkg">858,408</ix:nonFraction>, US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_l1eIcRB9c0irX2bqc-nBIQ">1,125,032</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_AxJYgLDMHkeXGVb115F-Zw">1,145,995</ix:nonFraction> respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_K-S1EGh2mkqbdbXemlWcqw_1_2"></a><a id="Tc_3hiKdaP1k0KRkL-D4bnxiQ_2_2"></a><a id="Tc_xBM2MCVa-0Ow3wz_DIvU2g_2_4"></a><a id="Tc_PkqKtTVGtkukLFMJDZUjoA_3_2"></a><a id="Tc_-Ix8xQ_LG0eDA09v6pTCOw_3_4"></a><a id="Tc_N0prbT6uwEKMzW-Zbph_0A_4_0"></a><a id="Tc_afJUCTFHcU-3nP5KVGyCtA_5_0"></a><a id="Tc_y77hzz7lv0uzl5RGfX7cUw_6_0"></a><a id="Tc_DfiRIYLgTEGPpnSZ3vVO9w_7_0"></a><a id="Tc_21sKzKU7YUih76MhYVSoTQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" id="Tb_7DeNrtKIW06ypqJAh7B2Mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6. ACCRUALS AND OTHER CURRENT LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued liabilities and other current liabilities consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_bjmx5O2OsU-bWk1NM0Q5FA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_kKqyB86pA0CmOVknDosZSA_4_2">935,434</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_TZqCnSs5LkWe6AUuuBeenw_4_4">1,647,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Payroll and related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_me_69K3Nik6SFjI_3G7SuQ_5_2">3,229,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_cddu-xssZUG6EeQ4OJtK6w_5_4">1,104,365</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Utility and maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedUtilitiesCurrent" scale="0" id="Tc_ATTVi32vsE-Il87YSrjK7Q_6_2">8,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedUtilitiesCurrent" scale="0" id="Tc_LkB-411Y40aaJqPESwZNMA_6_4">40,718</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other taxes and surcharge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="0" id="Tc_R7PDqC2UVUanxszh9ZjGHA_7_2">62,270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="0" id="Tc_01ZNkV8vQ0uGj0Nw-oBU4A_7_4">349,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_whz141km-kCOIo0ur88Kog_8_2">143,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_QY5PgYAvw0SH4SwjTzdecg_8_4">71,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_2xTTOm6c002FPmhv8NVq7Q_9_2">4,379,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_HbuDdwiolEyLR8RC0ZA4IA_9_4">3,212,809</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Tc_CMKEu03fr0ylxtacF78XQA_1_2"></a><a id="Tc_ttQXMXHqm0ibqQDz_HDHJg_2_2"></a><a id="Tc_b8asIdxTtkWwYzpVf365og_2_4"></a><a id="Tc_RweQSKJzZkO7-SdnMv-YPg_3_2"></a><a id="Tc_x5YkMj0a4Ueew7ye1PHKhw_3_4"></a><a id="Tc_I-vBEPWEHkm82ubHT2pRfg_4_0"></a><a id="Tc_jzjv1eQZ7EyAfA8l9sS2SQ_5_0"></a><a id="Tc_7cPWtZ6qG0q-RT97PXRLqQ_6_0"></a><a id="Tc_ATnHS1LCckyFk9fHqgFZUQ_7_0"></a><a id="Tc_Ub3m-67TUkG6PcHtsBSRvQ_8_0"></a><a id="Tc_yLAn0jWq0kugic75naJhIg_9_0"></a><a id="Tc_zGbx0pc5tEmcFsnlMAY-UQ_10_0"></a><a id="Tc_69x1p7GulEG99pR7YQcmEg_11_0"></a><a id="Tc_Mc4UadXOdUShnKSltgoqZw_12_0"></a><a id="Tc_CvxIzKZ7U0mcdZicDCMqyg_13_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:DebtDisclosureTextBlock" id="Tb_MUIU4zi7lEW2Y-x9I46Vjg" continuedAt="Tb_MUIU4zi7lEW2Y-x9I46Vjg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;">7. BORROWINGS</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_Ommf9mGvCUudHE0jLAkHOg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Short-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_SCxCbb4m0Ee9gaMy_63ShA_6_2">3,121,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_CT1bkwwVt0iQo29dwUPS5Q_6_4">10,768,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_lo5mhzCvVUyz5A-MoXn3LQ_7_2">1,376,319</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_fS2ujro_80qixd2tz7tV9Q_7_4">2,850,128</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="0" id="Tc_KVP_3Gq_P0yGzgbBcLaumQ_8_2">4,497,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="0" id="Tc_hOnbTMhzKkigAXuSjbqluA_8_4">13,618,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Long-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansFromBank" scale="0" id="Tc_X4olMBleO0uQhYO7AEsnUg_11_2">2,991,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansFromBank" scale="0" id="Tc_AOAsauPjgUGWeGCHTcDfpw_11_4">14,146,541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total non-current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_A6879VUzh06PgnxYReLqpg_12_2">2,991,829</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_DZboN3KfiUq0MRXnIGdzVw_12_4">14,146,541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_45LVwOjBrEGD2t2kzDg1Lw_13_2">7,489,374</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_UKd-93sMcEWOQ_ne7BF7VA_13_4">27,765,414</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Short-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_dJtQgQmGpkSyvl6NW8DTsw">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Yhct7b_2s0GQZKJAgjW4QA">1,532,591</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_GObFgSRwTUiB_WsA8h6l6g" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_0p46sV5__UOcToLno0Uyqg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_z7ZoUe9CjkSaDjoYW07Abg">4.2</ix:nonFraction>% per annum. The borrowing was repaid in June 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_PP1bUu4P3EGvxBLvW5Qmdw">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_KWfaaATlLUm12PLe3TjCYA">766,295</ix:nonFraction>) from Bank of Ningbo Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_o0zaN5JGjUuNPtedN9XKFA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_FOnhhGmvEUKDs0hWkrSHLA">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_o48XoU5f30CfQPN3UVpu2w">4.2</ix:nonFraction>% per annum. The borrowing was repaid in September 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_vWO3zbZuYk6wU41xEOCggw">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_iHTwPZ33aU6glZi44eVQqg">770,962</ix:nonFraction>) from China Merchants Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_mUP8HKs3QE-VA88oUIhohw" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_huegp8hvuk2Y37NsJ3poJQ">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_gZAptPM9uk6fdauE64kA4Q">4.1</ix:nonFraction>% per annum. The borrowing was repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed another loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Ckq5BWrsrkaRx_4G3JeCvA">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_AN1LUXCvGkK2ATl3VmqCyQ">770,962</ix:nonFraction>) from China Merchants Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_UzX_9ytflk6kC_qnriMQxQ" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_bsaAnjfn1kePws-Eeuc_lA">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_gqbVO4Y3b067XSug4cmIcA">4.1</ix:nonFraction>% per annum. The borrowing was also repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_koLsd2qFukmYlgKj1hkgWA">9,900,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_1XRMt-1MRkCjt7OQuR-ngw">1,552,771</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_m85-xLE3m0awlOkyhyozPA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_5wtLKt-z9EmArlL3bM6zhg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_zbrpteom1kmXlawQoAoCog">4.05</ix:nonFraction>% per annum. The borrowing was repaid in May 2022.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_MUIU4zi7lEW2Y-x9I46Vjg_cont1" continuedAt="Tb_MUIU4zi7lEW2Y-x9I46Vjg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Group borrowed another loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_j90WgpJdm0u-UjrTfmgeWA">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_NBO8FHemdkKbebc7xb2axg">1,568,455</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_M1R5q493x0epZjiLXZubXA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_bUsy4wczQkuu30yIOMz9Pg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ShGfP5DbAEqipZZ3dzFyqg">4.05</ix:nonFraction>% per annum. The borrowing was repaid in August 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Zf_Ct_HIyUCJlu5cR6IqIw">9,900,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Bvp6fpP1dU-1vM0rjfAJ-Q">1,421,474</ix:nonFraction>) from China Merchants Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_qhmYvReawUyRvQAZITHLMw" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_FpF_BcPutE-GImMfvsypAA">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_POa51v5tkkSjAtU5aEtLjw">3.90</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Group borrowed another loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_6L8lgSUWaEuoM8GJ5gWLjQ">20,100,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_2chMPEQpUU6UdoTWupcflg">2,886,024</ix:nonFraction>) from China Merchants Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_1aTpF0ph_0-mY4m38ylZKg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_1BKbBfypMk-Yva-YskZHmw">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_JeOtfB6s502ZVvx20iRN0Q">3.70</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_bJ6QtnqHIkqBWZYPB8wHqw">20,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_c9cy98YC90Sjcv1tVqzuLw">2,871,665</ix:nonFraction>) from Bank of Jiangsu Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_Cvjhq1dzz0iJpxmkLeqhQg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_YEpxfu5fhU2h90x79XeMIw">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Hw3cxMBIAEa0igC2yY2oHw">3.70</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2022, the Group borrowed another loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_tOIuKgMFuUuhZJAXSngHzA">25,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_o-8RrLxI_kmQKc4icrOLug">3,589,582</ix:nonFraction>) from China Construction Bank Corporation for a term of <ix:nonNumeric contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_7-okYR-WZkiKB1VW-JL4qw" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_6jkQwqZJNki-DexqsGjjbQ">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_xp09Unw5nUK4CtMDtbv6gw">3.65</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Long-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_eSUrY_sBdke15hxLC_kVEw">7,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_LoUih4YrvEanRbjeyYLZ1Q">1,076,874</ix:nonFraction>) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of <ix:nonNumeric contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_NHWc7CtpgUiJIg8gFfBOYw">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_4_kU3jqipkekC1in-ph41Q">5.46</ix:nonFraction>% per annum. The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_mtdgNiOXz0Od9s3DiXLFWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_8UHSWfPGjkemgAQ72IyBDQ">375,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_mtdgNiOXz0Od9s3DiXLFWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_3L5BvUCdKEmmBXmE5MTceQ">53,844</ix:nonFraction>) in 2019, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_jTkNK83fPE6etG2zBbgm_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_2S1SSJfNJ0SCurCrEmh1MA">1,250,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_jTkNK83fPE6etG2zBbgm_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_4CygRwwBp0aAVx_kjU7bPg">179,479</ix:nonFraction>) in 2020, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vDDRVJHJWEiIRkoC0j_pHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_RzJ9E2WBqEeHaBMJzhHF7Q">3,375,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vDDRVJHJWEiIRkoC0j_pHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_2BJ-fi2lyEWvvVpxMlDAuQ">484,594</ix:nonFraction>) in 2021 and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ZBzOSEd9-keWfT5F8GU35g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_bBFC6tXjv0i6d3AKNJq6RQ">2,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ZBzOSEd9-keWfT5F8GU35g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_N6W6UEP-kU-o3IbNmigLAw">358,958</ix:nonFraction>) in 2022. As of December 31, 2021, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vOz3vIv740GU9REG4Z_wcA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_-1_eWhoLxUWErDsCyvNOsA">2,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vOz3vIv740GU9REG4Z_wcA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_CEk5vtMa20-hhHyLksUdrg">358,958</ix:nonFraction>) repayable within twelve months for this agreement was classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets. The loan was fully repaid in February 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_UXpbzTtVI0K5-8ZNnj5B2w">6,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_kooD17M7NkKGuEWkwqsJsw">861,500</ix:nonFraction>) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of <ix:nonNumeric contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_jxMYYez8a0-dRjO8rc7gSg">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_uDt5Iv8BS0-rXM3SVij4PA">5.23</ix:nonFraction>% per annum. The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_53NbnrlZsUSgSYUOMp8aRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_TEAwzh3tzE2tvigdxORabg">300,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_53NbnrlZsUSgSYUOMp8aRQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_DIDkrBc9HEO1L-iq_BwqEw">43,075</ix:nonFraction>) in 2019, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_1rOMO6-cAU-GIBzCBWWxnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_cA3K6D4KW06ISX_b6sdr3g">1,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_1rOMO6-cAU-GIBzCBWWxnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_4kS3IP6YbkqvAl5bi7KnMw">143,583</ix:nonFraction>) in 2020, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_hHC55XuXUE2hmp5hAZXI4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_uhd8oBDf902JLwZ3S5whXw">2,700,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_hHC55XuXUE2hmp5hAZXI4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_kO8-Vlxxm0GUROpRfDTlLQ">387,675</ix:nonFraction>) in 2021, and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TIiFTeaXkUeerjdaxd6jwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_4337Vrdc5UWkV3mHS7TqWw">2,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TIiFTeaXkUeerjdaxd6jwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_E1zmkmPdsUS0ZsXIvEkc_g">287,167</ix:nonFraction>)in 2022. As of December 31, 2021, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_v_9yYOSrf0y4xth99sJ-dg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_--CDcZdYTEaAgDgEqgke0Q">2,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_v_9yYOSrf0y4xth99sJ-dg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr__EV0f1vVZUut-Uz05YJAYg">287,167</ix:nonFraction><span style="white-space:pre-wrap;">)  repayable within twelve&#160;months for this agreement was classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets. The loan was fully repaid in June 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_dWXC7gHSN0u46LgMJr5PdQ">16,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_48PXDDXW-kajfCJ4EWjUBg">2,369,124</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_lNg2qdd-e0WmpxMg2HTp3A">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_e92jqG0EWk26qgsEOyiMGA">4.27</ix:nonFraction>% per annum.The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_3nKdmvhHQ0e0MXKzpN6qwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_mJJIodXTWEyt6ub4mDxTWA">1,650,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_3nKdmvhHQ0e0MXKzpN6qwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_qOy9k0x5ckefpQrq3eu5rQ">236,912</ix:nonFraction>) in 2021 and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_0q1bEcQFREGMTjD4ZvPvnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_-VhkBSMhc0m5DS_ainHMOw">3,850,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_0q1bEcQFREGMTjD4ZvPvnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_U3BFLLmMmU24-HfUggbOVQ">552,796</ix:nonFraction>) in 2022. As of December 31, 2021 and 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_BtH_9qawAU6ZHHYCSElW5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_ui8JT2HcIUqggeSv1iCs_Q">3,850,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_BtH_9qawAU6ZHHYCSElW5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_djUrnolp4UqImMDyB3n_5w">552,796</ix:nonFraction>) and RMB <ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_Kyvt-xNRBUiAu-DLngZgGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_kTm-IIxQq0euLdeB1HfrNQ">11,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_Kyvt-xNRBUiAu-DLngZgGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_gDX4J8IKnkK2KDN_kk-0Sg">1,579,416</ix:nonFraction>) repayable within twelve months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_8AwN1ytiokSUc3XzyDc1zw">8,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_DHJTrQojikKClJyaipi1tg">1,220,458</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_C5VplAhQ0kaAuf-ay_AIqg">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_dk2XqU1yy0CgVe5uqbWlaQ">4.05</ix:nonFraction>% per annum. The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_hlw_TK4DbU6yZTcHfKFcyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_zDJ-IlY8tkSeh1iOLXweEA">425,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_hlw_TK4DbU6yZTcHfKFcyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_08buR5ve8ke2cN9irXunnA">61,023</ix:nonFraction>) in 2022. As of December 31, 2021 and 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_CaP4Z8PlL0OapP5FtNaLKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_p35U893ZU0upOMV6s2KhNw">425,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_CaP4Z8PlL0OapP5FtNaLKQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_x7aYulKlG0OGzk7mYdcE6Q">61,023</ix:nonFraction>) and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_ymVbWklhkUCmOkHyKVKxVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_GHXQsrfF4EOSRM6Uhs8bDg">850,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_ymVbWklhkUCmOkHyKVKxVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_P7dII-qSE0G77ZE06rDiLw">122,046</ix:nonFraction>) repayable within twelve months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_PuycR4ec30y3CyBp4UbTjQ">30,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_yvm2Elp4K0mrfBdlHdLLjw">4,307,498</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_BBHUOxUU1EKMR9X9h0NFlA">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_eUG46GISVkiLZSLlKHRcXw">4.00</ix:nonFraction>% per annum. As of December 31, 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_EiHF3gmZ_U-INkw151eN-g">3,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_mWQVdP6wMUiokIYuwg1mcA">430,750</ix:nonFraction>) repayable within twelve months for this agreement was classified as &quot;Current portion of long-term borrowing&quot; on the consolidated balance sheets.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b17c34fd_f8a6_407d_9e13_2abe3c6f7584"></a><a id="Tc_szxiETN-YkmPNY7erpUl_w_1_2"></a><a id="Tc_m_0f0bDp2Eic9XZq8aCLAQ_2_2"></a><a id="Tc_WSMBTz9kZ0u0Eo3dhclh7w_2_4"></a><a id="Tc_urEaqPHkO0a4UXInKwoRBg_3_2"></a><a id="Tc_LwCfHHNPDkS79MOHi2iPqg_3_4"></a><a id="Tc_vLKgX_FxGkazmudhigoVhg_4_0"></a><a id="Tc__qexaSXVPUWapkB4DjO_Jw_4_4"></a><a id="Tc_VejJMD3Lm0mY8_wRD1BOBA_5_0"></a><a id="Tc_9dZQeHw5_UyVwhGL74P2pg_6_0"></a><a id="Tc_iOK9R0BfPke1o8AoebJ8NA_7_0"></a><a id="Tc_wx40SxCbikuAUMXu4d0a-Q_7_2"></a><ix:continuation id="Tb_MUIU4zi7lEW2Y-x9I46Vjg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in May 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_TXKutQJfU0eMArhAlf5Myg">20,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_K9vI2U-xp0ebd64COQUDIw">2,871,665</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_0mPtjCyzjU6M_iXf9wOFUg">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_s4Rs2sXnGE2Qo_AbwyFtJg">4.00</ix:nonFraction>% per annum. The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_yuDqrjY2ZES39bMfzJzDpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_D1dwG2fHVEmMrmRTiHCjyw">500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_yuDqrjY2ZES39bMfzJzDpw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_TMfgsbdgXkyztM7WW6SS7g">71,792</ix:nonFraction>) in 2022. As of December 31, 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_zUL5X-s5MEOb_qYJhHPkHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_byYbx620ZkmfFFHIAxHqpw">1,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_zUL5X-s5MEOb_qYJhHPkHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_WIx2MMVK806HnoEMiSVEjA">215,375</ix:nonFraction>) repayable within twelve months for this agreement was classified as &quot;Current portion of long-term borrowing&quot; on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Pi4796Z8w0-aL-Ukhua-Cg">9,900,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_6FNtOFwTKUq3GiFETl50Jw">1,421,474</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_u6I_x4qrHEe_4xZeRHLdaQ">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Dq8OHpCOYEaLBCmE2GmCFw">4.00</ix:nonFraction>% per annum. As of December 31, 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_pt5AptktukOvNAZzs_aUtA">1,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_SAG2Tqqbnk6a4ds2EzQ7EA">143,583</ix:nonFraction>) repayable within twelve months for this agreement was classified as &quot;Current portion of long-term borrowing&quot; on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in August 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_HttQ527cXE2heeRT-Vp1UQ">20,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_z_Lq_P_DOESZFYCTvUs95w">2,871,665</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_HqzJIj65aE-zGnQlEd0dGA">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Al-PzU0qrUaBvsiJKZLMFw">4.00</ix:nonFraction>% per annum. As of December 31, 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_tHkOGLmG7kWYIeDJOJTVtg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_rlmL5NR0EUS2dHXk3hG-mQ">1,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_tHkOGLmG7kWYIeDJOJTVtg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_D1UH4HBN3EKNGfQKOpISOA">143,583</ix:nonFraction>) repayable within twelve months for this agreement was classified as &quot;Current portion of long-term borrowing&quot; on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_F3wtBFVkqUaPii7SapVXUw">9,900,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Tx_vnk7DLEmZil8FD8efvw">1,421,474</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_GIPqz5K36kqncKQaNcjlAg">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ILXiS60y6EWawlHAd1KCfA">4.00</ix:nonFraction>% per annum. As of December 31, 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_im1p4S7UIk-Va6Iyo1ACQw">1,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_3sdZiZd5O02nAk7npA55ow">143,583</ix:nonFraction>) repayable within twelve months for this agreement was classified as &quot;Current portion of long-term borrowing&quot; on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in November 2022, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_L4i-FjPK5U-9aKDfk9P-Ig">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_ouP_nCm4LUG5n6b0Qn5jUQ">1,435,833</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_PkcydvLiX0K_vRZ1yl8Lkg">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_lVmoyBbR-kuH7t846zzCww">4.00</ix:nonFraction>% per annum. As of December 31, 2022, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_qYhrznmDM0a0FqD3lA6Fbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_rP4DNZydC0it0UMJkQD0eg">500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_qYhrznmDM0a0FqD3lA6Fbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_nzNdlf8kvEGODyXRHxelsw">71,792</ix:nonFraction>) repayable within twelve months for this agreement was classified as &quot;Current portion of long-term borrowing&quot; on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The proceeds from the loans were primarily used to pay for the Group&#8217;s research and development activities in China, including CMC costs of clinical and preclinical programs. As of December 31, 2021 and 2022, none of the Group&#8217;s borrowings were collateralized in the respective loan agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Future maturities of short-term borrowings and long-term borrowings</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" id="Tb_ImSw9U6bREGgwv0CvnwSJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2021 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" id="Tc_69GVtUdgXU6qjuqBX9tpqA_4_2">4,497,545</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="Tc_XRtS6Vd5z0mBWzxuuFYPjg_5_2">1,858,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="Tc_cXDJ0xvzX0KtNMv416qHnQ_5_4">13,618,873</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="Tc_gem6VjUmhE-HKMlTJp1ONQ_6_2">1,133,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="Tc_rODn480srEKsgBd4EK5mJw_6_4">4,124,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="Tc_lOSQcEYXwU66uAnRBj7wAA_7_4">10,022,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_k48v9sNmBE2vhziMlaZ3fg_8_2">7,489,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_DbyfIx3oBUqTO1jp6NTcJg_8_4">27,765,414</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock" id="Tb_dxPV4dNWl0ulIJZKxRqW6A" continuedAt="Tb_dxPV4dNWl0ulIJZKxRqW6A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2011, the Company issued convertible notes (&#8220;Series Pre-A Convertible Notes&#8221;) to certain investors in the amount of <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Tc41LxgyGUCL4pVauK0nXg">4,590,908</ix:nonFraction>. The notes carried a simple interest (non-compounding) of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_fLlJxpskgEGCjvq49kVBFg">6</ix:nonFraction>% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the convertible redeemable preferred shares of the Company at a price no more than US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_RsEXs85nV0OOAZi_KhRCfw">1</ix:nonFraction> per share.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4e9d750f_8b02_418d_8626_4d543144bc82"></a><a id="_4e9d750f_8b02_418d_8626_4d543144bc82_2"></a><a id="_4e9d750f_8b02_418d_8626_4d543144bc82_3"></a><ix:continuation id="Tb_dxPV4dNWl0ulIJZKxRqW6A_cont1" continuedAt="Tb_dxPV4dNWl0ulIJZKxRqW6A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2014, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_YUb_RBfSLEO6_Ii2KjdzgA" decimals="INF" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_o3pIZCiIi0az4Ta0T3sNGw">5,473,957</ix:nonFraction> Series A-1 convertible redeemable preferred shares (&#8220;Series A-1 Preferred Shares&#8221;) to certain investors upon conversion of the Company&#8217;s Series Pre-A convertible notes at a conversion price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_1YpVsNTuokSIfl2TMrVz6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_OMcslYdUZ0eY9E0qETsYUw">1</ix:nonFraction> per share. Concurrently, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_wIkgvAtqC0W5o3H3Cfgn_w" decimals="INF" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_mjSreb-wz0eZpjZNdYOaLw">2,370,414</ix:nonFraction> Series A-2 convertible redeemable preferred shares (&#8220;Series A-2 Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_vua2vlRLFESfuxZbRFuRuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_n3BsjizyOUeujmA5oR6kqA">1.27</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_wIkgvAtqC0W5o3H3Cfgn_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_Ty71NGYeIEq0iJmeq3GSAQ">3,000,000</ix:nonFraction>. Series A-1 Preferred Shares and Series A-2 Preferred Shares are collectively referred to as the Series A Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From January through June 2016, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_wh21KqXIxUieE_LnSC8fWA" decimals="INF" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_BQxrTIfZf0iio3qv29mOcA">7,494,537</ix:nonFraction> Series B convertible redeemable preferred shares (&#8220;Series B Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_vrEMPt5leE2LUHWCygtNag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_BcPZyG9LUUStsoWJB4FOWQ">3.74</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_wh21KqXIxUieE_LnSC8fWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_YeCMTbGMl0yybRZRuYlP8Q">27,999,995</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February&#160;through May&#160;2018, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_eIoK0LUqmECLHEJOC58yjQ" decimals="INF" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_hQK6LEl7HkatklFiHAjzng">5,597,354</ix:nonFraction> Series&#160;C-1 convertible redeemable preferred shares (&#8220;Series&#160;C-1 Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_zXGYISRRU0mn6bkSMKyVSQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_tbSBPHvx_USqOasHhoGoOA">8.93</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_eIoK0LUqmECLHEJOC58yjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_B4WpCm2EmEC7BBZ8HQZ3_Q">50,000,033</ix:nonFraction>. Concurrently, in February&#160;2018, the Company also issued warrants to <ix:nonFraction unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA" contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZBLOK46STEKlz-d2OVI5uw" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfInvestorsToWhomWarrantsWereIssued" scale="0" id="Narr_KoddusfaEUexZrenysvRNA">two</ix:nonFraction> Series&#160;C-1 investors at <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WtkVxDqueEGxL4XHYvRZcQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_vwC_bc-k3E6Qqi4rE_WDxA">nil</ix:nonFraction> consideration (&#8220;Series&#160;C-1 Warrants&#8221;). The Series&#160;C-1 Warrants allowed the holders to purchase Series&#160;C-2 Preferred Shares (defined below) at the exercise price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_Kp5I1u1AQkCMEJ0paDZCvA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_D9XoNYClW0SmO8LacEfNGQ">10.21</ix:nonFraction> per share for a total consideration of up to US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_2_1_2018_To_2_28_2018_lP6oVbKR6UmaFzbif9o9lA" decimals="0" format="ixt:numdotdecimal" name="adag:MaximumProceedsReceivableFromExerciseOfWarrants" scale="0" id="Narr_BPTad3bRFUOlrq4_D_sqgw">7,500,000</ix:nonFraction>. Series&#160;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&#160;April&#160;1, 2019, ii)&#160;a deemed liquidation event or iii)&#160;the closing of the Qualified IPO. Series&#160;C-1 Warrants expired on April&#160;1, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From June&#160;through November&#160;2019, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Y81m7zrxYE2aoB4C9ZGt2A" decimals="INF" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cZ0GVFybdUehqan9WAEaNw">1,861,121</ix:nonFraction> Series&#160;C-2 convertible redeemable preferred shares (&#8220;Series&#160;C-2 Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_QTNt0bXsx0a3cvqcs-sJBg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_PhgKqR8Z6EStiIUuAArq5Q">10.21</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Y81m7zrxYE2aoB4C9ZGt2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_YS4Sc1MQq0mATDik6CTu6w">18,999,999</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_gn5TOqPkiEmr84V7LuQlbQ" decimals="INF" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wG48F6XAu0-jLxC3MnifzA">4,452,441</ix:nonFraction> Series&#160;C-3 convertible redeemable preferred shares (&#8220;Series&#160;C-3 Preferred Shares&#8221;) to a certain investor at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_MvdjFPDEXkW0jwwbZh-cTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_u0Xi5l2RMUWxlqietSmOsA">11.23</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_gn5TOqPkiEmr84V7LuQlbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_ANyDR86w6UGcnlZ0nUYh1w">50,000,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Series&#160;C-1 Preferred Shares, Series&#160;C-2 Preferred Shares and Series&#160;C-3 Preferred Shares are collectively referred to as the Series&#160;C Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the IPO on February 11, 2021, each of the then outstanding Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares (collectively the &#8220;Preferred Shares&#8221;) was automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SbWl9Shq4E6nlxFVgDBgpg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_oA41z1UBIE2AHowRdhoVZg">one</ix:nonFraction> ordinary share. As of December 31, 2021 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_0iE_lHwbqUe523QL-FRm1Q"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_GpPe78BRVkO_ydFn-y13XQ">no</ix:nonFraction></ix:nonFraction> preferred shares issued or outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accounting for Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Preferred Shares were classified as mezzanine equity in the consolidated balance sheets because they were contingently redeemable upon the occurrence of an event outside of the Company&#8217;s control (e.g.&#160;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&#160;31, 2025 (&#8220;Target QIPO Date&#8221;)). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares were initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any Preferred Shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, the Company concluded that the Preferred Shares were not redeemable, but were probable to become redeemable. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest redemption date for the year ended December 31, 2020, and to the IPO date for the year ended December 31, 2021, using the interest method. No accretion charge was recorded as the redemption value was fixed to original issue price for the periods presented, except for Series C-1 Preferred Shares issued with detachable warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Modification of Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company made several amendments to the Preferred Shares, mainly including: 1)&#160;added redemption rights for Series&#160;A Preferred Shares upon the issuance of the Series&#160;B Preferred Shares; and 2)&#160;extended the Target QIPO Date upon the issuance of the Series&#160;C-1 Preferred Shares and the Series&#160;C-3 Preferred Shares. These amendments were accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_yrOvq9OM4E-U41lizcbpaQ_1_0"></a><a id="Tc_lvYZhZ11zkiEByYSv1apFw_1_2"></a><a id="Tc_QqMp3moszka5iafFFSqCVA_1_4"></a><a id="Tc_mYF5V64eJUK2sCpqcpyFKg_1_6"></a><a id="Tc_nnGQzZoz5UeK3kjwZr7Iiw_1_8"></a><a id="Tc_WVHdcTDk2EmAEa9RzN3w2g_1_10"></a><a id="Tc_9onkQjZ6ckSNYYAfdLk81w_1_12"></a><a id="Tc_fNTBClHAUkC2Nq1onMxrfw_1_14"></a><a id="Tc_a8z2CW_0ZEKwGTPbR5lxTA_2_2"></a><a id="Tc_f9hK74TIjkWPFKD9X0VZGQ_2_4"></a><a id="Tc_Dq71zMT3j0ayvkWuz_u-fg_2_6"></a><a id="Tc_YO9G7hAn_UysdsJWY0FN4w_2_8"></a><a id="Tc_y39p75xz7Ua6KzWrB7ZqLQ_2_10"></a><a id="Tc_jwSI_EiCCkuERU6dz80OLg_2_12"></a><a id="Tc_ryaYrh0T50u_ODvnv41M1Q_2_14"></a><a id="Tc_U0I9FgwDtkGrEtoq2NY0Dg_3_0"></a><a id="Tc_p7lQfdhtsUu-F5jvHavEPg_4_0"></a><a id="Tc_obzkgC6-6Eq91O6u7yyxHw_4_2"></a><a id="Tc_WDxC0VrGO0-rE0AaZANV5A_4_4"></a><a id="Tc_UOZjXzcLBkCSCC2yfn53jQ_4_6"></a><a id="Tc_bBkfc2YYCU6mF6agG3Sj6A_4_10"></a><a id="Tc_4KYNZ6GQPUGDw2j8AYTIwg_4_12"></a><a id="Tc_r-l-MysnPUKGrIa78zw8vA_5_0"></a><a id="Tc_EEdPPw_YokuUpEGMLJU5Bg_6_0"></a><a id="Tc_8QgM8GYb2kWOePZiznT_0w_7_0"></a><a id="Tc_SQMVEh_2yEm61vhOOIMVmg_8_0"></a><a id="Tc_DBdoIjqvGEi6bGK3iqJgTw_8_2"></a><a id="Tc_MghY86HtbE25WNjUp4Uq_Q_8_4"></a><a id="Tc_xfwxCSYkBEab4DGnk5ul5A_8_6"></a><a id="Tc_rT0Ww2C1PEGrbTd2SQYdgA_8_8"></a><a id="Tc_7WXZAYJm2E6IscBMHfVB1g_8_10"></a><a id="Tc_94yAOoOpz0eHT9ERf8QX8Q_8_12"></a><a id="Tc_nWir3wc0-0OrHpNtcKEsRA_8_14"></a><ix:continuation id="Tb_dxPV4dNWl0ulIJZKxRqW6A_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s Preferred Shares activities for the periods presented were summarized below:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_gQE9Vm16yUaAnDvUO1PYZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_m7mB-vO98k6ssn4DOuHCmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_wVOBfsK6WU-dY0fgUdB7ww_3_2">5,473,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_LetG2TvOqky7qj1cVnqr1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_h1QhhOAlKEm1QWy2qYShkg_3_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_o9la4OH3f0S73pFAL_jdvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_RkStX5_6J0C0Wbo1W7ZFzA_3_6">27,999,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_WRGc8jvai0S64dQK-czIGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_M5A3PnQEKU6iLUk40KKlsA_3_8">48,727,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_L7regPgk0U6wE3_qz1Zy6A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_0x2VQWGOv0uEUhM-cheMDQ_3_10">18,999,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_MvdjFPDEXkW0jwwbZh-cTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_fBe8Jplp2E2XoGuhVfPSmA_3_12">50,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_8ioQgjt4Rk6RewnF7dKMbw_3_14">154,201,294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_VrdzSlGiIU21zpTy5Vhp1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_ZyczbEdl_U6OSd83mBKRrw_4_8">248,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_VrdzSlGiIU21zpTy5Vhp1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_v9a18L7BhkmNFw4YkUX-Uw_4_14">248,113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_WRYTAw9fyUK5wNbAtUEgzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_0aeCECzOT0mtGKB3cHlrcg_5_2">5,473,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_CtbvulJUiUmHT0BVyHHTeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc__sebbmJsaUallarl-p5gCQ_5_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_LM0cYbNYBkuxPFEH3zcWdA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_qYPzwqhlBkWlstG8x0dg_g_5_6">27,999,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_-lU6hnUg1USHN9tNgX6z5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_OHGDEwfynEONVtFNrrFPkw_5_8">48,975,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_g02U-ugGTkWtKxibVH1wIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_B6ZcAWgh4Eqb4o5x8wmq2A_5_10">18,999,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_k-Tj_Iz31EmvHKgzizS4_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_79G-kPl6ZEC_d3dHcuaUZA_5_12">50,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_qEj5T7RgDkuCqt1iYofrkw_5_14">154,449,407</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_d6-yG3ZmJUiU55b-W768XQ_6_8">28,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_ICG7ogEC1kKBgnRIR2pJOA_6_14">28,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Preferred Shares to Ordinary Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_5kY-i-Zg3k-S2BENf9UwDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_yUP39Bs0MkeIsmTv0s_8mQ_7_2">5,473,957</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_2hVJvj7Zgk2flnbUuLCHEA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_IdU7cbhuPEqVZ6JceJ8TWg_7_4">3,000,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pizwZd0AoUe6Rr73Pf4YZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_k2G4ksp7OEmeyzm36uz1ng_7_6">27,999,995</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_y6HAQLXOfUKby5wHfpwwZQ_7_8">49,004,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Fsp_-okReEKrd3koR5i-HA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_GR2cRE8Vl0W7rRDJ9EC9BQ_7_10">18,999,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_kqrGAtT1eEGm0zzWRDQUBg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_xYWa-dt2J0mi2LqaMoNRuA_7_12">50,000,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_hY7ep-Ysn0K8pofcopR8pA_7_14">154,477,960</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_eLOwzXMN40SaKS77zUBpVg" continuedAt="Tb_eLOwzXMN40SaKS77zUBpVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9. SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November&#160;7, 2015, the Company adopted a share incentive plan (the &#8220;2015 Plan&#8221;). Under the 2015 Plan, the Company&#8217;s Board of Directors has approved that a maximum aggregate number of shares that may be issued pursuant to all awards granted shall be <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_Q157HUAGCUiQ3O7w3B8ZAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_biSLSBdkQ0CW6VfCTp3fLw">4,336,126</ix:nonFraction>. In September&#160;2017, the Company replaced the 2015 Plan with the amended and restated share incentive plan (the &#8220;2017 Plan&#8221;) and increased the maximum number of shares issuable to <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_JHoh1u6SlUWt5wpfBqAllA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_D-MU10OUQECRDPIkFqWG3g">6,336,126</ix:nonFraction>. In December&#160;2019, the Company replaced the 2017 Plan with the second amended and restated share incentive plan (the &#8220;2019 Plan&#8221;) and further increased the maximum number of shares issuable to <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_HX6qRchl3UOJYp2kC_kivw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_CqGyQY5RO0CMq5ku30pkCQ">11,391,131</ix:nonFraction>. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the Company may issue under the respective plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_EJ0fi0sr6k2AD6FT92wY0w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_qUtN6XbVGkaZ5Aq8qgCZdg">five years</ix:nonNumeric>, under which the grantee earns an entitlement to vest a certain&#160;percentage of his option grants at the end of each&#160;month or&#160;year of completed service. The share option awards shall expire no more than <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_EUkzQAH7_EWqwroRyBYXgw">10 years</ix:nonNumeric> from their grant dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence of their applicable performance conditions (including but not limited to the occurrence of an IPO, the completion of business and operational goals, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 15, 2020, pursuant to a board resolution, <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ymf1E7tmdEWfCfZo72BFWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_X8HYzO3kT0uKNtPw6NPpgg">184,692</ix:nonFraction> share options that granted to a senior management was modified and the vesting period of such share options was shortened from <ix:nonNumeric contextRef="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wZ9cdC31zEC6F4Aji6T7Lw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OV0mhPtmUUmx_mgSzBwJLQ">5 years</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ymf1E7tmdEWfCfZo72BFWA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_RUzUDRGu4U2acn9LmM7xOQ">4 years</ix:nonNumeric>. Since the fair value of the modified award was lower than the fair value of the original award immediately before the modification, <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" id="Narr_FYu-66C2gEqpBRpBqq67UQ">no</ix:nonFraction> incremental compensation cost was recognized for the modification during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A" decimals="INF" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" scale="0" id="Narr_MEaEnF9iaU6JXSbBT_ubJw">2,375,000</ix:nonFraction> share options granted to certain management members. Pursuant to this board resolution, these management members exercised all related share options at the original exercise price per share ranging from US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__xADkSqTO0S-DY3ZQNH76A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_WeLUUorYJ0GnTyGAorFK7g">1.83</ix:nonFraction> to US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_DQ9yn7uS2EGDv6fQLKvPeQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_nSkrhh3_qUWZumW_5tJjww">2.26</ix:nonFraction>. As a result, <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_AHJ3j5FUL0C0oDN_1piqkw">2,375,000</ix:nonFraction> ordinary shares were issued to these management members. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Narr_p1EZa5TmQES1TTELniqttw">5,197,650</ix:nonFraction>. The Company had the repurchase right to buy back such shares at the original exercise price if the grantees did not meet the original vesting conditions. The Company assessed and considered that in accordance with guidance set out in ASC 718-10-55-31, given such arrangement allows the shares received on exercise be returned to the Company if the original vesting conditions are not satisfied, there has been no substantial change to the vesting conditions and the Company shall continue to account for the share awards in accordance with their original terms. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_QB4Okja9ZEGLGUBdgEeHpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_pp0API8t3EmV9dlnRMN28g">1,585,000</ix:nonFraction> shares unvested according to the original vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w" decimals="INF" format="ixt:numdotdecimal" name="adag:NumberOfSharesSurrendered" scale="0" id="Narr_n8Ku5mjGokS2sZ9IUb_JMg">491,119</ix:nonFraction> ordinary shares as repayment for their respective promissory notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way of new option grants with an exercise price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_y9DsCNW3xEuO7w5WTrVCaQ">13.85</ix:nonFraction> per share. The fair values of these share options were US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_hR9QVWGmd0e4_33kwUamwA">7.85</ix:nonFraction> per option, determined by using the binomial option valuation model. The share-based compensation expense related to these share options were recognized immediately upon grants.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_q314nrd5KEKEcjLHkGMKSw_1_6"></a><a id="Tc_mC8cDS-ACE2QhuNFQ0maJg_2_6"></a><a id="Tc_kc_csBfkzUGeN3EUbijLlA_2_8"></a><a id="Tc_-F5vTrcgakuLj0G1tVIQmw_3_4"></a><a id="Tc_HNCsHf39F0i0IMoX03EJHA_3_6"></a><a id="Tc_rZlh5b_MpEC8Av0OGGZ5Uw_3_8"></a><a id="Tc_YV8dC5DRIkGvt1zvwF5zfw_4_4"></a><a id="Tc_xY262k74a0ulP7dh-tdSZQ_4_6"></a><a id="Tc_eMRQrN9LFEi1bFlBnMxU4Q_4_8"></a><a id="Tc_fGWPxwUNdkecXgyQ4VZQ4g_4_10"></a><a id="Tc_GtnmEjROhkOxPNf1w28AGg_5_2"></a><a id="Tc_JtZR3eSCn0qWnZPd8ivCsw_5_4"></a><a id="Tc_vsCN6ZrKo0qJh6LvULnd0Q_5_6"></a><a id="Tc_0K828MwrZE-mf4OQfb-c9w_5_8"></a><a id="Tc_fHiB5TriD0anU2feEymSLw_5_10"></a><a id="Tc_oDzTOZg8PkurI7j-gRspCA_6_2"></a><a id="Tc_jhnhcg2yO066pTAbgffGhw_6_4"></a><a id="Tc_ilJA7bfcuUS1Yq5mXlGl5g_6_6"></a><a id="Tc_5TkFN8H3jkWZeY46qKYhDg_6_8"></a><a id="Tc_PemXr_F1n0yJyLKqdLzUIg_6_10"></a><a id="Tc_8566Q6_8t02sW3zJPKIAKQ_7_4"></a><a id="Tc_zAe4Oe7ztkSM2_ggvAYYlA_7_6"></a><a id="Tc_Eb9sSN_itkWkK_go9aFLSg_8_4"></a><a id="Tc_QUrqcwQdz0-9r_UV0-lp1g_8_6"></a><a id="Tc_q4Fah0yW3EiLQ0iBsaQ-DA_8_8"></a><a id="Tc_OfNx3aXW6EmRwWiUH1OlCw_8_10"></a><a id="Tc_ayGmYIpjekyof6lz_B_hxA_9_0"></a><a id="Tc_ypt2fDW9s0eI4QZFzk7i6g_10_0"></a><a id="Tc_He3PwQGxGU-b014HOg_CFA_10_8"></a><a id="Tc_QrsLp9ZTaUO9mPWY6nTYEA_10_10"></a><a id="Tc_ly9s4HRogkuRTV5apOJvhQ_11_0"></a><a id="Tc_n8x8KHQBYkeg0rS4mo4rFA_11_8"></a><a id="Tc_ly4t_T2B0UC7P5eZzlPRow_11_10"></a><a id="Tc_znxJ1eExhEausksbHHTXJQ_12_0"></a><a id="Tc_o2X84Ldf4EeYCHNreYnGgA_12_8"></a><a id="Tc_pjkXgMV2mU6ZCgXkCudpaA_12_10"></a><a id="Tc_2HAyHizdRUWB_QSKUVOKnw_13_0"></a><a id="Tc_r0lHNmm6cEehAlDmNb_ZOw_14_0"></a><a id="Tc_E3GfSK4K50aqdsJ2PMnqgg_14_8"></a><a id="Tc_jVMcsioKtkS2YHCV41io_Q_14_10"></a><a id="Tc_6ItsOZT0U0KTTmFKRZLB3w_15_0"></a><a id="Tc_ALRBTJH88ku_Opj2FTvMuw_15_8"></a><a id="Tc_DRvonfLFxUmwRTMCdNU1pA_15_10"></a><a id="Tc_4r4ifPPcQUaY4jkGPtD6-A_16_0"></a><a id="Tc_bcg_LNyzMUeA-fSAxlFNyQ_16_8"></a><a id="Tc_1fg1gprYSUKut-copDEQbg_16_10"></a><a id="Tc_0CPt6OYOO0WlrCMPvoOw5Q_17_0"></a><a id="Tc_iak0VGdMhEirOIegKjIR5w_18_0"></a><a id="Tc_XUMXfZGGeES1SOWkYqgpsA_18_8"></a><a id="Tc_JpoyrBPYD0SDmpHXVQYj6g_18_10"></a><a id="Tc_uBY6QVdBU02SEAXeXpILRQ_19_0"></a><a id="Tc_wcNQtXSkO0aNi93UZTb6TQ_19_8"></a><a id="Tc_SHUyljZ1Y067jlOgtDzJlA_19_10"></a><a id="Tc_2piYtGS6rUWCbjfhULivhw_20_0"></a><a id="Tc_fxXmiMBRLkuYmlJ4rojExA_20_8"></a><a id="Tc_x641Y-s0Ak2_kJtMUzQ4bQ_20_10"></a><a id="Tc_lhHQA-teAUan904z4nkm0Q_21_0"></a><a id="Tc_nKHB1D-Kl0OpdCou0mHZSg_22_0"></a><a id="Tc_nhZsswfFZUCWPZQEINJZ0g_23_0"></a><a id="Tc_IV-7y722skKNxnN23FDVkw_24_0"></a><ix:continuation id="Tb_eLOwzXMN40SaKS77zUBpVg_cont1" continuedAt="Tb_eLOwzXMN40SaKS77zUBpVg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the same board resolution, the 2021 Performance Incentive Plan (the &#8220;2021 Plan&#8221;) was also adopted, under which an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_hl4SM9JGdEip0cnxdAqRJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_B7f4iuj5vE6Jt5BruVCGZQ">2,994,000</ix:nonFraction> ordinary shares shall be reserved for issuance, and the share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_p76MqEtu0ESUlhT30hlMQw" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" scale="-2" id="Narr_M9Ww8zlXsUyrBO7PH5hy-Q">5</ix:nonFraction>% of the total number of the Company&#8217;s outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by the board of directors. From March 12, 2021 to December 22, 2021, pursuant to the 2021 Plan, a total of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_fLrvwshp_kef4yuIOIUV5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ssaJofcsZ0CLp-ge0cb7Vg">1,303,000</ix:nonFraction> share options were granted to certain employees by 15 batches, with exercise price ranging from US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_mYqtV1u_dUOeGU09TxPkwQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_qNIQJ20L20aRmNdWCjWz4g">5.92</ix:nonFraction> to US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qodzJmIask-OtNzB-p7X4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_gsOrC883TEunKfzzIgShUA">17.56</ix:nonFraction>, respectively. In addition, <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_1eP-WkT9Skmw68n0YD2iXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_uFvpBIP4AUO89x4oltU08w">23,734</ix:nonFraction> ordinary shares were issued to certain management personnel on March 16, 2021 pursuant to the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_7_2022_To_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember__79tbn2a-EGdvybT6uk1ww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_9JYeUilXMEqx2hJY_35N6A">2,060,308</ix:nonFraction> share options granted to certain employees were modified. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) 25% of the total number of share options of each grantee (&#8220;Annual Cap&#8221;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#8220;Credited Shares&#8221;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. As a result of the modification, the Company recognized an incremental fair value of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_FuMVl1AODUSWgqaccUaZLw" decimals="0" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" scale="0" id="Narr_Tz3ozw9xhUqjP-9Pt8Yu_Q">2,337,697</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February 7, 2022 to December 27, 2022, pursuant to the 2021 Plan, a total of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_2_7_2022_To_12_27_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_lXgW5nkfeUOQyYVN7MFj6w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_FTSGRVPOaUy75IOEIttnnQ">2,640,598</ix:nonFraction> share options were granted to certain employees, with exercise price ranging from US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_PEIXHzXukUSrP_zBNlrOtA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_8cr7zRgldEaZta5YEj4ddw">0.80</ix:nonFraction> to US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Cc4l6GLQ9UWIXpyBn68CYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_uaB4BYDIe0-DwhUwG_L2Fg">5.60</ix:nonFraction>, respectively. In addition, <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_o7k1J95q30-im7Wsqr0zgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_kpLKKzMu6UmVCl3E55QuVA">99,999</ix:nonFraction> ordinary shares were issued to certain management personnel on March 8, 2022 pursuant to the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2022, among all the share options granted to date, <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_sTKKUtyqS0eFI2J-zEunNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_sHAVyuBNXkKGwaCzKpWcRg">2,483,808</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_cp16D7zq-k6IluFfoJ6iCg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_KyyQNIxkCEm2_zWYm_8CpQ">4,776,906</ix:nonFraction> share options contained both service conditions and performance conditions, respectively. All other share options granted contain only service conditions.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_D2ouv3Ric0GWnvJk0hAexg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_gmXc0JL0Vk2CRRfCOI1TAw_9_2">866,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_QVDuGGoN0E6L6AdTYWRTDQ_9_4">0.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_PM7MolKgR0uAFa0xMEVVCA_9_6">3.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_EMWaJe9pw0yONDIyRxQ1EQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_pZbL-Bv2J0KL6UqREMU4DQ_9_8"><span style="font-size:10pt;"> 7.27</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_3coMph1zIUSnPEdw8RxPmg_9_10">6,328,171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_KY9jtXnVfk2Eaq9EsBqppw_10_2">6,313,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9X0ruNO17ki1iVD8UCggOg_10_4">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_GFetRWR52Em_VoyenyWrZw_10_6">7.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_MmaFath0_02K5ba0PG8Biw_11_2">3,694,934</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_oK5MXcLhX0m5gcQj6ednIA_11_4">1.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="Tc_BNiRNwq3iUCT1rBFpbnqpA_11_6">6.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_cOiNUzP4JEqokfupTEnFlw_12_2">190,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_FTXniDpPrUeRmf58XfCRlA_12_4">1.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_Ior7fE08rEWqLODYitzwVg_12_6">6.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_N8UUfA-450WXcwY72vEaIA_13_2">3,294,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_CMhu2H4Ez0KUEgEK4VFmyg_13_4">1.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_2NJcYSFhmUiIFSmE8qYEog_13_6">6.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_eVY5BDVctUiTrKzoBKK1Ug_13_8"><span style="font-size:10pt;"> 8.78</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_pyeGKLmTlUWJ5260Jr3g9Q_13_10">33,410,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_DgbU7uKIHE6QMzFjqpTR1g_14_2">1,894,119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_iwxRGcgbv0eTIPgPdpgqdQ_14_4">12.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_xxWi4iq-PkOyFFEwMupcdQ_14_6">8.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_OVj8PvQhyEWThbRmfVK14Q_15_2">233,958</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_CIPHo8TQUUWE5SQCwvCWgw_15_4">0.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="Tc_sPPDoF4HJkqujY7aDnOvQg_15_6">5.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_Htwrk91_GUmV_a4yXK7sNQ_16_2">145,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_0gRfQxev6kq_4dm0yFemnQ_16_4">3.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_2KFeedhHykSZDhihT2d69A_16_6">7.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_VW0jxX3lzUyRgkbYqPQkEQ_17_2">4,809,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_TXxt5JE5UUmQl2BjhmfG8g_17_4">5.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_xjhsvc9Yq0GadiaSrjYAQQ_17_6">7.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_M6vi5gMdpkqV8cWrmBjGrw_17_8"><span style="font-size:10pt;"> 8.68</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_HmK7GTgsEUyYY_--B8CHuw_17_10">2,619,574</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_bMYFvAOeMUacS-wjz9gmyg_18_2">2,640,598</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_NJm8rQSuTEC0gkdHerc6JA_18_4">3.28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_rnG6PKQjUUunvtdfjJIWOg_18_6">2.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc__pwrftRXPk-H7ajUpqhx5Q_19_2">197,975</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_xgv7C9B4IUKnZ3AD0jOXfA_19_4">2.08</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="Tc__-1uYsCIi0yjkJGneQfR2Q_19_6">6.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_F2TJjy0as02ECEhgcyRsOQ_20_2">964,789</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_sQQPg-9U_02U2ayGQ4Yg9Q_20_4">6.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_xLEYyZIWN06QlUUplU5atw_20_6">7.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_jNh7c-Fa2kyMRJi4jxXr-w_21_2">6,286,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_IUq1S6PhIUeVfC1lex2RNA_21_4">4.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_VKz2Cpmg60-MNxfnk9VYJA_21_6">5.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_D3dhzrJCKkCmPH2WnhtYXQ_21_8"><span style="font-size:10pt;"> 8.44</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_dUVF5OdOF0-WKUF8yYTpqA_21_10">94,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_HKs310u5vUuOcv9NCy6D3g_22_2">6,286,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_loFCerBjykOC41bxySQxzA_22_4">4.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" scale="0" id="Tc_WGtVysdpQ0adkDU9mKkl_g_22_6">5.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_WF7lFLAyRkCGUtFQgJK_Pg_22_8"><span style="font-size:10pt;"> 8.44</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="Tc_TGE4fQw6UE2LOF-Y_Og1SQ_22_10">94,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_VQ1TTF2xXki99JqrkkTQmA_23_2">1,486,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_EZEwuT-U4Em9a_bb9nJV0w_23_4">5.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="Tc_TfSJk5vJq0OIjKMSgje2Iw_23_6">7.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_NxuGb_BqEU-VP0KwbklJqQ_23_8"><span style="font-size:10pt;"> 8.20</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_9xewROXI7UmaoPDAuFEUbg_23_10">874,180</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_CIizPFgC70yCNXnRRq9spA_24_2">2,070,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_hkGltAc3dEyJnx88hYG3GQ_24_4">6.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="Tc_AChZ3WEXfEyvsYYmz_Hp3A_24_6">6.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_2O47MqB41ES_fATD7N6vqQ_24_8"><span style="font-size:10pt;"> 7.62</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_VTdqrCXCpku7Tw1BYv6l7g_24_10">55,880</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-0pko16x_k-sVHlC5BmYcw_1_2"></a><a id="Tc_a5xX3Lp4tkmbLE2Gk5ItHA_2_2"></a><a id="Tc_K0tOK0DZy0SwnBJLYn6lJw_3_2"></a><a id="Tc_41vGHKLXMkK5Py2gvXjznw_3_4"></a><a id="Tc_gjRrtgDGpU2_hlZ37r-plA_3_6"></a><a id="Tc_l565mMPrhkW8nW9aXJGf9Q_4_0"></a><a id="Tc_qE7F5yI4wkeTmFTBpVnEhg_4_2"></a><a id="Tc_lmzfMyn8AUqkBT8CVFBfRg_4_4"></a><a id="Tc_DO1HYDQUwkirLTxz_tGEww_4_6"></a><a id="Tc_2C8sFkm_6U20IyO2YgSDRA_5_0"></a><a id="Tc_HOkaHKurekKCqYUS4P0y4g_6_0"></a><a id="Tc_GN-m9kTRAUqk4SRZyYECpw_6_2"></a><a id="Tc_OiCavSqHAECRV_zKR21Dkw_6_4"></a><a id="Tc_VKMs6h8CQEKyV4GMyl9UuQ_6_6"></a><a id="Tc_TcQYzMpLjkiz1LQJFL4zKw_7_0"></a><a id="Tc_mLWIVEpRSk2d3WLjdl4aSA_7_2"></a><a id="Tc_BThiCVDz-EqABIM3LsKfgg_7_4"></a><a id="Tc_jNdGjBF7cUurLPy-KkokCA_7_6"></a><a id="Tc_EKpMhcD1cUeOs5pPPVvfVw_8_0"></a><a id="Tc_8g5k-YTdd0uiLW0brdD9sw_1_2"></a><a id="Tc_S3EoRWxYlUu3yv9-M-SwBw_2_2"></a><a id="Tc_BfFXtt09_UCB6WCExpEt_g_2_4"></a><a id="Tc_tK-Fhlny-k-_YhCoaTSw0A_2_6"></a><a id="Tc_h6telsMaU0aoSvHHSJsrOA_3_2"></a><a id="Tc_zmjjPeiThE6qgBT8M0Jhkw_3_4"></a><a id="Tc_q3voVAOZUk6EL5qp1PdjWA_3_6"></a><a id="Tc_K2FYUOp3NUaZwD_eHinNMA_4_0"></a><a id="Tc_Ju2BGAp-bkOY5CtzJLGITQ_5_0"></a><a id="Tc_judlgAi-FESP-9doqg8zwg_6_0"></a><ix:continuation id="Tb_eLOwzXMN40SaKS77zUBpVg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate fair value of the equity awards vested during the&#160;years ended December&#160;31, 2020, 2021, and 2022 was US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_uN_zkf4SnU-_QdEONasakg">8,430,085</ix:nonFraction>, US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_pQisboXEIEGfJlJXaDEb4g">13,833,856</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_aFXdE_F7AkazU7pR9oC_MQ">11,929,903</ix:nonFraction>, respectively. As of December&#160;31, 2022, the total unrecognized employee share-based compensation expense was US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_keYlEQYlskG7ZvGL0F7Frg">23,635,444</ix:nonFraction>, all of which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_cjcEfI07_kG4Sjuelz-wAA">2.20</ix:nonNumeric>&#160;years as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fair value of share options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The assumptions used to estimate the fair value of the share options granted were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_HP_j78j0S02WMTqpyhw0Ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_x7sFslLuLU-Hkz6EcppOKQ">0.68</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_Zrl-SAKjwkmVS826cZoabg">0.83</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_a6LspgPqQkCDK0-aVfVzHg">1.11</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_ksyN9_vx9UyAAi9hfVvKlw">1.67</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_9SHGDZIYq0-2HSFwH2KRdg">1.92</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_dXOlcPZPU0S_JK_gQcFX-Q">4.25</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_hqN5MrYH_E2oSKi2zXt9VA_5_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_uULxVvRy2E6W2ciN0kEgHw_5_4">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_QKitKTAb00yW9TGi6nTCsQ_5_6">0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_wLXW2_PdNkOHCgsNNC_Qmw">72.3</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_ypGu9osdmUWtDdrBkKbzwQ">73.4</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_yoOPQXp3zkezPirsBrUjxg">73.1</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_J81XneodV0atfpq_xpIOUg">75.5</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_nOUf0Izgck-Kp5xexHSiNA">74.2</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_CirebvrJj0ur29RM4j4NOg">74.9</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" scale="0" id="Narr_tKHfqzAaWU-mM5u2IxUPaQ">2.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" scale="0" id="Narr_l6u-pfwZ0kS4tMrE6JWE-w">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" scale="0" id="Narr_mGT053lPlEKtn5-kmILdSw">2.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" scale="0" id="Narr_kOjItlcIx0OKY2ti6QHK2A">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" scale="0" id="Narr_MPvZx-lnXkKq62ibcCQdKQ">2.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" scale="0" id="Narr_Y1EJtQD9kkyVAIEAC1TjPQ">2.8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_dKILBlbsj0mzlz2gfb1FAQ_8_2"><span style="font-size:10pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_IecdsQhOp0KDmo7tTcDBhg_8_4"><span style="font-size:10pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_OJyZJ7BIhU-uUi9N5tVLmA_8_6"><span style="font-size:10pt;">10 years</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Total share-based compensation expenses recognized for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_KQs2OLZ7F0aB-sVyBe4pTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ER1dY2hYkkebuGSCOwJV8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_gnL0erHiu0CPXWSpFa8GMg_4_2">6,472,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XApzz6RZb0COodakWjZlyQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_WT11oTFvXU-TuUKCZGTrNw_4_4">13,582,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KuH9w-ji8E6oP8LOHD8eoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_fN49D-DHCUSbO68iVaiIdw_4_6">7,227,298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9u6PsJmRs0uWqcLpDwttXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_mQBYJBLbyESxvCMlaX21XA_5_2">3,657,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kkEXFXNRGUij0o1EOEbICA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_OVsFh-Bl_UGfnwh83rQ6qg_5_4">5,096,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DQhBNix_zU24lt2mhsh67Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_I91l48nCN066BDQfTubAgw_5_6">3,292,984</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total share&#8209;based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_kw4UBb3V-UGhdYclGBCdpw_6_2">10,129,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_YEiWyFrbCEGfuvzKStDwZw_6_4">18,679,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_mT_pAauQO0GpGZZwJv4ymQ_6_6">10,520,282</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_ySDHHMj5-UmN3GwJmkWh2Q" continuedAt="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10. COLLABORATION ARRANGEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, the Group entered into (i)&#160;a collaboration agreement (the &#8220;Sanjin Greater China Agreement&#8221;) that covers Greater China with Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. (&#8220;Sanjin&#8221;) and certain of its subsidiaries (collectively, &#8220;Sanjin Parties&#8221;) and (ii)&#160;a collaboration agreement (the &#8220;Sanjin ROW Agreement,&#8221; together with the Sanjin Greater China Agreement, the &#8220;2018 Sanjin Agreements&#8221;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the &#8220;PD-L1 Project&#8221;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#8217; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group (i)&#160;single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit&#160;percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_tTZstbN-BUm8IILyqOZ0MA">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_OsxVmO242Uenpox7kLDMFw">1,511,168</ix:nonFraction>) upfront fee upon the effectiveness of the agreement from Sanjin Parties, which was recognized as revenue in 2018. No revenue related to this agreement has been recognized in any of the years presented in the accompanying financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Sanjin&#8217;s affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expect to receive from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in the Group&#8217;s notice to Sanjin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the <ix:nonNumeric contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg" format="ixt-sec:durwordsen" name="adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" id="Narr_-kTensWrlEK9VHkowiEd5Q">three-year</ix:nonNumeric> period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#8217;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the 2018 Sanjin Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Sanjin has the right to claim back all the payment made to the Group. The Group considers the possibility of occurrence of such event is remote.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont1" continuedAt="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Group entered into (i)&#160;a collaboration agreement that covers Greater China (the &#8220;Dragon Boat Greater China Agreement&#8221;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#8220;Dragon Boat ROW Agreement,&#8221; together with the Dragon Boat Greater China Agreement, the &#8220;2019 Dragon Boat Agreements&#8221;), with Dragon Boat Biopharmaceutical (Shanghai) Limited (&#8220;Dragon Boat&#8221;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the &#8220;Specified Project&#8221;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#8217;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&#160;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug (&#8220;IND&#8221;) approval in PRC and completion of clinical phase I test in PRC) and (ii)&#160;a single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2019 Dragon Boat Agreements, the Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_Y1LEBiLCsUiXix5-VE8rGQ" format="ixt-sec:durwordsen" name="adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" id="Narr_C7ItNLD8DUG51XKtERJJUA">three-year</ix:nonNumeric> period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#8217;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Dragon Boat has the right to claim back all the payment made to the Group. The risk of failure is considered remote upon recognition of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2019, <ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_ydcSvQ_MrUWX4ODW9D_Low" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_XhU6IQTKVk-u2zvRXbaXJA">no</ix:nonFraction> revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont2" continuedAt="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, upfront fee of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_80zcx-OHFkad9LIMU0xM8A">4,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_naGUoo3VDkSbfWvPu7Z_pQ">573,378</ix:nonFraction>) that was received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance obligation had not been satisfied by the Group and <ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_7LA0b5MKXkShuU6m70I2Ag">no</ix:nonFraction> revenue was recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, milestone fee of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementMilestonePaymentReceived" scale="0" id="Narr_GFlJveUpNUiMggwkiRnxaw">4,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementMilestonePaymentReceived" scale="0" id="Narr_-_HDyMDIJ0SYXTs6F_p2dg">620,011</ix:nonFraction>) was received related to the launch of pre-clinical safety evaluation animal test and the receipt of IND approval in PRC. For the year ended December 31, 2021, a total of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_oJfk2nCFp0S7zM59DWy_9w">8,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_CVsfAwAy7kyYspd5qAos4w">1,240,022</ix:nonFraction>), including the aforementioned upfront fee and milestone fee were recognized as licensing revenue in the consolidated statement of comprehensive loss as the performance obligation was satisfied by the Group and certain milestone events were achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_Y1LEBiLCsUiXix5-VE8rGQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_QKYP2Lp6IEixtB5IfX6OOQ">No</ix:nonFraction> additional revenue was recognized for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics&#160;SA License and Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2019, the Group entered into a material transfer and collaboration agreement (the &#8220;ADCT Collaboration Agreement&#8221;) and a license agreement (the &#8220;ADCT License Agreement&#8221;) with ADC Therapeutics&#160;SA (&#8220;ADC Therapeutics&#8221;). These two agreements are combined as a single contract as the agreements were negotiated as a package with a single commercial objective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to <ix:nonFraction unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA" contextRef="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AVPy-5gte0WCo8vAl_mD9Q" decimals="0" format="ixt-sec:numwordsen" name="adag:MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" scale="0" id="Narr_KNdQhfvCTU6Ty4VAI_ILLg">two</ix:nonFraction> exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group&#8217;s technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group&#8217;s exclusivity obligations, upon achievement of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics&#8217; election to proceed with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug" format="ixt-sec:durwordsen" name="adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" id="Narr_XbwSRREPy0uxoOu1hEI9rg">thirty days</ix:nonNumeric>&#8217; prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#8217;s uncured material breach of the agreement or the other party&#8217;s insolvency-related events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group also granted ADC Therapeutics an exclusive target reservation right for <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug" format="ixt-sec:durwordsen" name="adag:PeriodForReservationOfTargetRight" id="Narr_cB3YMjb7-EWuQ5A8QtCt3g">one year</ix:nonNumeric> from the commencement of the agreement and an option to renewal for another&#160;year with a consideration of low-six-figure dollar amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by the Group under these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit&#160;percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont3" continuedAt="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug" format="ixt-sec:durwordsen" name="adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" id="Narr_x-qQc3iGnk2NKNmwNE-n-A">thirty days</ix:nonNumeric>&#8217; written notice to the Group, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#8217;s uncured material breach or insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2020, the Group recognized US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_BH3baoGYjECWp2ep1hunvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_e61Osxmly0Wzl8I2xeBOhw">225,000</ix:nonFraction> of licensing revenue upon delivery of such results. For the year ended December&#160;31, 2020, the Group recognized US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_BH3baoGYjECWp2ep1hunvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="0" id="Narr_Qd35a72O5EWDLyu3E2ngwQ">100,000</ix:nonFraction> as other income due to the expiration of exclusive target reservation right, which is not related to the Group&#8217;s major operation activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Group recognized US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_3qRSyDBk-U6_JWTPepBfbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_h9hZ2tCqJ0GbxCYrpa3ObA">225,000</ix:nonFraction> of licensing revenue upon delivery of additional research results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the Group did not recognize additional revenue associated with the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ADCT Material Transfer and Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Group entered into a material transfer and option agreement (the &quot;ADCT Material Transfer and Option Agreement&quot;) with ADCT. Under the agreement, Adagene agreed to provide antibodies or antibody sequences to ADCT to conduct further development for a non-refundable fee of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_8_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_WFeE0wneck-MydNDO4uWyw" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceivable" scale="0" id="Narr_F-Lr9MvrAkCQ4FncGCHapg">300,000</ix:nonFraction>. ADCT has an exclusive option to negotiate a separate license agreement with the Group, however, there is no requirement for either party to enter into such a license agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the Group recognized revenue of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_VsC-jPAYAUqbiloJ81rslQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_DRfF9Har0EWxcUinIQIfgg">300,000</ix:nonFraction>, which was received in October 2022, upon delivery of the sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exelixis, Inc. Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Group entered into a collaboration and license agreement (the &#8220;Exelixis Agreement&#8221;) with Exelixis, Inc. (&#8220;Exelixis&#8221;), pursuant to which the Group agreed to generate masked antibodies with its SAFEbody technology against an initial target selected and a second target to be selected by Exelixis. The Group will generate masked antibodies in the form of alternative compounds in accordance with the program plan for each target at its own cost and deliver the related data packages to Exelixis. Exelixis will select lead compounds (the &#8220;Lead Compounds&#8221;) to further develop, obtain regulatory approval and commercialize product(s) for each target (the &#8220;Products under the Exelixis Agreement&#8221;). Under the Exelixis Agreement, the Group will also grant Exelixis an exclusive, worldwide, sublicensable license (the &#8220;Adagene License&#8221;) upon delivery of the data package to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group with respect to both targets. Exelixis will own the inventions relating to the Lead Compounds arising in connection with the Exelixis Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exelixis Agreement will remain effective until the expiration of the defined royalty terms of the Products under the Exelixis Agreement, unless terminated by either party. Exelixis may terminate the Exelixis Agreement for any or no reason, in its entirety or on a target-by-target basis. Any payment received by the Group before the termination shall be non-refundable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Exelixis Agreement, Exelixis agreed to pay the Group an upfront non-refundable fee of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceivable" scale="0" id="Narr_USr4dyYQgEyfnwJuAZBScQ">11,000,000</ix:nonFraction>. For each target, the Group will be eligible to receive up to US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA" decimals="0" format="ixt:numdotdecimal" name="adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" scale="0" id="Narr_1zU83P0vIUOJsd8CA9AbRQ">127,500,000</ix:nonFraction> of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA" decimals="0" format="ixt:numdotdecimal" name="adag:MilestonePaymentsReceivableSalesBasedMilestones" scale="0" id="Narr_DEm3qgkgaUKh8bax3a7mgw">262,500,000</ix:nonFraction> of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Exelixis Agreement worldwide, subject to certain reductions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Group entered in a letter agreement (the &quot;Exelixis Letter Agreement&quot;) in reference to the Exelixis Agreement with Exelixis for expanded collaboration in SAFEbody discovery. Under the Exelixis Letter Agreement, the Group will generate additional masked antibodies against the target selected by Exelixis per the Exelixis Agreement. Exelixis agreed to pay the Group an additional upfront non-refundable fee of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_4_30_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ay_6hRJo4U6yLXVvpTOGEQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceivable" scale="0" id="Narr_j6NZejSryEGkW_RPWe9-8A">1,100,000</ix:nonFraction>.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont4" continuedAt="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determined that generating masked antibodies with its SAFEbody technology is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Exelixis Agreement, the delivery of data packages for each target, along with the Adagene License used to develop the related compounds, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations using the relative standalone selling price method. The Group records revenue at a point in time, when the data packages for each target were delivered to Exelixis. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the Adagene License granted are recognized when (or as) the later of (1) the subsequent sale or usage occurs, or (2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Group received US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_rvKTnfEkyUSop_lAg3fNuw" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_34SM4PPoP06lP2k-XXM6CA">11,000,000</ix:nonFraction> upfront payment and<span style="font-size:11pt;"> </span>recorded accounts receivable of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_CH2MGlfLkEa-Mm5SY3caCw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Narr_uRakZG01gE-6RbFWx7a6pQ">3,000,000</ix:nonFraction> milestone payment, which corresponds to the successful nomination of lead SAFEbody candidates for the initial target under the Exelixis Agreement. The milestone payment was subsequently received in January 2022. For the year ended December 31, 2021, US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_rvKTnfEkyUSop_lAg3fNuw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_udjbpt_m-E-DT_AZBZF_5g">8,500,000</ix:nonFraction> was recognized as revenue upon delivery of data packages for the initial target and achievement of the milestone event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the Group received US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_jfKRlHoZrkOzsx-d3nM1UQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_mRv1XN9R4Em_NMSzs0QKWA">1,100,000</ix:nonFraction> upfront payment under the Exelixis Letter Agreement. <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_jfKRlHoZrkOzsx-d3nM1UQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_VP4Y1vBwL0aONK3SL2SaeA">No</ix:nonFraction> additional revenue was recognized as relevant performance obligation has yet to be fully satisfied under either the Exelixis Agreement or the Exelixis Letter Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sanofi Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Group entered into a collaboration and license agreement (the &#8220;Sanofi Agreement&#8221;) with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (&#8220;Sanofi&#8221;), pursuant to which the Group agreed to perform early-stage research activities to develop masked versions of Sanofi candidate antibodies (each a &#8220;Target&#8221;, and together, &#8220;Targets&#8221;), using Adagene&#8217;s SAFEbody technology for development and commercialization by Sanofi. Sanofi has the ability to advance two initial Targets in the collaboration, followed by an option for two additional Targets. The Group will generate masked antibodies in the form of customized compounds and complete the compound research activities in accordance with the program plan for each Target at its own cost and deliver the compounds and related data packages to Sanofi. Sanofi is solely responsible for later stage research and all clinical, product development and commercialization activities. Under the Sanofi Agreement, the Group granted Sanofi an exclusive, worldwide, sublicensable license to research, develop, use, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Sanofi Agreement will remain effective until the expiration of the defined royalty on a product-by-product and country-by-country basis, unless terminated earlier with cause or by mutual agreements of both parties. Sanofi may terminate the Sanofi Agreement without cause, in its entirety, or on a Target-by-Target or country-by-country basis.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ySDHHMj5-UmN3GwJmkWh2Q_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Sanofi Agreement, Sanofi agreed to pay the Group an upfront non-refundable fee of US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_MSt1DxwXfUKQtc262Vnbaw" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_m1otLnc-PUWFq-rZKqw11w">17,500,000</ix:nonFraction> in consideration of the license granted and the early-stage research activities to generate the compounds. Sanofi is obligated to pay an additional fee if Sanofi exercises the option for additional Targets. For each Target, the Group will be eligible to receive up to US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_aR_5qQM_PUCejdDJoX8SrQ" decimals="0" format="ixt:numdotdecimal" name="adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" scale="0" id="Narr_9kZeIxxd1k-s-wXrjJnzbA">173,500,000</ix:nonFraction> of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_aR_5qQM_PUCejdDJoX8SrQ" decimals="0" format="ixt:numdotdecimal" name="adag:MilestonePaymentsReceivableSalesBasedMilestones" scale="0" id="Narr__KUxYwygfka5fkEN9KqV4A">450,000,000</ix:nonFraction> of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Sanofi Agreement worldwide, subject to certain reductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group then determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Sanofi Agreement, the performance of early-stage research activities to develop compounds for each Target, along with the grant of the license, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations based on the relative standalone selling price. Since the early-stage research activities does not generate an asset for alternative use and the Group has an enforceable right to the upfront payment, the Group records revenue over time using labor hour as the input to assess the satisfaction of the performance obligations. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the license granted are recognized when (or as) the later of (1) the subsequent sale or usage occurs, or (2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the year ended December 31, 2022, the Group received US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_zebDcdEQ3kW1LZbwJkj0Dw" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_Kfv0VigL00K4pqicA1KDcg">17,500,000</ix:nonFraction> upfront payment under the Sanofi Agreement. For the year ended December 31, 2022, US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_zebDcdEQ3kW1LZbwJkj0Dw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_0le1RdjBBUWxmx_ovFRxcw">8,992,724</ix:nonFraction> was recognized as revenue over time using the input method.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_D3W6tX_8KkqaQRYp82eReA" continuedAt="Tb_D3W6tX_8KkqaQRYp82eReA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">11. INCOME TAX EXPENSE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">PRC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective from January&#160;1, 2008, the PRC&#8217;s statutory, Enterprise Income Tax (&#8220;EIT&#8221;) rate is <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_9BXgsqEAak6neZEeIkuLdQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_9r_Nd8jJ4UWedHommtRpJw">25</ix:nonFraction>%. In accordance with the implementation rules&#160;of EIT Law, a qualified &#8220;Technology Advanced Service Enterprises&#8221; (&#8220;TASE&#8221;) is eligible for a preferential tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_b2-6zipvrUqdvncotPk1BQ" decimals="2" format="ixt:numdotdecimal" name="adag:PreferentialIncomeTaxRate" scale="-2" id="Narr_TZfOn87zHkaQu1xT2ozueg">15</ix:nonFraction>%. The TASE certificate is effective for <ix:nonNumeric contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_b2-6zipvrUqdvncotPk1BQ" format="ixt-sec:durwordsen" name="adag:EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" id="Narr_hH6Z9fdY2UOsA-ZvB94Qng">three years</ix:nonNumeric>. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every&#160;year. Dividends by PRC entities, to non-PRC resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CN_4etyAVb-kUilTpUBQYyO4Q" decimals="INF" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_bxSPVyyEPEu0K5EyPt3wDQ">10</ix:nonFraction>% EIT, namely withholding tax, unless the respective non-PRC resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Suzhou) Limited was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and November 2021. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_avqczjeiakGTBo6mGn9tGg" decimals="2" format="ixt:numdotdecimal" name="adag:PreferentialIncomeTaxRate" scale="-2" id="Narr_t4NwDpr7M0KApQPBzD2RHg">15</ix:nonFraction>% from 2015 to at least 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cayman Islands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&#160;Inc. is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_q-33VdxI8Ue44xf78M0a1g_1_2"></a><a id="Tc_wdZ5eHSQBkuOG9hQHPP93A_2_2"></a><a id="Tc_3FAmN8LFaEqhXLGLaKSVAQ_2_4"></a><a id="Tc_IovOePOW4k-kosOEh1CyOw_2_6"></a><a id="Tc_0zOTllGE4EWgESaxwH21Jg_3_2"></a><a id="Tc_YKTUBsQeeESNl9-vU4J4Qg_3_4"></a><a id="Tc_hQrMWYCnZ06DXb4CF06TVg_3_6"></a><a id="Tc_nRAtfb6SmUm0hqTHgM49tg_4_0"></a><a id="Tc_-_BO4WliDEinSyjDQdu3CQ_5_0"></a><a id="Tc_wZGBtN1eDEuttmHrBF7_EQ_6_0"></a><a id="Tc_qvKsIhs930SqxJgJAf_ZZw_6_2"></a><a id="Tc_-pOCU5Trf0ePy3jcxHtlkw_7_0"></a><a id="Tc_IppftBBIIE2iY4BSi1PcEQ_7_2"></a><a id="Tc_FZmnfyLhCE2MB3Vwyy38Uw_8_0"></a><a id="Tc_zcoJnA2XpUqGRELY9Z7GWA_8_2"></a><a id="Tc_m1p4CPX62kiLO7CQM9zMKg_9_0"></a><a id="Tc_CMes3vnjzkuT0NxAw7BbVQ_10_0"></a><a id="Tc_SBKG4mYUpkiamnjnYXA4_Q_11_0"></a><a id="Tc_NqAnh0NTY0qKYIxkFM5pow_11_2"></a><a id="Tc_R1Zx-IV780OoMgANyvV1IA_12_0"></a><a id="Tc_OKsM8lifcUCQKhCmqhduxQ_12_2"></a><a id="Tc_baQtiCH90kavbZ5Pgcs5Tw_13_0"></a><a id="Tc_OFdapmGPPEqgRFf2VJPlPw_13_2"></a><a id="Tc_VXHLnQ_koEueyeMqa4oNxA_14_0"></a><a id="Tc_4YPRSzYx8EuyOGv4i7EAvA_14_2"></a><ix:continuation id="Tb_D3W6tX_8KkqaQRYp82eReA_cont1" continuedAt="Tb_D3W6tX_8KkqaQRYp82eReA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_X7h_82d2c0KzwUudQtykwA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_qu9T49kkXkGJ8jyDru20sA"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_FibIWHTvR0OvdHAkZv3YsA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_s9KOShcZW0KvWQP3Orv7fA">16.5</ix:nonFraction></ix:nonFraction>%. For the&#160;years ended December&#160;31, 2020, 2021 and 2022, Adagene (Hong Kong) Limited did <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_a1oYWpJoW026Q5lt5DP2dQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_vs1OX_1cMEy2evt8cnH6mw"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_DZY2VoRVfUyY29viuxBhrQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_5ETtAjpzkUebBAbdZSz8Kg"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_7v2coKKIyUmDdlmU0Olo6A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_gZKro3q__kSauIskyMMtnQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t make any provisions for Hong Kong profit tax as there were <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_a1oYWpJoW026Q5lt5DP2dQ" decimals="0" format="ixt-sec:numwordsen" name="adag:AssessableProfits" scale="0" id="Narr_l413yuGt7kGBmGs-O5I-yg"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_DZY2VoRVfUyY29viuxBhrQ" decimals="0" format="ixt-sec:numwordsen" name="adag:AssessableProfits" scale="0" id="Narr_Yui87O4YR0WBQiJzqQ21cg">no</ix:nonFraction></ix:nonFraction> assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_ee_5WiU0cUurw-SNNKSXuQ" decimals="0" format="ixt-sec:numwordsen" name="adag:WithholdingIncomeTaxes" scale="0" id="Narr_spmar6fZLEGAlEmeQo9hwg">no</ix:nonFraction> withholding taxes in Hong Kong on remittance of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Australia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Australia Pty&#160;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AU_c4N8MZWDzESe5gDU2Tk-5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_Pu11HQSe30m33rwI-UFWZA">30</ix:nonFraction>%. Adagene Australia Pty&#160;Ltd. has <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_aTNTT8uQeEK_xzzYuJc0jQ" decimals="0" format="ixt-sec:numwordsen" name="adag:TaxableIncome" scale="0" id="Narr_nWOZw8ktH0eySUuTCXTk8Q"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_wbQEbLCaH0CT2Hi48HK61Q" decimals="0" format="ixt-sec:numwordsen" name="adag:TaxableIncome" scale="0" id="Narr_9KRGjIsnn0KmC2AOq61Adw"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_xlZey60WBUuy5XYgHHijLw" decimals="0" format="ixt-sec:numwordsen" name="adag:TaxableIncome" scale="0" id="Narr_Y14QQ-Wv5k2wnPu2WgAtWg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> taxable income for all periods presented, therefore, <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_aTNTT8uQeEK_xzzYuJc0jQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_mSRPvpGtsEWoy6iX7aq0fg"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_wbQEbLCaH0CT2Hi48HK61Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_qgClhaCR_0Cq-okLitcaUQ"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_xlZey60WBUuy5XYgHHijLw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_UtMPITtVyUCe3krAAp7Jbg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income taxes is required. Dividends payable by an Australian entity, to non-Australian resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AU_c4N8MZWDzESe5gDU2Tk-5A" decimals="2" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_rFYJWiw6Sk2sW7_ofGwF1w">30</ix:nonFraction>% withholding tax, unless the respective non-Australian resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Australia that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_E-IfTqEmFkC8P1gI378n2w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" id="Narr_ST73msUaRESDDksr5Hbj7Q">21</ix:nonFraction>%. Adagene Incorporated is also subject to state income tax in California of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_stpr_CA_J0BfSQ8UxU6Mwv9l4cdG6Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" id="Narr_i70Ovoksa0eZURMSMLYeow">8.84</ix:nonFraction>%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_E-IfTqEmFkC8P1gI378n2w" decimals="2" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_lKm0SugICEyRhfHzXy_0ew">30</ix:nonFraction>% withholding tax, unless the respective non-U.S. resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene AG is incorporated in Switzerland and is subject to federal corporate income tax at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CH_otva1hRmgEGFbXAakLJRqg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_V-jpgkalAEWasL28rTKSZA">8.5</ix:nonFraction>%. Adagene AG is also subject to cantonal income tax of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_3KyS7h9LmU6xtV1jimeGaA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_AHtW-58yfEeS7RkdehY48A">6.5</ix:nonFraction>% as well as capital tax of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_3KyS7h9LmU6xtV1jimeGaA" decimals="3" format="ixt:numdotdecimal" name="adag:CapitalTaxRatePercentage" scale="-2" id="Narr_v2AOH-NtM0SVJcbrtNXOeQ">0.1</ix:nonFraction>% in the Canton of Basel subject to certain tax benefits and relief. Dividends payable by a Swiss entity, to non-Swiss resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CH_otva1hRmgEGFbXAakLJRqg" decimals="2" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_YVWX4y1olEibtwn5rBZU-g">35</ix:nonFraction>% withholding tax, unless the respective non-Swiss resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Switzerland that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Income tax expense (benefit) of the Group for the years ended December 31, 2020, 2021 and 2022 were composed of the following current and deferred amounts:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_bxBvE6lY1E6MGmS23Naj6g" continuedAt="Tb_bxBvE6lY1E6MGmS23Naj6g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Tc_H11Do2ptVkO-GzHGq_Mz-Q_6_4">1,290,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Tc_H_Hoh7LjRUGzmCqL0DFkFg_6_6">672,064</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="Tc_tXjLgTWzq0SpitbBV-RzTQ_7_4">367,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" sign="-" scale="0" id="Tc_pFTHJ0OuPk2BepgIf2COFA_7_6">168,846</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="Tc_zUEIaf8zhUWTmn7Skv0sjg_8_4">1,657,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="Tc_inqYHOSX0UKHLRvad6hd_A_8_6">503,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="Tc_DGjgrEb7dU-EbvBf5lKiig_11_4">96,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_qj6jIi6GEkWh9s3Fs4Rw3A_11_6">96,804</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_Y2q8Tl0DbE6n1MZfCA_Otg_12_4">52,641</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" id="Tc_GQN4NkBHA06Oz_G30Ou-_g_12_6">52,641</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="Tc_KGtl3p7wz0KmSdkkI6eBwQ_13_4">44,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_XyVTnW7VpEiHlRFn3HOiLw_13_6">44,163</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_ZLtEFAOqtEC3sWH-qc0_aw_14_4">1,701,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_dt75h1fnzkmFoRszHT_z_Q_14_6">459,055</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_f0b33bdf_7ca9_42fa_9bc7_34ce797ede61"></a><a id="Tc_u5EdrlwL3kWvW57MgeUSxA_1_2"></a><a id="Tc_PTj1JmXiyUWhEoF7fZfCHA_2_2"></a><a id="Tc_JyAcbcGlwk6QVXHsZOoiuw_2_4"></a><a id="Tc_GSMWppJdU0qV1QSoSgNM8w_2_6"></a><a id="Tc_FlBvHXODVU-iVVDw50sX_A_3_2"></a><a id="Tc_cedZtmMvKUmYoyls1ju-RA_3_4"></a><a id="Tc_yf1gerVbyUeMEePOlZAAHg_3_6"></a><a id="Tc_Fqf_9L08DUeifpWigHl-yQ_4_0"></a><a id="Tc_dc-1xXzR7USlElEbefJVNQ_5_0"></a><a id="Tc_lTJgxPTHqEW6M_PABcOYgg_5_3"></a><a id="Tc_INLiA10jHku2aTGa3kPe5A_5_5"></a><a id="Tc_NhYQhl15PUCMgaL7jpH3-A_5_7"></a><a id="Tc_058dHll130yCn05ifbb_pg_6_0"></a><a id="Tc_bbqnZ6WvLkuo2iwCjmH1vQ_7_0"></a><a id="Tc_vyBD5DHyPU6sp5LuWSxXsQ_8_0"></a><a id="Tc_IdSNuvst8EG1HjLnjw8jqw_9_0"></a><a id="Tc_oVZdq22mjEqRuLnyKaYXXw_10_0"></a><a id="Tc_LnRFDmWLk02tTAwUgNNBKg_10_2"></a><a id="Tc_4KRZyMpBO0S_s074oif8Wg_10_4"></a><a id="Tc_0keonLcaTkyz5UykpdjS6Q_11_0"></a><a id="Tc_iRSk3xcugUyB0MQDGapysA_12_0"></a><a id="Tc_5TdtBMZIn0iL64c2FRJ94g_12_2"></a><a id="Tc_7DnjC7QiY0OSYRcuhUxcjg_12_4"></a><a id="Tc_LnLT4E21_0W-0VSYim4gsw_13_0"></a><a id="Tc_A55MS6Id00OaCcIFCTFU8A_14_0"></a><a id="Tc_geJcVA66xUS5MIVJRqMNLw_14_2"></a><a id="Tc_Oznc26j_C0OCoNoecvlzbw_15_0"></a><a id="Tc_eDu-7pIPp0OvBVgQdC4esA_15_2"></a><a id="Tc_zmaJqatjHEyrg4z5xoZMmg_16_0"></a><a id="Tc_jqOqGTa6AUeA5VK-lLqjrg_16_2"></a><a id="_bacfe475_e80e_408e_8de6_3bb0f568f15d"></a><a id="Tc_Zn7YbTHLXEKtXUVWLSWH3Q_1_2"></a><a id="Tc_xy7wlRHUsEu9tbUy5iqBcQ_2_2"></a><a id="Tc_7DVilkNiOUuvRhogi-tDiQ_2_4"></a><a id="Tc_aTJO90hkjUaDHyDwjReaMQ_3_2"></a><a id="Tc_ykEOEltcFEOHzjqH7MQTEQ_3_4"></a><a id="Tc_Td4SR6GAm0WD9ORish9mxA_4_0"></a><a id="Tc_sojqXUoEyECI5HDmuEH4Qw_5_0"></a><a id="Tc_pvpmI5EzIEapqlIDLu97aA_6_0"></a><a id="Tc_RURUDE0miUSoDZPCt8ozIg_6_2"></a><a id="Tc_f9AwWCnxV0i_VJ28cuXiVA_7_0"></a><a id="Tc_8SSRC4hCPE2kq_6YpnV7_g_7_2"></a><a id="Tc_xszmeT528kSqbzehtH_dzw_8_0"></a><a id="Tc_m8at3utu40Of1_WXkhPMQg_9_0"></a><a id="Tc_X6nmwg30v0KqmgwErxH70Q_10_0"></a><a id="Tc_DFKzWS-ooUKdh1Gk86YhFA_10_2"></a><a id="Tc_WC0_ehaKnU6Ujh7XAwVygA_11_0"></a><a id="Tc_CQfSpprZGkGXCszndWhAlA_11_2"></a><a id="Tc_hwLpvymoM0SzXXREFF1o1g_12_0"></a><a id="Tc_MJBP3Ky4qUSPLC1rKDtRow_12_4"></a><a id="Tc_1aDO3xIiMUWDRL1-cBCOMw_13_0"></a><a id="Tc_GYsGZO4vxkO4t2--ZK2Z2g_14_0"></a><a id="Tc_vl0gayc4a0KvKyKV8pj9ng_15_0"></a><a id="_caa45214_87a3_449f_961d_998930fbb8e5"></a><a id="Tc_F27z7taQg0SL6Wlh5IAwLg_1_0"></a><a id="Tc_M4GXzruaLEanJxSRaEEEuQ_2_0"></a><a id="Tc_wUBCt_2w3UKzS2-4Uifd7A_3_0"></a><a id="Tc_fdeQK5lf8Uu0flEM8gBMgQ_4_0"></a><a id="Tc_f9HBfVt_FEKZvjVrIgkGwQ_4_4"></a><ix:continuation id="Tb_D3W6tX_8KkqaQRYp82eReA_cont2" continuedAt="Tb_D3W6tX_8KkqaQRYp82eReA_cont3"><ix:continuation id="Tb_bxBvE6lY1E6MGmS23Naj6g_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Reconciliation between the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_xPPkY8C6Lk61xH27GmqsLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_F0faT6xtD0OqjpVhvrD42Q_4_2">42,397,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_rF9bq7SsMEGn186WP1ra1w_4_4">71,476,322</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_vt2uTAPUQEyUyE2sJa-UpA_4_6">79,512,792</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">PRC statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_Zy8_49KCkkyJNf2fDGtu1g_5_2">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_zPQNo7a_mUOHd1t2dAOcLw_5_4">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_lGG58Tq9DUSHTLY6F_CpBw_5_6">25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax credit computed at PRC statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_QeW6GvQEz0SNVCttuytDxg_6_2">10,599,320</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_c39PQijTiUKbMcYD6xrtmA_6_4">17,869,081</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_CpvK5pu7wECLPsjvCwt7qQ_6_6">19,878,198</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Impact of PRC preferential income tax rate as qualified TASE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="Tc_0nGQz-Cu8Ea3cDlPUCT3YQ_7_2">4,239,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="Tc_F2WpXcYnz0aejwvSffrPVg_7_4">7,147,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="0" id="Tc_C_gy8Bxn90q_XVWRIp-71Q_7_6">7,951,279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Difference in income tax rates of overseas entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="0" id="Tc_ZTnup3kOPkCbsa1xfqhouA_8_2">5,286,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="0" id="Tc_xOPywTx4XkSgO0cWk_dekw_8_4">10,549,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="0" id="Tc_mWa5pMtv2UikffEivNBn7w_8_6">10,560,029</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development super-deduction<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" scale="0" id="Tc_8PxALRVqSUys0XA9pfbVYQ_9_2">718,979</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" scale="0" id="Tc_KM4zWvDD9ECOYHvp8g-4Nw_9_4">569,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" scale="0" id="Tc_2_zFwhrQbkexNJWLXpiDXw_9_6">1,724,740</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" id="Tc_9qkjoLXM3kmw0Om8glHwaw_10_6">569,575</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_5vz8CZiyDE623DWbXyhwsQ_11_2">1,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_FhvJ2-1h00mA0xekcrQBCQ_11_4">1,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_YsbcSGliuUqqiRA7bYLp-A_11_6">3,695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign derived intangible income deduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" scale="0" id="Tc_a2lW7tCBOUqrjZqkeX4DmQ_12_6">487,183</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_YijB6Ont00-aagm9zq4-fQ_13_2">1,790,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_oY2jbLiSp0S5fpUXgXc6QA_13_4">2,277,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_kP63yFglBkO7-vJOsW3tbg_13_6">4,517,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">State tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="Tc_aAWtFnguPUGk0YRe1T-Yog_14_4">291,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="Tc_h4LLla6RE0mnwBbgaOaFiw_14_6">76,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" sign="-" scale="0" id="Tc_AXIy9q83UkyJaiafNy-grQ_15_4">127,880</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" id="Tc_fbpYQABaO0KY8aYXJYq1BQ_15_6">10,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_GE0CGBvVcEap_F21Iq4u0Q_16_4">1,701,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc__C1rBg5NvkSZzlt0nzV6uQ_16_6">459,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#8217;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2020, 2021, and 2022.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December&#160;31, 2021 and 2022 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_JVQdluwfGk-X14qMrlon_Q" continuedAt="Tb_JVQdluwfGk-X14qMrlon_Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_HDzITyp1y0OcmAf1MuDH5Q_5_2">4,949,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_p4TqBlpCIk2dm7wropcHgA_5_4">8,217,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Tax credit carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" id="Tc_tPVKPcRGOEGkf1s_NmMRwA_6_4">391,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" id="Tc_9bnuW0ltS02yQCJ_mqAQCw_7_4">756,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="Tc_ALXi-INRBkW4-E4M3ZAaLw_8_2">95,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="Tc_Jy62tGkuVEuQzqb1HvqmBA_8_4">94,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Unrealized foreign exchange gain/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="0" id="Tc_ocyj3BOglUKLbN1lHXy5QQ_9_2">39,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="0" id="Tc_jVkBa2z8rU2LH58cky8ROg_9_4">116,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" id="Tc_2jytFQ7j9E23sHMv5nrTKQ_10_4">29,702</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Amortization of right-of-use assets and interest of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="adag:DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" scale="0" id="Tc_-ERh1P5Kd0-96M_rzs-KYw_11_4">546</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="adag:DeferredTaxAssetsDepreciationAndAmortization" scale="0" id="Tc_pN7JCXOOr0a2PYMzzkU8jA_12_2">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_-QxEhSmowk2Ox9O2SKmTPw_13_2">5,083,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_5ayJFYMzxkiDJidjeZ8V9g_13_4">9,607,456</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc__3XLvibje0WcNMCneZ1KWQ_14_2">5,007,139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_BDKRGrLxNkGM4WUDSd14hw_14_4">9,524,497</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_hvzldZX2vk-sHBmVXSDU6A_15_2">76,695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_6pvawlbaaUmjDRPBuDGpgQ_15_4">82,959</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_TA-XBWf6GUecP4ZkHvpwcQ_2_2">120,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_0QEUhnjWPk-nD4S-OiCO5A_2_4">82,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_xISp4NUQ3Umk3kShWI81hw_3_2">120,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_shUe0GD6S0Wzcz2wlHsFPw_3_4">82,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred tax liabilities, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="0" id="Tc_n4syQvUPlkS-mdOAj1RRDA_4_2">44,163</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_J8nqjCbQS02lUrvvF5zw0Q_1_2"></a><a id="Tc_v2R0E29OqEqnJtcfaHseqQ_1_4"></a><a id="Tc_rq8PAdlw9EyDvh7G4IGTCg_2_2"></a><a id="Tc_xMaOG8ixaEeHWB8wGCNvmQ_2_4"></a><a id="Tc_7Cu-uc8CekuD2Hqgqy-8kw_3_0"></a><a id="Tc_8JU_MLwv5USbgfonwJ2xcQ_4_0"></a><a id="Tc_ISmiSDURt0OcnW-LKnJ3SQ_5_0"></a><ix:continuation id="Tb_D3W6tX_8KkqaQRYp82eReA_cont3"><ix:continuation id="Tb_JVQdluwfGk-X14qMrlon_Q_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Movement of the valuation allowance was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="Tb_hmhGGhUTXkmH-f9VjD7hdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_pr2DkB--w0iwquen_l87hw_3_2">2,729,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_fQV1fSaWSU2rURBBcGXQGA_3_4">5,007,139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Tc_kmjQOlBwGkKj2_uLMNjnog_4_2">2,277,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Tc_Si8gBqxUqUKfcPpzocWxNg_4_4">4,517,358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_KbW-bRTBx02syOAakZaSzw_5_2">5,007,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_9fX1R1_Cr0OIfIvP0Z6ISw_5_4">9,524,497</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#8217;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has incurred net accumulated operating losses for income tax purposes since its inception. As of December 31, 2022, the Group had net operating losses for income tax purpose of approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_kOVvUoPckkeIVIIEP6Svtw">50,742,841</ix:nonFraction>. The net operating losses were primarily comprised of: US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CN_pERkzB2zbEuJoXns9cPQzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_t9wAyUMSLE-55XxVJJ9Uhg">17,886,069</ix:nonFraction> from an entity in PRC which expires in years 2028 through 2032; US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CH_u8WhTZKTgk6uGwI8YPJBBQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_LnhV4lc-dUe-1bFUwc-ObA">8,272,007</ix:nonFraction> derived from an entity Switzerland which expires in years 2027 through 2029; US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_HK_Otsf7MqCgkyOm-luahjSsQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_cJa5QQLJPUCTNPALRbMyQA">5,445,071</ix:nonFraction> derived from an entity in Hong Kong that have an indefinite carryforward; US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AU_iIjaBK7jEEatSAUYG4p5Sw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_ixX2xjv5m0uASxrAdlag5Q">7,511,343</ix:nonFraction> derived from an entity in Australia that have an indefinite carryforward subject to meeting certain criteria; US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_US_9sDKIIcAC0O2whabXRhATQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_264xDG46oUSA6yrAw4ALUA">10,807,828</ix:nonFraction> derived from an entity in the United States which expires beginning year 2038; and, US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_SG_aoUeaWEODUuRBoaCnL4L8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_QBqO8iEvkEWfoHPJ0bd-4g">820,523</ix:nonFraction> derived from entities in Singapore. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the near future. Therefore, the Group has provided full valuation allowances for the deferred tax assets for all subsidiaries as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2021 and 2022, the Group did not have any significant unrecognized uncertain tax positions. The Group does not anticipate that the amount of unrecognized tax benefits will significantly change within the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Group conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December 31, 2022, PRC tax matters are open to examination for the years 2020 through 2022, U.S. federal and state tax matters are open to examination for the years 2019 through 2022, and Australia tax matters are open to examination for the years 2019 through 2022.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_f8A9msVjr0qHk7yd5WXXEg_1_2"></a><a id="Tc_OVFPdt2nXESQhCOM6KjJnA_2_2"></a><a id="Tc_Yj8T1SKsREGk1CgtQVgQRQ_2_4"></a><a id="Tc_yjB1dOaWCEOQehKBx-OOTw_2_6"></a><a id="Tc_Yu2c7mw3d0qBTXgFepnlQg_3_2"></a><a id="Tc_WNdYdalqyEaOHBJDG7mT6w_3_4"></a><a id="Tc_AMaXNcc6akmb5La14fGTXg_3_6"></a><a id="Tc_1O862lTIekup4UKEAS2NTQ_4_0"></a><a id="Tc_lJvWD_17eEWNQW31sr1tUQ_5_0"></a><a id="Tc_5i8k1cgQ20ebe1A375fFjA_6_0"></a><a id="Tc_dPsb5D5jSUa1Z67_F338lg_6_6"></a><a id="Tc_gDc5jHh1p0ysk-O4Nz2HbQ_7_0"></a><a id="Tc_xh438mI770uaqOPj6_faVA_8_0"></a><a id="Tc_ifNy7ZBJOUmha6a-ni9O5w_9_0"></a><a id="Tc_dZKxNQtLfEKL0jhu0Urwmg_10_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:EarningsPerShareTextBlock" id="Tb_BSpXlj0E1ECpL_iaq9S0yw" continuedAt="Tb_BSpXlj0E1ECpL_iaq9S0yw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Basic and diluted net loss per share for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were calculated as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_KTvrqmO5kkmfKwRome1JGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_TCZhTZymAEmpMxHDTfQ6KA_5_2">42,397,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_tn1KdQin9kCj5N5LSscqlw_5_4">73,177,935</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_MFm5svCLDU2OkgV5BpztLA_5_6">79,971,847</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_MPA8DvvHlkWJm1KEQRRZPg_6_2">248,113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_AqRC9Z2FckGtwNpRiV3rLw_6_4">28,553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_0uoKh7g2L0K2MbEaRB5KVQ_7_2">42,645,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_asJVFQ3H0021v0YqaT-omA_7_4">73,206,488</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_ARmGGYk42kGHsSDScVrs-g_7_6">79,971,847</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted&#8209;average number of ordinary shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_oRVNHEOUdEe-u-J37BIdLw_9_2">15,950,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JTNnX-RO7E-dwVSLZYZ1aA_9_4">50,032,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_bqr8L2Pu30OIvxt_x-1TbA_9_6">54,135,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net Loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Fo0gSjnCxkKZlsIIjsxiBw_10_2">2.67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_182PwYgS_k2W7KD5ZsCR6g_10_4">1.46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_66hzm-JD3kqm5qd1YZBI8Q_10_6">1.48</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the&#160;years ended December&#160;31, 2020, 2021 and 2022 as their effects would be anti-dilutive.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_sLwEEnN-bkGqkHoJYX4HtA_1_2"></a><a id="Tc_Q_iAqd_0EU-nswea1_hJ2w_2_2"></a><a id="Tc_DQnPljT8gUS91m_H8cbupQ_2_4"></a><a id="Tc_ehpc-lf9AUKlbVzzRkfJkA_2_6"></a><a id="Tc_asILCOPbZUWLuhueYa0TOA_3_0"></a><a id="Tc_Zsar9retiky9UoiK8EhBmg_3_4"></a><a id="Tc_z8mB8PKuG0mces0wpU4sKA_3_6"></a><a id="Tc__xEGZLlIck6RkguJKjVvag_4_0"></a><ix:continuation id="Tb_BSpXlj0E1ECpL_iaq9S0yw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_Dkq-D1kW_UGv5j2PtmrhBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Convertible redeemable preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_n1ed7fGyz0KAIk8k73AxhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_i7-Q9T1zq0Kn2WwfDnxC3A_3_2">27,249,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Share options and share grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_x3zBUisNukS5eVvI4gf_kg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_efi0kdEDhES_af4XqtqIUA_4_2">1,795,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xEF_4pgz1k6DXF8uNNBIvQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_DfCUvh-TMkerZo_xKuFOAg_4_4">1,739,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_IfdRhB-Ii0Onl99aJ0jfJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_PNeoVK4I00u6AuSTp4sDdQ_4_6">530,298</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0ded37a5_4c6c_4e28_bb24_b81ff8e9bf88"></a><a id="Tc_FguxrGEpuUe6wJ7DO6-70Q_1_2"></a><a id="Tc_TsIEsfsb4k-GSAt_YyNoDg_2_2"></a><a id="Tc_-1jytdQqn0u-TL1xixANmw_2_4"></a><a id="Tc_CxK2mDihREm7csKbPSHJiw_3_2"></a><a id="Tc_VqSGpoVd2kGqCiBW1uQ6nQ_3_4"></a><a id="Tc_wXWwdT0kekah2QiDuXVzgg_4_0"></a><a id="Tc_Xxu1t0JddU2AFXYRwk__qg_5_0"></a><a id="Tc_u6XHyGDbhEy0zpp5XPmPMA_6_0"></a><a id="_5c35fe04_05d0_42e1_b1f0_e82a033bed13"></a><a id="Tc_FuV8mUGKiEWsg1APabkt6Q_1_2"></a><a id="Tc_qA63xUOKYU6raqbz1reeuw_2_2"></a><a id="Tc_2yxRkCXj_kW-IGlLuleQGQ_2_4"></a><a id="Tc_s4KjzKLGuEy_QgnjmnTr_g_3_2"></a><a id="Tc_mSxfSg-p10uaThUPvxrUcw_3_4"></a><a id="Tc_gK6fitPptE6lu7w8DfDBpA_4_0"></a><a id="Tc_9Xsm3IHti0a4nUt9oCrdwA_5_0"></a><a id="Tc_3dCJi28kQ0GfX8wl5bY7ZQ_6_0"></a><a id="_eab2d572_ac98_4daa_bc32_cc30c9731250"></a><a id="Tc_1Gc3AoZEcUyAu5fiEaYXZg_1_2"></a><a id="Tc_GDCur_m_hUS6V4w_RPV0SA_2_2"></a><a id="Tc_irPDWumvh0GK5UhNJooUQQ_3_2"></a><a id="Tc_EGpNrz_F8UuYLskm2MkAbw_3_4"></a><a id="Tc_zRCBl2lvRkyKjVP8RMducg_3_6"></a><a id="Tc_7fnIRt_JT0akTGLdNDgdPw_4_2"></a><a id="Tc_bP0FUFOzj0itKPmh-SRpRQ_4_4"></a><a id="Tc_bEfPbqnVTEa4zpBos541Ww_4_6"></a><a id="Tc_lt00xqsR7UuWDFXiFKy21w_5_0"></a><a id="Tc_nultlx7KAEGZwHOywOpTvg_6_0"></a><a id="Tc_zw96c86oEU20Ral9lOiHfw_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_YdKOFnV2xUCNgs8Yyyf4og" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">13. RELATED PARTY TRANSACTIONS</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_qtM0R7HTfkOKzz9fKjp6gA" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Related Parties</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Relationship</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chairman, Chief Executive Officer and a principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Four senior management personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Management and ordinary shareholders of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Co., Ltd. (&#8220;WuXi AppTec Group&#8221;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">A principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Controlled by the ultimate controlling party of a principal shareholder of the Company</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party balances as of December 31, 2021 and 2022:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_R1F5ndSVPkCgXKmwyzbScg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_CsOE23afx0y0D9Dq0kp_-w_4_2">3,080,116</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_IGFUJEto00G2d7K3PSE_Og" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_JFqv8Xm0YUebGF-Y7l7UFA_4_4">503,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_t_0MJ4wuNkyxIV4bgXJFmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_ENohm8Gmpkm_3OkO1W9o2w_5_2">1,426,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_0M5cOB2hoEaTbUgHkdCREw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_VW-qIBUiRUOVQ1xmKomL5g_5_4">115,491</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due from related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_7i6cRJwN70mSTWGZMYZUAg_6_2">4,506,670</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_deMQ-bEIc0G7hm9ACsQtLQ_6_4">619,432</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2022, the amounts due from related parties represented prepayments made for the CRO and CMO services.<br /><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_t_0MJ4wuNkyxIV4bgXJFmg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_9vz1E6Ad0Eea6gtGyTfOTA_4_2">10,292,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_0M5cOB2hoEaTbUgHkdCREw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_F_8L-FpwfUGAtiDpksd4mw_4_4">17,840,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_R1F5ndSVPkCgXKmwyzbScg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_vLnMiBIF4EyP_JhvoVai9g_5_2">173,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_IGFUJEto00G2d7K3PSE_Og" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_XZpQ6-4BP0-oF7EkAe3N3g_5_4">1,482,461</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_R_ZQ6FXwC0q00kWVhWNfYg_6_2">10,466,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_p7ExStvRYUq54yW9hz57Rw_6_4">19,323,337</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2022, the amounts due to related parties represented payables for the CRO and CMO services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party transactions during the years ended December 31, 2020, 2021 and 2022:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Receipt of CRO and CMO services:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_f5vXDOcWdkSV-l04XmsJrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_A-eYZTVjo0uuPc6eIp9RtA_6_2">7,217,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_fmpyuXJQ_EqCRbO-JtqTjw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_UsXXRWuH8kunQ10TAd23qQ_6_4">12,561,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_XfcO1vA5gES98UF8hk_gOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_y5ZDMHlm3ECWx-SHPV_waw_6_6">27,764,750</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Itm1UFewfkK9c21wwIKhCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_j18J2w5dXUue-zM8RfR3rA_7_2">2,674,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_lU_OCdJ2sUCF8wkKIvaYFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_oACoST3djkGhh3-BfOZUFA_7_4">517,742</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Xo3frStwAkqUZlLqb4wjJA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_1IreS7jxt0WEu947S2a1tg_7_6">7,362,713</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_MJlpRPr5HkyPVxy3B1RlaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_K85vtKtriUq3xJdbKAjKcA_8_2">9,892,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_jQzQ-Qs4jUWen2BvHNx06Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_Gvt5DMt9l0a3w8_uxP2vhg_8_4">13,079,018</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_r4lFa-Ww0kCU3jAskRrUVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_Ker9_ASaMUSZel3kHB-eig_8_6">35,127,463</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_YZbbaML1UUKgc7fccj4zsQ_1_2"></a><a id="Tc_r2a9JdPQv0S2qnQhSl9huQ_2_2"></a><a id="Tc_J9t6QXm6kUOobQTzzOBfFA_3_2"></a><a id="Tc_nNKXMfwIkkilvB2W683SAg_4_0"></a><a id="Tc_0xO-G8sA5U-XeTNSRwAlBw_5_0"></a><a id="Tc_gtmZoYnIg0mrCl6PBFqlRw_6_0"></a><a id="Tc_w0-vEn_Tk06afauRzH0sBg_7_0"></a><a id="Tc_V0QNSAgoAU2pRB7Joz759w_8_0"></a><a id="Tc_JEcmQ00awU2Q5tioEZQBfQ_9_0"></a><a id="Tc_KKXiKpk3-0WJ8cBmOwF5ag_10_0"></a><a id="Tc_FwhRZoX5sE6FUA6R1QSuhg_10_3"></a><a id="Tc_5aUT9Ym4RkKBkEN3wsaZ5w_1_2"></a><a id="Tc_HbZN6hoiZEKZZA1H_GA5GQ_2_2"></a><a id="Tc_fsaNXpqcw0-IzSW5Ue1_8A_3_2"></a><a id="Tc_cbq5gFdAhU-2ObuvewIEFA_4_0"></a><a id="Tc_mgUhgQ1QTEC4ytr1i5SAjA_5_0"></a><a id="Tc_PkGQw6OETEuxm9hbMzL6Rw_6_0"></a><a id="Tc_Xr3DKmUg9kmiLwvoMd469w_7_0"></a><a id="Tc_j5OJU-XU2Ey8JDXrz-dd-Q_1_2"></a><a id="Tc_Mg3rqcxT_k2x6nKjoDp2fw_2_2"></a><a id="Tc_abb7JgzU5UKnpylUiBzgLQ_3_2"></a><a id="Tc_Y7jAOCE5VkuNRfX6QNQ9rw_4_0"></a><a id="Tc_9NBQqQlrW0KScQFKgktKBQ_5_0"></a><a id="Tc__c55MbgZWEmDvylVaRh-jA_6_0"></a><a id="Tc_SQL_jnslS0a7UFG1tySWQQ_7_0"></a><a id="Tc_qvLj4no3SkOoZO5lSMc9-A_8_0"></a><a id="Tc_c9nuAY3uok6RbbAPQYseFg_1_2"></a><a id="Tc_blwGlIVTDEuvskZUukChMQ_2_2"></a><a id="Tc_T15LaaZyZk-Cs75DtaDdEA_3_2"></a><a id="Tc_aGrEnkvmd0SQMYplXvSi9g_4_0"></a><a id="Tc_T-7SZ_EWlEuf8l5CHJCfjw_5_0"></a><a id="Tc_ntmfbRs6bUqzJeOq_n8RRg_6_0"></a><a id="Tc_hJKvdCUTSUWrEw6wBLGH3Q_7_0"></a><a id="Tc_GjSVmiwK3kymiKnI0KELQQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_VjuVQTL9C0-p3CRmDZnUVg" continuedAt="Tb_VjuVQTL9C0-p3CRmDZnUVg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">14. LEASES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Group has operating leases recorded on its consolidated balance sheet for certain office spaces that expire on various dates through 2024. The Group does not plan to cancel the existing lease agreements for its existing office spaces prior to their respective expiration dates. The Group&#8217;s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. All of the Group&#8217;s leases qualify as operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information related to operating leases as of December 31, 2022 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:InformationRelatedToOperatingLeasesTableTextBlock" id="Tb_vBdp2if0a0eEViQPqNa4mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_p0gtKk-AMEiZ3hDSFHmW6A_5_2">191,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_ZVPLq5eHxUKksWcvBcVwTQ_7_2">151,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_h6aNHTorOUCCJNfW2I2CRQ_8_2">53,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_WDt1rpMuZkCGvHAJaEegxQ_9_2"><span style="font-size:10pt;"> 1.3</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_DMgpR2YaukustCRYXw7o8Q_10_2">4.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Information related to operating lease activity during the year ended December 31, 2022 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="adag:InformationRelatedToOperatingLeaseActivityTableTextBlock" id="Tb_UM8UA_R0qUimnp7fAhw6Sg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease rental expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" id="Tc_d-pF9t0E_Eq3WheDF4jflA_5_2">283,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Expense for short-term leases within 12 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermLeaseCost" scale="0" id="Tc_r3twlxpaJU6WAk2HZG0rkQ_6_2">34,729</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Interest of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:InterestOfOperatingLeaseLiabilities" scale="0" id="Tc_s5yWOlcaSUe3PEEe3SSerg_7_2">20,259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="0" format="ixt:numdotdecimal" name="adag:OperatingLeaseRentalExpense" scale="0" id="Tc_qTZ4a6ieQEC3UCGFKPIx7Q_8_2">338,264</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year as of December 31, 2021 under ASC 840, <i style="font-style:italic;">Leases</i>, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="Tb_w8ZJ4cCwLEa_6kpV1u9CuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">For the years ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="0" id="Tc_XTnO08uLvU-xofUAf12H1g_5_2">412,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="0" id="Tc_625iwuXQIUe5pKdtO0GbjQ_6_2">255,309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="0" id="Tc_OTILTwlWj0ajGbRvdcI4Qg_7_2">70,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" id="Tc_6eStvupZKU6RupRKnEkilw_8_2">738,430</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Maturities of lease liabilities were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_IsqOz10U90qhyUBulvXU0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_xykPJJvySE2EsfxRd2DlRw_4_2">157,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_vstD3M-_M0mZ3lNRaIMoyg_5_2">54,823</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_3hxNTryWA0KGqN3Zri0vPw_6_2">212,426</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_fXYRw95IzUSVhiD5FftqqQ_7_2">6,609</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_smaflCeqTUWvsBl3dUWfVA_8_2">205,817</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VjuVQTL9C0-p3CRmDZnUVg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_tZQNS0iMeEGyp-kxll3gfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group&#8217;s business, financial position or results of operations.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:RestrictedAssetsDisclosureTextBlock" id="Tb_LTVC1Un_nkmWdbCF6lkznQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16. RESTRICTED NET ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#8217;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S.&#160;GAAP differ from those reflected in the statutory financial statements of the Group&#8217;s PRC subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" scale="-2" id="Narr_cuvMsgZNTUijCSpndn7JHA">10</ix:nonFraction>% of its annual after-tax profit until such reserve has reached <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" scale="-2" id="Narr_QdInbK5oEUyvrajAn-RP_w">50</ix:nonFraction>% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#8217;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the abovementioned restrictions on distributable profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021 and 2022, the total restricted net assets of the Company&#8217;s subsidiary incorporated in PRC and subjected to restriction amounted to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="0" id="Narr_FEDLgXQJdU6V8YsUVCPhkg"><ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="0" id="Narr_YNIBKj-xSk-VuXZ7RZoYVA">1,860,667</ix:nonFraction></ix:nonFraction> for both years. Other subsidiaries are not subjected to such restriction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:AfterTaxIncomePercentageAppropriations" scale="-2" id="Narr_jRr5wl9FZEy1UNN6YOOgzw">10</ix:nonFraction>% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#8217;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign exchange and other regulations in the PRC further restrict the Group&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2022, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries was US$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="0" id="Narr_KR_2r23zSE2cs1Wv-XwWGA">1,860,667</ix:nonFraction> from the PRC subsidiary, and the Group had a consolidated shareholders&#8217; equity. As the restricted net assets of consolidated subsidiaries do not exceed <ix:nonFraction unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw" contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" decimals="2" format="ixt:numdotdecimal" name="adag:ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" scale="-2" id="Narr_VBkRzN96h0ajFG3POnaKiw">25</ix:nonFraction>% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:TreasuryStockTextBlock" id="Tb_H38E9ugGDUWwpNMLKr-Ejw" continuedAt="Tb_H38E9ugGDUWwpNMLKr-Ejw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17. Treasury Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group accounts for treasury shares using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account in the consolidated balance sheets. At retirement, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is recorded entirely in additional paid-in capital (up to the amount credited to the additional paid-in capital upon original issuance of the shares). In the event that treasury share is reissued at an amount different from the cost the Group paid to repurchase the treasury share, the Group will recognize the difference in additional paid-in capital by using the specified identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On July 7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_kmEX4yG-ZEuDCtdXxBARXw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="Narr_c8Fz_k3ofUCOg_OzuS65mQ">20</ix:nonFraction></span><span style="font-size:10pt;"> million of outstanding ADSs of the Company, from time to time over a </span><ix:nonNumeric contextRef="Duration_7_7_2021_To_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_skBGvFvBgEm6UOz4-CGzgA" format="ixt-sec:durmonth" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="Narr_f-znbbnsj0-7mIjBJpeeuw"><span style="font-size:10pt;">12</span></ix:nonNumeric><span style="font-size:10pt;">-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer (the &#8220;2021 Share Repurchase Program&#8221;). The 2021 Share Repurchase Program commenced on July 20, 2021. During the year ended December 31, 2021 and 2022, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yBEmNnp9JkKRwrCjjyfHqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_wWEfPntAVkKgTgEM95znwQ">236,139</ix:nonFraction></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_c6cCpTT3-UCFa3iydypLlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_lFj1vKlZRUKjDBshf6PoKQ">1,170,446</ix:nonFraction></span><span style="font-size:10pt;"> outstanding ADSs (</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_GF6f3RbJt0mSKdc-gIpyMA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_87mqU-N81Eq9q8e2FKRN6A">295,174</ix:nonFraction></span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_Z9mphkrR0kmVJfMEZDudGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_wlV7tcW4pEKpeYXJYjnvaQ">1,463,057</ix:nonFraction></span><span style="font-size:10pt;"> ordinary shares) were repurchased with a total consideration of US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yBEmNnp9JkKRwrCjjyfHqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Narr_izF3QuAewUu1v8uRwQQ48w">2,361,576</ix:nonFraction></span><span style="font-size:10pt;"> and US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_c6cCpTT3-UCFa3iydypLlw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Narr_oeiZk3GmN0eboQ8-DBR5bQ">3,904,399</ix:nonFraction></span> <span style="font-size:10pt;">respectively, under the 2021 Share Repurchase Program.</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_H38E9ugGDUWwpNMLKr-Ejw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On June 29, 2022, the Board of Directors authorized a share repurchase program to repurchase up to US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="As_Of_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_EzSDNbQB5EWZPn-NGBx2SA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="Narr_CKI3Pg9wG0-YbcGh6O6M4A">10</ix:nonFraction></span><span style="font-size:10pt;"> million of outstanding ADSs of the Company during a period of up to </span><ix:nonNumeric contextRef="Duration_6_29_2022_To_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_ALi5xN2v_Ui4UIlZQtgALA" format="ixt-sec:durwordsen" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="Narr_lhR_32dqHE-X0drRlN-9FA"><span style="font-size:10pt;">12 months</span></ix:nonNumeric><span style="font-size:10pt;"> commencing on July 20, 2022 (the &#8220;2022 Share Repurchase Program&#8221;). The 2022 Share Repurchase Program was subsequently terminated in July 2022. During the year ended December 31, 2022, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_OffjEdDiwUq_QKSdjqfmkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_hOoizyVq6kOJZGIxaye7KQ">39,900</ix:nonFraction></span><span style="font-size:10pt;"> outstanding ADSs (</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_H1fu9nxkjU2h3rSJ7njn8g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_yQAGEWIpOEmZShdsWHuIJg">49,875</ix:nonFraction></span><span style="font-size:10pt;"> ordinary shares) was repurchased with a total consideration of US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_OffjEdDiwUq_QKSdjqfmkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Narr_VdnWZS_TqEOUtZ7VlvZn8A">72,282</ix:nonFraction></span><span style="font-size:10pt;"> under the 2022 Share Repurchase Program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the year ended December 31, 2021 and 2022, <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_FfVHeu36qEOc41XZB5QsSQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_OWsOv12jWkKtEc7X3ONY8w">160,880</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_xhNNg3sLMESa0Vn3QOWKRQ">1,285,604</ix:nonFraction> ADSs (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_PpX3jqVYjUKGSc4PUVCqbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_SIHAf74CCU-eTyFc2HvH-w">201,100</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_CvRrfdUqEk-V4W-jq06BRQ">1,607,005</ix:nonFraction> ordinary shares) repurchased have been retired<span style="font-size:11pt;"> </span>, respectively. As of December 31, 2021 and 2022, there were <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_AEEEQVw_NU6BvaZkgLzS0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Narr_8ndVf7okF0ODUbtD2c0urg">75,259</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_V8r0Nfbtg0etm8S7eTVjcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Narr_ZkMCWpdEa0q92l-lcn8jFQ">1</ix:nonFraction> ADSs (<ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_8Qw98XWW1UumdeUdUM175Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Narr_lM4TXEluLU6G8tEXVnsZcQ">94,074</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_sQqB69UJ9UC_sksuTF-VLg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="Narr_n4FcblGofEKOCXTjd6Wk4w">1</ix:nonFraction> ordinary shares) held as treasury shares, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow" name="us-gaap:SubsequentEventsTextBlock" id="Tb_WWzKYUTFaEab57HklZx6yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">18. SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From January to April, 2023, a total of <ix:nonFraction unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA" contextRef="Duration_1_1_2023_To_4_30_2023_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jbskMAiPskm8ahOT8fG0aQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_zVFEIMvOcE64ndQNF0ETuw">582,630</ix:nonFraction> ordinary shares were issued to certain management personnel pursuant to the 2021 Plan.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.5
<SEQUENCE>2
<FILENAME>adag-20221231xex2d5.htm
<DESCRIPTION>EXHIBIT 2.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:13 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;2.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Rights of Each Class&#160;of Securities Registered under Section&#160;12 of the Securities Exchange Act of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1934 (the &#8220;Exchange Act&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">American Depositary Shares (&#8220;ADSs&#8221;), each representing one and one quarter ordinary shares of Adagene Inc. (&#8220;our company&#8221; or &#8220;us&#8221;) are listed on the Nasdaq Global Market and the shares are registered under Section&#160;12(b)&#160;of the Exchange Act. This exhibit contains a description of the rights of (i)&#160;the holders of ordinary shares and (ii)&#160;ADS holders. Shares underlying the ADSs are held by JPMorgan Chase Bank, N.A., as depositary, and holders of ADSs will not be treated as holders of the ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description of Ordinary Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following is a summary of material provisions of our currently effective seventh amended and restated memorandum and articles of association (the &#8220;seventh amended and restated memorandum and articles of association&#8221;), as well as the Companies Act (as amended) of the Cayman Islands (the &#8220;Companies Act&#8221;) insofar as they relate to the material terms of our ordinary shares. Notwithstanding this, because it is a summary, it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire seventh amended and restated memorandum and articles of association, which has been filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) as an exhibit to our Registration Statement on Form&#160;F-1 (File Number 333-252210), as amended, initially filed with the SEC on January&#160;19, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Type and Class&#160;of Securities (Item 9.A.5 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Each ordinary share has US$0.0001 par value. The number of ordinary shares that have been issued as of the last day of the financial year ended December&#160;31, 2022 is provided on the cover of the annual report on Form&#160;20-F filed in April&#160;2023 (the &#8220;Form&#160;20-F&#8221;). Our ordinary shares may be held in either certificated or uncertificated form. Certificates representing the ordinary shares are issued in registered form. We may not issue share to bearer. Our shareholders who are non-residents of the Cayman Islands may freely hold and transfer their ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Preemptive Rights (Item 9.A.3 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our shareholders do not have preemptive rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Limitations or Qualifications (Item 9.A.6 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Rights of Other Types of Securities (Item 9.A.7 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Rights of Ordinary Shares (Item 10.B.3 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">General. </font>Immediately prior to the completion of this offering, our authorized share capital is US$80,000 divided into 800,000,000 shares comprising (i)&#160;640,000,000 ordinary shares of a par value of US$0.0001 each, and (ii)&#160;160,000,000 shares of a par value of US$0.0001 each of such class or classes (however designated) as our board of directors may determine in accordance with our seventh amended and restated memorandum and articles of association. Holders of ordinary shares will have the same rights. All of our issued and outstanding ordinary shares are fully paid and non-assessable. Certificates representing the ordinary shares are issued in registered form. We may not issue share to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold, transfer and vote their ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Dividends. </font>The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors subject to our seventh amended and restated memorandum and articles of association and the Companies Act. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Our seventh amended and restated memorandum and articles of association provide that dividends may be declared and paid out of our profits, realized or unrealized, or from any reserve set aside from profits which our board of directors determine is no longer needed. Dividends may also be declared and paid out of the share premium account or any other fund or account which can be authorized for this purpose in accordance with the Companies Act. No dividend may be declared and paid unless our directors determine that, immediately after the payment, we will be able to pay our debts as they become due in the ordinary course of business and we have funds lawfully available for such purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Voting Rights. </font>In respect of all matters subject to a shareholders&#8217; vote, holder of an each Ordinary Share is entitled to one vote for each Ordinary Share registered in his or her name on our register of members. Voting at any meeting of shareholders is by way of a poll unless a show of hands is permitted. A poll may be demanded by the chairman of such meeting or any one shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A quorum required for a meeting of shareholders consists of two or more shareholders holding not less than one-half of the votes attaching to the issued and outstanding shares entitled to vote at general meetings present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders&#8217; annual general meetings. Our seventh amended and restated memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place as may be determined by our board of directors. We, however, will hold an annual shareholders&#8217; meeting during each fiscal year, as required by the Listing Rules&#160;of the Nasdaq Global Market. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting. Shareholders&#8217; annual general meetings and any other general meetings of our shareholders may be called by a majority of our board of directors or our chairman or upon a requisition of shareholders holding at the date of deposit of the requisition not less than one-third of the votes attaching to the issued and outstanding shares entitled to vote at general meetings, in which case the directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our seventh amended and restated memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders. Advance notice of at least seven (7)&#160;days is required for the convening of our annual general meeting and other general meetings in accordance with our seventh amended and restated memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution also requires the affirmative vote of no less than two-thirds of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting. A special resolution will be required for important matters such as a change of name or making changes to our seventh amended and restated memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Transfer of Ordinary Shares. </font>Subject to the restrictions in our seventh amended and restated memorandum and articles of association as set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our board of directors may, in its absolute discretion, decline to register any transfer of any Ordinary Share. Our board of directors may also decline to register any transfer of any Ordinary Share unless:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the instrument of transfer is in respect of only one class of shares;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the instrument of transfer is properly stamped, if required;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">in the case of a transfer to joint holders, the number of joint holders to whom the Ordinary Share is to be transferred does not exceed four;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the shares are free from any lien in favor of us; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If our directors refuse to register a transfer, they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The registration of transfers may, after compliance with any notice requirement of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the registration of transfers shall not be suspended nor the register closed for more than 30 days in any year as our board may determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Liquidation. </font>On a return of capital on winding up or otherwise (other than on conversion, redemption or purchase of ordinary shares), if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them. Any distribution of assets or capital to a holder of ordinary shares will be the same in any liquidation event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Calls on Ordinary Shares and Forfeiture of Ordinary Shares. </font>Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The ordinary shares that have been called upon and remain unpaid are subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Redemption, Repurchase and Surrender of Ordinary Shares. </font>We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders thereof, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by an ordinary resolution of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by an ordinary resolution of our shareholders, or are otherwise authorized by our seventh amended and restated memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company&#8217;s profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the Company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)&#160;unless it is fully paid up, (b)&#160;if such redemption or repurchase would result in there being no shares outstanding, or (c)&#160;if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Requirements to Change the Rights of Holders of Ordinary Shares (Item 10.B.4 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Variations of Rights of Shares. </font>If at any time our share capital is divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided by the terms of issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of holders of not less than a majority of the issued shares of that class or series or with the sanction of a special resolution at a separate meeting of the holders of the shares of the class or series. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking <i style="font-style:italic;">pari passu </i>with such existing class of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Limitations on the Rights to Own Ordinary Shares (Item 10.B.6 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There are no limitations under the laws of the Cayman Islands or under the seventh amended and restated memorandum and articles of association that limit the right of non-resident or foreign owners to hold or vote ordinary shares, other than anti-takeover provisions contained in the seventh amended and restated memorandum and articles of association to limit the ability of others to acquire control of our company or cause our company to engage in change-of-control transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Provisions Affecting Any Change of Control (Item 10.B.7 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Anti-Takeover Provisions. </font>Some provisions of our seventh amended and restated memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Ownership Threshold (Item 10.B.8 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There are no provisions under the laws of the Cayman Islands or under the seventh amended and restated memorandum and articles of association that govern the ownership threshold above which shareholder ownership must be disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Differences Between the Law of Different Jurisdictions (Item 10.B.9 of Form&#160;20-F)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are incorporated under, and are governed by, the laws of the Cayman Islands.&#160;The Companies Act is derived, to a large extent, from the older Companies Acts of England, but does not follow many recent English law statutory enactments. In addition, the Companies Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the significant differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the State of Delaware.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Mergers and Similar Arrangements. </font>The Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (a)&#160;&#8220;merger&#8221; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (b)&#160;a &#8220;consolidation&#8221; means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (a)&#160;a special resolution of the shareholders of each constituent company, and (b)&#160;such other authorization, if any, as may be specified in such constituent company&#8217;s articles of association. The written plan of merger or consolidation must be filed with the Registrar of Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a declaration as to the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these statutory procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose, a company is a &#8220;parent&#8221; of a subsidiary if it holds issued shares that together represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Save in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled to payment of the fair value of his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court) upon dissenting to the merger or consolidation, <i style="font-style:italic;">provided </i>that the dissenting shareholder complies strictly with the procedures set out in the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Separate from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate the reconstruction and amalgamation of companies by way of schemes of arrangement, <i style="font-style:italic;">provided </i>that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent three- fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the statutory provisions as to the required majority vote have been met;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests adverse to those of the class;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Companies Act also contains a statutory power of compulsory acquisition which may facilitate the &#8220;squeeze out&#8221; of a dissenting minority shareholder upon a tender offer. When a tender offer is made and accepted by holders of 90.0% of the shares affected within four months, the offeror may, within a two-month period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If an arrangement and reconstruction is thus approved, or if a tender offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Shareholders&#8217; Suits. </font>In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule&#160;a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands court can be expected to follow and apply the common law principles (namely the rule&#160;in <i style="font-style:italic;">Foss v. Harbottle </i>and the exceptions thereto) which permit a minority shareholder to commence a class action against or derivative actions in the name of the company to challenge actions where:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a company acts or proposes to act illegally or ultra vires;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not been obtained; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Indemnification of Directors and Executive Officers and Limitation of Liability.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cayman Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our post-offering memorandum and articles of association provide that that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person&#8217;s dishonesty, willful default or fraud, in or about the conduct of our company&#8217;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we have entered into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our post-offering memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Directors&#8217; Fiduciary Duties. </font>Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As a matter of Cayman Islands law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he owes the following duties to the company&#8212;a duty to act bona fide in the best interests of the company, a duty not to make a profit based on his position as director (unless the company permits him to do so), a duty not to put himself in a position where the interests of the company conflict with his personal interest or his duty to a third party, and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under our post-offering memorandum and articles of association, directors who are in any way, whether directly or indirectly, interested in a contract or proposed contract with our company must declare the nature of their interest at a meeting of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Shareholder Action by Written Consent. </font>Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. The Companies Act and our post-offering memorandum and articles of association provide that our shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Shareholder Proposals. </font>Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association. Our post-offering memorandum and articles of association allow our shareholders holding in aggregate not less than twenty percent of all votes attaching to the issued and outstanding shares of our company entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. Other than this right to requisition a shareholders&#8217; meeting, our post-offering memorandum and articles of association do not provide our shareholders with any other right to put proposals before annual general meetings or extraordinary general meetings not called by such shareholders. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#8217; annual general meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Cumulative Voting. </font>Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#8217;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder&#8217;s voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our post-offering memorandum and articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Removal of Directors. </font>Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post-offering memorandum and articles of association, directors not appointed by Peter Peizhi Luo, JSR Limited, and General Atlantic Singapore AI Pte. Ltd. may be removed with or without cause, by an ordinary resolution of our shareholders. A director shall hold office until the expiration of his or her term or his or her successor shall have been elected and qualified, or until his or her office is otherwise vacated. In addition, a director&#8217;s office shall be vacated if the director (i)&#160;becomes bankrupt or makes any arrangement or composition with his creditors; (ii)&#160;is found to be or becomes of unsound mind or dies; (iii)&#160;resigns his office by notice in writing to the company; (iv)&#160;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his office be vacated; (v)&#160;is prohibited by law from being a director; or (vi)&#160;is removed from office pursuant to any other provisions of our post-offering memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Transactions with Interested Shareholders. </font>The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#8220;interested shareholder&#8221; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#8217;s outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, the directors of the Company are required to comply with fiduciary duties which they owe to the Company under Cayman Islands laws, including the duty to ensure that, in their opinion, any such transactions must be entered into bona fide in the best interests of the company, and are entered into for a proper corporate purpose and not with the effect of constituting a fraud on the minority shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Dissolution; Winding up. </font>Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Variation of Rights of Shares. </font>Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law and our post-offering memorandum and articles of association, if our share capital is divided into more than one class of shares, we may vary the rights attached to any class with the written consent of the holders of not less than a majority of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Amendment of Governing Documents. </font>Under the Delaware General Corporation Law, a corporation&#8217;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under the Companies Act and our post-offering memorandum and articles of association, our memorandum and articles of association may only be amended by a special resolution of our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Rights of Nonresident or Foreign Shareholders. </font>There are no limitations imposed by our post-offering memorandum and articles of association on the rights of nonresident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our post-offering seventh amended and restated memorandum and articles of association governing the ownership threshold above which shareholder ownership must be disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes in Capital (Item 10.B.10)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may from time to time by ordinary resolution:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">sub-divide our existing shares, or any of them into shares of a smaller amount; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so canceled.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Debt Securities (Item 12.A of Form&#160;20-F)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Warrants and Rights (Item 12.B of Form&#160;20-F)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Securities (Item 12.C of Form&#160;20-F)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description of American Depositary Shares (Items 12.D.1 and 12.D.2 of Form&#160;20-F)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">JPMorgan Chase Bank, N.A. (&#8220;JPMorgan&#8221;), as depositary registers and delivers the ADSs. Each ADS represents one and one quarter ordinary shares, deposited with the custodian, as agent of the depositary, under the deposit agreement among ourselves, the depositary and yourself as an ADR holder. Each ADS also represents any securities, cash or other property deposited with the depositary but which they have not distributed directly to you.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary&#8217;s office is located at 383 Madison Avenue, Floor 11, New York, NY 10179.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As an ADR holder or beneficial owner, we will not treat you as a shareholder of ours and you will not have any shareholder rights. Cayman Island law governs shareholder rights. Because the depositary or its nominee will be the shareholder of record for the shares represented by all outstanding ADSs, shareholder rights rest with such record holder. Your rights are those of an ADR holder or of a beneficial owner. Such rights derive from the terms of the deposit agreement to be entered into among us, the depositary and all holders and beneficial owners from time to time of ADRs issued under the deposit agreement and, in the case of a beneficial owner, from the arrangements between the beneficial owner and the holder of the corresponding ADRs. The obligations of the depositary and its agents are also set out in the deposit agreement. Because the depositary or its nominee will actually be the registered owner of the shares, you must rely on it to exercise the rights of a shareholder on your behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The following is a summary of what we believe to be the material terms of the deposit agreement. Notwithstanding this, because it is a summary, it may not contain all the information that you may otherwise deem important. For more complete information, you should read the entire deposit agreement and the form of ADR which contains the terms of your ADSs. You can read a copy of the deposit agreement which has been filed as an exhibit to a Registration Statement on Form&#160;<font style="white-space:pre-wrap;">F-6 (File Number 333-252543).  The form of ADR has been filed with the SEC as an exhibit to our Registration Statement on Form&#160;F-1 (File Number 333-252210), as amended, initially filed with the SEC on January&#160;19, 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share Dividends and Other Distributions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">How will I receive dividends and other distributions on the shares underlying my ADSs?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may make various types of distributions with respect to our securities. The depositary has agreed that, to the extent practicable, it will pay to you the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, after converting any cash received into U.S. dollars (if it determines such conversion may be made on a reasonable basis) and, in all cases, making any necessary deductions provided for in the deposit agreement. The depositary may utilize a division, branch or affiliate of JPMorgan to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement. Such division, branch and/or affiliate may charge the depositary a fee in connection with such sales, which fee is considered an expense of the depositary. You will receive these distributions in proportion to the number of underlying securities that your ADSs represent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Except as stated below, the depositary will deliver such distributions to ADR holders in proportion to their interests in the following manner:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">Cash. </i>The depositary will distribute any U.S. dollars available to it resulting from a cash dividend or other cash distribution or the net proceeds of sales of any other distribution or portion thereof (to the extent applicable), on an averaged or other practicable basis, subject to (i)&#160;appropriate adjustments for taxes withheld, (ii)&#160;such distribution being impermissible or impracticable with respect to certain registered ADR holders, and (iii)&#160;deduction of the depositary&#8217;s and/or its agents&#8217; expenses in (1)&#160;converting any foreign currency to U.S. dollars to the extent that it determines that such conversion may be made on a reasonable basis, (2)&#160;transferring foreign currency or U.S. dollars to the United States by such means as the depositary may determine to the extent that it determines that such transfer may be made on a reasonable basis, (3)&#160;obtaining any approval or license of any governmental authority required for such conversion or transfer, which is obtainable at a reasonable cost and within a reasonable time and (4)&#160;making any sale by public or private means in any commercially reasonable manner. <i style="font-style:italic;">If exchange rates fluctuate during a time when the depositary cannot convert a foreign currency, you may lose some or all of the value of the distribution.</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">Shares. </i>In the case of a distribution in shares, the depositary will issue additional ADRs to evidence the number of ADSs representing such shares. Only whole ADSs will be issued. Any shares which would result in fractional ADSs will be sold and the net proceeds will be distributed in the same manner as cash to the ADR holders entitled thereto.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">Rights to receive additional shares. </i>In the case of a distribution of rights to subscribe for additional shares or other rights, if we timely provide evidence satisfactory to the depositary that it may lawfully distribute such rights, the depositary will distribute warrants or other instruments in the discretion of the depositary representing such rights. However, if we do not timely furnish such evidence, the depositary may:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">sell such rights if practicable and distribute the net proceeds in the same manner as cash to the ADR holders entitled thereto; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">if it is not practicable to sell such rights by reason of the non-transferability of the rights, limited markets therefor, their short duration or otherwise, do nothing and allow such rights to lapse, in which case ADR holders will receive nothing and the rights may lapse.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">Other Distributions. </i>In the case of a distribution of securities or property other than those described above, the depositary may either (i)&#160;distribute such securities or property in any manner it deems equitable and practicable or (ii)&#160;to the extent the depositary deems distribution of such securities or property not to be equitable and practicable, sell such securities or property and distribute any net proceeds in the same way it distributes cash.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the depositary determines in its discretion that any distribution described above is not practicable with respect to any specific registered ADR holder, the depositary may choose any method of distribution that it deems practicable for such ADR holder, including the distribution of foreign currency, securities or property, or it may retain such items, without paying interest on or investing them, on behalf of the ADR holder as deposited securities, in which case the ADSs will also represent the retained items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any U.S. dollars will be distributed by checks drawn on a bank in the United States for whole dollars and cents. Fractional cents will be withheld without liability and dealt with by the depositary in accordance with its then current practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">The depositary is not responsible if it fails to determine that any distribution or action is lawful or reasonably practicable.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><i style="font-style:italic;">There can be no assurance that the depositary will be able to convert any currency at a specified exchange rate or sell any property, rights, shares or other securities at a specified price, nor that any of such transactions can be completed within a specified time period. All purchases and sales of securities will be handled by the depositary in accordance with its then current policies, which are currently set forth on the &#8220;Disclosures&#8221; page&#160;(or successor page) of www.adr.com (as updated by the depositary from time to time, &#8220;ADR.com&#8221;).</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Deposit, Withdrawal and Cancellation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">How does the depositary issue ADSs?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary will issue ADSs if you or your broker deposit shares or evidence of rights to receive shares with the custodian and pay the fees and expenses owing to the depositary in connection with such issuance. In the case of the ADSs to be issued under this prospectus, we will arrange with the underwriters named herein to deposit such shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Shares deposited in the future with the custodian must be accompanied by certain delivery documentation and shall, at the time of such deposit, be registered in the name of JPMorgan Chase Bank, N.A., as depositary for the benefit of holders of ADRs or in such other name as the depositary shall direct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The custodian will hold all deposited shares (including those being deposited by or on our behalf in connection with the offering to which this prospectus relates) for the account and to the order of the depositary, in each case for the benefit of ADR holders. ADR holders and beneficial owners thus have no direct ownership interest in the shares and only have such rights as are contained in the deposit agreement. The custodian will also hold any additional securities, property and cash received on or in substitution for the deposited shares. The deposited shares and any such additional items are referred to as &#8220;deposited securities&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Deposited securities are not intended to, and shall not, constitute proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in deposited securities is intended to be, and shall at all times during the term of the deposit agreement continue to be, vested in the beneficial owners of the ADSs representing such deposited securities. Notwithstanding anything else contained herein, in the deposit agreement, in the form of ADR and/or in any outstanding ADSs, the depositary, the custodian and their respective nominees are intended to be, and shall at all times during the term of the deposit agreement be, the record holder(s)&#160;only of the deposited securities represented by the ADSs for the benefit of the ADR holders. The depositary, on its own behalf and on behalf of the custodian and their respective nominees, disclaims any beneficial ownership interest in the deposited securities held on behalf of the ADR holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Upon each deposit of shares, receipt of related delivery documentation and compliance with the other provisions of the deposit agreement, including the payment of the fees and charges of the depositary and any taxes or other fees or charges owing, the depositary will issue an ADR or ADRs in the name or upon the order of the person entitled thereto evidencing the number of ADSs to which such person is entitled. All of the ADSs issued will, unless specifically requested to the contrary, be part of the depositary&#8217;s direct registration system, and a registered holder will receive periodic statements from the depositary which will show the number of ADSs registered in such holder&#8217;s name. An ADR holder can request that the ADSs not be held through the depositary&#8217;s direct registration system and that a certificated ADR be issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">How do ADR holders cancel an ADS and obtain deposited securities?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">When you turn in your ADR certificate at the depositary&#8217;s office, or when you provide proper instructions and documentation in the case of direct registration ADSs, the depositary will, upon payment of certain applicable fees, charges and taxes, deliver the underlying shares to you or upon your written order. Delivery of deposited securities in certificated form will be made at the custodian&#8217;s office. At your risk, expense and request, the depositary may deliver deposited securities at such other place as you may request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary may only restrict the withdrawal of deposited securities in connection with:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">temporary delays caused by closing our transfer books or those of the depositary or the deposit of shares in connection with voting at a shareholders&#8217; meeting, or the payment of dividends;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the payment of fees, taxes and similar charges; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">compliance with any U.S. or foreign laws or governmental regulations relating to the ADRs or to the withdrawal of deposited securities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">This right of withdrawal may not be limited by any other provision of the deposit agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Record Dates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary may, after consultation with us if practicable, fix record dates (which, to the extent applicable, shall be as near as practicable to any corresponding record dates set by us) for the determination of the registered ADR holders who will be entitled (or obligated, as the case may be):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">to receive any distribution on or in respect of deposited securities,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">to give instructions for the exercise of voting rights at a meeting of holders of shares, or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">to pay the fee assessed by the depositary for administration of the ADR program and for any expenses as provided for in the ADR,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">to receive any notice or to act in respect of other matters,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">all subject to the provisions of the deposit agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Voting Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">How do I vote?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If you are an ADR holder and the depositary asks you to provide it with voting instructions, you may instruct the depositary how to exercise the voting rights for the shares which underlie your ADSs. As soon as practicable after receipt from us of notice of any meeting at which the holders of shares are entitled to vote, or of our solicitation of consents or proxies from holders of shares, the depositary shall fix the ADS record date in accordance with the provisions of the deposit agreement, provided that if the depositary receives a written request from us in a timely manner and at least 30 days prior to the date of such vote or meeting, the depositary shall, at our expense, distribute to the registered ADR holders a &#8220;voting notice&#8221; stating (i)&#160;final information particular to such vote and meeting and any solicitation materials, (ii)&#160;that each ADR holder on the record date set by the depositary will, subject to any applicable provisions of Cayman Islands law, be entitled to instruct the depositary as to the exercise of the voting rights, if any, pertaining to the deposited securities represented by the ADSs evidenced by such ADR holder&#8217;s ADRs and (iii)&#160;the manner in which such instructions may be given or deemed given in accordance with the deposit agreement, including instructions for giving a discretionary proxy to a person designated by us. Each ADR holder shall be solely responsible for the forwarding of voting notices to the beneficial owners of ADSs registered in such ADR holder&#8217;s name. There is no guarantee that ADR holders and beneficial owners generally or any holder or beneficial owner in particular will receive the notice described above with sufficient time to enable such ADR holder or beneficial owner to return any voting instructions to the depositary in a timely manner.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following actual receipt by the ADR department responsible for proxies and voting of ADR holders&#8217; instructions (including, without limitation, instructions of any entity or entities acting on behalf of the nominee for DTC), the depositary shall, in the manner and on or before the time established by the depositary for such purpose, endeavor to vote or cause to be voted the deposited securities represented by the ADSs evidenced by such ADR holders&#8217; ADRs in accordance with such instructions insofar as practicable and permitted under the provisions of or governing deposited securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To the extent that (A)&#160;we have provided the depositary with at least 35 days&#8217; notice of the proposed meeting, (B)&#160;the voting notice will be received by all ADR holders and beneficial owners no less than 10 days prior to the date of the meeting and/or the cut-off date for the solicitation of consents, and (C)&#160;the depositary does not receive instructions on a particular agenda item from an ADR holder (including, without limitation, any entity or entities acting on behalf of the nominee for DTC) in a timely manner, such ADR holder shall be deemed, and in the deposit agreement the depositary is instructed to deem such ADR holder, to have instructed the depositary to give a discretionary proxy for such agenda item(s)&#160;to a person designated by us to vote the deposited securities represented by the ADSs for which actual instructions were not so given by all such ADR holders on such agenda item(s), provided that no such instruction shall be deemed given and no discretionary proxy shall be given unless (1)&#160;we inform the depositary in writing (and we agree to provide the depositary with such instruction promptly in writing) that (a)&#160;we wish such proxy to be given with respect to such agenda item(s), (b)&#160;there is no substantial opposition existing with respect to such agenda item(s)&#160;and (c)&#160;such agenda item(s), if approved, would not materially or adversely affect the rights of holders of shares, and (2)&#160;the depositary has obtained an opinion of counsel, in form and substance satisfactory to the depositary, confirming that (i)&#160;the granting of such discretionary proxy does not subject the depositary to any reporting obligations in the Cayman Islands, (ii)&#160;the granting of such proxy will not result in a violation of the laws, rules, regulations or permits of the Cayman Islands, (iii)&#160;the voting arrangement and deemed instruction as contemplated herein will be given effect under the laws, rules&#160;and regulations of the Cayman Islands, and (iv)&#160;the granting of such discretionary proxy will not under any circumstances result in the shares represented by the ADSs being treated as assets of the depositary under the laws, rules&#160;or regulations of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary may from time to time access information available to it to consider whether any of the circumstances described above exist, or request additional information from us in respect thereto. By taking any such action, the depositary shall not in any way be deemed or inferred to have been required, or have had any duty or responsibility (contractual or otherwise), to monitor or inquire whether any of the circumstances described above existed. In addition to the limitations provided for in the deposit agreement, ADR holders and beneficial owners are advised and agree that (a)&#160;the depositary will rely fully and exclusively on us to inform it of any of the circumstances set forth above, and (b)&#160;neither the depositary, the custodian nor any of their respective agents shall be obliged to inquire or investigate whether any of the circumstances described above exist and/or whether we complied with our obligation to timely inform the depositary of such circumstances. Neither the depositary, the custodian nor any of their respective agents shall incur any liability to ADR holders or beneficial owners (i)&#160;as a result of our failure to determine that any of the circumstances described above exist or our failure to timely notify the depositary of any such circumstances or (ii)&#160;if any agenda item which is approved at a meeting has, or is claimed to have, a material or adverse effect on the rights of holders of shares. Because there is no guarantee that ADR holders and beneficial owners will receive the notices described above with sufficient time to enable such ADR holders or beneficial owners to return any voting instructions to the depositary in a timely manner, ADR holders and beneficial owners may be deemed to have instructed the depositary to give a discretionary proxy to a person designated by us in such circumstances, and neither the depositary, the custodian nor any of their respective agents shall incur any liability to ADR holders or beneficial owners in such circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">ADR holders are strongly encouraged to forward their voting instructions to the depositary as soon as possible. For instructions to be valid, the ADR department of the depositary that is responsible for proxies and voting must receive them in the manner and on or before the time specified, notwithstanding that such instructions may have been physically received by the depositary prior to such time. The depositary will not itself exercise any voting discretion in respect of deposited securities. The depositary and its agents will not be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any voting instructions are given or deemed to be given in accordance with the deposit agreement, including instructions to give a discretionary proxy to a person designated by us, for the manner in which any vote is cast, including, without limitation, any vote cast by a person to whom the depositary is instructed to grant a discretionary proxy (or deemed to have been instructed to grant a discretionary proxy in accordance with the deposit agreement), or for the effect of any such vote. Notwithstanding anything contained in the deposit agreement or any ADR, the depositary may, to the extent not prohibited by any law, regulation, or requirement of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of or solicitation of consents or proxies from holders of deposited securities, distribute to the registered holders of ADRs a notice that provides such ADR holders with or otherwise publicizes to such ADR holders instructions on how to retrieve such materials or receive such materials upon request (<i style="font-style:italic;">i.e.</i>, by reference to a website containing the materials for retrieval or a contact for requesting copies of the materials).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have advised the depositary that under Cayman Islands law and our constituent documents, each as in effect as of the date of the deposit agreement, voting at any meeting of shareholders is by show of hands unless a poll is (before or on the declaration of the results of the show of hands) demanded. In the event that voting on any resolution or matter is conducted on a show of hands basis in accordance with our constituent documents, the depositary will refrain from voting and the voting instructions received by the depositary from ADR holders shall lapse. The depositary will not demand a poll or join in demanding a poll, whether or not requested to do so by ADR holders or beneficial owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">There is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reports and Other Communications</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Will ADR holders be able to view our reports?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary will make available for inspection by ADR holders at the offices of the depositary and the custodian the deposit agreement, the provisions of or governing deposited securities, and any written communications from us which are both received by the custodian or its nominee as a holder of deposited securities and made generally available to the holders of deposited securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, if we make any written communications generally available to holders of our shares, and we furnish copies thereof (or English translations or summaries) to the depositary, it will distribute the same to registered ADR holders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amendment and Termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">How may the deposit agreement be amended?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. ADR holders must be given at least 30 days&#8217; notice of any amendment that imposes or increases any fees or charges (other than stock transfer or other taxes and other governmental charges, transfer or registration fees, SWIFT, cable, telex or facsimile transmission costs, delivery costs or other such expenses), or otherwise prejudices any substantial existing right of ADR holders or beneficial owners. Such notice need not describe in detail the specific amendments effectuated thereby, but must identify to ADR holders and beneficial owners a means to access the text of such amendment. If an ADR holder continues to hold an ADR or ADRs after being so notified, such ADR holder and any beneficial owner are deemed to agree to such amendment and to be bound by the deposit agreement as so amended. No amendment, however, will impair your right to surrender your ADSs and receive the underlying securities, except in order to comply with mandatory provisions of applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Any amendments or supplements which (i)&#160;are reasonably necessary (as agreed by us and the depositary) in order for (a)&#160;the ADSs to be registered on Form&#160;F-6 under the Securities Act of 1933 or (b)&#160;the ADSs or shares to be traded solely in electronic book-entry form and (ii)&#160;do not in either such case impose or increase any fees or charges to be borne by ADR holders, shall be deemed not to prejudice any substantial rights of ADR holders or beneficial owners. Notwithstanding the foregoing, if any governmental body or regulatory body should adopt new laws, rules&#160;or regulations which would require amendment or supplement of the deposit agreement or the form of ADR to ensure compliance therewith, we and the depositary may amend or supplement the deposit agreement and the ADR at any time in accordance with such changed laws, rules&#160;or regulations. Such amendment or supplement to the deposit agreement in such circumstances may become effective before a notice of such amendment or supplement is given to ADR holders or within any other period of time as required for compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Notice of any amendment to the deposit agreement or form of ADRs shall not need to describe in detail the specific amendments effectuated thereby, and failure to describe the specific amendments in any such notice shall not render such notice invalid, provided, however, that, in each such case, the notice given to the ADR holders identifies a means for ADR holders and beneficial owners to retrieve or receive the text of such amendment (<i style="font-style:italic;">i.e.</i>, upon retrieval from the SEC&#8217;s, the depositary&#8217;s or our website or upon request from the depositary).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">How may the deposit agreement be terminated?</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-indent:18pt;margin:0pt;"><font style="font-size:10pt;">The depositary may, and shall at our written direction, terminate the deposit agreement and the ADRs by mailing notice of such termination to the registered holders of ADRs at least 30 days prior to the date fixed in such notice for such termination; provided, however, if the depositary shall have (i)&#160;resigned as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered ADR holders unless a successor depositary shall not be operating under the deposit agreement within 60 days of the date of such resignation, and (ii)&#160;been removed as depositary under the deposit agreement, notice of such termination by the depositary shall not be provided to registered holders of ADRs unless a successor depositary shall not be operating under the deposit agreement on the 60</font><font style="font-size:6.5pt;">th</font><font style="font-size:10pt;"> day after our notice of removal was first provided to the depositary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the shares are not listed or quoted for trading on a stock exchange or in a securities market as of the date so fixed for termination, then after such date fixed for termination (a)&#160;all direct registration ADRs shall cease to be eligible for the direct registration system and shall be considered ADRs issued on the ADR register maintained by the depositary and (b)&#160;the depositary shall use its reasonable efforts to ensure that the ADSs cease to be DTC eligible so that neither DTC nor any of its nominees shall thereafter be a holder of ADRs. At such time as the ADSs cease to be DTC eligible and/or neither DTC nor any of its nominees is a holder of ADRs, the depositary shall (a)&#160;instruct its custodian to deliver all shares and/or deposited securities to us along with a general stock power that refers to the names set forth on the ADR register maintained by the depositary and (b)&#160;provide us with a copy of the ADR register maintained by the depositary. Upon receipt of such shares and/or deposited securities and the ADR register maintained by the depositary, we have agreed to use our best efforts to issue to each register ADR holder a share certificate representing the shares represented by the ADSs reflected on the ADR register maintained by the depositary in such registered ADR holder&#8217;s name and to deliver such share certificate to the registered ADR holder at the address set forth on the ADR register maintained by the depositary. After providing such instruction to the custodian and delivering a copy of the ADR register to us, the depositary and its agents will perform no further acts under the deposit agreement or the ADRs and shall cease to have any obligations under the deposit agreement and/or the ADRs. After we receive the copy of the ADR register and the shares and/or deposited securities from the depositary, we shall be discharged from all obligations under the deposit agreement except (i)&#160;to distribute the shares to the registered ADR holders entitled thereto and (ii)&#160;for its obligations to the depositary and its agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the shares are listed or quoted for trading on a stock exchange or in a securities market as of the date so fixed for termination, then instead of the provisions in the prior paragraph, after the date so fixed for termination, the depositary and its agents will perform no further acts under the deposit agreement or the ADRs, except to receive and hold (or sell) distributions on shares and/or deposited securities and deliver shares and/or deposited securities being withdrawn. As soon as practicable after the date so fixed for termination, the depositary has agreed to use its reasonable efforts to sell the shares and/or deposited securities and shall thereafter (as long as it may lawfully do so) hold in an account (which may be a segregated or unsegregated account) the net proceeds of such sales, together with any other cash then held by it under the deposit agreement, without liability for interest, in trust for the pro rata benefit of the registered ADR holders not theretofore surrendered. After making such sale, the depositary shall be discharged from all obligations in respect of the deposit agreement and the ADRs, except to account for such net proceeds and other cash. After the date so fixed for termination, we shall be discharged from all obligations under the deposit agreement except for our obligations to the depositary and its agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Notwithstanding anything to the contrary, in connection with any such termination, the depositary may, in its sole discretion and without notice to us, establish an unsponsored American depositary share program (on such terms as the depositary may determine) for our shares and make available to ADR holders a means to withdraw the shares represented by the ADSs issued under the deposit agreement and to direct the deposit of such shares into such unsponsored American depositary share program, subject, in each case, to receipt by the depositary, at its discretion, of the fees, charges and expenses provided for under the deposit agreement and the fees, charges and expenses applicable to the unsponsored American depositary share program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Limitations on Obligations and Liability to ADR holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 9.35pt;"><font style="font-style:italic;font-weight:bold;">Limits on our obligations and the obligations of the depositary; limits on liability to ADR holders and holders of ADSs</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Prior to the issue, registration, registration of transfer, split-up, combination, or cancellation of any ADRs, or the delivery of any distribution in respect thereof, and from time to time in the case of the production of proofs as described below, we or the depositary or its custodian may require:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">payment with respect thereto of (i)&#160;any stock transfer or other tax or other governmental charge, (ii)&#160;any stock transfer or registration fees in effect for the registration of transfers of shares or other deposited securities upon any applicable register and (iii)&#160;any applicable fees and expenses described in the deposit agreement;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">the production of proof satisfactory to it of (i)&#160;the identity of any signatory and genuineness of any signature and (ii)&#160;such other information, including without limitation, information as to citizenship, residence, exchange control approval, beneficial or other ownership of, or interest in, any securities, compliance with applicable law, regulations, provisions of or governing deposited securities and terms of the deposit agreement and the ADRs, as it may deem necessary or proper; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">compliance with such regulations as the depositary may establish consistent with the deposit agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The issuance of ADRs, the acceptance of deposits of shares, the registration, registration of transfer, split-up or combination of ADRs or the withdrawal of shares, may be suspended, generally or in particular instances, when the ADR register or any register for deposited securities is closed or when any such action is deemed advisable by the depositary; provided that the ability to withdraw shares may only be limited under the following circumstances: (i)&#160;temporary delays caused by closing transfer books of the depositary or our transfer books or the deposit of shares in connection with voting at a shareholders&#8217; meeting, or the payment of dividends, (ii)&#160;the payment of fees, taxes, and similar charges, and (iii)&#160;compliance with any laws or governmental regulations relating to ADRs or to the withdrawal of deposited securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The deposit agreement expressly limits the obligations and liability of the depositary, ourselves and our respective agents, provided, however, that no disclaimer of liability under the Securities Act of 1933 is intended by any of the limitations of liabilities provisions of the deposit agreement. The deposit agreement provides that each of us, the depositary and our respective agents will:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">incur or assume no liability (including, without limitation, to holders or beneficial owners) if any present or future law, rule, regulation, fiat, order or decree of the Cayman Islands, Hong Kong, the People&#8217;s Republic of China, the United States or any other country or jurisdiction, or of any governmental or regulatory authority or securities exchange or market or automated quotation system, the provisions of or governing any deposited securities, any present or future provision of our charter, any act of God, war, terrorism, epidemic, pandemic, nationalization, expropriation, currency restrictions, work stoppage, strike, civil unrest, revolutions, rebellions, explosions, computer failure or circumstance beyond our, the depositary&#8217;s or our respective agents&#8217; direct and immediate control shall prevent or delay, or shall cause any of them to be subject to any civil or criminal penalty in connection with, any act which the deposit agreement or the ADRs provide shall be done or performed by us, the depositary or our respective agents (including, without limitation, voting);</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">incur or assume no liability (including, without limitation, to holders or beneficial owners) by reason of any non-performance or delay, caused as aforesaid, in the performance of any act or things which by the terms of the deposit agreement it is provided shall or may be done or performed or any exercise or failure to exercise discretion under the deposit agreement or the ADRs including, without limitation, any failure to determine that any distribution or action may be lawful or reasonably practicable;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">incur or assume no liability (including, without limitation, to holders or beneficial owners) if it performs its obligations under the deposit agreement and ADRs without gross negligence or willful misconduct;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">in the case of the depositary and its agents, be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities the ADSs or the ADRs;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">in the case of us and our agents, be under no obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities the ADSs or the ADRs, which in our or our agents&#8217; opinion, as the case may be, may involve it in expense or liability, unless indemnity satisfactory to us or our agent, as the case may be against all expense (including fees and disbursements of counsel) and liability be furnished as often as may be requested;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">not be liable (including, without limitation, to holders or beneficial owners) for any action or inaction by it in reliance upon the advice of or information from any legal counsel, any accountant, any person presenting shares for deposit, any registered holder of ADRs, or any other person believed by it to be competent to give such advice or information and/or, in the case of the depositary, us; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">may rely and shall be protected in acting upon any written notice, request, direction, instruction or document believed by it to be genuine and to have been signed, presented or given by the proper party or parties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Neither the depositary nor its agents have any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities, the ADSs or the ADRs. We and our agents shall only be obligated to appear in, prosecute or defend any action, suit or other proceeding in respect of any deposited securities, the ADSs or the ADRs, which in our opinion may involve us in expense or liability, if indemnity satisfactory to us against all expense (including fees and disbursements of counsel) and liability is furnished as often as may be required. The depositary and its agents may fully respond to any and all demands or requests for information maintained by or on its behalf in connection with the deposit agreement, any registered holder or holders of ADRs, any ADRs or otherwise related to the deposit agreement or ADRs to the extent such information is requested or required by or pursuant to any lawful authority, including without limitation laws, rules, regulations, administrative or judicial process, banking, securities or other regulators. The depositary shall not be liable for the acts or omissions made by, or the insolvency of, any securities depository, clearing agency or settlement system. Furthermore, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, the insolvency of any custodian that is not a branch or affiliate of JPMorgan. Notwithstanding anything to the contrary contained in the deposit agreement or any ADRs, the depositary shall not be responsible for, and shall incur no liability in connection with or arising from, any act or omission to act on the part of the custodian except to the extent that any registered ADR holder has incurred liability directly as a result of the custodian having (i)&#160;committed fraud or willful misconduct in the provision of custodial services to the depositary or (ii)&#160;failed to use reasonable care in the provision of custodial services to the depositary as determined in accordance with the standards prevailing in the jurisdiction in which the custodian is located. The depositary and the custodian(s)&#160;may use third party delivery services and providers of information regarding matters such as, but not limited to, pricing, proxy voting, corporate actions, class action litigation and other services in connection with the ADRs and the deposit agreement, and use local agents to provide services such as, but not limited to, attendance at any meetings of security holders of issuers. Although the depositary and the custodian will use reasonable care (and cause their agents to use reasonable care) in the selection and retention of such third party providers and local agents, they will not be responsible for any errors or omissions made by them in providing the relevant information or services. The depositary shall not have any liability for the price received in connection with any sale of securities, the timing thereof or any delay in action or omission to act nor shall it be responsible for any error or delay in action, omission to act, default or negligence on the part of the party so retained in connection with any such sale or proposed sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary has no obligation to inform ADR holders or beneficial owners about the requirements of the laws, rules&#160;or regulations or any changes therein or thereto of the Cayman Islands, Hong Kong, the People&#8217;s Republic of China, the United States or any other country or jurisdiction or of any governmental or regulatory authority or any securities exchange or market or automated quotation system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, none of the depositary, the custodian or us, or any of their or our respective directors, officers, employees, agents or affiliates shall be liable for the failure by any registered holder of ADRs or beneficial owner therein to obtain the benefits of credits or refunds of non-U.S. tax paid against such ADR holder&#8217;s or beneficial owner&#8217;s income tax liability. The depositary is under no obligation to provide the ADR holders and beneficial owners, or any of them, with any information about our tax status. None of the depositary, custodian, us or any of their or our respective directors, officers, employees, agents or affiliates shall incur any liability for any tax or tax consequences that may be incurred by registered ADR holders or beneficial owners on account of their ownership or disposition of ADRs or ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Neither the depositary nor its agents will be responsible for any failure to carry out any instructions to vote any of the deposited securities, for the manner in which any voting instructions are given or deemed to be given pursuant to the terms of the deposit agreement, including instructions to give a discretionary proxy to a person designated by us, for the manner in which any vote is cast, including, without limitation, any vote cast by a person to whom the depositary is instructed (or deemed to have been instructed to grant a discretionary proxy in accordance with the deposit agreement), or for the effect of any such vote. The depositary may rely upon instructions from us or our counsel in respect of any approval or license required for any currency conversion, transfer or distribution. The depositary shall not incur any liability for the content of any information submitted to it by us or on our behalf for distribution to ADR holders or for any inaccuracy of any translation thereof, for any investment risk associated with acquiring an interest in the deposited securities, for the validity or worth of the deposited securities, for the credit-worthiness of any third party, for allowing any rights to lapse upon the terms of the deposit agreement or for the failure or timeliness of any notice from us. The depositary shall not be liable for any acts or omissions made by a successor depositary whether in connection with a previous act or omission of the depositary or in connection with any matter arising wholly after the removal or resignation of the depositary. Subject to certain customary exceptions, neither the depositary nor us, nor any of its or our agents shall be liable to the other for any indirect, special, punitive or consequential damages (excluding reasonable fees and expenses of counsel) or lost profits, in each case of any form incurred by any of them, or liable to any other person or entity (including, without limitation holders or beneficial owners of ADRs and ADSs) for any indirect, special, punitive or consequential damages (including fees and expenses of counsel) or lost profits, whether or not foreseeable and regardless of the type of action in which such a claim may be brought.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the deposit agreement each party thereto (including, for avoidance of doubt, each ADR holder and beneficial owner) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the shares or other deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory). No provision of the deposit agreement or the ADRs is intended to constitute a waiver or limitation of any rights which an ADR holder or any beneficial owner may have under the Securities Act of 1933 or the Securities Exchange Act of 1934, to the extent applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary and its agents may own and deal in any class of securities of our company and our affiliates and in ADRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Disclosure of Interest in ADSs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">To the extent that the provisions of or governing any deposited securities may require disclosure of or impose limits on beneficial or other ownership of, or interest in, deposited securities, other shares and other securities and may provide for blocking transfer, voting or other rights to enforce such disclosure or limits, you as ADR holders or beneficial owners agree to comply with all such disclosure requirements and ownership limitations and to comply with any reasonable instructions we may provide in respect thereof. We reserve the right to instruct you as ADS holders to deliver your ADSs for cancellation and withdrawal of the deposited securities so as to permit us to deal directly with the holder thereof as a holder of shares and, by holding an ADS or an interest therein, you and beneficial owners will be agreeing to comply with such instructions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Books of Depositary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary or its agent will maintain a register for the registration, registration of transfer, combination and split-up of ADRs, which register shall include the depositary&#8217;s direct registration system. Registered holders of ADRs may inspect such records at the depositary&#8217;s office at all reasonable times, but solely for the purpose of communicating with other ADR holders in the interest of the business of our company or a matter relating to the deposit agreement. Such register may be closed at any time or from time to time, when deemed expedient by the depositary or, in the case of the issuance book portion of the ADR Register, when reasonably requested by the Company solely in order to enable the Company to comply with applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The depositary will maintain facilities for the delivery and receipt of ADRs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Appointment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the deposit agreement, each registered holder of ADRs and each beneficial owner, upon acceptance of any ADSs or ADRs (or any interest in any of them) issued in accordance with the terms and conditions of the deposit agreement will be deemed for all purposes to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">be a party to and bound by the terms of the deposit agreement and the applicable ADR or ADRs,</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">appoint the depositary its attorney-in-fact, with full power to delegate, to act on its behalf and to take any and all actions contemplated in the deposit agreement and the applicable ADR or ADRs, to adopt any and all procedures necessary to comply with applicable laws and to take such action as the depositary in its sole discretion may deem necessary or appropriate to carry out the purposes of the deposit agreement and the applicable ADR and ADRs, the taking of such actions to be the conclusive determinant of the necessity and appropriateness thereof; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">acknowledge and agree that (i)&#160;nothing in the deposit agreement or any ADR shall give rise to a partnership or joint venture among the parties thereto, nor establish a fiduciary or similar relationship among such parties, (ii)&#160;the depositary, its divisions, branches and affiliates, and their respective agents, may from time to time be in the possession of non-public information about us, ADR holders, beneficial owners and/or their respective affiliates, (iii)&#160;the depositary and its divisions, branches and affiliates may at any time have multiple banking relationships with us, ADR holders, beneficial owners and/or the affiliates of any of them, (iv)&#160;the depositary and its divisions, branches and affiliates may, from time to time, be engaged in transactions in which parties adverse to us, ADR holders, beneficial owners and/or their respective affiliates may have interests, (v)&#160;nothing contained in the deposit agreement or any ADR(s)&#160;shall (A)&#160;preclude the depositary or any of its divisions, branches or affiliates from engaging in any such transactions or establishing or maintaining any such relationships, or (B)&#160;obligate the depositary or any of its divisions, branches or affiliates to disclose any such transactions or relationships or to account for any profit made or payment received in any such transactions or relationships, (vi)&#160;the depositary shall not be deemed to have knowledge of any information held by any branch, division or affiliate of the depositary and (vii)&#160;notice to an ADR holder shall be deemed, for all purposes of the deposit agreement and the ADRs, to constitute notice to any and all beneficial owners of the ADSs evidenced by such ADR holder&#8217;s ADRs. For all purposes under the deposit agreement and the ADRs, the ADR holders thereof shall be deemed to have all requisite authority to act on behalf of any and all beneficial owners of the ADSs evidenced by such ADRs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Governing Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The deposit agreement, the ADSs and the ADRs are governed by and construed in accordance with the internal laws of the State of New York. In the deposit agreement, we have submitted to the non-exclusive jurisdiction of the courts of the State of New York and appointed an agent for service of process on our behalf. Any action based on the deposit agreement, the ADSs, the ADRs or the transactions contemplated therein or thereby may also be instituted by the depositary against us in any competent court in the Cayman Islands, Hong Kong, the People&#8217;s Republic of China and the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the deposit agreement, by holding or owning an ADR or ADS or an interest therein, ADR holders and beneficial owners each irrevocably agree that any legal suit, action or proceeding against or involving ADR holders or beneficial owners brought by us or the depositary, arising out of or based upon the deposit agreement, the ADSs, the ADRs or the transactions contemplated thereby, may be instituted in a state or federal court in New York, New York, irrevocably waive any objection which you may have to the laying of venue of any such proceeding, and irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. By holding or owning an ADR or ADS or an interest therein, ADR holders and beneficial owners each also irrevocably agree that any legal suit, action or proceeding against or involving the depositary brought by ADR holders or beneficial owners, arising out of or based upon the deposit agreement, the ADSs, the ADRs or the transactions contemplated thereby, may only be instituted in a state or federal court in New York, New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Notwithstanding the foregoing, (i)&#160;the depositary may, in its sole discretion, elect to institute any dispute, suit, action, controversy, claim or proceeding directly or indirectly based on, arising out of or relating to the deposit agreement, the ADSs, the ADRs or the transactions contemplated therein or thereby, including without limitation any question regarding its or their existence, validity, interpretation, performance or termination, against any other party or parties to the deposit agreement (including, without limitation, against ADR holders and beneficial owners of interests in ADSs), by having the matter referred to and finally resolved by an arbitration conducted under the terms described below, and (ii)&#160;the depositary may in its sole discretion require, by written notice to the relevant party or parties, that any dispute, suit, action, controversy, claim or proceeding against the depositary by any party or parties to the deposit agreement (including, without limitation, by ADR holders and beneficial owners of interests in ADSs) shall be referred to and finally settled by an arbitration conducted under the terms described below. Any such arbitration shall be conducted in the English language either in New York, New York in accordance with the Commercial Arbitration Rules&#160;of the American Arbitration Association or in Hong Kong following the arbitration rules&#160;of the United Nations Commission on International Trade Law (UNCITRAL).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jury Trial Waiver</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In the deposit agreement, each party thereto (including, for the avoidance of doubt, each holder and beneficial owner of, and/or holder of interests in, ADSs or ADRs) irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any suit, action or proceeding against the depositary and/or us directly or indirectly arising out of or relating to the shares or other deposited securities, the ADSs or the ADRs, the deposit agreement or any transaction contemplated therein, or the breach thereof (whether based on contract, tort, common law or any other theory), including any claim under the U.S. federal securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If we or the depositary were to oppose a jury trial demand based on such waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable state and federal law, including whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. The waiver to right to a jury trial in the deposit agreement is not intended to be deemed a waiver by any holder or beneficial owner of ADSs of our or the depositary&#8217;s compliance with the U.S. federal securities laws and the rules&#160;and regulations promulgated thereunder.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>adag-20221231xex8d1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 8.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Subsidiaries</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Place&#160;of&#160;Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hong Kong</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRC</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene Incorporated</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware, United States</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAGENE PTE. LTD.</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Singapore</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAGENE AUSTRALIA PTY LTD</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAGENE AG</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene Project C1 Pte. Ltd.</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Singapore</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene (Suzhou) Limited Beijing Branch</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRC</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>adag-20221231xex12d1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 12.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certification by the Principal Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Peter (Peizhi) Luo, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I have reviewed this annual report on Form 20-F of Adagene Inc. (the &quot;company&quot;);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</p></td></tr></table><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 28 2023</p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:50.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:50.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:bottom;width:44.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>adag-20221231xex12d2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 12.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certification by the Principal Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Man Kin (Raymond) Tam, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">I have reviewed this annual report on Form 20-F of Adagene Inc. (the &#8220;company&#8221;);</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</p></td></tr></table><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 28 2023</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:48.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:48.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:45.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:48.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal financial and accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>adag-20221231xex13d1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:27 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 13.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certification by the Principal Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 24pt 0pt;"><b style="font-weight:bold;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Adagene Inc. (the &#8220;Company&#8221;) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter (Peizhi) Luo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 28 2023</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>adag-20221231xex13d2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:28 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 13.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Certification by the Principal Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Adagene Inc. (the &#8220;Company&#8221;) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Man Kin (Raymond) Tam, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr><td style="vertical-align:bottom;width:50.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 28 2023</p></td></tr><tr><td style="vertical-align:bottom;width:50.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:50.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.71%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:50.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: </p></td><td style="vertical-align:bottom;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal financial and accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>adag-20221231xex15d1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:29 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 15.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;"><img src="adag-20221231xex15d1001.jpg" alt="Graphic" style="display:inline-block;height:58.5pt;width:203.25pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34/F, Tower 3, China Central Place, 77 Jianguo Road, Beijing 100025, China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="white-space:pre-wrap;">T: (86-10) 5809 1000   F: (86-10) 5809 1100</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">April 28 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adagene Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4F, Building C14, No. 218</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xinghu Street, Suzhou Industrial Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suzhou, Jiangsu Province, 215123</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">People&#8217;s republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(as the &#8220;<b style="font-weight:bold;">Company</b>&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dear Sirs,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the references to our firm under the headings &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8221; and &#8220;Item 4. Information on the Company&#8212;4.A. History and Development of the Company&#8221; in Adagene Inc.&#8217;s Annual Report on Form&#160;20-F for the year ended December&#160;31, 2022 (the &#8220;<b style="font-weight:bold;">Annual Report</b>&#8221;), which will be filed with the Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;) on&#160;April 28 2023 and further consent to the incorporation by reference of the summaries of our opinions under the headings &#8220;Item 3. Key Information&#8212;3.D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company&#8212;4.A. History and Development of the Company&#8221; and &#8220;Item 10. Additional Information&#8212;10.E. Taxation&#8212;Material PRC Income Tax Considerations&#8221; in the Annual Report into the registration statements (No. 333-255250) on Form S-8 and (No. 333-264486) on Form F-3. We also consent to the filing with the SEC of this consent letter as an exhibit to the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section&#160;7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Yours faithfully,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jingtian &amp; Gongcheng</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Jingtian &amp; Gongcheng</b></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>9
<FILENAME>adag-20221231xex15d2.htm
<DESCRIPTION>EXHIBIT 15.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:32 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 15.2</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4.5pt 0pt;"><font style="font-size:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">28 April 2023<font style="display:inline-block;width:192.12pt;"></font>Our Ref: NASD/KH/A6545-H22467</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Adagene Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4F, Building C14, No. 218</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Xinghu Street, Suzhou Industrial Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Suzhou, Jiangsu Province, 215123</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">People<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Sirs or Madam</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADAGENE INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM 20-F</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We consent to the reference to our firm under the heading <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Item 10.E. Taxation <font style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</font>Cayman Islands Taxation<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> and <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Item 16.G. Corporate Governance<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> in the Annual Report on Form 20-F of Adagene Inc. for the fiscal year ended 31 December 2022 (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Annual Report</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>), which will be filed with the U.S. Securities and Exchange Commission (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Commission</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>) under the U.S. Securities Exchange Act of 1934, as amended (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Exchange Act</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>) in the month of April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We hereby consent to the filing of this opinion as an exhibit to the Annual Report and to the reference to our name in the Annual Report, and further consent to the incorporation by reference into the Registration Statement on Form S-8 (No. 333-255250) and Registration Statement on Form F-3 (333-264486).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under the Exchange Act, or the Rules and Regulations of the Commission thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 48pt 0pt;">Yours faithfully</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/S/ WALKERS (HONG KONG)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WALKERS (HONG KONG)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><b style="font-weight:bold;">Walkers (Hong Kong)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><b style="font-family:'MS Gothic';font-weight:bold;">&#28377;&#22025;&#24459;&#24107;&#20107;&#21209;&#25152;</b><b style="font-weight:bold;"> (</b><b style="font-family:'MS Gothic';font-weight:bold;">&#39321;&#28207;</b><b style="font-weight:bold;">)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">15th Floor, Alexandra House, 18 Chater Road, Central, Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">T</b><font style="white-space:pre-wrap;">  +852 2284 4566  </font><b style="font-weight:bold;">F</b><font style="white-space:pre-wrap;">  +852 2284 4560  www.walkersglobal.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Bermuda | British Virgin Islands | Cayman Islands | Dubai | Guernsey | Hong Kong | Ireland | Jersey | London | Singapore</p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><font style="white-space:pre-wrap;"> *England and Wales; **BVI; ***Cayman Islands; ****New South Wales (Australia); ******Victoria (Australia); *******Bermuda</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.3
<SEQUENCE>10
<FILENAME>adag-20221231xex15d3.htm
<DESCRIPTION>EXHIBIT 15.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:42 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 15.3</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;"><img src="adag-20221231xex15d3001.jpg" alt="Graphic" style="display:inline-block;height:43.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:266.7pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nancy E. Taylor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tel 202.331.3133</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fax 202.261.0133</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">taylorn@gtlaw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">April 28 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adagene Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4F, Building C14, No. 218</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xinghu Street, Suzhou Industrial Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suzhou, Jiangsu Province, 215123</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">People&#8217;s republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To Whom It May Concern:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the references to our summary of opinions under the headings &#8220;Item 4.B. Business Overview&#8212;Regulation&#8212;United States Regulation&#8221; in Adagene Inc.&#8217;s Annual Report on Form&#160;20-F for the year ended December&#160;31, 2022 (the &#8220;<b style="font-weight:bold;">Annual Report</b>&#8221;), which will be filed with the Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;) on April 28 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We hereby consent to the filing of this opinion as an exhibit to the Annual Report and to the reference to our name in the Annual Report, and further consent to the incorporation by reference into the Registration Statement on Form S-8 (No. 333-255250) and Registration Statement on Form F-3 (333-264486).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section&#160;7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Best regards,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Nancy E. Taylor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Nancy E. Taylor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Shareholder</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.4
<SEQUENCE>11
<FILENAME>adag-20221231xex15d4.htm
<DESCRIPTION>EXHIBIT 15.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:45 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;15.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File No. 333-255250) and Form F-3 (File No. 333-264486) of Adagene Inc. of our report dated April 28, 2023 relating to the financial statements, which appears in this Form 20-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/PricewaterhouseCoopers Zhong Tian LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shanghai, the People&#8217;s Republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 28, 2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.5
<SEQUENCE>12
<FILENAME>adag-20221231xex15d5.htm
<DESCRIPTION>EXHIBIT 15.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/28/2023 10:19:50 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 15.5</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">April 28 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">VIA EDGAR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Division of Corporation Finance</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">U.S. Securities &amp; Exchange Commission</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">100 F Street, NE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Washington, D.C. 20549</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.25pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:16.55pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">Re:</font></p></td><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">Adagene Inc.</font></p></td></tr><tr style="height:16.55pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">Submission under the Item 16I(a) of Form 20-F</font></p></td></tr><tr style="height:16.55pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td></tr><tr style="height:16.55pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><i style="font-size:11pt;font-style:italic;">Attn:</i></p></td><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><i style="font-size:11pt;font-style:italic;">Division of Corporation Finance</i></p></td></tr><tr style="height:16.55pt;"><td style="vertical-align:top;width:7%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td><td style="vertical-align:top;width:93%;margin:0pt;padding:0pt 0pt 0pt 10pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:10pt;text-indent:-10pt;margin:0pt;"><i style="font-size:11pt;font-style:italic;">Office of Life Sciences</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">Dear Sir/Madam,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">In compliance with the Holding Foreign Companies Accountable Act, Adagene Inc. (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Company</b><font style="font-size:11pt;">&#8221;) is submitting via EDGAR the following information as required under Item 16I(a) of Form 20-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">For the immediately preceding annual financial statement period, the Company&#8217;s auditor, PricewaterhouseCoopers Zhong Tian LLP (a registered public accounting firm that The United States Public Company Accounting Oversight Board was unable to inspect or investigate completely) issued an audit report for the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">To the Company&#8217;s best knowledge and based on an examination of our register of members and public filings made by our shareholders, including among others, the Schedule 13G/A filed by JSR Limited on February 6, 2023 and by FMR LLC on February 9, 2023, the Schedule 13G filed by FIL LTD on February 2021 and by WuXi PharmaTech Healthcare Fund I L.P. on January 26, 2022, and the Schedule 13D/A filed by Peter Luo Acting-in-Concert Group on February 17, 2023 (collectively, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Public Filings</b><font style="font-size:11pt;">&#8221;), the Company respectfully submits that it is not owned or controlled by a governmental entity in the foreign jurisdiction as of the date of this submission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">Based on an examination of the Company&#8217;s register of members and Public Filings made by the Company&#8217;s shareholders, no shareholder owns more than 5% of the Company&#8217;s outstanding shares as of March 31, 2023 other than Peter Luo Acting-in-Concert Group, JSR Limited, Asia Ventures II L.P., F-Prime Capital Partners Healthcare Fund III LP, Wuxi Pharmatech Healthcare Fund I L.P. and General Atlantic Singapore AI Pte. Ltd. (collectively, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Principal Shareholders</b><font style="font-size:11pt;">&#8221;). The Principal Shareholders collectively beneficially own 68.9% of the Company&#8217;s total outstanding shares. Based on the Public Filings made by the Company&#8217;s Principal Shareholders, none of the Principal Shareholders is owned or controlled by a governmental entity in the foreign jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">In addition, the Company is not aware of any governmental entity that is in possession of, direct or indirect, of the power to direct or cause the direction of the management and policies of the Company, whether through the ownership of voting securities, by contract, or otherwise.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Very truly yours,</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter Luo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Peter Luo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>adag-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2023 10:19:42 AM-->
<!--Modified on: 4/28/2023 10:19:42 AM-->
<xsd:schema targetNamespace="http://www.adagene.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:adag="http://www.adagene.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" id="DisclosureAccountsReceivableNetDetails">
        <link:definition>40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" id="DisclosurePrepaymentsAndOtherCurrentAssetsDetails">
        <link:definition>40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" id="DisclosurePropertyEquipmentAndSoftwareNetDetails">
        <link:definition>40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" id="DisclosureAccrualsAndOtherCurrentLiabilitiesDetails">
        <link:definition>40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" id="DisclosureBorrowingsComponentsDetails">
        <link:definition>40701 - Disclosure - BORROWINGS - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" id="DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails">
        <link:definition>40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails">
        <link:definition>41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" id="DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails">
        <link:definition>41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" id="DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
        <link:definition>41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" id="DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails">
        <link:definition>41402 - Disclosure - LEASES - Information related to operating lease activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" id="DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails">
        <link:definition>41403 - Disclosure - LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>41404 - Disclosure - LEASES - Maturities of lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" id="DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2">
        <link:definition>41404 - Disclosure - LEASES - Maturities of lease liabilities (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" id="DisclosureOrganizationAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails">
        <link:definition>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" id="DisclosureBorrowingsShortTermBorrowingsDetails">
        <link:definition>40702 - Disclosure - BORROWINGS - Short term borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" id="DisclosureBorrowingsLongTermBorrowingsDetails">
        <link:definition>40703 - Disclosure - BORROWINGS - Long term borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails">
        <link:definition>40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails">
        <link:definition>40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>40901 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails">
        <link:definition>40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" id="DisclosureCollaborationArrangementsDetails">
        <link:definition>41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" id="DisclosureIncomeTaxExpenseDetails">
        <link:definition>41101 - Disclosure - INCOME TAX EXPENSE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
        <link:definition>41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureTreasurySharesDetails" id="DisclosureTreasurySharesDetails">
        <link:definition>41701 - Disclosure - Treasury Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41801 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" id="StatementConsolidatedStatementsOfComprehensiveLossParenthetical">
        <link:definition>00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation" id="DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNet" id="DisclosureAccountsReceivableNet">
        <link:definition>10301 - Disclosure - ACCOUNTS RECEIVABLE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets" id="DisclosurePrepaymentsAndOtherCurrentAssets">
        <link:definition>10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet" id="DisclosurePropertyEquipmentAndSoftwareNet">
        <link:definition>10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities" id="DisclosureAccrualsAndOtherCurrentLiabilities">
        <link:definition>10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowings" id="DisclosureBorrowings">
        <link:definition>10701 - Disclosure - BORROWINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrants">
        <link:definition>10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10901 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangements" id="DisclosureCollaborationArrangements">
        <link:definition>11001 - Disclosure - COLLABORATION ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpense" id="DisclosureIncomeTaxExpense">
        <link:definition>11101 - Disclosure - INCOME TAX EXPENSE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11201 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11301 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>11401 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11501 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssets" id="DisclosureRestrictedNetAssets">
        <link:definition>11601 - Disclosure - RESTRICTED NET ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureTreasuryShares" id="DisclosureTreasuryShares">
        <link:definition>11701 - Disclosure - Treasury Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11801 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables" id="DisclosureOrganizationAndBasisOfPresentationTables">
        <link:definition>30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetTables" id="DisclosureAccountsReceivableNetTables">
        <link:definition>30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables" id="DisclosurePrepaymentsAndOtherCurrentAssetsTables">
        <link:definition>30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" id="DisclosurePropertyEquipmentAndSoftwareNetTables">
        <link:definition>30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables" id="DisclosureAccrualsAndOtherCurrentLiabilitiesTables">
        <link:definition>30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsTables" id="DisclosureBorrowingsTables">
        <link:definition>30703 - Disclosure - BORROWINGS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables">
        <link:definition>30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables" id="DisclosureIncomeTaxExpenseTables">
        <link:definition>31101 - Disclosure - INCOME TAX EXPENSE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31203 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeasesTable" id="DisclosureLeasesTable">
        <link:definition>31403 - Disclosure - LEASES (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails">
        <link:definition>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails">
        <link:definition>40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails" id="DisclosureShareBasedCompensationShareOptionActivitiesDetails">
        <link:definition>40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" id="DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails">
        <link:definition>40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" id="DisclosureShareBasedCompensationFairValueOfShareOptionsDetails">
        <link:definition>40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails" id="DisclosureIncomeTaxExpenseValuationAllowanceDetails">
        <link:definition>41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41201 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails" id="DisclosureLeasesInformationRelatedToOperatingLeasesDetails">
        <link:definition>41401 - Disclosure - LEASES - Information related to operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails" id="DisclosureRestrictedNetAssetsDetails">
        <link:definition>41601 - Disclosure - RESTRICTED NET ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="adag_SummaryOfPrincipalSubsidiariesTableTextBlock" name="SummaryOfPrincipalSubsidiariesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneHongKongLimitedMember" name="AdageneHongKongLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneIncorporatedMember" name="AdageneIncorporatedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneSuzhouLimitedMember" name="AdageneSuzhouLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneAustraliaPtyLtd.Member" name="AdageneAustraliaPtyLtd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" name="AccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="adag_RestrictedNetAssetsAbstract" name="RestrictedNetAssetsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" name="MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" name="StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AfterTaxIncomePercentageAppropriations" name="AfterTaxIncomePercentageAppropriations" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" name="ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_Series1RedeemableConvertiblePreferredStockMember" name="Series1RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_Series2RedeemableConvertiblePreferredStockMember" name="Series2RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC1RedeemableConvertiblePreferredStockMember" name="SeriesC1RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC2RedeemableConvertiblePreferredStockMember" name="SeriesC2RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC3RedeemableConvertiblePreferredStockMember" name="SeriesC3RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ResearchAndDevelopmentExpenseThirdParties" name="ResearchAndDevelopmentExpenseThirdParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" name="RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_WuxiApptecGroupMember" name="WuxiApptecGroupMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_CollaborationArrangementsAbstract" name="CollaborationArrangementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" name="GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdctCollaborationAgreementMember" name="AdctCollaborationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_CollaborativeArrangementUpfrontCashPaymentReceived" name="CollaborativeArrangementUpfrontCashPaymentReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" name="AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" name="MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" name="MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_PeriodForReservationOfTargetRight" name="PeriodForReservationOfTargetRight" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PreferentialIncomeTaxRate" name="PreferentialIncomeTaxRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" name="EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AssessableProfits" name="AssessableProfits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_WithholdingIncomeTaxes" name="WithholdingIncomeTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" name="EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" name="DisclosureOfTemporaryEquityAndWarrantsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" name="DisclosureOfTemporaryEquityAndWarrantsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC1WarrantsMember" name="SeriesC1WarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_NumberOfInvestorsToWhomWarrantsWereIssued" name="NumberOfInvestorsToWhomWarrantsWereIssued" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_MaximumProceedsReceivableFromExerciseOfWarrants" name="MaximumProceedsReceivableFromExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" name="ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" name="BorrowingsFromAgriculturalBankOfChinaLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromBankOfNingboCo.LtdMember" name="BorrowingsFromBankOfNingboCo.LtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromBankOfJiangsuCo.LtdMember" name="BorrowingsFromBankOfJiangsuCo.LtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" name="BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" name="BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" name="AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_GovernmentSubsidiesPolicyTextBlock" name="GovernmentSubsidiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_NumberOfMajorSupplier" name="NumberOfMajorSupplier" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_Plan2015Member" name="Plan2015Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_Plan2017Member" name="Plan2017Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_Plan2019Member" name="Plan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" name="DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PayablesForDeferredInitialPublicOfferingCost" name="PayablesForDeferredInitialPublicOfferingCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_AdagenePte.Ltd.Member" name="AdagenePte.Ltd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneAgMember" name="AdageneAgMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PercentageOfDepreciationOfForeignCurrency" name="PercentageOfDepreciationOfForeignCurrency" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ChinaMerchantsBankCo.LtdMember" name="ChinaMerchantsBankCo.LtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" name="ChinaMerchantsBankCo.LtdLoanTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" name="BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_NumberOfSharesSurrendered" name="NumberOfSharesSurrendered" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" name="ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_PerformanceIncentivePlan2021Member" name="PerformanceIncentivePlan2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_StatusForTaxabilityAxis" name="StatusForTaxabilityAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_StatusForTaxabilityDomain" name="StatusForTaxabilityDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TechnologyAdvancedServiceEnterprisesMember" name="TechnologyAdvancedServiceEnterprisesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TaxableIncome" name="TaxableIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" name="ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_EmployeeDefinedContributionPlanPolicyTextBlock" name="EmployeeDefinedContributionPlanPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_FinancialAssetsFairValueDisclosure" name="FinancialAssetsFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_ElectronicEquipmentMember" name="ElectronicEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" name="CashAndCashEquivalentsAndShortTermInvestmentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_MainlandOfChinaMember" name="MainlandOfChinaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_OutsideMainlandOfChinaMember" name="OutsideMainlandOfChinaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ConcentrationRiskSuppliersAxis" name="ConcentrationRiskSuppliersAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ConcentrationRiskSuppliersDomain" name="ConcentrationRiskSuppliersDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_OneSupplierMember" name="OneSupplierMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RetirementOfTreasuryShares" id="adag_RetirementOfTreasuryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NonCashActivitiesRetirementOfTreasuryShares" id="adag_NonCashActivitiesRetirementOfTreasuryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharesSurrenderedSharesForRepaymentOfPromissoryNotes" id="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockSurrenderedValueForRepaymentOfPromissoryNotes" id="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentReceived" id="adag_CollaborativeArrangementMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExelixisIncAgreementMember" id="adag_ExelixisIncAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementUpfrontCashPaymentReceivable" id="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" id="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentsReceivableSalesBasedMilestones" id="adag_MilestonePaymentsReceivableSalesBasedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ServiceConditionsAndPerformanceConditionsMember" id="adag_ServiceConditionsAndPerformanceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockSubscriptionsValue" id="adag_CommonStockSubscriptionsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="InterestIncomeExpenseOnPromissoryNotes" id="adag_InterestIncomeExpenseOnPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" id="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WithholdingTaxRateOnDividendsPercentage" id="adag_WithholdingTaxRateOnDividendsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CapitalTaxRatePercentage" id="adag_CapitalTaxRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GovernmentSubsidiesReceived" id="adag_GovernmentSubsidiesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdageneProjectC1Pte.Ltd.Member" id="adag_AdageneProjectC1Pte.Ltd.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" id="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdctMaterialTransferAndOptionAgreementMember" id="adag_AdctMaterialTransferAndOptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SanofiAgreementMember" id="adag_SanofiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" id="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InformationRelatedToOperatingLeasesTableTextBlock" id="adag_InformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InformationRelatedToOperatingLeaseActivityTableTextBlock" id="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OperatingLeaseRightOfUseAssetsAbstract" id="adag_OperatingLeaseRightOfUseAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OperatingLeaseRentalExpenseAbstract" id="adag_OperatingLeaseRentalExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InterestOfOperatingLeaseLiabilities" id="adag_InterestOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseRentalExpense" id="adag_OperatingLeaseRentalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" id="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WuxiBiologicsCaymanInc.Member" id="adag_WuxiBiologicsCaymanInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChinaConstructionBankCorporationMember" id="adag_ChinaConstructionBankCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" id="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareRepurchaseProgramOf2021Member" id="adag_ShareRepurchaseProgramOf2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareRepurchaseProgramOf2022Member" id="adag_ShareRepurchaseProgramOf2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>adag-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2023 10:19:42 AM-->
<!--Modified on: 4/28/2023 10:19:42 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccountsReceivableNetDetails" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePrepaymentsAndOtherCurrentAssetsDetails" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePropertyEquipmentAndSoftwareNetDetails" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsComponentsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" roleURI="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" />
  <calculationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637516889408721249" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638182739806185301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_OtherAssetsNoncurrent_638182739806185301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638182739806185301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638182739806185301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638182739806185301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638182739806185301" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638182739806185301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_AssetsCurrent_638182739806185301" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638182739806185301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638182739806185301" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638182739806185301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638182739806185301" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_638182739806195299" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638182739806185301" xlink:to="us-gaap_AccountsReceivableNetCurrent_638182739806195299" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638182739806185301" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638182739806195299" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" xlink:to="us-gaap_Liabilities_638182739806195299" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638182739806195299" xlink:to="us-gaap_LiabilitiesCurrent_638182739806195299" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_AccountsPayableCurrent_638182739806195299" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_638182739806195299" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638182739806195299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638182739806195299" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638182739806205301" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638182739806205301" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_638182739806205301" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_LongTermDebtCurrent_638182739806205301" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638182739806195299" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638182739806205301" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638182739806195299" xlink:to="us-gaap_LongTermDebtNoncurrent_638182739806205301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638182739806195299" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638182739806205301" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638182739806205301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638182739806195299" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638182739806205301" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638182739806195299" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638182739806215301" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" xlink:to="us-gaap_StockholdersEquity_638182739806215301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638182739806215301" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638182739806215301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638182739806215301" xlink:to="us-gaap_AdditionalPaidInCapital_638182739806215301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638182739806215301" xlink:to="us-gaap_CommonStockValue_638182739806215301" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638182739806215301" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638182739806215301" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue_638182739806215301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638182739806215301" xlink:to="us-gaap_TreasuryStockCommonValue_638182739806215301" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637516889408811006" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638182739806225302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637516889408811006" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638182739806225302" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638182739806225302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637516889408811006" xlink:to="us-gaap_NetIncomeLoss_638182739806225302" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638182739806235300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_638182739806235300" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638182739806235300" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638182739806245301" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638182739806235300" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739806245301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" xlink:to="us-gaap_InterestExpense_638182739806245301" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" xlink:to="us-gaap_OtherNonoperatingIncome_638182739806245301" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" xlink:to="us-gaap_InvestmentIncomeNonoperating_638182739806245301" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638182739806245301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739806245301" xlink:to="us-gaap_OperatingIncomeLoss_638182739806245301" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638182739806255305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638182739806245301" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638182739806255305" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638182739806255305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638182739806245301" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638182739806255305" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_638182739806255305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638182739806255305" xlink:to="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_638182739806255305" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ResearchAndDevelopmentExpenseThirdParties" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_638182739806255305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638182739806255305" xlink:to="adag_ResearchAndDevelopmentExpenseThirdParties_638182739806255305" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638182739806255305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638182739806245301" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638182739806255305" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739806255305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739806255305" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_RepaymentsOfDebt_638182739806275301" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_ProceedsFromContributedCapital_638182739806275301" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638182739806275301" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638182739806275301" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638182739806275301" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_638182739806275301" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RetirementOfTreasuryShares" xlink:label="adag_RetirementOfTreasuryShares_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="adag_RetirementOfTreasuryShares_638182739806275301" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638182739806275301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739806275301" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638182739806275301" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739806285300" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739806285300" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638182739806285300" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739806285300" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_638182739806285300" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739806285300" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_638182739806285300" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_ProfitLoss_638182739806285300" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638182739806285300" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" xlink:label="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_638182739806285300" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638182739806285300" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_ShareBasedCompensation_638182739806285300" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InterestIncomeExpenseOnPromissoryNotes" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="adag_InterestIncomeExpenseOnPromissoryNotes_638182739806295301" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" xlink:label="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_638182739806295301" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739806295301" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638182739806295301" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638182739806295301" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_638182739806295301" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638182739806295301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638182739806295301" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638182739806305303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638182739806305303" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638182739806305303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638182739806305303" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_638182739806305303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_638182739806305303" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638182739806305303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638182739806305303" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638182739806305303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638182739806305303" order="16" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638182739806305303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638182739806305303" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638182739806315301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638182739806315301" order="18" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638182739806315301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739806285300" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638182739806315301" order="19" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638182739806315301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638182739806315301" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_638182739806315301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableGross_638182739806315301" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638182739806315301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_638182739806315301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_638182739806325301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_638182739806325301" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638182739806325301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638182739806325301" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent_638182739806325301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_TaxesPayableCurrent_638182739806325301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedUtilitiesCurrent_638182739806325301" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638182739806325301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638182739806325301" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638182739806335301" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - BORROWINGS - Components (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtNoncurrent_638182739806335301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansFromBank" xlink:label="us-gaap_LongTermLoansFromBank_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_638182739806335301" xlink:to="us-gaap_LongTermLoansFromBank_638182739806335301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtCurrent_638182739806335301" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent_638182739806335301" xlink:to="us-gaap_LongTermDebtCurrent_638182739806335301" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent_638182739806335301" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_638182739806335301" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638182739806335301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638182739806335301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638182739806345301" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638182739806345301" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount_1" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638182739806345301" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638182739806345301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638182739806345301" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638182739806345301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_638182739806345301" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638182739806345301" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638182739806345301" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638182739806345301" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638182739806345301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638182739806345301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_638182739806345301" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638182739806345301" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638182739806355302" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_638182739806355302" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_638182739806355302" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_638182739806355302" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638182739806355302" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_638182739806355302" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638182739806355302" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638182739806355302" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638182739806355302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638182739806355302" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638182739806365301" order="10" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet_638182739806365301" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsGross_638182739806365301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="adag_DeferredTaxAssetsDepreciationAndAmortization_638182739806365301" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" xlink:label="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_638182739806365301" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638182739806365301" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_638182739806365301" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638182739806365301" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsInventory_638182739806365301" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638182739806375303" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638182739806375303" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638182739806375303" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638182739806365301" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638182739806375303" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638182739806375303" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638182739806375303" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638182739806375303" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" xlink:type="extended" xlink:title="41402 - Disclosure - LEASES - Information related to operating lease activity (Details)">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRentalExpense" xlink:label="adag_OperatingLeaseRentalExpense" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InterestOfOperatingLeaseLiabilities" xlink:label="adag_InterestOfOperatingLeaseLiabilities_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_OperatingLeaseRentalExpense" xlink:to="adag_InterestOfOperatingLeaseLiabilities_638182739806375303" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638182739806375303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_OperatingLeaseRentalExpense" xlink:to="us-gaap_ShortTermLeaseCost_638182739806375303" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638182739806385304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_OperatingLeaseRentalExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638182739806385304" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" xlink:type="extended" xlink:title="41403 - Disclosure - LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638182739806385304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638182739806385304" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638182739806385304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638182739806385304" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638182739806385304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638182739806385304" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41404 - Disclosure - LEASES - Maturities of lease liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638182739806385304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638182739806385304" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638182739806385304" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638182739806385304" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended" xlink:title="41404 - Disclosure - LEASES - Maturities of lease liabilities (Details) Calc 2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638182739806395302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638182739806395302" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638182739806395302" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638182739806395302" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>adag-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2023 10:19:42 AM-->
<!--Modified on: 4/28/2023 10:19:42 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePropertyEquipmentAndSoftwareNetDetails" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsShortTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureCollaborationArrangementsDetails" roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureTreasurySharesDetails" roleURI="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.adagene.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="adag-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.adagene.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis_1" xlink:title="adag_ConcentrationRiskSuppliersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain_1" xlink:title="adag_ConcentrationRiskSuppliersDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="adag_ConcentrationRiskSuppliersAxis_1" xlink:to="adag_ConcentrationRiskSuppliersDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:adag_ConcentrationRiskSuppliersAxis_1 To adag_ConcentrationRiskSuppliersDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis_1" xlink:title="adag_StatusForTaxabilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain_1" xlink:title="adag_StatusForTaxabilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="adag_StatusForTaxabilityAxis_1" xlink:to="adag_StatusForTaxabilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:adag_StatusForTaxabilityAxis_1 To adag_StatusForTaxabilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis_1" xlink:title="us-gaap_ShareRepurchaseProgramAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain_1" xlink:title="us-gaap_ShareRepurchaseProgramDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareRepurchaseProgramAxis_1" xlink:to="us-gaap_ShareRepurchaseProgramDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareRepurchaseProgramAxis_1 To us-gaap_ShareRepurchaseProgramDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="44" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CommonStockSubscriptionsValue" xlink:label="adag_CommonStockSubscriptionsValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="adag_CommonStockSubscriptionsValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneHongKongLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneIncorporatedMember" xlink:label="adag_AdageneIncorporatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneIncorporatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneSuzhouLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneAustraliaPtyLtd.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdagenePte.Ltd.Member" xlink:label="adag_AdagenePte.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdagenePte.Ltd.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneAgMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneProjectC1Pte.Ltd.Member" xlink:label="adag_AdageneProjectC1Pte.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneProjectC1Pte.Ltd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio" xlink:label="dei_EntityListingDepositoryReceiptRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="dei_EntityListingDepositoryReceiptRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_FinancialAssetsFairValueDisclosure" xlink:label="adag_FinancialAssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="adag_FinancialAssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adag_ElectronicEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsProductLineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="adag_ConcentrationRiskSuppliersAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="adag_ConcentrationRiskSuppliersAxis" xlink:to="adag_ConcentrationRiskSuppliersDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OneSupplierMember" xlink:label="adag_OneSupplierMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="adag_ConcentrationRiskSuppliersDomain" xlink:to="adag_OneSupplierMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MainlandOfChinaMember" xlink:label="adag_MainlandOfChinaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="adag_MainlandOfChinaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OutsideMainlandOfChinaMember" xlink:label="adag_OutsideMainlandOfChinaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="adag_OutsideMainlandOfChinaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfMajorSupplier" xlink:label="adag_NumberOfMajorSupplier" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="adag_NumberOfMajorSupplier" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adag_ElectronicEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - BORROWINGS - Short term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromBankOfJiangsuCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfJiangsuCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_BorrowingsFromBankOfJiangsuCo.LtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_BorrowingsFromBankOfNingboCo.LtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaMerchantsBankCo.LtdMember" xlink:label="adag_ChinaMerchantsBankCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_ChinaMerchantsBankCo.LtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaConstructionBankCorporationMember" xlink:label="adag_ChinaConstructionBankCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_ChinaConstructionBankCorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - BORROWINGS - Long term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1WarrantsMember" xlink:label="adag_SeriesC1WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adag_SeriesC1WarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_NumberOfInvestorsToWhomWarrantsWereIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_MaximumProceedsReceivableFromExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2015Member" xlink:label="adag_Plan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_Plan2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2017Member" xlink:label="adag_Plan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_Plan2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2019Member" xlink:label="adag_Plan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_Plan2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_PerformanceIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ServiceConditionsAndPerformanceConditionsMember" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="adag_ServiceConditionsAndPerformanceConditionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" xlink:label="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfSharesSurrendered" xlink:label="adag_NumberOfSharesSurrendered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_NumberOfSharesSurrendered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdctCollaborationAgreementMember" xlink:label="adag_AdctCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_AdctCollaborationAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ExelixisIncAgreementMember" xlink:label="adag_ExelixisIncAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_ExelixisIncAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdctMaterialTransferAndOptionAgreementMember" xlink:label="adag_AdctMaterialTransferAndOptionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_AdctMaterialTransferAndOptionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SanofiAgreementMember" xlink:label="adag_SanofiAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_SanofiAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementMilestonePaymentReceived" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PeriodForReservationOfTargetRight" xlink:label="adag_PeriodForReservationOfTargetRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_PeriodForReservationOfTargetRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MilestonePaymentsReceivableSalesBasedMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAX EXPENSE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_IncomeTaxDisclosureTable" xlink:label="adag_IncomeTaxDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="country_HK" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU" xlink:label="country_AU" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AU" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="country_US" xlink:to="stpr_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="country_SG" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="adag_StatusForTaxabilityAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="adag_StatusForTaxabilityAxis" xlink:to="adag_StatusForTaxabilityDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TechnologyAdvancedServiceEnterprisesMember" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="adag_StatusForTaxabilityDomain" xlink:to="adag_TechnologyAdvancedServiceEnterprisesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneSuzhouLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneHongKongLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneAustraliaPtyLtd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneAgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PreferentialIncomeTaxRate" xlink:label="adag_PreferentialIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_PreferentialIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AssessableProfits" xlink:label="adag_AssessableProfits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_AssessableProfits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WithholdingTaxRateOnDividendsPercentage" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_WithholdingTaxRateOnDividendsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CapitalTaxRatePercentage" xlink:label="adag_CapitalTaxRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_CapitalTaxRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WithholdingIncomeTaxes" xlink:label="adag_WithholdingIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_WithholdingIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TaxableIncome" xlink:label="adag_TaxableIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_TaxableIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WuxiApptecGroupMember" xlink:label="adag_WuxiApptecGroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="adag_WuxiApptecGroupMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WuxiBiologicsCaymanInc.Member" xlink:label="adag_WuxiBiologicsCaymanInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="adag_WuxiBiologicsCaymanInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Treasury Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ShareRepurchaseProgramAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareRepurchaseProgramOf2021Member" xlink:label="adag_ShareRepurchaseProgramOf2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="adag_ShareRepurchaseProgramOf2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareRepurchaseProgramOf2022Member" xlink:label="adag_ShareRepurchaseProgramOf2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="adag_ShareRepurchaseProgramOf2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_PerformanceIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>adag-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2023 10:19:42 AM-->
<!--Modified on: 4/28/2023 10:19:42 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">American depositary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No Trading Symbol Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due from Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts due from related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, equipment and software, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net book value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts due to related parties</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Bank Loans and Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long-term borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long term borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non current borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity (deficit):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 54,595,667 shares issued and outstanding as of December 31, 2021; and 640,000,000 shares authorized, 54,065,709 shares issued and outstanding as of December 31, 2022)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares, at cost (94,074 shares as of December 31, 2021 and 1 share as of as of December 31, 2022)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and collaboration revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ResearchAndDevelopmentExpenseThirdParties" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ResearchAndDevelopmentExpenseThirdParties" xlink:to="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research and development expenses resulting from transactions with third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Third Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third parties</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:to="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research and development expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Research And Development Expense from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange loss (gain), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain (loss), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to Adagene Inc.'s shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to Adagene Inc.'s shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustments, net of nil tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss attributable to Adagene Inc.'s shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of convertible redeemable preferred shares to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of convertible redeemable preferred shares to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to ordinary shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares used in per share calculation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weightedaverage number of ordinary shares outstanding-basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weightedaverage number of ordinary shares outstanding-diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per ordinary share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per share-basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per share- diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustments, tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Common [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from Stockholder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscriptions receivable from shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon exercise of share options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares under performance incentive plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares under performance incentive plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CommonStockSubscriptionsValue" xlink:label="adag_CommonStockSubscriptionsValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CommonStockSubscriptionsValue" xlink:to="adag_CommonStockSubscriptionsValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CommonStockSubscriptionsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CommonStockSubscriptionsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Subscriptions, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CommonStockSubscriptionsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription from shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Shares to Ordinary Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred shares to ordinary shares upon the completion of initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares upon IPO, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares upon IPO, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares under share repurchase program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration of share repurchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares under share repurchase program (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares repurchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Retired, Par Value Method, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Shares, Retired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased shares retired (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of treasury shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:to="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of shares surrendered for repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Surrendered, Value, For Repayment of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender of ordinary shares for repayment of promissory notes</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:to="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number shares surrendered for repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Surrendered, Shares, for Repayment of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender of ordinary shares for repayment of promissory notes (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" xlink:label="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" xlink:to="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of loss on disposal of property, equipment, software and operating lease right-of-use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain Loss On Sale Of Property Plant Equipment and Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss on disposal of property, equipment, software and operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InterestIncomeExpenseOnPromissoryNotes" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_InterestIncomeExpenseOnPromissoryNotes" xlink:to="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest income (expense) on promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense) On Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income on promissory notes</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" xlink:label="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" xlink:to="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of amortization expense for right-of-use asset and interest of lease liabilities from operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset and Interest of Lease Liabilities, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of use assets and interest of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due from Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due from related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due to related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withdrawal of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from disposal of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash generated from (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Contributed Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from share subscriptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of underwriting commissions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount repaid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of initial public offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Repurchase of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares under stock repurchase program</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RetirementOfTreasuryShares" xlink:label="adag_RetirementOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_RetirementOfTreasuryShares" xlink:to="adag_RetirementOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_RetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of retirement of treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_RetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of Treasury Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_RetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs for retirement of treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash generated from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow disclosures:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow disclosures:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash paid for amounts included in the measurement of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for operating lease obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PayablesForDeferredInitialPublicOfferingCost" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PayablesForDeferredInitialPublicOfferingCost" xlink:to="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payables for deferred initial public offering cost in non-cash activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables For Deferred Initial Public Offering Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables for deferred initial public offering cost</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NonCashActivitiesRetirementOfTreasuryShares" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NonCashActivitiesRetirementOfTreasuryShares" xlink:to="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of retirement of treasury shares in noncash investing or financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non cash Activities, Retirement of Treasury Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of treasury shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xlink:to="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of common stock shares surrendered for repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender Of Common Stock Shares For Repayment Of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender of ordinary shares for repayment of promissory notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS RECEIVABLE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS RECEIVABLE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAYMENTS AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on prepayments and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAYMENTS AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY, EQUIPMENT AND SOFTWARE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY, EQUIPMENT AND SOFTWARE, NET</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUALS AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on accrued liabilities and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUALS AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BORROWINGS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BORROWING</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BORROWINGS</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xlink:to="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for temporary equity and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Temporary Equity And Warrants [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborationArrangementsAbstract" xlink:label="adag_CollaborationArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborationArrangementsAbstract" xlink:to="adag_CollaborationArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COLLABORATION ARRANGEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COLLABORATION ARRANGEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX EXPENSE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX EXPENSE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RestrictedNetAssetsAbstract" xlink:label="adag_RestrictedNetAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_RestrictedNetAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_RestrictedNetAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No Definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_RestrictedNetAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RESTRICTED NET ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RESTRICTED NET ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract" xlink:label="us-gaap_TreasuryStockSharesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAbstract" xlink:to="us-gaap_TreasuryStockSharesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="us-gaap_TreasuryStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockTextBlock" xlink:to="us-gaap_TreasuryStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xlink:to="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for accounts receivable and allowance for doubtful accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable And Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable and allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GovernmentSubsidiesPolicyTextBlock" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GovernmentSubsidiesPolicyTextBlock" xlink:to="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for government subsidies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Subsidies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government subsidies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for Employee defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Defined Contribution Plan [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee defined contribution plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xlink:to="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of principal subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Principal Subsidiaries [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of principal subsidiaries</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of estimated useful lives of property and equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant And Equipment, Estimated Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of estimated useful lives of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of prepayments and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure on accrued liabilities and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued liabilities and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of borrowings</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xlink:to="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of maturity and sinking fund requirement for short-term debt and long-term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Maturities Of Short-Term Debt And Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future maturities of short-term borrowings and long-term borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Company's Preferred Shares activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assumptions used to estimate the fair value of the share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of total share based compensation expenses recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation between the income tax expense and the actual provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of tax effects of temporary differences that give rise to the deferred tax balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movement of the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities that are not included in the calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of related party transactions</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InformationRelatedToOperatingLeasesTableTextBlock" xlink:label="adag_InformationRelatedToOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_InformationRelatedToOperatingLeasesTableTextBlock" xlink:to="adag_InformationRelatedToOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_InformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of information related to operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_InformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information Related to Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_InformationRelatedToOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of information related to operating leases</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InformationRelatedToOperatingLeaseActivityTableTextBlock" xlink:label="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock" xlink:to="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of information related to operating lease activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information Related to Operating Lease Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of information related to operating lease activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of maturities of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information on organization, consolidation and presentation of financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation And Presentation Of Financial Statements [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneHongKongLimitedMember" xlink:to="adag_AdageneHongKongLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneHongKongLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene (Hong Kong) Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneHongKongLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene (Hong Kong) Limited</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneIncorporatedMember" xlink:label="adag_AdageneIncorporatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneIncorporatedMember" xlink:to="adag_AdageneIncorporatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneIncorporatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene Incorporated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneIncorporatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene Incorporated</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneSuzhouLimitedMember" xlink:to="adag_AdageneSuzhouLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneSuzhouLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene (Suzhou) Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneSuzhouLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene (Suzhou) Limited</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneAustraliaPtyLtd.Member" xlink:to="adag_AdageneAustraliaPtyLtd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene Australia PTY Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene Australia PTY Ltd.</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdagenePte.Ltd.Member" xlink:label="adag_AdagenePte.Ltd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdagenePte.Ltd.Member" xlink:to="adag_AdagenePte.Ltd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdagenePte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Adagene PTE. Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdagenePte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene PTE. Ltd.</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneAgMember" xlink:to="adag_AdageneAgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Adagene AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene AG</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneProjectC1Pte.Ltd.Member" xlink:label="adag_AdageneProjectC1Pte.Ltd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneProjectC1Pte.Ltd.Member" xlink:to="adag_AdageneProjectC1Pte.Ltd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneProjectC1Pte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Adagene Project C1 PTE. Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneProjectC1Pte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene Project C1 PTE. Ltd. Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AdageneProjectC1Pte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene Project C1 PTE. Ltd.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' option</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of legal ownership by the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in USD per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio" xlink:label="dei_EntityListingDepositoryReceiptRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingDepositoryReceiptRatio" xlink:to="dei_EntityListingDepositoryReceiptRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingDepositoryReceiptRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Listing, Depository Receipt Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityListingDepositoryReceiptRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ordinary shares represented by each ADS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrecurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items}</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_FinancialAssetsFairValueDisclosure" xlink:label="adag_FinancialAssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_FinancialAssetsFairValueDisclosure" xlink:to="adag_FinancialAssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and tools</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ElectronicEquipmentMember" xlink:to="adag_ElectronicEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ElectronicEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Electronic equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ElectronicEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Electronic equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY, EQUIPMENT AND SOFTWARE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="us-gaap_DefinedContributionPlanAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee defined contribution plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:to="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of cash and cash equivalents and short term investments when it serves as a benchmark in a concentration of risk calculation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services purchased</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ConcentrationRiskSuppliersAxis" xlink:to="adag_ConcentrationRiskSuppliersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ConcentrationRiskSuppliersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information about suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ConcentrationRiskSuppliersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Suppliers [Axis]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ConcentrationRiskSuppliersDomain" xlink:to="adag_ConcentrationRiskSuppliersDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ConcentrationRiskSuppliersDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ConcentrationRiskSuppliersDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Suppliers [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OneSupplierMember" xlink:label="adag_OneSupplierMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OneSupplierMember" xlink:to="adag_OneSupplierMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OneSupplierMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One supplier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OneSupplierMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One supplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MainlandOfChinaMember" xlink:label="adag_MainlandOfChinaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MainlandOfChinaMember" xlink:to="adag_MainlandOfChinaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mainland of China.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mainland of China</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OutsideMainlandOfChinaMember" xlink:label="adag_OutsideMainlandOfChinaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OutsideMainlandOfChinaMember" xlink:to="adag_OutsideMainlandOfChinaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OutsideMainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outside the mainland of China.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OutsideMainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outside the mainland of China</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2016-02 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfMajorSupplier" xlink:label="adag_NumberOfMajorSupplier" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NumberOfMajorSupplier" xlink:to="adag_NumberOfMajorSupplier_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NumberOfMajorSupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of major supplier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NumberOfMajorSupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Major Supplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_NumberOfMajorSupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major supplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PercentageOfDepreciationOfForeignCurrency" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PercentageOfDepreciationOfForeignCurrency" xlink:to="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of depreciation of foreign currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Depreciation Of Foreign Currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation of foreign currency (as a percent)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GovernmentSubsidiesReceived" xlink:label="adag_GovernmentSubsidiesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GovernmentSubsidiesReceived" xlink:to="adag_GovernmentSubsidiesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GovernmentSubsidiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of subsidies received by the entity for Government.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GovernmentSubsidiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Subsidies Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_GovernmentSubsidiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government subsidies received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, before Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net, by Type [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY, EQUIPMENT AND SOFTWARE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional service fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Utilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Utility and maintenance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other taxes and surcharge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrentAbstract" xlink:label="us-gaap_DebtCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrentAbstract" xlink:to="us-gaap_DebtCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term borrowings:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Other than Long-term Debt, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term borrowings:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansFromBank" xlink:label="us-gaap_LongTermLoansFromBank" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable to Bank, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Long-term and Short-term, Combined Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Short-term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromBankOfJiangsuCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfJiangsuCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromBankOfJiangsuCo.LtdMember" xlink:to="adag_BorrowingsFromBankOfJiangsuCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromBankOfJiangsuCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Borrowings from Bank of Jiangsu Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromBankOfJiangsuCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings From Bank of Jiangsu Co., Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_BorrowingsFromBankOfJiangsuCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Bank of Jiangsu Co., Ltd</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:to="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Borrowings from Bank of Ningbo Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings From Bank of Ningbo Co., Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Bank of Ningbo Co., Ltd</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Borrowings from Agricultural Bank of China Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Agricultural Bank of China Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Agricultural Bank of China Limited</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaMerchantsBankCo.LtdMember" xlink:label="adag_ChinaMerchantsBankCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ChinaMerchantsBankCo.LtdMember" xlink:to="adag_ChinaMerchantsBankCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to China Merchants Bank Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Merchants Bank Co Ltd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Merchants Bank Co., Ltd</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:to="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to China Merchants Bank Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Merchants Bank Co .Ltd Loan Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Merchants Bank Co., Ltd., two</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaConstructionBankCorporationMember" xlink:label="adag_ChinaConstructionBankCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ChinaConstructionBankCorporationMember" xlink:to="adag_ChinaConstructionBankCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ChinaConstructionBankCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to China Construction Bank Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ChinaConstructionBankCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Construction Bank Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ChinaConstructionBankCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Construction Bank Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount borrowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Series Pre A Convertible Notes issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Pre A Convertible Notes, Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., one</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., two</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., three</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, Four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., four</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, five.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., Five [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., five</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, six.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., Six [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., six</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, seven.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., Seven [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., seven</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Pre-A Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Series1RedeemableConvertiblePreferredStockMember" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Series2RedeemableConvertiblePreferredStockMember" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-1 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-2 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-3 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-3 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1WarrantsMember" xlink:label="adag_SeriesC1WarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC1WarrantsMember" xlink:to="adag_SeriesC1WarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC1WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series C 1 Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC1WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C 1 Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of new stock classified as temporary equity issued during the period, upon conversion of convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion of Series Pre-A Convertible Notes (in shares)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration from issuance of convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:to="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investors to whom warrants were issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Investors To Whom Warrants Were Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Series C-1 investors to whom warrants were issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration from issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:to="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of proceeds receivable from exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Proceeds Receivable From Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total maximum consideration from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares on conversion of each convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Preferred Shares to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2015Member" xlink:label="adag_Plan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Plan2015Member" xlink:to="adag_Plan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Plan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Plan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2017Member" xlink:label="adag_Plan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Plan2017Member" xlink:to="adag_Plan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Plan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2017 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Plan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Plan</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2019Member" xlink:label="adag_Plan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Plan2019Member" xlink:to="adag_Plan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Plan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Plan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PerformanceIncentivePlan2021Member" xlink:to="adag_PerformanceIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PerformanceIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Performance incentive plan 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PerformanceIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Incentive Plan 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PerformanceIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ServiceConditionsAndPerformanceConditionsMember" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ServiceConditionsAndPerformanceConditionsMember" xlink:to="adag_ServiceConditionsAndPerformanceConditionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to service conditions and performance conditions related to share options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service conditions and Performance conditions</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" xlink:label="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" xlink:to="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the modification of vesting schedules and condition of share options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification Of Vesting Schedules And Conditions Of Share Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Modification of vesting schedules and conditions of share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate number of shares that may be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental compensation cost to be recognized</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options for which the vesting schedules and conditions are waived.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vesting Schedules and Conditions waived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options, vesting schedules and conditions waived</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares unvested</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfSharesSurrendered" xlink:label="adag_NumberOfSharesSurrendered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NumberOfSharesSurrendered" xlink:to="adag_NumberOfSharesSurrendered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NumberOfSharesSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares surrendered by the shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NumberOfSharesSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Surrendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_NumberOfSharesSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares surrendered</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value (in USD per option)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate ordinary shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:to="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of increase in shares reserve annually based on shares outstanding under share based compensation share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Share Based Payments, Shares Reserve, Incremental, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental percent of shares</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate fair value of options outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value of options exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value, at which grantee can acquire shares reserved for issuance. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted-average grant date fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate fair value of the equity awards vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized employee share based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period to recognize unrecognized compensation cost (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used to estimate the fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum exercise multiple assumption that is used in valuing an option on its own shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise multiple, minimum</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum exercise multiple assumption that is used in valuing an option on its own shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise multiple, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:to="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:to="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdctCollaborationAgreementMember" xlink:label="adag_AdctCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdctCollaborationAgreementMember" xlink:to="adag_AdctCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdctCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to ADCT Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdctCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADCT Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ExelixisIncAgreementMember" xlink:label="adag_ExelixisIncAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ExelixisIncAgreementMember" xlink:to="adag_ExelixisIncAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ExelixisIncAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Exelixis, Inc. Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ExelixisIncAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exelixis Inc Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdctMaterialTransferAndOptionAgreementMember" xlink:label="adag_AdctMaterialTransferAndOptionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdctMaterialTransferAndOptionAgreementMember" xlink:to="adag_AdctMaterialTransferAndOptionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdctMaterialTransferAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for ADCT material transfer and option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdctMaterialTransferAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADCT Material Transfer and Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AdctMaterialTransferAndOptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADCT Material Transfer and Option Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SanofiAgreementMember" xlink:label="adag_SanofiAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SanofiAgreementMember" xlink:to="adag_SanofiAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SanofiAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for sanofi agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SanofiAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sanofi Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_SanofiAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sanofi Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from upfront cash received in collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Upfront Cash Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment received</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:to="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The agreed period for not to grant rights associated with antibodies to third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreed Period for Not to Grant Rights Associated With Antibodies to Third Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreed period for not to grant rights associated with antibodies to third parties</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementMilestonePaymentReceived" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementMilestonePaymentReceived" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from milestone payments received in collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone fee received</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:to="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of selected targets, agreed for generation of antibodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number of Selected Targets, Agreed for Generation of Antibodies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of selected targets, agreed for generation of antibodies</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:to="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum threshold written notice period for termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Threshold Written Notice Period for Termination of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum threshold written notice period for termination of agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PeriodForReservationOfTargetRight" xlink:label="adag_PeriodForReservationOfTargetRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PeriodForReservationOfTargetRight" xlink:to="adag_PeriodForReservationOfTargetRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PeriodForReservationOfTargetRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for reservation of target right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PeriodForReservationOfTargetRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Reservation of Target Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PeriodForReservationOfTargetRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for reservation of target right</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Upfront Cash Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of upfront-refundable fee</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:to="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable upon achieving certain development and regulatory approval milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Receivable, Development And Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable based on development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:to="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments conditioned upon achieving sales based milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Receivable, Sales Based Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable based on sales</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_IncomeTaxDisclosureTable" xlink:label="adag_IncomeTaxDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="adag_IncomeTaxDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="country_HK" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hong Kong</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU" xlink:label="country_AU" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Australia</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SWITZERLAND</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="country_SG" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_SG_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SINGAPORE</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StatusForTaxabilityAxis" xlink:to="adag_StatusForTaxabilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StatusForTaxabilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to various tax status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StatusForTaxabilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status for Taxability [Axis]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StatusForTaxabilityDomain" xlink:to="adag_StatusForTaxabilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StatusForTaxabilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents various tax status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StatusForTaxabilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status For Taxability [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TechnologyAdvancedServiceEnterprisesMember" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TechnologyAdvancedServiceEnterprisesMember" xlink:to="adag_TechnologyAdvancedServiceEnterprisesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents an entity classification of Technology Advanced Service Enterprises that receives preferential tax treatment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TASE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRC statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PreferentialIncomeTaxRate" xlink:label="adag_PreferentialIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PreferentialIncomeTaxRate" xlink:to="adag_PreferentialIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PreferentialIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferential income tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PreferentialIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferential Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PreferentialIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferential tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:to="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The effective period of Technology Advanced Service Enterprises certificate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Period of Technology Advanced Service Enterprises Certificate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective period of TASE certificate (in years)</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AssessableProfits" xlink:label="adag_AssessableProfits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AssessableProfits" xlink:to="adag_AssessableProfits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AssessableProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of assessable profits or earnings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AssessableProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assessable Profits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AssessableProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assessable profits or earnings</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WithholdingTaxRateOnDividendsPercentage" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WithholdingTaxRateOnDividendsPercentage" xlink:to="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of withholding tax rate on dividends.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding Tax Rate On Dividends, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends withholding tax rate</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CapitalTaxRatePercentage" xlink:label="adag_CapitalTaxRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CapitalTaxRatePercentage" xlink:to="adag_CapitalTaxRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CapitalTaxRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of capital tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CapitalTaxRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Tax Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CapitalTaxRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital tax rate for Canton of Basel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WithholdingIncomeTaxes" xlink:label="adag_WithholdingIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WithholdingIncomeTaxes" xlink:to="adag_WithholdingIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WithholdingIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of withholding income taxes on remittance of dividends.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WithholdingIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_WithholdingIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding tax</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TaxableIncome" xlink:label="adag_TaxableIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TaxableIncome" xlink:to="adag_TaxableIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TaxableIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of taxable income during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TaxableIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxable Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax credit computed at PRC statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of PRC preferential income tax rate as qualified TASE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference in income tax rates of overseas entities</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:to="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Deduction, Research and Development Expenses, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development super-deduction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nondeductible expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, FDII, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign derived intangible income deduction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Unrealized Currency Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized foreign exchange gain/losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" xlink:label="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" xlink:to="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax asset and lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Rights Of Use Assets And Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets and interest of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of January 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movement of the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Addition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options and share grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities not included in the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WuxiApptecGroupMember" xlink:label="adag_WuxiApptecGroupMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WuxiApptecGroupMember" xlink:to="adag_WuxiApptecGroupMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WuxiApptecGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to WuXi AppTec Group .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WuxiApptecGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WuXi AppTec Group</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WuxiBiologicsCaymanInc.Member" xlink:label="adag_WuxiBiologicsCaymanInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WuxiBiologicsCaymanInc.Member" xlink:to="adag_WuxiBiologicsCaymanInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WuxiBiologicsCaymanInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to WuXi Biologics (Cayman) Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WuxiBiologicsCaymanInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WuXi Biologics Cayman Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_WuxiBiologicsCaymanInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WuXi Biologics (Cayman) Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:to="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to receipt of contract research organizations ("CRO") and contract manufacturing organizations ("CMO") services with related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of CRO and CMO services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transactions</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRightOfUseAssetsAbstract" xlink:label="adag_OperatingLeaseRightOfUseAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OperatingLeaseRightOfUseAssetsAbstract" xlink:to="adag_OperatingLeaseRightOfUseAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OperatingLeaseRightOfUseAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OperatingLeaseRightOfUseAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right of Use Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_OperatingLeaseRightOfUseAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRentalExpenseAbstract" xlink:label="adag_OperatingLeaseRentalExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OperatingLeaseRentalExpenseAbstract" xlink:to="adag_OperatingLeaseRentalExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OperatingLeaseRentalExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OperatingLeaseRentalExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Rental Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_OperatingLeaseRentalExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease rental expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense for short-term leases within 12 months</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InterestOfOperatingLeaseLiabilities" xlink:label="adag_InterestOfOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_InterestOfOperatingLeaseLiabilities" xlink:to="adag_InterestOfOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_InterestOfOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of interest of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_InterestOfOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest of Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_InterestOfOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRentalExpense" xlink:label="adag_OperatingLeaseRentalExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OperatingLeaseRentalExpense" xlink:to="adag_OperatingLeaseRentalExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OperatingLeaseRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of operating lease rental expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OperatingLeaseRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Rental Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="adag_OperatingLeaseRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating lease rental expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">For the years ending:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xlink:to="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of the profit after tax to be transferred to statutory reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Percentage Of Profits After Tax To Be Transferred To Statutory Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of profit after tax to be transferred to statutory reserve</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xlink:to="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Required percentage of statutory reserve on registered capital to be maintained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory Reserve Maintenance Required Percentage On Registered Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory reserve required percentage on registered capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:to="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total restricted net assets</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AfterTaxIncomePercentageAppropriations" xlink:label="adag_AfterTaxIncomePercentageAppropriations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AfterTaxIncomePercentageAppropriations" xlink:to="adag_AfterTaxIncomePercentageAppropriations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AfterTaxIncomePercentageAppropriations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of after-tax income to be set aside as a general reserve fund.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AfterTaxIncomePercentageAppropriations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">After Tax Income Percentage Appropriations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AfterTaxIncomePercentageAppropriations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">After tax income, annual appropriations, percentage</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xlink:to="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage on restricted net assets of PRC subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage On Restricted Net Assets Of PRC Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on net assets of PRC subsidiaries , threshold percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Treasury Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramAxis" xlink:to="us-gaap_ShareRepurchaseProgramAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareRepurchaseProgramAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Repurchase Program [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareRepurchaseProgramDomain" xlink:to="us-gaap_ShareRepurchaseProgramDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareRepurchaseProgramDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Repurchase Program [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareRepurchaseProgramOf2021Member" xlink:label="adag_ShareRepurchaseProgramOf2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareRepurchaseProgramOf2021Member" xlink:to="adag_ShareRepurchaseProgramOf2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareRepurchaseProgramOf2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the 2021 Share Repurchase Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareRepurchaseProgramOf2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Repurchase Program Of 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareRepurchaseProgramOf2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Share Repurchase Program</label>
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareRepurchaseProgramOf2022Member" xlink:label="adag_ShareRepurchaseProgramOf2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareRepurchaseProgramOf2022Member" xlink:to="adag_ShareRepurchaseProgramOf2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareRepurchaseProgramOf2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the 2022 Share Repurchase Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareRepurchaseProgramOf2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Repurchase Program Of 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareRepurchaseProgramOf2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Share Repurchase Program</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Class of Treasury Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Program, Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share repurchase program authorized amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Program, Period in Force</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of share repurchase program (in months)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of ordinary shares issued</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>adag-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2023 10:19:42 AM-->
<!--Modified on: 4/28/2023 10:19:42 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveLossParenthetical" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureOrganizationAndBasisOfPresentation" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccountsReceivableNet" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePrepaymentsAndOtherCurrentAssets" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePropertyEquipmentAndSoftwareNet" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccrualsAndOtherCurrentLiabilities" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowings" roleURI="http://www.adagene.com/role/DisclosureBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrants" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureCollaborationArrangements" roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpense" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureNetLossPerShare" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeases" roleURI="http://www.adagene.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureRestrictedNetAssets" roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureTreasuryShares" roleURI="http://www.adagene.com/role/DisclosureTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.adagene.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureOrganizationAndBasisOfPresentationTables" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccountsReceivableNetTables" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePrepaymentsAndOtherCurrentAssetsTables" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePropertyEquipmentAndSoftwareNetTables" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccrualsAndOtherCurrentLiabilitiesTables" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsTables" roleURI="http://www.adagene.com/role/DisclosureBorrowingsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseTables" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesTable" roleURI="http://www.adagene.com/role/DisclosureLeasesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccountsReceivableNetDetails" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePrepaymentsAndOtherCurrentAssetsDetails" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosurePropertyEquipmentAndSoftwareNetDetails" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsComponentsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsShortTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationShareOptionActivitiesDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureCollaborationArrangementsDetails" roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureIncomeTaxExpenseValuationAllowanceDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesInformationRelatedToOperatingLeasesDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureRestrictedNetAssetsDetails" roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureTreasurySharesDetails" roleURI="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20221231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638182739807095311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentInformationTable_638182739807095311" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638182739807095311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638182739807095311" xlink:to="us-gaap_StatementClassOfStockAxis_638182739807095311" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638182739807095311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638182739807095311" xlink:to="us-gaap_ClassOfStockDomain_638182739807095311" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638182739807095311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807095311" xlink:to="dei_AdrMember_638182739807095311" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807095311" xlink:to="us-gaap_CommonStockMember_638182739807175293" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638182739807095311" xlink:to="dei_EntityAddressesAddressTypeAxis_638182739807175293" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_638182739807175293" xlink:to="dei_AddressTypeDomain_638182739807175293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_638182739807175293" xlink:to="dei_BusinessContactMember_638182739807175293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638182739807095311" xlink:to="dei_DocumentInformationLineItems_638182739807175293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentType_638182739807175293" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentRegistrationStatement_638182739807175293" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentAnnualReport_638182739807175293" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638182739807175293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentTransitionReport_638182739807175293" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentShellCompanyReport_638182739807185297" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentPeriodEndDate_638182739807185297" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityFileNumber_638182739807185297" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityRegistrantName_638182739807185297" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityIncorporationStateCountryCode_638182739807185297" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityAddressAddressLine1_638182739807185297" order="10" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityAddressAddressLine2_638182739807185297" order="11" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityAddressCityOrTown_638182739807185297" order="12" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityAddressStateOrProvince_638182739807185297" order="13" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638182739807185297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityAddressPostalZipCode_638182739807185297" order="14" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityAddressCountry_638182739807195314" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_ContactPersonnelName_638182739807195314" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_ContactPersonnelEmailAddress_638182739807195314" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_CountryRegion_638182739807195314" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_CityAreaCode_638182739807195314" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_LocalPhoneNumber_638182739807195314" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_Security12bTitle_638182739807195314" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638182739807195314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_TradingSymbol_638182739807195314" order="22" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_NoTradingSymbolFlag_638182739807205315" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_SecurityExchangeName_638182739807205315" order="24" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityCommonStockSharesOutstanding_638182739807205315" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityWellKnownSeasonedIssuer_638182739807205315" order="26" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityVoluntaryFilers_638182739807205315" order="27" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityCurrentReportingStatus_638182739807205315" order="28" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638182739807205315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityInteractiveDataCurrent_638182739807205315" order="29" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638182739807215315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityFilerCategory_638182739807215315" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638182739807215315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityEmergingGrowthCompany_638182739807215315" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638182739807215315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityExTransitionPeriod_638182739807215315" order="32" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638182739807215315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_IcfrAuditorAttestationFlag_638182739807215315" order="33" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_638182739807215315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentAccountingStandard_638182739807215315" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638182739807215315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityShellCompany_638182739807215315" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638182739807225316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_EntityCentralIndexKey_638182739807225316" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638182739807225316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_CurrentFiscalYearEndDate_638182739807225316" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638182739807225316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentFiscalYearFocus_638182739807225316" order="38" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638182739807225316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_DocumentFiscalPeriodFocus_638182739807225316" order="39" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638182739807225316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_AmendmentFlag_638182739807225316" order="40" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638182739807225316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_AuditorName_638182739807225316" order="41" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638182739807235314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_AuditorFirmId_638182739807235314" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638182739807235314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638182739807175293" xlink:to="dei_AuditorLocation_638182739807235314" order="43" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637516889407883481" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638182739807235314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889407883481" xlink:to="us-gaap_AssetsAbstract_638182739807235314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638182739807235314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638182739807235314" xlink:to="us-gaap_AssetsCurrentAbstract_638182739807235314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638182739807235314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638182739807235314" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638182739807235314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638182739807235314" xlink:to="us-gaap_AccountsReceivableNetCurrent_638182739807245315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638182739807235314" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_638182739807245315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638182739807235314" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638182739807245315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638182739807235314" xlink:to="us-gaap_AssetsCurrent_638182739807245315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638182739807235314" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638182739807245315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638182739807235314" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638182739807245315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638182739807235314" xlink:to="us-gaap_OtherAssetsNoncurrent_638182739807245315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638182739807235314" xlink:to="us-gaap_Assets_638182739807245315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889407883481" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638182739807245315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_AccountsPayableCurrent_638182739807245315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638182739807255314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638182739807255314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_638182739807255314" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_638182739807255314" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_638182739807255314" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_LongTermDebtCurrent_638182739807255314" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638182739807255314" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638182739807245315" xlink:to="us-gaap_LiabilitiesCurrent_638182739807255314" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_LongTermDebtNoncurrent_638182739807255314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638182739807255314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638182739807255314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638182739807265311" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638182739807265311" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_Liabilities_638182739807265311" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_CommitmentsAndContingencies_638182739807265311" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638182739807245315" xlink:to="us-gaap_StockholdersEquityAbstract_638182739807265311" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638182739807265311" xlink:to="us-gaap_CommonStockValue_638182739807265311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue_638182739807265311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638182739807265311" xlink:to="us-gaap_TreasuryStockCommonValue_638182739807265311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638182739807275310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638182739807265311" xlink:to="us-gaap_AdditionalPaidInCapital_638182739807275310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638182739807275310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638182739807265311" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638182739807275310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638182739807275310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638182739807265311" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638182739807275310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638182739807275310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638182739807265311" xlink:to="us-gaap_StockholdersEquity_638182739807275310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638182739807275310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889407883481" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638182739807275310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638182739807275310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638182739807275310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" xlink:to="us-gaap_CommonStockSharesAuthorized_638182739807285310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" xlink:to="us-gaap_CommonStockSharesIssued_638182739807285310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" xlink:to="us-gaap_CommonStockSharesOutstanding_638182739807285310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" xlink:to="us-gaap_TreasuryStockCommonShares_638182739807285310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637516889408781088" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_CostOfRevenueAbstract_638182739807285310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract_638182739807285310" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638182739807285310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_OperatingExpensesAbstract_638182739807285310" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638182739807285310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ResearchAndDevelopmentExpenseThirdParties" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638182739807285310" xlink:to="adag_ResearchAndDevelopmentExpenseThirdParties_638182739807285310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense_638182739807285310" xlink:to="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_638182739807285310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638182739807285310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638182739807285310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_OperatingIncomeLoss_638182739807295310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_InvestmentIncomeNonoperating_638182739807295310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_InterestExpense_638182739807295310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_OtherNonoperatingIncome_638182739807295310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739807295310" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739807295310" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638182739807295310" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638182739807285310" xlink:to="us-gaap_NetIncomeLoss_638182739807295310" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638182739807295310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638182739807295310" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638182739807295310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638182739807295310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638182739807295310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_NetIncomeLoss_638182739807305309" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807305309" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638182739807305309" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807305309" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807305309" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638182739807305309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807305309" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638182739807305309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_EarningsPerShareAbstract_638182739807305309" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638182739807305309" xlink:to="us-gaap_EarningsPerShareBasic_638182739807305309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638182739807305309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638182739807305309" xlink:to="us-gaap_EarningsPerShareDiluted_638182739807305309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_638182739807315309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_638182739807315309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637516889408820980" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638182739807315309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637516889408820980" xlink:to="us-gaap_StatementTable_638182739807315309" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638182739807315309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638182739807315309" xlink:to="us-gaap_StatementEquityComponentsAxis_638182739807315309" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638182739807315309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_CommonStockMember_638182739807315309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember_638182739807315309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_TreasuryStockCommonMember_638182739807315309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember_638182739807315309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_ReceivablesFromStockholderMember_638182739807315309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638182739807325310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638182739807325310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_RetainedEarningsMember_638182739807325310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638182739807315309" xlink:to="us-gaap_EquityComponentDomain_638182739807325310" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638182739807315309" xlink:to="us-gaap_StatementLineItems_638182739807325310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807325310" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockholdersEquity_638182739807325310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_SharesIssued_638182739807325310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TreasuryStockCommonShares_638182739807325310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_NetIncomeLoss_638182739807325310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638182739807325310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_638182739807325310" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638182739807335310" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638182739807335310" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638182739807335310" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638182739807335310" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CommonStockSubscriptionsValue" xlink:label="adag_CommonStockSubscriptionsValue_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="adag_CommonStockSubscriptionsValue_638182739807335310" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638182739807335310" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807335310" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638182739807335310" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638182739807335310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638182739807335310" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638182739807345310" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638182739807345310" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_638182739807345310" order="17" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TreasuryStockSharesAcquired_638182739807345310" order="18" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_638182739807345310" order="19" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TreasuryStockSharesRetired_638182739807345310" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_638182739807345310" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_638182739807345310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_638182739807345310" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638182739807355311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_StockholdersEquity_638182739807355311" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638182739807355311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_SharesIssued_638182739807355311" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares_638182739807355311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638182739807325310" xlink:to="us-gaap_TreasuryStockCommonShares_638182739807355311" order="25" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638182739807355311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638182739807355311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638182739807355311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638182739807355311" xlink:to="us-gaap_ProfitLoss_638182739807355311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638182739807355311" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638182739807365312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset" xlink:label="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset_638182739807365312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="us-gaap_ShareBasedCompensation_638182739807365312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InterestIncomeExpenseOnPromissoryNotes" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="adag_InterestIncomeExpenseOnPromissoryNotes_638182739807365312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense" xlink:label="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense_638182739807365312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638182739807365312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638182739807365312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638182739807365312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_638182739807365312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638182739807365312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638182739807365312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638182739807375323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638182739807375323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_638182739807375323" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_638182739807375323" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638182739807375323" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638182739807375323" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_638182739807375323" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638182739807365312" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638182739807375323" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739807375323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638182739807355311" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638182739807375323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638182739807385316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_638182739807385316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_638182739807385316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638182739807385316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638182739807385316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_638182739807385316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638182739807385316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_ProceedsFromContributedCapital_638182739807385316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638182739807395315" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638182739807395315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_RepaymentsOfDebt_638182739807395315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638182739807395315" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_638182739807395315" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RetirementOfTreasuryShares" xlink:label="adag_RetirementOfTreasuryShares_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="adag_RetirementOfTreasuryShares_638182739807395315" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739807395315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638182739807385316" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638182739807395315" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638182739807405315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638182739807405315" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638182739807405315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638182739807405315" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638182739807405315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638182739807405315" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381827398074053151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381827398074053151" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638182739807405315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" xlink:to="us-gaap_InterestPaidNet_638182739807405315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638182739807415317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" xlink:to="us-gaap_IncomeTaxesPaidNet_638182739807415317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638182739807415317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" xlink:to="us-gaap_OperatingLeasePayments_638182739807415317" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638182739807415317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638182739807415317" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638182739807405315" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807415317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807415317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_638182739807415317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" xlink:to="us-gaap_ConversionOfStockAmountIssued1_638182739807415317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PayablesForDeferredInitialPublicOfferingCost" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_638182739807425322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" xlink:to="adag_PayablesForDeferredInitialPublicOfferingCost_638182739807425322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NonCashActivitiesRetirementOfTreasuryShares" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_638182739807425322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" xlink:to="adag_NonCashActivitiesRetirementOfTreasuryShares_638182739807425322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_638182739807425322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638182739807415317" xlink:to="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_638182739807425322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638182739807435318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638182739807435318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231714822595" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638182739807435318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231714822595" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638182739807435318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNet" xlink:type="extended" xlink:title="10301 - Disclosure - ACCOUNTS RECEIVABLE, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638182739807435318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638182739807435318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets" xlink:type="extended" xlink:title="10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_638182739807435318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_638182739807435318" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet" xlink:type="extended" xlink:title="10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638182739807445317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638182739807445317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_638182739807445317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_638182739807445317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowings" xlink:type="extended" xlink:title="10701 - Disclosure - BORROWINGS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638182739807445317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638182739807445317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants" xlink:type="extended" xlink:title="10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_638182739807445317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_638182739807445317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - SHARE-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715122844" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638182739807455319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715122844" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638182739807455319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCollaborationArrangements" xlink:type="extended" xlink:title="11001 - Disclosure - COLLABORATION ARRANGEMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborationArrangementsAbstract" xlink:label="adag_CollaborationArrangementsAbstract_637517385843023440" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_638182739807455319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_CollaborationArrangementsAbstract_637517385843023440" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_638182739807455319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpense" xlink:type="extended" xlink:title="11101 - Disclosure - INCOME TAX EXPENSE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289524508" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638182739807455319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289524508" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638182739807455319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638182739807455319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638182739807455319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11301 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637517388289524508" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638182739807465319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637517388289524508" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_638182739807465319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureLeases" xlink:type="extended" xlink:title="11401 - Disclosure - LEASES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638182739807465319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638182739807465319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11501 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637517388289524508" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638182739807465319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637517388289524508" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638182739807465319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRestrictedNetAssets" xlink:type="extended" xlink:title="11601 - Disclosure - RESTRICTED NET ASSETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RestrictedNetAssetsAbstract" xlink:label="adag_RestrictedNetAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_638182739807465319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_638182739807465319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureTreasuryShares" xlink:type="extended" xlink:title="11701 - Disclosure - Treasury Shares" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract" xlink:label="us-gaap_TreasuryStockSharesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="us-gaap_TreasuryStockTextBlock_638182739807475317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockSharesAbstract" xlink:to="us-gaap_TreasuryStockTextBlock_638182739807475317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11801 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638182739807475317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638182739807475317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638182739807475317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638182739807475317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_638182739807475317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_638182739807475317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638182739807485318" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_638182739807485318" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638182739807485318" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_638182739807485318" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638182739807485318" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638182739807485318" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638182739807485318" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638182739807485318" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638182739807485318" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638182739807485318" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GovernmentSubsidiesPolicyTextBlock" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_GovernmentSubsidiesPolicyTextBlock_638182739807485318" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638182739807485318" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638182739807485318" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638182739807495319" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638182739807495319" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638182739807495319" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638182739807495319" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638182739807495319" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_EmployeeDefinedContributionPlanPolicyTextBlock_638182739807495319" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638182739807495319" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638182739807495319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638182739807495319" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables" xlink:type="extended" xlink:title="30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_638182739807505321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_638182739807505321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715142892" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_638182739807505321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715142892" xlink:to="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_638182739807505321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNetTables" xlink:type="extended" xlink:title="30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_638182739807505321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_638182739807505321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638182739807515323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638182739807515323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" xlink:type="extended" xlink:title="30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638182739807515323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638182739807515323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_638182739807515323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_638182739807515323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsTables" xlink:type="extended" xlink:title="30703 - Disclosure - BORROWINGS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_638182739807525322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_638182739807525322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_638182739807525322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_638182739807525322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" xlink:type="extended" xlink:title="30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_638182739807525322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock_638182739807525322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638182739807525322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638182739807525322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638182739807525322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638182739807525322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638182739807525322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638182739807525322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables" xlink:type="extended" xlink:title="31101 - Disclosure - INCOME TAX EXPENSE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638182739807535322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638182739807535322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638182739807535322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638182739807535322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638182739807535322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638182739807535322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_638182739807535322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_638182739807535322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31203 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638182739807535322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638182739807535322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638182739807535322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638182739807535322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637517388289534549" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638182739807545320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_638182739807545320" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesTable" xlink:type="extended" xlink:title="31403 - Disclosure - LEASES (Table)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InformationRelatedToOperatingLeasesTableTextBlock" xlink:label="adag_InformationRelatedToOperatingLeasesTableTextBlock_638182739807545320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="adag_InformationRelatedToOperatingLeasesTableTextBlock_638182739807545320" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InformationRelatedToOperatingLeaseActivityTableTextBlock" xlink:label="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock_638182739807545320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="adag_InformationRelatedToOperatingLeaseActivityTableTextBlock_638182739807545320" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_638182739807545320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_638182739807545320" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638182739807545320" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638182739807545320" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638182739807555321" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638182739807555321" xlink:to="srt_OwnershipAxis_638182739807555321" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638182739807555321" xlink:to="srt_OwnershipDomain_638182739807555321" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdageneHongKongLimitedMember_638182739807555321" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneIncorporatedMember" xlink:label="adag_AdageneIncorporatedMember_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdageneIncorporatedMember_638182739807555321" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdageneSuzhouLimitedMember_638182739807555321" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdageneAustraliaPtyLtd.Member_638182739807555321" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdagenePte.Ltd.Member" xlink:label="adag_AdagenePte.Ltd.Member_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdagenePte.Ltd.Member_638182739807555321" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdageneAgMember_638182739807555321" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneProjectC1Pte.Ltd.Member" xlink:label="adag_AdageneProjectC1Pte.Ltd.Member_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638182739807555321" xlink:to="adag_AdageneProjectC1Pte.Ltd.Member_638182739807555321" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638182739807555321" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638182739807555321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807555321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638182739807555321" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807555321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807555321" xlink:to="us-gaap_IPOMember_638182739807565321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807555321" xlink:to="us-gaap_OverAllotmentOptionMember_638182739807565321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638182739807555321" xlink:to="us-gaap_StatementClassOfStockAxis_638182739807565321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638182739807565321" xlink:to="us-gaap_ClassOfStockDomain_638182739807565321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807565321" xlink:to="dei_AdrMember_638182739807565321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_638182739807555321" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638182739807565321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" xlink:to="us-gaap_SharesIssuedPricePerShare_638182739807565321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638182739807565321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638182739807565321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638182739807565321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingDepositoryReceiptRatio" xlink:label="dei_EntityListingDepositoryReceiptRatio_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_638182739807565321" xlink:to="dei_EntityListingDepositoryReceiptRatio_638182739807575323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715492893" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715492893" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638182739807575323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638182739807575323" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638182739807575323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638182739807575323" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638182739807575323" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638182739807575323" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_638182739807575323" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638182739807575323" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638182739807575323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_FinancialAssetsFairValueDisclosure" xlink:label="adag_FinancialAssetsFairValueDisclosure_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638182739807575323" xlink:to="adag_FinancialAssetsFairValueDisclosure_638182739807575323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_638182739807575323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638182739807575323" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_638182739807575323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715502636" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715502636" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807585322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807585322" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638182739807585322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638182739807585322" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" xlink:to="us-gaap_MachineryAndEquipmentMember_638182739807585322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" xlink:to="us-gaap_VehiclesMember_638182739807585322" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" xlink:to="us-gaap_FurnitureAndFixturesMember_638182739807585322" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" xlink:to="adag_ElectronicEquipmentMember_638182739807585322" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807585322" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_638182739807585322" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807585322" xlink:to="srt_RangeAxis_638182739807585322" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638182739807585322" xlink:to="srt_RangeMember_638182739807585322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638182739807585322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638182739807585322" xlink:to="srt_MinimumMember_638182739807585322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638182739807585322" xlink:to="srt_MaximumMember_638182739807595331" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807585322" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638182739807595331" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638182739807595331" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638182739807595331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_638182739807595331" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_638182739807595331" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638182739807595331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanAbstract" xlink:label="us-gaap_DefinedContributionPlanAbstract_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedContributionPlanAbstract_638182739807595331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638182739807595331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanAbstract_638182739807595331" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638182739807595331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715532875" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715532875" xlink:to="us-gaap_ConcentrationRiskTable_638182739807605327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638182739807605327" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638182739807605327" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638182739807605327" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638182739807605327" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638182739807605327" xlink:to="us-gaap_GeographicConcentrationRiskMember_638182739807605327" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638182739807605327" xlink:to="us-gaap_SupplierConcentrationRiskMember_638182739807605327" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638182739807605327" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638182739807605327" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638182739807605327" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638182739807605327" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638182739807605327" xlink:to="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_638182739807605327" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638182739807605327" xlink:to="us-gaap_CostOfGoodsProductLineMember_638182739807605327" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638182739807605327" xlink:to="adag_ConcentrationRiskSuppliersAxis_638182739807605327" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_ConcentrationRiskSuppliersAxis_638182739807605327" xlink:to="adag_ConcentrationRiskSuppliersDomain_638182739807605327" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OneSupplierMember" xlink:label="adag_OneSupplierMember_638182739807605327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_ConcentrationRiskSuppliersDomain_638182739807605327" xlink:to="adag_OneSupplierMember_638182739807605327" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638182739807605327" xlink:to="srt_StatementGeographicalAxis_638182739807615329" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638182739807615329" xlink:to="srt_SegmentGeographicalDomain_638182739807615329" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MainlandOfChinaMember" xlink:label="adag_MainlandOfChinaMember_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807615329" xlink:to="adag_MainlandOfChinaMember_638182739807615329" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OutsideMainlandOfChinaMember" xlink:label="adag_OutsideMainlandOfChinaMember_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807615329" xlink:to="adag_OutsideMainlandOfChinaMember_638182739807615329" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638182739807605327" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638182739807615329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638182739807615329" xlink:to="us-gaap_TypeOfAdoptionMember_638182739807615329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638182739807615329" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_638182739807615329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638182739807605327" xlink:to="us-gaap_ConcentrationRiskLineItems_638182739807615329" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638182739807615329" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638182739807615329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfMajorSupplier" xlink:label="adag_NumberOfMajorSupplier_638182739807615329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638182739807615329" xlink:to="adag_NumberOfMajorSupplier_638182739807615329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638182739807625326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638182739807615329" xlink:to="us-gaap_ConcentrationRiskPercentage1_638182739807625326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638182739807625326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638182739807615329" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638182739807625326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638182739807625326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638182739807615329" xlink:to="us-gaap_OperatingLeaseLiability_638182739807625326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" xlink:type="extended" xlink:title="40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715562911" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PercentageOfDepreciationOfForeignCurrency" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_638182739807625326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715562911" xlink:to="adag_PercentageOfDepreciationOfForeignCurrency_638182739807625326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GovernmentSubsidiesReceived" xlink:label="adag_GovernmentSubsidiesReceived_638182739807625326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715562911" xlink:to="adag_GovernmentSubsidiesReceived_638182739807625326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableGross_638182739807635322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNet_638182739807635322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_638182739807635322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent_638182739807635322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent_638182739807635322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638182739807635322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807635322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638182739807635322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807635322" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638182739807635322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638182739807635322" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" xlink:to="us-gaap_MachineryAndEquipmentMember_638182739807645324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" xlink:to="us-gaap_LeaseholdImprovementsMember_638182739807645324" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" xlink:to="adag_ElectronicEquipmentMember_638182739807645324" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" xlink:to="us-gaap_FurnitureAndFixturesMember_638182739807645324" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" xlink:to="us-gaap_VehiclesMember_638182739807645324" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638182739807645324" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_638182739807645324" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638182739807635322" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638182739807645324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638182739807645324" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638182739807645324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638182739807645324" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638182739807645324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638182739807645324" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638182739807645324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638182739807645324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638182739807645324" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638182739807645324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638182739807655323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_638182739807645324" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638182739807655323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638182739807655323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638182739807655323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638182739807695322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedUtilitiesCurrent_638182739807695322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent_638182739807695322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_638182739807695322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_638182739807695322" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - BORROWINGS - Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrentAbstract" xlink:label="us-gaap_DebtCurrentAbstract_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtCurrentAbstract_638182739807695322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="us-gaap_ShortTermBorrowingsAbstract_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtCurrentAbstract_638182739807695322" xlink:to="us-gaap_ShortTermBorrowingsAbstract_638182739807695322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_638182739807695322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract_638182739807695322" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_638182739807695322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract_638182739807695322" xlink:to="us-gaap_LongTermDebtCurrent_638182739807705322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract_638182739807695322" xlink:to="us-gaap_DebtCurrent_638182739807705322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtCurrentAbstract_638182739807695322" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638182739807705322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_638182739807705322" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_638182739807705322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansFromBank" xlink:label="us-gaap_LongTermLoansFromBank_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract_638182739807705322" xlink:to="us-gaap_LongTermLoansFromBank_638182739807705322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract_638182739807705322" xlink:to="us-gaap_LongTermDebtNoncurrent_638182739807705322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtCurrentAbstract_638182739807695322" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_638182739807705322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - BORROWINGS - Short term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_638182739807705322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638182739807705322" xlink:to="us-gaap_DebtInstrumentAxis_638182739807705322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638182739807705322" xlink:to="us-gaap_DebtInstrumentNameDomain_638182739807705322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromBankOfJiangsuCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfJiangsuCo.LtdMember_638182739807705322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807705322" xlink:to="adag_BorrowingsFromBankOfJiangsuCo.LtdMember_638182739807705322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807705322" xlink:to="adag_BorrowingsFromBankOfNingboCo.LtdMember_638182739807715322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807705322" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_638182739807715322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaMerchantsBankCo.LtdMember" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807705322" xlink:to="adag_ChinaMerchantsBankCo.LtdMember_638182739807715322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807705322" xlink:to="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_638182739807715322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ChinaConstructionBankCorporationMember" xlink:label="adag_ChinaConstructionBankCorporationMember_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807705322" xlink:to="adag_ChinaConstructionBankCorporationMember_638182739807715322" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_638182739807705322" xlink:to="us-gaap_ShortTermDebtLineItems_638182739807715322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638182739807715322" xlink:to="us-gaap_DebtInstrumentFaceAmount_638182739807715322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638182739807715322" xlink:to="us-gaap_DebtInstrumentTerm_638182739807715322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_638182739807715322" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638182739807715322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - BORROWINGS - Long term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638182739807715322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638182739807715322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638182739807715322" xlink:to="us-gaap_LongtermDebtTypeAxis_638182739807725324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_638182739807725324" xlink:to="us-gaap_LongtermDebtTypeDomain_638182739807725324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_638182739807725324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_638182739807725324" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_638182739807725324" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_638182739807725324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_638182739807725324" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_638182739807725324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_638182739807725324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_638182739807725324" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_638182739807725324" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638182739807715322" xlink:to="us-gaap_DebtInstrumentLineItems_638182739807725324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638182739807725324" xlink:to="us-gaap_DebtInstrumentFaceAmount_638182739807725324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm_638182739807725324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638182739807725324" xlink:to="us-gaap_LongTermDebtTerm_638182739807725324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638182739807725324" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638182739807735326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638182739807725324" xlink:to="us-gaap_RepaymentsOfDebt_638182739807735326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638182739807725324" xlink:to="us-gaap_LongTermDebtCurrent_638182739807735326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_638182739807735326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638182739807735326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638182739807735326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_638182739807735326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_638182739807735326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_638182739807735326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" xlink:to="us-gaap_DebtInstrumentAxis_638182739807745322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638182739807745322" xlink:to="us-gaap_DebtInstrumentNameDomain_638182739807745322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638182739807745322" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_638182739807745322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" xlink:to="us-gaap_StatementClassOfStockAxis_638182739807745322" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638182739807745322" xlink:to="us-gaap_ClassOfStockDomain_638182739807745322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807745322" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_638182739807745322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807745322" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_638182739807745322" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807745322" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_638182739807745322" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807745322" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_638182739807745322" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807745322" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_638182739807745322" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807745322" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_638182739807745322" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638182739807745322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638182739807745322" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638182739807745322" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638182739807755325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1WarrantsMember" xlink:label="adag_SeriesC1WarrantsMember_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638182739807755325" xlink:to="adag_SeriesC1WarrantsMember_638182739807755325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638182739807755325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638182739807755325" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807755325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638182739807755325" xlink:to="us-gaap_IPOMember_638182739807755325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807745322" xlink:to="us-gaap_TemporaryEquityLineItems_638182739807755325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_DebtInstrumentFaceAmount_638182739807755325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638182739807755325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_638182739807755325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638182739807755325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638182739807755325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_638182739807755325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_SharesIssuedPricePerShare_638182739807765324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_638182739807765324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="adag_NumberOfInvestorsToWhomWarrantsWereIssued_638182739807765324" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638182739807765324" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638182739807765324" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="adag_MaximumProceedsReceivableFromExerciseOfWarrants_638182739807765324" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638182739807765324" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638182739807765324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_PreferredStockSharesIssued_638182739807765324" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807755325" xlink:to="us-gaap_PreferredStockSharesOutstanding_638182739807775330" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_638182739807775330" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807775330" xlink:to="us-gaap_StatementClassOfStockAxis_638182739807775330" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638182739807775330" xlink:to="us-gaap_ClassOfStockDomain_638182739807775330" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807775330" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_638182739807775330" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807775330" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_638182739807775330" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807775330" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_638182739807775330" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807775330" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_638182739807775330" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_638182739807775330" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807775330" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_638182739807775330" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739807775330" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_638182739807785323" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_638182739807775330" xlink:to="us-gaap_TemporaryEquityLineItems_638182739807785323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_638182739807785323" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638182739807785323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638182739807785323" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_638182739807785323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638182739807785323" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_638182739807785323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638182739807785323" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_638182739807785323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6381827398077853231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_638182739807785323" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6381827398077853231" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638182739807785323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" xlink:to="us-gaap_PlanNameAxis_638182739807785323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638182739807785323" xlink:to="us-gaap_PlanNameDomain_638182739807795321" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2015Member" xlink:label="adag_Plan2015Member_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638182739807795321" xlink:to="adag_Plan2015Member_638182739807795321" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2017Member" xlink:label="adag_Plan2017Member_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638182739807795321" xlink:to="adag_Plan2017Member_638182739807795321" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_Plan2019Member" xlink:label="adag_Plan2019Member_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638182739807795321" xlink:to="adag_Plan2019Member_638182739807795321" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638182739807795321" xlink:to="adag_PerformanceIncentivePlan2021Member_638182739807795321" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" xlink:to="us-gaap_GranteeStatusAxis_638182739807795321" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638182739807795321" xlink:to="us-gaap_GranteeStatusDomain_638182739807795321" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638182739807795321" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638182739807795321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638182739807795321" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638182739807795321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" xlink:to="srt_StatementScenarioAxis_638182739807795321" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638182739807795321" xlink:to="srt_ScenarioUnspecifiedDomain_638182739807795321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ServiceConditionsAndPerformanceConditionsMember" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638182739807795321" xlink:to="adag_ServiceConditionsAndPerformanceConditionsMember_638182739807795321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember" xlink:label="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_638182739807795321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638182739807795321" xlink:to="adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_638182739807795321" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" xlink:to="srt_RangeAxis_638182739807805323" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638182739807805323" xlink:to="srt_RangeMember_638182739807805323" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638182739807805323" xlink:to="srt_MinimumMember_638182739807805323" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638182739807805323" xlink:to="srt_MaximumMember_638182739807805323" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638182739807785323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638182739807805323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638182739807805323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638182739807805323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638182739807805323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_638182739807805323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_638182739807805323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_638182739807815322" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638182739807815322" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638182739807815322" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638182739807815322" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638182739807815322" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_NumberOfSharesSurrendered" xlink:label="adag_NumberOfSharesSurrendered_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="adag_NumberOfSharesSurrendered_638182739807815322" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638182739807815322" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638182739807815322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638182739807815322" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_638182739807825323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_638182739807825323" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue_638182739807825323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638182739807805323" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue_638182739807825323" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638182739807825323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638182739807825323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638182739807825323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638182739807825323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638182739807825323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638182739807825323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638182739807835323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638182739807835323" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638182739807835323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638182739807825323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638182739807835323" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638182739807835323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638182739807835323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638182739807835323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638182739807835323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381827398078353231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381827398078353231" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638182739807835323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638182739807835323" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638182739807835323" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638182739807845326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638182739807845326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638182739807845326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_638182739807845326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638182739807845326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6381827398078453261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6381827398078453261" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_638182739807845326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638182739807845326" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_638182739807845326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638182739807855325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638182739807855325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638182739807855325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638182739807855325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638182739807855325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638182739807855325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638182739807855325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638182739807855325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6381827398078553251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6381827398078553251" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638182739807855325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638182739807855325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638182739807855325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638182739807845326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638182739807855325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638182739807865324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638182739807865324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638182739807865324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638182739807865324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638182739807865324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638182739807865324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715602905" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715602905" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638182739807865324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638182739807865324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638182739807865324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638182739807865324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638182739807875322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638182739807875322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638182739807875322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_638182739807875322" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_638182739807875322" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638182739807865324" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638182739807875322" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715612895" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715612895" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638182739807875322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638182739807875322" xlink:to="us-gaap_IncomeStatementLocationAxis_638182739807875322" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638182739807875322" xlink:to="us-gaap_IncomeStatementLocationDomain_638182739807875322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638182739807875322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638182739807875322" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638182739807875322" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638182739807875322" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638182739807885325" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638182739807875322" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638182739807885325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638182739807885325" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638182739807885325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborationArrangementsAbstract" xlink:label="adag_CollaborationArrangementsAbstract_637517385843288507" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_CollaborationArrangementsAbstract_637517385843288507" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638182739807885325" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638182739807885325" xlink:to="us-gaap_TypeOfArrangementAxis_638182739807885325" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638182739807885325" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" xlink:to="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_638182739807885325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" xlink:to="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_638182739807885325" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdctCollaborationAgreementMember" xlink:label="adag_AdctCollaborationAgreementMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" xlink:to="adag_AdctCollaborationAgreementMember_638182739807885325" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ExelixisIncAgreementMember" xlink:label="adag_ExelixisIncAgreementMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" xlink:to="adag_ExelixisIncAgreementMember_638182739807885325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdctMaterialTransferAndOptionAgreementMember" xlink:label="adag_AdctMaterialTransferAndOptionAgreementMember_638182739807885325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" xlink:to="adag_AdctMaterialTransferAndOptionAgreementMember_638182739807885325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_SanofiAgreementMember" xlink:label="adag_SanofiAgreementMember_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638182739807885325" xlink:to="adag_SanofiAgreementMember_638182739807895324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638182739807885325" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceived_638182739807895324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_638182739807895324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638182739807895324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementMilestonePaymentReceived" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceived_638182739807895324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_638182739807895324" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_638182739807895324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PeriodForReservationOfTargetRight" xlink:label="adag_PeriodForReservationOfTargetRight_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_PeriodForReservationOfTargetRight_638182739807895324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="us-gaap_OtherIncome_638182739807895324" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_638182739807895324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_638182739807895324" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_638182739807905324" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="adag_MilestonePaymentsReceivableSalesBasedMilestones_638182739807905324" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638182739807895324" xlink:to="us-gaap_AccountsReceivableNetCurrent_638182739807905324" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAX EXPENSE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_IncomeTaxDisclosureTable" xlink:label="adag_IncomeTaxDisclosureTable_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="adag_IncomeTaxDisclosureTable_638182739807905324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_638182739807905324" xlink:to="srt_StatementGeographicalAxis_638182739807905324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638182739807905324" xlink:to="srt_SegmentGeographicalDomain_638182739807905324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807905324" xlink:to="country_CN_638182739807905324" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_HK" xlink:label="country_HK_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807905324" xlink:to="country_HK_638182739807905324" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU" xlink:label="country_AU_638182739807905324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807905324" xlink:to="country_AU_638182739807905324" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807905324" xlink:to="country_US_638182739807915325" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="country_US_638182739807915325" xlink:to="stpr_CA_638182739807915325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807905324" xlink:to="country_CH_638182739807915325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG" xlink:label="country_SG_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638182739807905324" xlink:to="country_SG_638182739807915325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_638182739807905324" xlink:to="adag_StatusForTaxabilityAxis_638182739807915325" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_StatusForTaxabilityAxis_638182739807915325" xlink:to="adag_StatusForTaxabilityDomain_638182739807915325" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TechnologyAdvancedServiceEnterprisesMember" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_StatusForTaxabilityDomain_638182739807915325" xlink:to="adag_TechnologyAdvancedServiceEnterprisesMember_638182739807915325" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_638182739807905324" xlink:to="dei_LegalEntityAxis_638182739807915325" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638182739807915325" xlink:to="dei_EntityDomain_638182739807915325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638182739807915325" xlink:to="adag_AdageneSuzhouLimitedMember_638182739807915325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638182739807915325" xlink:to="adag_AdageneHongKongLimitedMember_638182739807915325" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638182739807915325" xlink:to="adag_AdageneAustraliaPtyLtd.Member_638182739807915325" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember_638182739807915325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638182739807915325" xlink:to="adag_AdageneAgMember_638182739807915325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_638182739807905324" xlink:to="us-gaap_StatementLineItems_638182739807925324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638182739807925324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PreferentialIncomeTaxRate" xlink:label="adag_PreferentialIncomeTaxRate_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_PreferentialIncomeTaxRate_638182739807925324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_638182739807925324" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AssessableProfits" xlink:label="adag_AssessableProfits_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_AssessableProfits_638182739807925324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WithholdingTaxRateOnDividendsPercentage" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_WithholdingTaxRateOnDividendsPercentage_638182739807925324" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_CapitalTaxRatePercentage" xlink:label="adag_CapitalTaxRatePercentage_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_CapitalTaxRatePercentage_638182739807925324" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="us-gaap_OperatingLossCarryforwards_638182739807925324" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WithholdingIncomeTaxes" xlink:label="adag_WithholdingIncomeTaxes_638182739807925324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_WithholdingIncomeTaxes_638182739807925324" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_TaxableIncome" xlink:label="adag_TaxableIncome_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="adag_TaxableIncome_638182739807935326" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638182739807935326" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638182739807925324" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_638182739807935326" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_638182739807935326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_638182739807935326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638182739807935326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_638182739807945325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_638182739807945325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_638182739807935326" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638182739807945325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638182739807945325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638182739807945325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638182739807945325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638182739807945325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_638182739807945325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_638182739807945325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_638182739807945325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_638182739807945325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_638182739807945325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638182739807955326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_638182739807955326" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638182739807955326" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_638182739807955326" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_638182739807955326" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638182739807955326" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289555277" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289555277" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638182739807955326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_638182739807955326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638182739807955326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638182739807955326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsInventory_638182739807965325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_638182739807965325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_638182739807965325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities" xlink:label="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities_638182739807965325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="adag_DeferredTaxAssetsDepreciationAndAmortization_638182739807965325" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsGross_638182739807965325" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638182739807965325" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638182739807955326" xlink:to="us-gaap_DeferredTaxAssetsNet_638182739807965325" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289555277" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638182739807965325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638182739807965325" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638182739807965325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638182739807965325" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638182739807965325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_638182739807965325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638182739807965325" xlink:to="us-gaap_DeferredTaxLiabilities_638182739807965325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails" xlink:type="extended" xlink:title="41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289565197" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract_638182739807975324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289565197" xlink:to="us-gaap_ValuationAllowanceAbstract_638182739807975324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638182739807975324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_638182739807975324" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638182739807975324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638182739807975324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_638182739807975324" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638182739807975324" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_6381827398079753241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_638182739807975324" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_6381827398079753241" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638182739807975324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_638182739807975324" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638182739807975324" xlink:to="us-gaap_NetIncomeLoss_638182739807985326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638182739807975324" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_638182739807985326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638182739807975324" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638182739807985326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807985326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807985326" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638182739807985326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807985326" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638182739807985326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807985326" xlink:to="us-gaap_EarningsPerShareBasic_638182739807985326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638182739807985326" xlink:to="us-gaap_EarningsPerShareDiluted_638182739807985326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638182739807985326" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638182739807985326" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638182739807985326" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638182739807985326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638182739807985326" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638182739807985326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638182739807985326" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_638182739807995325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638182739807985326" xlink:to="us-gaap_StockCompensationPlanMember_638182739807995325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638182739807985326" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638182739807995325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638182739807995325" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638182739807995325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637517388289565197" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637517388289565197" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638182739807995325" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638182739807995325" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638182739807995325" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638182739807995325" xlink:to="us-gaap_RelatedPartyDomain_638182739807995325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WuxiApptecGroupMember" xlink:label="adag_WuxiApptecGroupMember_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638182739807995325" xlink:to="adag_WuxiApptecGroupMember_638182739807995325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_WuxiBiologicsCaymanInc.Member" xlink:label="adag_WuxiBiologicsCaymanInc.Member_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638182739807995325" xlink:to="adag_WuxiBiologicsCaymanInc.Member_638182739807995325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638182739807995325" xlink:to="us-gaap_RelatedPartyTransactionAxis_638182739807995325" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_638182739807995325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_638182739807995325" xlink:to="us-gaap_RelatedPartyTransactionDomain_638182739807995325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_638182739807995325" xlink:to="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_638182739808005325" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638182739807995325" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638182739808005325" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638182739808005325" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_638182739808005325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638182739808005325" xlink:to="us-gaap_DueToRelatedPartiesCurrent_638182739808005325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638182739808005325" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_638182739808005325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - LEASES - Information related to operating leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRightOfUseAssetsAbstract" xlink:label="adag_OperatingLeaseRightOfUseAssetsAbstract_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="adag_OperatingLeaseRightOfUseAssetsAbstract_638182739808005325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OperatingLeaseRightOfUseAssetsAbstract_638182739808005325" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638182739808005325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638182739808005325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638182739808005325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638182739808015328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638182739808015328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638182739808015328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" xlink:to="us-gaap_OperatingLeasePayments_638182739808015328" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract_638182739808005325" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638182739808015328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails" xlink:type="extended" xlink:title="41402 - Disclosure - LEASES - Information related to operating lease activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRentalExpenseAbstract" xlink:label="adag_OperatingLeaseRentalExpenseAbstract_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="adag_OperatingLeaseRentalExpenseAbstract_638182739808015328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OperatingLeaseRentalExpenseAbstract_638182739808015328" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638182739808015328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OperatingLeaseRentalExpenseAbstract_638182739808015328" xlink:to="us-gaap_ShortTermLeaseCost_638182739808015328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_InterestOfOperatingLeaseLiabilities" xlink:label="adag_InterestOfOperatingLeaseLiabilities_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OperatingLeaseRentalExpenseAbstract_638182739808015328" xlink:to="adag_InterestOfOperatingLeaseLiabilities_638182739808015328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_OperatingLeaseRentalExpense" xlink:label="adag_OperatingLeaseRentalExpense_638182739808015328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OperatingLeaseRentalExpenseAbstract_638182739808015328" xlink:to="adag_OperatingLeaseRentalExpense_638182739808015328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails" xlink:type="extended" xlink:title="41403 - Disclosure - LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_638182739808025325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_638182739808025325" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_638182739808025325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_638182739808025325" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_638182739808025325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_638182739808025325" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_638182739808025325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_638182739808025325" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_638182739808025325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="41404 - Disclosure - LEASES - Maturities of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638182739808025325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638182739808025325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638182739808025325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638182739808025325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638182739808025325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_OperatingLeaseLiability_638182739808025325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - RESTRICTED NET ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_RestrictedNetAssetsAbstract" xlink:label="adag_RestrictedNetAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_638182739808035329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_638182739808035329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_638182739808035329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_AfterTaxIncomePercentageAppropriations" xlink:label="adag_AfterTaxIncomePercentageAppropriations_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_AfterTaxIncomePercentageAppropriations_638182739808035329" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_638182739808035329" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Treasury Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAbstract" xlink:label="us-gaap_TreasuryStockSharesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockSharesAbstract_1" xlink:to="us-gaap_ClassOfTreasuryStockTable_638182739808035329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_638182739808035329" xlink:to="us-gaap_StatementClassOfStockAxis_638182739808035329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638182739808035329" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638182739808035329" xlink:to="us-gaap_ClassOfStockDomain_638182739808035329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739808035329" xlink:to="dei_AdrMember_638182739808045327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638182739808035329" xlink:to="us-gaap_CommonStockMember_638182739808045327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="us-gaap_ShareRepurchaseProgramAxis_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_638182739808035329" xlink:to="us-gaap_ShareRepurchaseProgramAxis_638182739808045327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="us-gaap_ShareRepurchaseProgramDomain_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramAxis_638182739808045327" xlink:to="us-gaap_ShareRepurchaseProgramDomain_638182739808045327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareRepurchaseProgramOf2021Member" xlink:label="adag_ShareRepurchaseProgramOf2021Member_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramDomain_638182739808045327" xlink:to="adag_ShareRepurchaseProgramOf2021Member_638182739808045327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_ShareRepurchaseProgramOf2022Member" xlink:label="adag_ShareRepurchaseProgramOf2022Member_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareRepurchaseProgramDomain_638182739808045327" xlink:to="adag_ShareRepurchaseProgramOf2022Member_638182739808045327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_638182739808035329" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_638182739808045327" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1_638182739808045327" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" xlink:to="us-gaap_TreasuryStockSharesAcquired_638182739808045327" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_638182739808045327" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" xlink:to="us-gaap_TreasuryStockSharesRetired_638182739808045327" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares_638182739808045327" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_638182739808045327" xlink:to="us-gaap_TreasuryStockCommonShares_638182739808045327" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638182739808055326" xlink:to="us-gaap_SubsequentEventTypeAxis_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638182739808055326" xlink:to="us-gaap_SubsequentEventTypeDomain_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638182739808055326" xlink:to="us-gaap_SubsequentEventMember_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638182739808055326" xlink:to="us-gaap_PlanNameAxis_638182739808055326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638182739808055326" xlink:to="us-gaap_PlanNameDomain_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20221231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638182739808055326" xlink:to="adag_PerformanceIncentivePlan2021Member_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638182739808055326" xlink:to="us-gaap_GranteeStatusAxis_638182739808055326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638182739808055326" xlink:to="us-gaap_GranteeStatusDomain_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638182739808055326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638182739808055326" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_638182739808055326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638182739808065324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638182739808055326" xlink:to="us-gaap_SubsequentEventLineItems_638182739808065324" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638182739808065324" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638182739808065324" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638182739808065324" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>adag-20221231x20f002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'K >,# 2(  A$! Q$!_\0
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MI5ICKY][&G\VKR5?V1]"U%UE\0>)/$7B"8?\_-V-OZJ3^M;5E^RG\-+-E8Z
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MZLZ3O!V.>MAZ6(CRU8W_ *Z=CYPM_B[X]^"5Q'8_$O2FUO0]P2/Q+IB;L#.
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MPWL>;CL7.FIT:*]]1YK_ #_,]&^%W[1]YK_B:#PSXT\.R^%-;NEWV9D5Q'<
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M<G*KQGIJI633=]-;66IO?$GP)\,/'7PFU/QCH.DQ)+%:N;:XTFW>)A+V5XD
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M9/['\HQ,KC^!SOPK#C)" D'C (-?4NGV,&F6-O9VL2P6UO&L442# 1%& ![
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M\+_$C3TQ<:3=+!>; 1YD#'^(CJ![T\,^>]%_:V]>G^0L<O9<N*CO!Z_X7O\
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M-YO#5S)S& 2;-S_"3_=/8_A7UF S#VMJ57XNC[_\$_/,WR7ZLG7PZ]WJNW_
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M6EG)*T3=,,%!VGCO7OFBW.I>$/VD=-LKNXCUB]U(6YFO[ZPCBN45EY4!>%;
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M7M[BYE:>/RF\TK@#/; %1W/@!"/W%VP/I(N?U% '&T5I:GX=O=*RTL6^(?\
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M03C_ ,<C']*]ZKP?]EYA!J/Q*LNA@\0S$KZ9+#_V6O>*^=Q?\>7]=#[/)O\
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MW=M$>R^N/4_X5R-=[XZ\"VD.GP^)O#,PU#PQ> .DD9R8"?X6[@9XYZ=#7!4
M%* 6( &2> *2NZ^#W@QO%WBZ#S$+6-H1/.>Q Z+^)H ^B/A;X>/AGP/IMHP
MF=/.DP,?,W/\L#\*\X_;$\4?V!\(+JU0XFU.9+5?I]YOT!KW(<"OA_\ ;@\8
MG5?'6FZ!$[>3IMOYL@!^4R/[>H _6O0P%+VN(BNVOW'B9S7]A@IOJ]/O_P"
M?-5=3\-O 5Y\1O%5MI-L?*B/[RYN6QMMX1R[G/H*Y:O:)G;X5_ F!(F,6N>,
MF+/(C?-'9(<;>G&X]1Z8K[.M-Q2C'=Z+^O(_,,-3C.3E4^&*N_\ +YO0Q_BQ
M\2;2_M8/!_A1&L?!^F,54*<-?RCK/(1][)Z ^WMCS.&WEN"1%&\A R0BDX%:
MO@[2;37O%6E:=?W:V%E<W*137+D 1J3R237Z"W'B/X;?L]>$1#;SV%C&L6Y+
M>W97N;LXX)Q\S$^IX&>PKBK5U@U&E3BY-_UJ>IAL)+,W.O6J*$8_AV26FA^<
M72DKVW5_@-XT^(VF:M\0['3;.UTZ]DDO(K 2[9VCR3E5QC]1GFO$R,$@\$5W
MTZL:J]UZK?R/(K8>I0:YTTGL[6NNXE*JEV"J"S'H .34UC93:E>06MM&TMQ,
MXCC11DLQ. *^E?!_P=UW]F_7M$\=>)4L+W1XW$5VEN[-+:>9P'P5P2N>QJ*U
M>-%6>[V7<UPV$GB7=+W5N^R[GS*R,C%64JPX((P17K7PH\<6.N:6WP^\7R&3
MP_?-BQO'.7TVX/W70GHI/45]4_'/X6>%?C!\/[KQ%I[6AU&&W-S:ZM;8/F@#
M.UV'WAVYZ5^?5<M&M#'4WI9K\&=^*PU3*:RU4HR7R:ZIF[XW\'W_ (#\37VB
M:DFRYMG*AL<2+_"X]B.:PJ]H\4'_ (6?\$M/\1D-)KGAF1=.O7P/WMNW^K8]
MR1T]A7B]=E&;G'WMUHSS<32C3G>'PM77I_P-@K]./@/8/IGP@\*V\@PZV:DC
MZDG^M?F?I]N;R_MH ,F614Q]3BOU<\-67]F^'=+M,8,%K%%CZ(!_2O$SF7N0
MB?5\,PO4J3[)+^ON-*BBBOEC] "BBB@ KGOB'+Y'@77W)QBQF_\ 0#70UQGQ
MEN_L/PL\3S'^&QD_EBM*:O.*\T85WRTIOR9\G_#OPJ][X)TB<+D/"#^IHKV7
MX&^$#??"3PQ<;,^9: _^/&BO9JXJU22\V?*4,"Y4H/NE^1-\#H_[%^-OQ=TE
M^&EO(;Y![.9'/_HU:]XKP?P\/[&_:\\312G8NJZ)'/"#_&5\I?\ V1_RKW<=
M*\W$ZS4NZ7Y'L93[M&=/^6<U_P"3-_DQ:***Y#V@HHHH **** /F3]N+1!/X
M8\.ZL$):VNWMBP'02)NY_&,5\>5^BG[1GAQ_$WP<\1VT2*\T,(NTR.1Y;!SC
MW(4C\:_.NOK<KGS4.7LS\7XMH>RS#VG2:3^[3]$%%%2VMK-?7,5O;QM-/*X2
M.-!EF8G  '<U[!\4DV[(T?"_A?4_&6N6ND:1:O>7URVU(T_4D]  .23P*^[?
M@I^S_H_PGL8[N=8]0\1.O[Z_8<19ZK$#]T=L]3^@/V?O@I:_"CPRMQ>11OXB
MO$#7<YY,2]1$I]!W(ZGV KQ_]HG]H:77+BY\,>&KAHM-C8QW=]$_-R>A1"/X
M/4_Q?3KX,I5LSK?5\/I%;O\ K\%U/UC*<IHY116,QBO5>R[?\'N^AW'Q=_:I
MT_PQ)-I?A58M6U-<I)>/S;PGN!C[Y^AP/4\BOE?Q5XUUSQO?F\UO4I]0FYV^
M:WRH#V51PH]@*IZ'H5_XEU2WT[3;9[N\G;:D<8S^)] .Y/ KU&VM=!^%EY%8
M6=K#XR\=.ZQA#&9+2SD.,*J_\M'R<>Q]".?I*.&PV7)0I1YI_CZM]%_6ITU*
M]?&MRJ2M#\/NZLY7PU\'O$OB2P.HBUBTO20H<ZAJ<HMX0OKEN2/< UJR>!/
M>C2JNJ>/OMKC[\.D6#R#\)2=I_*NM^)/P=\=2>$KOQ9XQ\06PEMU##3WD)V
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M"",@UT5?>I4Y>37W/_@GE8+]WB\32\XR_P# HV_.+)****Y#VPHHHH ****
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M>DR@^*[V,'5M1C/-LI&1;QGL<=2/7Z8\Y\,^)M0\(Z]:ZQILP@O[=BR2.@<
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MM8;VWD@N(DG@D!5XY%#*P/4$'J*\1\>?LC>$?%4LMUI+R^&[UR6(MAO@)/\
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M_GL?#9EF-7 YI!4Z3;FE&[V>JLU;M=W6FY^CX.12T@Z4M>.?<A1110 4444
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M:1GO+SR)8L\-;0B-5]OO$FO2_AU^TG<^!M'UZSGT6+4)=2NI;Q)%F\L1R/\
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M"^NH+:]5A_J3_!,ONIYJA\8OA??_  G\:7>D74;FT9C)9W+#B:+/!SZCH?\
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MJ"JOX59!7<?"CX<2_$+7R+B066A6*_:-2OY.$@A')Y]3T J_X"^"6J^*M/\
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M6>,T5O$7@R^\-7Y;,EYX5G7RW_[8R_*H^G-17'@7X27DH>S^)][IT+#(AO\
M0)977V+(0#^ KR.BI]AR_!-KYW_.Y7UOF_B4XR^5O_26CUVV\%?"'3B\M_\
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M\L;<DX&36+X)O8K+]F*YN+N(W=M#YS/ 3]]!)DK^/-97['W_ ")7BK_KHO\
MZ U3Z!_R:9JW_7*Y_P#0S7RM:E&G7G3CLIP7X,^AIU)2HPG+=QG^:/)/CO\
M&J/XI7&GV>E03V6BV: K!, K-)C&< D8 X'XU6UJ+_A7/PL@TE@$USQ(5N;I
M3D/#:J?D7VW'GW'TJK\._"-GI>FOXT\41%-#M&_T2V<<ZA/_  HH/501R?8^
M^.-\5^);SQ?X@O-7OWWW%R^XCL@Z!1[ 8%?3TJ,+QH45[D-_-]OEN_D>#4J3
MLZU3XY;>2[_HOF9-%%%>P>8%%%% !1110 4444 %%%% !1110 4444 %%%%
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M-U).<MV==&G&C3C3CLE8****@U"BBB@#D/BMX$A^(W@;4M&?:MPZ>9:R,/\
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M>L'NOU1Y6.P$,7&ZTDNO^9^:5%>H_&+X#ZQ\+;R2YC5]1\/NW[J^1>8\]%E
M^Z>V>A]CQ7EU?H]&O3Q$%4I.Z9\/5I3HR<*BLPHHHK<Q"BE52[!0,DG %=5J
M7PN\3:182WEUIH2*%4:9%N(GEA5ONF2-6+(#ZL!6<JD(-*32N:1A*=W%7L<_
M+J]]/-;2RWMQ)+;*J0.\K%HE4Y4*<_*!V K2C\>^)HHY8T\1:LD<K%I%6^E
M<GJ2-W)/O6A?_"KQ-IUK>3R6,,@LT$ES';WD$TL*D9#/&CEE&#GD=*;=?"WQ
M/9Z?%>2:6?)E\K"I/&\B^9Q'NC#%EW=L@5S^UPTTKN+^XV]G7C?1K[S$TOQ#
MJFB3O/IVI7EA-)P\EK.T;-]2I&:M67C;Q%ITUQ-::]J=K+<$--)#>2(TI' +
M$-R1[T[Q%X+U?PK'%)J-O'''([Q+)#<1SJ'7[R$QLP##/(.#6)6J5*JN9)-,
MR;J4WRNZL:9\4ZT1> ZO?D7IS<C[2_[_ /W^?F_&F1^(M4BTY=/&HW?]G*V_
M['Y[B'.<YV@XS[UGXK1/AW4%\/KK9@_XEC7'V43[U_UFW=MVYST[XQ5.-.-K
MI"3G+9LFO?%FJ7FO3:PMY-:ZA+UFMY75P-NW&[.[H,9))/<FJEAK>HZ6LBV5
M_=6BRE6<03,@8@Y4G!Y(/(K<T;X9>)-?TV&^LM/$EO.66'S+B*)IBHR1&KL&
M?&#]T&G:5\+_ !'K-M!-;6<&+AWCACFO8(I967A@J.X8D>PK!U</!<KDM-.A
MJJ=>3YDGKJ9.K>+-;U^)8M4UG4-2C0Y5+NZ>4 ^H#$T/XLUN33?[.;6+]M/
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MQSU!7L,^[U&(H.A/E;NGJGW7<NC65:/-L^J[,****YC<**** "BBB@ HHHH
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M[&O>A4A57-3DFO+4\B<)TW::MZB4445H9A1110 4444 %%%% !112@9.!R:
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MO0M!L/#6E6^FZ;;):6=NNV.*,8 ']3[UZJ4< KO6K^$?_MOR/-][&.RTI_\
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M\\GS2[O].P4445Q'6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZO<<<+%OFJOF?GM\EL1P01VT210QK%$@VJB !5'H *DHHKSSN"BBB@ HHHH
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MHVOSN'L:\?AJ_>D_RL>?6/[0_P .]1<+%XGMD)_Y[QR1#\W4"NEL_B)X5U$
MVOB72+C/_/.^B)_]"JO>?"[P=?[OM'A;1Y"W5C8Q@_GMS7'>(?V=_AXT33CP
MW'')_P!,KF9!^2N!^E4E@INRYE]S_P A-XJ/\K^]?YGIT.LZ?<@&*^MI0>FR
M53_(U:617&58,/8YKY0\4?"#PCIR.;?2?+(Z?Z3,?YO7EVJ^%=+M&/DVQ3![
M2/\ XUWT\LI5O@J/_P !7_R1Q3S"I2^*"^__ (!^@.1ZU#+?6T'^LN(H_P#?
M<"OSWM] L)9 KPEAZ&1O\:['PS\//#^HR 7&G^8"?^>T@_DU:5,HITOBJ/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>adag-20221231x20f003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'A _X# 2(  A$! Q$!_\0
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MW_[Y-'V>7_GF_P#WR:_:;%&*^_\ ]:W_ ,^/_)O_ +4_,?\ 4K_J(_\ )?\
M[8_%G[/+_P \W_[Y-'V>7_GF_P#WR:_:;%&*/]:W_P ^/_)O_M0_U*_ZB/\
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M\F_^U#_4K_J(_P#)?_MC\6?L\O\ SS?_ +Y-'V>7_GF__?)K]IL48H_UK?\
MSX_\F_\ M0_U*_ZB/_)?_MC\6?L\O_/-_P#ODT?9Y?\ GF__ 'R:_:;%&*/]
M:W_SX_\ )O\ [4/]2O\ J(_\E_\ MC\6?L\O_/-_^^31]GE_YYO_ -\FOVFQ
M1BC_ %K?_/C_ ,F_^U#_ %*_ZB/_ "7_ .V/Q9^SR_\ /-_^^31]GE_YYO\
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M\ F7!?,K?6/_ "7_ .V/Q.^PRX(\M_R-1FQD_P">;_\ ?)K]M<4M92XC<O\
MEU_Y-_P"/]25_P!!'_DO_P!L?B4+.1.?+?\ [Y-/C@ES_JW_ .^37[8XHP*G
M_6)_\^OQ_P" '^I*M;ZQ_P"2_P#VQ^,-C;CS1]HBD:(\80<U>N;*$R*+>VD"
M8[CFOV0Q1BE_K"_^?7X_\ PEP+S.ZQ-O^W/_ +8_&W[)<Q(/+$JJO(X-9[/=
MP2LIC>3G.2IK]HL48%9SS[G_ .77X_\  .F'!DXJWUK_ ,D_^V/QKMQ),HS;
M-G_=-:<<+.@+1OGI@J>*_8'%%8_VSI;V?X_\ T7!\NN)_P#)/_MC\AK>V"2(
MSP2/&I^9<<$4PVDI<N(G!8Y "GBOU\I:C^V/^G?X_P# -/\ 5#_I_P#^2_\
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M9],_\-_?$+_H%^'_ /P'F_\ CM'_  W]\0O^@7X?_P# >;_X[7S-11]3P_\
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M%XHYB!'*Z;\JA)QN.!P?0T_88-=$2L3CWK=_<>I?\-_?$+_H%^'_ /P'F_\
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M#_R(/[0Q7_/QGTS_ ,-_?$+_ *!?A_\ \!YO_CM'_#?WQ"_Z!?A__P !YO\
MX[7S-11]3P_\B#^T,5_S\9],_P##?WQ"_P"@7X?_ / >;_X[1_PW]\0O^@7X
M?_\  >;_ ..U\S44?4\/_(@_M#%?\_&?3/\ PW]\0O\ H%^'_P#P'F_^.T?\
M-_?$+_H%^'__  'F_P#CM?,U%'U/#_R(/[0Q7_/QGTS_ ,-_?$+_ *!?A_\
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M_':/^&_OB%_T"_#_ /X#S?\ QVOF:BCZGA_Y$']H8K_GXSZ9_P"&_OB%_P!
MOP__ . \W_QVC_AO[XA?] OP_P#^ \W_ ,=KYFHH^IX?^1!_:&*_Y^,^F?\
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MU7_P61?_ "11]D\.?]!75?\ P61?_)%',OZ0<C\OO1B45M_9/#G_ $%=5_\
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MR>'/^@KJO_@LB_\ DBC[)X<_Z"NJ_P#@LB_^2*.9?T@Y'Y?>C$HK;^R>'/\
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M:A)M*VY@T5+=6[V=U-!(07B<HQ7ID''%151(4444".L\+_\ (E^,O^O:W_\
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M_P"$?LTX-]>.)!YF GE,'+HVYFRNW%?,U%3]5BU9M_AVMV*^NSO>R_'O?O\
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M,:*Q\T2(H8DC&,88<Y_"OHWPY\3O"S>--1\1S>-)-/OYK32C<(EQ+:Q7<BQ
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M:\6L_9PYG-JW6R_R/8>BW.NHHHKJ+"LOQ19S:CX;U2UMT\R>:VDCC3(&6*D
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M^\T?^$CU;_H*7G_@0_\ C1_PD>K?]!2\_P# A_\ &LZBCECV#VM3^9_>:/\
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M2\_\"'_QK.HHY8]@]K4_F?WFC_PD>K?]!2\_\"'_ ,:/^$CU;_H*7G_@0_\
MC6=11RQ[![6I_,_O-'_A(M6)!_M.\X_Z>'_QH_X2/5O^@I>?^!#_ .-9U%'+
M'L'M:G\S^\T?^$CU;_H*7G_@0_\ C4MKXMUNRN8KB#5[V.:-@Z.+AL@CH>M9
M-%'+'L"K54[J3^\^QO@A\?K7QU##H^M/'::^HVJ_W8[KW'HWJO?MZ#VBOS4C
ME>&19(V*.IRK*<$'U%?8W[.7Q)U_QSH4MOK%E+,ED!&FKGA9C_<;/5P.X_'G
MKX&,PBI_O(;'[)PQQ+/&R6!Q=W/I+O;OY^?7KKO[+1117D'Z8%%%% !1110
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MI+_NT 3T444 %%%% !11535=5L]"TRZU'4;J&QL+2)II[FX<)'%&HRS,QX
M!))H MT5YI:_M&^ KVUFN+?4M0F6.-9Q''H=^TLL+'"SQ1B'?+"3P)4#)_M5
M-X;_ &@O OBW2$U73=5NGTR2XMK2*\N=*O+>*66XE$,*QM+$H?=(0N5R!GG
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MC_AF/X??] J?_P #)?\ XJC^T:/9A_J1F7\\/O?_ ,B?$U%?;/\ PS'\/O\
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MS'<74T*3"WBA26$*%BFA9I6EZR!0AY8 'LGV:7_G[F_[Y3_XFC[-+_S]S?\
M?*?_ !->4^/?B;XS\*Z!X&O[32= NH]4U?2]/UB]CU"2:"%;F\@MS]E 13*2
M)6(9R@7 .'^[3OC[XW\=_#;P[J?BO03X9.@:+:K=W%CJJ3M=ZDV_YX(9$95@
M<KM6,E9M[R %5 RP!ZI]FE_Y^YO^^4_^)H^S2_\ /W-_WRG_ ,37AOB?]H"6
M3XJWWA'3_%7@WP8FDFUBN6\5/YMS?W,R+)]GMX1<0E=L;Q9D)?+3*H7Y3GWD
M<@4 0?9I?^?N;_OE/_B:/LTO_/W-_P!\I_\ $U8HH K_ &:7_G[F_P"^4_\
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M$?O9^@'_  L;PE_T/&D?^#"VH_X6-X2_Z'C2/_!A;5^?]%']FP_F#_7O$_\
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M\+&\)?\ 0\:1_P"#"VK\_P"BC^S8?S!_KWB?^?$?O9^@'_"QO"7_ $/&D?\
M@PMJ/^%C>$O^AXTC_P &%M7Y_P!%']FP_F#_ %[Q/_/B/WL_0#_A8WA+_H>-
M(_\ !A;4?\+&\)?]#QI'_@PMJ_/^BC^S8?S!_KWB?^?$?O9^@'_"QO"7_0\:
M1_X,+:C_ (6-X2_Z'C2/_!A;5^?]%']FP_F#_7O$_P#/B/WL_0#_ (6-X2_Z
M'C2/_!A;4?\ "QO"7_0\:1_X,+:OS_HH_LV'\P?Z]XG_ )\1^]GWU+\1/"9F
MA(\:Z2P#')_M"V^7@U-_PL;PE_T/&D?^#"VK\_Z*/[-A_,'^O>)_Y\1^]GZ
M?\+&\)?]#QI'_@PMJ!\1?"9( \;Z02>PU"VK\_Z*7]FP_F#_ %[Q/_/B/WL_
M2.*-IXDDCOI)(W 97780P/0@[:?]FE_Y^YO^^4_^)KY$^!_[0%QX(EBT;77D
MNM!8[8Y/O/:GU'JGJ.W4>A^N]/U"VU6RAN[.=+FVF4/'+&V58'N#7DUZ$Z$K
M2V[GZ/E&<X?.*//2=I+>/5?YKLP^S2_\_<W_ 'RG_P 31]FE_P"?N;_OE/\
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M2><)QP?]FI_LTO\ S]S?]\I_\323_P#'U;?5O_035F@"O]FE_P"?N;_OE/\
MXFC[-+_S]S?]\I_\35BB@"O]FE_Y^YO^^4_^)H^S2_\ /W-_WRG_ ,35BB@"
MO]FE_P"?N;_OE/\ XFC[-+_S]S?]\I_\35BB@"O]FE_Y^YO^^4_^)H^S2_\
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M=>5>1YTXBSN;K?,O) Q:L,''WL]JZ]=6L7DM(UO+=GNT,ENHE4F90 2R#/S
M @Y'J*!%NBBB@ HHHH *@OO^/27_ ':GJ"^_X])?]V@">BBB@ HHHH ****
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MU]-WT445X9^NA1110 4444 %%%% %>;_ (^;?ZG^56*KS?\ 'S;_ %/\JL4
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M&3_"I+B\0SVQV2\.?^63?W3[58^VI_<F_P"_3?X478>QI?RK[BG_ ,(MHO\
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M<F_[]-_A1]M3^Y-_WZ;_  H L457^VI_<F_[]-_A1]M3^Y-_WZ;_  H 2?\
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M-ROV+Q%=BWP-PGM;;=G//2/'3%>645?U.ES\]OET^XR_MW,?9JE[:7KS2O\
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M)_:'B&]/39]FMK;\<YCKRFBH6!HJ+CW^_P"1H^(,Q<XS]J].EW9^NNIZG?\
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MZ5HT4<FK=WJ%CFM.7Q(-4MO[5?3&MOFXM%D#YVG'WCBIM77Q.;UO[,DTI;3
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M?_#'WAK_ *#6J_G%_P#$4?\ #'WAK_H-:K^<7_Q%=OU^AW_ ^4_U.S;^1?\
M@2/DRBOK/_AC[PU_T&M5_.+_ .(H_P"&/O#7_0:U7\XO_B*/K]#O^ ?ZG9M_
M(O\ P)'R917UG_PQ]X:_Z#6J_G%_\11_PQ]X:_Z#6J_G%_\ $4?7Z'?\ _U.
MS;^1?^!(^3**^L_^&/O#7_0:U7\XO_B*/^&/O#7_ $&M5_.+_P"(H^OT._X!
M_J=FW\B_\"1\F45]9_\ #'WAK_H-:K^<7_Q%'_#'WAK_ *#6J_G%_P#$4?7Z
M'?\  /\ 4[-OY%_X$CY,HKZS_P"&/O#7_0:U7\XO_B*/^&/O#7_0:U7\XO\
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M'?\  /\ 4[-OY%_X$CY,HKZS_P"&/O#7_0:U7\XO_B*/^&/O#7_0:U7\XO\
MXBCZ_0[_ (!_J=FW\B_\"1\F45]9_P##'WAK_H-:K^<7_P 11_PQ]X:_Z#6J
M_G%_\11]?H=_P#_4[-OY%_X$CY,HKZS_ .&/O#7_ $&M5_.+_P"(H_X8^\-?
M]!K5?SB_^(H^OT._X!_J=FW\B_\  D?)E%?6?_#'WAK_ *#6J_G%_P#$4?\
M#'WAK_H-:K^<7_Q%'U^AW_ /]3LV_D7_ ($CY,JWI>EW>MZA!8V%O)=W<S!(
MX8ERS'Z5]22?LA>&TEB4:SJF')!_U?H3_=KT'X;?!?P_\,?-EL%EN[Z7AKRZ
MP9 O]U<  #Z=:B>84E&\-6=6%X+S"I6C'$6C#J[IOY+N<U\$O@):> ((M5U=
M8[OQ ZY'\26N>R^K>K?EZGV.BBOGZE2567--ZG[-@L#0R^BJ&'C:*_'S?=A1
M1169WA1110 4444 %%%% !1110!7F_X^;?ZG^56*KS?\?-O]3_*K% !1110
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MU_\ 6H 6?_CXMO\ >/\ Z":GJC-:XGMQYTO+'^+_ &34WV0_\]YO^^O_ *U
M%BBJ_P!D/_/>;_OK_P"M1]D/_/>;_OK_ .M0!8HJO]D/_/>;_OK_ .M1]D/_
M #WF_P"^O_K4 6**K_9#_P ]YO\ OK_ZU'V0_P#/>;_OK_ZU %BBJ_V0_P#/
M>;_OK_ZU'V0_\]YO^^O_ *U %BBJ_P!D/_/>;_OK_P"M1]D/_/>;_OK_ .M0
M!8HJO]D/_/>;_OK_ .M1]D/_ #WF_P"^O_K4 $W_ !\V_P!3_*K%4)K7_28/
MWTO4\[O:I_LA_P">\W_?7_UJ +%%5_LA_P">\W_?7_UJ/LA_Y[S?]]?_ %J
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"/VO\ _D0M)_["2_\
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MJ#_43"_\_I?<C\_/^%3^-/\ H5=8_P# &3_"C_A4_C3_ *%76/\ P!D_PK]
MZ*/[2G_*@_U$PO\ S^E]R/S\_P"%3^-/^A5UC_P!D_PH_P"%3^-/^A5UC_P!
MD_PK] Z*/[2G_*@_U$PO_/Z7W(_/S_A4_C3_ *%76/\ P!D_PH_X5/XT_P"A
M5UC_ , 9/\*_0.BC^TI_RH/]1,+_ ,_I?<C\_/\ A4_C3_H5=8_\ 9/\*/\
MA4_C3_H5=8_\ 9/\*_0.BC^TI_RH/]1,+_S^E]R/S\_X5/XT_P"A5UC_ , 9
M/\*/^%3^-/\ H5=8_P# &3_"OT#HH_M*?\J#_43"_P#/Z7W(_/S_ (5/XT_Z
M%76/_ &3_"C_ (5/XT_Z%76/_ &3_"OT#HH_M*?\J#_43"_\_I?<C\^V^%7C
M)2 ?"NL G@#[#)S^E+_PJ?QI_P!"KK'_ ( R?X5]]7/_ !\6O^^?_035FC^T
MI_RH/]1,+_S^E]R/D3X/_LWZEXBU(7WBFSN-,TJ!_P#CTF4QS7!';!Y5?4]^
MWJ/K.PL+;2[*&TLX([:VA4)'%$NU5 [ 58HK@KXB=>5Y'V.4Y-ALGI<E!7;W
MD]W_ ,#R"BBBN8]T**** "BBB@ HHHH **** ()_^/BV_P!X_P#H)J>H)_\
MCXMO]X_^@FIZ "BBB@ HHHH **** "BBB@ HHHH **** *\W_'S;_4_RJQ5>
M;_CYM_J?Y58H **** "BBB@ HHHH **** "BBB@ HHHH K3_ /'U;?5O_035
MFJT__'U;?5O_ $$U9H **** $90ZE2,@C!%?+OBO]GWQ;=^#-5\!)X9\(^*M
M"EN[BZT77=6NFBNM',TC2,?*-O)ET9VVNCJ2#@XZU]1T4 ?.>M? 3Q7'XGU7
MQ%ILFF7=W#JVF:I86=S</$ET+:)DDCD<1MY9.?E8!O<57UOX)^/-<N+KQ2+7
M0K7Q'<^(].UH:,U_(UM'%:=$:X$.6=LG)$>!QUKZ4HH ^<)_A+\2##JNM0BS
ML]1U[71?ZKH.FZ]/9JUJL'E1QK>QPB0/N =BJKD +FK'PF^ WB;P;JGP^N]1
M>Q5=";5FNTCOI;IO])=VC"R2(&D(W#+/@GD\FOH>B@ HHHH *9-_JG_W33Z9
M-_JG_P!TT ,L_P#CTA_W!_*IJAL_^/2'_<'\JFH **** "BBB@ HHHH I6UP
M4BQY,C89N0!CJ?>I?M1_YX3?D/\ &EL_]0/JW\S4] %?[4?^>$WY#_&C[4?^
M>$WY#_&K%% %?[4?^>$WY#_&C[4?^>$WY#_&K%% %?[4?^>$OY#_ !H^U'_G
MA-^0_P :L5F+XHT=_$;>'EU:Q.O):B];2Q<)]J%ONV"8Q9W;-WR[L8SQG- %
MO[4?^>$WY#_&C[4?^>$WY#_&N5'QG^'Y\1_\(\/'/ALZ_P#:#:?V4-7M_M7G
M X,7E;]V_/&W&<U9\8?%/P;\/9K>'Q/XJT?P_-<J6ABU*^B@>11U959@2!W/
M0=Z .A^U'_GA+^0_QH^U'_GA-^0_QK)G\>^&K6QTB]F\0Z7'9ZQ+%!IMPUY&
M([Z23'EI"V<2,V1@+DGM5#Q;\7? O@#48=/\3^-/#WAR_FC$T5KJVJP6LLB$
MD!E61P2,@C(XR#Z4 =+]J/\ SPE_(?XT?:C_ ,\)OR'^-<[JGQ4\&:)XFM_#
MNH>*]&L=>N'2.+3+B_B2X9W_ -6HC+9RW.T8RV#C-=50!GV5O:Z:LPM-.%J)
MI6FD$,2IOD;EG;'5CW)Y-6/M1_YX3?D/\:L44 5_M1_YX3?D/\:/M1_YX3?D
M/\:L44 5_M1_YX3?D/\ &H;RY+6LH\F4?+U('^-7J@OO^/27_=H 3[4?^>$W
MY#_&C[4?^>$WY#_&K%% %?[4?^>$WY#_ !H^U'_GA-^0_P :L44 5_M1_P">
M$WY#_&C[4?\ GA-^0_QJQ10!7^U'_GA-^0_QH^U'_GA-^0_QJQ10!7^U'_GA
M-^0_QH^U'_GA-^0_QJQ10!7^U'_GA-^0_P :/M1_YX3?D/\ &K%% %?[4?\
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M'_GA-^0_QH^U'_GA-^0_QK\=_P#AHGXH_P#10O$O_@TF_P#BJ/\ AHGXH_\
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M'^-6** *_P!J/_/";\A_C1]J/_/";\A_C5BB@"O]J/\ SPF_(?XTV6Z)B?\
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M444 03_\?%M_O'_T$U/4$_\ Q\6W^\?_ $$U/0 4444 %%%% !1110 4444
M%%%% !1110!7F_X^;?ZG^56*KS?\?-O]3_*K% !1110 4444 %%%% !1110
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M[N%Q@-[]:TM&^'OACPZ-.&E>'M,TT::)%LA:6B1BV$GWQ'M VALG.,9KH**
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M '\-'V0?\])?^_AJ>B@"#[(/^>DO_?PU#>VH%K*?,D/R]W-7:@OO^/27_=H
M/L@_YZ2_]_#1]D'_ #TE_P"_AJ>B@"#[(/\ GI+_ -_#1]D'_/27_OX:GHH
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M!!]D'_/27_OX:/L@_P">DO\ W\-3T4 0?9!_STE_[^&C[(/^>DO_ '\-3T4
M0?9!_P ])?\ OX:;+:@1/^\EZ'^,U9IDW^J?_=- #+/_ (](?]P?RJ:H;/\
MX](?]P?RJ:@ HHHH **** "BBB@""S_U ^K?S-3U!9_Z@?5OYFIZ "BBB@ H
MHKSKXD?%34O!GBSP[X<T7PG<^*]3U>TO;X16][#;>5#;-;JYS*0&8FY3 R.A
MR10!Z(P)4A3@XX)'2O!HOV4+"V\#Z79PZ_>#QE8:G'KB^(9'G>%M0^T_:)9?
ML9F\L*[-(I7KM<\D\G7MOVDK'Q3IWAG_ (0KP]J/BK6=?TU]7BTSS8;0VEJD
M@C=[AY'VH1(?+"KO)8''R@L)]#_:'LM5O=#LKO0-0T:]N]>E\,ZC;WK1[M-U
M!;4W*(Q4D2)(@78Z$@^8F<$D  P)_P!G;Q5/I7C'PT/'EA:^#?%.JWFH7]M;
MZ"PU'R;I\S6Z7+7+1J"I*;_)R <C!Q6_=_!OQ!X<\6:UK'@+Q+IFAVFN) =0
MTC6M(DU"V\Z*)85GAV7$)C8QI&K E@WEJ>#R6VG[2OAV]MOBQ<16UTT/P\$C
MWC<#[4B12,[19["2&XBY_BB:BP^-GB'7/&U_X>T?X?W-\=+CL6U.ZDU2"$6S
M7$0EVA6Y?8"<XZD4#,V^^ 'B*U^$_@3P+H7B[3+2V\,R:?<27FHZ))<O=36=
MQ%/$0J748C4O%AE^8D-PRD9K9^)'PU\=?$3PS?\ AV;Q=X=MM'U;3?L&I*WA
MN664,Z%9I+=C> )NSE0ZR;#CEJS8_P!I+'B[4;"?PCJ*>'K/Q)%X4;7H[F!U
M%]+Y(CW0[@XC+3QKN&[!89&,XW/ /Q\\.>,=>U/0;S4-,T7Q#;ZQ>Z5:Z1-J
M49NKU;9RIFCB.UB#M8X .-IY.#0(XKQ=^R]J&O)XQTVR\3:;%HGBI;5+M]2T
M5KO4K98(8XE$%R+A H'E^8FZ-MDCNPSNQ7T"HVJ .@XKFT^)OA"3QBWA)/%.
MBMXI49.B#4(C>CY-_P#J=V_[GS=.G/2N5\9?M ^%O"_BO1?#MKJNDZMJ]WJT
M>F7]E#J<0GTQ6AEE\Z6,98 >6!AMOW@<^H!Z?163;^+=#NQHY@UG3YAK,?FZ
M88[I&^W)L\S=#@_O!L^;*Y^7GI6M0 4444 %07W_ !Z2_P"[4]07W_'I+_NT
M 3T444 %%%% '!>+_BK:>#?B3X6\-:@UI:6>M65]='4+NY$(B:W, " -P=WG
M'N,;>^:\Z\2?M.WEMHUS=:'INBW<G_"9#PI;W&H:J8+)E^SK-]H>9(WVC+%<
M 'IUKMO'_P (;?X@?%3P=KVJZ?I.K:%HVGZC;SV>I0B8M+.;<QLB,A4X$+Y)
M((R,9R<>9:_^S/K$.AS66C:-X6OK*/QX/%$&AWLK6UE)9_95B\EMMO(%;<"<
M!&7'?- '3Z_\9/'&E1^"M/M='\'W^O>(Y[Q1)'K\YTV*."(R9$XMBS,0I&-F
M >]:'A[XK^-?B%\-M*\2>$_#.@M=2RW<%]'J^M2Q6R&"9X2T$L5O)YR.T;,K
MD(-N#WK,U?X$O\0+[P!_PDO@SPAI^@Z%+?F[\.VLGVZS*S0,D;1J]M$I;>VX
M@HN.H)-8NI_";XJ:=\,-#^'^D2:%J7AVSN[BUO'N=:N+*[N=(5O]%M1,EK+L
M8QD1R,!G;'\I!?<@,[CP=^T=X6UWP)H_B#6[@>&KB\T(Z_-9W88B.W0A9720
M+ME56(QM^8JZ$J-P%07GQ7\8>*/&&MZ/\/\ PUI.IVFA>1'J%[XAU*?3]T\L
M2S"&)$MY6RL;QEB^W!D P><<I\4O@5XL^*]CX1)M/#?A27PG#]NTS3[29KRW
M;4(W @@D=K:,_9!&@WJJ@DN, >4I;H+3P?\ $;P)XT\4:OX8T[PWJ^G^*9(-
M0NK+4]5GM#IUZL$<,A1DMI//C98HSR(SE3_>X *-S\9OB1>>)?'%MH/@70M4
MT_PE-#!=0S:]+!>W#O9PW+K"OV9HR1YVT%G4$KSMSP?$#]H?6=!\!Z1X]\.Z
M/H6I^$+[3+?4DBU36'M-4N3+@B""W6!U>3!4 >9\S-MQQDLMO ?Q5\/^*OB'
M/H]KX2EM_%MU;W2ZI=ZE<H]FRV,%M(?LBVY$F&B9E'GKD$ D<U1\8_ 35Y/A
M]I7@/1_"_A76+/3-%BTK3/%6K7CPZCILBQ[/M"(ML_S*5612DJ$MQ\N-U 'T
M-&_F1JVTKN .UNH]C3JJZ7:26&FVEM-</=S0PI&]Q)]Z5@H!8^YQG\:M4""B
MBB@#YS_;Y_Y-SU;_ *^[7_T<M?EQ7ZK_ +;GA[5?%'P%U+3M%TR\U?4)+JV*
M6EA;O/*P$JDD(H). "3QT%?G!_PHGXE?]$[\5_\ @DN?_B*_2^&ZM.&#:G)+
MWGU\D?#9W3G/$IQ3>B_-G#T5W'_"B?B5_P!$[\5_^"2Y_P#B*/\ A1/Q*_Z)
MWXK_ /!)<_\ Q%?5?6*/\Z^]'SWL:O\ *_N.'HKN/^%$_$K_ *)WXK_\$ES_
M /$4?\*)^)7_ $3OQ7_X)+G_ .(H^L4?YU]Z#V-7^5_<</17<?\ "B?B5_T3
MOQ7_ ."2Y_\ B*/^%$_$K_HG?BO_ ,$ES_\ $4?6*/\ .OO0>QJ_RO[CAZ*[
MC_A1/Q*_Z)WXK_\ !)<__$4?\*)^)7_1._%?_@DN?_B*/K%'^=?>@]C5_E?W
M'#T5W'_"B?B5_P!$[\5_^"2Y_P#B*/\ A1/Q*_Z)WXK_ /!)<_\ Q%'UBC_.
MOO0>QJ_RO[CAZ*[C_A1/Q*_Z)WXK_P#!)<__ !%'_"B?B5_T3OQ7_P""2Y_^
M(H^L4?YU]Z#V-7^5_<</17;GX%_$E2 ?A[XJ!)P =$N>?_'*7_A1/Q*_Z)WX
MK_\ !)<__$4?6*/\Z^]![&K_ "O[CAZ*[C_A1/Q*_P"B=^*__!)<_P#Q%'_"
MB?B5_P!$[\5_^"2Y_P#B*/K%'^=?>@]C5_E?W'#T5W'_  HGXE?]$[\5_P#@
MDN?_ (BC_A1/Q*_Z)WXK_P#!)<__ !%'UBC_ #K[T'L:O\K^XX>BNX_X43\2
MO^B=^*__  27/_Q%'_"B?B5_T3OQ7_X)+G_XBCZQ1_G7WH/8U?Y7]QP]>T?L
MS_L_^+/C)XNM[O1IYM#TO3ITDN-=7*F!@00(B,;I.X /'<BNJ_9__8J\6?$S
M7_-\6:;J7A'P[:L#.U];-!<W'^Q$C@'G^^1@>YXK]*O"OA/2/!&@6>BZ%80Z
M;IEHFR*WA& !ZD]23W)Y)ZU\QF^>0PT71P[4IOKNE_F_Z9[V795.NU5K*T5]
M[_X!?T^U:QL;>W>XENFBC5#//@R2$#&YL #)ZG  ]JL445^8[GWFP4444 5K
MG_CXM?\ ?/\ Z":LU6N?^/BU_P!\_P#H)JS0 4444 %%%% !1110 4444 %%
M%% !1110!!/_ ,?%M_O'_P!!-3U!/_Q\6W^\?_034] !1110 4444 %%%% !
M1110 4444 %%%% %>;_CYM_J?Y58JO-_Q\V_U/\ *K% !1110 4444 %%%%
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M: )Z*@^TG_GC)^0_QI?M!_YXR_D/\: )J*A^T'_GC+^0_P :/M!_YXR_D/\
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M^-'V@_\ /&7\A_C0 V;_ (^;?ZG^56*I33L;F#]S)U/IZ?6I_M!_YXR_D/\
M&@":BH?M!_YXR_D/\:/M!_YXR_D/\: )J*A^T'_GC+^0_P :/M!_YXR_D/\
M&@":BH?M!_YXR_D/\:/M!_YXR_D/\: )J*A^T'_GC+^0_P :/M!_YXR_D/\
M&@":BH?M!_YXR_D/\:/M!_YXR_D/\: )J*A^T'_GC+^0_P :/M!_YXR_D/\
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M\Z?M[L4_9TU8J2I^UVO(/_39:_+O[1+_ ,]7_P"^C7ZA_M\_\FYZM_U]VO\
MZ.6ORXK]0X9_W*7^)_DCX+/?]Z7^%?FR3[1+_P ]7_[Z-'VB7_GJ_P#WT:CH
MKZVR/G;LD^T2_P#/5_\ OHT?:)?^>K_]]&HZ*+(+LD^T2_\ /5_^^C1]HE_Y
MZO\ ]]&HZ*+(+LD^T2_\]7_[Z-'VB7_GJ_\ WT:CHHL@NR3[1+_SU?\ [Z-'
MVB7_ )ZO_P!]&HZ*+(+LD^T2_P#/5_\ OHT?:)?^>K_]]&HZ*+(+LD^T2_\
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MY'Y045^K_P#PQ!\%/^A+'_@TO?\ X]1_PQ!\%/\ H2Q_X-+W_P"/4?ZSX/\
MDE]R_P#D@_L'$_S1^]_Y'Y045^K_ /PQ!\%/^A+'_@TO?_CU'_#$'P4_Z$L?
M^#2]_P#CU'^L^#_DE]R_^2#^P<3_ #1^]_Y'Y045^K__  Q!\%/^A+'_ (-+
MW_X]1_PQ!\%/^A+'_@TO?_CU'^L^#_DE]R_^2#^P<3_-'[W_ )'Y045^K_\
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M &_1110(*9-_JG_W33Z9-_JG_P!TT ,L_P#CTA_W!_*IJAL_^/2'_<'\JFH
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M]0_95_OR_P#?PT?95_OR_P#?PT 345#]E7^_+_W\-'V5?[\O_?PT 35!??\
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M\!9/_CM=_P#JWCO[OW_\ X_[<PGG]Q^G=%?F)_P\(^*?]W1/_ 63_P".T?\
M#PCXI_W=$_\  63_ ..T?ZMX[^[]_P#P _MS">?W'Z=T5^8G_#PCXI_W=$_\
M!9/_ ([1_P /"/BG_=T3_P !9/\ X[1_JWCO[OW_ / #^W,)Y_<?IW17YB?\
M/"/BG_=T3_P%D_\ CM'_  \(^*?]W1/_  %D_P#CM'^K>._N_?\ \ /[<PGG
M]Q^G=%?F)_P\(^*?]W1/_ 63_P".T?\ #PCXI_W=$_\  63_ ..T?ZMX[^[]
M_P#P _MS">?W'Z=T5^8G_#PCXI_W=$_\!9/_ ([1_P /"/BG_=T3_P !9/\
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M% !1110!!/\ \?%M_O'_ -!-3U!/_P ?%M_O'_T$U/0 4444 %%%% !1110
M4444 %%%% !1110!7F_X^;?ZG^56*KS?\?-O]3_*K% !1110 4444 %%%% !
M1110 4444 %%%% %:?\ X^K;ZM_Z":LU6G_X^K;ZM_Z":LT %%%% !12,0H)
M)P!R37A5I\6/&'BR&Z\0:9J_@WPMX96^ELM.MO$:2O<:KY3E)&\Y9HU@!96"
M@1S' R1VH ]VHKQG3OCD-'\5^.[?Q+,HL-*N["TTZWT^V>>>>6>-CY:*@+2,
M6  P/RK.^('[25KIND:-?Z(MY#+%XDL](UG3;O3)3>P)*XW*(0"Q8J<J4# ]
MLT >[T5Y]IWQMT+6-"N-1L+#7+R>VNVL+C3(=)G-Y!.%#%)(]OR#:00S$*<C
M!K M/C6/%'Q#^'UKX?G$OA[7H-0:X%Q;-'.LD"D;"& 9"KJ001VH ]@HHHH
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M!-3U!/\ \?%M_O'_ -!-3T %%%% !1110 4444 %%%% !1110 4444 5YO\
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M:#J6M:E:ZQX?TRP6-I)]8TR:V\S>=J+$I7,C%L*%4$DLH )(IV8KH[3?<_\
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M!7CBR\<VVJ3V44\"Z?J=UI<@N H+202%'9<$_*2..AQU HL%T;F^Y_YY1?\
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M+QV?AKX,O_$US8_;(=,C>X:WBFVM( IX!*\5\Q?\/+]%_P"A&O\ _P #T_\
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MK/\ X*5^'YKN%+CP9J%O S@22K>(Y1<\G;M&<>F:^ **/[+PO\OXL/[=Q_\
M/^"_R/VM\)^,+'QQX?L];T.YM=1TR[3S(IX9B01W!^7@@\$'D$8-:^^Y_P">
M47_?P_\ Q-?DM^S]^T=XA^ FO>;9LVH:#<.#>Z3(Y"2#^^G]QP._?H<BOU$^
M&?Q/\/?%OPK;:]X<O5NK24 21-@2V[XYCD7/RL/R/4$C!KYG&8*>%E?>/?\
MS/MLMS2GCXVVFMU^J_K0Z7?<_P#/*+_OX?\ XFC?<_\ /*+_ +^'_P")J>BO
M-/;*-P]QYUOF*,?.<?O#_=/^S4^^Y_YY1?\ ?P__ !-)<_ZZV_WS_P"@FK%
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M_P")J>B@"C,]Q]I@S%'G)Q^\/I_NU/ON?^>47_?P_P#Q-)-_Q\V_U/\ *K%
M$&^Y_P">47_?P_\ Q-&^Y_YY1?\ ?P__ !-3T4 0;[G_ )Y1?]_#_P#$T;[G
M_GE%_P!_#_\ $U/10!!ON?\ GE%_W\/_ ,31ON?^>47_ '\/_P 34]% $&^Y
M_P">47_?P_\ Q-&^Y_YY1?\ ?P__ !-3T4 0;[G_ )Y1?]_#_P#$T;[G_GE%
M_P!_#_\ $U/10!!ON?\ GE%_W\/_ ,31ON?^>47_ '\/_P 34]% %"=[C[3;
MYBCSDX_>'T/^S5C?<_\ /*+_ +^'_P")IL__ !]6WU;_ -!-6: (-]S_ ,\H
MO^_A_P#B:-]S_P \HO\ OX?_ (FIZ* (-]S_ ,\HO^_A_P#B:-]S_P \HO\
MOX?_ (FIZ* (-]S_ ,\HO^_A_P#B:-]S_P \HO\ OX?_ (FIZ* (-]S_ ,\H
MO^_A_P#B:-]S_P \HO\ OX?_ (FIZ* (-]S_ ,\HO^_A_P#B:-]S_P \HO\
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M444 >0?M9?\ )!/%W_7C+_Z :_).OV!_:)\+ZGXT^$?B#1-&M3>ZI>VTD5O
M'5-[%3@98@#\37YV_P##%7QG_P"A,?\ \&%I_P#':^HRFM3ITI*<DM>K/A,_
MP]:M7@Z4')6Z)OJ>(45[?_PQ5\9_^A,?_P &%I_\=H_X8J^,_P#T)C_^#"T_
M^.U[GUJA_P _%]Z/F/J.+_Y]2_\  7_D>(45[?\ \,5?&?\ Z$Q__!A:?_':
M/^&*OC/_ -"8_P#X,+3_ ..T?6J'_/Q?>@^HXO\ Y]2_\!?^1XA17M__  Q5
M\9_^A,?_ ,&%I_\ ':/^&*OC/_T)C_\ @PM/_CM'UJA_S\7WH/J.+_Y]2_\
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MXVXQ5<Q/*?'EO->V5AJEB))2/C9:I=VQ=BS1?:+\Q2;0?XH]/O+<D=!]G)Z
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M:*3-&: %HI,T9H 6BDS1F@"&?_CXMO\ >/\ Z":GJ"?_ %]M_O'_ -!-39H
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3** .PL_^/2#_ '%_E4U%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>adag-20221231x20f004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #L AT# 2(  A$! Q$!_\0
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M<_RE=DJXW+R.<9'(XIV=KF;J04E!M7?0T****1H%%%% !1110 4444 %%%%
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M@_8KDKNR:5[WU4FK7UU<I*]K:I>AX;X5TC6O&6L/%:RZU% ^H:M;7^IM=O\
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MU_ZZ6?\ Z(%)&Q)_PFNI?]"9KO\ WU:?_'Z/^$UU+_H3-=_[ZM/_ (_75T4
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MZ*N3^%'_ "3?P[_UYI_*HE-S6I48*&QUE%%%9F@4444 %%%% !1110 4444
M%%%% !7,?$[0;SQ1\/M?TG3U1[V\LWAA5VVJ6(XR>U=/151DXM270QK4HUZ4
MJ4]I)I_/0\<\0^$O$7B)M!N[SPQ;WUOI]I/9/HMY>1LK.Z($N <%>,,,'D Y
M%85W\#]=DTF\BGAMM1U*+0["SLKQY1N2YBE+.5)Y7"D -U.*^@**Z5B9Q5E_
M74\*ID6%K2<JC;;]/Y>7MVM;LUI;6_S;X4M/M7QDNY)(2VH2:AJ*6TR1!IK)
MBF!/,KIDQX7"9?&6X&#7J?B7P=K>I7W@F0W:ZI)I6IM=7=W(JPG88I%!"#@D
M%E&!7?T4IUW)II;*Q>%R>%"E.G.;?-+FTTZI[7:>JWWMHK(^=['X(Z_:^'M?
MM9+9Y-8GTZZLQ>?;8A!>-)*&4E1&'SQG,C$J>!D&MSQQ\&+C5A?)INDV2QIX
M=2QLEW*GE78G+LR_W3@YW]<D^IKVRBG]:J7N8KA[!JFZ6K35NE[:^7G^".$\
M >"I_"6O^*F2U@L]*O6M7M(H&&W<L 64E1T)8=>_6N,T_P"$.MV/PLT_36>2
MZU&*ZBN+K2+B^)M9HDG9VA7LNY2,]B>M>W45"KS3OZ?@=DLHPTH*#O9*:7ES
MN[Z=+:=+:.YXII7POUVWN[6Y6PM=/MFU#4KM=.AG!2RCFM#%&BXXY?YB%X&Z
ML=O@YXE;38K*33[.YNYK#3+>WU22Y ?1WMP/-"#&3D@D%.N>:^@Z*M8J:.26
M0824>5M]>W5*+Z6V73;I;2WS[XB^$7C.'Q!JM]H3VZPV5U-=Z-&TX4,UT,70
M;^[CDCUKK_$_PLU:;X<7'AS2]31[6/3X;:VTV2%$3S(RAW&7[WS%#UX^:O4Z
M*3Q,W;;3^OZ]6:0R/"051)R]]-/7:^FEO*RL[JT8Z:'SYXJ\,ZVMZ;_5=!@D
M?6/%5C<1:9]I$BNB6C1E7<# ^[W&.?2NML?AYK-M\$=>\.>1!%J5^EXUO8I+
MF*V$KLR0A^F%! STKU:BAXB325MOT"EDM&G.I-R;YE)=/M:RV6]]NB['C"_"
MC4U\2/J_V&V%X/$EI?)="0>8MFD*I( >HR0?E[U?^*'PWUGQ7XKDU735B5[7
M1]MC,\@!6]2X66,8]"%()]Z]8HI?6)W4NQH\FPKI3HZVD[O;?7R\_P CP*Y^
M"_B1]*U.&)H1>7^D6XN9O."^?=_:VGN$/!P&#%0Q!'3(Q6CIOPMUJP_L:73[
M$6;07U[=R0ZA=12K&9+7RU.V)$4*7ZJH]3WKVRBJ>)F_Z^1A'(,)&2DG+2W5
M=)<RZ=SYUTSX-^)WTS5(+K3;>%;R32F> 3PJCF&8M.P6-54#:>.K$=236T_P
MIU?3[\2IHMEJNB6VMWMU%H#S(D+PRQ*L;@$% 58,=I'&21S7N%%-XJ;_ *^1
M,.'L)"*2<KKKI?XG+M9ZO9Z/JCP"Y^"&M3^'H[.ZM;2_NK?PU/8V[O+D0W;7
M!DC52W("*=H?MBKE_P#"C7++^UX=+TNQ_LZZFTV4VH,1+^7$ZSL@D5D$A8I\
MS Y&3UKW.BE]:J?U]X_]7\&OANG:U[J^B<=[=G^1YO\ #SX7P6W@/1M,\4Z7
M:W=]822M&KD2B-3*S*H8  C!'RXQ[<5Z.JA5"@  #  [4M%<\YRFVV>UAL+2
MPE.-.FMDE?J[*RN^H5R'A?\ Y'[QK_UTL_\ T0*Z^N0\+_\ (_>-?^NEG_Z(
M%2CJ/*D^)WC63P7%\3AJUD/#[ZNML/#!L1_QYF]%IGS]V_S^?,_NY^7;WKJ/
MA]XXUV\^)>LZ%XIU)].U$/=/9:%-IHCAGM4E BN+:Z!_??NRAD4\JSXVJ ,Z
MT?P%\+1ZXM\#J1L5OSJB:&;^0Z:MWO\ ,\X09VYWDOC[NX[L9YK2T+X3Z/H?
MBO\ X2$W>JZG?QK,EH-4U"2YCLEE(,BPJQ.W=M4=S@  @<55T39GF?Q4^-6N
M6'B;6M/T1YK73M"@FFNY+*&"2XE$,,<L[YG(1403PH%P6=W(!4+D]]\-?%>O
M^(?"WB&+4?(N=<T>^GTY;B*/REN66-)$9DR0K?O C $C<C8P.!A>,/@*NN^)
M=1U.V.A7MKJ$IN9;#Q#I37B0S-$D4CQ,DL9VNL<>Y&W#<@(P:](T'PMIWAKP
M_'H^EVL6FV:(RA+-3& S9+,.2<DDG)).>YH;5M 2=]3SKX%^,->U2:]T;QCJ
M.I-XLALK:\GTW4=,@M!"K[E9X6A+++&75ER6R-O(&:K:C^TYHFE:(FH76E7L
M3QVUS->VQ>,/9R17B6:PR$G 9YWVJ<XPK,< 5W7A'X<:;X0U*]U-+K4-5U:[
MB2WDU#5;IKB;R4+%(E)X5 68X &2Q)S7+Z9\!])?6/B/>:M&DJ>+KV"?R[21
MXV@2&-/+96R"LGFJTN5P-Q!ZBC2X:V,H_M,:<?!-UKZ:4I>SOI+"XBDU2VCA
MWI$)<Q3LP67*L,! 3G<"!M)JT_[0T4RZI=Z?X4U;4=(TW1+?6[B]B:+<$GA:
M6*)8MVYG(4YP,+US6WJOP0T;7+#3X;_5=>N;NQDF>#4WU-_M2K,@CECWCHC*
M , #&,C!R:T-(^%&C>'M/OK32IK_ $[[78VFGM/;W3"6.*VC,<.QCT8*>3W[
MT>Z'O$#^*!XS^$.J:P(H(5NM-NF5;:\CNXR C@%98SM8'';ITKI_#/\ R+>D
M_P#7I%_Z *YB;P7IO@/X7>(M-TP3-$]K>W4TUS(9)9II%=Y)'8]2S$GC ]JZ
M?PS_ ,BWI/\ UZ1?^@"DRD:=%%%2,\J\6>(/%.A?%[PII]CKEMJ-CK%S(L_A
M[[ H:VLD@8R71G#%LK+Y:\@*?,"@9&:XKP_\0/B%:Z;K6GZQ<:F?'#61O+72
M)]'@6(0K<JDTMJ\;-YYC1U.QR&)*Y'S5Z<GP>TR'XAWOC*#6-=M]3O6A-S!'
M?G[-*L2E4C,9'"#+':"!EB>IJ?2OA1IFF:E?ZFVI:Q?ZK=6CV"7][?-)-:P.
M=S)">B98*<@9)5<DX%7=$69P?PQ^-%YXD\3Z?H^M:C'9R0QRVKK+9M')J%UY
MD@3) *0[8XCE<@M)YB@?NB*]QKB+?X.>&;/6=&U&VMIK<Z5###!:QSL(&\H2
M")W3^)T\Z7#'G+DG)Q7;TG;H4K]0K)\6?\BKK/\ UY3?^@&M:LGQ9_R*NL_]
M>4W_ * :D9%X'_Y$O0/^P?;_ /HM:VZQ/ __ ")>@?\ 8/M__1:UMT"6P5YM
MXI\3^)M'^,_@C2H[FQ3PQJZWD<EL("UR\D=N9 QD)PJ@@ *!DY.3T%>DUQGB
M/X76'B?QGHWB6YU35X+W2&+6D%K=[(%)!5\ICG<IVG/;TIH&>*V_QK^( U0V
M BDN/$.I6NJ;= ETAX?[,FMV!A\N5@!<!H\G&X[B5((!Q74_#WXU7FL^*=-T
M/6=2^QFWEN+:66ZL&BEU&8RNENA &V A%!8$C,AV*,JPKT73OAEIUAKMWK,E
M_JM_J<L,MO!<7UZTILHY"&=8 >$R53G!/R*,X&*J0_!?PS;7NA7$$%S"-(2)
M(H4N&\N8QNTD;S#_ ):,LCN^X\EG).:JZ)LSNJ***@L*Y/X4?\DW\._]>:?R
MKK*Y/X4?\DW\._\ 7FG\J?074ZRBBBD,**** /.OB#XI\2>'_'?@6VL'L$\/
MZE?2VM\DB,]U*PMYI$6/^%5S&"3R3T&.M>):5\;/'>J'1M-;Q;I<<WBV*RO(
M=2CT^,C0!-),K0;2VV4XB"J9.=V[.> /J>[TNTOYK6:YMHIY;63SH'D0,8GV
ME=RGL=K,,CL37-/\(_!#:=K6GGPCHQLM;E\_4K?[!'LO) <AY!CYB#R">AYH
M P?A[\4;_5OAKX=UG4=,O=:OKQ)4FFT6U#Q.T<C1^;@M\H?;N R>M8.E?M3:
M#JWBVPT0:-K-A'>%UBO=2@%NDC*0"$!)W]1TY.>,U['IVGVNDV4%G96\5I:6
M\:Q0V\"!$C0# 55'  '85XPOP>T'XL_!?1;;4[14U*.V+66IPX6YM95<E&1^
MHY X[U,KI70U;J>W@Y)%+7S'\)OV@-3\$WX\!?%'SX?$%K*8;75IH_+BNX%5
M<,SDX>3D].H&>:^FE.12A-5(J4=F#3BVF.HHHJQ!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YK9^*H=!^(
MOC&*33]4O"[6;;K&QDG0?N.A*@@'VKTJN0\+_P#(^^-?^NEG_P"B!30F._X6
M/;?] /Q%_P"">?\ ^)H_X6/;?] /Q%_X)Y__ (FNMHHT#4Y+_A8]M_T _$7_
M ()Y_P#XFC_A8]M_T _$7_@GG_\ B:ZVBC0-3DO^%CVW_0#\1?\ @GG_ /B:
M/^%CVW_0#\1?^">?_P")KK:*- U.2_X6/;?] /Q%_P"">?\ ^)H_X6/;?] /
MQ%_X)Y__ (FNMHHT#4\Y\:?$*VF\&Z]&-%\0*6L+A=S:3, /W;=3MJSX=^(E
MM'X?TQ/[%\0-MM8AD:1.0?D'^S70^.O^1(\0_P#8.N/_ $4U6?#/_(MZ3_UZ
M1?\ H I] ,7_ (6/;?\ 0#\1?^">?_XFC_A8]M_T _$7_@GG_P#B:ZVBEH&I
MR7_"Q[;_ * ?B+_P3S__ !-'_"Q[;_H!^(O_  3S_P#Q-=;11H&IR7_"Q[;_
M * ?B+_P3S__ !-'_"Q[;_H!^(O_  3S_P#Q-=;11H&IR7_"Q[;_ * ?B+_P
M3S__ !-9GB?XAVTOAK5T_L7Q NZSF&6TB8 ?(?\ 9KT"LGQ9_P BKK/_ %Y3
M?^@&C0#D/!OQ#MH?"&AI_8OB!MMA -RZ3,0?W:]#MK8_X6/;?] /Q%_X)Y__
M (FM+P/_ ,B7H'_8/M__ $6M;=&@(Y+_ (6/;?\ 0#\1?^">?_XFC_A8]M_T
M _$7_@GG_P#B:ZVBC0-3DO\ A8]M_P! /Q%_X)Y__B:/^%CVW_0#\1?^">?_
M .)KK:*- U.2_P"%CVW_ $ _$7_@GG_^)H_X6/;?] /Q%_X)Y_\ XFNMHHT#
M4Y+_ (6/;?\ 0#\1?^">?_XFD^$<@E^&7AIPK*&L8VVN,,,CN.QKKJY/X4?\
MDW\._P#7FG\J.@=3K****0PHHHH CF!:-@K%6((##L?6OA+PO9>(HX-7AUVT
MU]_!$%Y:Q^*9H!J?VJ^E$TWF2NCCS 2/),BVVY NW!(X'W>QP.F:Y]OB'X66
MRU2]/B32!9Z3)Y6H7!OXO+LW_NRMNQ&?9L&@#BOA9_PFD/PH\*K##"UZ()/,
M7Q%+,MRL/F-]G#X4G?Y6S=NYSUYS70_!I9&^%_AWS@GF_9OG"$E0VXYQGG&:
MZ^TNH+ZWCN+:6.>"5!)'+$P974C(8$<$$=ZY7X/_ /)--!_ZX'_T)J .)_:2
M^#VE?$OPFYEL;F?6(>;5[3.=PZ;L>@'!]<5R'[-'QQUS75M_!?B.!YM;TQ!$
MUS*#YUW%N91-]5V@,"!ZYKZ38?G7RO\ '_P==?"'QMHGQ3T)+V2RL;O?JL4#
MD[89&_?*1QE&'."< CWKRZO/AZZK+6$K*2[/I+]'Y6?0ZX<M6G[-_$M5Y]U^
MJ^?<^JJ6LGPSXDL/%FAV6K:7<)=65W$LT;HP/##.#@G!&>16M7IIW5SD"BBB
MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(3?^ 5Q_\17844:!J<?_ ,+;\*_]!";_ , KC_XBC_A;?A7_ *"$W_@%<?\
MQ%=A11H&IQ__  MOPK_T$)O_  "N/_B*/^%M^%?^@A-_X!7'_P 17844:!J<
M?_PMOPK_ -!";_P"N/\ XBC_ (6WX5_Z"$W_ (!7'_Q%=A11H&IYMXT^*WAB
MX\':]$FH2EWL)U -E..3&W^Q5GP]\5_"\/A_3$;4)=RVL0.+*?\ N#_8KI/'
M7'@GQ#_V#KC_ -%-5KPR<^'-*_Z](O\ T 4]+!J8/_"V_"O_ $$)O_ *X_\
MB*/^%M^%?^@A-_X!7'_Q%=A12T#4X_\ X6WX5_Z"$W_@%<?_ !%'_"V_"O\
MT$)O_ *X_P#B*["BC0-3C_\ A;?A7_H(3?\ @%<?_$4?\+;\*_\ 00F_\ KC
M_P"(KL**- U./_X6WX5_Z"$W_@%<?_$5F>)_BMX7F\-:M&NH2EFLY@,V4X_@
M/^Q7H=97BPX\+:S_ ->4W_H!HT#4XSP=\5O#$'A#0XGU"4.EC I LISR(U_V
M*V/^%M^%?^@A-_X!7'_Q%:O@CGP7H'_8/M__ $6M;=&@*YQ__"V_"O\ T$)O
M_ *X_P#B*/\ A;?A7_H(3?\ @%<?_$5V%%&@:G'_ /"V_"O_ $$)O_ *X_\
MB*/^%M^%?^@A-_X!7'_Q%=A11H&IQ_\ PMOPK_T$)O\ P"N/_B*/^%M^%?\
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M)<OIJON>OXG*VW[,7@VT\!:)X/2357T71H+B*T$]ZTLJO*23*SL"6==SA<\
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M'_GDG_?(H^S0_P#/)/\ OD4:!J<]_P +.\'_ /0U:+_X,(O_ (JC_A9W@_\
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M]US14*51VI5/O5OQU1[%N&*\/\7_ +77A'P-<>)[?5M)\06]SH%Y;VDT+6:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6CRU(J2\U<N,Y0=X.S.^;X.:-:Z@UYHUU?\ AV1T\N1=+N#&D@]2I!&?I0/
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MCP3D@UZ%K7Q(\"^,;*YT7Q#I$]_$I5KC2M4T9YP.<HS1E&'4$@^WM3M*\:^
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M+OPB+O(4?R%3*2@G*3LD-)MV1Z'17!Q_&KP>]S+$VNVJ*@!$I)VOZ@<=J?\
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M3[E3&"NR36;M-I/\8;>W.,@CN.XK4M_V:O#<=A'!)J_BAI!&$:5=>NE).,9
MWX'TK"6"PL_BI1?R1HJ]9;3?WLZ4_!OPEC_D&R_^!D__ ,77+:S\!M$O9YV6
M\2SB##:':1S%Z#)D[U/!\ Y+6".&+XC^.Q'&H11_:ZG '3DQUYSXN_9+US76
M3RO&>J7B(TF]=2U!F\\MT<XC^4CT.[/8BN>KE6"JKEE1C;TM^1I'%XB#NIO[
MR[H'[-^F^(H;F7^W'CEBNIH=JQ!R51R@)R>AQG\>IK6B_9/L$D5GUR64#^!K
M88/U^:OGNQ_8^\:V5J^HV?BJTMEAFEM'G%_);D.LNP99EZ,V .<]/6JLW[+G
MQ&:\G8^.=-;[-<K;S[O$# QRM]V-AC"N<C"GGFO._P!6\JO?V"^]_P"9U_VK
MC?\ GX_P/I1OV6[&5%676Y92I^5G@R0O]W[_ $KH?"'P/B\%Z@+RRU'?.N/+
M9XF_=C^(*-^/F'7(KY]TC]EWXF36$"?\)E)--;S-'(8=3$BQX!&SE,Y!ZJ?K
MP0*O>%/V6_B9HWB&WO;S7FN@B@&1M48@29Y?&S)P.>N2>M=%+(\NH352G22D
MNNO^9C/,,54CR3FVC[%C^[^-/J"QADM[.&.60S2HBJ\I&"[ <MCWZU/7O'GA
M1110 4444 %%%% !1110 4444 -;/:O%]0^.GB!GUO3K'PDEMKL.O6^A:9;:
MI>A(YS+;^>)YFC#^6FQ7.T;FX'0GCVJN"\3_  ;T'Q5'K!N&U"SNM2O(-0-]
M87;0W%O<0QB..6%Q]PA1CN#DYZT )X4^,&CZKX*T77=;GM_#\VH+(K6MQ.#L
MEB<QRJK<;@&4X.!D8J?X.M#??"[P[(I66*2VWJPY#*6)!K>\*>$]-\&>'-/T
M/3(#%I]C$(HED<R,>Y9F;EF))))Y))-<KX GU.T^#>F3:-9P7^II:$V]M<3>
M3'(V\\,X!VCWP: .HM_!^G6LL,B+*WDL61'E9E!.<\'ZFH_&W@G2_B#X-UCP
MOK$<DFD:M:O9W4<+F-C&XPP##D<=Q7E:^+_C2?$13_A"])(S_J/[6/V?R]O7
M?Y/WL]\Y[;<<UJ_'X^)-1_9B\<%+*:U\42Z!<;;32)7ED2<QG"Q.H#,<]" #
M6<*<*?PJPVW+<Z32O@SX7T7PSXGT*UM95L?$;W,FH%I29',\8CDVOU4%0, =
M*DUKX1^'/$'@#2/!EW#<-H>E&Q-M&DS*Z_9'1X,MU.#$N?7!KXLL_@1\3M;\
M3_$3QW;WEQHEE87.K%#_ &AJ+:EJ<7]G[([5+4M]G$1D8,KJ-^5XYKTCX\Z?
M?W?[./PW@$7BQ?&<.BVLFF-ID-U(IU!8(<Q3^4P*3/AE224%48N6'&#H(]^\
M/? GPEX:^(>H^-+&VNAJ]XT\GER73O;6\DY4W$D,1.V-Y3&A<CKM^M<]8_LG
M?#[3+6Q@M[*^$=E!96T(-ZYPEK>->0Y]<3.Q/J..E>:?'3Q3\7K;XEI!X6U/
M5]%TBWT_0F:UM-+BO(WFN=0:"[W2-&<F.$[L @# 8\=?*_B'\??B[X1\&02:
MGXCU70KRQTJ[>TN4T6*1]4N8]6:V!NE,9$0^S"-@P"*Q<L"<!: /8_AY^QH/
M#WQ27Q1K^M1W^FZ9),^BZ18>?'#;E[P70W+)(ZJJNH(C3"DY)[ ;?B?]CSPW
M!X.O+#P1C0-7E-O(EW<RS,IEANVNHYB8W5A,KR2!90=P5L<@8KQ&TU#XJ:+\
M<-!\26EOKEOX5UZ,7OB*589)9K.VEU:584AB<%0=@@\S WI$6('>NT_9X^,W
MCGQ9\>;70/$>OWMTMQI&KWNI:++IT<5M87,.H1PPI;S*H,J"(]=S ELDY.
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MR[X%^"O%GP_L-8T?Q!=6=YID5SNTV>!<33!BS2RS''+.S!CG)SNYQBO4:**
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M% ''_"OX>1_#'PA#HB7S:C)Y\UU/<^0D"/++(TC[(D^6-,L<(O 'KUKL***
M/)$_9ZTYOCB?B/<:@L\Z$RP6?V"%)(YC#Y.6N -[H$+80]"QR2  /6J6B@#D
M_%O@:7Q%KNF:Q::K)I=_IMG>VUM(D*R!7N$11)AN"4* @=#T-8OP6^%NJ?"S
M0KS3]4\2KXHFN)_M#7S:>MK/)(1^\DF8.QE=C@[CC      'HU% #)H_-A=,
M[=RE<CMFO$];_9CAUFQ\*:<WB)DTS1[2WLKJ)],MY)KI(91*ACF8;[=BPY*$
MY&, $9KV^B@!!G'-<1XY^%UOXYU"XN9]2N;$3:+>:*1:X5U2X:,F16[,OEC
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MSD_'V3XF:7\6?A[:^%_B9_PC>A^)]2.F2::="MKKR?+MIIVD623YB7\H+CH
M<BO+_#O[:/CF<P6=MX>TC6=EW:VD]YJ&H-;RM)=ZI=6,(58XBNU# K$]<9')
MYH ^NO '@Z#P!X/TS0+>YEO([.,JUS/C?,[,6=V X!9F8X' SBN=^+_PKO?B
MIIT6G1>)9M$TV1'@O[064-TEU$^,[?,'[J5<';*O*[CP3@CP7P_^V]KOB+Q+
MX.TFV\!?:6OH8)-9>WN\K"9+V:TS;LP 95:!G.[!((4#--\;_M8^,O"7B+Q6
M--TC2]8M+75]9M+:UO[AK86]OI5A#<3-N1&+O*[OC/ ^7MF@#W'P]\&9])^)
M*>*K[Q-=:O%9036VF64MK%&]M'+MW)).HWSJNT! _P!W)ZGFO2;J$W-M+$)'
MA,BE?,C.&7(QD'L17RG:?MA^)K^V73%\-:%8^)IM3>VCDOM5=-,C@&FQZB"\
MWE[A*8Y!&%VX+!CG:*JVG[:?B'7=0LKG3?"&GP>'[N32[-'O;Z07D=S?Z>]U
M%F,)M*(R;2=P+*00* .YO?V4KC5))]5O_&?]H^*O/1H-4O-"M9(5C6.2/$MM
MC9+(RRONE.&)"XP!MKV7P+X1MO 7@W1?#EG--<6NEVD=I'+<',CJB@9;'&3C
MMP.U?'WPY_:[^(\]QH.J>(K;P]JFB7NF>&I+^*PF:)[>;4IYH=\/RG<<B,LK
ML NT@&MJR_;#\3ZWIVLRW>D6?AG5- UW2A<:0KM<27&G75Z;5OG*^6V<AEDB
M8@D8XP<@'O?Q(^$-U\1=>TJ>7Q/<66AVTL$]SI"VD4GFR0R^8CQ3$;X&) #%
M2=RC''6L_P"$7[/FG_"GQ7X@\0)?IJ-_J@,2M'80VGEPF5I2'\L#S'+-RYQP
M!P.<^LT4 8GC/PE8^._"^I^']4,_]G:C UO.+:9H9"AZ[74@K^%>+7/[*-[8
MZ;;:;H/Q!U.WTQ-7N-8N+/7+?^U8[J5]GE"3S) 2L6W(4D@L=Q!(%?0E% $4
M$;QP(DDGFR!0&D V[CCDX[9]*\N\9?LZZ'XQ^(>G>,GU?7--U6VNH+B6*RU&
M5+>X$44D:(T6=H_UI.0.><]37JU% 'F7PB^"H^%^HZM?SZPFL7E]%#:*\.FP
M6"1V\)<QJR0@+))F1LR$ G@  #%==X[\%:=\1?"M_P"'M6-R-.O0JR_9+AX)
M<*P88="".5'2M^B@#YPU+]B_3;O3M+LHO%NJ2QVES=S--JT2:C.%N+@3DP22
MY-O,I4 3)SC/&:^C478H7).!C).33J* /+#\#5E^+D7C2?6O-MH+AKV#31IT
M"2I<-!Y))NE D:/82?+/<C)(  [+P1X13P7I5U9)=/=B>_NK\R.H4@SS/*5X
M[ OC/M70T4 <I\2_!$OC_P ,/IEOJ2Z5<K-'<0W,ME%>1JZ-D;X9 5=3W'![
M@@BO,=*_9!\.Z5?>%]1BU[78M3T:[@O)GM;Q[>VO&C:5]IMD(CC3=,Y"J, '
M%>\T4 -"G'7FO)5^ 3#XDW_BP^(F4NMVUC;Q:;!'+:S7$8C=WG4!YE &51^A
MQDG QZY10!C>#O#%MX+\*:1H-F<VVG6L=JC;0"^Q0-Q [DY)]S7)?&+X/1_%
M:VTEX]1BTK5-+EE>VNKC3X;^(++&8Y5:&7Y3E3P>H([C(/HU% 'CGA+]G.'P
M?K^CR6OB:^G\-Z9+'?1:)/#&Q>^2V%L)VGQOQY8SY?3=SG'%>Q4M% '@OA[]
MEF3PA-JD^A^,)=+G:V-EI;0:3; 6L#3^<\=P,?Z7DC;E\';G')+'U#X9> X?
MAKX-L]!AO'O_ "6EEDN7C6+S)))&D<K&N%C7<QVHO"C '2NJHH \P^-/P0A^
M+RZ;,FJ)I&H645Q:BXET^&^5K>=5$JA)1A6^12KCE2.A!(K%\$_LRZ;X%^(-
MIX@L=8E?3K%II[73WLXA,)Y8A%(\MT!YDJD D(W 8@Y.U0/::* $' I:** "
MBBB@ HHHH **** (YX?/A:/>\>X8W1G##Z&H=0L1J%A-:^?/;>:I7SK=]DB>
MZMV-6J* *=_IWV[3WM?M-Q;[@!Y\$FV48(.0WOCGZFKE%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*^T:PU.Z
MLKF[LX+FXLI#-:RRQAF@<J5+(3]T[6(R.Q-8\'PS\)6K;H?#.DQ-OCDREG&/
MF21I4;IU61V<'LS$]372T4 <R/ACX0%YI5V/"^C_ &K2F=K";[#'OM"[%G,1
MVY3+$L<=R3UJM!\)/",.J:QJ#:%:7%QJT\ES=?:8Q*K220K#*RALA?,C1%<#
M 8#G-=?10!R^H_"[P=J^FW&GWWA;1[RQN)8YYK:>QC>.22- D;LI7!9555![
M  =*N/X'\.R77VEM#TYKCSH;GS3:IN\V)-D3YQ]Y%.U3V' K<HH Y:P^%G@W
M2K<V]EX5T>T@+QR&*&QC1=T;F2,X ZJ[,P]"215*X^"O@B6(Q1>&M/L8GU&'
M5ITL8%MQ<7,3[XWEV ;]K_-ALC(S7;44 %%%% !1110 4444 %%%% !1110
J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>adag-20221231x20f005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "[ >X# 2(  A$! Q$!_\0
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M,R_^ <W_ ,31_P --?#S_H,R_P#@'-_\37Q%11_9U'N_Z^0?Z\YG_)#[I?\
MR1]N_P##37P\_P"@S+_X!S?_ !-'_#37P\_Z#,O_ (!S?_$U\144?V=1[O\
MKY!_KSF?\D/NE_\ )'V[_P --?#S_H,R_P#@'-_\31_PTU\//^@S+_X!S?\
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MT&9?_ .;_P")H_X::^'G_09E_P# .;_XFOB*BC^SJ/=_U\@_UYS/^2'W2_\
MDC[=_P"&FOAY_P!!F7_P#F_^)J:;]H_P#!;V\SZQ(([A6:,_9)>0K%3_  ^H
MKX<K6U;_ ) >@?\ 7*?_ -'-2>745;5_U\C2'&^924FX0T79]TOYO,^Q_P#A
MIKX>?]!F7_P#F_\ B:/^&FOAY_T&9?\ P#F_^)KXBHI_V=1[O^OD9_Z\YG_)
M#[I?_)'V[_PTU\//^@S+_P" <W_Q-'_#37P\_P"@S+_X!S?_ !-?$5%']G4>
M[_KY!_KSF?\ )#[I?_)'V[_PTU\//^@S+_X!S?\ Q-'_  TU\//^@S+_ . <
MW_Q-?$5%']G4>[_KY!_KSF?\D/NE_P#)'V[_ ,--?#S_ *#,O_@'-_\ $T?\
M--?#S_H,R_\ @'-_\37Q%11_9U'N_P"OD'^O.9_R0^Z7_P D?;O_  TU\//^
M@S+_ . <W_Q-367[1W@'4+N.V@U>1II#A5-I*,\9_N^U?#E:_@__ )&?3O\
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M=2M-H_TF+I_>J>9<SU-W0J^RC[CW?1]HEJBJW]IVG_/S%_WU1_:=I_S\Q?\
M?55S+N8>PK?R/[F6:15"C   ]JK_ -IVG_/S%_WU1_:=I_S\Q?\ ?5',NX?5
MZO\ (_N99I"H;&0#CID57_M.T_Y^8O\ OJC^T[3_ )^8O^^J.9=P^KU?Y']S
M+-%5O[3M/^?F+_OJC^T[3_GYB_[ZHYEW#V%;^1_<RS15;^T[3_GYB_[ZH_M.
MT_Y^8O\ OJCF7</85OY']S-_6?\ D%:#_P!>LG_H^2LFK>KZO8OI>AA;N%BE
MLX8!QD'SI#S^%9?]IVG_ #\Q?]]5,9*VYO5H5>9>X]ET?9%FBJW]IVG_ #\Q
M?]]4?VG:?\_,7_?55S+N8>PK?R/[F6" >HS2U6_M.T_Y^8O^^J/[3M/^?F+_
M +ZHYEW#V%;^1_<RP0#C(Z4M5O[3M/\ GYB_[ZH_M.T_Y^8O^^J.9=P]A5_D
M?W,LT56_M.T_Y^8O^^J/[3M/^?F+_OJCF7</85OY']S)Y/N-]#6SXN_Y&&Y_
MW(?_ $4E<Z^I6A1O])BZ?WJU_%6KV,NO7#I=PNI2+#*X(_U2"ES*ZU_K0W5"
MK[*7N/=='VD4Z*K?VG:?\_,7_?5']IVG_/S%_P!]4^9=S#V%;^1_<RS15;^T
M[3_GYB_[ZH_M.T_Y^8O^^J.9=P]A6_D?W,LT56_M.T_Y^8O^^J/[3M/^?F+_
M +ZHYEW#V%;^1_<RS15;^T[3_GYB_P"^J/[3M/\ GYB_[ZHYEW#V%;^1_<RS
M6MJW_(#T#_KE/_Z.:L#^T[3_ )^8O^^JU=3U6SDT70E6ZB9DBF# -DKF9B,^
ME2Y*ZU-J="KRS]Q[=G_-$IT57_M"V_Y[I^=']H6W_/=/SJN9=S'V%7^1_<RQ
M15?^T+;_ )[I^=']H6W_ #W3\Z.9=P]A5_D?W,L457_M"V_Y[I^=']H6W_/=
M/SHYEW#V%7^1_<RQ15?^T+;_ )[I^=']H6W_ #W3\Z.9=P]A5_D?W,L5K^#_
M /D9]._WV_\ 0&K _M"V_P">Z?G6MX4U2SA\26#R7,2(';+,V /D;O4RDN5Z
MF]"A5]M#W'NNC[F?']Q?H*=55+^VV+^_3IZT[^T+;_GNGYU7,NY@J%7^1_<R
MQ15?^T+;_GNGYT?VA;?\]T_.CF7</85?Y']S+%%5_P"T+;_GNGYT?VA;?\]T
M_.CF7</85?Y']S+%%5_[0MO^>Z?G1_:%M_SW3\Z.9=P]A5_D?W,L457_ +0M
MO^>Z?G1_:%M_SW3\Z.9=P]A5_D?W,Z7P%_R/7AS_ +"5M_Z-6OT3K\X_ FI6
MB>.?#C-<Q*HU*V)9FP!^]7J:_1RO"S)IRC8_8^!(2A0K\RMJOR8QHD<Y9%8^
MI%)]GB_YYI_WR*DHKQC]1(_L\7_/-/\ OD4?9XO^>:?]\BI**!W(_L\7_/-/
M^^11]GB_YYI_WR*DHH"Y3U&"+^S[G]TG^K;^$>E<,(TQ_JT_[X%=YJ7_ "#[
MG_KFW\JX4=* NQOEI_SS3_O@4>6G_/-/^^!3]C;=VT[>F<<4E 78WRT_YYI_
MWP*/+3_GFG_? IU1-=0+<I;M/$MPZETA+@.RCJP7J0,C)]Z N/\ +3_GFG_?
M H\M/^>:?]\"G@%C@#)]!3597W;65]O7:P./K0%V)Y:?\\T_[X%'EI_SS3_O
M@4ZG>6^W=M.WUQQ0%V1^6G_/-/\ O@4>6G_/-/\ O@4ZB@+L?+''Y4/[M/NG
M^ ?WC47EI_SS3_O@5/+_ *J#_=/_ *$:BH"[&^6G_/-/^^!1Y:?\\T_[X%.)
M  R0,G R<9/H*,C<5R"P&2N>0/I0%V-\M/\ GFG_ 'P*/+3_ )YI_P!\"G44
M!=C?+3_GFG_? H\M/^>:?]\"G57U+4;71M.GU#4+F*QL($,DUU<.$CC4=2S'
M@"BU]!-V5VR;RT_YYI_WP*/+3_GFG_? I4=9$5T8.C ,K Y!!Y!%+0.[&F-,
M?ZM/^^!4MS'&)V_=IT'\ ]!3#TJ6Z_U[?0?R% 79!Y:?\\T_[X%'EI_SS3_O
M@4ZB@+L;Y:?\\T_[X%'EI_SS3_O@4ZG&)U(!1@3T!'6@+LC\M/\ GFG_ 'P*
M/+3_ )YI_P!\"GN#$0'^0DX ;C)]*3(SC(SC.,\T!=C?+3_GFG_? H\M/^>:
M?]\"G44!=C?+3_GFG_? KK/#4$9TP$QI]]OX17*UUOAG_D%C_?:@+LTOL\7_
M #S3_OD4?9XO^>:?]\BI** N1_9XO^>:?]\BC[/%_P \T_[Y%244!<C^SQ?\
M\T_[Y%'V>+_GFG_?(I7E2(H'=4+MM7<<;CZ#WXI0ZEBH8%AU&>10%QOV>+_G
MFG_?(H^SQ?\ /-/^^14E% 7(_L\7_/-/^^11]GB_YY)_WR*DHH$1_9XO^>:?
M]\BC[/%_SS3_ +Y%244#N1_9XO\ GFG_ 'R*/L\7_/-/^^14E% 7(_L\7_/-
M/^^11]GB_P">:?\ ?(J2B@+D?V>+_GFG_?(H^SQ?\\T_[Y%244!<C^SQ?\\T
M_P"^11]GB_YYI_WR*DHH"YR_Q)@B'P]\2_NT_P"0;<?PC_GFU=+#_JD_W17/
M?$K_ ))YXF_[!MQ_Z+:NAA_U2?[HI]">H^BBBD,^3_BCKGC2S^*7Q\A\-6^F
MWME%X(TV2X.I:M/:M:$QZG\\")%("Q ))RG*KSW'-_#^^\(:_KDZ?%KQ ]C%
MIOA?P_/X834=6ELE^SO8J\]U;%9%\R<W'F*SC<X\N,<;N?LYK.W9YG,$9>90
MDK%!EU&<!O4<G@^IJ&?1["Z:T::QMIFM"&MS)$K&$CH4R/E/ Z4 ?,WPKNO!
M>L>/?$NI>.]>,'Q0M?&%W9V5G=ZK+!<P6HFVV$5O;AQN@DMS&YPI5S)(6R0<
M?4M57TNRDU"._>T@:^C0QI=-$IE53U4-C(')XJU0!6U+_D'W/_7-OY5PHZ5W
M6I?\@^Y_ZYM_*N%'2@#P6'Q)H&F_M=K9Q>)A-<7FA36\]E/J)D6.]\]-D"1D
MX1M@R$ SC)[U7^,WQ5\<^%?%'C5?#^I:9::7X9TK3=2-K>:?YSW+3RM&R;]P
MVKWSR> !C)KWK^SK/[1]H^QVWVC.[SO(3S,^N[&<^]4;[PKIFI7$T]Q#))),
M ),3NJL!T! .,=>/<^M=GUB*E&7)>R2U]?3MH<$<(Y1E"51QNV[Q7=6M\2ZZ
M[Z]CY[\0?&GQMX2UJY\.ZOXFT2TGMO$=MIT_B"72]MO%;3V1GRT6[JC8&<\C
M&>,UQ=_\8_%4^L>&?%^VUN]2@TG5K(ZW#9GR!9+?11G41!G+*$^;8#@]>F:^
MH=8^%^B:U>:;<S-?QO977VK$5X^)VV%-LN22RX8\<'WK1'@K2,*/)F(5#& ;
MJ7 0]5^]T/.1T.35QQ<8I/V2OUU\K/[/7[B99<IMKZS*W3W;]4U]OIM??S/,
M/VC?$U[:>"O#>FZ9=S7D.N22++<V,GE/?QQVKS+"CIC;Y[*H^7G:2!UKR/X+
MZ%J-M\3/#W]F:)<Z7=PW4$UQ>VNBW&F6\^G-;.UQYXD8ASYI1$W?.=F[ S7U
M7KG@?0?$WAP:#J^EP:EI(VXMKG+;2O*L&SD,.Q!R*C\&^ /#_P /K6ZM_#^G
M#3XKJ02S_OI)6D8# )9V8\#CK54\5&G0=-+5_=_7R.>O@95<4JO-[JMZZ>6N
M[UW_ .#XK\?_ (X^(OA_XIUW3],US2O#\>F:'%J%E;:C8^?)K$\CLK1QL2-O
ME@ \9YZ\5S_B/6;<?M'^$KG2=9@GU"\OQ;7EKIVI7,M]'*]M@_:+5SY*6R,0
MWR#D=Z^CO&O@W3/'WAC4M"U6-C:7]NUM)+#M69$;&=CD':>*U+:PMK3RS'!$
M)4C6(3;%\PJ   6QD\"B&(IP@K1ULT_FEY#J8.M5J-RG[MTUY6;T6NFEE='R
M@_[4GC6WM2LEK;&XAM9/#\S"U&#XCWMY8 _N%5!V].:^LK.*X@L[>.[E6>[2
M)5FE50H>0 ;B .@)SQ2?8[;G_1H.7\T_NE^__?Z?>]^M35SUJL*EN2'*=6&H
M5:-_:5'+]"67_50?[I_]"-15++_JH/\ =/\ Z$:BKF.X\ _: UWPSX>^+OPJ
MU"_O#;ZK9:JL]TQ\YUALC'*H?: 4 ,AP2!N.!G@5B:1>>#-:_:KAFTAU\.WN
MESW,%T[^?]HU^]D4[DP05$,>&.21D\ 8KZ;#%1P<4;SC&>*[HXE1ARV=[-;]
M_*QY<\$YU'/F5N92^'LEUOY+7]-#YR^,GCKQ[HWBGQW+H'B*73;#P[:Z3<6U
M@-.CG2Y>X?9(&9ANVCJ0#G('(%4->^(_C?PKJ>J^'=6\775OI-CXDCL;SQFN
MD(\UK;/9B91Y:H4 ,GR!MIP.*^G-Q&.>E =AT)%$<3!))TU^'EY>OW^0IX*I
M*3E&JU?UMN]-_-+2VVEKGRW8_$#XE^)['0K>/Q'<Z*9=#UG4?[1728Q)?I:S
M 6TIC=<1F1,9 '()P.<UQWBK7=;UVR\<7VLZ[J(N/$'@"QU&#1Q:?Z-<N8\R
MHN%^3RF^;@AB7P<X K[5+$]232[V]36D<9&+NJ:_#O?M_72QC/+ISC:55OUO
MVMW]7\];GRMXG^('CWP+IOB719/&6]K"/1[FVU2XTY(G6.>&1I;:,K&Z*?D4
M*TBGT)R:^AOAWJ]QX@\ ^'=3O/M/VJ[L8II3>P""<L5Y+QKPK>PXKH@[#H:0
MDDY/)KGJUHU(I**3[_+T^9VT,-.C-MU&UV=^]^K?H!Z5+=?Z]OH/Y"HCTJ6Z
M_P!>WT'\A7*=Q%1110!!?/#'873W,I@MEA=I90Q4H@4[FR.1@9.?:OC?0[[1
M_$'A[XE7W@OQU#X?T.ZBM(K33=6UZ5II(XYU$]U,Y9GMA-GRP>N'R<9K[.(#
M @@$$8((R#5:/2;"(.(]/LXPZ[6"6Z#</0X'(]C770KJBGI>]OP=SS\5A7B7
M'6UK]-=5;>Z_X)\;:3X>O?%?@+5K];R*/1[37YK/P[I:7$VI)<2311#;8SN5
M9W21#ME8;5W2'H,U[/\  WQE<7WC;Q3HNJV<,WB)Y)KG4=3AN?,8R0RB 0M'
MM'E1@']T,G<H9CR37M*V\2K$JPQ*L7^K 0 1]OEXXX)Z>M"011R22)%&DDF"
M[J@#/CIN/4_C6M7%*K%Q<?3^NO=^9A0P#H3C.,]M]-_\NRMLA]%%%>>>N%=;
MX9_Y!8_WVKDJZWPS_P @L?[[4 :U%%% !7C?[6NLZKH?P4OI=+O!IJSZCIUI
M?7[SR0);64MY#'<2/+'\\:"-FW.N"JEB",9'LE,FACN(GBE19(G4JR.,A@>"
M".XH ^%GTF/Q+X+9=(B\/QOH6OSZ#I::!)/<6FL7<_V*Y2XT^21R8IXS$T3O
MEEC N&W85@?:OV8/',FLZQXITB_LHY=>::34M3U>*X,C33BZGM6BE0J/(V?9
M1Y4>3B'R\_-N)]XMM+LK*&WAM[2""*VSY$<42JL600=H ^7@GIZFGV]C;6DL
M\D%O%#).V^5XT"F1L8RQ'4X &30!/1110 4444 -<X1B.N*^ _@[K_B#P5I?
MP)\)W=_J&I:9XEU"#Q%H-]=3R/\ O#8W1O=/EDSDJLKQS)NZK*P_Y9"OOZJX
MT^U5+=!;0A+<YA41C$1P1E?3@D<>M 'RO^SKH7PQ^(7@;PVWB+5O[<^)FM63
MCQ)87VJS?;I;P?-=0W%L)/D2*52%4J%0(FW&1G@/ WAKPQH'PD^%$NIXTKPI
MXB\6:A:>*+^6^EBCN(H6U+[%#<3%^(O.2%<$A20BGK@_<L.E65O?3WL5G!%>
M3@++<)$HDD Z!F R<>])-I-C<6#V,MG;R63Y#6SQ*8VR<G*XP>>: /BDZWI-
MA\,? FIZEXQGL=*TSXE&'PT+K7&AAN](760D<C;G!N8TARJ,Y91&0?0U=U#Q
MS.G[2.JZIJRZ'K]];>,-/T?2-'GU&Y75(K">WM]EU90JWE&(&6:9VVD.$E!<
M;% ^P=0\,:/JJ0)>Z38WB0+LB6XMD<1KQPN1P.!P/2K TBQ6\ANQ96XNH8_)
MBG$2[T3^XK8R%]AQ0!\%VFLZ7\+/!WCSP_:ZQI6OW5YX4U"_D\=>!;Z6>_M?
M])C1%NP[LL;.;@$.'7 @E.%"Y&/;:FMIX8U7PR=3T.VN+KQ=I9^PV&OS2>"R
MAL)7:"2]+>9&'$,DCIC)F6W 5PY+?H59Z+I^GBY%K86UL+EB\XAA5/-8]2V!
M\Q^M1)X;TB+2WTU-+LDTYSEK-;=!"3G/*8QUYZ4 ?%(\/Z!X]_9N\$:#]E.K
M^.]?U.[\*:5J,UT\XLE%U.UW<6DJOF6UMH4F:"0DDK'""<FH/$M[:Z1^TI$;
M34RFGZ)XJT718XI-5D77X0+>&/[/:VA?;-I\A>-I9"-YWW+ -M##[GCT^UB^
MS[+:%/LR[(=L8'E+@#"_W1@ 8'I3'TBQDU)-0:RMVOT3RTNC$IE5?[H?&0.3
MQGO0!C?$K_DGGB;_ +!MQ_Z+:NAA_P!4G^Z*Y[XE?\D\\3?]@VX_]%M70P_Z
MI/\ =%/H+J9U]XIT73+EK>\U>PM+A0"8I[E$<9Z9!.:@_P"$X\.?]#!I?_@;
M'_\ %5>N=%T^\F,MQ86T\IX+R0JS'\2*B_X1O2/^@79?^ Z?X4:!J5O^$X\.
M?]#!I?\ X&Q__%4?\)QX<_Z&#2__  -C_P#BJL_\(WI'_0+LO_ =/\*/^$;T
MC_H%V7_@.G^%&@:E;_A./#G_ $,&E_\ @;'_ /%4?\)QX<_Z&#2__ V/_P"*
MJS_PC>D?] NR_P# =/\ "C_A&](_Z!=E_P" Z?X4:!J9VH>-O#KV-PHU_2R3
M&P'^FQ>G^]7%CQ7H6/\ D.:7_P"!T7_Q5=]J'AS25L+@C2[+(C;_ )=T]/I7
M$C1=-Q_R#;+_ ,!D_P *- *__"5Z%_T'-+_\#HO_ (JC_A*]"_Z#FE_^!T7_
M ,55C^Q=-_Z!ME_X#)_A1_8NF_\ 0-LO_ 9/\*0RO_PE>A?]!S2__ Z+_P"*
MH_X2O0O^@YI?_@=%_P#%58_L73?^@;9?^ R?X4?V+IO_ $#;+_P&3_"@"O\
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M\)7H7_0<TO\ \#HO_BJL?V+IO_0-LO\ P&3_  H_L73?^@;9?^ R?X4 5_\
MA*]"_P"@YI?_ ('1?_%4?\)7H7_0<TO_ ,#HO_BJL?V+IO\ T#;+_P !D_PH
M_L73?^@;9?\ @,G^% %?_A*]"_Z#FE_^!T7_ ,51_P )7H7_ $'-+_\  Z+_
M .*JQ_8NF_\ 0-LO_ 9/\*/[%TW_ *!ME_X#)_A0!7_X2O0O^@YI?_@=%_\
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M>D?] NR_\!T_PHT#4K?\)QX<_P"A@TO_ ,#8_P#XJC_A./#G_0P:7_X&Q_\
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MS_H8-+_\#8__ (JC_A./#G_0P:7_ .!L?_Q56?\ A&](_P"@79?^ Z?X4?\
M"-Z1_P! NR_\!T_PHT#4K?\ "<>'/^A@TO\ \#8__BJ/^$X\.?\ 0P:7_P"!
ML?\ \55G_A&](_Z!=E_X#I_A1_PC>D?] NR_\!T_PHT#4Y7XB>,O#]QX!\1Q
M1:[IDDCZ?.JHMY&2Q\ML ?-UKN8?]4G^Z*X[XC>']+A\ >)'33+-773K@AA;
MID'RVYZ5V,/^J3_=% =1]%%%(845\G?%'6?&=I\4_C[%X:@TR\LHO!&FR7)U
M/5)[9K7,>I_/ D<4@+$ DDE.57GN.;\ 7W@[7-<G3XMZ\UE%IWA?P_/X734M
M4ELU^SM8JT]S;%77S)S<AU9EW./+B'&X9 /M6BOEGX5W/@K5_'WB74?'FN>3
M\4K7QC=V=E9W>IRP74%J)MMA%;0!QN@DMS&YPI5S)(6R<X^IJ *VI?\ (/N?
M^N;?RKA1TKNM2_Y!]S_US;^5<*.<4 .,;A=Q4[?7'%-KY>GU2PM?VL-!DTG5
M8;_[5?W=M>6FF:E<RWB/Y6#]L@D_=QPHP.WRP.W-;OQG^*GCCPKXI\:KX?U7
M3;/3/#.E:;J1M;O3Q,URT\K1LA?<"J]\\G@8QS7=]4DY1BGNKZZ=;>?4\K^T
M(*$YR7PMK3797OTZ'T)437<"W26S3Q+<NI=("X$C*.K!>I R,GMFOFCQ#\:O
M&OA+6;GP[J_BG1K2:V\1VNG3^(9-+"P16T]DT^6BW=4;&#GD=>,UQE_\8_%4
MVK>&?%_^BW>HV^D:M9'7(;/]P+);Z*,ZB+?^)0GS; <'&>F:TC@:DK.ZU_RN
MOZW\C*>:T875G=;[=TGUZ?=YGV@ 6. ,GT%-1UDW;'5]OWMC X^N*\4_:-\3
M7MKX)\-Z=IEY+>P:Y+(LMS92>4]^D=J\RPHZ8V^>RJ/E()4D#K7DGP7\/ZE;
M?$SP]_9NA76EW<%U!-<7MMHDVF03Z<ULYN/M =B'/FE$3=\YV;L#-1#"\])U
M'*V_X&E7'^SKJC&%]E>_?\]#['IWEOMW;3M]<<5\Y?M ?'#Q'X \5:[I^FZ]
MI?AZ/3=#BU"QMK^P\^36)Y'96CC8D;?+ !XSSUXK \1ZO;_\-(>$KG2=8M[C
M4;N_%O>6NG:A<R7\<KVV#]HMG/DK;(Q#?(.1WHA@YRBI-Z--_=K_ %N%3,:<
M)N"5VFD];;MK3?MUL?55%?([_M1>-[>T*R6UN;B&UD\/3,+08/B/>WE\=D*J
M#MZ<U]9V<5Q!9V\=W*)[M(E6:55"AY !N8 = 3DXK&MAYT+<_4Z<-C*6*O[.
M^GZEJ7_50?[I_P#0C452R_ZJ#_=/_H1J*N8[1PC=E+!20.I H,;A=Q4A?7'%
M?-/[1VI^%[CXD^'-'7Q$WAOQAYEM>3:Q=:M):VVG62.20L>X))++R H!)ZD@
M"J<&IV%O^UGH[Z/JT-_'>7=]!=VNEZE<S72-Y?)OH9/W<<2L"%$8 Z5WQPKE
M!2OT;V[?/K_2/*GCU"HZ=D[24=^_E;IU_.^A]045\\?&#XK^.O"_BCQO_8.J
MZ9::7X9MM*N19WFGB9KDW+[&4R;@57/.1SQ@8JAK7QF\9^&=5U'PQK/B71].
M>T\1II=SXQFTP+;VD#V@G7=#NVABWR L<8Z\THX.I))IK7U\GV\T.>8TH2<6
MGH[=+;M=_)[VVUL?2U1W-Q#96TEQ<S1VUO&-SS3.$1!ZECP!]:^9+'XS?$3Q
M38:'#I^KZ7IDTVC:SJ4FHOI7F1WR6<P6*:*-F&Q95^HY) Z5QOC'QYKGBC2O
M'MQK'B>.*UUGP%8ZK;^'V@ CF\R,LXA);Y?+;)9@,L& /05I' S;M)K\>]OZ
M_&QC/-*<8WC%O[ETOW]/OTN?:"L&4,""I&00<@BEKY>\0?%_QWX$TSQ#HUUX
MCT%KW3(](N+?4I;1+8+;W$+L\*([;&D C&TR,-W/.2*^@?A[K\GBKP'X>UF6
M4S2W]C%</*UO]G+EEY)CR=F?3)^M<U7#RI14F]'_ )7.RAC(8B3A%--=[=[=
M^YT!Z5+=?Z]OH/Y"HCTJ6Z_U[?0?R%<QW$5%%% !3S#(I *,">F1UJIJ,B1:
M;>/))Y,:P2%I<$[!M.6XYXZ\>E?'OPUET30M,\9>'Y=?T/7](71;627QA;7^
MH06IG,P"6]V_F,4+'EC%M.,@@"NJC0]K%N^UNG?^OF<&(Q7U><8M;WZVV5^S
M^_H?94G[H@2$1DG #G&3Z<TF1N*Y&X#)&>17Q9X=T-O%7PEG8:F+I]*\0WEC
MIT"M+>VU_+<"/RAIKNP?,93Y9')VYD8\5[1\#?&-S?>-O%.B:K9PS>(FDFN=
M1U2&Y,C&2&40B%H]H\J, _NAD[E#,>2:VJX3V<6T[V.>AF"K2C%QMS6MK?\
M3O\ Y]K^V4445YYZX5UOAG_D%C_?:N2KK?#/_(+'^^U &M1110 445\^_M!Z
MGX=\/?%[X.ZKJ?BM=+U!->\@:=<ZP+>W^SM97NZ4VY8!R7"+O8'!  P2<@'T
M%4274,L2RI-&\;'"NK @G., _7BO@:S5?%_Q\U"!?$#6X\0>(-?T.&ZM=1=O
M$4!:UGC$=Y9[]J6$+([1, &&RU)"[RS:F@>)Y_AQK>D7]QI^G:SX4BU&[U'1
MK+3V>TL[JY1[2SFFLHB&\Q@9F,*$@.1=2@\QL #[JHHHH **** "BFN<(Q'7
M%? ?P>US7_!&E_ CPG=7U_J6E^)=0@\1:#>W4\CXE^PW1O;"63))597CFCW=
M5E<#_5B@#[^HKY._9TT+X7_$#P/X<_X2+4EUOXFZU9./$MA?ZG*;Z6\'S7<-
MS;;_ )4BE4A%90J!$VXR,\!X'\,^%_#_ ,(_A1-JBII7A/Q#XLU"T\4WTMY)
M%%<10MJ7V**XE+\1><D*X)"DA%/7! /O"BOAUM:T?3OACX#U+4_&$UAI6F_$
MHQ^&5N]<:&&ZT@:R$CE(9P;B)(<JC.641D'T-7=0\;S)^TEJNJ:LNA:_?V_C
M#3](T?1KB^N!JD6GS6]OLNK&)6\HQ#S9IG;:0X24,XV*  ?:M%?G_9ZOI7PN
M\'>//#]GJ^D^(;B\\*:A?R^.O EY+-J%K_I,:1K>!W949S< APZX$$IPH7(Q
MK;44M/"^J^&CJ>@V\]UXOTL_9-/UR:3P24-A*[027A;S(PXA=W3J9A;@*P<E
M@#]&:*^%U\.^'_'O[-W@C0/L?]K^.O$&IW?A32M1GN'N!9(+J=KNXM)0^9+6
MVA29H),DE4@!.35?Q+=V>D_M+1&TU+98:)XJT71HX)-4D7Q!"!;PQB"TM2^V
M;3W+QM*Y&XAKEL-M#  ^S/B5_P D\\3?]@VX_P#1;5T,/^J3_=%<]\2O^2>>
M)O\ L&W'_HMJZ&'_ %2?[HI]!=1]%5+C5[&TE,4][;PR#DI)*JD?@347_"0:
M7_T$K/\ [_K_ (TAEHVD#/*YAC+2J$D8J,NHS@'U')X/J:BFTFQN6M6FL[>4
MVI#6Y>)3Y)'0ID?*>.U1?\)!I?\ T$K/_O\ K_C1_P )!I?_ $$K/_O^O^-
M$[Z;:27\=\UK U[&AC2Y,8,BJ>JAL9 ]JLUG_P#"0:7_ -!*S_[_ *_XT?\
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M^O\ C1_PD&E_]!*S_P"_Z_XT :%%9_\ PD&E_P#02L_^_P"O^-'_  D&E_\
M02L_^_Z_XT :%0"QME2!!;Q!8#F)0@Q&<$97TX)''K5;_A(-+_Z"5G_W_7_&
MC_A(-+_Z"5G_ -_U_P : )XM,LX+V:\BM(([N8!9;A(P)) .@9L9./>DETNS
MGL7LY;2"2S?(:W>-3&V3DY7&#SS4/_"0:7_T$K/_ +_K_C1_PD&E_P#02L_^
M_P"O^- "7WAS2=42%+S2[*[2!=D2SVZ.(UXX7(X' X'I4XTJR6[BNA9P"YBC
M\F.81+O1/[H;&0/8<5#_ ,)!I?\ T$K/_O\ K_C1_P )!I?_ $$K/_O^O^-
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M!_Z 6E_^ ,7_ ,36K11<#*_X1+0?^@%I?_@#%_\ $T?\(EH/_0"TO_P!B_\
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M_P#A!?#?_0O:5_X!1_\ Q-'_  @OAO\ Z%[2O_ */_XFMRBBX6,/_A!?#?\
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MA58<%1P1P:I1?#'P=!HK:/'X3T./26E2<V":;"(#(F-C^7MV[EVC!QD8&.E
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ML_/_ (;\?N+-%%%<AZ 4444 2R_ZJ#_=/_H1J*I9?]5!_NG_ -"-14 %%%%
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MM8VMM/Y*6_FPPJC>4OW(\@9VKV7H.U:SK0GSOEU>WD<]+#U:?LTIZ1O==_\
MABW1117(>@%=;X9_Y!8_WVKDJZWPS_R"Q_OM0!K4444 %<W\1A;-X(U=+N<V
M\3P[ 5U(Z<78D!8_M*D&+>V$W Y^;BNDJIJVD6.O:=<:?J=E;ZC87"[)K6[B
M66*1?1E8$$>Q% '@?[+&O:C<^!_B-IEWJ4ECJ&B^(;RWCBOM0;5K;2(VMX98
M8DO&?-S&JN)#N92I=HSMV"M/]EGXX:Y\<M+UW4-:CTW3WTUK:R6PLUD#RGRM
M[7X+G/V:YW!X./N+DL22%]>TWPEH>CZ"VAV&C:?8Z*R/&VFVUK'';%7SO4Q@
M!<-DY&.<G-6+/0]-TZZ>YM-/M;6Y>&.W::&%4=HH\^7&2!DJNYL+T&XXZT 7
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** .;^)7_)//$W_8-N/_1;5T,/
M^J3_ '17/?$K_DGGB;_L&W'_ *+:NAA_U2?[HI]!=0:>-20TB@CL2*3[1%_S
MU3_OH5D:AX'\.ZM>27=[H6G7=U)C?-/:H[M@8&21D\ 56_X5MX3_ .A9TC_P
M"C_PHT Z#[1%_P ]4_[Z%'VB+_GJG_?0KG_^%;>$_P#H6=(_\ H_\*/^%;>$
M_P#H6=(_\ H_\*- U.@^T1?\]4_[Z%'VB+_GJG_?0KG_ /A6WA/_ *%G2/\
MP"C_ ,*/^%;>$_\ H6=(_P# */\ PHT#4U]1N(CI]S^]3_5M_$/2N&$\6/\
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MG_?0H^T1?\]4_P"^A7/_ /"MO"?_ $+.D?\ @%'_ (4?\*V\)_\ 0LZ1_P"
M4?\ A1H&IT'VB+_GJG_?0H^T1?\ /5/^^A7/_P#"MO"?_0LZ1_X!1_X4?\*V
M\)_]"SI'_@%'_A1H&IT'VB+_ )ZI_P!]"C[1%_SU3_OH5S__  K;PG_T+.D?
M^ 4?^%'_  K;PG_T+.D?^ 4?^%&@:G0?:(O^>J?]]"C[1%_SU3_OH5S_ /PK
M;PG_ -"SI'_@%'_A1_PK;PG_ -"SI'_@%'_A1H&I'\2;B(_#WQ+^]3_D&W'\
G0_YYM72P_P"J3_=%<_\ \*W\)Y!_X1G2.#G_ (\8_P#XFNCH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>adag-20221231x20f006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $] ; # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%&A*,I)N[M;17Z,ZZV"E1@YMHZ^BBBOU<\X**** "BBB@ HHHH HZK_J[?\
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M!Z5]744 9GB:-IM OT099HF %<*/!^K8'^B_^1%_QKT#6?\ D%W/^X:N#H*
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MYD>IZ/\ \>"?[S?^A&KM>.IJ][&NU;J51Z!C3+K7+];:4B\F!"GG>?2FO%S
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M.K^7E@,MDE>#TKZ6HH S/$L;3:!?HHRS1$"N)'@O5,#]TG_?==YK/_(+N?\
M<-7!T% 'F_\ PA>J?\\D_P"^Z/\ A"]4_P">2?\ ?=>DT4 >;?\ "%ZI_P \
MD_[[H_X0O5/^>2?]]UZ310!YE)X)U4MQ"I_X&*9_PA&K?\\%_P"^Q7J%%?E.
M8>&^3YEBZN,K2GS5&V[-6N^WNGHPQU6G%126AY?_ ,(1JW_/!?\ OL4?\(1J
MW_/!?^^Q7J%%>?\ \0IR+^>I_P"!+_Y$O^T:W9'ED'@_4[F,2)"I4DC[P['%
M)<>!M7D@D40+DJ0/G%>CZ/\ \>"?[S?^A&KM->%61)WYZG_@2_\ D1K,JR=[
M(^7I/@;XM:1B+.+!)_Y;"MCP7\'_ !-HWB?3[VYM8U@AD#.1*"0*^B:*^SI<
M*X&C.,XN5T[[KI\CVJG%&.JTY4Y*-FK;?\$****^R/D HHHH *I6_P#R%+O_
M '4_E5VJ5O\ \A2[_P!U/Y4 7:*** "BBB@ HHHH **** *.J_ZNW_Z[+_6K
MU4=5_P!7;_\ 79?ZU>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH @OKQ-/LI[J0,T<*-(P7J0!GBO./AY\<#\0XK:]A\%>(]'T*XC>5-
M:U/[&EMM4D9.RX9P#@]5^N*] URUDO=&OK>(;I98'103C)*D"OG_ ,-?L^:I
MX,^ &I:=I5H)_&]SI,]J;+4K]IK-I'9B%VEB@!R/:@#U36/C?X(T6PM[V7Q%
M8SV\]Y'8H]K,LH$SG"J=IX^IJ]8_$_0)K);B_O8=$WW$UM'%J,\4;2&-RI9<
M,00<9'.<$9 /%?(VE_LW>.UU.[U>Y\&F>W\_3)XM.N[K3_/;R)<R +$5A4[3
MQ\W(')!XKC_B3X<N?A-_;>G^)-'TC4M3\0VFJ)IVGZI<JA@,M^TL;VY*LLKL
MKKF.,F08'&,D 'Z"CQ!IC1O(-0MBB,J,PE7"LV-H//4Y&/K4-EXLT34M6GTR
MTU:RN=1@&9;2*=6E3ZJ#D5\H_P#"GOB(^E:CHMGX966SUB^T?51JK7\,:VZP
MQQ++&T9._P P;,C P<]<\5?^"W[//BKP?\5=,U#6=-O-FF7=[<MK?]HVWD7*
MS!PJK&B^<Q.X9$F ,9!/% 'U#XH8IX>U!E)#"%B"*\Z&MZAC_C\G_P"^S7HW
MB6)IM OXU&6:)@*XD>"M5P/W*?\ ?P4 4/[;U#_G\G_[[-']MZA_S^3_ /?9
MK0_X0K5?^>*?]_!1_P (5JO_ #Q3_OX* ,_^V]0_Y_)_^^S1_;>H?\_D_P#W
MV:T/^$*U7_GBG_?P4?\ "%:K_P \4_[^"@#/_MO4/^?R?_OLT?VWJ'_/Y/\
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M5M?4****](\T**** *6C_P#'@G^\W_H1J[5+1_\ CP3_ 'F_]"-7: "BBB@
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M':1*\1"_NA&;AI 3L*DA".=W:L^']G/Q[J.AZ;I?_"$V&AW&C^%%\/R7T=_
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MRMX8V()X+/$W7IU-?:%% 'QCK7[/OC*^L)[\^$KQ+EM2@N[:'2]6M(;RT"V
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M"?[S?^A&KM !1110 4444 %%%% !5*W_ .0I=_[J?RJ[5*W_ .0I=_[J?RH
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M%?#NH%201"V"*\W&JWN/^/N?_OX?\:])\2QM-H%^B_>:(@5Q0\$ZK@?NH_\
MOX* .-\;ZYJ-MX?G>&_N8G!&&29@>OUKRW_A,->_Z#6H?^!3_P"->V>+/AOK
MFJZ-+;VT$;2L1@&4"O/_ /A0WB__ )](/_ A:_,N),-CJV,C+#1DX\JVO:]W
MV/TOAO$X&CA''$SBI<SWM>UEW.P_9]UK4-5U+4A>WUS=JL8VB>5GQSVR:]PK
MR;X,_#W6O!=]?2:I#'$DR!5*2!^<^U>LU]9D%.M2P$(UTU+7???S/E,^J4:N
M/G*@TXZ;;;!1117T)\^%%%% %+1_^/!/]YO_ $(U=JEH_P#QX)_O-_Z$:NT
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M/17B\1RA$C8M"]Q<PO;M''MW$9B8Y '8]Z^\6174JRA@>Q&:"BE=NT;?3'%
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M?\Q6[_[_ #?XU]8^-;22_P#">K6\0!EEMW103@9(KY]_X4'XL//DVO\ W_\
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M' H B^VV_P#SWC_[[%'VVW_Y[Q_]]BE:Y@1BK2QJ1V+ 4GVNV_Y[1?\ ?8H
M/MMO_P ]X_\ OL4?;;?_ )[Q_P#?8I\<L4N=CH^.NT@T_ ]!0!#]MM_^>\?_
M 'V*/MMO_P ]X_\ OL5D+X[\,OK0T=?$&E-JQD,(L!>Q^>7 R4V;MVX#G&,U
MJV^H6=W<3P07,$T\!"S11R!FC)Z!@.1^- %74KJ&06ZI*C-YR\!@?6M.J.J@
M;+?C_ELO]:O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !117B_B/\
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M:=\?O ]WHUQK%WX@TW1]'CDAC2_O]2M5BE:6-9$ *RMM.&'RN%)[ C!,:?M
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M5N.F#;B_9O\ &.I>(+?^V]!T6X$]WH=Y>WEMY:V[+:S*9HMFT$_*.!C!QVH
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M7'BJUU@R7K:GX>O9//<N3YZZC'(D<:!3_$) >F,\5T?[/G@OXE^&OC%XZO\
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M9VUBXN-&N[2_LHKP323W[AGC6)V92KPA  =B+Y:JV!@D]37OXZ4M% !1110
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>adag-20221231x20f007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "H ?@# 2(  A$! Q$!_\0
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M6PN9=5NC+-;QR/@1@9*@G^#WJ[LO/^@K=_\ D/\ ^(JEX7_Y%K2?^O2'_P!
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MU/*9I2"A4&0LP\ORRO&W&#Q0!]87-XUG)!'<:[-!)</Y<*2/$ID;&=J@KR<
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MSGG [CPSX=>(M!\::O=S?$;3O#]OI=IX7O[/3)([5+>PNECGD6XN+>,_*N]
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M_P")UJ''3Y;?C_R%7044 <;HWPQL] EU"6RU348Y;^X:ZN9&,+M)(W4DF,\
M8 '0  "M/_A%)/\ H-ZC_P!\V_\ \:K?HH Y'7_#$D6A:D_]LW[[;:0[66#!
M^4\'$6:*W/$G_(NZI_UZR_\ H!HH J^$WN/^$5T;$49'V*'_ ):'^X/]FKUY
M:?VA$(KJRMKF,,KA)3N 92"IP5Z@@$'L15?PE_R*FB_]>4/_ *+6J_CG7]0\
M+^$]2U32M$G\1ZC;1%X=,MI CSMZ;B#@=S@$X' )XH MZCI4&L(BW^F6=ZJ;
MMHN ) N5*G&5[@D'V)%/LM/CTYIFM-/M+5IF#2F'"%R%"@MA>2% '/8 5YS\
M%/B)J/CQ=4GUG7-);5H54S>&+"UEAFTK.2!*9PLKDC'SF.-3@X%<%8^-?%4$
M?A7QO+XDO+B'6_%;Z+-H#I%]DCM3=2VR",! X==@<L6R3D'C% 'T9ON/^>,?
M_?P__$T;[C_GC'_W\/\ \37F7QRL_$D&F?VSI.L>(([2PMW;^Q_#%K UW<W&
M5V.TDIV^6H#93'.>O&#U'PF\077BKX:>&=6OKJ&]OKNPBDN)X%*HTNT;\ @8
M^;((P.0: .EWW'_/&/\ [^'_ .)HWW'_ #QC_P"_A_\ B:GHH @WW'_/&/\
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M Y8\"MW?<?\ /&/_ +^'_P")J>B@"#?<?\\8_P#OX?\ XFL_17N/LTW[F/\
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M23U-=U10!S/_  L+2_\ GUUS_P $%_\ _&:/^%A:7_SZZY_X(+__ .,UTU%
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M/PS\>-8UW4-!U670[.#P5K^L7&BV%RMPQO5DC\P132)MV[)/(DX!RN4SG)P
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MA<Z?>Q+-!-L*[T/(." 1^(H T:SK7_D-7W^XG\JT-H]!6=:J/[:O>!]Q/Y4
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M9Z(+!].EM)8IH[BWN$EC8PR(<JP&1GN,>A-0)X$T3_A)4\22>!-*D\2A0#K
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MB/[R[?RE9Y)C_$PF)&6Y&2*^C#J%^1@Z1(1_UWC_ ,:P= \(:/X4U&]U#1/
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MXY\+ZWJ#:Q<^%]52SAU26-$EN8)+>.=#*$"KO7S&4E54$*#C.:K:E\-M!OM
MO]/AUJ^LKN;6CK]MJ$,.9+2ZWAU*AD*LH(QM8$$$@UL_#OP[H_@"VU5_[3N=
M5U75[QK_ %'4KF J]Q,45!\JJ JJB(H4< #U)- '?T5F_P#"16'_ #V;_OT_
M^%'_  D5A_SV;_OT_P#A0!I45F_\)%8?\]F_[]/_ (4?\)%8?\]F_P"_3_X4
M :5%9O\ PD5A_P ]F_[]/_A1_P )%8?\]F_[]/\ X4 )K_\ QZ1?]=D_G6G7
M-Z]X@L6M(L2M_KD_Y9/Z_2M+_A(K#_GLW_?I_P#"@#F/BI!JK:;!<V_B_P#X
M0O1+4//J6H0Q1/<% /E6,RHZ+SU)4GH!7C6H>+/B;)\%;7Q=>Z[JNF_9+6XD
MBBT?18Y[[47W'[/+/&T;K'&5 +A53&2<KQ7HWQ?\ VOQ7_L79XKO]!&F7'VE
M8[>QCN(II,?*7CFC96V]1D'!YJC??#N^OK>VD;XG:\FJ"VDLKJ^2Q@47,+$D
M PB(1HZY(#JH/KF@#T3X>:[<>)O VA:K=S6L]U>6<4TLED^Z%G*C.T^F:T;7
M_D-7W^XG\JQO!]MH/@?PSIVA:9)*MC8PB&/S$=F('<G')/6K%KX@L1K-Z?-;
M!1/^63^GTH Z*O()/%WC:+]I;3O#]X=/M?!EQHE[<VUO 3)<W$L<EN!+(2H"
M "1@$7/J3R /3?\ A(K#_GLW_?I_\*YK4-'T74O'FF>*9+V<75AI]QIZ0+$V
MQDF>-F)XSD>4,?4T >)?!;XE>+[_ ,>:9+\0+SQUX?;Q!=WXTK1]5TNQ@TMU
M1V,<(*Q_:D=8@&'FE=^UB,@5W/QA^+]_X*\2Z]'92!;7POX1N?$UY$RY%PQ,
MB0(>,[08)20.3\M)X6^$.GZ%K^B7>H^-==\1:7H$LTVCZ9J4886KR KN>4)Y
MDQ5&95+G@$]3S5GQEX-L/$7Q,EU.:)K[0]>\.R^'-9C *%(@[R1,,@$@^=,I
MQD@E>,9( /&=+^,GQ B\(>+H;'5O%FK^++CPS#JFE:;K'AV!+MY9)1&UU91P
M+AH 7&8I@9$PN[AJZBP^(GB+1O GQ&:/Q/XJN?&W@M+?6[W1O&%IIZ2&S56E
M9$:SC$;QW$4<R!PS%'4=-N#TL'P)TV9;NXU3QWX@U#65TN/1],U>.);:XTVW
M2591L\N,*[F2.,L7!#; ,8R#1\5?"FXC\*>.%LM:N?$WC+QU!;Z'J6N7\"VZ
MV>G -&QCB10H$<<UPRJ 6>1QDXY4 ^@-+U"+5M,M+Z DP74*31D]=K*"/T-0
M:/UO_P#KZ?\ D*JZ;J6E:5IUK96\CK!;1)#&#$_"J !V]!4&D>(+%3?9E;FY
M8_ZI_0>U &_*VR)VR!@$Y8X'XU\M?!GXR^+?$WQ2TFTU+6-0NK/4I=32YBN[
M"*'22L4A%O\ V;<J@:=MH&X;WR-Y.W;7TG-KFFSQ/$\K,CJ58>4_(/X5Y9X0
M^$FD>%-0T$-XIU74M"\/22S:-H]Q;J([1G#*,R+&'D"*[JH8\ \Y(!H ZOQ?
MXBU)_B%X9\,Z9<_9//BN-1NI-H.^.( +'TX!D=,XYP"!C->22_$'QUX'\>:M
MH%UK.I>)[XZ%=W_D7.DK!%)>+AHHM-"QJTX520RDR$;<DYXKTGQG8I>^._#?
MB"R$EU'#'/IM_&@:-UMY@,R*3CE71"0.<9QDX%<Y#\%M*NKFV?6_&FOZW'IU
MK/::4)%\F2Q64%2_F1H&DD"G:&8G ]3S0!SGPY\6>+)M U72]>\2>+;/QTNA
MQZFEIXBT^PBAR "[P?9XQD!OE*2-N 89 ->]>"?$0\7>$='UH((OMUK'.4'\
M)902/P.:\IE\"3Z#8:MJPU_4?&WBF33#I-A)J$20+!"<9^ZB@DD LQR3MX%>
MC>#1IOA'PII&BQW+2K86L=OO\EQN*J 3T[GF@#JZSD_Y#TG_ %[C_P!"I/\
MA(K#_GLW_?I_\*ST\06']NR'SFQY _Y9/_>^E '15X'XW^-FIR_&/PEH/AZZ
MAA\/QZM_9^KW,@4_:)3&6\F,GLN!N8=^*]J_X2*P_P">S?\ ?I_\*\U\2_!O
MX;^)/$>CZX^B:?:ZAI]__:#30:8H:YDP1^\;9D\\_44 =-\5O$]WX=T;38-.
ME\B^U748-/BF !,>\DLP!_V5/YUSVK^(_&5E\;/#VC2S65KX4O+2Y$:19DNI
MY$5#YCDJ H&[A1GU)[5H?%2UC\3:'ISZ:QEU'2]0@U"WA*,OF%"05R1@95CU
M]JU-1LM)UGQ/H7B":YGANM,BE1(!$Q4^8%W;N.VWL: //=-TWQA<_&J71;/X
MC:Y?Z)IML;C58KRVL=H>4'R88S';HRD#YR2Q_A]Z[WX1>*-0\2^&9X]7D2?5
M]+O)]-NYXUVK,\3E=X';( .*B\-:5I/@J\\4:I;7-UJ5[K-VU_(DD9#;MH"Q
M(2     ,FJOPDM!X4\,2_P!K2JNL:E=S:C>I"CLD<LKEBBG'(&<9]J /1ZSM
M,_X_=2_Z[#_T$4G_  D5A_SV;_OT_P#A6?IOB"Q%[J),S<S#_ED_]T>U '15
MX*^L>-?#_P 6O#6E3>,6\0:KJE[<3:CX=M+.(6.GZ6 YCEWA!+&X/DJ"[GS"
MSX7CCV@^(;#'^N;_ +]/_A7D'P_^%-Q\/_$][JL'Q*UB_@U"]>]OK2[TJV8W
M3,2=K3>3YNU<X4!L*  ,#B@#MO'_ (DO[;Q9X.\.:;.UM-JEQ-=7$J %C;6R
M!V09! WNT2$]=K-C!P1X7X$^.FKW'B_P):ZAXR;5]4\6:C?:9K'AD6T41T%U
MBFDBV!4$D;)Y(3]\S>8&9UX%>R^/(?MGBSP;XCTM6N[G2+N2"XMPI1FM;A0D
MK L ,HPCD(ZD(P&20#CZ-\--,T;Q-9:[?^(M6\3?V,]S<:38WD*[H)9592S2
M;0TKK&[1HTC?*K'OS0!U/P=\3ZAXD\(21ZQ,MUK.D7USH][=(@07,EO*T?G;
M1PN]0KD#@%B!TKN:\V^#]K_PBGA!O[8=8M;U2]N=7U"&%7=(9[B5I&B5MOS!
M P3=WVY[UV__  D5A_SV;_OT_P#A0!I5GZ)_QZS?]?$O_H9IO_"16'_/9O\
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M*K&2'1]K##C<NTCT;..*S8?AGX2^'NI>)_$_A#0K9=;U"P6U@L;.SCME0J&
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M?3_2Y_\  R;_ .+H_P"$7T_TN?\ P,F_^+HHH ;)X2TV50'CG< YPUW*>?\
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M7/\ X&3?_%T44 '_  B^G^ES_P"!DW_Q=-C\)Z;$"$2X4$DD"[E')Z_Q444
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/AE:ZE((]""W-%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>adag-20221231x20f008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *% YT# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_$UBFEZ/HNBOJ&D:4\2YP&(61VQD[L9QFN^\5_"C5K;]IKX0ZIIEK/=>'M
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MDLX<.Z)Y*#"(R@@, /6O9:* /-+/]G7X>:;-X6D@\,VL<GAIV;2BI;%L6Y)
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M0-:GJ$WQ7\*6LWB**XUNTMF\/[?[3:20*+;<,KN)Z'%0)\:/ [>"_P#A+/\
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M,?BQXJ7P[X5\46VKZHT1F6*$<%1UP:!'KE%%% !1110 4444 %%%% !1110
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M.0>3CK6[/^Q_X>NM+\16<NMZH1K>CP:-.X9,I%%C#+\O4XKWVB@=V?-?B/\
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MK?\ PQ?\'K7Q#I^O:5X,M/#^LV,Z3Q7VC226CDJ<[6V, RG R"*0SV\'-+2
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MPD4.O:(A6UNPRY( )897O@FE<+'MM%%%,04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%(3@4 ?+/[?7Q$\1?#KP/X/GT;Q<_@:
MPO\ 7H[/5-<@C$DMM T;?,JGDX(YQVK5_9*\16.M3:JEI\<9OB^Z6L;,LL00
M6X\QP)!CUQM_X#6=^V1\/-9^-FC>$3X!L=#\7:SX8U];VYT^]O(FA"K&5:.5
M"2#G(!!Y%=)\#;K6/!]Q='QSX&\#_"XW,44-LNBW,2-<R&1_W?1<C&" .['B
MD5T/?Z*0'-%,DX7XL?&'1?@_H=OJ6KV^H7GVF?[-!;:9:/<2R2;2V,*#C@'D
M\5YJG[<?PWG^%D/CJ"74)]/?4AI#6B6K&Y2Z.<1E.N>*T_VN/C_!^SW\,_[9
M%@VH:K?3_8-.CY").Z'$CL 2%4<G KY/\+^%?@M_PS=I.F:Q\7CIVK?\)$FL
MZCXJT:SD(CU(AG1!OC("J!@'&,K2N4EH?6-Q^UWX,TSX<CQAJUKK&CVDE_\
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M:I*MAI&G1G]Y-._ (7J0O4UZWJ>HP:3I]Q>74JPVT"&221SA54#))/85\A_
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MAG8W6FWJZ3J>I:;%-%=M'YOD2/&#NV\!L$U\^?!3XL>)/ GPU^,6L^)]7O\
MQW<>$]5F6,W4BQO*B("47 (09Z#!Q7NUEX3\4Z*VJP:=K]I'I8L(;;1[*:SW
M"R=%VEG8$%P>./:O&/#7[+?CFQ\,?$?0M6\9:/>V?C(S3S-;:9)$T,[J!N&7
M.5&.E,0MA^UUXQU'4-$TZ+X42+?Z]IS:GIJMK2;&A49;S3Y7R''3 -=#'^U-
M<ZGX?\'3Z;X6C.L^(Y)X5L[_ %(00VSPY\P-*(VSTXPO.>U:NE?L_7&E^)_
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MG%>_TAOL%9OB/G0=0'_3!_Y5I5D>*W9/#VH%<<0MR?I45/@?H3+1,YKX*?\
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MF('S'W-8/PD^%]M\*?"ITBWNY;YY;N:]GN95"O))(VYLXH!L[BBBB@04444
M%8WB_4;?2O#&JWEU9-J-O;VSR26@0.9E"DE=I!!STQ6S7E/[0ME\5KWPM:I\
M);_2+#6Q/F=]8C#QM%CH >^: /AGX@?&/PS\9KCP_P"'_ GP!N]"\1C5[>:+
M4%T:&$1!7!8DI&,C'7)K]-;)9%LX%F"B41J'"],XYQ7Q5H-G^V"_B*UMKSQ7
M\/Y$CE0W5M;00^>(LC=@ 9!QFOM>V\P6\7FD&7:-Q'3..:13'[%]*#&I!!&0
M:@?4[2.[%J]S$MR4,GE%QNVCJ<=<>]5-/\4:/JLLL5EJEI=21 M(D,ZL5'J<
M'BF2:6P>E!  JA;>(M+O+&:]@U"VFM(21)/'*I1".N3G Q4VGZG::O9QW5C<
MQ7=M(,I- X=6^A% 'A/[('_(&\??]C5??^A"OH"OG_\ 9 XT;Q]_V-5]_P"A
M"OH&DAO<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *2EI&&00>E 'R[^U7IT?Q8U7P_I?@C7O#U[\1
M/!.K1ZN/#>KRKMGS$1L=#ZA@1]:Z+]GGX>^.!XTU[XC_ !!T[3?#OB'6;"#3
M6T+1W+V\"0R.5DW$G+,&'TYKQK]K/Q!\'/$OQ"U'PK#\.=8\:_%:W\HRMX<@
M>VN4W("A>Z Q]TKV./:O2?V*_ WQ2\&Z-?+X[^WV.CR0J-.TG6-3%_>V[>8Y
M8O*.VTI@?RQ2ZE=#Z=HHHIDGAW[9OAEO$'[/'C"6+5-0TJ73[*2_5].G,+R&
M-20C,.=I/45\]_$'P3XW^)G[)OP%D\,:1J?BUK.YM[[5K*RU'[++<VHBD#*9
M68'DD#N?:OK+XZ_!Z'XY> ;GPK<Z[J>@6MRX,T^EN%DD3G,9R,%3GFO+;;]B
M]M,^&FD>$-+^*OC72UTNXDE@O[:[19?*9<>25QMV#M2:*3T/F&/Q;HWQ%L?@
MIX!TFUUWPCH]YXPN;'Q#I%SJDKS>:@3,!ER"RD/G XYK$NI-0?XUQ_!!=8U2
M'P$WQ(%L$6]D,IMS;%S;"3=G;NYQ7UK>?L&^#9?AMHWABTUO6]/U'2]3?68?
M$D$R_P!H->.,-*SXZXQ^0I9OV$?"4_PUM_#3:]K8UN#5FUT>+5F4:HU\05\T
MR8[*<8]J5BKHXK]G35]>^'/B_P#:%\+^&K.\\4V7AF]BFT31Y[PEF9XRQ@61
MR<<CO7/> ?'WC;Q_^V]X0N_''P^G^']]#H-RD-K/>)<F9,GY@5Z>E?4/P,^
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MJ</@WQC'K,T%QJB^);P7,UJA2)Y,C)53D@>U?2%?/W[((_XD_C[_ +&J^_\
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MPY'I4J#;B>-#(2!@G(YKM@H P.!Z"OACX*?MT>(8_A]IZ>(O!.N>(KV(&/\
MM73X08Y5&,$CU]Z[U/V_-&A;%YX \70 ==EEN_K7I49T:<5%,[:6(HJ"29]5
M8%<EXO\ AKHOC:=9M229G5 G[N0J",YZ?C7A)_X*&_#Z( 3^'/&4!/9M(_\
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MBI]:I36?QM^"3&2UEA\?^&H>L<A_TN-!VSD$_K53X>6_PC^-5H5M;(^%-=0
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M31=!U'X%>,[/5]99UT^TDN;0/<LGWPOS]LBL715[ILYWA;ZQDT_O_,;\/_\
M@GAX5T[P?I-KJOB?QA%<);();6RU?R88WQE@H"GC-=3#^P!\,U_U]YXHO?\
MKYUEV_DHJ$?M;>.A_P V[>.\?]=[3_XNN>UK]O;7?#FN:+H^J? ?QI8ZEK,A
MAL+:6XM UPX'*K\_6K5&"6Q:PU-.ZBKG=6_["7P@@CVR:#=W;8QON-1F8_HP
MKQ'XF?\ !,Q/$/BU[_PIKMEH&DN1FQFCDD* #'RMS^M>K']K;QW@D?L[>.C_
M -M[3_XNL#Q!^WEKGA2_T>QU?X%>,["\UBX^R6$,US: W$O7:OS]:3HTWT(J
MX2E6CRS7Z'K?PR_9D\#>!/"FG:7=^%M!U:\MX$CEO;G3HI7E8#EB74GFNWA^
M%O@RVQY/A'0HL?W-,@'\EKPM?VN/'3(&/[.OCL?6>T_^+K"\4_MX:]X*;3EU
MOX$^,M..HW*V=H)KJS!FF;[J*-_)-:J$4K6-XTHQ5DCZ@B\&:!  (M#TV,#L
MEI&/_9:MQZ'IT( CL+5 .RPJ/Z5\XC]KCQV03_PSKX['UGM/_BZPO%O[>&N^
M!;:UN=>^!'C33(+JX2UADGN+0"25LX4?/[4^6/8I071'UBMA;1CY;>)?H@%>
M6_%+]F#P)\8=3@O_ !+I\UW<0KLC*2[,#.?2O/4_:X\=LH/_  SMXYY&>+BT
M_P#BZPO%W[>.N> [*"[\0? GQII-O/,MM')<W%HH:1CA5'S]34RIQENB9T8U
M5RSC='TEX&^'6B_#S0+?1M'MS%80+MCCD.[ KH#8VQ_Y=XO^^!7S.G[7?CIF
M _X9U\=8(R&6XM""/KOK'\9?MVZ[\/="EUKQ%\"?&>DZ5$Z1O=3W%H%5G8*H
M^_W8@?C34(Q5DBE345RI:'U7)H]A+]^RMV^L2G^E>&?'K]C[PQ\=[VSN;V:3
M2I+5-B-8HJ,><\G'2L"/]KSQQ*H9/V=_';*0"&\^TP<\_P!^L;QC^W5XB\ Z
M'-K.O_ 7QIIFF1%5>YGN;0*"Q"J/O]R12E3C)6:(G2C47+)71ZU\+/V9_!WP
MS\'Q: -,M-6B20R&>^M8I)&SV+%<FM'6/V;OAKKH(N_!FD/GJR6<:'\U4&O*
MK3]L'QO>VT5Q%^SQXY>*50Z,+BTPRD9!^_Z5E^+_ -NGQ%X"T*XUKQ!\!?&N
MEZ5;C,MU/<V@10>!GY_6I5*FE:PE0A%)*)WM[^Q%\'[[.[PL(B>\%S)'C\C7
MSC^TM_P3^N!'I\WPNT^YN2I/VBWO=0W#V*[NE>RV/[8?C/4K*WN[;]GOQQ-;
M7$:S12I<6A#HP!4CY^X(-9WBC]M[Q-X.T.\UG6?@'XWT[2[-"\]S+/:!8U'<
M_/TJ'0IM:*QE6PE.M!P:W///V>?^"?!'AVZ?XC3ZQI6HM-F*VTC4_*39CJVT
M$$YKUD_\$]_AF_W]0\52CTDU@D?^@54TO]LCQEJ]A;WMG^SWXXN;2XC66*9+
MBT(=6&01\_0@TW6_VT?%OAS2;K4]2_9_\;6=A:QF6>>6XM L: 9)/STXT:=K
M-7%#!TH14>6_J7!_P3Q^%/\ $WB"3_?U,G_V6I8O^">WPFB_Y9:VW^]J;?T%
M9NA_MI^+/$NE6NIZ7^S_ .-[S3KI!+!<QSVFV13T(^>I-4_;*\8Z+I]Q?7O[
M/?CBWLK=#)+.]Q:!44#))^?TJE2I_P J']3H7O[-7]$:P_8"^$P'-GJ[?74W
MK@OC/_P3K\.:SX5"> GGT_6HW# :C>O)%(OIR#@^];OA?]M[Q-XTT*TUG1?@
M%XVU#3+M=\%S#<6A61>F1\]7+S]L?QII]M-<7/[//CJ"WA0R22O/:!54<DD[
M^ *3HTWT+>%I-6Y$9O[%G[(VN? /4-4UOQ)=0-J5W#]FCM[.7S(T3(.2<#)X
MKZU' KY(\(?MV>(/'^@6NM>'?@+XVU;2KK/DW=M<6C(^"0<'?V(-;%S^V!XU
ML[>6>?\ 9Y\=1PQ*7=S/:8  R3]^M(Q4%9%TJ,:,5""T/J"BODGP?^W7K_C_
M $*#6O#WP&\:ZKI4Y98[J"XM"K$'!_CK9F_:[\<00R2O^SQXY5$4LS&XM
M,DGYZLULSZ=HKY)\(_MU>(/'NCC5?#_P'\::KIQE>'[3;W-H5WJ<,/O]C6Q+
M^UUXYB0LW[.WCH*!DGS[3 _\?H"Q]/45\D>$_P!NW7_'6G37^@_ ?QKJ=G#/
M);/-!<6A42(<.OW^H-;G_#6WCK&3^SMXZ _Z[VG_ ,70%CZ;HKR;]GKX_P '
MQ^T'5=1B\.ZAX:FTV\:RGL]1DC>19%ZCY"17K- M@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF/]
MMWXEO\(;'X?>*ETN\UP6.N!FTZQ8B2<>6>!V/XU].5QWCGX<VWCG6?"VH3WD
MUL^@W_V^-(E!$S;2NUL]!SVH ^2] _X*;C7=<L-/'P8\66_VN=(1-(5PFXXR
M?EZ#-?<-O+Y]O')M*;U#;6ZC(Z4[RU]!^5.I#"BBBF(:SJ@)8A0.I--6194#
M1N'4]"IR#7SM^W%J%T?AMHF@0W4]G:^(=:M=+O)+:3RY/(D;# -U!(]*\^^
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M_!0GX=VNG6NH3^'_ !U%87;*EO=/X7N!%,QZ!&Z,3[&I6_;]\!IJHTQO"_Q
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M%!%&8RD2GY0P)/S8Z^]>=>(OVFOBCX>^+-N;WPM96'PZEUA=&1;@,-1G8_\
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M;XB6.IV]],][9Z=,TE@F\@H\#;?X\,QY/:OUTV_6C;[G\Z!WL+11102%%%%
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MX/AS+\(?$_C/PUK4&IOHX\O[+,#&YE;A 5/.#7QG=^*H_#/AKXE>)(M:\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG\1XH ^AJ*X[X2?%#2?C+\/M'\8:$MPFE:I%YL N4V28R1R/PKL,T +124M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P %1O ]OXE7S;./1"^DQ7(#1&?YLE0>,]*^I_@Q^SMX7^![ZE-HD^K7U[J
M5;B[U?49KN1E7[JC>QV@>U2?&K]G+P-\?-/MX/%FD^?=6K!K74;61H+NW.<_
M)*I##\Z0'@W_  4Q\):/K'[-OB6[CN39:I:/#/,EC*L;W SM F &649XSWKQ
MSXS_ /"5_"7]E;X'67@OQQKND:CK%Y:J]_)=%WC66,94?[ SP*^O_#?[(7PW
M\.^!]?\ ##:7<:M::\NS4;K5KN2ZN9Q_"#(Y) &!@9XJ@G[%OP\_X0GP[X5F
M75;O2]!OAJ%B+F_DD:.0=!DG.T=ATH ^<?B-X U3X;?M _LT:'J_BF_\8W\=
MU<R2ZMJ;9EE+ $CJ>!VK]!E;.1W'%><?$/X'^'O''BSPUXOO;2:YU[PN))-,
M"SE$WE>C>O05P_[)?P7\4_#&T\9:UXRN5;7/$^K27YLHKAIDM(\G8@8\=^PH
M \Y^/7PB^+'@CXY>(?CGX!U+PS):P: EI/I>L&59'2,LS88*5&>V37GWQ'_:
M,\5?M _ /X2>)/#6K:C\/=6UWQ --O)=.?(4C*OM/\2GM7TM\5/V._ /Q?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\[G6Y5M'?U9Z[HPH8%5:B]ZH_=\HQW?S>GR9L4445U'D!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP>#ITLJH-RG22YGT4NJ\W^6I/1117NGYR%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2^ ^6ZO7&)9 >C+&,@8Z5BZ7X3U[XA^%-+TV]U:>^EF):P\/Z<N203_KIB.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/
M>OS4\#WG[0/_  M#XN'X2W7A'PUH/_"2S";3-?G'F^<.&E4'D!_O5^E;_=.?
MTK\E/BNO[+MC\6?&D^J^./BWINNSZI,VHIID$JP^:&((4A.5'(!]*: _1O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'VA?$O03HWB*Q34=.,J3&%SQO1MRG\"*Z"*%((DC10J( J@=@.E/HH ****
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M;X7\9:%XVT_[=X?UFQUNR#;3/I]PLR ^F5)YH VJ*** "BBB@ HHHH ****
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M_$?2O(U6U\/ZCXTM]/N)-&M?$5PX@7Y?G?RP<,1V)'%?/WP[\$?#+XJ?LO\
MAC3[B/3-5\9Z99WMMHUKXMNW>#[0N1(Z1JV'0?PD@XXK[$^*7P%\"?&?[$WC
M#P];ZO+99^SS,S1R1@]0&4@X/<5C>(_V4_A3XJ\.Z3HE]X+T_P#L_25*V*VX
M:%[<'[P5U(//?GF@1P_[ VJZ7>?LOZ%#9/<^3ILMS8W+7;@@2QN0^P@_ZO\
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M6NJ3:39W/DZ)<VV?DMD8D["PX8'J:])_83EUBP_:(^)VF+X5L?!&A_9K>=M
MTRY$UO;2D=05X#$=0*^HM#_9?^%_A[P7K'A.R\(6*:)K!#7\,FZ1KDCH7=B6
M)'8YXK<^%WP4\&?!G3[BS\(:%!I$=RX>>1"SR3,. 7=B2?SH [FBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9_%C^]7US_P3]\*?\(O\,=>$'B?1?$FFWFKR7-O_ & )1:6N0-T2>9SC/3%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>adag-20221231x20f009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &W SL# 2(  A$! Q$!_\0
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MGG':O@CQ1)X-T#PW\6]!\5:#-XL^*#ZXWV+QS;RF:VM\O\I:<'$6.<@_3C%
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MP^&6I_"#PS\+KW5=0BO9CH_B^VD1K2.-V!WL#Q[\D=3D5H_M(?LV>/K[Q?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9)?$&III-J84!"RLK,"^3PN$//- '7455O\ 4(-,L)[RZF6"W@C:6660X5%
MR23Z 5C> ?&EK\0/"=AXALH+FWL=00S6PNX]DCQ9(1]O8,!N&>2"* .CHI P
M-(6 H =17A/B']KWPEX>U;64?2_$-YH6C7G]GZGXDLM.,NG6<^0"CR Y.TD!
MB 0O<UZ*?B5I:>.=/\*N94O=2L&U"PG(!@NHU(WJC9^\H96(/8Y% '8T4@I:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^2?CO^T#X
MO^#_ .TII!C9[WX<6FBI<^(+-57=;))<"(72G&[Y"5)&<8S0!];45X%J?Q3U
M.U_:CT70UUH#PA-X3N-5DA 4Q.ZNNV7=C/W3ZXHTO]L?P;JEYH__ !*_$MGH
M>LW8L=/\1WFE-'I]S*6VJ%D)R 2."1@T >^T5X%H_P ?/#_AKQIK^GZMXFU;
M4A<>(X=$A2ZT]8[?3IY(]R1"1>J-C[[=^*[/Q7\=_"W@KQ1J6AZQ=3VL^F:.
MVN7ESY),$%L'V?,W]XMP% R:!GI5%>.^#/VF/#_B[Q)IFASZ/XB\,7FK(9-*
M?Q#IK6D>H*!N/E,2?FV\[3@X[5V'Q0^*FA?"3PS_ &UKLL_E-*EO!;6<)FGN
M9G.$CC0<LQ/:@1V5%>&:/^UUX.U'5-=TJ\L/$.AZOHFEOJ]_I^JZ8T$L-NO?
M!.&)SQ@U%IO[8/@W4O",OB4:;XE@TEY8(-.:;2)%?5I)L^6MHO64D@@XZ8H
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M0V5P1T_X_9O_ (JN#\#_ ++^C^'O%6OW]ZIN;&67&G0I*Z-#&>6RP(.<DK]
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M'!\V4] OXUXG\-_CKX\\86OQ5T'0/%">+;W0=-BU'0];O]&^PRSDYS&\1 #
MXX< =:]V^-7P9O\ XD:IX5US1=9@T;7_  W=M=VCWMF+NUDW*599(\J>AX8'
M(-9OPP^ VM>#/B5XE\::[XL_X274/$%C#:W4'V%;>*$QL2HB 8X3!(P<G/.:
M .&U?]IZ_P!>NOAN_A41_8M0T:;Q-KVY YALXH\-$"?NL9CMS_LFO+;']K7Q
M2=$T[QE'XVCU:ZNY8Y9? T'AF<0I;.P_=Q76S)E53G<3M)S7N_P<_9+T?X3Z
MSX\NVOWUBV\3.\<-M)%L&GVCLSM;(<G*EW+9XJMHW[//C_0]$T_PC:?%*:U\
M$6$RFW6UTX1ZJ+=6RML;G?C:.FX+NQQ0!C>$O'7Q*^(_QL\<6EAXELM&\(^%
MY[5TL9M.1I;M98!(8I)"<H!_>Z@_2O+-6_:D\5>&M9T*_3XE:7XKOKC68K'4
M_"^DZ,9--M89)=FU+X+RZ@CDMR>U?3?AKX&1Z+XA^)&HSZK)<P^,C'OA6/8]
MJ%A\K ?)W$]<\5Y=/^R%XLU+P+H7@^_^(=LGA_P]=0W6FPV.BK$\QBDW)]I8
MR'?@<?*%R>3Z4#T)+[Q[\3/B-J?Q(UGP=XGL?#VB^#[J73K+3+C35G&HSQ1!
MY6G=B&1<L%79Z9YKSNV_:X\2:UX.^%^F:AXEB\)ZMX@TF75M7\00:0UZ\2K(
M46.&%01N8]6(P *?\5-27PCXT^)^CZ=XFUWP++X@;=+H7_"/&_;696A"";3I
MU&$+\(P;.",UV_PH_9F\2:/\,/A7JVFZLOA#XA>&]*:SD%Y:_:H)8)6+-;SQ
M[E.1D<@Y!% CK?V9/C'J_P 1+SQ1HFJW_P#PD*:-)&UIXB339+$7T3@\/$Z@
M"12.=O!KB_VA_C5XN\$_%(Z1<>)Y/AOX5%@LVGZ\^B?;[6^NRQ!BN)<$0HO'
M8$YZU[E\,/ /B7PK+J^H>*?%]SXIU;4Y%D9%A^SV5HJC C@AR2H]222:YSQ[
M\'?&.I^,M0USPMXVBTVVU2S6ROM&UK3S?V?RYVRQ+O78^"0>H- :'C?CJ^\6
M^//BW\!9]&\2:)8^(+[2=3-QKFF1_;;11Y2^8]NI(#$CH&X!//2ET_\ :5\<
M^'/!_C;0+Z>RU_QEHWBBW\,:=J[VP@BG,X4I--&IQE0W('!Q7I_P]_98M/AS
MK7P]O;'6I9X_"D&H1O'+ H-W)=\NXVG$8!)PH!XXJC??LB6FK0_$9;O7YEG\
M4ZU!KMG<V\ 5],N(441D9)#X*YYQG.* .?\ $OB[XJ_"CQ78^&-1\5VOBUO$
MNGW0TO4'TR.WELK^*,N%*+\KQ-@@9Y%<[>?M<>(;B;X43:>MO]BNH89_%HFB
M :,/*+?:O]P^;D^P%>O>&O@7XBOOB%IGC'Q_XJMO$VHZ/;26VF6MAIWV.WA,
M@P\S NQ:0CCJ *X^T_8CTVV\.?$O2O\ A(;ASXM<FTF,/_(+3>9 B#=\V)"6
MSQ0!S&I?'3XDZ\UE<>&]5TZTM-=\=-X=TQ[RQ#I':1QL'<X(+DN"0?;%>A?"
M37?%%]X^^(/PR\=:S!XOCTZTMKJ#4_L26KRP7 =6BDC7Y>"O!'8UIZ7^S;'I
M'A+X6Z%!K+%?!.HIJ3W#P M?. ^_(S\FYG)SS6M=>#8/AOX]\<?$Z\U)I;:^
MTJW@>Q2 [H_L^]L@@G<6WXQB@1B_LF:Y-<>"];\-SNTC>%-:NM&B9FW9@1MT
M(SWPC!?PKW.O(?V9?!=YX5\ 37^IP-:ZOXBO[C6[N"3[\1F;*(WNJ!0?>O7J
M "BBB@ HHHH *0]#2T4 ?$O_  4E\-?$76/A!XKU"U\2V6C?#C2]-@N+C3+:
M%C?:G=F<(8Y'Z) H9&P.2PY&!6#^U5C_ (92^!S7UY)<: )])&I^'K2X:.\U
MN(P+^X@"\NXY;;D?6OJ#]J?X4:I\;_@)XM\$:+<6MIJ>KP1Q0S7A(B4K*CG=
MM!/137G/QA_9B\4>,_AG\*(O#FL:?I_C?X>26MU9/>JSV5Q)'$L;JV!N .W(
M./K0-'RW\.?&4GPU^'/[4>J^#!J/@C2+"UB&E^"]5DD74]*=PL9N#&Y;RP=Y
MQACVST%6?A=X0L_@5XO_ &5O%OAVXOH]3\>V[0>(VDNI)5U#SHU?<RL2 07&
M,8^Z._->^>&?V1?%WC6^^+GB'XHZQI4?B#QYI*:,MMH".UM90H 4?+X+,&53
M^'6LGX1?LC?$VR\<_#&;XAZ]H%YX8^&D$L>B1:.D@GNW(VQM-O&!M7'3^Z/K
M0,^;->T-/B-\$OCW^T!?WNHQ^/\ 0/%NW0;Y+R1#IT4,T*K$J [2NV3&"/X1
M[Y_1O3OC/I&D^!?".K>);J2UN]:TNWO<6]C/,I9HD=_]4C;>6Z'%?+_B[]B/
MXDS/\0? OAOQ'H-K\*/'>N+K.H&ZB?\ M"S!D5Y880/D()0 $]@.G-?;>AZ+
M;^'M#L-+M%9+2QMX[:%2V2$10J@GZ 4$GD/[+>L6GB'3_B/J5C(TMG<^-=0D
MB=XFC)&R#JK ,/Q KVZO'_V=O];\4?\ L>-0_P#0(*]?+8]Z # Q1P*S=>UV
MQ\-Z5=ZIJ=W'8:?:1F:>YG;;'&@ZDFO/?@K^T5X.^/$&H2^&+Z1Y[&9HY;.Y
M3RYM@/RRA>Z,.0>W0X-*Z3L0YQ4E%O5GJM%1"7Y@,-CU(J3-,LA>TB>X6<HG
MG!=@?:-V/3/7'M236<-T )HTF"D, ZA@".AY[UP/QY^)TGPG^'5_K%E#'=ZW
M,T=AI%E("5N;Z9Q'!&0.<%F!.#T!JG\(OB;J?CKX6RZOJUM!9>)],>[L-7LH
M,^5!?6[,DB+DY*$A64YY5@: /0?["T\S>:;*V,A.[>8$W9]<XJV;<'/S$5\J
M?"_XF_M%?$_X9:1XZTJS^'EQ9:C;M<PZ7-]LAG<!F&S?DJK';UZ<UT.H?M:+
M>?"GPMK/A_0'U#QMXGOWT:P\-3SA/+OXR5G6609Q''M)+#DC'K0,]_&@Z>M]
M]M%G;?;/^?GR5\W_ +ZQG]:N&!64@\@]01G-?.6K^+?V@?AO%;:_K^F>%/&F
MA^?&M]H_A>WN8]0MHV8 O"78B8KG)!"Y -:W[4/[25Q\#/!MS<:)X?O?$'B#
M[$U\J&W<6=I &56FN)> H!8 (#N8X&,9- CW>"WBM8%AB18HU&%5%"@?0"HU
MLHHR[*JHSG+E5 +'U/K7(^/?B-:_#KP<FN7MEJ&IR2&.*&PTNU>XN+B>0?)&
MBKTR>YP!U)KRGX3_ +4<_BC]G#7OBGXITI=,&F7-\CZ=9$LP6&38D>23ER<*
M3TS0![^NCV:WWVP6T(NR-IN/*7S"/3=C/ZU9>(,A!/'3%>!^ _B7\7+WQ)X;
M;Q#X?\-W>C:QC[;9:#=.U]H(9"\;W.]L.O16P!@D8S7LOC3Q3I_@CPIJGB#5
M9OL^F:9:R7ES)C)6-%+-CWP* ,#X7?#C_A6.D7VB6FH-=:']MFN=-M7CPUC%
M*Q=H V?F0.SE>F P7L*[);*%49 B!&)+*%&&)ZY]:\<U'XXZIX.^$>C^)=?\
M/W=_XGUE&DL?#VBP/*^YU,D43OT3;'MWR,0H.['85G:;^T;<VW[*FG?%?6--
MB;4;JP6<:;:N51[AY/+CC#'H"Q4$_4T >Z&Q@_=?NT_=8V#8/EQZ>GX5S'Q*
M^'W_  GWA'4M(MM7OO#E]=!&AU?2F\NX@D1@\;Y_B 8#*GAAD'K7F/AKXM_$
M#PK\4?#'A/XE:;H*Q>*;::73K_0'EVV]Q$F][:59"<_+G#CJ1TKIU_:I^$TF
MM6&E+X\T@WM\YC@3S3L+@D;&?&U&RIP&()QQ0!F>"_@'JT'CRR\6>./%L/B[
M4-,M)[33;6UT:+3[6W$Y7SI616<R2.$49)  SQS7L!TZ Q1Q&)#%'C9&4&U<
M=,#'&*XOP+\>/ 'Q,O-4M/#'BG3]7N=,7S+N*)RK1ID@288#<F0?G&5]ZR=%
M_:D^%7B#58=-L/&^F7%]/=+9V\.YU-Q*20!$2H$@R"-RY&1UH Z;XC?#^W^(
M'A/5-'.HWNB7-W%Y<>J:7+Y-U;,"&5D<<\$ XZ'H>M>=^$?V?-<B\=:!XG\;
M^-E\6S^'EE.EVMIH\6G1)-(GEO<2[&8R2%,@= ,GBLGXY_M"ZY\/-2\;0:%9
M6-W'X9\.)JUP]TKMFYEFV11Y!  V*[$=>E>KZ+\2]"N[_2]%N=5M$\1W>FIJ
M;:<CYD6$J"TA'\*Y) +$4#-;PSX3L?"HU'[%YI:_O9;^X:5]Q:5\9/L %4 =
M@*U6M8C,9MBB4C:7"C<1Z9]*\QT_]J/X5:KK TNU\;Z7+?/=I811[V GG9]@
M2)BN)?FX)0D ]2*]3#9&:!$-O9PV@(AC6-222$4*,]SQ4Q&1BN+\>?&CP3\,
M9X8/%/B2RT6>:%[B&&Y8[Y44@,44 EL$@8'//2JEC\?OAWJ'@:+QC%XPTE?#
M$DWV8:G-<"*(2YQY;%L%6S_"0#0!V":+96]U)=Q6D$=U)P\Z1*'?ZL!D_C7)
M>&/AH-'^(OB7QE?ZBVIZGJJ16ELOE>6EC9Q\B%>3N)<L[,>I(&,"H?#_ ,?_
M (<>,M6@TG0?'&@ZQJDX8Q6=C?QRRR;5+':H.3@ G\*\,D_:@\?0^$C\2FTK
MPPWP^&N-I7]EI<2G5_+%T;8R;L[/-W#=Y6.F.: /K7-+7E[?$S4-'^--MX.U
MBV@33-;L6N]#OHR0[RQ &>"4$XW8(9<=L^E>G)]T4 .HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 2EHHH **** "BBB@!*6BB@!,44M% ##'N.<D
M>U"1A.E/HH 2EHHH **** "BBB@ IC1ASDT^B@!BIM;.33Z** "BBB@ I,BJ
MU]>P6EL\D\\<$8ZR2N$49XZGBOF'XD^)OCY\0_'NH^&? %]X0^'^F6<CQ+J&
MIWR7VHW<8^[,ML@/EHPY&[GN: /J<$'H:6OC>Q^#W[6_@DF\T_XQ>'O%[ [F
MT_7-/,:/_LAU3*U]+_"W7?%>O>$H9_&OAV'PQX@CE>&>SM;L7,+A3Q+&X_@8
M<@'D=#0!V!HKYB_;$_;)L?V<]$N],T2QDU_QT;);^.S\EVMK.V+[?M%RZ_=3
M(*@9R3Z5?^*W[4=[\-O@GX"\16^BQ:UXR\9"SMM,TH2&*!KJ:-7;<W4(N?KT
M^M 'T=Q1Q7S%X0_:(^(?A3PC\0-6^+/@NRTZ#PM8_P!H0ZOX=O/M%AJ Q_J$
M9CD2 D Y]:Y3X0_MB^/=;\<_#ZU\?^#]*T3PU\1XI)?#=WI=T\LT)4;E2X#<
M99<<KZB@=C[(XH/2OB'QA^W)XWL=2\;^+/#W@W3-1^$G@?65T76;V>[9=0N&
MWJCS6Z_<VJ6'!Y.1Z\?9^CZS:ZWHUEJ5I)YEI>6Z7$+X^\CJ&4_B"*!'E_[.
MW^N^*/\ V/&H_P#H$%>F>(O#=AXJTJ;3=3B:>SFQOC65XR<'(^92"/P->9_L
MZ\R_%'_L>-1_] @KV"@'J>(_$C]E#P/XZ\'ZEH:6UWILUW'B.[COIY#$X.5;
M8[E6&0,@CI7C7[,O[!J> =4U'5_'5TNH7V^2VM+33[B2.+RL\2LRE6);&0O;
M/.37VE@9S1M&>E9.E!N[1S2PU*4U-QU1QOACX2>&/!^J#4-)L)K:Z"&/>]Y-
M*-IZC#N1^E=B[!%SUQ2@8H(!ZUHDEL="26B/E+X]:7XI^,_[0WA3POX0U2QT
MC_A![8>);R[U.T:[M?M<I,=JAB5EW, )'!SQU]*J?#JT\7_!_P"-OC#PWXVU
M33]97Q_I$NN6=YI5DUG;B^M8Q%<1B(LV'>(QN2#\VPFOK1+6&.9YEB197 #.
M% 9L=,GO226D,TD;R1([QYV,R@E<\'![4QGQM^RW^U'\,_AS^S)X,TG6?%-L
MFMV%@R2Z3#'))=F3S'(C$:KDL<C ]ZYGP_X)\3_#'P;\-/BG?>'[^>.Q\4ZK
MK^L:+%;%[NSL]0RH<1C)+1J$9E'/S&ON:+0M.@E$D5A:QR*<AT@4$?CBKNT4
M#/AC]IKXQ:#XTT&ZUKX7_&CQ,_C&XLUM](\*>%979;BXR2#)$(]RGGYB2,8K
MUW]K);V3]C/QBMX)9-1.A1>>'&7,O[O?GWW9_'->^VN@Z=8W3W-M86MO</\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^2;Z1_VU_\ 1KT =M1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%;.:*Y#37L Q'+<I@Y93O)W#UKL_#?A;2/AUJ_[%NM^&M/@T[5=8A\G49[1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.B\5?M7?&'4M(^)_Q;\-:QI%K\._ 7B!=)7PU-8+(VJP+(B2R&X^\C_.I '
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M[_=BFG V(QR.">,\XYKW,,&7(H \A_9U_P!=\4O^QXU'_P! @KV"O'_V=?\
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M'!4#&3ZUW]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR?=02')!..@P*]5KYZ_;<^%EW\4_A%'!:>(](\)-I&H0:LVLZR"(K419(=6
M^5L[>?PH ^@LIGL33A@CBO@K]G;XA_%'XE_$32[6V_:.\&^,].L+E7U+1[/3
M_*NKFW7[^S=&I.?[PK[SB^X* 'U\P_MP?"OQ9\0=+\ ZOX9T-/%T/A?7TU2_
M\,O*J?VC$!@ ;OE)4Y.#ZU]/4A7- 'P-X>_9N\;?%VY^/^M7G@X?#;3?&^CP
MZ?I>@WLJ;VN8R'$\BQY5<LH&?>JWPJ^$7Q5\>^,_@5I'B_P'/X1T/X5P/]KU
M.[NHY$U&54V1"$*<X(53D^_M7Z [: @% [GYLZQ^S_\ %WPO\/\ XE_ '0_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $.,<UY-\<RIU+X=GC'_"2VV>/9J]
M8894BOSW_:(_:A\76/Q2N-$C@TTVGAO5DN;-FA8NS(.-YW<CDT ?9/C6^N/$
MFKQ^#M+D>)KA/.U.ZB.#;6N<;0>SR<J/3D]J[72]-M]*L(+.V@6"V@C6**)1
MPJ@8 'X"O%OV0O$MYX\^&$OB?5/+;5]1U&=[J9!CS"N OT ' %>ZT %%%% !
M1110 4444 %%%% !7R[_ ,%"?"&M>+/@O8/IVF7>O:5IFM6FH:UI%CDS7=BC
M$R*H'WL=2/Q[5]15\_?MI?$'QK\._A;9W/@F\M-%N[_5;;3;O7[Z/?#I4$K;
M3.PYP Q4;B"!GWH ^5++5OA[\;OCI\(C\!O 6H^&=0T#54N]:UE=+:Q@M[%1
M\T,IZ.3RO/7..<U^E,9RO'3-?''PT^%?QGTOQSH%[J_[3>E>)M(BNXY;O1X+
M2!3?1_Q1@J<_-ZU]CQG*YH ?7F_QR^.'AWX!^#CXA\1/<RQRW"6EI8V,?F7-
MW._W8XD[GJ?85Z17Q!_P4MM;][CX*W-MJ0T6VB\5B.359%#)9R.BB.4AN#MP
MQ&>,B@#U_P"&?[7OAWQQIOC!]<T/7/ .I>%;47^IZ=X@M]DD=L02LJE>&! Z
M=>161\(OVXO"_P 5_&^E^'&\/>(/#*Z[')-X?U'6;=8[?5T3[QB(/!X. ?2O
MF7XC^)/&.D:3^T=\)V\;7OQ&TFP\*P:S;:W?F)[J M)&987DC !!7=@=JLVV
MIVOB"Y_8?LM#NH9]0@A\R1('#-&B0*)"P'(Y5AS[T%6/H/Q1^WUX+\,>/-4T
M9M#U^]\-:-J*:1K'B^VMP=.T^[8[1&YSN(!X+#@8/6OJ"&5)X$DC<2(RAE=3
MD,#T(-?E!H^IVNC_ /!/O]H?PYK%Y GBY/&,T%Q;2R#SY)FN+78 .K$E),<=
MC7Z+^';3QI8_#GP9:Z.^D6UU!I%K%>IK,,SOY@A0$#RV7&"#G- C,_9U_P!=
M\4O^QXU'_P!%P5[!7BG[+XOA9?$G^TVMWU#_ (374//:T5EB+>7!]T,20/J:
M]KH$%%%% !1110 4444 %%%% !1110 4444 %%%% !29I:BGWE&$9 ?!VENF
M?>@"6DW#UKR:ZU[X@6_C2S\._P!HZ 7NK26[6?[!-A0C ;2/,Y//7VKK-5UG
M4<6NB6;Q3:[-"&N+F-<16J]&F()SUSM7N?8$T )K=W<>)]1FT+396AMTP-0O
MD/\ JP?^6*'_ )Z,.I_A'N173V-C#IUI%;6\2PP1*$2-1PH':JVA:':Z!IT5
MI:*PC3)+.=SR,3EG8]V)Y)K1H Y_Q5KE]HMO&;+1+S6VE)4I:,BF/CJ=Q'Z5
MRWPEN]9T[1;'0]2\-7^F_9TD+7<SQF,DN6 &UB?XJ]'V_C05% #J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBD- $5S<Q6T$LLKB..-2S,QP% ZFO@/XH_LY-\
M0/&J>+H=<-KIWBK7TL;17M,MY;#'G?>&5RIP.XYXKZ_\<7,OB[7(?!]DY6%P
ML^K3H<&*WSQ'GLTA&![9-8OQIM8[.\^&T$$8CBC\1VJ)&BX"J 0 !0!J? ;X
M1M\%/ 4'AHZG_:XCN)9_M7D^3G>1QMW-TQZUZ32#I2T %%%% !1110 4444
M%%%% !7R=_P4?M;.X^#.AMJ<6JZAI$7B&T>^TG28Y&>_@&[?$2G*\9()XR*^
ML:\I_:*\+^,/%G@R"S\%>/8/AWJRW:2-JD\8=7C .8\'U.#^% 'Q;\$!^RJW
MQ7\'GPO\)?&VC^)O[1A-A>7UI=B&WGS\K.S2%<#N2"*_26+A:_/ZY?XR?!;X
ML_"[_A+?C];^+/#FNZ_%IUS9V,*;VR"0K*.=C'"E@>,BOT!B^YZ=>*!CZYKQ
M[\/?#_Q.\.7GA_Q3I%KKFB78 FLKQ-R-CH1W!'8C!%=+10(\V^&?[//P^^#^
MB:AI/A#PGIVC6.H\7B*IE:Y&,;9&<DLN"1M)QSTJA\.OV7/A?\)?%-YXC\(^
M"M,T36KI61[N!6+(K?>6,,2(P>X7'ITKU5)4=F"NK%3A@#T/O0DJ.S*K!BO#
M './K0!Y/KG[*WPL\1_$>'QYJ7@?2;OQ7%*LXOW0_/*OW9'CSL=QQAF4G@>E
M>L@83!ZTAF02",NH<C(7/)_"G'I0!X_^SM_KOBC_ -CQJ/\ Z+@KV&O'_P!G
M;_7?%'_L>-1_] @KV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BF
MD6)&=CM5023Z"I:S]<U&VTG3)[N\<);1H2Y(SD>GN3TQ[T ?+7B3]HW'Q-36
MK#2TEM;*":QB\V0@R*S E^!QRO ]*^D_ VGP6VA07B2F[GU!5NY[QUPTS. 0
M<=@ 0 .P%?-'_#/_ /:'Q(L-/GNO[.M-2@EU(VRH6>",./W6<\G#=>U?5^F6
M46FV%O:0+L@@C6*-<YPJC 'Y"FP+5%%%( HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***IZIJUGHMF]W?W<%C:I]^>YE6-%^K,0!0!;)P,USOC;Q3'X6T1[L1M<
MW3L(;6U3[T\S'"(/J:;!\1_"UW+'##XFT:::0[4CCU"%F<^@ ;)/TKG?#$9\
M?>+'\2RDMH^GE[;2HV^[))TDN!^JK^)[T#-KP%X1F\.Z2\E\Z3:S?2&ZOYU)
M.^4_P@_W5&% ]O>L'Q!^SMX#\5:M-J>JZ+)=WLLGG-(U_<* _P#>50X"GZ 5
MZ2HVJ!UIU C$\)^$-,\$Z1'I>CV[6MBC%UC>=YB">OS.2?UK;HHH **** "B
MBB@ HHHH **** &29V''6OE?6]8\&_M<>(/B3\,_'MB-+TOP1KD$4$\6J^1)
M>/L8A^V ,XQSUKZHE)"<5\,Z+^PQHGQ8^/'QE\0_$[PSJ(L+S6DFT&ZBO3"M
MQ 4_>, AR>0/O8H&>D_"[]B[X#_#3QKIOB'0X4OM<LY ]D;_ %?[4(I.S(A.
M"WIUKZ=BX4 U\V^"?^">_P &OA]XNTCQ+HVCZC#JNE7*7=M))J<KJLBG()4G
M!^AKZ448% A:\B_:5^,S?!OP ]UIMLVI^+=5F73?#^E1C<]Y>R<(-O=5SN;V
M'O7KM>.?'?\ 9;\'_M":GH6H>)KG6[6[T1919RZ/J+6C)YFW<<J,Y^4#(QWH
M ^*_@1XV\8_"GX _M4:SJVJ7$_C#2=0\N6]#ES'=L"C,I/ VL_&/2G_"K1;C
MX%>,_P!F;Q=INO:S=7?Q'@>/Q)'?7KSQW;2QAPVUC@$%AS[5Z/\ "[_@GC/X
M>L_C'9:QJEPD7B1+BPT23^U)+M1:O@K+=1LH#S!E0[N3C/-6OA%^RY\6IO''
MPI7XCMX>M_"WPN@DCTR32+EYIM3D*[8V=64; !C.?[OO05<^?[XZI\1?@A\7
M?VEW\2:W:^-?#_BPIH1AO76&UMHIH%$)BSM*E9L8_P!GW-?HP?CMX3\-^#O"
MNK>+-;LM GUS3H;V*.X) 8M&CMMP#P"XKY*\0?L;?%JWTSQW\*?#EUX=3X2^
M-/$(UF?5)YW6]T^ R(\L"P[<,Q,:@'.#M'3)K[MT70[30]%L-,MH\6ME;QVT
M*OR0B*%4?D!0(\C_ &6->T_Q1IGQ&U;2KN.^TZ[\::A+!<Q'*R+L@Y%>WUX]
M^SH-LGQ1 X \<:CP/]R"O8:!!1110 4444 %%%% !1110 4444 %%%% !111
M0 UC@&N,2.7QIK37*[&T739"+=7^[<W*\;SZHAX'J<GM5KQ5?3ZG>)X>T^0I
M<W*[[J=#S;6_0MGLS<JOXGM70Z=8P:99PVMK$(;>% D<:]% Z"@#RVY\*_$>
M?Q?:^(-WAG[1;6LEHD69]A5V!)/?/%>IZ=]I^Q0?;!$+ORU\X0YV;\<[<\XS
MZU8HH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M444R1BHX- $&HZC;Z9:37%U*L,$2%WD<X"J.I)KS/3?"DWQ0-SX@U2XU#2$F
M4Q:/]BG,%Q;0'K*#CY7D^F0N!W-6M0'_  M+Q0^FE2_A;2I0;MA]V\N1R(?=
M%ZMZG KTF.-8P JX XQZ4#/,/#WP!T_PSKCZK:>*?%KW$TZ7%RL^L,\=RR@
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M!_(U/0(3'N:-OU_.@UX1^T=^T/J?PEOO#'AKPIH47B?QQXGN3;:;I]Q,8H4
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M.E+110(1NAK\\/VSOC;\./B'8>)]!UK^W/#7Q)\%7@_X1[2[K+)JD[%2DB0
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M_6@=P\+6+Z7X<TRQD.Z2UM8H&/J50 _J*U:15"C I:!"5\%?M^^$--MOC/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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L 4UD#CFBB@!!& >I/U-/HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>adag-20221231x20f010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %  Q$# 2(  A$! Q$!_\0
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M>^EZS8:Y;FXTZ]M[^ ,4,MM*LBAAU&5)&1Z5<K\Y_A_^T%XG^&OP+\*#X?\
MAWP_I]_X@\9WFE?9+GSC;[B_W\ERP)/)_E7T/^S/\8_B'XC^)7CSX=_$I-%N
M-=\."&X34-"C>."2.7HNUCG(]>* L?1QE0/LW#=UVYYIPYKY1\0NW_#Q?PDF
MYMG_  B5V=N3CKZ5K?ME?M+ZO\#HO"NB>&[C1M.UOQ#</'_:GB!7-G90J/FD
M8)R>>U CZ9HK\]K;]M[XES_#'6]8@G\.ZSJ'A#5[:/5=0TFV<V.HZ?*<&2+?
M@QL._P#*NL\<_MN>(] U;XD>)-)33K_P3X9TVSCM(9+<_P"DZC< $*9E;.P
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M^(.AZY<?$6P@TZYM[H+:1BRDMG:-LL&.[@KM( [COS7T"'!'4?G0 ZBDS2T
M%%%% !1110 AYKD?BEX8U7QAX%U;1-&U--(O-0C^S&]*DM#$Q D*8_CV%MIZ
M X)KKZ0@&@#YM7]DJ/2?B[H7B/1M3MK#P]ICVDD5CY!-S"+>)HTACDS@1.&R
MX/)([UZ?\;/@];?&GP9#X?N-3GTJ*.^MK[SX(UD8F&0.%PW&#C%>A[0.U+3
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M* "BBB@ HHHH **** "H+MVBA:1<$J"<&IZ9(@E0J>A&#0!\KQ_MCZJ?$_\
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M/(TGVN4I]X #'!STKW!CBN)N_C9X&T^[EM;CQ-80W,+F.2)G.58=1TH X_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBDS0 M>4?M#?";Q%\8/!BZ!H/BI?"\<TRM>.UL9OM,0Y,1PPPI/7U'%>K9
M'K2T ?/WB[]F[7?%?@'PKIR^*;/2O$V@%UAU.PTM8[<Q.I1HQ;YPHV''7KS5
M'QA^R&NI^$?!VE^'O$;Z'?>'K.;3A>R6XG\^WF7;,I4XP6['M7T?10!\X>/O
MV13XATKPY9>'_$TF@#3=(?0+IGMUG^U63X\Q>?NL<<-VS1\2_P!D)/&%]I+Z
M-XCDT.UAT:/0-0@:W$WVJS1E8*"?NME>OO7T?10!XW\1OV8OAYX[LX+S7]$D
MO[O3=/%I;RK?7$.V-$^4%8W4'IW%8W[#UK%:?L\:##"NR*.YO$1<DX G< <^
MP%>X:W_R![[_ *X2?^@FO%/V)O\ DW[1O^ON]_\ 2AZ!GO%>/_&;X_V_PCU6
MRM)M*DOS<H7#)(%VX[&O8*\-_:9^$K^/?#0O]*TN?4?$-NRI L4@'R$_-P2!
M30C9\#?'W3O%'@/5/%=W92:=8V!(D0'S'('< 5)X*_:1\(>/O$5MHNE->M>7
M )3S;<JO R>:^0I?"_B[X1:;?MXAT*[L[#58'LAOF4+N89R &(S@=Q7H/[(/
MA33]9\<W&KQ/<PSZ7%N".RLLF_Y>2!560'V@*6D%+4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'RS\5/!NL^+OVG$C\%>/[OP=XK7PL@O5ATR.
MYB^QBY8H69^A+D\ =JUOV:O#LWACXG_%2SUOQ?=>+?&0DT[^TYKJR2V C\EO
M(9 O#*06&>.5J[\:/ /A'QYXY@OK7XA7'@+Q]IL<-@;W2KI$G:*<EHH9$;A@
MY5BN?0UU_P %?@SIOPEM]7E76;_Q-X@UB9;C4]:U.4/<7#(N$4XX55&<*/4T
MP.^\0>&=*\7Z3<:5K>F6FK:9.-DUG?0K-%(OHR,""*S;WX9^%-2\+0^&;OPQ
MI%UX=A"K'I,UE&]J@7E<1D;1@^@KIU^Z/IWI:0%:TLX-/LXK:V@CM;>%1''#
M$H5$4<!0!P !VKYQ_8G_ ./?XK_]CM?_ ,Q7TJ_W:^:OV)_^/?XK_P#8[7_\
MQ0!]+UXE^TE\%]:^+T.BII$UI"UDTC.;IBN=P &, ^E>VT4 >)? ;X&7GP^\
M+:_HOB1+'4+?4YE=HH260H%P0V0*[O0_A%X.\-ZE!J&F>&K"QO8"3'<0QX92
M>#@UV5%.X"*,*.,>U+112 **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7B_P"T
MQXIU[PUX4TE/#VNR^'M4U'5(+".^BM4N-OF,!RC<8YKV@]*^=?VV?#FL>)/@
M\\6B>%;CQ=?P7<4XL;2>2*1 ISO#(0W'7B@"G\!M/^)GBG44U_4/BO+K^@6-
M_/8W6F3:'%;-.\1*-AU)(&>0:^B-3UNPT+2[C4-2NX;"QMD,DUQ<.$2-1U+,
M> />OS._9)U&WM_CSX?TV0V&AZ@MR[RZ/<ZU?B[WE26Q!*-C'UR:^X/VHOAR
MGQ(^"7B73_LUUJ-U'9R3VEG:,P::95.Q2J_?&?X?I38SO]=^(?ACPOX=BU[5
M]?T[2]%E"&/4+RY2*%]WW<.Q .>U5M=^*G@[PSI%CJNK>*-(T[3+XJMK>7-[
M&D4Y;H$8G#9]J^8OVA_AWXJU7X5?">;3]/U>0:-'%_:%KIE@EW=Q,;?:#Y#\
M-AN#QP":Y7XB?#WQK)X)^&-]JO@>YU$VFCZAIUWI.CV*L;:XGCVP2&%>%P>6
M(^[2 ^R_$7Q-\)>$8;"76_$NE:3'?NJ6CWMXD0G8] A8_-GVH\1_$WPEX0N]
M.M=;\2:5I-QJ)VV<5Y=I$UP?]@$_-U'3UKXT^*OPH\6Z;X;\%P7?A+4?%,W_
M  AL^A!;&W%R;.^DV['?GY%&,%^V*A^-_P )_&2ZAHT3^%-1\2RWG@N#0X+F
MQMQ<+97RR(S-(V?W8P/O^U C[GUF16T:](8$&!R"._RFO%_V)QC]GW1_^OR]
M_P#2AZ9XX\&?&&31-,C\*>--$T&PMM*C@N[;4=+^U2/*L>'8/D=>E,_8>6:/
M]G?0EN)5EF%S>!W1=H+>>^2!V&<T >^UYW\1_C?X:^%U];VFNO=K+.I=!;P&
M08]^:]$->6_%C]G_ $CXN:G:WFHZC>6DEO&8U6V"X(]\BF@,G6_&OP\^+'P]
MO?$.I:9/J^BZ0Q=HYXFC<-CJ &&>#ZUSWP1^)GPP?Q6NC^#?#]SI-]?J0SLA
M"L%YY)8UVWA[]G_2/#G@#5O"4.H7DEEJ.?,F?;YBY].,5F?#W]E_0/AWXIM-
M<L=3U"XN;;=M2<KM.1CG IZ >S"EI.E+4@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %(:6B@#X[_ &[O@YX4U71M,\5OIT$7BJ[U.STQ-3N[Z2ULXURP
M1KEE_@7)Y'//6KW[#NE6WA+4/B#X3:'3;G4M*FLVN=7T/4)KRPO!)&Q4(922
MKI@A@/[PKU[]H[QEI?A7P/9P:MX0E\<6VL:C!IG]B11H[S&3/(5R 2,=,CZU
MY=\$OCWX#L_%FF^#/ _P^NO#GAW46CC;4HH888XK]XWD^SR1!B^X+$X+C*@K
MC/2@#ZH%+3 X"]^/:@S*%W$X'K0 K_=KYJ_8G_X]_BO_ -CM?_S%?2A8,F1T
M-?-?[$__ ![_ !7_ .QVO_YB@#Z7HHHH **** "BBB@ HHHH **** "BBB@
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MD<A^;RS\N$).W''%,.AW2#:H'I3J11@4M(!K_=KYJ_8G_P"/?XK_ /8[7_\
M,5]*O]VOFK]B?_CW^*__ &.U_P#S% 'TO1110 4444 %-9=Q'/'>G4F: .*^
M*OPSL?BIX.U#0=32-H;B,A),<QO_  N/<&LCX-_"/2_@UX0M=$TV)6G^]=78
M'S328Y8^WH*]*=A@CU%?*W[0WP>\=^(?B)X>O?"&O:K9Z;J$ZP:G'!>.B6ZC
MDRXSP",CZXK&:47SI79QU[4G[>-/FEMIO:Y]10198N< GJ1WJS65X<TQ-$TJ
MVL4EDF6WC5-\SEW; ZDGJ:U0P-:HZUL+1113&%%%% !1110 4444 %%(&!Z'
M-&10 M%)FEH **** "BBB@ HHHH ***KW=W'9QO)-(D,2+N:20[54=R2> *
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M-;LGT6/Q!JDUW<^0]M9NRJ"@Q\[Y;I[4 ?2&M_\ ('OO^N#_ /H)KQ3]B?\
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MT8V\G%>CC_@G_P#"\?\ +;Q-QT_XG]UQ_P"/T+^P!\,%!Q<>)QGKCQ!=#/\
MX_0,]V\$W5W>>%-'GO[*33KZ6TB>>TE<NT+E02A8\G!XR>:W#( ><_E7S8?^
M"?\ \+E'RR>)O_"@NO\ XNK/[./P9OO@Y\4_B-96<&IIX.GCLFTN;4+U[D2N
M$/F[2[$\-UH$?1@.X9%+2*,  4M !1110 4444 %<O\ $WPY<^+O >O:/9[/
MM5]9R6\?F'"[F4@9/I73YHR* /!OA)^R5\/_  U\-?#>E>)?AYX1O]>M+)(K
MVY;28)C)*/O,7*9;ZFNO_P"&9OA&?^:8^#__  1VW_Q%>E4M 'F9_9E^$?\
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M&Z;X#\(Z3X>TN(QZ?IMNEM K\MM4=2?4]3]:\'_8F4"V^*P]/&M__,5]+/\
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MS0H]%\:76F+::K:VTVZ&4D#,<H'RR[#G:QSBO3(8%@4A>!Z4 24444 %%%%
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M14 [ 5Z:!B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>adag-20221231x20f011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %! V(# 2(  A$! Q$!_\0
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M4HF4^OTQ7YX?$SX">$_V;SX=U&Q_:%O_  5\5AY=_P#:O%6JRW%EJ84[9M\
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M^U_Q%;>)[?3-/)72K22W,GEVXX^4$32@D# P@Y KL[+X-?&K]H/XT_#CQ/\
M%S1- \'>'? TQOH]-TR^^U2:A>X4^:-I.Q=R+P6X Q\V<U]J>2N>E'DH.-M
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M*>"<$CGUKIXH4@B$<:A$ P%48 'H* N?&_[2G[+7C']IO]H[PHVJRS:+\,-
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M1_\ $RU&T;[?>:O*J!5:$Y'V<Y&[=UZU]\! !@# I%C53D#% 7/SZT;]G_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HIN]?44O6@!:**KG4;47PLS<Q"[,?FBW+CS"F<
M;MO7&>,]* +%%-\Q?[P_.F374-O&7EE2-!U9V  _$T 2T4WS$QG<,>N:/,7^
M\* '44WS%_O"H;N_MK"VDN+FXBMX(QEY97"*H]R>!0!8HK(T?Q=H?B'3?[1T
MO6+#4;#./M5K<I)%_P!] XK4::-$+,ZJH&22> /6@!]%0V=[;ZA;1W%K/'<0
M2#<DL3AE8>H(X-34 %%%% !112=* %HINX9QFCS%]10 ZBF>8O\ >%*)%/\
M$* '44@((R.12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%(6 ZD"EH **** "BBB@ HHZ
M4W<#W% #J*0$$9[4!@>AS0 M%%% !1110 5Q7QB\-7_C3X6^-/#VEO'%J>KZ
M+>:?:R2N41998'C0LPY W,,D9Q7:TTHI.2!GUH ^2OV.? 'Q%\'>)IX]7L?$
MWAWP9;>&;"QET;Q/J,=YNUF-B)IK+9(_EVHC4*!\@.X808KB/V^?V7/A9X2^
M /CSQWI/@RPLO%SW-O<G54:4R&2:\C$K8+E<L';MWK[L5%7.% ^E?,__  4?
M'_&'OCD_[=C_ .EL- SZ#\(_\BKH_P#UYP?^BUK7K'\(?\BKH_\ UY0?^BUK
M8H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!'-,((V=@2 ">/:O&=4_:L\+6=A
M=2Q:7K\DT4;,J2:7+&C,!P"Y&%&>_:O:2 >HS4<\"3PR1R()(W4JR/RK ]00
M>HH ^6[3XV^._#6E^%/&7B'4-,U#PUK]PT1TFQMB+BV7G!4CEF&.GT'?CUCP
MO^T'X:\3Z[9Z19V.N17-T_EH]SI<L48.,_,Q&!1X;_9V\$^%O%"Z]8:3(EY$
MYDMXI9VD@MG/5HT/ /YX[8KTU%^49)/U)H >#D5\<_'SQ!?>$_VL-?UK2KVR
MTW5=/^#&IW-K>:B2(+>1;]2LDA )"*<$G&..>*^QZR;GPIHU[JKZG<:187&I
M-:M8&]EMD:8VS'<T)<C/ED\E,[2>U 'YOZ1^U%\2_!'A'QTDGBO5[C5X?#%E
MJ<">(H[/4UM3)<QP2:E#=6C;/(PY802*''!R0#5']I[QKXITWPGX[\"I\5+G
MXD>'_P#A&M/\027X6 365Q]MBC,;RQ#'E2;BZI]X849P"3^BGAGX0>!O!4&H
MP^'_  ;H&APZBI2\BT[3(8%N5(P5D"J PP3P>.3Q1H_P?\#>&]%U+2-(\&>'
MM,TO4AB]L;32X(H+KK@2HJA7'/1@:!GQ=\1_B]\2?A1XEU+P+IGC"\UV?QMH
M^D1> ]3N/)F:.Z:=(;OF)-K%59I-QXPHX.><OXH?&?Q_X?G^/M[!\89-(NOA
MW=VCZ+H<D5J9-1/DIO24,-SI(W "#[S$\\"OK*Y_9RTJX^*WA+Q:;QK?2?"-
MM+%H7A>SL;>WL+&61-CRJ44.3MZ*3M!Y R!3/#W[+_@W3?B#XK\7:MI=EXFU
M+7=4CU6$ZOIT$QTV5(U3%NY4LN=BG.<Y ]!0!\C>//VE_BQ=^/?&>J:=JFH>
M')/#FM6&GV?AJ4Z9'IKQ/%"[BZ>>X2<O-YI,95"%^49SD#W7]MZ2"[T'X66G
MB,-:>!+_ ,7V,?B-9F B$1!,<<[=!&9,!LG' YKWS6?A)X)\1^)+?Q%JW@[0
M-3UZWV^3JEYID,MS'M.5Q(REA@\CGCM6YK?AW3/$NF3Z=J^G6FJZ?.NV:TOH
M%FAD'HR,"#^(H"Y^??[6VE?"'1OAQ\9K;X:3R:/XGM]*TV[UJV\..4TEXC=(
ML:N$S"LISD[</A?3.>W\/7/C_P 9?&#QIX>M/BG>2^!_!NA:9?R6YAM[B35_
M-M)2\;RH %C;!W%1DE5QT-?6>C?"CP7X=\/WF@Z5X0T'3M#O01<Z;:Z;#';3
MYZ^9&%VO^(-6]"^'WACPM'-'HOAO2-(CF@2VE6PL8H!)"@(2-@BC*J&;"G@9
M..M 7/*OV&0!^R/\*\$$?V)%R.G5J]VJCHVB:?X=TRVTW2K"VTS3K9/+@L[.
M%8H8E_NJB@!1[ 5>H$%%%% !2'I2T4 ?*G[97B+Q[X7\6_">;1_$D&E^$M1\
M7:9IUY86L#I>W$C2,QW3AL>3M4 Q[<DGDD<5X=^U+\:?'>A_&7XC7>B>+/$-
MMI/A!=+CL;K041]'T>6>11<#5EQN;*YP%#$ C[IK[@^*7PBT/XM?\(XNN?;,
M:!J\&N6?V2;R_P#28<[-_!W+R<CCZUP?CW]CSP%\0_%6IZW?)K-@FLR0RZYI
M6EZD]M8:TT3!HVNH0,.05 R"I(X)- SYY\5?%7QU<:M\2_B/!XTU6"'P/XUT
MS0[+P[8*@TZ[L99+9)UDC(W.\GF[@Q;*D*!U.9O#_P 3_'+:AX>^*,WC#69X
MM5^)MWX1N/"_R'3AIHN)H8ECCQE9$\O<7R223G@ #Z&U?]D3P+K/Q'?Q=(NK
MP&?4+75[O1+6_,>F7E[;+B">6 +\SIA3]X E02#BG:?^R9X*TSXE1^,H6UDO
M!JL^NVVB/?DZ7;:A,N);J.WV\2-R>20"Q( )H YWXB?MAW'PQ^)T/A34OA;X
MO;29=5M=)A\5"!4TV:2<H%*R-U +D8'.5-?2(.:^;_VWQCX?>! 1C'CK1./^
MWBOI!>GXF@0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !3'<(,G\J=7#>// FL>+KR";3_&6L>&8HXC&T&G+
M$4D).=S;U)SVX[4 5++X^^#+_P 7'PY#JC'4?/:U1C X@DF7K&LN-I;MC->A
MJVX BOD&WM=2O_ FD?"J+P]J6G^*;/5U>35DML0Q*LI<W2R^I4^N>.O:OI+P
M#X0U3PG'=IJ/BG4_$YG961]36-3%@8(78HX/OZ4 <S^TU\7+CX#_  :\0>.;
M73(M9GTL0;;*><PI)OF2,Y<!B,;\].U4+K]K'X<:;X]A\'WNM26^K-<Q:<]Q
M]BG:PBOY%4I9M=A/*6<AAB,MGD#@\5)^U=\)-7^./P+\2>"M#N;6TU+4Q;B*
M6]+"%=DZ2'<5!/13VZUX7K'[+/Q)M_V@$\1>&/[%\.Z5<^(;;6K[7--U*[MV
MNK6(*'M;G3MS033/F3$X Z@\&@9[@/VMOA<?&9\,?\),AOQ>G3/M*VLYLS>@
MD&T%R$\LSC'^K#9_&N>^#'[:G@KXLZ?9O<K<>&=1U#6[C0K"QOXY6^U31Y(V
MR",("R@G:2",8/->7V'[*7Q+LM)L_A@;GP^?AE:^+!XF771++_:;0B[-R+;R
ML;1+NX,N<;?>N'^)7P0\4? W]FGQ7I6K7-C=ZM;^+QXB\$W>B6]S=73W[SM(
MJ31["J?+D9SMY.3TR!H?5^I_M7?"[2+6UN)_%"/'=ZC<Z3:BWLKF9KF[M\>=
M#$$C)D9<XRN1G@&JA_;!^%1\$:;XHB\3?:;'4;F:QM+2VLKB6^ENHEW2VXM5
M0R^8@QN4KQD9/(S\[>/OA7XF^%4W[*.B>%M,AU'Q!I-]J$]TUV)$MGO);0O,
MT\D:DIN=W 8]\#D5GW'[$GQ(_M&S^)DMS9WWQ%O-6O[_ %?1+'7KO2K86]T$
M"Q6]U;%'22/8-S=)!P<XS0!]FV/Q>\+:Q\,9/B!IFJQ:GX36PFU$:C: LKPQ
MJQ<@$ [AL8;2 <C!YKQWP1\>?BOXET?PKXMG^%%I-X(\0R(T:Z7K+3:MI]K)
MDI<W%N\2(5VX++'(S#/ )KI_A!\ I/"?[/$GP[\0_9A/J=M?1ZE_95Q<2P*]
MTTAD\IKAWD_CR23R^YL#-<#\-_AE^T/X>TGP3X(N]?\ #.C^%_#$UNESXBTT
MR3W^K6<6=L AD79$2H57;\5H V/ 7[>'PX\1^!)/$?B&ZD\'0_VK<Z3##?Q2
MR&>2(MCRV6/#%E4D)U!PIY(%=+\(?VBH_BK\6_%GA:RTAK;2-*T;2M8M+^X,
MD5Q<)>1LX62!U!B*XQ@G/J!7BO@C]C3Q[H5WX-L-5O/#5WH'AGQW<^*8FB>9
MIKBWF9W*,C)M#JQ3 !QP3G.*]S\!_!S6?#?[27Q*^(5U=6DFD>)=.TRSM8(V
M;ST>V5PY<$8P=PQ@F@-#V8<BB@44"%HHHH **** "OF;_@H__P F>^./]^Q_
M]+(:^F:^9?\ @H__ ,F>^.?]^Q_]+8: /H/PA_R*NC?]>4'_ *+6M>LCPA_R
M*NC?]>4'_HM:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **3- .: %HIAE4'!(I58-T.: '4444 %%%% !1110 444A
MH  <T5!=3""W>0DA44L2.N ,UX!/^VW\.(TDVW&KF100 =,FP2.WW:B4HQW9
MS5L31P]O:S4;]SZ&)P*3)]*^)?"W_!1$ZIXFM+/5_"T>GZ4\A$UW;7$DTJ+@
MX(C"\D\<>]>X>#?VL? GCCQ+I^AZ9-J;:A>R>5$)M/EC0GKRQ&!TJ(UJ<MF<
M6'S7!8K^%46]NVOS/;*K75]%9H7FD2*,'!:1PH_,U8S7Q7_P45\5Z9K:^"/A
M7J.H7FGZ9K]S-JNM3Z;;27-Q%9VT9$/R1JS8>Y>(9Q_ >>HK8]8^RI]2AM4#
MSR1PHQPKR2!0?Q-+#?QW"*\161&&0R,&!^A%?G'K7Q"M_CI^S9^S>OBB)+JX
MMO'UCX>U^WNR0LKP12Q2>;D@_.@5CNP?FZ5!\:=7N/@CXF^.^B?"*]ELO"T7
M@ZQN[FVTVX:X@TV\ENUB<Q?,?()@9S@<#KQB@=C]((-6MKF1XXIXI73[RI(K
M$?4 \4_[?&96B#(954,4##<!ZXZX]Z^$QH'P[^#/Q@^!<7AOP9J%@-6N;:UL
M?&6C:Y 5U=Y8?WJW<)+23(.I8@?,>#76_!W0;K0/V^_B_9W&N:EK+R^$M.N!
M<ZA(K/'YD[$(@4!55.BC'US0%C[ 2]1W9%(+KC* C(STR.V:(;U)VPA5P#M)
M5@V#Z<5^?^I7OB/X4^&OVTI]-\0ZKK6NZ9_9QAU>]</=+YED-[ H %V+(VW:
M %"C&,5V/[&V[P%\9=8\%WND6^F:A?\ A>PUQ&T35)[NPEB.5#2I+G;<DDEG
M! ?).* L?;%%)2T""BBB@ HHHH **** "BFLZKU(%'F*>XH 6EIGFH/XA1YJ
MXSN&* /G3]N3_D0? O\ V/6A_P#I37T:O3\37SC^W$0? '@7'(/CO0__ $HK
MZ.7I^)H'T%HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4F: %HI,TA8#//2@!U%,\U1WIP8&@!:*** "FN,J1FG5Q_C/XL>#_ -W;V?B
M+Q'I^C7-PGFQ1W<P1G0-M+#VSQ2;2U9$YPIKFF[+S.I,>.A.WZU,.E?%.D?\
M%"7OO'5KI%UX>T^TT>34/LLFK-?L42'S"OG8VXQM^;K7UCX,^)/A?XA1W+>&
M]<LM:2U*K,UG*'$9;.,^F<&LX5(SV9PX7,,+C&U1G=KY?F=-28&:P/'/BRS\
M"^%-9\1:C*(;#2K*6]G8D ;(T+'KWXQ^-?+W[/W[7'B_XC_#KXE7GBG2M/T?
MQ9H.AKXGTRSA1U2:PN+1Y[9F5CDE63:Q!Q\P]:U/1/L#K2,F1C)'N*^*?!'[
M3_Q=TOP5\)/'WC"'PMJG@[Q[J%CIK6VDV\\-]8O=!A$V68HX#*<BI)?VFOB=
MX[T3Q?XY\*ZIX*\,^$-#UBXT;2;'Q))Y<NO30L0ZF=Y$6$M@[1Z]>!F@=C[.
M^S@=&.:EP*^7?BE^TKXY\)ZE\&18^$+6#1O&>I:;9W^KR:A#=0P/<$[[:(1M
MEV"@D2\H1C&:Z/XA_'3QCX3_ &A?AYX%3PD+/PSXBU*:U/B*YNXY/M:I9R3%
M(8E.^,JX +.,$ XZT >_XXHQBOCOPI^V1K/COXX3Z#I>J^"=/T2#Q'-X?30=
M7NIHM8O%A)66YC< Q EPVR(\L%Z@FOL0'- A:*** "BBB@ HHHH **** "OF
M7_@H_P#\F>^.?]ZP_P#2V&OIJOF7_@H_Q^Q[XY_W['_TMAH&CZ"\(?\ (JZ/
M_P!>4'_HM:V*R/"'_(JZ/_UY0?\ HM:UZ!!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1137^Z: %S1FO//C7<>(;3P-?WOASQ/9>$[NR
M!N9;[4+5;B,QJI)3:Q !)P,URG[*GBOQ;X[^&UMXG\6>)K/77U15E@M[2S2!
MK'&0T3E3\S'@]!CTKH5%NBZUU9.UM;_E;\3-SM/DL;GQ_P#B;XD^%'@V;Q%H
M/AZUU^VL0\^I"YO/L_V>!5SO7@ESGC J]\#O'GB#XD^![;Q#X@T*WT!KW$MI
M#;77V@2P,H*N3@;2>>*\@_;[\<:KX7^$,6G::81;ZY=&POV<*SBW,;'"@G(W
M, -P''MFN'_9K_;'\/>&?A9IFA>++J>;6;&1K2UM=(T^2>4VR ;&=4&,]1D'
MD#) KU88*=7+U6IT[OFM=7O;\MSE=91K\DI:6/8?VJ_BSXU^#?AFU\0^&-/T
MF]TN)RFH/J1)9&) C"*&!;/.>N*[WX):]XK\3> +'5/&5GI]CK%T3,(M,??"
M86PT39R>2IYYKX<_;+^-EK\9+#14TC1_$FFV.E2R332:O9&UAE#A52103N)S
MD<C@&O2/V7_B=\2?"'PMTWP]8_"G7/%,%NTLD&HG4X8(?+9LK&OF< +G[N?P
MKHJY=*. A-I*=];NSMZMV_I$QQ"=9K5JW]=#[8!I:^=M*_:5U[1_&NFZ7\1?
M"5A\-M*NK>:;[;JOB"W=W9=H4(BG)!)()[<5[GX8\4Z1XRTB+5-#U*VU;392
MRI=V<HEC8@X(##@X((KP:M"I1^):=TTU]ZT.R%2,]C6HHHK T"BBB@ HHHH
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MC_@H_P#\F>^./]^Q_P#2R&@#Z#\(_P#(JZ/_ -><'_HM:UZR/"'_ "*NC?\
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M9^(I++P;#<?#WPQX@LO#>L:Q/?\ E7J3W#1H)8X-NTQQM,@;<P/7CBI-'_;
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M;1_^O.#_ -%K6Q61X0'_ !2NC_\ 7E!_Z+6M>@ HHHH **** "BBB@ HHHH
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M]!>$/^15T;_KR@_]%K6O61X0_P"15T?_ *\H/_1:UKT %%%% !1110 4444
M%%%% !1110 4444 %%%% !11378*,T <W\0O&UK\/O!VM>(KZ-Y+33+5[F1(
MAEV ' 'N3@5\D_LE?$&/XZ?M&^-/&6LPFVU>+28XM-LE.^.VMC(%<!_[WW!T
MYWM7L7[8_C!]#^$-UH-C;_;-:\4S)HMC;!=Q=I#\Q ]E_4BMSX#_ +/'A7X'
MV)?2[5Y-<N;9(K[49Y"[R$8+*HZ*FX9P/;DU[%%TJ&#J2FO?GHO16O\ Y'+/
MFG5BELM6>N(NT8%.I!TI:\<Z@HI&;:":R-1\4:3IUO/<7>IV=K!;J7EEFN$1
M8U'4L2> />@3:6YKYS5>ZNTMHVDD8(B*69FZ  9)KYMUS]J?5?'>NW&@_!SP
MM+XPNH3MGUJYS#I]N<D9W'&X<>HSVIA_9O\ '?Q05[KXG?$*[>-L,FA>'B;>
MU0XZ,>IZGIZ]:RY[_ KGF_7E5NL-%S\]H_>]_E<[R[_:R^%%I:RROXXTMS&I
M9EC9F8X[  <GVKXT_;,^+_ACXT:SX=O/#5S=W"Z=;RPN9[)XEDWNK!D)ZXVX
MZ=Z]9^%W[!6J^"/B'H>OZGX@TG5].LK@RS6+6DC><NUAMPV1W'7TKZ\_X131
MY(8H9-)L)(X1MB1K9"J#T48X'TK%QJ58VEH>//#8_-<+*CBTJ=WM:][6=[\W
M<^(/V=O'_CZ/X+67A+1OA+-XOT.=KM)+^YN1%;3;Y7+H<C&!]TY/)KK/!W@W
MXL>']?DU+PW\&/ _A"Z >.*ZEF(D1&'(+*YSGCL/I7U_9:9;:=&(K6WBMH02
M1'"@11GV%6BH]*M4K)7>QW4,K=*G"$JK?*DEI%=.GNM_B>&?##4?C-#XX_XN
M#=>%H?#Q@<^3ILH\Y9.-G7G'6O<HI4FC5T8.C#(93D$5\/?M9_LW?$'XH?%Z
MXUSPWI4=YIC6,$"RM>1Q?.H.X;6(/>OJWX+>'K_PI\*/"NC:G%Y&HV&GQ6]Q
M&'#!75<$9'!Y[BG3;3<6OF:8*I656IAYPERQVDW?F_!';T445N>R%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<M\2M!U[Q+X.U#3O#/B
M0^$M;FV>1JXM%N?(PP+?NV(#94$<^N:ZFO.OV@-;E\-_"/Q'JL7B^/P)]A@%
MP^ORV@NA;(K M^Z)&\L,J!URPQ0!\[_%7X%^,%\/6$WQ:^.=YXB\!)J^FB]T
M:V\.0P_;G:\A6")V5B=IF,0/MD]A7V8.E?FS<_%FS^)EOX5TW7/VD+GQ!8ZI
MK5C(?#T7@LQ7@>"\BDC$ZJVZ!&=$P[<$,#R*_28=*!L#7SF_[:OAG_A8\F@Q
M:'K$GAFWU@>';OQD80NFVVILP5;=B3NP691OZ D=N:^C&Z&OSZ^('[+?B;QM
M\9-2\/6'A'7_  UX5U'Q5;^(+W4;378Y-#G@20/+<?9V7>MVQ4*(^5&=U *Q
M[]H7[9.@ZQX\M=*ET'5--\+:CJD^A:5XONPJV-]J$(<R0*OWU&8Y KD88H0*
MD^%G[8.B?$KQIH^AOX>U;P_9^)8+BZ\+:MJ2*L.N00D>8\8!W1G!#!7Y*D$=
M:\)\._LU>.]5@\%_"K4_#DVD^&/!WBN_\1/XP^V12P7UI.+P110H#O\ .)N
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M)-Q[D9"_\!KT\# Q38QC/'7N*?5)65D:TJ<:-.-..R5@HHHIFH4444 %%%%
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M'/\ OV/_ *60T ?0?A#_ )%71_\ KS@_]%K6O61X0_Y%71_^O*#_ -%K6O0
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MPOXV\,QZ'?7]J]W82VLF])%0 NC<G# &O8P<BD M%%% !1110 4444 %%%%
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M1\:V-W\,IO&NBK9>&TML3P/YJ $R;!G#!S]X_>%?=B]/Q- /86BBB@04444
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MOA'Q4/$.K^(M3\4:O# UK:S7[86"(]0!DY..,Y_"O50,"EHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-_X1O2?[8&K
M?V99_P!J!#&+W[.GGA#U7?C=@X'&>U:5% &=%X=TJ#5Y]5CTVTCU.=!%+>I
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MS_[*@+'VOD>HHR/45\4_:_VX?^?'X=?]_/\ [*C[7^W#_P ^/PZ_[^?_ &5
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M\\OB[\;/VOO@CX4C\1>)[7P'%IKWMOIX-JAF?S9GV)\H?IGJ>U=M]L_;@/\
MRX_#H_\ ;3_[*@+'VOD>HHR/45\4B[_;AS_QX?#K_OY_]E0;S]N#_GP^'7_?
MP_\ Q5 6/M;(]11D>HKXH^U_MP_\^/PZ_P"_G_V5+]L_;@Q_QX?#K_OX?_BJ
M L?:V1ZBC(]17Q3]K_;A_P"?'X=?]_/_ +*C[9^W!_SX_#K_ +^?_94!8^UL
MCU%&1ZBOBDWG[<'_ #X?#K_OX?\ XJC[7^W#_P ^'PZ_[^'_ .*H"Q]K9'K2
MU\E_LX_%SXU7_P"T)K?PY^+<7AZ&:U\.)K<(T)"?OW C7+[CV#\8]*^M*!!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #&D52<L!CK21SQ
MR_<=6'L<U\_?MS:OJ6E? /4$L9Y;*SOM4TO3M5O8)C%);6$]Y%'<.&'3*-M)
M]'-8/[)VGVGA/XU_'[PAX>WP^"M'U'29-*LUF::"WDFL=]P(W8D\L$)7/!/O
M0,U/VXR/^$!\"\_\SUH?_I17T<O3\37Q[^U'X'_:$^*/B(:3X<\/>$I?"&E:
MU9:QIEW=:BT5U*T&UP)%Q@ ON''8"L8?'']JUOB8? P\!^!QK/\ 9G]K>;]L
MF^R^29/+V^;TWY_AZXYH#H?;=(QQUZ5\#7/[4_[3MI%HCOX \)$:OXBD\,V^
MV6X.VZ21HRS_ -V+<AQ(>",'O69'^V+^TI+?I9CX?>&/->]U>P!)N-OF:;%Y
MMP<_W2O^K;^,\"@+':_M2?M;^,/AI\5[KPSX=%M:VFGPQ-))+&)&F=U#<Y!P
M "  />O4_ W[:/PZO_"&D77B3Q+::3KDULCWEDL,S+#(1R 0I&/QKXCU'PI\
M9?VKOB=XEOAX5\/6?B#3;+3GO88M1-O&%N+<2PD[P26V,H8<8(QUKU'PS^SY
M\<?#>G6%L/@_\+=1FM%4&[O=3D>29A_$_."3Z8Q7.E5YFWL?.4X9HL55;:]G
M]F__  -?O/7_ -H']KGP%J_PF\16'A#QD[^))XD2S:Q2:*16\Q22'VC'R@]Z
M^;O@7^UIK/PN\0ZQJWBO4=;\56DFGM!;6<]^S(DYD0AF+DA1A2,@$\]*ZKQ-
MX0^.'C;5M7^'\GP>^&6FW[:;%?2WVG2& QQ/*R#RYPN ^8SE>P(]:XJV^#/Q
M>_9[US0Y9_AYX7\4R>)[^+0;>+6;S[=%%-)EU=E1 $4",YD;.,X[UI&BI2]I
M4G:W1+?TZ?>88C+\PKXNG7]JDH]KVZ]&W?<].?\ ;RUCQY<R0V^O^&_AQIY)
M'VB]AGO[G&1C:JIMSC/M]*^9OBOJ%MJ?CC5[NU\42^,8Y]D@URX0QO=,8QD[
M6P0 <J!Z**^A?$9^-'AGQAX7\,W?P*^$K:AXC:=;-[:#S(4,*!W\UPN(\@\9
MZGBO)?'_ ,+?%.JOXY\4^*/!MKHD_AC4;?3[O2_#.Y[>9I50QB!2,E1O&YAP
M.?2O0E0R^M:/-./F[2^5E8,PR:KC:*A.K=IWO^&UTOPN?;?A+]L;X-^'_"FC
MZ==>+8K:[L[&&&6W6RG^1UC4,O$>.H/3BN:^)'_!0#P-;>!]8E\$WLNI>)8X
M";2"ZM'CB#%@"[$]0H)..^,5X'#\8?C3X$N)?"G_  J'P-<2:+JEAX=:62V>
M8O-<(3"_F;<.F!\\G13UHM_%WQG_ &B;74O!=O\ "[X?6,LVF0ZG-\S64T<#
M7,L*D-C(8O;R<'M@]Q6E.>"BUS0D[>:_*WZGT7LZJC9-?=_P3K/@5_P4(UBT
MLM:3XCQ3ZX(MCV<^DVBK,68D&-E&%VX!(;VQSFO0K_\ X**:=+:K)HOP\\1:
MA(6QBZDBMTQWPPW<^V*\S^%7[/WQ\^#.JW=]X9^'W@BXDN8Q&S:OK1G9><G;
MA0!V_7UKL-4^(O[3^D>,]#\,3_#;X=MJ.L07-Q;/'.[0JL 0OODQA"=XP#UP
M?2NK$XG!2JRE2H:/;6WX+_,BG3K**4IZG@?QN_:Y^(WB?XE6>K:;?ZAX0MK1
M(6M-'MKLLA/4F0# D)/!!&,<5Z];?%3QMX_M8Y?%?QI/A.WFRSZ=X:T1EDC5
MUY0RGN.1U..H-<3\;_ WQS\/Z9KWCCQ)X!\)HDCPJ\6B7GGLKNRQAE0H6&20
M3M(P 37IFK^-/VF?A]#X6TN3X:_#LQ:G>Q:-9"WN7F"2&-V4R$#Y5VQG+'N1
MZU5;,82I4X4:2BXK5V3^ZZ_/44,.U*3E*Z9S7B#X8_"#7M)ETW2-3USQCXVU
MNZBLX-5\13S,;0R.N^5>@!&#USG)!R*[SX+>%M'_ &,/&_B+0M7N+G76U6SM
M[J/4+&S9G"JSCRVC!X .3G_]5>;?$GXB_M#^(H?&_AC4OAWX.MIO"FGV^N7E
MUIL\J,$(:2,V\@'[QQY;94>H'>L+P]\;?V@?!.K:CKW_  AFD:SJ%UHVF:@U
MWJMQ--,MG<RK%!&NT !@[@NF,J.3TKAGCL14INE*;<7T_K;Y&ZH4TU)+5'V>
M?VI_!V.+375SW_LJ2N1N_'?COQII?B'Q[X;UV/3=#T.X=+;1)[8*;J*-5,AF
M+<JQ!.!V[5X-X1_;!_:*\;_$G_A!;'P+X.AU_P#TTJEY+-#&PM9!'*P9NHW'
MY3T(YK1UWX6?M1:_=Z[,?#GA.QM]9ECFO=/LM>9+6=QC<74J3\V!T(KA1K8^
ME+3]J?PM+;12/8:^KNBLRKI<K $C/![CWKE/&/[1,GC>*Q\-^&[;6?#E[JU_
M%9'5;R#RQ#$S<LG/WC@8![$UYOXB^,W[57@/6O"6@7'@+P/YNOW3:=8"TO9I
M(HV2(R?O6'W%VJ0">^!5/XS^(?VHKCX:ZY=>)O O@:;2-/@-_(=.U.9[F,Q_
M,'B"\EQVQ0%CU@?$N]^ 'C#4?#&JW6M^-=->WBO+60*)KJW9B0R.Q/W>,BM3
M_AKK2BN/^$0\3=/^?5?_ (JOFBW\3?M*?LZ>&O\ A);GP;X7U>76[NTM)+Q]
M0GN[MFE.V(,HY5 3R>U=SJGQS_:MTGQ]9>$)_ W@EM4N].FU2.2*\G:W$43!
M6#2= ^2,+U-,+'877B;Q-XL\%>)_BK:^*-1TIM%NI&LM!'RP"&(KF.9,\LX)
MYKZ@T:_.IZ39W97RS<0I+MSG;N4'&?QK\K_&'C?XW76SQA>^!M(CTO6-%F\7
M7.DVMW<B&YB@:(-YL742DR)^[ZMANF*].7]L;]HV'QKIGA)_ _@^WU2_U*'2
M+4233)$\TEFMVH#9QM$3 $CHV5ZT@L?H=1FOD[_A*_VPB/\ D2?AU_X-9:Y3
MXC?'/]JSX7:!#J^L>!/!$UK+>06*KI]Y-<2>9,X1"57D+D\GL.: L?;F1ZTF
MX9QGFOD'6OB%^UWH6D7VHW/@GX>M!9P27$BQ:G*[E44LVU1R3@' KV/]F#Q]
MXS^)_P (=$\4^.-*L=&U75E-W!:6!?:MJX!B+AN5<@G<IZ<4!8]=HHHH$%%%
M% !1110 4444 %%%% !1110 4444 %%%% !535M*M-<TN\TZ_MTN[&\A>WGM
MY1E)(W4JRL.X()!^M6Z* /,_A%^SUX+^"<M]+X8T^YAGNX8;5Y[Z^FNY$MXL
M^5 C2L=D2;FPHXYK?^)OPRT'XO>#]0\*^*+$ZCH5]Y9GMA,T6_8X=?F0AAAE
M!X/:NMKBOBS\4M/^$G@Z\U[4()KQD9+>ST^UP;B^NI#MBMX@2 7=CCV )/ -
M '5:?9+86\5O$NR&%%C1<YPJC 'Y"K6*X#X%?%N'XX?#'1?&5OID^D1:DLA%
MG<R*\D121D(++P>5/2O0* "BBB@ HHHH *2EHH 0UQ$GP>\+S?%:'XC/IK'Q
M;#8-IB7_ )[X%N3DIY>=OXXS7;DX!Q7A?Q2_:<N?A'X]TC2];\ ZV/"NI:G;
M:/%XIBE@: W,RY4+ '\YE!X+!>S>G(![K14<3EP<C!!Q4E !1110 4444 %%
M%% #)HQ+&R'D,"#]#7%?"3X.^%O@CX;FT#PAIK:5I4MW+?-"UP\Q,TF-[;G)
M/.T<=*J_&[XQZ?\ !#P)=>)-1M9;_%Q!96EC;LJR75S,XCBB5F(5<L?O,<
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M/[1^F>//C9KGP_TW2;MHM,LYK@:XSI]FN9(9U@GBB&=Q\N1MI;IN5@.E>P4
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M6/3//K5#X _'9?C6?&%O)X<OO#&H^&-6;1[ZROIHI6$RH&.&C)7 W =:\?\
M@;:?%CX)W?C71)?A+=ZOI>L^-=5UJ+6(->L(HTM;JYW*YC:3?P@W$8SVQFK_
M .Q'JUCKGC?]HF_TV\M[^QN/'T\D-Q:RK+'(I@CPRLI((/J*!'U71110(***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LAPA-?&_[)_CKPUX
M2^+O[2,&M:]I>CSW'CZ=HH[V[CA:0;,9 8@GGBOLAE#C!Z5YYJW[.WPQU[6+
MG5=2\!>'[_4[F8SSW=QI\;R22$Y+LQ&22><T ?'GC+]HCX@+;_%3QY;?$>TT
M=O!WBM=&L/ QMX3'>P"5$V.6'F&64;RI4@<'H*P/'O[3GQ#AT_QGXF@^)T7A
MS5K/QY;^&;7P3)9VY<6/GQ NH8&02;6?<YRN%8#DC'W?JOP6\!ZMXK@\47O@
M[1;KQ# 0T>HS6,;3!AC#;L<D8&">1BO$OB#^Q9'\2_B#=ZSK/B];C0KO4K74
MIK'^P;5;\>1)YB0+?* XB+ 9!4M@ %L4%7.$F^)[> /"7[4?Q1NVW>,;?Q'<
M>%]*CE ,L4<,44-C#&!SM=YC-@==Q/6O _@UXFM/AU\-_C1\+"-7BM=9\%MK
MUFNMV3VLKWJ6X2_55< D%_F! QA3GFOT!M_V>_#Y^(WBKQ!=1PZCI7B.6TO[
MO0KRV62!-1MUV)>(>H<H%4CU0-UKM?$GPT\*^,+Z"]USP_I^K7D$$EM'<7EN
MLDBQ.,/&&/.TYY'2@5SX7^&/C'Q$U_\ "?P#>>-[;X@^!?'_ ()NX]2TH6D2
MII*0VA \MH_F ! CR^3D'OC'J7PO\2:CXM_X)HW>HZM,;F\'@K5K4S/DF1(8
M[B&-CGJ2D:\]Z]MU3X!>%;#0_$D?@_2M-\$Z[K5BUBVN:7I\8N(59=N5Z=!V
MSUP>U73\)=$M_@S/\,[ 2:?H$FBR:(K0 >8D3Q&-G&>-^&+9(Y8DT!<^6_"'
MQ5/P?;X,^&[/5M-\+>&-2^%UUK$MMY<,$4^HK% 4EW$#+DLY(S\Q))S7(>#?
MVB_B!X[TCX26NM?%*'P"NH>";KQ%=ZY=6UL%U6]2Y9%BPRX"HJ@LJ@$@\9-?
M1&D?L<>'EUKP/=>)=3D\;6/A319]$MK+7;""19(GDC:)FV@#,0C"K\N2#R<U
MJ_%/]FI?&5OX<M?"^KZ9X2T[1(I(;?2Y_#=KJ-HF\Y\R-),&.13T*MCU4T#/
MB^3XY^-OB[\';'QA<ZV+W6OAQX=U'Q-<:FMO'Y?]IRSM!8X3;MRD(D< ^H/4
M5W=WX\^,XDO;5?BW=([?#>/QZ9ETBVREPJ _9T&.(CGYB<DD=J^M?A/^SCX*
M^%WPQD\#VNE0:GIMU%LU.:_@5GU-CDLTPQALYX'0#@5V9^&WA9G9SH&GEVT[
M^R"QMUR;+&/L_P#US_V>E KGQO\ LT_&&PUC]H2_\9>+]7TS1KWQ#\,/#%],
M]U<)!&\S^<SA=Q'<YQ[UZ.]EHW_#?GAK5=(M[%1JO@2ZNY;VS1/]+)N8PLC.
MOW_E"@-D\ 5[!JO[.OPQUO[*;_P%X?O#:6L=E;^?I\;^5!&"(XUR.%4$@#M6
M-H'[/MCH'QF@\>QZS?.+'23H>F:&L$,=E86AV'RX]JAL ID9)QD]J /7J6D'
M2EH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #3_ $I1U_"BB@"G
MJ?\ QX7G_7)__037P3_P3Y_Y+=\6O^O^;^4-%% S[!^$/W?&/_8RW_\ Z&*]
M '2BB@1P/Q"_Y&7P%_V%G_\ 266N'_;#_P"26P?]?R?^BWHHH&;?P*^]XQ_[
M",7_ *20U\??'K_E)%X&_P!U/_0:**!H_1I/N_C3FZ?C1102177^HE_W&_E7
M@O['/_(G:[_V$!_Z+%%% UL?0-%%% @HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@!#TI.U%%  *4=*** %IO\ %110 HZ4>E%% "#H
M:=110 4AZBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>adag-20221231x20f012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (J H(# 2(  A$! Q$!_\0
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MV(8S)*88FDV)_>; .![GBO4[']F'QG=PP+))I-EJ=Q'YT&DW5^B7;K_N=O\
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M'0\<4I"GD@9'0GM2_B*!]: L'%(%"]%"^PXI>OK1_GF@!-JXQM&WTQQ2# (
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M)Z[MK3H>+@93'^S_ $KZ7\=\:M^SYCG_ $&V_P#0XJ\X_P"&:/B7CCPI=?\
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MD?\ \52^LT?YU]X?V1F/_/B7_@+_ ,CS+//:@GW'YUZ;_P ,T?$H?\RG=?\
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M ,57N7[)GPD\7> /&FK7GB#19=-MI;'RDDD=2&;>#C@GM7%C:]*>'DHR3?\
MP3Z#A_+<;1S.C4JT9**;U:=MF?5-%+@T5\@?N8ZBBB@ HHHH *0J#2T4 -V"
MEVBEHH ;M%&T4ZB@!NP4;0:=10 W8*-HIU% #=@HV@4ZB@!NT4;13J* &[!1
ML%.HH ;M%&P4ZB@!NP4;!3J* &[!1L%.HH ;L%&P4ZB@!NT4;!3J* &[!1L%
M.HH ;M%&P4ZB@!NP4;13J* &[!1L%.HH ;L%&P4ZB@!NP4;!3J* &[11L%.H
MH ;L%&P4ZB@!NP4;!3J* &[11M%.HH ;L%&P4ZB@!NP4;!3J* &[!1L%.HH
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MJ0J2#TH GHK/M]9M;B\>UCGC>XCP7B5P67TR.H_&M"@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +12;AZ
MT @]* %HI,BC<* %HI,T$@4 +129'K10 M%)10 M%(#FEH **0\4M !1110
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M,\8KG/&?AGX/?!OQ/\+=3\/^%/%E_;23:?<0>,]!\1)Y5W<2R ;)ED)+<G+
M*.#CBOM_X7?LD?#_ .#.G:[8^&]'F8:Y%Y.I76HWCW4]S'@KL9W.=N&/ QUK
MD/"?_!/#X,>$/$5GK%IX8N[B:QF6XL[:^U2:XMK5P<@I&S8X//.: 1XOXK\!
M^(_"_P#P40^$^JZ]XJGUL:Z^K/:6 C$5OI]K'"_EPHH/+=RQZFIO'W@CQ)X8
M_;Y^#VK:[XKN=;36]0U);338H1#;6%JD+>7& #EFP?F8]37USXC^".@>*/B5
MX5\<W\-P?$'AE)X].E28K&HF4A]R?Q<'\*7Q3\$]!\8?$'PGXSU"&=M;\,B7
M^SY4G*HAD7:Q9?XN*0'YI>'?$6I#QUXY^(7BO0]-UW3]*^*,.FS2SW<\&J0,
M9FC@%N%(3RE&TE3][!K[/_;26;4-%^&'A!;EK>S\2^-K"QOY%X)A0M,5^C,B
M_AFNKU+]CSX>:OX_?Q;/HEPVH37Z:G<VRWLBV=S=1_<GD@SM9P>AJY^TQ\&=
M6^+/@S2(="N(;?Q)H>LVFN:=+=.5C,L+_,C,.0&1G&<'J*!H^1?%)?4?C+\8
M?$5VI'B#P[X^\+Z=HLK-A[6U9P#&G^RX9L^N/:OIO]K6[^&EE\-(M?\ B;=S
M/X>\/ZG'>"RM)CFYNL,L<#(O^LSD_(<#C)X%=)K?[+W@OQ/\18?'>H:7/_;G
MFP74\<%ZZ6UQ-#GR7EB!VR-'N.TFL3XA_L6^ _BI:ZE:^(!K,\%_K8\03Q0Z
MHT:_;! (0R<':H4<*.,DFFK"U.&_80\):W9^%_%_B?4]'F\):-XO\0/K&B^&
M97R^FV;JHC!'\.\8;;VXKQG7?VLOC=I'A;4/&-KJWAN72X/'ESX3ATN?226=
M1-Y:.TH?C;QP!DX/-?;7PP^#UI\*;>[M].U37=52>1'W:[J37K1[1@!"P&U?
M:N.NOV._A_?>%)?#LUA?'2Y/$+>*&C6\8-]O9]Y?./N;A]VACT/ =<_; ^)'
M@#P=\5M-U271=6\5>&?$MCX>L]8%D;:U_P!+"XEDBW'B,L>_/%5M=_:'^)'A
MK6/V@O!GBS6](UP^%_"<;:;=Z;8?93)>786"+<H9B/GG7('2O;/BO^REIVO>
M%_B-!X>T^PGUGQI<17U^-?FE:U>:,!5*^40\1 &05S@XS7 _!7]AR^TSQ)XJ
MU[Q\UN[:Y_9X&FZ;J,UU_P >LB2AY[B4!I2TD:$C&,#%%A'@OAWQ'KGP2_;8
MU_X?Z#=_V7#>:;X9\.2ZW=Q^?;:>D5O$#N7H9)FC\I"3C=)DUZ3\1_VK/BS_
M &=\:O$'AO5?#FBZ+\/M2CTB+2K^P,UU>$NJM,S[QM)W?*N"#SZ5]'>,?V2/
M _C3Q/XO\17UIJ UGQ0MF+ZYM[UHRC6DB2V[Q8'R,KQH<]^1WKP3XV?L,>+?
MB3XW\73Z?%X:LM-\3S6[7&I_;KR.9/+93YTUJ,Q3S8# -E0"2<4>0]#T71KZ
MZT7]MSPI-'+F/QAX%EDOX4^[YMM*C))CMD2$?@*^KZ\'\,_!+68/VC&\?:G+
M!_96F>'$T'1K>*4M("SAYY9!C )VHHP3TS7NZ\*,TK6%N+1110 4444 %%%%
M !1110 4444 %%%% !12 @TM !12%@*3S%_O"@!U%%% !1110 4444 %(QVJ
M3Z4M1S\1-QGCI0!Y1^TG\<9/@3\++[Q/::8-=U5KJVT_3=)\SRS>7<\JQQQ;
ML'&<D_137ENI?MHSG]E*T^+>C^'H-0U5[R#3KC0);HQ^1=/<"!XC)@_=8CG'
M0BJO[6OP_P#B/\7/B#\,O#_@AH-%L]&OI/$USK^I6S7%DEU;J%M86C!RQW.[
M8Z?**^=-3^ 'QC^'WPW^*W@"ZT27QFEYKNE^*M,O-$@\FWN93=H]U B,?D(V
MAL=.30!]*^"?VO\ Q!:^*M7\.?%7P&WP]U2TT:?7K9X;Y;Z"[M8L>;M=0,.N
M>A]:P_#G[9/Q6UZWTOQ);? C4+GX?:I.JVNI6^I1R7S0.<).;8#(4]<9Z5S+
M?##XA?M4>.+W7O%_@NY^&>AV/A2]T"PAO[I)KJYN+DC<[",C:B;!UZY->6>)
MOAE^T7XDT#P?X"L/#?B'PEK/A>R32EU_0]?B@T2[MPXVW$B8+L^T8(!S0.Q]
M1_$3]M&Q\(?'[P7\*;#1YM2UC6K^"SU&YD!CAT\2IO0;L?.Y4AMHZ \FI?%?
M[8>GZ/\ M*>$_A!INES:EJ6IW36VI7[!DAL3Y/G*BMC]Y(5*D@< ,.<USOQ\
M^%.MZK\7?V>=7TC09;T:+X@CNM=O[>,'8!"B>9(W4_=/)K1^.?PRU36?VF_@
M'X@T/0WGL-)U+4;W6K^VC"K&7MXTC:4]R=H'X4"9'=_MDZK>?&6_\%>&O"MA
MK-CI.LQ:+J-U-K,=M=M(PS(]O;L/WJ1@_-R#D$ 5[5\3_BC_ ,*]TS2I5MQ>
MWFJ:K:Z39V^=HDDFD"Y)[!5W-_P''>OA+Q_^R?XSB^-'C1M)\'R7&K>(O&MG
MXFT;QU'-&$TNU#A[B)\L&#?> 7'S<5]4_M/Z=*^I_";4ER;+3O&MC+=K@])
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M\0^#-!F\3^"_ $FEVR^!3\1=6@&B",?8V\NP\Z&$IC 42LY"=,_6OH1OV>?
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M@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $5R"8SCTKP;QC^S5X<\7_$/6?%NL6&G:Q?7EM;QVD&JV
M,=REK/$LB+("PRRE7Y0_+D XS7OK?=-9NJQC:#[YH"]CXG^&?[8_@_X(Z%I?
MPQTGPCX\\80:#.^D-X@T_12UE/*)F$K(P. BNS# X4+@<"OMR>[5+42-&W&.
M,=S7Y1:?>>.;#X@Z[YFH?'?14N?%%W<"R\*:*4T5D>Z.&'S#Y67ECCNQ[U^J
MLD'FV!C<,=R$'MR??UI@8&E_%+PSJ]UX@M+#58+RXT$@:G%;MO-HQ3?M?'\6
M.<=:Y+PQ^U#\-?&OBBQ\-Z1X@^U:U?JYMK-[6:,RA%+,060#  ->;_LV^#-)
M\$?&[XWZ'H5@FGZ5;WVEB"*/=@L;-"S;CRQ+DEFZY)J[\(-._P"$V^(GQ'^(
MMZ6=DNI_#^B2%=WV:TM_ED:,>LDH8GN=H%%F&AZ7X*^/7@GXBZM?:7X?U9-1
MN;)7:58X) H5&V.0[*%(!XX/K1X#^/?@+XE>(+S1O#'B.RUG4;2-II((&.2@
M;8SJ2 '4-\I*Y&:^6/@[?ZMIW]H^"_!WCZ[^(OAZ3PIJ:SI-9"!M)OMK"%0=
MH*&1G8>6V6R,]JZKX1^)O"_C#Q7\"M.\)213WOAK0KV+6([:$JVFQM911&*<
M8&PM<* %/)*$]LT)V ]0SG]N:QQQ_P 6YG_].:5] 5\C_#/Q3XL\3?ML._BO
MPBOA&:#P'/%:1C48[S[5#_:2'S<I]SGC:>:^MZ0"T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6[U[PU?1:G<VX^?4HA9P7!FE8<NRS@?,>?G(H&SU&>-4_;EL !@?\*ZGZ?\
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M6M1U72)/#^IW7C^_EN=+FF29[5S;VN8RZ?*Q'J..:^DU^Z*"1:***!A1110
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M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>_22.V>X,D\CC]ZLF#\ZXY(K[FUJPAU.![>YC$MO(A62-_NNIX*D=P0:\?\
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M7T IR!4@+1110 444UF"#)H =13=XQGM2ALTK@+130^6QBG4P"BBB@ HHHH
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M?P3X*\.+JMKJMIK;//'$L%E<*[88X+<'H!R:] T3XM>%=<M8)[7Q)I4B3+N
M^W1!ORW5\[_&']@W0_%VL6=QX,BT?P5;1PM'+;6=A@2N6R&.".W%=;\-?V)?
MAEX5\(V%EXI\&>&_%&M1%O/UBYTU1).2Q(SGG@$#\*JFZG/:6Q-.6)=:4:D5
MRI*S\SW;_A+M*D4@:I8A>H/VJ/\ ^*KF=3^-?AG0O%&DZ'<ZO9BZU21HK;;.
MC*65=QR0<#BO$/BO^Q9X(\1>+/A_=>'O!_AG3=(TK6!=ZU;&U$8OK7RV7R<
M$-\Q!P<#BN,^('_!/VS\1>+;N[\-7.B^&M'DV>5HUMIA$0"XR& /S%CG/M5S
ME*,;I&U:=6$4Z<>9W[GV</&6CGC^U].SZ?:X_P#XJG'QCHH/_(7T_P#&[C_^
M*KR#2/V.O@T+:-;WX5>$Y)MH#-_928+8Y//OFM%OV-?@:>3\*/"0'?.E1_X5
MHCHO='H]YXST5(6<:QI^%&?^/N/_ .*KG/"GQI\+^*KS5[2QUBS,FFW'V:??
M.BX?:#P2>1SU%><^,/V-?A#?:#?6VB_#CP?I]_)$R0WG]EH?(<CAB!Z5X_\
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MB'266\#+"AN5S\ISNCE!4'/H:7]E7XEW_P /8M<6QCN9(;B=9Y?L5BMR@8(
M PW!A_P&O;_C-^P5HVHZ1:K\/;=].U"*XW2'6-7O+F,ICHHE=P#GOCIWKC-#
M_8-N%^&7CU-<2*^\8W%G<#0)M/U2>WCAG\AA%O(95/[S!RP( ZT.C-2]UD2P
M&(_M2-:#?*HVNWU]#UC0_P!L*+9:QW\FE([L5<78FL91[!74C\R!7>:3^TUH
M>H@9LYSEL&2RECNTC]V,;' KSSP/^P;\*H?">B?V[X=NY/$"V-N-0F36KL[K
M@1J)"")<$;]V".#VKH#^PA\'X)!+%X=O%DXPZZO=;A^._-=*C6WO<^C4<1'2
MZ9YCK_\ P4+FTSQ;>:;;^&$N+&WNO(6Z:X*EDW ;B"./H:^E[;XZ>#+FSBD?
MQ'ID3LH8JUTF0?3K7QIX@_8#\:GQA>3:3>Z8/#[W),<=Q=3-.(=W()())QGG
M.:^@8?V)/A)%;(L^CZHTZKAV&O7P&<=<"7BIIJLV[GGX&6.E.HL3:U]/0[;Q
MA^T;X0\.^%M0U"SUO3+VZMH7EBMDNTS*R@D*,'O7CWP?_;I?XC>-;30M3\.I
MHL%Q$\B7ANMXRHS@Y%<Y'^P_I$OBGXFF2SN8]&G@L!X5-QKUS(L,@@D%RTB>
M83@R[.'SGMQ5WX0?L,0>&?$=EJWB:_MM>AAA97L-CB,N1Z@C('/%*;K*6FQK
MB/KWUBFJ-N3[1]1-\4/"UM.D4WB/2HIF7=Y;WD8./IFM?3_%-CJ\0>QNH+J/
MIYD3[E_,5YMJ/[*_PIU2VE27P#HJR3(5::&WV2 'KA@<@^]<RG[%/PITX>7'
MI.J6L(!PJ:_>HOY"45LG,]3WK]#M/B#^T!X*^%^M0:=X@UJ"PO9XO.2*4G)3
M.,]/6NP\$^-].\=:!9:UHUTE_IEXI>&XC!PZ@D9'X@C\*^*?CG^Q#?7/B;3;
MGX=0Q#3/+6"Z@U75)I7!:0YD#2LQVJI&0#VX!->B?##]A+P19^#=*MO&.GW]
M_P")$B/VRYL-<OH+=VW$@HJ2JH&TKP .0:(RFY--:'!1J8F6)G"I%*"V?<^M
M?-Q1Y@/_ .JOGT?L*_"!_P#F"ZR,>OB74?\ X_0?V$O@^ 2=&U?_ ,*74?\
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M OA?X]\9>%++3O"'CR].GPW6DWLDLUA=>8ZHLJ.HW(X1OF4DC!R*^FI/V@_
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M2+!*WV:.,DQ[FWC>6&,X'!/%=BW[1GAGP+JD'AGQKJL=AXLMK"&^OH;>WE:
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M5\N^*&00L=O!*@D>N*T6_:J^&B^&+77AX@5K&ZO9M.A58)#,]Q#GS8Q'C=E
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M1110 4444 %-90W6G44 ,\I?04UK=&&,#'TJ6D)_.@"!;*-3G:":>+:-3D*
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M;B>G3UHX/'7\* $!+]BHI0N*"X'4T!U/>@!U%-#ANAIU !1110 44F:"0.M
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MG?7Y(@^FZ=XMFM;MG'*-<6CI$Q_X$N/J17B^E?LP>/9]=T/P!=^'7@\*Z/\
M%&Y\>_\ "5)<QM!+:%&:*$1YW^;YC[3QC"GGF@#ZP^+GQ \=^';GP_IO@?P2
MGB:[U&X:&XO+B[$%GIT:C.^5N6Y/0 =C4'[./QZD^./@"ZUV?3$TO4-/U*ZT
M>\MHI_-B\^"38[1OCYD/4&O%?VGM=^//CCP5/H7@/X?ZGH-W>:Q<V=YJL%S
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M6BHOM$?][!]#2^>G'S=: )**A:ZB4@%P">@J0.",@YH =13"V1\O- 0]V)H
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MM[.]5WAB'!=L?PCN1P*J>&/VG?AKXR\0VNA:'XYT/5M7N7>.*RM+M7E=D&6
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M@ZC*+35+5K:ZBS;VGRR1-\R-QT//2OHY?NCZ5("T444 %%%% !1110 4444
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MFZ7RA\K.1\NXYP.E-B/=_%OQ.\'?#^.V/BKQ-HOAJ*Z8B!]7U"*T$A7J%,C
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M3XF,W[,WAV62%H)'OM28Q28+QDWDF5."1D=#@XXKZ9I %%%% !1110 4444
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M9M4MM/M4MX/O-W9V(Y9F/+$^IK>B@6($ 4K2*A SUZ4>>F2":/43=R2BD!!
M(.0:6F(**** "BBB@ HHHH BN?\ 4OGIBOB#]L+QAK?A_P")^DIKNH>/M*^&
MTNE%HKCP#;&21M1$O*W#)\RKY>"O8DU]O74GEQ,Q.T <DU\#_MH_&O6/!7QL
MT3PY_P +?N/A1X>GT5KU9]*T9M4GFN?.*%943E$VX*D\$@CM0![M^QUK/BGQ
M%\*&O_%1UN4/JMTNCS^(X1%J4NFA@+=[E,\.1NZ]1@U]"R_ZL\XKYX_8S\6+
MXO\ A9<WW_"RKWXJ*FI31?V[?Z2^FR+@+^Z\IN2%Z[O>OH=AOC/N* /D[]J_
MX>>/_B-X]\.)X>TR\U#PUI^G327*V7B9M%:2X9P%4NFYVP@.!MP2>HKD].UN
M+XTZC\(O ]KJGB30/!NI:#>ZC<I'J;)J,LMNPC$$MR#N;#;B2#S@5[E\8_V=
M[/XG^)+77;?Q/XB\'ZW!:&QDOO#MVL+7%L6W-%(KJRD=<'@C/!%9WB;]E[P]
MKOA/PGI>CZQK/A"Z\+H8])UC1+A4O+="-K@LZLK;@3G<#DG-,+WT/"/!$VM?
M&#Q!X2^&6O>*M=CT6VAUN>XU"PO6M[O4/LEZL$"/.G)PKY..6*\UZ=\*OVAK
M3X<?!"PU#QM>ZSJ:VVO7^@PWUKITVH7%PL$T@1Y! C'[B8+D8+#WK=OOV1_#
MG_"(>%M(T+6M>\+:CX:,K:?XATB[6._'G9\\NSJRR>:22VY>IR,8%>L_"WX<
MZ/\ "OP/I/AG0EF33;%"J--)OED9F+.[M_$S,6)/<F@+'BW_  3UOA??LR^'
M)HL^3->ZE*N]2K$&[D(X(R.O0\U]-U\X?L +N_9HT0GD_P!HZGS_ -OLM?1U
M)[@+1110 444TL ,DTK@.HIAE4=Z=UI@+1132X'4T .HIN]2<9%!< ]Z '44
MP2J>].# ]Z %HI <TM*X!12;A0"&&13 6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 0]*^*_P#@HQ9)Y7P^U-M7\&:7+IFJ27,:>-?,-K<CR\&,
M*BMNSG)SCIQ7V?<2&),@9^@R:^;/V@?$MSXXB^Q>"_A_X:^+>I:/?26FI6.K
M7"(-,?:"/O _,?04#1Y_^PEXS/BKQ?XEB!^%++!9Q-_Q;RWFBGY?_EOYBC*^
MF.]?;'05\@?LA?"SQCX9^+'C?Q9XB\!:'\.;#6+&UMX-&T6995:6,G=*2 -N
M0<8^E?7^>*!'G/Q8\4^+M%L+"W\&>'K37-5O+L6[2:C=&WM+.((S--*R@L1\
MH4*H)+,,X'->.^+OVF/$G@SX56>K:AIGARP\6/XD/AN=+G4W72H70,\DQG*A
MM@0#MG/%=M^U!KOC[1/"%I!\/=%O=4U/4+T6UW=6$<;W%A:E&,DT2NP5I#@*
MI8X4MD@XKR^#PQJ&F_!SPE%I_P &)M<MM+U::2\T#Q-/'-J6U@V;Q')*22,[
MDD-U!/3%-#.GO?VB?$>F_"C0M;AL?#GBCQ+XAU==*TB+P[J,DNG2LX)#/,5W
M *$8M@<8%=K\%OBIK?CB[\3:#XITBTT3Q3X<O([6_M]/NFN+9TEB$L4J,P!P
MRGH1VKP*R^"WCK1_!T_BG1_",&CZI%XX7Q59>#(YD BM!;B!X0P^1)'^:3 X
M!->C?#/P+XB\1)\5O$_B*VU/X<WOC*: 0BVND^VV%M;VPACDWX*K(?F/?%(1
MT?[*S ZO\;\<_P#%QM2_])[2O>8^4%?+7[%5SIWABV^*.A'Q-+K]TGCF_P#+
MOM2NDDN[U/L]M^]8KC<3@\@8^6OH_4->M-)MFEN[N"TC ^_/($'YDTG=.U@2
M-252<8-4KJ\$<I3/.*\[O_C_ .%UE,&FW=QKMSR%AT>V>Y)8=0& VY^I%?*G
M[>7Q$\0ZAX#T"9] UOPOMU',%]_:*PR'*'AXHR3M(]2,&NG#T)8FK&DM+BF^
M1.3/O&"\$C*N#TY-3R3 ';G'<5^<?[(7QJUG1? %_81:VDNI37K-$MXDE]=3
M9 ^8%Y%2-![D=^M?1&AR?%KQA.IO?'^B^&[7J/L=G!/=D9'&T.R*?Q-.MA)4
M*LJ<I;#B^9<R)_CY^VMX<^ 7C>#PUJV@:SJ=U+9K>B;3Q%Y81F90/G<'.4/Y
MUVG@_P#:<\#^)O"^CZY/K%IHJZG )HK*_N$%PN>S*I//TKXF_;.\'^$-$\>:
M!:>)_&GBG5_$%RT=S<W5S9)-%_9Y9E=+?RE55=64';R/F.:^J_A1X"N4\':%
M?^$_$$<6D7%NDL%OK7AZW,WE8PH)0H0>.IR>:Z*M"A##4YQOS/>^Q*;<FGL>
M@_\ "_/"]Q<F"Q?4M2E SBSTRX=3]&*!3^=)<?%"\U6QD&F>#/$<Q92/,F@2
MUQVR#(XJ!YOB/96Q\FQ\.:J@/RPI++:''OD,,_2JEW\1O%&G6TZ7WP_U2)47
M<)[&>&Y1CC^%00Q_(5Y_(NGYEMJQ\N_#&Z^..I?'C4]%EUC4)[+P^PN;M-9F
MV6SJZDPQ%HU._((SM/\ #7U>OA[XBZT@%QXMTO2(F4!AI.EF61#ZK),Y!'U2
MOE3X9?MA_$/7_C*WA?5_"5E:V]I._P#:[6UG*US%$H.WY03AC\@&?6OJRV^-
M-@D0\O0_$5PX&"D.ER?UKT,=&K&I'FBEHMC.E)23:(-3^!-OK=K)%X@\3>(-
M?AF79-;SW@A@D!&#F*)5'?I7/_LY_LQ:1^S[H^K6MC?-J%U?7C3M=R1!66(<
M1Q=\A1W[GFG_ !-^-VN'P1K!\)>%O$47B,0,UDU[HS-")!S\XWCC ->(_LK_
M +3?Q7^*,^LW_B#0SK6CVH%M"NE6(A87.<L&=WQP.,>IK&%.O.C-I^[I=7+;
M5TF?<,2A449Z"AY-IP:\KM_B!X\O$\NV^'=U:N =KZCJ<"HWIRA8C\J?%K/Q
M1U$?/X>\.:8Q)P6U.6X&/?;&M<CBRK'::IXJT[2KCRKR[M[5F&[]]*J9'3/)
MZ=JJWOCG2--TS^T;C4;."R'_ "\/.H0_1LX-?'7[8G[/?Q'^+-AI&NI'H]]K
M6F2_91::,)E+02,,LQD./D;!X]37N_P5_9K\.?#;PWH]G=K)KEU8VZ(D^I/Y
MJ1OC+>6A^5 6)/3-;SI4HT8U.>\GTL3=WM8VS\3M7\5/CP?X=FOK9SM&JZFW
MV:T'NH(\QQ]  ?6O(O'?[&3?$[XO^%O&NOZ]#>O:SI)JUE%9B**YCB^:*-!D
MD#=C)8DD>E?4ZV]O"K%548[ 8%?'?QO_ &Z]7^#?Q7U7P>WP_;5FMWB-I=)J
M83[4K@%2$\LD')(Q[5>%=>4_]G6MG]P2Y;>\?8]G9"W/&%![#\_\:M/,L*'&
M6P,X%>16?Q1\2^)+>$>'O"5[,\BJ3=ZJ_P!EM4RH)/(+OUP,*,D=JLR>%/'7
MB2,IKGBY=+MW WVWART\IC_VWD+./P /O7&TXO4JUS;^)OQ 7P9X.U/48I]/
M@U&"V>2UAU*?RHY9 ,JI(YP>G [U\^?LI_M7>./V@_&VJV%_X4TO3-(TRWW7
M=W:S3,ZS,V$C ;CG#'Z#WKW70?@QX6\/7"72Z?\ ;[_.?MVJ2-<SDD8W;GSS
M],5J^"_AOX;\#WFLW&CV$=C/K%T+N\,1XDE"[<^W Z?6NF-2E&E*,HW;V?85
MM59G9VQ+0J2-N1T]*FID> HQTI]<Z$%%%%, HHHH **** (;LXA;@GV%?GW^
MV-XA3X>_M$:?KUC\1?#?A#4W\/)9-::WX?FU'SHC.SA\H"%P>!W'/K7W_J4X
MMK621R%C12S,>P'-?*WCCQ5X_P#BT]GX@^$7ASP)XS\*W$+PMJ7B+S$F\^*5
MXY$4;?NJ5(^N:8'2_L8^/9_B#\*[G4IO$^C>,7_M2:'^T-$TIM.@^4+\OE,,
M[ADY;Z5]%L<1D^@S7A'[*?PO\1?"_P #:Q;>+(=)LM7U;7[O6'T_0E(M+19R
MI$4><<#:3CU->ZS ^5@'!I >,_&C7?B?:ZFJ>"X?#FEZ-;V37=YK7B+S)4=E
M)/D+'&RE>!DR$X&>E>/>._VN=9TWX8_"K7+:;1/!>I^+T>>ZF\06\UU:6D4<
M3.WR1,LC;F"A<?WAFN@_:HT7XJ>-/$FFZ%X>\'OXB^'[6PDU6&UUF+3YKZ3=
M_P >[NP)$6 -P49;.,BM?Q';_$:'1_!NNZ/\-/#]Y>V=NT5WX6NKF(3V9(VK
M]GNRI0!0 "H7D4 9H^-7CSQ%)X'\+^#]5\'Z[XK\06%SJMSXA6"<:5%:0NJ;
MDA#F1F9G5,%QMY)Z8KT_X!_%BZ^)_P .K/6M4T^/2]5CNKC3]0LH)3(D5S#,
MT4FPGDJ2N1GL:\%\._!7XC_" >#/&7A[0=,U[Q+:+J=OJ?AQ+S[- L5Y<"<+
M;RD%?W3JN<CY@#BNS\(?LPVGB/X/Z-X:\>7=_;ZI_:=SKMX_A[4I;$+=7$DC
M.@=""\:^9MP>NT&D/T+W[ 3D_LUZ(!_T$=3^O_'[+7TB.IKYA_X)]QIIW[,G
MARU1V\N&]U&)=[;FP+N0#)/).._>OH]M0C@5B\B@#DLQQBBZ$7R<5').$&1S
M7G7C+X\>"?!(*ZMXITVUEV[Q")@\A7U"+DFOC[]I_P#;JUJQFT73?AK?-:PR
M&62[U2ZLL,^" B1!QR.22V/05V8?"5L345.G'5DRDH1<F]C]"$DW*#C%17#!
M$)KX/\$_MZ^+9_!>CO?^&]*O+XVP6>]DU<1-*X)4OY"H2N<9QFMFY_;.\7W>
M0;;P_:QL.!#'=3NO'?*[3^%.6"K*3B[77F4FFKGUQ>^-=%TS4X=,N]3L[;4)
M?]7:S3JLK_1<Y-;L%VDD2$GDC/%?B1\5_'>O>*_BCJWB._OW;54N0\-Q$&B\
MG9C;Y8/*CCI7W1X+_:"M-;L;47_Q,\2Z9,EO&TQATJRD1&*CC<(V.?PS7=BL
MIJ82G"I>_,C&G6C5E**Z'VH+A2< @'WK/U74XM.B>:9T2)5+,[' 50,DD]@*
M\.\/:GH/B:3RH_C)JM[)@'RFGMK5QZ9 C4_A6EXG^ \'B?1;RU?QWXM=+J%X
M]XU@^7RI!)"C!7!Y'>O'<4G[SM\C>QM?#C]H?P#\6=9O=.\*>(K75[ZR&ZXA
MCWHRKG&X!E&X9'45W-[XPT?2W"W>IV-L2.D]TB'\B<U\)?LL?L<:;8?$/4M0
MU[Q1HWB2RL5DM5L-$NWW9)ZS,I!7 'W1WK[-L?@MX"M60IX5TJ0Q_P"K>> 3
M./\ @3Y-=&*I4:55PIR<D3%MJ[1YM\<_VOO"/PC\,W=[97=IXEU97$4.F65V
MNXL>C.1G:HXS^E8/[.?[;_AWXLZ/=IXH-CX.URSE$;V\EYN@G##*M$[ $^A!
MY_"O8_'/P8\'>/\ PQ=Z!JVCVSZ9<+M:.*-8ROHRD#*D=C69\*/V>?!GPDT2
M71]"TF+['._G3/>8GEE?IEF8<X' %">&^KN+3]I?1^0-RY[K8[?3?&VA:LJF
MTUBQN-WW1%=(Q/X9K1-XLB+CHW?-<U>_!GP/J$C23^%=*,K<&5+94<_\"7!_
M6N6N?V>/"UK"XTJ76]!=C_K-(U6>)AS[LU<BY>Y9V'B/XB>'?!TEI%K6LV.E
M27C^7;K>7*QM,_\ =4$\FNEL+A+JU25"&5AD%3D5^>7[5/['OQ(\<>/+*_T*
M^O/%NFR1+ AU6]4R6![G) R#UR.>*^FO I^)GPP\&Z-HE[I=AXMATZTC@:YT
M^Z:&Y<J ,[)1M;OD[A774H4X4H3A43;W78A.[:L>]YHW5Y78?'31!=+9:V;O
MPU=MP(M8MS "Q.  _*'\ZS-0_:B^'NF^/XO!\GBFT;6I2JK&IW1AST0N/ER?
M3-<\85)Z1C<&TCVBBJ<-TKA<N.?>IVFV@]#CT-1<9+159K@KSC\*2.Y9F (&
M#1>P%JBD!SFEI@%%%% !1110 4444 %%%% %2^8[ !QG()[BOA3PG^SK\4?$
M/QM^-6K:/X^UKX9Z7J'B,W%M%;6<<B7Z;!B8%P>.W%?>;1A\;AFF"U0'//YT
M >/_  1^#OCGX<:QJ%UXK^)^I>/K>XA6.&"_M8XA;L#DL-@&<CBO91THI: &
M&)3G(ZTAB7^[Q4E(>E '(?$7XE>'?A3X>N-<\27RZ;ID!56E<$Y9CA54#EB3
MT KCU^(?A_\ :%^$OB8>#]1^U1W5M<Z:7EB9&AG\L@JZ'# C<#@^M<7^V3=6
M&D+\,=6UA5_L&Q\7VDM_+,?W4"F.54DDSP%#E>3P"17-?#[7=5U7Q#^T/XC^
M'!TO7VEN[%-%5IA]AN;Z*R59P9%."-Y&6!ZCK33L[B/S^^%$'B;P1\0'N-*T
MC6;G4M$EDM;K^R;=Y)H'P8V!VD;2<'G.:]XT[Q7J^IW#-K%OJ6F*2H-UJ7AR
M?4[C:/4MD!AV)S6Q\"=9_:BM-9^)UUX8\ ^"+V^N?%=R-:EN=1*-'>+%#NA0
MB09C564J?5FYKU8>,/VTU.W_ (5Q\.L8Q\VKG)_\B5[.(S%8F7-*FMDB:</9
MJR9B:)\2_AWH^GI_PEGQI\8LJMDPK:/I*?[I6&$?S%>7?M.^/_@P? \-K\/8
M-/\ $VIWTC175]>7-U)=VBE<B9&D;[VX>E>US>+/VS9AB3X:?#EQ_P!A3(_(
MR5R/Q#\)?M1_%3P]?Z)XB^%/PW6QO83!)/#J 6>(9R&C</E6'8URT,3&G7C4
MFG9>?_ "47./+<I_LV?'SX0-\.8K#Q]I7A3P_/:.+6"![(RM/$H_UCE@Q))K
MV.W^)?[.=W%_H46CLC#@66FR(3G_ '5%>->*K[XS?!'P)'JFH_!_X:6VC:<;
M6Q60%)YF:61((\DL2<NZY)]2:Z&.V_:F2=_)^"WPHX)7F>/<,<'.&J*U6C4J
M.<4U?S_X!23@K'B'[5_C_P &3^,=(A\*:/;+I4$2W'GD3)+.V6$D3%V^YPAX
MQS7N_P -/CGX$F\"Z0^K>(_%'A+6!:KY]OITEP]O&W81JX=<  5YY\2/@O\
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M->O0I4)8&K4DESIJVIA*4_:)+8_56*3>N<$5(#Q7SE;#]J!HLB?X6 >ZW_\
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M_!_B77/"%]X53POX>?2Y?MS*1/>2;%?RMI.Z-0F0_?-?3ME$/L\3'J5!P>U
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M5+>%Y;I$.52221Y64$<<;\?A7L%("M<6Z".1@H#8.&[UX!X>^-H\8?M :_\
M#;_A'KF/1K719+S^T]1B*1WSK,(9$BC<8:)2=I<C#$'&17T-,,Q,/8UX-+X/
MU<?M:P^)%TR<Z O@QM.:].-@N/MGF>7ZYV\^E%["W.7\+?';Q3XI^*6K^'="
MM?!L'AW2=;ETCR[O5FAU*2.':)'BMP,$ Y  X^6OIRW421YP,$>E?$?C'X=:
MWXL\76VD6'P;A\.ZO%XLCU9O&]NT @-ND_F&X5P?-,DB94ICJ3VK[?@)*DD8
MYZ4/48&!2N,8'M7FOQ>\0>+/#NFVP\%Z!%X@UJ[O8K9(+NX^SVUM$0S//+(
M2$4+C@$DL!7IQKQ']ISQ-XXT#P?$G@#1;[5-9O;^&TEN+&-)9+"V.3+<*CL
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M** "BBB@ HHHH **:6 ]_I0#D<C% "%P1\OS'VIKP^<A5^AZ@5(JA1@# I:
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M6WR=/GN46:3=G;A2>^#CUP<5\%^+?B;<>!OVE/ /QNN%OX/"GBJ6X\-ZA+<
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MI%D98&,I8MN&5P50Y/K76?"S]ICQW=^//AM9WOBLZK;:CXLU[1+VUE2,;[6
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M'Q@M;6Z1D_B!T]JBU?P!I>JV5W"L*6<\ZR8N[:)%FBD=2IE5L<.,YS[5TU%
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C %5%& H] /2K-%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>adag-20221231x20f013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'N GP# 2(  A$! Q$!_\0
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MY'M70)J5NTA03)N R1GD"@1;I&8*,DX%5UOX6S^\7CKS2/=12K@,K@\<<YH
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MV*^\_@A^S#;?"_6?$>N:OJ">)_$&N3022WDEE';QP+$I6-(HU)"@ GFO6)O
MNE&._!TNS?[?C[7^['^D8X&_U_&J!>1^?OQ&\3:3J_Q1^*T/BKQ5K&CV.D:#
M;3>#HK6[DA1@\.6:, _O&)P#U[FH_A-J^H:CXA_9 OFO+JZU*[%^EY-,Q9Y(
MMC$[VZD9 ZU],?%']E[Q%X\UR6?3/'+:%H[6IM(]+;28+A;1"NUC;N2&4L.M
M:_PP_99TSX<^*?#.I1W\][9^&M'_ +,TVTF0?([-NDG)S]YNF*6A29[M:#G/
M/W0 #VJU4,,11RV3@@<>E34B0HHHH **** "BBB@ HHHH **** "LS7_ !%8
M>&-,N=1U.=;6QMHS+-._W8T'5B>PK3KSCX_Z5J.N_"KQ-IVCZ=#J^JW=A-#;
MV-P<1S,5Z$]* .>TC]L7X2ZYX6UGQ#:>*E?3=',7VS=9SK*GF'$1$13>X<_=
M*@Y[4^__ &O_ (3Z9X)T_P 6W'BE4T*_G>VMYUM)V=I$_P!8OEA"XVCELCCO
M7PW\/OA%XUT7=X@'@_Q'?:=HFH>';Z[75HH_[2N?LI83VT*@X:*(,&4=^U;L
M'PS\<>&;K3_'-QX%U2[TV^U/Q%(F@QQ(]S:I>Q;+=G3/ 8]?3- S[0U7]J[X
M7:+K.A:5=>)XUO-;BCGL56WE99(Y#B-RX3:BL> 6(YKU&VU.&[0/%N922N<=
MQUK\Q+7X%?$#PQHTWAVX\(ZCJM]XCT72;*WU"!59-.EBN?,DCD);Y=B\\5]*
M?M 77Q0^%_AV'Q=HGCY+/1X+K3[-M"DTF&3?ND2-B96RW.2:!VN?5T4RS*2O
M8X(/:I*J:;&T=JH;&<#..F<"K=!(4444 %%%% !1110 4444 (<YXI!DGD4Z
MB@!**6B@!.:.>]+10 4444 )]**6B@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ;)((D+-T R:\^^*/Q]\$?!FSL[CQ=K']F"\D,=M$D$D\LS 9.V.-
M68@#DG&!7?7(+0N!UQ7QQ^VWX&U_Q-K/@N[T_2-5N;*P:Y,^H>'%5]1@9XBB
M(F[^!B<-^%.PCVG6_P!KSX2^'9/#ZW_B^WB&O0)<V#I!-(DD3ML1V94(0%N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLY_%708K+QI8Z'I]YXPN]0UJXOM#.H*D4$=]'L3;,1ABF 3ZU]]?V7&@8)E
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M'P:\6W<D@3&G3*"3C!92 !^)%.FN:I&/=CZ'@O["_AP:OJ/C3QW(/WNI:A+
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M\/DDZEJ#M*Q)/<1[>>OS5][V3 Y 7;C]:.@[]"W1112 **** "BBB@ HHHH
M**** "BBB@ HHHH 9, T; ]",=:^<OVS-$C\0?!B[MVUG2M&F2Z@EMY=;;;9
M2RHX(BF./N'H<\5]&S?ZMOI7DGQV\&:Y\0/ USHVA6^@7-W<,BN/$EJ;BV6/
M/S-L'#,.P-,9X=^R7\*?%+_%J^^(_B&+PAI%M)I7]F6NG>#Y$:*8%U;S9-@"
MD\''&>17V7Y*,I!48/-?,O[,/[(UK^S]K=YJZ>)K_4+V^5DFL(D6VTV,L03Y
M5NO Z<$U].+]T4A$:VL2]$4'UQ3C A(.T9%244 1B!%.0H!KPJ(8_;(N /\
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M*>&O"<8_?6=J)+EN<>=(=[_J<?A03IN>R4444AA1110 4444 %%%% !1110
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M0!\^2?MY?#".ZCMGD\0)<2 E(6T28.V.N%QD_A4I_;E^'&=OD^)F/_8 G/\
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M23);RSR=O  ZX]Z=AWL>:_LNZEXHUGX*^$[SQA9FV\020'SXQ$L9V[B$;8H
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MQQS].M6*CBC,8&2"?6I* "DQ2T4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 F*6BB@!"HSG%5#9?,<8 SFKE% #6!VX%0&W+$9P1Q5FB@!JJ
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MZTWPG\4_!GCKQ!+JOC30],_M6TU":0&412VQ;"X^7Y6_E0/2US[J_M&/J77
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M]*B^W+@9[CMW/-?+OC;]OGPOX7C\2WT>@ZOJ7A_P_="PNM:M;<FW-SD!HQ[
M\;NE>0_M4?'3Q?IFM^/+[PUXAN]#TK0]*T4*L"X"S7-P&DW9Z$1E?S- TC]
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M88*"9RRC'^Z17T34%K9Q6<>R(%5],\?EV_"IZ!!1110 4444 %%%% !1110
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M-$P!5U]B#6M7EW[+RX_9U^&I[GP[8Y_[\K7J- @HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@.?VQ;K_ +$__P!NHZ]J@U.SNV=(KF&1XCAU20,4^N#Q^->*0G/[8MQCD?\
M"'GG_MZCI=4#V/=UI::M.H&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MBN)^,_'PG\9G_J#7?_HEJ[>N(^-1S\)?&8'_ $!KO_T2U &-^R]_R;G\-/\
ML7K'_P!$K7J%>7_LO?\ )N?PT_[%ZQ_]$K7J% !1110 4444 %%%% !1110
M4444 %%%% !1110 4TL!C/>E9@HYJ*:Y6)D!YW'% #WE5" 2!]:2*82DX/3K
MQ7E'QC^+"^$X[33-*A;5?$.HMY5EI\1Y=L?>8_PH.YK7^#.G:YI^ASGQ%J9U
M/59Y#-(VT*L0/1$ _A'8UGSIRY49>T3ER(]$HHHK0U"BBB@ HHHH **** "B
MBB@ HHHH CG!,38.TX//I7A'[5>KQZ5\(=4F;5=%TRW;:DW_  D5L9[2XC)^
M:)D'/S#C*\CM7N\P+1L!U(KR;X[_ !$\)?##P:NM>-(T.B17D,;221ATA=F
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MPTT<0(_=Q'E5P.F,]*\5^ OPNMO'FM)XIU"9[G2X'+6\ET0TVH3 D&=O1!_
MO8<U]@:3&(-\8"@8!&P8&*PP49M>TD]#+!PK-N=26G1?JS1HHHKUCU@HHHH
M**** "BBB@ HHHH **** &2\1M]*^<_VS]=;0/@CJ-Y]DL9V\Z*%[G4(#/;V
M(+8-P\8!W!.I%?1K_=-?/?[9'C?4/ 'P5U75--O]/T>8R10R7NIP"XAAC=PK
M,8\'>1UVXI@>#_L6>(+5/C9J&B:?K/ASQSIZZ3]M;Q)X?TG["+>0N@-N_ W9
MSFOLSQM\6O"7PUM(KGQ-KMIHUO*VR-KIR"Y]@ 2:^1/V+/&RZU\0;[3X_B]X
M6\:VW]GO,VD:%X=_LZ2-]R_.S;%S@=O>NU_;&\81>%+'1OL7A'_A(/%%Z\EM
M8ZG)I\ES;Z5'(NV2=U"MG:"2 !2LD5NSW75OC]X T.71([_Q5IML^MQK+IRM
M-G[2C'"LI'8G@$\5<'QF\&GQBWA0>(;'_A(EC,K:;YG[T #)XZ9QSC-?G9K?
MP\_X1'P\= LM UCQ?#JOAC3=/\.:HFF2?ZV.X8R$AAF AFWX.!@5O-\/?%2_
M$.X\-'0-3'B__A*)=4_M_P"QL8?LGV/9N,V,;2?E"YZ]J!'WKX1^,O@[Q]JF
MH:=X?\0V.JWNGD+=0VTFXQ9]?7\*\ZM95E_;&N"/^A0_]NDKYH_9=\$>*I?%
M/@Q-&T*Y\-:IX<\,:AI^L76HV+Q1&]EG=H Q('F\8;(SP<5ZG\#=#^).A?M7
M:K%\2=>TG7]0?PMOMIM(MC B1_:4X(/4TNJ$UH?7R]_K3J:O?ZTZF 4444 %
M%%% !1110 4444 %%%% !1110 F<5$TZDE>?0Y'%2.?E)XZ=ZQM2U&"SMI)'
M<K"%)>0=% ')- )7=C@/C'\6XOAEI,4EO9/JNHW,X@MK.%OF<GO^%;GPT^(F
MF>.] AU6QDVB0!9H&/S0RC[R,#T(KR;X=V/_  M3XD:GXWNB)=*L-^GZ1">!
MP?FF]#GH#3/&>@7OP3\8-XUT&T>Y\/WA']N:?%R8SG)N%';'?%<JG*_M&_=_
MK4^C>#P[@L(M*RUOT;_E_P"#W/I""]28X4Y/IBK*L&&:Y7PWXDL_$,%E?V-P
MES:3Q"6&2-@0RFNE1LMG^]77:ZNCYQWC)Q:U1-1112 **** "BBB@ HHHH *
M*** "BBB@!&[52U0_N"N 02!5UNE9'BG41H^A:A?LGF+:V\DYC_O[$9BOXXH
M _,[XY^(?$_PU^./Q,OM$U?5=.TZ_OUGGQX"_M&!&6%5W+.6PPXZBOT%^#]Y
M+K_PR\-7LMP;J2XL(I&G:W$'F94?,(Q]SZ"OC+4/'"_'#2O^$BC_ &EXO N@
M^(;<2-X6FN;42V,3+M>$YYSP?SK[:^$>C:;H/@#0-.T>_P#[4TNULHX;>]+A
MS,@& ^X<'- S>AT14W B-C@ _(!FG_V.&@6-]A /88X[?C[UJ!<,3V-+BC<D
MRH]&41A#M5!SM SS]2*YKXO6ZVGPB\: <C^Q[LC_ +\M7=UQ'QJ./A+XTX_Y
M@UW_ .BFHZ,>S,;]E[G]G/X:?]B]8_\ HE:]0KR_]E__ )-S^&G_ &+UC_Z)
M6O4* "BBB@ HHHH **** "BBB@ HHHH **** "H+J3RXP3GKVJ>J>J2^3:M)
MQA<L?P!I/S ^8OVXOB4F@?#B/1;>?R]2U.4)Y98?ZH'Y^_?@?C7SG\"OAUXM
M^*F@:A:Z1;Z:="M)EEGBOE=1>R9Y02!6(5<"LW]H#Q#>?&_XZ/I.D9N[>VF^
MQV/E_,#G!9AU]^?:OOSX.?#*S^&7@O3](LH\B.(%F<#+.>6)P.3DUXLJ:Q55
MWV/CJ,99EF$ZK?[N'N^KZGS!JMAK'@"9IK30?$/@F^&-]QI@-_IA]S&N"H_X
M"*^EOV?/%FI^+_"37>J7MCJ,R.8Q<Z<'6)@.Q5@"K>HKOFT^*8L#&@9O5 2*
ML:;I\=@'6...('DB-0H)]>*[Z5#V4M'H?2TJ'LY<REIV+U%%%=AV!1110 44
M44 %%%% !1110 4444 ,D.%)[5\T?MOV%WJ/P9G2RDO8+J*\@GB>QTDZE*KJ
MX9?W.?F'%?2TY*QDKC(Y&>E?-'[2/Q872]>L_!*^-!\-[S4K1KV+Q--+$B1[
M",Q?/P2<]/:F!X[^Q7\1_$GB;XR7^A:]KES=2Q:6TWV*Z\&KH[@;U 8N#DX)
MZ5]UR:8LS!G57QTW5\G_ +-7A/29OC!<>)[OXVP_%/Q-_9S6<<$5S#MA@WJQ
M.R,<G(Z^]?8*]*0[F4FC[5P%C'!Y5<8-":0 "6",<Y"] ?KQ6M28H$4+>S:W
MDW#;CH3W/Z5XO!_R>'<?]B?_ .W4=>[,/EKPF C_ (;'N!_U)Y_]*DH$>[+_
M %IU-6G4#"BBB@ HHHH **** "BBB@ HHHH 1CM'0GZ4WS,_PD?6AY G6J[7
MJL#M&<=33%>PKS8#@\=\UX=\>?$TUU!IO@W1Y636?$<WV=G49,-N>'<XZ#'>
MO5_$7B>S\/Z-<7MS<1P00QEWE<C  &<<UX[\#])N/&7B35/B+JH=;B^+6VFQ
M/C]U: C:0.V[DUS5I7M3CUW]#V,!35/FQ=1:0V\Y/9?+=GJW@_P;#X3T&QTV
MUV>7;0K%D# 8@=2.^?6M74M+2[LYH;B.&6%E*LC#A@>QS5I6=23DX]A3+BY&
MPYZ8[\8KH22C9'ERG*<^>6[UN>!>$+:]^!WQ#CT:2*>]\':Q*[V,B(6&GR\D
MQ?[K$\>E?0D-R-RJ5()R1GM62LUJDT<;F)&.0!(06S[9_I6E  MQ@+PO&3_C
M40CR72V.G$XAXAQJ35I6U\[=?N-!3E0?6EI!T%+5G&%%%% !1110 4444 %%
M%% !1110 5E^)-(_M_0]0TWSF@^UV\EN95&2H="N?PSFM2B@#YZ^'W[$'PK\
M'>#-&T.]\(:%KUUI]L()=1O=-C,MRW.7<XZG->ZZ'H=EX=TRWT_3[:*SLK=0
MD4$"!$C4=  .@K0HH ***0\"@!:XGXTC/PG\9C_J#7G_ *):L/XS?M">%?@>
M-/\ ^$@ENFEO0[QPV-LT[B-!EY&51\J*.K&G?$#Q;8>+/@;XBU;3I1/IVH>'
M[BXMIQTDC>!BI ]Q0[M: M]1/V7^/V=/AIZ?\([8_P#HE:]1KR3]F6^2/]GG
MX; D KX=L003C_EBM>E/JL2;OF7([;A2NNH:&@6 IOF+ZU36^CD7<<?F*C;4
M(@3PN,]=]%T+4T/-7UH\U/6J2WD+J&RH/?YJ8MY%YG5<9QD-FE="U-(,",T9
M%4A<0LH(E0?\#%5VU*(.5\]% ''S4<R&:N11N%9WVV'_ )^4_P"^A40U2(D$
M3)M)Q]\4<R"YK9%&X5FM?1)UN$^FX5&=4B0Y,RG';<*.9 :QJ/SAGIQ67+KM
MO%&S&>)?K(/\:S-1\>:+I<$DMYJEM!&@RV^50/YT<\5JQ.26[.G>;9SC@<DU
MXO\ M2_%@?#7X67]W RC4YW%K;QD\DMD$_@#FL3QW^V5X \+L]O:WKZQ<D85
M+*)G7/H6 P*^3/B[\4+[X]>.=&L=6M?^$>T>!FG!EDR63@EB#W[8'/-<%;%4
MU%J+U/$Q^94J5-PI23F]%ZL]._8<^$P,MUXSU2'?N8QV,D@^8C^)\'H2>*^U
M[>Z6&0 DY8=">!7S/X5\7>)_$VC66B_#S15TCP_!'Y0UO41Y8(]8XSRWXUTD
M7P)N8[/[3??$'7%U)OFDNXY% )] G0#FBC/V<4HQOYF^!I+"T%2IINVK;TNV
M>^K>HQ&T;AZBIX9-Y;D'Z5\B>+/&6L_"^Y6*/XG0ZTX_U=E=V8EF..W[OG//
MI7M?P%\=Z_XY\*2:CXATT:9=&4HD91DWH.C[6Y&:VIUU-\MM3OA64Y<MM3U7
M.:6JYGZ;0#Z\TY9%<<\'ZXKJN;DU%5995C)P,C'K3XI$E!(.![TP)LBEJM),
MJ-@*3[@TZ.19%SQ^=&H$Q.*,@U5:90QSP,XR2:?&RNH((_.D!/2U4-V@W#N,
MCFK$;;D!]J8#Z*** &NNY2/45XU\0OV:?#?Q/^)>E>*/%,%KKMKI]E):1Z5?
MVRRP;F(_>8/\0 Q^->STF!0!Y[X(^ O@3X<ZR=4\,^$M&T.^,9B:XL;-8I&0
MG.,CM7H0X%+10 4456U"\2PM);B0A4C4LS'H .230!8/ KP:)O\ C,><#G/@
M_P#]NHZUOA?^U%X*^+FOW6DZ!=7+W<433Q&YM7A2YC4E6>)F #J"""17+3:S
M9:7^US/=:A<16<1\);0TT@52?M*<9-*Z6K>@^24O=BKL^AS-M;&.*D5P5SVK
M@[GXM>#[-Q]H\0::A)P/])7/\ZIM\?O ,1*?\)/IRGT$N2*S]I!;R1U1P>)E
M\-.7W/\ R/1_-7.,TWS@,[N!7E5Q^TI\.X'Q_P )19E@.B[CG\A69?\ [5O@
M.*,BSO)]6FQD165K([']*GV]+K(VCEN-EM2E]S/8_MT8<*6 )J7SQNQP17RQ
MXD_;9T[2E8VWAB]+] +EU0Y_W>M8VG?M#?&3Q[=1KX>\#VME:.?EN+YR !Z\
MXKEGCJ"=HML]:'#>8\GM*T%"/>34?S9]>27BIE3]_P!*A_M' SMR.^"*^>!X
M(^+?B\+_ &_XWAT&$_>BT:-2Y'IDFIYOV<)I+0^5\2/$HG;G]Y> CZXK3V\V
MKQ@_O1Q/ X>$N6>(C\E)_H>_MK-NHP9$!'8N!5.X\6Z?:Y,]W;Q+ZO*H_K7R
M?J/[+?C2&^>2W\='6("?EAU"X>/]5:LBX^$NM^'9@=8^'EEXGMT^_)9ZU*[-
M[['>L5B:J=I0M\[_ )(]/^Q\$TO9XI2?9*W_ *4T?7%Q\3O#-HN9=<T]#Z-=
M)G^=49OC3X(MX]TGBC2E/H;I./UKYKLKWX9Z2J+K?P?OM*4+\\LEF9T4_P#
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MU4,R9X&?QQ4R2HR#! _&D!+15.>[$>0N"V,@$]:GMY?.B#8I@2T444 %%%%
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M_ED\3DG/7D''%>TK8(&5NI!R*?LH=A?5J78^4YOV$Y74,WQ0U^0#JIMH^?\
MQ^N7N?\ @GS<:AXFA5O']Y+H!A8RQS6*-+Y^1M(R^"N,U]M20^8A3[H/<5%#
M9+%(K<Y48']:7LH=B'@Z$MX(^.3_ ,$X])MH78>.-1(](M/B0_\ H55O#_[
MMSIGB^YND^(-XEDL2BV=],CDE1\_-G<Q [8-?:DL6\ 9*\@Y%-CM5C8,#T&
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M?#/[/7Q8;2U_M?X^^(?MV]]WV;3[;9MW';U'7&,U](2VXE=6)(P,<4Z&!;=
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M9.33 ^A\T9KPKQ9\;G\'_&NZTC4_$.BV?AVP\,MK5WITD3_;EVS%#-NQM$0
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,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>adag-20221231x20f014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %( G0# 2(  A$! Q$!_\0
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M?O?^A<U3_ONV_P#CU']OWO\ T+FJ?]]VW_QZ@#3O;V+3[=IYV*QKU(&:H?\
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M0Z?HUGI5S':K'8W=SYMY?W$I/F0P-&VU?+&/F(8-GC &:]D\Q0JEB$R,X)H
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MO3.T:VL5U#"9H&R<O@'D*#QSFN[\ 67V'PY&C6UU;3/(\LPO%59'D8Y9B%)
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M"C(W+!?[PX--*XF['K?]KO\ ] Z]_P"^%_\ BJH7VK.=1L#_ &?>#!?C8O/
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M%EJSC4]0_P")=>')C_@7C@_[5=!5"Q_Y">H_6/\ ]!-(8TZNY_YAU[_WPO\
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M_02U+_P*-;=% &)_PBR?]!+4_P#P*-'_  BR?]!+4_\ P*-;=% &)_PBR?\
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MA$1$+N0  .K')K=OI$_M+3_G7J_?V%==]BM_^>$7_? K-U"S@&J:=^XCZO\
MP#T%3N,I>8G]]?S%8'CGPRGC/P[)I7VQ;3?-!-YNT/CRY4DQC(Z[,=>]=]]B
MM_\ GA%_WP*X'QY\4+#P5K(TJW\.7WB"^CLVU&ZBTY(1]FM@2OF-YCKDDJV%
M7).T^V0#G?&GP[U7Q9+=VJ>*$@T&^6-;JQN+3SG4(03Y$GF*(]V!G*M[8JWX
M_P##LMW#X>O+!?M,NCWB2^2&^9XRI1\>^&S^%>CZ'>Z9XCT>RU2Q2*6SNXEF
MB?8.589%7OL5O_SPB_[X%.XK'B<?P'\,VGC'1?$&FF?338)<9MDO)V#O+L^8
M9EPN-IX P<\]!4MAX"U72]8M=:UGQ"/$0T:"86$,5GY=S+N_YZR>8WF-@ #"
MH.^*]G^Q6_\ SPB_[X%'V*W_ .>$7_? I\S"R/,_A9X=E\)^"K.RO707TKRW
M=RH886661I' ]@6(K>CD3^W9OG7_ (]T[_[35UWV*W_YX1?]\"LV.S@_X2&<
M>1'C[,G\ _O-4[C*7F)_?7\Q7E/BCX+3>+?&;ZC?:W83:-)=0W36[Z6AOD$>
MTB!+H.,0EU#%2A;DC=CI[K]CM_\ GA'_ -\"O,M2^-6BZ=XGO-._L"^GTJPO
MXM*O==CCA^RV]U(%*QD%PY WH"P4@$X[' !1^*F@7.HIX8UG38_M5YX>U:.^
M%NA!:6%D>&8*.Y"2LP'<ICO63J?PFU7Q#KUNVK^+$U'PU;:BVJ06$UG_ *6K
MD'$)N/,QY2[CA1&&Q@%CBO<!9VY&1!%C_<%+]BM_^>$7_? H \&\+_"*]\(W
MVC7%[X@36='\+07"Z)IT-EY4X+C:#-)YC"5E0;%VJGWB2">G2_"'PW/X5\&Q
MQ7^V._O)YKZXCW#Y'E<OM_ $#\*]4^Q6_P#SPB_[X%'V*W_YX1?]\"@# \Q/
M[Z_F*SYY$_X2"R^=?^/6?O\ [<-=?]BM_P#GA%_WP*S+BS@_X22P'D1X^RW'
M\ _OPT 4_,3^^OYBO*_B-^SSX5^(%^^I-YMAJLU[;7ES=0WEP!/Y. %,:RJH
M.U0-P&17N?V*W_YX1?\ ? KS?QE\8M(\'^(+[33X?OM3M]+A@N-6U"SCA\G3
MTF8K&7#.K-G:Q(0$@#)[4 4OBYX7F\4> )[+3=LE_9SVNH6<3/Q)+;3QSHA)
M_O&,+GWJWK/A=/%>O^$=?-T;(Z2TMQ]EDC^9_-BV[3R-I&?0UZ/%!:3Q))'%
M$\;J&5@@P0>AI_V*W_YX1?\ ? H \/N/A3J^H^)+.?5O%PU/P_IVK/K-G9R6
M?^FHY)98&N?,(:%"QVJ(PVT*I8@<Z_PHT*YTJV\0ZIJ$?V6\UW5IM0-NY&Z)
M,+'&#[[(U)]S7K/V*W_YX1?]\"C[%;_\\(O^^!0!@>8G]]?S%4+*5/[4U'YU
MZQ]_]DUUWV*W_P">$7_? K,T^S@.L:I^XC_Y9_P#^Z: *9D0@C>OYBO*=*^"
MUQI_B*T:3Q%#-X7L=4FUBTTH6>V=+B3<2&G\PAHPSNP 0')Y8XKW0V=N!GR(
MO^^!7FVF?&;1=2\4Q:8-!OH--N+Z33+76Y(X?LMQ=1@EXU ?>.C ,5 )4B@#
MJ_,3^^OYBCS$_OK^8K?^Q6__ #PB_P"^!1]BM_\ GA%_WP* ,#S$_OK^8H\Q
M/[Z_F*W_ +%;_P#/"+_O@4?8K?\ YX1?]\"@# \Q/[Z_F*:\B;&^=>GJ*Z'[
M%;_\\(O^^!39+*WV-^XBZ'^ 4 5?#ASHMKCGY?ZT4[0 %TFW    / ^M% &A
M1144-U#<,ZQ31R,APP1@2I]_2@"6BHDN89)FB65&E7[R!@6'U%$=W!+-)$DT
M;RQ_?16!9?J.U $M%,CE292T;JX!*DJ<\C@BGT %%%% !1110 4444 %%%%
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MF:#HVM6QN+'5=3NH0[1EX]8N2 RG!!_>=010!U59EQ_R,MA_UZ7'_H<-4_\
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M_0/O_P#P'/\ C6M10!D_\)"O_0/O_P#P'/\ C1_PD*_] ^__ / <_P"-:U%
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M%VJ1RSM Q)5?NJ,OP!D]* .BK,C_ .1BG_Z]D_\ 0FJ3[/J7_/[!_P" Q_\
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M JVSR&Z*;U,<; $;DD.\C(P&!Z<U](?9]2_Y_8/_  &/_P 72?9M1_Y_;?\
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M]IT34H-)B@S)=W36;7<PC Z11#AF)]:J_!'QM>_$+X<:9K6H/ ][+O25H$*
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M?_?Y?\:/^$MT7_H+6?\ W^7_ !H UJ*R?^$MT7_H+6?_ '^7_&C_ (2W1?\
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M(L1^6U4@D,Y]R" .^#6+XV\%WNE?"#1K 2OJ,^A2VES,5!)E2)AOP/89./\
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MZX'IB-OTK(^"&FS!?&.N/$T%OKNNSWMLCC!,2JD2OC_:\O=_P*@#TVLO3_\
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MOO\ H*R_]^8_\*TJ* ,W^SK[_H*R_P#?F/\ PH_LZ^_Z"LO_ 'YC_P *TJ*
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M:\=_\@E/]^N C^^OU%=_X[_Y!*?[]<!']]?J* /7-/\ ^/&#_<'\JL57T_\
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M "YB)/ &X5:KR+3O^0A;?]=5_G7K@Z4 +57^U+,?\O,7_?8JR>E>.S?ZU_\
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M?M?"VB%XT?E-<;!O*9SMW=<9[4 >7_"'XBZCXBO[+3;N&Q%I=:,FJ6JV.?\
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M>?\ /RG_ '[JY17J8/!X? 4(87"P4*<59);)$2DY/FEN8FIZ!+JIC,UT 4!
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ME/\ OW6;K'AN36_+\^Z \O.-J8ZUO5#=7D%C TUS-';PKUDE<*H^I- ',0>
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M#N2MEK^V2\2T:XB6Z=2ZP%P'91U(7J15B@"GY-Y_S\I_W[JGJNBSZO:^1-=
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MJ@R ,8KZ*MK6*T5A%%'&6.YS&@7<W<G'>@":FLP122< 5!=ZC;6,%Q-/,B)
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MV%O"(XXBD8!2)0J@XYP!T&:I^(?$^F^%K-;G4[G[/&S;5"HTC,?0*H)/X"@
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M"_AO5/#7AIH+V6]CL6?-C8:B5:XM8L<*[*3R>N,G&<5Z#37=8D+NP10,EF.
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M1M.M].A=MSK FW<?4^M97@/PN-,\*65OJ=A&FH"1KBX5W$P\\L2SJV.YY''
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M1.K_ #95!M  (QQ0 WX9^$-:U_5X=3?2OW,LKQRZBZ0B&:U);S$E0LTC2LQ
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M3U/0T 5/AGX+N_&>C:!?WMQ-;>&[*?[98Z1>P,UW:N!@)'=A_GMP3E#MW%2
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MV/DP3#HV.A'8@]J .-UOXO'6-+U:RMM#\0:=<V\>VYF^S*9+)F&8G=%8L48
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MC;)E4\;3QC.>,<W?"MLOCS4;;1(=:\02^="7U^UO;II7T^Y4!XIH7D#!-SC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+X@?$33_ EG"DL]HVJW;"
M.RLKFX$/G,6"Y+8.%!89.#5WQ3X\T/P9Y?\ :UX;<R N D3R%5'5V"@[5']X
M\5Y_=>'[SQKXIOO$-AIA?3+@+IES;:G+F+4+8=9HEY\O:2<'^(<^] '#ZEI7
MB;QOX]U 2Z';->H$E>PDO%3[).JXBN!*4S+;Y&\! #N!!7CCZ"\/>'X-$LH0
M8H'O_*5;B[2)4>=P.6.!W/-.\.Z!#X<TNWLH99KA85V))<-ODV]E+=2!6I0
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MA1U!&,JPY!]Z\2B\)^(;/QO%:WJ+JEZ(/LS7=VI-MJECGE9, B.9,]<8;\>
M"G%HVH>*O'U_!KNE>=<WL40F".";0*28[FTFP"4R>5Z@_6O<=$T./2+=#(RW
M5\8UCFOFC599MHP"Q'6F^&_#EIX7TF#3[/S3;P B,3R&1D4G.T,>=HZ >@%:
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>adag-20221231x20f015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $B N4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHVL#WDOD6RR3*#-)C.Q.?F/!X% &A1110 4444 %%%% !1110 4444 %%%%
M!17.>(_B/X5\'W:6NN^(]+T>Y==ZPWUW'"S+Z@,1Q4>@?$_PAXKU 6&B^)](
MU6]*EQ;V=['+)@=3M4DXH6NP/3<Z>BBB@ HHIDLJ01/)*ZQQH,L['  ]2: '
MT5R>A_%GP5XFUEM)TGQ9HVI:HN<V=K?1R2C'7Y0<UUE'F'D%%4KG6M/L[Z"R
MGO;>&\G5GB@DD =U7[Q ZD#O3M*U>QUVPBO=.NX+ZSESLN+>0.C8.#@C@\@T
M 6Z*** "BBB@ HHHH **** "BBB@ HHHH ***0D*"2< =2: %HKD8/B]X'N=
M?&AP^+]$EUDOL%@E_$9MWILW9S[5<\2?$3PMX.N8K?7?$6EZ//*N]([Z[2%F
M7U 8C(H\P\CHJ*R_#_BG1O%=H;K1=5L]6M@<&6RG650?JI-0)XV\/2:\VB+K
MFGMK"C)L!<H9Q_P#.:.M@\S;HJ)KF%9U@,J"9@66,L-Q ZG%9WB/Q9HOA"S2
M[US5K+1[5VV+-?3K$A;T!8CF@#6HKB[3XT^ +ZZBMK;QIH,]Q*P2.*/48F9V
M/0 !N379.ZQHSNP55&2Q. !1Y@.HKD]+^+7@G7-<.BZ?XMT6]U<$J;&WOXGF
MR.HV!LUUE'F'D%%4[O6+"PO+6TN;R""YNB1!#)(%>4@9.T'DX'I1I6L6.NV8
MN].O(+ZU+,@FMY Z%E.&&1QD$$&@"Y1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G'QJ^%GA#
MQWX8U._\1>&]-UJ\LM/G%M/>VZR-$-I/RD].>:]'K.\1:6VMZ!J.GI((FNK>
M2$.1D*64C/ZUE5BY4Y);V9I3:C--[7/SR\ >-O!_[-?[+_PK\5:5X<\/V'CK
MQ'>/I-IX@O[?"6@8R&6:5D&XJ$4C ZY KO-"_:A\2?$:V\>> ;7Q?H/B'4CX
M:N=3L/$^BZ=-'!%L4B6&6-\8?!^4@]\]J]'/['MP?@9X%\)Q^(X[3Q9X+OAJ
M>E:W';[HEG!;(>,GYD97*D9KI/"OP6\?W$OB:\\9^,[*_GU+2)M*M-.TBQ^S
M64&]2#*P)+,^3Z]*TK>_[1;WO;TY=/\ R;T\]":;Y73?:U__  +7\/ZN?$7A
M+X0^(+KP-^S-:?VCX=.G:]>?:?LSZ(&#R>2S;KCYOWS8SR>YS7Z$_'+Q,?AI
M\#?$%Y:*D=U;Z?\ 8[..%=J^<X$<84=AN88%<%H'[+VH:-H?P/L&URWD;X>M
MNN'$+ 7G[HI\O/R]<\UZ+\8/AO>?$U/#-C'=10:79:O#J%_&X),R1$LJ#_@6
MT_A6E2TU*'1R?W.RO]US.G>+4WNH_BKNWY$OPZ^&&E:!\&= \%7]C!?:=!IL
M5M<V\Z!DE.T%]P[Y8DGZU\O:'\!OAU+^WQXGT!_!6BMHL/@JTN8[$VB^4LIN
M'!<+C&XCC-?;P&  .E>3:;\%+NQ_:<UGXI'4XFL[_P /0:*NGB,^8C1RLY<M
MG&#G&*3?-651_P!Z_P XRM^+06Y:+@O[MOE*+?X)GF'@;XF_$'4?B3\0=,TZ
M70-#^'/P^ODMGMA9LUQ<6XA$AC0@@)M .#[CTKQV+_@H9K3:/%XUC\1^%;O3
MWNU_XH6&UN#J7V4R!,K,!M,H4[MN,<8S7UE\._@@WA+Q#\4;W4;Z+4++QGJ
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MSSM]:A)I3MI?E_.5_P R[IN%];<WY*WY'G?Q2_:7\>?!JW\*:!XI\1^%M/\
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M7\S6U**G*S/-S"O/#T>>GO<]O_X>$^!_^@%KG_?$7_Q='_#PGP/_ - +7/\
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M7QNUKXL_M3? F#5OA;XN^'JVE]?.DWB6".-+DF#E8]C-DCOGU%?>% !1110
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M5-1,UN"YR7VD?>SW]Z*7NPY7I?7Y_P"7]>I4]Z2DNGY?U_7;VBBBB@ HHHH
M^7/AM_RD,^,O_8I:)_Z%+7U'7RY\-O\ E(9\9?\ L4M$_P#0I:^HZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^3?VU=1T2S\9_#-?%7BG5?"
M/AWS[IY-2T$,MVDPCP@WJK,J')SCVKL/V6=2\$:A<>(1X0^(_B7QZRK#]I7Q
M!<RRBV'S[2F]%QNYSCT%>MZ]XI\/6GBO1O#FIB.35-3CFEM(Y8-ZE8P"_P Q
M&!P1]:W;.RL[,O\ 9+>" M][R45<_7%$/=3\[A/WFO*Q:HHHH **** /F7]N
M+_D%_"[_ +'33_\ T(U],CH*^9OVXO\ D%_"[_L=-/\ _0C7TR.@H 6BBB@
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M9FO-05R"/EVLF>@P*]T_98\4:IXM^$%A>ZIJ,VLE+B>"VU2X3;)>0)(5CE/
MY8#KWKY.GT;7[B<RRZ3^T!)+M*>8UY;EMIZKGK@^E?8/[.EK/9?"S3()[?Q'
M:NA<"'Q2ZM>J,\!BO&/2M*:M!I_U_7ZOI:TS=YJW]:?U]R\SO?$'B#3?"FBW
MFKZQ?0:;IEG&9;BZN'"1QH.I)-<_XW^+_@GX:Z=8W_BKQ1I?A^SOO^/:;4+E
M8EFXS\N>O%>8?MP> ]+\9?L\^+[K5#<3)I.FSW<%LD[)"\P7Y&D4'#[3R >
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M\X5]'_L%?\EQ?_L&3_S6LJOP,[<%_O,/4_1>BBBO)/T **** "BBB@ HHHH
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M?A5JVC6$NF3:B][#<W<TD<BHMM;P1EY)&SU[  >M8?[/7[0&I_&&ZU73]?\
M"I\)ZK;6MMJEO +L7*SV5QO\F0D*-K?NV!7'''-%/?W=;?K_ ,,_Q\PJ;:];
M?\#]/P\CVD9P,]:Y>Y^%_A.\TG7],GT"RFT_7W:35+>2/<EV[  LX/? '/M7
M4T4FD]QIM;'F^A?LZ?#CPYX0U;PQ8^%+-=$U;_C^MIB\QN,=-SNQ8XP,<\8X
MQ6_\._A?X7^%&BOI/A72(M)LI)#-(J,SO*YZL[N2S'W)-=3157>Y-EL?,O[<
M7_(+^%W_ &.FG_\ H1KZ9'05\S?MQ?\ (+^%W_8Z:?\ ^A&OID=!2&+1110
M4444 %%%% !7YU?MZ_\ ):X?^P=%_,U^BM?G5^WK_P EKA_[!T7\S73A_C/%
MS?\ W;YH^;J***](^,"OH_\ 8*_Y+B__ &#)_P":U\X5]'_L%?\ )<7_ .P9
M/_-:RJ_ SMP7^\P]3]%Z***\D_0 HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O&OVD?B)K'P^T[1)=(\;^%?!3W,LBR2^*
M+66=)P "!&$=<$9YSZBO9:Y'XK2PZ=X"US5SH]MK=WIME-<VUM<P+*"ZH2
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M*^F:^9OVC?\ DYO]G?\ [".H?^DXKZ9H **** "BBB@ HHHH 0]*_)#XV?\
M)7/%O_81E_\ 0J_6\]*_)#XV?\E<\6_]A&7_ -"KKPWQ,^=SG^'#U.)HHHKT
M#Y0*_0/_ ()\?\DEU?\ ["C_ /H*U^?E?H'_ ,$^/^22ZO\ ]A1__05KFK_
M>OE7^\KT9]1T445YI]L%%%% !6;XEUZV\+^'M2UB\S]EL+>2YEV]=J*6./RK
M2KF_B1H#^*O 'B+1XYX[:2^L)K=9I?N(60C<?85G4;4)..]BX).24MCY;C\+
M?%_XQ>$&\16GACX<V'AG5&&HV_A75-+,TMTO5'EE& LC#O@XS7T)\ O'5K\0
M?AAI>HVVCQ>'WA+V=QI4  CM9HF*.BXP-H(./:OFCPCX_P#C3H'PE;5](\8_
M#C4/"'AZ,V4NHQ65W)@0_(WW3\V,=1Q7NW[)WARXT#X06DUUK.FZ]+JMU/J9
MOM(S]F?SG+_)GG SWKHLES*/PZ6[^7WK\M#%M^ZY;Z^GG]SM^ID_MM>!='\6
M_L]>,+W5;=KI])TNXNK6,R,(UE"_*[*#AB.HST-9(DLH/V@_";ZV\*6+>!Y/
MLYNB G!4S8SQ]WK[5]!:YH6G^)M'N]*U:RAU'3;N,PW%K<('CE0]58'J#7/>
M.OA#X,^)FEV>G>*?#=AK=E9D-;PW461%QCY?08XQTQ6'*];=?\I+]?P-6[I)
M]+_G%K_TG\3XO_9CEL+>"YD\1/ FF2>!;IM,^UD!#9_:IB=N>VTK^&*]3\%V
M/QNN/V??A/\ \*YO] L6714^WCQ!"\CL"%\G9CI\G7/M7NWB[X(^ O'EEI-G
MX@\)Z7JEKI0"V,4]N-MNH  50.BX XZ<5V<$$=K!'##&L4,:A$1!A54#  '8
M5MS:-=[?@Y/[_>_#S,W=RYOZVBM/+3^K'Q7^RM!X[M_VVOC$GQ'N=+N_$O\
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M</\ V#HOYFNG#_&>+F_^[?-'S=1117I'Q@5]'_L%?\EQ?_L&3_S6OG"OH_\
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M X7=SER<CM7;P_%;1?A;\"O"WB;Q3=7*67]EV0EFB@>XD9VA7DA02<GO6O\
M'GP'?_%#X-^+_">ERP0:CJ^G2VD$ET2(E=AP6(!./H*WO!OAQM#\#Z!HM^L-
MS-86%O:RX&Y&=(U4D9'3(XJ(:*2]/U_X!4M>3RYO_;;?J?&WC#]I#P/\<?VJ
MO@+9>$[R]NKBRO+^687-A+;J%,  P7 R<^E?=%?+_P"T-86MI^T[^SPT%M#"
MQU#406CC"G'V<>E?4% !1110 4444 %%%% "'I7Y(?&S_DKGBW_L(R_^A5^M
MYZ5^2'QL_P"2N>+?^PC+_P"A5UX;XF?.YS_#AZG$T445Z!\H%?H'_P $^/\
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MZ+^9K]%:_.K]O7_DM</_ &#HOYFNG#_&>+F_^[?-'S=1117I'Q@5]'_L%?\
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MBA*[FR<$UDQ_L9^'!!/I\WB7Q!<Z EO=P:=HTMRIMM.^T1LC-&-N20';:&)
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MZ1\2;#7]&M_"^J^*;?2%\/MIP,L%FUUY/F>?NR9#@Y!&!GCI7N7_  S5H"^
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M=J^RZ^3?B-X^N_VGQX:\*>%O _B&R\C6K/4KK7M<TYK.+3HX)0[%"^"TAQM
M7U.:^LJT5U3L^[_*.OZ?(S=N?3LOS?\ P_S"BBBI*/F;]HW_ ).;_9W_ .PC
MJ'_I.*^F:^9OVC?^3F_V=_\ L(ZA_P"DXKZ9H **** "BBB@ HHHH 0]*_)#
MXV?\E<\6_P#81E_]"K];STK\D/C9_P E<\6_]A&7_P!"KKPWQ,^=SG^'#U.)
MHHHKT#Y0*_0/_@GQ_P DEU?_ +"C_P#H*U^?E?H'_P $^/\ DDNK_P#84?\
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M2X26SE\B[L[V!H+BW?&0'1AD9!!'K0M;VZ ]+7ZGB_[<7_(+^%W_ &.FG_\
MH1KZ9'05\S?MQ?\ (+^%W_8Z:?\ ^A&OID=!0!7U+_D'W/\ US;^5>*CI7M6
MI?\ (/N?^N;?RKQ4=* "BBB@ KU'P%_R+4'^^_\ Z$:\NKU'P%_R+4'^^_\
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MO@/:P(/_ !)9JY__ (9\_:F_Z*KX(_\ !/-7VA10!\7_ /#/G[4__15? _\
MX)YJ/^&?/VI_^BJ^!_\ P3S5]H44 ?%__#/G[4__ $57P/\ ^">:MG3?A/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>adag-20221231x20f016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $9 DL# 2(  A$! Q$!_\0
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MAKK/''PVFTC5M%L[#5M2N_%&M++(MFIC\FP)MTBOKX,$$F?*'EH&8KOF7CT
M/H#P_P"(;#Q1I46I:;-]HLI2PCEVE0VUBI(R.1D'!Z'M6E7C'[/GQ$OO%,E]
MHCQ:4VF:7IUG) ^DPR1K:.[3HUE-ND?,L:PQL2-IQ*,JO&?8IS,%7R51CN&[
M>Q&%[XX/- $M%4A)J'&8+;MG$S>^?X?I0)-0[P6W;_ELWIS_  ^N* +M%4O,
MU#_GA;=/^>S=<?[OK^GY4&34>T%MW_Y;-Z<?P^N: +M%4FDU'#8@MB<G&9FZ
M<8_A^OZ4/)J +[8+8CG;F5AGD8S\OIF@"[15+S-0S_J+;'_75O[W^[Z?K^=
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M;$\]9F]L?P_6@"[15(R:CAL06Q.3C,S=,\?P^F:#)J'S8@MCZ9E;U_W?3]:
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MMNHSB9OQ_AH$FH8YAML\?\M6_'^'Z4 7:*I>9J/_ #PMO^_S>G^[ZT>9J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LGQ60/
M#FHDG $+<FM:DZT 4H-5LO)C_P!,@^Z/^6J^GUJ3^U;+_G\M_P#OZO\ C5C8
MO]T?E1L7^Z/RH K_ -JV7_/Y;_\ ?U?\:/[5LO\ G\M_^_J_XU8V+_='Y4;%
M_NC\J *_]JV7_/Y;_P#?U?\ &C^U;+_G\M_^_J_XU8V+_='Y4;%_NC\J *_]
MJV7_ #^6_P#W]7_&C^U;+_G\M_\ OZO^-6-B_P!T?E1L7^Z/RH R-(GCN-8U
M1XI%D7]V-R,".AK9I  .@Q2T %%%>2?&'XK^)OAK)?:A#HNF#PW86\+F[U&^
M$4NH3NY'V:V1<DN /XL;BR@9Y( /6Z*\0\;_ !WU_0[OQE>:1X?M;W0?!=M;
MW.M-<3LERX>);B585 (RD+!OF(R3CWJ5_P!H46?C&X@NX;)?#2-=(+F.5C<H
ML-JMR9W7&/+96V@^I7UH ]JHK$\%:O?Z_P"%]/U'4[--/O+J,3-:HQ;R@W*J
M2?XMI&??-;= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5XW\9?!OC;QC+J>D6NB>&?$_AO4K=([0ZQ,8)M&N=DBO<
M")_-&"I7:58'(Z'(]DHH ^</$WP3\=VUAXP\-:&^FZEI/C;3;6PU'6K^]>*X
ML72T6TGE\H1MYV^)%*C<OS$YP.:] \9?"A/$6IZ%IUI8V=GHL42G5+\(GVF[
M2#;]FM2<;C'OQ(V3C]T%_B->GT4 >1? _P"&WB'P-K&N7.L"VMK:YMK:W$%K
M>/<"ZN8Y)VEO6W*NQI%EB7')_=<GI7K,T"7 4/DA6###$<CZ5)10!3&DVR@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M07]U=7=C<P)I=T'DC9 6>+&2,?WZ /"CUKIOAS_R-MI_NO\ ^@&C_A7.O?\
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M[/\ Z\U_]#:O,Z]J^*'@77?&>N6]Y8V!2*. 1$3S1J<[B>S'UKCO^%+>*O\
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M[[M[A8D.T 9;AI-B1AWQEBI]>?2**R/$WBO2?!^G&^UB]CLK;=M#N"23UP
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M7L9R"LGRA7)VC8XRKCGV[X8?"BP^'-L\JW,^HZI-#'!)>72QAQ$F2D0\M5!
M+,<D%B68DG-+J!)\./AA:>!H)IYVM[_6+B1Y)KV.V6$98Y;8HSL#'YF ."Q)
MQS7;T44P"OGKXS^.8_$^NV>G:)KEI81::UR9YM01Q:WEQ%L+6B.<*LJY#K(I
M)0KP#AL;OQ@^(-Y>:9XDTS1;>\QHDL<-Y+#.L)NIY(U>&RC96\Q6D,L(WJN/
MF*@YSB/X!?#&_P!)TB_N_$4LFHI=R*8X[ZW$9N=H&+F:%P=DV=PR#DKM+9;F
MEN,A^"?PH4Z?I/B/4?-@4M]NM=.*B,)(R<3N@ \N8AF5PAV/@,1EB*]QZ4
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MLH:2*8#*S*[Y3^$+&S'(KU?PW\$-,M]&GM]=E?5KB[N#=7!CS;1R,1AMR1L
M=W5Q]USDD5VOA71[G0_#FFZ??745_=6D*PM<Q6X@5\# (0$A>,9P<?3I6O0
MU$6)%1%"(HP%48 'I5'7]?T_POH]WJNJW266G6D9EGN),[8U'4G%:%1SP1W4
M$D,T:RQ2*5='&0P/4$4 ?.?Q&^/L&LPW6FZ!K=EJ-K?1>?I4VA7@,]\RH6-E
MG.8Y7(&UAU!(Z@9T_@S\&[BYLH]4\47-Y>QK>"[@L[N!K=;EU V7$]NXRL@;
M)&<'Y5+#(KO?#7P8T+PY?3YMK34--29;G3K6\M$DDTYP<D12G+!,X(7^'G!Q
M@#T"D 5F^(_$6G>$]$O-7U:Z2RTZTC,DT\AX51_GI6E5/5M(L]>TVYT_4+:.
M\LKA#'+!,H974]00:8'A_B3XXZYJ\JV5KH.J>$K*.1&U+4KQ(I9[2TE1Q!<"
M)&;:"ZJ&#?,@.2O7&K\//A)J2^,I_$OB"+3[;9LDM(M)G9HY;@Y\RZ&54Q>8
MNT-&"RG&3DXKJ?A=\,/^%:IK5DERE_IUU<"6VDGW/<HFW'E2.Q.]5QA3V'!K
MO0H4    < #M0 M%%% !7F/Q5^"=A\0+ZSU:"*U&IP,BSP7BEK34(5;/DW"#
M[ZC)(R#@]NHKTZB@#!\)>!= \"VLUOH&D6NCV\S;W@LTV1[O91P/H *WJ*BN
MKF*RMY)YY%BAC4N[L<!0.IH +FYALK>2>>5(88U+/)(V%4#J2>U?-/QH^*5S
MJGB'2I?#R17EK:2+)::EI;"6Z8D[6>+#;)%#%5,)!+Y.,$"G?$3XA2_$N.YB
M\/V=[+HMQ/\ V<]U!."+ID&=JIUA?+;E+C;)C!P",^J> ?A78Z:UKKFL:5IX
M\3,@,TEHA$)<<"98V'[N1E"[@.AXR< TMP!?AE;^+M1\,>+-=M+:S\6:;AGF
MLUW1S+S\K"10<=&&1N0]#QSZ+165XG\26?A+1;G5=0\T6=NN^5H8FD*KW.!S
M@=Z8%C4-5@LF$!GA%[*K&"WDD"M*0.@!ZU\M>*OC/XF^(6C6MM#]I\*:JDQL
M[[2X(WN=D@+;G?;&3)"VPQJ5Q\[C.!@GM_%D7A7]HVVLX(H;C1_$%O'_ &AH
M&HWT&U;A"/OQX;+QL,;ERK8(/'!KNOA=\+8/!5L;V\:6XUFY_>2_:+@7(M69
M0'2*4HKLA*@_/D\"D!4^$7PUN_#ECI6K:Y<33:W'IHLDMGE$D=C$Q1VA5MJE
MAE$Y;)&W&>Y],HHI@%>>?&W3KN_\+6K1:?<:QIT%[#-J6F6H+2W5J&^=54$%
MN.=O\0&.]>AT4 >&:+X1TOXE^*)9M*L]2T#PC8Z:EA"\%K)IK7)9B9(-DB*S
M1@ 9.T8)PI^]CVZVMXK.WB@A18X8E"(BC 50, #\*EHH *\K^*'QD7PAJTVA
MVD<RZH+,W*E[)Y4V$,/-5@P#",@%U'S8(P#6S\2?B5_PAYL-/TZSCU/6M2F^
MSV\,MU]GB5MI/SR[7"$@':"/F. .M>/_  ^^&6N^,]:6?79]0ET<SR37330)
M9.DP! 56$CSF520"X9(RO1><4MQE'P)H%S\7/$=O#?:MJT=[IUJDVISW(@D5
MY6& UJ^#O@D!9E_N\=&!%?3/A_0-/\+:)9:1I5K'9:=91+#!;Q#"H@& !2Z9
MH6GZ/'$EE9PVPCC\I3&@!"YSC/UY^M7Z8@JCK>MV7AW2KK4M0N$M;.VC,DLK
MG 50,FL;Q_X]LOA_HZWUVAGDD<1P6RN%>9_[BD\%C@X'?I7AWBOQAXO^+^EH
M=&@M=)L+I'ET^.Z)N(Y9(G)_>2)&&M9U*YV,)5(X/-*XRMXZ\<:C\4&MXK#4
MI=,6[EM9-+TA[4I<7MO+C]\DBDYP#DHV5 X<#M[/\//A58>"([>YF=M0U>.W
M%L+F9RX@CSDQP[LE$)P=N3T'8"I_A+IUG:^"K"[L[.73$OT%T^GNS%+:1AET
MC#?=3=G Z=^]=G3%N%%%% !1110 4444 -?=L;9C=CC/3-?)_B-)M0L[FQ\0
MZ]JW_"RY;^*VN/#;7TK6.J022<+:VV=B1K&K.LZ!9(VB+._# _6557TRSEU"
M*_>T@>^AC:*.Y:,&5$8@LH;&0"54D#K@>E(#C/AW\(M.\"7$VH27%QJNM3%_
M,OKF:0@[B,LL18I&[!$WL@7>5!-=[1534+J&&+RI+N.TEF!2)G8 [CTP#U/M
M3 K>)_$$'A7P_J&KW*L\%E \[HGWF"@D@?E7S_XA\.:]\6O'CV&KW<UFL]E:
M:E816;F>WTQ<W"%+A R+,EPH<,58' "G P2V]\":]XT^(ZZ7XPLEUBZM+188
M=1""(VT>X[=0LGQA9"Q5)HLY(VXRIVGV_P "?#O1/AYIQM])LH8)9$19YT7#
M2[0=HZG:HRV$&%7<< 9-+<!W@/P3;^!]"2Q247=RTDLTUUY0CWO)(TC!5'W$
M!8A4R<  9)R3TM%%,!#G!P<'UKYO\2>%/%7Q$\<KX>\27]GHVLZ793R:7J5I
M9[H==B?Y)(YU;($6TA9( <DL&5AA2/I&DI6 X/X<?"#1/A_HS6T4#W,T\$,,
MPNYVN4C2/<R0QE_^6:-)(1GGYB22:[VBBF!G>(M>L_"V@ZCK&H.\=A86[W,[
MQQEV5$4LQ"J"2< \#FO$/BI\;-)\4Z-H^D>'-5MV&NS1Q1O=&2V6[C<;E$,A
M #JS 1OM)*;B2!BN@^-NG>.-,O[7Q)X:U6>YT6&$V^J: +5;A7C)YG1.'<J#
M\R*P)7.W+  T?AO\"#:^ ;S2M:DB@AOV6465BQDMH620M'/$)$#1R,NS<,<%
M<]<DK<9-\,?@;INGZUJ&NZIX?&E,UU'-IVE_;WF2U"*#@A6V,HDW.BL&$9)*
M[<X'M%-1=B*N2<#&2<DU6U74[;1=-NM0O91!:6L332R'HJJ,D_D*8B>:>.VC
M+RR+$@P-SL .>G)KQWXK?%?6-"U*;0+:WNM$E,B2C5+>)+F5[(*#--;QLK!Y
M(S]Y""0OS -TK+U,7_QMEL]2L-8BT^]TY8]6TSPU<%9(IDWGRIKP $C>!\J_
MP$;N2./4=,M;;X@:#HVH:[H$NGZA:SK<K:7@'FVES&Q7*LIY&0<,#AE/HV*0
M'G/P\^%.KZB8+K7M=M]4T--0;5K:WM8$,5Z\D9 FWY^6-A(6,6#\W1MORU[<
MJA%"J J@8 '0"@# I:8!1110 4@4 D@ $]<4M% !7$_%+XHZ;\-?#]W=S7%K
M)?Q1><EE)-M<IN"M(5&6V+G)(!Q57XA_%-/!UZ^DQ6A.K75HTNG23.JV\\XS
MB$L6^5R 2-V V& )(Q7A7@OPUKWQI\4ZM>W-W+ C/#)<ZK97&RUN8@65(C&C
MAEF"C+1.6CVR@D;F(*W&>D:9IMM\?M-2;7-/31M?TR18[J&/]_#-;2_-Y,@.
M,B2/:Q4X9"RD<BO8M+TV'1].MK*W,AAMXEB1II6ED(4 #<[$LQP.I))[U7\/
M>&M)\):7'INB:99Z181DE;6PMT@B!/)(1  "3UXK3IB"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***P?''B^W\!^%[_7;NUNKRVLT\R2&S56E
M(SR0&91QUY(H UM0O$TZPN+J1D2.&-I&:1MJ@ 9Y/85\R^+OB_=?%33[O2X?
M[0T6SDL=K6!T>2Y^UW#$XBD.S>D;IAHW7;NR<-\N#'XR^*<OB_6;_3K?Q1J*
MZ/>1F"/3++2F.H6ETX 6"[MF0R&)^S@ 9;[V"#7KGPH^&$GAB*PUO6+NYO?$
M+:7#8G[25)M8P QA!7[^&_B.3\HY]5N/8N?##X?#PYIUIJ.IHLOB![1+:>Y4
M%&DB7!C650=KNGW=^,]<8R17?444Q&)K_C?P_P"%;NPM-8UJPTR[OW\NTM[N
MY2.2X?\ NQJQ!8^P]17SQ\1/BKJOQ!\36>BZ5#>:.D,Q%L3N9+Z8JQ6-@LD8
M$@52XBD)4@@L.@._\5_AAKMUXQD9;FXN?#/B.:&WO[RUM!<WUAM/[M%!Z6Y?
M!8@$J>>F2/2_!'PNMO"VI76KWMY)K.NW+EY+V0&-3E57<(0Q17*JH+* 2!2W
M&0_"+X?R^"_"]K'J#;K^0FX>V 4PVDC??$(Q\BMU*@[0Q.T &N^HHIB"BBB@
M HHHH *\]U?Q)K.I?$I?#FG:I::-!:VBWTHGMO.ENU+[2J9=0H'<\GD5Z%7.
M^+?A]X?\<"V.M:>+J6V):">.5X9HLC!"R1LK $<$ X/>@#Q3PG\+T^(.OKJ5
MSIM@^E6^IWAGU0LRW=]&=R^1(H&& ?:0V[C8I&&%?1,$*6T,<29V(H4;F+'
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M>-T?1@,X)'/6Z+\+-#T*70WMQ<M_8LDSV"RSLP@$B%&0>JA6( /3\!7844K
M%%%%, HHHH **** "BBB@ HHHH *\LUCP;XM\+ZQ>CP:]G=Z-K<CFZL]4E.S
M39GY>XB&#O1N<Q<98@@@$UZG10!R?A#X9:#X,>SN+"R2+4+>R^P&ZC+*7AW[
M]A&<;58L54Y";F"X!.>LHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *:D:Q#"*$&2<*,<GDTZB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>adag-20221231x20f017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %> >,# 2(  A$! Q$!_\0
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M 'T?\:/LZ?[7_?1_QJ6B@"+[.G^U_P!]'_&C[.G^U_WT?\:EHH B^SI_M?\
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M]'_&C[.G^U_WT?\ &EMKF*\MXKBWE2>"5 \<L;!E=2,@@C@@CO4E $7V=/\
M:_[Z/^-'V=/]K_OH_P"-2T4 1?9T_P!K_OH_XT?9T_VO^^C_ (U+10 U4"C
MZ>YHIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4*2C+ND76QV)Q$>2K4<EYLY7QK\,]$\>7&G7>H+=VNIZ<7-GJ6FWDMI=0!P
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MS&3.XE]X.]@.@7A@V?3*8!15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q15?SYO\
MGV;_ +[%'GS?\^S?]]B@"Q15?SYO^?9O^^Q1Y\W_ #[-_P!]B@"Q1349F4%D
MVGT)HH =1110 C*'&& 8>A%1_9H2TC>4FZ0;7.T98>A]:EHH :$4-NVC=C&<
M<XIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9U[
MK]GI\YAGD99  <!2:\['9C@\LI>WQU6-.%[7DTE?M=EPA*;M%79HT50L-;M-
M3E:.W<LRC<<J1Q5^KP6/PN945B,'5C4@^L6FM-]4$H2@[25F%%%%=Q 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<)XO_Y#+_[B_P J[NN$\7_\AE_]Q?Y5^%^,
M?_)-Q_Z^Q_*1ZN6_Q_D3^"?^0C/_ -<OZBNTKB_!/_(1G_ZY?U%=I7H>$O\
MR2U+_%/_ -*(S'_>'\@HHHK]D/-"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Q?$7B[3_"PA;4/M*12$ S16LLL<8R!
MEW52$&2!DD?D#BC=_$G0;&^FM;BXGB>(L@D-I*8Y74A6CC8+B1P2!M7)SG .
M#BMX]T77]=GTVWTZWTR[TA)/.O+:^NI(&F92#&N4C?* _,1QDJHSC(.9)X U
M*ZU I=1Z=<:9:7-Y?6B/(Y>>:?>0L@V814,C?,I8G"G Q2 Z[1_%&G:^ZKI\
MS7*F!9RX0J$5ONALX*L<'Y2,C'.*UJX?PCX$U#PKK8>/4%?2C"2\0)7?*0H(
M\O&T*"I(8'."$QA1GN*8!147V=/63_OXW^-'V=/[S_\ ?QO\: ):*B^SIZO_
M -_&_P :/LZ>LG_?QO\ &@"6BHOLZ>LG_?QO\:/LZ>LG_?QO\: ):X3Q?_R&
M7_W%_E7;?9T]9/\ OXW^-</XL4)K#@$GY%ZDGM[U^%^,?_)-Q_Z^Q_*1ZN6_
MQ_D6?!/_ "$9_P#KE_45VE<5X,02:A,"2/W79B.X]*[#[.GK)_W\;_&O0\)?
M^26I?XI_^E$9A_O#^1+147V=/5_^_C?XT?9T]7_[^-_C7[(>:2T5%]G3UD_[
M^-_C1]G3U?\ [^-_C0!+147V=/63_OXW^-'V=/63_OXW^- $M%1?9T]9/^_C
M?XT?9T]9/^_C?XT 2T5%]G3UD_[^-_C1]G3UD_[^-_C0!+147V=/63_OXW^-
M'V=/63_OXW^- $M%1?9T]9/^_C?XT?9T]9/^_C?XT 2T5%]G3UD_[^-_C1]G
M3UD_[^-_C0!+147V=/63_OXW^-'V=/63_OXW^- $M%1?9T]9/^_C?XT?9T]9
M/^_C?XT 2T5%]G3UD_[^-_C1]G3UD_[^-_C0!+147V=/63_OXW^-'V=/63_O
MXW^- $M%1?9T]9/^_C?XT?9T]9/^_C?XT 2T5%]G3UD_[^-_C1]G3UD_[^-_
MC0!+147V=/63_OXW^-'V=/63_OXW^- $M%1?9T]9/^_C?XT?9T]9/^_C?XT
M2T5%]G3UD_[^-_C1]G3UD_[^-_C0!+147V=/63_OXW^-'V=/63_OXW^- $M%
M1?9T]9/^_C?XT?9T]9/^_C?XT 2T5%]G3UD_[^-_C1]G3UD_[^-_C0!+147V
M=/63_OXW^-'V=/63_OXW^- $M%1?9T]9/^_C?XT?9T]9/^_C?XT 2T4U4"@
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M5?0]?/'QK_Y'J;_KA'_*@#3^ ?\ R,FH?]>O_LZU[I7A?P#_ .1DU#_KU_\
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M?_13UU'[07_']HO_ %SE_FM<O\(/^2A:7])?_13U^O'G'TC7G_QO_P"1(/\
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M&Y-Z@Y7(Y&>HH Q_ =O-H_A'3+.\AEAN88RKQE"<'<3U'%;WVI/[LG_?IO\
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M[6&1E3R,T 1:&QM-%L()HY$EBMXT=?+8X(4 CI5R2Y1D8!9,D'_EDW^%6**
M/F7_ (5AXI_Z \W_ 'TO^->V?#2QN=!\'V=E?V\MO<HTA:,H6QER1R,CI70Q
MZWITNK2Z4E_:OJD,2SR62S*9DC)(5RF=P4D$ D8XJ[0 U7#J" <'U4BBG44
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MZF[M?@O\'1X9M;/7?$*-<^)@9W4RA5$!D=MTWE*S1Q7$R;#.8=L;/N(49)*
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MW^#ES<Z;X@LOB%80ZA?_ &RVBMKRPVVEJ]I:C-D;:.$AX-FYRRDY$COM8Q[
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M$/XU:AJ-CXDGNM'TS_1IM1>_B:4M,DK,AL]GEQVEQ&$3;+;RW,>UE8LTGSL
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M+&T[MM\V5E0!2N0SJ5\R\&?"S6/C3X\\3>(/$=MI=O$-3_L[4[?SDNFB\N&
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MBC.%4?*JA54!5 &VQVJ2>@YXH;.T[<;L<9Z9KY;URV\9_%;Q_<Z?<VEGX?\
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M&BA5&3DG@#DG)JS;6T=G D,2[8T& "23^)/)/N>34M @HHHH&%%%% !1110
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M*LP'U^0",'D5F>'/#&E>$=..GZ-91Z=8F:2<6\.1&KR.7?:O1068G P!G@4
M4O '@JR^'OA'2] L7DF@L+=(!-,Q9W"C'4DX Z!1PHPHP !70T44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %07
MME!J5G/:7423VTZ-%+%(,JZD8(([@@U/10!\^>$OV3[+POJD>CQZC._P\L9)
M9;+09)O.@:*:&6&6SEBE5QY:B4E7B:,MNPZN5WGZ!CC6*-40;548 '84ZB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>adag-20221231x20f018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $H 4X# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<8=CO)Z@=.GM7 0_L=?"&+5QJ \'0-*)C<""2XF:W#YS_J2^S&?X<8'I7M6
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MA-XACTJ2?44L)&-U_8<2!FW$\A(P3P?5SM7)QUJQK/AW7]$U*T\2:-HUIX=
M,5O)"]UR4W!5\Q%!!XX(Z]/2O19;6'PYX[-QY2I;ZV-K3XY%PB\*3Z,N?Q6K
M/Q#F1O"\T0*F622)8U[NWF*<#WXKH51JR2T ZJT,IA3S@JRX&\(<@'OCVS5B
MHXSG)XJ2N8D****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #9%WJ1ZU\T_M:>"-%TKP[_PFRQBS\0VD\4?VBW.U[N,G!C?^]@9([CUQ
M7TQ7E/[1OPNO?BK\/;C3-,D2/4X)%N;99?N2.N?D8]@1D9[9IIV-J,N2HI7L
M?)OPIT+1WTAO%NN:UL>\D,J)+-E(E/W5%=/XE\1V=A=V6N:'K5K?BT?=+:>:
M,L/8=J^1/$VFZIX*\3Q:'J-Q=:=%:7#07&DW#?\ 'O)C(P>X/;MZ5U/V6TN+
M<!)2=P^88_K7N4,)&M34VS]+P&%IXF@IIV/3?$G[0>OZIKLFH7\=KY".2\$J
M< =^?I44O[1]J9XI+'PZ/[-(VO(6((.>6!]!Z8KPGQ/-H^FQ,UW>RRJN<0!C
MM'UH\-_$'2]2TYK>VDC(!P4XXKUOJ=!I*WZ'L>QP\6H629^@.D>)M-\2^&]/
MFT*]2]AFB!:2,\*W<'TQ7AOQ"^)]W\,_$MZ]K!9ZI9SQB.:\MW.Z&0'H6 ["
MO$?AK\4%\&^+DCM-;2Q@+A9(3(""K<,-OTKH/C3JNDZ7X):ST'4A?17#M-.1
MSEB"%.?QIX?A_!XSFIXV"J0=K)K3377^M3\1XVS'$9?B*>#PTFHO5R77R^13
M74?%FK>)VU/0KRYL[O5'+1RQ-L5SZ GC&:S_ !MXGO-?::SU9I)]2MH_+N9[
MB3?)*,Y4#LH&.@ZFN435-:AT33;6%)IC"H6-=Q"Q C)Y[#-7+.W:*Q,VK19G
ME7][)&WS( 3MV]CP>?6OIYY9@E5IUO91YH+1I)-+:VG2W38_-:%6M"G.#E9/
MO>S=_P"OU/T5^$G@3POX]^&>C7CZ?&-/?3H;:S2T8QE(U'S$D=6+[CSG%&MP
MW_PG\5:<\?B-H]"U&$V;7%S;"XG@\O+C/0, I;YB#@=<UYG\&?#VJ:M\(M(\
M-6&L:C820P?:9A-<+;QPJSEE= 5WD8/J*R[>Y\86WQ#&G^(;_4=?TS3[&Z6W
MU(V9G60RX0R1J%SC9E,MWR:_,*E7EQ$U>\+O?\]3]!IU[0@I+HM>FQ]%7GA_
M3/$,LUF[7WC&?8!(U]<8L8]PR,JN%)Q@X )Z=*\FT"ST?PQ=:_=ZE,@\$PZG
M)8+96\SQ11R+M\R6*/)W*),KCJ,9I/@E\99/#O@0:3>Z/>)!9VSR0:A!"9%V
MDN%,B\-\K#:3_L\U!%XHT/0/"G@V^^SPWZ6"NMVL]Q$9+KSLF4B+).=S$Y..
M#7,\4X4VX/33?31]?N[ \92=/VD7]_;N:7Q%37+O0;.^T<:Y:>'EO[78FH7(
MEDN6,@V^5$X.T=\L1]*DTWP%J_BBQN_^$2\37":'%)B?0]40+&9&!WI'MR8B
M..#E2>PKA_%7B3Q5I-C8Q3Z3JD7PZ6_BEM8)8@9?+WAE5I,_* >%''!'/%>N
M>!?"WC'4_$DOB(6MKX2TRX@$26"$2LR]I).Q?TQQZDTU.M0C!J7,FWJTO+7_
M ( 0<N:Z;:>^GXKR\CA?A=\9T^&MU<6&K026VF37LWVF&2)8W@D&!OCP ''R
M_,H&>A!/2OHS3/BKX5U;1X-3M];LA8S*"CRS",GZJV"/Q%>3Z3JVJ^!)]3\/
M^)(=+OD1Y[^VDNP(S=P%BQ=&(*EU)^9, C@CBO.M,TK7K[P%INLW5CIVB^%K
M65'BB4(]UJH:0X:5B/W:8(^098D<FNG%2I-.HU]SW7S.F554UKT/:[GQQIGQ
M$U.\6QO%FTG1C]J\N+B2\F1OE*MVC4X&1R2>W?M]&T)FGCU74I!=Z@5W+SB.
MW!_AC7M[D\FO#?&44^@Q0^(-+33K1+6,M?6>F,SJT1 WG:%P" ,G!YQFNW\"
M_$FU^,TMY:Z7=QPZ;9.([EH90SSY (",.B$'D]>U8U5&"CRO1_U_P31S2:3Z
MGK=EJ%O?1L]M+',JL48QN& 8=0<=Q5L&N/M/AW!IE]>7.F7UUI2W6PRP6K+Y
M191@,%(."1@$]\"MG3M%N;&?S)=5N[M-N/+FVXSZ\"L"G8V****!!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !367=WIU% 'SC^TM^QSX
M<^/D4VHK>3>'_$FP(FHVH#+)C[OFI_%CUZXKX7\1?LT?&?X;:PVE7/AZ^\1P
M*<6^I:/&98IU[$C.4/L:_70X[U#<!<$&NW#8RIA7[NW8]3!YC7P3O3?R>Q^,
MOQ,_9G\>^"M.TCQ)XST\:?I6J7/V5+9;@--#(02HE4=,@'O[4NA? VQN QLK
M:0$KEFB<C%?07[9OQ^N?&WBJ/P)I2Q)X:TJ]/VRX=?GGNX^RG^%%)(]SFO(+
M7QW'X89<W*H#RP)X/UKZ7#RKSI*I->\_R/T/+H3K8=UL3%<SUU['FNN?"U+'
M46"H8[I6X9Q\PQW)J^N@:J+*U>]F$]D)=K':<$@9 )K:U+QG:>+-;E,,XW \
MJIY_#UKMK)_M/AG^QPBM$[^>"1E@^,?RK[G#2<:49-)-[V/YHX@IPI9A5HTG
M>,7U=[=_EJ<GH^I3V=^(HVBO<QN%\WE_+8#(QZJ<8([5Z)\'?!\_Q;^)ECH,
MC0QV-F/M]Z\@'S0Q\[ .Y8\?3->4W<2^'/$]RWV.:[E"@);EL*ISR<]?P%>U
M_ CQ,5TV;Q$0^EPVFIM975Y%"&FMR\7[MBG62,Y*MZ<'O7BYKB9X?#U)4X;Z
M7>F_;7_(XL%:OB%&>J2N^SMZGU-KUYX;N_"^A26.J6J>(])0&&/#/'-QS;RA
M.J$<8/W3@XK6^'?Q)T;QK\0]4X_LR^@T6W\ZSN%*F'$C&09.!@$C!'4&N8^&
MOB74K'PA'-9KI]N\<S-:Z?:6'EI<ID[I&8<''))X/'O7.^,_AN-:\4>'_&9G
MU*9-2>6VO9=+8"=XE7>LI0Y! ((V8^Z!WK\MP3=6C:?5>[^#[^1^@4:LYPC*
M.W;R^\]!_LBRT+PO'#97\4 L9YY?^$B=,01K+,S^2!C]Z,'!7IQUS7E_@G1_
M#GB+Q[HNF:AI=G="">8M=F00FXN-^5;G&X*F,(/[U=;JFER:-X>GU32O&&L>
M*K:V4RS0LF^U\E<GRI-H_=N #@@#!ZCFN2T^'POKI\6:CH[&V87<-RUI>@O$
M(FA0MYBD@JX?.UE(;/2JC"+A*C45HI7^[N^VNUB*BA*U.2245>SUT1]%?&K2
MXI/ACJB^4&AB\J5XMN0R+(I88[Y&:X.7Q:WAJ\O=!\+ZQY&G,%>VEN86NO(<
M'YH(%'+\D'&<+7FGBS7]3_X19K"YU76+33+BU9DE>Y+37 VD!6+<+&3CYB-V
M./>N^\$Z7<>(_#.E:[X=F>+5]&")#I<NV-UC9,2Y##&6/S*3P<#FNET7[)7E
M[CZ]]K6[>IU)NI9PV&>/-,\;>)_#MK>^(++3+./2)8KR-XRQDF;>H!92#L^4
MG<N3G.*YS7KB^TWX2WEIJ=S#+%X=NKRW2RBCVN\D,@,?).26## QU-;GBKXC
MZKXRT^]\,7EM<:1J20RQF(*(S?2[08T5CE5R1D\^F.M2?#7PQHFN^(='UN[D
MEU2'7;1-3MFN)698KU,"52">7 QUZ%36:@U1G3MO>U_3H^V_W&,H\ZDH:WTN
M_P"NATG@CP&GQ$\.V>M:WK>H3IJ,?V@6%A<>1;1HWW4P@!.!P<GJ#5JX\%Z-
M\&=9T75="LHM,T;>;._BB7Y0LA&V4^^[ )]ZW_A5;CP]J6O>&P$2.QNC/;(@
MP!#)\P ]@<BNE\<W^CV'AO4)-?6)M+$3&=91E67'3'?/I],5Y$(QG2YGHU^:
M'&G%P4K>\NOFCHH+H3IO1E=<9!7D&K YKR/X(V^O6OA^XFOEF@TNXDWZ7IUU
MDW%M;]A(WOU"]5'!KUF.0,@Y[5W0DYQ4FK'1"7-%.UB2BD!S2U984444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Q\0?$+>$_"6O:
MTL?G'3K":\6/^\40MC]*Z>L7Q5H<'B+1-2TRY)^SWUK):R<9PKH5/\Z-+ZE1
M:339^1]O+#XOAFO-2/VJXO97NIY0<'S'8LQ4_4FO1?A)^QA:?'3PUXEUAM4U
M32DB/V;1I6<-#+,O+LZD99 ?D.,=_2L[1O@#\3O!>JS>$_\ A#+W4'B)M[?4
M8$#6LT>?ED\PG"\8)SR.:^NOA/I_B>ST33?!>@75GI]OX:C-OJ6IS6Y99[P_
M.88ER#M&[E^_:OH,?CU1IKV+U>UC[G/,PH_4H4J#3<M++>UOD?EGXJ\.:M\,
M/&T]EJ-HUIJNGRF&YM9,H6 /WESU!Z@CJ*]W^$7C&PN+>>:Z7,!M9&B=D)<2
M@';C'7FOLSXN^#_$OB;5=(3Q)X3M==T-6\J_N-(BC>XD!.%*[P2JCDE1SZ&M
MGQ!^Q+\,O%6HZ;J2V5_H\MI$D7E:9=&!)57D;QCKVR,5TT.)9U+P=/E75OOY
M+SZZ_(_#<7E%7%\WLY:KK*^OEY^I^:UKJ>H^(_&$TD5A>WSHA4?9K:28N<\M
MD*<]*^F_@QX&\2^'-#O9M5\/7&D6VKWT8:758'BCB78%C+\<*Q))^@!Q7M^K
M>%I_ 7Q,T'PAIE[=Z3X/UF0H(XYP""J,S;&Q\G( Q[YKU:]\(:U;Z9<V:SQ^
M(-+GC\N2UU'_ %Q4C!42#M]1^->#FN?5LVP\\)['E5]=;[:KMH;8/+;7DV^:
M.CVM>R^=G^NQX5X4T:\CMKKR]>N-.TFR"VUU<$*(;><G+1RIU$?0!OZ5N:'?
M>.7O+&[L=,M=4MKNXFE@NK2XCB8 +Y;.B-A0",L#GFLW3-5M/#AO]0D3[#J5
MC/+8W-O+'N34+?.W+'HSKTSW':NE\,^#;W3]1'_"+7C1MI%I#?0:?-(9(!/+
MNW0J?X4>/.5Z X(Q7E8.O'$.U]8KU79/R?X'MX10E:*;32Z/Y==C/\5_8+G7
M[?PY%9ZOX3>\A\[59(E:5K^$$94JF0Y;G+\$<CO2Z?\ "NY^*TFM:Y'K.GVM
ME)J+1P.+!D95BVJ"OS#^[C# C(SBO5Y=/TCXN^%[>_\ *FL=1@+-#<I\ESI]
MPIPP![$,,$="/8UY/\+OC%)X%FU'0O%'G70EO)KBQN[-!*9%+?.&122N&R0,
M=&IJI4IN5*O._;\+HN?+"?[]Z/9_H]3T3Q;X/TC3=*TGPW' #:ZI>J;^ZN2'
M:6*-2[*S?[6 ,#'&<5R_B#P=9:C?&3X;Z9>V6KA?+&LV=^;>TMUR#A@Q;S!_
MLJOY5.-:N?CA;ZE]EF2TBTR3S+#3'!2>9T_CF!P0K<@+Z'FO6/!>JV6L^&K"
M[L(!:0.F&@Q@Q.#AD/T(-=$*U2<8SIO3KY_\ [8R<]8?#_7W'B&OZG/%\+-5
M\.6QM5\>BZC26VOLN)KDRHWFCH2K*F<KT]JP?"5_JZKI/V6+3M'CN-1?58RM
MP\\6GS.S),A^4%8W<D!6Z'BNY^/.D6&DZ]HOB&Y6VNK=IU2>SN%)WND4FQ@1
MR.&P?HOI7BD%G:2ZEJT>L:7#8:7K"EM]GI\LAACW9,L"CYL'E=Q[Y.*UDZ4;
M?O.6-KM+S=K^B.2O4C3J17-9=4NE]F?4.@^&]3T36;KQ)KFMQ7DIM3#+';6P
MC0("6!R.3BN,\<_$?2?$<?A6>XL=26PCU..=S<V#F.5 K;<<?,,X(KF])^+N
MF:U\-G\,Z=?SW.K7,KV$"3V\GR6QD*AV8@8VQY)R:[*"5_'=UI6E:!;,^C:3
M<0O/JT@VPDQ\;8A_&>Q(X%>+62BW2I/;YW=R7.,TX4))K[[NYTJ?%G3KY#;^
M'8)==U%_^7>")E$9]9&.-HS6AX7T?Q&U])J>NZK^]E3$=A:?ZB'/;IEB.F:[
M2.SCBR54*S=6 Y-2K JG/)] >U=BI2D^:<K_ (([E!WO-W_!#T! P>:=24M=
M1J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3&CR
M>3D>E/HI;@4KBT#;=I/7I7E?BS7]/^%7C>RU&ZN%@L-9W17*,?N2+C;+].Q-
M>N2L4(.,^GUKS'6-+B\1?&&"&]ACN;6TT=F:*0!ER\N 2#_NUQXB+<5R[W5C
M"LFXKEWNK&9J7QYTK4-332_#P@U6]9B/-EN1!"#C@!B/FSTX%=EX2\=V_BBR
M(:)K6]@.RYM)#\\3C^8]#WKD_BQI/A_2_"[IY5AIMYN$MF0BQEWC(?:#]%J]
MK?A:7Q%;67B'1)%L=?$".LO\%PNT'RW'I[]JYH3KQG)2:E;HOT\_GKY&,955
M-J3OMHOZW_,R_BAX+B\>^,O#VGS3& 1V=W<V\T8^:.8/$%8'Z$U!9?$W5O!=
M\OA_Q'I$UU+&H:._M&W>>N<9"=2>.13]&\;)KOQ#\/V][:OI>KP6MW!<64_=
MCY9!0]&4[3@BNA^,%E'<>"M5NE0"XM81-#-C!C*D'(/:LY>\IUJ4K-?Y+1HS
MY;\]:D[/KYV2T9Q?@IM"\7_"_P 1)>20A/M5W+=O,/FM0S%E+ ]" ,_A7F_P
MQ\8V^DZ-J=T^IZQILT=P4DN8[7[3;2*/E0$=5( [XZT]9M2TU_%N@3VD>GCQ
M#=+?1F\5HXVB5P'0N >&7G(]:BCUV^T?Q#JEK<ZMIV@1W5R\PGLX9KN*5'4?
M+E< !2.^*>&J48PA*I)7=XRUMMJF<BJ17LYRMI=/IZ/R_P"":^A:Y;^,_!GB
M>X76+MKTZIY/V*$"!6DG=1&_!W'*8/7C%5_#&CZ(VL6,NCRVNDZ_X=-[)=WM
MR#E!NVJDH."0P[_E72^&]1\ >"-"5/#,$'B#Q$X5GN8(&9I9P,"5QSM SG\,
M5B:5H/AC5O'MVOBS[7-?2PP3VU_.DD DSE9 1P  P&,\<BNF<J-3$3JT7=V=
MM?EN:-4Y34H6;]=OGW]#%\3^//$MSJ/_  D;?9]"TV6V> O;L4-XJ'<51R,@
M^AQ4/@+XN6OA'2K>PF\2Q6VD7*R332#]_=6[D[B6_NANV<G\Z]8^(W@+2=,L
M-,UF[FNKZRTN]CNI+:>;S$"#@D ]<9S7CWQITF^TBVL_&"Z##9>'=8NH(;ZQ
MMT_?*H;]U*_&!DY! ]17(Z56C1]V\G)MOY?UZG'B*>)PZ=2,KO?\NVR\C;T*
M-/&WCFUU;6YXX=!MKE9(;;5;U!))%Y;8D9,YW,2I"X  %=C>>)X9?%\/BJ"X
MC2PM+I='M;<'*W$/WIF!'8'&,>F.]>G:)\/_  S)I-L4\/V#J55QYUNK-DCN
M2,]ZY3X<:/I7C;7KW6C:Q6]OH]W-8V.FJ %@*,0\C+V9B. >@KU:%.[4VDHK
M>VM[^?J>S"ARM/YO^NQ+X-^%&F:[X<+ZUIH2>XNY[E&8&.81/(656(Y^Z<$5
MZGI>BVVD6<-K:1K!;Q*%2.,8"CTJU!%Y:XQS4U:6BY.=K-G2HI.Z0F/QI:**
MHH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I*6B@"&X#' '0FO-O$C_P#"/_$C1M0?=';:E&VGRMC@N#NC&?<YKTXUPOQ>
MT*YUCP5?O8C_ (F5EB^L^,YEC!91_.N>O%N%UNM?N,JJ;C=;K4Y7XRZ?%KFJ
M>#]/\B*]FFOY%-NV"PB,+*[?0=:Y3X:Z[K/A?P?;WK7KWVE6EVUCJ%G<J1)9
MNLOEDHYZJ."0>QK0^%WC?3OB!XXEU:Y>6WO8[2.&PM+A"A$;*&D=21ALMD':
M3@"N@T;2(+;QIXR\-W*?Z#K$8U&(8X+.-DI'T(4UYEE4G[:.C;LONTOZVZ]S
MAY%.?MHO5_Y+?[NOD-^-?AHW?A]/$NB[%\1:(PO[*8?QH!\\>?1E+?CBM32M
M8MOBY\,+@6KFWFO;9H94E'S028Z,.OI^%<=XD\:%_AMJGA[4?W.O0JEB8B=I
MF'F!5=#WRF"<>]7O%^A'P>;6YT#5+FPUB]"0062*KQSL% RP([#J:)55*3G'
MX;*ZZ_\ #] <ES2G'6+6J\]?QZ?<9EMKLEK\5M-M_$8BL#9:28!(SAH9"S@!
ML_PY Z&O88M.L;J,,D5M(CCEA$OS#W/I7@5U/KFC^+O$MWK-M8^);>WM;:"]
M0*8SL8%@0!D<'K6_\//$GB>\\+_V5ING);K92RQ/J&H.'B10=RJH4Y9L'O@5
MEA\0H3=.:>M^FO\ DPHUTIN$D[MOIKV]-CJ_ ^BV=O\ $KQE<6EC#9VL0MK-
M5@0(K.$+NV!W^=1^%7/B+X*N_$.H:1?Z8EFU[9M+%*E]N\IX)%VLI Y."%8#
MU%<E\.OAW#XMT";6-7U6]NKG4;N:27R)3"C8<J, =.%%;UW\.(O!Q75_#K7#
MWEMEW@N)WD6=!]Y<$]<=*[*$YPIJ48:._P!S\O3H;49.,+J.CN]^^IP?BS]G
MO6/$MG;Z)J.O376DR0D-<)(T;VK 9 C0'!&['+9. 0:T_AGKVK>+?A=;Z7J/
MAF3Q'!'YNG37:3Q1PW0C<IYB[CG''7'4<=*] UF]N?B!X OQX;NX;.^N[9XH
M)[@'$,C#!W <@C)_&LSP=X*\4>&O#FF:+!J>EZ?:6,"V\0@M7D;"CJ2S8))R
M<X[UZ]*:=/5Z=.R]+;(Z81C'6.J+?POCU[PWX>NK;Q28;>WLI,6EU/<JTGV;
ML)FZ;EZ;NX%<E\/8I+309/%^DYO%>_O6O(HV!^U6WGL0Z8X+ #*^HX]*ZI?@
MM::W>1WOBK4[WQ3-$VZ*WOF"VD?IB!<(?JV:[Z*QBLX%AC1$A5=HC10J@>@
MXQ[53J))VZ_<;#="UBVU_2K34;.43VEU$LT4@&-RD9!K1K@/@_;3:1HNHZ).
MCH-)OYK6%G4C?#NW1D>HPV/PKOZR:LVD)Z,****!!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56_B,T++@$'U]*M
M4UTWJ1@?C0!X7XB^#^H:7I[+H5['/;)(TUO97?RM;N26/E2CE>3TZ5S$<_C7
MQ=9Z7K:6,D L(Y(+JYM;A?.N(=P$B(,<,-I^IZ5])7-M'Y1!&..QKRWX0ZC:
MVEKJ^CW$Z)=6VI7!\AVVN(R^5.#VP>M>/5PL/:)7LG^AP3H1]HDFTGY]MCA/
M"/ANT^)/P4CT^UD,FNV$DLF92?.BF\UV5'8\C*D UV_PJT*&_L5UN2>XO;X*
M+8PWC[FLRIP\8/U'7OQ7,P*^E:1KGQ&M2+0/>37,ELAPEQ:H/+"X_O%ER#[^
M]=K\($GU2UU/Q \#65KK$RW$%JPQM 4#<1ZMU-88>,95(.VK7WI;2_X!AAXQ
M4H76MOP6S*NLVG_"&^.[C4;M$FT77@D-P[C/E2*NU<_[)'ZUYWJ]QJGPKF\2
M:=HRVVJ:7J8\RW07.;BW8C:0%&2>#^E?1.J:!9Z]:7%E>1^=;R)L="QY!_E5
M#2? VC>&(46PL(X2.#*?FD/U8\FNBK@YS?N.V_JK[_>=-6@ZC]UV[/JK[G@?
MP_\ B/K$NCV^FV&HV5I>6$?E+I+V;))<E1NV!B>I 8YKWSPKX@M/%NCV^H6S
M?NY1RC?>0]P?ITKPOXE*?#GQ]\/W%A!YYNY;>4V4( ,SXDC9L]B%(S7HTG@3
M7=)UJZO/#.I6VFVM]A[F&XB,NR3^\GU&.*PPDJL.:$O>Y79_H]7^!RX6I43E
M!Z\KL_T?^9<UKX?A;Z74-'U2XT&X?)E$+9B?'\3(>*J?#'Q1K6MZCJ5O>26]
M]I]H=D.IVX*B9\\@ \<>HJ:Y^&^M:V!#KGBN[N[5O]9;VEO' KCT+#YL&NXT
MC0;/2;"WM+2!8+:!-B1IP *[J<)RJ<R3BO7?Y*Z.V,9.7,ERK\_S+]JVY&.2
MW/4U(R!NM)'$(EPHP*?7?8ZA@C53D"GT44P"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BGP4(/3!ZU
MY[X^^&UGXPMIGBC^Q:L8V6"^A;RW#$$ ,1U7GI7H4_\ JSZXKP_XMCQ[9:DT
MVD32W>AO&8_L^GJJ7,$N.');ADSC.,$=>:Y,3;D?-&Z,*[2IOFCS'GB>,)]2
M^'6G:%J1B^SV>I_9+[[.IREK$0&=US]TR$#(ZC!KZCT=88]/M1;K&MN$ C$?
M0+CC'X5X3\._ VE3:M/-:1;M(33FL=0O+@[UN[A\-)C/\*$'D=S[5W_P9U">
MY\./:L[W-E9W$EO:W+_\M858A2/PX_"O.P'-!KGZJWW?I^IP8/G@E[36_P"G
M]?>>D JO/ S5:_G6.$EI%C4<EB:FVB0!@.,8KRSXV^(-:T30C!8V4+V5\CVT
MU]+*RK:%EPK-@$XSQGH.]>M5J>R@Y/H>E4FJ<'-]#C(6M_&'Q*TWQ;YJNB:]
M'I-G&IW;8TBE+L<?WFP1["OH9(?E&YBU?+_@K0M5L-(T#QQ-=0RZ;8/&]UIU
ME$$P(@\;2$Y^9N23TR*^F=,U*&_M(9H2621%93QR",@UY>6MVDY;NS];]?T^
M1Q8/52DU9O7U\RWY8SUIP&!@4M%>T>B%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #),;
M<'N*X?XJ:)JVM>%I+;2<M,77S8D;:\L7\2*W8D<5W1SVIKKE3ZUE4A[2+B^I
M,XJ<7%]3PN[U*R\:VFB>#M&#Z18NA>_3'ERQ)&<& #^\S8)]OK7IHUG0?".E
M017%Y:Z=#"@18V<*0 .!BN,^)7PM3Q3)_:.G74NEZU;_ .KEA^7S3S@$_IFF
M?#?P;X?U;28M1DL1<:FKM'</?MYTB2J<.,MGO7E4O;4ZKBXJ_1^2Z)')'VD9
MN-EZ^7IY'I6D:]INM6HN+"\ANH3T>)P17/>.?&.BZ-;_ &*Y'V^YN,H-/@7S
M)9<\8V_U-9&L_"/2I[S[?I4LV@ZDQ_UNGN8UD]FC^ZWY5P/PD\&:[>Z3/XAL
MO$"_VA=7$T4DEW:!W.URN W7' XK>K6K)JFHZOK_ ,!CE4J)J"CO?[M.A6T0
MW=O\-M9T1;9K?^TM:;3+2PW;C;K(RNRY]EW\=J^@]+L4L((88H]L4:A(^,;5
M XKQJ?PK<^%?$'@"&^NA>7-QX@N+B>15VJ7:%RO'M7ND1^1><\48.#BWS;JR
M_7]2<-!QO%]++]?U'T44E>F=PM%(S;: <T +112'CWH 6BDSFEH **** "BB
MB@ HI/PI: "BBD)P: %HI*-P]: %HI"<4=: %HI"<=:6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH KSPEUP.<UY5%X:\6^$O%WB.XT6RTR^TS5+I;Q
M$N;AXVB<HH<$!<<L":]=IAC4GD UE4I^T5KV]")1YK:['ENI3_$Z\C\FVTWP
M]9S,,"6YNI7C3GKM5<GZ9'UK<^&?A2Y\'>%K;2[NX2[N4+R2SQ(41G9MQP"3
M@<\5VYC4G..?6C8%!P *B-%1:DVV_,2A9W;NSS?XPZ=.-#M=;M03=:'>1ZBH
MQG*KE7'_ 'RQ_*NUT>\@O;&&YMG#PS*'1@<Y4CK5F_L8KVUE@E0/'(I1E/0@
MC!%9/@WPR/"F@VVFK*\T5ON$;2-EMN> 3[# HC!QJN2V:_(2@U4<EL_S7_ +
MGB;Q%:>%M%O-4OG:.TM(S+*R+DX'8#N:R_ /Q$TGXBZ7+?Z1),T$4IA=9X_+
M96P#T^AK@/VA+N77G\.>#;-V^U:S>J9E0_=@3EL_S_X#6;X&MD^&7QVU?PW&
M/)TC6[9;JR11A0ZCD#WP'_3I7GSQ<XXI027(FD_5JZ_3[S&562JV^SL_5_U^
M)Z7X_P#B7I/PYCLGU47;"]D,4(M8#*68#.,"N5/[2GA.(I]HBUBSC+!3-<:;
M(B+]35'X]G=XF^&N/^@TO\UKUV\LH;ZVEAN(TG@<%7BE4,K#N"#P:KGQ%6M4
MA3DDHVZ7W5^Z'S5)5)1B[)6Z?\$CT?6;/7-/@OK"ZCO+2==\<T3;E8>QKE?&
M_P 7?#O@6Y2UO[MYM0D^[8V2&:<CL2HZ9]Z\Z^%5P/ ?C7XD>'H3G2],_P")
MC!&3A8P1DJ!UZ$#\*O\ [.7A^.]T>[\97T8N-:UBYE?[1( S)&#@*#VS_0#M
M6<<74K*%.FDI.]^J7*[/UUV$JLII1CN[W\K:&QI/[1'AJ^U""ROX]1\/7$YQ
M&=6MC%&W_ N@_&O5%=2H.X>N:\M^(OBCX>>*=,U'PYKVOV$<@)1@[_O;>0=&
M7(X8?_6[UT/A:SL]9^'5K8:+XAN+NV%L;2'6(6!F^7*[P<8W#&.G:MZ%:?/*
MFY*5ETLGZ-7_ !*IS?,XMI_F:\_BW3H?%5OH!N#_ &G/;M=)"%)'EJ<%B<8%
M:&IZK::1I\U[>W,=K:PJ7DFE8*J@=R:\-\,^"CX+_:'LX9-7OM:GN]'FGDN=
M0<-)G=MQD=N*[_XK>!KWX@Z18:5!/!#8K>Q3WHF+ RQJ<E!CU]Z*=>M.G4ER
M^\FTE]PXSG*,G;5%&T_:(\"WE_':IKGEF1@JRS021Q$_[Y&!]37H&I:O9Z5I
MTU]=W45M:0KYDD\C (J^I-><_&R[\.Z)\-=3TZ^6V02VQ@L+-5!<RXQ'L4<\
M''(Z<UY[XVNKJR\$?##PQXEO4M+>Y"S:LTQ*$0Q*&5'_  .TCN0*PGBZF'<X
MU&I-)/335NUGJS-U94VU*S_#K;7<]1T7X[^"]>U6+3[76E^T3,$C,L3QI(WH
MK, ,_P Z[^XN%AB>0L J LQ] !FO$M8^(/P\\=:;:Z!JEEJ&F:?*Z"RNIK(V
MT:L#A3%)CY?KZ5V?Q0OY-(\!S65C*?MU^(],LBS99Y)"$S[D*2?PK:EB).$Y
M2DI)=M/E;7Y=RX5&TVVG;L=7X<\0VGBC1+;5+!WEL[A2T4CH5+ $C.#SVKF=
M)^+WA[7/&UUX6M;B9M5MO,#9BQ&Q3&\*V>2,_H:N:WJEG\,OAS/< !+;2;+9
M&!QDJH51T[MC\Z^<KCPI>^!? '@SX@%&;54U)K^_?!#&.8@J#^"^G\=8XK%5
M:#BDD[*\O31:?C]Q%:K*FU;IJ_3^OR/JK6M9AT#1KS4KHO\ 9K2%II/+7<VU
M1DX'<UYK%^TMX6EB62.TUR2-AD.NER$$>Q%=3X^O(=2^%6O75NX>"?2I948'
M(*F,D<U0^!4>[X1>%L$Y^R#_ -":MJE2K+$*E2DDN6^U^J7=%SE-U%"#LK7[
MFIX(^)F@?$**1]'OA))%_K;:52DT?/5D/./>K_BWQEI'@O3#?ZQ?Q6-MNVJ6
M.2[>B@<L?85Y1\6;:W\!_$_P9XKM4^RF]NC8:@8.#.K8 RO<X/7V'I2S64'Q
M$_:&OK+58Q<Z;X9L8W@M)3F-IW*DN1WZC@_W1Z5C]:JQ3HM+VETO+57O]U_F
MB?:S2Y?M7MY;7N:;?M,>'(2))--UU-//2_;3V$7_ .JO3?#?B33_ !3I4.HZ
M9=QWMG-]R6,Y'N#Z$>AK*\4^,O#?AB.*UU[4[2RCND8)%=GY9%'#<8P1SC\:
MY;X06?@[3+W78O">NIJ,-S*+N2QC<,EKU "<# /OZ5M3JU(5E3G4C+RV:^5W
M=%1E)3Y7)/\ !G<^+/%VE^#-&EU/5;D6]JC*A8 L2S'   Y)K4AG62)'W?*P
M##/'&*^<OVC? ,UAH;Z_<>(M4U#_ (F$8AT^Y=3;P!R<[ !V' KWB]TN35_#
M;6<-[/ITLUL(UNK4CS8B5'S+GC-:4Z]2=:<)1LDE;SO?_(J,Y.<HM6M_P1'\
M6Z?%XI@\/M.?[3FMVNEA"G'E@X))Z#GM6G>7]O86LMQ<S)!!$I>221@JJ!U)
M)Z"O"?"/@P^"_P!H>&W;5KW69;G1Y;A[G4&#2;BX&,@=.*V_VC]00:1X>T:Z
MNC9Z?JNI+%>R[@JB!1N8$]O_ *U8K%SC1G5J*SB[6_+7YD^U:A*<EL;NG?'W
MP1JNK1:?;ZZ@EE<1QO)$Z1.QZ .0!7HB/E<YS7AFM?$7X<>(]"C\.7]G>V6A
M3;8+>]DLFA@X( *28^7_ 'L>M>T:3;QVFF6T$4K3Q1QJB22/N9@ ,$GOD=ZV
MPU:51OFDI>G^6OR?4JE-SOJGZ%ZBBBO0-PHHHH **** "BBB@ HHHH ****
M$(![4V7A#Q3Z9+&)493G!!!Q28'SM;>'+CXS_%CQ%K%IJ]YI%EH^VQM;NQ;Y
MF;G=@]@>2<52^*_P^U'X<Q:-XQ_X2/5-=N-,OH@S7S[S%&3SCV) ![<U] >'
M/".D^$;*2TTBSCL8))#*ZQY^9SU))ZFK&L:#9>(--N-/U&!+NRN!MEAD'##.
M?Z5XLLMC.E+F?[QMN]W:^Z^[0XGAE*+O\3UOYGC7QSU:UEU'X9ZB9DCM&U1+
MCSG.%"$(V2?H:]&O_BMX0L;.6XD\1Z<4C4L1'<*S$>P')-2ZI\+_  UK.DV&
MFWNEQ7-C8#%M#(6(C^G-4+/X'^!K&XCGB\.68D0Y!92PS]"<5LJ.)A4G.'+[
MUM[]%8TY*D9RE&VMCA_@_P"'KWQ3J'C/Q=J%L]O!XB8P6JRK@FWP0&V_3;S[
M&JWP,\60^"#J'@/Q%,FFWUA<L;4W+;!<1L>-I/'7&/7/M7NT<"PHJ( B@8"@
M8 'M6%XG^'^@>,HE36=,M[_;]UY%PZ_1AR*E8.5)0E2?O1O>_6^K_$%2<;.+
MU7XWW/._BT? &@:'J5Y/I6E7VN7L<@MHHHD>>>9A@-QD\$Y)[8K2_9I_Y([H
MP/)$EP.?^NS5TOAKX3^%/"%X;K2=&M[6ZQ@38+NH]BQ./PK=T'P[I_AC38]/
MTRW6TLXRS+$F< LQ9NOJ2354L-45?V\DEHU9?+6^EPC3DJG.[+3I\CSC5 %_
M:4T;L#H$W_HPUI?&?XA3> ?#,;V+1#5;^=;6T,Y 1">KMGC"CFNSE\-:=/KL
M6LO;(=3BA-NESSN6,G)7TQFJGBCP+HGC.&"+6K"/4(X&+1K+G"DC!/!K25"J
MJ=54W:4G=/MHBG"24N5ZL\I\&Z#X%T>\BUK7_%>G^(_$WWGOKR\5E1O^F:$X
M&.QJ/X\VMC=ZEX#\2SB*\T"WOMES,IWQ^7)M96/4%<J<FNY_X4+X#_Z%NT_\
M>_QKJAX6TO\ L)=%-E$^EK"(!:NNY-@& N#7.L'.5&5&48K9Z7>J=];[F?LF
MX.#27^9YO\=/$6@7'POU&U-U:W4]Y$JV$,+AWDD)&PH <]QR*73;:;7O&7@_
M2[C<W_"/:4E_=HW/^D.@CC!]P-QKI=$^"O@SP[J45_8:'!#=Q',<C%GV'U )
M(!]ZZ6R\/6.GZE>W\$(2\O2AN)N2S[1A1] .U:+#U9U/:5;+;1=E=^74ODE*
M7-(\A^/\T_BC6/"_@&TE>-]7N1-=[#T@0]2/08+?514FM_L_7MYH=Q8MXVUR
M\@,)5+2XD#1-@?*I'IP!7JC^$=)?Q(-?-FAU<1>2+HY+!/0=A6LT8;OBD\!"
MK4G4K:WT6KT7;\V)T(RDY3UO^1X%X \2OK/[.WB"PN'S?:197-C+&>&4*IVY
M_#C\*Z/X,^//#FE_"WPY:7>N:?:W,5J%DAFN%5U.X\$9XKNK7X>Z!9+JRP:=
M'&FK9^W*"<3YSG(S[GI6%_PH7P'Q_P 4Y:_FW^-9PPN(I2A.+3:CRZW[Z?@B
M(TJD'%IIV5CA?$FIVOQ?^+'AO3](8:GHN@RM>7]TOS0%^-J@]">/U/I2^(M0
M3X4?'5]>U$&/0O$EHMO+=D96&=,=3V' _//:O9-#\,:9X:LUM=+LH+"W'_+.
MW0*"?4^I]ZEU?0K'7K-K34;6&]MF.3%<('4GZ&K>#J2BYN7[RZE?I=*UO2W^
M93HMIN_O7OY=ONL<QXGD\$:SI2:KKAT>^M+>,M'<7)20*A[K]<#I7E_P N]/
MU#XH^-KK2K,6&ES0Q-:PK'Y:^7N(# >AP3^->CV?P&\"V-Y'=1>';7S4.Y=Y
M9US_ +I)%=79^&--T_5)]1MK2.&]GB2"25!@LB_=7TP*;PU6I6A5FHKE?35O
M1K>R#V<I34W96_R/,OVHL?\ "L%Q_P!!&W_F:]7TW']GVW_7)>O^Z*I^(?"N
MF>*]/^PZM:I>VN]9/*DSC<.AX]*TXH5AC5%X50 ![5V1I.->57HTE]U_\S91
MM-R[V_4\HNR!^TMIXQQ_8,G_ *&*I?M)Z;&^F^%]4N8?/TK3=522^79N'E-@
M$GVX_6O4SX8TYM?36S;(=42$VZW/\0C)R5_.K5_IMOJ=K+;7427%O*I5XI4#
M*P]"#UKGGA'4I5*;?Q._Y6_(SE2YH2B^IYS\7?$WAFZ^$^L%KRRNK:YM&2T1
M&5]\A'[O8H[@X^F*Z;X:6MYI_P /O#T&H#=>1V42R#&,':, ^X&!^%9^E_!#
MP3H^HQWUKH%LES&V]&;<P5O4 G%=RJ!5QUJZ5*I[1U:MD[6LOO\ (J$9<W/+
MT'4445WFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>adag-20221231x20f019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (K Z<# 2(  A$! Q$!_\0
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MLL.2._(ZTTON&X#J>@ZBOSK\'_'GXM6O[%VF_'A/%,5_J-B99]4TV[M T-U
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M*#1D9QWI"Z@X+ 'TH 6@C-&X'N*6@ HHHH 0\T8!I:* $VCTHQBEHH ****
M"BBB@!-HHI:* $Q1@4M% "4M%% !1110 F.:6BB@ HHHH *3&:6B@ HHHH *
M*** "BBB@ HHHH **** $(S2T44 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110!5O23 ?2L[GM6C?\PG\*S>M?.YA_%7H=E'X0+
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M'IFF6W,UU*K%8_<[03^E<KX>_:'^'/BF_M++3/%^G75S>*&MT^>,3 Y^ZSJ
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M)V<6?I^\F%ZY[BOD7]LCQ[+=Z_IOA6WD(M85%W=(/XFQ\H/X.>*^?-2_:?\
MB#I-RUM>>/&@G15=HR&RBDX#-\_ )!Y]JI3^)=7\7:I)JNLZC_:5[.JDW/9U
MP-N#D]L5U8? ^RGSRDG8\;-,7S8?EBFKM'6Z,-PB)8KG'7ZUZ-X>/[QAM[$@
MYX'X5YSI"+MA!R1P<]<&O1- 1@2.PYX/45I6\CP,.=SIMTMG"MQ<!(X8D)9B
MY!Q@\XZ<].:\O\1>)+GQAJS'.VRC8^3&O"D=B?<UK^.-9>'3HM+B?<L_[R4
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ML=M*E&DM!XI:2EKE-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDOHX)EA\J-5;9@\<#ITZU]6_%3]GS0?$\*&72+?4+-)EF%I)'D0N&!#IZ$$
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M_K57XFRKJ'[1OPRTYX]R0B:Z:0]#F.9<5X-9?Q5WE!?^DGW.%=EA7_+2JO\
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MB@9Y!']:W?)-W9QJ52GHM3IW\42*N?,WDG/':LF\\1O([[GXSDY.,9]JRO\
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MPOJVNR+'9:?,S< M+&8U'XFO0A",(WN<DI.3M8Z73951"7./3WK3.O&.,#S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH C8_-CIQ7@/[/[?\7;^*XR/^0I(?_(C5[\W7/?M7
M@7P 9?\ A;?Q6 !&-4DSZ']X:ZZ/\*IZ+\SFK?Q*?J_R9[^>17@NAY'[6_B0
MY./[$LN/7YKBO>F&17@6CNP_:Y\1GH1HEEC_ +ZN**&U3_#^J%6WAZ_HSWU3
MQ3JA$A"DY&!WH,Q SW]*Y#J)J*3/%(S;>: '45 )SNQUSW%34 +13)9/+&3P
M!R33%FW=<*>PZT 345"9^XP1G'XT-,5YQD>W:@":BHDEW$#'./6I* %HHHH
M**** "BBB@#"\7>(;7PCX>U?7+[<MCIMI+>SD=DC0NQ'X*:^<?V</B?\0/VF
M?".H>/HM7M?#>@7%W/!HVFVUFEQE8W9/,DD."=Q7..1\WM7T;XQ\.6OB_P ,
MZQH=Z7^Q:G9S64X3[WERH4;';HQKY^_9[^#GCW]FKPM/X&TXZ9K_ (3@N)9]
M*NB'6:W61RY6;)&>6_A':@#B?BQ\8?BKX*^*WP<\'W&OV5G-XD+0:PL6GQ2
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MYAGND!@Z\2 GY>AQ]#7QM^S<]U+JWQZBBMC]LN=7D>Q66T<8?['$J.A*X^\
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M2IG:,G)JO&X\M<<\#G\*L(25&1@^]=QWCJ***8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $;'YOI7@?P +?\+:^*X[?VK)CCC_6&O?7&:\ ^ ((^+?Q7
MY_YBLG3I_K&KKI?PZGHOS.:K_$I^K_(^@"<#_"O ]'#?\-;^),!2#HECG/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQM<^Y]:[9:JA-SIJ4MQ8JG&E6E".R\[_ (CZ***W.4**** "BBB@ HHI,\T
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M[9TRDZ_,I'!!KN/#WBJ/Q=H$=P=HN(28[A.F&'?\>:R:ZQV-8]F<OXEV@G:
M/0"O-==W8D !9MW&/6O2?$A^5O3/>O-_$ P)&7)P<_XUK3,I['M'PI^,NCVO
MAN.TUB]\BZA^4;QC(_$UW$?QB\*2$[=4C;'H1_C7RG<6]EHNG-J6I7,=I9Q
M,\DV HSQ_,BHH?&OA:&'S!>*4\L2;/*;)0_=?[O0X/Y4G1@NHE4EV/K=?BOX
M9<9748R/8C_&K"_$KP\Z@C4(SGW'^-?(NG?&7P'/HBZNFM0_V:QVK=>4^UL/
ML('R]GX_"O4QID5G:2WMP5AMH8C*\C\>6@&6)_"LO9P[FG/(]L3Q]HCC(O4_
M3_&H+WQ/HVJ64]JU[Y<<R,CM&VU@",'![&O,-$M;35+*&]M)8;JUG7='.F2'
M'J,"I$U;2(_$PT#[? ==DM_M7V+!WF$[OGZ8Q\K=^U2X11:DS2/A#3O"LOG:
M7KFM3><A_<75Z98&&>N,8S5K3-;N=)F5HY28P<F-C\I]>*ZB3PZ-6T:U:,JD
M\:X5FX!%<SJVGZAX9M)K]K,3+;J6/=6KSJV!]O)3HSY9';0QWU=.G5AS19TU
M[\3-*T^>.&<R"0H&8*F=N1_]>MS0O$=CX@MS-9S;P#AE(PR_45\WZQX[;Q%J
M"3W5G#:,4VDPYP1VSD^E=]\-]"U>/5K:]BC:.R=26<-E7&.*X*L\PPF*5*M3
MO!O1I?K^9ZL*.7XG".K1J6FEJFSV8,#2U&O85)7LG@A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<K\3W>/P!XA:*S74)18RE;22/>LQV_=*CJ
M#Z5U5<O\2T>7P'X@2*\CT^0V,H6ZE)"Q?+]XX!.!["L:W\*7HSIPW\>GZK\R
MWX3=I/#^G,]L+5_)7,(38$]L=OI6YM'I6+X21H?#^GI)<+=N(1F=22'/K6W5
M4O@CZ&=7^)+U9!,VQUZ@'J?2OG/X$_M;6_Q=^.'Q#^']S9KIMQX<E$=J9,AK
MI0\JNPSC@",'/O7H?Q_^(J> O" 2)V74=4<6-KA20&<@%FQR %)/X5\-?'[P
M5XE_9O\ CW\,/BUI\=OJ06VBTK5X=)$C--;KM5I6#  LZNYR:LR/T#\;_$_P
MS\.HDE\0:S;:8K@-^^D "H3@.V2,+GC/K7E/C;]LCPCX7^,'@WP':2G4;C7[
M<WK7EL/,A2%L>448</N^;OQ@=<UXE\8_%&E:3^U%8ZOX^L9M2^%_C;PF-(MY
MV5C!;S&83A'QRKYC(RH_B'.*S_$?@:W\#_MC? S6=,\/7%OX&M?#BZ39LZ"4
M1$)MC1V8DDC>O))/O3 ]N\$_M&ZE_P )U\4Y_%>M>'X? _AQHS9R6C*+JW0K
M%DW WDCYG/4+U%>KZ3\9O"FN67A^[L-7CNK;7?,^P2Q8(G"!2Y7GH P.>>M?
M(O[.W@J'Q9\>_P!H[2-2LLV.N#RHA-%^[D7RH5!''9Q^E7_V-/ ^O^"_A3XQ
M\/>.-&FU+3?!5UJ=AICQ#9<W$041R+&<C&50;3D')H&?5%K\=?!%[XFM/#\7
MB2P;5KS>+. 3+_I10D.L7/SD%6R!TVMZ5YQ\+OVP_#?Q4^,OBKP-IJ3*NAXB
M^ULAQ-,&82#'91M!SDYS7P5H7BFSU'Q#\"]3TC3[G0=$TSQ=>0)IAC:22S#/
M=EO-E;<Y9B2<;BN&[5ZM\*?!/B31?C3^U?HL>BW6G:QXCAOY=!NA$JJPD,WE
MM&PY&01TQ2 ^]O#GQ2\+^*]1NK'2==L[ZZMP[O'#*K?*C;9&&#R%;Y2>QXKY
MR_:+_;%3PM<>#Y?AUXCT751=^(H='U"*1!<+(CSP1L(RKCYE61CGGJ.*\#_9
M:\)MXN\%(EGJ6LVWQ4\*:-J&C7&FO"L<,9DN?,9Y&'+;B,\[C\PKSJ#4+$_L
MX_!7P]'I3KXIT/Q;;KJT!ML3P.EQ:,[.V.<@'G)^Z:!'Z\--A6 /(..>HKPK
MP%^U-I/C+]H?Q=\+\+;W.CP1/:2.<&[<M*) GJ%6,'//6NP^,WQ/A^'?@2;4
MH@[W=Z1!9JJ$_O'!()]L9KX/_:3^&OB_X&?%/X5?%[2&MM5OM-5;&_CTP2&2
M: <-(VY0"Q65QSZ4#/IG]K?XV^-?A+XS^&UCX7O=/AM/$VK1Z7=I>VAG9%;?
M\T9#KM/R^]4M+_:?\2?#W]I2S^$_Q"2RO+?6[07>C:W80&%2,,?+D4LV6^7K
MD?>Z5Y_^V=XEM/%^L? /7--CN);8:[;:I+'Y9+6\3(['?[KO .*I^,OAKJO[
M4'[9/AOQ%I5C<6G@CPC8B"XUN8%4NY2' 6''/&5/('!I@>O>#?C[XM^._P 8
MO&_AOP5]BT?PKX/G_L^^U:\MS-+<W0+*Z1*&7: T<@S\W0>M=YX7UWXG:?\
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MQVT#1'_T(UK:=\3O%5TI$WB"]*R-_%,<]^!_CVKT70_V-](T^,"_URZNAG.
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M?EP1Z<FMZU_:'^'6I6D\UGJYNS',ELD-M!OFFD;.T1J#E^G;U'K7(?&?X/\
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M\TUY-\<HVECDX KTOQ&ZHQ((QDD@9S7FNO$ .0Q!SQFM*9%0R?CC\(IOB_\
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MG\A5Q1@"N:I.$W>,;&L(RBK-W&JA4GG\J?116)H%%%% !1110 4444 %%%%
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M9[$GTS7FW]OL,KYA_#O2-KXZJ"#V!/6DX!SG2Z\Z31@JQP23CTKSG6T:4-&
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MXZ # %3BFF/)!I]?2'S(4444 %%%% "$X!J";'E2;LX"^M3,,@@>E0S#]VQ
MR<'CUXI,:.%^$2::L7B<Z;--,IUV\,_GG)67>-X' XSTKOU.#CO7$?"XW)A\
M1&XTM=+_ .)S=; HQYR[^)?^!=:[=<$Y[US8;2E$[<:[UY?YW_(?11174<(4
M444 %%%% !1110 UL\5X_P#%'X$KXWU<ZO8W8M+YU"RK*NY'P,#ICT]:]A(S
M2;*N,G!W1,HJ2LSPKPU^SW-!L.IZD#&.'6V7:?S.:]4T'P+HWAN-4LK-0Z_\
MM).6/UKH=@'3CZ"@+C_Z].524]V*,%'88(UQ@*,>PH8 C[H&>.13]O4=C2!,
M=ZS+/)/B]\*SKED^J:.B0ZI$I+Q#A9U')_'_  KY@EU^:*=D8^6Z?(T;]5/?
M\J^^'4<< U\E_M._!F?17N_%_A]'D@D;=?6J#_59R?, ].I/X5Z6%J)OV<WZ
M')6@TN:)Z/\ LLWAN_#>K,<'%V1D'_82O<0<]\U\T?L2:@^H>"M<F),F-1*Y
M"@ CRX^E?2Z]/>N;$QY*TD:T7S4TQ:***YC8**** $Q2T44 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28I:* $I:** "BBB@
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MJ"-@NL[",\@X(/3/>NB*8'([=JBF7]RY)P<8S^%#G>7-9!&ERPY.9^O4^?\
M0)/C'+%?R6MIH=H3=RB2/+MN?/+<2=_?FO;_  H-670K,:WY/]IE3Y_D9V Y
M[9)/3'>N8^$UK#;Q>)A'J0U+=KEX[$-GRFW\Q_\  >E=\!QP/SKFH3<J,58[
M,315/$S:;?WV_$\S\?1?$AO$!/A9]+&F>4N/MBR%R_.[[K@8Z53\)P?%1-?M
M#KTND-I1;]_]G602 8/W<N1UQVKU=4(ZCGMWQ2;/FS@GZ^M=GM-.6R^X\]T$
MY\_,_OT*6O"^DT6\736C6_,+B RY*A\';G'.,XKQ_P"P_&O_ )^]"&!_<FY_
M\B5[ACCA>3360KRH!_I4PFX*UDRJE%56GS->C.9\ Q^(X=$V>*);:74P[9-J
M&";.,?>).>O>L+XAVOQ N=4MF\)W6GP60C(E6\60L6SQC:P[5Z($/<9HV-G.
M!24[2YK%2I)PY+OUOJ>-Z/IOQ?75K0ZA?Z,; 2J9UC27>4R,XRY[9KUG4EN&
ML9A:L$N&4B-F!(#=LXJT%.[IQ]*"O3@DTY3YFG9!3I*FFKM^K/$6TCXTL2JZ
MIHBKV_=S9 _[[KO?AO9^+;*PND\6W-G=79D!B>T5P O.<[B?:NQ"$8X />E"
MD<8&/>G*HY*UD9T\.J<N92;]6<3\2;+QC?P6B^$KRSM) Q\]KM7((XQC:1[U
MPJZ#\9FD0OK6CE W(5)AD?\ ?=>WLC'L.U#+D'Y<T1J.*M9?<$\.IRYN9KT9
M#;!Q:H)6#2[1N8=":\?U;P[\7)-7NGT_7-+BLFF9H8Y$E++'D[<X;KC%>S+'
M@8 _[ZH*G. M3";ALBZE)5$DVUZ.QP'PVTCQSIM[>'Q9J=I?P,@$"VRN,-GG
M.XGM6M\0K'Q+?Z.D?A>]@L;_ ,U27N%8KLYR."/:NJ52 .*3:<<C/M1SOFYK
M#5)*')=_?K]YX<?"GQD<A?\ A)M+7."3Y<O3_OJO8M$CO(M'LX[^19[U(E$\
MB@A6<#DC/;-:"K@=.12!3CISUIRFYZ-(5.BJ5[-OU=SR#Q#X7^*5UKE[-I?B
M/3[;3G?,,4B2EE7 ZX..N:U/A[X>^(&F:XTWB?7+/4K 1LHB@5PVX]#\Q->E
M;3GH0/:E"_[.#5.JVN6R^XA8>,9<]W][,+QG8ZOJ'AZ[@T*ZCL=4<#RII 2J
M\C.<<],UY6O@KXP@%3XOT\@_Q^7+G\.:]Q*D'H?RI0O&,?CBIC4<5:R^XJI0
MC5=VW\FT8'@NRU?3?#MM!KUVE]JB9\ZXC!VM\QQC//3%<?X]\+?$#5M>:?PY
MXDMM,T[RP!;RJY8MSD\''I7IQ1NP YHV'CC\>])3:?,.5)3@H-NR\]?O/)_"
M7A#XEZ?XAL[C6O%-I?Z:C9F@CCD!<8/')KTC7;:]N]%O(=/G6TO7B9893G".
M1P3CWQ6CMZG'(_6@*<\T2GS.['3I*G%Q3?S;9X@OP_\ BWM&?'%GGOB.7_&O
M1_A[I.OZ+H7V?Q'J2:KJ/F%OM$88#;@<<_C74;3TQ0%/X54JCDK.WW$4\/&D
M^9-_-MGG/Q$\*>-M=U6"?PUXDAT6U2)E>*1')9LC!^7\:Q-%\!?$ZSU>SFO_
M !K;7=G%(&EA6.3,B]QS7L!!(.!S2X.>F<4*JTK67W"EAH2ESMO[W^1%,K-
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M@CFC:<]..U/VT^7EOH0L+34^?6^^[_S,'QKX<F\5^'+K3+?4;C2I9EVK=VI
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MM2N!!'<%I]/%K;23+YB;?XFCQSZT ?8LU];VQ599X8F8?+YCA<_G4I8+DYX
MR">E?&/['>MI\;OA5XC^*GQ"UF\ENKC4[V%H9+MDMM-MX9"%\M,[8R%(!8 $
MXJ7]K;Q9!IG[%,WB#X>^.=1OK>UOK%+37;/5)))+I'O8XW4SALL,,PP3VQ0!
M]E*5<$@[LC[V>QJ6 8C ZX[FN/\ A+/+<_#'PC--(\MQ)H]H[R2N6=F,2DDD
M]3FNRC8L,D8^M #CT-02G*'J< YX]JG;H?I4$I;:P&,X.#F@:.(^$]U:74?B
M4VFGMIX37+Q) 1CS7#C=)^-=Z#FN-^&RZD(M?&I/;NQU>Z,)M\<1;OD#8_B]
M:[%:Y<+_  8G;C=:\G^M_P 1])2T5U'"%%%% !1110 E+110 4444 %)2T4
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M7/1_'OX>S,P7QOH+#S?(P+U.).?D^O!X]J .^/S9!)(]J\@^.'P4/C9(=?\
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M4NE[-:NT 5-OG8?_ %O09+=<UW*_>KFPO\&)WXZ_UB=_Z^X?11174< 4444
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MNL>)'CTSR/&GAN*1-HO-\C8D(Z[>>/QKTG7%/]C:@!@C[/(,8_V#7S'^SA\
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MG[H\_?\ 7MTKNE3))IPC'/O7']77\S^]G3];E:W+'_P%=[_UY'G#Z/\ $?\
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MB<$,DBAE(/4$&F6>GVNGVZP6MO%;0+]V.% BCZ 58HH ;L7T%&Q< 8X%.HH
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M:^,-#N-5GGEMH[!-1B,[2QD+)&J;MQ920" ,@GFNV% "T444 %%%% !1110
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M*)KJXQ&@"E\ [1L7CGI2 ]-MSDKGN./\:LU!$S%P#P<<CM4], HHHH ****
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M_9N81QE&74^D]6^,G@CP?J=Q8W.HPVEU&=LD21;"#W[<UGR?M1_#Z'(_M<$
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MW7OV8KNUT3Q"\NN> )IO*L=:)+2:?D@".?K\O0;OE')->E*I+%PY;^\NG?\
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MR-)R2W3CUK.U[0;+Q)HUSIFIVL5Y8W*&.6&09#*1@_3ZTW[5-R/,Q^!I3=3
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M3W-I<HSARC9R03@]>.M>O:]K=WXK^(_QPM]9OKB"U\+^!+:ZT,&8(J2XN_\
M2$SU8E%Y']T42PZ2T\_T!3;/N>2]AB95>6-2WW0S@9^F3S2PW27$0='1U/\
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M"NZ25 )$;!P%4'!_.O.Y1$)G$3L\0)VL1R:]IU+X,:9H?A6Z,T\UQ>\/YJD
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MXQM4X/?-%>V&%<]**^2IY'.FN58B5CVGC$]>1&.#VQC%!8#J<4#J:CD&1WP
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M6FES2S:K,Z2V!6UB5HX0-V=S<GE><]:?JOAWQ)XF^+GCN#6KG5=,MI=3@OM
MU*V@$L<MJEP'6.-BRE00I!QU#=Z^L/&'P-\,:I?ZO//!<%-59)+ZUWH8I]@
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M?^$3? .UCZ#N:]$U_P"&;WKF33=3FL7)R5;#*/IQ5#3OA5J2S@WVO2RP]UA
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M/PWI7"_ +]LR\\<Z1\3O%7C#3F\.^%O#=W-$MP[AQ"D3.&4J"69^!G'&1P*
M/KV@\=\5X1H7[7?@_4=?L=(U(7.A7FHZ:VJZ>MV-PNK==^67 X.(W.#S@=*R
M!^U7H_CKX?:OJ^A0ZI%I\FFW=U9ZM:O&2RPJ"S+\I$;_ ## <?AUH ^C<]\Y
M]Z=7R!\%?VKM*T?X4?#Y=4\0ZKXU\0^)S</9O>M%'/,J/-G<VQ$X$; # )V]
M\U]1^#O$\7B_PSIVL00S6T5Y"LPAN4*R)D=&! (/X4 ;>:6HT.6J2@ HHHH
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M!A0/:@!$!'48I]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>adag-20221231x20f020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (Q YT# 2(  A$! Q$!_\0
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M** "BBB@ HHKBOC)\4]*^"GPR\0^-M:$CZ=H]L9WBBQOE;(5(USQN9BJCZT
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M:KAU?5O@=<?#_4['5?#WC7Q*^E7\\L#>:D:0,[1[3@Q2!@,AAD>E=78_M?\
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M'4@4"%HII=1_$/SHWJ.X_.@!U%)N'J/SI ZGHP/XT .HI 0>A!^E+0 4444
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MK748K>;45O)I1++(F2R *%_=\#KD'- 'OU%%% @HHHH **** "BBB@ HHHH
M***3</6@!:*0$'O2TK@%%%%, HHHH **** "BBB@ IDK%(V95W,!D*._M3Z*
M /!=<^,/Q7M=(O9K?X*7:3QP.\;'6[:8!@I(S&@W/S_".3T%<)\%?V@?C)XM
MT._GU/X7S:\\-P4CNH)5TI0.Z;)A\Y4]UZ=#S7UD8D(QM&*0PH>2,GW.:SY9
M7OS'F2PE9U(S5>5E?2T?\CE?AYX@U_Q'I<UUXB\,2>%+P2%$L9;Z.Z9D&/GW
M(,#)R,=>*\G_ &O?'^MZ'HWAKPEX5UF^T#Q)XIOS$NI:9927ES9V<*&2XF2*
M-'8X_=I]T_?[=1]!)$J'(7%5KC1;"[U*UU":RMYK^U5TM[IXE,L*O@.$<C*A
ML#.",X&:M'HQ3BDF[GPA9?M!:U\4?$GP_35_B/>_#2SG\!:G>ZM+;W%O:B#6
M;.\6VE>1)DP=K)(3$V!CMQFF:?\ M$>/OB#IWA%_$FI77A"XE\%1Z_'I^FZC
M:Z*VO7;7#0R,+BX5Q&D<863R@,DL"<KQ7V=?_!WP%JDRS7O@GP[>3+/)=+)<
M:3;R,)G8,\F2A.]F );J2 36EXI\ ^&?'%M#;^(_#VE>(+>%_,BAU6RCNDC;
M&,J)%(!QQD4R[GS/H_Q;O+WQS^SI>6_C_4#H7BK3)FN=&UB2S2:?-D9(I;@H
MJEI&DP!MVJ2,!<FO/KCXM^,_#FK_ !HU[PI\2M2\:^$_#7AJZB@_MB6S>1]:
MC?\ >2VT4:*WD0+]XE=I.0"V":^S;OX3^";^_L;^Y\'Z!<7U@D<=I<S:7 TE
MNL9S&L;%,H%/*@8QVJ/2O@_X$T'4IM1TWP5X=T_4)D>*2[M-*MXI71_OJSJ@
M)#=P3@]Z /+?V1?B)=^+M$\0Z-JL^J7NMZ)/:B[O=0U>#5$G,]JDRF*:%$4#
M!.4"_*3P3FOH&LCPSX1T/P98-8Z!HVGZ'9,YE-MIMK';QESC+;4 &3@<^U:]
M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDA(7@XYQ
MFOCBR_:>^+_C#Q]>VNB67PXT#0K#7I-&N+'Q%KC1ZMB*?RW;RN &9?F5<'.X
M4 ?9)&:3;[THZ4M #=N>]?,?Q!&/^"@/PC_[%/6?_0XZ^GJ^8?B#_P I ?A'
M_P!BGK7_ *''0-'T]1110(**** "BBB@ HHHH ***0D#K0 'BJTNHP0/MED2
M,^CN!G\S5@R+C[P_.OEGXJ^-_ L?QSU#2M=T:7Q;?2Z7!#;6MB@G-M*KR;PX
MWKL)#)U]*VI4W5;2Z'+B*ZH14G;5VU/J(7((!"DYY&.:43^JE?K7P)XT^*7C
M_P"%WPHT&#7V\,W.F:-+90S>'TU8-J5Y&,G=*58E0"8]RJ#P1V!KE/A[^T]'
MKVN:]J9\7S_"6SF6WBCTZPLI-760JK;I &!*8R/8DUZ<,JKS@ZL=8]UK^6OX
M')''\R3]F_1Z/\;?BT_(_25KC;_ :D#@X]Z_'+X;?&#Q%;?$W3KC4?B)K&DZ
M>MT[/J?SW6P?-AO(R0V>/EQQGVKZ1TC]JG6M"\9O<6WQ7TSQ1H5K;@O;>)(?
M[(:X=@W"KY18A<#YAU)Q71BLEK8:5D^;2^S_ ,K?B9QS%Z<]-[VT:?\ D_N3
M/OT'-+6'X(UY_%'A#1=8DB6!]0LX;LQ(=RH70-@'N!GK6Y7SUK:,]A--7044
M44#"BBB@".>=+:%Y9&"1HI9F8X  &2:\;U/]L;X/:=I]U=+XZTJ\:"-I!;6L
MN^67 SM1<#+'H!7LTB+(C(RAE88(/0BN,U?X->!M8TRZT^X\(Z,+>YB:&3RK
M"*-MI&#AE4%3[@YK>DZ*?[Y.WE;]29<WV3ROP;^WI\(O%\]S')K4WAT0(K"3
M7(A;K)GLA!;)'>O7_ /Q2\*?%&SN;OPIKUCKUM;2"*:2REWB-B,@'TXKCO W
M[+7PP^'MS=3Z/X0LE>Y18Y/M@-T, Y&!+N"GGJ*]&T/PQH_AH3+I&DV6EK,0
M9!96R0AR.A(4#./>M\0\(V_JZE\[$0]I;W[?(Y3XV_%!OA/X"O-;MM*?7M6>
M>"QTW1XI/+>_O)Y5CAA5L'&2V2<<!2>U>42?M5ZSKMO\.5\%>"$\1ZGXLTN\
MU.:RN=5%H;/[*T:3PABC;Y [E<';R.V>/0_C1\"=+^.%]X7B\07=W_86BWLF
MH/IEK(\/VN<Q&.%FE1E=/+W,PVGDD>E>7Z5^Q9+X-U6RN/!WC[5/#$=A-J?V
M",6B7;6=O?-$TL4;RL3D-$6#MDY<UPFPQOVU(_$FC>&IO!_A,WVJ:IIUQJM_
M!K^I1Z9;:/;P3FWD-Q<,K*&\Y2@ &"1UKM-4_:!OM)O?A="_A3S[;QE>QV$V
MI6NJ136EG*Z2,%C=,^?GRF.0 ,8R<\5S%W^Q3HNFZ)H%KX4\07NB7NFZ9<Z1
M=7&H6L>HQZI;3RF:47,,F%9C*S2!AC!-7Y_V5;ZT\*?"_P /:)XWGTO3? <L
M5U:>;I<4\EQ<1AU$CDD8&V1QM''(/:@-"KK?[6LWP_\ 'GBO1/'/A(:!8Z1X
M<N/$T%Y::G'>2RVT<R1*DL84>5)(TBA!N().,UV_P9^.1^(/@'6?$NL6NCZ;
M#ISR-*FBZRNJJD:1[VWE%!1QAALP<XR"0:\\A_8P:^MOB#8:[XTFUS3_ !LE
MPNK2S:7$M^Q;F#;<[B0D#!2D8&WY>1R:]/\ @W\%4^& \2WEYJK:_K7B*ZBN
M=0NS9QVD3"*!((D6&/Y5 C09/)8DD]J *+_M7_"^2REN$\3QRQQZ;8:L?)@D
M=FM[R016S !<DNY"[1R"1D"N+\)?M?:9JOB+0/#NIZ9(FK:])JOV"738Y9K9
M%M+AH569B@*NQ5MW\*8Y(R*YSP]_P3T\*>'?$.B:G'KM](FFZT=2DMC$!'>6
MR/&]K92\G,<)C4J>_)//-=OX=_9:'A75O"FH:=XINTET276?-C>T1DNX-1N/
M/EB.3E"K!<,.PZ<T#T+G[,_[3F@_'WPS8-%<10^*DTV*_P!2TV*"6..+>S(3
M$T@Q(@=2I92<$8)KH;[]I?P!I&N^)=(U'6)=.O/#UI+?7PO+*:)/)CD2)WC9
MD E DDC7Y,Y+J!G-8WPF_9PL_A1KWA[5+?5[F_?1O"47A1(I(51942X:;SFP
M>&);&/QK@7_88L;O5/%EU?\ C75[YM<L+JP2YE@5KR 37L%XCO.Q/FF*2W14
M!  4D8H$:GCO]N3P9X=D%G:6>L375SH5UJ]I-<Z3=QQ*\3F,13((S)&"P)+[
M<*!SU%=;X-_:I\#:WX=L+B\U5+?4Y+C3]/N;2&"9A'>7< FBC3*Y=&4DAP,8
M&:HWO[.^MZYK>G:UK'C^\U+6%T34="U&8Z;%''=V]T0V$53^ZV,J$8)) P>M
M85C^Q?HFG>./#OB2#7M0AN-*\/0Z*\<**GG3PVC6L-\&ZI,D;MCKV]!0/0M^
M-?VX_ASX6TZ.>,:OJ4PU>UTFYM(],GBGMO/#%)C&Z!BF$;&!EB,+DU+X9_;"
M\&W/AFYUO6+MK2"?7;W2=,M;.RN9KNX2W569GMQ'YB,%)+@KA1CFN0T;]A*#
M2-*U9#XVO6UFYN])U"VU2*P16AN+!G,4CJ6/G,_F-O+'D\UT3_LCSV6KGQ!H
MOCF_TCQ7_:>JW_\ :JV$4@*7ZQB>(Q,=O#1JZL,$'U'% M#J+S]L/X3V6LZ9
MIC^*5:?48[&:WECM)G@,=XNZUD:4)M19.@+$?-QUKK/%_P ;_"/@;Q9I'AG5
M=0D&O:H \%A:6LMS(L9<()9!&I\N/<<;VP,YYXKR9/V)O#=I\/O$O@^SU6[M
M]*UBPT2P5VA1Y;8::<K(">&>0DL3@8+'%=UXM^"=UJ_Q5L?'FA>)KGPUJ?\
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M2$@9P0@;/..G;->J?#O]F;PSX*O]5O\ 4-/TO6;^]D5TD_LN.&.W4)MVH@R
M#U/O6+X)_8L^'O@'QE8^)M.AU!]0M)7FC2XE5XBS @@KMY'S']*OVF5MS?LY
M:[:Z?UZW"^.TVZ_GI?7MV,"Z_P""BOPPL647%AXEA+9*A]- )'KR]/?_ (*'
M_#2.U^TMIGBA8-N[S#I@"X['.^M_XV?LDZ)\:/%5GK-Y<QVAM;$626_V0.@
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M(W*V.C$-Q7UHAR,YS[T"'4444 <[\0F4>"/$.^&.Y0:;<EH9GV(X\IOE9LC
M/0GM7Y]_L0^-+6Y\5_#72HOBI\.;O%L4'A2R\-+%JZ8MI#Y(NMN2\>.7_B5#
MR=V3^AGB^[FL?#6K7%NL37$-G/)&)U+1EE1B-P')7(&0.2*^*?V6/BQJ7B_Q
MOX+CUWQOKC:U=H[76@-\-DTZR67R9"T:WHBRB+C*MN!; !^]B@#[O'2EIN\
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MM?QPX*SL5\L;>#F(#(#&O K#]D#XJ7/A^YTJY@M+&7^S(M/U.[CUQW;Q%/\
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M@^]L_#7A%-9G\1:7'*YO9)8[H+]G <JF#"&SEL$8Y%7?V<?&^J^-OBMX4O\
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M'%=W3A%QO<VPE&K0YU4E=-^[NVEYMMA1116AZ 4444 %)2T4 %%%% !1110
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M]LJ8?"F<>"7^SQD^NO\ X$[_ *A1115G:%%%% !1110 4444 %%%% !1110
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MK!!N^]4E=!]$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDQA)) W!3QD@\^U>7^%B&_;:\=D'(_X0S2?_ $JN: /?Z*** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$$X]*G\,_ ;PA\"?VZOAE8>$+2\M+:_\,:O-.+N^ENB64HHP9&.!@]!7W"$
M/2OF/X@\?\% /A)_V*6L_P#H<= 'T]1110(**** "BBB@!#5>]N([:VEED.(
MXU+L?8#)_2K!KY-_:M^,MKX*\=V_AC7_ !3JGAOPWJ>A.[?V18)<R7$C2M&Z
ML6^Z-G0C')-=%"A/$U%3@KLPK5?91YK7+'["%H_B/0_B'X]N5)G\4>)[B9)
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M_!.I(Y/@7>7;.SWUSK5Q+=2R$EG;;'@DGKQWKZM!S6N8:8F4/Y;1^Y6,L/\
MPD^^OWBT445YYTG%_%WQI'X ^&_B37G8 V5G(Z<9S)C"#'?YB.*R?V<_";^"
M?@SX5TR9"EW]C6XN0>#YTN9'X[<M7C_[1GQ-T'XB>-]"^#EE=R'4+O7+5=48
MQXB2)?WGE[CPQ)V\"OJ.V0(N  %&, =AVK%-2FVNAYU*<:^(G.+NH+E^;U?Y
M(FI:**V/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=^(,&JW'A#44T7
M7;7PUJ00/'JM[:BYAMPK!F9HRR@C:&'+#&<]J_.O5'\-V6J:7\.=/^+EIX_B
MN_%*:W=:/X/\&+=LDPNUFD\R>.<^7&)#DG)('?'%?HC\1_ .D_%'P-K7A/7(
MY9=(U:W:UND@E,3E#UPPY!XKYST#]D?QI\(_%_A76/ /C:PU33=!BGL+?1_$
M^F)&8K2=H3,!<6H0R28A7:TBD^I- UH?6 I:04M @KYB^(/_ "D!^$?_ &*>
ML_\ H<=?3E?,7Q!_Y2!?"/\ [%/6?_0XZ /IZBBB@ HII8 CWI0P.?:@!:0G
M S2%P*CD<%,9P3Q0 _?E<]J^+_VM?"FF_'7]HKX7?#F-Y#<P1W5[JD]NPW06
M;;&(Z<,?+X)Z;AZT[4/^"A6FZ)K5Q97^CVI6UNY;>XC@N+AIT5"PW<P!#]T<
M!S][VKM/V1OASKMY?>(/BYXSB:#Q/XQ(>"S9<?8[$'=&N.Q;"G_=5<\FO=H4
MJV7)XJHN5V]WS;5OP6OW=SR_;PQC]E3V3UT:T^??_,^@/!/ABS\%^$]'\/Z>
M)!8Z5:164'FG+E(U"KN.!DX')K=IHXZTI.!ZUX;DY/FENSU-MA:*3.>U&?7B
MD '.:BG/R'@TLDZQC).!ZFOG3XE_'^'QS<?\(%\*=2@UKQ;J3R6TU[;DF'2X
M5XEG9\;21G QGD]>!F924=SGKUX4(WF]7LNK?9=V<%XB^%VE_M,_M-ZGJ$#W
M%MX>\,106U]?P'<+R[1]PBC/(  ZD>G3FOLI5X/.<^M<3\(?A=I/PB\&6OA[
M1T<Q1DRSW$IS)<3-C?*Y]2>W88KN:BG'E5WNS#"894%*<E[\W>7KV^6WXB 8
MI:**U.\**** "BBB@ HI,TM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >>?&V;QH/!TUKX'T6RUK4
M[P26TJWFI?8?(B>-@94?8V7!Q@?K7QI\$?@]>?#+XV_!W3=7\.^"?!VO:6\\
M5]>Z9XG,^J:XQL9U_>6YY<$CS&SG!3@@#%?7_P"T7\*M;^,OPNU+PQH'BNZ\
M&ZA<O&ZZE:%PS*K9:)BC*P1^A*G.*^=OV<O@)XG^!GQ[EN]6^%FBR66L6<5F
MOB;P]J!O([&6(7#R7$OVH_:$:??&I +<J.2.@,^UQT%+24M @KP'PQ_R>SX\
M_P"Q,TG_ -*KFO?J\!\,?\GM>._^Q,TG_P!*KF@#WZBBB@ HII8 <\4H8&@!
M:0G%(S '&>?2HYVS'D8R/>@"0G*G'I7S3^V?J;:WX7\,_#G3V!U?QIJT-@N,
M;X[96#3/[#  -8?C_P#;ZT7X=?%+4O!E]X6OF6POELYM26ZB$2J2NZ3;C=@
MDXZ\5H_ NPNOCM\6M1^,VH1RP^'[..32O"=K.NUC#G$MT0>A8Y ^I]*]BCAJ
MN$MBJT;12NO-]/\ /T3.252-7]W!W[^G7_(^C?#OA^R\.Z)8Z;80K!9VD*01
M(HP J@*/Y5J@8IL8VH!Z4[/->.]7=G6!Z5%)(R =\^E.EE2.-V<A54$DD\ 5
MXG\=?C7#H6A6>A^#KB'6O&GB%FL]*MK.02>63\K7#;<@+'UYZGZ&I<E%79C5
MK0HP<Y]/ZT.-^&_P\T'XF?M*>,_B+]A5K'1[R.QT^96/EW%[&F)I_<KD+Z=Z
M^H$7;G'2N(^$7PYA^%_@'1_#T$BS26T>ZYN0N#<3L<R2'W+$\GMBNX'&:F$>
M5>9CA:/L:>JM*3;=N[U_#86BBBM#L"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#S_P"-OQ@T_P""O@Z/6KRTGU*[N[R#3=.TRU*B:]NYFVQQ(6(
M).22>  363\)_CM#\1-+\4_VKH\_A77/"MXUEK>F74J3&V81B4.KIPZ,AR&
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M$X] S<USMS^SI\*[GXQ-\0C\8-.2].MKK7V(75IY>\2B39N\S..,9KT'XZ>
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MA H "J, #T%<E_PN;P#_ -#GX?\ _!I!_P#%TA^-'@($_P#%9^'_ /P:0?\
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MV#@#TJMX)^,OAGQ]X$G\7Z7J(71;7SQ>O=QM!)9/#GSDF1AF-DP<@]*\N_;
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MF^B;<JM%!"0\LVX@($0<MDD8Q7#6OP1@\,-?1>%-9.D6&IV_V:_M[H?:MXY
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M /%/V6O@EJ'P+^'4^D:E<6+WM_J=UJLMAHZLNGZ>9GW?9[8/\WEJ,#)QDYX
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MT8CRM[S1ODAL_-TYX^ROB;\'/^$]\:^!?$]OJ(T_4/#-Y.[!D9A=6EQ$8[B
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M*J/K7"? O]HRV^+GP2O/B)?Z)/X<BL)+Y+NPDE$SQ&U8B3# #)^4\<<\5O\
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MR7"*7\S.S&3SNP<>N.*YCXG_ !S\)_"%M-7Q+?\ V)M02Z>!<9+"WMWGD_\
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MV7(&3V&:^-/V6OVD=2^)NO>$X_$/QEAO?$&H&3[5X1M?#?EP^8 _[I;KH0
M=PZX]Z!V/N"DIL;;US3Z!"5\V/\ \I!H?^R?'_TMKZ4KYKD_Y2#P_P#9/C_Z
M6T#1]*4444""BBB@ HHHH **** $/ K$\:>*5\&^&-1UEK"\U,6<)F^R6$?F
M3RX[(O<UMGD5P?QNBN&^$WB_[+&9[E=+N)(X]V-Q5=V,]NAJZ:4II/N1-N,6
MUN<'\+_VN?#GQ1N]32/1=:T'3]/BEDNM4U:%(K6(QD!D9PQPPST-?&=S\+_'
M'QD^-^M?$GX?0S76E2:^;FPU&9'6,890K\XRHQD@=JS/V9/"-]^T/XVG\-^6
M=*\*B>75=<6TE($\+2AX[?W&\ #VR>U?J)H^CV>CZ=;6%A:Q6-C;((X;>!0J
M1H.  !T%?48B<<GJRA17O25FGJDO\W^7J>6H3QL$YOE2?3K^!\#?M!_L_P#[
M06M7&CSR>([KQI,QF=ETAOLD5EDKE,97<">G7 2KB?LV_%70OV?I-:E\>>*K
M+Q'!;X'A9)V= QF"A=P8G[IW5]]>2O7;G%*(E /RG\#7GQS>M&$8*,59WV6O
MEV_ U>"BY2ES/7S/SU^ /P(^*_C/5M9LO$/C_P 4^%(K>&*6&YMIY)$G+,5*
MY8CD  \>M<]\&/C'\4_"'[0=GX5N-?U77/#]WXA32[BXU:-I@T2S,FY'/"%N
MY']*_2KRQP#DD>IK@K7X"^![37(M8BT5EOXKK[8DANYBJR[MV[87V_>).,8K
M59M[15%6IIJ2LM%H^^P/#3@XRIRUZZO\M3T)#D#Z4ZFC H+ #K7SR/2%S0#F
MOG;Q%^V9H7AOXC7/@J3PUK]SK$5V+15A@3]ZQ/#("V2".1QR*]A\4?$/0O!&
MFV]]XAU:TT6VF8(DEZXCW,1G'/>I4XRV9RT\51J\W))>Z[/R9U!.*6JUE?0:
MA;0W-M.EQ;RH'26-@RLIZ$$=JGWJ>XJSJ*VIZK::-:-=7US#:6ZD!I9Y B@D
MX&2>*\Z^)/[2'@3X6Z#%JVK:S%<6TEPMN%T]A<2;F!()5"3CY3S]*[/QIX)T
M3XA>';K0O$6G1:KI-T%$UK-G:V"&!X((((!R*\.\9?L(?"/Q+IJ6ECH+^&Y%
ME$AN],F;S6 !^0^86&#G/3/ KLPRPSDOK#EOT2V^_P#0SGSV]P]'\ ?M!>"/
MB-X9@US3-:MX+29W14OI%@E!4X.48@BN^L=0M]2M([JUFCN+>0;DEB<,K#U!
M'!KP+PG^PO\ "'0-(CL;WPU_;TR%F^W:C,_G/DY .PJO'0<5[CX:\-:;X.T&
MRT;1[./3]+LHA#;VL7W8T'0"EB/JRE_L[=O-+;[PASV]\\^^/'[1?A[]G[2=
M)O\ 7;34+Y-0N7B$>G0B1X8HT+S7#@D8CC7EC[@=ZQ?B'^U/IGP_\2^(M-;P
MMKVM6?ARPM=3U;4]+BCDAM;:<.1(07#,%6-V.T'@5#\6?V<#\9/'YU;5_$5_
M8Z'%X=N=#BTW3L*SFY<&Y:0NK*59$C3 &>,YX%>;6O[(_P 1HM+U'26^(FFB
MQU_PU8>&=<O/[,D>\EAMTEC+PL7"JSI*5.X&N0U/1O$?[4UJWB>\T;PCX7U+
MQFNEPV]QJMW8S0PQVJSQ^9%&IE9?,E9<'8.QZU/!^TO8W/Q@UGX>0>%]=DUG
M3=!?75!B5?M2JR+Y4(+?,Q+X#<*2IY[UYI\3/V*=6UUO%5GX2\2Z=I^B^)TL
MGOK?6+!YYK:XMHEA2>VD1UVLR* <@]\5L:G^S=\1A\=+GXAZ-XTT.PD_X1T^
M&K6&73)9'A@VAED)WX:02@-G&,<8H#0TM+_;)T>7PCXFU#6/#6J:)KN@Z[;^
M'9M#N)(S))>3X,*++N"8(;+$D! &)X%>N:%\3+1?AU9>*?$RVWAFWD5?.\Z^
MBGAB+2>6F)D)1@S%<$'^(=Z^>+#]C3Q#=_"N'PSXAUSP]K&I6'B&U\26]])I
MLS+J%TA87'V\.Y,PEC=DXQM&,# KTGP_^SC%IW[-NI_"R]OX9%OX;_-Q:6YC
M@MI+B>2=5AC))6.)G4(.H"C&* .T\1?&OPCI5CJSQ:]I=Q?:?//8M:/>I&3=
MQPF4V[$\*VU<G/0<GBO,M8_;4\*Z;X1\57:VWG:[X;TJRU2]TM+J-D*7!0'R
MYERKA X+,..1ZUPGA#]A/5-!OKRZU+QHFK/>Z)?1W*RVC8;6;J"2WDOPQ.<>
M4^S8>P_&M*\_8UUV;2/%6CP>)-*32_$'AK2-%N/,T]S*D]B(P)%8-CRW"OE<
M9Y7GB@-#Z#\)?%KP?XQ\-ZCKFB^(;+4=)TZ1X[N\BE_=P,@RVX]L+@_0@]#6
M)%^TO\-IO"^I>(5\568TK3KH65S(^Y72=@2D80C<S. 2H .X<C-<_HWP$O=!
MD^,3Z;K46FGQQ*DMBUO:#&F,MHL ;8?E<Y4-T XQ7EVC_L@>-M%$^KP^+])G
M\4Q:YIFMVDU_:7%W SVEA/9D3;WWL6^T-("" K*H   H#0]&UO\ :_\  L>J
MZYI.EZC:7VKZ7<V%L(;B\CMHKD72Q.'BD8X8*DH)'<C Y(KT%_C9X&AM+2X;
MQ1IAAN[26_MV6X4^=!$VV210.H5N#CH>*\5U_P#93U[7]4\9W#:[HL,'B@:%
M=7$<>ELIMKS3VMMS1'=Q%(MNV%Z@N,D@'.;9?L9ZUHU]\1-0TKQFNG7VK>;;
M^&GCM"?[$M)KLW5Q![^8[,-ZX*@\4!H>B7G[7OPQ.K:79P>([:4ZC8W-[#<.
MWEQ+Y+*C12%L%)"S8VD9X-;'AW]HCP9=6OA==8U[2=(UO7;.WNHM.%\DX7SB
M%C42K\K;F.%/&XYQ7D/@K]CSQ)X0UO1M8'B;2;N\2[U<ZC'<V$LZ36]^T3E8
MW=RXD0Q##L3G)K+T_P#88UBQT>W\/CQ;8G0;VTT&#6'&GM]K+::25^RN6Q&'
MXY8$KSB@-#Z4T'XU^!_%/BN3PUI'B;3M1UR.%[AK*WG#/L1RCD>NUA@CJ.]-
MU+XV^"-'\57_ (<O?$=C:ZQ86;7UW!+)M%O"H#%I&^ZORD-@G..<8KRGX;?L
MM3> _%'A/6GU6SN9]&U+Q'?2M%:E'G34Y=Z)NZ_N^^>O:LSQS^RCKWBV?XH:
M9#XHL+;POXXN/[2E633F>^M;Q4B$8$N[:T.81E",E68 C- 'JB_M+_#$Z$VK
MGQEI:6*S-;EWFVMYH0OLV'YMQ0%@,9(Y&:Y[XN_M;> OAE\/1XCCUBQUJ:[L
M#J.EZ?;W(#:A&&"Y1L$ $G&3W&.M<+I/[)&LW_Q0TOQ[XHU[2KS5(=9@O[JP
ML;!DLW@AL6M8T5&)_>$MN+GMA1TKBM4_8#UY="N=*T?Q9I$-OJ.DW&CWRWNF
MO*(H6OWNX3;88>65WA#G^[D4 >S6_P"U?X5T[4+"T\22V^B-J6JWNF6<PO8[
MB(_9H%E=Y64_NS\P78WS!B!WK8T3]ICP0OA[P_J/B#7](T*YUJ*2:VMO[02=
M#$LSQB3S$^7:2H&XX&X[>HKS[1/V3=8\-:EHFI6'B#3)+_3O&=_XD*WFGM+#
M+:W< @F@(W APHRK=,X)'%<U+^Q'KT'A^YT2P\5:5%8:OX?_ .$<U:2XTQI)
M4MAJ-S=A[8[@$<K=,OS<;D5ATH ^BT^.?@.3QPO@Y?%&FMXF,K0?V8LX,PE5
M0QC([-@@[>I&3VKB/&7[7_@CP1\78_AUJ"W_ /;KW%E;[X[<F$&YW$$OTP@4
M%C_M#&<''+S?LC3#Q-I^K0:U;1R6GCM/%PD:V)G>!;-+<6Y?KN^3=GISTK7N
M_P!F>\O?CW_PL2?Q1=FW35H;^/3E_ABCLWA$.<=/,D=N.-K$=3F@-#J_A?\
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MJ!5  (&2<[^H?LBZK+XUN_&]KXJM(O%9UBTUJW#Z>?L2S1636DBO&&R597+
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M!L@!0@]#P:^:_P!C]#KNN_&#QA)Y+RZOXLGMU=!SY< V*,^G.?SKW_Q;J_\
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MT)KF]UA9_P"S[5(3(%M$VAMH&<9./K0!]<KTI:0=*6@04444 %%%% !1110
M5Q_Q>\1+X3^&'BG5VS_HFFSR *VTYV$#!]<D5UYKY_\ VWO$G]@?LW^+!M8R
M7RQV494XP7D')]L UT8>G[6M"'=I?B85Y.%*4ENDR?\ 8@TB32?V:_"+22>:
M]ZLUZ68<_O)G.#[U[R*XWX/Z"/"_PN\*:4=C&STNVB9DZ%O+7)'U)-=G1B:G
MM:\ZG=M_B73BH045T04445SF@4444 %8_BS7)/#?AW4=3BL;C4I+2%I5L[4
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M=HHHK4[PHHHH **** "BBB@ HHHH *3%+10 F**6B@!*,4M% !1110 4444
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MA?2K;P+8W<+W,-PRFW^;5FEP)6<C[P3G&>A4YK[NL8D@@$<2A(T&U548 4#
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M=7$LQ5& [ K&I^N:^B:[<;I7E'^6R^Y)?H8T?@3[Z_>%%%%<1L%132^4"3T
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M-(88E$<<4:A511P  .@%>(? "UE\<>-_'OQ+F :WU6\_LK27/7[%;DJ2/9I
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M2T7P?^WVEIH>D6.CVK^ 6D:&PMUA1F^V ;B% !. .:^J=H]*^;7_ .4@T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLFVTVU2V5CU8J/F;\3D_C72U'"FQ<'K4E:I65CTXQ4$HQV04444R@HI,T9H
M6BDI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@8 'L!62M.7-V/+BH8O$*M:\8:)^;W:]-O6Y9 P /2EHHK8]4**** "BBB@
MHHI,T +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /9O FMS^)/!^D:G=1B*XNK=97500"3W /0'J/8UO5X/%^V]\#(HU0?$?0U
M&,+-@#]*<W[<?P,523\2-$ ')/G_ /UJ!'NU%5M-U"WU?3K6^M)DN+2YB6:&
M:,Y5T8!E8'T((-6: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \K_:"^+^H_"7P]HG]AZ&?$7B/7]5
MAT72[%I?*C:>0,VZ1\':@5&)..U<]\'?VB+WQM\._'6M^)M#CT35_!6H7NG:
MK9VEQY\;/;Q"0M&^!D,&%;_[07PHUOXGZ3X:G\-:O;:-XA\-ZU!K=A+>1EX)
M9(U=#'(!SM9789'->=>#_P!FGQQX>T#4].E\4Z4$\7ZQJFJ>+XX;5RLBW4'E
M1Q6A/*["%)+=>:!F5\-OVR]7O/$.DQ?$?PU8^"M"U_PW/XJTK4DO_/"6<1CW
M>>-HV';*K9_#WJA\/OBCX5^*_P"W<-5\):Y9Z]80^!&MY)[*3>JR"[!*GWP0
M?QK9^$'[*GBC1/%7AG4?B-K.B>)+'PIX8E\+:5;6-JX6X@E:/>]RL@VGY(U4
M*..IKA=<^(/PQ^!'[=DSWE]HG@_38?!8MKA(HDMXQ</<"158* -Q3!^E 'W!
M56\N/LMK-,1D(I? ZG S_2O$S^W%\#?^BDZ)_P!__P#ZU0W'[;/P+N(7B;XD
M:*5=2&'G]01CTH%9GBGA[]O3QG\3O&D/A;P9X+T[^U;J1UMEO[P[2$!+9( Q
MD XK.^*7[<'Q7^#GB@>'_$WA/0(-2^S)=;()WD78V<'(/^R:O?#W6_V2OAGX
MUMO%6A^/[)-6MC(T33:B70%P0WR[?0FNC^(7Q._9.^*>O#6?$WBO0=2U(0+;
M^>;QT.Q22HX_WC7T;Q66QK+EHWA;SO?[]CRHT<6X>]+WK_A\D<?\?_B%^T7/
MX*TB\?2(O#T4]RCPS^&)WFGE#1D[77G"8.<^H%/^ GA#X[?&'P/>0ZSX]O?#
MNCFYEM[@7UIYE]*I5<@%@,)C@?4]:]WLOVUO@186D-O%\1]$6*%!&H\_HH&
M.GI4P_;A^!G_ $4C1/\ O_\ _6KF_M+EH^RA2BG>][7_ #N="PS]ISRDVNQL
M?!3]F3P5\#H?M&B6#7&LR1^7/JUV=T\@/) [(#Z**ZWXI_$?3/A)X&U'Q1JH
ME>SLPH\N%=SR.S!44?5B.>U>>?\ #</P-_Z*1HG_ '_KG?'G[57[.WQ&\+7O
MA_6_'^AW6FWB[9(S<$$$'*L#C@@@$&O(JU:E:3G.5Y/N;SC*--QHV3MIVN)X
M>_;R^'^K:9%<W<&J6%RQ*M;_ &4R[2#_ 'EX]ZHV7[?_ ()NM;OK1],U9+.
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M=?:?*C'1$W#@?J>YH ]=/QOTZ2*?4H+26X\+V\ZVT^O1LOV='.,G&<E02 6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O#_C/\#9/BA\:/A/XF>VTRYTCPQ-?MJ4-]&)&G2:%4C15*D,
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M_P#"&^'^O_0+@_\ B*ZF#.TCT)Z51U;7M.TA8A?WMO9>:VR/SY53>?09/)H
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MI>&]8ALH[&Q+$Q1RVRSA)6).Z10X4D8&0:^BZ "BBB@ HHHH **** "BBB@
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M_"'>*-:BTB:_N96>[=V5F<(BD! H4?,Q.2>E SV ?"3P/CCP;X?_ /!7!_\
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M%1:Q&-U ?"YY)Z]*]V^"7Q"3XL?"CPIXQC@^R_VYIL%\T'/[MG7+*,\X#9%
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MA3PKX8ELM-GM=0URRGG6^EGDN1(D<R2+&NU8$QN[R"@1[J/A)X'_ .A.\/\
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MX/X0_9D^)'AOXF>/_&<OQ)TZ74/%UDMM<&/1!A'BC\NV8*S8PJ\,/XJ^IZ*
M/!O@9^SI??#3QUXL\<>(=?AUKQ1XCCAM[A=-L_L=DD40 3$0)R_RC+'GMWKK
M/$7P3TFWU/Q'XL\'V>G^'OB+JUL8/^$CDMS,P)V<NF<,,(!CCH*]-HH ^,[+
M]BSQ[IWP*UCX:V_Q.@MK#4M8?4)YK?3FC,D,I=[BW8ALE9'92<$?*"O>O?/A
M7\,M5T#X:W'A#QI?Z9XBM&1[2.+3[#[';I9&-4%OY8)X #\YZ-[5Z?BC% SY
MG^,G[(A\2>#- \'_  ZU'2_ 'AO3M235Y;)-/,PFNHW5XGW;LC!7D'KQ4/Q8
M_9N^)'Q.UWX?ZJ_Q#TVUNO"<T6HQ'^QR1+?*&5Y<;_NE2/E[8ZU]/48'I0!R
M/CSX7>&?BOX8AT7QGH]MXAL(Y%N#!<*0AE52 X /!Y;\Z\:\7_LX^--;^.W@
M_P =:5XUT_2M)\*QR6FE:2=*+F&TE2-)XB^_YB5C !XQFOI/H*K27T$4T<32
M*LLF=B%@"V.N!WQ0(^:O!W['ESX9\<>'?-\5F[^'WAO6[WQ%I'ATV>)4O+AG
M;][*2=ZQ&639@ _-S7T?KF@V'B71[W2M4MDO-.O86@N+>3[LD;##*?8BKJR!
ME!Z9IVX4 ?.GQ$_96_M'P];>%/ =QH7@SPD8)H+FTDT9;N:-I#\\MO(S?(Y4
ME><]B.:]K^'_ (-T_P"'G@S1?#&DQ^5IND6<-C;J0 =D:!03CN<9/N36C<:_
MI]KJMOIDMW"FH7$;RPVK2 22(F-S*O4@9&3VS1-K^GV]M=W$EY D-FI:XD:0
M8A &27/\.!ZT <[\0_A'X0^*4>F#Q7H-KK@TRX^UV8N@2(9>/F&"/05\^>#O
MV*-0\->/-+U&Y\8I>Z%I/B>Z\56I^P8U2:YGR&CGNMWS1X8@@#D #MQ].R>+
M]$C\,_\ "1-JMF-"^SBZ_M$S+Y'DD9$F_.-N.^<5->^(-/TW2I=3N[J&VT^*
M+SI+J60+&J8SN+'@#'.:!FAC<HS7#ZQ\'O">H>.X?&_]@V3>,[:W\BUUF52T
MD(VLJ]\8 8]NA-=%I/BW1]>M[6?3=2M+^&ZC\Z![>=7$J?WEP>1P>1Z4[4?%
M6DZ1#=S7NH6UK'9QF:X>:95$*#JSY/RCGJ:!' _L\_!A/@EX)ETJ>_&LZU?W
M]QJFJZL8MAN[F9RQ8C)X VJ/85ZGVJCH^MV'B#3K>_TV[AOK&X3?#<V[AXY%
M]58<$5?H ^=_B?\ L?\ A;Q'9)>^#+2R\'>+(->MO$<>JK;F59KJ%F(\Y,_,
MI\Q^ 1R:[#]G;X*2_!7PUK<%]JPUK6]>UFYUS4[R.'R8FN)B,B-,G:H"CJ:]
M7I:!W,/QKX(T/XB>&[O0/$>FPZMH]WM$]G/G9)M8,N<>A /X5X;\8/V8-7^(
M6@6W@'1O$MEX8^%36UM:W.A0::);A4BD9RL,S-\H;*CD$C;P>37T=10(@L[6
M*RMXH85V11H$1<YPH& /R%<I\0?@_P"#OBH=,/BS0+37O[,F,]G]J!/DR'&6
M&"/[J_E7944 ?+5M^P7X,\/_ !.\'>*?#UYJFFVVAW]QJ,]@]_-(L\LA#+LY
MP@W@EA_$#@U]119V\]:?10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MUE##!Z4ZFN-RD>M 'QEIGCG3/ _[>7QGN-2O[:V>3PAI(L;>ZG$?VF8*S"-
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M#5]]?&3X):?\8O#.EZ3<:E>:&^EZC;ZI97FF;!)!-"?W9 8%<#TQVK;/PO\
M#,]E>VUWH6FWRW\T=U>M<6J-]KG3&V608P7R,YH"Y\ ? KP/>Z'X7_:KT/Q6
MBZAJ/_")66J7\-U^]07L]A<W#L V0&5V'(Z%1CH*^\_@<!_PIOP&?XO[ T__
M -)HZK_$+X.:9XY\+>*M)MIF\.77B6V6TU'5M+BC6ZFB V[2S*0?D+)R. QQ
MBNH\)>&H/"'AK2-%MG>2VTVSALHFD^\R1QJBD^^%% ,V:***!!1110 4444
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K HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>adag-20221231x20f021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %G R$# 2(  A$! Q$!_\0
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M'AC3H?'>H6FN6OC8^'#KD:H&NX,[09%QM<CK[FD!^L*W*.0!GGVKC?B?\;/
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M&H]J?0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX\7^#O&MU?Z]JNFQ_#W06T>_N(97B,VH^;AILC[Q$8!S[T"/T?,P'8_E090
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MX\L#\A0(^Z <@&EIJ?=%.H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9C,LX'WY5ZJAXP,\TQV/T9N[BUT/3Y[E8ECAB5I76&/J!R2 HY-.\+^)-/\
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M)#:^8#S*X&6;C) XKS+Q;^T7XW^#4_BJPG\71>.(=.L(5NM6FL0J:9J,KA1
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MXXK\VOVB_C?XE^('QZTSQKX)\"WOB+PG\&]1G&JZ@LPC^T2L@$R1KU.P#K3
M_1S1=.@T?2+.PM8Q%;6T*PQ1@D[448 Y]@*NURWPN\?Z;\4OA[H'BW2&9].U
M>T2ZAW_> 8<J?<'(/TKJ:0!1110 4444 %%%% !1110 4444 %%%% !1110
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M*N1D GIFOLRV_P!2OI[T ?!7[77BV]^(7QLT_P"'_B+PGXM'PQT"XMM5O9]
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MC!YJQK?[:?CNQ\5WGB"W\.Z._P ,+'QE!X-D:623^T7D<JK7 Q\H4,X^7J:
M/;_VY?\ DT7XL?\ 8OW7_H-;_P"RG_R;;\,O^Q>LO_10KPW]N?\ :8^&EO\
M _XK_#^?QII47C(Z//9C1GD(N#,R JFW'4@@_C7N7[*9S^S;\,O^Q>LO_10H
M ]6HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BN&*1DCJ.E #W.%)K
MXD_:-$O[1W[4W@CX.VDLC^&O#^WQ%XHV<(0IS!$3WR>WO2?&?_@H3X@^$?Q#
MU?PEJ/P=UA_LL$][#?\ ]I0HMQ9QG#7*J1D+QT)S73?L"^"M3O?"VN_%KQ*D
MP\2_$&^?4&688,-FI(MXQZ#;S0!]8V<2PVZ(H 51@ = .PJ>FJ,"G4 %%%%
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M+^ Q7Y0_"#X+:SXW^.'ASP=XXUV_\.^$O'UM=>,;[PAIEV8;6$^86BA<'H6
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M[-T"WOXC$6N&&99"AZ$5]X(,** '4444 %%%% !1110 4444 %%%% !1110
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M^/\ XI_$+2]6U/XA:KX/UG3V>-=,N?"-R)D.,^;YA!X_AP/K7T<3A2:^+_V
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M,8!&H>(39S\S G/;=BOI+]E(8_9L^&7_ &+UE_Z*% 'J]%%% !1110 4444
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M[>7GV5-OGS,>7;GDFOL;0O%FE>);5I]+U&SU*%&V-)9W"RJ#Z$J37RYKO/\
MP4G\($=/^$/N_P"= 'UY1110 4444 %%%% !534KZ+3K22XGE6&")2\DCD *
MH&2235EFV@U\5?M)?$_6/VA?B&?@+\.+IXHR0WBS7X>4L;7^*%6'\;=/QH P
M99-2_;X^,#VJ-);_  )\*7NZ1^5&OWJ'A1ZQ*17UOKWP0\">,'MI-=\':%K$
MEO"L$+WUA'*8XQT5=PX ]*N_"_X9Z-\*O!6D^&= MDM=)T^%8HHU7DXZLQ[D
MGDFNPH SM"T&Q\.:;;Z?IMG!8V-NNR&VMHPD<:CLJC@"M*BB@ HHHH ****
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MJSGEAH_6:=6IK+77MZ'T!#;J%Q@<=/:I$@*XYZ=>.M.B&!4E=VQ[(A %> ?
MH _&3XMY'_,13_T&O?-^<^U?/_P+E*_&3XMD*/\ D))CW^6L)_%$Y*W\2GZO
M\CZ#48%,FD$<;,QP ,DGM3D;>N<8J*ZM5NX9(G/R.I4CV(Q6YUGSG\(=;L9O
MVCOBOY=[;/Y\MKY6)0?,PG.WGG%?22G(!KRCPU^S#X!\)>(HM<TS26M]3C<N
ML_G.W)Z\$UZN!@ 5E34DK2.3#4YTX.,][M_>[BT445J=84444 -D7>I'3-5]
M/TVVTR%HK:".!'=I&6- H+$Y).!R3ZU:HH 0*!T%+110 A /6D,:GL*=10 W
MRU_NBCRU'8<4ZHS.@)&1^- 'AO[<Y _9%^+'_8OW7_H-;_[*C#_AFSX9DG'_
M !3UE_Z*%>7?\% OB=IFB_ OQ!X*_P"/C7O%FFW%G9P*X&Q> TK$]%!8#W)K
MD/@3^V!X:\'_  .\(Z!+I^IWOB'2=/@TY]-LH/-:1HU"[PPXVG'UK.52,79L
MY)XNA3G[.4TI=KZGVC)<*I # 'WKQ[]HW]H[3?V>O"T&IW=A<ZWJ%Y(8;#2[
M-@LERX&6^9N%51R2:\OO?BI\>OBE<-'X1\%6OA#3'&U=1UCYYL>NTX ^F#7"
M>*/V'OB#X^B&J^)_'C:]XCC<F%;R1W@A#??V#HOIP*B51V]Q7.>MBING)X>#
ME+II9?C8Z?P-_P %+?!&I>'[J[\;:5J7@74XCB+3I(C?&Z7^]$T0.<="& K!
M\4?\%1=(PT/@KX=>)/$L^<++?!+"#_Q[+'\JZ/X&_L-6OA+4[ZY\=+9>($>-
M4MK="3$ISEF8$=> *^D_#WPE\'^'HU&G>'--LR.C1VJ!A^.*4)5)+706'GC:
ME-2JQC%]M7_7WGYF_'7X^?%K]H_PP-.\4>!K'PSX'AN([NZAMS<2R3[,[5>3
M 79DC([US'P[^#*?'GXE6UT/ ]CKL=A:!+O2-/N/[+@N8E&(_,V$9"L1[GO7
MZZWWAZQU"QDL;JVCNK.0?/!.@=&^H/%5]%\#Z%X?N#<:;I-E83.NUGMK=8R1
MZ$@5+IS<D^8PJ8/%5*\:GMVHKHE;_,^=O!?A?XI^"=*BTOP?\,/ O@RQC78H
MCN6) ]]@R?QS71?\(;\?-453<>-/#NC*?X;#33(1]"W6OH(1+CGD^I'-."X4
M#/XUHJ?=L[OJM_BG)_.WY6/FCQ'\!/B5K^AW]K?_ !6O[QY8746<5E%#%(Q'
MW6/4 UXS\+/V.OBS\._%MKK6GZII6E7,*.JS%O/ R,;2N.AZ9K[Y%N 3R3DY
MIYB&*AX>,M3EJ97AZLXU)7O'9W9\]I\4OB[X#A'_  E'P_A\0V4?#ZAX:N-S
MD?WO);G\JVO#O[6'@37+S['<ZG)X>O@.;/7+=[5\^F6X->S/:HQ!R5QZ5S'B
M_P"&WAWQK8R0ZSI%GJ09"%^TPJY!QQR1D53C./PO[SJ=*M#^'._D_P#-6.0T
M#]I[X>^)M=M='TSQ);W>HW4GE10HC_,WIG&*]76X0XRP!(Z5\$^&_P!@WQ;I
M7C"#4/\ A(+:PLTG,JR:>[":)<G&TD8R!7MX^#/Q7\.$-H/Q/EU")>D.M6PE
M'T+#FLX3J?:B<6$Q6,E%O$T;:]+?YGT7O4]Z7</6OGTZ[\?O#R@S:!X8\11K
MU^S7$D#L/;/%/_X:)\7Z(FSQ#\*-=MG'WI-/9+A!^7-:>U770[_K,%\2:]4S
MW_</6@,&Z$&OB+5/^"A&HVGB>XT^/PA#%91W/E^9=S.DRIG!W)CANO%>T6_[
M8?PX(02:S-&Q W9LI<*<=,XYH5>F]F84<QPM>ZA/;Y?F>[4T.I&<BO%#^V!\
M,2!_Q4# GULY1_2O)_&?_!0/3-"\2W5AI6AKJ^GQA?+O?/,8?(Y^4KD8H=:G
M%7N56S#"T(\U2:2/L3(]:6O(]"_:=^'6IZ?:S3^+=+M)Y8U=X9)]I0D<@Y]*
MZ2Q^,_@?5& M?%VC3'_9O$'\S6BG%[,Z8UZ4M5-?>=OD"C(]:Q(?%VD7B9MM
M4L9_]RY0_P!:Y;Q=\=?!?@.^CL]=\06>G7$L?F)&QSE?7(H<XK=ERJ0@N:32
M1Z)G-!(%8GACQ;IOB[2(-4TJ\CO;&<9BFCZ,,UJM. <Y'UIJ2>Q:::NB;(QF
MEK!UKQCH_AXH-5U2ST_S<^6+F98]V.N,GFK.F>(;+6[07.GW5O>VK9 E@D#J
M2/<4[J]A<RO:^IJT57%VF.3S[<T];A&Z-3*):*KSW*1#YF4?4TBWB.I*NK8_
MNG-*Z LTA.* <@&HY)1&>>E,"6BHHYPYX(/I4M+< HHHI@%%%% !1110 4C9
MQQ2T4 ?)/[37[+VK?M"?M"> ;J2[UC1/"6FZ1?P7^KZ)>BVN8Y7V^7&#R2&P
M<X'2MWX5?L*>'?A-XXT[Q/8^.O'6JW-D6(M-6U@SVTF1C#IMYKZ8Q2T ,C38
MH'I3Z** "BBB@".9]B,<XP,U\+^&/BOX:^*/_!2;2?\ A'=0_M Z/X<O;"\_
M=,GES*>5^8#/U'%?<TXRC<XXKXKU/6=!TS_@I#X8$-Y80;?"]U#+Y;(F)V/"
MMC'S'T/-)NP71]M4UG"C)( ]ZYW7O'FA>%+1[G6=7L=+@C&6DO+E8P/S->+>
M-_VYOA=X9@<6>KS^(Y^B0:-:O,6/IN.%'YU+G%;LSE4A#XI)'T.;J)>LBXKE
M_B%\4O"_PP\/RZUXFU^PT33X@29KR8(#CLHZL?85^5?C?X_?$[QG\19?$UIX
MRU_PZ/./V31;:8""),_(K1=')&,YSFO9_!G[!OBGXS:I:>+?BOXIN]6DN5$T
M<=U(97B#<@)&?DCZ] *S592ORZGFT\RHUY2A03DUO;;[]C9^)'_!1;6/'@FT
MKX.Z$B0$^6?%?B*(QP*<]8+;EYCW%>#V&B?$?PXWB&"U;7]3;Q,[3ZQ>G2VM
MA?LXP<Q@':O8#TK])/AM^SAX&^&-M$=)T>&2]0 ?;KI!),<>A(X_"O2OL:YR
M2Q/K4RA.HM7;T%B,+B,7#EE4Y/\ #O\ >?+7PD\7^._@_P##O0?#T7PAU*?2
M-/M5CAELK^.5RO7)4X(//2NQA_:TL[,XUGP5XNT=APWF:6TJC\5S7O*VRA,9
M.*;]C4_QM],U7)-;2.E4*T5:-5_-+_@'BEI^V'\-[ABEQK-QIC_W=0L)H<?B
M17D7QZ_; NO#FLZ>O@;Q%I%]83Q!I2+8W!4YZY!&/IUKZXU'PII>I0NMY8V]
MX"/^6\*O_,5\;_M1_LRZGXG\4Z=<^#?!ZBW$6V=K%HX$///''/O6-555'1GG
MY@\=3P[=%IR\DT_U/H?X;?''P[K7@[2KS5?%6C+J,T"O,#.D/S'K\A;(^AKJ
M6^+?@LG_ )&O1>G_ #_1_P"->;?#C]F;P1'X*TA=<\%Z>=46!1/]JA5Y-W?<
MPZFNJ?\ 9J^&(7/_  A6D#C_ )]UK2/M6EL=U-XKD7-R_B>#_M@_&CP1=^'(
M-*M9[76M2ED1X[BS\N98E5@64L#QD5]!_!KQ9I'B[X=Z/J>APBUT^6(!8=@0
MJ1P>!P.:^;?VM_@#X'T/PM;:KI4=MH%W#*D2VELJ1B4,P!8CJ<5UGA+]D^ST
MOP]877@_QYK^CW#1*_GVDX>"1B,DE<XK"/.JC=CS:4\9'&U.>*<;+9Z_B?4:
MW!QU!KF/&?Q.\/?#Y8'\0ZQ::2LY(C-R^T-7D0G^.?P^C -KHWC^QCZNKFVN
MB/H>":\C_:1_:&L/$/@N71-=\!ZCIFM3#;&^HPKMB/<HYZ_A6LZW+&^S\SNQ
M&.C1I2G+W6NZ=OP/L7PEXYTCQQIRW^AZE:ZG9EBOGVS[ER.U;TDZ18W, /K7
MS3^SW^T+\/Y? &FP/?:;X5N(0(GLYY%C+D#!?MUJ']ICXSZ?8>"X;_PU\04T
MN^WMY7]F,DYG..%/)VCWJU57)S7+6-I*A[9R3TOO_F?3<4YD;'RX]0:X/XS>
M,?$G@CPC<:OX;TRSU6:U!EGBO)C&JQ@9)&.I]J\)^#7[4/A[P]X%CG\2>-+[
MQ3KDQW-;BS+31G'W%"CD9[URW[1_Q:\;?%#P"R^'O!NOZ+HL;[YM0G/E-(F.
M04'.WZU$JR<+HPJYA2=!S@[NU[+5_A='T9\"/B3XF^)/A--;\0:39:2ESA[5
M;68OO3U8'H:[[5/$^F:) 9-0U&UL4'\=Q,L8_4U\/_LN?#+XB>./!<PE\9ZQ
MX7T,2CR8H5.^5<=48]%^E>]:%^QWX*2Y^V^(I=2\77F<[]8N6D7/KMZ4J<ZD
MHK0,+B*]:A"4:>ZWD[?D;'B']JSX=^'[AK5=>75KP<"WTJ%[ER?^  BO(_C3
M^T/XH\7^!-3C\)>"?$MA 5 ;5[F#R<+WPARQR*^F/#OPT\,^$XU31]$L=.5>
MAM[=4/Y@9JQXJ@5-"U'<Q(%M+U_W35RC-Q=W8WJ4L15@XRJ<OHOU9\.?L6>
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MDC'I2,FX<,5^E9N$9--F,Z,)R4Y;K82 $1+GKBI*0# QUI:T-@HHHH ****
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M/C_\3/AM::YXE\/7>E^%)(5U&'58'C0&/;D,=C9 QSS5OX4_$SXW?#KP-?\
MB'PSX9N?$7AN:'^T)M2N662,1*I^92[@D8!Z>E?H+X$^&>G>#_AOHW@Z3_B9
MZ=IUBE@?M<:GSD5<?.O0Y':MNW\(Z5:Z0NE0V%O'IBQF$6:1 1!#_#M'&.3Q
M67L%S<USC_LV/M_;JI+:UKL^)/"W[5/[1/B;P-:^,;'X:QW7ANXMC>17R^6
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M&H?$K4[[P?%XSC\5>(=&_LF4:1IL<^GWD9;A)IG_ -5MZDXZ=*^Q?@OX0N_
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M'UQ3\<8I:* &-$K=5!I!"@QA0,5)10 E1F!"V2@SZU+10!%]GC_N+^52  #
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M "T4FX>HHS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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=7:!D_6NI'2BB@!:*** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>adag-20221231x20f022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %# L # 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444QY57J<&@!])FN8\<?$#1O GAC4M=U:^CM=.L(&GGEW#(51V'K7R
M%I7_  4C5M1TR_UWX<:]H/@/5;D6UCXHG<&-MS85V3'R@_6@#[D%!.*S-*U2
MWN[>-TN$D$@#(0PY!&0:OS9:([: ) :6O/W^*FF:;X\U7PU>L;)]/TY-2FO+
MB15A6)F(Y)Z8QWJ_:?%WP9?^'[G7;;Q3I4VCVQVS7Z7:&&-O1FS@&@#L*,UY
M;XR_:)\!>%OA]<>,I?$UC=Z#;RI"US8S+*&=F "C!Y/.<>@-=!X,^*/A?QM
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MA:1A<D=3_C5FFH@08 Q3J!!1110 4444 %%%% !1110 4444 %%%% !1110
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MTAX2-=Q; _$F@1OT444 %%(6"]3BC<!0 M%-+@4;QZT .KYX_;]_Y-.\?_\
M7E_[,*^A=X]:^>OV_.?V3O'^#G_0O_9A0!Z#^SG_ ,D&^'W_ & K/_T4M>C5
MYU^SI_R0;X??]@*S_P#12UZ+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1129H \1^/'[6?@S]GJ_AMO%5GKK+)%YWVK3M+DN8(USCYY%X4^
MQK:^!G[07A[X\Z7>7WA^QUBSM[9E4G5]/DM#(&&0R;_O#W%<-_P4 4']ECQR
MW<6R]O\ :%>H_!B%5^%7@ML_\P>TX/\ UR6@#O*6D[5$TC9<>@H +HXC'U%>
M"^#I(Q^U/XQP?F_LFWZ_[U>H^//'FG>!?#MSJNK74=O;PKD!C\SMV"CN37P_
M\)/B_P"(+G]IV\UR\TN]-GJJBWEB\EOW,)/[MB.P]ZY*M2*E%,\K&8F%&I2@
M]6W]Q^ARG(S2TR%@T:D=,"GUUGJA1110!G:ZMVVFW(L=HO/+;R2_3?CC/M7S
MIX:\<?%K4?B9=>&9GTG;IYCDN&10"4/7!]:^F)%W$?E7AO@I,?M*^,QV%K%7
M;AVN6=TGI<B70]OM_,P-^,XYQ4](.E+7$6(Q('%5S<JJDG@]<59JO<6B7"%6
MSR",TF!074X2Q8R1A?7>,UBZ=\2?#^I^([[1+?489=1LE5IH@1P#TY[UYKXH
M_91\(WSW]_#%J,FH2AY%7[?(J,YR<=>.:^7_  [^R'\0K7QM'>ZG8H=)DN,3
M1QZ@1(8B?[PY.!7)4J5(M>Z>5B,3B:$HJ-+F3??9=]C]"AJ\#2!$EC9O0,,U
M>$G[O>>F*\=\%?LV>$O!^M6^KV*W_P!MA!V^=>.ZY(YX)YKUR5-EH5]!BNF+
M;6JL>E!R:]Y6/*_VA_C]H?P%\+V.M:O;7-^ES=+;I;V8S(1U=\'^%1R:J?$W
MX\6OP]T/PQJ%EH=YXHD\27*6NG6FFR(KRLT?F [G('0>M>;>/O!WB+XQ?'^^
MA;247POX=TF2RADU-&\FZGN%P[IZ[5XS7E5N?%W@_P &?#C3?$OAO6+L^ ?%
MSP3SV-F\[3V8A<1S(!R5^8"KN6?2GA#]IG0-:N-=L/$>G:AX&UK0[/\ M"_T
M[755&2UY_?(ZDJZ\8RIZUF>&/VH;KQ;=6=WI'PU\5WGA*]E$5OXA2.,1LI.!
M)Y)/F;/]HCIS7B_Q-\ >)OVJ]=\4ZMHV@ZEX8TJ#PM+H^GS:W ;:349WF27;
MY9Y6,;-N3W:L?7/%WCK5X/ .FZ#:^/O"7B_2[BSL-2\/VEF5TM[=#B65I<;6
M! &"#TH ^G-5_:)T73_B_HWP_%AJ5SJ&H&53>?9REM&Z('*;R/G.#_#G%9WQ
M/_:2'PJU:=M1\">()_#%I+'!=^(XE06\)<@ A2=[J"1E@*\W^-7C:*V_:&^&
M5RFC:_=V_AZ2Z&H7-MI4LD2&6-0F&48;)ZXZ5E_'WXD3_$+QP/!6M:#XEL/!
M&G7-O=W5SI^D2W+:LR_.(05X2,'&3U)I-V&M3VCQG^T -(\4IX=\,>%-5\<Z
MXMG'?W=MI;1QI:PR9\LR/(0-S $A>N*[G4_%,.E^";KQ%JD$FFPVM@U]<Q2D
M%X55"S*V.,C!%?&OQA\&K:?%3XA:M=Z;XW"^(='L9O#$OATSHOVA+;RA%((S
MA75PI^?C;7MGC[P_XJO_ -C'6-+UEWD\7+X7VWISEWF2,-(,]V^5@??-/<-C
M4M_CMXA@^&GAK7E^'NK:]J6L6IO#I^D.FRWCQN&^20@9(QQU-=Q\/OCIX5\=
M^ ]*\4PW\>F6-_&Q":C(L+QLG$B-N(&5((->%_$3XU:EX:^#7@73O"FB:E>_
M\)%I,<;:SI]F]RFF1&$ R;4^\XR<+QS7-P?#'0/&%[\ ]*TWPWJEYX3TFZO%
MOH]8T]X26$/^LF1O[[\\\$T M3Z[C^(GAR::RACUS3I)KT$VL:7<;-< =XP&
MRW0]/2H[GXE^%K._^P3^(=+@OR=OV26]B64$]!L+9SSTQ7Q[\)_@%9>&]$U_
M4CX1-KJUE\18Y-.N'MR)(;%;I<&(G[L6QFZ<8KRKX63^'-4O_#&L>*-(FLK6
M'QO=7R^*)=+^T17DKR2QQP-<D\IGD,1U7&!B@+'U[\:/C?J'@;QMI>C:+;V]
M^T6E7^NZK!)G,=I!&?+P1]TO)QG'0&NY^%'Q5L?&_@3PYKUVUOIMWK6G1ZBM
MB9@65",DC/)49ZU\]>$]-N/BIX8^-GQ.B@EN9O$-C=:-HD(7<396Z,B;/^NC
M[CCZ5XGX=\+>(/A'\#?&D?BW1;U]8U7P:AT[Q,[,GV6'"J=/(/\ J74D$ 8W
MYH ^Z?&/Q9TV/PSK]QX5U+1_$.NV=G-=6^F0W\;M,T:DE2JDGH,5T'PM\;6O
MQ(\"Z!XHL2/LFK6,5VB9^X77)7Z@Y'X5\<?L\W'@WP]\4DUO4](?PAK:^"EC
M@TZXT;[(EQ;VYW3W:R9.6.X CT/4U[_^Q%IUSIW[,O@)+I3&\ED]PB..1')-
M)(G_ (ZRT >\8S12T4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** (KB%)X]KJK#(.&&1D5X'^VSK>I^%/V<_&^JZ'J\>@:M;6(:'4F.UH
MP9%W*K=0S#('N:^@&Z5XM^UUX/L_'GP)\6Z'?ZKIVAVEW:#S-3U4'[-;!7#!
MWP<\$#'O2Z@?)G[%>N^#-8^(_AB:R^('Q-UKQ%/:;Y;#7X)!IYD*9?YB,8!S
MCGTK]&H_NU\'_LG_ !5U34?'_A_PN_QY\!>.+&VMOLZZ3H^G/%>RA$PI#D 9
M ')K[PC.5_&F ^DI:* ,/Q<MY+HMW%87,=I?/"RV\\J[ECD(.UB.X!P<5^=?
MPP\9?$+X2_M,^,=//CVZ^*&A:3X:O-7\12,A6WLKI(F>.%#D@$N ,>A-?HEX
MST&Y\1>'-1L;*]?3+RYMI((;R-=Q@9E(#@'J03G\*^6?@?\ L/>)_@_#=:7)
M\3!K'AG4C,=8L'T6-9M0\Q&5]\^XMGYL@T ?._A#XN?$GX7Q_"SXU:YXRNO$
MEA\2+R>UO_#+KB"U1D9X_*YX*[!GBJ_ACXV_$CPU:> OC[J'BZYU33_&'B&7
M1[GPIMQ;V]ME@NPY^\-G7%?0WP__ ."?M[X>U/PC9>)/'TWB;P3X.FGGT+0C
M8+$Z-*I7][+D[MH8XP*B\%?\$\I_#FL>'-.U/QU-K7P\\-ZK+K.E>'6L51TG
M?/$DN?F49.!B@9\\S?&;XF3Z1;_M"Q^,+F.S?Q=_8(\)X/V46OF;!GG[_P"%
M>Q?MX?M+:8/A7XY\ MX8\3O?36<0&J)IKG3UWA7&9NF!G!]ZZ&'_ ()VSKJ<
M>CR>/KA_AK'KQ\1IX<^PJ)?M);=M,V?N9[8KT/\ ;PL6MOV2_'R@@*+$ *,@
M#YA0!Z7^S>?^+"?#[U_L*S_]%+7I%><?LX*%^ GP^ Z?V%9_^BEKT>@04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !45P2%R#BI:K7LJQ1J6]>*
M /SP_;4^(TOQ*^+VH_"G6_&@^'O@2PLHI]1NT@,T]_)(V$C1.XSCI7I_[&/C
M?Q/HWQ \9?!_Q!KJ^++;PK;VT^FZULVN]LZC;&X'0@8XKY1_;PB'QU^*_B[Q
M1X<46.G?#BR6*YUB$?-<7988C![[?TK[8_8F_9ZM?A!X&37GU6;6]6\4P0:A
M=WUX,S,S(&VEL\@9I7%?6Q]-B0'@')'6N:\;>,M*\#:1>ZMJETMO:PIN9F/7
MT ]S5CQ5XGL/".BW6IZC<1VEG;H7DD;MBOGK0])U3]IGQ1;>(-8@FT[P+82[
M[&Q<8:^8'AW']WVK&<[/E6YA5J<ON0UD_P"KCO"/AW5?V@O&%OXL\1VDMCX5
MLFW:9I<V?](;M*X]/2MSP1:)'^T_XQ@$:+&FDVX Q@#YNU>TW'V+PSI37,[I
M:6%M'EF8[4C45\T^"_C'X-D_:3\27R^(K)K6^L8+>"0/P[[N5'O6,HQ@XM[W
M.*I&%&4.9ZMZ^>C/K*)0D:@= *?4<!5HU*'*D @^U25VGJA1110 U^E>&^"N
M?VEO&?\ UZQ5[C)TKPWP7_R<OXS_ .O2*NNA\-3T_5$2Z'NB]*6D'2EKD+"B
MBD) Z\4 ,<9XJ+R IR<>W%4O$/B;3O"^E7.HZE<K:V5NNZ69N0H_"O-1^U7\
M,F*JOBFU))P/E?\ PK2-*I4UA%L5TCU=R5XP3[BI@NY,'GZU5L+V'4;2.Y@D
M#PRJ'5NQ!Y!JX.GM62O?49$+= ,  ?A3O)7_ .O7->/OB3X<^&6EQ:GXGU>V
MT73Y)DMUN;IMJ&1CA5Z=2:V1JT;PQR*0R. RL&'(/<4P+@A4#@#\J&A##'Z5
MFZCXDL-'MEN+^Z@LH&D6))+B4(&=CA5!/<GH*S(OB'H\OBR;PVEV&UJ&U6\>
MT"MD1$X#YQC&1ZT =((1WYI1"%'' ]!7"_$3XX^"_A.EB_B[Q!::"M\S+;?:
MMQ,Q49;:%!/%96H_M,_#72O"%AXHNO&.F)X?OYS;6U^LK/'+(.J#:"=P],4
M>GB!1TQ^55K^Q2YM7B*!E<%2I7((/!!]>*Y;X?\ QA\(_%/3YKWPGKUEKL$,
MGERFTER8FQG#*<,I^HJ_XR^(>@_#_0[C6/$>JVNB:9;C,EU>RA$'MGN?8<T
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MKY<84C)XY/2N=\"?$G1_B!;7TVE2R/\ 8KZ;3[F.5"CQ3Q-M=64\CU![@@T
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M_,'"X&.30!Q'P0_:L\)_%EM-%IX?O_#EQJ.JS:1%#>VZQR&5(A-\V " R$$
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M,<,>F:_1B+ 0 5^7_P"Q_<> 8?CKX&3X37'C:?5)+>4>,8_$GG>0B^7SG>
M_F=-M?J!$,*!3&/HHHH$%%-9PO4XJ#[8"6 '0]^E %FBJC7I&,+E3T(/7WIP
MNM_('R^M %FOGC]O[_DT[Q]_UY?^S"O?DN\@<8)-> ?M]G?^R=X^/_3E_P"S
M"@#T+]G/_D@WP^_[ 5G_ .BEKT:O.OV=/^2#?#[_ + 5G_Z*6O1: "BBB@ H
MHHH **** "BBB@ HHHH **** "HI)@A )Q^%2$BO)_VD/C-8? KX7ZQXJO2K
M/#%Y=K!_%/.W"(!WR<4 ?/'[32W7[2_QVT#X*:3<%= TMEUKQ3<0G($:G]W
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M]3Z4>$/"VI_&S6[?Q;XLMWM-%A;?I6C-R&7M+)ZD^E>]VMLEO&(U4(B_=4#
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MOV<_^2#?#[_L!6?_ **6O1:\Y_9S_P"2#?#[_L!6?_HI:]&H **** "BBB@
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MZ'I>@:AXDTW4KJU>TMP6C<>8TK9Y8L:]*_9S^ 5M\*W&MPZM-?OJEG'OCDC
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M6?\ Z*6O1J\Z_9T_Y(-\/O\ L!6?_HI:]$S0(6D9@JDGH*0L!7GOQR^*=O\
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M7NK*Q.02#C% 5D4#.3GK6,Z5.HU*2NT=V'QV*PD90H5'%2WL]_49:Q>4-O.
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M/AOX\DU2&,326::9F9$/ 8IU SWK["TK0HM$TNVL+");6UMT$4,,9PL: 8
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MJ(HPJCT '%8=G\.M#TWQC?>)[32;>VUZ_C6"ZU*-<33QJ<A6/<"@:/E+5_\
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MR?*7&=W?- 'L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K%\9''A36,]/L<O\ Z :VJCGA2XB>
M.10R,"K*PR"/0T ?DC<_%3P5JG[!MM\.H+^UU7Q_>:I+%8Z/;#S+J*4W>5?
M'RX&>:Q/VF/%EO ^NV4.GM9>+O"6G:9%<:SJ7B.:&Y28JO%I:@[6_P!KCZU^
MK6C_  @\&^'M0_M#2O"F@Z9J')^UV>EPQ2Y/?>J@_K46K?!OP=K^M/JVJ^&-
M$U/4V39]LO--AEEV_P!W>RDXH _-3XX^/_&GPE\1:CX;L+S4KA?BWX;TS^S9
MEE9O)O2(TF*G/RDJQ/'<U>\6:5;? KX^Z)/K]S:^/M*273=&@ABUV5-5T:Y2
M-01Y(?YD9B6)((.>M?>7CG]FW0/'_P 1O!/BK4KB8?\ "(LTFGZ;%&@M]Y
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M]CO+1)8>.GR,"./I5+3/A5X4T;09=#L/#VCV6CS B73[:PBC@DSUW(!@_B*
M/S/\;:S\-['X:?##PEHEE'XA:\T26]^UZIXJGM+"WE" R98-\T@/1>W2LGP)
M#J/Q=\-?LT^&]<\0:LVF:K>ZA97?V6_D1YH%)PAD!R1CC/6OTV?X$> 9-,LM
M/?P9X<:QLY#+;6QTF QPL3DLBE<*3ZBM6T^&?AJPDL'MM"TNW:P=I+0Q6,2&
MW9OO&/"_(3WQC-(9\"_"?X6^ OA_^W_XBTF:ZN+"6RL;:71HKO4Y=\\N,$8)
M_>#'8UVO[:.JZ7J?Q\^&GACQYK5QHOPSO;6YFNV6[>UBEN5'R*[J17V)>?#+
MPYJ/B.UU^[T33+K6[7_4:E-91O<Q#_9D(W#\ZE\5_#OP_P".;,6GB'1M.URU
M5MRPZE:)<(K>H#@@?A0(_'ZZTB/QK\%]0BN=0U'5O"VF^/[:QT&YDO92IMY#
MB15;/S=L'MVK[U_:^\.6GA#]B'Q9I%EYBV-GI<4</GRM*X4$?>=N3^-?1"?#
M+PRFCVVE#0-*&F6TBRPV2V,7DQN.C*F, CU S6KJ_AK3]>TJ33M1M+>^L95V
M26US"LD3KZ,K @B@+GYE?$;XA^&_BWX3_9\\(^!;^W\0>-].FM;B7^SAO>QC
M1!O$C <<CI7EFO>(=/OO _B[Q;J?BW4H_CM:^+/LMA9+J,BS+$) %180<%2/
M:OUR\-_"[PIX.DDDT'PYH^BR2##OIVGPV[-]2BC-59_@[X-G\1C7G\+Z&VM@
M[O[2;383<Y]?,*[L^^:8'YRZIK$G@C]IC1_$7BVZM?' UG4+2VB%GK4D>I:)
M=;%W1&V5AE,G)R,&L/5]0U7Q#X!T[3Y=<U.W2^^*UQ8R2V]XZ2"%FP4# Y P
M3Q7Z<M\(?!Y\2?\ "0MX8T5O$&=QU4Z;#]J)]?-V[L^^:G7X8^&?)2,Z!I(1
M+DWBJ+"+"S_\]1\OW_\ :ZT ?ESXBU2^^$?AO]H?P;HNMZK'X=TC6;..VMYK
MV1RL;N/,0RDY4,,@MFO>?^"=7AK3;OQ!XQ\5V5W9VT%V\<5GH5MK;7YLH@!G
M=\Q R>:^E?C%^S'X6^,/AZZTNY!T)KJZCO)[W28(HYYY$Y4RDJ?,QZ-FLCX(
M_LE:'\$_&&J>)[/6[[6=9U.)(;BXO8H8P47H%6)5 _*D/H>]#I2T@Z4M @HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I***  T"BB@!:*** "D'2B
MB@!:*** "BBB@!!1BBB@!:*** "BBB@!*6BB@ HHHH **** $Q1@>E%% "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>adag-20221231x20f023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $N S(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH ***3- "T4F:,T +1249H 6BDR*,T +1249H
M 6BDR/6@G% "T4@/X44 +13"6R<8Q3J %HI,T9% "T4F:,T +12$TS<V#^G%
M $E%(#Z]:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB YI::GW13J!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHK#\9^,-+\!>&[[7=9NDL],LD\R:9@3@>P'4DX
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M@6$MG%:Z;J5S?O<LRE0S/,H,: $X09QP,U]BXHP!0 #@4M%% !1110 4444
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MCDV-+Y<JN4#=B0I /K7LE-9 W49H _/GP]\)/B?X>NM'\3VOA#Q%=:!H>O\
MVJR\*:OJ"76II%)9M#-()&<@J92"%+<#./2O9/ G[/%_9_LZ^'])U_7?$'AS
M5]*BO;V2#0=2^S8:5WD$4A"MOV@@>QW5]0^2G]T5E^*E"^&-6P,?Z)+_ .@&
MF!Y]^RUJ=[K?P \"7VH74U]>3Z7&\MQ</ODD;+<LW<UZQ7D'[(W_ ";;\/O^
MP4G_ *$U>OT@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGVH _+WPC\<_%EWX:UQ=5\7>*;/4KW^SWUR[CU?[1%IMNVI+%<OM W6$H0[
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M_P"DAH ]R1MZYIU-C^[3J!!1110 4444 %%%% !1110 4444 %%%% !1110
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MM^'O_8*3_P!":O7Z\@_9&_Y-N^'O_8*3_P!":O7Z "BBB@ HII<#J:-Z^HH
M=13=ZYQD9IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#EQ;P>;(<(K.PP,GUKVV-BQ((Q0 ^BBB@ HHHH **** "BBB@ HHHH ****
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MM!_V+/#<VG%Y?$WB:7Q*VH)J1\4-<P_;_,6$PJ/]7LV^62,;>^>M>G:!\/\
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M-A?<F3Z9ZCO74HI!)/>GT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI?"FS^)MOH<5S>360TK5(-40PH&,C1'(4YZ YKO:* &(N">P/:GT44 %%%%
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MM% "8I:** "O#/C;_P ES^!?_84U#_TD->YUX9\;?^2Y_ O_ +"FH?\ I(:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6M'+=007&PV(;9\JD#._G&.M7;341]:JV0#TS3JYCPCX=UK07N#JOB2?Q )
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSP$7.LWMM*-/MY-GSF,.Q$88# P. <5]PM($ XR30-DE9/BS_D6=6_Z])?\
MT U?-T!_"Q..F*S/%$P?PWJP _Y=)<_]\&@1YU^R-_R;;\/?^P4G_H35Z_7D
M'[(W_)MOP]_[!2?^A-7KU '&_%+PYIOB/P9JT>I6,=['!;R31K,N0CJA(8>X
MJO\ !CPOI7A[X?:,VG6$-DUW:0SSF(8\R0H,L?>MGQS<Q_\ "'ZZNX;C8S8
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MZG@5YI^SY\._$W@C4]5DU^T-M'/$B1'[0LO(.2."<4P-W_AD[X._]$W\.?\
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M50>,= P'Z4S0O@QX.\,ZE;W^F:.+6Z@_U;BXE8+QC[I8CI[5VI.*3>,X[^]
M"@;0!Z44#FB@#FO%/CK1O!QB;6-5@TU9<A//?:&^E6]$\06GB&QBO=/NTN[2
M3[DR'*MCKS7$_'#X41_%;0(+(2I#=03+)'(YP /XA^(IGB35C\%/AO;/9:0^
MKVNGHL<D<,H1@O=NASS7'*K.$Y.2]U=3BE5J4ZDW45J:5[]?/3R/3M[X&"".
M^:E'2N#^%'CRX^(OAB/6FTI]*MIV80QRR;F91_%C [UW<>0@SUKIA-5(J4=F
M=-.I&K!5(;/8=1115F@4444 %%%(6Q0 M%,\P X[]:4.#CWH =1110 4444
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M.HWA>0MYDY4*6 /W1A0,"NHHH 0# HQ1FC- $9?YNAP.^:Y+XG7I@\#:P_\
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M?_84U#_TD->Y5X;\;O\ DN?P+_["FH?^DAH ]P3[M.IJ?=IU !1110 4444
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M1110 4444 %)BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ"M6F.A8C#%<>E9\BO>Q*C%.]A5&%'&*=24M:%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%(3@4 +7AOQN_Y+G\#/\ L*:A_P"DAKV_S!DC
MTKP_XV,&^.?P,Q_T%-0_])#0![BGW13J;']P4Z@ HHHH **3-+0 4444 %%%
M% !2$ CIFEHH 0#':HI;.&9LR11N?5D!J:B@!B0I&,(BJ/0#%/HI"<4 +4<F
M"0,$]\BI*2@"#:-V-I()JQ28I:2 ****8!1110 4444 %%%)F@!:*** "BBB
M@ HI,TM !1110 4444 %%%% !1110 4444 %%%% !1110 QID1L,<'WK)\5R
M!O#>J@?\^DO_ * :\4_:E\6>)+/7/AYX3\.:[+X7E\2ZG-!<:O;(K30QQ0-)
MA W&6( ^E87@+X_:UJG[.WA[5M3\*^)/%VLZK%>6$TOAS3A<8:)GC$LHW#:&
MP#D=\T >A?LC?\FV?#[_ +!2?^A-7K]?)_P(^-FJ_#7X0>%/#.J?"+XERZAI
MEBEO.UKH >,L"2=I,@R.17>?\-2S?]$=^*?_ (3J_P#QV@#W2BO"_P#AJ6;_
M *([\5/_  G5_P#CM'_#4LW_ $1WXI_^$ZO_ ,=H ]THKPH_M2S8X^#WQ3'U
M\.K_ /':SM#_ &R+#Q+%<RZ3\+_B3J<5K</:3O:Z"KB.9#AXV_>\,#U% SZ&
MI*\,_P"&IIO^B._%/_PG5_\ CM*/VI9?^B._%/\ \)U?_CM CW.BO"_^&I9O
M^B/?%3_PG5_^.T?\-33?]$=^*G_A.K_\=H ]THKPO_AJ:;_HCOQ4_P#"=7_X
M[1_PU+-_T1WXI_\ A.K_ /': /=**\+_ .&I9O\ HCOQ3_\ "=7_ ..T?\-3
M3?\ 1'?BG_X3J_\ QV@#W%HU;JHIP ';%>&?\-2S?]$=^*?_ (3J_P#QVE_X
M:EES_P D>^*?_A.K_P#': /<ZCGSY1P,^U>#ZC^UK'I-C<7M[\)OB=:6=NAE
MEGG\/JJHH&2Q/F] *BTK]KJ'7]+M-2TWX5?$R_T^[B6>WN;?0%9)8V&593YO
M((H Z#XI? K1?B)%>7D\#1:N8=D-P#@ CIQ]:Y#P]^R7H=K?6LMYYD\,=H$D
M0Y!:7NV?2MD_M/R$Y/P>^*GX>'5_^.T[_AJ&4=/@[\5!]/#R_P#QVN*6#H3E
MSRCJ>?4R["5:GMITTY=SU_0-&AT2QM[.VC$<$"!$4#L!6M7A8_:DE'_-'OBI
M_P"$ZO\ \=H/[4LW_1'?BI_X3J__ !VNQ*RL>@E961[I17A?_#4LV/\ DCOQ
M4_\ "=7_ ..T?\-2S'_FCOQ4_P#"=7_X[3 ]THKPL?M2S?\ 1'?BI_X3J_\
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M25H8VE0$+(5!9<^AZBIPH4 #H* /#EL_VBR,C4OAJ1_UZ7__ ,52_8_VB_\
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M?Q/IT$OP^M7T'4!I\LMQ9WVV=C$DF],-]W$@'/=37TG/-'%$SR,J1J-S,QP
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M]#STH N8'H*,#T%+10 F!Z"@J".E+10 @%+110 4444 %%%% !1110 4444
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M.M^%?"/B'2M.^):6":E9VVJ(&1X=_P P7=A3(5#;5/7ZXKR#X&^+?'_Q7O\
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M-'+*N!+N;<V",+G  KZ7BC\M< YI$0 9(Y]:DH$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 5[VS2]@EAD&8Y$*, 2#@C!P1R/PKY2\ ?LTW_ ,+?C]I#
M>1=:_P##ZW2]O=%=Y4SHM],,3&;/S2[TRJL2<9-?6M0M"C."1DCD4 <?X%^#
M_A+X;WVK7OAG0+'19]6F^T7K6D6WSG_DHSD[5P,DG&2:[:D4 #CI2T %%%%
M!1110 4444 %5KYY8K69X(Q+,J$I&3C<V.!GMDU9I" >HS0!^>OB/XO^-KG2
M->LOB5X?\17FEZU<1V5_IDMS%IK:<SR,J)IT2GSK@ 8)<Y4X[U[5^S3\(O$?
M@CQWXEO/%T+7-Q:V-KI.EZM%#'#!?6"$M$TBK@F=>%8L.,#%>\7/PV\*7GBR
M'Q/<>']/G\110^3'JDENK7")GH'(R*Z-;:-6/R\_6@9(@( SVIU%% @HHHH
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>adag-20221231x20f024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &( : # 2(  A$! Q$!_\0
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M!SZ5VNC^ =3L_BWXR\0S-"--U;3[:UM]KDN&3?NW#' ^8=Z]'I:<JTI-OO\
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MT,)U)5%%/HK!1114&04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MAX5^'=K ;B<E+N]F<[(E_B/3DX[5]K?#'X/Z;\.H?-$SZAJ;H$DNI?;^ZO\
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MZQ2@O/5_<FDOO9YX/CS>R -'\.?&+H>C?V>F"/7[]'_"]M0'7X;^,OPT]/\
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M59'WU2I*M-U)N[>K"BBBF9A1110 4444 %%%% !1110 4444 %%%% !1110
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M*"H/#_A"?5(;O4[.[C$4<IC@NY!F4H/]KZYKN+0W&N:LE[?S;3<0$A5/0XK
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M_+!=[+URI4D>M+XY\4Z>MW>6&J^"=1U=O+V03PV2SI*".F[JO/K4?PQT[7/
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MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3Q)I/CJVMM>L9-,UF5_+Q.@5HO3(_J*W?%/@G7?&<,3V5A_:NN7"-/;2 \$
M9;\<=J_4)XJG5H2J1FK+5_GIY6.+E:=FCF?!/A#PKX"U/5-7\6Z@VM:JL^Y+
M2+D2]3P>U?=7[(/@V]MM"OO&-S#!8P:^!);64 X2('@GT)]*^1_@%^S%X@^+
M7BJ"ZNKF[TNRL75M0N9HMI!S_JD5AR3ZXP*_3C3K"'2["WM+>-8H(4"(B
M#V%?G>?9A",/JE!Z/5]?-?/JSKI0UYF6:***^#.H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/EX49 YQF@:/J[2-276-+M+Y8)[9;B)91#=1F.5 1G#*>5(SR*N444 %%%%
M!7CDY_X6/^T"D _>:/X*MQ+(/X6OYA\@^J)SGL2:]'\<>*K7P3X2U77+L@0V
M5NTNW."Y ^51[DX'XURGP#\*7/ASX?P7>I@G7-;F?5]18C!\Z8[MN.VU=JX[
M$&MH>[%S^2_KT/)Q7[_$4\,ME[TO1?"OG+7TBS'^.MM)X6O_  [X^M5.[1;D
M17VT?>M)"%?/L"0:]:MKB.[MXIXF#Q2*'5AW!&15/Q#HEMXDT*_TJ[3?;7D+
MP2#V88KS[]GW7+F7PI=>&=2?.K^&+EM,GW=6C7_5/]"F.>^#0_>IW[?D$?\
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MHKGN6H?M4^"8;SPK;Z6NK>)O^$FLVO\ 3I="L&N4:%9%C=G(QY>PO\P;&-K
M\C%+8_M4>!]1\51:/#_:QM9[HZ?;:\=.D&EW-WNV_9X[C&TN6X!X4G@,3Q6)
M\)/@CXA\">(-!EU66SN_*T+4H;V[LODB6\N[];IDB0G=L7<X!.,A1G&<5S<7
MPK^(]_X1T7X7WVAZ;#X?TS5[:]?Q5%?@+-:PW2W"HD/,@G)4*<@(.2&/ JA:
MGIMM^T5X;N_ &G>*X[/5#%?:LVAIIGE1&\2\6Z:V:-T$FT$.A)^;[O-5K']J
M'P3?>+4T1?[5CM9;K[!#K\NG2)I4UUG'D)<D;2V01G[I/ )/%<'9?L[:\G[2
MFI:E+':+\,?,?Q+9PK%$)%UR6 6D@P#N"B-1-NQ_K&)SFN+\+_LP>)M'O=-\
M/W7A=KZULM7^W?\ "17?C+4WT][<3F9=NGK<@"<$@ %/+R,\]"D-G5_'S]KR
M#P[H]S:>"X=7;4(-8LM-_MV31I'TII#>I#<6ZSLNTN%WC/W<\!BW%>[_ !%^
M).C_  OT%-4U@7<RRRK;V]II]L]Q<7,S?=CCC49+''L/4BOF+Q5\&/BC:?"S
M_A5>C>%++4])@\2)J<7B&75HP'LSJ'VO!B8!_/&=I&-N!N#$X6O<_P!HSP)>
M?$'P'%IUKX7TWQA''>13SZ7?W4EG*Z*<EK:X1E,,R]5;(Z=11T#J01_M/>"_
M^$.;7KA-8LIEO5TS^Q+G2YEU,WK*'6V6#!+.5(/RDKCG=@$UYI\7_P!L!X_A
M+J.I>"-%\06OBB'4(-,NK+4-*5+K2I)6PK2Q2N%;< =I5F4Y'-84?P:^,=CX
M,>"WO?$3:#+XDBO&\*MXL8ZRFEA,-;IJA8NI,FU]JS [%*B4$FJ&G_LV>/!I
M?CR/^Q&LUUO5](O[&WO/$,NJ3I# S>8LUQ<2,YD ()&XKSA2<9H8(]=C_:A\
M-^#HK72M?;Q%J5W8PH-;UJ+1&:VTV0KN_P!*>$&.,X/(3<%[X'-9MQ^UDFA?
M$CQ[I.L^%]87PUX>CTYHM8M((GC(N"X,CDS9V<*00O17R.F?-?&/[+7B2U\3
M_$"WL/"TOBRS\6WK7EOJ$OC&_P!.L+7S0%E2\LX+B/S54 D; Q<?*=O6N^/P
MEN_#/B/Q_I^L:79CP#KWAG3[$ZM]J58K62UBFC,;12.9,$2*0V6Z<DGFCS ]
MJM?B+I=]X^F\(VR7$^I06*W\TT:J8(XV;:H+;L[CU QT[UU-?.G[$_AC6(?A
MY=^*?$DR7>M:Q,(([E4 WV=L##;D'K\RJ6_&OHNF(****!A7*:1\2]$UOQ[K
MWA"VF8ZQHL4,UTC8"[9!N7:<\\=>.*ZNOA?XZ:-:V7Q6^-4.EV)B\0:EIFD7
M+1V$+"^N]-66,:CY!4;F/EA@P7GMUQ0!]NIJME+!).EY \,9P\BR*54^A.>*
MJ>(/$,6A:9-=+"]_-&H=;2W=1+("P&1N(&!G/6OC_P#M;X41?$*ZU3P/!;?\
M*W@\%W\7C.32(66PE9GA%E"P VM=?\?.% WA6P1R*\^\-VFM>&?A'\0]+\<V
M^JP>.[K3;&YT:349O-D_L07,8@MU954"6($"4=<D$T ?H:=2MHW@CEFCAFF&
M4BD<!V]@._X5PNO_ !NT7PIJ>FV6LVUUI\NIZVNAV1DV$32%0PDX;A.2,GG(
MZ5\PWDO@#2O$7Q03XO:1<ZMXQNM2BD\.6444AU*_L3!"+2/3&0@[O,#*=C H
M^XN5'-<]XCTG3I]?&L>(K!3I>G?&%3<7&H)YBVT+6EN/G;D!=V!G.,T+=(.A
M]^"^MC!YXN(C#G'F;QMSG&,_7BIZ^,]-T34D^.]M\&(XY1X6M]>/CQ9T$BQM
M8 "2&WW="/MCYQGI >*^MO#_ (JTGQ7'?MI%_#?K87DNGW)A.?)N(CB2-O\
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M?$)$GU4Q::-'2[B>1F8V0W):;03YQ8(2J_,<*1G!Q!UGW5)J-K%.(7N8DF)
M$;. Q)Z<54#:1'J%U>J;,7\<0CN)UV>:L:DD*S==H))P>.37Q?X \!Z[K?BS
MQ=<ZU83WWCS3_A_IHLGN 3+;WQAD&Y=WW9LX!;KG-4O"UEX+U74O@WI'PVL(
MX_&D-T5\8V[VK_:(].^RRK>IJ!VX#-(8PHD.6<J5SC--H5SZ*\#_ +25OXVL
MM>U6+PSJ%MX=TZ>ZBM]5,\3I=I;^8)) @;<HW1,H!Y.0>E=_X(^(>D^.?!&B
M>*+67[)I^K0+<6XNV"-AN@//6OCCP3X6LO#OPO\ !2Z9ID>GFY?Q9]H%O%L\
MS;]N6/=CKA0 ,]L5P>AV3I8>!?\ A-M=\->'_#+>"[9='?Q=X?N-1M&EW/\
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M6=7_ .^XO_BJ/^'@7A?_ *%G5_\ ON+_ .*KYV3]DGXKLV/^$3D7W-Y;X_\
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MA7X0Q63>([U[=[PL((HHFD=@N,G ' &1S[UW=<[XI^'?AKQM-!+KNC6NJ20
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>adag-20221231x20f025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '2 W8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **XSQQ\8/"GPXO+:U\1:F;&>YC,L2K;2R[E!P3E%..?6K_@CXB:!\1K
M">]\/7QOK6&7R9',+Q8? .,. >A% '24444 %%%)O .,\T +12*P89!R*6@
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M_0PZ;_X$K_C1_P +$\+_ /0PZ;_X$K_C0!T-%<]_PL3PO_T,.F?^!2_XT?\
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M_P#1:UP_[;7_ "-WAK_L'R?^C:[C]BG_ )$+6O\ L)'_ -%K3$?1%%%%  >
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M<E6&T_-[T!T/)!CVI,#/05U.FV'A^2":YDM]1OI9)MD.F6DH$D:?WGDV$'Z
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M^*K_ ,1VV@SR^';*SOM8 'EV^H3&&$^N7 )'Y4AG1L=P91P:^8_B.6_X3K6
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M$'.<$;AG\Z]D7I7S&00Q4*%18J]^>=K]N;2WE8Z*SBVN7LA:***^G, HHHH
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M ,NUV/\ MZ:G=B=CY>Q[TN/]JOJ ?L_>#P/^/:[_ / IJ/\ AG[P?_S[7?\
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M-EU(OD,6BVO_ *LGJ5],U]2)X2T/:#_9%EG_ *X+_A3O^$1T/_H$67_?A?\
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M-[H>I216%FEY<72A-CD@#!ZYH+/?^M%4K*\<VT9NFB68C+",Y4?2I_MUN/\
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MA/5+--6&HK-=&8SK 8=GR 8P2?3-:?Q/&-4M\?\ /+^M:OPOC+Z5<G.,3?\
MLHKR(8F;Q;H=/^ 9*3Y[&@VNZ45Q_P )05/M+'Q_X[35UO2U/_(V,WUEB_\
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M5_Y%C_\ B:7^W=*_Z&H?]_8__B:Z;'N?S-&/<_F:+!<YC^W=*_Z&K_R+'_\
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MZ4?VM_<_$?M?(]W^UP_\]8_^^A1]LA/26/\ [[%>#LS*<;B:;N(Q\Q--9O\
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M]?2P,<<:2Q;V=HRZ!R> 7(.#CGGUHLQ<R.G.OZ7_ -!6U_\  E/\:!X@TO\
MZ"MK_P"!*?XUB:AJMI!=0VEMIT,]Q+((XV(1(F;:6(#8.< 9JS]EDCU*(RP6
M0M'0JRK""PDR-HSZ'D=/2DM1O0TCXATL?\Q6U/TN5_QH_MZPS\NH6[#'!%PO
M^-<SXROTT.*$&U6"UG1D>]MH5>6!\9!";3D8SS@X]*\E\1Z7XDUSPSIFO0I9
M:M%"@>(-;F!IL$$3.FT8;@Y3'3D$5$I<JNR9245<^A!K&GD?\A*W_P# A?\
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M1ZUXYX3^$6H^&?,N)M3TZ_GFMDM)+2:P/V<1)G8BG=N)!)RQ^]D\#BNK\/\
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MJ_\ Z$:ZL)&K"G:MN<N+G2G4<J.WS_4N4445VG$%%%% !1110 4444 %%%%
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M\'_%@_YAJ_\ @1'_ (T?\*>\68_Y!J_^!$?^-+V<^PO9S['&11+),BNXC5F
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M^FW!SU^4?X5S?@OX9ZGJ=E?R>(K=]+N$OYH[>.$JPDM@V(Y#UP2,G%>SRMM
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M-!\.7UM?P2V<TMP2N<;@-HY'XUY1^U7>7-KXCT..*>6$&U<GRY"N?G]J[_\
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M?\-?#;^)?%5NI3-M;GSI#].@KZ;A38H&[( Q7GOP1\,G2/#:WDJXN+S]X?\
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MR0/^$FU+_O\ FL/4]6O-:NFNKZZEO+EL!I9FW,<=,FJC%Q=SGQ&*C6ARI%3
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M:\/!X_ZU.4''EDMU?N3.GR6=S2%%%%>T8!1110 4444 %%%% !1110 4444
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M<>IAL"58CDXK[-\&_%CPI8^%-'MKC7+:.:*TBC=#OX(0 C[M?&3=#Z8K[[\
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M2[U MM^R0KQGY@.E2B35#TM8/P44_:6_X<R6']?N.9:T5LXX[8'!J&YTFUU
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MX_XNKJG;Y8__ $ 4XR;9Q8O#TX4^:*/,B<U;T>P&J:O8V1?R_M,Z0[\9V[F
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MMSSD_G5+!QZLGV\NQV_]O642'8KR^X%1?\).HR%MF/IN<#^5<>#@<4X3.O\
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MY\</!_\ PEO@:]2-<W=J/M$) YR!R/Q&::ERNYRXBBJT.7J?$FG3^3=1L1@
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MVN_]!K4O_ V7_P"*I/\ A+-=/_,:U+_P-E_^*H]IY"]JC]!]XR.13@<U\@?
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M_1@K%./6MCP6P'B_1,G_ )?H#_Y$6LCFCNC]!D^Z*6D1@R@CH12UUG>%%%%
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M;L+J9L10SI(Q'7 8$\?A7&GJ<,=)*Y]QV^5B4'GBI,GTKRR+]HGPB$7=)?9
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M,@4 %&><4A/'6JS33"ZV>6/**Y\S=W],4 6J*13E12T %%%% !1110 4444
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MTF*]L]*6V\,-:W-NMW.+UY]NTI_ 9">=NWN*H0ZH+#0_#UK-/##8W.H2)>)
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M^29Z#_U[C^9KQ+]HWCQ_$0/^7*/^;5[;\%_^2::#_P!>XX_$UQTU^]D<5/\
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MMU\/--F32H(X/*M+"0ND&,JV0003UQ\Q-=(=9T[H;VW_ !E%)_;-AWO;8_\
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MZ$HPH!YI<5CS2[G9[&G_ "K[CSS_ (4#\._^A.TK_OU_]>@? +X=?]"?I/\
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M\\]8L?W.!BJ7CGX'_P#"<:T=3/C/Q1H;[ GV;2+X0P\=]I4\UZ?12L"T.-\
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MJDBJ%75XV>U//S;@.>GI7844[L5D?(%K^Q]XJU7Q+;W&LS>&K#2B^;B'17N
M^/\ 8$@(S^-?1/@CX0^&? ,:C2M+ACF"@-<N-\K?5C_2NVHIN4GHV8QH4H/F
MC%7&"(  #C'I2B,#U/U-.HJ3<**** "BBB@ HHHH **** $V\8R:$39W)^M+
M10 4444 %%%% !1110 4444 %%%% !1110 4$9HHH 0H"<TUX@ZD=*?10!6%
ME&KAA'&".C;1D59P***  #%%%% !1110 4FT9YYI:* $(XXXI:**5NH!1113
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>adag-20221231x20f026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O T$# 2(  A$! Q$!_\0
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M*.:/\OYB]G/^=_A_D<1_PF_B7_H0=3_\#K7_ .+H_P"$W\2_]"#J?_@=:_\
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MM?\ XNNWQ1BCFC_+^8_9S_G?X?Y'$?\ "<>)?^A!U+_P.M?_ (NC_A./$O\
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M).D6)+$V5N2S!B3$O)'0GCK[T'2+$];.W^]O_P!4OWO7IU]Z.:/\OYA[.?\
M._P_R/.(_C3/,8Q'X>WF61HHPNM6!WNOWE&).6'<#D4D/QLEN#$(_#_F&7=Y
M876[ ^9M^]M_>?-C!SCIWKTD:39 KBSMQM.X8B7@^HXZTU=&L%*D65L"N=N(
M5XSUQQQFCFC_ "_F'LY_SO\ #_(\Y3XU32+&R>']PEC:5"NMV!#HOWF'[SE1
MW(X'>C_A=<H4-_8 VF'[0#_;=ACRO^>G^M^[_M=/>O1UT>Q3&VRMP I48A7@
M'J.G3VH&CV &/L5MC;LQY*_=].G3VHYE_+^8>SG_ #O\/\CSAOC5,J.[>']J
MQQ+.Y;6K !8V^ZY_><*>S'@TLGQJFA\_S/#_ )8@"&4OK=@/+W?<W?O/EW=L
M]>U>CMI-DX(-I 0RA2#$O('0'CI[4C:/8-OW65L=^-V85^;'3/'.*.:/\OYA
M[.?\[_#_ "/.9/C1<1F4-X>*F*189 =:L04=ONJ?WG#'L#R:&^,]Q'*T;^'B
MKK-]F*G6K$$2_P#//'F?>_V>OM7HS:38N26L[=B6#',2G)'0].M+_9-B23]C
MM\EMY/E+][UZ=?>CF7\OYA[.?\[_  _R/.$^-%Q(T:IX=,C22F! NM6)+R#J
M@_><L.ZCFDB^-,\YA$?AXR&8N(PNM6!WE/O[?WG.WG..G>O2%TJR3;MM(%VM
MN7$2C!]1QU]Z1=(L5VXL[<;<[<1+QGKCCC-'-'^7\P]G/^=_A_D><P_&F><1
MF/P]Y@DC:5"FMV#!T7[S+B7D#')' [T@^-<Q0,/#_P IA^TAO[;L,&+O(/WG
MW/\ :Z>]>CC2+$;<6=N-H*KB)> >H''2D_L:PP!]BML!=@'DK]W^[TZ>U'-'
M^7\P]G/^=_A_D>;R?&V6%79] "JD0N'9M;L %B/W7)\SA3V8\'UIT_QJFMO.
M\WP_Y7DJCR^9K=@OEJWW"V9. W8GKVKT=M'L&5E-E;%64(085P5'0=.GM0VD
M6+[]UG;MO #9B4[@.@/'.*.:/\OYA[.?\[_#_(\WD^-<T/G>9X?,9AD6*4-K
M5@#&[?=5OWG#-V!Y/:E/QIG5RI\/%6686S*VM6((E/2,CS/OG^[U]J]';2+%
MPX:SMSO(+9B7YB.A/')I3I5D<YM(#EMYS$OWO7IU]Z.:/\H>SG_._P /\CS:
M+XUSS2K&GAXN[3&V55UJQ):4=8Q^\Y?G[O7VI8OC5-,81'X?WF9WCC"ZU8'>
MR_>5<2<D=P.1WQ7H_P#9%CN#"RMPP;>#Y*\-_>Z=?>A=(L4*[;*W7:25Q$HP
M3U(XXS1S+^7\P]E/^=_A_D><1_&N680F/0!*)T=XMFMV!\Q5SO*XEY"X.2.F
M#FA/C7+)&DBZ &1X6N%9=;L"&B7[T@_>\H,'+=!ZUZ.NCV";=ME;KM!"XA48
M!Z@<<9[THTFR"JHL[<*JE !$HPIZCIT]J.9?R_F'LY_SO\/\CS8_&Z0*Q_L!
M=JP"Z8_VY886$G E/[W[G3YNG/6B7XUS0K.S^'PBP1K-*6UJP'EQM]UVS)PK
M9&">#VS7HYT:P((^Q6V"GED>2O*_W>G3VI6TBQ<,&LK=@ZA6!B4Y Z \<@>E
M'-'^7\P]G/\ G?X?Y'G-Q\:9[0SB?P_Y)@*"82:U8KY1?[@;,GRENV<9[42_
M&>XA:57\.E3%,MO)NUJP&R5ONQM^\X8]E/)]*]&;2+%RQ:SMV+X+$Q*=V.F>
M.<=J4Z39'=FT@.Y@[?NEY8=&/'7WHYE_+^8>SG_._P /\CSC_A<]SYHC_P"$
M<;S3<?9 G]LV.[S_ /GECS/O_P"QU]J6#XS7-R\*P^'3*TTK01!-:L&,DBC+
M(N).6 Y*CD=Z]&_LJRSG[)!G?YF?*7.[^]TZ^_6@:39+LQ9VXV,77$2C:QZD
M<<'WHYE_+^8>SG_._P /\CS>#XU37(@,7A[S1.',)36[ ^9L^_MQ)\VWOC..
M^*$^-4TJ1NGA_P Q986N8V36K!@T2G#2#$G*#NPX'<BO1UT>P0(%LK90F[:!
M"ORYZXXXSW]:1='L%4*ME;JH4H (5 "GJ.G0]QWHYH_R_F'LY_SO\/\ (\Y/
MQKE$:R'0 $:W^UACK=A@P9QYN?,_U>>-_P!W/>B3XUS1),TGA\1K#"ES*S:W
M8 1Q/C9(Q\WA&R,,>#D8/->C_P!DV/\ SYV_W/+_ -4OW/[O3I[=*#I%BP8&
MRMR&4(1Y2\J.@/'('I1S1_E_,/9S_G?X?Y'F\WQKFMOM!G\/^1]GV>=YNM6"
M^5O^YOS)\N[MG&>V:63XT3PR3))X?,;0RK!*'UJP7RY&^ZC9D^5CV4\GL*](
M;2;)PX:SMV#XW Q*=V.F>.<4C:18N6+6=NQ9@[$Q*<L.A/')'K1S1_E_,/9S
M_G?X?Y'G)^-%PCLC^'BKK<?9&0ZU8;A-_P \L>9]_P#V/O>U$7QHGG:%8_#V
M]IIFMHU76[ EY1]Z,#S.7&1E1R,]*]&_LBQSG[';YW^9GRE^_P#WNG7WZT+I
M%BA4K96ZE7,BD0J,,>K#C@^]',OY?S#V<_YW^'^1YO#\:YKD0^3X?\WSV=8M
MFMV#>:4^^%Q)\Q7OCIWHA^-LMQY'E: )O/C>:(QZY8-YB)G>ZXE^95P<D<#!
MSBO24TFRC"!+.W0)DJ%B4;<]<<<9I%T>P79BRMAL!5<0J-H/4#CH:.:/\OYA
M[.?\[_#_ "/-E^-LKJK+H 96@-TK#6[##0CK(#YG*#NW3WI7^-LD:,SZ $58
M!<L3K=@ L1Z2']YPA[-T/K7I']CV&T+]BMMH3RP/)7A?[O3I[=*3^QK @C[#
M;8*["/)7[O8=.GM1S1_E_,/9S_G?X?Y'G4OQJG@$QD\/;! B22EM:L!Y:/C8
MS?O/E#9&">#GBFR_&N:W\_S?#_E>0R)*'UJP'EL_W V9."W8'KVKTDZ39'?F
MSMSO #9B7Y@.@/'-(VD6+[MUE;MN(+9B4Y(Z$\<XHYH_R_F'LY_SO\/\CSIO
MC-<H[HWATJT<PMG#:U8 K*>D9_><.?[O7VH7XSW#R"-?#I9S.;8*-:L<F8=8
M_P#6??\ ]GK[5Z,VDV39S:0'+;SF)>6]>G7WI/[(L<Y^QV^=_F?ZI?O?WNG7
MWHYH_P OYA[.?\[_  _R/.HOC-<3^3Y7ATRF9VCB$>M6+>8Z_>5<2?,1W Y'
M>FQ?&J:=(7C\/^8LX=HBFMV!$@3[Y4^9\P7OCIWQ7HZ:38Q[=EG;IM)9=L2C
M!/4CCBA=(L4"!;*V4("%Q"HV@]<<<9HYH_R_F'LY_P [_#_(\X3XU3.J%?#^
M\/"UPI76[ AHE^](,2<J.[=!2'XV2JK,V@;56$7#%M;L !$>!(?WGW/]KI[U
MZ2-)LAC%I ,+L&(EX7TZ=/:D_LBQP1]CM\%=A'E+]WTZ=/:CFC_+^8>SG_._
MP_R/.9?C3-")2_A_8(D661FUJP 1&^ZS'S. >Q/![4DWQIGMFG6;P_Y30%!*
M)-;L%\LO]S=F3C=VSU[9KT=M'L7#!K*W(8!2#$O('0'CI2-H]@Y8M96[%L;L
MQ*<XZ9XYQ1S1_E_,/9S_ )W^'^1YT_QIGC\P/X>V^7*('#:U8#;(>B',G#'L
MIY/I2?\ "Z9]^S_A'CO\[[/M_MJPR9?^>>/,^_\ [/7VKT<Z/8DL396Y+,'.
M85Y8=#TZ^]+_ &59 Y%I #NWY$2_>]>G7WHYE_+^8>SG_._P_P CS>'XU37!
MA$7A[S6FD:&,)K=@Q=U^\JXEY8=P.1WHB^-<LYA$>@"0S;O*V:W8'S-OWMO[
MSG'?'3O7HZZ18J5(L[=2K%E(B48)ZD<=:!H]@NW%E;C;G;B)1C/7''>CFC_+
M^8>SG_._P_R/-D^-LLJ1LF@!EDC:9"NMV!#1K]YQB3E1W(X%+_PNR4*&_L#*
MF'[0#_;=ACRO^>G^L^[_ +73WKT==%T]0H6QMEVJ5&(5& >HZ=/:E_LBQ _X
M\[<?+L_U2_=].G3VHYH_R_F'LY_\_'^'^1YL_P ;I(UD+Z"$$<8F<G6[ ;8S
M]US^]X4]B>#3I/C3/")?,\/%/)"&7?K5@/+#?=W?O>,Y&,]<\5Z.='L"&!LK
M<A@%.8EY Z \=*Y[X@6]IIWA#5[E,6#);LWVJWLUFDCQT8(?O$=A1S1_E_,/
M9S_G?X?Y&9<?$#7[:TDN)? VHI"B&1G%[;'"@9S@/S76>'-7&NZ1:7Z*R1W,
M2RJKXW $9P<5G7^)O MRY=IBVGD^8Z[6;]WU([$]<4GPYX\%:&.WV*+C\*;L
MXW2L*/-&IRN5]/+]#I:***R.DX7Q1_R53P-_N:C_ .BHZ[H=!7"^*/\ DJG@
M;_<U'_T5'7=#H*UG\,/3]6<=#^)5_P 7_ML0HHHK([ HHHH **** "BBB@ H
MHHH ***JZK//:Z=<S6RQM/'&S()B0F0,C..<?2@"U17SO\)/VH-1^(=Y?^&-
M8T6R\*^/]/G@DFTBYG>6*XL92-EU;N "ZD'GC@]:]1@^-'@NXN[FUC\16DEQ
M MP[(@=MP@_U^P[<2&/^()DCO0!V]%>36'[5GPJU32K?4K3QA;7%A/);PQW$
M=M<%&><L(E!\OJQ5@![<UJ^'/VA/AYXLU"ULM*\4V=U=7(N/*C*R1Y,'^O4E
MU #)U920P'.,4 >B45XG\3_VG_#_ (7^&OBOQ'X6O;#Q)J&A6$6HM8-(\0DA
MD;"2!MN2C8.'7(.*ZWQ-XP\2VO@^SU[1]/TV6+^SVO[M;Z:10F(=X1-@R22<
M9/0<^U '?T5\X>&_VF?$&H?!?PO\0]3TSP[IMGXA:T2VMYK^X01M+-Y;(S^4
MV6QRO !/!(ZUZM=_&WP3IZWS7'B&VCCLYC;S2[)"BRAE4QA@N&?<RC:I)R1Q
M0!W-%><:W^T/\/O#DEI'J?B.*RDNK:YNX4EMIPSQ0?ZYL>7D;,<@\^U;!^+7
MA%=1TVP.O6HN]0CAEMHOFRZS?ZDDXPN_^$,03VH Z^B@<BB@ HHHH **** "
MBBB@#G=%C4>+=><0VR,R0 RQ2EI7PK??7/RX[<#//6NBK T?9_PEFN[19[MD
M&XPY\_[K?ZSV_N^V:WZ "BBB@ HKPCXK_&SQC\./'?@S0DT;0[B#Q3JSZ;:S
M2W,X>%0FX2.%7!)_NC&/6NMN/CMX9\*_;=/\7ZQ9:1K^EVL5WJ=K"DTL=O'(
M^R-PVSE6.![9YH ]*HKS75?VCOASH>KW.EW_ (HM[6]MIH8)HY()@(WE&8@6
MV;1N[<\].M7+7X[>!+W2H]1@\1V\MM)<2VBA8Y#(98QF1/+V[\J!D_+P.: .
M^HKSK5_VAOAYH5[IUK>^*+2.;4;9;RS5$DD%Q"S! Z%5((W''7([UG?'OXG^
M)?A3X#U[Q?I6EZ9J6E:1IYO'CO)Y8Y)WW ;%VJ0HP<Y.?I0!ZM17BUK\:M<L
MO^$"_MBVT"V/BR9/(5;R=&$9A\Q@F8B'D'H2H(YSVKJA\>/ C01RKXA@:.:3
MRH2L,I\]N>(@$_>?=;[N>E '?T5YW??M!> --DO8[KQ)#"]D+8W :WF_=BX.
M(2?DZ,> ?SQ6[:_$SPQ>>)CX>AUJUDU@,4-H"=P8*&*9QC<%(.W.<'.* .GH
MHHH **** "BBB@ HHHH **** "BHKNZCLK:6>5@D4:EV8]  ,FO&O"7[3>E^
M+/@_XM\<Q:7>6S^&FO8[S29EQ<+);[CM8 ';N 4Y(X#9/2@#VJBO#?AW^TK'
MXGU[1-)UK3ETNXUC2#KUL]N)WCBM!L&9F>-=K;F8$C*@*#N^8"NON?V@?A]:
M:;'J$WBBTCLI+F&T6<I)M\R5=T7\/"NO*M]UNQH ]#HKSCQO\>?#'@WX/7GQ
M(%RVI>'XK=9H#;J5>Z9F"1H@< @LQ Y''6J.I>/_ !WHO@<^)+SPYI046$]]
M/9QWDA>SV0-*JNQ7#Y*A"5 P3G!% 'JM%>7^ OCUH/B'P1X+U77+VTT75_$6
MF6FH#3ED:3RO/PJ MMX4N=@9L9/ YK2?X\> U:]5?$EM,;.RFU&7R$DD!MXG
M*32(54B148%6V;MI'.* .^HKBX?C%X/GTFRU--=@^P7L=O):SF.0"X\_/D*F
M5RSO@X098^E5;GX\> [30['6)/$UH-/O8KF:"0+(6=+<$W#; NX"/:=V0-N.
M: .^HKB[3XR^#;ZYTN"'7[<S:FD,EHC*ZF19=WDDY4;?,V-LW8W8.,UV@.1F
M@ HHHH **** "BBB@ HHHH **** "BB@].* "BOF+XJ_M9:U\.?'/Q!T1-'T
M2YA\*Z19ZK EQ?2Q7&IM.S*MM$H4CS"5PN,Y) P*[*T_:5TW3=:UY/%@L_"V
MFZ/X>L==O8[F69[ZS$^0ZSQ+%A54X7<K,20V0,4 >UT5P%E\>? >I:+-JMMX
MDMI;.*^BTQCY<@?[5(JM'"(RN\NP=" %.0P(KSOP9^T_<^)8],DNK#2K"*\\
M97WA8-)=3*9$MPY62(>4<R-M_P!6Q7 SR<4 ?0=%>:^%/VC_ (;^-94CT?Q;
M973/:SWREDDA#00/LF<&15!"-PWIWK;\(_%GPIX[U*XL-!UA-1NX+6&^DC2&
M1<02@F*0%E *N 2""<XH Z^BO+O"W[1/A/Q)#X@N'N)].MM(UIM!\R\MY%-Q
M<C:-L:[<L2S;0HRQQG !%=6OBX>)_"4NK>#IK'6Y7+1P&69DA\Q6VNKD#<I4
M@@C&01B@#IJ*\)^'7QN\6^,O&OCG2+G2-%M[+P?JL.GWL\$\[231O")&E12O
M!4'[O.<=:ZJR_:1^'&HQ0R6WBBWF2;2I=;C98)L-91,5DF'R=%8$$=?:@#TR
MBO*+7]J?X67EM]HB\8VC0^3!<%S!.H$4QVQ2G,8PC'C?]W/!(KJV^*WA-?$+
M:'_;EM_:BSFU-N-Q_?B/S#%NQM\S9\VS.[':@#K**X?P3\;/!?Q'U"6Q\-:]
M!JUU$DDDD4,<@*!)/+?.Y0 0_&.OMBN9\$_&;5OBIK7BQ?"FE61T/P]>OI9U
M#4)W4WUT@S(L:HIVJIPNYB<GMQ0!Z]17!_\ "U],LEM-.U:[M-+\4S1(7THR
M-*(I7#%(V<#&6VMMS@M@X%>2_#S]K>Z\4>(/!MKK.DZ;HVFZWI>JZC<WHNW(
MM/L<YC_B4 JP&23C'O0!]+45D>&?%FE>,+$WFD77VNV! W^4\><J&! =02""
M"".#FM>@ HHHH *YSX@S&#PCJCB:]@80,1)IR[KE>.L8[MZ5T=<W\0T=_"&J
MB-+YY#;OM73&Q<DX_P"69_O>E #KYM_@:Z.Z1LZ>3NF&)#^[ZL/7U]Z9\.?^
M1+T/_KRB_E3[T%? UT&\T-_9YR)S^\_U?\7^UZ^],^'7_(F:'_UY1?RK3['S
M.=_QOD=+11169T'"^*#_ ,74\#?[FH_^BHZ[I>@KA/%'_)5/ W^YJ/\ Z*CK
MNQT%:S^&'I^K..A_$J_XO_;8A11161V!1110 4444 %%%% !1110 56U.WEN
M].N8(&1)I(V1&D!*@D8!(!!Q5FB@#R#7/V==+\5:C\/->U*9(/%7A!HA'J5@
MAC%Q$J;'A8$DE&'."3@\UQ^C_L@)HMWIQB\1>9::-_:[Z7%);G<)+\,&\YMW
MSA-S8  )XSTKZ/HH ^>=*_9>U32?@M\,O L?B2S:?P=J%I?-?&R<+=""4R;0
M@DRA;.,Y.*Q?!7['^K^$_%FA:TWBZSG;3-8UO5MB:>XW'4%("?-(1^[SG)SN
M]!7U!10!\C3?L.ZW>Z3XTCOO'=K>ZEXFT"'19KHZ6R*C1S&02[1*>H.-HV@8
M&,#BOI'4/"-S=?#N3PY%=0I<MIOV#[0Z,4!\K9NV@YQWQG\:ZBB@#YQD_94U
M.3]G?P5\,_\ A);,3>'+RTN/[2^Q/MG6";S-OE^9E2>F=QQ4NJ_LC6>J^(_&
M&I276G&R\31;-0T8VLOV*[?S PFDC\WY9E4;1)'M.?F/(KZ)HH ^5_%?[%6H
M:]X=\*6,'CJ5KS0],U'21=:G;/=;X+I<!0?,#?NQM +$D@<UU>@?LO-H?Q$L
M/$KZKI^H6_\ 9MA9WEC>V#R_OK08BG@;S (S[,K8ZCFO?:* "BBB@ HHHH *
M*** "BBB@#G=%=3XMUY!+:LR)!F.*(K*F5;_ %C8^;/;DXYKHJP-(G63Q5KD
M2W"R>6L&81#M,>5;J_\ 'G],5OT %%%% 'DGQ@^"NH_$WQQ\/=>MM7M-/B\*
M:B=0,$ULTK7)*[=H8,-GUP:Y/XS?LM:G\2O%_B/6],\46ND#7M)MM,NH+G3V
MGVB&82*R,LBXSC!R#7T/10!\U^)?V4-9U_5M?NU\3V$*:IJ6EW_EFQE8Q?8P
M!MSY@SO]>,>]-T']D2_T34YM87Q1;OJXUG4-3@;[$_DA+M-CQLIDR2O4,"/I
M7TM10!X;X!_9K?P!X\\(ZS:ZY'<Z=H&@2Z+]FEMCYT[22&1I=X;"\DC;M/'>
MNT^.?PVNOBW\*/$7@ZSU"'2WU>V^S&[GA:41@D'.T,N3QZUWU% 'BVO_  #U
M/7&^%#_VY9POX(E\V3-H[B[_ '/E8 W_ ">O.[TKB;C]BBRN-(\1Z8=1LUTS
M6+L7R::D,Z6]A<@'_2+7$NZ&0L=QVG;VQ7T_10!\N^)?V.=9U>YU"2W\<QR_
MVC;:7#=RZGI[33R/9N&#;UD7[^.>"1ZUVO@?]F]?!?Q3USQ5_:-CJ5GJ5\=4
M2"ZL6:YL[ED"/Y4OF;0A _N;NV:]MHH **** "BBB@ HHHH **** "BBB@#F
MO'7AN^\4Z5'I]K<6L-K+.AO4N8W;S8 <LBE6&TD@<\\ \<UX]>?LNZC:>(OB
MC-H&OV.EZ!X[THV=SIDMG+,T-T8C&;KS#+R2#RN!G YKZ&HH \"M_P!F"X^V
M>'9;GQ#$T5EX/E\(7L4-JRF:)\?O8FW_ "-QT.X5D:5^R7J.G^#?#FCOKVCR
MWVD:IIUTVIII+I+>6]F6\F*7]Z<MAL9&%&.%KZ4HH XGXO\ PITSXS_#G5_!
M^LR2PVFHQ@?:+? DAD5@R2+GC*L <'KTK+F\!>,-4\ W?AK5/$FG3F73)M.:
M]AT]T:<O$8Q)(ID(7&=Q"XR>X%>E44 ?.6B?LFW.DWG@J:;7-.U.VT?P_9^'
M]1L;[36DBNTMI/,AFB_>#RY Q)^;>!P0,BKG@?\ 9BU7P[\58?&.M^*[;Q"%
MM-0L'M#IOD!X+F<2A?ED*KM'RX"@$<]22?H&B@#PC3/V9KKPI\(H?!/AKQ4]
M@\6K1WJZA>VGVIOLJ3[UM!E@RJ(\1AE8, #@C)KRKQG\ /$_@;1/"?AW2=&T
M_P 9V]G#K:3WTL=W9!8;Z3+0!X!,XRKN"" . 0P(K[,HP"<XH ^;/ /[.-Q/
MXHT3QE<6&G^&[:?2]-@O/"%W UZNGS60(MVMIA(H4J#C+HQ'48.:^DP, "@
M"B@ HHHH **** "BBB@ HHHH **** "@\CBBB@#YJ^)_[)VK?$7QE\1=6_X2
M/3+.T\8Z-;:*Z2::\TUDD3,?.C;S #(=QQP " >:S_%_[&%]X@B\<6]MXO1(
M/$'@RQ\(PR7MH\TT(MR3]HD8./,9LG@8P<<U]2T4 ?,L'[']]#%<3?\ "46K
M:A#XHT[Q1I[FR?RDDM;6.V,4J^9EU=8R<@@@M[5>L/V6=8LTT??XHLIY;'QO
M=^,I'-@Z^:TZR*8 /,^4#S/O<].E?1E% 'R%HO['^M_#C1-)NUUJQ\42:!X>
MUW3%TP:;(/[0:^E:91@S<!20N.X/45U?[+'A+Q)X>UF]D\1^"+31KDZ)8V(U
MN&]NI7=+<;$M2EQ&A4*"S#9D<G))P:^DL9H  H ^?[?]ERXM/M[Q^(XGD7QI
M_P )GIY:T8>7*?O02X?YUQN *[2,^U>C?"'X7Q_"GPI<Z5'>M?W%YJ%UJES<
M%-BF:>4R,%7)PHR !DGBNZHH \D^&/P5U#P)XP^)FLWFK6E]%XQOX[T0P6SQ
MM:[8?*VEBYW\#.<#FO*M!_8IU?1!%&?&-C/;VWA2_P#"UNHTQU8)<2M(LS'S
M3DKNP5 &<<8KZPHH ^1E_8>U==!O--'C&P/VCPSI7AT2'39/E^QR^9YN/-_C
MZ;>WJ:[:#]DRV@\6C4EUMO[.'BG_ (3 6OE-YGVTP^7LW[O]5N^;&,]LXKZ#
MHH \W^!/PHN?A#X&DT"\U&WU61M1N[[[1! T(/G3-)@J6;E=VW.><"LCP+\$
MM4^%.M>*7\*:W9IH7B"_?5'TW4;1G-E<N/WC1.CKN5CSM8<'O7K]% 'A]S^S
MC<3_ !3O_%DNL6&I6NI0VS7=EJ6G%V2[MPPBGA99 J'YCP5;'8BN1\*_LA:K
MX?OO#,\_B32KY-&TK5M-,,NENT=Q]ME,FYE:4C"YQM[CN*^GJ* /-_@/\'E^
M"7A&Y\/V^HO=Z>UY)<VMKND:*QC8#]Q%YC,P0$$@$\;L5Z1110 4444 %<U\
M1;5[SP=JT*6EQ?-);NHMK6;R99..BO\ PGWKI:YGXDVPO/!.L0-:+?B2V=?L
MSS^0)./N^9D;?K0!)>QF+P)<H8VA*Z=CRY&W,O[OH3W(]:9\.O\ D3-#_P"O
M*+^5+=IY7@.Y3RQ#MT[;Y8;=MQ'TSWQZTGPZ_P"1+T/_ *\HO_0:O['S.9_Q
MOD=+1114'2<+XH_Y*IX&_P!S4?\ T5'7=#H*X3Q1_P E4\#?[FH_^BHZ[I?N
MCZ5K/X8>GZLXZ'\2K_B_]MB+11161V!1110 4444 %%%% !1110 4444 %%%
M% !1110 $A1D]*R;W7TAXA3S#G[Q.!2:]=F-1"I(+#DUS[8'!KAK5W%\L3NH
M4.=<TC0?Q!=')#(H] M1CQ)=KCYD;ZK67(^#Q5:291]?2O/=>HGN>I'#4W]D
MZ.'Q:P<":$8]8S_C6M9ZY:7O"2;7_NOP:X$R;B<"CS2N/YU4<9.+L]29X&G)
M7CH>F@Y%%<+IGB2XL6".?-B_NMU'T-=;IVIP:BF^*3/JI/(^M>I2KPJ[;GDU
ML/.C\6Q=HH!&/:BN@Y0HHHH **** ,#2+AI/%.MQ&XED6-8,0O%M2+(;[K?Q
M9[^F*WZP=(9F\4:UF2[90L&$E7$*\-_JSWS_ !?A6]0 4444 !.*,TCYVG'!
MKR?Q'\2=?TGQK>:1:PVUZ(6M]EJD+^=*LGWCN#8&WKDC%<U>O"@E*?4Z*-"=
M>3C#H>L%L4$X'2O#M,^,NMS^(38,+*[?^U9+(V5O&RS+"HR9LER.._&*NO\
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MW&,>G%;NBZ5:Z+8V]C:1"*"!-B*.< 5>9U!))(Q60?$=I%K\.ELS?:98S(H
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M"IJ5H+VV>,G! R"/6N(N4:%F5U*D'!!KT$KG/K6'X@T8W"FXA&90/F7^\/\
M&N+$TN=<RW._"5O9RY9;,XV1L9KG=?OS A0'!ZFNCD7!)/4=17*>*K9V8,HR
MI%<N70@\2E/^F>SB)/V6AQE[K_ER$;N_4UH:)K;,P*G/MZURVJZ=+-+CD<]J
MU-"LGC9<U]U4IPE3M):'CI\KNMSTZQD$\88=Q6A&/>LW2(BEH@/&:U$4[AV%
M?F=:G&G6E&&R9]'&;E33EN6;=<+D]#6UH%W]FNE4G"2<'^E9,8Z5;A&T*1R<
MUT4FXR31Q5XJ<6F=PK!AQ2U';OYD*-W(!J2OH%JCYG8****8'/Z/ (_%>N/]
MGCC9T@S,LVYY,*WWD_AQV]<UT%<_HZK_ ,)7KCB.U5F2 %XY"9FPK?ZQ?X0.
MWKS704 %%%% !1110 4444 %%%% !1110!PWQ0\27_AVPMI;&012-+@MMR,8
MZ&N7^'"WWB?Q=<:[=@;8EVY PN3Q@5ZAK&@V6O6Y@O($GB)SM;U]<T_3=(M]
M)MT@M(D@B3A408 KXC%9'BL9G,,96K_N(6:AK\2Z]O,]FGC:5'!NC"'ONZ<O
M)EZBBBOMSQ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R8*X_6
MOF[Q1J5QK?B.Y:\EV#SC&/,R5B4''3TQ7TD1FN%\2_"BP\0WK7:3/8W#G,AC
M4,KGUP>]?G?&>2X[.L)3IX)WY97<6[*2]?(]_)\91P=:4JW56O:]C7\$>'[;
MP]I44-I,;B-U\QI2<AR<<CT'M72$X!/I6/X8\.1^&=.2SBGEG1,_-,<GGT]!
M[5L5]IE]'ZOA*5+V:A9)<J=TO)/KZGCUY^TJRES<UWOW.0U+QOY][/9:'IEW
MKMW;MLF> K%;Q.#RC3.0N[U"[B.X%?!_QJ\,:CX:^(NJIJ%F+%[R1KR*$3"8
M;')/#@ '!SFOT>"*O10/H*\N^.WP7M/BUH"HI2VUFU.ZSNR.!ZHW^R?TKZ'
MXA8>K>6S/D>(,LEF>$Y:?QQ=UY]U\_S/S^L+VYTR]AN[.X>WN86#QRQ-@JPZ
M&OT/^!OQ'7XF> K#5'PMZI:WND':1<9/T/!_&O@OQ=\/O$7@?56L=7TFXM9
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MVYTG;M=7.2M3]E4E3O>SL%%%%=IB%%%% !1110 4444 %%%% !1110 4444
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M>F M%5I]2M+4XGNH8#Z22!?YFFP:O8W)Q#>V\Q](Y58_H:GFC>URN65KV+9
M/4 _6N>UCP+HVMWJ75U9(\P_B!*[OJ!UKH!(I[U7EU.S@8K)=0QL.S2 &N;$
MX?#XJ'L\1!2CO9I-7^9=.=2G*]-M/R'PPQVD"1HJJBC: HQ@5*K9'&/PK)U7
MQ-INF:?->S7MNMO$N6<R CV''<GBOGOQ#XMU?4+FYOO-G9(@TIB$XA\J,<D@
M,5&0.W6OG<YSV.3.A2ITG4G5?+%)I?B]/1'?A<$\4ISG+EC!7;9]-!@:6OFC
MPC^U[X;2ZM]+OX-1$.0G]ISJN/JRJ20/?)KZ.L;^#4;>&XMI%F@E0.DB'(8'
MH17UWLZL81E6@XMJ]GT\CY^AC<+BW)8:HI\NFA9HHHI'8%%%% !1110 4444
M %%%% !1110 44$A1D]*0.",YXH 6J]W?16<?F2R)'&.K,<50\0Z[%HMH78;
MY3PD?]X_X5YG?:G<:I/YMS*TA[+T51[#M7G8G&1P_NI79Z.%P4L3[STB=GKG
MQ%M["W(L+9]3N6.U$#B&,>[.W0?0'Z5H^&+K6;R(R:M#86Y.&C2QGDF&".<L
MRKD_05YK! ]S.D42[Y'.% YKUG1ECM-/M[42HSQ($.&!-1@L34Q-^9:(O'86
MGAN51>K[FA12!@3@4M>H>6%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1103@9- !6;XDG^S:%?2_P!V%C^E6;W4K33;9[B[N8K6W09:6=PB*/<GBN5\
M2^*=-UWP;JLVFW:7D49\EGC!QNR.A(&>O49%5%7DD-;GE+R *,<\56DDPW>E
M=ACZ57FF ..]>]%'8]Q9)\9YZ=JK/.6;)P*8\@P<G!J"1PN35C2N2M.6;.?T
MH\\KW'Y55\X#L:8]PO0=:NP^4N>>?6@3D'K^E4UF!)S^E/\ .!Z46#E-&.;(
MZ]JE24@GFLQ)3Z'%64E'_P"NIL.QMZ5J+Z??P72'#1.&KZ#LKA;NUBF0Y210
MP/UKYJCD!^AKVWX9ZI_:'AR.)FW26S&,^N.HKS,7#121SU%H==1117G'.%<S
M\2+47G@O5H3:QWP>W=3;2S>2LG'W2_\ "/>NFKFOB-$DW@S5HWAL[D-;N/)O
MY/+@?CH[9&%]\T .O(_*\"7*>6(MNG8\M6W!?W?3/?'3--^'//@O1/\ KQB_
ME2W8">!+D!8T T\C9$<HO[OHI[CT--^'/_(EZ'_UXQ?RJ_L?,YG_ !OD=-11
M14'2<+XH_P"2J>!O]S4/_14==TOW17">*/\ DJG@?_KGJ/\ Z*CKNE^Z/I6T
M_AAZ?JSCH?Q*O^+_ -MB+1116)V!113''#'MB@#&\526MWI-[ITU[#:/<PO$
MIDD"GD8SS7R#JNE7.AWTMC=)LEB.TX((8>H/<'K73_&+2[W3O'>HO?!VCN'\
MR"5N0R8' ^G2N-9F< ,Q< ?+D]J^OR_#^QAS*5U+4\#%5?:2Y6M4;WA/QQJW
M@J\6?3;AA%D>9:N<QR#T([?6OJ?P3XNMO&>AP:A;94N,21'DQN.JFOFKP9\.
M)O'-M*VG:G;)=0D>;;7"LK 'HP(SD?E2^)[+Q!\+[]=&CU2>&&11/OM&:)7.
M,'WXQBL<70HXJ?)!VFC2C5J48\TE>)]9ALG&#2U\H^'OC-XGT&53+?MJ5N#S
M#=G=D>S=17OW@'XBZ=XZT\R6Q,=Y&!YUJYRR$^_<>]>+B,%6PRO+5=T>C2Q-
M.J[+<ZYY!&,GH.37(:K\4M TR5H?/DNY4ZK;Q[AGTW=/UK4\9:=/J_AV\M+6
M3R;F5<*V<9]L^_2OGW4=+N]'E\J\MY;9QD8D7 /T/>ODLRQU?"V5*-[]3ZG*
M\#A\9=UIV:Z:7/7K7XPZ+/)B5+JU7^\\88?H376VOB73;W3Q?0W<3VO_ #U#
M<#V/H?:OFV"%[F58XE:65N B#+'Z"N^\.> ]9@TR6YEC:(NP86C'#'_:(]?:
MN#"9GBZTFG3NO)6/0QN58.A%.-3E?F[G?7/Q TZ-\0I/./[RJ /U-4[SXD1Q
M6;-:6<MQ=G CAF=8U))QEGZ #J>#]*XN:.2W?9)&\3C^%UVFI+6QN-1D"6]N
M\S?[*]/QKH6.Q/-\/X&']GX91UE\[EKQYXO\2^"/!5YXDU#7-/W0)E+6ST_=
M#(Q^ZN]Y-Q^O'TKY_P#"?[87BNU\1Q2Z^MM>:3*^)8((@C1*>ZGN1Z&O3/VH
MM)O+#X)00;LF.^C>8*> ISQ^=?&PZ5^B9;AJ=?#\]6.K_ _"N*,VQ>"S"-+#
M3:C%7\GK^1^I.CZU:ZWIMM?6<GG6UQ&LD<@Z%2*T*\(_9!\0S:S\+OLLSE_L
M%TT*$G/R'D?UKW>O&K4_95'#L??X+$K&8:G77VDF%%%%8G<%%%% !1110 44
M44 %%%% 'F'C_P 3:AX2M?$=_I_VIIA]G13<+N@3(;)C_P#9O?%>&ZI\2_$6
MMV+V>HWPOK:3DQRPJ0#[8&17TJNA0:MK?B&"[M+DVUS'"A:9P89!M;/EC'RD
M=_?%>"^/?@_JOA2ZEFL89-1TO.X21KEXQZ,!_.O=RV=#6%1+FZ,\S%PJ?%'8
MX."&2=UCC0O(QP$'))]!6C;Z'K-M=H\>FWJ31'>#Y+#;COG%9+,%.-S(WJ.U
M>\^$?C-IFF^$K.V\0337%V 8]J1%RT?0$]J]O%5:E.*=./-<\^C",G[SL8J_
MM&ZI"T2+I%M+'&H5FDE8.Q Y/'%=]X-^.6B^)9DMKL/I5XQ 5)CF-C[/_C7S
MWXI&DOJ\\VC7+SV4K%PDJ;'B)_A/K]:QV'<']:Y7EU"K33C'E9LL55IR=W='
MW*C!U!'(/>N(^*6NW^AZ,C6),1FDV/,HY4>WH37(_ 7QQ=ZS;7.CWTAG^RH&
MAE8\A.FT^N*[WQWXFTSPQH$USJ<8N8'^18" ?,/85\EC,)5?-AHNTGLT>_A<
M33C*->:O%;IG@4\CW$C23,TLC'+.YR3^)IJ'RG5D&UAT*\$?C6/JWC);V\:2
MSTR&P@))$2R,Y_,_TJ&P\7RV=RLDMC:WL8.3%,6 /Y$5\O\ ZI9G*5WR^MS[
M'_6?+E'2_I8]:T'Q5K-UHC0S2RO;A]JW!ZL/[N[OB@_,22"6/<]:U?#7Q0T7
MQ!X<9%TY(IXL(UAGY!Z$''3]:RKBY661FC@2!2>%1F./SKOED>,:47*]NYX\
M<[P<9-\O+?70:Z(Q4E<E2&!QR".AKG_CA9Q0_!O5M7-FD>HNR1"Y (9E+<DU
MU&GWZ64PD>UBNL<XF)(K0^*6G#XC_"+6[6UA/GB$NL2C.&3YL"NG"Y.Z%:%3
M%14DFFNMGWUV9Y&;YI'&8.K2PMU)Q>NSVV/S[QNX''^%?:?[''C:?7_!MWH]
MW*TLNEN%C9^3Y;?='X5\6R!HW9&4JRG:0>QKZC_8;@D^W>*)AS!LA0_[W)K]
M S**EAVWT/PGA>K.GF<(1VDFG]U_T/K:BBBOCC]R"BBB@ HHHH **** "BBB
M@ HHK/UW4%TG2+J\896",OM]<=!4R:BKL:3DTD9_BCQAI_ABVW7<N96SY<*<
MN_\ A]37F.J?%_6;J9C9)%91?PC:';\2>/TKC]5U6XUG4)KRY=I)I3DY/0=@
M/850GN8[>)I)&"JHR2:^%Q&:8C%5/9X>Z3V2W9^@87*,-A:?/B+-];[(]!TC
M6=8\<S,DR"ZFM4SN0!>"?3IVJU?Z5<Z;&'NHA#N.%5F&X_A7'^&OB_IO@^W>
M.TTN:^EE(:6Y:01AN. HP< ?6MZ;Q7'XT/\ :<,<L<3ML$3\E".HST/X5]A@
M\AJRC&ICKW>^Q\=CL\ITY2A@TN5;:?B/\XY.,HI'4'DU<T%)GU>U6VW>:9 0
M%/;/.?PS1INA7VJN%M[9F7N[#"C\37HWAKPI!H,>]CYUT?O2'M["OI).AA*?
MLJ22\D?,+VV+J>UJ-OS?Z&ZH&<^M.H Q17CGKA1110 4444 %%%% !1110 4
M444 %%%% !117+>-/&MKX4MAN FO)1^[@!Z^Y/85E5JPHP=2H[)&M*E.M-4Z
M:NV=06Q7)>*_%[6):TL]IGQ\\AYV>WUKRK4?B/KU],9!?&V3M' -JC\>I_&N
MLL/#]U=>'TUC4[ORY)5,CAX_G//R_B1BO$6/>-;I86+OW/=>7+ VJXN2MVW,
MV[EFU24"=GN9&((60[N<\8!XZUUGC";RO ;Q23K-.BQK(=^XYR*XF23#';GV
M(ZT^[TR>3P]>7I#+ FT9/\1+"OH,#EL\,O:UY>\^G]=3Q,3F=/%58TJ$?=77
M^NAS$KG;UJE)(!DYP:FE;8WK4-O$;J=8P.">?85]&M%<Z%N3:?IDFIN3GRX0
M>7(Z_2MF+1-.A&&B,A/=V//Y42W"P1K&@VJHP*HOJ 4D%C63YI!S%BZ\.:?<
M*?*!@?L5;(_(URVIZ;-I<@$GS(>DB\@UOKJ"\?/D_6IW,5_;/!,-R,,9/;WJ
MDY0!2.,$I_O<4]9/F'-5;^WDT^^:W;)P<AO[P[&D1SGU-=:2:NC2QHB0=C5F
M)LC.<BLR-B.>,U;@<XK-H#320,!D\UZ5\'-0,>H7EH[<21AUSZC_ /77EJ-G
M:1QQ74^ ]0^P>*+"0MA6?82??BN2O'FIM&,U=,^@Z* ,45X9Q!7-?$<QKX+U
M<R/8H@MWRVI*6MQQ_P M .=OK72US7Q&G6U\&ZM*]S;V:);N3/=P^="@QU=/
MXA[4 +>8_P"$#N=IB(_L[@P#"?ZO^'V]/:D^'0QX,T/_ *\HO_0:6\82>!;E
ME=)0VGY#QKM5OW?4#L/:D^'(_P"*+T3_ *\HOY5?V/F<S_C?+]3I:***@Z3A
M?%'_ "53P-_N:C_Z*CKNAT%<)XHY^*G@?_<U'_T5'7=+PH^E:S^&'I^K..A_
M$J_XO_;8BT445D=@4444 8'BWP7IGC+3FM-1A\P=8Y0/GB/JI[5X7KW[/FO:
M>[G2I8=2@'W0S"*3'N#Q^M?2=(5R#UKKH8NMA](/3L<]2A"K\2/E[3M"\4?"
M6&7Q!/:1VQ8?9ECD<."6_B8*>@Q^>*P_$GQ$U7Q?:+!JPM;DQMNCE6$))&>^
M"#T]C7U5XA\/VWB31KK3KM-\$Z[2.X/8CW!KY?\ &_PNUGP7=RLT+WFGY^2Z
MB7( _P!H#H?TKW,'B*6(GS5DE/HSSL12G2C:FWRG)0VMQ>2".WA>>3!.R-2S
M$>P%=K\*+37=,\:6MU9Z;?/#&2;A5C*@QXY!S@?K7$VMW-8W4-U;3/'<1,&1
MT."#V-?34GBZZU#P)IDB?\A+480CJG52?E8CWS@#W85U8^M*G%044U+0PP\(
MMN3=FM275OB;,^AZG<:;HNH2S6L9.Z2)=BGGDX8YZ9XKYMUGQ+JOB.=I[^_G
MN'8YP[G:/H.@KZZ\,:$FCZ+#:E0SXS(V<Y8CG\!T'L!7.:W\$O"VN3O.]F]K
M*YRS6LI0'\.E>+@\50P\I*4/GN>A6HU:L4U(^6UGEB<.LKHR]&!((_&O6?AO
MX_\ $EQI=W:3RRW-M$ %NW&YHR?X=W?/O7>VG[/WA>VE#R)=7('\,DYP?K@"
MN[T_P[IVE6 LK2SA@M ,>2B_*?KZUTXG'8>I'EC"YE3PU5-MRL>/O*\S%Y&>
M1CU+L32Q7$D#@QNZ-V9"17IUSX$TN=]PB:/V1R!4EGX)TJT<-Y!D8=#(Q-<_
MUNE;X2/JE3:YR/BCPU-\2_A?J&E7C$7-Q$PBD8?Q#E3^=?GYJ^E7?A[4[C3M
M0A-O>0.8WB;@@CZU^IGDJ%VJ !Z#M7+>(OA7X4\67T5[J^@V.H7<9RLLT66_
M'U'UJ<+COJ[DG'1GC9WD#S2,)TYVG'2[V:/,_P!D'PW=Z)\,FNKJ-HC?W33(
MC#!V 8!_'FO>*@@L8K6!(8$6&) %5$&%4#L!VJ>O.JU'6FZCZGTF#PT<'AX8
M>+NHI(****R.T**** "BBB@ HHHH **** ,#2+58O%.N2BV:/S$@'GF<,)<*
MW 3^''ZYK>* C!KG]&@$?BS7I!;PQEU@S*L^^23"M]Y,_+CMP,YKH: ,6\\'
M:)?2^=<Z597$N<[Y+=2?SQ7B7QU^']Q9:@-;L8,V3($F6)>(B.AP.U?0]1SP
M)<1M'(HDC88*,,@CT(KJP^(GAZBFM3"K2C5CRL^'5)(KJOA_:Z'JVM0Z9K=N
MYCN&VQW,,I1D;T/8@U[+XI_9]TC6+A[C39WTF5^3&HWQ$_[IY'X&N>T;]GJZ
MTS4$N[C68G^SL)(EBA/S,.F<G@5]'+,,/5IM<S3^9Y*PM6$[VNC=UGP'X=\)
MZ<+'3+!9KZ[('FSL7<#/KV]*U-3^#FEZKX66PVB"] WBZ RP?TZ].U2^%()_
M$&O76I:C'LFLW\H1=0C#T]L=_>O0ATKYR=:I!KWG?<]2%.,DW;0^7M3^ WBV
MR?%O;P7Z9X:*8*?R;%1Z?\"O%U[*%FLX;).[RS*<?@N:^I2,TFT#V^E=G]J8
MBUM/N,OJ=*YYGX;^#5KX>T1X5N&FU&0[GN"N%_W0/2HIO .K1MA$BE7U5\?S
MKU+%%<JQ=9-MN]RY86G+H>8VOP_U.5QYQC@3N2V3^5=WH^APZ+8?9XR6!Y8M
MW-:17/<CZ&EK.K7G5TD73H0I:Q/F;XJ?LCIXE\0S:KX;U"#3?M3[Y[:XC/EA
MCU*D=/I7K'P9^%=K\)O#"Z9#*+FZE;S+BYV;?,;_  ':O0"N1T!^M"KM&*<\
M35J05.3T1Q4,KPF&Q$L32A:;_I_>+1117,>J%%%% !1167XD\16/A?2Y+_4)
MA#;Q]^I8]@!W)II.3LA-I*[-2BOGW6_VD=2DF==(TR"*'HKW9+.?P&!6;;_M
M%>)XI 9K;3Y4_N^6RY_(UZ4<MQ,E>WXG(\723M<^E*"0.IQ7DNA?M!:5?Z7<
MS:C$UA=P+N,"G<)?9#_0UPNN?M#^(+^1ETV*WTV'/!*>8^/<GC\A40P&(G)Q
MY;6[E2Q5**3ON?20D4G 8?2H[RSBO[:2WG020R*5="."/2OEN'XW>,8I YU%
M)>>5>!,?H*]-^'WQRC\0S&RUB-+*["[EEB!*R8ZC;U!]AUIU\NKTHMR2:\A4
M\73G*R=F'COP7X<\%:)<:I-]JF(.V&V\[ 9ST&<9Q_A7S]=7<M[,\DAX)R$'
MW5KZ+\4:9/\ %^QGT^#&G6]G()8YIP=\C%>,K_".>_/L*Y#3_P!FK4FN!]NU
MFWBA[_9XRS'Z9P!6F64<#@4YRBE/TU^16-Q.,Q=H\[<?4\DTW3KK5[Z*SM86
MN+B9MJ(@Y)KZO^'?@I?"7A:UL)BDMQDR3-MR-YZXJ3P;\-]&\$Q_Z# 7N&'S
MW,OS2-^/8>PKJ0,<48W&_67R05HHRPV']DKRW&B)0  , 4\#%%%>4=P4444
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M-P?U62<?A9YN'KJLK/=&I1117FG8%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!@:0B+XKUTA+0.4@W/$Y,S?*V/,'0?[/MFM^N>T9PWBW75#6AP
MD'RQ+B8?*W^L..?]GKQFNAH **** &2$+AB<8[5CR>*=*2]-FVH6XN@<>49
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MF".+:\65;[S8^;/;DXQ6]6!HT^_Q1KD7VEI#&L!\@P[1'E6Y#_Q9_3'O6_0
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MW?PXA</>FX:ZP'>'*IQGCU/7O7VM7$X/,Z2G1GJ]M#XR5#$Y=4<*T=CW=7#
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MZ9?)<. GE<CY"N""!SDYJSXKU.*VT30#!<H=0EUFR2]MK+4&:,(SD!2=W1U
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M\1#._J/K6Y38UV*!T]J=7V.&HK#T844[\J2N_)'DU)>TFY]PHHHKI,PHHHH
M*"0.M%!XH ,CUHW ]ZSM3UJTT6TEN;N000J>78]_0>],T3Q!:^(-.2\LR[0N
M2%+K@\''2N5XFBJWU?G7/:]KZVVO;MJ:>SGR>TMIM?I<U** 01Q175N9C)9
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MH:YS0+CS?$FLQ?:DE\N.W/DB(*T65;JV/FS^F/>NCKW5L?//0****8@HHHH
M**** "BBB@ HHHH *,9HHH ,4444 %%%% !1110 4444 %%%% !2,>WK2T$9
MH \N^-5O</IUA*H)MTD;S,= 2.":Y3PU\0]0T'3(-,L[*&X.\[2V[<Q)SC ^
MM>YW>G07L+13()(VX96 ((].:R].\#Z+I%S]HL["*";LX&2/IGI7YEF7#&8U
MLX_M3+\3[/F2C+2[LK;:-:V78^CPV98>&$^K5Z7-9W7:_F:E@TKVL33*%E*
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M_9/M_F6[K]G^T>1YG'3S/X?K0 M\I7P+= J\>-/(V2MN9?W?0GN?4TSX<_\
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MW!@O9O*A?CH[_P (]ZZ:N8^)**_@S5@XL2GV9\C4V(MCQ_RTQ_#ZT 27B!/
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M5KDAMYHS(D'[YY04DPK?=7^''0^N:WZV,0HHHH **** "BBB@ HHHH ****
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M $)WBK_P7+_\<KM]H]*-H]*?/3_E_$/98C_G[^".(_X6@_\ T)WBK_P7+_\
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FK <@UNM&K#!IR*$4 # %3*2:M%6-*=*<9<TYW?I86BBBLSJ/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>adag-20221231x20f029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231x20f029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '" \(# 2(  A$! Q$!_\0
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M,LCF]NAN9HU)/$O<DUJ_\.Z?V=_^B:V?_@;=?_':]T\!_P#(D>'_ /L'V_\
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M=2L[F_M<>?:PW"/+#GIO0'*_B* NSP#_ (=T_L[_ /1-;/\ \#;K_P".T?\
M#NG]G?\ Z)K9_P#@;=?_ !VOI&B@+L^;O^'=/[.__1-;/_P-NO\ X[1_P[I_
M9W_Z)K9_^!MU_P#':^D:* NSYN_X=T_L[_\ 1-;/_P #;K_X[1_P[I_9W_Z)
MK9_^!MU_\=KZ1HH"[/F[_AW3^SO_ -$UL_\ P-NO_CM'_#NG]G?_ *)K9_\
M@;=?_':^D:* NSXUA_9U^'?P&_:L^%?_  @GAJ'P^=0M]0%SY4\LGF!8LKG>
MS8Q[5]DCI7S]\6?^3K/@U_UPU+_T57T".E A:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2OG[XL_\G6?!K_KAJ7_HJOH$=* %HHHH **** "BBB@ HHHH **** "BBB@
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MZ>7.JAF7YL9X8<C(YKZ9;[IKQ+]FG_D(_%7_ +'"Y_\ 1,- S/\ ^%T?&_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW37B7[-/_(1
M^*O_ &.%S_Z)AKVUONFO$OV:?^0C\5?^QPN?_1,- 'MU%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]%:\,_\ A&'_ .3*/^$!^.O_ $5KPS_X1A_^3*]NHH \1_X0'XZ_]%:\,_\
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MLZ66@&QDB:)5((?SY,@[NF*^A*\1^)W_ "<C\)?^N&I_^@1T >VCI2T@Z4M
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MQNI?^$AI?_Q% SWW-&:\"_X4E\:O^CC=2_\ "0TO_P"(H_X4E\:O^CC=2_\
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MD-+_ /B* /?<T9KP+_A27QJ_Z.-U+_PD-+_^(H_X4E\:O^CC=2_\)#2__B*
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M*/Q5HKO)(P5547T1))/ %>MCXK^"1_S.&@=?^@I!_P#%T =717*?\+8\$_\
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MZ/\ AO#X*_\ 0T7W_A/ZC_\ (] CU*\^%/A2\\70>*GT&R?Q'!$(H]19#YF
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M%W@K0/'VC2:3XDT:QU[2Y&5WL]1MUGB9E.5)5@0<'D5P?_#*'P8_Z)5X-_\
M!';_ /Q%>K44 >4_\,H?!C_HE7@W_P $=O\ _$4?\,H?!C_HE7@W_P $=O\
M_$5ZM10!Y3_PRA\&/^B5>#?_  1V_P#\11_PRA\&/^B5>#?_  1V_P#\17JU
M% 'E/_#*'P8_Z)5X-_\ !';_ /Q%'_#*'P8_Z)5X-_\ !';_ /Q%>K44 >4?
M\,H?!C_HE/@W_P $=O\ _$4?\,H?!C_HE/@W_P $=O\ _$5ZO10!Y1_PRA\&
M/^B4^#?_  1V_P#\145W^RE\&4M96'PJ\' A#@_V';\<?[E>N5!>_P#'I-_N
M'^5 'RQ^R[^S=\*?$GP;TV_U7X;^%=1O7OM11KBZTB"1V5;V95!8KG 4 #T
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M>#?_  1V_P#\11_PRA\&/^B5>#?_  1V_P#\17JU% 'E/_#*'P8_Z)5X-_\
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M9JU/_HMOQ0_\&=E_\B5[8.12T >)?\,U:G_T6WXH?^#.R_\ D2C_ (9JU/\
MZ+;\4/\ P9V7_P B5[;10!XE_P ,U:G_ -%M^*'_ (,[+_Y$H_X9JU/_ *+;
M\4/_  9V7_R)7MM% 'B7_#-6I_\ 1;?BA_X,[+_Y$H_X9JU/_HMOQ0_\&=E_
M\B5[;10!XE_PS5J?_1;?BA_X,[+_ .1*/^&:M3_Z+;\4/_!G9?\ R)7MM% '
MB7_#-6I_]%M^*'_@SLO_ )$H_P"&:M3_ .BV_%#_ ,&=E_\ (E>VT4 >)?\
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MW'3-5K_]HO7[;4)--@T:VNKW3M0FT^]>-)"EQ*D\<82$9RK,DGF<EL 8Z9-
M&O\ \,U:G_T6WXH?^#.R_P#D2@_LUZF/^:V_%#_P9V7_ ,B5Z1X:\4R>(M0N
MB@ACT]<+;Y;][,0</(!G[F> <<X)SS72,0!R: /'OV3?$.L>)O@MIEWKNK76
MMZBMQ<P/?7K*TTH29E4L5 &< = *]BKP[]C4C_A1UA_U_P![_P"E#U[C0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %07O_ !Z3?[A_E4]07O\
MQZ3?[A_E0!X_^R%_R0K2_P#L(:G_ .E\]>SUXQ^R%_R0K2_^PAJ?_I?/7L]
M!1110 4444 %%%% !1110 4444 %%%<?\7?B)'\)_AOK_BV6PDU./2;5KDVD
M,@C:7'\(8\#/O0!V%%?/%C^T#\7=2LK>[M_V>-7DM[B-98W_ .$GTX;E8 @X
M+>AJ?_A>GQC_ .C==8_\*C3?_BJ /H"BOG__ (7I\8_^C==8_P#"HTW_ .*H
M_P"%Z?&/_HW76/\ PJ--_P#BJ!GT!17S_P#\+T^,?_1NNL?^%1IO_P 51_PO
M3XQ_]&ZZQ_X5&F__ !5 'KNM>!;'7?%6AZ_//=)>:.93;)%(!&?,0H^Y<'/R
MDCK65;_!OPU;ZR]_]FED0SS7:63R9MXIY4V2RJF.&9<CK@9) !.:\W_X7I\8
M_P#HW76/_"HTW_XJC_A>GQC_ .C==8_\*C3?_BJ /3/"WPHT3P=+)-IQNOM'
MV06$$LTWF-:VP.1%'D<*#CKD\#)X%4O$_P #_#7BJPTZUNDN8Q9QR0B2&7:\
MJ2?ZU7)!SOZDC!ST(K@/^%Z?&/\ Z-UUC_PJ--_^*H_X7I\8_P#HW76/_"HT
MW_XJ@#UKQ]XRLOACX&U/Q#>6=[=Z?I5N9I8-.A$LWEJ.=J$C.!VS7R?^Q=^U
M?X.^(WQ"\9^&]$L];GOM<UJYUJ"62R"PQ6QCC :5]_RG*D8P>HKT^]^-'Q=U
M"TFMKC]G'5I8)D,<B-XHTW#*1@C[U>$_LR_#CXA?LU:QXRU'3/V?M6OKC7;T
MR0,?$FG*;2USN6 ?/SAB>?9?2@#[\'2EKY__ .%Z?&/_ *-UUC_PJ--_^*H_
MX7I\8_\ HW76/_"HTW_XJ@#Z HKY_P#^%Z?&/_HW76/_  J--_\ BJ/^%Z?&
M/_HW76/_  J--_\ BJ /H"BOG_\ X7I\8_\ HW76/_"HTW_XJC_A>GQC_P"C
M==8_\*C3?_BJ /H"BOG_ /X7I\8_^C==8_\ "HTW_P"*H_X7I\8_^C==8_\
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110!\^_%G_ ).L^#7_ %PU+_T57T".E?/WQ9_Y.L^#7_7#4O\
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M +(7_)"M+_["&I_^E\]>SUXQ^R%_R0K2_P#L(:G_ .E\]>ST %%%% !1110
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MBQ>:1D< [ 3@^F*SG\ Q^-M7AUCQ38V=["+'[,FCWU@LHMI2?WCARQ#9Q@$
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MST\5?^$=JW_R/1_PW-\+/^>GBK_PCM6_^1Z /H&BOG[_ (;F^%G_ #T\5?\
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M ./T?\,-?"W_ )Y>)_\ PK-3_P#C]?0-% 7/G[_AAKX6_P#/+Q/_ .%9J?\
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M_P"&7/@Y_P!$J\&?^"&U_P#B*/\ AESX.?\ 1*O!G_@AM?\ XBO4** /+_\
MAESX.?\ 1*O!G_@AM?\ XBC_ (9<^#G_ $2KP9_X(;7_ .(KU"B@#R__ (9<
M^#G_ $2KP9_X(;7_ .(H_P"&7/@Y_P!$J\&?^"&U_P#B*]0HH \O_P"&7/@Y
M_P!$J\&?^"&U_P#B*N:1^SI\*_#^I6^HZ7\-_"FG7]LXDANK31K>*6-AT*LJ
M @_2O1** "BBB@ HHHH **** "BBB@ HHHH 0C-&T>_YTM% ";1[_G1M'O\
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M+Y3D%HRR,I*$@':<C(SBJE_\+/"6I1:3'<:!9-#I,$UM8PK%L2WBE4+(BJN
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M_P!2U^_AGL],O'1UMDC@6%6D8''.9"P4G*D#GD4#/3M,\56VL:K)9V://'%
MDLMR.$0N 43UW%?FQV&,]16I>_\ 'I-_N'^5>0)X*\<:'\0]-.EWTDN@>9;2
MW,S3*L<G^N-X98\Y9Y"T&P@';LP"H'/HGCGQMX?\!:!+J/B76]/T#3S^Z^UZ
ME<I;Q;S]U=S$#)["@1YU^R%_R0K2_P#L(:G_ .E\]>SU\Z_L5_$CPIX@^%5E
MH6E^)-)U'6K>ZU&YFT^UO(Y)XXFOIBKL@.0I#*02,'</6OHJ@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0E$@/[IB&.1W'>@#VNBBB@04444 %%%% !1110 4444 %%%% !1110 4444
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M=*T6PTG36@W/$[VUQ'/YTF5!4.\$0V#.T;N3Q7:Z1\+KVTF\8ZU=6VFW&O\
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MB7_T;GXU_P#!II7_ ,D4?\-%?$O_ *-S\:_^#32O_DB@1]!T5\^?\-%?$O\
MZ-S\:_\ @TTK_P"2*/\ AHKXE_\ 1N?C7_P::5_\D4 ?0=%?/G_#17Q+_P"C
M<_&O_@TTK_Y(H_X:*^)?_1N?C7_P::5_\D4 ?0=%?/G_  T5\2_^C<_&O_@T
MTK_Y(H_X:*^)?_1N?C7_ ,&FE?\ R10!]!T5\^?\-%?$O_HW/QK_ .#32O\
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M1E67((&".: .Z^)GQPTOPCH.GWNC7>G:Q<7D]F(XQ,Q1X;B1460.@(Y!)7)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXWT^SN?+D@AF,;NJ[6;Y/E#$]P3P*W]1^,/@[2IX8KC7;<&4VX5HP\B9GSY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\^_ML?\DOT'_L;-$_]+HJ^@5Z?B:^?OVU^?A?H..?^*LT3_TNBKZ
M5N._7TH =12;A[_E1N'O^5 "T4FX>_Y4;A[_ )4 +12;A[_E1N'O^5 %35]4
MM]%TN[O[N016UM$TTCGHJJ,D_D*\J/QT86GAZ%M.FCU3Q+I-SK.G'[.SV]O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>adag-20221231xex15d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231xex15d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !U 9<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBO&/VK/'?C[X:?#4^)/ @\.A[&</J4GB6X,$
M$=L1MW!\@ [RO4]Z /7(=6LKC4;C3X[N&2^MT5Y;=9 9(U;[I*]0#@XJMXF\
M4:1X,T6XU?7=2MM)TNW*"6[O)1'%'N8(N6/ RS*/J17Y:WGPX_:M^'?[7/AW
MQ9;^(?#=UXM^),<T#B$[[!+2U2*1D=2 0B)LP5)).>3FO<OVF_A+K?[5_P 4
M?$WP@O/C VA"STRUUR+PS9:0?L[0%U7?/,6S(WF L%7@#!(XS0!]U1R+*BNC
M!T89#*<@BG5\"?\ !/W4OCYXE2X@UCQ[X>UGP)X3UJX\.212P&:]NH[4&/='
M(A "D[,,^20*^^NU !FC(]:^//$/[*/QT'Q<UOQ5X<_:#OM.TC4+R6YBTN[L
M1/';(YRL2H?EVJ#@$8. *^4OC5\//VJ?AIX_\&:;XQ^.BV/ASQ+K9TN#78;Q
M8(K<D,^Z1-JD91#@=,X&>: /UBU'7=.T@*;Z_MK,,<#SY53/YGVJY%*D\:R1
MNLD;#*LIR"/4&OSD;_@EG#XWN8M5^)7QYUSQ0[R%D(E&QE(XV,\A"]<\#%?>
M7PH\!Z9\,/AQX>\*:->7.H:7I-FEM;W-Y/YTLB#H6?OU^@& .E '64E!Z>E?
M"GAKXV^./AY_P4TU_P"&&JZY+XD\'^+[);_3[,L&.DLL!<  ?='[N12#U#(U
M 'W62 ,DX% .17R9_P %0/%WBCP;^R?JU[X5U*[T>>74;.VO;^R9EEAM7<AR
M&7E1NV D<X/O7O7P/ET__A4GA*#3O$8\66UMIEO;_P!LF;S6NV6-09&;KEB,
MG///- '=4TNH;;D9ZXI20H))P!7Y5_M)?&GX>_$;X[77BOP?^T=XG\"7NF!+
M2>TBL;F?3F:/Y=\(7Y"#SG(.3DY] #]5:ADO;>&XBMY)XTGE!,<;, S@8S@=
M\9%?*_A7_@H#\.9?B?H/@>\UQ/[-O/#":Q%XNU BUM[J8/Y;1[&QM8[)&] 0
M17S+^U'^VA\*]>_;)^ ^K:-XD-]HGA2\F;6=7L9'^SHDQ4*O'#A2NYL9&#B@
M#]1\C.,\^E+7P=^S-XQO_B[^VAXR\9)\;-'UK0VMIHM-\%:)>M,KV:$)%*Z$
M;4(W!B1\Q9N>*^N?C5XK\4>"/AEKFM>#/##^,/$EK$#::/'*(S.Q8 \_[();
M Y.,"@#M\T$@=3BOB?\ 8>\"_M :9XV\6^/OC7XI>QL=8@DGB\)W$ROY#%PW
MF[<_N4105"]]W/3-8?[2OBC5?B[JM[<>&OVHO"O@;X>7$06*"RD47>^./$H,
MH.2"V3P1QCTY /MOPMXST+QOI\U]H&K6FL6<-Q):23V<RR(LL;;70D=P1@BM
MJOQA_8[\-6/@KP5XKUK2OVJ+'P/=66H7!ATM,/;7!C9E6XECEQE9512-H)VD
M=^*^\_V"/VR+/]ISX:6\.O:IIB?$.RDFBOM.M3Y;2QHPV3I&3G:59<^A!H ^
MJB<5SOASXB^&/%VM:WI&BZ[8:GJFBS?9]1M+6=7DM9,9VNH.5->3_M5?'[PO
M\*])M/">N^++CP%J/BZRO8-,\3"WWP6$T:+AG8\ Y<8!ZX-?)G["WC7]G7X"
M?$"_TNW^(FH>)?B-XLF6UFUW4[26WMKMFEW!(F88.^0_?).XXQCN ?I;D>M(
M751DD >]?";?!+]L#1_%_BB_3XW>'AHDHEEMVOK8%(07W* FSY,#C))&/6OG
MCX0?#OX]?MG:)J>N:S^T5;Z'8PZE+I\EAIUZ8Y T3D9"P[<*Q *\\J0: /UT
M!R,CFBN'^"?PZO\ X4?#'0O"VI>)K_Q??:=$8Y-8U,YFG)8L,]> #M&23@#)
MKY+^.-]^U'\.+_Q[XYU3XC>$?"_PVTP3R6V+%KB1+<D+#A -QE.Y1R<;NV,4
M ?;NOZ_IWA;1+_6-6O(=/TRQ@>YN;JX<+'#&@+,S$]  ":3P]XBTSQ9HEEK&
MCWT&I:7>Q":WN[:0/'*AZ,K#@BOQU^._QI\7?$GX"7UW<_M)VNL17%E(9_#U
MGHDMK]L1EYA9PG4_=.<#GK6=^S9\3O'GP[^"VE7&G_'T>$]!AA*+IU[X?N+F
MVT]GD+;3+Y149)SD$CYJ /VK!!I:^/OV4/ WQ[TSQK8^)/$GQ>T;XE?#'5M-
M-Q'+!'\[NP/EM$0@P,GDD]..M>]?M">//%GPV^$^M:_X)\*2^,_$EN$%MI,+
M8+EF"ESCDA0<D#GB@#T>L+Q9XZ\/>!+6WN?$6M6.BP7$GE127UPL*N^,[06(
MR<5\ 7O[3'[4'@_P]JGBSQC??#/PQ!96LEU-X;U*X*WL8505C*JY(=CP%/.3
MS7GG[?7Q6O?VJ/V2/@[XKTCP7J4>IZCK\L<EH]N[M!*L+(R+@?,DC8*MW"^N
M: /U=CD66-71@Z, 58'((/>G5^??A+]HW]KCQ'X3L+/P]\$]!L[FR$5I.USJ
M8S$50#:\)(,9Q@X)X'K7W7X-N-;N_">D3>)+.WT_Q!):QM?VMI+YL44Y4;U1
M_P"( YP: -@D"C(SUKY(_;7T+XPS>)/#&K?#?XN:)X L(8?+GTS5Y$B%S,'+
M>9N93N&-J[>.A]:\#\%']I76?C!H,%[^T=X'N)OM433:-:W43B:(<LHB"9;<
MN>ASS0!^FE)N&<9&?2OSSF_:._:6^.7Q\^+G@3X366@:=H'AC4O[._M?5X2K
MVFW<F>6^<NR,P^4X '%=7\!?V:/VB_#_ ,?[#XA_$WXOVNHV,<3P7&B6<CF"
MYB*L!&(L*BX8JVX#=Q0!]Q44@I: "BBB@ HHHH **** "BBB@ KX6_X*':C\
M4O$GA3Q/X6;_ (1KP1\'Y;>"._\ %6MW.^:Z8D2>7%$O(.Y0 ,$G!K[IKYI_
MX**?#71?B;^R?XRM=9U:'1!I<0U>TO+AL(+B$,40^N\%DQZL* /CCXDP+\*?
MB1X/N?&'QY\9V'B[0[>/3+#Q-)X>SHULLL*DQACPVZ,C<^,Y'/2K.G_":'QO
M\4/'I\+Q>//B[\2?#LT>D:WXH;78]'M=I4[HHBO)&0PV]/ES7!?$#XI>-?C?
MX*^!OAOX^:DWA_P-XLE>YL[/0=*+7\IMA'##+)D\"4RL1@<#GH:]-^+WA/3?
M!O[67Q1U#P+XQ\1>'_".B^&6\1^.5T*=447\2D0VZL00))1@GT+-0!4^#G[.
MW@_7OB?K_P ,='U'X@? CXF6MB-1N=/BU475I>19'[U&7 ?EEY/. ?>OTO\
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MQMKW@341H/P,\ Z]:R:M=+-JGB.]42I('QY*HV2%3E1CKCO7Z7? []E?X<?
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MK<TD/F!BMO8[=F&E(_O;CCM\IK@OV&OV5?B-^S5I4%GXC^(C:YX>?3P$\-B
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M^<9)YP,G Z#- 'Y_?\%BO@UHS-X"^)VI:O>1VPOX="O].27=FW.^4R0(3@2
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M\.7-QYBQ1*XEV#E=X!VEATSWK[)_X;(^"W_11-'_ .^G_P#B:/\ ALCX+?\
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M)*#<"ZG'(#*"I(Y&:PO^&R/@M_T431_^^G_^)H_X;(^"W_11-'_[Z?\ ^)H
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M6,)O[+;O\[)I?-^I]0?\(3X=_P"@!I?_ (!Q_P#Q-'_"$^'?^@!I?_@''_\
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MK6>XZF$KT7)5(-<MKWZ7T1O_ /"$^'?^@!I?_@''_P#$T?\ "$^'?^@!I?\
MX!Q__$USWQ(^,6B?"_6?".F:M'=27'B;4!IMF;= RK*2H!?)&!\PZ9KCOB+^
MU;X<^'/Q N_!TVA^(=9UBVMX[J1-'L?M $;C(/!SW';O2=2,=V.E@\16M[.#
M=TVO1.S_ !/4O^$)\._] #2__ ./_P")H_X0GP[_ - #2_\ P#C_ /B:\E\+
M_M9:3XI\1Z9H\7@KQI9R7]RELMQ>:.T<,18XW.V?E49Y-=3H'[07A+7_ (NZ
M[\-X[B6V\2Z2%9HKE0J7 **Q\HY^8@,"1C/7T-"J0>S*G@<33OS0>BN_3:YV
M/_"$^'?^@!I?_@''_P#$T?\ "$^'?^@!I?\ X!Q__$UHZA?1Z;87%W+DQ01M
M*VWKA02<?E7)_"'XL:/\:? ]IXJT*.YBTZYDDC1;M D@*-M.0">XJ[J]CE5.
M;@ZB7NII7\WM^3-O_A"?#O\ T -+_P# ./\ ^)H_X0GP[_T -+_\ X__ (FO
M'?B#^VK\._ ^LW.C6LM_XIU:WR)K?0;?[0L1!P0S@X_+-;'PJ_:Q^'WQ;U@Z
M+IU_/I>O#C^R]7A^SSL>X4$D$^V<^U9JK!OEOJ=LLNQ<:?MG2?+WMT[^A[&J
MA%"J J@8  P *6BBM3S@HHHH **** "BBB@ HHHH *\N_:A_Y-V^(_\ V ;O
M_P!%FO4:^2/VA?CWKWC'PYXR^&6@?##Q;-KVI"32K:ZGL<6LD3?*TV_. "N[
M;DXZ$D<BL:LE&+OU/3RZA4K8B#@M(M-ZI65]]3B_'7_)"OV4?^PUI7_HJE^,
M_P '[3XV_MG^)/#T]S)I]ZOA**[T^_B)#6URCKL?CJ.2"/0^M=5\:/AOJ_A;
MX>_LY^'([6XU.YT+7]-BO)+2!I%CV1X=SM!PH.>3Q736&B:BO[?NKZH;"Z&F
MMX22);TP/Y)?>GR[\;<^V<UQN%_=DNJ_(^JAB?9Q=:E+51JM/_M]-&A^S5\=
MM6UG4K_X9?$1%T[XBZ!B(M(<#5(!TGC)^\< $XZ@[O7'B?P8\;7_ ,._V6/C
MOK^E,8]2M?$%ZMO*HR8W?RXPX]UWY_"OHK]I+X O\5;#3_$'ANZ_L7XA>'G^
MTZ/J<>%+,IW>3(>Z,1WZ$]P2#Y/^QE\-+_Q+\#?B3X7\>:/=Z?+K.MW45[;W
M,!A;+Q)N9,C'#9((R,CBK:GSJ#[.S.6E5PCPU3$I))RAS0[6>MO)_AL>F_LJ
M_"K0OAY\$]"U:WLDU#6]7T]-4O\ 4)$#W%S)*GF;2QYP,A0/;U)KQ+XJ?M ^
M#_$"Z?K_ (U^!'B1%T6=+B'4+NW$(B8'"AGVC*DD?*>,XK9\%>-OBE^R/IB^
M#?$_@K4/'W@VQ8KI>OZ IDFC@+<1R1X)XR< XQT!( Q2\9S?$O\ ;5N=+\-1
M>$+_ .'GPU6X2ZU*_P!6&VYNPIRJHA /T &,\D\ 5,I>XH1T?:QM2HVQ4\5B
M&I4V[\_/:R[))WO;3EMY'V%X;UB'Q/X<TK6(X3%'J%K#=)&^"RB10P!]QFOF
MC]@%0WAGXDY /_%7W?\ Z"M?46FZ=!I&FVMC:QB*VM8DABC'144!5'X "OFS
M]A30]1T/PY\0TU'3[O3WF\5W4L:W4#Q%T*KAEW 9'N.*Z97]I#YG@4)1^IXF
MW>%OO9A_MEC'QW_9O'_4PO\ ^CK2O5_VL_BN?A!\$->U:WD$>JW:?V=I^6 /
MGR@J&'^ZNYO^ UYO^UWH.IZM\;_V>[FQTZ[O;>SU]Y+F:WMWD2!?.M?F=E!"
MC@\G'0^E2?%?P;/^T)^U#H/A35M(N9_ 'A"R?4+]YX72WO+N4#9&&(P^ 4X!
M[/64FTYJ.[:7X'J4H4JE/"2J_!",I2]%-Z?-V7S/"8+;PG^S1/\ !CQKX?\
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MQ3&VEN[:6!)AUC+H5#?AG-?%?P.^+2?LO> [WX:?$#X?:VFJVUU/Y,^E:?\
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M2#'0KYI))YW<FO5_V3_A#X?^'GP9\-7%G9PS:IJ]A#J-_J#H&EGDF02'+'G
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M\#M$U&R_:T^.U_<6%U!8W9T_[/<RP,L4V(L'8Q&&Q[&M)6J<J;OK^C.*BZF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>adag-20221231xex15d3001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20221231xex15d3001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Z 60# 2(  A$! Q$!_\0
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M110 44TL >2!1O7U% #J*;O7U%.H **** "BBB@ HHHH ***3(SCO0 M%%%
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M/]KSQS^TO8:)9^+8M+2'29I)K?\ L^W:(EG"JV[+'/"BOW:TG_D&VG_7%/\
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MK7RE_P %$_C+XC^%_P +_#VC>%]2ET/4_%FK)I;ZM"2);6#&7*$?=8Y49!!
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MDY;  SS2_$OX5^%?C#X7G\/^+]%M];TJ7YO*G!#1MV=&&&1AZJ0:!W/'HO\
M@GW^SQ-$LL?P\M7C89#+J-X01]?.KN+'X">%/!/P:\4^!_A[HUIX>L]6L;R
M"%V;=/+$T>]Y&+,V"0.2< 8'3%>03_\ !/VUL;1],\-_%SX@^'_#K +_ &1#
MJ?F1*,8*J3C QQCM7T7\,/AUIWPG\#:5X4TB>[N-/TV-DBFOYO.GD+.79G?
MR26- C\]_P!A7]GWX(_$_P (:MX3^('@^%_BEX<OY[;4K6]O;B">2,/\CJB2
MJ"%Y0X'!7GJ"?J>W_8$_9^TN[@N4^'=BLD4BNGG7MTZE@1@%6E(;G'!!!Z8K
M<^,W[(/P\^->MQ^(=0M+S0O%<0PFOZ!<FTNS\N!N8</@8Y(S@8SBN1\)?L01
MZ3XUT/Q%XB^*7CCQD=%NHKVRT_5-0_<+-&ZNA<#.X J.*!W/._\ @K);I#^S
MOX;AB18XU\10(J(,!1Y$P  ["OLGP9#]F\):)$>J6,"_E&HKS_\ :-_9UT/]
MI3P?8>'=>O[[3[2SOTU!7L"H=G564*=P(QAC7J5G;)96D-NF=D2+&N>N ,#^
M5 CXI2;R_P#@JU<+_P ]/""K_P"0R?Z4OQST%=8_X*4_! LP58=$N+O).,F+
M[0PKW]_V<-#?]HU?C%_:-\-=&G_V;]B&S[.4V%,]-V<'/6L_]H#]D[P7^T/?
M:;JFMR:GI/B+3(S!9:QI%V89HE)+;<<@C<2>@/OB@=SV&_U&VTJQFN[VXBM;
M6%#))/.X1$4#)9F/  ]:^'?V7[NW^-_[=WQ:^+.@*S^$;+3X]%M[T#Y+N;;"
MF]#Z%8&;Z,OK73ZA_P $Z(?%306OB[XQ^//%&B1$ Z;=7@",H_A).1V':OIW
MX<_#3PW\)?"=GX:\*:3#I&CVH)2&+)+,?O.['EF/=B2:!'YX?#GX'_#*+]L;
MXK> OC/X?AO=0US4'U?PS>WEU-;13QRR22-&A1U#,PD'7O$P'/%?59_X)\?L
M\JFX_#JU"^O]HWG_ ,>KT+XT_L\>!/C[I,-CXQT9+U[8EK6_@8Q7=JQ[QRCD
M?0Y!XXXKQ6[_ ."?L-^B:;<_&+XBW'A=7_Y TFJ94Q_W-_7\<4#N=S^T1X.T
M/P#^QO\ $'0?#6G6^DZ)9>&KJ.VM;8?(J^6><\EB>I8DDDDDDTS]@>/9^R)\
M-AC'^A3'\[F4UZ;XU^&.F^-/A5J?@&>:XMM*OM,.E-+$P,J1%-F02,$X'>D^
M#_PQT_X-?#;0_!FEW,]W8:1"T,4]UCS'!=GRV !U8T"/E/\ X*HR:#!\)?##
M7^C7$NOR:N(M)UV*1HH]*? 9WD<*?E8*/DX)*[@?DYP? W[&-]\>++1=0\>?
MM#7GQ1\+6^R5]*TFY,EM)(N.#*9#Z,"VP/[@UN_&#39?VK_VQ[SX+ZUK5UI_
MP_\ ">C1ZO?Z;8N(WU&Z8Q%0S<\*)HR..-K8P3FK_CG_ ()R:!X;@N_$'P;\
M3ZY\.O%4$9DME@OW>UE95X1\_. >>26QGICB@H^Q=*TJST+2[/3;"WCM+&TA
M2WM[>(82.-0%50/0  5\'_MS?\GG_LV?]?R?^E<=>Z?L)_'K6OVA?@1;Z[XC
M2,Z[IU_+I5W=1*%6Z:-4<2[1PI*R*"!QD$C (%:OQH_9;L?C+\7OAYX]N=>N
M=,N/!\RS1645NKI<D2K)AF)!7[N. >M EH:/[87_ ":W\4?^Q?N__0#6'^P2
M,?LB?#8?].$G_I1+7I_Q9^'\7Q5^&GB3P?/>/80ZU8RV+W4:!VB#C&X*< X]
M*I_ _P"%D'P4^%GA_P $6NH2:G!HT#0)=S1B-I 9&?)4$@?>Q^% =#YU_;<^
M*7BF7XD_#'X,>$O$C^#9_&=SG4-<AR)XH-^Q$C8<@L0_0@DA1D FO+_VJOV+
M?AY\'_V=O$OB>^\4>*=8U^T@1;675]8W)<7+RJ%'E8PQY)P.RD]J^J?VFOV6
M= _:3T;2A>ZA=^'_ !%HLK3:5KEA_K;9C@D$9&Y<JIZ@@J"".<^-:'_P3JE\
M2ZS'>?&#XH^(/BA:6R.MIIUS))##&64C>29&.1G(QCD#.1Q0-,ZCX*VSZA_P
M3BL[9$:62;P1?1*BC)8F&8  =ZB_X)CZU9ZC^R1X>M;>=)+C3[V]@N8P>8W,
M[2 '_@,B'\:]8_9U^"5Q\!/APO@Z;Q1>>*[&WGE-D;V!(_LMNS$K" O+ 9.2
M2>3P ,"O$?$7_!/8Z%XEU76OA%\3-=^%AU1]]UIUD#+:G.>%4.A &> 2<=J"
M3AO^"HNHVQ\2? VQ6XC-V->>9H XWA-]N Q7KC((S[5T?_!4Z,3?#/X=HRAE
M;Q=;*01D$&-ZT)_^";^CZW9Z=?>(/'NM^(O&L.J6VH7/B745\Z66.$'%LB,Q
M\N,L<DY)R!Z5[1^TI^SG9?M'Z!X>TN]UF?15T?5HM522W@64R,@(V$$C .>M
M [GL,8Q&H'& *^&_CI_RE#^!W_8 D_EJ%?<P&!7BGC3]FJQ\9?M(^#?B]+KE
MQ;7OAJP:QCTM(%:.<'S_ )B^<@_OST'\(]: 1P7_  4@LO!TW[,^J7?BZSO[
MEK:YB.E2::%\V*]8,L9);@(1N#9['CG%>(?#O]G;X^?'SX7:)IOB3X\Z?)X!
MOK2)9[/2'6[N6AV_ZJ25$7>=O!W2,/4'%>I_MBZQK_Q8^+W@7]G;2-071=)\
M56<NJ:_J!B221K.-F(BC#=#F%CD<Y*<X#5DWG_!-BT\"QG4OA#\2?$W@CQ!%
M'E6FN?-M[B0?\] @4@'H>&^AZ4#/JWX7?#?0_@_X T7P?X?A^SZ3I4'DPB4Y
M=R269V/=F8LQ/J317QK\(?\ @H5=>&-!U+PW\7+"2;QOH&I3Z5=W-BI19_*V
MC>RHI4-N+ [< [0<#.**!6/RDHHHH- HHHH **** '+]\?6OZ1=)_P"09:?]
M<4_]!%?S=+]\?6OZ1=)_Y!EI_P!<4_\ 0103+<N4444$!1110 4444 %%%%
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D*KXW\37]Y+J.I:Q=[@9)Y H8+E@=HVCD\DDGC. 5]*44"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300248080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adagene Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4F, Building C14, No. 218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Xinghu Street, Suzhou Industrial Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Suzhou<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">215123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">54,065,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers Zhong Tian&#160;LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Shanghai, the People&#8217;s Republic of China<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10179 Huennekens Street Suite 103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Peter Luo<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">peter_luo@adagene.com<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">87773616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American depositary shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value US$0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388299014704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,758,678<span></span>
</td>
<td class="nump">$ 174,391,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">619,432<span></span>
</td>
<td class="nump">4,506,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepayments and other current assets</a></td>
<td class="nump">4,937,323<span></span>
</td>
<td class="nump">4,055,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">149,315,433<span></span>
</td>
<td class="nump">185,953,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">2,782,963<span></span>
</td>
<td class="nump">3,487,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">191,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">109,572<span></span>
</td>
<td class="nump">69,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">152,399,845<span></span>
</td>
<td class="nump">189,510,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,666,124<span></span>
</td>
<td class="nump">3,321,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">15,107,276<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">19,323,337<span></span>
</td>
<td class="nump">10,466,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="nump">3,212,809<span></span>
</td>
<td class="nump">4,379,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,657,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term borrowings</a></td>
<td class="nump">10,768,745<span></span>
</td>
<td class="nump">3,121,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">2,850,128<span></span>
</td>
<td class="nump">1,376,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">151,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">55,080,402<span></span>
</td>
<td class="nump">29,821,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term borrowings</a></td>
<td class="nump">14,146,541<span></span>
</td>
<td class="nump">2,991,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">53,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">28,718<span></span>
</td>
<td class="nump">94,107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">69,309,495<span></span>
</td>
<td class="nump">32,952,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 54,595,667 shares issued and outstanding as of December 31, 2021; and 640,000,000 shares authorized, 54,065,709 shares issued and outstanding as of December 31, 2022)</a></td>
<td class="nump">5,497<span></span>
</td>
<td class="nump">5,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury shares, at cost (94,074 shares as of December 31, 2021 and 1 share as of as of December 31, 2022)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(619,605)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">342,739,268<span></span>
</td>
<td class="nump">336,099,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(849,305)<span></span>
</td>
<td class="num">(93,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(258,805,106)<span></span>
</td>
<td class="num">(178,833,259)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">83,090,350<span></span>
</td>
<td class="nump">156,558,713<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 152,399,845<span></span>
</td>
<td class="nump">$ 189,510,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388299438080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">640,000,000<span></span>
</td>
<td class="nump">640,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">54,065,709<span></span>
</td>
<td class="nump">54,595,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">54,065,709<span></span>
</td>
<td class="nump">54,595,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">94,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295647728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Licensing and collaboration revenue</a></td>
<td class="nump">$ 9,292,724<span></span>
</td>
<td class="nump">$ 10,175,258<span></span>
</td>
<td class="nump">$ 700,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(81,339,540)<span></span>
</td>
<td class="num">(68,099,385)<span></span>
</td>
<td class="num">(33,538,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ResearchAndDevelopmentExpenseThirdParties', window );">Third parties</a></td>
<td class="num">(46,212,077)<span></span>
</td>
<td class="num">(55,020,367)<span></span>
</td>
<td class="num">(23,645,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty', window );">Related parties</a></td>
<td class="num">(35,127,463)<span></span>
</td>
<td class="num">(13,079,018)<span></span>
</td>
<td class="num">(9,892,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="num">(11,873,867)<span></span>
</td>
<td class="num">(14,439,962)<span></span>
</td>
<td class="num">(10,314,536)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(83,920,683)<span></span>
</td>
<td class="num">(72,364,089)<span></span>
</td>
<td class="num">(43,151,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">377,501<span></span>
</td>
<td class="nump">76,166<span></span>
</td>
<td class="nump">629,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(693,323)<span></span>
</td>
<td class="num">(363,762)<span></span>
</td>
<td class="num">(202,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">2,168,388<span></span>
</td>
<td class="nump">1,778,822<span></span>
</td>
<td class="nump">971,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="nump">2,555,325<span></span>
</td>
<td class="num">(603,459)<span></span>
</td>
<td class="num">(644,693)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(79,512,792)<span></span>
</td>
<td class="num">(71,476,322)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(459,055)<span></span>
</td>
<td class="num">(1,701,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">(79,971,847)<span></span>
</td>
<td class="num">(73,177,935)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, net of nil tax</a></td>
<td class="num">(755,324)<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="num">(6,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">(80,727,171)<span></span>
</td>
<td class="num">(72,920,935)<span></span>
</td>
<td class="num">(42,403,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">(79,971,847)<span></span>
</td>
<td class="num">(73,177,935)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,553)<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (79,971,847)<span></span>
</td>
<td class="num">$ (73,206,488)<span></span>
</td>
<td class="num">$ (42,645,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of ordinary shares used in per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">-Basic</a></td>
<td class="nump">54,135,084<span></span>
</td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">-Diluted</a></td>
<td class="nump">54,135,084<span></span>
</td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per ordinary share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">-Basic</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">-Diluted</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ResearchAndDevelopmentExpenseThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses resulting from transactions with third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ResearchAndDevelopmentExpenseThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301986528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295865584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Subscriptions receivable from shareholders</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2019</a></td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (197,068)<span></span>
</td>
<td class="nump">$ 6,789,542<span></span>
</td>
<td class="num">$ (344,894)<span></span>
</td>
<td class="num">$ (63,258,045)<span></span>
</td>
<td class="num">$ (57,008,946)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,193,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,975,124)<span></span>
</td>
<td class="nump">7,115,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">3,694,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,694,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,129,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,129,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2020</a></td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,172,192)<span></span>
</td>
<td class="nump">23,786,652<span></span>
</td>
<td class="num">(350,981)<span></span>
</td>
<td class="num">(105,655,324)<span></span>
</td>
<td class="num">(89,389,956)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2020</a></td>
<td class="nump">18,888,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,177,935)<span></span>
</td>
<td class="num">(73,177,935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of ordinary shares under performance incentive plan</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of ordinary shares under performance incentive plan (in shares)</a></td>
<td class="nump">23,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CommonStockSubscriptionsValue', window );">Subscription from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,679,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,679,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,553)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering</a></td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,475,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,477,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred shares to ordinary shares upon the completion of initial public offering (in shares)</a></td>
<td class="nump">27,249,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares upon IPO, net of issuance cost</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,094,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,095,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares upon IPO, net of issuance cost (in shares)</a></td>
<td class="nump">10,571,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares under share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,361,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,361,576)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares under share repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 1,741,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,750,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="num">(201,100)<span></span>
</td>
<td class="nump">201,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_StockSurrenderedValueForRepaymentOfPromissoryNotes', window );">Surrender of ordinary shares for repayment of promissory notes</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,790,910<span></span>
</td>
<td class="num">(6,800,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes', window );">Surrender of ordinary shares for repayment of promissory notes (in shares)</a></td>
<td class="num">(491,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">$ 5,627<span></span>
</td>
<td class="num">$ (619,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,099,931<span></span>
</td>
<td class="num">(93,981)<span></span>
</td>
<td class="num">(178,833,259)<span></span>
</td>
<td class="nump">$ 156,558,713<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="nump">56,274,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,971,847)<span></span>
</td>
<td class="num">$ (79,971,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">197,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of ordinary shares under performance incentive plan</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of ordinary shares under performance incentive plan (in shares)</a></td>
<td class="nump">99,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,520,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,520,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares under share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,976,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,976,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares under share repurchase program (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,512,932)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares</a></td>
<td class="num">$ (160)<span></span>
</td>
<td class="nump">$ 4,596,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,596,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (in shares)</a></td>
<td class="num">(1,607,005)<span></span>
</td>
<td class="nump">1,607,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2022</a></td>
<td class="nump">$ 5,497<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,739,268<span></span>
</td>
<td class="num">$ (849,305)<span></span>
</td>
<td class="num">$ (258,805,106)<span></span>
</td>
<td class="nump">$ 83,090,350<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2022</a></td>
<td class="nump">54,965,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance at the end (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CommonStockSubscriptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CommonStockSubscriptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number shares surrendered for repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_StockSurrenderedValueForRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of shares surrendered for repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_StockSurrenderedValueForRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300359920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (79,971,847)<span></span>
</td>
<td class="num">$ (73,177,935)<span></span>
</td>
<td class="num">$ (42,397,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,145,995<span></span>
</td>
<td class="nump">1,125,032<span></span>
</td>
<td class="nump">858,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset', window );">Net loss on disposal of property, equipment, software and operating lease right-of-use asset</a></td>
<td class="nump">6,811<span></span>
</td>
<td class="nump">18,973<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10,520,282<span></span>
</td>
<td class="nump">18,679,658<span></span>
</td>
<td class="nump">10,129,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_InterestIncomeExpenseOnPromissoryNotes', window );">Interest income on promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense', window );">Amortization of right-of use assets and interest of lease liabilities</a></td>
<td class="nump">303,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss (gain), net</a></td>
<td class="num">(2,555,325)<span></span>
</td>
<td class="nump">603,459<span></span>
</td>
<td class="nump">644,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepayments and other current assets</a></td>
<td class="num">(881,402)<span></span>
</td>
<td class="num">(231,287)<span></span>
</td>
<td class="num">(2,337,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="nump">3,887,238<span></span>
</td>
<td class="num">(4,374,274)<span></span>
</td>
<td class="nump">1,300,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(40,297)<span></span>
</td>
<td class="num">(24,210)<span></span>
</td>
<td class="num">(13,292)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">344,509<span></span>
</td>
<td class="nump">1,511,640<span></span>
</td>
<td class="nump">1,097,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">9,607,276<span></span>
</td>
<td class="nump">4,774,464<span></span>
</td>
<td class="num">(267,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Amount due to related parties</a></td>
<td class="nump">8,857,276<span></span>
</td>
<td class="nump">7,930,703<span></span>
</td>
<td class="nump">639,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="num">(823,928)<span></span>
</td>
<td class="nump">1,057,491<span></span>
</td>
<td class="nump">1,243,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(280,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="num">(1,657,450)<span></span>
</td>
<td class="nump">1,657,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred tax liabilities</a></td>
<td class="num">(44,163)<span></span>
</td>
<td class="nump">44,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(29,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">48,611,687<span></span>
</td>
<td class="nump">43,414,619<span></span>
</td>
<td class="nump">28,529,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Withdrawal of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of property, equipment and software</a></td>
<td class="nump">4,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of property, equipment and software</a></td>
<td class="num">(690,938)<span></span>
</td>
<td class="num">(2,509,926)<span></span>
</td>
<td class="num">(935,199)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash generated from (used in) investing activities</a></td>
<td class="num">(686,046)<span></span>
</td>
<td class="num">(2,509,926)<span></span>
</td>
<td class="nump">7,072,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">25,830,030<span></span>
</td>
<td class="nump">4,386,860<span></span>
</td>
<td class="nump">6,083,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from share subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">323,212<span></span>
</td>
<td class="nump">231,521<span></span>
</td>
<td class="nump">140,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,411,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of borrowings</a></td>
<td class="num">(4,353,588)<span></span>
</td>
<td class="num">(5,089,717)<span></span>
</td>
<td class="num">(1,063,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,595,088)<span></span>
</td>
<td class="num">(721,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares under stock repurchase program</a></td>
<td class="num">(3,976,681)<span></span>
</td>
<td class="num">(2,361,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_RetirementOfTreasuryShares', window );">Costs for retirement of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash generated from financing activities</a></td>
<td class="nump">17,822,973<span></span>
</td>
<td class="nump">145,357,142<span></span>
</td>
<td class="nump">4,439,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="nump">842,195<span></span>
</td>
<td class="num">(192,352)<span></span>
</td>
<td class="num">(364,177)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(30,632,565)<span></span>
</td>
<td class="nump">99,240,245<span></span>
</td>
<td class="num">(17,381,790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of year</a></td>
<td class="nump">174,391,243<span></span>
</td>
<td class="nump">75,150,998<span></span>
</td>
<td class="nump">92,532,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of year</a></td>
<td class="nump">143,758,678<span></span>
</td>
<td class="nump">174,391,243<span></span>
</td>
<td class="nump">75,150,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">603,680<span></span>
</td>
<td class="nump">359,569<span></span>
</td>
<td class="nump">202,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income tax paid</a></td>
<td class="nump">2,433,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities</a></td>
<td class="nump">313,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">217,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,553<span></span>
</td>
<td class="nump">248,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,477,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PayablesForDeferredInitialPublicOfferingCost', window );">Payables for deferred initial public offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,276,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_NonCashActivitiesRetirementOfTreasuryShares', window );">Retirement of treasury shares</a></td>
<td class="nump">$ 4,596,282<span></span>
</td>
<td class="nump">1,741,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes', window );">Surrender of ordinary shares for repayment of promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loss on disposal of property, equipment, software and operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_InterestIncomeExpenseOnPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) on promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_InterestIncomeExpenseOnPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NonCashActivitiesRetirementOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of retirement of treasury shares in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NonCashActivitiesRetirementOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset and interest of lease liabilities from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PayablesForDeferredInitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payables for deferred initial public offering cost in non-cash activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PayablesForDeferredInitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RetirementOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of retirement of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RetirementOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common stock shares surrendered for repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388302032032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">1. ORGANIZATION AND BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. (the &#8220;Company&#8221;) is a limited liability company incorporated in the Cayman Islands on February&#160;25, 2011. The Company, together with its subsidiaries (collectively, the &#8220;Group&#8221;), are principally engaged in research, development and production of monoclonal antibody drugs for cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 8, 2021, the Company&#8217;s registration statement relating to its initial public offering (&#8220;IPO&#8221;) of its American Depositary Shares (&#8220;ADSs&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) and the shares of its ADSs began trading on the NASDAQ Global Market on February 9, 2021. The public offering price of the ADSs sold in the IPO was $19.00 per ADS. The IPO closed on February 11, 2021, pursuant to which the Company issued 8,457,100 ADSs, including the exercise in full of the underwriters&#8217; option to purchase 1,103,100 additional ADSs from the Company. The Company received net proceeds of approximately $145.9 million, after underwriting discounts, commissions and estimated offering expenses. Each ADS represents one and one quarter (1.25) ordinary shares of the Company. Upon the completion of the IPO, all outstanding shares of the convertible redeemable preferred shares were converted into ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company&#8217;s principal subsidiaries are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;legal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Place&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">by&#160;the&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal&#160;activities</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 12, 2011</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Hong Kong</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment holding</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Incorporated</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September 20, 2017</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The United States of America</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 28, 2012</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;)</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Australia PTY Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 30, 2018</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Australia</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2020</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene AG</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 31, 2020</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Switzerland</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Project C1 PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388304565344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). References to specific U.S. GAAP principles throughout these notes to the accompanying financial statements are to the Accounting Standards Codification (&#8220;ASC&#8221;), as published by the U.S. Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated, Adagene PTE. Ltd. and Adagene Project C1 PTE. Ltd. is the United States dollar (&#8220;US$&#8221;). The functional currency of the Company&#8217;s PRC subsidiary is Renminbi (&#8220;RMB&#8221;). The functional currency of the Company&#8217;s Australian subsidiary is Australian dollar (&#8220;AU$&#8221;). The functional currency of the Company&#8217;s Swiss subsidiary is Swiss Franc (&#8220;CHF&#8221;). The determination of the respective functional currency is based on the criteria stated in ASC 830, <i style="font-style:italic;">Foreign Currency Matters</i>. The Company uses US$ as its reporting currency. The financial statements of the Company&#8217;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China (the &#8220;PBOC&#8221;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Accounts receivable and allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#8217;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group applies ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2021 or 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2021 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property, equipment and software</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">4 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;"> - </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#8217; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No impairment loss was recorded for the&#160;years ended December&#160;31, 2020, 2021 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Segment reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 280, </span><i style="font-weight:normal;">Segment Reporting</i><span style="font-style:normal;font-weight:normal;">, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief Executive Officer. The Group&#8217;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#8217;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> Upfront non-refundable payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. For licenses determined not to be distinct, the Group accounts for the promise to grant a license and those other promised goods or services together as a single performance obligation when recognizing revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i><span style="white-space:pre-wrap;">:  The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contract assets and contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;) and contract manufacturing organizations (&#8220;CMO&#8221;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2021 and 2022, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#8217;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2021 or 2022 as the Group did not have any plan to cancel the existing CRO or CMO contracts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Government subsidies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#8217;s PRC based subsidiary received government subsidies from certain local government. The Group&#8217;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. In addition, the Group&#8217;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies of US</span><span style="font-style:normal;font-weight:normal;">$0.8</span><span style="font-style:normal;font-weight:normal;"> million, US</span><span style="font-style:normal;font-weight:normal;">$1.4</span><span style="font-style:normal;font-weight:normal;"> million and US</span><span style="font-style:normal;font-weight:normal;">$2.1</span><span style="font-style:normal;font-weight:normal;"> million were received and recognized as other income during the years ended December 31, 2020, 2021 and 2022, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the adoption of ASC 842, <i style="font-style:italic;">Leases</i> ("ASC 842") on January 1, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases, mainly leases of office spaces where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon and hereafter the adoption of ASC 842 on January 1, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determines if an arrangement is or contains a lease at inception. For arrangements that meet the definition of a lease, the Group determines the classification of the lease based on the relevant factors present and records a right-of-use ("ROU") asset and lease liability at the lease commencement date. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. As the rate implicit in the Group&#8217;s leases is not typically readily available, the Group uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Group could borrow the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Group will exercise that option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use assets and lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) elect for each lease not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component; (ii) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii) the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January 1, 2022 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the adoption of ASC 842 on January 1, 2022, the Group recorded an impact of approximately US$0.6 million and US$0.6 million for the recognition of operating lease right-of-use-assets and operating lease liabilities, respectively, on its consolidated balance sheet, which are primarily related to the lease of the Group&#8217;s offices. The adoption of ASC 842 did not have a material impact on the Group&#8217;s consolidated statements of comprehensive loss and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC&#160;740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation-Stock Compensation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; (b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or (c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 260, </span><i style="font-weight:normal;">Earnings Per Share</i><span style="font-style:normal;font-weight:normal;">, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employee defined contribution plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#8217; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#8217;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$622,377 , US$2,223,493 and US$2,984,251 for the&#160;years ended December&#160;31, 2020 , 2021 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2022, the amount of cash and cash equivalents of US$3,650,474 and US$8,617,157 respectively, were held at major financial institutions located in Mainland China, and US$170,740,769 and US$135,141,521,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s research and development services were purchased from one supplier group, who collectively accounted for 21.5%,18.5% and 34.1%of the Group&#8217;s total research and development services purchases for the&#160;years ended December&#160;31, 2020, 2021 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#8217;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#8217;s ability to attract employees necessary to support its growth. The Group&#8217;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#8217; invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 2.29% in the year ended December 31,2021 and appreciation of approximately 9.24% in the&#160;year ended December&#160;31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#8217;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is an emerging growth company (&#8220;EGC&#8221;) as defined by the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU No. 2016-02 (&#8220;ASU 2016-02&#8221;), <i style="font-style:italic;">Leases</i> (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-10 (&#8220;ASU 2018-10&#8221;), <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#8220;ASU 2018-11&#8221;), <i style="font-style:italic;">Leases (Topic 842): Targeted Improvements</i>, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current U.S. GAAP (Topic 840, <i style="font-style:italic;">Leases</i>). Further, the FASB issued ASU No. 2020-05 (&#8220;ASU 2020-05&#8221;), <i style="font-style:italic;">Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities,</i> which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted.<span style="font-size:11pt;"> </span>The Group adopted the new guidance on January 1, 2022, using the alternative transition approach. For additional information, see Note 14, <i style="font-style:italic;">Leases</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and does not expect the adoption of ASU 2016-13 to have a material impact on the financial statements including the notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. This update simplifies the accounting for income taxes as part of the FASB&#8217;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, <i style="font-style:italic;">Income Taxes</i>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2021. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted ASU 2019-12 in 2022 and the adoption of ASU 2019-12 did not have a material impact on the financial statements including the notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</i>, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Group is currently evaluating the impact of this accounting standard update on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In March 2022, the FASB issued ASU 2022-02, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings (&#8220;TDR&#8221;) and Vintage Disclosures</i> (&#8220;ASU 2022-02&#8221;). ASU 2022-02 eliminates the TDR recognition and measurement guidance, enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. For entities that have not yet adopted ASU 2016-13, the ASU is effective upon adoption of the amendments in ASU 2016-13. Early adoption is not permitted before an entity's adoption of ASU 2016-13. The Group has not adopted ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305036896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>ACCOUNTS RECEIVABLE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3. ACCOUNTS RECEIVABLE, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388304565344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">PREPAYMENTS AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4. PREPAYMENTS AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepayments and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,161,910</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deposits (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,873,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,970,421</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 619,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 804,992</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,055,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,937,323</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="font-weight:normal;">Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on prepayments and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388304981728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, EQUIPMENT AND SOFTWARE, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5. PROPERTY, EQUIPMENT AND SOFTWARE, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment and software consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,293,386</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,152,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,055,271</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863,963</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,684</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,266</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 371,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369,698</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,809,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,692,268</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,322,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,909,305)</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,487,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,782,963</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Depreciation and amortization expenses recognized for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were US$858,408, US$1,125,032 and US$1,145,995 respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305158560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock', window );">ACCRUALS AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6. ACCRUALS AND OTHER CURRENT LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued liabilities and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 935,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,647,490</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Payroll and related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,229,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,104,365</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Utility and maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,718</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other taxes and surcharge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349,039</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,197</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,379,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,212,809</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305073440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>BORROWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">BORROWINGS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;">7. BORROWINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Short-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,121,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,768,745</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,376,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,850,128</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,618,873</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Long-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,146,541</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total non-current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,146,541</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,489,374</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 27,765,414</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Short-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Group borrowed a loan with the amount of RMB10,000,000 (equivalent to approximately US$1,532,591) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in June 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$766,295) from Bank of Ningbo Co., Ltd. for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in September 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed another loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was also repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,552,771) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum. The borrowing was repaid in May 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Group borrowed another loan with the amount of RMB10,000,000 (equivalent to approximately US$1,568,455) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum. The borrowing was repaid in August 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,421,474) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 3.90% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Group borrowed another loan with the amount of RMB20,100,000 (equivalent to approximately US$2,886,024) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 3.70% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2022, the Group borrowed a loan with the amount of RMB20,000,000 (equivalent to approximately US$2,871,665) from Bank of Jiangsu Co., Ltd. for a term of one year at the interest rate of 3.70% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2022, the Group borrowed another loan with the amount of RMB25,000,000 (equivalent to approximately US$3,589,582) from China Construction Bank Corporation for a term of one year at the interest rate of 3.65% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Long-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, the Group borrowed a loan with the amount of RMB7,500,000 (equivalent to approximately US$1,076,874) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.46% per annum. The Group repaid RMB375,000 (equivalent to approximately US$53,844) in 2019, RMB1,250,000 (equivalent to approximately US$179,479) in 2020, RMB3,375,000 (equivalent to approximately US$484,594) in 2021 and RMB2,500,000 (equivalent to approximately US$358,958) in 2022. As of December 31, 2021, RMB2,500,000 (equivalent to approximately US$358,958) repayable within twelve months for this agreement was classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets. The loan was fully repaid in February 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Group borrowed a loan with the amount of RMB6,000,000 (equivalent to approximately US$861,500) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.23% per annum. The Group repaid RMB300,000 (equivalent to approximately US$43,075) in 2019, RMB1,000,000 (equivalent to approximately US$143,583) in 2020, RMB2,700,000 (equivalent to approximately US$387,675) in 2021, and RMB2,000,000 (equivalent to approximately US$287,167)in 2022. As of December 31, 2021, RMB2,000,000 (equivalent to approximately US$287,167<span style="white-space:pre-wrap;">)  repayable within twelve&#160;months for this agreement was classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets. The loan was fully repaid in June 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB16,500,000 (equivalent to approximately US$2,369,124) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.27% per annum.The Group repaid RMB1,650,000 (equivalent to approximately US$236,912) in 2021 and RMB3,850,000 (equivalent to approximately US$552,796) in 2022. As of December 31, 2021 and 2022, RMB3,850,000 (equivalent to approximately US$552,796) and RMB 11,000,000 (equivalent to approximately US$1,579,416) repayable within twelve months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Group borrowed a loan with the amount of RMB8,500,000 (equivalent to approximately US$1,220,458) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.05% per annum. The Group repaid RMB425,000 (equivalent to approximately US$61,023) in 2022. As of December 31, 2021 and 2022, RMB425,000 (equivalent to approximately US$61,023) and RMB850,000 (equivalent to approximately US$122,046) repayable within twelve months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, the Group borrowed a loan with the amount of RMB30,000,000 (equivalent to approximately US$4,307,498) from Agricultural Bank of China Limited for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB3,000,000 (equivalent to approximately US$430,750) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in May 2022, the Group borrowed a loan with the amount of RMB20,000,000 (equivalent to approximately US$2,871,665) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.00% per annum. The Group repaid RMB500,000 (equivalent to approximately US$71,792) in 2022. As of December 31, 2022, RMB1,500,000 (equivalent to approximately US$215,375) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,421,474) from Agricultural Bank of China Limited for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB1,000,000 (equivalent to approximately US$143,583) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in August 2022, the Group borrowed a loan with the amount of RMB20,000,000 (equivalent to approximately US$2,871,665) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB1,000,000 (equivalent to approximately US$143,583) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,421,474) from Agricultural Bank of China Limited for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB1,000,000 (equivalent to approximately US$143,583) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Also in November 2022, the Group borrowed a loan with the amount of RMB10,000,000 (equivalent to approximately US$1,435,833) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB500,000 (equivalent to approximately US$71,792) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The proceeds from the loans were primarily used to pay for the Group&#8217;s research and development activities in China, including CMC costs of clinical and preclinical programs. As of December 31, 2021 and 2022, none of the Group&#8217;s borrowings were collateralized in the respective loan agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Future maturities of short-term borrowings and long-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2021 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,858,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,618,873</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,124,429</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,022,112</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,489,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,765,414</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305116896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock', window );">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2011, the Company issued convertible notes (&#8220;Series Pre-A Convertible Notes&#8221;) to certain investors in the amount of 4,590,908. The notes carried a simple interest (non-compounding) of 6% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the convertible redeemable preferred shares of the Company at a price no more than US$1 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2014, the Company issued 5,473,957 Series A-1 convertible redeemable preferred shares (&#8220;Series A-1 Preferred Shares&#8221;) to certain investors upon conversion of the Company&#8217;s Series Pre-A convertible notes at a conversion price of US$1 per share. Concurrently, the Company issued 2,370,414 Series A-2 convertible redeemable preferred shares (&#8220;Series A-2 Preferred Shares&#8221;) to certain investors at US$1.27 per share for a total consideration of US$3,000,000. Series A-1 Preferred Shares and Series A-2 Preferred Shares are collectively referred to as the Series A Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From January through June 2016, the Company issued 7,494,537 Series B convertible redeemable preferred shares (&#8220;Series B Preferred Shares&#8221;) to certain investors at US$3.74 per share for a total consideration of US$27,999,995.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February&#160;through May&#160;2018, the Company issued 5,597,354 Series&#160;C-1 convertible redeemable preferred shares (&#8220;Series&#160;C-1 Preferred Shares&#8221;) to certain investors at US$8.93 per share for a total consideration of US$50,000,033. Concurrently, in February&#160;2018, the Company also issued warrants to two Series&#160;C-1 investors at nil consideration (&#8220;Series&#160;C-1 Warrants&#8221;). The Series&#160;C-1 Warrants allowed the holders to purchase Series&#160;C-2 Preferred Shares (defined below) at the exercise price of US$10.21 per share for a total consideration of up to US$7,500,000. Series&#160;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&#160;April&#160;1, 2019, ii)&#160;a deemed liquidation event or iii)&#160;the closing of the Qualified IPO. Series&#160;C-1 Warrants expired on April&#160;1, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From June&#160;through November&#160;2019, the Company issued 1,861,121 Series&#160;C-2 convertible redeemable preferred shares (&#8220;Series&#160;C-2 Preferred Shares&#8221;) to certain investors at US$10.21 per share for a total consideration of US$18,999,999.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the Company issued 4,452,441 Series&#160;C-3 convertible redeemable preferred shares (&#8220;Series&#160;C-3 Preferred Shares&#8221;) to a certain investor at US$11.23 per share for a total consideration of US$50,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Series&#160;C-1 Preferred Shares, Series&#160;C-2 Preferred Shares and Series&#160;C-3 Preferred Shares are collectively referred to as the Series&#160;C Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the IPO on February 11, 2021, each of the then outstanding Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares (collectively the &#8220;Preferred Shares&#8221;) was automatically converted into one ordinary share. As of December 31, 2021 and 2022, there were no preferred shares issued or outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accounting for Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Preferred Shares were classified as mezzanine equity in the consolidated balance sheets because they were contingently redeemable upon the occurrence of an event outside of the Company&#8217;s control (e.g.&#160;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&#160;31, 2025 (&#8220;Target QIPO Date&#8221;)). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares were initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any Preferred Shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, the Company concluded that the Preferred Shares were not redeemable, but were probable to become redeemable. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest redemption date for the year ended December 31, 2020, and to the IPO date for the year ended December 31, 2021, using the interest method. No accretion charge was recorded as the redemption value was fixed to original issue price for the periods presented, except for Series C-1 Preferred Shares issued with detachable warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Modification of Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company made several amendments to the Preferred Shares, mainly including: 1)&#160;added redemption rights for Series&#160;A Preferred Shares upon the issuance of the Series&#160;B Preferred Shares; and 2)&#160;extended the Target QIPO Date upon the issuance of the Series&#160;C-1 Preferred Shares and the Series&#160;C-3 Preferred Shares. These amendments were accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s Preferred Shares activities for the periods presented were summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,727,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,201,294</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,975,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,449,407</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Preferred Shares to Ordinary Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,473,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,999,995)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,004,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,999,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (154,477,960)</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for temporary equity and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305046304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9. SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November&#160;7, 2015, the Company adopted a share incentive plan (the &#8220;2015 Plan&#8221;). Under the 2015 Plan, the Company&#8217;s Board of Directors has approved that a maximum aggregate number of shares that may be issued pursuant to all awards granted shall be 4,336,126. In September&#160;2017, the Company replaced the 2015 Plan with the amended and restated share incentive plan (the &#8220;2017 Plan&#8221;) and increased the maximum number of shares issuable to 6,336,126. In December&#160;2019, the Company replaced the 2017 Plan with the second amended and restated share incentive plan (the &#8220;2019 Plan&#8221;) and further increased the maximum number of shares issuable to 11,391,131. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the Company may issue under the respective plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than five years, under which the grantee earns an entitlement to vest a certain&#160;percentage of his option grants at the end of each&#160;month or&#160;year of completed service. The share option awards shall expire no more than 10 years from their grant dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence of their applicable performance conditions (including but not limited to the occurrence of an IPO, the completion of business and operational goals, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 15, 2020, pursuant to a board resolution, 184,692 share options that granted to a senior management was modified and the vesting period of such share options was shortened from 5 years to 4 years. Since the fair value of the modified award was lower than the fair value of the original award immediately before the modification, no incremental compensation cost was recognized for the modification during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of 2,375,000 share options granted to certain management members. Pursuant to this board resolution, these management members exercised all related share options at the original exercise price per share ranging from US$1.83 to US$2.26. As a result, 2,375,000 ordinary shares were issued to these management members. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$5,197,650. The Company had the repurchase right to buy back such shares at the original exercise price if the grantees did not meet the original vesting conditions. The Company assessed and considered that in accordance with guidance set out in ASC 718-10-55-31, given such arrangement allows the shares received on exercise be returned to the Company if the original vesting conditions are not satisfied, there has been no substantial change to the vesting conditions and the Company shall continue to account for the share awards in accordance with their original terms. As of December 31, 2021, there were 1,585,000 shares unvested according to the original vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of 491,119 ordinary shares as repayment for their respective promissory notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way of new option grants with an exercise price of US$13.85 per share. The fair values of these share options were US$7.85 per option, determined by using the binomial option valuation model. The share-based compensation expense related to these share options were recognized immediately upon grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the same board resolution, the 2021 Performance Incentive Plan (the &#8220;2021 Plan&#8221;) was also adopted, under which an aggregate of 2,994,000 ordinary shares shall be reserved for issuance, and the share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&#160;5% of the total number of the Company&#8217;s outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by the board of directors. From March 12, 2021 to December 22, 2021, pursuant to the 2021 Plan, a total of 1,303,000 share options were granted to certain employees by 15 batches, with exercise price ranging from US$5.92 to US$17.56, respectively. In addition, 23,734 ordinary shares were issued to certain management personnel on March 16, 2021 pursuant to the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of 2,060,308 share options granted to certain employees were modified. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) 25% of the total number of share options of each grantee (&#8220;Annual Cap&#8221;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#8220;Credited Shares&#8221;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. As a result of the modification, the Company recognized an incremental fair value of US$2,337,697.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February 7, 2022 to December 27, 2022, pursuant to the 2021 Plan, a total of 2,640,598 share options were granted to certain employees, with exercise price ranging from US$0.80 to US$5.60, respectively. In addition, 99,999 ordinary shares were issued to certain management personnel on March 8, 2022 pursuant to the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2022, among all the share options granted to date, 2,483,808 and 4,776,906 share options contained both service conditions and performance conditions, respectively. All other share options granted contain only service conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 866,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,328,171</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,313,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,694,934)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,294,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,410,968</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (233,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,809,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,619,574</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,640,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (197,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (964,789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,286,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,286,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,486,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 874,180</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,070,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.62</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,880</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate fair value of the equity awards vested during the&#160;years ended December&#160;31, 2020, 2021, and 2022 was US$8,430,085, US$13,833,856 and US$11,929,903, respectively. As of December&#160;31, 2022, the total unrecognized employee share-based compensation expense was US$23,635,444, all of which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be recognized over a weighted-average period of 2.20&#160;years as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fair value of share options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The assumptions used to estimate the fair value of the share options granted were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.68% - 0.83%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.11% - 1.67%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.92% - 4.25%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.3% - 73.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">73.1% - 75.5%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">74.2% - 74.9%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Total share-based compensation expenses recognized for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,472,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,582,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,227,298</p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,657,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,096,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,292,984</p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total share&#8209;based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,129,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,679,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,520,282</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388490803280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborationArrangementsAbstract', window );"><strong>COLLABORATION ARRANGEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION ARRANGEMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10. COLLABORATION ARRANGEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, the Group entered into (i)&#160;a collaboration agreement (the &#8220;Sanjin Greater China Agreement&#8221;) that covers Greater China with Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. (&#8220;Sanjin&#8221;) and certain of its subsidiaries (collectively, &#8220;Sanjin Parties&#8221;) and (ii)&#160;a collaboration agreement (the &#8220;Sanjin ROW Agreement,&#8221; together with the Sanjin Greater China Agreement, the &#8220;2018 Sanjin Agreements&#8221;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the &#8220;PD-L1 Project&#8221;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#8217; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group (i)&#160;single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit&#160;percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB10,000,000 (equivalent to approximately US$1,511,168) upfront fee upon the effectiveness of the agreement from Sanjin Parties, which was recognized as revenue in 2018. No revenue related to this agreement has been recognized in any of the years presented in the accompanying financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Sanjin&#8217;s affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expect to receive from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in the Group&#8217;s notice to Sanjin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#8217;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the 2018 Sanjin Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Sanjin has the right to claim back all the payment made to the Group. The Group considers the possibility of occurrence of such event is remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Group entered into (i)&#160;a collaboration agreement that covers Greater China (the &#8220;Dragon Boat Greater China Agreement&#8221;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#8220;Dragon Boat ROW Agreement,&#8221; together with the Dragon Boat Greater China Agreement, the &#8220;2019 Dragon Boat Agreements&#8221;), with Dragon Boat Biopharmaceutical (Shanghai) Limited (&#8220;Dragon Boat&#8221;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the &#8220;Specified Project&#8221;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#8217;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&#160;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug (&#8220;IND&#8221;) approval in PRC and completion of clinical phase I test in PRC) and (ii)&#160;a single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2019 Dragon Boat Agreements, the Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#8217;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Dragon Boat has the right to claim back all the payment made to the Group. The risk of failure is considered remote upon recognition of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2019, no revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, upfront fee of RMB4,000,000 (equivalent to approximately US$573,378) that was received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance obligation had not been satisfied by the Group and no revenue was recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, milestone fee of RMB4,000,000 (equivalent to approximately US$620,011) was received related to the launch of pre-clinical safety evaluation animal test and the receipt of IND approval in PRC. For the year ended December 31, 2021, a total of RMB8,000,000 (equivalent to approximately US$1,240,022), including the aforementioned upfront fee and milestone fee were recognized as licensing revenue in the consolidated statement of comprehensive loss as the performance obligation was satisfied by the Group and certain milestone events were achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No additional revenue was recognized for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics&#160;SA License and Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2019, the Group entered into a material transfer and collaboration agreement (the &#8220;ADCT Collaboration Agreement&#8221;) and a license agreement (the &#8220;ADCT License Agreement&#8221;) with ADC Therapeutics&#160;SA (&#8220;ADC Therapeutics&#8221;). These two agreements are combined as a single contract as the agreements were negotiated as a package with a single commercial objective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group&#8217;s technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group&#8217;s exclusivity obligations, upon achievement of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics&#8217; election to proceed with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days&#8217; prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#8217;s uncured material breach of the agreement or the other party&#8217;s insolvency-related events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group also granted ADC Therapeutics an exclusive target reservation right for one year from the commencement of the agreement and an option to renewal for another&#160;year with a consideration of low-six-figure dollar amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by the Group under these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit&#160;percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon thirty days&#8217; written notice to the Group, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#8217;s uncured material breach or insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2020, the Group recognized US$225,000 of licensing revenue upon delivery of such results. For the year ended December&#160;31, 2020, the Group recognized US$100,000 as other income due to the expiration of exclusive target reservation right, which is not related to the Group&#8217;s major operation activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Group recognized US$225,000 of licensing revenue upon delivery of additional research results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the Group did not recognize additional revenue associated with the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ADCT Material Transfer and Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Group entered into a material transfer and option agreement (the "ADCT Material Transfer and Option Agreement") with ADCT. Under the agreement, Adagene agreed to provide antibodies or antibody sequences to ADCT to conduct further development for a non-refundable fee of US$300,000. ADCT has an exclusive option to negotiate a separate license agreement with the Group, however, there is no requirement for either party to enter into such a license agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the Group recognized revenue of US$300,000, which was received in October 2022, upon delivery of the sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exelixis, Inc. Agreements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Group entered into a collaboration and license agreement (the &#8220;Exelixis Agreement&#8221;) with Exelixis, Inc. (&#8220;Exelixis&#8221;), pursuant to which the Group agreed to generate masked antibodies with its SAFEbody technology against an initial target selected and a second target to be selected by Exelixis. The Group will generate masked antibodies in the form of alternative compounds in accordance with the program plan for each target at its own cost and deliver the related data packages to Exelixis. Exelixis will select lead compounds (the &#8220;Lead Compounds&#8221;) to further develop, obtain regulatory approval and commercialize product(s) for each target (the &#8220;Products under the Exelixis Agreement&#8221;). Under the Exelixis Agreement, the Group will also grant Exelixis an exclusive, worldwide, sublicensable license (the &#8220;Adagene License&#8221;) upon delivery of the data package to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group with respect to both targets. Exelixis will own the inventions relating to the Lead Compounds arising in connection with the Exelixis Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exelixis Agreement will remain effective until the expiration of the defined royalty terms of the Products under the Exelixis Agreement, unless terminated by either party. Exelixis may terminate the Exelixis Agreement for any or no reason, in its entirety or on a target-by-target basis. Any payment received by the Group before the termination shall be non-refundable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Exelixis Agreement, Exelixis agreed to pay the Group an upfront non-refundable fee of US$11,000,000. For each target, the Group will be eligible to receive up to US$127,500,000 of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $262,500,000 of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Exelixis Agreement worldwide, subject to certain reductions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2022, the Group entered in a letter agreement (the "Exelixis Letter Agreement") in reference to the Exelixis Agreement with Exelixis for expanded collaboration in SAFEbody discovery. Under the Exelixis Letter Agreement, the Group will generate additional masked antibodies against the target selected by Exelixis per the Exelixis Agreement. Exelixis agreed to pay the Group an additional upfront non-refundable fee of US$1,100,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determined that generating masked antibodies with its SAFEbody technology is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Exelixis Agreement, the delivery of data packages for each target, along with the Adagene License used to develop the related compounds, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations using the relative standalone selling price method. The Group records revenue at a point in time, when the data packages for each target were delivered to Exelixis. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the Adagene License granted are recognized when (or as) the later of (1) the subsequent sale or usage occurs, or (2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Group received US$11,000,000 upfront payment and<span style="font-size:11pt;"> </span>recorded accounts receivable of US$3,000,000 milestone payment, which corresponds to the successful nomination of lead SAFEbody candidates for the initial target under the Exelixis Agreement. The milestone payment was subsequently received in January 2022. For the year ended December 31, 2021, US$8,500,000 was recognized as revenue upon delivery of data packages for the initial target and achievement of the milestone event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the Group received US$1,100,000 upfront payment under the Exelixis Letter Agreement. No additional revenue was recognized as relevant performance obligation has yet to be fully satisfied under either the Exelixis Agreement or the Exelixis Letter Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sanofi Agreement </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2022, the Group entered into a collaboration and license agreement (the &#8220;Sanofi Agreement&#8221;) with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (&#8220;Sanofi&#8221;), pursuant to which the Group agreed to perform early-stage research activities to develop masked versions of Sanofi candidate antibodies (each a &#8220;Target&#8221;, and together, &#8220;Targets&#8221;), using Adagene&#8217;s SAFEbody technology for development and commercialization by Sanofi. Sanofi has the ability to advance two initial Targets in the collaboration, followed by an option for two additional Targets. The Group will generate masked antibodies in the form of customized compounds and complete the compound research activities in accordance with the program plan for each Target at its own cost and deliver the compounds and related data packages to Sanofi. Sanofi is solely responsible for later stage research and all clinical, product development and commercialization activities. Under the Sanofi Agreement, the Group granted Sanofi an exclusive, worldwide, sublicensable license to research, develop, use, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Sanofi Agreement will remain effective until the expiration of the defined royalty on a product-by-product and country-by-country basis, unless terminated earlier with cause or by mutual agreements of both parties. Sanofi may terminate the Sanofi Agreement without cause, in its entirety, or on a Target-by-Target or country-by-country basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Sanofi Agreement, Sanofi agreed to pay the Group an upfront non-refundable fee of US$17,500,000 in consideration of the license granted and the early-stage research activities to generate the compounds. Sanofi is obligated to pay an additional fee if Sanofi exercises the option for additional Targets. For each Target, the Group will be eligible to receive up to US$173,500,000 of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $450,000,000 of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Sanofi Agreement worldwide, subject to certain reductions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group then determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Sanofi Agreement, the performance of early-stage research activities to develop compounds for each Target, along with the grant of the license, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations based on the relative standalone selling price. Since the early-stage research activities does not generate an asset for alternative use and the Group has an enforceable right to the upfront payment, the Group records revenue over time using labor hour as the input to assess the satisfaction of the performance obligations. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the license granted are recognized when (or as) the later of (1) the subsequent sale or usage occurs, or (2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the year ended December 31, 2022, the Group received US$17,500,000 upfront payment under the Sanofi Agreement. For the year ended December 31, 2022, US$8,992,724 was recognized as revenue over time using the input method.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388490803280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAX EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX EXPENSE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">11. INCOME TAX EXPENSE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">PRC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective from January&#160;1, 2008, the PRC&#8217;s statutory, Enterprise Income Tax (&#8220;EIT&#8221;) rate is 25%. In accordance with the implementation rules&#160;of EIT Law, a qualified &#8220;Technology Advanced Service Enterprises&#8221; (&#8220;TASE&#8221;) is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every&#160;year. Dividends by PRC entities, to non-PRC resident enterprises shall be subject to 10% EIT, namely withholding tax, unless the respective non-PRC resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Suzhou) Limited was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and November 2021. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate of 15% from 2015 to at least 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cayman Islands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&#160;Inc. is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the&#160;years ended December&#160;31, 2020, 2021 and 2022, Adagene (Hong Kong) Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Australia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Australia Pty&#160;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Adagene Australia Pty&#160;Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. Dividends payable by an Australian entity, to non-Australian resident enterprises shall be subject to 30% withholding tax, unless the respective non-Australian resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Australia that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. Adagene Incorporated is also subject to state income tax in California of 8.84%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to 30% withholding tax, unless the respective non-U.S. resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene AG is incorporated in Switzerland and is subject to federal corporate income tax at a rate of 8.5%. Adagene AG is also subject to cantonal income tax of 6.5% as well as capital tax of 0.1% in the Canton of Basel subject to certain tax benefits and relief. Dividends payable by a Swiss entity, to non-Swiss resident enterprises shall be subject to 35% withholding tax, unless the respective non-Swiss resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Switzerland that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Income tax expense (benefit) of the Group for the years ended December 31, 2020, 2021 and 2022 were composed of the following current and deferred amounts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,290,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672,064</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (168,846)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,657,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,218</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96,804)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,641)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,641</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,163)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Reconciliation between the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71,476,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,512,792)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">PRC statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax credit computed at PRC statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,599,320)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,869,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,878,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Impact of PRC preferential income tax rate as qualified TASE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,239,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,147,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,951,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Difference in income tax rates of overseas entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,286,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,549,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,560,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development super-deduction<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (718,979)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (569,016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,724,740)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (569,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign derived intangible income deduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (487,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,517,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">State tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (127,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#8217;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2020, 2021, and 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December&#160;31, 2021 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,949,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,217,976</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Tax credit carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391,843</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 756,197</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,954</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Unrealized foreign exchange gain/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,238</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,702</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Amortization of right-of-use assets and interest of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 546</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,083,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,607,456</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,007,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,524,497)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,959</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,959)</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,959)</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred tax liabilities, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,163)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Movement of the valuation allowance was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,007,139</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,517,358</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,007,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,524,497</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#8217;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has incurred net accumulated operating losses for income tax purposes since its inception. As of December 31, 2022, the Group had net operating losses for income tax purpose of approximately US$50,742,841. The net operating losses were primarily comprised of: US$17,886,069 from an entity in PRC which expires in years 2028 through 2032; US$8,272,007 derived from an entity Switzerland which expires in years 2027 through 2029; US$5,445,071 derived from an entity in Hong Kong that have an indefinite carryforward; US$7,511,343 derived from an entity in Australia that have an indefinite carryforward subject to meeting certain criteria; US$10,807,828 derived from an entity in the United States which expires beginning year 2038; and, US$820,523 derived from entities in Singapore. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the near future. Therefore, the Group has provided full valuation allowances for the deferred tax assets for all subsidiaries as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2021 and 2022, the Group did not have any significant unrecognized uncertain tax positions. The Group does not anticipate that the amount of unrecognized tax benefits will significantly change within the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Group conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December 31, 2022, PRC tax matters are open to examination for the years 2020 through 2022, U.S. federal and state tax matters are open to examination for the years 2019 through 2022, and Australia tax matters are open to examination for the years 2019 through 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301410624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Basic and diluted net loss per share for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were calculated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,177,935)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,971,847)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (248,113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,553)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,645,392)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,206,488)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,971,847)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted&#8209;average number of ordinary shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,950,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,032,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,135,084</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net Loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.48)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the&#160;years ended December&#160;31, 2020, 2021 and 2022 as their effects would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Convertible redeemable preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,249,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Share options and share grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,795,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,739,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530,298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300051952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">13. RELATED PARTY TRANSACTIONS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Related Parties</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Relationship</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chairman, Chief Executive Officer and a principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Four senior management personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Management and ordinary shareholders of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Co., Ltd. (&#8220;WuXi AppTec Group&#8221;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">A principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Controlled by the ultimate controlling party of a principal shareholder of the Company</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party balances as of December 31, 2021 and 2022:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,080,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,941</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,426,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,491</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due from related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 619,432</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2022, the amounts due from related parties represented prepayments made for the CRO and CMO services.<br/><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,292,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,840,876</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,482,461</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,466,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,323,337</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2022, the amounts due to related parties represented payables for the CRO and CMO services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party transactions during the years ended December 31, 2020, 2021 and 2022:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Receipt of CRO and CMO services:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,217,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,561,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,764,750</p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,674,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 517,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,362,713</p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,892,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,079,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,127,463</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305096288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">14. LEASES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Group has operating leases recorded on its consolidated balance sheet for certain office spaces that expire on various dates through 2024. The Group does not plan to cancel the existing lease agreements for its existing office spaces prior to their respective expiration dates. The Group&#8217;s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. All of the Group&#8217;s leases qualify as operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information related to operating leases as of December 31, 2022 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 1.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Information related to operating lease activity during the year ended December 31, 2022 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease rental expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 283,276</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Expense for short-term leases within 12 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,729</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Interest of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,259</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 338,264</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year as of December 31, 2021 under ASC 840, <i style="font-style:italic;">Leases</i>, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">For the years ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412,754</p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255,309</p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,367</p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 738,430</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Maturities of lease liabilities were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157,603</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,823</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212,426</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,609)</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205,817</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388304919520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group&#8217;s business, financial position or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301410624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED NET ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_RestrictedNetAssetsAbstract', window );"><strong>RESTRICTED NET ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">RESTRICTED NET ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16. RESTRICTED NET ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#8217;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S.&#160;GAAP differ from those reflected in the statutory financial statements of the Group&#8217;s PRC subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#8217;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the abovementioned restrictions on distributable profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021 and 2022, the total restricted net assets of the Company&#8217;s subsidiary incorporated in PRC and subjected to restriction amounted to approximately US$1,860,667 for both years. Other subsidiaries are not subjected to such restriction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#8217;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign exchange and other regulations in the PRC further restrict the Group&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2022, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries was US$1,860,667 from the PRC subsidiary, and the Group had a consolidated shareholders&#8217; equity. As the restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388304565344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAbstract', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Treasury Shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">17. Treasury Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group accounts for treasury shares using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account in the consolidated balance sheets. At retirement, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is recorded entirely in additional paid-in capital (up to the amount credited to the additional paid-in capital upon original issuance of the shares). In the event that treasury share is reissued at an amount different from the cost the Group paid to repurchase the treasury share, the Group will recognize the difference in additional paid-in capital by using the specified identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On July 7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US</span><span style="font-size:10pt;">$20</span><span style="font-size:10pt;"> million of outstanding ADSs of the Company, from time to time over a </span><span style="font-size:10pt;">12</span><span style="font-size:10pt;">-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer (the &#8220;2021 Share Repurchase Program&#8221;). The 2021 Share Repurchase Program commenced on July 20, 2021. During the year ended December 31, 2021 and 2022, </span><span style="font-size:10pt;">236,139</span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">1,170,446</span><span style="font-size:10pt;"> outstanding ADSs (</span><span style="font-size:10pt;">295,174</span><span style="font-size:10pt;"> and </span><span style="font-size:10pt;">1,463,057</span><span style="font-size:10pt;"> ordinary shares) were repurchased with a total consideration of US</span><span style="font-size:10pt;">$2,361,576</span><span style="font-size:10pt;"> and US</span><span style="font-size:10pt;">$3,904,399</span> <span style="font-size:10pt;">respectively, under the 2021 Share Repurchase Program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">On June 29, 2022, the Board of Directors authorized a share repurchase program to repurchase up to US</span><span style="font-size:10pt;">$10</span><span style="font-size:10pt;"> million of outstanding ADSs of the Company during a period of up to </span><span style="font-size:10pt;">12 months</span><span style="font-size:10pt;"> commencing on July 20, 2022 (the &#8220;2022 Share Repurchase Program&#8221;). The 2022 Share Repurchase Program was subsequently terminated in July 2022. During the year ended December 31, 2022, </span><span style="font-size:10pt;">39,900</span><span style="font-size:10pt;"> outstanding ADSs (</span><span style="font-size:10pt;">49,875</span><span style="font-size:10pt;"> ordinary shares) was repurchased with a total consideration of US</span><span style="font-size:10pt;">$72,282</span><span style="font-size:10pt;"> under the 2022 Share Repurchase Program.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">During the year ended December 31, 2021 and 2022, 160,880 and 1,285,604 ADSs (201,100 and 1,607,005 ordinary shares) repurchased have been retired<span style="font-size:11pt;"> </span>, respectively. As of December 31, 2021 and 2022, there were 75,259 and 1 ADSs (94,074 and 1 ordinary shares) held as treasury shares, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305109696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">18. SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From January to April, 2023, a total of 582,630 ordinary shares were issued to certain management personnel pursuant to the 2021 Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388299094512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). References to specific U.S. GAAP principles throughout these notes to the accompanying financial statements are to the Accounting Standards Codification (&#8220;ASC&#8221;), as published by the U.S. Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated, Adagene PTE. Ltd. and Adagene Project C1 PTE. Ltd. is the United States dollar (&#8220;US$&#8221;). The functional currency of the Company&#8217;s PRC subsidiary is Renminbi (&#8220;RMB&#8221;). The functional currency of the Company&#8217;s Australian subsidiary is Australian dollar (&#8220;AU$&#8221;). The functional currency of the Company&#8217;s Swiss subsidiary is Swiss Franc (&#8220;CHF&#8221;). The determination of the respective functional currency is based on the criteria stated in ASC 830, <i style="font-style:italic;">Foreign Currency Matters</i>. The Company uses US$ as its reporting currency. The financial statements of the Company&#8217;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China (the &#8220;PBOC&#8221;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock', window );">Accounts receivable and allowance for doubtful accounts</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Accounts receivable and allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#8217;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group applies ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2021 or 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2021 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, equipment and software</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property, equipment and software</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">4 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;"> - </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#8217; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No impairment loss was recorded for the&#160;years ended December&#160;31, 2020, 2021 and 2022. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Segment reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 280, </span><i style="font-weight:normal;">Segment Reporting</i><span style="font-style:normal;font-weight:normal;">, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief Executive Officer. The Group&#8217;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#8217;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> Upfront non-refundable payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. For licenses determined not to be distinct, the Group accounts for the promise to grant a license and those other promised goods or services together as a single performance obligation when recognizing revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i><span style="white-space:pre-wrap;">:  The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contract assets and contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;) and contract manufacturing organizations (&#8220;CMO&#8221;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2021 and 2022, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#8217;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2021 or 2022 as the Group did not have any plan to cancel the existing CRO or CMO contracts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_GovernmentSubsidiesPolicyTextBlock', window );">Government subsidies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Government subsidies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#8217;s PRC based subsidiary received government subsidies from certain local government. The Group&#8217;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. In addition, the Group&#8217;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies of US</span><span style="font-style:normal;font-weight:normal;">$0.8</span><span style="font-style:normal;font-weight:normal;"> million, US</span><span style="font-style:normal;font-weight:normal;">$1.4</span><span style="font-style:normal;font-weight:normal;"> million and US</span><span style="font-style:normal;font-weight:normal;">$2.1</span><span style="font-style:normal;font-weight:normal;"> million were received and recognized as other income during the years ended December 31, 2020, 2021 and 2022, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the adoption of ASC 842, <i style="font-style:italic;">Leases</i> ("ASC 842") on January 1, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases, mainly leases of office spaces where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon and hereafter the adoption of ASC 842 on January 1, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determines if an arrangement is or contains a lease at inception. For arrangements that meet the definition of a lease, the Group determines the classification of the lease based on the relevant factors present and records a right-of-use ("ROU") asset and lease liability at the lease commencement date. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. As the rate implicit in the Group&#8217;s leases is not typically readily available, the Group uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Group could borrow the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Group will exercise that option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating leases are included in operating lease right-of-use assets and lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) elect for each lease not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component; (ii) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii) the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January 1, 2022 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the adoption of ASC 842 on January 1, 2022, the Group recorded an impact of approximately US$0.6 million and US$0.6 million for the recognition of operating lease right-of-use-assets and operating lease liabilities, respectively, on its consolidated balance sheet, which are primarily related to the lease of the Group&#8217;s offices. The adoption of ASC 842 did not have a material impact on the Group&#8217;s consolidated statements of comprehensive loss and cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income (loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC&#160;740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Borrowings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation-Stock Compensation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; (b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or (c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 260, </span><i style="font-weight:normal;">Earnings Per Share</i><span style="font-style:normal;font-weight:normal;">, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_EmployeeDefinedContributionPlanPolicyTextBlock', window );">Employee defined contribution plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employee defined contribution plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#8217; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#8217;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$622,377 , US$2,223,493 and US$2,984,251 for the&#160;years ended December&#160;31, 2020 , 2021 and 2022, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of risks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2022, the amount of cash and cash equivalents of US$3,650,474 and US$8,617,157 respectively, were held at major financial institutions located in Mainland China, and US$170,740,769 and US$135,141,521,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s research and development services were purchased from one supplier group, who collectively accounted for 21.5%,18.5% and 34.1%of the Group&#8217;s total research and development services purchases for the&#160;years ended December&#160;31, 2020, 2021 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#8217;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#8217;s ability to attract employees necessary to support its growth. The Group&#8217;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#8217; invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 2.29% in the year ended December 31,2021 and appreciation of approximately 9.24% in the&#160;year ended December&#160;31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#8217;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is an emerging growth company (&#8220;EGC&#8221;) as defined by the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU No. 2016-02 (&#8220;ASU 2016-02&#8221;), <i style="font-style:italic;">Leases</i> (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-10 (&#8220;ASU 2018-10&#8221;), <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#8220;ASU 2018-11&#8221;), <i style="font-style:italic;">Leases (Topic 842): Targeted Improvements</i>, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current U.S. GAAP (Topic 840, <i style="font-style:italic;">Leases</i>). Further, the FASB issued ASU No. 2020-05 (&#8220;ASU 2020-05&#8221;), <i style="font-style:italic;">Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities,</i> which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted.<span style="font-size:11pt;"> </span>The Group adopted the new guidance on January 1, 2022, using the alternative transition approach. For additional information, see Note 14, <i style="font-style:italic;">Leases</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and does not expect the adoption of ASU 2016-13 to have a material impact on the financial statements including the notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. This update simplifies the accounting for income taxes as part of the FASB&#8217;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, <i style="font-style:italic;">Income Taxes</i>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2021. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted ASU 2019-12 in 2022 and the adoption of ASU 2019-12 did not have a material impact on the financial statements including the notes to the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, the FASB issued ASU 2020-06, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</i>, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Group is currently evaluating the impact of this accounting standard update on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In March 2022, the FASB issued ASU 2022-02, <i style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings (&#8220;TDR&#8221;) and Vintage Disclosures</i> (&#8220;ASU 2022-02&#8221;). ASU 2022-02 eliminates the TDR recognition and measurement guidance, enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. For entities that have not yet adopted ASU 2016-13, the ASU is effective upon adoption of the amendments in ASU 2016-13. Early adoption is not permitted before an entity's adoption of ASU 2016-13. The Group has not adopted ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable and allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_EmployeeDefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Employee defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_EmployeeDefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_GovernmentSubsidiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government subsidies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_GovernmentSubsidiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301428592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_SummaryOfPrincipalSubsidiariesTableTextBlock', window );">Summary of principal subsidiaries</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;legal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Place&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">by&#160;the&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal&#160;activities</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 12, 2011</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Hong Kong</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment holding</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Incorporated</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September 20, 2017</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The United States of America</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 28, 2012</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;)</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Australia PTY Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 30, 2018</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Australia</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2020</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene AG</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 31, 2020</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Switzerland</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Adagene Project C1 PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 25, 2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_SummaryOfPrincipalSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of principal subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_SummaryOfPrincipalSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300226896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Summary of estimated useful lives of property, equipment and software</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">4 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;"> - </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of estimated useful lives of property and equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388405156368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>ACCOUNTS RECEIVABLE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of accounts receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388405142304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of prepayments and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,161,910</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deposits (a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,873,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,970,421</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 619,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 804,992</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,055,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,937,323</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="font-weight:normal;">Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301310880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property, equipment and software</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,293,386</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,152,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,055,271</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863,963</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,684</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80,266</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 371,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 369,698</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,809,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,692,268</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,322,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,909,305)</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,487,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,782,963</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388306837008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Summary of accrued liabilities and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 935,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,647,490</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Payroll and related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,229,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,104,365</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Utility and maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,718</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other taxes and surcharge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,270</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 349,039</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,197</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,379,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,212,809</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure on accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388387140608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>BORROWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of borrowings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Short-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,121,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,768,745</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,376,319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,850,128</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,618,873</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Long-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,146,541</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total non-current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,146,541</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,489,374</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 27,765,414</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock', window );">Schedule of future maturities of short-term borrowings and long-term borrowings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2021 and 2022 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,858,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,618,873</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133,210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,124,429</p></td></tr><tr><td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,022,112</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,489,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,765,414</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for short-term debt and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388306842832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Company's Preferred Shares activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,727,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,201,294</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,975,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,449,407</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Preferred Shares to Ordinary Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,473,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,999,995)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,004,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,999,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (154,477,960)</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305986256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 866,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,328,171</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,313,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,694,934)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,294,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,410,968</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (233,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,809,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,619,574</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,640,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (197,975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (964,789)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,286,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,286,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,990</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,486,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 874,180</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,070,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.62</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,880</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used to estimate the fair value of the share options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.68% - 0.83%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.11% - 1.67%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.92% - 4.25%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.3% - 73.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">73.1% - 75.5%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">74.2% - 74.9%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of total share based compensation expenses recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,472,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,582,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,227,298</p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,657,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,096,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,292,984</p></td></tr><tr><td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total share&#8209;based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,129,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,679,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,520,282</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300097200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAX EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,290,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 672,064</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (168,846)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,657,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,218</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">U.S.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (96,804)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,641)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,641</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,163)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459,055</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation between the income tax expense and the actual provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71,476,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,512,792)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">PRC statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax credit computed at PRC statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,599,320)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (17,869,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,878,198)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Impact of PRC preferential income tax rate as qualified TASE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,239,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,147,633</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,951,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Difference in income tax rates of overseas entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,286,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,549,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,560,029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development super-deduction<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (718,979)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (569,016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,724,740)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (569,575)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign derived intangible income deduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (487,183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,517,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">State tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (127,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#8217;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2020, 2021, and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of tax effects of temporary differences that give rise to the deferred tax balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,949,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,217,976</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Tax credit carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 391,843</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 756,197</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94,954</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Unrealized foreign exchange gain/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 116,238</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,702</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Amortization of right-of-use assets and interest of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 546</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,083,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,607,456</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,007,139)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,524,497)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82,959</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,959)</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82,959)</p></td></tr><tr><td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred tax liabilities, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,163)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of movement of the valuation allowance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,007,139</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,517,358</p></td></tr><tr><td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,007,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,524,497</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295577168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,177,935)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,971,847)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (248,113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,553)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,645,392)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,206,488)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (79,971,847)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted&#8209;average number of ordinary shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,950,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,032,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,135,084</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net Loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.48)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities that are not included in the calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Convertible redeemable preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,249,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Share options and share grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,795,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,739,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 530,298</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301364304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Related Parties</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Relationship</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chairman, Chief Executive Officer and a principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Four senior management personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Management and ordinary shareholders of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Co., Ltd. (&#8220;WuXi AppTec Group&#8221;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">A principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Controlled by the ultimate controlling party of a principal shareholder of the Company</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party balances as of December 31, 2021 and 2022:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,080,116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 503,941</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,426,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115,491</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due from related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 619,432</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2022, the amounts due from related parties represented prepayments made for the CRO and CMO services.<br/><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,292,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,840,876</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,482,461</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,466,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,323,337</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021 and 2022, the amounts due to related parties represented payables for the CRO and CMO services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party transactions during the years ended December 31, 2020, 2021 and 2022:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Receipt of CRO and CMO services:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,217,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,561,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,764,750</p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,674,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 517,742</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,362,713</p></td></tr><tr><td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,892,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,079,018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,127,463</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300186160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_InformationRelatedToOperatingLeasesTableTextBlock', window );">Summary of information related to operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 191,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 151,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 1.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_InformationRelatedToOperatingLeaseActivityTableTextBlock', window );">Summary of information related to operating lease activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease rental expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 283,276</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Expense for short-term leases within 12 months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,729</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Interest of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,259</p></td></tr><tr><td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 338,264</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">For the years ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412,754</p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255,309</p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,367</p></td></tr><tr><td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 738,430</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157,603</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 54,823</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 212,426</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,609)</p></td></tr><tr><td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 205,817</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_InformationRelatedToOperatingLeaseActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to operating lease activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_InformationRelatedToOperatingLeaseActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_InformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_InformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295791296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,411,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">8,457,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds | $</a></td>
<td class="nump">$ 145,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares represented by each ADS</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option | American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">1,103,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneHongKongLimitedMember', window );">Adagene (Hong Kong) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneIncorporatedMember', window );">Adagene Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneSuzhouLimitedMember', window );">Adagene (Suzhou) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneAustraliaPtyLtd.Member', window );">Adagene Australia PTY Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdagenePte.Ltd.Member', window );">Adagene PTE. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneAgMember', window );">Adagene AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneProjectC1Pte.Ltd.Member', window );">Adagene Project C1 PTE. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneSuzhouLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneSuzhouLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneAustraliaPtyLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneAustraliaPtyLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdagenePte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdagenePte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneProjectC1Pte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneProjectC1Pte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301931072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details) - Nonrecurring basis - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_FinancialAssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300156464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and tools | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and tools | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember', window );">Electronic equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300170272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of long lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAbstract', window );"><strong>Employee defined contribution plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefit expenses</a></td>
<td class="nump">$ 2,984,251<span></span>
</td>
<td class="nump">$ 2,223,493<span></span>
</td>
<td class="nump">$ 622,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388298908032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 191,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">205,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Concentration of credit risk | Cash and cash equivalents and short-term investments | Mainland of China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents</a></td>
<td class="nump">8,617,157<span></span>
</td>
<td class="nump">$ 3,650,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Concentration of credit risk | Cash and cash equivalents and short-term investments | Outside the mainland of China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 135,141,521<span></span>
</td>
<td class="nump">$ 170,740,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Concentration of suppliers | Research and development services purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_NumberOfMajorSupplier', window );">Number of major supplier | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Concentration of suppliers | Research and development services purchased | One supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of risks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">34.10%<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
<td class="nump">21.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NumberOfMajorSupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NumberOfMajorSupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adag_CashAndCashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=adag_CashAndCashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=adag_MainlandOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=adag_MainlandOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=adag_OutsideMainlandOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=adag_OutsideMainlandOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ConcentrationRiskSuppliersAxis=adag_OneSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ConcentrationRiskSuppliersAxis=adag_OneSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300097200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PercentageOfDepreciationOfForeignCurrency', window );">Depreciation of foreign currency (as a percent)</a></td>
<td class="nump">9.24%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_GovernmentSubsidiesReceived', window );">Government subsidies received</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_GovernmentSubsidiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidies received by the entity for Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_GovernmentSubsidiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PercentageOfDepreciationOfForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of depreciation of foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PercentageOfDepreciationOfForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305917248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, NET (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>ACCOUNTS RECEIVABLE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388298851552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">$ 1,161,910<span></span>
</td>
<td class="nump">$ 1,562,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">2,970,421<span></span>
</td>
<td class="nump">1,873,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Others</a></td>
<td class="nump">804,992<span></span>
</td>
<td class="nump">619,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepayments and other current assets</a></td>
<td class="nump">$ 4,937,323<span></span>
</td>
<td class="nump">$ 4,055,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300507088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">$ 8,692,268<span></span>
</td>
<td class="nump">$ 8,809,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,909,305)<span></span>
</td>
<td class="num">(5,322,264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">2,782,963<span></span>
</td>
<td class="nump">3,487,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,145,995<span></span>
</td>
<td class="nump">1,125,032<span></span>
</td>
<td class="nump">$ 858,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">5,293,386<span></span>
</td>
<td class="nump">5,252,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">1,055,271<span></span>
</td>
<td class="nump">1,152,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember', window );">Electronic equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">1,863,963<span></span>
</td>
<td class="nump">1,863,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and tools</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">29,684<span></span>
</td>
<td class="nump">81,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">80,266<span></span>
</td>
<td class="nump">87,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">$ 369,698<span></span>
</td>
<td class="nump">$ 371,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295490192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional service fees</a></td>
<td class="nump">$ 1,647,490<span></span>
</td>
<td class="nump">$ 935,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related liabilities</a></td>
<td class="nump">1,104,365<span></span>
</td>
<td class="nump">3,229,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedUtilitiesCurrent', window );">Utility and maintenance</a></td>
<td class="nump">40,718<span></span>
</td>
<td class="nump">8,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Other taxes and surcharge</a></td>
<td class="nump">349,039<span></span>
</td>
<td class="nump">62,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">71,197<span></span>
</td>
<td class="nump">143,060<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="nump">$ 3,212,809<span></span>
</td>
<td class="nump">$ 4,379,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedUtilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedUtilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388300144096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BORROWINGS - Components (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank loans</a></td>
<td class="nump">$ 10,768,745<span></span>
</td>
<td class="nump">$ 3,121,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long term borrowings</a></td>
<td class="nump">2,850,128<span></span>
</td>
<td class="nump">1,376,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total current borrowings</a></td>
<td class="nump">13,618,873<span></span>
</td>
<td class="nump">4,497,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Bank loans</a></td>
<td class="nump">14,146,541<span></span>
</td>
<td class="nump">2,991,829<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total non current borrowings</a></td>
<td class="nump">14,146,541<span></span>
</td>
<td class="nump">2,991,829<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total borrowings</a></td>
<td class="nump">$ 27,765,414<span></span>
</td>
<td class="nump">$ 7,489,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295354944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS - Short term borrowings (Details)<br></strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfJiangsuCo.LtdMember', window );">Borrowings from Bank of Jiangsu Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,871,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfNingboCo.LtdMember', window );">Borrowings from Bank of Ningbo Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember', window );">Borrowings from Agricultural Bank of China Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="nump">&#165; 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,568,455<span></span>
</td>
<td class="nump">$ 1,552,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,532,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdMember', window );">China Merchants Bank Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 20,100,000<span></span>
</td>
<td class="nump">&#165; 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,886,024<span></span>
</td>
<td class="nump">$ 1,421,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdLoanTwoMember', window );">China Merchants Bank Co., Ltd., two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_ChinaConstructionBankCorporationMember', window );">China Construction Bank Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="nump">&#165; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,589,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfJiangsuCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfJiangsuCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfNingboCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfNingboCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdLoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdLoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_ChinaConstructionBankCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_ChinaConstructionBankCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388290291632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS - Long term borrowings (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="8">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,353,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,089,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,063,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,850,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,076,874<span></span>
</td>
<td class="nump">&#165; 7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.46%<span></span>
</td>
<td class="nump">5.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,958<span></span>
</td>
<td class="nump">&#165; 2,500,000<span></span>
</td>
<td class="nump">484,594<span></span>
</td>
<td class="nump">&#165; 3,375,000<span></span>
</td>
<td class="nump">$ 179,479<span></span>
</td>
<td class="nump">&#165; 1,250,000<span></span>
</td>
<td class="nump">$ 53,844<span></span>
</td>
<td class="nump">&#165; 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861,500<span></span>
</td>
<td class="nump">&#165; 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.23%<span></span>
</td>
<td class="nump">5.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="nump">$ 143,583<span></span>
</td>
<td class="nump">&#165; 1,000,000<span></span>
</td>
<td class="nump">287,167<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">387,675<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,075<span></span>
</td>
<td class="nump">&#165; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,369,124<span></span>
</td>
<td class="nump">&#165; 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,796<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="nump">236,912<span></span>
</td>
<td class="nump">&#165; 1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,579,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,220,458<span></span>
</td>
<td class="nump">&#165; 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,871,665<span></span>
</td>
<td class="nump">&#165; 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,792<span></span>
</td>
<td class="nump">&#165; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,871,665<span></span>
</td>
<td class="nump">&#165; 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,435,833<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember', window );">Borrowings from Agricultural Bank of China Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421,474<span></span>
</td>
<td class="nump">&#165; 9,900,000<span></span>
</td>
<td class="nump">$ 1,421,474<span></span>
</td>
<td class="nump">&#165; 9,900,000<span></span>
</td>
<td class="nump">$ 4,307,498<span></span>
</td>
<td class="nump">&#165; 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,750<span></span>
</td>
<td class="nump">&#165; 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388298973648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>BORROWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,497,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">$ 13,618,873<span></span>
</td>
<td class="nump">1,858,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">4,124,429<span></span>
</td>
<td class="nump">1,133,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">10,022,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total borrowings</a></td>
<td class="nump">$ 27,765,414<span></span>
</td>
<td class="nump">$ 7,489,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295113776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MaximumProceedsReceivableFromExerciseOfWarrants', window );">Total maximum consideration from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares on conversion of each convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adag_SeriesC1WarrantsMember', window );">Series C 1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Consideration from issuance of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of Series Pre-A Convertible Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember', window );">Series A-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,494,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,999,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember', window );">Series C-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,597,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_NumberOfInvestorsToWhomWarrantsWereIssued', window );">Number of Series C-1 investors to whom warrants were issued | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember', window );">Series C-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember', window );">Series C-3 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued</a></td>
<td class="nump">4,452,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares | $</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Series Pre-A Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount of Series Pre A Convertible Notes issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Series Pre A Convertible Notes, Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MaximumProceedsReceivableFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of proceeds receivable from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MaximumProceedsReceivableFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NumberOfInvestorsToWhomWarrantsWereIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investors to whom warrants were issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NumberOfInvestorsToWhomWarrantsWereIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of new stock classified as temporary equity issued during the period, upon conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adag_SeriesC1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adag_SeriesC1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295315728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 154,449,407<span></span>
</td>
<td class="nump">$ 154,201,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(154,477,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,449,407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">5,473,957<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(5,473,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember', window );">Series A-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">27,999,995<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(27,999,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember', window );">Series C-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">48,975,456<span></span>
</td>
<td class="nump">48,727,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of Preferred Shares to redemption value</a></td>
<td class="nump">28,553<span></span>
</td>
<td class="nump">248,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(49,004,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,975,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember', window );">Series C-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">18,999,999<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(18,999,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember', window );">Series C-3 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">$ (50,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388287833824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 08, 2022</div></th>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Jan. 16, 2021</div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Aug. 15, 2020</div></th>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Dec. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 07, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640,598<span></span>
</td>
<td class="nump">1,894,119<span></span>
</td>
<td class="nump">6,313,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation cost to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,975<span></span>
</td>
<td class="nump">233,958<span></span>
</td>
<td class="nump">3,694,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,212<span></span>
</td>
<td class="nump">$ 226,781<span></span>
</td>
<td class="nump">$ 140,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_NumberOfSharesSurrendered', window );">Number of shares surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value (in USD per option)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=adag_ServiceConditionsAndPerformanceConditionsMember', window );">Service conditions and Performance conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,776,906<span></span>
</td>
<td class="nump">2,483,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employees | Modification of vesting schedules and conditions of share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,060,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue', window );">Incremental fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,337,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived', window );">Number of options, vesting schedules and conditions waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,197,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management personnel | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management personnel | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_Plan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares that may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,336,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_Plan2017Member', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares that may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,336,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_Plan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares that may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,391,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent', window );">Incremental percent of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">2021 Plan | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303,000<span></span>
</td>
<td class="nump">2,640,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">2021 Plan | Employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">2021 Plan | Employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.56<span></span>
</td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">2021 Plan | Management personnel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="nump">99,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NumberOfSharesSurrendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares surrendered by the shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NumberOfSharesSurrendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options for which the vesting schedules and conditions are waived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of increase in shares reserve annually based on shares outstanding under share based compensation share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=adag_ServiceConditionsAndPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=adag_ServiceConditionsAndPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_Plan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_Plan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_Plan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_Plan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388289997952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share Option Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,809,078<span></span>
</td>
<td class="nump">3,294,467<span></span>
</td>
<td class="nump">866,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,640,598<span></span>
</td>
<td class="nump">1,894,119<span></span>
</td>
<td class="nump">6,313,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,975)<span></span>
</td>
<td class="num">(233,958)<span></span>
</td>
<td class="num">(3,694,934)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(964,789)<span></span>
</td>
<td class="num">(145,550)<span></span>
</td>
<td class="num">(190,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,286,912<span></span>
</td>
<td class="nump">4,809,078<span></span>
</td>
<td class="nump">3,294,467<span></span>
</td>
<td class="nump">866,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,286,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,070,533<span></span>
</td>
<td class="nump">1,486,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 13.85<span></span>
</td>
<td class="nump">3.28<span></span>
</td>
<td class="nump">12.31<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75<span></span>
</td>
<td class="nump">3.02<span></span>
</td>
<td class="nump">1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80<span></span>
</td>
<td class="nump">5.91<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.35<span></span>
</td>
<td class="nump">5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.38<span></span>
</td>
<td class="nump">6.65<span></span>
</td>
<td class="nump">3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">2.13<span></span>
</td>
<td class="nump">8.39<span></span>
</td>
<td class="nump">7.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95<span></span>
</td>
<td class="nump">5.13<span></span>
</td>
<td class="nump">6.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.57<span></span>
</td>
<td class="nump">7.71<span></span>
</td>
<td class="nump">6.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
<td class="nump">7.38<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue', window );">Vested and expected to vest at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Exercisable at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 8 days<span></span>
</td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
<td class="text">8 years 9 months 10 days<span></span>
</td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 13 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,619,574<span></span>
</td>
<td class="nump">$ 33,410,968<span></span>
</td>
<td class="nump">$ 6,328,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,990<span></span>
</td>
<td class="nump">2,619,574<span></span>
</td>
<td class="nump">$ 33,410,968<span></span>
</td>
<td class="nump">$ 6,328,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,880<span></span>
</td>
<td class="nump">$ 874,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average grant date fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average grant date fair value, at which grantee can acquire shares reserved for issuance. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295771776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate fair value of the equity awards vested</a></td>
<td class="nump">$ 11,929,903<span></span>
</td>
<td class="nump">$ 13,833,856<span></span>
</td>
<td class="nump">$ 8,430,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized employee share based compensation expense</a></td>
<td class="nump">$ 23,635,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305846016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate the fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.92%<span></span>
</td>
<td class="nump">1.11%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">0.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.20%<span></span>
</td>
<td class="nump">73.10%<span></span>
</td>
<td class="nump">72.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">74.90%<span></span>
</td>
<td class="nump">75.50%<span></span>
</td>
<td class="nump">73.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum', window );">Exercise multiple, minimum</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum', window );">Exercise multiple, maximum</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum exercise multiple assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum exercise multiple assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388302022768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share based compensation expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expenses</a></td>
<td class="nump">$ 10,520,282<span></span>
</td>
<td class="nump">$ 18,679,658<span></span>
</td>
<td class="nump">$ 10,129,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expenses</a></td>
<td class="nump">7,227,298<span></span>
</td>
<td class="nump">13,582,746<span></span>
</td>
<td class="nump">6,472,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expenses</a></td>
<td class="nump">$ 3,292,984<span></span>
</td>
<td class="nump">$ 5,096,912<span></span>
</td>
<td class="nump">$ 3,657,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388299976400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION ARRANGEMENTS (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,292,724<span></span>
</td>
<td class="nump">$ 10,175,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember', window );">Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,511,168<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties', window );">Agreed period for not to grant rights associated with antibodies to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember', window );">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,378<span></span>
</td>
<td class="nump">&#165; 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties', window );">Agreed period for not to grant rights associated with antibodies to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,240,022<span></span>
</td>
<td class="nump">&#165; 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementMilestonePaymentReceived', window );">Milestone fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,011<span></span>
</td>
<td class="nump">&#165; 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember', window );">ADCT Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies', window );">Maximum number of selected targets, agreed for generation of antibodies | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement', window );">Minimum threshold written notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PeriodForReservationOfTargetRight', window );">Period for reservation of target right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember', window );">Exelixis Inc Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable', window );">Payment of upfront-refundable fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones', window );">Milestone payments receivable based on development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MilestonePaymentsReceivableSalesBasedMilestones', window );">Milestone payments receivable based on sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_AdctMaterialTransferAndOptionAgreementMember', window );">ADCT Material Transfer and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable', window );">Payment of upfront-refundable fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_SanofiAgreementMember', window );">Sanofi Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,992,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones', window );">Milestone payments receivable based on development and regulatory milestones</a></td>
<td class="nump">173,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MilestonePaymentsReceivableSalesBasedMilestones', window );">Milestone payments receivable based on sales</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The agreed period for not to grant rights associated with antibodies to third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from milestone payments received in collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementUpfrontCashPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from upfront cash received in collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of selected targets, agreed for generation of antibodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable upon achieving certain development and regulatory approval milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MilestonePaymentsReceivableSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments conditioned upon achieving sales based milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MilestonePaymentsReceivableSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum threshold written notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PeriodForReservationOfTargetRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for reservation of target right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PeriodForReservationOfTargetRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_AdctMaterialTransferAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_AdctMaterialTransferAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_SanofiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_SanofiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388298779984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">108 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2008</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,742,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,055<span></span>
</td>
<td class="nump">$ 1,701,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,886,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC | TASE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PreferentialIncomeTaxRate', window );">Preferential tax rate (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate', window );">Effective period of TASE certificate (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC | TASE | Adagene (Suzhou) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_PreferentialIncomeTaxRate', window );">Preferential tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,445,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_WithholdingIncomeTaxes', window );">Withholding tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong | Adagene (Hong Kong) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AssessableProfits', window );">Assessable profits or earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,511,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia | Adagene Australia PTY Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_TaxableIncome', window );">Taxable Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,807,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">State income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">State income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,272,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">SWITZERLAND | Adagene AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_CapitalTaxRatePercentage', window );">Capital tax rate for Canton of Basel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">SINGAPORE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AssessableProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assessable profits or earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AssessableProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CapitalTaxRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CapitalTaxRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective period of Technology Advanced Service Enterprises certificate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PreferentialIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferential income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PreferentialIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of taxable income during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_WithholdingIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of withholding income taxes on remittance of dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_WithholdingIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_WithholdingTaxRateOnDividendsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of withholding tax rate on dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_WithholdingTaxRateOnDividendsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_StatusForTaxabilityAxis=adag_TechnologyAdvancedServiceEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_StatusForTaxabilityAxis=adag_TechnologyAdvancedServiceEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneSuzhouLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneSuzhouLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneAustraliaPtyLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneAustraliaPtyLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388290109824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Income tax expense (benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 672,064<span></span>
</td>
<td class="nump">$ 1,290,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(168,846)<span></span>
</td>
<td class="nump">367,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">503,218<span></span>
</td>
<td class="nump">1,657,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(96,804)<span></span>
</td>
<td class="nump">96,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">52,641<span></span>
</td>
<td class="num">(52,641)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(44,163)<span></span>
</td>
<td class="nump">44,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 459,055<span></span>
</td>
<td class="nump">$ 1,701,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388293513360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Income tax reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAX EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (79,512,792)<span></span>
</td>
<td class="num">$ (71,476,322)<span></span>
</td>
<td class="num">$ (42,397,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">PRC statutory income tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax credit computed at PRC statutory income tax rate</a></td>
<td class="num">$ (19,878,198)<span></span>
</td>
<td class="num">$ (17,869,081)<span></span>
</td>
<td class="num">$ (10,599,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Impact of PRC preferential income tax rate as qualified TASE</a></td>
<td class="nump">7,951,279<span></span>
</td>
<td class="nump">7,147,633<span></span>
</td>
<td class="nump">4,239,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount', window );">Difference in income tax rates of overseas entities</a></td>
<td class="nump">10,560,029<span></span>
</td>
<td class="nump">10,549,985<span></span>
</td>
<td class="nump">5,286,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount', window );">Research and development super-deduction</a></td>
<td class="num">(1,724,740)<span></span>
</td>
<td class="num">(569,016)<span></span>
</td>
<td class="num">(718,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(569,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible expenses</a></td>
<td class="nump">3,695<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount', window );">Foreign derived intangible income deduction</a></td>
<td class="num">(487,183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">4,517,358<span></span>
</td>
<td class="nump">2,277,418<span></span>
</td>
<td class="nump">$ 1,790,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">76,127<span></span>
</td>
<td class="nump">291,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Others</a></td>
<td class="num">(10,263)<span></span>
</td>
<td class="nump">127,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 459,055<span></span>
</td>
<td class="nump">$ 1,701,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295589936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 8,217,976<span></span>
</td>
<td class="nump">$ 4,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carry forward</a></td>
<td class="nump">391,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development expenses</a></td>
<td class="nump">756,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Capitalized inventory</a></td>
<td class="nump">94,954<span></span>
</td>
<td class="nump">95,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized foreign exchange gain/losses</a></td>
<td class="nump">116,238<span></span>
</td>
<td class="nump">39,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">29,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities', window );">Amortization of right-of-use assets and interest of lease liabilities</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization of property, equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">9,607,456<span></span>
</td>
<td class="nump">5,083,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(9,524,497)<span></span>
</td>
<td class="num">(5,007,139)<span></span>
</td>
<td class="num">$ (2,729,721)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">82,959<span></span>
</td>
<td class="nump">76,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization of property, equipment and software</a></td>
<td class="num">(82,959)<span></span>
</td>
<td class="num">(120,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">$ (82,959)<span></span>
</td>
<td class="num">(120,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388301486352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Valuation Allowance (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Movement of the valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance as of January 1</a></td>
<td class="nump">$ 5,007,139<span></span>
</td>
<td class="nump">$ 2,729,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Addition</a></td>
<td class="nump">4,517,358<span></span>
</td>
<td class="nump">2,277,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance as of December 31</a></td>
<td class="nump">$ 9,524,497<span></span>
</td>
<td class="nump">$ 5,007,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295895136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">$ (79,971,847)<span></span>
</td>
<td class="num">$ (73,177,935)<span></span>
</td>
<td class="num">$ (42,397,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,553)<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (79,971,847)<span></span>
</td>
<td class="num">$ (73,206,488)<span></span>
</td>
<td class="num">$ (42,645,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weightedaverage number of ordinary shares outstanding-basic</a></td>
<td class="nump">54,135,084<span></span>
</td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weightedaverage number of ordinary shares outstanding-diluted</a></td>
<td class="nump">54,135,084<span></span>
</td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share-basic</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share- diluted</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388298949792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,249,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share options and share grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the computation of diluted net loss per share</a></td>
<td class="nump">530,298<span></span>
</td>
<td class="nump">1,739,882<span></span>
</td>
<td class="nump">1,795,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388288899680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">$ 619,432<span></span>
</td>
<td class="nump">$ 4,506,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">19,323,337<span></span>
</td>
<td class="nump">10,466,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember', window );">Receipt of CRO and CMO services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions</a></td>
<td class="nump">35,127,463<span></span>
</td>
<td class="nump">13,079,018<span></span>
</td>
<td class="nump">$ 9,892,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember', window );">WuXi AppTec Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">503,941<span></span>
</td>
<td class="nump">3,080,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">1,482,461<span></span>
</td>
<td class="nump">173,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember', window );">WuXi AppTec Group | Receipt of CRO and CMO services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions</a></td>
<td class="nump">7,362,713<span></span>
</td>
<td class="nump">517,742<span></span>
</td>
<td class="nump">2,674,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsCaymanInc.Member', window );">WuXi Biologics (Cayman) Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">115,491<span></span>
</td>
<td class="nump">1,426,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">17,840,876<span></span>
</td>
<td class="nump">10,292,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsCaymanInc.Member', window );">WuXi Biologics (Cayman) Inc. | Receipt of CRO and CMO services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions</a></td>
<td class="nump">$ 27,764,750<span></span>
</td>
<td class="nump">$ 12,561,276<span></span>
</td>
<td class="nump">$ 7,217,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsCaymanInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsCaymanInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295831024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Information related to operating leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OperatingLeaseRightOfUseAssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 191,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">151,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 53,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 313,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 217,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_OperatingLeaseRightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_OperatingLeaseRightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305072736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Information related to operating lease activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OperatingLeaseRentalExpenseAbstract', window );"><strong>Operating lease rental expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 283,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Expense for short-term leases within 12 months</a></td>
<td class="nump">34,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_InterestOfOperatingLeaseLiabilities', window );">Interest of lease liabilities</a></td>
<td class="nump">20,259<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_OperatingLeaseRentalExpense', window );">Total operating lease rental expense</a></td>
<td class="nump">$ 338,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_InterestOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of interest of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_InterestOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_OperatingLeaseRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of operating lease rental expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_OperatingLeaseRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_OperatingLeaseRentalExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_OperatingLeaseRentalExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388295570016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>For the years ending:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 412,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">255,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">70,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 738,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388294712640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of lease liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 157,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">54,823<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">212,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(6,609)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 205,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305843152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED NET ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_RestrictedNetAssetsAbstract', window );"><strong>RESTRICTED NET ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve', window );">Minimum percentage of profit after tax to be transferred to statutory reserve</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital', window );">Statutory reserve required percentage on registered capital</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries', window );">Total restricted net assets</a></td>
<td class="nump">$ 1,860,667<span></span>
</td>
<td class="nump">$ 1,860,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_AfterTaxIncomePercentageAppropriations', window );">After tax income, annual appropriations, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries', window );">Restrictions on net assets of PRC subsidiaries , threshold percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AfterTaxIncomePercentageAppropriations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of after-tax income to be set aside as a general reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AfterTaxIncomePercentageAppropriations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of the profit after tax to be transferred to statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No Definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required percentage of statutory reserve on registered capital to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage on restricted net assets of PRC subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(3)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388290060576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2022</div></th>
<th class="th"><div>Jul. 07, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total consideration of share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,976,681<span></span>
</td>
<td class="nump">$ 2,361,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">94,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=adag_ShareRepurchaseProgramOf2021Member', window );">2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Term of share repurchase program (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=adag_ShareRepurchaseProgramOf2022Member', window );">2022 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program authorized amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Term of share repurchase program (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285,604<span></span>
</td>
<td class="nump">160,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">75,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares | 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,170,446<span></span>
</td>
<td class="nump">236,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total consideration of share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,904,399<span></span>
</td>
<td class="nump">$ 2,361,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares | 2022 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total consideration of share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607,005<span></span>
</td>
<td class="nump">201,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">94,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares | 2021 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,463,057<span></span>
</td>
<td class="nump">295,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares | 2022 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Treasury Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=adag_ShareRepurchaseProgramOf2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=adag_ShareRepurchaseProgramOf2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=adag_ShareRepurchaseProgramOf2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=adag_ShareRepurchaseProgramOf2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140388305156896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="1">4 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent events | 2021 Plan | Management personnel</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Total number of ordinary shares issued</a></td>
<td class="nump">582,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>adag-20221231x20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adag="http://www.adagene.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adag-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_PpX3jqVYjUKGSc4PUVCqbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_FfVHeu36qEOc41XZB5QsSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_H1fu9nxkjU2h3rSJ7njn8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_OffjEdDiwUq_QKSdjqfmkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_Z9mphkrR0kmVJfMEZDudGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_c6cCpTT3-UCFa3iydypLlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_GF6f3RbJt0mSKdc-gIpyMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yBEmNnp9JkKRwrCjjyfHqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_sQqB69UJ9UC_sksuTF-VLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_V8r0Nfbtg0etm8S7eTVjcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_8Qw98XWW1UumdeUdUM175Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_AEEEQVw_NU6BvaZkgLzS0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_k-Tj_Iz31EmvHKgzizS4_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_g02U-ugGTkWtKxibVH1wIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_-lU6hnUg1USHN9tNgX6z5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_LM0cYbNYBkuxPFEH3zcWdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_CtbvulJUiUmHT0BVyHHTeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_WRYTAw9fyUK5wNbAtUEgzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_L7regPgk0U6wE3_qz1Zy6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_WRGc8jvai0S64dQK-czIGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_o9la4OH3f0S73pFAL_jdvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_LetG2TvOqky7qj1cVnqr1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_m7mB-vO98k6ssn4DOuHCmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_VrdzSlGiIU21zpTy5Vhp1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_29_2022_To_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_ALi5xN2v_Ui4UIlZQtgALA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="Duration_7_7_2021_To_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_skBGvFvBgEm6UOz4-CGzgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-07-07</endDate>
        </period>
    </context>
    <context id="As_Of_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_EzSDNbQB5EWZPn-NGBx2SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="As_Of_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_kmEX4yG-ZEuDCtdXxBARXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">adag:ShareRepurchaseProgramOf2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_B7KydVxEvkqzOuPCW8zKlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_kqrGAtT1eEGm0zzWRDQUBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Fsp_-okReEKrd3koR5i-HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pizwZd0AoUe6Rr73Pf4YZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_2hVJvj7Zgk2flnbUuLCHEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_5kY-i-Zg3k-S2BENf9UwDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TTeXW30sp0OT1Sxf3PgmKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_x6getxpL9EmAJ2xaJGImaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_VElBgd6POkGwMjlKJdoNAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DcS5Ka-g5Uuv_EvSXAJk_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E1yBXnv1JEqkFifQJ0DCkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r4Z52hagwUK01HtKpXLekA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_ancTWgsA3EaZqftsGC9BMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Za0p7Lfn0SI4LJAXHWLYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8CaGtWv9QUicSDrtUt3MzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Q0akVaGa0UGbNziyt_b1ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KG8su_uOu0a0KunRTlLxoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_OPji8N90TES4hj8qFG2_Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pNeBwXPMFUiQuaK_5XpBZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UKTQnfrtqE-IQhyGVhZXZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J78E05vN20erGsltKQSaYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ZAIqUZ6DnEaGRXvod8zuFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-fGWKFY2rEOZsvz04ykZLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pIuFXCNeoUy7CaDSOhk2xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_MvdjFPDEXkW0jwwbZh-cTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_QTNt0bXsx0a3cvqcs-sJBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_zXGYISRRU0mn6bkSMKyVSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_vrEMPt5leE2LUHWCygtNag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_vua2vlRLFESfuxZbRFuRuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WBu5OJOR70SEMOJWhuD6rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_25mz8MzMZU6-TK20uJ2UWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YPqb6m0diEulW2HtfQSfmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_PEIXHzXukUSrP_zBNlrOtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-12-27</endDate>
        </period>
    </context>
    <context id="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Cc4l6GLQ9UWIXpyBn68CYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-12-27</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_mYqtV1u_dUOeGU09TxPkwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qodzJmIask-OtNzB-p7X4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__xADkSqTO0S-DY3ZQNH76A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_DQ9yn7uS2EGDv6fQLKvPeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_4_30_2023_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jbskMAiPskm8ahOT8fG0aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_EMWaJe9pw0yONDIyRxQ1EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_QB4Okja9ZEGLGUBdgEeHpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_o7k1J95q30-im7Wsqr0zgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-08</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="Duration_2_7_2022_To_12_27_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_lXgW5nkfeUOQyYVN7MFj6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-12-27</endDate>
        </period>
    </context>
    <context id="Duration_1_7_2022_To_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember__79tbn2a-EGdvybT6uk1ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_cp16D7zq-k6IluFfoJ6iCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_1eP-WkT9Skmw68n0YD2iXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_fLrvwshp_kef4yuIOIUV5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_sTKKUtyqS0eFI2J-zEunNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_HX6qRchl3UOJYp2kC_kivw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_JHoh1u6SlUWt5wpfBqAllA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_Q157HUAGCUiQ3O7w3B8ZAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_EJ0fi0sr6k2AD6FT92wY0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ymf1E7tmdEWfCfZo72BFWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-15</startDate>
            <endDate>2020-08-15</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wZ9cdC31zEC6F4Aji6T7Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_VsC-jPAYAUqbiloJ81rslQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctMaterialTransferAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_3qRSyDBk-U6_JWTPepBfbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_ydcSvQ_MrUWX4ODW9D_Low">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TIiFTeaXkUeerjdaxd6jwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_0q1bEcQFREGMTjD4ZvPvnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ZBzOSEd9-keWfT5F8GU35g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_hlw_TK4DbU6yZTcHfKFcyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_yuDqrjY2ZES39bMfzJzDpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_hHC55XuXUE2hmp5hAZXI4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_3nKdmvhHQ0e0MXKzpN6qwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vDDRVJHJWEiIRkoC0j_pHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_1rOMO6-cAU-GIBzCBWWxnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_jTkNK83fPE6etG2zBbgm_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_53NbnrlZsUSgSYUOMp8aRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_mtdgNiOXz0Od9s3DiXLFWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_XfcO1vA5gES98UF8hk_gOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Xo3frStwAkqUZlLqb4wjJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_r4lFa-Ww0kCU3jAskRrUVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_fmpyuXJQ_EqCRbO-JtqTjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_lU_OCdJ2sUCF8wkKIvaYFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_jQzQ-Qs4jUWen2BvHNx06Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_f5vXDOcWdkSV-l04XmsJrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Itm1UFewfkK9c21wwIKhCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_MJlpRPr5HkyPVxy3B1RlaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_pvNixmkY0UODGpGvN2b_aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_U14hTTfIw0aauKmk513MSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_V0FQCFIXf0qnsEhwdlQOIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xRsWSZSyjEauMH-_N844Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2h413p21UkmzRBTslwlxxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KrbO3xolp0mWoDpH-tUPDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_-m_klozaH0y8y3effakxHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_E2F3cjJxskiJsRXhTacDag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_Ed31KlzZbUezDqBMeti4vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_HEZrgDuwzU2I-5vwCDZhrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DNi18GaWDEuLxJST1LKg5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_rn5z_oGtm0i4zKXJtLEPBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_sW55u4h2J0OcuFvypf5muw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_ITtG4X4HskK8vTiFNbmV8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MipZoRX4l0apHBHgnqY4mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_-deeomKWdka8knVPbfU3GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-htfaRs6hE-PttrYcJWsUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_O5OcHRqnw0Wo-gX84ILHew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EML4beDnNUeNnibb9wySxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WtkVxDqueEGxL4XHYvRZcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_8PMoYsniJEKQ59jVt_gtxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_BH3baoGYjECWp2ep1hunvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iYVX4_oPbUSXBpxQ0gDPag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZgaIiUt-UEqjj7jLhIpMZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GClxeG8xvEeEJiRr287NPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_US_9sDKIIcAC0O2whabXRhATQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_SG_aoUeaWEODUuRBoaCnL4L8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_HK_Otsf7MqCgkyOm-luahjSsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CN_pERkzB2zbEuJoXns9cPQzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CH_u8WhTZKTgk6uGwI8YPJBBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AU_iIjaBK7jEEatSAUYG4p5Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TiCAjHF8_U-6H2PHnG8Zpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJZYhVw9NU-SOXmev5aACA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IvlyyVsaP0qH00DZs-cOzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_pEeZWdw_fkSZYD0_eWIssg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_G1AQfi6p4E24BfwphzFniA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdagenePte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneProjectC1Pte.Ltd.Member_umWeTmICo062uH3oJz8eNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneProjectC1Pte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneIncorporatedMember_BR7xdhRIAki49kFwg0OQzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_LuGkr2nW5UuEFN70Vzi-Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_HRsrjutOV0G30qtLf1pIow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAgMember_Pnv6Ik0j60COLF1wUWv5dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_Kyvt-xNRBUiAu-DLngZgGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_tHkOGLmG7kWYIeDJOJTVtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_qYhrznmDM0a0FqD3lA6Fbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_ymVbWklhkUCmOkHyKVKxVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_zUL5X-s5MEOb_qYJhHPkHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_v_9yYOSrf0y4xth99sJ-dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_BtH_9qawAU6ZHHYCSElW5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vOz3vIv740GU9REG4Z_wcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_CaP4Z8PlL0OapP5FtNaLKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_7v2coKKIyUmDdlmU0Olo6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_stpr_CA_J0BfSQ8UxU6Mwv9l4cdG6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_FibIWHTvR0OvdHAkZv3YsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_X7h_82d2c0KzwUudQtykwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_9BXgsqEAak6neZEeIkuLdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2008-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_0M5cOB2hoEaTbUgHkdCREw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_IGFUJEto00G2d7K3PSE_Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_t_0MJ4wuNkyxIV4bgXJFmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsCaymanInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_R1F5ndSVPkCgXKmwyzbScg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_7-okYR-WZkiKB1VW-JL4qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaConstructionBankCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_Cvjhq1dzz0iJpxmkLeqhQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfJiangsuCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_1aTpF0ph_0-mY4m38ylZKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_qhmYvReawUyRvQAZITHLMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_M1R5q493x0epZjiLXZubXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_m85-xLE3m0awlOkyhyozPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_mUP8HKs3QE-VA88oUIhohw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_UzX_9ytflk6kC_qnriMQxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_o0zaN5JGjUuNPtedN9XKFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_GObFgSRwTUiB_WsA8h6l6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaConstructionBankCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfJiangsuCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_1YpVsNTuokSIfl2TMrVz6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-30</instant>
        </period>
    </context>
    <context id="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SbWl9Shq4E6nlxFVgDBgpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_AXlFqdkG3UW_uqmcSDFkCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_qXLooUnAXE2ppSJQSdpERw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XFO8ZN7Etk2rs2waJjZ9vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_hl4SM9JGdEip0cnxdAqRJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-16</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_Kp5I1u1AQkCMEJ0paDZCvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_ZkAGkZRbN0SrE5hh7uf0cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_Ony51QAJ_02DctV0aevFAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember__YdfUW6IYUmfXgc9SfOrnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_8B7AeaXkck6JwjDBIkApxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_IfdRhB-Ii0Onl99aJ0jfJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xEF_4pgz1k6DXF8uNNBIvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_x3zBUisNukS5eVvI4gf_kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_n1ed7fGyz0KAIk8k73AxhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KuH9w-ji8E6oP8LOHD8eoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DQhBNix_zU24lt2mhsh67Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XApzz6RZb0COodakWjZlyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kkEXFXNRGUij0o1EOEbICA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ER1dY2hYkkebuGSCOwJV8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9u6PsJmRs0uWqcLpDwttXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_CH2MGlfLkEa-Mm5SY3caCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_E-IfTqEmFkC8P1gI378n2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CN_4etyAVb-kUilTpUBQYyO4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CH_otva1hRmgEGFbXAakLJRqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AU_c4N8MZWDzESe5gDU2Tk-5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_ee_5WiU0cUurw-SNNKSXuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_gn5TOqPkiEmr84V7LuQlbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Y81m7zrxYE2aoB4C9ZGt2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_eIoK0LUqmECLHEJOC58yjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_wh21KqXIxUieE_LnSC8fWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_wIkgvAtqC0W5o3H3Cfgn_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_YUb_RBfSLEO6_Ii2KjdzgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_xlZey60WBUuy5XYgHHijLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_wbQEbLCaH0CT2Hi48HK61Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_aTNTT8uQeEK_xzzYuJc0jQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_p76MqEtu0ESUlhT30hlMQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-16</startDate>
            <endDate>2021-01-16</endDate>
        </period>
    </context>
    <context id="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="As_Of_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_FuMVl1AODUSWgqaccUaZLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_avqczjeiakGTBo6mGn9tGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2021-01-16</startDate>
            <endDate>2021-01-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_mXd1utWD0Uy80tRoBoh-xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_MoK8o28CCE-5S19pyoHFfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LdAvTZA4DkCZZqMFxvFSkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZBLOK46STEKlz-d2OVI5uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_aR_5qQM_PUCejdDJoX8SrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SanofiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_lP6oVbKR6UmaFzbif9o9lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AVPy-5gte0WCo8vAl_mD9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Hp2hcBhCBUKfwPXhVKSC_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_b2-6zipvrUqdvncotPk1BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2008-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_VXRQnsAoMkSLLvY_DjFWlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_MSt1DxwXfUKQtc262Vnbaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SanofiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_zebDcdEQ3kW1LZbwJkj0Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SanofiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_jfKRlHoZrkOzsx-d3nM1UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_rvKTnfEkyUSop_lAg3fNuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_WFeE0wneck-MydNDO4uWyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctMaterialTransferAndOptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ay_6hRJo4U6yLXVvpTOGEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_3KyS7h9LmU6xtV1jimeGaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_DZY2VoRVfUyY29viuxBhrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_a1oYWpJoW026Q5lt5DP2dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_Y1LEBiLCsUiXix5-VE8rGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA">
        <measure>adag:item</measure>
    </unit>
    <unit id="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      id="Hidden_gDsuqX0SREaLUckfrpidUA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      id="Hidden_Vh7sy4pjdUyIhle5YQXnBQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Hidden_1ECxitTWhE-HpyA0a6D4Gg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">15950698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Hidden_TGXO-tvayEmVbbOXVwm15w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">50032009</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Hidden_1xSUIEfuCE-FTf5Pm-Ozaw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54135084</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Hidden_51Bi1WeiWUGX73SptRbRfg"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-2.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Hidden_0kOo5P5xz0yt2vmjurC3Gw"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Hidden_EpgFPY8zJkq1AhHJZ6OD6Q"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Hidden_rP_ZtM9G8EmayLsfIZ8I3w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54595667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Hidden_sRbjWAccFkeLc4ATnl88EQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54065709</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_9K7cV1YfHU-8QZKA6FCK4w_3_1">0001818838</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_sOGEf9SyNkKgDCDpnoZlzA_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_LG0WloTBDE6809hH9klFmQ_5_1">2022</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_k9ajP9SXf0G3lgt5ZDmjZQ_6_1">false</dei:AmendmentFlag>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Tc_C2CSsuf1v06ggA8VQ0aqUA_7_1">10179 Huennekens Street Suite 103</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Tc_1WVtGXqTSU2vawPyz9oHnQ_8_1">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Hidden_rZAIXyRXfEaKYXOQHkHLpg">CA</dei:EntityAddressStateOrProvince>
    <dei:NoTradingSymbolFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw"
      id="Hidden_GqZ4e-5sDUeUrCQEYrvXig">true</dei:NoTradingSymbolFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Hidden_TMpIxqHNTkuI5ZxoBGbcRg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Hidden_YJ-Y0N5DlEGk0tP_BHb2Lg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_J0jbBEHJ6EqWaoZtt0U8Ng">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_Awpc6V3Knku2O0H6YRgV9w">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_JKtm9RujfEK3w4PZW1DRzA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_JgteUCE9xUm3SEXE5Q1gog">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_Bb8iFzyDA0CuPJoO2qtLLA">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_DG8SYxGyMU-6HKWDsaFuFg">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_mNXdCXjRckykO17xfjplRA">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_j0olXLsmLkC56Z6Z9Rav4w">001-39997</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_ezM64_6ZiUSSlFVjVprlzw">Adagene Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_gvZjuv4wW0ajIUsn4f-ZYg">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_pRWgxVsZwE-hFxSx0eQVqA">4F, Building C14, No. 218</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_p8IUyPZFVE-Vdp2C3AUbFA">Xinghu Street, Suzhou Industrial Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_OEvsn-H--kmO-svT02VGVw">Suzhou</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_JpNS1_lbiUmO-SOa3yQfNQ">215123</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_bGZwwp2KX0KPz5xOVUYZxA">CN</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Narr_2rDQJtB7jEy_2FQbaj3oEw">Peter Luo</dei:ContactPersonnelName>
    <dei:CountryRegion
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Narr_Yv2fFE7KREqmKDUSz7748g">86</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Narr_ymB8yrFkKkKtGqiZWaIJbw">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Narr_D8_MTmvhTkyv6mW-d-B32g">87773616</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_BwbcpZp3G0GAySmu4uP6aw"
      id="Narr_zFnQoxFvokiu9lKbnF7cmg">peter_luo@adagene.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g"
      id="Narr_23833KN79ESPKaMvy2ehXA">American depositary shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g"
      id="Tc_QcIC-eFT2UKlTgTHA9QfFg_2_2">ADAG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g"
      id="Tc_2lwHM13jcE2OzJWKWxj1IA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw"
      id="Narr_ZpTA33FTYUKpSs3ADwBszg">Ordinary shares, par value US$0.0001 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw"
      id="Tc_REz6X-oq2E6bvkBmO6I8lQ_5_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Narr_czG0_YkXMUSo7thK4dEpcg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54065709</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_jdT4se-gOE-wCD83e17MJQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_u_5E_u8Zy0aFiBpuImpdvg">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_5wtuXgdG3Uux8q2qFfXSRA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_iIrWrqBgN0KyhI6v2uNxHA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_Vd154OiwQUKlMHbKmXvc7Q">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_GCeyWOK6u0u76CVTKc-8pw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_7_NyEsuR_0GxoxPcMftBSA">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_64ZbDr8go0iH2IVNpaDpnw">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_pVHx7Nof4EuM6y6Kybf-8Q">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_WzZx6NyVZEaVoYbSj2qKIw">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_FveG66kJh0Cy7mjHFIPc7Q">1424</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_7mHoRbRjckKtQjIZ3sANnw">PricewaterhouseCoopers Zhong Tian&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_X78HSeahnk6xEqTK-SdNnQ">Shanghai, the People&#x2019;s Republic of China</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_otGRtl_iDUGEqm2Jildqcw_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">174391243</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_X5FxQlK0t0mCcZn-cP6I6g_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143758678</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_p05vVqV47EmU0QigpFggeg_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_LZ3d8L1V3kmoywsbSCVs5A_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4506670</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_xLnCkwtOq02t0AHWaAP_5Q_8_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">619432</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_VnQaBJXHYkeDaB68gJMZ6Q_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4055921</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_9iQwttJN1kq4FHqvN9A4cw_9_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4937323</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_FhUUISS5_k2Y_bdaq6Ps7g_10_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">185953834</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_kkvbL0GueUy9_hHHq2yxVQ_10_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">149315433</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_5EDpeIAIzke5BCYTOMnqNw_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3487617</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_bZUDiCxJxEO7mxKaiBYgtA_11_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2782963</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_jZAftmJX3EevdkcMCX7l2w_12_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">191877</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_135X03FOX0eUlJcH7BE4lw_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">69275</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_ZOT7uc80hUibAdmbfiqWvw_13_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">109572</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_G891cCHygUqTpligB_60Hg_14_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">189510726</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_fcNh3lB_MkKc98Y5yV74yg_14_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">152399845</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_LJU7qfSUKEGysJ6R38f6wg_17_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3321615</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_p-5_yCCT60a2WSVDvPOBtw_17_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3666124</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_Ji1eVDzovEaTMnWhaqNZ3g_18_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_v3awmWNNWkOJTIFbe1Yf7A_18_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">15107276</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc__cmryureJ0GeB-oLC_aCqQ_19_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10466061</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_8RgI9f3CHkOqFA7A4QIoAQ_19_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">19323337</us-gaap:DueToRelatedPartiesCurrent>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_TX1jtQkksU-PUznbCO_brw_20_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4379243</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_CClrUBRSqUWVTs8JNRTk-g_20_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3212809</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_UG5OsuTnd0SHed3gBdMnyQ_21_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1657450</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_rDA6uJmlIE2HYZs-LVAqMg_22_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3121226</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_leClezLNxE-3vCW1Gub2TA_22_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10768745</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_xPaPy9uxCEKGf2IiWGFfMw_23_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1376319</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_V5uySfpTvE6OG83YJD95HQ_23_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2850128</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_rXcCiiHgSUe1tMb9VYewew_24_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">151983</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_b5XMu3gcekSBk_ui8kGG1w_25_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">29821914</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_vZnJqjsRw0Gfw1jKKo30pg_25_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">55080402</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_9UFFxymeZE6yqhRBtCcNPQ_26_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2991829</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_8QQs_FfSYEutASPS7YywMQ_26_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">14146541</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_mPcHnrIEL0OFi5X-B7WLzg_27_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">53834</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_VWUeDOSukUin8Kgw-neGMQ_28_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">44163</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_q51H4n5T90WPaa5rzgT0hA_29_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">94107</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_1wxQMsOZ2EmOkgQCm-VgzQ_29_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28718</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_jQXA9oAdGUKvMfNaX9yWgw_30_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">32952013</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_6riIwNAawk-Gr-qag4McCw_30_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">69309495</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Narr_B7mbxkC3m02IVBVZ2d_6Eg"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Narr_hmUInQMH5UGhsSf2BIaauw"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Narr_Yz55Cu8ENk-Dyvyvx8ci-w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">640000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Narr_Bn0Uh1CwzEetpv3SHNeecA"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54595667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Narr_6wFWtTrryk6dKMsqOmIywQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">640000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Narr_-Vy9EetzzESqCn3ocVWaQA"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54065709</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_jTcFqC2Us0Cqx5vUiWUnLg_33_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5627</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_iX_IAaTIKEqCm5qxAzay8Q_33_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5497</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Narr_FVzABJNctEa0nnUsvgJjmg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">94074</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Narr_JUzhoovy0kGlyjaYOBPFHg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_L_R9tO1TRE-KFwavDfdZwA_34_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">619605</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_bjMUlz-2Yku0OxhKieWjMA_34_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_Dbd_ygPIS0255KSLHfOy1Q_35_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">336099931</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_ASffXZXcEkCguOc-9sE8ag_35_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">342739268</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_n4d6lDU6akadfUvjOlUj7A_36_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-93981</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_sZWoxyg8W0CJJGswWyZKbA_36_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-849305</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_MqtWgbLI-0yb1meJyGVliw_37_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-178833259</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_Y3L1t1a7SESf8K3blCRXLQ_37_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-258805106</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_ZKACWStI8UaMA85xquPmNA_38_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">156558713</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_gqScXx-YXku82-QxXiFtsw_38_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">83090350</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_V5GFwXl7EUm6mYSTbHbnnw_39_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">189510726</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_zaw12crZp0OYIEDKzW4gfQ_39_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">152399845</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_cWSph83BskeBPg1le1UOAw_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">700913</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_gHDbFRNcME25N0-u3NmpnQ_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10175258</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_G9X8uYMlSUGSvuU7feoo6w_6_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9292724</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_VlT5XcMSjkC8w3Ur1mNECA_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">33538035</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_QInRhcFLMUaRf4ZKRUCm8Q_8_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">68099385</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_a2g0VyHfLE-GYzEJnv4JrA_8_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">81339540</us-gaap:ResearchAndDevelopmentExpense>
    <adag:ResearchAndDevelopmentExpenseThirdParties
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_paaCQ31HLEarMqs2phvSAg_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">23645740</adag:ResearchAndDevelopmentExpenseThirdParties>
    <adag:ResearchAndDevelopmentExpenseThirdParties
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_ysKxNPBuwUOJncTqX5Geag_9_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">55020367</adag:ResearchAndDevelopmentExpenseThirdParties>
    <adag:ResearchAndDevelopmentExpenseThirdParties
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_z8KMWcDYmk6wZy-gOD5h1A_9_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">46212077</adag:ResearchAndDevelopmentExpenseThirdParties>
    <adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_U5BZkWuzZ0efBDj2eLQK9Q_10_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9892295</adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_MG0ylQ7fpkCXMiXD_R07gg_10_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13079018</adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_OOpb41L7kk6jfhtlGW6L2A_10_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">35127463</adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_VPciAjgmaUqekEAJqvxOEg_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10314536</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_SwNs-ofv3kuHRNu4VaGNrA_11_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">14439962</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_rF4iH4ku0k2UiLywkqe-wg_11_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">11873867</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_wIYGieTEg0SRoROMaH2THw_12_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-43151658</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_UeJZunLapUeTAORbhXVRKQ_12_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-72364089</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_TXDOD9Dw_USVp4UnUbhPpA_12_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-83920683</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_xQr8rIcMT0GwgY5OcykUrg_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">629288</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_o4AzmV8ifU6WewD-X8_B-A_13_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">76166</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_PRYGDukkGUyvWHRp4FT8sg_13_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">377501</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_bbio_aQaNEWOIvHkqa5FgA_14_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">202165</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_OVCIs9YVQkGi1S3q-QgSoA_14_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">363762</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_gFDGsJ-4qEe8Z-EqXTlvRQ_14_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">693323</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_zL9OAErI6UCYrNL1hx62BQ_15_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">971949</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_JNg8W316QUG4EYiCdVYnNg_15_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1778822</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_O_jfrbujzUqXJIUOVNTnXA_15_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2168388</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_cdvN78HAoEqJ8BQ22XlE-Q_16_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-644693</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_WK55f_NHpku29mNlRnn_ng_16_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-603459</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_XOrC_i444E6FNExWoAKVEA_16_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2555325</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_kggjuTRiE0ew0qB6Y8QCVA_17_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_sM0X6ChnPEeO7XbulkmvrQ_17_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-71476322</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_CxHLFX6y20CXGXe6irEPPA_17_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79512792</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_G3R4JUftbUqYlYYRVOTXSg_18_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1701613</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_7kLNOIYQcE6qZIYB7UjmfQ_18_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">459055</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_25pcWkGHM0eyTUQLMlT-9A_19_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_cmTt25v8QECS2nS5mlz1UA_19_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_LRnEaEmhUE6X5P3lgjXbpQ_19_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Narr_-O6MMF-QeUGJqAwfJdN2bQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Narr_8Cr4c9W88UC-FNmRgke3hA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Narr__nxZEdUAWES5JbB1JFQUhQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_pVjOzs1wG0WGcIRVxzTurg_21_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-6087</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_SmKphJ_uv0qmHi8zZye4Yg_21_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">257000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_zizRTqkEdk2e-pi5fVsXjQ_21_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-755324</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_mE9ff2ckjEWxiVCmfOvrwA_22_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42403366</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_GLDVx7e5X02DcqY3EDZYCg_22_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-72920935</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_Fkq_VnrTT0yJEhvYha2Lrw_22_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-80727171</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_b83FmH3H90ONJwW85MoSkA_23_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_UPPro85Of0-sFPUSPp0X1g_23_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_CKHYSW62Ek24KgubUYXw2Q_23_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_boxHExmfoEq2ISprMPM42Q_24_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_cs7qHknTzEGY6mWyJc8XZw_24_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_klrWIfoiz0ylrlD4RHXJtQ_25_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42645392</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_wJkrLzg5SUiydBGoSWfWaA_25_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73206488</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_6-aL7eVwj06K8PpxTdw_sQ_25_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_ocqf5Kz8tkygnTYWncETLA_27_4"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">15950698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_JtEQJoPNxUSoGb4eWQuoSg_27_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">50032009</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_Kc91rSv4cE-Qlg6zxEBSdw_27_8"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54135084</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_jGqBrTXQe0GcAHho_TDuIA_28_4"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">15950698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_tBynbnKsP0WnC3wNd6EeUQ_28_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">50032009</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_g1GfbDhwXkCjBDEkggVrFg_28_8"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54135084</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_yOA_0anJAE2caTuzN947Sw_30_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_Jv9heSOXP0CxO6tSGNJryA_30_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_c5EAaavd0EWiaiufmqNAeQ_30_8"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_HJtyKtA29km6dMqv9q0jXQ_31_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-2.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_0guKDFQ6FkG_AjHgW7GO0g_31_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_J6owIEqUFEeYJ9QrgmW4Tg_31_8"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA"
      decimals="INF"
      id="Tc_eeLjBK3bNE6uqS6GX-yqig_6_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">15193136</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA"
      decimals="0"
      id="Tc_8JU-nLujLEmdxlqbRRlLKQ_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ZAIqUZ6DnEaGRXvod8zuFg"
      decimals="0"
      id="Tc_pC34tqrHtkq_pB69qmVhEA_6_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-197068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-fGWKFY2rEOZsvz04ykZLA"
      decimals="0"
      id="Tc_2QKxF9Xs-EW09BzHwdimOg_6_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6789542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_pIuFXCNeoUy7CaDSOhk2xQ"
      decimals="0"
      id="Tc_Fk0cHSCsj0GHIqHBExZAjw_6_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-344894</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_J78E05vN20erGsltKQSaYQ"
      decimals="0"
      id="Tc_qP71QPanZ0O5NP9j-YhGwQ_6_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-63258045</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="0"
      id="Tc_1sAq8L8SPk-nZCF6FXbbLQ_6_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-57008946</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IvlyyVsaP0qH00DZs-cOzg"
      decimals="0"
      id="Tc_VqKZCjoEkUWozwQHa3-QyQ_7_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_4ZJm1UztLEKg2W8DSSuVYw_7_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_GClxeG8xvEeEJiRr287NPw"
      decimals="0"
      id="Tc_4PAG-YW9QUOIOMBTe12C_w_8_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-6087</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_RYjOLXatNUevIgh-aBJRjg_8_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-6087</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TTeXW30sp0OT1Sxf3PgmKg"
      decimals="INF"
      id="Tc_S8EmWOVh6UClmfZLRZXHvw_9_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">3694934</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TTeXW30sp0OT1Sxf3PgmKg"
      decimals="0"
      id="Tc_ASHW5MG0RUmwhhmI5QUlmw_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">370</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_B7KydVxEvkqzOuPCW8zKlg"
      decimals="0"
      id="Tc_1TrjROnzAkW_8dBy8q62eg_9_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-6975124</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ"
      decimals="0"
      id="Tc_JavwC_Nuh0e0V41z0vw28A_9_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7115682</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_cQ_tk7Eu00OD7klz2Lojkg_9_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">140928</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ"
      decimals="0"
      id="Tc_vzkvYtBRvUK8IEndv5N9hg_10_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10129541</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_cq0_iXhcfkWyJdEjbk69ug_10_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10129541</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kuqtEEslP0G9k7LlpJJTbQ"
      decimals="0"
      id="Tc_U0N_buSCv0q5Ovu2LpjwFw_11_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_Slxw7FBBy0qmmOAhnrN5OQ_11_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YPqb6m0diEulW2HtfQSfmw"
      decimals="INF"
      id="Tc_12R6OSS4tEmnvVi5Uo2QRA_12_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">18888070</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YPqb6m0diEulW2HtfQSfmw"
      decimals="0"
      id="Tc_MkzVrUWWZk6LtKTumbk4SQ_12_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_OPji8N90TES4hj8qFG2_Ug"
      decimals="0"
      id="Tc_F60iGJ4jSkmBOQUyeVDyfw_12_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-7172192</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pNeBwXPMFUiQuaK_5XpBZA"
      decimals="0"
      id="Tc_vKhG99Ikf0OndUmqgPjg4g_12_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">23786652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_UKTQnfrtqE-IQhyGVhZXZg"
      decimals="0"
      id="Tc_qvVoPj45Bk-NekfTVEkqVg_12_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-350981</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KG8su_uOu0a0KunRTlLxoQ"
      decimals="0"
      id="Tc_VYRi63G1_E2M8XJGB3G-aA_12_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-105655324</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="0"
      id="Tc_WQoqxeotjUKfcEvc_eGaug_12_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-89389956</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jJZYhVw9NU-SOXmev5aACA"
      decimals="0"
      id="Tc_DkPphyiTJkCv_-JzLsftNg_13_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_pe-_z9QAEkewYqIlba-Wbw_13_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ZgaIiUt-UEqjj7jLhIpMZw"
      decimals="0"
      id="Tc_hKDFM-7BnUiq_5z1mPt1sg_14_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">257000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_4aDSf256l0Wda1kra_7Wlw_14_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">257000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="INF"
      id="Tc_j-UujZnfhk-U6gPi0IAFMg_15_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">233957</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="0"
      id="Tc_A94Is4-1mEuIT5q1VlJ2Ng_15_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">23</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_VHf6QePCYUKcjCiLotiVvw_15_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">226758</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_ScAcRfNBmku8EMFJIVusoQ_15_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">226781</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="INF"
      id="Tc_rhpCnCUj6ku5xsB-BlJd8A_16_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">23734</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="0"
      id="Tc_yjFhjhO1XUGqlcdlRpbaVw_16_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_lkczTdzQl0mh_9pge1IcfQ_16_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">416749</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_UvuErkevF0m5b2B6wROFRw_16_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">416751</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <adag:CommonStockSubscriptionsValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_VXRQnsAoMkSLLvY_DjFWlA"
      decimals="0"
      id="Tc_4ivjtRz0wUeIZTYYHhPFUQ_17_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">381282</adag:CommonStockSubscriptionsValue>
    <adag:CommonStockSubscriptionsValue
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_kL8cCo83pEuxzrzXE_d9iA_17_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">381282</adag:CommonStockSubscriptionsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_i7rQtGVo-kW0Iz0JMhDVDg_18_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18679658</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_2JHylzS0jU-eDVKaeI-spg_18_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18679658</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_433n4PZx2EiXC_Gshu_hUQ_19_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_g8PmP6BkFk21z44q9IJKPw_19_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="INF"
      id="Tc_jtusZggYKE6nU86GU3YnTg_20_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">27249824</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="0"
      id="Tc_l5HyIxmyeU2-9X88yhvBcw_20_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2725</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_IR63wEwyUEiHGO69smGECw_20_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">154475235</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_XhsaCZgg40KchIZvmiugwA_20_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">154477960</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="INF"
      id="Tc_Iwv20QfVNUOTsCEcjZprgQ_21_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">10571375</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="0"
      id="Tc_VaMpIOWEA0WBoDGRcQfCpA_21_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1057</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_g7IgLCYfkU-Qn0aNwgJrLQ_21_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">147094280</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_i27PqkWjLkiziKNLEZFGkw_21_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">147095337</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w"
      decimals="INF"
      id="Tc_yzlsZtYzsU2tsON83gd17g_22_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">295174</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w"
      decimals="0"
      id="Tc_ZPWYb5RQXE6x_VDeC5Imeg_22_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2361576</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_45Ve-0Gv4EKiD_WFxY8EpQ_22_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2361576</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="INF"
      id="Tc_Ijf5xj_PckyyYGEjeaoRPA_23_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">-201100</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="0"
      id="Tc_X1T3tBV00U6w1yRXAZYn-Q_23_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">20</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w"
      decimals="INF"
      id="Tc_HKYgfdIL9kqUo4pte8jcEQ_23_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">201100</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_GuQNFM0qf0m6QJMdAmpQ7w"
      decimals="0"
      id="Tc_ECK0HrhdK0qq0oeVIVSo4Q_23_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-1741971</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_iDpnkbVCfE2rVvU23Qlw9A_23_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1750041</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_72csQG6SB0-ExDw5W-jM-A_23_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8090</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <adag:SharesSurrenderedSharesForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="INF"
      id="Tc_fpzb3XPV1kS_7mMzynOeaQ_24_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">-491119</adag:SharesSurrenderedSharesForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_snsyhuYWJkGIImr-GzbuHQ"
      decimals="0"
      id="Tc_tWNIOLt2sEiG5RopTGhJQg_24_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-49</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_VXRQnsAoMkSLLvY_DjFWlA"
      decimals="0"
      id="Tc_VC30ftt7m0mtGoJ5rcKC4A_24_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6790910</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_EaSPlVCD2ECijnrRJn9K3A"
      decimals="0"
      id="Tc_THbLNonyKUiI5-X9bqCRHQ_24_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-6800807</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_ejAICKVmbkyssHTGD5rFhA_24_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-9946</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_25mz8MzMZU6-TK20uJ2UWA"
      decimals="INF"
      id="Tc__hlTisnAbE6C9731TeUyiw_25_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">56274741</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_25mz8MzMZU6-TK20uJ2UWA"
      decimals="0"
      id="Tc_5p62u1Q8iUy60hSwLj9elQ_25_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5627</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_ancTWgsA3EaZqftsGC9BMw"
      decimals="INF"
      id="Tc_UD3q8LEEfEm7AdllP0nZkg_25_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">94074</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_ancTWgsA3EaZqftsGC9BMw"
      decimals="0"
      id="Tc_4urnMTY-BUG6IvDGtdT0VQ_25_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-619605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8CaGtWv9QUicSDrtUt3MzQ"
      decimals="0"
      id="Tc_MhyBeWRRc0KGS6JsiLpdoA_25_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">336099931</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Q0akVaGa0UGbNziyt_b1ZA"
      decimals="0"
      id="Tc__nqDt4OQn0ON83t_882XLA_25_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-93981</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7Za0p7Lfn0SI4LJAXHWLYA"
      decimals="0"
      id="Tc_PjyLQpJlGEGI19cEaGr35Q_25_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-178833259</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_FPfd_kQGUEq-JBB1C1rClQ_25_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">156558713</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TiCAjHF8_U-6H2PHnG8Zpg"
      decimals="0"
      id="Tc_orOjso31RUWjM5HUUBodDA_26_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_t0793F4PXUOn1AwBkHZAtQ_26_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_iYVX4_oPbUSXBpxQ0gDPag"
      decimals="0"
      id="Tc_-9aC5PGRu0GGd9UKvnjIRw_27_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-755324</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_y_89qmgwZ06Od5Th6N4JyQ_27_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-755324</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"
      decimals="INF"
      id="Tc_ERSaFCIXd0ySdZdYwcs1Cg_28_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">197975</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"
      decimals="0"
      id="Tc_2xfECp0ffU2zq_30UFAmpw_28_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">20</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA"
      decimals="0"
      id="Tc_smhY5XHuPEKVomWH4kYElQ_28_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">323192</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_TK3hWVWhCUWNDe356z-p-Q_28_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">323212</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"
      decimals="INF"
      id="Tc_P4ButmeZ8E-1eiW7slXJyA_29_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">99999</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"
      decimals="0"
      id="Tc_d1NcWp-wtESpoa_TTGfaFA_29_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA"
      decimals="0"
      id="Tc_qSZn0_r9ZkOfaKIRlPMu3w_29_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">391985</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc__PnSMKtirUOZDIRBJ7kQcw_29_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">391995</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA"
      decimals="0"
      id="Tc_35SLsOTAKkeD2BwOviq4yw_30_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10520282</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc__AVo_RsktUyrN6YJDDnnkA_30_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10520282</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA"
      decimals="INF"
      id="Tc_B7IQYcslcUm8aMWaUk-suw_31_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1512932</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA"
      decimals="0"
      id="Tc_azteZO1qq0SLxeQgr4RagA_31_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3976681</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_UN4wZHF9_UGBcDdtFSelWQ_31_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3976681</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"
      decimals="INF"
      id="Tc_0mN-uxDutkSszkDUxQrNvg_32_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">-1607005</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_g9O94K6Bmk6gZtN3DIU77A"
      decimals="0"
      id="Tc_A7HfSDQh20aYa6htDwEqjQ_32_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">160</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA"
      decimals="INF"
      id="Tc_kL54arQo4kivvLHCkUN1ww_32_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1607005</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_C9P98BkG_UGFo4PujxC7vA"
      decimals="0"
      id="Tc_fp-CdTP-BUq8PM6v9f7ouQ_32_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-4596282</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_duop_7mhW02r3ub31tx5HA"
      decimals="0"
      id="Tc_8ZzwmhCBz0i5Z3RA0nY2bQ_32_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4596122</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WBu5OJOR70SEMOJWhuD6rA"
      decimals="INF"
      id="Tc_siYtY1u9Ck-5IAiPiFgilQ_33_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54965710</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_WBu5OJOR70SEMOJWhuD6rA"
      decimals="0"
      id="Tc_-0q55o8jZE2fU0zmV28RHA_33_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5497</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_VElBgd6POkGwMjlKJdoNAw"
      decimals="INF"
      id="Tc_pdQccY9330SfW13OZQRuFg_33_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockCommonMember_VElBgd6POkGwMjlKJdoNAw"
      decimals="0"
      id="Tc_1x4uH_FWIkOW-kK6eVg-Bw_33_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-4</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_E1yBXnv1JEqkFifQJ0DCkw"
      decimals="0"
      id="Tc_qxXdfXyBOU2cNUkOVelChQ_33_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">342739268</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_r4Z52hagwUK01HtKpXLekA"
      decimals="0"
      id="Tc_nwA2wO2Puk6tDmU22kJZNQ_33_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-849305</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_DcS5Ka-g5Uuv_EvSXAJk_g"
      decimals="0"
      id="Tc_TFxyY9XQ80qI4l8uyxuPSA_33_16"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-258805106</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_X5n3Zriwrky755ON--yk0A_33_18"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">83090350</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_VWDKGGuj10C8KJZdB4aw6g_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_1TwQ3wl4vEuNyyrVqWD1og_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73177935</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_oZ59jc1aekukF2h2JcKQEQ_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_-_9ClzmHl02vK9xpjf3o-g_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">858408</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_F7PICqvRAUyiAmJwB9jnKg_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1125032</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_-kkCHaz5CUiTmUSI8ICs5w_8_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1145995</us-gaap:DepreciationDepletionAndAmortization>
    <adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_XNTF7yc6QUipOxsO49B-yQ_9_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">327</adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset>
    <adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_Wmw_kiN_rk-47iRuy5cepA_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18973</adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset>
    <adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_VG-NEqc59UaXo_Q-pL1ruA_9_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6811</adag:GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_ITlq5-NRuESNAZMkCcLqwg_10_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10129541</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_cgx5b9lV10CwX_n3LJ5kGw_10_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18679658</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_n2WCOX4XYk-GHL_eBy0CWg_10_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10520282</us-gaap:ShareBasedCompensation>
    <adag:InterestIncomeExpenseOnPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_xMRUHKYTTU61iTpvkK26zA_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9946</adag:InterestIncomeExpenseOnPromissoryNotes>
    <adag:OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_D1-YUGKGG0SLGSE2n0qLVQ_12_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">303535</adag:OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_qLg87hOmk063OIQSed2udw_13_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-644693</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_vA0laYK_uEqHCf3qBZtOXA_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-603459</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_U29t_RItdkmgbsYWRWhWLQ_13_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2555325</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_XIfhCMMae0Os4hpquzW9HA_15_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-480000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_ZmHWyuMseUGxV1YlA4QUpw_15_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_z7R2tLnOA0u14aa003_SSA_15_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-3000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_deh8iHDt6ke9Gj_QY8U5Ew_16_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2337011</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_qNg7CRj6WEm-8iAjWSGafA_16_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">231287</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_ImHjBI8D802zzYWp2KzGuA_16_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">881402</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_t6owjbDjmE2XDk3ZZJ3BRg_17_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-1300790</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_IH5NyybvlkeT4CDPa4vR0g_17_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4374274</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_XJcnHkSBIk25kOSkXlOIaQ_17_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-3887238</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_uENx1kXsN0-HjqpUrCvHuw_18_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13292</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_ic_GFvLB6EeL7lPTubGuJA_18_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">24210</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_eXxv0BSMFkiRl2xzzkEnFg_18_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">40297</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_RmgUj26CMkyfWdKSrCLeEw_19_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1097261</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_R9vtN9neTE-LGOhPbnwyzA_19_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1511640</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_ghA07XXR80KdaR_2eAtz7Q_19_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">344509</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_ILkHtVLi9EKbYYzFArORYg_20_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-267842</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_bFGwNhA5X0mYBFaqDZxEcA_20_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4774464</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_Mg8IMHmjGUyBs_NEjS4oFQ_20_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9607276</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_3_fLfBD2TkCd4o5rJphfnA_21_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">639579</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_4ESRWkQqyk-lDrJZ9Y6Utw_21_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7930703</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_AfEr0Wz7IECUzGsKqZnImw_21_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8857276</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_6F8v6NmHLk-yPaZnawGiBA_22_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1243150</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_v_WQulDCHUqB8kC8KnBuYQ_22_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1057491</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_NHYZciKMmk-Dt7qqR9L5_w_22_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-823928</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_qJ37veS2ZUi1D5LxHF_5gw_23_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-280465</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_HmhVPZf4rkSpXNZji3KF0g_24_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1657450</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_-BIYmeExhEOxTCiQF-qCzw_24_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-1657450</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_3Qqky96OeUKOkSme60m78w_25_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-44163</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_nRZbFIw9cUqRTNi_GGquog_25_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">44163</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_AaIwKMCIDki6T-E1XzvlJw_26_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">91955</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_jvsmubriKUGQwT-81gIlmQ_26_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-29732</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_TkqYyrp1QEupvM1RaoMe4w_27_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-28529720</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_xe3xnTnuHUWXsV001O0lNA_27_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-43414619</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_7DU6LUih9EGUcf8GNi-ZcA_27_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-48611687</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc__u0DzD70I0uJJyULCnrhzg_29_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_ca1mkeTLXk6hOmPJ7bJsIA_30_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7930</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_W2a3x6UeaEyyLRhdZR6OKA_30_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4892</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_RfUxfmpEH0G6lLhl8j53DA_31_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">935199</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_reknxDswCEqnAAqv3bsiWg_31_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2509926</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_UwupB3CVGEOBWMuo9HJiIQ_31_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">690938</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_y_Z93hJCEUChV874Pr7VCg_32_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7072731</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_CX6rTnXuFESLkp9sjJ_cSQ_32_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-2509926</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_hx56_sAj-UCfD0TWd0fbOw_32_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-686046</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_eYkAgqeAAEqS-ITW4beqvA_34_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6083650</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_LhPPDEzX50OxC1HOrrEdCQ_34_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4386860</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_LsOCftJKAEue_PPwyLFg0w_34_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">25830030</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_3yONXQdIEk6isS3ZpjsxbQ_35_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">381282</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_UZviajpPMkW7_BFXAQ60Aw_36_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">140928</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_FHmLEl_UckSxKaNhT7XA6w_36_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">231521</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_sSektnXC9kqI6ahf4GSc0Q_36_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">323212</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_kp7ZgRVQckyOdDfBtv-l1g_37_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">149411950</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_DsHloF9mzE-oCJDzrrajMg_38_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1063670</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_fzmaV1Yo3E24rdNbCYcwHw_38_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5089717</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_sVbyE6pUkUm5Q0hLcX_LHw_38_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4353588</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_8l77VfKNXEi8em6hY79IYQ_39_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">721532</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_owgepjfavUCgMdIzzbb5cQ_39_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1595088</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_X9zClO9R6Eqd2B2hEPnNtA_40_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2361576</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_UJwaM-1Kt02rDgRyuZr-hQ_40_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3976681</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <adag:RetirementOfTreasuryShares
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_clHJFch1S0qEnJSYsPlE4Q_41_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8090</adag:RetirementOfTreasuryShares>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_wAvovPLCTk-hH3gC3mA5Og_42_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4439376</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_3MiQz4vHikGRuYvsgOa2og_42_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">145357142</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_qPxEnIvkJkyWcNdLga9HcQ_42_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">17822973</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_K-G4Lj2_SkyjNeUjLTpVlQ_43_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-364177</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_vdck2qVxMEWmwFrgyv_Nww_43_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-192352</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_JO-7pEZcMkGBUwSVGOrR9A_43_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">842195</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_X4TOWEJRp06f5Au6nVbI0g_44_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-17381790</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_7oJuEVPAc0KoTLh-HmspAA_44_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">99240245</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_CZwvi7GZC0ihHvOemXruaw_44_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-30632565</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="0"
      id="Tc_26Zc6s--80mcBNGkJpVOIA_45_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">92532788</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="0"
      id="Tc_dHAL3xvHjUG_0-z0GBa0mg_45_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">75150998</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_wWNy6W287E6sgIzwrznx7g_45_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">174391243</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="0"
      id="Tc_giz2c9oHP06TXKFogGAfEw_46_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">75150998</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_BxTkvFOEoUekqJDZxMH1mw_46_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">174391243</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_5eUpzUHA0kWP06pB6WP-8A_46_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143758678</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_V2y4FIqfgU6RfsbblvdSJw_48_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">202165</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_dJG8jbEdlEqIYPtNkdeuyA_48_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">359569</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_gCiuzyQmO06VtvZ_mkL2MA_48_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">603680</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_91DiWBvyqk6BUCLoigNx4Q_49_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2433241</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_VaUzelfNLUiU3daRs1ITWQ_50_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">313929</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_otOcVNZANEqF05TTVVaBUg_51_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">217227</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_ZnqE8HQEjkeSyDqUTyUNEg_53_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_hV-XPZ9T6U-TM1gXYpfI5w_53_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc__bTg5AV2dk-ls12GhLCJvA_54_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">154477960</us-gaap:ConversionOfStockAmountIssued1>
    <adag:PayablesForDeferredInitialPublicOfferingCost
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_698CHEJKV0WvJxkQemLeVg_55_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2276183</adag:PayablesForDeferredInitialPublicOfferingCost>
    <adag:NonCashActivitiesRetirementOfTreasuryShares
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_5oaBv_F04UG79-xRu0XrOw_56_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1741971</adag:NonCashActivitiesRetirementOfTreasuryShares>
    <adag:NonCashActivitiesRetirementOfTreasuryShares
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_OsvZGUKTAUWuKqc4DzRWcA_56_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4596282</adag:NonCashActivitiesRetirementOfTreasuryShares>
    <adag:SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_jZn2V1P6R0-7H54k_yla5g_57_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6800856</adag:SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_6JdgnMnXhU2qGDI73l021w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;1. ORGANIZATION AND BASIS OF PRESENTATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene&#160;Inc. (the &#x201c;Company&#x201d;) is a limited liability company incorporated in the Cayman Islands on February&#160;25, 2011. The Company, together with its subsidiaries (collectively, the &#x201c;Group&#x201d;), are principally engaged in research, development and production of monoclonal antibody drugs for cancers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 8, 2021, the Company&#x2019;s registration statement relating to its initial public offering (&#x201c;IPO&#x201d;) of its American Depositary Shares (&#x201c;ADSs&#x201d;) was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and the shares of its ADSs began trading on the NASDAQ Global Market on February 9, 2021. The public offering price of the ADSs sold in the IPO was $19.00 per ADS. The IPO closed on February 11, 2021, pursuant to which the Company issued 8,457,100 ADSs, including the exercise in full of the underwriters&#x2019; option to purchase 1,103,100 additional ADSs from the Company. The Company received net proceeds of approximately $145.9 million, after underwriting discounts, commissions and estimated offering expenses. Each ADS represents one and one quarter (1.25) ordinary shares of the Company. Upon the completion of the IPO, all outstanding shares of the convertible redeemable preferred shares were converted into ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company&#x2019;s principal subsidiaries are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage&#160;of&#160;legal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Place&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ownership&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Entity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;by&#160;the&#160;Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&#160;activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Hong Kong) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 12, 2011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Hong Kong&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment holding&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Incorporated&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;September 20, 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The United States of America&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Suzhou) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;February 28, 2012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The People&#x2019;s Republic of China (&#x201c;PRC&#x201d; or &#x201c;China&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Australia PTY Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;May 30, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene PTE. Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 27, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene AG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Project C1 PTE. Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw"
      decimals="2"
      id="Narr_Zlj0nScBWU-c4g2DG5w44A"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">19.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_8PMoYsniJEKQ59jVt_gtxQ"
      decimals="0"
      id="Narr_gvAEAetTG0meUqlloOMRdA"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">8457100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_x6getxpL9EmAJ2xaJGImaw"
      decimals="0"
      id="Narr_2JSkUBs7UEWQje2rf7dNMg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1103100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_8PMoYsniJEKQ59jVt_gtxQ"
      decimals="-5"
      id="Narr_cE7zs8IeiEeaDVZTEMFpeA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">145900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw"
      decimals="2"
      id="Narr_b2tvTAPqvkeXwBsfNc276w"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1.25</dei:EntityListingDepositoryReceiptRatio>
    <adag:SummaryOfPrincipalSubsidiariesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_pdT3yzQYV0a8xpqHL9vShg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage&#160;of&#160;legal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Place&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ownership&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Entity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;by&#160;the&#160;Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&#160;activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Hong Kong) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 12, 2011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Hong Kong&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment holding&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Incorporated&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;September 20, 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The United States of America&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Suzhou) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;February 28, 2012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The People&#x2019;s Republic of China (&#x201c;PRC&#x201d; or &#x201c;China&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Australia PTY Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;May 30, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene PTE. Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 27, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene AG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Project C1 PTE. Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 25, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:SummaryOfPrincipalSubsidiariesTableTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_LuGkr2nW5UuEFN70Vzi-Qg"
      decimals="2"
      id="Tc_eO7oNSZBuUyiEGilf9q5Jw_4_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneIncorporatedMember_BR7xdhRIAki49kFwg0OQzA"
      decimals="2"
      id="Tc_6zktEILzd0SejX0k6g-okQ_5_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_pEeZWdw_fkSZYD0_eWIssg"
      decimals="2"
      id="Tc_Y8uS8pdX1kiwjon4YhDYVw_6_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_HRsrjutOV0G30qtLf1pIow"
      decimals="2"
      id="Tc_hwIVHJxJ0UyMx8k09SLDFg_7_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_G1AQfi6p4E24BfwphzFniA"
      decimals="2"
      id="Tc_KPyeJ1_M30aXl0D09U6YPA_8_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneAgMember_Pnv6Ik0j60COLF1wUWv5dg"
      decimals="2"
      id="Tc_lAa2zufa_U--HLHASz01QQ_9_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2022_srt_OwnershipAxis_adag_AdageneProjectC1Pte.Ltd.Member_umWeTmICo062uH3oJz8eNw"
      decimals="2"
      id="Tc_x3IKNbwDS0CXvRu_mTdvxA_10_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_qlAUkrP4eE2wdGN_eHTVzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;). References to specific U.S. GAAP principles throughout these notes to the accompanying financial statements are to the Accounting Standards Codification (&#x201c;ASC&#x201d;), as published by the U.S. Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated, Adagene PTE. Ltd. and Adagene Project C1 PTE. Ltd. is the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company&#x2019;s PRC subsidiary is Renminbi (&#x201c;RMB&#x201d;). The functional currency of the Company&#x2019;s Australian subsidiary is Australian dollar (&#x201c;AU$&#x201d;). The functional currency of the Company&#x2019;s Swiss subsidiary is Swiss Franc (&#x201c;CHF&#x201d;). The determination of the respective functional currency is based on the criteria stated in ASC 830, &lt;i style="font-style:italic;"&gt;Foreign Currency Matters&lt;/i&gt;. The Company uses US$ as its reporting currency. The financial statements of the Company&#x2019;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#x2019;s Bank of China (the &#x201c;PBOC&#x201d;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable and allowance for doubtful accounts&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#x2019;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#x2014;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#x2014;Other inputs that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#x2014;Unobservable inputs which are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2021 or 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2021 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Property, equipment and software&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; -  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease terms or estimated useful lives of the assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#x2019; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No impairment loss was recorded for the&#160;years ended December&#160;31, 2020, 2021 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Segment reporting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 280, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief Executive Officer. The Group&#x2019;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#x2019;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of Intellectual Property:&lt;/i&gt; Upfront non-refundable payments for licensing the Group&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. For licenses determined not to be distinct, the Group accounts for the promise to grant a license and those other promised goods or services together as a single performance obligation when recognizing revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and Development Services&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;:  The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone Payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets and contract liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#x2019;s technologies under development and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;) and contract manufacturing organizations (&#x201c;CMO&#x201d;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2021 and 2022, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#x2019;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2021 or 2022 as the Group did not have any plan to cancel the existing CRO or CMO contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Government subsidies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#x2019;s PRC based subsidiary received government subsidies from certain local government. The Group&#x2019;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. In addition, the Group&#x2019;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Government subsidies of US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$0.8&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million, US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$1.4&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million and US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million were received and recognized as other income during the years ended December 31, 2020, 2021 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the adoption of ASC 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; ("ASC 842") on January 1, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases, mainly leases of office spaces where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon and hereafter the adoption of ASC 842 on January 1, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group determines if an arrangement is or contains a lease at inception. For arrangements that meet the definition of a lease, the Group determines the classification of the lease based on the relevant factors present and records a right-of-use ("ROU") asset and lease liability at the lease commencement date. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. As the rate implicit in the Group&#x2019;s leases is not typically readily available, the Group uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Group could borrow the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Group will exercise that option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in operating lease right-of-use assets and lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) elect for each lease not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component; (ii) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii) the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January 1, 2022 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the adoption of ASC 842 on January 1, 2022, the Group recorded an impact of approximately US$0.6 million and US$0.6 million for the recognition of operating lease right-of-use-assets and operating lease liabilities, respectively, on its consolidated balance sheet, which are primarily related to the lease of the Group&#x2019;s offices. The adoption of ASC 842 did not have a material impact on the Group&#x2019;s consolidated statements of comprehensive loss and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC&#160;740&#x201d;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation-Stock Compensation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; (b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or (c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Earnings Per Share&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Employee defined contribution plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#x2019; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#x2019;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$622,377 , US$2,223,493 and US$2,984,251 for the&#160;years ended December&#160;31, 2020 , 2021 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of risks&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2022, the amount of cash and cash equivalents of US$3,650,474 and US$8,617,157 respectively, were held at major financial institutions located in Mainland China, and US$170,740,769 and US$135,141,521,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s research and development services were purchased from one supplier group, who collectively accounted for 21.5%,18.5% and 34.1%of the Group&#x2019;s total research and development services purchases for the&#160;years ended December&#160;31, 2020, 2021 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Business and economic risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#x2019;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#x2019;s ability to attract employees necessary to support its growth. The Group&#x2019;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency exchange rate risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#x2019; invoices, shipping documents and signed contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 2.29% in the year ended December 31,2021 and appreciation of approximately 9.24% in the&#160;year ended December&#160;31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#x2019;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group is an emerging growth company (&#x201c;EGC&#x201d;) as defined by the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02 (&#x201c;ASU 2016-02&#x201d;), &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-10 (&#x201c;ASU 2018-10&#x201d;), &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/i&gt;, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#x201c;ASU 2018-11&#x201d;), &lt;i style="font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/i&gt;, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#x2019;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current U.S. GAAP (Topic 840, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;). Further, the FASB issued ASU No. 2020-05 (&#x201c;ASU 2020-05&#x201d;), &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities,&lt;/i&gt; which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted.&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;The Group adopted the new guidance on January 1, 2022, using the alternative transition approach. For additional information, see Note 14, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#x2019;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and does not expect the adoption of ASU 2016-13 to have a material impact on the financial statements including the notes to the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. This update simplifies the accounting for income taxes as part of the FASB&#x2019;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2021. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted ASU 2019-12 in 2022 and the adoption of ASU 2019-12 did not have a material impact on the financial statements including the notes to the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt;, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Group is currently evaluating the impact of this accounting standard update on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In March 2022, the FASB issued ASU 2022-02, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings (&#x201c;TDR&#x201d;) and Vintage Disclosures&lt;/i&gt; (&#x201c;ASU 2022-02&#x201d;). ASU 2022-02 eliminates the TDR recognition and measurement guidance, enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. For entities that have not yet adopted ASU 2016-13, the ASU is effective upon adoption of the amendments in ASU 2016-13. Early adoption is not permitted before an entity's adoption of ASU 2016-13. The Group has not adopted ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_A1qFhi9mkEicutDEMuBPcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;). References to specific U.S. GAAP principles throughout these notes to the accompanying financial statements are to the Accounting Standards Codification (&#x201c;ASC&#x201d;), as published by the U.S. Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_kF8NOqhY0Uuk3QGFGAup4A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_AzUt4jkjsE6koFTm0VvesQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses, and measurement of right-of-use assets and lease liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_J7bUbe7ul0-38zpx-zO-1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated, Adagene PTE. Ltd. and Adagene Project C1 PTE. Ltd. is the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company&#x2019;s PRC subsidiary is Renminbi (&#x201c;RMB&#x201d;). The functional currency of the Company&#x2019;s Australian subsidiary is Australian dollar (&#x201c;AU$&#x201d;). The functional currency of the Company&#x2019;s Swiss subsidiary is Swiss Franc (&#x201c;CHF&#x201d;). The determination of the respective functional currency is based on the criteria stated in ASC 830, &lt;i style="font-style:italic;"&gt;Foreign Currency Matters&lt;/i&gt;. The Company uses US$ as its reporting currency. The financial statements of the Company&#x2019;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#x2019;s Bank of China (the &#x201c;PBOC&#x201d;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_uHVFkIWhWkCbzbqOJPkMnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <adag:AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_A6_2Q2B3VkOJoAq2eGQ1Pg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable and allowance for doubtful accounts&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#x2019;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.&lt;/span&gt;&lt;/p&gt;</adag:AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_yWXtcNbKvU6Dd0OJeacxDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#x2014;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#x2014;Other inputs that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#x2014;Unobservable inputs which are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2021 or 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2021 and 2022.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Hp2hcBhCBUKfwPXhVKSC_w"
      decimals="0"
      id="Narr_vfRrcHTwO0iYdeiFxyA_WA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg"
      decimals="0"
      id="Narr_PT2qB1PrXkGZwCcJcVeYng"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <adag:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Hp2hcBhCBUKfwPXhVKSC_w"
      decimals="0"
      id="Narr_gX8g6SakFUWoi8s5CH0SCA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:FinancialAssetsFairValueDisclosure>
    <adag:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg"
      decimals="0"
      id="Narr_ss1gURjfGEaFDTv5V6zVyA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:FinancialAssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_KSWmmDDc306P2XUV2GWKZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Property, equipment and software&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; -  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease terms or estimated useful lives of the assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_4ZB1WLCj4ESjJgqYsqwXlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; -  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease terms or estimated useful lives of the assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KrbO3xolp0mWoDpH-tUPDg"
      id="Tc_ULDzVv0P9U26VbNwq5VA3w_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_2h413p21UkmzRBTslwlxxQ"
      id="Tc_syB7WbvC90qx9qgiPlsWiQ_3_2">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_U14hTTfIw0aauKmk513MSQ"
      id="Narr_pWJhk8g2a0OG1LFLJlnZQw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xRsWSZSyjEauMH-_N844Nw"
      id="Narr_c0dK0TgTcUKKLI9dN6hwtg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_-m_klozaH0y8y3effakxHA"
      id="Tc_LMcdJ0vJu0OU8N04AKS49A_5_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_pvNixmkY0UODGpGvN2b_aA"
      id="Narr_TkTSgyJLUUWIpgBKOaiqhg">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_V0FQCFIXf0qnsEhwdlQOIA"
      id="Narr_p0UjiZW7V0yYR6J5KwgWmg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_edL_oDUsjkC-CL8z_y4BDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#x2019; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No impairment loss was recorded for the&#160;years ended December&#160;31, 2020, 2021 and 2022. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Narr_isDTYBAoI0GOk6c9ZCp1Mg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Narr_NcLHq80Nb0u_QzgOlw640A"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Narr_SvT_k85RbEaWZE488hFn5Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_vuFlB-xj0UCRGKZLfo6Iag">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Segment reporting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 280, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief Executive Officer. The Group&#x2019;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#x2019;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_IqWuhsuYLk-mb5XH3mwRiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of Intellectual Property:&lt;/i&gt; Upfront non-refundable payments for licensing the Group&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license. For licenses determined not to be distinct, the Group accounts for the promise to grant a license and those other promised goods or services together as a single performance obligation when recognizing revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and Development Services&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;:  The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone Payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets and contract liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_S0a5CS6IAEOmeC5IGQnHow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#x2019;s technologies under development and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;) and contract manufacturing organizations (&#x201c;CMO&#x201d;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2021 and 2022, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#x2019;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2021 or 2022 as the Group did not have any plan to cancel the existing CRO or CMO contracts.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <adag:GovernmentSubsidiesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_RNMPOOypbk2l-YvcVZ8pZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Government subsidies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#x2019;s PRC based subsidiary received government subsidies from certain local government. The Group&#x2019;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. In addition, the Group&#x2019;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Government subsidies of US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$0.8&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million, US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$1.4&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million and US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million were received and recognized as other income during the years ended December 31, 2020, 2021 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</adag:GovernmentSubsidiesPolicyTextBlock>
    <adag:GovernmentSubsidiesReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="-5"
      id="Narr_6vC4CRWwm0uNS2bO1nkTAw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">800000</adag:GovernmentSubsidiesReceived>
    <adag:GovernmentSubsidiesReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="-5"
      id="Narr_SCGf8ENIIUCuo12f3nYYIw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1400000</adag:GovernmentSubsidiesReceived>
    <adag:GovernmentSubsidiesReceived
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="-5"
      id="Narr_w4AVGft190i_9gTmUA_Iug"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2100000</adag:GovernmentSubsidiesReceived>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_D7yeO-mp5kS4JcSZd1LAkQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the adoption of ASC 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; ("ASC 842") on January 1, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases, mainly leases of office spaces where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Payments made under operating leases are recognized as an expense on a straight-line basis over the lease term. The Group had no capital leases for any of the years stated herein.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon and hereafter the adoption of ASC 842 on January 1, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group determines if an arrangement is or contains a lease at inception. For arrangements that meet the definition of a lease, the Group determines the classification of the lease based on the relevant factors present and records a right-of-use ("ROU") asset and lease liability at the lease commencement date. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. As the rate implicit in the Group&#x2019;s leases is not typically readily available, the Group uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Group could borrow the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Group will exercise that option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating leases are included in operating lease right-of-use assets and lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has elected to adopt the following lease policies in conjunction with the adoption of ASU 2016-02: (i) elect for each lease not to separate non-lease components from lease components and instead to account for each separate lease component and the non-lease components associated with that lease component as a single lease component; (ii) for leases that have lease terms of 12 months or less and does not include a purchase option that is reasonably certain to exercise, the Group elected not to apply ASC 842 recognition requirements; and (iii) the Group elected to apply the package of practical expedients for existing arrangements entered into prior to January 1, 2022 to not reassess (a) whether an arrangement is or contains a lease, (b) the lease classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the adoption of ASC 842 on January 1, 2022, the Group recorded an impact of approximately US$0.6 million and US$0.6 million for the recognition of operating lease right-of-use-assets and operating lease liabilities, respectively, on its consolidated balance sheet, which are primarily related to the lease of the Group&#x2019;s offices. The adoption of ASC 842 did not have a material impact on the Group&#x2019;s consolidated statements of comprehensive loss and cash flows.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w"
      decimals="-5"
      id="Narr_oy690xxky0O7vM2NEm7ocQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w"
      decimals="-5"
      id="Narr_jzVPSRMxa02oPKNM1XHE8w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_jjSdptbvSU6TVFwceui9Wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_dG1hfLckBkqTSpplj2Awtw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC&#160;740&#x201d;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_Elyr8z5J8U6QqBqevA8YoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_OvFr4MAzlk29qqYFmc6uUQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation-Stock Compensation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses (a) immediately at the grant date if no vesting conditions are required; (b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or (c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_cfqZNG-nEESC9iuOpRkFlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Earnings Per Share&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <adag:EmployeeDefinedContributionPlanPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_AwKgeMC-RkSwljK4CmDhqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Employee defined contribution plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#x2019; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#x2019;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$622,377 , US$2,223,493 and US$2,984,251 for the&#160;years ended December&#160;31, 2020 , 2021 and 2022, respectively.&lt;/p&gt;</adag:EmployeeDefinedContributionPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Narr_AYHWSzrwM0eLqiW00fAPmQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">622377</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Narr_FuDFetTnaEKjgCN3ykxcGQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2223493</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Narr_RqBR9jUnSkWL2qXBQsxhwA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2984251</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_0Z11wV4gvkagLyMd8PXYCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of risks&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2022, the amount of cash and cash equivalents of US$3,650,474 and US$8,617,157 respectively, were held at major financial institutions located in Mainland China, and US$170,740,769 and US$135,141,521,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s research and development services were purchased from one supplier group, who collectively accounted for 21.5%,18.5% and 34.1%of the Group&#x2019;s total research and development services purchases for the&#160;years ended December&#160;31, 2020, 2021 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Business and economic risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#x2019;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#x2019;s ability to attract employees necessary to support its growth. The Group&#x2019;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency exchange rate risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#x2019; invoices, shipping documents and signed contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 2.29% in the year ended December 31,2021 and appreciation of approximately 9.24% in the&#160;year ended December&#160;31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#x2019;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_8B7AeaXkck6JwjDBIkApxg"
      decimals="0"
      id="Narr_dMbp6dzwI02E8MlPWpDEsw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3650474</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_Ony51QAJ_02DctV0aevFAQ"
      decimals="0"
      id="Narr_hdEQPKInIUa15kST6JmVKg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8617157</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember__YdfUW6IYUmfXgc9SfOrnw"
      decimals="0"
      id="Narr_G5C8pXJfFE-S-t8iz-Hx_g"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">170740769</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_ZkAGkZRbN0SrE5hh7uf0cQ"
      decimals="0"
      id="Narr__y37xiSslEGqDXpURnI-Vw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">135141521</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <adag:NumberOfMajorSupplier
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LdAvTZA4DkCZZqMFxvFSkQ"
      decimals="INF"
      id="Narr_r6prjLR9uUWiBXI8wXlFBg"
      unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA">1</adag:NumberOfMajorSupplier>
    <adag:NumberOfMajorSupplier
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_MoK8o28CCE-5S19pyoHFfQ"
      decimals="INF"
      id="Narr_0kYqk-jSO0aaIxrv9JVmWw"
      unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA">1</adag:NumberOfMajorSupplier>
    <adag:NumberOfMajorSupplier
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_mXd1utWD0Uy80tRoBoh-xA"
      decimals="INF"
      id="Narr_1Ao81w4hVE623ePpt_q9TQ"
      unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA">1</adag:NumberOfMajorSupplier>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_XFO8ZN7Etk2rs2waJjZ9vA"
      decimals="3"
      id="Narr_S4m-vsT4fkavF-wtmBq1ng"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.215</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_qXLooUnAXE2ppSJQSdpERw"
      decimals="3"
      id="Narr_Upi3Ciay30Oa05tOr50eyA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.185</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_12_31_2022_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_AXlFqdkG3UW_uqmcSDFkCQ"
      decimals="3"
      id="Narr_VNq5WPOG7kO8OVvBG_aVug"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.341</us-gaap:ConcentrationRiskPercentage1>
    <adag:PercentageOfDepreciationOfForeignCurrency
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="4"
      id="Narr_aGhNH7jbQE-T7t3UWrVGUA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0229</adag:PercentageOfDepreciationOfForeignCurrency>
    <adag:PercentageOfDepreciationOfForeignCurrency
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="4"
      id="Narr_qNdU47UY2UugPEjsqispdw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0924</adag:PercentageOfDepreciationOfForeignCurrency>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_jr5G1eI5HkGIo9yAV-W-Uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group is an emerging growth company (&#x201c;EGC&#x201d;) as defined by the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02 (&#x201c;ASU 2016-02&#x201d;), &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-10 (&#x201c;ASU 2018-10&#x201d;), &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/i&gt;, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#x201c;ASU 2018-11&#x201d;), &lt;i style="font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/i&gt;, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#x2019;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current U.S. GAAP (Topic 840, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;). Further, the FASB issued ASU No. 2020-05 (&#x201c;ASU 2020-05&#x201d;), &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities,&lt;/i&gt; which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted.&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;The Group adopted the new guidance on January 1, 2022, using the alternative transition approach. For additional information, see Note 14, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#x2019;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, the FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and does not expect the adoption of ASU 2016-13 to have a material impact on the financial statements including the notes to the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. This update simplifies the accounting for income taxes as part of the FASB&#x2019;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2021. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group adopted ASU 2019-12 in 2022 and the adoption of ASU 2019-12 did not have a material impact on the financial statements including the notes to the financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt;, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Group is currently evaluating the impact of this accounting standard update on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In March 2022, the FASB issued ASU 2022-02, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings (&#x201c;TDR&#x201d;) and Vintage Disclosures&lt;/i&gt; (&#x201c;ASU 2022-02&#x201d;). ASU 2022-02 eliminates the TDR recognition and measurement guidance, enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. For entities that have not yet adopted ASU 2016-13, the ASU is effective upon adoption of the amendments in ASU 2016-13. Early adoption is not permitted before an entity's adoption of ASU 2016-13. The Group has not adopted ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_dDF9wb-wTEuPsr3eaEe_jw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;3. ACCOUNTS RECEIVABLE, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for doubtful accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_Exg80oELbUK0TrE3LemoOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for doubtful accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_CEQODxnys0-PXlXuV7R7rQ_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableNet
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_XWz7Vj_OH0-2fR0W2597Jw_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:AccountsReceivableNet>
    <adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_5EsVINau-keawlUg2lCiWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;4. PREPAYMENTS AND OTHER CURRENT ASSETS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepayments and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepayments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,562,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,161,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposits (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,873,843&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,970,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 619,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 804,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,055,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,937,323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.&lt;/span&gt;&lt;/p&gt;</adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_QRCjj2FYn06TGdYn_zpyEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepayments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,562,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,161,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposits (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,873,843&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,970,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 619,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 804,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,055,921&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,937,323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_1Q5UYZP_kk-tX8zp4Cm-eA_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1562177</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_Z-9bgQoiyU6DLTJ-_YSpbg_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1161910</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_pkrb3Au55EuO-cfLt88Qew_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1873843</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_hYUSDSI8-E6RL-r8NjvWRQ_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2970421</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_F3fNjr9cREqT8PFRkmExzg_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">619901</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_ve9mzQx78k-eM1UFhP495g_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">804992</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_hYa6H5kTO0uarzESDcLSpQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4055921</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_MWxlk47lwkOkNDvYE-Yh3w_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4937323</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_yD5dSVaSE0KcXXUemWYWiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;5. PROPERTY, EQUIPMENT AND SOFTWARE, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property, equipment and software consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,293,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,152,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,055,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,863,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,863,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,266&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 371,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 369,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,809,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,692,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,322,264)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,909,305)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net book value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,487,617&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,782,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Depreciation and amortization expenses recognized for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were US$858,408, US$1,125,032 and US$1,145,995 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_WbohXBQ-EEKNWKG03T31xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,399&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,293,386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,152,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,055,271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,863,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,863,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80,266&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 371,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 369,698&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,809,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,692,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,322,264)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,909,305)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net book value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,487,617&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,782,963&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_-deeomKWdka8knVPbfU3GQ"
      decimals="0"
      id="Tc_T2KE8isYpEWf7n4Cd9D8PQ_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5252399</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_HEZrgDuwzU2I-5vwCDZhrA"
      decimals="0"
      id="Tc_3FxB0pnlnEq9fQqc3F_AtA_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5293386</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-htfaRs6hE-PttrYcJWsUA"
      decimals="0"
      id="Tc_zzuFDu-yY0SCNA0g6AP1zg_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1152743</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_DNi18GaWDEuLxJST1LKg5w"
      decimals="0"
      id="Tc_nQRHpTOfIkeyQB3NjsilyA_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1055271</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EML4beDnNUeNnibb9wySxQ"
      decimals="0"
      id="Tc_nbZaaVeOVke6X4mdvqRKnw_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1863956</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_sW55u4h2J0OcuFvypf5muw"
      decimals="0"
      id="Tc_SYSuVoKkMUScTY973NGb0g_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1863963</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_O5OcHRqnw0Wo-gX84ILHew"
      decimals="0"
      id="Tc_UxkA7wWnZ0a4HYiKB0vI2Q_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">81467</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_rn5z_oGtm0i4zKXJtLEPBw"
      decimals="0"
      id="Tc_a7FQdsq1XEyg-QsvF0BT1g_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">29684</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_ITtG4X4HskK8vTiFNbmV8w"
      decimals="0"
      id="Tc_SBF3eeY2zUCBh9csHILMyA_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">87680</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_E2F3cjJxskiJsRXhTacDag"
      decimals="0"
      id="Tc_BWhrAZMuwkqaULN4VFPz5g_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">80266</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_MipZoRX4l0apHBHgnqY4mA"
      decimals="0"
      id="Tc_C9A7lgxKXke9ZHDbR0EvEA_9_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">371636</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_Ed31KlzZbUezDqBMeti4vA"
      decimals="0"
      id="Tc_IBdOgoKdg0qotDXqql3Buw_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">369698</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_bvz92vUUQESelLcccdCrZg_10_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8809881</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_fm5HyhODf02_QeynWBayAw_10_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8692268</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_HdrPW95NZUC1xuoji0GitA_11_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5322264</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_Yh0AaYsep0OORTWGmPMIzg_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5909305</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_SNqsLWet5UKyZLgJsrY_Uw_12_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3487617</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc__8E78h90TEWCXrJKwLA1Pw_12_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2782963</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Narr_lE-Bi9dgV06SYBUx5alNkg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">858408</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Narr_l1eIcRB9c0irX2bqc-nBIQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1125032</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Narr_AxJYgLDMHkeXGVb115F-Zw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1145995</us-gaap:DepreciationDepletionAndAmortization>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_7DeNrtKIW06ypqJAh7B2Mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;6. ACCRUALS AND OTHER CURRENT LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Accrued liabilities and other current liabilities consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 935,434&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,647,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,229,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,104,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Utility and maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes and surcharge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,270&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 349,039&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,379,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,212,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_bjmx5O2OsU-bWk1NM0Q5FA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 935,434&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,647,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,229,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,104,365&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Utility and maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,718&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes and surcharge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,270&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 349,039&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,060&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,379,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,212,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_kKqyB86pA0CmOVknDosZSA_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">935434</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_TZqCnSs5LkWe6AUuuBeenw_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1647490</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_me_69K3Nik6SFjI_3G7SuQ_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3229794</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_cddu-xssZUG6EeQ4OJtK6w_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1104365</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_ATTVi32vsE-Il87YSrjK7Q_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8685</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_LkB-411Y40aaJqPESwZNMA_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">40718</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_R7PDqC2UVUanxszh9ZjGHA_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">62270</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_01ZNkV8vQ0uGj0Nw-oBU4A_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">349039</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_whz141km-kCOIo0ur88Kog_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143060</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_QY5PgYAvw0SH4SwjTzdecg_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">71197</us-gaap:OtherLiabilitiesCurrent>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_2xTTOm6c002FPmhv8NVq7Q_9_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4379243</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_HbuDdwiolEyLR8RC0ZA4IA_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3212809</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_MUIU4zi7lEW2Y-x9I46Vjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"&gt;7. BORROWINGS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,121,226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,768,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Current portion of long-term borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,376,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,850,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,618,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,146,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,146,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,489,374&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 27,765,414&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Short-term borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Group borrowed a loan with the amount of RMB10,000,000 (equivalent to approximately US$1,532,591) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in June 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$766,295) from Bank of Ningbo Co., Ltd. for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in September 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was repaid in November 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the Group borrowed another loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was also repaid in November 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2021, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,552,771) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum. The borrowing was repaid in May 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Group borrowed another loan with the amount of RMB10,000,000 (equivalent to approximately US$1,568,455) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum. The borrowing was repaid in August 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,421,474) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 3.90% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2022, the Group borrowed another loan with the amount of RMB20,100,000 (equivalent to approximately US$2,886,024) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 3.70% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In July 2022, the Group borrowed a loan with the amount of RMB20,000,000 (equivalent to approximately US$2,871,665) from Bank of Jiangsu Co., Ltd. for a term of one year at the interest rate of 3.70% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2022, the Group borrowed another loan with the amount of RMB25,000,000 (equivalent to approximately US$3,589,582) from China Construction Bank Corporation for a term of one year at the interest rate of 3.65% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Long-term borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2019, the Group borrowed a loan with the amount of RMB7,500,000 (equivalent to approximately US$1,076,874) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.46% per annum. The Group repaid RMB375,000 (equivalent to approximately US$53,844) in 2019, RMB1,250,000 (equivalent to approximately US$179,479) in 2020, RMB3,375,000 (equivalent to approximately US$484,594) in 2021 and RMB2,500,000 (equivalent to approximately US$358,958) in 2022. As of December 31, 2021, RMB2,500,000 (equivalent to approximately US$358,958) repayable within twelve months for this agreement was classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets. The loan was fully repaid in February 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2019, the Group borrowed a loan with the amount of RMB6,000,000 (equivalent to approximately US$861,500) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.23% per annum. The Group repaid RMB300,000 (equivalent to approximately US$43,075) in 2019, RMB1,000,000 (equivalent to approximately US$143,583) in 2020, RMB2,700,000 (equivalent to approximately US$387,675) in 2021, and RMB2,000,000 (equivalent to approximately US$287,167)in 2022. As of December 31, 2021, RMB2,000,000 (equivalent to approximately US$287,167&lt;span style="white-space:pre-wrap;"&gt;)  repayable within twelve&#160;months for this agreement was classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets. The loan was fully repaid in June 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2020, the Group borrowed a loan with the amount of RMB16,500,000 (equivalent to approximately US$2,369,124) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.27% per annum.The Group repaid RMB1,650,000 (equivalent to approximately US$236,912) in 2021 and RMB3,850,000 (equivalent to approximately US$552,796) in 2022. As of December 31, 2021 and 2022, RMB3,850,000 (equivalent to approximately US$552,796) and RMB 11,000,000 (equivalent to approximately US$1,579,416) repayable within twelve months for this agreement were classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, the Group borrowed a loan with the amount of RMB8,500,000 (equivalent to approximately US$1,220,458) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.05% per annum. The Group repaid RMB425,000 (equivalent to approximately US$61,023) in 2022. As of December 31, 2021 and 2022, RMB425,000 (equivalent to approximately US$61,023) and RMB850,000 (equivalent to approximately US$122,046) repayable within twelve months for this agreement were classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2022, the Group borrowed a loan with the amount of RMB30,000,000 (equivalent to approximately US$4,307,498) from Agricultural Bank of China Limited for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB3,000,000 (equivalent to approximately US$430,750) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Also in May 2022, the Group borrowed a loan with the amount of RMB20,000,000 (equivalent to approximately US$2,871,665) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.00% per annum. The Group repaid RMB500,000 (equivalent to approximately US$71,792) in 2022. As of December 31, 2022, RMB1,500,000 (equivalent to approximately US$215,375) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2022, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,421,474) from Agricultural Bank of China Limited for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB1,000,000 (equivalent to approximately US$143,583) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Also in August 2022, the Group borrowed a loan with the amount of RMB20,000,000 (equivalent to approximately US$2,871,665) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB1,000,000 (equivalent to approximately US$143,583) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2022, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,421,474) from Agricultural Bank of China Limited for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB1,000,000 (equivalent to approximately US$143,583) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Also in November 2022, the Group borrowed a loan with the amount of RMB10,000,000 (equivalent to approximately US$1,435,833) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.00% per annum. As of December 31, 2022, RMB500,000 (equivalent to approximately US$71,792) repayable within twelve months for this agreement was classified as "Current portion of long-term borrowing" on the consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The proceeds from the loans were primarily used to pay for the Group&#x2019;s research and development activities in China, including CMC costs of clinical and preclinical programs. As of December 31, 2021 and 2022, none of the Group&#x2019;s borrowings were collateralized in the respective loan agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Future maturities of short-term borrowings and long-term borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2021 and 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,858,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,618,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,124,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,022,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,489,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,765,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_Ommf9mGvCUudHE0jLAkHOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,121,226&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,768,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Current portion of long-term borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,376,319&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,850,128&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,618,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,146,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,146,541&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,489,374&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 27,765,414&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_SCxCbb4m0Ee9gaMy_63ShA_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3121226</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_CT1bkwwVt0iQo29dwUPS5Q_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10768745</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_lo5mhzCvVUyz5A-MoXn3LQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1376319</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_fS2ujro_80qixd2tz7tV9Q_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2850128</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_KVP_3Gq_P0yGzgbBcLaumQ_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4497545</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_hOnbTMhzKkigAXuSjbqluA_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13618873</us-gaap:DebtCurrent>
    <us-gaap:LongTermLoansFromBank
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_X4olMBleO0uQhYO7AEsnUg_11_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2991829</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermLoansFromBank
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_AOAsauPjgUGWeGCHTcDfpw_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">14146541</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_A6879VUzh06PgnxYReLqpg_12_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2991829</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_DZboN3KfiUq0MRXnIGdzVw_12_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">14146541</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_45LVwOjBrEGD2t2kzDg1Lw_13_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7489374</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_UKd-93sMcEWOQ_ne7BF7VA_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27765414</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ"
      decimals="0"
      id="Narr_dJtQgQmGpkSyvl6NW8DTsw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ"
      decimals="0"
      id="Narr_Yhct7b_2s0GQZKJAgjW4QA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1532591</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_GObFgSRwTUiB_WsA8h6l6g"
      id="Narr_0p46sV5__UOcToLno0Uyqg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_cIToTEKhfkCOzkRRQd5qkQ"
      decimals="3"
      id="Narr_z7ZoUe9CjkSaDjoYW07Abg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ"
      decimals="0"
      id="Narr_PP1bUu4P3EGvxBLvW5Qmdw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ"
      decimals="0"
      id="Narr_KWfaaATlLUm12PLe3TjCYA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">766295</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_o0zaN5JGjUuNPtedN9XKFA"
      id="Narr_FOnhhGmvEUKDs0hWkrSHLA">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_wgUGVoYCjEi-m8V0f5S6GQ"
      decimals="3"
      id="Narr_o48XoU5f30CfQPN3UVpu2w"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ"
      decimals="0"
      id="Narr_vWO3zbZuYk6wU41xEOCggw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ"
      decimals="0"
      id="Narr_iHTwPZ33aU6glZi44eVQqg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">770962</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_mUP8HKs3QE-VA88oUIhohw"
      id="Narr_huegp8hvuk2Y37NsJ3poJQ">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yIYGZLTtM0298TBZ0m1ZHQ"
      decimals="3"
      id="Narr_gZAptPM9uk6fdauE64kA4Q"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ"
      decimals="0"
      id="Narr_Ckq5BWrsrkaRx_4G3JeCvA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ"
      decimals="0"
      id="Narr_AN1LUXCvGkK2ATl3VmqCyQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">770962</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_UzX_9ytflk6kC_qnriMQxQ"
      id="Narr_bsaAnjfn1kePws-Eeuc_lA">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_X_lzBuVBfEKnFz4N0VTDEQ"
      decimals="3"
      id="Narr_gqbVO4Y3b067XSug4cmIcA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw"
      decimals="0"
      id="Narr_koLsd2qFukmYlgKj1hkgWA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">9900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw"
      decimals="0"
      id="Narr_1XRMt-1MRkCjt7OQuR-ngw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1552771</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_m85-xLE3m0awlOkyhyozPA"
      id="Narr_5wtLKt-z9EmArlL3bM6zhg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7o-M3oCxv0e4BZvpFuDHvw"
      decimals="4"
      id="Narr_zbrpteom1kmXlawQoAoCog"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ"
      decimals="0"
      id="Narr_j90WgpJdm0u-UjrTfmgeWA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ"
      decimals="0"
      id="Narr_NBO8FHemdkKbebc7xb2axg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1568455</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_M1R5q493x0epZjiLXZubXA"
      id="Narr_bUsy4wczQkuu30yIOMz9Pg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_Y00OYdOB00-5Dg30H0xnLQ"
      decimals="4"
      id="Narr_ShGfP5DbAEqipZZ3dzFyqg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw"
      decimals="0"
      id="Narr_Zf_Ct_HIyUCJlu5cR6IqIw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">9900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw"
      decimals="0"
      id="Narr_Bvp6fpP1dU-1vM0rjfAJ-Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1421474</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_qhmYvReawUyRvQAZITHLMw"
      id="Narr_FpF_BcPutE-GImMfvsypAA">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_3_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_QpMn4a1BCUiEd5PEcZpniw"
      decimals="4"
      id="Narr_POa51v5tkkSjAtU5aEtLjw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0390</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw"
      decimals="0"
      id="Narr_6L8lgSUWaEuoM8GJ5gWLjQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">20100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw"
      decimals="0"
      id="Narr_2chMPEQpUU6UdoTWupcflg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2886024</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_4_1_2022_To_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_1aTpF0ph_0-mY4m38ylZKg"
      id="Narr_1BKbBfypMk-Yva-YskZHmw">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_4_30_2022_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_epR2r2LgbkuKj6OZULvEMw"
      decimals="4"
      id="Narr_JeOtfB6s502ZVvx20iRN0Q"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w"
      decimals="0"
      id="Narr_bJ6QtnqHIkqBWZYPB8wHqw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w"
      decimals="0"
      id="Narr_c9cy98YC90Sjcv1tVqzuLw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2871665</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_7_1_2022_To_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_Cvjhq1dzz0iJpxmkLeqhQg"
      id="Narr_YEpxfu5fhU2h90x79XeMIw">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w"
      decimals="4"
      id="Narr_Hw3cxMBIAEa0igC2yY2oHw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q"
      decimals="0"
      id="Narr_tOIuKgMFuUuhZJAXSngHzA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q"
      decimals="0"
      id="Narr_o-8RrLxI_kmQKc4icrOLug"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3589582</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_12_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_7-okYR-WZkiKB1VW-JL4qw"
      id="Narr_6jkQwqZJNki-DexqsGjjbQ">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_adag_ChinaConstructionBankCorporationMember_vF5-VuUHo0aaIEZhrLqX7Q"
      decimals="4"
      id="Narr_xp09Unw5nUK4CtMDtbv6gw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0365</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w"
      decimals="0"
      id="Narr_eSUrY_sBdke15hxLC_kVEw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w"
      decimals="0"
      id="Narr_LoUih4YrvEanRbjeyYLZ1Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1076874</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w"
      id="Narr_NHWc7CtpgUiJIg8gFfBOYw">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w"
      decimals="4"
      id="Narr_4_kU3jqipkekC1in-ph41Q"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0546</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_mtdgNiOXz0Od9s3DiXLFWg"
      decimals="0"
      id="Narr_8UHSWfPGjkemgAQ72IyBDQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">375000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_mtdgNiOXz0Od9s3DiXLFWg"
      decimals="0"
      id="Narr_3L5BvUCdKEmmBXmE5MTceQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">53844</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_jTkNK83fPE6etG2zBbgm_w"
      decimals="0"
      id="Narr_2S1SSJfNJ0SCurCrEmh1MA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1250000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_jTkNK83fPE6etG2zBbgm_w"
      decimals="0"
      id="Narr_4CygRwwBp0aAVx_kjU7bPg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">179479</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vDDRVJHJWEiIRkoC0j_pHA"
      decimals="0"
      id="Narr_RzJ9E2WBqEeHaBMJzhHF7Q"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">3375000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vDDRVJHJWEiIRkoC0j_pHA"
      decimals="0"
      id="Narr_2BJ-fi2lyEWvvVpxMlDAuQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">484594</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ZBzOSEd9-keWfT5F8GU35g"
      decimals="0"
      id="Narr_bBFC6tXjv0i6d3AKNJq6RQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">2500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ZBzOSEd9-keWfT5F8GU35g"
      decimals="0"
      id="Narr_N6W6UEP-kU-o3IbNmigLAw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">358958</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vOz3vIv740GU9REG4Z_wcA"
      decimals="0"
      id="Narr_-1_eWhoLxUWErDsCyvNOsA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">2500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_vOz3vIv740GU9REG4Z_wcA"
      decimals="0"
      id="Narr_CEk5vtMa20-hhHyLksUdrg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">358958</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ"
      decimals="0"
      id="Narr_UXpbzTtVI0K5-8ZNnj5B2w"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ"
      decimals="0"
      id="Narr_kooD17M7NkKGuEWkwqsJsw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">861500</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ"
      id="Narr_jxMYYez8a0-dRjO8rc7gSg">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TC8O1lAbDk6qE-xSDR1DhQ"
      decimals="4"
      id="Narr_uDt5Iv8BS0-rXM3SVij4PA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0523</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_53NbnrlZsUSgSYUOMp8aRQ"
      decimals="0"
      id="Narr_TEAwzh3tzE2tvigdxORabg"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_53NbnrlZsUSgSYUOMp8aRQ"
      decimals="0"
      id="Narr_DIDkrBc9HEO1L-iq_BwqEw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">43075</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_1rOMO6-cAU-GIBzCBWWxnQ"
      decimals="0"
      id="Narr_cA3K6D4KW06ISX_b6sdr3g"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_1rOMO6-cAU-GIBzCBWWxnQ"
      decimals="0"
      id="Narr_4kS3IP6YbkqvAl5bi7KnMw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143583</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_hHC55XuXUE2hmp5hAZXI4w"
      decimals="0"
      id="Narr_uhd8oBDf902JLwZ3S5whXw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">2700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_hHC55XuXUE2hmp5hAZXI4w"
      decimals="0"
      id="Narr_kO8-Vlxxm0GUROpRfDTlLQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">387675</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TIiFTeaXkUeerjdaxd6jwg"
      decimals="0"
      id="Narr_4337Vrdc5UWkV3mHS7TqWw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">2000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_TIiFTeaXkUeerjdaxd6jwg"
      decimals="0"
      id="Narr_E1zmkmPdsUS0ZsXIvEkc_g"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">287167</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_v_9yYOSrf0y4xth99sJ-dg"
      decimals="0"
      id="Narr_--CDcZdYTEaAgDgEqgke0Q"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_v_9yYOSrf0y4xth99sJ-dg"
      decimals="0"
      id="Narr__EV0f1vVZUut-Uz05YJAYg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">287167</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA"
      decimals="0"
      id="Narr_dWXC7gHSN0u46LgMJr5PdQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA"
      decimals="0"
      id="Narr_48PXDDXW-kajfCJ4EWjUBg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2369124</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA"
      id="Narr_lNg2qdd-e0WmpxMg2HTp3A">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_E2vR6f-v_Ue79O_jM1PKWA"
      decimals="4"
      id="Narr_e92jqG0EWk26qgsEOyiMGA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0427</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_3nKdmvhHQ0e0MXKzpN6qwA"
      decimals="0"
      id="Narr_mJJIodXTWEyt6ub4mDxTWA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1650000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_3nKdmvhHQ0e0MXKzpN6qwA"
      decimals="0"
      id="Narr_qOy9k0x5ckefpQrq3eu5rQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">236912</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_0q1bEcQFREGMTjD4ZvPvnQ"
      decimals="0"
      id="Narr_-VhkBSMhc0m5DS_ainHMOw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">3850000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_0q1bEcQFREGMTjD4ZvPvnQ"
      decimals="0"
      id="Narr_U3BFLLmMmU24-HfUggbOVQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">552796</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_BtH_9qawAU6ZHHYCSElW5Q"
      decimals="0"
      id="Narr_ui8JT2HcIUqggeSv1iCs_Q"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">3850000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_BtH_9qawAU6ZHHYCSElW5Q"
      decimals="0"
      id="Narr_djUrnolp4UqImMDyB3n_5w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">552796</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_Kyvt-xNRBUiAu-DLngZgGQ"
      decimals="0"
      id="Narr_kTm-IIxQq0euLdeB1HfrNQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">11000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_Kyvt-xNRBUiAu-DLngZgGQ"
      decimals="0"
      id="Narr_gDX4J8IKnkK2KDN_kk-0Sg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1579416</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg"
      decimals="0"
      id="Narr_8AwN1ytiokSUc3XzyDc1zw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">8500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg"
      decimals="0"
      id="Narr_DHJTrQojikKClJyaipi1tg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1220458</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg"
      id="Narr_C5VplAhQ0kaAuf-ay_AIqg">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_3nx-vi0DAUuaS4LwhcmcVg"
      decimals="4"
      id="Narr_dk2XqU1yy0CgVe5uqbWlaQ"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_hlw_TK4DbU6yZTcHfKFcyw"
      decimals="0"
      id="Narr_zDJ-IlY8tkSeh1iOLXweEA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">425000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_hlw_TK4DbU6yZTcHfKFcyw"
      decimals="0"
      id="Narr_08buR5ve8ke2cN9irXunnA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">61023</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_CaP4Z8PlL0OapP5FtNaLKQ"
      decimals="0"
      id="Narr_p35U893ZU0upOMV6s2KhNw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">425000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_CaP4Z8PlL0OapP5FtNaLKQ"
      decimals="0"
      id="Narr_x7aYulKlG0OGzk7mYdcE6Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">61023</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_ymVbWklhkUCmOkHyKVKxVg"
      decimals="0"
      id="Narr_GHXQsrfF4EOSRM6Uhs8bDg"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">850000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_ymVbWklhkUCmOkHyKVKxVg"
      decimals="0"
      id="Narr_P7dII-qSE0G77ZE06rDiLw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">122046</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"
      decimals="0"
      id="Narr_PuycR4ec30y3CyBp4UbTjQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"
      decimals="0"
      id="Narr_yvm2Elp4K0mrfBdlHdLLjw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4307498</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"
      id="Narr_BBHUOxUU1EKMR9X9h0NFlA">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"
      decimals="4"
      id="Narr_eUG46GISVkiLZSLlKHRcXw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"
      decimals="0"
      id="Narr_EiHF3gmZ_U-INkw151eN-g"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">3000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_9kXBQmeey0WAppCZJLOv7A"
      decimals="0"
      id="Narr_mWQVdP6wMUiokIYuwg1mcA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">430750</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg"
      decimals="0"
      id="Narr_TXKutQJfU0eMArhAlf5Myg"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg"
      decimals="0"
      id="Narr_K9vI2U-xp0ebd64COQUDIw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2871665</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg"
      id="Narr_0mPtjCyzjU6M_iXf9wOFUg">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_PgLhYb4MJE6cuiOSsHqENg"
      decimals="4"
      id="Narr_s4Rs2sXnGE2Qo_AbwyFtJg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_yuDqrjY2ZES39bMfzJzDpw"
      decimals="0"
      id="Narr_D1dwG2fHVEmMrmRTiHCjyw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_yuDqrjY2ZES39bMfzJzDpw"
      decimals="0"
      id="Narr_TMfgsbdgXkyztM7WW6SS7g"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">71792</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_zUL5X-s5MEOb_qYJhHPkHw"
      decimals="0"
      id="Narr_byYbx620ZkmfFFHIAxHqpw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember_zUL5X-s5MEOb_qYJhHPkHw"
      decimals="0"
      id="Narr_WIx2MMVK806HnoEMiSVEjA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">215375</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg"
      decimals="0"
      id="Narr_Pi4796Z8w0-aL-Ukhua-Cg"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">9900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg"
      decimals="0"
      id="Narr_6FNtOFwTKUq3GiFETl50Jw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1421474</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg"
      id="Narr_u6I_x4qrHEe_4xZeRHLdaQ">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_QvjElY6Ppkyb7R9ffoU7cg"
      decimals="4"
      id="Narr_Dq8OHpCOYEaLBCmE2GmCFw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw"
      decimals="0"
      id="Narr_pt5AptktukOvNAZzs_aUtA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw"
      decimals="0"
      id="Narr_SAG2Tqqbnk6a4ds2EzQ7EA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143583</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig"
      decimals="0"
      id="Narr_HttQ527cXE2heeRT-Vp1UQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig"
      decimals="0"
      id="Narr_z_Lq_P_DOESZFYCTvUs95w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2871665</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig"
      id="Narr_HqzJIj65aE-zGnQlEd0dGA">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_TfnCUFU6G0Wk70W-XsxTig"
      decimals="4"
      id="Narr_Al-PzU0qrUaBvsiJKZLMFw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_tHkOGLmG7kWYIeDJOJTVtg"
      decimals="0"
      id="Narr_rlmL5NR0EUS2dHXk3hG-mQ"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember_tHkOGLmG7kWYIeDJOJTVtg"
      decimals="0"
      id="Narr_D1UH4HBN3EKNGfQKOpISOA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143583</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg"
      decimals="0"
      id="Narr_F3wtBFVkqUaPii7SapVXUw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">9900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg"
      decimals="0"
      id="Narr_Tx_vnk7DLEmZil8FD8efvw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1421474</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg"
      id="Narr_GIPqz5K36kqncKQaNcjlAg">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_PXz-WjGmN0u9GleqT3_Npg"
      decimals="4"
      id="Narr_ILXiS60y6EWawlHAd1KCfA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw"
      decimals="0"
      id="Narr_im1p4S7UIk-Va6Iyo1ACQw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">1000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_W_TgXvPzskmFbEaVfuL8Sw"
      decimals="0"
      id="Narr_3sdZiZd5O02nAk7npA55ow"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">143583</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA"
      decimals="0"
      id="Narr_L4i-FjPK5U-9aKDfk9P-Ig"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA"
      decimals="0"
      id="Narr_ouP_nCm4LUG5n6b0Qn5jUQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1435833</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA"
      id="Narr_PkcydvLiX0K_vRZ1yl8Lkg">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_HUrFbggTuEqFy7Q1u63EIA"
      decimals="4"
      id="Narr_lVmoyBbR-kuH7t846zzCww"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_qYhrznmDM0a0FqD3lA6Fbg"
      decimals="0"
      id="Narr_rP4DNZydC0it0UMJkQD0eg"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2022_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember_qYhrznmDM0a0FqD3lA6Fbg"
      decimals="0"
      id="Narr_nzNdlf8kvEGODyXRHxelsw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">71792</us-gaap:LongTermDebtCurrent>
    <adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_ImSw9U6bREGgwv0CvnwSJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2021 and 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,858,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,618,873&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133,210&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,124,429&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,022,112&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:76.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,489,374&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,765,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_69GVtUdgXU6qjuqBX9tpqA_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4497545</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_XRtS6Vd5z0mBWzxuuFYPjg_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1858619</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_cXDJ0xvzX0KtNMv416qHnQ_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13618873</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_gem6VjUmhE-HKMlTJp1ONQ_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1133210</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_rODn480srEKsgBd4EK5mJw_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4124429</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_lOSQcEYXwU66uAnRBj7wAA_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10022112</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_k48v9sNmBE2vhziMlaZ3fg_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7489374</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_DbyfIx3oBUqTO1jp6NTcJg_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27765414</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_dxPV4dNWl0ulIJZKxRqW6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2011, the Company issued convertible notes (&#x201c;Series Pre-A Convertible Notes&#x201d;) to certain investors in the amount of 4,590,908. The notes carried a simple interest (non-compounding) of 6% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the convertible redeemable preferred shares of the Company at a price no more than US$1 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2014, the Company issued 5,473,957 Series A-1 convertible redeemable preferred shares (&#x201c;Series A-1 Preferred Shares&#x201d;) to certain investors upon conversion of the Company&#x2019;s Series Pre-A convertible notes at a conversion price of US$1 per share. Concurrently, the Company issued 2,370,414 Series A-2 convertible redeemable preferred shares (&#x201c;Series A-2 Preferred Shares&#x201d;) to certain investors at US$1.27 per share for a total consideration of US$3,000,000. Series A-1 Preferred Shares and Series A-2 Preferred Shares are collectively referred to as the Series A Preferred Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From January through June 2016, the Company issued 7,494,537 Series B convertible redeemable preferred shares (&#x201c;Series B Preferred Shares&#x201d;) to certain investors at US$3.74 per share for a total consideration of US$27,999,995.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From February&#160;through May&#160;2018, the Company issued 5,597,354 Series&#160;C-1 convertible redeemable preferred shares (&#x201c;Series&#160;C-1 Preferred Shares&#x201d;) to certain investors at US$8.93 per share for a total consideration of US$50,000,033. Concurrently, in February&#160;2018, the Company also issued warrants to two Series&#160;C-1 investors at nil consideration (&#x201c;Series&#160;C-1 Warrants&#x201d;). The Series&#160;C-1 Warrants allowed the holders to purchase Series&#160;C-2 Preferred Shares (defined below) at the exercise price of US$10.21 per share for a total consideration of up to US$7,500,000. Series&#160;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&#160;April&#160;1, 2019, ii)&#160;a deemed liquidation event or iii)&#160;the closing of the Qualified IPO. Series&#160;C-1 Warrants expired on April&#160;1, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From June&#160;through November&#160;2019, the Company issued 1,861,121 Series&#160;C-2 convertible redeemable preferred shares (&#x201c;Series&#160;C-2 Preferred Shares&#x201d;) to certain investors at US$10.21 per share for a total consideration of US$18,999,999.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the Company issued 4,452,441 Series&#160;C-3 convertible redeemable preferred shares (&#x201c;Series&#160;C-3 Preferred Shares&#x201d;) to a certain investor at US$11.23 per share for a total consideration of US$50,000,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;C-1 Preferred Shares, Series&#160;C-2 Preferred Shares and Series&#160;C-3 Preferred Shares are collectively referred to as the Series&#160;C Preferred Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon completion of the IPO on February 11, 2021, each of the then outstanding Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares (collectively the &#x201c;Preferred Shares&#x201d;) was automatically converted into one ordinary share. As of December 31, 2021 and 2022, there were no preferred shares issued or outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Accounting for Preferred Shares&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Preferred Shares were classified as mezzanine equity in the consolidated balance sheets because they were contingently redeemable upon the occurrence of an event outside of the Company&#x2019;s control (e.g.&#160;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&#160;31, 2025 (&#x201c;Target QIPO Date&#x201d;)). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares were initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any Preferred Shares issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the IPO, the Company concluded that the Preferred Shares were not redeemable, but were probable to become redeemable. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest redemption date for the year ended December 31, 2020, and to the IPO date for the year ended December 31, 2021, using the interest method. No accretion charge was recorded as the redemption value was fixed to original issue price for the periods presented, except for Series C-1 Preferred Shares issued with detachable warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Modification of Preferred Shares&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company made several amendments to the Preferred Shares, mainly including: 1)&#160;added redemption rights for Series&#160;A Preferred Shares upon the issuance of the Series&#160;B Preferred Shares; and 2)&#160;extended the Target QIPO Date upon the issuance of the Series&#160;C-1 Preferred Shares and the Series&#160;C-3 Preferred Shares. These amendments were accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s Preferred Shares activities for the periods presented were summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Mezzanine equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,727,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,201,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,975,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,449,407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of Preferred Shares to Ordinary Shares &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,473,957)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,999,995)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,004,009)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,999,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (154,477,960)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ"
      decimals="0"
      id="Narr_Tc41LxgyGUCL4pVauK0nXg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4590908</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ"
      decimals="2"
      id="Narr_fLlJxpskgEGCjvq49kVBFg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_ZeGKQjabT0mj5PrqauBRuQ"
      decimals="0"
      id="Narr_RsEXs85nV0OOAZi_KhRCfw"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_YUb_RBfSLEO6_Ii2KjdzgA"
      decimals="INF"
      id="Narr_o3pIZCiIi0az4Ta0T3sNGw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">5473957</adag:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_1YpVsNTuokSIfl2TMrVz6w"
      decimals="0"
      id="Narr_OMcslYdUZ0eY9E0qETsYUw"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_wIkgvAtqC0W5o3H3Cfgn_w"
      decimals="INF"
      id="Narr_mjSreb-wz0eZpjZNdYOaLw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2370414</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_vua2vlRLFESfuxZbRFuRuA"
      decimals="2"
      id="Narr_n3BsjizyOUeujmA5oR6kqA"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1.27</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_wIkgvAtqC0W5o3H3Cfgn_w"
      decimals="0"
      id="Narr_Ty71NGYeIEq0iJmeq3GSAQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_wh21KqXIxUieE_LnSC8fWA"
      decimals="INF"
      id="Narr_BQxrTIfZf0iio3qv29mOcA"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">7494537</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_vrEMPt5leE2LUHWCygtNag"
      decimals="2"
      id="Narr_BcPZyG9LUUStsoWJB4FOWQ"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">3.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_wh21KqXIxUieE_LnSC8fWA"
      decimals="0"
      id="Narr_YeCMTbGMl0yybRZRuYlP8Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27999995</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_eIoK0LUqmECLHEJOC58yjQ"
      decimals="INF"
      id="Narr_hQK6LEl7HkatklFiHAjzng"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">5597354</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_zXGYISRRU0mn6bkSMKyVSQ"
      decimals="2"
      id="Narr_tbSBPHvx_USqOasHhoGoOA"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">8.93</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_eIoK0LUqmECLHEJOC58yjQ"
      decimals="0"
      id="Narr_B4WpCm2EmEC7BBZ8HQZ3_Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">50000033</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:NumberOfInvestorsToWhomWarrantsWereIssued
      contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZBLOK46STEKlz-d2OVI5uw"
      decimals="INF"
      id="Narr_KoddusfaEUexZrenysvRNA"
      unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA">2</adag:NumberOfInvestorsToWhomWarrantsWereIssued>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WtkVxDqueEGxL4XHYvRZcQ"
      decimals="0"
      id="Narr_vwC_bc-k3E6Qqi4rE_WDxA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_Kp5I1u1AQkCMEJ0paDZCvA"
      decimals="2"
      id="Narr_D9XoNYClW0SmO8LacEfNGQ"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">10.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adag:MaximumProceedsReceivableFromExerciseOfWarrants
      contextRef="Duration_2_1_2018_To_2_28_2018_lP6oVbKR6UmaFzbif9o9lA"
      decimals="0"
      id="Narr_BPTad3bRFUOlrq4_D_sqgw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7500000</adag:MaximumProceedsReceivableFromExerciseOfWarrants>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Y81m7zrxYE2aoB4C9ZGt2A"
      decimals="INF"
      id="Narr_cZ0GVFybdUehqan9WAEaNw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1861121</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_QTNt0bXsx0a3cvqcs-sJBg"
      decimals="2"
      id="Narr_PhgKqR8Z6EStiIUuAArq5Q"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">10.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Y81m7zrxYE2aoB4C9ZGt2A"
      decimals="0"
      id="Narr_YS4Sc1MQq0mATDik6CTu6w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18999999</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_gn5TOqPkiEmr84V7LuQlbQ"
      decimals="INF"
      id="Narr_wG48F6XAu0-jLxC3MnifzA"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">4452441</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_MvdjFPDEXkW0jwwbZh-cTA"
      decimals="2"
      id="Narr_u0Xi5l2RMUWxlqietSmOsA"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">11.23</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_gn5TOqPkiEmr84V7LuQlbQ"
      decimals="0"
      id="Narr_ANyDR86w6UGcnlZ0nUYh1w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">50000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_SbWl9Shq4E6nlxFVgDBgpg"
      decimals="INF"
      id="Narr_oA41z1UBIE2AHowRdhoVZg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Narr_0iE_lHwbqUe523QL-FRm1Q"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Narr_GpPe78BRVkO_ydFn-y13XQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_gQE9Vm16yUaAnDvUO1PYZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Mezzanine equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,727,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,201,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,975,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,449,407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of Preferred Shares to Ordinary Shares &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,473,957)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,999,995)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,004,009)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,999,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (154,477,960)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_m7mB-vO98k6ssn4DOuHCmA"
      decimals="0"
      id="Tc_wVOBfsK6WU-dY0fgUdB7ww_3_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5473957</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_LetG2TvOqky7qj1cVnqr1Q"
      decimals="0"
      id="Tc_h1QhhOAlKEm1QWy2qYShkg_3_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_o9la4OH3f0S73pFAL_jdvw"
      decimals="0"
      id="Tc_RkStX5_6J0C0Wbo1W7ZFzA_3_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27999995</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_WRGc8jvai0S64dQK-czIGw"
      decimals="0"
      id="Tc_M5A3PnQEKU6iLUk40KKlsA_3_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">48727343</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_L7regPgk0U6wE3_qz1Zy6A"
      decimals="0"
      id="Tc_0x2VQWGOv0uEUhM-cheMDQ_3_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18999999</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_MvdjFPDEXkW0jwwbZh-cTA"
      decimals="0"
      id="Tc_fBe8Jplp2E2XoGuhVfPSmA_3_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">50000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="0"
      id="Tc_8ioQgjt4Rk6RewnF7dKMbw_3_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">154201294</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_VrdzSlGiIU21zpTy5Vhp1A"
      decimals="0"
      id="Tc_ZyczbEdl_U6OSd83mBKRrw_4_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_VrdzSlGiIU21zpTy5Vhp1A"
      decimals="0"
      id="Tc_v9a18L7BhkmNFw4YkUX-Uw_4_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_WRYTAw9fyUK5wNbAtUEgzg"
      decimals="0"
      id="Tc_0aeCECzOT0mtGKB3cHlrcg_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5473957</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_CtbvulJUiUmHT0BVyHHTeQ"
      decimals="0"
      id="Tc__sebbmJsaUallarl-p5gCQ_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_LM0cYbNYBkuxPFEH3zcWdA"
      decimals="0"
      id="Tc_qYPzwqhlBkWlstG8x0dg_g_5_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27999995</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_-lU6hnUg1USHN9tNgX6z5Q"
      decimals="0"
      id="Tc_OHGDEwfynEONVtFNrrFPkw_5_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">48975456</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_g02U-ugGTkWtKxibVH1wIw"
      decimals="0"
      id="Tc_B6ZcAWgh4Eqb4o5x8wmq2A_5_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18999999</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_k-Tj_Iz31EmvHKgzizS4_w"
      decimals="0"
      id="Tc_79G-kPl6ZEC_d3dHcuaUZA_5_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">50000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="0"
      id="Tc_qEj5T7RgDkuCqt1iYofrkw_5_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">154449407</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA"
      decimals="0"
      id="Tc_d6-yG3ZmJUiU55b-W768XQ_6_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA"
      decimals="0"
      id="Tc_ICG7ogEC1kKBgnRIR2pJOA_6_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_5kY-i-Zg3k-S2BENf9UwDw"
      decimals="0"
      id="Tc_yUP39Bs0MkeIsmTv0s_8mQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5473957</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_2hVJvj7Zgk2flnbUuLCHEA"
      decimals="0"
      id="Tc_IdU7cbhuPEqVZ6JceJ8TWg_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pizwZd0AoUe6Rr73Pf4YZQ"
      decimals="0"
      id="Tc_k2G4ksp7OEmeyzm36uz1ng_7_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27999995</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_0bzlcIgKTEy8gzwt_wHkmA"
      decimals="0"
      id="Tc_y6HAQLXOfUKby5wHfpwwZQ_7_8"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">49004009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_Fsp_-okReEKrd3koR5i-HA"
      decimals="0"
      id="Tc_GR2cRE8Vl0W7rRDJ9EC9BQ_7_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18999999</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_kqrGAtT1eEGm0zzWRDQUBg"
      decimals="0"
      id="Tc_xYWa-dt2J0mi2LqaMoNRuA_7_12"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">50000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_hY7ep-Ysn0K8pofcopR8pA_7_14"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">154477960</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_eLOwzXMN40SaKS77zUBpVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;9. SHARE-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;7, 2015, the Company adopted a share incentive plan (the &#x201c;2015 Plan&#x201d;). Under the 2015 Plan, the Company&#x2019;s Board of Directors has approved that a maximum aggregate number of shares that may be issued pursuant to all awards granted shall be 4,336,126. In September&#160;2017, the Company replaced the 2015 Plan with the amended and restated share incentive plan (the &#x201c;2017 Plan&#x201d;) and increased the maximum number of shares issuable to 6,336,126. In December&#160;2019, the Company replaced the 2017 Plan with the second amended and restated share incentive plan (the &#x201c;2019 Plan&#x201d;) and further increased the maximum number of shares issuable to 11,391,131. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the Company may issue under the respective plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than five years, under which the grantee earns an entitlement to vest a certain&#160;percentage of his option grants at the end of each&#160;month or&#160;year of completed service. The share option awards shall expire no more than 10 years from their grant dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence of their applicable performance conditions (including but not limited to the occurrence of an IPO, the completion of business and operational goals, etc.).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 15, 2020, pursuant to a board resolution, 184,692 share options that granted to a senior management was modified and the vesting period of such share options was shortened from 5 years to 4 years. Since the fair value of the modified award was lower than the fair value of the original award immediately before the modification, no incremental compensation cost was recognized for the modification during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of 2,375,000 share options granted to certain management members. Pursuant to this board resolution, these management members exercised all related share options at the original exercise price per share ranging from US$1.83 to US$2.26. As a result, 2,375,000 ordinary shares were issued to these management members. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$5,197,650. The Company had the repurchase right to buy back such shares at the original exercise price if the grantees did not meet the original vesting conditions. The Company assessed and considered that in accordance with guidance set out in ASC 718-10-55-31, given such arrangement allows the shares received on exercise be returned to the Company if the original vesting conditions are not satisfied, there has been no substantial change to the vesting conditions and the Company shall continue to account for the share awards in accordance with their original terms. As of December 31, 2021, there were 1,585,000 shares unvested according to the original vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of 491,119 ordinary shares as repayment for their respective promissory notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way of new option grants with an exercise price of US$13.85 per share. The fair values of these share options were US$7.85 per option, determined by using the binomial option valuation model. The share-based compensation expense related to these share options were recognized immediately upon grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the same board resolution, the 2021 Performance Incentive Plan (the &#x201c;2021 Plan&#x201d;) was also adopted, under which an aggregate of 2,994,000 ordinary shares shall be reserved for issuance, and the share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&#160;5% of the total number of the Company&#x2019;s outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by the board of directors. From March 12, 2021 to December 22, 2021, pursuant to the 2021 Plan, a total of 1,303,000 share options were granted to certain employees by 15 batches, with exercise price ranging from US$5.92 to US$17.56, respectively. In addition, 23,734 ordinary shares were issued to certain management personnel on March 16, 2021 pursuant to the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of 2,060,308 share options granted to certain employees were modified. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) 25% of the total number of share options of each grantee (&#x201c;Annual Cap&#x201d;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#x201c;Credited Shares&#x201d;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. As a result of the modification, the Company recognized an incremental fair value of US$2,337,697.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From February 7, 2022 to December 27, 2022, pursuant to the 2021 Plan, a total of 2,640,598 share options were granted to certain employees, with exercise price ranging from US$0.80 to US$5.60, respectively. In addition, 99,999 ordinary shares were issued to certain management personnel on March 8, 2022 pursuant to the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2022, among all the share options granted to date, 2,483,808 and 4,776,906 share options contained both service conditions and performance conditions, respectively. All other share options granted contain only service conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 866,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,328,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,313,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,694,934)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,294,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,410,968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,894,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (233,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (145,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,809,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,619,574&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,640,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (197,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (964,789)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,286,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,286,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,486,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 874,180&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,070,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate fair value of the equity awards vested during the&#160;years ended December&#160;31, 2020, 2021, and 2022 was US$8,430,085, US$13,833,856 and US$11,929,903, respectively. As of December&#160;31, 2022, the total unrecognized employee share-based compensation expense was US$23,635,444, all of which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be recognized over a weighted-average period of 2.20&#160;years as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Fair value of share options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The assumptions used to estimate the fair value of the share options granted were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.68% - 0.83%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.11% - 1.67%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.92% - 4.25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility range&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.3% - 73.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;73.1% - 75.5%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;74.2% - 74.9%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise multiple&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Total share-based compensation expenses recognized for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,472,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,582,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,227,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,657,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,096,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,292,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total share&#x2011;based compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,129,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,679,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,520,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_Q157HUAGCUiQ3O7w3B8ZAQ"
      decimals="INF"
      id="Narr_biSLSBdkQ0CW6VfCTp3fLw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">4336126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_JHoh1u6SlUWt5wpfBqAllA"
      decimals="INF"
      id="Narr_D-MU10OUQECRDPIkFqWG3g"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">6336126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_HX6qRchl3UOJYp2kC_kivw"
      decimals="INF"
      id="Narr_CqGyQY5RO0CMq5ku30pkCQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">11391131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_EJ0fi0sr6k2AD6FT92wY0w"
      id="Narr_qUtN6XbVGkaZ5Aq8qgCZdg">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_EUkzQAH7_EWqwroRyBYXgw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ymf1E7tmdEWfCfZo72BFWA"
      decimals="INF"
      id="Narr_X8HYzO3kT0uKNtPw6NPpgg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">184692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_wZ9cdC31zEC6F4Aji6T7Lw"
      id="Narr_OV0mhPtmUUmx_mgSzBwJLQ">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Ymf1E7tmdEWfCfZo72BFWA"
      id="Narr_RUzUDRGu4U2acn9LmM7xOQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Narr_FYu-66C2gEqpBRpBqq67UQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived
      contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A"
      decimals="INF"
      id="Narr_MEaEnF9iaU6JXSbBT_ubJw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2375000</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember__xADkSqTO0S-DY3ZQNH76A"
      decimals="2"
      id="Narr_WeLUUorYJ0GnTyGAorFK7g"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_DQ9yn7uS2EGDv6fQLKvPeQ"
      decimals="2"
      id="Narr_nSkrhh3_qUWZumW_5tJjww"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A"
      decimals="INF"
      id="Narr_AHJ3j5FUL0C0oDN_1piqkw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2375000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_AQUXTJcK3UKObPfjeHwZ4A"
      decimals="0"
      id="Narr_p1EZa5TmQES1TTELniqttw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5197650</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_QB4Okja9ZEGLGUBdgEeHpw"
      decimals="INF"
      id="Narr_pp0API8t3EmV9dlnRMN28g"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1585000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <adag:NumberOfSharesSurrendered
      contextRef="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w"
      decimals="INF"
      id="Narr_n8Ku5mjGokS2sZ9IUb_JMg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">491119</adag:NumberOfSharesSurrendered>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w"
      decimals="2"
      id="Narr_y9DsCNW3xEuO7w5WTrVCaQ"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">13.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_16_2021_To_1_16_2021_3O4qoFLhXUmwO1ykMYJv6w"
      decimals="2"
      id="Narr_hR9QVWGmd0e4_33kwUamwA"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_hl4SM9JGdEip0cnxdAqRJw"
      decimals="INF"
      id="Narr_B7f4iuj5vE6Jt5BruVCGZQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2994000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <adag:ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent
      contextRef="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_p76MqEtu0ESUlhT30hlMQw"
      decimals="2"
      id="Narr_M9Ww8zlXsUyrBO7PH5hy-Q"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.05</adag:ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_fLrvwshp_kef4yuIOIUV5g"
      decimals="INF"
      id="Narr_ssaJofcsZ0CLp-ge0cb7Vg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_mYqtV1u_dUOeGU09TxPkwQ"
      decimals="2"
      id="Narr_qNIQJ20L20aRmNdWCjWz4g"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qodzJmIask-OtNzB-p7X4w"
      decimals="2"
      id="Narr_gsOrC883TEunKfzzIgShUA"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">17.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_1eP-WkT9Skmw68n0YD2iXQ"
      decimals="INF"
      id="Narr_uFvpBIP4AUO89x4oltU08w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">23734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_7_2022_To_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember__79tbn2a-EGdvybT6uk1ww"
      decimals="INF"
      id="Narr_9JYeUilXMEqx2hJY_35N6A"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2060308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue
      contextRef="As_Of_1_7_2022_srt_StatementScenarioAxis_adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_FuMVl1AODUSWgqaccUaZLw"
      decimals="0"
      id="Narr_Tz3ozw9xhUqjP-9Pt8Yu_Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2337697</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_7_2022_To_12_27_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_lXgW5nkfeUOQyYVN7MFj6w"
      decimals="INF"
      id="Narr_FTSGRVPOaUy75IOEIttnnQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2640598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_PEIXHzXukUSrP_zBNlrOtA"
      decimals="2"
      id="Narr_8cr7zRgldEaZta5YEj4ddw"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_7_2022_To_12_27_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Cc4l6GLQ9UWIXpyBn68CYA"
      decimals="2"
      id="Narr_uaB4BYDIe0-DwhUwG_L2Fg"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_o7k1J95q30-im7Wsqr0zgQ"
      decimals="INF"
      id="Narr_kpLKKzMu6UmVCl3E55QuVA"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">99999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_sTKKUtyqS0eFI2J-zEunNg"
      decimals="INF"
      id="Narr_sHAVyuBNXkKGwaCzKpWcRg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2483808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_cp16D7zq-k6IluFfoJ6iCg"
      decimals="INF"
      id="Narr_KyyQNIxkCEm2_zWYm_8CpQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">4776906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_D2ouv3Ric0GWnvJk0hAexg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 866,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,328,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,313,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,694,934)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,294,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,410,968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,894,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (233,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (145,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,809,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,619,574&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,640,598&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.28&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (197,975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.08&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (964,789)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,286,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,286,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,990&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,486,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 874,180&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,070,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,880&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="INF"
      id="Tc_gmXc0JL0Vk2CRRfCOI1TAw_9_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">866028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="2"
      id="Tc_QVDuGGoN0E6L6AdTYWRTDQ_9_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="2"
      id="Tc_PM7MolKgR0uAFa0xMEVVCA_9_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">3.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_EMWaJe9pw0yONDIyRxQ1EQ"
      id="Tc_pZbL-Bv2J0KL6UqREMU4DQ_9_8">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw"
      decimals="0"
      id="Tc_3coMph1zIUSnPEdw8RxPmg_9_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6328171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="INF"
      id="Tc_KY9jtXnVfk2Eaq9EsBqppw_10_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">6313373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_9X0ruNO17ki1iVD8UCggOg_10_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_GFetRWR52Em_VoyenyWrZw_10_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">7.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="INF"
      id="Tc_MmaFath0_02K5ba0PG8Biw_11_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">3694934</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_oK5MXcLhX0m5gcQj6ednIA_11_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_BNiRNwq3iUCT1rBFpbnqpA_11_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.55</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="INF"
      id="Tc_cOiNUzP4JEqokfupTEnFlw_12_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_FTXniDpPrUeRmf58XfCRlA_12_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_Ior7fE08rEWqLODYitzwVg_12_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.91</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="INF"
      id="Tc_N8UUfA-450WXcwY72vEaIA_13_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">3294467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="2"
      id="Tc_CMhu2H4Ez0KUEgEK4VFmyg_13_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="2"
      id="Tc_2NJcYSFhmUiIFSmE8qYEog_13_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      id="Tc_eVY5BDVctUiTrKzoBKK1Ug_13_8">P8Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="0"
      id="Tc_pyeGKLmTlUWJ5260Jr3g9Q_13_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">33410968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="INF"
      id="Tc_DgbU7uKIHE6QMzFjqpTR1g_14_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1894119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_iwxRGcgbv0eTIPgPdpgqdQ_14_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">12.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_xxWi4iq-PkOyFFEwMupcdQ_14_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="INF"
      id="Tc_OVj8PvQhyEWThbRmfVK14Q_15_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">233958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_CIPHo8TQUUWE5SQCwvCWgw_15_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_sPPDoF4HJkqujY7aDnOvQg_15_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.13</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="INF"
      id="Tc_Htwrk91_GUmV_a4yXK7sNQ_16_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">145550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_0gRfQxev6kq_4dm0yFemnQ_16_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">3.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_2KFeedhHykSZDhihT2d69A_16_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">7.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Tc_VW0jxX3lzUyRgkbYqPQkEQ_17_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">4809078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="2"
      id="Tc_TXxt5JE5UUmQl2BjhmfG8g_17_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="2"
      id="Tc_xjhsvc9Yq0GadiaSrjYAQQ_17_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">7.38</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      id="Tc_M6vi5gMdpkqV8cWrmBjGrw_17_8">P8Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_HmK7GTgsEUyYY_--B8CHuw_17_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2619574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="INF"
      id="Tc_bMYFvAOeMUacS-wjz9gmyg_18_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2640598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_NJm8rQSuTEC0gkdHerc6JA_18_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">3.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_rnG6PKQjUUunvtdfjJIWOg_18_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="INF"
      id="Tc__pwrftRXPk-H7ajUpqhx5Q_19_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">197975</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_xgv7C9B4IUKnZ3AD0jOXfA_19_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc__-1uYsCIi0yjkJGneQfR2Q_19_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.95</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="INF"
      id="Tc_F2TJjy0as02ECEhgcyRsOQ_20_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">964789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_sQQPg-9U_02U2ayGQ4Yg9Q_20_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_xLEYyZIWN06QlUUplU5atw_20_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">7.57</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Tc_jNh7c-Fa2kyMRJi4jxXr-w_21_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">6286912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="2"
      id="Tc_IUq1S6PhIUeVfC1lex2RNA_21_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="2"
      id="Tc_VKz2Cpmg60-MNxfnk9VYJA_21_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.16</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_D3dhzrJCKkCmPH2WnhtYXQ_21_8">P8Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_dUVF5OdOF0-WKUF8yYTpqA_21_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">94990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Tc_HKs310u5vUuOcv9NCy6D3g_22_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">6286912</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="2"
      id="Tc_loFCerBjykOC41bxySQxzA_22_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_WGtVysdpQ0adkDU9mKkl_g_22_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.16</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_WF7lFLAyRkCGUtFQgJK_Pg_22_8">P8Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_TGE4fQw6UE2LOF-Y_Og1SQ_22_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">94990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="INF"
      id="Tc_VQ1TTF2xXki99JqrkkTQmA_23_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1486318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="2"
      id="Tc_EZEwuT-U4Em9a_bb9nJV0w_23_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">5.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_TfSJk5vJq0OIjKMSgje2Iw_23_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">7.05</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      id="Tc_NxuGb_BqEU-VP0KwbklJqQ_23_8">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_9xewROXI7UmaoPDAuFEUbg_23_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">874180</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="INF"
      id="Tc_CIizPFgC70yCNXnRRq9spA_24_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">2070533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="2"
      id="Tc_hkGltAc3dEyJnx88hYG3GQ_24_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_AChZ3WEXfEyvsYYmz_Hp3A_24_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">6.87</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_2O47MqB41ES_fATD7N6vqQ_24_8">P7Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_VTdqrCXCpku7Tw1BYv6l7g_24_10"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">55880</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Narr_uN_zkf4SnU-_QdEONasakg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8430085</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Narr_pQisboXEIEGfJlJXaDEb4g"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13833856</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Narr_aFXdE_F7AkazU7pR9oC_MQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">11929903</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Narr_keYlEQYlskG7ZvGL0F7Frg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">23635444</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Narr_cjcEfI07_kG4Sjuelz-wAA">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_HP_j78j0S02WMTqpyhw0Ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.68% - 0.83%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.11% - 1.67%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.92% - 4.25%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility range&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.3% - 73.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;73.1% - 75.5%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;74.2% - 74.9%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise multiple&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="4"
      id="Narr_x7sFslLuLU-Hkz6EcppOKQ"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="4"
      id="Narr_Zrl-SAKjwkmVS826cZoabg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="4"
      id="Narr_a6LspgPqQkCDK0-aVfVzHg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="4"
      id="Narr_ksyN9_vx9UyAAi9hfVvKlw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="4"
      id="Narr_9SHGDZIYq0-2HSFwH2KRdg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0192</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="4"
      id="Narr_dXOlcPZPU0S_JK_gQcFX-Q"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_hqN5MrYH_E2oSKi2zXt9VA_5_2"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_uULxVvRy2E6W2ciN0kEgHw_5_4"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_QKitKTAb00yW9TGi6nTCsQ_5_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="3"
      id="Narr_wLXW2_PdNkOHCgsNNC_Qmw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="3"
      id="Narr_ypGu9osdmUWtDdrBkKbzwQ"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="3"
      id="Narr_yoOPQXp3zkezPirsBrUjxg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="3"
      id="Narr_J81XneodV0atfpq_xpIOUg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="3"
      id="Narr_nOUf0Izgck-Kp5xexHSiNA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="3"
      id="Narr_CirebvrJj0ur29RM4j4NOg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="1"
      id="Narr_tKHfqzAaWU-mM5u2IxUPaQ"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.2</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="1"
      id="Narr_l6u-pfwZ0kS4tMrE6JWE-w"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.8</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="1"
      id="Narr_mGT053lPlEKtn5-kmILdSw"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.2</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="1"
      id="Narr_kOjItlcIx0OKY2ti6QHK2A"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.8</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="1"
      id="Narr_MPvZx-lnXkKq62ibcCQdKQ"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.2</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="1"
      id="Narr_Y1EJtQD9kkyVAIEAC1TjPQ"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">2.8</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      id="Tc_dKILBlbsj0mzlz2gfb1FAQ_8_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      id="Tc_IecdsQhOp0KDmo7tTcDBhg_8_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tc_OJyZJ7BIhU-uUi9N5tVLmA_8_6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_KQs2OLZ7F0aB-sVyBe4pTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,472,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,582,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,227,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,657,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,096,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,292,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total share&#x2011;based compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,129,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,679,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,520,282&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_ER1dY2hYkkebuGSCOwJV8w"
      decimals="0"
      id="Tc_gnL0erHiu0CPXWSpFa8GMg_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6472083</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_XApzz6RZb0COodakWjZlyQ"
      decimals="0"
      id="Tc_WT11oTFvXU-TuUKCZGTrNw_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13582746</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_KuH9w-ji8E6oP8LOHD8eoQ"
      decimals="0"
      id="Tc_fN49D-DHCUSbO68iVaiIdw_4_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7227298</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_9u6PsJmRs0uWqcLpDwttXQ"
      decimals="0"
      id="Tc_mQBYJBLbyESxvCMlaX21XA_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3657458</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_kkEXFXNRGUij0o1EOEbICA"
      decimals="0"
      id="Tc_OVsFh-Bl_UGfnwh83rQ6qg_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5096912</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_DQhBNix_zU24lt2mhsh67Q"
      decimals="0"
      id="Tc_I91l48nCN066BDQfTubAgw_5_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3292984</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_kw4UBb3V-UGhdYclGBCdpw_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10129541</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_YEiWyFrbCEGfuvzKStDwZw_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">18679658</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_mT_pAauQO0GpGZZwJv4ymQ_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10520282</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_ySDHHMj5-UmN3GwJmkWh2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;10. COLLABORATION ARRANGEMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2018, the Group entered into (i)&#160;a collaboration agreement (the &#x201c;Sanjin Greater China Agreement&#x201d;) that covers Greater China with Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. (&#x201c;Sanjin&#x201d;) and certain of its subsidiaries (collectively, &#x201c;Sanjin Parties&#x201d;) and (ii)&#160;a collaboration agreement (the &#x201c;Sanjin ROW Agreement,&#x201d; together with the Sanjin Greater China Agreement, the &#x201c;2018 Sanjin Agreements&#x201d;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the &#x201c;PD-L1 Project&#x201d;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#x2019; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group (i)&#160;single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit&#160;percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB10,000,000 (equivalent to approximately US$1,511,168) upfront fee upon the effectiveness of the agreement from Sanjin Parties, which was recognized as revenue in 2018. No revenue related to this agreement has been recognized in any of the years presented in the accompanying financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Sanjin&#x2019;s affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expect to receive from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in the Group&#x2019;s notice to Sanjin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#x2019;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the 2018 Sanjin Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that the failure of the development of the product candidate solely arises from the Group&#x2019;s research and development basis specified under this agreement, Sanjin has the right to claim back all the payment made to the Group. The Group considers the possibility of occurrence of such event is remote.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2019, the Group entered into (i)&#160;a collaboration agreement that covers Greater China (the &#x201c;Dragon Boat Greater China Agreement&#x201d;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#x201c;Dragon Boat ROW Agreement,&#x201d; together with the Dragon Boat Greater China Agreement, the &#x201c;2019 Dragon Boat Agreements&#x201d;), with Dragon Boat Biopharmaceutical (Shanghai) Limited (&#x201c;Dragon Boat&#x201d;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the &#x201c;Specified Project&#x201d;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#x2019;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&#160;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug (&#x201c;IND&#x201d;) approval in PRC and completion of clinical phase I test in PRC) and (ii)&#160;a single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2019 Dragon Boat Agreements, the Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#x2019;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that the failure of the development of the product candidate solely arises from the Group&#x2019;s research and development basis specified under this agreement, Dragon Boat has the right to claim back all the payment made to the Group. The risk of failure is considered remote upon recognition of revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;year ended December&#160;31, 2019, no revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2020, upfront fee of RMB4,000,000 (equivalent to approximately US$573,378) that was received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance obligation had not been satisfied by the Group and no revenue was recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, milestone fee of RMB4,000,000 (equivalent to approximately US$620,011) was received related to the launch of pre-clinical safety evaluation animal test and the receipt of IND approval in PRC. For the year ended December 31, 2021, a total of RMB8,000,000 (equivalent to approximately US$1,240,022), including the aforementioned upfront fee and milestone fee were recognized as licensing revenue in the consolidated statement of comprehensive loss as the performance obligation was satisfied by the Group and certain milestone events were achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No additional revenue was recognized for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;ADC Therapeutics&#160;SA License and Collaboration Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2019, the Group entered into a material transfer and collaboration agreement (the &#x201c;ADCT Collaboration Agreement&#x201d;) and a license agreement (the &#x201c;ADCT License Agreement&#x201d;) with ADC Therapeutics&#160;SA (&#x201c;ADC Therapeutics&#x201d;). These two agreements are combined as a single contract as the agreements were negotiated as a package with a single commercial objective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;ADCT Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group&#x2019;s technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group&#x2019;s exclusivity obligations, upon achievement of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics&#x2019; election to proceed with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days&#x2019; prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#x2019;s uncured material breach of the agreement or the other party&#x2019;s insolvency-related events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group also granted ADC Therapeutics an exclusive target reservation right for one year from the commencement of the agreement and an option to renewal for another&#160;year with a consideration of low-six-figure dollar amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;ADCT License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by the Group under these programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit&#160;percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon thirty days&#x2019; written notice to the Group, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#x2019;s uncured material breach or insolvency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;year ended December&#160;31, 2020, the Group recognized US$225,000 of licensing revenue upon delivery of such results. For the year ended December&#160;31, 2020, the Group recognized US$100,000 as other income due to the expiration of exclusive target reservation right, which is not related to the Group&#x2019;s major operation activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2021, the Group recognized US$225,000 of licensing revenue upon delivery of additional research results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2022, the Group did not recognize additional revenue associated with the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;ADCT Material Transfer and Option Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2022, the Group entered into a material transfer and option agreement (the "ADCT Material Transfer and Option Agreement") with ADCT. Under the agreement, Adagene agreed to provide antibodies or antibody sequences to ADCT to conduct further development for a non-refundable fee of US$300,000. ADCT has an exclusive option to negotiate a separate license agreement with the Group, however, there is no requirement for either party to enter into such a license agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2022, the Group recognized revenue of US$300,000, which was received in October 2022, upon delivery of the sequences.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Exelixis, Inc. Agreements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2021, the Group entered into a collaboration and license agreement (the &#x201c;Exelixis Agreement&#x201d;) with Exelixis, Inc. (&#x201c;Exelixis&#x201d;), pursuant to which the Group agreed to generate masked antibodies with its SAFEbody technology against an initial target selected and a second target to be selected by Exelixis. The Group will generate masked antibodies in the form of alternative compounds in accordance with the program plan for each target at its own cost and deliver the related data packages to Exelixis. Exelixis will select lead compounds (the &#x201c;Lead Compounds&#x201d;) to further develop, obtain regulatory approval and commercialize product(s) for each target (the &#x201c;Products under the Exelixis Agreement&#x201d;). Under the Exelixis Agreement, the Group will also grant Exelixis an exclusive, worldwide, sublicensable license (the &#x201c;Adagene License&#x201d;) upon delivery of the data package to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group with respect to both targets. Exelixis will own the inventions relating to the Lead Compounds arising in connection with the Exelixis Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Exelixis Agreement will remain effective until the expiration of the defined royalty terms of the Products under the Exelixis Agreement, unless terminated by either party. Exelixis may terminate the Exelixis Agreement for any or no reason, in its entirety or on a target-by-target basis. Any payment received by the Group before the termination shall be non-refundable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Exelixis Agreement, Exelixis agreed to pay the Group an upfront non-refundable fee of US$11,000,000. For each target, the Group will be eligible to receive up to US$127,500,000 of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $262,500,000 of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Exelixis Agreement worldwide, subject to certain reductions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2022, the Group entered in a letter agreement (the "Exelixis Letter Agreement") in reference to the Exelixis Agreement with Exelixis for expanded collaboration in SAFEbody discovery. Under the Exelixis Letter Agreement, the Group will generate additional masked antibodies against the target selected by Exelixis per the Exelixis Agreement. Exelixis agreed to pay the Group an additional upfront non-refundable fee of US$1,100,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group determined that generating masked antibodies with its SAFEbody technology is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Exelixis Agreement, the delivery of data packages for each target, along with the Adagene License used to develop the related compounds, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations using the relative standalone selling price method. The Group records revenue at a point in time, when the data packages for each target were delivered to Exelixis. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the Adagene License granted are recognized when (or as) the later of (1) the subsequent sale or usage occurs, or (2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2021, the Group received US$11,000,000 upfront payment and&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;recorded accounts receivable of US$3,000,000 milestone payment, which corresponds to the successful nomination of lead SAFEbody candidates for the initial target under the Exelixis Agreement. The milestone payment was subsequently received in January 2022. For the year ended December 31, 2021, US$8,500,000 was recognized as revenue upon delivery of data packages for the initial target and achievement of the milestone event. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2022, the Group received US$1,100,000 upfront payment under the Exelixis Letter Agreement. No additional revenue was recognized as relevant performance obligation has yet to be fully satisfied under either the Exelixis Agreement or the Exelixis Letter Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sanofi Agreement &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022, the Group entered into a collaboration and license agreement (the &#x201c;Sanofi Agreement&#x201d;) with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (&#x201c;Sanofi&#x201d;), pursuant to which the Group agreed to perform early-stage research activities to develop masked versions of Sanofi candidate antibodies (each a &#x201c;Target&#x201d;, and together, &#x201c;Targets&#x201d;), using Adagene&#x2019;s SAFEbody technology for development and commercialization by Sanofi. Sanofi has the ability to advance two initial Targets in the collaboration, followed by an option for two additional Targets. The Group will generate masked antibodies in the form of customized compounds and complete the compound research activities in accordance with the program plan for each Target at its own cost and deliver the compounds and related data packages to Sanofi. Sanofi is solely responsible for later stage research and all clinical, product development and commercialization activities. Under the Sanofi Agreement, the Group granted Sanofi an exclusive, worldwide, sublicensable license to research, develop, use, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Sanofi Agreement will remain effective until the expiration of the defined royalty on a product-by-product and country-by-country basis, unless terminated earlier with cause or by mutual agreements of both parties. Sanofi may terminate the Sanofi Agreement without cause, in its entirety, or on a Target-by-Target or country-by-country basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Sanofi Agreement, Sanofi agreed to pay the Group an upfront non-refundable fee of US$17,500,000 in consideration of the license granted and the early-stage research activities to generate the compounds. Sanofi is obligated to pay an additional fee if Sanofi exercises the option for additional Targets. For each Target, the Group will be eligible to receive up to US$173,500,000 of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $450,000,000 of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Sanofi Agreement worldwide, subject to certain reductions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group then determined that this collaboration is more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Sanofi Agreement, the performance of early-stage research activities to develop compounds for each Target, along with the grant of the license, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations based on the relative standalone selling price. Since the early-stage research activities does not generate an asset for alternative use and the Group has an enforceable right to the upfront payment, the Group records revenue over time using labor hour as the input to assess the satisfaction of the performance obligations. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the license granted are recognized when (or as) the later of (1) the subsequent sale or usage occurs, or (2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;For the year ended December 31, 2022, the Group received US$17,500,000 upfront payment under the Sanofi Agreement. For the year ended December 31, 2022, US$8,992,724 was recognized as revenue over time using the input method.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg"
      decimals="0"
      id="Narr_tTZstbN-BUm8IILyqOZ0MA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">10000000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg"
      decimals="0"
      id="Narr_OsxVmO242Uenpox7kLDMFw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1511168</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg"
      id="Narr_-kTensWrlEK9VHkowiEd5Q">P3Y</adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties>
    <adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_Y1LEBiLCsUiXix5-VE8rGQ"
      id="Narr_C7ItNLD8DUG51XKtERJJUA">P3Y</adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_ydcSvQ_MrUWX4ODW9D_Low"
      decimals="0"
      id="Narr_XhU6IQTKVk-u2zvRXbaXJA"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ"
      decimals="0"
      id="Narr_80zcx-OHFkad9LIMU0xM8A"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">4000000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ"
      decimals="0"
      id="Narr_naGUoo3VDkSbfWvPu7Z_pQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">573378</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_RB010OHo9ECJnRF4cM9PQQ"
      decimals="0"
      id="Narr_7LA0b5MKXkShuU6m70I2Ag"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementMilestonePaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg"
      decimals="0"
      id="Narr_GFlJveUpNUiMggwkiRnxaw"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">4000000</adag:CollaborativeArrangementMilestonePaymentReceived>
    <adag:CollaborativeArrangementMilestonePaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg"
      decimals="0"
      id="Narr_-_HDyMDIJ0SYXTs6F_p2dg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">620011</adag:CollaborativeArrangementMilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg"
      decimals="0"
      id="Narr_oJfk2nCFp0S7zM59DWy_9w"
      unitRef="Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_8o62Fx1VYEqJwSbj84QNhg"
      decimals="0"
      id="Narr_CVsfAwAy7kyYspd5qAos4w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1240022</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_Y1LEBiLCsUiXix5-VE8rGQ"
      decimals="0"
      id="Narr_QKYP2Lp6IEixtB5IfX6OOQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies
      contextRef="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AVPy-5gte0WCo8vAl_mD9Q"
      decimals="0"
      id="Narr_KNdQhfvCTU6Ty4VAI_ILLg"
      unitRef="Unit_Standard_item_kIb8rhOtuEaxsO8QQVuMbA">2</adag:MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies>
    <adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug"
      id="Narr_XbwSRREPy0uxoOu1hEI9rg">P30D</adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement>
    <adag:PeriodForReservationOfTargetRight
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug"
      id="Narr_cB3YMjb7-EWuQ5A8QtCt3g">P1Y</adag:PeriodForReservationOfTargetRight>
    <adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember__idJklnihk6TRIHvTO1hug"
      id="Narr_x-qQc3iGnk2NKNmwNE-n-A">P30D</adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_BH3baoGYjECWp2ep1hunvQ"
      decimals="0"
      id="Narr_e61Osxmly0Wzl8I2xeBOhw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_BH3baoGYjECWp2ep1hunvQ"
      decimals="0"
      id="Narr_Qd35a72O5EWDLyu3E2ngwQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">100000</us-gaap:OtherIncome>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_3qRSyDBk-U6_JWTPepBfbA"
      decimals="0"
      id="Narr_h9hZ2tCqJ0GbxCYrpa3ObA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceivable
      contextRef="As_Of_8_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_WFeE0wneck-MydNDO4uWyw"
      decimals="0"
      id="Narr_F-Lr9MvrAkCQ4FncGCHapg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">300000</adag:CollaborativeArrangementUpfrontCashPaymentReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_AdctMaterialTransferAndOptionAgreementMember_VsC-jPAYAUqbiloJ81rslQ"
      decimals="0"
      id="Narr_DRfF9Har0EWxcUinIQIfgg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceivable
      contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA"
      decimals="0"
      id="Narr_USr4dyYQgEyfnwJuAZBScQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">11000000</adag:CollaborativeArrangementUpfrontCashPaymentReceivable>
    <adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones
      contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA"
      decimals="0"
      id="Narr_1zU83P0vIUOJsd8CA9AbRQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">127500000</adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones>
    <adag:MilestonePaymentsReceivableSalesBasedMilestones
      contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ZAURCcsm1k6dl6EqKuLTfA"
      decimals="0"
      id="Narr_DEm3qgkgaUKh8bax3a7mgw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">262500000</adag:MilestonePaymentsReceivableSalesBasedMilestones>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceivable
      contextRef="As_Of_4_30_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_ay_6hRJo4U6yLXVvpTOGEQ"
      decimals="0"
      id="Narr_j6NZejSryEGkW_RPWe9-8A"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1100000</adag:CollaborativeArrangementUpfrontCashPaymentReceivable>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_rvKTnfEkyUSop_lAg3fNuw"
      decimals="0"
      id="Narr_34SM4PPoP06lP2k-XXM6CA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">11000000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_CH2MGlfLkEa-Mm5SY3caCw"
      decimals="0"
      id="Narr_uRakZG01gE-6RbFWx7a6pQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_rvKTnfEkyUSop_lAg3fNuw"
      decimals="0"
      id="Narr_udjbpt_m-E-DT_AZBZF_5g"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_jfKRlHoZrkOzsx-d3nM1UQ"
      decimals="0"
      id="Narr_mRv1XN9R4Em_NMSzs0QKWA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1100000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_jfKRlHoZrkOzsx-d3nM1UQ"
      decimals="0"
      id="Narr_VP4Y1vBwL0aONK3SL2SaeA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_3_1_2022_To_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_MSt1DxwXfUKQtc262Vnbaw"
      decimals="0"
      id="Narr_m1otLnc-PUWFq-rZKqw11w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">17500000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones
      contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_aR_5qQM_PUCejdDJoX8SrQ"
      decimals="0"
      id="Narr_9kZeIxxd1k-s-wXrjJnzbA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">173500000</adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones>
    <adag:MilestonePaymentsReceivableSalesBasedMilestones
      contextRef="As_Of_3_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_aR_5qQM_PUCejdDJoX8SrQ"
      decimals="0"
      id="Narr__KUxYwygfka5fkEN9KqV4A"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">450000000</adag:MilestonePaymentsReceivableSalesBasedMilestones>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_zebDcdEQ3kW1LZbwJkj0Dw"
      decimals="0"
      id="Narr_Kfv0VigL00K4pqicA1KDcg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">17500000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_adag_SanofiAgreementMember_zebDcdEQ3kW1LZbwJkj0Dw"
      decimals="0"
      id="Narr_0le1RdjBBUWxmx_ovFRxcw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8992724</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_D3W6tX_8KkqaQRYp82eReA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;11. INCOME TAX EXPENSE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;PRC&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective from January&#160;1, 2008, the PRC&#x2019;s statutory, Enterprise Income Tax (&#x201c;EIT&#x201d;) rate is 25%. In accordance with the implementation rules&#160;of EIT Law, a qualified &#x201c;Technology Advanced Service Enterprises&#x201d; (&#x201c;TASE&#x201d;) is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every&#160;year. Dividends by PRC entities, to non-PRC resident enterprises shall be subject to 10% EIT, namely withholding tax, unless the respective non-PRC resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene (Suzhou) Limited was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and November 2021. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate of 15% from 2015 to at least 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Cayman Islands&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene&#160;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&#160;Inc. is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Hong Kong&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the&#160;years ended December&#160;31, 2020, 2021 and 2022, Adagene (Hong Kong) Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Australia&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene Australia Pty&#160;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Adagene Australia Pty&#160;Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. Dividends payable by an Australian entity, to non-Australian resident enterprises shall be subject to 30% withholding tax, unless the respective non-Australian resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with Australia that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;United States&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. Adagene Incorporated is also subject to state income tax in California of 8.84%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to 30% withholding tax, unless the respective non-U.S. resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Switzerland&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene AG is incorporated in Switzerland and is subject to federal corporate income tax at a rate of 8.5%. Adagene AG is also subject to cantonal income tax of 6.5% as well as capital tax of 0.1% in the Canton of Basel subject to certain tax benefits and relief. Dividends payable by a Swiss entity, to non-Swiss resident enterprises shall be subject to 35% withholding tax, unless the respective non-Swiss resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with Switzerland that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Income tax expense (benefit) of the Group for the years ended December 31, 2020, 2021 and 2022 were composed of the following current and deferred amounts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,290,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 672,064&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (168,846)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,657,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 503,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (96,804)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,641)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,163)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Reconciliation between the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (71,476,322)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,512,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;PRC statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax credit computed at PRC statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,599,320)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,869,081)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,878,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Impact of PRC preferential income tax rate as qualified TASE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,239,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,147,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,951,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Difference in income tax rates of overseas entities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,286,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,549,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,560,029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development super-deduction&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (718,979)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (569,016)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,724,740)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (569,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign derived intangible income deduction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (487,183)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,517,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 291,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (127,880)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#x2019;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2020, 2021, and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December&#160;31, 2021 and 2022 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,949,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,217,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax credit carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 756,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrealized foreign exchange gain/losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 116,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of right-of-use assets and interest of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,083,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,607,456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,007,139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,524,497)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total deferred tax liabilities, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,163)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Movement of the valuation allowance was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of January 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,007,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,517,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,007,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,524,497&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#x2019;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has incurred net accumulated operating losses for income tax purposes since its inception. As of December 31, 2022, the Group had net operating losses for income tax purpose of approximately US$50,742,841. The net operating losses were primarily comprised of: US$17,886,069 from an entity in PRC which expires in years 2028 through 2032; US$8,272,007 derived from an entity Switzerland which expires in years 2027 through 2029; US$5,445,071 derived from an entity in Hong Kong that have an indefinite carryforward; US$7,511,343 derived from an entity in Australia that have an indefinite carryforward subject to meeting certain criteria; US$10,807,828 derived from an entity in the United States which expires beginning year 2038; and, US$820,523 derived from entities in Singapore. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the near future. Therefore, the Group has provided full valuation allowances for the deferred tax assets for all subsidiaries as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2021 and 2022, the Group did not have any significant unrecognized uncertain tax positions. The Group does not anticipate that the amount of unrecognized tax benefits will significantly change within the next 12 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Group conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December 31, 2022, PRC tax matters are open to examination for the years 2020 through 2022, U.S. federal and state tax matters are open to examination for the years 2019 through 2022, and Australia tax matters are open to examination for the years 2019 through 2022.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_9BXgsqEAak6neZEeIkuLdQ"
      decimals="2"
      id="Narr_9r_Nd8jJ4UWedHommtRpJw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <adag:PreferentialIncomeTaxRate
      contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_b2-6zipvrUqdvncotPk1BQ"
      decimals="2"
      id="Narr_TZfOn87zHkaQu1xT2ozueg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.15</adag:PreferentialIncomeTaxRate>
    <adag:EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate
      contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_b2-6zipvrUqdvncotPk1BQ"
      id="Narr_hH6Z9fdY2UOsA-ZvB94Qng">P3Y</adag:EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CN_4etyAVb-kUilTpUBQYyO4Q"
      decimals="INF"
      id="Narr_bxSPVyyEPEu0K5EyPt3wDQ"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.10</adag:WithholdingTaxRateOnDividendsPercentage>
    <adag:PreferentialIncomeTaxRate
      contextRef="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_avqczjeiakGTBo6mGn9tGg"
      decimals="2"
      id="Narr_t4NwDpr7M0KApQPBzD2RHg"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.15</adag:PreferentialIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_X7h_82d2c0KzwUudQtykwA"
      decimals="3"
      id="Narr_qu9T49kkXkGJ8jyDru20sA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_FibIWHTvR0OvdHAkZv3YsA"
      decimals="3"
      id="Narr_s9KOShcZW0KvWQP3Orv7fA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_a1oYWpJoW026Q5lt5DP2dQ"
      decimals="0"
      id="Narr_vs1OX_1cMEy2evt8cnH6mw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_DZY2VoRVfUyY29viuxBhrQ"
      decimals="0"
      id="Narr_5ETtAjpzkUebBAbdZSz8Kg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_7v2coKKIyUmDdlmU0Olo6A"
      decimals="0"
      id="Narr_gZKro3q__kSauIskyMMtnQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:IncomeTaxExpenseBenefit>
    <adag:AssessableProfits
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_a1oYWpJoW026Q5lt5DP2dQ"
      decimals="0"
      id="Narr_l413yuGt7kGBmGs-O5I-yg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:AssessableProfits>
    <adag:AssessableProfits
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_DZY2VoRVfUyY29viuxBhrQ"
      decimals="0"
      id="Narr_Yui87O4YR0WBQiJzqQ21cg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:AssessableProfits>
    <adag:WithholdingIncomeTaxes
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_ee_5WiU0cUurw-SNNKSXuQ"
      decimals="0"
      id="Narr_spmar6fZLEGAlEmeQo9hwg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:WithholdingIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AU_c4N8MZWDzESe5gDU2Tk-5A"
      decimals="2"
      id="Narr_Pu11HQSe30m33rwI-UFWZA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <adag:TaxableIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_aTNTT8uQeEK_xzzYuJc0jQ"
      decimals="0"
      id="Narr_nWOZw8ktH0eySUuTCXTk8Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:TaxableIncome>
    <adag:TaxableIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_wbQEbLCaH0CT2Hi48HK61Q"
      decimals="0"
      id="Narr_9KRGjIsnn0KmC2AOq61Adw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:TaxableIncome>
    <adag:TaxableIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_xlZey60WBUuy5XYgHHijLw"
      decimals="0"
      id="Narr_Y14QQ-Wv5k2wnPu2WgAtWg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</adag:TaxableIncome>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_aTNTT8uQeEK_xzzYuJc0jQ"
      decimals="0"
      id="Narr_mSRPvpGtsEWoy6iX7aq0fg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_wbQEbLCaH0CT2Hi48HK61Q"
      decimals="0"
      id="Narr_qgClhaCR_0Cq-okLitcaUQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_xlZey60WBUuy5XYgHHijLw"
      decimals="0"
      id="Narr_UtMPITtVyUCe3krAAp7Jbg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">0</us-gaap:IncomeTaxExpenseBenefit>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_AU_c4N8MZWDzESe5gDU2Tk-5A"
      decimals="2"
      id="Narr_rFYJWiw6Sk2sW7_ofGwF1w"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.30</adag:WithholdingTaxRateOnDividendsPercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_E-IfTqEmFkC8P1gI378n2w"
      decimals="2"
      id="Narr_ST73msUaRESDDksr5Hbj7Q"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_stpr_CA_J0BfSQ8UxU6Mwv9l4cdG6Q"
      decimals="4"
      id="Narr_i70Ovoksa0eZURMSMLYeow"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.0884</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_US_E-IfTqEmFkC8P1gI378n2w"
      decimals="2"
      id="Narr_lKm0SugICEyRhfHzXy_0ew"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.30</adag:WithholdingTaxRateOnDividendsPercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CH_otva1hRmgEGFbXAakLJRqg"
      decimals="3"
      id="Narr_V-jpgkalAEWasL28rTKSZA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.085</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_3KyS7h9LmU6xtV1jimeGaA"
      decimals="3"
      id="Narr_AHtW-58yfEeS7RkdehY48A"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <adag:CapitalTaxRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_3KyS7h9LmU6xtV1jimeGaA"
      decimals="3"
      id="Narr_v2AOH-NtM0SVJcbrtNXOeQ"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.001</adag:CapitalTaxRatePercentage>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementGeographicalAxis_country_CH_otva1hRmgEGFbXAakLJRqg"
      decimals="2"
      id="Narr_YVWX4y1olEibtwn5rBZU-g"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.35</adag:WithholdingTaxRateOnDividendsPercentage>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_bxBvE6lY1E6MGmS23Naj6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,290,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 672,064&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (168,846)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,657,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 503,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;U.S.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (96,804)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,641)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,641&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,163)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459,055&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_H11Do2ptVkO-GzHGq_Mz-Q_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1290009</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_H_Hoh7LjRUGzmCqL0DFkFg_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">672064</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_tXjLgTWzq0SpitbBV-RzTQ_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">367441</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_pFTHJ0OuPk2BepgIf2COFA_7_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-168846</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_zUEIaf8zhUWTmn7Skv0sjg_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1657450</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_inqYHOSX0UKHLRvad6hd_A_8_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">503218</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_DGjgrEb7dU-EbvBf5lKiig_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">96804</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_qj6jIi6GEkWh9s3Fs4Rw3A_11_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-96804</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_Y2q8Tl0DbE6n1MZfCA_Otg_12_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-52641</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_GQN4NkBHA06Oz_G30Ou-_g_12_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">52641</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_KGtl3p7wz0KmSdkkI6eBwQ_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">44163</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_XyVTnW7VpEiHlRFn3HOiLw_13_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-44163</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_ZLtEFAOqtEC3sWH-qc0_aw_14_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1701613</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_dt75h1fnzkmFoRszHT_z_Q_14_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">459055</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_xPPkY8C6Lk61xH27GmqsLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (71,476,322)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,512,792)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;PRC statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax credit computed at PRC statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,599,320)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (17,869,081)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (19,878,198)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Impact of PRC preferential income tax rate as qualified TASE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,239,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,147,633&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,951,279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Difference in income tax rates of overseas entities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,286,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,549,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,560,029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development super-deduction&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (718,979)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (569,016)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,724,740)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (569,575)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign derived intangible income deduction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (487,183)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,517,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 291,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (127,880)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459,055&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#x2019;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2020, 2021, and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_F0faT6xtD0OqjpVhvrD42Q_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_rF9bq7SsMEGn186WP1ra1w_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-71476322</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_vt2uTAPUQEyUyE2sJa-UpA_4_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79512792</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_Zy8_49KCkkyJNf2fDGtu1g_5_2"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_zPQNo7a_mUOHd1t2dAOcLw_5_4"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_lGG58Tq9DUSHTLY6F_CpBw_5_6"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_QeW6GvQEz0SNVCttuytDxg_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-10599320</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_c39PQijTiUKbMcYD6xrtmA_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-17869081</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_CpvK5pu7wECLPsjvCwt7qQ_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-19878198</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_0nGQz-Cu8Ea3cDlPUCT3YQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4239728</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_F2WpXcYnz0aejwvSffrPVg_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7147633</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_C_gy8Bxn90q_XVWRIp-71Q_7_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7951279</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_ZTnup3kOPkCbsa1xfqhouA_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5286487</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_xOPywTx4XkSgO0cWk_dekw_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10549985</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_mWa5pMtv2UikffEivNBn7w_8_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10560029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_8PxALRVqSUys0XA9pfbVYQ_9_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">718979</adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount>
    <adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_KM4zWvDD9ECOYHvp8g-4Nw_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">569016</adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount>
    <adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_2_zFwhrQbkexNJWLXpiDXw_9_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1724740</adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_9qkjoLXM3kmw0Om8glHwaw_10_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">569575</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_5vz8CZiyDE623DWbXyhwsQ_11_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1238</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_FhvJ2-1h00mA0xekcrQBCQ_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1054</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_YsbcSGliuUqqiRA7bYLp-A_11_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3695</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_a2lW7tCBOUqrjZqkeX4DmQ_12_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">487183</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_YijB6Ont00-aagm9zq4-fQ_13_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1790846</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_oY2jbLiSp0S5fpUXgXc6QA_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2277418</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_kP63yFglBkO7-vJOsW3tbg_13_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4517358</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_aAWtFnguPUGk0YRe1T-Yog_14_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">291500</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_h4LLla6RE0mnwBbgaOaFiw_14_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">76127</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_AXIy9q83UkyJaiafNy-grQ_15_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-127880</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_fbpYQABaO0KY8aYXJYq1BQ_15_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10263</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_GE0CGBvVcEap_F21Iq4u0Q_16_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1701613</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc__C1rBg5NvkSZzlt0nzV6uQ_16_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">459055</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_JVQdluwfGk-X14qMrlon_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,949,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,217,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax credit carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 391,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 756,197&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,589&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrealized foreign exchange gain/losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 116,238&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,702&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of right-of-use assets and interest of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,083,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,607,456&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,007,139)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,524,497)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82,959)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total deferred tax liabilities, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,163)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_HDzITyp1y0OcmAf1MuDH5Q_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4949000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_p4TqBlpCIk2dm7wropcHgA_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8217976</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_tPVKPcRGOEGkf1s_NmMRwA_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">391843</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_9bnuW0ltS02yQCJ_mqAQCw_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">756197</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_ALXi-INRBkW4-E4M3ZAaLw_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">95589</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_Jy62tGkuVEuQzqb1HvqmBA_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">94954</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_ocyj3BOglUKLbN1lHXy5QQ_9_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">39166</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_jVkBa2z8rU2LH58cky8ROg_9_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">116238</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_2jytFQ7j9E23sHMv5nrTKQ_10_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">29702</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <adag:DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_-ERh1P5Kd0-96M_rzs-KYw_11_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">546</adag:DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities>
    <adag:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_pN7JCXOOr0a2PYMzzkU8jA_12_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">79</adag:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_-QxEhSmowk2Ox9O2SKmTPw_13_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5083834</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_5ayJFYMzxkiDJidjeZ8V9g_13_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9607456</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc__3XLvibje0WcNMCneZ1KWQ_14_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5007139</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_BDKRGrLxNkGM4WUDSd14hw_14_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9524497</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_hvzldZX2vk-sHBmVXSDU6A_15_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">76695</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_6pvawlbaaUmjDRPBuDGpgQ_15_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">82959</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_TA-XBWf6GUecP4ZkHvpwcQ_2_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">120858</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_0QEUhnjWPk-nD4S-OiCO5A_2_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">82959</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_xISp4NUQ3Umk3kShWI81hw_3_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">120858</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_shUe0GD6S0Wzcz2wlHsFPw_3_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">82959</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_n4syQvUPlkS-mdOAj1RRDA_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">44163</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_hmhGGhUTXkmH-f9VjD7hdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of January 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,007,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,517,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,007,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,524,497&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw"
      decimals="0"
      id="Tc_pr2DkB--w0iwquen_l87hw_3_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2729721</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_fQV1fSaWSU2rURBBcGXQGA_3_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5007139</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_kmjQOlBwGkKj2_uLMNjnog_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2277418</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_Si8gBqxUqUKfcPpzocWxNg_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4517358</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_KbW-bRTBx02syOAakZaSzw_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5007139</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_9fX1R1_Cr0OIfIvP0Z6ISw_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9524497</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Narr_kOVvUoPckkeIVIIEP6Svtw"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">50742841</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CN_pERkzB2zbEuJoXns9cPQzw"
      decimals="0"
      id="Narr_t9wAyUMSLE-55XxVJJ9Uhg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">17886069</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_CH_u8WhTZKTgk6uGwI8YPJBBQ"
      decimals="0"
      id="Narr_LnhV4lc-dUe-1bFUwc-ObA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">8272007</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_HK_Otsf7MqCgkyOm-luahjSsQ"
      decimals="0"
      id="Narr_cJa5QQLJPUCTNPALRbMyQA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">5445071</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_AU_iIjaBK7jEEatSAUYG4p5Sw"
      decimals="0"
      id="Narr_ixX2xjv5m0uASxrAdlag5Q"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7511343</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_US_9sDKIIcAC0O2whabXRhATQ"
      decimals="0"
      id="Narr_264xDG46oUSA6yrAw4ALUA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10807828</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_srt_StatementGeographicalAxis_country_SG_aoUeaWEODUuRBoaCnL4L8Q"
      decimals="0"
      id="Narr_QBqO8iEvkEWfoHPJ0bd-4g"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">820523</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_BSpXlj0E1ECpL_iaq9S0yw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;12. NET LOSS PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Basic and diluted net loss per share for the&#160;years ended December&#160;31, 2020, 2021 and 2022 were calculated as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to Adagene Inc.&#x2019;s shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,177,935)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,971,847)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of convertible redeemable preferred shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (248,113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,553)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to ordinary shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,645,392)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,206,488)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,971,847)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted&#x2011;average number of ordinary shares outstanding&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,950,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,032,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,135,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Loss per share&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.67)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.46)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.48)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"&gt;&lt;span style="margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the&#160;years ended December&#160;31, 2020, 2021 and 2022 as their effects would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible redeemable preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,249,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options and share grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,795,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,739,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_KTvrqmO5kkmfKwRome1JGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to Adagene Inc.&#x2019;s shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,177,935)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,971,847)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of convertible redeemable preferred shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (248,113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,553)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to ordinary shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,645,392)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,206,488)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (79,971,847)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted&#x2011;average number of ordinary shares outstanding&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,950,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,032,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,135,084&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Loss per share&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.67)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.46)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.48)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"&gt;&lt;span style="margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_TCZhTZymAEmpMxHDTfQ6KA_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_tn1KdQin9kCj5N5LSscqlw_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_MFm5svCLDU2OkgV5BpztLA_5_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_MPA8DvvHlkWJm1KEQRRZPg_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_AqRC9Z2FckGtwNpRiV3rLw_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_0uoKh7g2L0K2MbEaRB5KVQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-42645392</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_asJVFQ3H0021v0YqaT-omA_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-73206488</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_ARmGGYk42kGHsSDScVrs-g_7_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">-79971847</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="0"
      id="Tc_oRVNHEOUdEe-u-J37BIdLw_9_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">15950698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="0"
      id="Tc_JTNnX-RO7E-dwVSLZYZ1aA_9_4"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">50032009</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_bqr8L2Pu30OIvxt_x-1TbA_9_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">54135084</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4aobGjgsCkKpplxhyUfjeg"
      decimals="2"
      id="Tc_Fo0gSjnCxkKZlsIIjsxiBw_10_2"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg"
      decimals="2"
      id="Tc_182PwYgS_k2W7KD5ZsCR6g_10_4"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Tc_66hzm-JD3kqm5qd1YZBI8Q_10_6"
      unitRef="Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_Dkq-D1kW_UGv5j2PtmrhBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible redeemable preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,249,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options and share grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,795,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,739,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 530,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_n1ed7fGyz0KAIk8k73AxhQ"
      decimals="INF"
      id="Tc_i7-Q9T1zq0Kn2WwfDnxC3A_3_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">27249824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_x3zBUisNukS5eVvI4gf_kg"
      decimals="INF"
      id="Tc_efi0kdEDhES_af4XqtqIUA_4_2"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1795932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_xEF_4pgz1k6DXF8uNNBIvQ"
      decimals="INF"
      id="Tc_DfCUvh-TMkerZo_xKuFOAg_4_4"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1739882</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_IfdRhB-Ii0Onl99aJ0jfJQ"
      decimals="INF"
      id="Tc_PNeoVK4I00u6AuSTp4sDdQ_4_6"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">530298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_YdKOFnV2xUCNgs8Yyyf4og">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;13. RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Related Parties&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Name of related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Relationship&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Peter Luo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Chairman, Chief Executive Officer and a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Four senior management personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Management and ordinary shareholders of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Co., Ltd. (&#x201c;WuXi AppTec Group&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;A principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party balances as of December 31, 2021 and 2022:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,080,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 503,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,426,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due from related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 619,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021 and 2022, the amounts due from related parties represented prepayments made for the CRO and CMO services.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,292,268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,840,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,482,461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due to related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,466,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,323,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021 and 2022, the amounts due to related parties represented payables for the CRO and CMO services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party transactions during the years ended December 31, 2020, 2021 and 2022:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Receipt of CRO and CMO services:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,217,709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,561,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,764,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,674,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 517,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,362,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,892,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,079,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,127,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_qtM0R7HTfkOKzz9fKjp6gA">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Related Parties&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Name of related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Relationship&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Peter Luo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Chairman, Chief Executive Officer and a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Four senior management personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Management and ordinary shareholders of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Co., Ltd. (&#x201c;WuXi AppTec Group&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;A principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party balances as of December 31, 2021 and 2022:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,080,116&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 503,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,426,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due from related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506,670&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 619,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021 and 2022, the amounts due from related parties represented prepayments made for the CRO and CMO services.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,292,268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,840,876&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,482,461&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due to related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,466,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,323,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021 and 2022, the amounts due to related parties represented payables for the CRO and CMO services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party transactions during the years ended December 31, 2020, 2021 and 2022:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Receipt of CRO and CMO services:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,217,709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,561,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,764,750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,674,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 517,742&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,362,713&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,892,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,079,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,127,463&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_R1F5ndSVPkCgXKmwyzbScg"
      decimals="0"
      id="Tc_CsOE23afx0y0D9Dq0kp_-w_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3080116</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_IGFUJEto00G2d7K3PSE_Og"
      decimals="0"
      id="Tc_JFqv8Xm0YUebGF-Y7l7UFA_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">503941</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_t_0MJ4wuNkyxIV4bgXJFmg"
      decimals="0"
      id="Tc_ENohm8Gmpkm_3OkO1W9o2w_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1426554</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_0M5cOB2hoEaTbUgHkdCREw"
      decimals="0"
      id="Tc_VW-qIBUiRUOVQ1xmKomL5g_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">115491</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_7i6cRJwN70mSTWGZMYZUAg_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">4506670</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_deMQ-bEIc0G7hm9ACsQtLQ_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">619432</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_t_0MJ4wuNkyxIV4bgXJFmg"
      decimals="0"
      id="Tc_9vz1E6Ad0Eea6gtGyTfOTA_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10292268</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_0M5cOB2hoEaTbUgHkdCREw"
      decimals="0"
      id="Tc_F_8L-FpwfUGAtiDpksd4mw_4_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">17840876</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_R1F5ndSVPkCgXKmwyzbScg"
      decimals="0"
      id="Tc_vLnMiBIF4EyP_JhvoVai9g_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">173793</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_IGFUJEto00G2d7K3PSE_Og"
      decimals="0"
      id="Tc_XZpQ6-4BP0-oF7EkAe3N3g_5_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1482461</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_R_ZQ6FXwC0q00kWVhWNfYg_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10466061</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_p7ExStvRYUq54yW9hz57Rw_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">19323337</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_f5vXDOcWdkSV-l04XmsJrw"
      decimals="0"
      id="Tc_A-eYZTVjo0uuPc6eIp9RtA_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7217709</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_fmpyuXJQ_EqCRbO-JtqTjw"
      decimals="0"
      id="Tc_UsXXRWuH8kunQ10TAd23qQ_6_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">12561276</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsCaymanInc.Member_XfcO1vA5gES98UF8hk_gOg"
      decimals="0"
      id="Tc_y5ZDMHlm3ECWx-SHPV_waw_6_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">27764750</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Itm1UFewfkK9c21wwIKhCA"
      decimals="0"
      id="Tc_j18J2w5dXUue-zM8RfR3rA_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2674586</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_lU_OCdJ2sUCF8wkKIvaYFA"
      decimals="0"
      id="Tc_oACoST3djkGhh3-BfOZUFA_7_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">517742</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_Xo3frStwAkqUZlLqb4wjJA"
      decimals="0"
      id="Tc_1IreS7jxt0WEu947S2a1tg_7_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">7362713</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_MJlpRPr5HkyPVxy3B1RlaA"
      decimals="0"
      id="Tc_K85vtKtriUq3xJdbKAjKcA_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">9892295</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_jQzQ-Qs4jUWen2BvHNx06Q"
      decimals="0"
      id="Tc_Gvt5DMt9l0a3w8_uxP2vhg_8_4"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">13079018</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_r4lFa-Ww0kCU3jAskRrUVw"
      decimals="0"
      id="Tc_Ker9_ASaMUSZel3kHB-eig_8_6"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">35127463</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_VjuVQTL9C0-p3CRmDZnUVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-size:11pt;font-weight:bold;"&gt;14. LEASES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Group has operating leases recorded on its consolidated balance sheet for certain office spaces that expire on various dates through 2024. The Group does not plan to cancel the existing lease agreements for its existing office spaces prior to their respective expiration dates. The Group&#x2019;s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. All of the Group&#x2019;s leases qualify as operating leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Information related to operating leases as of December 31, 2022 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Information related to operating lease activity during the year ended December 31, 2022 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease rental expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Amortization of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 283,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Expense for short-term leases within 12 months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 338,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year as of December 31, 2021 under ASC 840, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;For the years ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255,309&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 738,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Maturities of lease liabilities were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 157,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,823&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212,426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,609)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <adag:InformationRelatedToOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_vBdp2if0a0eEViQPqNa4mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 191,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Current portion of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 151,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</adag:InformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_p0gtKk-AMEiZ3hDSFHmW6A_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">191877</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_ZVPLq5eHxUKksWcvBcVwTQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">151983</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_h6aNHTorOUCCJNfW2I2CRQ_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">53834</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      id="Tc_WDt1rpMuZkCGvHAJaEegxQ_9_2">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="3"
      id="Tc_DMgpR2YaukustCRYXw7o8Q_10_2"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.046</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <adag:InformationRelatedToOperatingLeaseActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_UM8UA_R0qUimnp7fAhw6Sg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease rental expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Amortization of right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 283,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Expense for short-term leases within 12 months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Interest of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:81.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 338,264&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</adag:InformationRelatedToOperatingLeaseActivityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_d-pF9t0E_Eq3WheDF4jflA_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">283276</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_r3twlxpaJU6WAk2HZG0rkQ_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">34729</us-gaap:ShortTermLeaseCost>
    <adag:InterestOfOperatingLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_s5yWOlcaSUe3PEEe3SSerg_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">20259</adag:InterestOfOperatingLeaseLiabilities>
    <adag:OperatingLeaseRentalExpense
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="0"
      id="Tc_qTZ4a6ieQEC3UCGFKPIx7Q_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">338264</adag:OperatingLeaseRentalExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_w8ZJ4cCwLEa_6kpV1u9CuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;For the years ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255,309&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 738,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_XTnO08uLvU-xofUAf12H1g_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">412754</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_625iwuXQIUe5pKdtO0GbjQ_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">255309</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_OTILTwlWj0ajGbRvdcI4Qg_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">70367</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Tc_6eStvupZKU6RupRKnEkilw_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">738430</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_IsqOz10U90qhyUBulvXU0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 157,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 54,823&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 212,426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,609)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 205,817&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_xykPJJvySE2EsfxRd2DlRw_4_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">157603</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_vstD3M-_M0mZ3lNRaIMoyg_5_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">54823</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_3hxNTryWA0KGqN3Zri0vPw_6_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">212426</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_fXYRw95IzUSVhiD5FftqqQ_7_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">6609</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Tc_smaflCeqTUWvsBl3dUWfVA_8_2"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">205817</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_tZQNS0iMeEGyp-kxll3gfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;15. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group&#x2019;s business, financial position or results of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RestrictedAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_LTVC1Un_nkmWdbCF6lkznQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;16. RESTRICTED NET ASSETS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#x2019;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S.&#160;GAAP differ from those reflected in the statutory financial statements of the Group&#x2019;s PRC subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#x2019;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#x2019;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#x2019;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the abovementioned restrictions on distributable profits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021 and 2022, the total restricted net assets of the Company&#x2019;s subsidiary incorporated in PRC and subjected to restriction amounted to approximately US$1,860,667 for both years. Other subsidiaries are not subjected to such restriction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#x2019;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Foreign exchange and other regulations in the PRC further restrict the Group&#x2019;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2022, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries was US$1,860,667 from the PRC subsidiary, and the Group had a consolidated shareholders&#x2019; equity. As the restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information.&lt;/p&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
    <adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Narr_cuvMsgZNTUijCSpndn7JHA"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.10</adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve>
    <adag:StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Narr_QdInbK5oEUyvrajAn-RP_w"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.50</adag:StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ"
      decimals="0"
      id="Narr_FEDLgXQJdU6V8YsUVCPhkg"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1860667</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Narr_YNIBKj-xSk-VuXZ7RZoYVA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1860667</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <adag:AfterTaxIncomePercentageAppropriations
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Narr_jRr5wl9FZEy1UNN6YOOgzw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.10</adag:AfterTaxIncomePercentageAppropriations>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA"
      decimals="0"
      id="Narr_KR_2r23zSE2cs1Wv-XwWGA"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">1860667</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <adag:ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      decimals="2"
      id="Narr_VBkRzN96h0ajFG3POnaKiw"
      unitRef="Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw">0.25</adag:ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries>
    <us-gaap:TreasuryStockTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_H38E9ugGDUWwpNMLKr-Ejw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;17. Treasury Shares&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group accounts for treasury shares using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account in the consolidated balance sheets. At retirement, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is recorded entirely in additional paid-in capital (up to the amount credited to the additional paid-in capital upon original issuance of the shares). In the event that treasury share is reissued at an amount different from the cost the Group paid to repurchase the treasury share, the Group will recognize the difference in additional paid-in capital by using the specified identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On July 7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$20&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of outstanding ADSs of the Company, from time to time over a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer (the &#x201c;2021 Share Repurchase Program&#x201d;). The 2021 Share Repurchase Program commenced on July 20, 2021. During the year ended December 31, 2021 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;236,139&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1,170,446&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; outstanding ADSs (&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;295,174&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;1,463,057&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ordinary shares) were repurchased with a total consideration of US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2,361,576&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; and US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$3,904,399&lt;/span&gt; &lt;span style="font-size:10pt;"&gt;respectively, under the 2021 Share Repurchase Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On June 29, 2022, the Board of Directors authorized a share repurchase program to repurchase up to US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$10&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of outstanding ADSs of the Company during a period of up to &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12 months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; commencing on July 20, 2022 (the &#x201c;2022 Share Repurchase Program&#x201d;). The 2022 Share Repurchase Program was subsequently terminated in July 2022. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;39,900&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; outstanding ADSs (&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;49,875&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ordinary shares) was repurchased with a total consideration of US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$72,282&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; under the 2022 Share Repurchase Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;During the year ended December 31, 2021 and 2022, 160,880 and 1,285,604 ADSs (201,100 and 1,607,005 ordinary shares) repurchased have been retired&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;, respectively. As of December 31, 2021 and 2022, there were 75,259 and 1 ADSs (94,074 and 1 ordinary shares) held as treasury shares, respectively.&lt;/p&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="As_Of_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_kmEX4yG-ZEuDCtdXxBARXw"
      decimals="-6"
      id="Narr_c8Fz_k3ofUCOg_OzuS65mQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">20000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="Duration_7_7_2021_To_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_skBGvFvBgEm6UOz4-CGzgA"
      id="Narr_f-znbbnsj0-7mIjBJpeeuw">P12M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yBEmNnp9JkKRwrCjjyfHqw"
      decimals="INF"
      id="Narr_wWEfPntAVkKgTgEM95znwQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">236139</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_c6cCpTT3-UCFa3iydypLlw"
      decimals="INF"
      id="Narr_lFj1vKlZRUKjDBshf6PoKQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1170446</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_GF6f3RbJt0mSKdc-gIpyMA"
      decimals="INF"
      id="Narr_87mqU-N81Eq9q8e2FKRN6A"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">295174</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_Z9mphkrR0kmVJfMEZDudGg"
      decimals="0"
      id="Narr_wlV7tcW4pEKpeYXJYjnvaQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1463057</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_yBEmNnp9JkKRwrCjjyfHqw"
      decimals="0"
      id="Narr_izF3QuAewUu1v8uRwQQ48w"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">2361576</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_c6cCpTT3-UCFa3iydypLlw"
      decimals="0"
      id="Narr_oeiZk3GmN0eboQ8-DBR5bQ"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">3904399</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="As_Of_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_EzSDNbQB5EWZPn-NGBx2SA"
      decimals="-5"
      id="Narr_CKI3Pg9wG0-YbcGh6O6M4A"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="Duration_6_29_2022_To_6_29_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_ALi5xN2v_Ui4UIlZQtgALA"
      id="Narr_lhR_32dqHE-X0drRlN-9FA">P12M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_OffjEdDiwUq_QKSdjqfmkw"
      decimals="INF"
      id="Narr_hOoizyVq6kOJZGIxaye7KQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">39900</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_H1fu9nxkjU2h3rSJ7njn8g"
      decimals="INF"
      id="Narr_yQAGEWIpOEmZShdsWHuIJg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">49875</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2022Member_us-gaap_StatementClassOfStockAxis_dei_AdrMember_OffjEdDiwUq_QKSdjqfmkw"
      decimals="0"
      id="Narr_VdnWZS_TqEOUtZ7VlvZn8A"
      unitRef="Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw">72282</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_FfVHeu36qEOc41XZB5QsSQ"
      decimals="INF"
      id="Narr_OWsOv12jWkKtEc7X3ONY8w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">160880</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_R89FhkUdGUKmFpmGsV-p9g"
      decimals="INF"
      id="Narr_xhNNg3sLMESa0Vn3QOWKRQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1285604</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_PpX3jqVYjUKGSc4PUVCqbQ"
      decimals="INF"
      id="Narr_SIHAf74CCU-eTyFc2HvH-w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">201100</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_KW2h7BOi7EOWdPe9_-W2vw"
      decimals="INF"
      id="Narr_CvRrfdUqEk-V4W-jq06BRQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1607005</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_AEEEQVw_NU6BvaZkgLzS0Q"
      decimals="INF"
      id="Narr_8ndVf7okF0ODUbtD2c0urg"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">75259</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_V8r0Nfbtg0etm8S7eTVjcg"
      decimals="INF"
      id="Narr_ZkMCWpdEa0q92l-lcn8jFQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_8Qw98XWW1UumdeUdUM175Q"
      decimals="INF"
      id="Narr_lM4TXEluLU6G8tEXVnsZcQ"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">94074</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_sQqB69UJ9UC_sksuTF-VLg"
      decimals="INF"
      id="Narr_n4FcblGofEKOCXTjd6Wk4w"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">1</us-gaap:TreasuryStockCommonShares>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow"
      id="Tb_WWzKYUTFaEab57HklZx6yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;18. SUBSEQUENT EVENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From January to April, 2023, a total of 582,630 ordinary shares were issued to certain management personnel pursuant to the 2021 Plan.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2023_To_4_30_2023_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jbskMAiPskm8ahOT8fG0aQ"
      decimals="INF"
      id="Narr_zVFEIMvOcE64ndQNF0ETuw"
      unitRef="Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA">582630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>123
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MYYQ%7.H#X/L;(52]H7]@_1[2X?]02P,$%     @ )#B<5BM2I7$9!P   !X
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ME?0_F>WD'K2Y!R^YQ]<BI87^7IOG>(1*(M":L JZ8M=>D?4R&\(ZQCV,L7X
MZ^U _RS;0?5;5/]UJ/45D4IE7- _D'8AUY[!%DOHX_JW1WU(Y0YXT((';P*G
M4E;=T,$3E,#'81#AXSWFKL+@. C#J!LY;)'#-R'KC5\J4NC)51=W>"AW5^%+
MW%'+';W(?:N/+EFUW%V,T9.E]U_?IQ7'/H[\/3)W:Y<U)]PW(E:TD(C!4NMP
M+](&HCXUZH[BI=UX[[C2V[AM9OJ@!6$*]/R2<_78,7MY>W3'?P%02P,$%
M  @ )#B<5K=^"/72!@  1QX  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6RM6=MNVS@0_17"N]C= DW,BZ[9Q$ 2I6B M@GBM'UF),;65A>O1#OIW^](
M<B1;&C'IPB^V)9\9Z@QGAH?BZ5->_"B72FGRG"99>399:KTZF4[+<*E261[G
M*Y7!/X]YD4H-E\5B6JX*):/:*$VFG%)GFLHXF\Q.ZWNWQ>PT7^LDSM1M0<IU
MFLKBYX5*\J>S"9N\W+B+%TM=W9C.3E=RH>9*?UW=%G U;;U$<:JR,LXS4JC'
ML\DY.PFX7QG4B&^Q>BIW?I.*RD.>_Z@NKJ.S":V>2"4JU)4+"5\;=:F2I/($
MS_'OUNFD';,RW/W]XOU#31[(/,A27>;)]SC2R[.)-R&1>I3K1-_E3Q_5EI!=
M^0OSI*P_R5.#=:T)"=>ESM.M,3Q!&F?-MWS>!F+'@#DC!GQKP/L&8R.(K8%X
MJX&U-;#JR#14ZC@$4LO9:9$_D:)"@[?J1QW,VAKHQUDU[W-=P+\QV.G9Y<V7
M^<VGZ^#\_BH@\WOX^GSUY7Y.;CZ0RYO/MW=7'Z^^S*^_79%/-_,Y.2)?YP'Y
MZ_=WIU,-@U<NIN%VH(MF(#XR$./D<Y[I94FNLDA%^PZF\-3MH_.71[_@1H^!
M"H^)8.\)IYPC#W3Y=G.&F =O-Z<&-J*="%'[$R/^[M1&96N%!;8QM'##JC&<
ME"L9JK,)5'ZIBHV:S/[XC3GT;RPHAW06',C97L"L-F"6R?OL4QQ6[2=;$)E%
M!.H@D0]Y(773D$:#V3AU:J=54]S,?.YSEUNGT\UNG(8X1IEK<]O;!P9#H$NI
MST0+VV-GM^QL8SI</4-G+U6)4; /F0^'=!8<R-E>Q)PV8HXQ'^[ HRS"99T.
M$21 DJ]@@=)$&4+9N+1W)N_(8T+XMD5[^8 @'8_ZOO#L7D(@2"%LX5%AXSGA
MM@Q=(\/[95Q$9"4+'>-LW.'(EL,9IZ[;8X,@;1L:F7!ZR !!<N%8MKL3H3TV
M7LO&>V6^$JF5D8^'1-)FW+4<T>.#()F@KD]9OUP1I._YG/LCD^.W='PCG?,(
M5N>XU%4'VBACTOG(PS+/%5X_^)<8TK*$[SN\1PM#4L$L6S@X+T8[A4#-C38O
M2_)8Y"D!M=DT6)36ULU^,0F?4\?K3Q<&=:NTHI[?(X9!+<%LYNQTXGUF.]J'
M&9E=9UI!(](DSL(\19>+K8?=X87KVI3U&0UQKL,<I\]F"'-@^?'&J/"."G\;
ME6WBH5PXTL-\(?A@>A"@<(0[R#H,6,DI9Z286*>&F%$[S&[T4A7;>7E/,J51
M0F(P/(SM"<_K$QH"F>MZ'A\0&@)]E_F6/\*G$RO,K%9@DP);D RF)US*;*'(
M O9DY*\$:NO=.#]KR,^V;<'M/K\A\,BAPK('U80!+0NR8(1@IU>8<7%ONL2#
M@IVHVDX;T?(9964CQ>]7?=WG?5X8E%FN(X8SAT M+GP7W(YPZY0%,TN+ZY:/
ML;R0A1]F@-J#V4* S*7,8:)/ROA<_U-0L4YO,+/@^*(TJ3*42*V+^&&MY4,"
M8<C)>207*E,$ G/\9TG*I2S4,D\B5> K R(B7!\*R[/Z*QX*%5"LONCK+ SZ
MRHQWVH1Y1OG=M!^8=8CKLMIF;-JL;FH6I6D4/+\JS _J+3B4M_UX=N*(F=71
M2_L+UT6ALO G 9V4E4FS6Y/1/^M25UJ]K%LAR1])%B>C_0/1.F[5%?M;. 3(
M;=B<T7XB(0X=ZKEX$O%..'&S<+K/M4QZ272(<N*8T**0]LSMRQ(,ZH+@H,-R
MPJ 6MZ@0SHB$Y)W0XF:A=:A&PH?R::R1H%"\D6!0<R/AG2[C9EUV'H:%JK,<
MDCK,LXV"W4Y%OE"14FD=!TB/1P5U$37\RRHPU=_IJC;<R 1_E6$>^E?[#<>T
MG =UU8\6AK,\-O;&@W>:CYLUWVB6Y$449[+X^7I^B,'+F-'\P* "-BM67ST&
M&-3BL <6.X)EGW.G"[EE7&B^UR^F8>HE9 ;4 LG6Z0,L/9 M^ZQ+LBX!!J(1
M-F'-+1+*)%PW3?0$#8=1D_YR@AS26W H;_MQ[^0J-\O5HPM9QB$:M*&0M"TF
M;.KUUQ<,22GD$.W+;@3);-^FCC^R\>.=-N5F;7H4Q,E:]U^H;ZD,A>88%00Y
M0F6(?(5*)S>Y:ZR%MOZK#-_/?I2=4;S^<G8?TEMP*&_[D>SD*S>_6S-D=V/H
M[>T]CJW^AGD$UG^=@<'XL3.FG#JYR,URT9C4_ML8X+ ! P2&,)CNG+"EJEC4
M)Y4E+.CK3#<G5NW=]C3TO#X#[-V_8"=!<Z;9N6F.6#_+8A%G)4G4([BDQRZ4
M6-&<6C87.E_5YW@/N=9Y6O]<*@E+806 _Q_S7+]<5 .T9\>S_P!02P,$%
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M<F=0^X!95=3M_][33M:_\+)MW53KW<7P!.N\['ZFSSM''%U @I$+Z.X":E[
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MK*T0TM8T\%Y1$9 FA[<MG(QNG7R=7<^2E:UL8\IRAS_;+8+$]_JJPZFV30'
MMZ5MDX-__]?S^?SX%8WZY?S\,_U]\NIPEES9I6TLP&V3KD[:K<V*99$E[LT0
M3+=NZGZU!J$&_X15)E7=\;ANN,[1I<%B].5SC^=U9ZK<-'F;7-0Y3LZD4YS/
MKR\4VS0Q;;+M%V4!)SU/%CL"1:B^<_.-0GY=P_\<R'?GUZ\]!3[[!<+V7;@-
MTOV[?\M@&"+R"U!G"YN5E7UNZ<E=;U\PL1) ,2G@<=LOVB(O3%/8=I:<ES"F
M6%5$CZH#J)UMA+X@?TM#.X9CN\94K2'A'C*/+0N0DX1SOX659.&Z9LE7V#U
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MN^VVT;09PC_AS2J[9VI7"$TX9 @-^I]Q^%6S'AK'R,J-Y%8:''!GYKA10=D
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MQLC<?9UQ-N;*+H#G$RG-XL(*:*="3_\!4$L#!!0    ( "0XG%;FU_)DI D
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MZQ6JN $B@T&,OPEN5DCB9H4A/2'TQF \Q-WN+0Y_&$(_\PO^KD]6!ZU/D;E
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M^<$HZO#0T_ZX];QML 7!D_*V\HKEZ1*V43GC2^'TBL8Z%"7T-$;LQP.Z=NP
M;)&.G-$I#S$?,_<LYMY8A/^,/S!>3!93K<&:Z%$1/(IAO';*UX[/''#U:VA$
MHJ9I55?K#YS9YOT#1YY)&NOW;L"_/R_,L^%A"-,GU?6?W[L3U,=)99*W#1K
M'<"3L+2+0[V5!]*2;CS><PR/?BOE%>KIZ'2IH6DA+I2X2Q&XRJ38I'\D_= W
MTGHA*CU7W;=2( QZ Z1X6P2GNU&*W[R1U6_ 87"X]=JNB;.@FR7LLCWB9^!Z
M;U? ]0Z3Y6^+\[B1&.Q%;8_XQ9=A'H81:5NJNFAK<PYT+/S:"T]*&$./$I)#
M"C7"<>&28HXEDU-W]\*+27I-A%EQJ+3NPP/H0QD.NIIN^=!_%0"_D@Y(]N)W
M;:SH*0Q17)$^8@QW6):E+ S 1BK@NG6</H9A#_)^F\0B+ET9?V=LB_,ULJ.
M'T5/=TLWDT)?#8KT5D#8Y7Y 6$K+*"S683X^<\#/+?!LEZ'R$O=FS]]52P00
M@5NN+S_QC;.;)1_.'Z>L7=,<>0<I7G-+H&H88J*9DK\'SL0ZV'."OQ_5&6O<
M\D%Z_7[?V._B.JY+3@J:"WK?1HU'6+7<H@[P.U!"*-DZ>FDX'JL/  V<%Q+L
MMN$->KC/Q ,_EQ[XN?2/+HZ=9K>&.7WZ/<!-P%IZ\ZJ==R7[5,MFQGOX>^^,
M$L..C=9&ZD!^6NTBH<H'AS")1.WFX!N'_.(OJ=^Y/0SU^/Y?"D,]>!C>"/V?
M D/U;69O$"J$N09S^RZ@0<]>== @DZTTE05_-%PQ[/N3A'1^F_0HA,!Y5XD[
ML :W0%)#_=NC%LD+J6X$+L!;^ ?I;N*A?Z8ZP'<55MO2@O-1-Z^US^ $4W%=
M[0HNS27YR3"1M.PA!-VF<8RD:$IF<#B;TT[2RFR)CU_XAXS7+3^$!=098VM&
M+$LLFYTY#?/P.ZKR'57YAJA*+\1_1U/N!'F$9&H<\^@&BWVWA/6?3'[\<3IY
M/'VPXP\U=%U/<#86 ![ZJUHGT5\^@Y"XH+_O9C@KY3^"YC_-W)^0.^>_G!8N
MY[\_]QX"%;ZLII1SN/7T^/'# W:C[I=&K^GOJ$&:#?&7?EQ**%YJO "^GVO=
MN%]P _^']9[_'U!+ P04    "  D.)Q6?L5 _;P.  #"+@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6S-6FESVS@2_2LHSV;*KF)DDA(E*E>5XWAF
MLIMD4G&R.U\A$K(PH0@-05IV?OV^;O"4)<>I2;;VBPX2:#3Z>'T S[:F^&Q7
M2I7B9IWE]OG1JBPW3TY/;;)2:VE'9J-RO%F:8BU+_"VN3NVF4#+E2>OL-/3]
MZ>E:ZOSHQ3-^]KYX\<Q49:9S];X0MEJO97'[4F5F^_PH.&H>?-!7JY(>G+YX
MMI%7ZE*5GS;O"_P[;:FD>JURJTTN"K5\?G06/'DYH?$\X-]:;6WOMZ"=+(SY
M3']>I\^/?&)(92HIB8+$U[4Z5UE&A,#&7S7-HW9)FMC_W5#_A?>.O2RD5><F
M^X].R]7SH_A(I&HIJZS\8+:_J7H_$=%+3&;Y4VS=V&!^))+*EF9=3P8':YV[
M;WE3RZ$W(?8/3 CK"2'S[19B+E_)4KYX5IBM*&@TJ-$/WBK/!G,Z)Z5<E@7>
M:LPK7[Q^=_[[VPOQ\>P/<?''^XMWEQ?/3DO0I;>G24WCI:,1'J 1A.*MR<N5
M%1=YJM(A@5,PU'(5-ER]#.^E^$HE(S$./!'Z87@/O7&[RS'3&_^M73H:D_TT
MR#N>V(U,U/,CF+]5Q;4Z>O'S3\'4?WH/AY.6P\E]U!_(X?TT@F D[M(1[S^<
MBXOE4K']BV5AUN*?,J_@@H(E[,>>*%>*QOW\4QP&LZ=6V%*656F*6P\Z+56Q
M*;15XG6>F+42'^6-.*:AH?_TXO5'_A4\/1&%+)705H31(S!"'I>8(I5YHF#4
MY8H7T>M-IN#4H,]N767*"K,4H"/>R*TGI/BKDIE>:I6*>HV/*EGE)C-7M^(L
MO29ZJ;B$_#4(=]S9FH^6M8]GEQ<M;V!+9?I*+S*(P!18!DI<J@*<:)F)$EMB
M]L%*0.Q_!*]$0"2J*,%-4N]-=8($E7)5*"5NE2SL2)SE@JB5MV(-OQ5+C:4*
M]5>E"_!KJ\W&@%)^)5*35"0!VTF%EI=5N3(%39=Y"DJV*K!(E8%.1L.)-1I;
M -$@A+)F#S-4H:58*#"D1&5I"1HWV!_MK<]A8JHL%7*SR6[KC>S9KKI6L!':
MW4B\TM<Z57EJQ>*6+8H):65A.T;D)G],#^$7-*JDMXU:A%W)+ -_D,'B3PB/
M)@3^(U*Y)W*Y5N"!)+$R6<K,RQM/5#D,P]8;MIM:YO>LTYKNGQ7^IMJ!/F2F
M8;0%9.\,;B4M=$_R+A'#( FRA:*0^97JZ>1\I7.,6LD28C2T<UM;#719D?WM
M,%P;#T9 Q#=JO>'%V-=V1D(+*:)=KL3Q9?5E9:H3\4:OH430!&]+7<!V"I68
MJUQ_P4/FMW,)5I+.Q5M9)"LX;Q"QN4#/:HO7> /L5.N%*NAES"_?F>OF21A\
M9?W:"FEEJ$GE?YK;N]:TXRUNG\P+YD!FF9+8!%8;C\2YO%U#**]M)LEZFL4!
M)2/RITX[CGM::SAE)#XAJC@33:J">!"9W-K&'[ZR0&[*ON$1Z]",=D@&A25R
MHTOLZ0H)#,DFU:0Z6.RMMX]\:I2C"2 S@$1YQQ) ?8,Y;$Q@,6T=!ZO#%0I%
M@Q4!QF\&4_Y%'ZU*VD>=5O8(J1T%\9KU1N;P0YC E;;PAITAL.Z!YW4O8-E+
M#29KIFL<DH20M7@D4278:G6CB[X[ME$"9IL#E\DVZ%GM2C+]$T#HYNZ+!2V2
M=3P1+Z1<!\"$3X BXJ@UN<'>()M@.B*\_J4&,<9BV"WRD,X3ZDS"Y\^ ?8(2
M"^]>N:<Z946OY6=PDM\Z)*!DU&'!KB =B#-D0>);^LCA#180:'D+C;RA? @O
M=5X#0N XA_'8X=88;K!J;>4;3#(P(DX] 'IIWRWNR._^G5$88XQJF*C5W?A&
MR1M$/IL_;GAM# *2<_N3;GL[QJ]V-L&).Q8M6?%];X"KP38*P)IL>>V>O <P
MORG3O0C1CCIL_!VA'>/O7OS_&'_'TX.,OQL.V8S]1Z/[Q$?1+C>[.V/30DB^
M8U.>4RXIWZ-YK<7SE,Y*2,VVS6WZR0&0CU=:4!;3<=3D'6VRT'OSX)P!F_V6
M/.'^);YKNM!3X8])&3[E[+B79%Z#$-?SC+N>\FET.6*7Q;N>'/GQ4L&U8;'M
MC#X(8 ^R#?!AT+.QW25E9DV?-CM GQ38.*?<Q0#C))&+1_'DT6&38>9VC(6?
M_2@S.43\NQH(+_*#;.,23[ZH@M*3#@I^W6</_9%WS>+A%A%SQ!VNM6L(":"-
MTJA!;%D*"M:$K%L%O>&[R;[JU_XH>-1E@42!GKZ45F4#XBA2) W#K 5X8"1W
M:7"FU?*0=9$ K-VU+O?PX>85?9-Y':3^7>VKK]D?9&:O.SVJFPW*4^06M>Q/
MFB3EU\)4F[:>_)94S.5+6(&2ZK2AMS199K;$0I/XT_B4*A&*]')M*HC@"?<)
M_/'3[_;]U62R&4@[<1OA3>S2^73YCX._S]V.OIUYQI)OWE'MW&QUX5,1>.'<
M]WQ_+J:ST/.G$Q=;6+Z927HCQ].9-YD$XCB8QEX\F9Z(CX8\MM%(1W$:863D
MB\@?>R%*SU>UGIY\'Y;G4R_V)^+8?9\<9/@X"KWI)#@1[KMFMS6:9MADX@73
ML3AVWR?[[+O;VLS']H*QF$1SSX^BEL</J-.1^2'RL^<L5+E5RL&7ODN/S+LB
M+"8PHM9+TZKI4LG6*8$TF0%RU&V=/A2[')SZV14V=BA'<]6\K7WH!SC)_])9
MWNP7Q?$D],;SF1?.YB?B>!9XD]G4&X<A_9E[41!ZLSG^-)2H<]2)ND>')=ZR
M&8E'O8^>722P']1YK1J!LP\C>1SX7C2?@S4?K 4S+Y["CN* _LR]>!9[P3SN
M^'R-JB;A?A^1'W1>=E> @G=Z0PV1B1>.Y]XLC-LG,R^8S+SI>-Q[,H\"DE[[
MY)5>\F()UQH[JW$_PURKPBIIVP9@.S?RPGCJ3>)9^X2V/9E[\S@:/)H"><)Y
MSXE C[I9#MRO568VW/"T%2H4E*"(7>Q>Q[*3$;0=>W/6>T3"#*8D3.QWXLTF
M_LG7B7<*M0-3)(<_])^7BF911_Z=R1L&*<NH/;VC".F.8WSZT42,O>D\ZKL-
M5=BBJ[!1)+O^="WV;N,/Y@_"]X)XW/%WOJ),@:OR:YE5#J8D(0)7HQV;,X0#
MH+L(80Z <<#W! XT\\919T .<4EPAQ@(YX$7^7YG8%,O"#M[^)W*R\/B/L98
M+XY[VH.UA-/.7@]@]#Y:'6:W#K&#W>\,-@.3>B)>58RW]?$$7(\-O7B@67I=
MZM,=GU0+)'Q:TOG)H7:KUW:85O+:=9@&%?8WI%%>FT>-VJA;MZ.LJE-CQ*@%
M A5[;'^,LB[W6L.G*WK6G2"H'+*H*3G_;WAJ.@<PJ^U*)_4A!A)(I*W P;1%
M$<L=&%*6HV0HFRX48TCJ^ARL33Y5<2W=O50XJ;VBI)H/HFIMI?V]+F0FW8I,
M9U=4N[GF]PR-9W=7[ 6]!\:[/8H[S-D[A?@ +4@^4>),(4%9P(<Y6UFDO3 P
M!P+[\,D821D ?S;E\[LFENV=M.M,8[AU/!FC).-JC4\'#KK''0S<I3:+@ KS
MV8":SJ\QEV)H,VH>>5'<!8DY-@(,_92C"G)3ZA8EUDL8Y+B#?TJBZ*V-$!A,
MIQTJ!%,&Y+,D*2K0^"JO(4*H'XJS-9W=?9%-C5;06?]CLWQ<T1% YV2:RCME
M.7;3(8@:N-VA12+@[BN%.)_4>207Z#M+(L^#OJENI;:;$S6-LV99;LG)6O'.
MVP4 2M8.O:1FMHO9?CSVXO%$S+VI3_G[5+Q!*?ODWG!QC&D8'(PI_"(B(NA.
MYK.3O=C3"P44_N(0>IP?M.M#WP/*/9E^W7?_OF 1EA ;(R1HQX[[DX/L[!N[
M4W_LS/!$#E=NJY!=TWA+1W>]P]]]6OE>B?[#H>JE@]H::=O+!$@>9N0P(-,:
M2'NBMC>S&!+J 6B/0&M?'=SN%8.V3=>#XXQK>;A*B?L$?/RPQT#U4@ (,1NE
M''5IZ/6:"HU,?Z:C:82>G,,TQR!+ 9I/\LEZ7!^]ULT^XEN-]S29PUX+=G5W
M@S!4<7MJ694(OGQK8BT_$Z;;"MB:*N#)6N=R)]$0RDF HAV$46A5\DG1QEC-
MK2<RX%Q=27=3 6'<%-P/S*JTB>[#C*4+)BMMW<4/F235NLJX>XB]Z427C@5U
M0V<M]8E.<[9P(/IS4X["O6S/&US8=_N@]A;8JEANY G]18<!KDX_>C7)IBJH
M781T2[,!E$Q+<1=KM"\HNT._LK>Z6_2!"Q$]U.V%N=%K, C;@#-$/@J.$.$Q
M</O:2X\SCDV!:87.;KF"I#R&&EU/B B5A*B=_.G<==_: Q.R%2H"79:%<*4+
ME\V[K! ;BND2BJFNZ#+ .&3_1*2GIHX_&QXU=D3[[<+#E&<]RN&<*4?>9 +/
MG 6'* ]._]AAZN06;\B&Z!S#)1UUSL%D9P"$P!LCPSA,=N>,Y2MD^QW;M5*L
MBZ9KW%R9X:518<0 FAAR/+PV6<SP"&8HM86ZTCF=X;+P2!'Q4S)]C[6!B!"%
M.UMKBV=JRV.BA.^HOF,LJ)-]W62^#J .HQ(8M.KK_M-'HZK4 S3*B?,&ACYV
MQX#EP%=;A%U6(+4'AKL:81\<-B>/;7VD#^;K85\:'=PI";E7>?\$P($>]0>&
M +=!@>>Z)O51:M=AK[,TLG\D@#(C59SP[<ZT/0VF2V>:&HMK**ZTKL:JJR0>
M4>6]:SK=,82UAM*-NMO>7N]JN+2'D*E_+Z$3^IT:T2+GY0M:B&@##O8+98"V
M[>453 :<;[B<K^VG%R4'9 =G+&Q /0X(RUSR37MM+>FF%$$(<Z4[H?WU$6&I
M:(;#4)%))R9T."[RBN7@@LG@/,0Z+Y*6PZ'7/W7F(RN=#?J!A8+YYDP5/E#J
M#5X/R5UE9D%W>^X)#P2W1 P07U*W@E) N@/-]Z%N9!.-=^IS;F[V\!*$!N>L
MG%&V_9-OI1W,=VCS8=_@XL#?)#G:=X?UM'>O&%YPQ;>G*5&"H;@KQNW3]H+V
MF;N7W UWM[O?R@(8:5$5+3'5'\VB(U=%-7]*L^%;R@M3EF;-/U=*0G@T .^7
M!NY<_Z$%VFOK+_X+4$L#!!0    ( "0XG%9J152,%@0  &X*   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;,56;6_;. S^*X1W&%K E]BRD]AM$J!O
MPP9LO:+9;KB/BLW$QFPI)\E-^^]'R8Z7] T%;L!]2/1&/GI(D32G6ZE^Z +1
MP'U="3WS"F,V)\.AS@JLN1[(#0HZ64E5<T-+M1[JC4*>.Z6Z&K(@& ]K7@IO
M/G5[-VH^E8VI2H$W"G13UUP]G&,EMS,O]'8;M^6Z,'9C.)]N^!H7:+YM;A2M
MACU*7M8H="D%*%S-O+/PY#RV\D[@[Q*W>F\.UI*EE#_LXE,^\P)+""O,C$7@
M--SA!5:5!2(:_W:87G^E5=R?[] _.-O)EB77>"&K[V5NBIF7>)#CBC>5N97;
MC]C9,[)XF:RT^X=M*QNF'F2--K+NE(E!78IVY/>='_84DN %!=8I,,>[O<BQ
MO.2&SZ=*;D%9:4*S$V>JTR9RI;"/LC"*3DO2,_/KJZ_P^:_% FZN;F'Q\>SV
M:CHTA&M/AUF'<=YBL!<P0@9?I#"%ABN18WX(,"1"/2NV8W7.7D6\Q&P 4>@#
M"QA[!2_JK8P<7O2?K&PQXN<Q;':<Z W/<.91^&M4=^C-W[\+Q\'I*PSCGF'\
M&OH;&;Z.$;(!/,6!<Z[+#+C((2^KQF .@I*]DEK#!BD_"ZX0*+W!% @/R)4&
MM.\(] I8+TFD>XG _8<.RCX,;)$T,UYE3<4M+M>$4U&>ZQ-X_RYA073ZV\8/
M'<%_B& ;9X?\'LM;OON+<'_!^L6WQ1_][[JI47$CU0E<[SS$C5'ELC%\62$8
M"6<YE2J!\$ED XL13DYUZ\)"5CF2[XYBYD?IQ&>3]!B.)I$?3B9^&HWL(O73
M2>@G\>08SK),H2M,<@69%'>H3&DO49@C%5X[I3A;H:*-]@9M"=CC>N,4[WC5
M(!RQ./'#,")\EOBC$4T<,7;ZLA52Y:6@&OR4^3@>$7O6,F?!V(^3Y!'S2Q22
M*E'KJ)T?O[ORA[E;IZ><S"%'@6C< Y&)AU=JH ^$-A1)I5AW=)=/XC0<^>DH
M\,=I C0$$?.#((51[(?1R ^2V!GX^2"07\0Z8H,QD3\*!_&X'9+CGOU7"BQ<
MK>A+H2U77E7[_-[\//:^-IVD>R$-!3D"EH@"\#ZK&ANU*R5K%\F9K#?T)+L8
MV!']'8E)B4@ZI>J-VLJFRHD(B9CR3W<5?0P'SO"--$B[9/0#[$Y 8]:HTI0V
MZ IN6D.$-*TQI>B,*45K2E<#'IGR3)WIF3D(]VE_GAMTTO][07&%Q+G7N?;B
MC;' J +$J9^PN$_'W;@X")%?0;-6Y $(_4E*<1\Q.XL((6$PB@*?419TG)[[
MW@SW>@ J8VO7Z6@*LD:8MAWH=_MFZJSM(7Z)MYW8%Z[6)3&K<$6JP6 R\D"U
MW4V[,'+C.HJE--2?N&E!#2$J*T#G*TDAU2WL!7V+.?\)4$L#!!0    ( "0X
MG%8C0>_H6 0  #<,   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;,U7
M;6_B.!#^*Z/L:;65+$B<D$ +2)2V=Y7Z@BA[>_?1)(98F]@YQRSEW]_84):V
M0%O=?K@/8'L\\WC>&;I+I;_7.><&'LM"UCTO-Z8Z;3;K-.<EJQNJXA)O9DJ7
MS.!1SYMUI3G+G%!9-*GOQ\V2">GUNXXVTOVN6IA"2#[24"_*DNG5.2_4LN<%
MWA-A+.:YL81FOUNQ.7_@YFLUTGAJ;E$R47)9"R5!\UG/&P2GYY'E=PQ_"KZL
M=_9@+9DJ]=T>KK.>YUN%>,%38Q$8+C_XD!>%!4(U_ME@>MLGK>#N_@G]RMF.
MMDQ9S8>J^"8RD_>\M@<9G[%%8<9J^0??V-.R>*DJ:O<-RS4O33Q(%[51Y488
M-2B%7*_L<>.''8&V?T" ;@2HTWO]D-/R@AG6[VJU!&VY$<UNG*E.&I43T@;E
MP6B\%2AG^N/+F\'D\@)&@_'D;YB,!W</@^'D^O[NH=LTB&^YFND&ZWR-10]@
M!11NE31Y#9<RX]ES@"8JMM6./FEW3H\B7O"T 6% @/J4'L$+M]:&#B_\)=:N
ML:+]6+9:3NN*I;SG83G47/_@7O_SIR#VSXYH&FTUC8ZA?U#3XUA!V(##>,!.
M8,P+9G@&(Z:-X#5\_M2F?GAV<+UC)0<UPZI<RU4;.8>#Q5;GHH(1-US#S4+!
M,&<"*T@2W D^@\M'GBYL-<+];"92Y&(R P:5%C(5%2N@SIGFN2HRO,-W3,YA
MJ,J*R15<J04V%2Z%TE@($CL']@@#%=>UDI(7</N3:&&5SH3$?K.+6;\$_;;X
M2\"@JB8\15J#P(W)&O#%VDO]L]W;W[5:5(X>G)W X'TZ.X!SH0HU%VD-7X9L
MA:J?P+7$_!YBS6A5%.C'Z<J)84<1V' XI)LK(>?.QRL+_$X_/<5J>@(3)#N]
M(6>98YHAJ%I:V-T0KK#!%4RF&$GF7(3UQ\LI8F]J,' >M<5X^F:.O+4.7K_P
MDL6]N'.@V\/7A]_<YU5D("1^VR=!$$/+#TDG"HX[/R 1C4FK%4$0M$C4"6"B
M##J6E6HA30W9 IVE5?DJU2/2\F,2)S[$08=$(3UFV#/7$1>!-Q_0W+45Z6AX
M0*VY%2A99N.GU\$>WSO<X>T]V!:$Q50W_D>A.>AVG] .)31N0Y"0=N23=A+O
MB6:0A"3IA#9,;4JB>%]XC'KE.X2/XICXR(_!"6E(PC#Y#P':\\2S\+ 5FQ9(
M?%]8TH]4I-%,ULR-,%87;3DL_XHS;&/<_M"^,L7_Y<7Z<KW:&+JKQ4N>M_+'
M_T RV<\8\41E;.SV^?>PD4<S,2$4,S#Q.Q!0THH#0C$1*5+BB"0M?T].4JQZ
MK/XV=A@K&5'$"&-*DB#</MDA;9O>G18$V)"2#O&#-H0M$B!R%&_Y]@T*S9UA
MKN1Z[D;6&G\*,!O7<]V6NIV*!^MA\"?[>J2^97HN,&T*/D-1OY&T/-#K,75]
M,*IRH^%4&1PTW3;'R9YKRX#W,Z7,T\$^L/VOT/\74$L#!!0    ( "0XG%;D
M@(!4U@0  'L,   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;+57;6_;
M-A#^*P=U*UI L?7FM\0VX*3)5B#!@KI=L8^T1%M$*5$EJ3C9K]\=)2M.XACM
ML'V)1?+NN>=>R4RW2G\S.><6[@M9FIF76UN=]OLFS7G!3$]5O,23M=(%L[C4
MF[ZI-&>94RID/PJ"8;]@HO3F4[=WJ^=355LI2GZKP=1%P?3#.9=J._-";[?Q
M26QR2QO]^;1B&[[D]DMUJW'5[U R4?#2"%6"YNN9MPA/SQ.2=P)_"KXU>]]
MGJR4^D:+C]G,"X@0ESRUA,#PYXY?<"D)"&E\;S&]SB0I[G_OT*^<[^C+BAE^
MH>17D=E\YHT]R/B:U=)^4MO?>>O/@/!2)8W["]M&-HP]2&MC5=$J(X-"E,TO
MNV_CL*<P#EY1B%J%R/%N##F6'YAE\ZE66] DC6CTX5QUVDA.E)24I=5X*E#/
MSJ\O%\O+Y;1O$8MV^FFK=][H1:_HA1'<J-+F!B[+C&=/ ?I(HF,2[9B<1T<1
M/_"T!W'H0Q1$T1&\N/,L=GCQ3WO6Z"6']:@+3DW%4C[SL,P-UW?<F[]]$PZ#
MLR.LDHY5<@S]"*OC>F'2@T87%@;4&C!<O%AQW87,!YMS^$VKNH*<H4S%-;.B
MW(#D6+8&6RA5&G,%V S"&DA5:904&;.XMV*2E2F'9A)@LT/*M<6F1EMK00<4
M$H,VF 5^7PG-">>.::%J P1"AVA]DQ,=I/NYHY,I/"R5A0J-@%60DBWI"/-[
M81Y9 MMHSK'ID1^1()Z=Q%,F%5K6!(8H0J-WIN*NQ1MZS#6]X[5'Y>V;<12.
MSLS.FM:LW+3V<H:ZI4*DDF^9Q  2A/%I WTV*8;(@::2U1A0.C!6"S=>,-Z:
M(DI$25P[2%9F: /M2(FL>%I3J+?"YDA:Z PJIJT@@@L4P*3:PSP-?*^9%.L'
M.)#7'GPLF^'<S$GI\HEQ>5$ ['#A@'!':R5Q0IM3(-M!?/;#OP?J\;F(,[-;
M?%G^LJ=K.,9IM_SC*670-%-/U/JDIF0ULN$D],>C4:=S+=A*2$%Q[/8N:NV2
M5BGMHH+\GD4#Y)Y:. C]R3A^E<:^["#VQW'2B7YU8Q\#CL6C\1;#!-!5^*AK
MN2[@W0-GVKR'L!>_KID)DZJ::@<SV(DEO2'\VJU^+-7-72?L V2UIEVJ*Z(
MG(;U?U<"5]2!B/T78;N+X(7(2UO/):@>7B0>L\>H9_#Q@<M%08G\F^V2>:@N
MHG'L1Z,A7+8Z-#Y,CGHG+@5M#U#SX5##ZZMHKJ\X\4?1! .+4MC.A/XRZ5'@
M1X-)QSB.QWXT?"R"J]K6U.5EB6U*M[0HZM8BU!@5C6.E/&F&'EM)_K(UW4Q
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M@D:]+]<!Z'8.M(Y5M>^]M;+4R=XL:72B=@&T7RAECXY+T WC]#=02P,$%
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MV0E0PY.!\_:/2 S/(7N:L&V3.KR&YK=W8.C4\%+:5GCT_'LDBFR5E2GPT77
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M;I^I.'$ IJ$X3B)5 A#"4O%[H?6<@J6,X5PZ9ABNHZS%D B%)\B.@+R(N#!
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M^?7185!G%E]0X%J ^3$%8V&EW,="7;$PWG.=SDCH:'<4W8!0,!_E6^=X.*/
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MJEHCKE(]0TT?P&B2[)0(;0VL;$@.<(#$WAEW^9<$^\L<A^OU5M0NCEIZ#8+
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MX4ORA[J4D>D)F.M!P_2 %'0$T$8/[I=73)BO7Z)W=C!_V-R[TXKL]$FE?HP
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M29>[6[%Q'Q=*#1:]Z">&7E\"H7XK;[&?4#[P5NQ$8#M?A?%E76LNFI(H)M"
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M=*XN/5!-6V\F1M:NE2ZDH<;LA@6]A%!9!5I?2FD.$^N@?5L-_P902P,$%
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M<7B"L@YXGTEI=AL;H!O'\5]02P,$%     @ )#B<5JP,8[(J P  ZP8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S N>&ULI57;;MLP#/T5PAV*%C#B:VYM
M$B!ML\M#VR!I-^Q1L9E8J&UYDIQT?S]*3MT4:_.PO=@2Q7-X2%KT:"?DD\H0
M-3P7>:G&3J9U=>%Y*LFP8*HC*BSI9"UDP31MY<93E4266E"1>Z'O][R"\=*9
MC*QM+B<C4>N<ESB7H.JB8/+W%>9B-W8"Y\6PX)M,&X,W&55L@TO4C]5<TLYK
M65)>8*FX*$'B>NQ,@XNKV/A;A^\<=^I@#2:3E1!/9O,M'3N^$80Y)MHP,'IM
M\1KSW!"1C%][3J<-:8"'ZQ?VSS9WRF7%%%Z+_ =/=39V!@ZDN&9UKA=B]Q7W
M^70-7R)R99^P:WQC<DYJI46Q!Y."@I?-FSWOZW  &/@? ,(](+2ZFT!6Y0W3
M;#*28@?2>!.;6=A4+9K$\=(T9:DEG7+"Z<E\,9M/?][.[AZ6,+V[@?N'K[,%
M7#\N%F2"Z7(YHX.S![;*49V//$TA#=!+]O17#7WX 7T0PJTH=:9@5J:8OB7P
M2&LK.'P1?!4>9;S!I -1X$+HA^$1OJ@M0&3YHO\HP'MY-ZSQ^ZSF*EVHBB4X
M=NBN*)1;=":G)T'/OSRB.6XUQ\?8)\OF!H%8 [%7[#?=$JV E2D(G:&D#T=*
M,@%3"K5Z3_[Q *<G@]"/+N%?WU-EM%&KL%B1'-.NER-J6V![]Q?H<?GIS7I^
MD%K@=GNA&_3[M IZ@3L,?**OA.)T>,;.R3SH1^X@CB!TAWW?C2G*O:F%@EXP
M=(=^  ,_=H?#U[BQZW>[[I <R1[UW2B,X$YH-'P7\) AW>Y]!%)BNEAJ3(%(
M@16B-K)TQK0U?)&BKJ!BG,X%&,CUXAZV6*:"%-#LA"V37-14EUHK4<N$F PE
MDTEF&Y?BEB9D9=*EIHJ-9 5U-$F$3'FY,:PFCD99V-H2MD([T6PDMI&(ME0=
MJ[S1@\_&1QFPQ$1LJ17Z,"V^MOLVW)KQ'$3C],H(3"(DK$QH=&+:>>_[]0X&
M4(%R8\>L@L14J9E%K;6=Y--F@+VZ-[^!6R8WO%20XYJ@?J??=4 VH[79:%'9
M<;82FH:C76;T-T)I'.A\+:B'^XT)T/[?)G\ 4$L#!!0    ( "0XG%:O 4%_
M-P,  "0'   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;*55;8_:.!#^
M*Z/T5'4E:_-*"%M 8KNL6NEV2X%M=1]-,A"K29S:SM+>K^\X@2S544ZZ^T+&
MGGD>/^-AQN.]5%]UCFC@>UE4>N+DQM0WKJO3'$NNKV6-%7FV4I7<T%+M7%TK
MY%D+*@LW\+S8+;FHG.FXW5NHZ5@VIA 5+A3HIBRY^G&+A=Q/'-\Y;BS%+C=V
MPYV.:[[#%9JG>J%HY?8LF2BQTD)6H' [<6;^S6UDX]N SP+W^L0&F\E&RJ]V
M\2&;.)X5A 6FQC)P^CSC.RP*2T0ROATXG?Y("SRUC^SW;>Z4RX9K?">++R(S
M^<1)',APRYO"+.7^/1[R&5B^5!:Z_85]%QL-'4@;;61Y )."4E3=EW\_W,,)
M(/%^ P@.@*#5W1W4JKSCAD_'2NY!V6ABLT:;:HLF<:*R15D915Y!.#-=+#\N
MYLOU7PSFGYX^+![FCVN8/=[!ZN/]^LML.6?P.%_#FS7?%*BOQJZA,RW230_\
MMQU_\!M^/X '69E<P[S*,/N5P"6QO>+@J/@VN,AXA^DUA#Z#P N""WQA?P-A
MRQ?^GQLXEWA'&YVGM<UTHVN>XL2A;M&HGM&9OG[EQ][;"Z*C7G1TB7VZZGH(
MY!9J11VJS \&^*T1-36, 5YEH.76[+G"<](OD[]^E01>^!;^ZW>FK2ZJ$Y8;
M5&VMCBZJF=\6[A^@I]4?O]@//,U)%^5HDRGX1BIN)"U?LCR&#U@P"%@X&EEK
M%+(PB>%/I%;-99&!*.F&GM$B= _QF4^08122Y0T(-O1A;B>%DI5(SYSALR0.
MV6@0'ZTXA/M&5<(T"EN)1E(K]O&)SZ)X",&(Q4D$GS$7*370BWM(^QXD'@OB
M&%:'4O7N<.BS.(PAC D_2F M#2_^M=(O["SQ1BQ)?++B44!G)'0A6M_0$$R;
MLBFXP8QF%_TQ4\&[Z4@\O)3*B+^[C2/7FP$+ TL175E[1,2A-[B"1WHP[+"%
M9UXT)\I99'/S*74V3(+VG@Z^<W][]V1RE:AV[7S6D,JF,MT0ZW?[)V#63;Z7
M\.[]>.!J)RH-!6X)ZET/!PZH;B9W"R/K=@YNI*&IVIHY/6.H; #YMU*:X\(>
MT#^,TY]02P,$%     @ )#B<5O'SDK#B @  = 8  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&ULI55M;YLP$/XK)SI5FX0*&/)"FT1*TDR-U)<H+]MG
M!XZ :G!F.TW[[V=#H.F6YL/V!?OL>YY[[FP?O3T7SS)%5/":LT+VK52I[;7C
MR"C%G,HKOL5"[R1<Y%1I4VP<N15(XQ*4,X>X;MO):598@UZY-A.#'M\IEA4X
M$R!W>4[%VP@9W_<MSZH7YMDF56;!&?2V=(,+5*OM3&C+:5CB+,="9KP @4G?
M&GK7H\#XEPX_,MS+HSF83-:</QMC&O<MUPA"AI$R#%0/+SA&Q@R1EO'KP&DU
M(0WP>%ZS?R]SU[FLJ<0Q9S^S6*5]JVM!C G=,37G^SL\Y-,R?!%GLOS"OO)M
MZXC13BJ>'\#:SK.B&NGKH0Y'@*[["8 < *34704J5=Y210<]P?<@C+=F,Y,R
MU1*MQ66%.92%$GHWTS@U&(['\]7P?@'#QUMX6MY-YC!>S>>3QR7<3X>CZ?UT
M.9TLX.N2KAG*;SU'Z: &ZD2' *,J /DD@$?@@1<JE3 I8HP_$CA:;2.9U))'
MY"SC+497X'LV$)>0,WQ^4P*_Y//_JP2G,J]X@].\YCE=RRV-L&_I]R)1O* U
MN+SPVN[-&=5!HSHXQSY85*\(>*)O=B1V& /+Z#ICF<I0 BUBX"I%H2^1$%BH
MX]U3N9R/=GG1):Y_ _\Z#J41JD\.\[769$ZOWM*GZ)5'^1=HM?CR83X3/$%I
MV@%E8.J910@)ZFQKK]!OV8$?@&>W@XX=A"[,Z)O@C)7U$,BH^J-.-=*W"0GM
M3A@T*Y[MN8'MMUNP4L;[K>0P?4YA00L=NO;LVNUN"P+7[GA=>"J+KNCKX1#D
M3D0I%9MW]S:Q2<<%/PAMUP\KP+L0+_!MM^U"1\</.\VR5M();1+X1JE'[*X;
MGKI$SE$GR%%'-?U.0L1WA:J:0K/:M-1AU4G>W:M^_*!%9X4$AHF&NE>=E@6B
MZG&5H?BV["MKKG27*J>I_BV@, YZ/^%<U88)T/QH!K\!4$L#!!0    ( "0X
MG%:50T&=3@,  '@)   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;*U6
MVX[;-A#]%4()@A9@5B(EV_+&-K#>-&V 7!;KI'FFY;$MK$2J)!6G?]\A9<MR
M5ZNDEP>;MSEGSI S(F<'I1_,'L"2;V4AS3S86UM=AZ')]E *<Z4JD+BR5;H4
M%H=Z%YI*@]AX4%F$/(K&82ER&2QF?NY.+V:JMD4NX4X34Y>ET'\NH5"'><""
MT\1]OMM;-Q$N9I78P0KLY^I.XRAL639Y"=+D2A(-VWEPPZZ7(V?O#7[/X6 Z
M?>(B62OUX 9O-_,@<H*@@,PZ!H'-5[B%HG!$*../(V?0NG3 ;O_$_L;'CK&L
MA8%;57S)-W8_#]* ;& KZL+>J\-O<(S'"\Q48?P_.1QMHX!DM;&J/()109G+
MIA7?COOP(P!^!'"ONW'D5;X65BQF6AV(=M;(YCH^5(]&<;ETA[*R&E=SQ-G%
M\N/]_<<O;S_\NB(_?1+K LS/L] BL5L.LR/)LB'A3Y P3MXK:?>&_"(WL+DD
M"%%1*XN?9"WY(.-KR*Y(S"CA$><#?'$;9NSYXN^&V1==@TWZL:XLKDTE,I@'
MF/<&]%<(%B^>L7'T:D!9TBI+AM@7*RRS35T 45NR5AK1N=R9/I7#/"^>I3R*
M7Y%_V]X8IP#W'<HU:+_WIR4\ ^8/XA'H\^KY1?^VUAJD?=+):J^T?6E!EYU8
MKY\T7PKY0 HEI&FG8LHXHYR/"8OH9)S223)JW5;([DH= RF4W/W=44O":#P9
MTYA-":?I*$+*E'Q25A18<0U3#RBAR71"1^B.Q73,4II.8O)!R9??"_I=CY1_
M%#.GTRFC*9\2EE"6C%$$.^J5Z'] \P"RQWI"DW2*6Y,0/L&]'=&$):?%@4P?
MM9D^^N%,W]:VUH ?,FQRFX-//M.7'43(3>]I]I7(L( WC=-*YS++*]R#_^*>
MB,<%XPO% 7RQ' "=H=56%7CU#1SY_U"B%Z7:&?"+\G2_B\ES3G>)&/?8N%,O
MZ2C%G)^>9\XE@)9)QY+%,>4LZKA@'-U@"J+A8S\M,*(HC#+V^"-S3LLVL#8]
M^](R[-R&)>B=O_,-R50M;7,QMK/ML^*FN4W/YLV;Y+W0NQPKL8 M0J.K"2:8
M;N[Y9F!5Y>_6M;)X4_ON'I]&H)T!KF^5LJ>!<] ^MA9_ 5!+ P04    "  D
M.)Q6E?"]!T\#  !7"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6S%
M5E%OFS 0_BLG-FV=Q H82$*71$I2IDU:NRCIMF<'+@D:X,QVFG6_?F<()%/3
M3),J[0%\=[[[[N[#QN[OA/RNUH@:?A9YJ0;66NO-E>.H9(T%5Y=B@R7-+(4L
MN"95KARUD<C3*JC('>:Z':?@66D-^Y5M*H=]L=5Y5N)4@MH6!9</8\S%;F!Y
M5F.89:NU-@9GV-_P%<Y1?]E,)6E.BY)F!98J$R5(7 ZLD7<U#HQ_Y? UPYTZ
MDL%TLA#BNU$^I@/+-05ACHDV")R&>YQ@GAL@*N/''M-J4YK 8[E!?U_U3KTL
MN,*)R+]EJ5X/K)X%*2[Y-M<SL?N ^WY"@Y>(7%5OV-6^'69!LE5:%/M@JJ#(
MRGKD/_<\' 7TW"<"V#Z 5777B:HJK[GFP[X4.Y#&F]",4+5:15-Q66D^REQ+
MFLTH3@\GGV^_QK.[C^-/,<SBZSB^&1EQ.HO?QS,RP/S#:!;/871[#=]&L]GH
M]FX.%W=\D:-ZTW<TE6" G&2?;ERG8T^D\QC<B%*O%<1EBNF?  [5WC; F@;&
M["SB-2:7X'LV,)>Q,WA^2XA?X?G/2,@I'NHLP>DL9JM=J0U/<&#17E(H[]$:
MOGKA==QW9WH(VAZ"<^C#.6W==)LCB"5,1+'AY<-K!5-:[R@EIC!?<TI:[XA,
M9ZA.-7 ^Q:L7/>;Z[^!_C3?XZQ<OJ2C ']M,/\ <)34"H[?>062-.&Z$R6%Z
M<IB>O/7A3FB>/TKS9?[RV>0QSWF9('!EO@NM6RP6*/=KUXM:W] .NKX=A5WP
M;==US0.L:T=11$\(0<_NDNH'/GB]O36"T&U]O3"P"=!F40"C))%8_?XHY1$'
MC]:"%O2+3;'85,[W/-_B'V1X[/'(J!3/\Y^TGVV8N2<:;BR'QAO+$0&-B;)$
M78H-.ZWIB) 6W'V$90@*@L@.W.[S$?0O(^O98>C_J_M$E/<HU;[64P5^EFE6
MTM':F!J BY;A-W#1<DOR@552B!'7#>B)2#DP2<J!0S-CV.M28(>T\Y_8^^L2
M^LMXZE_H'!UV!<I5=:0K2,2VU/6YUUK;6\.H/BP/[O65XX;+558JR'%)H>YE
M-[1 UL=XK6BQJ8[.A=!T$%?BFFX^*(T#S2^%T(UB$K1WJ>%O4$L#!!0    (
M "0XG%;K1%%@FP4  .L1   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;,U867/;-A#^*QBUSL0S" 6 %YC8FO&5)@^)/9:33!]A$9(XYJ$"D&SWUW=!
M4B0<ZW#3M-,'"<1R\>T-+'AT7ZD[/9?2H(<B+_7Q8&[,XNUPJ"=S60CM50M9
MPIMII0IA8*IF0[U04J3UHB(?,D*B82&R<C ZJFE7:G14+4V>E?)*(;TL"J$>
M3V5>W1\/Z&!-N,YF<V,)P]'10LSD6)HOBRL%LV&'DF:%+'56E4C)Z?'@A+X]
MC2Q_S? UD_?:>4;6DMNJNK.3C^GQ@%B%9"XGQB((&%;R3.:Y!0(U_F@Q!YU(
MN]!]7J._KVT'6VZ%EF=5_BU+S?QXP <HE5.QS,UU=?]!MO:$%F]2Y;K^1_<M
M+QF@R5*;JF@7@P9%5C:C>&C]\)(%K%W :KT;0;66Y\*(T9&J[I&RW(!F'VI3
MZ]6@7%;:H(R-@K<9K#.C\8>3ZXLWIR?CBW-T=OGIZN+S^.3FX^5G]/I&W.92
M'QX-#8BQS,-)"WG:0+(MD)2A3U5IYAI=E*E,GP(,0;].2;96\I3M1#R7$P_Y
M%"-&&-N!YW=&^S6>_S>-WF1K@Q1L1K(E\U8OQ$0>#Z FM%0K.1B]^H5&Y-T.
M/8-.SV 7^FC<5 JJI@@287*'JD6?RIEYW*3O;L17OW!&_'?H_S)^JZM&I@TA
M^?D"3E92P>:R1>#/T/0W)4JS5=Z/Z@G%W$^NI=U>LW+6L\]F2LY<GO7X>5G<
M2F539DVY>)!JDNF>];W(5#<Y@U)5D%!+D7>TCT#*8-^==)3+.O$TNE+91**O
M(E]*="-5T3[NL^[+^%>TD&KK_$?'MAZV3'^70NDG,B^71AM1IM:5PB#85V3M
MK69OH4G'S*,($\81\:(0^5X4H]AC,8JPSSBF,6VB[J01O*$^]F,?,8\0X":T
M?D?9NVY<!Z)?]=K'41+@Q \.$?42'T5>&#Y;!\?/5&:NM-<T(9@0<MA1J!>3
M7ADOH4]\M49SY[M]P7HT'S/0,0 ?.,)"1UC43[@7\WZACP-*<!+Q9^ZBF ,F
M=3Q.F>=3!\=/]EJPP9\,9"8A[_U"O*0'"CWJ[T7=Y.T@Q&$(WO8]PB"V\?/8
M[O%F;UF .4DP 3>%-DJQYW.P%ES$<$03',;!,V?!FX#@,'$\Z[%^PEYBU09?
MT23&21P>.D"$.V%-PA_Q51(%..;)H0/D)$OLA?%>U#V^9$[1,1[AA/:4P./$
M#7?D9%00=!-;<PE!7Z6VNH,H)!\6T"?"Q%1H!>1_5W ;#=MA[<X6B@-NMQ;N
M8//8<2=Q:\\I6AY#>?&]DGH#&.0D))GO.X'SW2I_(C;J%X8AYKWM.[J>L.MZ
MPI=V/4+#9:$]>I:ZB0X$)ROLR6?F$DWM4;:JSR!@MQ0]%TJV)X%&LZ:4-C5*
MNY7XIR?3]R-42JW>8WTF2=L8/^-Y$IPN+G8KKG.B#M=UIN_:#F2JI$09F*=L
MOBKK$CBN^ %Z R/W#YSMFE)+I7".N=2$66K@L?  G4-#F8):Z#&3>8I(S_?T
M\6)=)ZLJ%R;+H0L%T25T+C%LX!8O]KV@7P*S6G8<>J%#!:$U-?"2@[Y!*> J
ME2T@4YG'X"WSW$UN.\5M8?)L*A$EK9\[6_<1=J1MU*5M]-*T-94!59I,M%?&
M%$VJ J[16M3]B=UK2BTU7&HGU:S,_MR<H+O%_1<)^I*$_!['MEG;GJ_AAB34
M9%[ON*E<R;Q:P 7?]!Z)<!##3L1]!-U4R!F.@PC%F#'XP?EWDL(5.-,0;7N7
M[Y=!&Q7&. CA4,4D:79FV[8PG/  W?3A:$MG5U"@8Z$,#N* (LIQ%"> S2TU
M9 2V_8WWSZ%S 2^DFM6?&30(6):FN8MWU.Y+QDES@>_9F\\@GX2:0>^-<CF%
MI00.SP%2S:>%9F*J17V=OZV,J8KZ<2Y%*I5E@/?3JC+KB170?=\9_0502P,$
M%     @ )#B<5FFV (GN!@  NQ0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&ULO5AK<]LV%OTK&+7;D680B^^'8WO&K^YF)TD]L;/;KQ )29R2A *
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MM<MA:\WJA96R-GNO^-'X8'SJ)GZ/[WH)H< #9SZRLFDIAY5H9YGQ<0\S1J$
M[Q,/X0""![$'2*"8^F$?0"T7&\/M ^"E+@T=IP^PB+I>'P^_@2?D?G./,9<F
MR<![B!8OZN-U#WOODM6S>9<0+UD=KH,R"*E3<M- IF@9V*:>:GGZN+"D=N$_
MI6A6%D3\5F'*3!5Y@9,")9<Y#@@UMKIOOBU%,R'OBZH ?5"2%SFIA29+]FB(
M?L@?<-G\>[QJ^-1>\6PP&E8].5"LHJY814<7*VMJ4,+:)IJCJ9-0"]@W1*&
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MEW!_^P#+=Y</MS#ZQ%<-ZK-98,B!50N*/=A5#\9> (L8?)3"5!IN18GE4X"
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M/*6$J/[&[@4CM^Z67$E#=ZZ;5O3(0645Z/M:4NWL!>M@>#8M?@!02P,$%
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MI="F;=UR:P8K2)M@SM="Z$-@>[<>U=$?4$L#!!0    ( "0XG%86#Q0FAP,
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M<*X<%,"<II$:\]4WV"1T8?!\'LGL%ZTV8ST'^:E4/-X$:P8Q2]97^K(IQ$X
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M;5VL#^SKAN++[)#\R)4^<F>W(=  A!F@G\\Y5]N&F2#_;-+\"U!+ P04
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MY0I(!%P;J.<+QN3KC>Z@.M*;_ =02P,$%     @ )#B<5B:GP2C2 @  Y@<
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ML?D&E1Z;8"PR99]D4\5Z#HE72HN\ F,&.>/EFSY5/NP _+-7 $$%"/8!G5<
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M*P.42[#[N93F'#@;]Y=0^A=02P,$%     @ )#B<5M-G!6*) @  [08  !D
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M>6$8:;"@,4G/V9(F\I<YXS$1\I8_&^F24S++G>+(0*;I&C$)D]YHD(]-^&C
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MWX_;GIP<#;[?WZV7U^7@S0RN+V\>_[_XNWPF7@P0Q3<&B.4 L>V 43E@U';
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M+".QG,0D"=+VDH3Q<Y(PKM._2-?+^YOU8%7<+BZKSB!\K1W>-44@L=DC=O*
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MT?A-E@K&9/!(S"4Q06(>B?DD%I!82&(1B<40I@1OL@G>1/L'[-/CXK/,JG6
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M42U M1#5(E2+*4V-45,U<?15D[]EV:2>4SG\-X\LNQTUM#2":@+5/%3S42U
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MQB,B+EE2+F&SMP.9$-?E2BR.GZFHDHW).YX>OZA_BLTS,\]V1":!^]U9T>U
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M8?*\1G)"@UW\R,-S0&G@Q8=;8J](R!NPS]=!0%].^ #94S/#/U!+ P04
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MNY,.[4I -0_5?%0+4"U$M0C58E1+4"VE-#'IVOX&3=[?\-[ENN7E5Z<7VIZ
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M'CU=JG=[,A8E-RQ$M0C58E1+4"VE-#&FVBX$X\(NA..QZ/F[:\G%JT,*[4U
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M<O^.W/ZB+K;M.UV/15T7F_;CBJ4+5C8 _OU34=2'BZ: XYN*L_\!4$L#!!0
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M_J'>&E[W^'HB666ZWB.3JH>:8::N1<AU@'H^8TR^3O0&[44K_ =02P,$%
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MOE)N1(EC6%KJSA# #V"%?_SF3IT_38G[E6+1+Q([2VK0)3484P\?B'A"*0=
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MSD56DEN/J@PF90;PC0Q,"&Y(P1,&+HL8QTT"7<BI-<&]I@GL9 QQ= XL\SN
M!H0M"4W?#S=;X.'[X4:'&JN>(4OQ61^<H3:G2R:[G4EN(1=LC2(\TL0>P3#=
M8BWX]L5TC1]M+O5)%O9$UG#0KAVTN]B#>\)1!MC_EG.;H26QJXCE%KH-3,,1
M$SL0ZVI[:%9+X,#U?-<9- /#-D83^HYMUH$-D4XMTND4.1>V(1HE !6QV/BV
M8D=?B_V9=\KKI/SH>NF3+.R)K&&E6UOI]E9Q;I\.]DD6]D36<-"K'?0^J^)*
M8N>@/CP(/>@?U='T=9QI.0/HV>Y1P;T.=&T/&@.KO=X&M<1!I\1Q++[&*>,4
MR8-+IZ1.HH^ND3[)PI[(&@;ZM8%^;U7F]^E@GV1A3V0-!TWCY?!F?%:=5<R'
M'R(+^J+.[*-":PET#-_US:-/8-C&Z#J>?? )+&7J!\?5'-.5.O8SD?JFX.4I
MKQZMKQ9C=: ^&I_(*X<Z!K_0E/>5&T17:<% AI>"TCCW1/W3\@I0=CA9JT/Q
M(^'BB*V:B;@V82H#Q/,E(7S?D2^H+V+!/U!+ P04    "  D.)Q6N@%CUS,,
M  "LJ@  &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6S%W6MSF\H=Q_&W
MPJB=3CJ31@(L7W(<S]CF?DLFR6FG#[&TENB10 4<)S-]\04)&V'AE91^ISD/
M3BR9_2P8\=>R_(0N'[/\CV(N1*E\7R[2XL-@7I:K]\-A,9F+95R\RU8BK7YS
MG^7+N*P>YK-AL<I%/%TW6BZ&VFAT.ES&23JXNEP_]RF_NLP>RD62BD^Y4CPL
MEW'^XT8LLL</ W7P],3G9#8OZR>&5Y>K>":^B/+WU:>\>C1\5J;)4J1%DJ5*
M+NX_#*[5]]')J&ZP7N+OB7@LMGY6ZDVYR[(_Z@?N],-@5*^16(A)61-Q]<\W
M<2L6BUJJUN/?#3IX[K-NN/WSDVZM-[[:F+NX$+?9XA_)M)Q_&)P/E*FXCQ\6
MY>?LT1'-!HUK;Y(MBO7_E<=FV=% F3P49;9L&E=KL$S2S;_Q]^8/L=5 TUYI
MH#4-M!<-U(M7&NA- _W0'DZ:!B>'-A@W#<:'-CAM&IP>VN"L:7!V:(/SIL'Y
MH0TNF@87AS901T][;G1PD^>=??#>5I]VM_IR?[_>Y&F'JP?O<?5IEZOK?3[<
MO'S7KWTC+N.KRSQ[5/)Z^<JK?U@?0.OVU4L^2>MC_4N95[]-JG;EU>W'(+B^
M^?CY^JO[,5*N/W^^CFPS-*.O7Y0WABCC9%'\]7)85CW5RP\GC7JS4;575%4)
ML[2<%XJ93L6TI[VUI[TF 8;5)CYOI_:TG3>:5 SC_)VBJV\5;:1IRN]?#.7-
MG_LV[%;.7*]J9E0SZH62E&+98QARPQ"3IU51SR6K8A[#W$;_5-[\Y4_JZ?BW
M/LLZV)+^=>S#&57".,<P>[;,/=P:25;).X;9LTK^X3ON8I\5['D]/LP.VG'A
MP2]K*1/)&4O<O5.T<]G^[QR\^G.1TM>N_EJ1RA:+^"[+XWI<H%SG>9S.1#7@
M*)4XG78>?RSG(E?*>9PJG49])6S3YTE_G_48ZWVQBB?BPZ :1!4B_R8&5_5^
M&OW65S9(S" QD\0L$K-)S"$QE\0\$O-)+""QD,0B".M4FY/G:G,BTZ\^BV\B
M?1!%7\V0MCRV9I"806(FB5D;['2-U:>>WZXNM OM3#NY''[;+@>[RZDC]6RL
MC<^["SKDVKF[O9Z-1A>JWNW3(_OT22P@L9#$(@CK',3CYX-X+#V(KR>3["$M
M"R47$Y%\B^\6XJV2BK+OH)9*QQ[4)&:0F$EB%HG9&VR\=0SJH_5_+PY\LE.7
MQ#P2\TDL(+&0Q"((ZY2'T^?R<"HM#_9#4CVE?(G3?U7_?)K'^;+JZJ%,)O&B
M.G-X]U8)RND[)4@F(BVJ4XY9+M8G&'WE0]K3L>6#Q P2,TG,(C&;Q!P2<TG,
M(S&?Q (2"TDL@K!.C3E[KC%GOV#6XHRL-B1FD)A)8A:)V23FD)A+8AZ)^206
MD%A(8A&$=:K-^7.U.9>.:'Y?W>=954LF<3%75O&/=6'9G/ST7H&YD7+'%A(2
M,\YW)P+&JJJ>OI@',#?+J7IGQJ#OQ,$B5\\F,8?$7!+S2,PGL8#$0A*+(*Q3
M "Z>"\"%?,:C/D>9*BN1)]E4N<]R)<U*I<R46370J$I!'7HHE+@HLDD2E]62
MCTDYKX8B97*731-1U(N6\R2OB#@OD_[Y3^DJ'%LT2,R0_W%TY8>(\[Y-,G^V
MH46NODUB#HFY).:1F$]B 8F%)!9!6*>HJ*,V'S*2'@!&'L^R5+G)XE*Y2;)5
M=ZKDS9?JI&4VCY._*D&R3.JR<M"<B;S38PL)JAFH9J*:A6HVJCFHYJ*:AVH^
MJ@6H%J):1&G=XK,53E-_P11*TRE5?$C-0#43U2Q4LU'-0347U3Q4\U$M0+40
MU2)*ZQ8?K2T^&CNC(O>.KBND9J":B6H6JMFHYJ":VVC;5[K'9[I^]F)FRVN6
MZTQMG?3-;/GH^@6H%J):1&G=:M!&4%5IYNS_,[TB7X>C*P@:2D4U$]6L/?ON
M]4D<&UT/!]5<5/-0S4>U -5"5(LHK5MWVC"J*HW)2=.H\J9'EPM2,U#-1#6K
MT;:O,+UX7[6;1;;?J56M>@O6M!>9M&;!SEOU>=];M8MN@]?7[\[@8/\R ;I6
M(:I%E-8]]-H(J2K/D(;)0A1EE@KE7@CYR!^-D**:@6HFJEFH9JN[.=)3;312
MU9>'[/C T;6+KI^':CZJ!:@6HEI$:=TRT$9%57E6]-JX_;H]J9BE>ZYMH(%0
M5#-0S40U"]5L5'-0S44U#]5\5 M0+42UB-*Z9:5-AZJ_(AZJHOE05#-0S40U
M"]5L5'-0S44U#]5\5 M0+42UB-*ZQ:<-BZKRM*AT5@%-AJ*:@6HFJEFH9C?:
M]LF,IHUW/Q.']NH>V*N']NJC6H!J(:I%E-8][-N(J"I/,X;Q]V3YL%32A^5=
M-:3([I7-7;?$5"GC?";*XJT2;RYTU%<X9B(5S1E/M>C6M8S_O';KFQOY"AQ=
M/"YV7X[=5Z*!=FBBFH5J-JHYJ.:BFH=J/JH%J!:B6D1IW3MLM5%131X5#9-T
M75W*>:7/L\54><R3LA1I?:DTF8CMBZ>ER)=)VM86V82*O-MC:PJJ&:AFHIJU
M9W?I(V4:_^B]*HJNAX-J+JIYJ.:C6H!J(:I%E-8M-6TP5)-FOZX^M95DPS]7
MDLTX9I/'Z"TF:/@3U0Q4,U'-VK-#U'7$HK>6H#E/5'-1S4,U']4"5 M1+:*T
M;BW1VEHBSWENIE>3=)(M>Z=4Y<V/KAAHK!/53%2S4,U&-0?5W$;KWKIL]W*R
MA_;JHUJ :B&J1936+1!M]%.3QP?-[V*1?$\*Q4TG\DN_<NCH4H'F-U'-1#4+
MU6Q4<U#-134/U7Q4"U M1+6(TKH%I<UT:B>_X-*O1F;O;E'-0#43U2Q4LU'-
M0347U3Q4\U$M0+40U2)*ZQ:?-M6JR5.M1W^L3>X=75?0<"NJF:AF-5KGK*#O
MM,#6=G.KS8(O+_:B*^BBFH=J/JH%J!:B6D1IW7+0IELU>;I5E@21-SWZR$>3
MK*AFHIK5:-L'],XQO[O(^;CWD$>3IZCFH9J/:@&JA:@645KWD&^3IYHT7';U
MJ7G3S^Z5A\U@X&^YN'](I_5=TNO/NO36 C18BFH&JIFH9J&:C6H.JKFHYJ&:
MCVH!JH6-MG><&+V^8+MDMR2T>5!-G@=M/^K6G!%L?W'"^LL4ITJ6*M-JL+#(
M5L]3%;F8/2SB,LM_*,LGH7\D@69*4<U -1/5+%2S4<U!-1?5/%3S42U M1#5
M(FTW_ZMJ9V-9C6G#I]J>\.EA-::(%Z_4$#1:BFH&JIFH9J&:C6H.JKFHYJ&:
MCVH!JH6H%C7:]C!%.]5D-41O(Z:Z/+-XS-<ZR:ECZP6J&:AFHIJ%:G:C;;\:
M^K_<">W6134/U7Q4"U M1+6(TKK5HDV)ZO)0XOJ3^V%<BCR)%\K7/$Z+>Y&O
MSUP^KO9_D%^N'UU T*@HJIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E%:M\IH;971
M?D&:0T=3IZAFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&E=8M/FTW5Y=E4V>5;
M>=.C2PC[%??L=]RS7W*O[TR"Z7VY#;17!]5<5/-0S4>U -5"5(LHK5L<VIRI
M+HV2_=R%7KEY=-4@-0/53%2S4,U&-0?57%3S4,U'M:#1=B>ONN\$(=IK1&G=
MJM$&1'5Y0/1+G&;WR9ZI$303BFH&JIFH9J&:C6H.JKFHYJ&:CVH!JH6H%E%:
MMY2TX5+]]%=,C:"Q5%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M8C2NL6GC;GJ
M\ICKT1]TT7OR=2^S+TW-0..KJ&:BFM5HX[U_$QOMUT$U%]4\5/-1+4"U$-4B
M2NO6@S;CJO_\/4_E38\>4J#Y5%0S4<UJM.V2>7YQH9UI)R^K QH]1347U3Q4
M\U$M0+40U2)*ZU:'-IVJ(^G4GT[ Z[NW,E7/]/[1!1I-1343U2Q4LU'-0347
MU3Q4\U$M0+40U2)*Z]28DS:]>K+O!JG_6P+^9#=+>;*I(#LU1+XFQ]805#-1
MS4(U&]4<5'-1S4,U']4"5 M1+:*T30T9%G,A2B,NXZO+I<AGXE8L%H6R3KG7
M\ZI;SU:UXKZ^Q?O[:VTPW'G^1GUOJCW/6^I[?_W\L.6O+E?Q3(1Q/DO20EF(
M^ZJKT;NS:FRROFWJTX,R6WT8J /E+BO+;+G^<2[BJ<CK!:K?WV=9^?2@[N Q
MR_]8;\[5?P%02P,$%     @ )#B<5C>261K\!P  T4P  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C(N>&ULK9QM;]LV%(7_"N$-0PMLL=[\DBX)D%ADFZU-
M@Z1=NWU3;3H6)DN>Q"3ML!\_2E9$469HJSCY$-LR[T/I'E&DCBF>/&;YW\6*
M<T&^KI.T.!VLA-B\&@Z+^8JOH^(HV_!4?K/,\G4DY,?\;EAL<AXMJJ!U,O0<
M9SQ<1W$Z.#NIMEWG9R?9O4CBE%_GI+A?KZ/\VP5/LL?3@3MXVG 3WZU$N6%X
M=K*)[O@M%Q\WU[G\-&PHBWC-TR+.4I+SY>G@W'W% K\,J$K\$?/'HO6>E(?R
M)<O^+C]<+DX'3KE'/.%S42(B^?+ 9SQ)2I+<CW]JZ*"ILPQLOW^BL^K@Y<%\
MB0H^RY)/\4*L3@?3 5GP972?B)OL\0VO#VA4\N994E3_R>.V;" +S^\+D:WK
M8+D'ZSC=OD9?ZT2T MS@F0"O#O"Z >-G OPZP#^TAJ ." X-&-4!HV[ Y)F
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M:ZKL% \][\0.["VT<;:(WVT^4'\$2F,HFBZ@\D<\NS_2_R= .["W@$:_8$=
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M/VO[062;:KVG+YD0V;IZN^+1@N=E ?G],LO$TX>R@F85L[/_ 5!+ P04
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M>033)NKO#O6-XJOJ)/[$%9SKJ\LEHU ]M0"\GW.N7F[T .W7G_%_4$L#!!0
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MP&B*F0J0]V>4BN<3]5VM^? Z_@]02P,$%     @ )#B<5H01,G&N @  _P8
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M*)W;OLJ*EUZSG$B6&_>U9E)Y.3-,E#T'K@/4_H8Q>9CH VK#/_X'4$L#!!0
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MYG_5M+R7UYLOA\],[;G0Q+<CT^!B3O=6-<VXF1A9N0:XE8;:J1OF] &#RKY
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MVDIC*](O:]L"03D'>UY):8Z&"S TU?P74$L#!!0    ( "0XG%8(6ZO$4P,
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M+GAM;%!+ 0(4 Q0    ( "0XG%;?LO(=[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "0XG%:97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ )#B<5LJK<Y=V!P  DR0  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "0XG%8K4J5Q&0<
M   >   8              " @;D/  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  D.)Q6'@>2 )("  #&!P  &               @($(
M%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ )#B<5K=^
M"/72!@  1QX  !@              ("!T!D  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( "0XG%8HQF#!>@(  +8&   8
M  " @=@@  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  D
M.)Q62$M$W5H,  !R=   &               @(&((P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ )#B<5L/L^K> "P  6#P  !@
M         ("!&#   'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( "0XG%:30)P*ZP4   @/   8              " @<X[  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  D.)Q6DN89>T(F   '>@
M&               @('O00  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ )#B<5OJ$F71. @  KP4  !D              ("!9V@  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  D.)Q61F^NB3$#
M  ! !P  &0              @('L:@  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( "0XG%9,XH1=C0,  !\(   9              "
M@51N  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ )#B<
M5F\<JJ/L @  U08  !D              ("!&'(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  D.)Q6!4-%IJ$'   A*@  &0
M        @($[=0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( "0XG%;FU_)DI D  /4>   9              " @1-]  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ )#B<5E8BAE'\#P  6S$
M !D              ("![H8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  D.)Q6-DK)<+49  !D;P  &0              @($AEP
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "0XG%9^Q4#]
MO X  ,(N   9              " @0VQ  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ )#B<5FI%5(P6!   ;@H  !D
M ("! ,   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  D
M.)Q6(T'OZ%@$   W#   &0              @(%-Q   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "0XG%;D@(!4U@0  'L,   9
M          " @=S(  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ )#B<5O'E@TV  @  F 4  !D              ("!Z<T  'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  D.)Q6GQG0C,L%  #;
M#@  &0              @(&@T   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    ( "0XG%9IX<04"@4   ,-   9              " @:+6
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ )#B<5B88
MI'%' @  '@4  !D              ("!X]L  'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    "  D.)Q6=I_V8,8G  "BA0  &0
M    @(%AW@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M "0XG%;@@&SYA@,  &<)   9              " @5X& 0!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ )#B<5BC?'0S$ @  4P8  !D
M             ("!&PH! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  D.)Q6RS6'%ED"  ":!0  &0              @($6#0$ >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "0XG%:L#&.R*@,
M .L&   9              " @:8/ 0!X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ )#B<5J\!07\W P  ) <  !D              ("!
M!Q,! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  D.)Q6
M\?.2L.("  !T!@  &0              @(%U%@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( "0XG%:50T&=3@,  '@)   9
M      " @8X9 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ )#B<5I7PO0=/ P  5PD  !D              ("!$QT! 'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  D.)Q6ZT118)L%  #K$0
M&0              @(&9( $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( "0XG%9IM@")[@8  +L4   9              " @6LF 0!X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ )#B<5O;Q?,&T
M P  0@D  !D              ("!D"T! 'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  D.)Q6>_;POV0$   E#   &0
M@(%[,0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( "0X
MG%;X!-S?] ,  %8+   9              " @18V 0!X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ )#B<5DA*_->L!0  BRP  !D
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M=#0T+GAM;%!+ 0(4 Q0    ( "0XG%8FI\$HT@(  .8'   9
M  " @6I. 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M)#B<5J?@]_@# @  D 0  !D              ("!<U$! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  D.)Q6TV<%8HD"  #M!@  &0
M            @(&M4P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( "0XG%8(P?OQ]P0  %8?   9              " @6U6 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ )#B<5C;D4??K @
M9 @  !D              ("!FUL! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  D.)Q63YJ;[M$"   S"0  &0              @(&]
M7@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( "0XG%;3
M8]J6$@L  .6S   9              " @<5A 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ )#B<5A'D%4JI%P  #=(! !D
M     ("!#FT! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "0XG%8/<2FVTP<  +4X   9              "
M@4NJ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ )#B<
M5AG7^4$? P  = D  !D              ("!5;(! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    "  D.)Q6&!Z)T8,#  "K#   &0
M        @(&KM0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( "0XG%:TQ)XH-P,  )0-   9              " @66Y 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ )#B<5KH!8]<S#   K*H
M !D              ("!T[P! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    "  D.)Q6-Y)9&OP'  #13   &0              @($]R0$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( "0XG%8\#O_;
M) ,  #P*   9              " @7#1 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ )#B<5FZ:_HNS!   "1(  !D
M ("!R]0! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  D
M.)Q6[F*]_:($  "$%0  &0              @(&UV0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "0XG%:$$3)QK@(  /\&   9
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M970W,"YX;6Q02P$"% ,4    "  D.)Q6<B8_XZ@"  !Z!@  &0
M    @('\\ $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M "0XG%87>#"I;P(  +4%   9              " @=OS 0!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ )#B<5F_=;NU: @  \P4  !D
M             ("!@?8! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    "  D.)Q6IAJI>Q(#  !8"0  &0              @($2^0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( "0XG%;QD',+* 8
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( "0XG%;^,)#>]@4  %8R   /
M      "  :4) @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  D.)Q6<WQX
M+%$"  #[+   &@              @ '(#P( >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  D.)Q6SA7,7P\"  #J*P  $P
M    @ %1$@( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5 !4  ,7  "1
%% (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>285</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>93</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - ACCOUNTS RECEIVABLE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccountsReceivableNet</Role>
      <ShortName>ACCOUNTS RECEIVABLE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets</Role>
      <ShortName>PREPAYMENTS AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet</Role>
      <ShortName>PROPERTY, EQUIPMENT AND SOFTWARE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUALS AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - BORROWINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowings</Role>
      <ShortName>BORROWINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - COLLABORATION ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCollaborationArrangements</Role>
      <ShortName>COLLABORATION ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - INCOME TAX EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpense</Role>
      <ShortName>INCOME TAX EXPENSE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureLeases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - RESTRICTED NET ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRestrictedNetAssets</Role>
      <ShortName>RESTRICTED NET ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Treasury Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureTreasuryShares</Role>
      <ShortName>Treasury Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11801 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccountsReceivableNetTables</Role>
      <ShortName>ACCOUNTS RECEIVABLE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccountsReceivableNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables</Role>
      <ShortName>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30703 - Disclosure - BORROWINGS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsTables</Role>
      <ShortName>BORROWINGS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureBorrowings</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31101 - Disclosure - INCOME TAX EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables</Role>
      <ShortName>INCOME TAX EXPENSE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureIncomeTaxExpense</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31203 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31403 - Disclosure - LEASES (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureLeasesTable</Role>
      <ShortName>LEASES (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureLeases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccountsReceivableNetTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAYMENTS AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails</Role>
      <ShortName>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUALS AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40701 - Disclosure - BORROWINGS - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails</Role>
      <ShortName>BORROWINGS - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40702 - Disclosure - BORROWINGS - Short term borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails</Role>
      <ShortName>BORROWINGS - Short term borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40703 - Disclosure - BORROWINGS - Long term borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails</Role>
      <ShortName>BORROWINGS - Long term borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails</Role>
      <ShortName>BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share based compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails</Role>
      <ShortName>COLLABORATION ARRANGEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureCollaborationArrangements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41101 - Disclosure - INCOME TAX EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAX EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Income tax expense (benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Income tax reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41201 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41401 - Disclosure - LEASES - Information related to operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>LEASES - Information related to operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41402 - Disclosure - LEASES - Information related to operating lease activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails</Role>
      <ShortName>LEASES - Information related to operating lease activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41403 - Disclosure - LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails</Role>
      <ShortName>LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41404 - Disclosure - LEASES - Maturities of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41601 - Disclosure - RESTRICTED NET ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails</Role>
      <ShortName>RESTRICTED NET ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureRestrictedNetAssets</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Treasury Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureTreasurySharesDetails</Role>
      <ShortName>Treasury Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureTreasuryShares</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="adag-20221231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41801 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. adag-20221231x20f.htm 229, 259</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 8 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. adag-20221231x20f.htm 229, 259</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. adag-20221231x20f.htm 257</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 9 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. adag-20221231x20f.htm 259</Log>
    <Log type="Warning">[dq-0551-EntityAddressPostalZipCode-Missing] Submission type 20-F should have a non-empty value for EntityAddressPostalZipCode in the context with EntityAddressesAddressTypeAxis and BusinessContactMember or UsAgentContactMember. adag-20221231x20f.htm </Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 13 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressAddressLine1, dei:EntityAddressCityOrTown, dei:EntityAddressStateOrProvince, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:PreferredStockSharesOutstanding, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  adag-20221231x20f.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  adag-20221231x20f.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="adag-20221231x20f.htm">adag-20221231x20f.htm</File>
    <File>adag-20221231.xsd</File>
    <File>adag-20221231_cal.xml</File>
    <File>adag-20221231_def.xml</File>
    <File>adag-20221231_lab.xml</File>
    <File>adag-20221231_pre.xml</File>
    <File>adag-20221231xex12d1.htm</File>
    <File>adag-20221231xex12d2.htm</File>
    <File>adag-20221231xex13d1.htm</File>
    <File>adag-20221231xex13d2.htm</File>
    <File>adag-20221231xex15d1.htm</File>
    <File>adag-20221231xex15d2.htm</File>
    <File>adag-20221231xex15d3.htm</File>
    <File>adag-20221231xex15d4.htm</File>
    <File>adag-20221231xex15d5.htm</File>
    <File>adag-20221231xex2d5.htm</File>
    <File>adag-20221231xex8d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>adag-20221231x20f002.jpg</File>
    <File>adag-20221231x20f003.jpg</File>
    <File>adag-20221231x20f004.jpg</File>
    <File>adag-20221231x20f005.jpg</File>
    <File>adag-20221231x20f006.jpg</File>
    <File>adag-20221231x20f007.jpg</File>
    <File>adag-20221231x20f008.jpg</File>
    <File>adag-20221231x20f009.jpg</File>
    <File>adag-20221231x20f010.jpg</File>
    <File>adag-20221231x20f011.jpg</File>
    <File>adag-20221231x20f012.jpg</File>
    <File>adag-20221231x20f013.jpg</File>
    <File>adag-20221231x20f014.jpg</File>
    <File>adag-20221231x20f015.jpg</File>
    <File>adag-20221231x20f016.jpg</File>
    <File>adag-20221231x20f017.jpg</File>
    <File>adag-20221231x20f018.jpg</File>
    <File>adag-20221231x20f019.jpg</File>
    <File>adag-20221231x20f020.jpg</File>
    <File>adag-20221231x20f021.jpg</File>
    <File>adag-20221231x20f022.jpg</File>
    <File>adag-20221231x20f023.jpg</File>
    <File>adag-20221231x20f024.jpg</File>
    <File>adag-20221231x20f025.jpg</File>
    <File>adag-20221231x20f026.jpg</File>
    <File>adag-20221231x20f029.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="943">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adag-20221231x20f.htm": {
   "axisCustom": 2,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 943,
    "http://xbrl.sec.gov/dei/2022": 48
   },
   "contextCount": 285,
   "dts": {
    "calculationLink": {
     "local": [
      "adag-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adag-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "adag-20221231x20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adag-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adag-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adag-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 633,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 12,
    "http://xbrl.sec.gov/dei/2022": 8,
    "total": 20
   },
   "keyCustom": 67,
   "keyStandard": 327,
   "memberCustom": 50,
   "memberStandard": 37,
   "nsprefix": "adag",
   "nsuri": "http://www.adagene.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.adagene.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - ACCOUNTS RECEIVABLE, NET",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.adagene.com/role/DisclosureAccountsReceivableNet",
     "shortName": "ACCOUNTS RECEIVABLE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets",
     "shortName": "PREPAYMENTS AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet",
     "shortName": "PROPERTY, EQUIPMENT AND SOFTWARE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities",
     "shortName": "ACCRUALS AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - BORROWINGS",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.adagene.com/role/DisclosureBorrowings",
     "shortName": "BORROWINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensation",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - COLLABORATION ARRANGEMENTS",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.adagene.com/role/DisclosureCollaborationArrangements",
     "shortName": "COLLABORATION ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - INCOME TAX EXPENSE",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpense",
     "shortName": "INCOME TAX EXPENSE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.adagene.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.adagene.com/role/DisclosureLeases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.adagene.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - RESTRICTED NET ASSETS",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.adagene.com/role/DisclosureRestrictedNetAssets",
     "shortName": "RESTRICTED NET ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Treasury Shares",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.adagene.com/role/DisclosureTreasuryShares",
     "shortName": "Treasury Shares",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - SUBSEQUENT EVENTS",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.adagene.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:SummaryOfPrincipalSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:SummaryOfPrincipalSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.adagene.com/role/DisclosureAccountsReceivableNetTables",
     "shortName": "ACCOUNTS RECEIVABLE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables",
     "shortName": "PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables",
     "shortName": "PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - BORROWINGS (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsTables",
     "shortName": "BORROWINGS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31101 - Disclosure - INCOME TAX EXPENSE (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables",
     "shortName": "INCOME TAX EXPENSE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - NET LOSS PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShareTables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:InformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - LEASES (Table)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.adagene.com/role/DisclosureLeasesTable",
     "shortName": "LEASES (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:InformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_VKfw90EYZkCikwiObqyzJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_nXhW1Y_RrUK0Q5EAqEjkMw",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_c3AsmrX6oUa7LYTjEHlEEQ",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "adag:FinancialAssetsFairValueDisclosure",
       "us-gaap:FinancialLiabilitiesFairValueDisclosure",
       "us-gaap:FinancialLiabilitiesFairValueDisclosure",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:FinancialAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "adag:FinancialAssetsFairValueDisclosure",
       "us-gaap:FinancialLiabilitiesFairValueDisclosure",
       "us-gaap:FinancialLiabilitiesFairValueDisclosure",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_Eru-aBuo-U2WPSVvE3V8cg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:FinancialAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KrbO3xolp0mWoDpH-tUPDg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KrbO3xolp0mWoDpH-tUPDg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_OXjZO9xKmUKUBkXG09TW_w",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "adag:PercentageOfDepreciationOfForeignCurrency",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "adag:PercentageOfDepreciationOfForeignCurrency",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails",
     "shortName": "ACCOUNTS RECEIVABLE, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails",
     "shortName": "PREPAYMENTS AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
     "shortName": "PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUALS AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBankLoansAndNotesPayable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - BORROWINGS - Components (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
     "shortName": "BORROWINGS - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - BORROWINGS - Short term borrowings (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
     "shortName": "BORROWINGS - Short term borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfJiangsuCo.LtdMember_JmFqVv933EK6PvG2aHAt5w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_CNY_eCqE8xC4T06vPvrMlEd2QA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - BORROWINGS - Long term borrowings (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
     "shortName": "BORROWINGS - Long term borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_SjjB1-5W1kWxwz-a7oCv4w",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails",
     "shortName": "BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_2_1_2018_To_2_28_2018_lP6oVbKR6UmaFzbif9o9lA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:MaximumProceedsReceivableFromExerciseOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_2_1_2018_To_2_28_2018_lP6oVbKR6UmaFzbif9o9lA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:MaximumProceedsReceivableFromExerciseOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2020_dfIP4lHixEuN929wsCEOtw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2019_IiZncobLHUm_DPGbrXG1tw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share Option Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_v49TX7bLvE6A_Z-aD1b2xA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share based compensation expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
     "shortName": "COLLABORATION ARRANGEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_kPVw0N4uYkeKdVofJcPYSg",
      "decimals": "0",
      "lang": null,
      "name": "adag:CollaborativeArrangementUpfrontCashPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - INCOME TAX EXPENSE (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
     "shortName": "INCOME TAX EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails",
     "shortName": "INCOME TAX EXPENSE - Income tax expense (benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails",
     "shortName": "INCOME TAX EXPENSE - Income tax reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails",
     "shortName": "INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails",
     "shortName": "INCOME TAX EXPENSE - Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_n1ed7fGyz0KAIk8k73AxhQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
     "shortName": "NET LOSS PER SHARE - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_n1ed7fGyz0KAIk8k73AxhQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_r4lFa-Ww0kCU3jAskRrUVw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - LEASES - Information related to operating leases (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails",
     "shortName": "LEASES - Information related to operating leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:InformationRelatedToOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:InformationRelatedToOperatingLeaseActivityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - LEASES - Information related to operating lease activity (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails",
     "shortName": "LEASES - Information related to operating lease activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:InformationRelatedToOperatingLeaseActivityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41403 - Disclosure - LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails",
     "shortName": "LEASES - Future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2021_vvW872CaDkS_YCiKRWuJnQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41404 - Disclosure - LEASES - Maturities of lease liabilities (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "LEASES - Maturities of lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_12_31_2022_OwopMfymrUSMdruDOUffHA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - RESTRICTED NET ASSETS (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails",
     "shortName": "RESTRICTED NET ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_Qvvuw2y2sUeTPZrWlUv8lw",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Treasury Shares (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
     "shortName": "Treasury Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:TreasuryStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "As_Of_7_7_2021_us-gaap_ShareRepurchaseProgramAxis_adag_ShareRepurchaseProgramOf2021Member_kmEX4yG-ZEuDCtdXxBARXw",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_dcfOCq06EUujlpmfjUv8Uw",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2023_To_4_30_2023_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jbskMAiPskm8ahOT8fG0aQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2023_To_4_30_2023_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jbskMAiPskm8ahOT8fG0aQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_WEPOeyY84EaipFiDxJkezA",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20221231x20f.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022__QNe6VvxHECAs1eRiv_aow",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 93,
   "tag": {
    "adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable and allowance for doubtful accounts.",
        "label": "Accounts Receivable And Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts receivable and allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities and Other Current Liabilities",
        "label": "Accrued Liabilities and Other Current Liabilities",
        "terseLabel": "Accruals and other current liabilities",
        "totalLabel": "Accruals and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "ACCRUALS AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://www.adagene.com/20221231",
     "xbrltype": "stringItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure on accrued liabilities and other current liabilities.",
        "label": "Accrued Liabilities and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on accrued liabilities and other current liabilities.",
        "label": "Accrued Liabilities and Other Current Liabilities [Text Block]",
        "terseLabel": "ACCRUALS AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_AdageneAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Adagene AG.",
        "label": "Adagene AG"
       }
      }
     },
     "localname": "AdageneAgMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneAustraliaPtyLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene Australia PTY Ltd.",
        "label": "Adagene Australia PTY Ltd."
       }
      }
     },
     "localname": "AdageneAustraliaPtyLtd.Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneHongKongLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene (Hong Kong) Limited.",
        "label": "Adagene (Hong Kong) Limited"
       }
      }
     },
     "localname": "AdageneHongKongLimitedMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene Incorporated.",
        "label": "Adagene Incorporated"
       }
      }
     },
     "localname": "AdageneIncorporatedMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneProjectC1Pte.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Adagene Project C1 PTE. Ltd.",
        "label": "Adagene Project C1 PTE. Ltd. Member",
        "terseLabel": "Adagene Project C1 PTE. Ltd."
       }
      }
     },
     "localname": "AdageneProjectC1Pte.Ltd.Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdagenePte.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Adagene PTE. Ltd.",
        "label": "Adagene PTE. Ltd."
       }
      }
     },
     "localname": "AdagenePte.Ltd.Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneSuzhouLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene (Suzhou) Limited.",
        "label": "Adagene (Suzhou) Limited"
       }
      }
     },
     "localname": "AdageneSuzhouLimitedMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdctCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ADCT Collaboration Agreement.",
        "label": "ADCT Collaboration Agreement"
       }
      }
     },
     "localname": "AdctCollaborationAgreementMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdctMaterialTransferAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for ADCT material transfer and option agreement.",
        "label": "ADCT Material Transfer and Option Agreement [Member]",
        "terseLabel": "ADCT Material Transfer and Option Agreement"
       }
      }
     },
     "localname": "AdctMaterialTransferAndOptionAgreementMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AfterTaxIncomePercentageAppropriations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of after-tax income to be set aside as a general reserve fund.",
        "label": "After Tax Income Percentage Appropriations",
        "terseLabel": "After tax income, annual appropriations, percentage"
       }
      }
     },
     "localname": "AfterTaxIncomePercentageAppropriations",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The agreed period for not to grant rights associated with antibodies to third parties.",
        "label": "Agreed Period for Not to Grant Rights Associated With Antibodies to Third Parties",
        "terseLabel": "Agreed period for not to grant rights associated with antibodies to third parties"
       }
      }
     },
     "localname": "AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_AssessableProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assessable profits or earnings.",
        "label": "Assessable Profits",
        "terseLabel": "Assessable profits or earnings"
       }
      }
     },
     "localname": "AssessableProfits",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Borrowings from Agricultural Bank of China Limited.",
        "label": "Borrowings from Agricultural Bank of China Limited [Member]",
        "terseLabel": "Borrowings from Agricultural Bank of China Limited"
       }
      }
     },
     "localname": "BorrowingsFromAgriculturalBankOfChinaLimitedMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromBankOfJiangsuCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Borrowings from Bank of Jiangsu Co., Ltd.",
        "label": "Borrowings From Bank of Jiangsu Co., Ltd [Member]",
        "terseLabel": "Borrowings from Bank of Jiangsu Co., Ltd"
       }
      }
     },
     "localname": "BorrowingsFromBankOfJiangsuCo.LtdMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromBankOfNingboCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Borrowings from Bank of Ningbo Co., Ltd.",
        "label": "Borrowings From Bank of Ningbo Co., Ltd [Member]",
        "terseLabel": "Borrowings from Bank of Ningbo Co., Ltd"
       }
      }
     },
     "localname": "BorrowingsFromBankOfNingboCo.LtdMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, five.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., Five [Member]",
        "terseLabel": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., five"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FiveMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, Four.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., four"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, seven.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., Seven [Member]",
        "terseLabel": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., seven"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SevenMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, six.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., Six [Member]",
        "terseLabel": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., six"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.SixMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, one.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., one"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, three.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., three"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, two.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., two"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_CapitalTaxRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of capital tax rate.",
        "label": "Capital Tax Rate, Percentage",
        "terseLabel": "Capital tax rate for Canton of Basel"
       }
      }
     },
     "localname": "CapitalTaxRatePercentage",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_CashAndCashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of cash and cash equivalents and short term investments when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Cash and cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ChinaConstructionBankCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to China Construction Bank Corporation.",
        "label": "China Construction Bank Corporation [Member]",
        "terseLabel": "China Construction Bank Corporation"
       }
      }
     },
     "localname": "ChinaConstructionBankCorporationMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ChinaMerchantsBankCo.LtdLoanTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to China Merchants Bank Co., Ltd.",
        "label": "China Merchants Bank Co .Ltd Loan Two [Member]",
        "terseLabel": "China Merchants Bank Co., Ltd., two"
       }
      }
     },
     "localname": "ChinaMerchantsBankCo.LtdLoanTwoMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ChinaMerchantsBankCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to China Merchants Bank Co., Ltd.",
        "label": "China Merchants Bank Co Ltd [Member]",
        "terseLabel": "China Merchants Bank Co., Ltd"
       }
      }
     },
     "localname": "ChinaMerchantsBankCo.LtdMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_CollaborationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "COLLABORATION ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborationArrangementsAbstract",
     "nsuri": "http://www.adagene.com/20221231",
     "xbrltype": "stringItemType"
    },
    "adag_CollaborativeArrangementMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from milestone payments received in collaborative arrangement.",
        "label": "Collaborative Arrangement Milestone Payment Received",
        "terseLabel": "Milestone fee received"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentReceived",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CollaborativeArrangementUpfrontCashPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment receivable.",
        "label": "Collaborative Arrangement Upfront Cash Payment Receivable",
        "terseLabel": "Payment of upfront-refundable fee"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontCashPaymentReceivable",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CollaborativeArrangementUpfrontCashPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from upfront cash received in collaborative arrangement.",
        "label": "Collaborative Arrangement, Upfront Cash Payment Received",
        "terseLabel": "Upfront cash payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontCashPaymentReceived",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CommonStockSubscriptionsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Subscriptions, Value",
        "terseLabel": "Subscription from shareholders"
       }
      }
     },
     "localname": "CommonStockSubscriptionsValue",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ConcentrationRiskSuppliersAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about suppliers.",
        "label": "Concentration Risk, Suppliers [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskSuppliersAxis",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_ConcentrationRiskSuppliersDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suppliers.",
        "label": "Concentration Risk, Suppliers [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskSuppliersDomain",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_DeferredTaxAssetsDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.",
        "label": "Deferred Tax Assets, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization of property, equipment and software"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax asset and lease liabilities.",
        "label": "Deferred Tax Assets, Rights Of Use Assets And Lease Liabilities",
        "terseLabel": "Amortization of right-of-use assets and interest of lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightsOfUseAssetsAndLeaseLiabilities",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_DisclosureOfTemporaryEquityAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS"
       }
      }
     },
     "localname": "DisclosureOfTemporaryEquityAndWarrantsAbstract",
     "nsuri": "http://www.adagene.com/20221231",
     "xbrltype": "stringItemType"
    },
    "adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for temporary equity and warrants.",
        "label": "Disclosure Of Temporary Equity And Warrants [Text Block]",
        "verboseLabel": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS"
       }
      }
     },
     "localname": "DisclosureOfTemporaryEquityAndWarrantsTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement.",
        "label": "Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement"
       }
      }
     },
     "localname": "DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for research and development.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Research and Development Expenses, Amount",
        "negatedLabel": "Research and development super-deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective period of Technology Advanced Service Enterprises certificate.",
        "label": "Effective Period of Technology Advanced Service Enterprises Certificate",
        "terseLabel": "Effective period of TASE certificate (in years)"
       }
      }
     },
     "localname": "EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_ElectronicEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electronic equipment.",
        "label": "Electronic equipment"
       }
      }
     },
     "localname": "ElectronicEquipmentMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_EmployeeDefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Employee defined contribution plan.",
        "label": "Employee Defined Contribution Plan [Policy Text Block]",
        "terseLabel": "Employee defined contribution plan"
       }
      }
     },
     "localname": "EmployeeDefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_ExelixisIncAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Exelixis, Inc. Agreement.",
        "label": "Exelixis Inc Agreement"
       }
      }
     },
     "localname": "ExelixisIncAgreementMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_FinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial assets.",
        "label": "Financial Assets Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loss on disposal of property, equipment, software and operating lease right-of-use asset.",
        "label": "Gain Loss On Sale Of Property Plant Equipment and Operating Lease Right Of Use Asset",
        "terseLabel": "Net loss on disposal of property, equipment, software and operating lease right-of-use asset"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipmentAndOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_GovernmentSubsidiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government subsidies.",
        "label": "Government Subsidies [Policy Text Block]",
        "terseLabel": "Government subsidies"
       }
      }
     },
     "localname": "GovernmentSubsidiesPolicyTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_GovernmentSubsidiesReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsidies received by the entity for Government.",
        "label": "Government Subsidies Received",
        "terseLabel": "Government subsidies received"
       }
      }
     },
     "localname": "GovernmentSubsidiesReceived",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement.",
        "label": "Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement"
       }
      }
     },
     "localname": "GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_InformationRelatedToOperatingLeaseActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to operating lease activity.",
        "label": "Information Related to Operating Lease Activity [Table Text Block]",
        "terseLabel": "Summary of information related to operating lease activity"
       }
      }
     },
     "localname": "InformationRelatedToOperatingLeaseActivityTableTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_InformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to operating leases.",
        "label": "Information Related to Operating Leases [Table Text Block]",
        "terseLabel": "Summary of information related to operating leases"
       }
      }
     },
     "localname": "InformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_InterestIncomeExpenseOnPromissoryNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income (expense) on promissory notes.",
        "label": "Interest Income (Expense) On Promissory Notes",
        "negatedLabel": "Interest income on promissory notes"
       }
      }
     },
     "localname": "InterestIncomeExpenseOnPromissoryNotes",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_InterestOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails": {
       "order": 1.0,
       "parentTag": "adag_OperatingLeaseRentalExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of interest of lease liabilities.",
        "label": "Interest of Operating Lease Liabilities",
        "terseLabel": "Interest of lease liabilities"
       }
      }
     },
     "localname": "InterestOfOperatingLeaseLiabilities",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MainlandOfChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mainland of China.",
        "label": "Mainland of China"
       }
      }
     },
     "localname": "MainlandOfChinaMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of selected targets, agreed for generation of antibodies.",
        "label": "Maximum Number of Selected Targets, Agreed for Generation of Antibodies",
        "terseLabel": "Maximum number of selected targets, agreed for generation of antibodies"
       }
      }
     },
     "localname": "MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_MaximumProceedsReceivableFromExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of proceeds receivable from exercise of warrants.",
        "label": "Maximum Proceeds Receivable From Exercise Of Warrants",
        "terseLabel": "Total maximum consideration from exercise of warrants"
       }
      }
     },
     "localname": "MaximumProceedsReceivableFromExerciseOfWarrants",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable upon achieving certain development and regulatory approval milestones.",
        "label": "Milestone Payments Receivable, Development And Regulatory Milestones",
        "terseLabel": "Milestone payments receivable based on development and regulatory milestones"
       }
      }
     },
     "localname": "MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MilestonePaymentsReceivableSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments conditioned upon achieving sales based milestones.",
        "label": "Milestone Payments Receivable, Sales Based Milestones",
        "terseLabel": "Milestone payments receivable based on sales"
       }
      }
     },
     "localname": "MilestonePaymentsReceivableSalesBasedMilestones",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of the profit after tax to be transferred to statutory reserve.",
        "label": "Minimum Percentage Of Profits After Tax To Be Transferred To Statutory Reserve",
        "terseLabel": "Minimum percentage of profit after tax to be transferred to statutory reserve"
       }
      }
     },
     "localname": "MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum threshold written notice period for termination of agreement.",
        "label": "Minimum Threshold Written Notice Period for Termination of Agreement",
        "terseLabel": "Minimum threshold written notice period for termination of agreement"
       }
      }
     },
     "localname": "MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the modification of vesting schedules and condition of share options.",
        "label": "Modification Of Vesting Schedules And Conditions Of Share Options [Member]",
        "terseLabel": "Modification of vesting schedules and conditions of share options"
       }
      }
     },
     "localname": "ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_NonCashActivitiesRetirementOfTreasuryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of retirement of treasury shares in noncash investing or financing activities.",
        "label": "Non cash Activities, Retirement of Treasury Shares",
        "verboseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "NonCashActivitiesRetirementOfTreasuryShares",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_NumberOfInvestorsToWhomWarrantsWereIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investors to whom warrants were issued during the period.",
        "label": "Number Of Investors To Whom Warrants Were Issued",
        "verboseLabel": "Number of Series C-1 investors to whom warrants were issued"
       }
      }
     },
     "localname": "NumberOfInvestorsToWhomWarrantsWereIssued",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_NumberOfMajorSupplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of major supplier.",
        "label": "Number of Major Supplier",
        "terseLabel": "Number of major supplier"
       }
      }
     },
     "localname": "NumberOfMajorSupplier",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_NumberOfSharesSurrendered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares surrendered by the shareholders.",
        "label": "Number of Shares Surrendered",
        "terseLabel": "Number of shares surrendered"
       }
      }
     },
     "localname": "NumberOfSharesSurrendered",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_OneSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One supplier.",
        "label": "One supplier"
       }
      }
     },
     "localname": "OneSupplierMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_OperatingLeaseRentalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of operating lease rental expense.",
        "label": "Operating Lease Rental Expense",
        "totalLabel": "Total operating lease rental expense"
       }
      }
     },
     "localname": "OperatingLeaseRentalExpense",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_OperatingLeaseRentalExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease Rental Expense [Abstract]",
        "terseLabel": "Operating lease rental expense"
       }
      }
     },
     "localname": "OperatingLeaseRentalExpenseAbstract",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset and interest of lease liabilities from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset and Interest of Lease Liabilities, Amortization Expense",
        "terseLabel": "Amortization of right-of use assets and interest of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAndInterestOfLeaseLiabilitiesAmortizationExpense",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_OperatingLeaseRightOfUseAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease, Right of Use Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsAbstract",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Organization, Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information on organization, consolidation and presentation of financial statements.",
        "label": "Organization, Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_OutsideMainlandOfChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside the mainland of China.",
        "label": "Outside the mainland of China"
       }
      }
     },
     "localname": "OutsideMainlandOfChinaMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_PayablesForDeferredInitialPublicOfferingCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payables for deferred initial public offering cost in non-cash activities.",
        "label": "Payables For Deferred Initial Public Offering Cost",
        "terseLabel": "Payables for deferred initial public offering cost"
       }
      }
     },
     "localname": "PayablesForDeferredInitialPublicOfferingCost",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_PercentageOfDepreciationOfForeignCurrency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of depreciation of foreign currency.",
        "label": "Percentage Of Depreciation Of Foreign Currency",
        "terseLabel": "Depreciation of foreign currency (as a percent)"
       }
      }
     },
     "localname": "PercentageOfDepreciationOfForeignCurrency",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_PerformanceIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Performance incentive plan 2021.",
        "label": "Performance Incentive Plan 2021 [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "PerformanceIncentivePlan2021Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_PeriodForReservationOfTargetRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for reservation of target right.",
        "label": "Period for Reservation of Target Right",
        "terseLabel": "Period for reservation of target right"
       }
      }
     },
     "localname": "PeriodForReservationOfTargetRight",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_Plan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 Plan.",
        "label": "2015 Plan"
       }
      }
     },
     "localname": "Plan2015Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_Plan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2017 Plan.",
        "label": "2017 Plan"
       }
      }
     },
     "localname": "Plan2017Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Plan.",
        "label": "2019 Plan"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_PreferentialIncomeTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferential income tax rate.",
        "label": "Preferential Income Tax Rate",
        "terseLabel": "Preferential tax rate (as a percent)"
       }
      }
     },
     "localname": "PreferentialIncomeTaxRate",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on prepayments and other current assets.",
        "label": "Prepaid Expense and Other Assets, Current [Text Block]",
        "terseLabel": "PREPAYMENTS AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of estimated useful lives of property and equipment and software.",
        "label": "Property, Plant And Equipment, Estimated Useful Life [Table Text Block]",
        "terseLabel": "Summary of estimated useful lives of property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to receipt of contract research organizations (\"CRO\") and contract manufacturing organizations (\"CMO\") services with related parties.",
        "label": "Receipt of CRO and CMO services"
       }
      }
     },
     "localname": "ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Research And Development Expense from Transactions with Related Party",
        "negatedLabel": "Related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ResearchAndDevelopmentExpenseThirdParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses resulting from transactions with third parties.",
        "label": "Research and Development Expense, Third Parties",
        "negatedLabel": "Third parties"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseThirdParties",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_RestrictedNetAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Definition available.",
        "label": "RESTRICTED NET ASSETS"
       }
      }
     },
     "localname": "RestrictedNetAssetsAbstract",
     "nsuri": "http://www.adagene.com/20221231",
     "xbrltype": "stringItemType"
    },
    "adag_RetirementOfTreasuryShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of retirement of treasury shares.",
        "label": "Retirement of Treasury Shares",
        "negatedLabel": "Costs for retirement of treasury shares"
       }
      }
     },
     "localname": "RetirementOfTreasuryShares",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_SanofiAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for sanofi agreement.",
        "label": "Sanofi Agreement [Member]",
        "terseLabel": "Sanofi Agreement"
       }
      }
     },
     "localname": "SanofiAgreementMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for short-term debt and long-term debt.",
        "label": "Schedule Of Maturities Of Short-Term Debt And Long-Term Debt [Table Text Block]",
        "verboseLabel": "Schedule of future maturities of short-term borrowings and long-term borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_Series1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series A-1 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "Series1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_Series2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series A-2 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "Series2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series B convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series C-1 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesC1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC1WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C 1 Warrants.",
        "label": "Series C 1 Warrants"
       }
      }
     },
     "localname": "SeriesC1WarrantsMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series C-2 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesC2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC3RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-3 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series C-3 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesC3RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ServiceConditionsAndPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to service conditions and performance conditions related to share options.",
        "label": "Service conditions and Performance conditions"
       }
      }
     },
     "localname": "ServiceConditionsAndPerformanceConditionsMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum exercise multiple assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Maximum",
        "terseLabel": "Exercise multiple, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum exercise multiple assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Minimum",
        "terseLabel": "Exercise multiple, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average grant date fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Fair Value",
        "terseLabel": "Incremental fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingFairValue",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average grant date fair value, at which grantee can acquire shares reserved for issuance. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and expected to vest at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options for which the vesting schedules and conditions are waived.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vesting Schedules and Conditions waived",
        "terseLabel": "Number of options, vesting schedules and conditions waived"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of increase in shares reserve annually based on shares outstanding under share based compensation share based payments.",
        "label": "Share Based Compensation Share Based Payments, Shares Reserve, Incremental, Percent",
        "terseLabel": "Incremental percent of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_ShareRepurchaseProgramOf2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the 2021 Share Repurchase Program.",
        "label": "Share Repurchase Program Of 2021 [Member]",
        "terseLabel": "2021 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramOf2021Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ShareRepurchaseProgramOf2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the 2022 Share Repurchase Program.",
        "label": "Share Repurchase Program Of 2022 [Member]",
        "terseLabel": "2022 Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramOf2022Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number shares surrendered for repayment of promissory notes.",
        "label": "Shares Surrendered, Shares, for Repayment of Promissory Notes",
        "verboseLabel": "Surrender of ordinary shares for repayment of promissory notes (in shares)"
       }
      }
     },
     "localname": "SharesSurrenderedSharesForRepaymentOfPromissoryNotes",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_StatusForTaxabilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to various tax status.",
        "label": "Status for Taxability [Axis]"
       }
      }
     },
     "localname": "StatusForTaxabilityAxis",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_StatusForTaxabilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents various tax status.",
        "label": "Status For Taxability [Domain]"
       }
      }
     },
     "localname": "StatusForTaxabilityDomain",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required percentage of statutory reserve on registered capital to be maintained.",
        "label": "Statutory Reserve Maintenance Required Percentage On Registered Capital",
        "terseLabel": "Statutory reserve required percentage on registered capital"
       }
      }
     },
     "localname": "StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_StockSurrenderedValueForRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of shares surrendered for repayment of promissory notes.",
        "label": "Stock Surrendered, Value, For Repayment of Promissory Notes",
        "terseLabel": "Surrender of ordinary shares for repayment of promissory notes"
       }
      }
     },
     "localname": "StockSurrenderedValueForRepaymentOfPromissoryNotes",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_SummaryOfPrincipalSubsidiariesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of principal subsidiaries.",
        "label": "Summary of Principal Subsidiaries [Table Text Block]",
        "terseLabel": "Summary of principal subsidiaries"
       }
      }
     },
     "localname": "SummaryOfPrincipalSubsidiariesTableTextBlock",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock shares surrendered for repayment of promissory notes.",
        "label": "Surrender Of Common Stock Shares For Repayment Of Promissory Notes",
        "terseLabel": "Surrender of ordinary shares for repayment of promissory notes"
       }
      }
     },
     "localname": "SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_TaxableIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of taxable income during the reporting period.",
        "label": "Taxable Income"
       }
      }
     },
     "localname": "TaxableIncome",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_TechnologyAdvancedServiceEnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents an entity classification of Technology Advanced Service Enterprises that receives preferential tax treatment.",
        "label": "TASE"
       }
      }
     },
     "localname": "TechnologyAdvancedServiceEnterprisesMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of new stock classified as temporary equity issued during the period, upon conversion of convertible securities.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities",
        "verboseLabel": "Shares issued upon conversion of Series Pre-A Convertible Notes (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of new shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage on restricted net assets of PRC subsidiaries.",
        "label": "Threshold Percentage On Restricted Net Assets Of PRC Subsidiaries",
        "terseLabel": "Restrictions on net assets of PRC subsidiaries , threshold percentage"
       }
      }
     },
     "localname": "ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_WithholdingIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of withholding income taxes on remittance of dividends.",
        "label": "Withholding Income Taxes",
        "terseLabel": "Withholding tax"
       }
      }
     },
     "localname": "WithholdingIncomeTaxes",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_WithholdingTaxRateOnDividendsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of withholding tax rate on dividends.",
        "label": "Withholding Tax Rate On Dividends, Percentage",
        "terseLabel": "Dividends withholding tax rate"
       }
      }
     },
     "localname": "WithholdingTaxRateOnDividendsPercentage",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_WuxiApptecGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to WuXi AppTec Group .",
        "label": "WuXi AppTec Group"
       }
      }
     },
     "localname": "WuxiApptecGroupMember",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_WuxiBiologicsCaymanInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to WuXi Biologics (Cayman) Inc.",
        "label": "WuXi Biologics Cayman Inc. [Member]",
        "terseLabel": "WuXi Biologics (Cayman) Inc."
       }
      }
     },
     "localname": "WuxiBiologicsCaymanInc.Member",
     "nsuri": "http://www.adagene.com/20221231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRC"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hong Kong"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_SG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE"
       }
      }
     },
     "localname": "SG",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdrMember": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS).",
        "label": "American depositary shares"
       }
      }
     },
     "localname": "AdrMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio",
        "terseLabel": "Number of ordinary shares represented by each ADS"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r365",
      "r533",
      "r560",
      "r590",
      "r591",
      "r606",
      "r608",
      "r617",
      "r661",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r365",
      "r533",
      "r560",
      "r590",
      "r591",
      "r606",
      "r608",
      "r617",
      "r661",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r362",
      "r365",
      "r396",
      "r397",
      "r398",
      "r532",
      "r533",
      "r560",
      "r590",
      "r591",
      "r606",
      "r608",
      "r617",
      "r657",
      "r661",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r362",
      "r365",
      "r396",
      "r397",
      "r398",
      "r532",
      "r533",
      "r560",
      "r590",
      "r591",
      "r606",
      "r608",
      "r617",
      "r657",
      "r661",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r233",
      "r366",
      "r631",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r278",
      "r279",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r607",
      "r616",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r278",
      "r279",
      "r574",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r607",
      "r616",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r233",
      "r366",
      "r631",
      "r632",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r187",
      "r281"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r555",
      "r575"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r141",
      "r154"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income Tax Payable",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedUtilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Utilities, Current",
        "terseLabel": "Utility and maintenance"
       }
      }
     },
     "localname": "AccruedUtilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r74",
      "r179"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r189",
      "r556",
      "r568",
      "r572"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r31",
      "r34",
      "r125",
      "r522",
      "r563",
      "r564",
      "r635",
      "r636",
      "r637",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital.",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r647",
      "r648",
      "r649",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r221",
      "r222",
      "r223",
      "r224",
      "r233",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r406",
      "r407",
      "r408",
      "r430",
      "r431",
      "r432",
      "r433",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r536",
      "r537",
      "r538",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r110",
      "r111",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Sharebased compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.",
        "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries",
        "terseLabel": "Total restricted net assets"
       }
      }
     },
     "localname": "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities not included in the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long lived assets"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r153",
      "r181",
      "r214",
      "r262",
      "r271",
      "r275",
      "r285",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r451",
      "r455",
      "r476",
      "r615",
      "r659",
      "r660",
      "r709"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r175",
      "r192",
      "r214",
      "r285",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r451",
      "r455",
      "r476",
      "r615",
      "r659",
      "r660",
      "r709"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r51",
      "r177",
      "r593"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r46",
      "r51",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of year",
        "periodStartLabel": "Cash and cash equivalents at the beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r46",
      "r130"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash activities:",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r214",
      "r237",
      "r238",
      "r241",
      "r243",
      "r250",
      "r251",
      "r285",
      "r302",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r476",
      "r592",
      "r630",
      "r642",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r145",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r296",
      "r297",
      "r577",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Aggregate ordinary shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r647",
      "r648",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 54,595,667 shares issued and outstanding as of December 31, 2021; and 640,000,000 shares authorized, 54,065,709 shares issued and outstanding as of December 31, 2022)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r35",
      "r194",
      "r196",
      "r202",
      "r551",
      "r557"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to Adagene Inc.'s shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r64",
      "r65",
      "r127",
      "r128",
      "r280",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r64",
      "r65",
      "r127",
      "r128",
      "r280",
      "r573",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r64",
      "r65",
      "r127",
      "r128",
      "r280",
      "r576",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r150",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of risks"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r64",
      "r65",
      "r127",
      "r128",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r61",
      "r64",
      "r65",
      "r66",
      "r127",
      "r129",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r64",
      "r65",
      "r127",
      "r128",
      "r280",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r348",
      "r349",
      "r360"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of preferred shares"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Series Pre-A Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r7",
      "r8",
      "r86",
      "r87",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of shares on conversion of each convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Research and development services purchased"
       }
      }
     },
     "localname": "CostOfGoodsProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r645",
      "r694",
      "r696"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r120",
      "r427",
      "r437",
      "r645"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r645",
      "r694",
      "r696"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "totalLabel": "Total current borrowings"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "DebtCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BORROWINGS"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r212",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r329",
      "r336",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "BORROWING",
        "verboseLabel": "BORROWINGS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r140",
      "r143",
      "r152",
      "r217",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r500",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r82",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r132",
      "r134",
      "r313",
      "r500",
      "r602",
      "r603"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Amount borrowed",
        "verboseLabel": "Amount of Series Pre A Convertible Notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r22",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "verboseLabel": "Series Pre A Convertible Notes, Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt instrument"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r217",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r500",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r86",
      "r88",
      "r89",
      "r90",
      "r131",
      "r132",
      "r134",
      "r149",
      "r217",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r500",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "verboseLabel": "Term of the debt"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "totalLabel": "Total borrowings"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of prepayments and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r645",
      "r695",
      "r696"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r49",
      "r120",
      "r428",
      "r436",
      "r437",
      "r645"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r142",
      "r151",
      "r421"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r645",
      "r695",
      "r696"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Capitalized inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r692"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r117",
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "terseLabel": "Unrealized foreign exchange gain/losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "periodEndLabel": "Balance as of December 31",
        "periodStartLabel": "Balance as of January 1"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r113",
      "r692"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r118",
      "r693"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation and amortization of property, equipment and software"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Abstract]",
        "terseLabel": "Employee defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employee benefit expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r49",
      "r260"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r370",
      "r401",
      "r402",
      "r405",
      "r410",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r188",
      "r304",
      "r305",
      "r306",
      "r310",
      "r311",
      "r312",
      "r526",
      "r594",
      "r646"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Amounts due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r16",
      "r304",
      "r305",
      "r306",
      "r310",
      "r311",
      "r312",
      "r526",
      "r646"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Amounts due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE",
        "terseLabel": "Net loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r203",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r234",
      "r237",
      "r241",
      "r242",
      "r243",
      "r247",
      "r466",
      "r467",
      "r552",
      "r558",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "-Basic",
        "verboseLabel": "Net Loss per share-basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r203",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r237",
      "r241",
      "r242",
      "r243",
      "r247",
      "r466",
      "r467",
      "r552",
      "r558",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "-Diluted",
        "verboseLabel": "Net Loss per share- diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r705"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r215",
      "r417",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax rate (as a percent)",
        "verboseLabel": "PRC statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Amount",
        "negatedLabel": "Foreign derived intangible income deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount",
        "terseLabel": "Difference in income tax rates of overseas entities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "auth_ref": [
      "r691",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "terseLabel": "State income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize unrecognized compensation cost (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r690"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized employee share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r171",
      "r198",
      "r199",
      "r200",
      "r218",
      "r219",
      "r220",
      "r222",
      "r230",
      "r232",
      "r249",
      "r289",
      "r347",
      "r406",
      "r407",
      "r408",
      "r432",
      "r433",
      "r465",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r522",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items}",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r469",
      "r470",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Nonrecurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign exchange loss (gain), net",
        "terseLabel": "Foreign exchange gain (loss), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and tools"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "Administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "Administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r63",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Concentration of credit risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r367",
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r367",
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r49",
      "r72",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r36",
      "r138",
      "r146",
      "r162",
      "r262",
      "r270",
      "r274",
      "r276",
      "r553",
      "r600"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAX EXPENSE"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r418",
      "r419",
      "r426",
      "r434",
      "r439",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAX EXPENSE"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r216",
      "r231",
      "r232",
      "r261",
      "r416",
      "r435",
      "r440",
      "r559"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r197",
      "r412",
      "r413",
      "r419",
      "r420",
      "r425",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r411",
      "r417"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Impact of PRC preferential income tax rate as qualified TASE"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Income tax credit computed at PRC statutory income tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Nondeductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "negatedLabel": "Others"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r691"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income tax paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accruals and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r534",
      "r640"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Amount due from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Amount due to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r640",
      "r706"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepayments and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "verboseLabel": "Increase (Decrease) in Temporary Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r133",
      "r148",
      "r201",
      "r259",
      "r499"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r206",
      "r209",
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r214",
      "r285",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r452",
      "r455",
      "r456",
      "r476",
      "r599",
      "r659",
      "r709",
      "r710"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r144",
      "r157",
      "r615",
      "r644",
      "r656",
      "r704"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r176",
      "r214",
      "r285",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r452",
      "r455",
      "r456",
      "r476",
      "r615",
      "r659",
      "r709",
      "r710"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Other than Long-term Debt, Noncurrent [Abstract]",
        "verboseLabel": "Non Current"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term borrowings",
        "verboseLabel": "Current portion of long term borrowings"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r80",
      "r217",
      "r331"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r80",
      "r217",
      "r331"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r80",
      "r217",
      "r331"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r80",
      "r217",
      "r331"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r183"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term borrowings",
        "totalLabel": "Total non current borrowings"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "verboseLabel": "Long term borrowings:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Debt, Term",
        "verboseLabel": "Term of the debt"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LongTermLoansFromBank": {
     "auth_ref": [
      "r4",
      "r143",
      "r155"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.",
        "label": "Loans Payable to Bank, Noncurrent",
        "verboseLabel": "Bank loans"
       }
      }
     },
     "localname": "LongTermLoansFromBank",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r23",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and laboratory equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Percentage of legal ownership by the Company"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash generated from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash generated from (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedTotalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r37",
      "r50",
      "r147",
      "r161",
      "r174",
      "r193",
      "r195",
      "r200",
      "r214",
      "r221",
      "r225",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r239",
      "r262",
      "r270",
      "r274",
      "r276",
      "r285",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r467",
      "r476",
      "r600",
      "r659"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Adagene Inc.'s shareholders",
        "totalLabel": "Net loss attributable to Adagene Inc.'s shareholders",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r228",
      "r234",
      "r235",
      "r240",
      "r243",
      "r262",
      "r270",
      "r274",
      "r276",
      "r600"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r262",
      "r270",
      "r274",
      "r276",
      "r600"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r508",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities",
        "verboseLabel": "Operating cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails": {
       "order": 3.0,
       "parentTag": "adag_OperatingLeaseRentalExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r514",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r513",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "For the years ending:"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesFutureAnnualMinimumLeaseUnderNonCancelableOperatingLeasesWithInitialTermsInExcessOfOneYearUnderAsc840LeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r191",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r121",
      "r122",
      "r124"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments, net of nil tax",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "auth_ref": [
      "r121",
      "r122",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Purchase of treasury shares under stock repurchase program"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r205",
      "r698",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchase of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r8",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepayments and other current assets",
        "totalLabel": "Prepayments and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAYMENTS AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r190",
      "r292",
      "r293",
      "r595"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from share subscriptions"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Proceeds from initial public offering, net of underwriting commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "verboseLabel": "Total consideration from issuance of convertible redeemable preferred shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Consideration from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposal of property, equipment and software"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Withdrawal of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r108"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r174",
      "r193",
      "r195",
      "r207",
      "r214",
      "r221",
      "r231",
      "r232",
      "r262",
      "r270",
      "r274",
      "r276",
      "r285",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r311",
      "r312",
      "r450",
      "r453",
      "r454",
      "r467",
      "r476",
      "r553",
      "r600",
      "r612",
      "r613",
      "r637",
      "r659"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, EQUIPMENT AND SOFTWARE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, EQUIPMENT AND SOFTWARE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r73",
      "r178"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "PROPERTY, EQUIPMENT AND SOFTWARE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r75",
      "r158",
      "r554",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Net book value"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "terseLabel": "PROPERTY, EQUIPMENT AND SOFTWARE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.",
        "label": "Receivables from Stockholder [Member]",
        "terseLabel": "Subscriptions receivable from shareholders"
       }
      }
     },
     "localname": "ReceivablesFromStockholderMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Convertible redeemable preferred shares"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r363",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r165",
      "r525",
      "r526",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r363",
      "r525",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r523",
      "r524",
      "r526",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r639"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of borrowings",
        "verboseLabel": "Amount repaid"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r112",
      "r164",
      "r717"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedTotalLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.",
        "label": "Restricted Assets Disclosure [Text Block]",
        "terseLabel": "RESTRICTED NET ASSETS"
       }
      }
     },
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r91",
      "r156",
      "r567",
      "r572",
      "r615"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r171",
      "r218",
      "r219",
      "r220",
      "r222",
      "r230",
      "r232",
      "r289",
      "r406",
      "r407",
      "r408",
      "r432",
      "r433",
      "r465",
      "r563",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r257",
      "r258",
      "r269",
      "r272",
      "r273",
      "r277",
      "r278",
      "r280",
      "r358",
      "r359",
      "r535"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Licensing and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r361",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r512",
      "r614"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations",
        "verboseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeasesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities that are not included in the calculation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of tax effects of temporary differences that give rise to the deferred tax balances"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation between the income tax expense and the actual provision"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r106",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of total share based compensation expenses recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "verboseLabel": "Summary of future annual minimum lease under non-cancelable operating leases with initial terms in excess of one year under ASC 840, Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r367",
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of assumptions used to estimate the fair value of the share options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions used to estimate the fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum aggregate number of shares that may be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Share options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Fair value (in USD per option)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end (in dollars)",
        "periodStartLabel": "Outstanding at the beginning (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Vested and expected to vest at the end (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental compensation cost to be recognized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Total number of ordinary shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r374",
      "r393",
      "r394",
      "r395",
      "r396",
      "r399",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r369",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r367",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Management personnel"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at the end (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Shares unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested and expected to vest at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of the equity awards vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Shares issued price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r15",
      "r160"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-term Bank Loans and Notes Payable",
        "terseLabel": "Short-term borrowings",
        "verboseLabel": "Bank loans"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Debt [Abstract]",
        "verboseLabel": "Short term borrowings:"
       }
      }
     },
     "localname": "ShortTermBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r510",
      "r614"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails": {
       "order": 2.0,
       "parentTag": "adag_OperatingLeaseRentalExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Expense for short-term leases within 12 months"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureLeasesInformationRelatedToOperatingLeaseActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r214",
      "r237",
      "r238",
      "r241",
      "r243",
      "r250",
      "r251",
      "r285",
      "r302",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r476",
      "r592",
      "r630",
      "r642",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r28",
      "r85",
      "r171",
      "r198",
      "r199",
      "r200",
      "r218",
      "r219",
      "r220",
      "r222",
      "r230",
      "r232",
      "r249",
      "r289",
      "r347",
      "r406",
      "r407",
      "r408",
      "r432",
      "r433",
      "r465",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r522",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r249",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share options and share grant"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r27",
      "r85",
      "r86",
      "r91",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred shares to ordinary shares upon the completion of initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of ordinary shares upon IPO, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of ordinary shares under performance incentive plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r85",
      "r91",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of share options (in shares)",
        "verboseLabel": "Shares issued upon exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r28",
      "r85",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of Preferred Shares to Ordinary Shares",
        "terseLabel": "Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r85",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares upon IPO, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r8",
      "r9",
      "r91",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of ordinary shares under performance incentive plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r85",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of share options",
        "verboseLabel": "Total amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Term of share repurchase program (in months)"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r70",
      "r615",
      "r644",
      "r656",
      "r704"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity (deficit):",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r495",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r495",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r495",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r495",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of movement of the valuation allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow disclosures:",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Concentration of suppliers"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Other taxes and surcharge"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "verboseLabel": "Accretion of Preferred Shares to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Accretion of convertible redeemable preferred shares to redemption value",
        "terseLabel": "Accretion of convertible redeemable preferred shares to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r1",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r302",
      "r305",
      "r306",
      "r307",
      "r311",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "verboseLabel": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r1",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "verboseLabel": "Schedule of Company's Preferred Shares activities"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Balance at the end (in shares)",
        "negatedPeriodStartLabel": "Balance at the beginning (in shares)",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r30",
      "r93",
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury shares, at cost (94,074 shares as of December 31, 2021 and 1 share as of as of December 31, 2022)"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r9",
      "r85",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Par Value Method, Amount",
        "negatedLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r9",
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Purchase of treasury shares under share repurchase program (in shares)",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r9",
      "r85",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "terseLabel": "Repurchased shares retired (in shares)",
        "verboseLabel": "Retirement of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasuryShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r85",
      "r91",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Purchase of treasury shares under share repurchase program",
        "verboseLabel": "Total consideration of share repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r221",
      "r222",
      "r223",
      "r224",
      "r233",
      "r283",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r406",
      "r407",
      "r408",
      "r430",
      "r431",
      "r432",
      "r433",
      "r444",
      "r445",
      "r446",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r497",
      "r498",
      "r502",
      "r503",
      "r504",
      "r505",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r536",
      "r537",
      "r538",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r252",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Movement of the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Addition"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r236",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "-Diluted",
        "verboseLabel": "Weightedaverage number of ordinary shares outstanding-diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of ordinary shares used in per share calculation:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r234",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "-Basic",
        "verboseLabel": "Weightedaverage number of ordinary shares outstanding-basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(3)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r619": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r627": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/subtopic&trid=2208821",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0001104659-23-052043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-052043-xbrl.zip
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MC08%- K,()W5.-\,L"5--*5-EPFC:,>$BGLLJ$5YEL*RG"?\G$G)!%KY%55
M=[MI;R#SVXD1>2VBWT);:8.F7$JMDLFS2EP/:.$YSM<KU=]XJU!?"6GNV7:M
M[/<JVZ&V^BGKW&QHN265()8]<_V?@A3^@UE09W2I/8LG'I3Y>.*RS1;WV.2S
M-:?+CR<(7*=WWNMU>Q?=?X&HI\\;*RR"Y!,P/S]PZ]3AJ[/>^?F%!'I?.T'#
M(0G"C125IPM!HWMY>7DF2@$1<30#?-BSD/D3[>Q84H$^JTJ5A*"!,EGDH:I,
M4(5:#14'NDI5<?9ZU_&$"CAG'E8?[%K1L!GW>XU85B3YSV?/KOF!;+<,)@M\
M%#RP;4=V"?$,'X$*\/L4-ME0=TN,'6="-)<:IROG$>R.G:%23C376-,-&3F&
M("-+NWG%\0^AS%-H*F!.W6I"J:;'SQ II'7>.>]V>MU\!HIJBM]N/48 W4N)
MKDU7..%FL[%?S>(\4:N#=#K=7J?[0VT^+LZ8[7KH<)?C053!7YVP'G)Q@5Q<
M=$MS$2?W7OPRO=+MAQ6PX?>EFUP2]T%0\-T.*M$M8X#Q2BM"MM(*J>6Y$9EJ
M]I@P:['_RE^J](1XE?#' 1RXWI97:3XJ+_ZJUG"F+@_2/SZIR8/+O4KMA^5E
MV_ KLUUJR1R,Z._AP/^O:-_]CC/;8%MBX<4B9C+"PU-["_KL75F.\?N)X/?C
M2<4ZS!(?[_YXXG$?^K"<B6"\ZHCQZ8,7%AUZ=(,^%$@,Y&#8%Y&96^[XVX\G
M*"S[P* (S OB;Y@OF&,N)#6?!TDS%*+&;VKL\EPR<6TC?E]CNKQA-HP;#.2*
M4F &45&I@*-0RE2+% V];WM5J _3^["&]]SP'^A0:(9 .4X,+R3Z+30%D[/@
MQCV*MN+4#M=8:$%'TE-?+K8^.?;J?T54= /DS3'=/% >2E]0IJ!SF,Z&,/L;
MR85;;'R+24URA,HLT&2)YOZ?:\=7X91=HLDR]7VD9C%RY[V,//,T4ZS<0HV4
M3-SW8&:PLQL>*I<;$<'1\M2D5+%.4R8E<7*>FK&3\OEGZ/N!=B-LZ]5MWC!:
M08X4[G4KOT4#R';'#J+P%M501W"UW6\<FWK@TAX@I5QL>N&K!V+ATO/CB?R<
MJ5+VC.W6_:ZN+M*X'CUF-MOXFSOP3=&[6U%<*SA+!EPO/<H7Y'GA7%%QUE/>
M6E@XZ/+YGL-?0%3*'R-?^SBD"LQ\*ZF_MI'O,S:&N=6CZ//2&7XW&;B/R6G/
MZ(JY(",U!V3+/$S6'RS #J?3#(6$$,I@[H[G_A8W!#D3%';]O6SI9@BW6,/B
M9NU8>UBD.C(:M!%?08?R'D*@&2J84V2GN[NF%+N[M+NQY,'\DO1::]1KI",K
MY>C5E+]2O0;+?U53_DKU&BS_H&X'J%:QR1JHVP6J56RR!B[J:J!2Q49J +T4
MPHTU>.?7])%:CKCT'UZ76S,NKO[$)KXJ%5[7J]_)M^?6F_2AT*O/O-6DE.V&
M.YOX#:A[YJWC='8*>A7:C=7EO?_,P,OSJ"%:2O:3O)>-[ NYB:+W5WQE"C9N
MW7?KPW+;GA/[W\R^6Q.^(0;UQ6>[!LXI[CN.F"&VYU:<BJI)).M7;R36?=/P
MDC!FBUVB7"/EB_'\2&,F^GF[Y([M#8B[OI-I>V3&)3Q%D#+N\C4;.SH)N'"1
M!L1N'#YQO(5SB[D79FRUA@[KNH[!<)S%(1<_Z/K@F+@7YV3-?<<BIM!6*.IK
MK_[&Y!FW;B8^&O%T.8<"N&Y=$+["_2LA*(AX2VW*@PC@3J!H_^= (@H]X*;)
MBO)75X/<P8I6\_><>1ZU 5D8S2*@%Y1OF!U*$ X >[M@=6DTP!@B)N6>5<"D
MA%&8=A3(*5&P ?)$]P]B:7'C9P04[QL<^9?+"GC$B!5)@-<K8V&VW +-V'/2
METN*-[&";@&F0XVU[5C.ZJ5O/N*8;L+*ZA'ZC0[]GV\Y<V&5A<LJO'6ZD_0(
M=!I@IKA#Z+HR0Y#8-8_FF8P7WVB&+1$BP<D.QSWL'*'5[>:(W+>-#?E$QI7H
M0^#L.+8!/K#0TS4U_>)EG=O?X"&[E-4>D7!SS>(ZV 0!,<-K"EM.#18>+P(1
MH#_^&="7&JI8Y]N84+'3&<M #",3'B<$3C"CHO<22_ZUOZJL7*MQ2\QR$J2"
MY-6K-24R'FX%ASQF;Q2GWC9RQ;BG>;%W.71=GYK7/AJ3G&IE"CNYV>D*[R^V
M\3FG!A2-KYB.351E\H+(JP<.*P@TH4_B52UMQ"M_<ZG#%=X04'$]A\.2]G[M
M;$+#O@>O4\H12EJE0@-6@7(="\Z6 2O66 YJW)?5G\$W!O]QNMQ]SC&Q_*U0
MK;';)'-C#8Z'!=R.B1=T-[R:#],M+EROZ0,F L;T0N'/G./GA]-IRMB^R[R*
M<,**G1F^!3(1ZXK8O\,0M8;E?.9QU5HU&SDG)"61W$_@YX,C-WU5<BM*OQE9
M_X<1^.V7%3:[^!N0=HY)DM:$W?DF=,W8>@/EDN),;:I20$4*?PV=+)Z< W42
MI]!(G:2_RX#+L##-QHW#KQW_P5OZ5EA0I -[D?]F'8<]#K6F3!*W#KBI-CX+
MSG@%'PQ*BUZJ9%/$"K\"@#D"<<*.O@:@0V,;C'!\=BG -&)+FNT('$2A*6H(
MO=@Q^;?#Y_YV:[%=7\][^>W=6=1Y[[S[/CDVI9XV<KP)N/PQD_<?WP3OEYF\
M7S:;]^PT7;'P[]7+KD@0_^T_$6X&N;3"Y8YY3S$.1,T^#'=D145X]!KZ>Y3Q
M*UHJ?,T6B\,?HJU7WR\Z4.8OL)@&06UQE4J$6AU\-/4]W*K$/?:OIO[CL/(7
MP26P113E:]M_V3;?NJ8C6?JNZV^20\ 8EM=L:]$@$G^PAJNU]1^A6;G5]74T
M&[75$,U>0Z=R["N'>%?,V2;.OH5+O& W1WV$[@AT&ND[ , B=3^NWX( WA#S
M0A'KSG^ )<YT"0]A0A@X[NXD2;4ZS0US!I>X[SQZFGO#._6RD3"&U]%7V;?4
M5\WF/GX),1XUGB[W$I/'SC*5KM",TS-BWW@,;:TQG+#;1$KB55BJD?#E<3UR
MB)W:9BM;N)&25M\C7,,L<.@^8X)&(_42G2(5$<VYZ'PF7HS=WW#)*O#-(Z2*
MI.=Q)\B5S =W@X<V3##X&&8].82H':PZY)HQ= $_(D\LS*K )1Y1?*1R8Z37
MW=LN*5.RD08L;GZC0[,@SS*WP4O_F471XOS71SES:C+@Q@U.+;ZF3-="N0JI
MH@*-1*G,2=&D15:JT4R9$1LK.'88B;7WL+DNMH@6;3UQ*DBH(SP;&<]>AOE%
MPO=C8OM+^%\<JDD4"I#;0_@U&VBD011\%BHGA%6Y5E/B.%'N.GFH--J$V!T\
M#$4L5;*IQTYUO'[#'9L94;0M:>>J HVT4[QLAMT._D..'XE%Y7?FHQ-%\H"9
M\(7VU@BUJC92"YA"!HS #$X.)>7,>]E(23 ZP$RJ%*B@3"/E.D8P!6:2\/1<
M,-68(K>Z>T_BUS._3E/??#T%/*'S+TOB]^/""+L;]ZD+2S78M<[G/>EAERC7
MR#XQQ82=DM.]#I[QHDD2A#ZAQ^1J>KI<<$I@[I<=*_@B1^"9YA<ZR"W85XA*
M@IVT2V*YM(*''>RK.+:8+*-/I)42O5*MQN@BUXF*#:[QK27Y0%QXW<JQ5*2X
MVS#7=?C+Q/$2.JE7_8#!]2#5Y"H!KR7$A! .<&D5U*C<&.LHZBEYJ1'&S,);
M#C9-)48HS,>07[4Q6BGH,_HSM1C,MD/;2,4K=TL31:$#!_MZHLJR58'.RX$A
M+X_73KXAJ[\RX-&Z\D"\]RTV=I@W%GH MW)&5_A1&.CG497X2'$@G;>OK3DL
M25WAIE?53W;--Z*18(=LM^C 3PWL-OUWSU.#2.6:#1Q9*D?N3F\<GZ=4<1B9
M!NH%%K-@LX'W\. :G 7+57E\+3:T*LLU9M(L<B6&&#N KBNWWX-K_5,[W[$J
M6^'-:"!R$G';?0=J-8>[/HW&Z*E@N(SESP@21DSM:UARF2"WNSO#$E-*Z1J'
MQH)?9?41I,$..,\4,+]((R7*N/F3L4!0EFJ,L19UZO# &W?^30UOT-T_^98Z
M-I=7L(%3U"TP@)]#GMKH?XDA97?%*0JHX&<.MO%O[(J\6-/E9Y>*F%(<\B,1
M;(QU% QE-9P6,/]C^#XQ,@TTK.H"S=GS$=02H_+7T H\M8^AESB=!FH&<Y*.
M8>;C#";!X.,:8I00D:#</9AJU1HH]YS8SI+E"YCSOH&2I/)<R02BNT$=E[9B
ML$]\)B<_MU:Y^F]DAZ#$=^OWKPS'EDF5ZQY^+.55W,9B28+8R\L!RL@CT5"=
M*!VA6&JT71"R9(4:@>'7'!_VV!9'>L.OYQ4*F5VZ81*&VQG399+[[/&N5.FW
MX@8KX"H'ZIL5-=G]8(K:X;H/9SS38Z%R#J7[5M2)7U.X8G@4F1GN@+QLB#VT
MC?3BNJ!< QTB<<8+/T ,Q43Z4^F.RP_8PL^4B&4K-%#6L6/*-,0,+YLISV,%
MEUV"HULI)1Q,J8':.?1\6RP!0>SZ^]%.ZF63?R..M9!L1K<^WIQS<?-MQ<EF
MNHS?K4EJJJ!P4^TGF^U>%1E[S9#QYS,4T84^O2&__#]02P,$%     @ )#B<
M5A"1N<UC%@  (40! !4   !A9&%G+3(P,C(Q,C,Q7V-A;"YX;6SM76USXKB6
M_KY5^Q^\V2_W5DTZ@23=25?WO44(F6&+!!;(],RG*<>(Q'>,Q,IV$NZOWR/Y
M!1LL6S(&A)FJKC0823[/>8ZDH[>C;__\F#G&&Z*N3?#WD\:G\Q,#88M,;/SR
M_<1W3TW7LNV3?_[C/__CVW^=GOYV.^P9$V+Y,X0]PZ+(]-#$>+>]5V-,YG,3
M&P^(4MMQC%MJ3UZ0833./S4_77VZ,4Y/PS)N31?R$&SPPIJ?&O$O[; \@K\:
MEV?-Z[/F>?,"2OC:N/EZV31:#W'*!Q!P:A<G=6S\YU?VYQE>:@!4['X_>?6\
M^=>SL_?W]T\?S]3Y1.@+9#^_.(L2G@0IOWZX=BKU^T64MG'VVT-O9+VBF7EJ
M8]<SL;7,Q8K)RM>XN;DYX[]"4M?^ZO+\/6*9'E=^H5R&, 7[=AHE.V6/3AO-
MTXO&IP]W$LFU)E8!>/C5SDD?PP8]&\8W2APT1%.#X_OJ+>;H^XEKS^8.*Y _
M>Z5H^OW$G)@O(&"SV6@&XOWWR /2F3VU"7:)8T^8#=R:#BM\](J0YYX8K/2G
M83<E#BL)8?3)(K,S]ON93$%G6Y$V?NCVIVTRFU/TBK!KOZ$><3>2OJ#@': Q
MW==[A[Q7AV)9X,;2W]FNY1#7IZAE6<2'\H?(0O:;^>R@1^3=(<^T'5G)90NK
M4.H!17-SP173PI.^]XIHVZ<4OK=<%\RU+ #I<BO%0N:(>HO.__GVG+T:WCPB
M4^_=I)MP(5MLM;9$?=-955W/-I]MQ_9L5)H7A9(KQ'-+*"7OT)^[K 4AF)E%
M602Y96U%YGO?@^\/)OSE&NI/1Z^$>F-$9\M$H- >P2_IAYMCK.#=%>JD"V[9
M#(W-C\[''#J!M>^W@&=JEZYIJL7O AFTP 1;4#>XAU0Y,D'Q6T1VAZ;@'Z,)
M/ F:8K">Q+,*VI@*WE@A_AX"C]+MXBFA,Z[D(7*81S F?6C6X0E^X4E:EF>_
MV=ZB+.K2[ZD<:]!FM#"&AO[!QO;,G_$?GO $T4>"V\P;=9A3D9;,_0&#J"X&
M)DR'M24 IO-A(1<:G3Y&OR.3\A):KG5]>1[DV$Q9^Q"T<FTGVV;^I((:I%#R
M/O"T3<=J;@]46'R(S()OOL-K5 ]PA&A8V9L/Q9+:0A\> JN9Q$]MC[T"!MKG
MY\:I$1<'G]O]QU&_U[UKC3MWQFVKUWIL=XS1+YW.>!0,14%LAUBIXATVQB8T
MS0:3WP4 ?%@[-=UG/K;UW=,7TYRS^83F&7(\-WK"B>.DA0_^"-K3J%"H*LCA
M4R:)'__X?/'EJO'Y^OKF\OSZ"_!^>1/I=F=B<E<S$ >JM17XG *I,],"B.O&
M=?/+Q<WU^>?&]=7%>2,!(F$B+9K&8U(K>@]\7+.:]'Q"F.+,]6=!$WYJ ^=1
M_BDE,RGEAN\G93 1"@W7]Q/XY+L@*IDS,4SGQ'A']LNKQW^94YM %5I\/VGN
MG,EH,#2 >L0&0O&@"$9" D+SLAPXK\K00GJ;NM*;[F>'3*;^] F<%J85487-
MRW/@!*MC"QF^R&-XQZ0&B-NYK6XJS8&35HPE).E2UVK(9\_L23A^BN9J9'B4
MR*DKNWGB936]Y8#JWL'>^>@>E!,.'@<F98YQ/N=Y6=(ZN+EJWMP<(-G*"'7O
M9S/G]PM:Z)PL]6!9&:%,7[M/EME"$[1,[#_F&;Z9#E\/\=HFI0MP*GXU'1\)
MZ);*6P_>RT/5O1]/S&VP12./6'^^$@=D=AE0;R'@OBA;X =]N;J\_GS]I?'Y
MYNIJ]TYE0L9B%/K9:2D5KYMN$4;=O8V$_/F]SWI"K3G-%"Z7/HE^1EL6HXYS
M8"Y8KRGG1Z03:\UFGHQB-T("X):)79]L9T_^X&OP:))N@@2K\2LD*N>O :_5
M8#Z $0$#&*^=%C7(PO0U8+P<1@UGWMH$>]2T/+9>V?9=#V#02!N+?'YELJ;4
MT#S78":G--6EX>H^!+CST9@HSN8(,M2(;D60(<E7NI*\W)-EXC][Q,2L=WHD
M'HJ<$ '7A?EJ1'DYK"'SGW5E/MIW=X>>"^;O,E+6B%U9="&?7S3JI--K?)+=
M<WZF&A%; FC(\;5&'"?-LW '2G9BK3DM44L+D.D^7A+89?'VHJ)\=>"Y'$@-
M!U#1-N%X")C0A7C'44&N.C!<!J+,4&D?&P.3HDOM#LS,D(;<.$A6%=')#(MV
M/1*27>/*7'+1E\!-%HDDH>K>X[8LRY_Y?,@>3+PF#X,&[1 [$@JM3W\*#9)X
MWE*E%/V,0I+-S-G,C9%KOQ(UF=B!2 /3ALZI;<YMC\F7;0O9J>O$N0)"W>L_
MV.N,8*Z*W(TK*\EJQ*84--TW)0W9(1N,)AV38GYX=-DL@5-I6[;(]2K.6".J
M2X+5?35B3&% Z-,%UTM@SGEU692\1D0K02QTN$]C/7P[6SFXMH73; 6A.9**
M%YYN:^:?;AN-X;^'SN-X9/3OX:>'P;#S2^=QU/VU8_3ZHUV?=\OPF0K\S9P<
MJ>,$UXW&^?GG_0R ,V2\)Q1,"@?3K-9B3$WLFA:O4GC"OX45;/(OW_7"(T<<
MU8!0_H/G4?O9]]C*RI@,S*(Q]:YD2->K)M2KYIZ;#E4+$0S;]ZI W<<%@&LY
MPA&882I-'<VD&*#N0X 4@M:;:3N!928<X[ /OC5=VY(A6J:4PS+6"^#R?,_&
M6I(H26L-$>K>Z C"QP@8%:1.([_4P-4M)F:=3!5PA;2>:L$K0\\.A;&=8S;V
M89 6KGJ!@WR+IB01AP:YG0^/F@#,QB9==$&U?&J=[3DC#HCVTL4>HLC-MXVM
MO+%.]K4[!>G>48H]OY]-&S,]!?H0CUL42M#/A'9M#NL&N:GZ]._; G6$[;FP
MW4JE^LM0LEJN8A45MC;[[A'Y !340*)]'X&^\L;[ZZG_L@[!R%Y251ING^GB
M-Q1,+(0#U@0289,ASO*7A62U'XKZTGV)H)\V]9PQ<$;*ORPDHPV15)/NAQQ^
MAC$C-9T6GK0F,QO;KL=@O:%\%Z0@5UH35Z")JST;C"Q=ZT27@:K]8'N(7 3J
M>^4Q6]^00WA\LWS.<_/4B7%UH-MV)05'CA-'K9)CH5SY67N92,N#KB;+62%_
M:^_1SV#4:5^:SF[5I#:,O:C,VG)PC%]M&IWYRS8AR<RUM(M-L*M-BBF374%7
M\H9P$,DKZ[AOY\-R?';I#XLA!/\FXLFQ$B7I9RV;=#O5P-=PQ#I&LSFAX'<'
MFWA8! #$I&*GA2?P&_O,]^<LU\Q%>Y?42]+/1BI8QZM*#V4]EYUOA%K>[B.U
M >I2:0-4:_2+<=_K_]CYQB= M1(@#3H+C]H6P \#J*4?)%(.$-#"C@JQO6[H
M#@7_P_>@F8#VXM7$+V@(*NA,I\@2QJ38L1"[7_=G,@\H>;/!4FX73RX[8'5O
M8Q-;K#D-;FX01SR3+R!=P[YH,$^R'P-;V7"PB?9T7[$9QA=B]:?L_*W0M4DG
MT\]2-N0IRYV1@*S]1 GHPT)H$D\S\HU[K*;DG8#)SW0$W)=0@,PP9X_<<Z>L
MSX5R.Q^(6K:[]#IRZ,_,=V06(*\#W4_9)%%U7==GM\Z$-Q8-_&?'MOK0#U+Q
M,IQT_B.S$'5=:'CJ?1!W=]S@(TQMX@KO\LG+<@PFH I?ZJ3.7AN($-$]H>#_
M^!0\9!?Q8SS1P+[ $L09C\@>%)50&$WL5+DQ$$Z!>S;E$PK]:7S$[-6DHCEO
M4>H:<UD&>6'X,'4"M]+5YP[QQ!EJS'9)\#*QQ/9\(B9+/\&NH WFC#(*2.OG
M6H-3)MK.&<EJ3_=MY%$W-R8M"S3'[R*?^ P3RKWYL3"??K:T(9-B%T%-!P<U
MS32"FM2?RMI$8<9C,(IR2M"^G5B#%4?;7>Y/E3>,K,Q':1S2BM!].DJ@JW@+
M0EDW):, _0Q%6S=%5GL:[M, *%/;R]D<ODR@GT%L2$=FRY$'5F9I<N>!5><4
M63;7%'QV4!B5HC5CD2?^S9\+F)7)>@2<EU9#]>M7@CFHZ*1C'\>NSO*VZOBJ
M:G:/CL*MSQ667&,CV;:6-.P1^*S=+<@_89%2$';SVI#LQ#4VB!+ JU^X$K03
MT7FF8*=AN-NXCP'TS'9=0A?\EHZL=D N9QK=C;ZSFB7K^09:4 @HMR')N6T,
MM$$1B/XT%3.>A3Y.=&C9YWZJ?T'=36;[RI*Y..=X@F+4RH*JTH:.BVGK ^WU
M6\$%QB&3]0BLHK0:"I?:M#"' 45STYY$]U^$36!T&6CN#'BYPH[29$HK)C2B
M&[V-Z"XX/)6^@%#::C)S'Z69R&LBF@([U]LPHG@OX:TKBLU)9NZC- QY342&
MD;_BNG?#6+E47-D%R;KC\H+=RW11?V.0T4%D!CKMZE]'DGM+L;1-Y)9RE!:B
MKI'(7G2: <WL'U>O.5;Q,E;S'J5MR.HAL@B=-OIGMH7L2OOTS6*\MUQ."2U_
M4^EF%(H]2CNJ0$61B>ETX5Z&[Y5]^:>\%YN=_RB-1D47D77H-.4JK :)<'<E
M7-KL$H[20M2T$=F(3O>?9W2YJY?+JK@MZWG3FM#AMJA=N"V2>H@L0O-IUY4!
M?1D?15S$41J(HCHB.Q'/K.[>3((-C_UI<A-D'V^TW3+>6'EGNW/BFL[/E/AS
M%@_-=JT@>"N*]LL0+#*^_0NFGTGO?Q>LIJR4#,A<<5PK)K!#7)^B]>4Z:(WN
MV'V4CEQ,J\MSP&6<&LLBX4NKW>X_L2A6PTZ[T_VU==OK_&0\=L;&W\*B_[[C
MB%:9, 7U69!V]Q=@KT@!UB;< "U(K5_#D$O$R@76THA*1F/:6J7B"YK!@;!H
MV-].KDVHU:_+]?HU&'8&K=^#0'&MQSNC/_ZE,S3:3\,A/#):HU$'?MA770N7
M<S.7<4,U"+?Q2^3<QVT7,L*O)]2O]BE0LW8Q13$TW8.BI=&KF&(FZN;A$BJ/
M3O?#B'<(/#$;VEF)&IJ9MC:<RJ,K>7YPB]UE<%0A>4IA1*;>NTG5O=&KK-ZR
M/^@,Q[__9'3^]ZD[>.!])/2:H_[]^$=KN&?7-'50 Y#'6A![J/E9=G\X+UN8
M/'\U/Y..=;*8I)4S>JKX=.\]P2'W9SY?&94YC2;4@'@$4TGQAV\[6]6$)H&U
M4Q,0U#>=U8%28H92K?W_G#D;,7QJ];*&2KUNZ[;;ZXZ[G=+C)<$1&/$*\#K"
MK!,N:OGW,2A*"" Q,EI/K4]-+4W8VB!)$J7N;7UR:3&?VXR4->-5%J'N(Z50
M#T^>5)T5I*X9MRHH=8^Z$F)AT2&0ZW+9[I$DS8),]61;!:SN]V=V9G.'+! *
MMRQ*=\F%^=+:N#ATZLOA+7E)YM9\Y5M"*7FW\8O+SO,3S!88U+SC+^O>\6U_
M..S_Z#[^/&*WT<3E[FT^A$7G[!'\XB$Z8Q-!+"H6^PRB/=L8L;&/GS/%)Y=Y
MQ]64B<0B>S'QEKLP!!BR$^M3(<L1E:R-"@AU]Y0C*#UB8A[+[=;$HF#:F6GU
MXU6!'3&UQ1AU9Y;!+UI/B%/HQV+YVED$2_>!3M)^\PG,2*DGD7G"Y3>O$D1J
M6P/C@)BL#>$-"A@R#V^3OXN\,%\=2"X'LF3=W8%'>^][\/W!A+_<+T_$0UTF
M HB1<2\?JGK E[D><""',8L%,<C4<)DH!FL^C>?XO8:))X8#XJS]4&/7^8_=
M;_Q--F=+^TC>XS:@-K;LN>ET\2,0/WY'SAMZ(-A[%:T_;E2FGLV'''?YO44U
MJM P JD2R-^12<?OI K3"8M*J^GRF"PF3P,:7JZGC@U>+')$RA5V[,8BU(&&
M<4B5T=T3GU9E+:RL(S<6H0KDXYENS;>-#^.%._E6O]]"OJFMMKVMT3AOKKJO
MW<=V_Z%CC%N_&9W?!IW'48<]Y"\S///#0,'KC+\]!R_\^][\4X$&!/5!D'H/
M'F@X,E,3/S^3?O4V1]WK%;4$. V]PA#%R#,]Q(>6H'=%>O/SZL=R">*$[)?
MKJ\1W".03)E^4:YZ$Z^$6D,G?^VXO!3E!;GTHURI12^#3F-J0Q,MQW!^9OV(
M+L.=V )*H->P68_0I#JI<N8@4T3=C:*T#N3;B-T/Q(;((C":=*(-]FH#L0O5
M@1A-O>ZP1V'[B!*319I O%;DHS"[]4&:Q3(_&'(1UBK>D:X-5U ;FGKZ UG5
M?ON:T+#+"$*&V&\H)7U: _"P[?-C_?]#GMT6BS#2/&]\R5U9V[C<@S:E[:#?
MV;UF,N+?(7ZK*\%#Y")0(XLB<X?>D$/X0:Q01VZFD6SG)0=I,3M41>%2PG[B
MH&6UN:QN@ -F\TA%'*U:[[6>_R"-HQJ4A<L"^O#^2)C?R>S\V8GN^5)C/JN$
M.G(OC5-F/[^&/L?]Q+8W=C"6A1RT"50 M?"R,GW:@#8/7;>,[PD)@O >OYJ.
M'W#D..3=Q)9BTZ!0\$&;RY;@%UYFIHT%9<_;Y 5252FECK:AA+7P&C-M#"$(
M(C3YE^]Z?"N%F@&LYJXC\5(8"Z\<TX;PJ(WK8)/%,BTU\Y5=1EHQGS68ZZZN
M1Y! 6GR[V.ZGM-<Z,CXBCI^5C:;2:*SOEL^<Y8[>Q>>Y32X!WQX_23YWEE+L
M<8M\EE(*%H!6$^]I*2LF5QP9+"NI?M4UGX2LY:="/(73R7MPZM>$SXN(EIU8
M:^[R&9$@4PRQ^M4!P?3NFDS)D%LKD;:R9FY5\A\ F6)&5J9I-\:]/X;Y!>CN
M\@9T?JILY>)S*:IE"JHUYZ45H/'&H1@<?%BYD9C-+-,W'GHDCEJW%I=$MGDO
M67Q-[&DG:M'PO,@:WB=,D>G8_T:38&^EM>B!]N3-2)2_[G:BA%O^,,C^#*&+
MWQ!F6R=DF8\SU)WJ?* :KNED(!A08B'7S5ZOEF<\MYBT>KYH<"->U7:@#K]P
MK4<#ZXB7KMLFI8LIH>\FG:CX$1FYZVX+"J@U7*M9@[.\^1-T4LH,Q"74W104
MD6NX8E-^=5=Y_5)+^C>809+$*Q7U?-^'D.0'D5E9M.99<I97&I?>\P<)Z55O
M05 L15_2I:G,K>2E=2 _N[BU)3H^$09.*_1&@=;"V+-CDK[G.[S==:&V,'>Y
M'@>@UVF-.B-^Y"1^IT&#EQH>,4CT6L-A[S7,\,457WR01C<$ADPG>_MB<?)*
M)H"[V$,4N5Y_FGW!NF"Z5R*;/M5/5O/Q7&Y9=!H>VXCCQ'$ ;>**&M?UA(=)
MH"(>#3O+%:!,C.4J0G+I*'_?LVHQ:?6PZ[,O#XCN2M#*SXEON6,,XBRV,/9-
MY\'&]LP/S/@)NCMV4WF;.?,."V29QNW^L+W7+H86RG28[4,/V_E@LT+0DF'$
M8@+Q$EJN=7UY'N10[5G7#G;&/6L8'-+D4ANS0.RP._79:PT,=%NQZ*M]KFN\
M@_2&'8C/XT:Z\,U ' &+-$DP,A8 (BRN-6H;@.,G(T"RMVTS*QR$P3H#_(,P
M.-.=+U=/A;GW$-E'4K(NYE')F'6)QF8E2M*G.2I!5%'[5%X#&KH8\M#>235&
M$I9SM":2AU][AT8(K.">-*5"CM,T\L!KX]LDHUBOCJI4G9&U_;>Q,_*0"E$=
M."$Z;+'M@2N#4/:P<E'L+,AGWW6L3TG!"L('JY6B7RU7I3<5W[,"\!JZ![*P
M9(.3ERSN.&U%2@L:1"&2[AK:\*KF+OL'@[W1:-:SF]C'A05YHCWA";#%#B>S
M'8YLV)][M+M46>DJ<*/!Z3P5MA2; B4E:-AY"&!)C1'BU'5C7 7F9FW[M[-
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MK%9YM'2,)61 D\)U#2E<:Y9"2V=80@8(*8SHQQE9X6?QH6\.I%8)M'2'A42
MX'\\1<[(G. GU[?%"X4(7*LD6GK&<DI B&..@]#R_MO=2U=M/K!64;1TDV5T
M@!!$:C543DI',*W,;^D=\RDPQ?9THX(ZBP'V?>0)G 8^F%:VMW2+^11 8?N8
MDNRE.J' _CRX5C&T=)?EE)@31SP,F4^)>:90X;E6AK?TE@NH&^,PF_,(L@0K
M:_ZQUNVNEHYO'G-3[&6%$[WY%OOB*%L91"N;6_JS9>Q-L3JMJ7*XNGY<L917
M#JO+(%I9W=)I+6-OBM4K8CFNOUD>=H_8X_"Y\%PKDUOZI07437%XBG.(W'G6
MAL-G+I16;K?T/;D$F)Y QB_VEM7<%)C<?#"M7&_I9O(I,.M@9G(]XR,7P2P*
MJ?_K,^40NIOR1EI%THGS*:?'K("^(L_[NX^?_26RJ(N G$D01))M0R&\5K&T
M=$XK2#$KD5^P1UT(B\2;G$2<D5R"TRJ!3K9Q2R08GJPB0N)4+I8[P5:ON,ZM
M>)H2@&N50R>;NR)*3&_RAHBPP@E/Z-8*K11)R>XN'UQK,F%'V[I\2LSGE)"1
M%:(-EH2*"U!:F=_)'FZ! +,\'^\0V= !^9G@YW";YG8)>2^ UBJ#3G9P!808
MEL7+.<TQ2?82"X(#JE4*G>SB\J@P)8*)O2;#R'%I/\,P1$%2MU?@/\N M8JA
MI1LMH\-T8N>Y2L62>3(6X8T&&;!60724Y\RCP^RDE,WY%4Y'>2"MC._$?\[C
M;]A'H)@3RYOX#GKY.Q+SO 2GE>V=^,<E$HQM9B4&\)T;V);W+V01<3ZY&%0K
M_]ONV@JI,#WMGU&ZH[_(3CB6(+4*H*5;+"0"!O\3:TQ- CE8K2>[6OK"$C),
M26%(\7%BG/B&9^&Y5FZW='X+J!OC<&+N"O9H<D^U<K>E6YM#W#!O[URRF_"L
M]<)SK?QMZ; 64#?,X?OT6DTQC\\06KG<TA\M(5_)YQ\ONRN9=JZ3="HZBIS3
MC\%L/8IW/8.)'V^R;;%'B0[&OT?LFC#Z2ML]UX^35U3[^(%55#MU33^/9M/E
M['YR.UR-;P?+%?WS,)ZNEH/9W6#T\W#Z>;P<3*:#Y<_#Q?CGV?WM>+$<C/_Q
M9;+ZU^ _;\=WD]%D]7_?:2B[UJJJ&:_\F@C(4.&U1)C,$\0^DA=OK6ACO ";
MG/W<TFM\2HR6JRJ@)*W )H %5H1-IF)9J0BH>2L>UKABFU27=-4/:U0]F2 K
MB,@AQBA!3EY"60P/H(:;LA@D9!@5QP+9R'UBLVG KOF+T4N, :E4JIL9K$I3
M6SC5U!B5T=!QW.3-<\MU)O[(VKNAY<EO/)>W,5BTIK9T*D@Q*QJ;.@11?$78
M+-PBPLBAUC1;39\0.W"^0W(QJ;<W6.FFOLC4R3(\^X64 N0<+S2MF//XP :+
MWS28Z?@T&)7"R9PL^=(B-R4#J+T*8#767'\$1.6_)M*APY79+N@6)7\G?F9]
M3",&"^QY=Y@\ES>V&_<"P+A3DW!MRN#43RXC*AQX94  3E!#U<R/SS)E@ 04
M)\#'F=:B@94' 3!JNA!*CB8XXN X<0FJZK[K$1Z >]2!H"0$PI':%(6)R7F/
M2^?7!3  W*,.I%,@"HY$1#X!I06Y&S])Z+!S%S/[3OS-B_=2SK= 41)GZY7U
M,F>I^/1!&!+W,0J9K;7"<XN3 F\(!P#>6P<:I9EI<#0VYE2R(-U&A-TV%F=8
M_&)Y$8J?S6+$@O$+(K8;B%?K^OT <"^[LK/J$0Y>^LE2UX'XI1T9K.[:O_RE
ME(-7@$1[&0DWE"L.FQCIK,C+9FC3D<%ZL[HF  'EX!4@5=\.-$#>D\$"N-KF
M@+YU@*7(Q(*]NOYX%0N7_9+='V5W5MO$3>:A6#$+,E1I8+(N;@>R4B$1SK#,
M7 >[PH)]HEBQ'HN*M4"4"X$;HB4B3ZZ-$E5<(!MO$JGQY*_OM2:K^78XXOMG
M%!Q=7*$=*RY-#@EGAC;E&L-DA1?(H<].2)^9(@H;->G)9.7A+B-*36B'HP0R
M*V>$_2?*!HK7;)U\#EWJ[J:%:%QA%+%EGR8+(FNR'Q6X %Y%$BNH8QU1[M1D
MK69=%N:?04MB=9^BY_A)DPDCT]9D46A-$T.&6O"B392TH6Q+C4T6G=8UH$%*
M-[<EEE@J-J64,/,V"!]0N"V5PJC7U&1=Z[ZV#H7$ I5KHG]'A%7$66QALBQV
M7U(LT@A4> OJ4.34;+AC=2I4I"AL:K+H=E_B%!(+5*Z)^J58JX_)4P.3A;W[
M'9(G$OL.IJ8A0[8+3/%%B1%&<5V@O75@OOIL/:?TND& R6&*PY*9T[@7D^7"
MNPJ[-J&[=XDFP?DS4LD/]67:J!^3E<D[DVHCRK4>%KYU Y9A'!$T(QO+=_^P
MTM2-&RMP X8="BB:\:^W+(/<.V?"R@X'?_/AZL/5X&)P[I]^F2T^#Z>3_QZN
M)K/I8#B]'=P,EY/X</!\,5Z.IZODR7^F+^KK*+! W[,,.!^=3KB19<-L?>?Z
MEF^[EG<^5<T[%-Q9KQVLK $),ZLJ_79>4>F77V?//M7HK;OGG!3F/#=^*KAC
M@;$1RR&S>P-'50S< \)<"+/'@H6Z4^)H%P=_!0-WF$QJ/V-_\W?Z_[V[<T/D
M< _T*, ;3&Z7J,!I39$CW[=-D+[]?)^J I]YP :3U6LPF8>Y)@XOHS^V.%)5
M92ZTP3SS&CSFHJZ)R<.(W=3LN=8\/-R'SOM*/HL:&$P:K\%J$?::N#T/T7LE
M+A<!#290U^!N$6M=.KRIUMJ-"4[^M;F>;G1K)L'_1G8XNE)745$+@RF[=715
MA+[9W;'H,7 =UR*'I>6AV3IVMF6EB\3P^AV4@I71@X.B0+99\9VQ8?7[9NO,
M61!IP2.5AD"J'U5I:$Y."F09%=AD/I-6/<@\!W#B5UV]<D>TSS28/??VA,C0
M\W"<MI:<=Y#R7@(/X*!O,UE(:()1A&+D64&@L.Z(X?6O.Q_UK3MBLLU6<\N@
M(UUG>(! UI4J#<R5=>.0H;-VJ\.O#U9X!F#%$"O&J5"KTTF9KSXV%.X%!7$Z
M[5E[!9T>^'+R;;J8]5Y?C9X'UX]=Y/@N-!2$)P]P3I<,1O(&W1RDQ^%K]6#0
M^.A)=QJQ 4X>3+9@RIPDQV7BWT3&BQC>8,"X9]E*B 8DR3];<O W>F7\ZO*%
MYP3;"#EQX5&&'24739A0+&\>/7JN/5NO$2E? -V@O<$0>L]BK\$$LQ=BW;L!
MNQ#M%NUQP&X'.,2E9_?A@A'.L:656AD,Z/<D5V72#:5)+:/=SB('ZE:X&]]=
MN[:5O>YN3AE@NW2^P3YAAXM(3$"=M*GK<MK4\LO#PW#Q+Y8GM9Q\GD[N)J/A
M=#48CD:S+]/59/IY,)_=3T:3\9("9]_<>R95ZRGPSG))<@(@"% 84*VY=ZU'
MUXL/93W$V:S(F?F+(T44($M@G*0FNX^AP_[UK@TGQ&\.*9KQG4,$_1ZQ,DN2
MZ)122^,)7+TI0'9M4&*%41/@A"$//VDP2ZDEC.A6#5WF2D]&(3CIY:9^:8A?
MN36 4%H-/:T2(9=$&&)L,0>)PG4]O<-8Z>M>>,55F?8+@O9@GB .?#)]$Y).
M%)Z-/%Z,5Z45@*W WA1"F0EP'/H3MAD65$N[=FL !83[GP94F0':#9P33"WB
M,*YHLX\O1O>=)5Z'SQ9!==W"ZU9NX1&3OPS0$9>!Y3N#(,4&OJNXM+?(B5C>
MP9&6N6?%'#UQ5WHSGW)S[4% /C8WAQ5]K<314VH)QM&K*[Y"C*^:4M.A7 %-
M]*52/TZI)0P_KH:J*DDO2Z%1Z3U8]I8N1N20Q4[JNTE; /#7:NAC;@]41I91
M$?V"MJ[M(?DU344@ .9Q0T$4*3%KUD:$<H\:'13_._>%?9++0=8 @/':4"8R
MJGK('J(.JAT2[+NV?$JJ @9PH45-AE=19':7/C68<Y;\$_+P/KER.PCE8Z-&
M>P 71S0<*C6(U'[&>L$N/Q<<<\\\,WZ"I(WA7*#%#(^YPZ#TU/SY]9)"Y#AH
M3$\?*#MVT4[(Q<)SP\?6.1(_LK& J'Y&6B]R1N:?&SZ:+F-D'E&8#F_51HA*
M0V.[&^I4Y58[Y1GZ]:47"RGZ$J!UY-V[:U' 3:DE9 ]-*G,EZD#'ID?89VG-
M),W/&A'DN.'"#7ZK&YC^IE5@.H?& *\'=HS(@%!,X >E<]@SYLE"T")@S<>E
MBEA4!IJE+< $F.6BR!V@DM%C]BA;B8:J\+&T!8RPL8+"2:4#)DS\&>$-L?9;
MUR[A*'7Y%=H!"!DKZ%Y63 I$&2XFL=][+KNRLHZH*EL!,%AJ"JJ2)%@SWLWA
M!OGVEAHPLB/8U<W Q&]:K4L%HH")ZHA<O16JU SL,L751+G$BK3U<6V=%6RI
MQ\'^,*_CR?)85B4+M6XQ"5>([";^$TKOWA)O&33J!N(Z)5##\Y5V30@U/-*"
M<+;^C+'#,HB<R(Y]4>G")6\"<=62B$V-J%YNA"P@>5P\ \Y:I-3">$$0]65(
MB9[^[^04O9^[R"BV,;O"U% M!3D<:>I;$C-6FS-YIW@1X0 97")J:="Y;D29
MAIY3BBLV+$XG),\^EN4)=BPEL/JG'L'V?_744T&)?@DD$?@L)L**W!)8\WN;
ME:ITXKZ8BA[FE@?:L6?YSFP]VKJ^)9Y?!("&-SLKU>,TMPCP[WWNCL+ =9 R
MF^7PAG=$U;DM)P/..9',W<AWF$S1<V9WAF"??K23HW*2"$C-/O0O!H*,(O5P
M2$T*S=Y&1?N>K8<.KJ[LR >%$0-II)BY&ZBXQ)D=;"<2Z&+H.Q9Q@B][ARZ+
MUQ^N_OKA6BHKQ;8 HB(R!<P-*C6*8 4:[RMR2F0-C.625%,AW_5ZK1DC+,ZF
M%FL32;-&!Q #6W(YUR"N;RMQ&C'Z9NL'Z]^8'%U@GGDH  20RJ_&?!D1<*S"
M$BWGPH-7JA-?K@F S/^6DV".'#B2FE&KUV)KZ#V[%7#A;K;A;/TE2 Y#"T15
MT09 KG\]6570 U58Q^/D!R4Q9: -5EKK0D 92@QE)<K.PD]16"_K\-MRE;3Y
M8C8?+U;_^LM@_(\OD_G#F*4<3F\'R]G=ZNMP,?[+8#I>P<\H?#OF_G;,_>V8
M^]LQ][=C[O\3C[G':S6[7WJRVQ/\A,0Y/$HM +C'#44D)>OMM'6'Q]M!G[9^
MM:4'NCD)KT+56UD.?>?:097E^)-6(A XOZ^Q$D$7EG75WL?;>=I7M3LBI&B*
MCO[%([NEV1;%$>MT -G\DVI '2+A1!J%6'\F.*@]?M-&D+TLH<XJR3(E$([\
MAK8=[2+/"I%SB_8$V6X<::6?/10SWG>&.TS"]+X+(6'B9(*.NH<\KI5THCM6
MP-$>&4<:S.6P7<EV(W\*:X=(104%$E1K"MGQ5)*D&IF&-I9N,"'XV?4WP2F-
MXOQ3O6VE[\I5EF]FB\7LZV3ZF16KB%\P".D;!H^G5[RF/:43AV[1H^(^$J^)
M[O'Y&$Y\JIU1O&THWBKB 0+<&1(+(3_FRL08GB:S"+%[OZ4[/F)P&-L\8JT2
M2R%+10]!Z/.TQ6ZSN['\WV;K_^=:]'LTPN_O0T<<DE9N"L"?J%*D4U1:F:B^
M,^5XB$SIUT?<1"Z\E@!,^E9BX=&D5RK##7'MR LC8GD)3O'ICWMWYU(W0U5"
M:KT ,,T;2DN-OMY/^2;G<HB]I=9HP/"H&D=5+0"8V,H2J:+%%/?OL>6OGG%]
M(10: MC?:2V+ DE:1,(N4*48VZSC!!.RQTFV7X5,%%H"V,*I)Q0%F@Q?O)ZQ
MXJMV:43 QG9FY-CS=V-X?LOKVX'):^&=9:/ACAV)4G)CLN  3#9U*8K)@!2'
MR^+(R%*220((P"1K*HV$ *ARF-"A3%# KMU&<3D!YWPJ0TD^\@X &&Y-Y28G
MS'@T]![[FW;!T(_28"CK__7%0@M#3Q("Y4)J3@>E+ Z/"ZX\39X/"B;Z*6%[
M+NV32X79E-P"2M*@IP@81LA3IDXR*6@+>2ZI%[;96NX\<B@*F42MLV,V$Q3"
M:]T;@,"H7-4$$9UZ5.J-R2G@)@TXM.D-@'G>ESPU!B;JXT:[ZW*$YOH#8.3W
M)M,LG>"D^OX.1Y(R@.WZ ^ "]"75')TP!.D^=3D\<_T!"/SV)\@,G2 $N71?
MNI1CICL H>+>Q)@A$X84Z:^2Z'[+#G5*\CO=DLP2^K:[W%!JWW<H-37J (4V
MJW9MA-#&MFTJ\)?$F-^V:\S[@XVE!W._YAA@CB<)\6Y-&0R &U=#%&7\X8C@
M?]I63>,1U'*O1IM %VAO'>)B![,UHT @MC(8 -^KAG#*^,,107:\CR)"Q">Z
MN)  O*>&D]N)!$-;ER/L/R$2NM1262 'H1VS6>94J(CBY5"?@ [@H>]\M0AA
MR5J%)_4V-[\O%Q ;S::_C!>KR<W]>+ 8WX['#T/V<;X8WXT7](?!\N?A8KR,
MBXI]'2X6P^F*;8.>T!@D>,#? EVA'<ND(G$IMO!P<QAY5D 'XC+$MO0"4Y6&
M;T=#ZF^.J@OD[8#(_XP#(ET4DSW.I0S#);(C.J.[%95:*EL!V"15R2)5IL=L
M!NGQ<I;L<)?,81)X_5.9P,5M-I5)*#,[BC+HR"^YY #"F,4JE2PW7CAD]!!:
M72)"Q^#5V<C+C-.S5<>0$ =6Z_<!8.X2Z],II%J?KMX$=-V!@.KT 2!"IRR@
M.G3U)J";#@14IP\ <3ME =6AJS<!C;J8XVIU B!&IRRB6H3U)Z,NIKE:G0 (
MU:G+",1$-_K8A8SJ= (@BJ<NHSJ$0;"GTPC>C,371D@\'@F\?H]'L"(U\W@D
ME,&3D(KKPV\!PP>J5+M*R?3N#(VNCF'M:G.@" G'L9&I36GQ+Y(!9P=H&3T&
MKN/2,;VTXH.O58$9,;S^:4I@E34,S(@I,RNA,S8L CA;KZ@J!59\6%PZ6ZDT
MA#%I52IA3DX*9!D5V&0^DT:>,\\!3&?JZI450H8&LY?1YH?Z?466FQC<6)I;
M%06Y*V<5)K:WM#>30;4ZTGP->6]_VJ0K-0^GAOQ>2]95'NN,#YU\9*OVG+BV
M\![.&NT!!.B:RU-*6=^'U@IHQ_/[) @BY-Q&A-U03OT*G"8#G;&;K3-(GS>
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MQB][E\3 "54R]>JF?P#[>3WJ5C<\ J9835B5.NUQ7#J8I)1])CCHW$J3O0G
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M %^NH<*>HK>-:>\[UG]+K WV;[ 5WKAXG\.,6A#^9FNY]^[.I0:%NJ#;]PG
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MF1Q$#>^0PTI-Q78IV\C/ 0NDVDG/ $Z[R!6B4VI[3SZD#Q';NW4M3R;"*F
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M?)FE"Q%)"SINX_#B\[J#S/]^G8_J3NBA19CZZ2NZ#;=1O&?CWK]R,09TK%P
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M8+9I2> E?7T@8J?T^:H#A2>B7(&#=[2 SLI_VJ7++8'(>9+@TTF16<HP06
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M:&.@ZF74!QS[D7=>QRDSM?CS<7M(?N_1A8 ] -GY3<3!9EP)X XLENS0YSZ
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M#*"];53 J38EX.#:7R_=,/G)"8ZL^(W+^&;5;C)L37*QL)=5IQ!J\QT*20@
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MYHQ1SMD*H(]OGWEQ$3.*/3^DK^)FT_18-(Y?;Q7C:3EG2)M4#"#D$!&XI>\
MJ)\.ZY"&B2Y#V*\EA:8S7>#;&::UU V_S0[3T9O2HE-+LDCV*1/R'2K2N/-(
M1$X8'IT@>$5\"AL5#:)CFJ0.?\K^2%?663D=WJZ2;"=^<<B4A)!$,[[I>4;X
MY?FJ0?PB%V9V,F14$C]G*),)2B+,^,84DSLS?RYW?.#D<B[+0)%MT S)9W+#
MB1G+&DO/K&,RR8'&D,K])WW;<C$II&,*XPF$L<&RM4QN+PD"SFSM'L&UM#B*
ME)XYQ4,"P3RK* C(NHU^.= .E)09S/%F'!N;W-FOYP1WFV5@??N?!"XG6.?S
MW#9<G^%_@X+//TP\5RT[4"AS)O\047RB*KB9$)=OB%D0+R:R"+TACX#,6UJ@
MB)R4Y<#@<)"T$&Z@=>K$Z>1-](B?_)#6/)_BP$)&V2WVZ>9^<9@XT&]1S^EM
M#RX-UC4YO-2P>;L#3).R$(880;XRH<,HAG['C1RRS91!AY@A;)W1;*P9,PGH
M_(FE+,]#6I8,N^3/340_&FNJWH']VP;9KK^#2>15Y?UVX;BS!2!@-!>:W8/.
MQ::U0.C'HZT1!L^S&^V7$:R)!6O2*QWR9<0D(#Z[ >@\!GA0+*_C\[9!6VI9
MD^A\QN3MPK!<50AX*T@W:4@U;V6!XL2Q4AA7FFYETZW][5@'4^J"O&VTU?]M
M!MH%5Y3B[>)U#UOH0DVW>AIO"7/L_H;_1)<>-7_,L/Z'QQ%0L\'* MM"E9^Q
M3^<&_6'JS^Q&O.PV_E'>V/8L#OC4K ICY&RKHY1;S6KQO*Y"3'P<'>0W,5I"
MKY,$$QY5A[$#B$)ZA>AOOI;>N#]23DUQ;)W&*%!SP&MC'.@NQAL?"31_%Z-C
M04<9WO!HH&L)$.-!;3[*&QT1QOZAJKDL$QD3>A\;6]AJZRW4Q,>+47ZS<1-C
MWNA8,HY=(&SCJ2?13'*L@?U#JN7<O*%A23@HMS#^J'-_VP--QU]AH&2>?\RA
MHZL!((P1E<2?MS@,C/6CU.<)0</WQW9#/DH,6508;ZUE.'],TMAQ&]\;'5N0
M":"^E=]FD(<.E*4 /A;8L86Q]"&5BK1O#'JL_YK_A)KV8MJC</\GM$"J<51Y
M< 5T1M$T?IA))15-UJ0#Y!4-5,&P./ON.D*.SQWF\&CI5S!6 U&=]1NOC*AA
MB-X3;B<;QYXHCPM/7D$1Y\)-JW[BB#8=8&^K=LHQVFL=#4]-3.VW 9M@96*"
M44U0 +#4U!$(YM@*PC3#+44[2_,/L#35MPF$@:-0(_\(%8H '4K>P \X0*K6
M0(NMSID%XZS"S(@%<P@!9""SZS8#,KWQ!9U)"_5=Z5U45GKH9*4WH_M&+SO?
MW?'O,4:N$R+'_?O1CW'C TKOZ<,AP='#9/1Y/*;D<Q1&*0K\O<\3AV;%$\S%
M8I+VY]QB3#@DI"6BI'V7/1[C1Q[:.9S.(\8A*E_//=+M+2(KD><\.8D/C1&5
M>^?C9SYPDC4L(4DX[JFTB$2JY_-]77]+!2D2F"G)&+O14^C_1LB\[ CC=(=?
M4>2ZQWA:RUX(G@<D']#^XY9OYA<=.S%PV!WGFKR:4?><5?F_X6F-SB]A>M]9
MB?D;GZAHF:+/"W$O2K,21.8 9/AFYUE.P(;O9(=QUNYTQI)4IBRT4].TA4X3
MLEG)(8KYM*3^P2"&=RY[XCT-7O.-<)8MQY^F8ZSH"Y=9;W0@LDYKOC"J XR7
M! IA?V-ZO\\T\D%[6'/N\26 $US[B1M$"9W_JZ1^#L@3YB@_JL5-9O0W,@2^
MBSVXVL;2-%=X[_@LR^0J"AF/HQ.@#8[W;- L7^6[)=_Z8>*[T\WDE*^T"BL(
M1J V^#C03K>>)!, &#N_CLF3-0TQ@(.1)6- F%LV[RO)L6^B!V@V?BXQ<Y'.
M+U\QF5U.,ANC\_Z<S*@?!OIYC0KXM@<3\[^ER3'&G'1O=^@9P$801J0>QR!O
M;K@"]!-W.!>9[@ GWX(:>R33D^1M#UD]?AV38Y.&&&]W$.IC# BC3?/>^K@#
MBEJQA8G]6 T;[9;'B1Y;D,( 7.SZM6:=#\1O I@_I*4'>@VAR@PX?@^J,@24
MKDS[F_?91[Z/#-+T[=>/K5\ZGHK=:N\83W+,:E]+%D=9HXQI?>1YVV->[U]J
MW$*D$F'>[IC9WR00QE3U?3;5(^Y1=]4F^?MU3RZ>^C9:U8 C[):=,YS 8#&H
MK0?:^SKA!ASNA]49 IY7=K(  35,R[?G?TX2>?D D[_=4*3+#GO>7LON;:-N
MFYW-GX6?\WJ[B-NJ,02\S>9RPI,PEJ[>@;=ZN7ZHEEUBH/OWHY^^(H?*D627
M56P [V)_"*)7C-?\AF[]$J,HO\#,EFRBU/G_V[OVW[AU*_W[_A5$?TJ R>W>
M=(%%BT6!B>TD;AW;.Y[T;C=8%++$L=7.2'/U<.S^]<M#ZL&9T8.2^#AR"A2W
M248\CT\\G\A#\G K_WX6I]EUG/V59JOJC.T=')HI$&YY<;9TXZ9DJV] YF<K
MBO&2M5WW=3!WQ<@UM<E%88XJFX)I[->,O-",U-8MR'(7YU'FA*KG@?G72"H5
M0 N3Q9&HH@R!+W]#(:,1I4[./1C#L_@6QDGQ3_!<VV#:NA$_*)]WOA,KQ-YH
MP0_(\-TXV*/Z5HH7!O(ST9*)KXORS;R$D^*I1<F:+*[KQY!<_D <? M\>",S
MW>-37_V0IOFN.',8!5]H]A@'\39^>#%UC':09MSL;Q%]+:N=ZFKQ\KQ-YT?G
M FH-)$_%\A=CO' 'Z0%("-0I@MF3QBI,__$QH9"[INQ=9ROFXY<P"G?YSL8;
M[%;_ ]&'PGLPQB$=NG\0(E%!P&$^MT[:$LGH!0&S"=A-2L,)6+X@A>WSNFW/
M]HOAZ&T O;!$+^'H[1K1>R7<[CT[Y?9*_8_.[8?OP2ZW"]T_,K<?(3 K;A>V
MOU)NU_1BVKF]$;WY<7NY+? \? H#&@4 GHV7UJ+W!V+S+N2-T7B3TA^$OSM=
M1TC<U4;ETF#.V_.G:R/OH<+H):1;)YLJC&#TEWC+Q&S#[,5R/J7/@!^0ISO?
MA7'";M3^@S%W-P:8*;RV_+4E5LR^FPK ITK\ZTFKM$!G+['29\"_2-Y2<J53
M^X]-\O@3+!TD_UHR+&;?33/)C\ZOZ+YDI!D0<?WHEWR;A?MMR\C<IEZ<7&T=
M^>F7B0Q0^EHO$1D#P93+0XH!774E-=D52HA7&2!N"0N+C11AQ+=-B,L\RELZ
MV/_"+"7Q]ZBX*&0F5W;8A-OH=[!X>Z7-;F8Y\WD7%\?=?<K4QLE7KW&J8E/O
M#_O5.YV86%/Z0W_U- UY^5=/R/K75\\\W):_>@ZF??-Y%TU?/<=KZ??]D-T/
MF28;J96LHA#GY] >UEHJ$?1J0YZ0,^LS2@HN\D?SJU5L'G>YEO,VW%#7!Y7\
M1QKD6WJS43HCMMQR,]B?;C;'I\#@?%BZAJ(V;6_%D"[D+&L2X0."-:$(,;<:
M==?8^=$+<5!=U.$[\_9AYFWED@#D&S?D_UR0P67DQSMZQ^9RW-BK K#E<]A6
M/:2[!>[ 5/!6#J^.Q_$&B8K18[NZD$TJX:243KZ!?$P]^#R&&P:&852UF64O
M/O18H1^+!K/KR4=F&^C+0H.3WKRB*1L8^H_+*#BG3W0;[\&VX@ORA>[N:=*"
MEEI+W#U[@/=R_U9HAK>7#S%^]!&*0@<?@02UEK*&3NJBJW^B$4V\+?-[&<"B
M"YSXSL(GJM+95=OB[NZ#$) [O%)#O%U^F/FCC_X?R';:U?5,5Z["B%ZRC]6D
MNGZ#M. .'T.H#B[II*X";TB:<M3AI!J,(=R:XY&<G8PD.D@_+U<7[SXL[R[.
MR=G-E]N+Z[OE^O+FV@4A%F[3H!F5XN6V *O<&#=]#<- 9B6UEGC)9J#]ICG$
M"3M8PH"7=.NMH>ED4%1G<\^@ OY]+ 9JTAN"HE#7+)!:?EZS/Z6>SU=LU!8A
M-"K"S2WFL&U>?M"E!2]G&?1U_+JBI.E@$1?&1/+?;[)'FL!&IH@<-G*X\K!F
MLF\VDI4=:PYMS^(.PDX/Y3AJ?!!O*'2;Z[(W.UN$.*4!KSGR.[-:PZ7@#H"1
MJ!P,=8>)P!LT8QUQ&4[CUT%:ML)_RD/VT)T7_3V,;MF8=.?Y-,]"'ZH._W25
M!3]=L8DR&X\N'Q+*C6L,EXFB<,:,#GRJ/>@CY2#?5C[5J_&K)WOF#P0NKQ@;
M1IN8Z>;SISU-,G&1/126%08282$Y-)'%UD\+ E:2PDQ2V6EWN[@K&,>BHX]^
MSA/O(8X^Q%[V(8SW!P:P67CT\.B%5^$N9)-R=1[2(!,Q(>E"K&*FJ0*14Y0V
M]XQSE;"4@*GDQ%;RIK3V+2GL=<U:SI&=#I@^(EL&?B:-U>)(@:@4VB F(E6/
M*Z+I:X"<2)3--TX4R_.S-3DPQ14%&,>DRU5]P7OQ3+?A<YA>1KY"V'8^C3A@
M^[VL0K7]4>1!JF"XIO#<<:D=45J: E<Q^S^YBE"#@)2BP3]3G]0O7D:3T-OR
M=,R&)LNHN*M4\?,ZH#WBR!V#Q,%G5[4Q\N@>Y<KXT^BL:Q=1GF9>%*3\%C'^
M1=H51I"LL(*G\(JSYYZ[;[$U<#@*I3:REE$0"FM"(-^$3KM;?E!#HK&2B1?%
MFU"!#-L>1,QZG;[5Q3V:GD+.8]TV:R:LE"MSQ4IF7!5247",'0==K*!JV%5Q
MU;,_6K,*G&1F$D]Y85:G?+RKMD:\=+FD>^5X4_0K U3?V*H-F*][%M=1=N:E
MC\4>UA7U*7LF:/H^C)*"D\@FHE(-V8:+0#Z>F^#0E%II/I,+":AM_)W &R*Y
MT"=^2 I54"#M((B)M,W%[F#0 4ZMA+(@A58":JO=Z*5B^P-)!^!\E?O+OD @
M:49@2B(/1K'U+>77<;:./S'_LA7<,)XNTS3V0]AX_TN8/2ZC++R/@Y"FZYC-
M:)+@UDLR]K?&^;TFP8CI5BMV=4Y0AU3DI*S7QRD\S:?> 2P/,%/XG#R*,U@B
M> !S2,+M@?J6A4'D.[.(#7A*D^#1#(QB,<JMLIQ81 &DL(+<UB!>"Q"Y*438
M0FIC"%A#E@<@<H-(89&#="0F(/7U1O,C[B_AEJ99'-$)X^T.&8CI?RPBO6/M
M-@'(27VT.UK'V;M26SEH2N<TVC:&5?ODO5*)>)QM#);:^0VE!H;710WBZQPR
MSS>;.[H5E3*]Y(&RKPJG>_:Y$24^Q+GV^N/2A-!4@8CY5 M6%;E.DH:<:?7X
MIJ,4?,1-(/&&I(41)!-6+,JA-8QB'BI+X-%ZO&*7=-W"5F@GUQ5DI0%D74*V
MK"'[= !9;8=]4L8!V\2>II'2Q8TG:_90^AAO@U^2,,MHQ&8,H4^K"0340@ZC
M$HYRJ; 1WFGR,!.Z!J1J/I\@##N=ZW!-QW5666D!^2Y,@.DGLT&>D&:U&3S"
MW&Q=< I9H9Q4VDFAG@C]<B)D?0A7VZ8!&S2. ;(I/4P?A5?>0J7'Y*GP5GS0
M>+ZG"3^51HC)6-GGBG%[6R"G577[IW"GU'&36@]T7#$\$4D[N^QHWG.)X5:'
M7@LM(N=KG^2L>M[QOEWL">.[+D2=YI;M)(=/X"2K#F_D#572SWCW0S49.;;?
MB3TU0IB3O4CZG0F;G+&X*:BA"-H4.3CC:3(RH[<&N:]0IGUSD)9"9!T[.T ^
MCH4(HPBT+T9T[/L!S7A6)(SB4SK.!A7%MK%WC/?R* #IL%*A,YMUN+*2UFY(
M]?674;"B#_D6Q+Y439H7*"8*1,RB6K"2$EH3I"'G53V^35_4.UH"YN&3[^$<
MH/\8TB<X#>R+@\$']SS ?N:DLHQX^WT2/WG;>FW9]L(%$CA+]1(C+XAD 6$F
MD-J&>FG9Q:H%$LR:NJ H+1QW=KI=&W9FR/[.8S_QNLJCZ;U%Q#P)O0L/%0IO
M:C]?TN[T1F.,L!<6A& ?"X\CGD[!A")R$/*P880:F9?K)%PI5JJUU7&:R)7W
M&'WD*5(?:^_Y/$S];9SF"6TJH][W+&(Z[/.PXKVV!Y$37*_9HXN=5?)@RM9>
M=D8DO$CF/=MF+F.N%_<",LE$0D%3H?24^C\]Q$^LX^91EKR()'CQESK_7?S#
MW\ZNCSP_^ %GW)W:#D%6_RN^W':#;:/3'*LSNSWD\Y];G.$_X.XAM>UR#_G\
M9[P]1+)M; _Y'#/B_#/[C]U^LOS:XA+_ 7<_J6V7^\GR*]Y^(MDV^MQ,#A<7
M;D//;C_A1C:Y-,AZ-_VDMEWN)U_O\/83R;;12R\1KS7+;S&>?(M3V5?2;)^(
MC@)_JGL)_.UO9\LC;^I_Q=D_CJR&SE'\$[Z><6S8Z/4H1AULS![9YH^SSVV#
MJ\]H^\>I[0<CUL_X>DF#;:-+/_URN?[?B]75\OK<;D^Y^]3B%/\!=T^I;9=[
MRMTGO#U%LFUT3[F\_K2\O5E=:*PGR+Y:>0I[=+UG[S[<AME+PR5@/8_B["HJ
M_M55!9N?0YY\ZK-:0^GC]L33DY>$<9Y"Y@G*#S)#+%<:-.2\D"LVVE>2QU]L
MIAYXXJXG15>KA^<5?(<^=H6?>')^ 7ADMX801!AHFIPL0NWC4:AIO_1L3?W'
M*-[&#R_+X,ECG38H;@2_B#*:[),PI<W7 @YOC3@<AZ-0Q:=Z4^0!.\(1#1'L
M183]/_1M?^NE:;@)_?IL0V41*4TBA4U$,@HJ'U:UNE+"1&]H D*A*#DCABRA
M7F;_S)Q%/-?+NS$#W\8)4D!#,3EB?Z@G1NPO?[NB#][V@K^LAH%P\Q,X8[[#
M&XCKAI_Q39ZZC!S;C[@\(@1JNJ^VOUL)=8TCO(:?\7:H)C_*WB3_AK,K-5HX
MMA^5/6C\:&7RZ:R+S8;ZL(F\6HI?>1E=47B);"PE;FC*/M* )MZ6#[9@&^#!
MPT<HZ96,LQ\;0$\^1:9!++[H,>'<Z, K;2#21A&03 [M6! V8BI,(94MQXT6
M<++>MWUZ'A.>E]4.(I( BF\\-F*%9 ^@\M8$+$\TN8_Q W.[.A,3;MYOPD.8
M-%8.D,;R7=S<^S!.NE7SL:X0T/8D\IEEO]VCNZ$\USOJA99K -CQ\8BA'9SX
MM^.G&N-.N>>R)%%18.!FHS)=/Z-))C(4C02D029BGM*%6'VSYD2!R%E/FWM3
MRJ70:D!8%$X9D%;S:ULL7]3I&KEZ&'T[&#7)#OOLC @YJ;\M[R[DSD3>A!%Y
MH5Z2:N3S9<H\26$;_&T2;\*L^9*$AH<0,VZK3_7E!<=/(.?$=GM';T7=P282
M7KBLDDWV0CB)$\*Z&:S*V[XG0+^?M7>%2 =%^TUZU?#.]+$#W"( 9?"8U&*X
M>A.=AT]A0*,@+9(<WD/CH$Z]*6(F&>A_Q2^*[9"SSE O)M0J*T0!'WVOM=;3
M&3B$7FJV2TFV0)#TU-G'FXA4NJJL(M-FG\-LP5#);.P'&HMP>?LP\[:%+]U4
MUO$L8N[J\[ NF-7R(')VZC5;#QWY0HVC])@Q)PO!IVL63MC%N)O5AP3V8)YY
M429VRL"1_ZV3(IA[7OX]>KB*T_3,2Y(79MAW+PG:KCGN;("3A=1]/:B8V?HT
MWB5,!9M'EZ L11.030Z$NZFO:<[7:\HFI)6_VQ@F.4;F,E4"OKEX4.N3..-,
MP;NFB8GT&/(O?8_14_*\7I4&D8>;<@$,F'HD=!=F&:0!X4GW$Q&=*,CSCGJ5
MS$5]'@L.LC>J<0LX["_?TL92UHT/(*:/1E_JO=KRK\C)HMG6Z6G23,@MN2'(
M$]ZA'N$ZMGV<\$^6R-U;WBZMU=]"6G,!;S0;$-D_WM$LV_(2MRD_)K^,@BMF
MSY2]/]U2<0:O9M2&;CKL$(EWM*[+,?.;#>&'VHR%* C!*W!R2_#O,S0)HP#C
M://2]'TODPGL+$]@-XZTC[#RF<%Q\;RG44H_T(ANPFQY#P5A_..+?":*PDU5
M4_"1^6F,'+RD-,F;T=DQH;3<T=Q ,,! A7+RIE#_EGPK+3@^HF"'>5QB]0?W
ME'+BHQ),3:WF1!2M7K=SPDF3N81_N^&:(KTYKA$$LW[/"\$.P[:;H+IAZ6T[
MBQ!60Z AD+L;H@]G1?.G!O715QM?<!O&H?8?XMAEJ%=3H2$QWMYH%L'=XW-#
M5+>T0!_.?79/C6,I'6 G?./,VRJ$KRF_UZ"?^$*)BZ@]AY,S"0UTS-7'RL(=
MXY,0DD-_E""\C##-G=&;XPJM<YNPNT7+R93]R.5A P/EQK,BCP$#!;66LZ$'
M4Q_08SZP/X(8&/FF@' XR2\]/""U<>&N*&(>03\$CZ;05VF/GP &>3&9!HX3
M 6CIP HL"-("I;_C^&#N%# BZF<;Z,9C&UURP+3G(CL0%%I<1&^]L>%@4T.+
MP^.JHNG6@9L9C" J\XA6!7A9QXR;IC<T*19/$WLN'14)PX6L5$?-9R089H3]
M?9_#Y4 ,2]W%Q$P1YMDC\YY>1A>1YS/31Q%BJXQ9$EXW(@J$UBQ@=H35XX;Y
M'9;" !8[I##!"@_USI/LPG6YVS-YL,D=&&7?41N.>"GY-8=KJ$* 2D/Y;(-;
MQ,_R+&5SS#_%]^G2SVXV[__]Y_\4[[0%=1UR<=.1-N1&;!1O%XJ7MO2Y9F>S
M.!C",QY@"F&V.&4Q]^B=AQO.93ZG^",R2X'QXB?P@M$:OTTAU'G@5,7]<QKD
M/OQA19D5B?_(@#BG3W0;[V'+?#':3!MIRY@2G!QF%M/3ZHJZ-" _+V?.7PUG
M[AXI">H0OJ?9=TJCXL =&X!( 4W+G-A]N>8-- @"X!>_]^EJ7G7_0KS]?OM2
MGNX+6)LT"WVR*6:NK3.N%*XP8Z,G^'OQTQLXQ/Z60 =F&AC#1#G(+0ZYQQ$C
MZRQ+POL\XZ?N6/N@A)I7JD@*O+DS08VXH[J2:+J(^E>QLFM!5C*8DFUE/C4U
M\K'\O0 WH@_,O*#I<XD4XU5+WR-ISKKONZJC(DHTP&""ITG2TOAA\ZO&]CB_
MAJ.14$@NG#;&.T(?[H*ED3C77I..(VZQ#U,K;=1)S,E7FFNDC.LX*IB,?8 +
M!AV&88N$6=)&%QH*Q-'4?';4T>F$>?(X4%\.33 F(XW@=.A],4QWPA<J [*/
M01A.SB@>",'-&N,P&9HKK"7@Y8Z1?IBGCX_GEY>.QQJ6L?D8)S1\B-A8(V$Z
M89J?,4&A7*L'X52E7,HI=]&P!Z"H=Y;^Q=OFXBJJ[3;^#C7'QJT1J0G&S3?Z
ML!NPI*H@%2\O:?3-YN)KM<L-GA66D<HT4MF&<1AD$UJA*P7$GBITO%(\(G9K
MWM][4FUSO)19\E8?*@HDU29B=HS4ZXAY^FG?+6\H%3R1:8Q!)H#(1M7&-,4@
M-]DC39;!W_.47T$_D#D:6L^2,=I04&"*XZ:S8XA6!\PS U=-)-TXL[?:$>("
MG61;3D9/UU3UP'U+$]SQKN)OT_F8IN?Q1K:2U9-/QL#"@L?%.SWI73DY^&Z'
M81)FUK&'W?XPH/F,NKW!.Q,:9L[L^X7MT@B;B)S>(D%\4$ *#2@XHEIX'<4/
MK:UGQ@W=*'3R0G/3&7%"CP-:^:#>D("1"PPAL98.3:&+_\OH-HE]FJ;-6[E4
MH>L7,S-&4,2EDQIZ9,R((U0]T4H6840*K:T[)G'PAFETBKOCPG\R@-HVXCK=
MHM" R!.S*4Y>U"&L&\R.*8Y\[>&$XNE91?^QS5KCO!*/)9IU>2O';=CBI)OX
M_!HE5!@F*FOZ+U?\DCM5C#K:SRQZ^Y#H#.:VQC.*[5X7M(9ZK8V4ZLA5T_6*
MCF+?&!J2XYMBFQ!]]L6V@P<OC'X[^I))(RF!\M^*W90PKDF>*!R.7/I^DGO;
ME/\_#:Y"[S[<\O.* V99(\7/C%HFXMB7=1@C>T;$--5#[7F+ZH=J*W1I$!^+
MER8M2&$4D:S"P6ZN("T!F3!%:3G9?.+B*GQXS-*;S=>4BG^ ;0J46=%.5),$
MX:2DZ=A4IY!'24%^TGB:3]-/$Y>EY.H%0U$<$C22;:W2[N%:-Z@TTJW03&XV
MA.DNMV$N87\4A\@5L;KM/$D6_E-LM&1=* &E[^+-NSREQ9HS[T-AQ*RG*>]F
M)_W)(.^>TWU"?;$;!#XFDKE*(':WGQ/+*B#13JX=C>?&J2JN3*32>PIS*;[O
MV*\BHV$_<MI&NLTE#_C?Z&X?)U[R(I5]2$7YA$!RC,><)[GFF+)-@M[(U.?'
M8,@J$9"S64 Z.@)TN7T"R__9RX+07_-0I.GAN33>9-^]Q,D^^1.$/B5QJCQW
M+Q_&2<AJ/G;.J_F3,YHE']JK-;2Y:*<%G35[R:4T? =P9-V4C]N]AO-T(P_,
MS?I$G(US68V!W'!^S='V<1L07-$T_8/"J30M[YM]WL,XN(B<>_W!VX(<*(O*
M!A[GU*>[>YJ0W_ULSNN[S$LR7'[_R8MR&+,?>^WLY( J,N+1F7&VY%_?"8$9
ML;)LK58:YMN!-\;9>/0@2X?CAU=E2$.L!8FHTYLUF9M2/F[0H9[6=K.)UV[/
M6X*WN=$L(KG'="UA+>D0L8WD:DL+[D-82VEEUX>=)'=OBXS++7,Q6T;!19EW
M&01:EY0YQGPO*OT,T"IB;GS0[XA^=KBM\H!<*\\!5GK=3\4LH3/C9&EU[%E]
MNU-+DWG01Y>_G9?EH=D#H$(,G5;K9P']^=3#:%\/OB?/B-]'@P,\8X-!1#B;
M4%4/TKF%I[7 O#Z9F3H)2\W^-DS%M[+7CN;CISG GHEX9P/<,=KOJQRG[4_C
MC54%F\?VWX8\F>LIMD%OO\1/E ]YB\M&D%35._7X.&U85AWLK#X\0LS<(EL-
ME^YX[Y8Q)Q90]$0C-RP:2G?"T4(_X;L@WYQ3\:>W3@OJ64=J&02AJX+#;%PE
MIAIPAJKG*]_V+&X:Z/10CO7&!_$&=+>YH^OAY#LHAA,G3A+&=_XC#?(MO=DL
MHRP,PFT.%?CNJ)\G?$1\\>QO\X &']D;/N-W<(G2=IL++XG"Z"&]I<G=HY>P
MB?/]MFUOCG8EN/N_&4SEP-&K 6_$&?)S="'6PAP8CLH&D=HB4IHD=D5+1D&C
MTBS"["+<,/*-FW8\<K<2^Q,Q_?#2+&#Y'+9EE<QJQ,T*%M"6*<*@.KQ\8</I
MT6/.%L+X!M(1Q?^UMZ/G\<X+CP^T#&@VQT@\];L_G.HV<XN)!LLU=^P% 1WD
MF]#BI(.O:$#I#KZO9W'T1!-^B.DV*>:6=UGL_^,+WQ': MV0]KB[_& DY+ZO
MW!AO$ QW871UHUH^22JM<.]PD8=)X4OC9 &0NPD?0!JE_ L(^QDZ Z"[!>XN
MK^#MP92J_7&\W5K%Z-&3'>BG[^#/ ;GU7G@:?IDDD(?C?_XF]+A9<S#N.(GW
M(%8<'^<A2QZ8[TX6!R>.:J_"B%YF=&=H4B:+Q\T(NG'4.-VJ9./E&NT>ZIY(
M#<Z\@$F$VV2$Q-@PX#[NIC$TF%Y?K,G5S=T=N;U8D;O/R]7%#(FN<[%5E^Q7
M37'MR[):!+]:<M.U+*F'V9RNY2)$,JV1C.(,;IT5:(81WU3B'^+)F[%?(YJ)
MVRGV#%<^ G2[/K>B6]@X=^LEV<N:#453C]^9FWYX.?A%:1ENF"S<E#<)H>9%
MM0&"\%+:-'=T+)$5T@D73V3-"W+_<O2SPW4P-7PZEK4&"< =3<.Q.,P4JK;&
M&S<C?!@;+$<1X&PA2':L<^FG\<'Y=.CVY9W3I^;1034MX1QUQ/%+-BV%$7_)
MG\/E?I]1_U,2Y_O&G'/G@SC[6+]O54W#QJ>0%R_LMGE\7]O#;2U1!O>D;^)D
M)T;><,J1=3JX$RZ+R2_Y_X2$Z5Y3GW#EQ&X)03.NGWBE-\(^A/$V?@C]],Q[
MV7G19>3_U!UI70V01UROKP>1U_KT#"*PWW8-D0CSX)YHK.P@;X0E;V$?N?VP
M-(?'D9M"/G?2S6*7?9>[WJS+J=CPN=><)UL#9U>SG$X9F#])TI',I22+E*=5
M36UFV8O5)ELG#6;7DXU,P0[ZLO;IV(KZ--QG-YNS..*'6,H;&F^2!R\JJH]
MP?[R]R]>E&_8_^<)&Q$</'1'DZ?0IVG[0-.D,IR!80?C:H!K3!/RP;%YOXU.
M<1-A/B3*_<+ ^AK36+:.O/G-V>KF-V_Y7J3JV9WLS6F#+] @+?PBW\/LD4D7
M%+-G%&/]'A7,;ZMZ$0QF#C)#K\(.T2#BJF<GET(SG(PYU&^%T<05_AU5RI8;
M&%-<M>Y]<MG!B_O74M@F(*^]_,+H2VXR#- !4F<9'D-14X@>59&S"Z[!CFF/
MO45Y4V)Q<8YLA?A.'S1ULHD'"WA[#EXFJ=(W";K9P[%[-K;@MY+QZ\KDV\J:
M"S,,:XF3349X7\TUU)HAGS@,=&+TGEJX.FO#QONB8-&3%VYABXO=8;<E7RLU
MXB["XJY"&%)+5Q4ZJE-E$X>ELYMS#ATL2^:]]!28Z6^%D\,&>BV/>'J:X!W1
MJ!JN+88K%:XKS)GVO/WF5 >A^PL%<J+!\HG]ZP-=T9W(&?$?US39_:R$DI*8
M.06W.B[MT=XO8R[A/\ 3;7Q0ZB2%4E)I+6X@!KT(",("-A447@%%4D$A[A=F
M)N_(FQ?J)>E;=)QR'J8^'+-8L4G6+64OH_74U @Q,^:4#ER4.:5!QDPYI<L3
M<YQ2:B6@=D$*Q?A8Q00Z)ZP2E& P.\8</U)+?<!<>5OD=@;D/5J:X8S_H7ZW
M93R:VLPKW='IP6O*=1AQ](C B-!2IG0QI3@,NR^&.8EPGPHU[@<Z1XD=^6+S
M @HEKE<2@Y/HIN+2/M#IES&7@<X 3_0F1-_%FW=50I0?TZXO>[IHC"$MR"A4
MHK .T/+HHJNDQ"=/J<,+R.\>F5DP1^0XG,5IV\RH\4'<E-#NV\$QZ).G\(9U
MAZWCJS\QD>] 9AFY(-9-D2O]WI7CE$T,-0W 4YZHX!]SL?H<1N3G]V071]FC
MQL76RXCIH2GCE.9<[NE%5 .:X8RZH7Y7,PZ%-LAG'$,\T'1XR>-U0^!#$A;*
MX<]BD"I=\&1W0F(#ATO)W>/)2?NZAH7IB&WG3]ZUE7S)P(D8;K92\%,E+X*<
MG50LU\Y*<>?$&4V>Q'!^Q @+M=TD:-Q7<9=@]YMUGQ))/^99GM O813N\EU1
MR34]S_MN&!PN!2>S342E/1_2*P+OO&FL(YI8(5T0H9(4.LL"PREA6MF/8>JS
M$/HK]1+RQ8,3(,;WH Q.D9@'[2.;H\%'A"\B$QH%3+63.Z(4'3_+DT1U)5E!
MR*M@DR-,1I!)(6'V7'+LAR4JN:;/&5E_I]LG]D134L/%4K)QD""$$3/%9;3^
M'@.[MQUD&R/G5?#%*3(C**,6,GO6:'#%.'$L@#F@."Q3S<<@J"E#(T(LG'^'
MFS680JJ'-V1)KX4Y3M 9QQV5F-? 'J?.6.0/4#X+!M&'$@ON_T#,(=.0>BU<
M,8$?9L\)=B<@5A.>MI'@^4\7P7Y%TY32EE-!DH<P^1-S/S'U:\%K@CC<=# 5
M)YD?QLK"2QB3/1I]W(PK7APOUTH'[A90(.B>,BH)@X7(@]Y$9LBD;Q#A#"57
MLQ%5A^&ML*G71-AJ*:^#2HY0&<,@A8CY$\>Q(U;Y@BE&S1>ZP'$UX5#U<R),
MKX88IC#"_*G ,@<XF798PT+LN\BC\G0<#8JM%_M""3H^^"K9>O'LLT<[[RH<
M*VO&3-&'D#)MM F:*8?TNF.24&3E1&@W<;7@[P5&$7V HE^C*<8H5'\@(=P2
MR&\-%'M.]6TO+5,SXA2Q]T!O-K=)O FS=+EANM;>\SK^0'G!-7&'_#J^R[PL
M9_)?H(IJ\M2X#56/6)R<HANW:ENK!IG(M[_J]'!L1)6ITGUE!.R1A<U.>VX*
M\< 4DGG/Q: FJ\V!?TE+@WC%9&:1W0VTF""LC2 W&U*80;@=A!E"UC'Y0(ED
M"_Q+90TIS+%_/  3AH?=<&07U/<]./;SBP??G,AC;+BBO^8ALT""+5K1AS"%
M;U)PYNU#-C1N@EN#3,1? EV(59^!J0*1?P.TN3?^G(30<A1Z)T%%XHC]L=1.
M?*&^B$BHN 0%]6E@E_Z=HW="WT0R@538RI^&B-1FD,(.^Z2/"+FR@R5-/;&I
MT[E(*H@)#-S@G&9)Z+/IQS7-1(W1CW%R%D=IO T#F#4MH^!KY$O_<)??IV$0
M>LGIT5K]TG%^&@RA**<B-(G&FYS0[>"$<A'%2;K:$L),*6L+PX%VV1I^C<>A
M/40VR,G:"!8P10(UJ8&,&)"C:VZTC&++8?PE\V-':UI?[MD >Y^$?'#2>.I?
MN25.VAGA?37N5&N&?'0YT(G1O1C2!0?#1SYE>P=3MI"K+L:)*>_=80!U98A'
M'FA$$]'_^0A@DT>6!Y"6 *J3 $*1/" \5&5_)&@5@KI'+-AW(<K9R_<.]"RD
MCJ2/ 6%;;?H8;X_&M"?<#YD/OV.\-ED88IZ<C%%%G:,E(6?3Z7Z-)]A"\\G<
MJ&'@ /Q[NSHCJ62!75;% -3QE+MIJ'HC@'(V&G4,5JF$WW?$>E-W%R(+DC5T
M0Q>3\;,M,_-FLTZHE^;)RUT6^_]80Y73EM%^U_,X&5G94WD*W/HPWDEMO\EC
M.S>7#/VXE$VX</*-BW=RU=[=HY?0%=TS !^9C;=)_)!XNXX;U3L;X.ZX_;X>
M5CIL>QIOUU6P>7SE0R::U+))(=SA9>K-WG;>I=[39([]M_TF]:[GY]:'-=VC
MWMZ+M5^CWNS'S88]^7/[?>A*K7!VTX%>UZNIO4V0S\$&.#"^E&';1>&P+084
MD;:N;7GUTSP6K3',IDX<B6]"D8,B^Q:\[WS75MCK_2CV>C]S]GH_G+W>SYV]
MCATPQE[O\;.7+BQZV.L]3O;2Y7WGNW8QA[CX-0^SEZ8I_U48T<N,[MHFPFHM
M<9+="._EB85",[SSBR'&CRZDSW4L2&O"!U01KLO-G:DV0*A]AGAW<U\'>'2:
M#\FSQS@)_TD#L>6B[<I4]=:XHWP@"@<I!+6F>*-]J /CMPY"7)]^TQ:DUF7B
M=)3R;2&V<.#?]J3&85\,;[P:!J\)!H=\<$N3, XNHX\Q0WT8&9PTG2,3-/O?
M3P.'[>;& 2W6ZR< H0A*OG%5B,)?,P3\6B38I]_& 6\8!N+N(">W'L-"-?TU
M9Y/ABR?VGZ[5V99'D4=WAW\'T=SP'.+H[;)V=+160@F7ZG0)]LA!IJIK_;7U
MZ7EUSB,ON_IG\>A\NNBQP=IZ*4AVN>!ZZF?W:FO'\[/KK1WKK&T/SZK'ZEIA
M;>ZSXY=7=??:QM6+OF=GU5M/5RHZ'YQ-+]65@3_JH6X&Y*9=HT^N:AT=N=:7
M1^]X?%91UYDQ;WMV-K&G+RU\.O1VG0PWY^K7#W<7__WUXGI-+O["_GOG;)?<
M!V9/<!;OX-8YO@Z[3!+F$X65X0\O]2-%(;;E=R\)1-K^,DUS&EQ&(E?0AJ!F
M'<@#WP2B)QOW="E 3#%&W)R4N7['=1'9'B(91.Z+U:SBN<(HPJU:% M=1!@&
M"3]AFJ/KP3&!*\X41SF,<OB%ITD01E[R(G*%*0FY.@FH__IM[10CY'_\\=_*
M?RED_O'_ 5!+ P04    "  D.)Q6^*44'<%C  "1(P< %0   &%D86<M,C R
M,C$R,S%?<')E+GAM;.V]:W/C.+(F_/V-V/^@K??+.1%35;Y6V1,SNR'+<K5V
M9$DCJ;JF]TL'34$2IRE2PXO+ZE^_ "^2*!(W$B!!R+%GIUTV "(S'R02B43F
MW_[WV\;NO +/MUSG[Q\N/UU\Z #'=!>6L_K[A]#_:/BF97WXW__K?_Q_?_N?
M'S_^ZV$Z["Q<,]P )^B8'C "L.C\M()U9^YNMX;3>0:>9]EVY\&S%BO0Z5Q>
M?+KZ=/OIOO/Q8S+&@^'#/J[3B0:[^G2Y_TLO&<]U_MJY^7QU]_GJXNH:CO#7
MR_N_WEQUNL_[EL]P@DN+WM2VG#_^BO[G!7ZT TEU_+^^^=;?/ZR#8/O7SY]_
M_OSYZ>?U)]=;P0$N+C__ZWDX,]=@8WRT'#\P'!-\Z,#V?_6C7PY=TP@B/AUU
M?WOQ['2 Z\_[;V%;H']]3)M]1+_Z>'GU\?KRTYN_^)!,$?V9X2-I<_17B]#^
MB):X?6[\A >7]_?WGZ._?H#<ZW3^YKDVF()E)_K=7X/=%OS]@V]MMC8:*_K=
MV@/+OW\P%L8*TG)U=7D54_+_/R8@2?_;=19])[""W<!9NMXFXN.'#AK_^W20
MF0L:"SC@D^EN/J._?V8;*B*-B6F?J](V"R!,T4QZKN.[MK5 J'TP;,3CV1J
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ML)C(5(1-NEXR,^[!'\?>W/U9=">!::FM^"@DIL(C>5IJ%5ZD]\?>Q'-?K;A
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M ZWA%:U#?&.=I,A)92K%(@^.TJZZ6.,<O['!JM[C1CJ)FI&Z5,0D-TY-!TB
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M]0?ANV@'"VYBI88*-H$/.!/( ?+^<=)*0Q30Z:OJ+Z?L#_6'<T31LL=XCU<
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MSUP;/D!UY_9UDRD PG<\/QAQ\J)J:'!-.47B"A:Q7V.?[;<H)3*EM?YX*,.
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M@*J6?6DS7BH2KEE2Y2G8&KNH.N]XB3B#0<MI,\TPP42>(%>9.CI$8&:TUB.
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MO=A0P#[DGM#["JS=7A0C(SWKAYSM(4V%"S&M5UU)H:AW)R:Q#@G7944]MJ2
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M(0P,(!\KO09A_XIR6&K2G*B#MU+C8NHW7A)N@ 7QO(_!,EMGY2!:!TSRX*S
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M5:$.8.RJB<RK4"OUS;4H?W_/V%J!82?$D46/:ZN)K+G(D_J:N?['$N-ME$G
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M<O!H8"LA,X,0/=E@<:,0(-_F$4$6\.-,]-CT;H0NRJ&@E*3R N>F6;?D*B%
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M@ JG.4YHV,^68VW"6.]]AP<";^0Z/50^)DHB?A(5@H)D!@Y<$X:-E*4?G<*
M[\.UXX#?@.%%(W1]\^[FHEP<R37V[!%/NF-$L^YLXFDG!XX0?;;CN,Y'<S_U
M?(3)3SC[CA5/OQ.@^<-_=4!$0<===EP'=':0B&2X[JS7@73\I3/4.4"E_BBX
M$TS%<DU@F/J/'D-:4D3.4;++^:KY:\F\&&CF:SD:M;->&9G"<X=-&T0Y\(@
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M1S$ABYZQM0)$31Y-5<=L+Y2D4"[U5,*-H^J%#")#""75RO'UR?5ZKN.[MK5
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MXC@)JH81\ W5L48&#$D-R6)./2%.A1<^?_L<XR&Y(_E?_P]02P,$%     @
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MAM/EJGP]BK0+/09Q9\*2UCO#(=/KS'4L,?_Q*P$U-M1?Z2^@"'Y $9SGFW5
M=F:+(DUE' RTE!DOF//K863!<B5:]B@:R;?E1$-'F)7@4X3 X@DT19Q)D9PR
M4R00*(:0)F(\X^AVCS0Y(5GMMR=T4:-IJ,$<963\^P.YM #A3XE#"[8!)^TT
M@!U0(J3* 1$26%;!(!6[7*&7C+.6VQJV9"@H^ .9_%H"G"\O[R( JC)FHI%8
MK-"EB\_TB6=3\0)$ ?9 D%]+@//%XUT$H*U1OM%/K<KJ%,N,B^4!R>3(9D"
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M][:!*=-Q-YBT9G5EH:M]E&-R!:LPJ^-#/GJ8O/XM2R=0=Z]NPZGD_=9AW<\
M<MZS#07J"Y_4>67AO]H@E\.(<;LME^:H('@574U@\1H;N45MQ)#[,CU_=Z@>
MO1[L.CJW@^:;5+[4D]&IX=#CN:0UF=)-Z-S+7A9VU[F1!/(K.G?1<KKL@%U.
M:,&K%1&^GB*(>N0B*Q%#[EWG'J0CG /%#A@KHK:%'SXFL+B%8YRJKUK9MJ/-
MM<4B<B;_72 YG.D=&&\ HR:(8\4 ]G*_78B2BCUDX@M3LU"]:^:L(N)RC5QD
MDR'/0LDKT[Y#Y@7(!$$=6@.B:YN&(CY%"Z+SJF:NA"*Z3"WC0)8%=1'=@W,G
MH24(SKPXXV\%E">7$%[$RM!X/BY.R@M'5<I.JS=N"V).^![ZXWI69N^JP2?,
M_7 5Z(\Q]_1E&2W%L8JV&@PYL,I-LS7@*L3LMC7!ERZ>(@N)UYR'(CVP1SEO
MON+P$I*8S:G<8&Q_#Q!\DO,06;97@>" L:E))=VRS5E0L7 C^[FZ@J4*0C='
M>]5%F6UCU<HH$;F%[;O8_LJT?PNVOQ+.L(W$BC<+KHXJQ*K2*[M5NI']'ES_
MG*!#Y)C^AK/O=!,)CQCC9901O?QL:<D)W;MMAG^>L_\)S,8NX;^7VFZ!Z!%%
M1ZVD9FTE7Q_JG=1M,_E3_?>+715^$>:>[K_7%&M@MGJ$A@I6,5L<&=,^H7\/
MU^VK_?=H0>(U_QV1 ##U2E=2A91J=!I#F8L7OD>(^//]]VBQ_37_'1F[LM!R
MR#&--%S7[HOEKL-]#]G_?/\]6FQ_Q7]G$HQ8;$V-.=HUD5$O192J1? ]+/VG
M^^_18/H;_CM=JQ)#D#/J'*@;RG"8GB_9&]\ _!+__6+,WF[4K*O482E_HP;G
M\=3ZS8;UE"8X#B-W!?_""9>Q6\IHO'?Y!@N?!QP*"[_?B'?753N+W-0#=&%1
M)7K%_JPU$"/+[1?GN+L@]<@DK[4;@Z40],0R<^NF>&KWB ]OV^'^W8V;LW"[
M-UN??G./;$@SUC5%-8"#!!0^(VU*@F_;>T-'D13!7K*"!O;;;UJ4&DSXFU2C
M9O8=0RG3E68B/>FX_,B-KHIXD1(_?D%2/&Y)\?&4E1=IN+,Y6R)>;8L0\Y&&
MG7@,[J#I]0\&?.3>J&PQ/A3,0G]"4UT+!Q8V]HQ99$$7R7NCHIB:_TQ?^=;9
M75*F;IF&[X8?Z*",*'JZ%QR:8-PQL/UF-AC[U)_Y]Z:;^J;NG-+O] C>; PY
MMI>U%DUTE&M$=X?YU=GOM,?)T_]6"0BGGOZ^-(0&(Z&D<"["T=/))#FICDM6
M;1#9I<_-0"C*Y[0O#:$"I2U (;68T8 N*RT;3R7KC3N$;M&0/=LS\S/!MQ0K
M '-D"];8O\$OP(IH>H9K+WF.Y=-.KE(JB1D*9?#Y6!CV6N-,.W*>BY_"_>)T
M?OP*Y_/(L3>VWW4JH]@"+Y@<$+HTD^.\5M84**-*5%.WRBBV\$T95:SPC.O(
MR=J4&JE+1D<T3QA/6.=6&56L?%-&477>HEOJ*HNOAK17-GN&DQ8;S57D[-^)
MC*+JWY511=Y+=<?M0:4]4DFO,"^E^HUR-GNK$D45ORFC,AROE"9"MI*<T+3@
MLAFN7R"L!'NK$I7A;HY1VS6 -/$<-]@HS)MV'<RA5^S/2C%&#=LTX$MQO8WX
M=.40-H+4,23!EAS.DB"=<!0C47RSY]:;#)CTHJ)S%2ZK]@IHNMV-[FT>9U'B
M8!7Q-BFB#H_+1K=:P!44 TBT8!O^10,A'-H*E9D4\RF>0\@BWB@:A=3 NO50
MUO&YWN-6YX)C4A[TQYUYNLXA+-/3P2PA9*);$2J:X+C]B-0+X"C-M.6RXP@-
M=%I$T=S 041F==<<MQEK8N8&L)VQ8NUOF@DC8 #66XU-KZKHB@NDD/46#09=
M:<[+*COHYU >=$N.$SG6^W[BP;RV6V0O32SJ'L&9K&NX(+A->!,OQC)-62$M
M@L:)K#RWQJN\H41.F[_!M<,Y?3>&V>8$B"Z%/>&<IW=!6R]1)DKB7C%NEE<I
M$,VR':]Q[OCDOAD+_2T*V_+WWK?:,MM*+J1QJY11%2*MYN<CE&FN;DWNGL_K
MFS&N:!JC"OQS:.FJ7D&U<:.;X#PZ7T^BG96"-&_-TAV=VC=C7\9S7%O0%*'A
M+O<T9['EV!//93IH(8Y.W:J,627SUC3G\;E]-P:.0I8UC!E94M$)B5),-8_-
MN>XL(=V:R&UF<W-,VA[6N.#EK[O[XOG*<N8BBWHKRRD9#\E5C=%@%-WC/1>]
M_G5'A3LHH!)CE46(";>H,H6J7DBJW7X)Y,I,N=UQ(R?PU\#$C@AW2/C4@)\:
M(2BF_;&],O1<#170_#07US)D?OB;@&)'ACLL(#WRIK<Y4+#4.\.NJHU5CM(9
MM;BL="J+SN^!BAT5[J#PR:',-C[%BJLF>HB3J-',$.J-\KC84(N1\_&O XHM
M%;X]*#(C6Q$]S?7@2LBG "-38\40#I?K7;X]ZLT:*T?5\T-:Z,A>-16]!(:S
MH7#*W&\, -A55AIS,P3"C$\O^PQKR^B26+CC=-HI(]%;1%YEG;&AP94 <?US
MQE=:>F;=(I^>"O,,1PZ*Q3[%TEHW<5]Z_GZ@8(P-)&;,*CXKS9($6N#2+;I
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M^AL+YUL;Z!NP9^"X)$7S_/C9+L6#7HB:)P')3_RB3-WRW* S1J8%V_ SPAK
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MT[-%X*S?CH$@!<(/?_#K'_A7S'&7&M0ANK! YHKDCA\Q%/WOORU!DA1CA&A
M=A\3#ZG4[B-;&8VWGYE.4$@)/D83_%)P?_]XTJL]4@S$-:U'''L@+??OO6?
MIM:FH0QU "(+NJ(M'__3ANZ%$ZN#>:QEZH+QG[_6G\!_':@YY/_\';1VE!6
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M!]]B^!_9/V-,RW]1@"_RL7:1CNWI^ZVNSU!M_VLL'2>V\A/0ZJ<O$S\#4;H
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MABRTQR!6%QQ)F,:"H<7\L_7 C56KU)LB\@X7(F*.E1_*@E8N-O6"9,B[F;N
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ME5*]4*K#][5,()%X"L73R?=)9-ZTYX(M(5735/W0?LE8[^1"G_XNH'<!?5U
MXW<!W1/01J;5+O$X3A#8.X71[R%6NLO=7>Y>E[O$7>[VO=,V7<-*.;K>+K7[
M/+2$>!)[IWL:I+,]Q$K2^BQW4,-1\<\*F+;S5XP%AF+:L=KVQ%20 I*1(#[A
M]W>QO8OM76S/$UN<R>?I%MN&?BS;+E$L3Q#Q=.(CTHL_Q!A9]D\;^D?6'$C*
M=:(6O;#6N;[^U(-MJ[N\WN7U+J_GR6N\0O</5IYQ,DE^1%SC#[$*6-Y7G7>Q
MO(OE^\62V)-)IMXNTA13:V3J?9Y,X4D<_8!\$@_[LKG)6@ZS]^^B>A?5UT4U
MA=]E]:FL9KAZBV:#0Q/0\<WGH:S6_ PR/H41!)[XB+!F'F*<80/'U/SCY_^7
MO7?OC=M*]D7_O\#]#L0^=PX2H*W1P]9C/'< 19(3S8XM'TF9G,'%A<%NKI88
M=Y,]9%-RY].?>JY5BV2KY4<R<H8;V!-+ZB87%ZMJU>-7OP(/>(JPOOF\%]8W
M*.N@K'&YY<7S05M;VOKBXNW9)9RK;[X_?G/ZZOS-\9N3\^,?+\_^<7[V,_SF
M[>7%U=O/T-@7$*TND&P.2R\8IMKNYKL<-@1_^;8J:XQ>!QT>='BC#@_><5N'
M]T_/+\].KB\NKZ[.WIRCG_SF^/LS/'-!@\]>O_WQXI]GGZ'#^UN;<\1G\\6L
M7#DW:/"@P9LT^&#PF2,-!AT[>)W^4E8TW>NVG&6NJD&I+A&<[+*W:;5<75?I
M9VCPP59"-TCL'4AOY1X)W20ACD*>"#8H\J#(FQ3Y:'M0Y)8B'WK_UF25WNT<
M'!T=?D[@>[AE'.<AESPHZ4<HZ0 R;"OIT?6MHQHJG( _\JCV=P<O]K>W=S]#
M18^VB-. :[-XM,J5!Q4=5'23B@X.<5M%=[:/X<I,:F=/TKT7!_M[GU/OV=G>
M2L*EA[-T4-1!43\+E[CSOWXZ1F#B\?7Y/\Z.WYS"CS_*3Z?G5R<_7ES]]#GJ
MNK.5_"^D LZ7U*A+)RO\8J8_G^8U3AYO<!#"\;ALEA#I5N_=,KG,Z_>#2@\J
M_;!*PY,/*MU6Z=W3LZN3R_.WA+9X=75V\M/E^?7YV=7%]0]GE]<_'+\YZ^<$
M?J1*[VXEIZZ>5/E"(1>&)([H4\&3AFN?_:M!B'+XXZ#.@SIO4N>APFO5F3IV
MSM\=[AT>;!]^3LO.T+,SZ-Y&W3L8=*]]E.[A_YZ>O3K^Z<?KJ]/S?V 7S^GQ
MY>79\>7Q]V=7X"^??LY1NH='Z31M9LMZ!*XPSLC"AIVJ<FF5WCBN\9PZ>&"D
M6)T,9^B@QX,>?XH>/W]]?'UV>7[\X^N+T_-7YR>$1+ZZ)H_X_/L?KJ\N7GV.
M'C_' NT2'C*=):\-XVRMI,B7^*VZY2O_8 JY/]7$<?BV*B?.9?76H.>#G@]Z
M_M%Z_@+I+B\O?KQB[./)V>E/EV=7[W9WMH\./M&!9@U_L47\HSA%4!"/$Y=A
MUFI0U$%1!T7]Z/K0_C%-;T3P?[Y<.N?A$=@'6RW?[;\X^AQUW=\ZWDKH#HF_
MA8%@\$T&U1U4=Y/J'GZMJOM)2OG=29FY<GJVO,TG];N]%[LO/IE(3=3P.SPW
M,_)M^:J#T@U*-RB=5;J3MU4.Q](BG1W[4=&OG$,(\96K[O*)^SP5/-E*_!V2
M<(L$[T'.K-QE4,U!-3>JYM$?135%!=.=_=.S#VY.M<QZ6I7SY:T3Z)^?(C0M
MJ\]0P8=GR 9&[LV7 V4^W4K"<A-<+^679,5F\!&LN>T #PH^*/A_HH*?O6VJ
MR6U:NQI<6P(EA"3L> 7J<U[7S5-1\#,XK76YY#6W411^<# .2F.H\O$4YX5S
M(Y!\=Z![&Y3]/U+97YW0D,J\N/0#,NL3?(+I"I8E[N]34?97$!WS3$V<X>L7
MC%*Y<_"R3L+"C>,^*/:@V!L4>^>K[>Q;K]C?GY35HJS@E/L>!P-A*M>].WRQ
M_WS_J6CS]YCKDC4F89&#O@[ZNDE?O]HFO_7Z^L-K^.Q5.G7+50#YOSLXVMD^
M>#(:^\-6@JM,>)FF&6'0V4%G_P-U]CQH 'BC:86+>556\-WB[Q!^UED^6>9/
M17G/MXS")GZ]B2PX"2LF(-9MNDS>5NX.*6_."^*K&G@R!DU_C*8/;8.V:L5-
M">?OGF_O'>Q\8GE8NA*&MH1!^S9JW]#A9[6/8(X'GND11Q.<,3WKB[WG+W8_
MAP)CY\#2U.!\ C<PLPY*.BCIIRGI8:^2;N\?['T.E=3.X:"D@Y(.2OJ%E/3H
M['__</[=.6CF[O/]P^>?U2-PA-B,6Q"Z01L';?QD;?PS#7_Z/=;?-]]]W:*_
MZ%M^6H_V927XCZ.+_DFRO%[,TA78I,*]_&*/M=VQV/U/]84-3);?_>VO\#]Z
MH\G,I15:EMO61??PQFQJ=K:W__1E3$KW81Z2V]WGP:"(4<G-4]#__M__EWV:
M<3IY?U.539$]FY2SLOK+_]BF_WMI'E-NO4LF\\8]&U<N??\LG<*-_Y+.[M-5
M+8]]>+BU^_Q/+\=EE<&?MG55N#')BZW#PS\EX9^X/9V]G:<?GID=C$YQ_I;^
MBDRI_JZLB=[M+Q62&^=W#J\=795>T[)<_&5W9VO_]WI+QLZ3K3>&WJ?0KR].
M/LV!N$:;CW O;#+L=><?E-MXF_OV+TWR[/_]KW>3+-U.]Z;[[]*]H_3=\S1+
MWQU.ISOOQL^W]W;&N]G><\KHX5WY&^?83GGZTPE-4SO:>;YWH'__,MML=V-<
MSK*/L^KT)G9V_9NPJ_U"UGB]QHKS&=NQ]HK./DP<_'!_ZRI'L+T)ON /RZ1$
MHJ3[O$;H3X;MX@+&1]PN?F[15/ B'4^TRO%O10,!7^46907?+N YZ G)6_#J
M3ZJ*JC]+%[7[B_[CTZWV ZJ@AG(G^-ZDE/@56M4S.#3*9OF7:?[!959)U:*P
M]L3AAWSLD/_6\@<_ZS%:SB2]0UCO>K>;%A%[E?_S?QSM'QR];*^KY7IV#,!G
M:<=FZX'GW.[VR^,,S#E6LYM?;\N&?KGS$B1FBB0#RS+1OW_#'_@V^3&?PZ-G
MHZ1LJJ1NQG6>Y6FU0C :BN#;RY-P=G;\TT'P!L%K"=YY,5'\4Q:)GRLFSDJ@
M_> ZZ?MIZVIK$+]!_!XA?J=7==?:H0P=S^'R$UA4YL@K0O&J<89&/4I<.KG%
MXQ1^P&'JQ0T<JLQ/BO_]5Y-6X&LDWT"X\>);/(512DM$&(2+#.(YB.<CQ!.D
M:UQFJV2,GA[(68Y>[!2>2X467#[Y;-K^+ BM6R/<W<\V=-6D7I3+&LTH^IKI
M!+S/?'F;Y/"[RDW*FX*B _HZ&.-!A@<9WBS#)[=@][KB"AYBOVR^=>5BYGP?
MPZ5;-.-9/J$(%R_U4@SMS!_W/BZ:@K%&=MDQBC3<(*F:&=KK67H/_UNYFV;&
MW%K^AQ(,<MHL;\LJ7ZY&=.6T6-%WT;)3TQ2L>0+_^M45==) X(8>!]K_<&WZ
MGKD\KY#H;&?N!D(O#,S2#\D\72[Q26G=[< ,CI4/DUD#3Y!<I_E]6HR2'TIX
MCO^&_^&5O4XG:3,HW:!TFY4.5,)/-P )RW)X8C@/5ET]S%8%K&C2_4BLE>Y#
M7B_)%P<MFY>4D8 G0W_'W@LO7"^K9K)$8&76D.NNMYC.\/?1M&W_6>XZ3I,;
M6$:1+*IRZ4!+:D?DE6Z$F0ZW<)0VP>^BDK:><4+=4'4".E*[#%L=X:UB'\5,
M3[E!=0;5V:PZ;I'#\P3/*:B*_(7E3YV@?G5!C#!2.08'BQRKZ)N];M8ZSVR0
MW4%V-\ON]Y5#+E%VE$8JFH_*"X\^T@V+O!/R3,A'8==ED-9!6C=+Z[R9+?-G
M:BI[78_4NP+N VX'CA*'P!96EU;)M"FH$2/YAASRM%:C^2WX)>#0(*_)9 EQ
M0I9/*9.X3& G04K!;5^XZA8D+8'-!'%L:KQR^!@.0KUS%$'#8NH<')DA8S/(
M]"-D^LW9!1[?/9*L!SL$>/#HX*'2F:^^<92TX8ZC-$L7R^0]O'C:,I!CN$Q3
MY. 2)^JDP">KLKFY38KRSLV2UQ?'(Q%FS#G*8I*EF]P6Y:R\60U"/ CQ9B%^
M>_'SV>4&,281;9;Y#.Y1D[1=';\Z:XD;?F-"/DE2P%K'N?>+KY]-W&R6N.(F
MO7$X7%XO_"RKFAOTBW]I;K"R/4('7/Z8XX^PRVCL,;Q438*[5)23'[M5"4X(
M^B^8?4D7#E8X2<#WABAR18Y/E?H)@/.R*/V"PBT&'1ET9+..7+[^KALA7KIB
MGA?CO#\HY%S@I*DJ+XV/R7<.XCB(XT9Q5./[@,4&6PLO$QS<+*0;8K=CGM;O
ML:K>;V+'(&INYL@U!F>$?&0B#I,T_/7KLQ&;VF5.[LH,,2)<'7VV!!EQF+J;
M/ELV<PQ(RP_D\^.W^6&298Z\9/7+)#S,SL'SEPF&JIA>QPPDKAYMN .A>^_K
M_05B4;BC!4X(B4^/&Z1$FN7PS[^G"\RG7\%B4@AV'>?3\:MG305^%+PRN$;Y
M4-SZM:,_=P;TYX#^_ 3TYW#&#&>,GC&!2/)XLNSW<>+/H&#N'.WMC3 YD\ZQ
M?I,-_LP@:YMEC>(RK.9595T_P^@.#%)OBC#\S1<50=)\WI#B5 &O_"I :?1Z
MZ+N:2?3I%"S02 UR,DMK^@6[+E2U#QE"6=\@S(,P;Q;FGZ[^'U^,T;(["D#5
M4V1$[&K2^NMCPLC(!R:,S"":@VAN%,U[UY;,IF[_!I-[DW(."USY/Z$9#7\>
M19+:@FMOP>F?G*0K6'QR7L^P_H+5G/D"Y56N2]?#@-2#N<&X;@T2/$CP(RLN
M>0OJ:C(?Z$;\QD67>JBZ#(+\N8+<ZA#HN@;Q[X-3T-->@%[! AS;NW0&@@O^
MQ_;6]O;V#I:]^1.#2 XB^?A"X ;K:FN!?ZQ2X%/WH[<'17D2BB("OT%/VA48
M$,R\^J(U&*ZM@&]3E:ZXRZNR0(:O+U*6>< ;[\^QDQ7WV?T_#KG)UUX)VATJ
M04,EZ--Y0-*C_?'.^,7XW8OTZ.#=\\/GV^_&D^GVN_T7NR_VL^SP:'\_Y@%Y
M=7'Y\_'EZ8\7%_]]_N;[\S?P\^MC(@79/=S>/3IXPJ0@LO1GLO;$+/[WX@BA
MDW#]"J^[!!_44Y 7U%%SGU;9LUE9OJ<#QC,^:E9\BD<)>6R<3EPF[@.RFYLV
MMKO<W5,X,6VHIX=8T.NMY!A<-G-![G:CGB#[VVD"ZUN6V$D]2Z9P7-5TI*U?
MV59R?>OJASY!%YBGF9-F/#SV-$!*IRZ!Z ;,C1[#BZI$LUX6\NDKYF[_G_]C
M9W_[Y>[.F:9/3=WJ[ .W$ID"UG-;P"(WE+ #YH/2.XB9AFE>A /Y;44'M+W^
MC_"?&^Z"NG38P11N=/1"G]\\;U[<E;,[E[P'#ZF@VS0%_[O*Z_>8>B@FX%_!
M*Z?+A]Y#W.\2'>J\P,9"W,9QLX1C?<D^ +L4DJGS *24CT!JW'+@%R.(8NFD
ML$*S+O .;@J><LJ.-.;MV%6'O^09)Z"I,1,DF]X\1*3-;,D]7CV?5F]GGJYH
M=76S($F>-A4]2 9"-RL7<VK^JJ+>S06^8+!_H1$4X=OH^,,3HH^#/:$3DH":
MI49FX(%E<W<XR[:G$Q2WL?)# 7INAY=M[UMG!Q[86 A0<G@FS'[.745TK'4S
MF;CZ@2W*IW)[<.@?NG8Y1E&@/9BC3. /5 R;:.,=-I'/4//1:"P0_U+!5_7&
M)F3#:^ Z>AX&MB]/J1V0>EFK#-,-M'$8YT'DU8!,TS.8ES>"%14-BB7H D+Y
MO:C6,D>X>R.55%QE2FXK6Q1>W2/V(?-!WK1A1QN?5"ZG5HX6/5_,G$BZE3C\
M>WA1^:^^@;%7[A]8$9TVN/NE717%B>.25Y.D-Y43O9<(%N]"W9=L!E$9;S"0
MA>TN(%R^S1?<HFPO4P> 4SY?I&Q>\*>3BW^<GS[;.8*O@RG#'"C<L[UDK[;1
MJS.R&MY;V$:RD/<8R*=XO&"?$9DG;A:=-C/JPZ@G35T'ZZBP2?A@\HJME1KN
M6N0U[ZX/)U86-[6/H9*KLY.MY I[0#[51I+IH<Y1.@U3U@TQ6]0M0JVF)/"5
MJJ\<I125S;'OBN.K4"26&;NX%W"NPM7PT5'-0-)R[E'%Y3]T&I[#>5K.P5+@
M4,]1 D$]2AOX51C.3>G[#Y^6> ]7@2UDE=9.&6W!25?M:L]]/INU?\=>0?NW
M&-GB:/!EIX:4YO/.)4" YST?16-49.W?+F9IT?[=&$P.['KG O6?T2.8Y>\=
M9>L[E]+0M_T'/"WRHK%4&F*,%!7 [PRE>ROY&3T+,-GC%%_BQFV?86 -ZT%+
M\9![!>;W%QDG Z:B;):QG\6\;IZS>PD7R<1[NX>U\(Z0\*8@=.++A<^C(28[
M,_)',-+1&*4=8]T"SQVQ+*O6'0OGLL<X9>QBN!%Y&/@^8B]C%#EP^)P#!=V0
M0N/ %47VIDQG+.PW57D/9ET/N@%B,TC/1ND1D^EM6>2W]!J^EI7S=G(0MD'8
M'A V2K'[P)+<:Z3$2OF(A;/\!AT&/MC5[8@$$(05? KO8-?+ABM9_C=+="+%
M084/H\>,TV!7?/%T/IC#04(WF4,3<MJB+$;Z5>Z(R?!4$#!O*TF.)#_FXPK_
M I[W$F,=RG*=OOUQQ(D@+$%A#%@P8P^G!MC,@H\(VX<1FL:P0ROE(*R?(*QI
M=D<1-@@JI8]"6H62)IS3D#P9)Q0T9],QH(/@#8+WR'.\XM1!?EN6&9[1)MVK
MB29*[4OJ=Q"M0;0VV33-==7J)1;-?(S94@3E+7-*@MS?EF#+,%.H:4*'WI[#
M/!_F=C"'PN@,S92ON1 E@S #Y(H*1 P3II1Q&@SB(+4?91!MC4,B''$;6Z=Q
M7(L:!&L0K,>Y>&K$0FB,+7C6GPOE02?.WF*!2?1>,:0Z7E_@3+\/U:JF=H/$
M#A+[6(F59&*HM*95A2B/N=9C_MRIMO9(]AC"X6G.61^NN9FK#!(X2. FF^EK
MJUG2,&<G>98*!*A<#3]/G)&]JIQ@L8[=2?PPYR9GB2<4 F=SH$$>I.]C I@
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MLK^SN[?]?+R_WWIAIYCCDA37N_W#O>>'3^<<V-MJY>"^X!OXG'5=-?,Y)FI
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MWKE^4=7=;NJ1G:B!)D5E'#9E0AEXU"M8F5&HFFGMP#J@-\Q&R-/;Z\>=E,!
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M -\49;WK!Z;H"N8>MDED-UDK>.67$H#6V,G#2*4Z5*^HXO/*C:L&V;Z?VRP
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M*9_[3L@$ZXO1LT$6(SX9.MGU+9S58O.K_.:&VH_0#F6\9GU >3CV6%'=RR)
M#WO?4KUNTX2.'L.OC=\7LY//,6M.3<CP6&IXD"Z&NX3P%&/R&HMVD+A 6X@F
M>35IYI@810:TZY9EZ[\%,G36)(D9G<&T;>E\0=ND0C7"\^ ]_0/SYM(^8:8"
M$0U$'5I7"5V08^5_@6-51AN%EQ+QVOZ@KQM"FJ*<8[='J7$8ISY'*N6W+ITM
M>8Q*N)9;3K:2[Q' %^K1YM0"(5VQA#+& 0M$<><WQ8=>&D:^RDD' #Z9YHG!
M>CF+&:5&5C7!9,-5$] )S[F-A1&PNAESN8#?$Z;,6Z^(3\4>1[I(S^JM%WG
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M:=KTT=0GN-32\$ (UJ2?'9O31TU$T:<60!.H(P3\Z-W)RL(+)P'7]QTJY^;
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M!O,GSH956M/PAN>HI['02/T*YRY;(GY,<TI\TBN=Z,1@4SQE('4P9%QO#R+
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MT%J;? G=@?'9AYF?UN!!>&J=YL+PV>AUT6BSVL?U)-\!TOX-O$L1;6VJU@1
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MRBY%B3G&I<Y<1.,)F[)J0_"RP&\@T0]EFZDU/WR9[T1BK8-L7O;$^_%64'0
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MVU!YPKMX:/T!_3?H$1V&T#:JK\!O6:[IW=,%R93>?BK4NOA*@,6D'[DPHR6
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M9YZP&!M;F ,^6G_[<SB?V>!F@_L ?\IGHS&BSRIW!P[,J$)LVB<*::@@0JC
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M5[F/B;XSE"V .A_8NG=*;6"QMFU95.>0]Z/W33MU8GIJS9*>[.XQ+QL3SPQ
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M$+I3(!(YOR"64S L?FNH D7?"JKF7;(R:=$5NN).+B?*8=E%U8,BCH3[> R
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M%9)D/,0E:270^3!F[DP_Y01=MU7C94(7;0GA^B+2\ACR[CVVA/'\HE@G,D[
MJ_SW:;'\"T!>*9()@!$H,DET26#$B]B(@3X#H".&#3]N8%+^:^$S6KN=O\(0
MP^S8L6BR%\DEILR74 GV72;2RGM _0)70ZX2W(Y3S0:6Q0A'TG((\I)XJZ#
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MY<TW[U^8I(XLJO5BVXR!CD8J2GD#MOD%PJ-FYM(BW4(#/_;=FPDWG0M)"P0
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MQ2/FY8@[!1#1W':'1>_1+2XL?/A%"0N.;F 3 .A*N9=.O0QZ&'>K(BZ+VF5
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M_(NBCJC.<=]OZ28:/%X1;]N:N,GLU)>5U/_)FEU^ HK1XV-T>CPSV1#0AI6
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M,A83*$@P4AQ20+ ),2]?BOEW#R%1!]U.:XI*2.WK54Z*Y%GGX^;H"Z&%3-$
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MPU0^*E;[B/\8F:5"^!#2M\9O'#=4-Z/J.A'P)4Q1LZ>EA[@G3$_9*YZMOL&
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MB7WF'.DP/E,-DXN94A1.),Y]S,*5[!&-3V&9UL_!*#@*!R8+^1PQAK>ZH(S
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M:/R_G2VDCVM5UH^/((N-G<J05>.D[HN66"*=H5F^['5TX;H_,#  [$S]D)0
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ME]]>NJ9HN?\D2<^6J:LX$45_Z^JF)SB_OXL4='+Z@W4&%Z(FG5))FV.K-68
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MIJ=Q\G5<.@.*;* /PIBJ;0]N9&V1@X+,J^9>SNJ+"9\S8>(Q1)V9E*68&$>
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M[$]]Y#D47Y <G?(2L"^E,XI)I\#:P<)V0ABUE.=F_#%/+%LY\19ZL#],71(
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MH\4N#',L[P,'(TM=.'>U4T'@KL\;&(<PVI3U[!4!Z9B+JGB.V+PMH!E!T1.
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MW+ID[<Q#-+MY]L/*2'F2;UPSB$>=;(B!62IJ/6VOP_\>.<\_H7+S9I>Q*^G
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MN[Z[4F)"N?2.V:?9*\V1S)6;J+P=&%I-1 E<("(B9*?OI G#"J$I5V'<-S*
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M/=8&*ZEV/>1PY^5<=/)K2<'%=\RDO$G38/'.T7]1JAKK\5PL]&*A9T7),0?
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M@VAWW#8ZJ%*\LA/CN/[V["(?PO%J7\\>_XCY*5I;=C*S^]&=%M<B#8F%EG,
M<E1^2$O]V.%XR[@<^S9_"":V'M=]L+_DL;T3QHEI)D<NB]W-#/ABXJ)IQ\.
MMG*5H\]AFHJ/Q"(17Q(K15M(T'1_F<AO,"G#U.$^"&D$>JA\?RQOB5G'SS9%
M/B_X>*Z%@K'$0$>_!->EU*OU:KRI,0=-E6",1K=UEZ@]_&3F-:&J^.^O>-/5
M]U#56!R)Q?&MY*U48._&,%?0\%<#_5PW8O&?K;[Y2&HYH_+OZW?A)H+<G5T?
M;)5&>(QM/QT@^\&L^/'_J/:$;\L ##-K8$D@&@V.UMQL; +PU=?OGZ!WU==(
M=_V>YL>WJU?2V*-7^"Z@H1</:KSD-_:2W[9P23EGD6VCE\]?OEB]=;3$\P_^
M,::*M*+TI\9628Y\Q_HR$B/ALF_5HM*UXT\JM("4H*=B(R+Y[BY>F:(A*O95
MS(%ZPT.D#S*0AX]42!$E;4=AZ'D!1:@#FM3P;V#C1!6&FTQU)B4$9QF7T:B(
MF"42]%-NA:*53$RDB>WEY.MANU+O.:9MY'@CQ;+Y[)NO&DG52$ K?ZD*.KH7
M_"=E=4418P?Z]RRNB];]$1.]:;_PMH T(9+VI3N);^;%\^K%R]]4OWWY1?32
M\4D.7.AZ67WYY:^KY\^?V];+M]OJGB">O )_HX(KT3W35YF<J1@"7D*^RQ>?
M[!7\]'= R/TJ6A\1%_%#UM?7))%WF#F#XHYPV?:HY[CW%6=>!CW'R^JW+WY=
M_?>+7Y^Z#3VJ]0E^57WYVR^K%U\\U^]>^ +;$6DD6_Y*= T'C';O0H,>YH96
M#E16@(6SF]PZWMXAQ@EW9&1L:C*5_SX>LS*^_N803?Z+U=?@K$/=_3W3ZWZ7
M\UQ^HSDOAF=??K7D1I[I[/M/E+FWX/;EC5(S&84:6'%FL&JDXVO0\O[&HH7S
MFSWG2LY4@#C\5JVI\V>8/W7@&"S/+U@-,QT5E2OXI$,M.Q/]*21J7"=H?7_)
M1%#_?>DN7[K+_S9$4)1A.2?EM5?!=-" ,L=QQJO(HRIRTM]VJBD1NNM:M$6!
M5.%2Z)"ZI> KS9!DJ7S:]5VI*KZH-L\.%Y&1U-$X?1X;G%]#35=[@H'Q@*0#
MB#=!&%$J22:Y&^IIF];)K9U(XOY#WM"SU7?9A9F@6F7B-RKZ&-]&8)YJ"09%
MDG8L]7>%"#=):G!6].?OWK[*J+%=-YVC!YPME%R/6YM,H,Q]&JOL"QSTEE<(
ML>=Z&L-R+69!D+F2J-TES9[$G.#GU.*LB?0WGI8LC$THJY;X9Z;.!8F>9Z5'
M:/VFX]4#=_HI7O-4)&9A]+U.:=):N2>T<DL-H0B3WD%Q>J30YL0S"^44V("9
M(!F+53DSJE8?FLT'.KG 7=WNKK;QBUGB6.NDM*[,0R82RJH*NOBU&?$DEUEN
MFG4#9B!B:&4->&@B-QM&@M+=3!TOC-.19;&:?<^\1UA#QEJ,/%FHS,*^'L"<
M3;[*N[C*HA?NMI/46ZBFUG3H . UF&.2CDQF(FA1!N-DH1R-_VK6V_$UG50;
M\CXLFF"JXW #B'P-\:*!*EFBS&BS0J?/)/C&5&IBXML@DVFLE)5D0RDP;5L3
M0$A^8ST=B"A7B&@Y"B%)"1:')78G"'?LCD)G<W!:"9DIJ5S0["8DG1:6J8$:
M7 *I"2C5LZ#H(<C?)OD/2K&50<]I5*3\D.J)?1*LFCHF%89T!O/@:UE.Y-]%
M !QS4SU](SXF?/<)4@-OH%.H.KLGVV%C/Z -,#5QTXXQ1]G;.&'MM;H+OZC;
M)A<=8AIRXC.?A+<)IH#-S_H"Y&:NB<'H &<H*8,2>HM\S&X"Y=LV[(1Q"!;9
MBLH%53)Y)@"61*<53@WR9_J5I8G*'I"HILR"-O'-M!5Q&.PA7<R<9L3"1431
MO"-#_$5QGC.I54QD'?9)BZ_D)ON.RQD[IN]+!1%LQR8F4?2*X#BN^T$55G:B
M:\U''C(P^HA=-FV=NL6>H@O@7F]8*YP^RV54+F#$&(\ "+3:J?[!AX;(5^(<
MHW6,OJ U2V&N=5%Q<_Z:=N=PR\)LY)ROATP)QUF8_8C']."-XMX-U^D\70B)
MZ%U%VV(/,E&1O=7KPB%/"I8HFPTS:O:2'M))CN9,93_=!%8T&&"&8I&GK%$-
M.#-R;$:_TU@(2&,.4M,I2^@^-*1%B8&(@N]05.?":,S".5"!7E*J%9S8('IS
M(A+#6U4:8K-[_,RKZM(E<;:9VD?FTVKB4#\S(?WTXFC/VSU$__&I/;%<],H:
M5C!7NT+EVDB(664Q8U YD2=(7GKF3&N$"(<8X&ZO=6>.X7!HS3"IK+*G6(@O
M+4<R[IF9Q^-&[5D:JN$0L])$(#TB$;9C.S>,9/FX"2:!Q1[7Q!GF';2RLY;(
MN2@TTB[Y7<VA"6J HRAY\)$TMZT4";LW(CMK9S>KM<BN=_?R4W"R4KC4$<LO
MBX3RG"H4\-I"5/BZ/W"%"XONEABK2@L2-%*1OF$VAC2D9J];_ME"9X],?TAW
M6?&0O\EH<9!8>;%+)6>5YV%OB <:Y\J)210M>=7V*!YLP7WA:KRX1@$X=Z/Z
M'A267"C<C]/(Z)1!V2OIN.BN^XRK0S<-!$9J[_5Q=]%]WLL&X%Z%/U!2TL7<
MN>:=/3K@2?B5=_& &;:MVT)[XF[DCC"%J1.CC3;@X9P9>-$-]OHYRN],"7I<
MHH#1>HGS,P!1C$W0<\AC* K;R2X4V''H+VR,%S"CSC(H^\DV[!'24G!Y4J>+
M7"H;*0BC1"'V@MB^V-@Y&\O ,BF[NIC-Q6S.F(V2+W$_7I"8^:PX!XS-+96L
M+]9TL:9ST]LJ'RX!L2 *$/Q3?'M]<4D7(WK(B J ,NC=+2,Q*G;B"%+U!4Y1
M+F9U,:LS9N43;JMI*U:J7SCKT"X3DL*+;5ULZRPIC\.;I8Y^O,R)-.\R 'DQ
MJ0=/058RU;[?P\CRGS4F^-G# +^\P  O,,!_&QC@3Z'$'8'2"KU7:39[^,^
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MZ,QW%(\#/9$82Q097PX9@J:%C4\+PS4B.Y@'51<V!3T.VNWH;HG.F6/1?9#
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MJA-M/#Z^R^,&(EVG>_(Q),>&D_I:2C8MIDC.BR;FX\^N'9F&(L=DQG DN+6
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M38B7LTXO<U9CTDPY-^FK6.IN:0;O_&-#@H:O6%CTFHXC:CI'?VCP#2685"'
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M0]L3"1Z5;AM(R.LWI4%7(@@O+@FENLI:Y['*PW;--8FE3=E&-C9OM76ZW0$
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MG'>NZEK-!\[%A&@M&E$M^!""H3[%LO$'T0Z-_R+Z[S\.9 SBT-C4X'!OL;N
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MU#]XN+M#DC'=%^#1#YFJ9&5E?G_+RS5!:_]-#I_/"?3V!'TH?FQ_SBQ*6QJ
M<<3>CL&[P;=W/$6[!)1**"0M'=\VF3U'<Z(R4/'LI'ZG4N%:XLH1:$1YE)0<
M@6(! G@FNEEJ-#V7P1!9"K-*#F4/2 ,A7\R/\G?(;J\N"$R@T-PT4DF8A_OM
ME\45M#ZB:AE)0-@OSR1H&'EVP$SN&3V+F2-@;J$1I2=R>,6N+LLHL&8R6.FL
MDDO*#-#:'8Q.6W 8F]E- NE6^=^LD@D%SP5=@/&WGV]AF4%D>J_WNA53C%1*
MPCV4\SH1G.2[_5!MN2@Y9]";Z5O-/H1.? ^.^A])&)#<8@S\Z<:C/)=750F-
M9]+LJSDRU'MU9JVKZ9+:O4G&.+<G5OM6O_.8DQVG*Q=*(2HLD4@7?Y*ZTX.I
M8423@FWZ5'+I(AY4R(TIKS;PI1SHZTC=>6H<@)U'-J=G#<4I$-&/H50G?9M%
M^30CNU()5]?MHJM<7?/67NINH(%N2E<>37=6M3ME.]9,#LR'?KOU@;?VX_'H
MAP@:DE>*PC?(?Q)8S/5 1_2<.EUSZ7.+N#+[>H79%3$)!.<EVT+.K=4C:O,*
M.VG=H-=I.CC>@R<I<BY5^G'CD[=)QM@AX8@5(P\)8LB58?N '9-T&7IKDGX\
MJ#\S@[[G9_A,[:<* Z?, *61PR5-];N;N_;,3%Y[:Z3'BC,$JLJ@<7I,@Z?]
M/ADGD:N<^ZK<+(T[68C=<D+4P[FR:>?\Z9'^LY^S"R-(%LK2I)PB16\*A2X+
M*F.2E78LJ:2(.IB[%0NJKIDGYQ'GT'@9NL0TP<232D1[7CW;C]U"DVUR;= 7
M:ME&61/B9326VPWQ3W!UV:CYA#S&AZY0$.*AO<@MRO'HETL0OL"1Q2_*,#=;
M)Q+1?YU:CH@&:*%OG)2FI3,\Z-V#.P)*WTE5J-8Q2W%@X$_3^\O3%=$@+";H
M^N2BR)E-+[72<EFB$9"PP3+P>NA[K7F) /RT40'U)7@%-4I);%-422WU!I&+
MTM=-<O649[S BP^XUERHWC5HJ3&K=/QYGW4;#]W9_;9N#^[16 ,$*PDR=_[M
M8'J,$09<2#L6NF#87-5TNS"3,[YWUS6W9>C!?;\HZP\2;/I,2DRGAQ+3H<2T
MGR6F/\!+?K8K9)%X5.^C8F&2U=923-F_&/IRRVVMEK17RW#?$@NOX<S0#0[T
MH;(26Q8[HZK;3*KVUY#T<7U(2PW:KK'S+V"=72$BTBL@\VA=-TD>/1IK:5DK
M&E,U'$#^V/QS%6=>DA0B71+B9PMCU6*Q4>WN@RS4@3Q=F/@Y/FJU=_5FT3W[
M6[8(%]Z*=> 3K@?TW)#W[%HB+?X9<L+"IF_BQXV5+Q>=7LWUM%'?#B!-WXOC
M9IXC(8I%'^,@1G$X KNTJ11@9C460S#/BZINC&4GII.XZ);N42$-\?P=$CI<
M ^[7\+'%7-[=R&G=-(8:_=TC7-^B44F(.LDEA"3>$90+X;;J1PZGY'!*/O*4
M@.FN;R?BJ"!L3<&]\30=]O9A;^^#$_1QGL^&=VB>P-+\AWKX^ZX+/ Y[][!W
M=^S=/L ,O.P=SH=U)RSRC%G+$M_EL.,..V[7CDL=W9M&8:YOK*U2OQU()XU=
M987(YD?#K-LMYECN(-'2"468VS:RX[#+#[O\&HG";F=L!U"]0Q$%B.3-JJEP
M\:.9K*5PD/;M2OUQ92 A#PRBA#6!WZ->BR>?BK5F?Y"4LDQK.4S/.2\]$[%*
M@$I:<9G]AB-'K;Z'$W(X(==%A,$VHV+LFU2E-BR>; >-GK"EQ3[9PV8[;+:;
M;[8^?FI#1@\0@,6ZCT#;R<9Z<@1'W4#^#%.N'_1G#UOS>OU9R_H:9C=R;:VN
MAV5$3!SX2IA8@4G'%?L6+VPD#5; ]H($;U"]F\^'^R2U<TT-/O]I*]0Z5$Q&
ML)@E)Q(A]75]I?J#\#.?,F26.<ZET<0CV1)U&\_.Z(O2>R_:1[1 I&,2'6YO
MRM>+;!656'PF)+;GB2P*39"0EB9Q+B59N$>1.C#.3D22Q82DF1:G%BT7<M0+
M4)W.LB:R55'7'V@T'.]2&!:/,V.V)&U,=$Q9"4M3FY*(W]B4]O0[7'N"<G&!
M\"#I>8S<I:"CYX_9%(Z-<BLA)M(6,'^?-@*EJ$6<8EDT7I4F2IY)&6# 7M$?
M:YNOQX>6Q''AFH[!V4PS'[7/T,<1#FRBJJF15?YN751YF!*P.X4!D#[81?%6
MZA>18!,]PL:M.2^K-AXVS E);@DUH",)IKZ4'#T;J_ _?:K2.@DZ;XIN=>_/
M,2:/5M5^B##YLJP:]$<VVE#7FK1$9I,F_IWV;5!R91W/?K!POVU8'<3SCN%7
MMC^XT9S)).E[6PF?K&(92>AG P:,\6)!SDYNW:*?A?^]'^8[)F7&"2>A<K$.
MYH2<6=(>"^* R_PO*+-#792R;$[,SFL$MF].BX-=3I\;8L%>C3OC<\$[GAWP
MC@>\X_\:O.//BLXS!@-G(GH-'6?&C)5 &>XD><VY-=4&:/4.FAEA1]+(PYG&
MIWY#WPE_H9CZ:VO_W";PGJ[HOAZ]:OBFHA\]S6=@X'Q:EN$J?EQMA#'CO*R)
MBV(:[M*&L^Y+JI8:"F:173D_*6STO!*!8J(Y"A^@)L"SDX??9\WT\NB7[%UX
MQ=$C>@;W.^/7IP_U0N"_*==T8VQ68#(UC^T(BUF!<CE3LOG-FAV]X->SAX:&
MF/F"J3GC'EB0MRCM\B:8%+Y$.XKT!D]RN^+Y/'W\J.?J-W)6PF .O!ZS DC4
MH7("CB(BK.6;8&7'+!4HC0OL'M*7HFY7-YG3) A#U>$S[O.(<*W>Q?44LRAL
M3[<I)7?P-)HKPW*T'^(]/AXDZW> M9)+.V&\<<E9@RIJ3]TZH=:0YI)4'@JP
MSO &&YHA]03H.>%5FPWF.#V3S'N:K8R",-(ICY@&=L?D&.U^BRXV:4R;R_:G
M[6Q;,<.^.J)]Y5XP#FVK=*B=,Z4$7XR4B3,;*3;\F#/XD--+HK<C+8?@FX1G
M?YF17."<?..O9$D(V,R[O#4.YV/J!$1&06$9LD9J_FJ"S+ T2/@K8L%AG@J4
M+5S(01U869THCVM-!(-6&1#F0K<>O9X75>]Z6<Z@?,@4*D[ EW[YO%H3SRC9
M'[(X<2UJZ%/8RW=,-V]$??E9^'M>!.A&5<S15.=,(LLO20>,H:N\8I=YUXV7
MYL:21T5/C3*9] ^BU-?9C-&#/'.F?Q?3,/O"5\($.9$49RRCY@4FHKX2>57=
M0N/D]$4QP5AD(M?;&"8=?>PNB3H)<&@A+JJ,6^[<64VWC0XFRD_ORV2&2Q5$
MUN-@*1.>8%".N+C*LBTP,U%T1JB^PT9W (YVB-:^,0A^1(Z,/P)?MNY?=VGA
MLS&$_TIT&>9@.LG"]7B%1':P5NK%8(-/P7J95Q>DK^[DJ,/*+BDN19HQF(;I
M&Z*=I&E@KFSY7NF)J'DC@$5]7@4/PG@-*'5_(<HKZ1M&5\V_8:&#Z'P5W<L7
MQ9*A 5<D.93Q51O,4@:V*F8>6Q<+CC_#UR[]79Q.>)@?L)T7=#\LP?1*RUK4
M[@5P/6OW;38K30$GKFN-YY I8?OVTX\O'D'J6V)L)3Z?5>$LQ"^CH;J'<!JH
MJ+63%:-F"0V$NV'TA*A?E<D?1= FTVI;9*\$67-I#8[HRZL0[#'+@Y?*VD1-
MJQX7E_Z.B=Q!$6VB S'9A.;-4>\]N0GONDCIJP<G@;/F[W4@4'($_,Z2G49M
MSI2^&/FGG.C])9$VU_GVR=R=/4O"^U-NN",][.O%;,^"EJ?(K(ZC,H)DXV*O
MKE5C5JDRJ5):69*X[VVCY&3XN\MB4D@^W-@$39()SGSPI^EQ>15)'R7][)RP
M='C(X$6N5Q6J2$J1QQ3<U\&6X*I(:*"29>4;."5TP.6[1H?Q-"),K6^A,PNJ
MP-"MAYH$ST7!K6.E@VYW=Q'TJLY;JE$;I9M*)&%;KQOQ,:8^:WR/7?8YAS;@
MAGW"GD4UN>>.XN,:L@I9!3>U\5*F "2ICL39SI>67&3/9U]\CQ\53,?Y< ;C
MZ0ZE^R7JC-,DA&VTW+U7=[=$KLR3:VW>UTB^$ :OWM9-OA0G?;6UE+UN/L%#
M0=N.*RD,ZU/VB1MRM;CMD;82H'.G:%IJS]Q1"15 05HYR<F4)*80P00;\KZL
M]0LG=07N*<Q;3_ECR,9<RUG >X&HM83.2EAJ0>;6")&LK\1D3!>@4Q@KW"(7
MOFE2_IW&<F7=!@[Q!JMPZNB?JZRJRJO%MJUOE.ICQP>Z!A'/MD)^=8E>KK;0
M<5W3:W8T.Q,!/K( 0I !GO+LBJ0=(P8V!+]-P?A_B0J9#,/K\PEK7W:54>LQ
M2UZNMF-O@V+-(KPO:9,4H'YK%;#\BK36?^>I%3:9>.$9#8QG/-5P/3$9<6"N
ME&XUT-VL*VJQ8][H,ZFRW#I460Y5EO\U59;=\853LX\<HY0@V#? R"^Y2\10
M1ELC<!MQXO7RG0=W*GX@N7JDWV:LK5_L@XAI;5)1X"Q51"M389(2G^LX,L[[
M;#GD52(#IPJBV3)74B<(^+8XMDH3.8POU".)O:Z*)<%W)U68@(2T*TD!ATC_
M@E<<'PRW]3*OVXX8@ZP6V]V4S\>C'X.S4B)O)A1=%L"QWBM??217S2^\:FTU
MQ ?!W<LK<)<TN<'HVJ!^9&RT=L=N0N8Q"T[_>'6#F(MS/K0)>($$[%()5[T;
M(?P#T'/-*LBM@+%*O%!2"5D0L5I"IZY\P<F[&G,6Y4*(&UZ4P30G+PIQ0M>.
M!,L\*RJ?KZ%<;SB!MI?83S&:7_7E[(L\Z[(E=W8L+N67GIN 7PFIHVK9/[>6
MF\,&(LGV\F+%6:5)!M+2SEK'F90]AQ:*_G"9WSH5(59WTMY)L5$]KR&V3]R7
M:T;"-1^W1R*]F6D]@T?V-<.TF/Y-G]WBG=.JV,4F_/]D]SC]!9K8W:-0BCT(
M[63&#]VEFH8=*6K1]AEZ*C]4NJFT_L??$AG>W8:!J:'<R#(8FYH%]2[*<H:3
M%WSN<@HUB$B(/OPJ'-CW>;Q5DM_R70<R")73005(GS]N[9N4Y7)6DE'57T[+
M]3:2O>Z*0\V9CHF$&'U<1P^7"+.G>M<[R/('Q'C_<-KLCG=PG8/F[M^7(4RK
M1R_=NH2-00++GW#J];DW(Y"Y]-KEM!9MHFDGM5!E!:0KUX6X!*T?K#A%PJ8,
M*%Z-,:7^TI&J'@^;,D5K7(0C6Q(2@$JVFOXGRM5XC232XB\W=5UDQN-,X;KN
MUI_?5)2N\V\(NS?=H)P+4Q6S/HM"^%32]#\0)J@=3"]+XHU,54A1\PAQ<PM9
M2,\A@LGD[?'R+G9%-S^5I_,_VQ.]=J<=]LV*D^J2"U3GQ>:$*&$+V%Q^$+VF
M_9UI6M#X+Q;EA-XZ\ECF[T@Z6Q)^R;@I4U0/[]><'$W:M1^P37/:I8:KD:'B
MS_@%X)CK;E852.&AKP25@.K6FKUNRIGDV4PU??#IV2B^"GTV_+Q4/439'X16
MKJJR(GYA:1?=XF&$?:Y'H%8FM!2K7+B@1+3W:O-8ZK ?I210V2!G\4O+RHW&
MT'4>6#0P@RV'<B]W?[%<9]C]^K?O9VSVQ,J\_WWVKW+3PSCN" UI?H/;M*KG
MK(.^U?G8LV#_7[9.%&[HB#F_P[MS4I9OK-PURY&O"?YC*O7L?H%Y85$KY']U
M$O@Y4 ?=,J8E[$E.D I&'?][13$*%25R*HU091%XJS[3R;B]"B5[">_I&V<;
MKK:ERI;=,5;Y?,.GG.(&?A-;L<KB5/LA)@%3%2%]5ZH,);-4[9HR[D> J@1,
MC9\+#OD,%V5_PM- 722SMT6MT5JX#>K2F#9%4,+)K@/%R, 9^:4S8&5+=7Y2
MSMCTL2H1VB(4[M1ZB1@3X0]47D?S]Z39-QJ0"O<Z/MW'?<JV@ IZ%"$QRJN(
M>2;LE8(]N@5L<C 7;Y$\6 PRUOGHAT3,.5IFS&"Y=_HTO>]N)J6BU)<0,_S\
MZC]/CA^<T,N$_SQ[</S@ 1U>^F"X'FBK<$L5MQ#I20O[Z:>LGF7_PW73]Y]F
M%R#.%QL*2!O:E#/ZY&S#=[PX:9-\6TK& VH Y4+UA-&O"C5A=^0F59D9,)XE
MHF;$(KO5!R8:,2U3A<M<QN..F;]Y8\>LJUKC.)E+X'RY13E%N$B1N8/KC**^
M-$UMKC3^A ZIC(NCXX0DQI-)'G>\IC3PR6OI&H45V"QS R6:+T"$-6&OA4':
M&M%G=!5,CD5Z5,&=XU3KTSDU0M\#;>^AYYR+4]2L&;& M(56.;'2O,TYCB"V
M&  #8!FR^C(<Q/+JP+%QV%0[-A4)CA+%^5*I# C1SY>RB!%FT^!]<2F3TME4
M@0H.Y-1$AB^+-4>KOY5%<,*H3D("[)0VV)A.\(&#Z[ A/V)#6C&03%M"<85T
MB60>WG_#??(XE-L'',H!A_(!.)2#I3U86@9P,%34TJ_4P+=D?8:M#Z:R5;;8
MU@=^P,.>VKFG7.C/40H'N*05ES<ADC[LG\/^V;E_LF)!2AC:Q1-B#"ZT@>6&
M!0>5OC0R!,! U490<]ACASUVLWM/DR=2^&@TIPOY9(>!M\2D!KV'+7;88KN"
M6,DPBS86[1KD1()'_R;?1D'NPS8Z;*,=VXCZH3,NRBS*Z9NCS=KI>6M%E\AP
M*FO>Y'N3NCN;C+OYJ'C:)+X\-3EF"]Z.CKFY\\'#[CSLSAV[<T8>O93:5_F%
M\'* D@!]]Q-JL=X(?#P*'H\[B'Q)V6G][;#M#MMNIU&,A":1J*L6O*(0*+>W
MU('0^["K=NZJ*'KL2-(B/0_MMI3>ZC,BTW8T, P?4\C.(JN$A*?>S,(S1RYT
M:AQJ11 1+#G2 K#L2^?\,]45K,,-5%]F5<Z<=LS\9T0ZGD2AG#>$C %=2.,=
MJ.DB(]PJ(_:X&UR;QYM+P@?&!T5A9N:]PM<YN*Y.91N:VD:S:%O?%4BE5F'&
MB6\,S=J=T8P)5L?0(&GD3SNZ(_=Q>C,;5COV^4<&AMB98A%R@N!UD!VF269*
MI(V@O*:MB)J957+1L2'F"6F8I.%[ !E1<$KO7U]KRXBV,7,U=*?AZC+'V,,Y
M)HQY;(8<=Q^^WC# 54;//O5NZ'$BWMJ"95*'/Q,+$((K?C,U]U//420;&.JO
M7*?P8J45:,_.3<CL^YJ%Y#7_V&ZAOZ!1F:"H2EA&Q^ZB*J^:2SF1"5NCD"RH
ML7H5S_<CZ6JF56F(2R02'SAZR;!.FVE.LP@243!5&5!UW_",<6:$C'5@@HR,
M-3)/ZC[_[^??OA(*V# WLFF'IR=_ER_7PMI%%L-/CB>S)S@<3FG'""?JX/WC
M99R? .?&K >08/+'T@_JEF>F;:&+;43Q9N$)#:#+1/;.EB 9<7BS5XS1_MM_
MG-X]>7C[Y+;MG*R:9,$0'CU_M\BWV#WA-V<G)V?,:%IR"RPXZ8@,!!P;@UNT
MU>C$^.D<9+;T*JVQ<[/&-8,?&QU4;;>\"9)E,$UXKM&&1@VR\'X,*B>\-G5%
MA*V>?=JPYG"1ILD0 WYJD3/,1,8 >NS)^C)JO\$E7#,C#@+<E/.&GC;G28N]
M)-(ISU<Z]3<37=],+DNF\U/8)W>C=!R"!&O:@T65R_ZOZ75[#R2U(P2UUT%7
M,+IGYXM-OIIRQUG?A$O#O"Q66?75IVW%NJL#%\I+X]C?7%V6K%-![LJLO%I=
MH"_XI@O"Y'&"TM9%:']9[+[N;#+[:J"%6>R*XPYJ2HM;D&>A7*G3P*N.AA1J
M:D@=RGCGB[*?. YC?&!3K=0'8MQWUP>M=@*>X;9]\MU.KT&:L<#;"E<E3^)<
M<J0XT<$UFN8%^=O7?7:>=#FPGUTG</Z!EFZV#7X!]NP4O]*$\74OJ/KM?)GS
M&XVU_P<SN9:+)6OD1' RFF>FG(8C/=XQ37V14K2+'=H1ZN,KJMU^O#!":@*\
M)!81 *E;#OYK_:8:W#$KN54+S(6\L/XQ_)9YE:-Q(YPCN#H3+?W4FL0GME1Z
MBCAEX37#& E^HVZ8BH>[+#_,A+1O)J0PW.;4]67984/,6[.FKG YY.^D*R6)
MAXWFDGH Y4T[2YK.C>\59*X:5Y,(GWRY6>3L-IW>OBT]L?J3>R>G@R.W[DOG
M+VHE)+)8?":<8G<.6,X#EO-_#:<8$2 L\^ :A2.^63(-$R67M2XI-#%DUZAI
MC6.FICBB@!/^4F2N5\:CFR5$8)^$UF4^<DE %$[)%:?V5+&6:G_VL,'Y%^'-
M!0$5-:J+*(OFK[AK[D8SS"P[!+1_SQ7Q:R!=XFRNY:J-TIC$MCGEE*#T(.J4
M:V:&I!O@BFZ$Z.>"$@J%)IV/ROF1_B5JWYGCG4V$#/Q. +FL<GX3$J,JWBJE
M0#L)G*T2T1GBBLU9,;:H;#\T$'')ET68(=F&H =UT8TT.88[=E;482P5,W3U
M<(?5>?X&OS+JS8&Y09ZWR7%+PL- ]"-B9FXV>"$G)1'$T_N&Z9X*!7\M:8[@
M3E2@A%#/0ET)R9R*:^ G9XP4+E'ET=N*NH!,"'E!+LJA;:['AB1YWLGTJ2 &
M-Q&M26F _A=/HY@/_PA+L\B1XN0]O)"2,G9AL<Z89HTI]IGY 3V5H/7P:NJC
M_]D$JZ/Z(N%Q"7U!BICP?9?!!),JW,QXS\)J*#>3_NAMR9D^^:<U?X<ID707
M1K$HPEZ?J:R#>TO9Z43&W28,O""=$G4*G97J8\QJV:F$+:-EPD+<2,'T2JA<
M8,E&+]KK:*QN0HDH>@Z2(,-;3K,%$:4(=],L+,^6:;B8&R_3/,?P-@9KX1OD
MP%3W)E8?> ,993,'T/V[.42>K!,UM"U]ZZX/$5A.FEC(E-6C-/YK*7/8S4"_
M?H_;05?1L^*MNB%,/ON4XV6P@VQJ"D?"&\EE^MMF=N%)M-V29J:")+WE])\K
MV$CP6+MBD@1?DK:@-6'RFD+M 3*=]!BG'TD)>-KZ)9-NF"*;-.KO923]/)TB
MI+]P5Q%E8S$3CA*Z.JJ\1__5=]4G,QD.!R<IT =W/**UPL,MT]NDLFJ@V@3"
M6FE<8M\GCAAK; A/=EU;.<V^,H-D*4,NR/-8,PU?. &D!/.Z/4)'2\A*366U
M)ADW"BTK8FP23TXHH4+H3JI*;<[K;'I9Y$S5#PI4\4/FA954AW="=TRV_P;C
M>#,-.W:HOMIZD4VY8.)::).7ZFY:_):3>$0Q]"F;!RDR0;QL(0I$2RWM=JA1
MU$N(Z7%G?6G-U/K&[(!=MUSV2#A;R-"$7Q<KD)GW4[NHSR.W _;@JA;;)99<
MOW;/S,;O.+>M%[W)_+[7Q!&M6Y:.3*F)\,CKQBY,^U?A\^"0I\L>0EHY5:HR
MSOU;S;'D>(%,GI,4%!XD*IN-*4])CI&DW"BU-XX%;ZJ*I[ 6MA<0AQJ+HL4
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MD)6=%0NSA7!?R+PA'3;;&/ \6*?(1!O)S6 =#,<J%+1[YL+^DG/>AIO]!?9
M_SOVUY^\A._.-4H*A]6W3RDQH%<[V5F\&@"(](^A#0@6D%[G^D),G_%&;_')
M>0>LE,B2_0/Y(-><&/7$R1WVDKHNTK"?U@&($3M .G8DAK(J 0#%YW5!H>DW
M]'EGG!TSY]GT$<;  =$;.$:$&H42YQ[&24[(#<?6V\&(N>;2KP?$M.!\*!^4
MY9N(M5+8VU>[_,QKF(ZO>"7X0QV_9EXL.-9WST/W7FQI2!&?<9G+R@=)J8@
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M:4-UP=[G7ICL9W,-#7=YE3.FA9"72WUR=GAV+,8XHE7#0]?9-ECE:#O4J?U
M-]Y3R466)_I4S+"7H( U/1UV.1Q\AE0 ZKI%V>YA-J[C?8A' .T@K>#$)RXF
M=@TP_%<QC3)>?YP1@PI*R2W"6"GKU-'A?*Z"H"G$/1Z]RO,4%'3B"'+#X;<
M6:!"K\,7N'_^J"D(3/U3F?IG//7ALY0$LZF7OU''[ZD$D\]B,'DNJ,:7=#8B
M ]8G&T@_F^OF9_AYRT4/!X$VQFD:'0%CA<+0A$6HZ9>P-]*,*L^2R_U#P]D]
MBV9O-%-?:O0Q3@(HM,^(=AUU=W\U/*7NIDC$4ELFZ"L7@YD^WKJ\HDR97X.N
M67*#SO1DI;@?AY\S?IX60!0)4/EC[0S*9Y9^<7&4F9TPS/.GYV-U&:ERL#X>
M/:(?LH?0&Y<R\Q!%0PC1!=/$,\6[SU[<=N%7W-*N*-LKNIQOO##AH==-BAW\
MQ ]P+IOSU*55YNFYRV0Z:VE=ZSPW'$ZI.71EUR;2>7*,Q<!8F3#3VJ"@RE*$
MZ>Z,78/IGVPE";8QJ*3[NS H2F&.!J>"0TU:PK[#;F9ZZ+SKC:8UY*&[Z!>#
MY,8DNLOO<J-!*U4J TJ[#H?7-"J:((!;KCT@GUX0\W[<SM[YK]*)Z_.H[ EM
ML]HUI]T-_=[.W[HD%QAB=PS=<]282JPCN8/PH$A;D"KN?![=]/=/#V7,0QGS
M \J8V:B8_=<7OV:SNV?S6W=GO][-[MS]]?;9].ZO#QY,LE_OW)K<SJ:3V_EL
M>N<+_E;^BV>OG_QX^]E/3Y^__/'1ZV?/?WK^T^OOGYP___'%HY_^]>O=^V?W
MSD[D\[_/M'?<NNO6P7LU8:RCVR&(CL,=A?\7!CR2$6,J92KNW+IU[_[]![=^
MG=Z?WO_U]G1^]NO]6W<?_'KOWO16/K]S]\%D,DVF(KO]Z/N"#.4V6/?'D?&K
MG ?+([[TKW<?W/F+YR/NR]O'C\)%S4/&C>0&;::<Q_V7^J4GOLKR-)]4FW##
M:07[]'0<8B02:<XITCD>767U!Y!19>QEE/,Y0;1R)50VBMO]F8#'X8ZG%G8_
M <0HZ?A_=#Z^_+X,K_#/\/]]-?I!:<A(CU1^;[^F2LE5>.7%]HB])^<Q73.7
M_AGUR.C3ECG_=7L>1WU+>#;N#BG]7GNC5YM_!_>@_W7X=V-KAZ;,!=.RL7_,
M38A+"KAFS+4=_(.LFEXJTV:4MXQI>^NMWI\=\"I?-^D6N-?9 KO64YF)&MPH
MD4FITQ21G"Q;#'$:I?IR\VGLZ;DHB;.!?.),]*<)VT9-3]O.LQAPC.^<$J?2
M#$\0IFO$C!1G,8:#=::F>02G!/\904JRJ6J*4*CYVD<4)8+VS%%-/=H0]WOP
MWL>C5V$K9^M2] U?!9?YWWE%!F1?2CC6OM0Z=SR=I>@K2$"H:TB_M]0_M:Q+
M@<-3#\CZO7AYGB2A-3G^\F_9<OWP\74K/HZ3R3.H\XF5BDR:\W*ZJ9-BBQ^+
MZ\$*X[%#GIH!Q%%?^IOA*R+DEZ@4S88:>I+!6E V;H.]@_*E!FE$2L#:L;%
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M@<Y%B:\J5V+7/8CV]YS7C\F)O&2LAK2"4"+ )0%^[S'N+M"]3R9GV4[T EE
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M8\3S[#WE6=LEUNR]'S$-K-PT.C:F[5.8\\MSTS8!;4O;(G#BP;&NV]<'%Z\
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MS2UF1:?1%K=+6\X]S ;(JF(NI7*I?7-'X,>LM,.WJ BIKK>1R82V7$=RFJ+
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M7CUZ^L27T6AG,'W)A#I(+LGQ\CS;8;I>_@@B4>UR291(6\/=BNLBZ5_Q38S
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MFQ5]EHN)T5R71&507KG79:."+PNVLRKSU=NB*E=++=Z^_O&)UMRTC"G?4X
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MU\%UVL*RQ&A9[3[S%;'(5,2VCHZ?_2<\)IQ"W#\'_;WZ!L(@5EW.>@]B@5C
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MJ#K"V?:?L+$]]W76G>9-LZTKMEX'QEPFX&>7+'T11>]2-*=9-:,U95O%*-]
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M+=HJQ,4\7,MYD;?Z#VM:%CBWL)KY)OF$'\:+(A")MWM V(:;>F-^._CVG(8
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MP7#!0!YQB'>"I<C%$D$F9["=DKFJI ;?DP\?P9CAG]T'8]YO#4)>_*Y_VGF
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MFLX=FT+FZ0^\_O6(!.<AIJATJ6;X6.ZIJ*GU4?M+47PRM$:><0/.+WZD+D+
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MG/4+6,0.5G!5+=(S#Z^4F""($0W<I7D-6@INA&,Z69+R6WMHG]\GV1E2P,J
M^(MB:;0?=N:S8B-840S[WI+@%(RGBK[I.9Q#W?HR3_-BASN@S 6X!6.SBBOU
M8J)CB46]A 2$R\L-"TIR-8%-(QD M'H9K@1V4"7#CWO*VZ )"(=6V:0-G@::
MC>M+I3/4&(2:]N2U-FLM;1NUX9IAK3A.#!E0E!160>:  7L/^C%3_7<(>>NZ
MJ 2WUUCQ7!<H@8FX6UUTK]&&*L:N<AM+;$I'],SJBX^.3FS'^UF:S5%51],$
M8X[D'O-*"*8: KL[5S6C) . +$?@1\#N_4FTED7C,C&G'^V]*AUE1<Z3A4LK
M;'\AP2"C4#8U,#MR[<W-ME9KLU[#JXU6^(?^&%XQ8;.30&/AT5&O[0FJ1U/F
MFFTH=O6:ZV?<7 S)B0T"[YR H;'I)_QW6DR:T,R(4I1MBPV+ZEE#0LR!UI 7
M*A'GR ]$8STY/4KFZ=6VB)CGS(.Y+H*J)]HA5:+-U%+US<Y^KP.06YS>O\LF
MRPGU0CV(*]X&G +WK/*IT?+S?5\@@Q->N7J&,#&>TPC4,:I##'+^_>DI4OZ[
MDR/"C6-6^[V]_[V;'/57-N=5A$X%&,[ESJT_23SQ8&^()P[QQ"V*)WYF%.[)
M#Q"%>YNN-N4^WR  MSZ:9D,CMLW8=?&YFP:\/CO6M&Y"-PV3W6 1[5C9D^BA
M;L!,H,CV1\^RHM6*\<X9ZD47:78W><.>A!!Y-$^&,=-N@Z#>^-J-%J3),L&K
M\(5A-HV(;@RW15%,7UOAK7P=QQE]5,Z68>B)RX5Q-L3FC&O_V\?GS,;O1J=P
MFY&Y%FF0YO\SQ>7LOGVWH%R'MKZQ![I#+)\?E>M.^;M'YL@7VQ>..WW[[*$O
M^W4'DUDO89A<?<=E\2E;<-F;/\[^U][N$ZTZ=K>O-%A;L'QYO.YSHH3QEBLG
M^\J07TP(="T8R%P%T.]-(F/4IC;$Z *A;8F*LDEBK0^"W9PS#)&P(1*V(1)F
M">E'B'WU\)EO&?_:<!M_P2!8Q'5:Q/-CA<.BF?^T,3&KA&^)N(L"8^MLQV\<
M'>N84D.$;%LB9.9X)M\I4'8#E\%WC);=*%BV[EY]8<1L")/=8IBL1V9^78PL
M$LI?'!Q;1S(^0K:6IGZD,%FT5U&LS$>9J"H"1<Z.SE[N[)^N#YT=//CMV='>
MWD,)H"TE(F9B6%\<V;I%__[&[*#/V,=N'*0=]?C".C(=)\>^:92*M$L?'6SN
M3G)MI-?SBXUJ1\ &S#%G,32;_?%#C?M#J'$(-6Y/0\+U%=O_?7R3-\+=G4__
MORZ+HTO!<A*VZ/=FB=8C,.:H$7#RW/<&.GQU^N+%VQ?O/L#&C;>EL71$"%<7
M6>UVX).)^QV;PU^!WMCMJ+&N6$OP-T1N'.:'H'3NK/O!2*P4+*2%&A7\EYBW
M%IYT^0754Z#:F'X[397%.4B\DHQV^,7SDS>^*ISXKD24NAPV0:HP3](EJZ&A
MOBF]*R[?3'9#'#_DBLZ4"/:!2OB@Q7W)X^B$R8U-@JDI8R\3:?-5#3<IJRZP
MN7(^#14:N=,4-U6B:P&?7V1+F=]E"@9=@V4&SN']_S1[*TV.QYU8IY\KCW!U
M ;N,?I9T15IL[DKU:,T:K-2SF_P5;<\C%DOD:>EU9RW![FNKPA3Q094IO8*%
M!*R-P%Z*WVD1-7$M%3TD)G:(_):5^UW_>/HM.(Z*:9S\4R,0\!&:U<X\7<&]
M^'V6?7)3*R!4FO$-K4OX_ZF_H_PSWHM__ZV>VB^_:AEPAXAL1- S>RN63RU7
MR OB"682<IHRV7_[UR</'SUYVIY7_*.N\+D%6,DFR?5WZUE6W\KS<C<YS<#\
M*Z=H^\ZGP(?@OVZFJN4;_GW!8?\/R.BQ;&C-AMGQ8M'DA=K6H-R]2X7COP:A
M5R=O&G)_3)-G\Z*8)L=Y56=U@TH_7CU]AW_(?T]T#4/,ZPLJ]O'N^/4H>??Z
MS;/C$?GLT?QO3(B+&W\Q4[2VFG=7)4>'ISL?DHEC>X^F&\P!=GR0JR:Y:%#:
MN7Q:@!6-K ;L1;3CR@9K[(! J*H0'+<>;I+S_(:/V31'UWJS*,J*O,FF;Z"T
M/,QA<#&'G&UG& /_V%V_ #O7Q/XBP<$&(VQ0 F0)0B"=,C_,&'F+GEN\^QH4
M""7),CF:R5J3R6W<M:"O(YG_AA?T-[K1 [L9V(TZGGM;7401U@ X"9TD6[4%
M0RM/[[=,^7*IR]+6%/^0YNG8):?23C!P,/*)8I_:@7 'PMTH)R_2*88T/ZJ4
M/')S:@![!UGLLS*KZF*^\W:%?OFS?S39>'S7%YJZC-MY!LG"1?KQ*Q@*I9>6
M?$1O(]!FC>+!JNT#F0YD^KGJW*MY^JDX6\"?_XD'F-RA>,9=TJ%>G?VG#S,C
MH(-@F(Z:$YZ#V1BWO[B EU&:;IX1B,T3M#+@!2;V+['._S*##66-C3YD;\#"
M+<;P7U\<_RGJ&MM,T7L#07]W@K8\]V]9FI]7#5@!^7G99,E;-\TF2--'TDU*
M@,M$VZT?MRE<6[!Y#CTIBZK:P= >Q:O0.9W9\"F#:#*R;G:TN]4&AMSO]"0F
MZ=VM?U6,80,Z_]V'%V_>O#CZ\,?AF^3D]/W)B],/_[,E+KB3$EU.UNSI#\EE
MZ&#*IRGJCZGO:C$O\O,=JDXIEI0.,D8Y"__>52#3A)N&$&)'?IIIH1$R?!C3
M8:*STAB8.RI*\'099JM-"%H.,YS51[B(.Q>@,AB$KYT4=KJ>N9R!4RZ'D<2_
MMP8_*"!R<H\MF4_;X7Q/R2R?H74'_S=*%EE% 1]0,0A\2->%+/8K!'5?9H6
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MA]:=J(M/&?IQ@0=.)F ?B?]:XX;D#Q?IG<+?JRK#@'QV6<R)(5"DW;/'7G:
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MV126=T<"PK-;M6PD2)B%<H\D--TG,1TH-U3/8)VH8YPFIXNHJ(C2:4A;L&J
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M$+F-=_*8NBHM\)76Z<;/V-Q'LZI3NG6M_O.SQ/7VA[C>$-?[;G&]VV]1A2Z
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M<YX1>;&]S',"*$VN[Z[ O,N]2 N'\#*L4U;M'TR,X[0&>:/>C.!M!.:%NZU
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M?^SM 8\X.55LV"!1P.9VG'AA*AK':0WTM<7N,9:0'S!",L6F&)H[T//V4/Z
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MSW].O1O!]79G!%YCWX>)X^$^3+G\IC,5+GS2H)=9"CD(,3_@EI-)-5'3-SU
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MKF;5R&7C Y=.!G;08/< E?0XU,-$76[2_.A-06] > ()R(6@G+'L>OT)HB1
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M$)]8W;FNQ%(Q*7XJJ>TTX2OQ,QX+U54U8'M60>VCH@Q$G)+<%7.FN")0GPB
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M5DA3'S);P+K BMEU\6T]3.ZC,7B##NDF\""S*@=SJE@,\[^R&(M9FKB(0'[
MOO-!&G0AG4>ASH^@+]4\-_5&L3!G6 IU79(&P@Y-1GZ*? W)Q;U[P7#&"_8N
M&XIB'U9B2U3ZRMB':U5,>7C4%MX,N;+$ #WY4N,2RWK>4I^4T_=N7X5_:*VO
M!<F&@,42N&SG>,]_%[3B^RDZOMD*%-"C) 5EZOT)]NY[KHS]"Y2=/K:TDG<7
M!:IL+ J6,0LD58](=F?MLM(?6'+3+X%\W_%!2WFFJU$M:YV8GJ2$8EU$,PJ6
MLG(FH[PXV#X^_-:"^4;Q3R,MS?CH0YO"V2N:K_XW.>*_8V7H%O;I7CW$A)W=
MH]FHJ6;M,O_B*LENA^;W7L8DOK.]<]@?<S #^2"YS!_OR@,QCHW:&8>>!PYJ
M**:]!U/='-V3/+KC[1?[FZ-[DD>WN75/]N@VM^[)'MWFUCW9HX-;MSFYO_+D
M* $PS,S\+)-@??;IJ"_6_,<W[D_E4)^]:T=]FS;H^.[?QE$P";MK! 7[8N=5
M]__^Y]]'X?Z P8N;]E_?''[S!_=J?V_[^/A);Y8Z8O]OGM7A!FUNVU=QV_IW
M[9$4]._<Q\VM_.8?;]##M[F.F^OXU^_C%[N.XF[6 J_%IX2:6"0:E'["U]6Z
MXC>W=G-KG^H^LE_I*[ZH&";KF $;FMO0W)]+<[L;FELWFOO:26YOHX=L])"G
MNH\/DPGR=ZK[_IIN[T^7?TLV N,[G[:UH;]_-_UMR.\O)K\-]<6J2Q1;W1DX
MC,!E]=*YK*)=^,IUHO[:U8U2M"X;N0EQ?/./9U3,4+5-5DZ:YU_"6O'E3M_]
MQWB<Y]/IGTIU.X^]K)R?_\5NU+]YN4_NDGV6ZK<&I&3VEE+F[=;NK]S:(5"9
MW;UTYWCW2W/VKX8.U] "_BK)<#\]/-C_&JGPC_*^O]3,^"I);/<XW=L[[FS5
M^FG\?TB)V/UR2L33Y-1KJ#%\!9=F/R5$@8W=MXZJP%= 7[N[Z=[^TR>PIRCE
MOP;J.4SW7G:-EZ_75;#S9%T%CUZNYN=OS*;5UOOASL$3MYLVI/&GD,9!^O+X
M:$,:&T,XIHR#]$4/S_@*[.#SE3 J:0^&BD,1;)Z$[OE7<\JO@/@/TY='+Y^2
MO;$Y\\]W8AREAYC\N#GT_W],PX.]7L?"UVD:K@RJ?ZB6V>R+)F\]Z>T8J/O^
M_\N &-Z@01ZZGQ[N'VW(:$-&GT5&+X[2G>/C#1G]662T'MOQ9U/1T6ZZ?[#3
MDQ^FG>#^##=_@/!\CU]_@$#^@*/_KP=#U?XN2_@"=7  DQJ;," D;86(PW<)
M(A,CM#OW6,BPO4*JX+J$CBM_-R#]U"9F.JWJI0#/4^.=$;9H0/Q81 +F]KK<
MU9G;O%D\66EJDPLF<)H44VP"@8CSKGD8@\UCOU[LG78-?T*8)08;5E1?@AA.
MJ7_$($@M0ML6!%4K&,]E.\_ACC5)3?V-<(T.Q):[4T7-/F3NN"'8VZC3*\N_
MC=/X[K' K)N.JU]IQTP"MQY7"[A/U.:$&Z)08[W4=;/CAA#-<K#5GL47EEX.
M/0TT/#KVI@WPABCO(4JEM[#_B*<RU]I#^#]W6:=G7/\N\U0U[6^>OB'%#2G>
M1XH@C!%GA;C@=89=<6!$T#C&C>D?9?'4M17>HJV;-M]0V(;"'L#L H46=A[8
M&'?Q[&ECN>%:&YIZD "E3K&^"8D5D]2W+@7Y6G_,7=_LH!?L.%MD(VG3_0K_
MO,Y$M[.AN;^>YK#S:Q,1':I=07/)U'2>K+3=BVU/Z>0GFM&.9JU%R\T8I2VM
M;X5)?4RJNVP&1J[O?(>-XZEKWO8P_?8W]R)&A@1 <,!KX"E!_0-V27LRB930
M76:O1Y-SC^?13'M(2TL6[67TL+8Y5<UCTNE(3U+\43I-][S!?9+G.9!=EC1
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M'R8\P*TL_<-XC)-<&GLA80EN.W:Z;)G6M+O30'.G?>D'5N#]HDE.BNDT)TY
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MJ%@Q]:C=U9:CP6CKN&>=@_[WO_Z/?9["%#O"V_/)"^TF6 =5'V^3(7PACT8
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MJ2P7X*B$)82"0:2*=Q4A*FW(";#TPG!1MN@U[H(V>&J%!-QJG5M16U6"+C=
M!^V88:%-/R[0]S"?-TOE"_T/>X-H+*FMH-'@L;&A35^RRT2>Q?H'MLKHEY+M
M9M6NJV>6K>4LT1O39V=;:;N[H,<=,@77U\I;EI"U/CHK8Z!/71&N_YM*_%^P
MH7L%<+K6QE1> 'U8/RI&8%WDF=RYN;FS>R-WNC92N!1WOODPW'CAO49==5'7
M;+0V7BBO<5==W-5LM[>H@[UN;/U5XZZZN*O9;F]15VN[A\;=#5O$7.L65 A.
M*YW!![K5?9V0NO\KVN74QFI CDJ[*)>_V3UVR_UV1V4 @=N+4/OGD]Z36P*K
MTVVT[IG([AM:KZW@1LJI[S*@:KX[$+Z[KJOI-I3T70&Y,_ZL<D.*N_'ONOX4
M=O%*S<XU.^\Q(-GR/EP6?O(CUT&/:K*K%MEAG.7 R:Y5DUWER.X12+MV;9+4
M)LD> _*Z8&#UF?"W\[_5HO]!NR=>F\BIB:@FHL<HB6YG#52]>^9&&-RB>FVG
MC%>%YK<':R94@3)O-KOJYN'&I]VV>]SMN9UA^UE-F?M F<V*C,^X=\KL=]QV
M\]CM#@8U9>X%93X:F=D?NL-^RQUT^\^J'@^YL;ESXN.E:._KB[UP#FY\O)V-
M::V  7\]<>]X:/&!X_.AO?H#Q.<A3,O8"TYWG!+D[@:J0W/D>:;;^34W _?5
MP'QP'5B%\]['H!BWU1ZZO>Y.1SD^-OK8!V_UEO0Q<(_!$3CN[7"J<'4<U/W4
MT0=*:4VWUVZZ[4%[1YJZ(M*&U?+)CB[A[X4]_/"ZNL+U*3MBEW9WX+9:G7TJ
MOWAX%?T(R&+@]GI[116'I)@/G[Y4J^"#=Z:O#9NO[ ]TZ)GQW0)PS;6W7=O&
M9:[L %?Z<8X8JB1;W@2$:U,WG;;;/NZ[_<Y^)Q6K36YKG/Y'2&Z]KML=#MQV
M?S%3N%_D=IA5U;5<+ CU>.AV>RVW=]P[O)3V[_0<M@C%-L<7THERNF&)#9%+
M=HAJ1,R#9E4+.=UC$OLV[(77\. AAKUECL7\ZIX42#]X\*!&>!T7J*"LN*[P
M;@O2^7Y6S*%%"8Z5I*&8R$L<N[&OMN^#Z],JG/<>DEH]=]AKNL?#?4^?/KCZ
MK<)Y=T\?0!O-3MMM-H=[3A\'I*T/E-*Z;JO3<YN#[B&FUY4*?L7SKO;"OGUP
MC7L 1'U_ZO5@,5\Y5[9JBK/6DH]%>NQ<)5;!<MAA.GMYU,@^9W<>7-]6X;P/
M?P^G"E"H_=8#Q_H!Z=DJ0&YGX>2'B!Y71+K<8ZBX(B=\!%[J9F)?6W;0;C2Q
M[\C^^"D/KC4/ >LX9WVOL'Y 6O,PZ*<]6*:?0_-,[S5^6]UCUR[F0^O/*L"J
M=D2KJ66KX'3MI^(]6"I;JXN?TW6?[T &&_!^%[3?Q[Y+HZ$7][WFB/NP]3+(
M=W<0X03^/Y]\Z4NO-1JW1E\&8V_PI=L9=KX,NW[WRV@P&(Y&H^..:![#CIX+
M_8;HO7P;_"</?/B B/Q3,0LR$7Z2:9PGGDR_M+O]3K>C7GGXH>"]QLN&8S9,
MP\#5EAVSYXH,F3\/(H_GR^,_Z *^ZUQ)9R(NZ:><[NGK5(E4T]KE!0U'=#R1
M3IPQ39=/XJD#)W/BF4RHOCYM.+]+Q\>Y\!DUY?$RO"MX(2-\0,)"<R>1ES+*
M);\]2V(_AX=2$6+M?@3_RY_+HRP(<5/Q*!-!!&]=8 U_G !H9_#6)< 5GTOS
M42K_D\.IPSGV!)K*Q M /OX%;T:2+@C !NE(4>;$B3/.LSR!/2;Y!1PE\@,?
M-L;[+C9,0'!0H..IX%/JA-&%!@EL"0$826&6Q.U8T(!G55NBU+D*PA 73:1(
MX<$4#X93W0,$!'P/'M1O)S*%-;T)+><#K,)X-L6]>V(FB-T"F;JPV*5,,[KH
MD$@/J '5F0,GR1A^Q4\)@(-_,QO [X#VBI.,#L(@Q@VO@#* YDUD0.$BP/]4
M4-KX'H(>T:TPH!%=@)Q(;A'D*2BV8 P;QP-;V"RU>4H=V'J9=%P'R/VK)*CC
M48&%\K'P "_P2\-Y%R<2YW^N_*:%9B\F^*5I#)_%^R9703:Q$ J8$\XL'X6!
M1PVHX("("B_,_1*^:9(HO [?"(%O0M<1GA<C34<7K@4MW'80:2CBBF$@D#GI
MN_*;-Q'1A73"(#4G.S\[A05 S"02R0).[L,_/5B-"7 ,T),);"K-$UH*Z&,:
MY%-XD&D Z29.>(O$LA612A^(2@"8P0PPP1(3J2<T,G4"X!])&;$(TD+%9TF"
MW @D 6:9C_#W),@JZT]!FN8$#A(:0#*:,/G:$!'Y:SE*<LP'XW0>EWD4,"+Q
M&_@H8"D#:M0$ *"62%[(0F!< <M>\7?PGA)^!30(_,,1%Q<)"D_ZY,#M]OIN
MJ]ET3EZ=IT@+,^1XH@QJ$]-ON9U^;_%:$SZ8YF&F/H>RV1P6B"Q/B=V0];X%
M4_@4",/?SO_6ZO8:0P=0&1+KXEOP&((#;%B97"4!+>@'*1&GDAS =G *) VF
M*'@>9)P$0IB)P$<9.A-SN@8^FN.783\@RR*@0>11HES\A 9/PSFAW=EC\1#"
M;:5S?-YIIS'0.Z45$<6T'?P'TCO(%*3WAC6AUAK2ZX4@-=&0GRQ8*AVDKEU/
MZ5U/ZZLZ K>[VC@WQ-XZ[B].VOVO_U,:.FQ\C2,O#N/DA;ZX:!U4?;Q-SL>%
M/.*9QF(,GWXAPBLQ3]7!!X-&V[1P>&$N/R)HG![&T)SBGPB@)>A.Q;<C"X;*
MU3D*Y3A[P6_IG\@IT;]=,UA9(2J+9R_:K<;Q]\+3@@CJ%%@!RW.2R/$_G_SW
MYP^G*\UC_#?XALE4A"5K4?WTY,?/Q!A [J?P5Z178PJ+'[>@W#*85\'OX07U
M[V@DPME(O8U!2J%81?FH[*"K./E*ZDR9O[:V4BS-?R!U"9(]QWN;(/KADW 8
MEMECH'R0XR)(M13G+Y$:!$ES:>P@K7S9',O6*8$- MS5.U>_XQYA.Y<LLOF9
MU.@+"3:#^KCYE/D"\&HH@,]8M9+*?<ZVBO4@_#V)KW#1JNC>E]12$QMXV<:R
M,7MFH6 /823# $Q2@+7(2L^N%==L^HXDV(UHF03X,)#-5,KR O@N&'T!:G\R
MO&Y%1&@7PLZ H\ V9H+XA@=UI@"K2=KX/$'K.\VYZUB*)V;-318Q&%FH.V%]
MH 7N,CH5<T3>)5GI<(JK)$9ZP0T ./"ON;*GQ:4(0F+^8LO*[0-+ 'P1'/4,
MX@2M"CXSD#J;H@WGI?0$+<3:.<K!\(U!M29!^E7[0V#5H:&(E+=DH>)+MJ^@
M]7C9?-YLBN.A\TBW=]' H*7%%,T#?%^[$ 7\XSP+0=.PJ5#V?#16P#0 MPZ-
M&5A8FU1WW7-56 ?LQAQ<U> O+8,*NPR9Y$K>1 XIFIJ*KP49H9](G7>(8M'M
M0BD$;B\8Q2 P"U_TXZ=3E_[Q&RP/GSO/&+<G>9HE %'A.C\#]3J_$@F?PP?%
M+%9^ZSF0T5\R 3[WT5<A7D-+#\@ *"( GHX FO977?SS18*.6AB+U3MKP >O
M)/E=.;I%BKP-A,!^Q%=@X\5K<R)$R\O$ORJ/B2,,YU)2JZ9V\X<WF9PZ'>=7
M.0?[?8PZ&)]1";=/P#S.:X&N46K]E#J?"N_L58QH>YFG0 $I0?)T GI&/5[^
M-#DC^JCDG9/CI5PJHF%X']]!<Y[X% \X'J<3!#.V2-)>GH@"%5:Y0+<TPI<U
MJF-RG5E&>'/53Q'-<2(-'_8^)QN<XB@9&N!$5WB$!0)4O+/.;4$QC(3&9XK+
MCO FXBOCRU4B%%R($ 4F6)_PM9!#8,+'S:,[(N"S'LO\L!0E(^')<40R*/*(
MW2<K)C)2^&D0VEL_8+"&@E5%X,F@3KO_<TUMQA<'6DV%QT\3C<DL"[E9Q"<9
M38-H%#0<]$*5I8%>*+*0TCD)N=+HJO$[OS7.&XZ/^CX!HOP-'2K8L_+4$41
MCR!2HL*-MZC8-9\DK(ZD[IM):R,8U,N*#@*EW(RZY'"" XP^+5E!@/QQD*%+
M5^#-)7LMP7@1>&Z%"@6(^/*(?5697 :>/-+ 6MJ[#3V7E X(?K228%/G)Z_/
MK*A<"A3%L1*ELAS090 519E^GBSI<X#M. _'8"I(GW&P(!,">"@,09@0U\Z0
M$< $!/GL$^970(N]XDT;!>8<Q[@H<>5V6[4DFEF'Q3I&5"X0ZJ)P@ZE'.7H!
M%IL[(H<ML06)QU*K@R('-YNUHB&-(%5FQV;B8#[",$_&H0I2U<P-"EHE:PE%
M<9ICB#%5'*+(HI!P -D8]B 4K2_#M^%\9I5C'PU)62!1IA134$UAD?"2P".B
M12&[/7676%9I.3;5JZ+]$0@%$66ZU6U*9,WN0@ABC_K51]0PD4!:Q-#AOP6=
M'<\V!T\P!>WAPR.+X9(F_6^+4(W1$X8 ?U''#+CI$?D@LU2^T/^P#XQ>MCHK
M>IL>>ZDZ9D(./1!HK']@=YY^*3G]5L)3/;,<9LD2O3$-7':RMRSNZ3:&O4W%
M3I8+;:V/Q(B U2DI_=^4[GS!$1+P+?QK@Q,J?$0?UH^*$: PS^3.XQ0[2Y+?
M*4=>Q*+NF"]OPU9KU.TEZH:-XXTEJC7J*HNZFNOV%G4UU^TMZFJNVUO4 =?5
MF'M(S-VTWO\ZEZ Z<!JLJB9[H.K5ZR14E0?DW@\<P3'&'__YI/?DEC#MM!O#
MX;T"=; #F&YJB?!:Q1S^P JV,PPYW*UK<,V;-6]6BC<?<&#)??.N'1NLN?8
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M0UP'-QKLU&HV!@2Z#^ONI3W\V*FM[M Y5R+%V=K=0>/8'JU-TZ-H?)<?X"Q
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M$O'1@$N@V!4H&5ILLW3B? :;Q7-*M>US$<7C +^Q3.%J?JYB@=4'')0.>(F
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M(0G!N)X'[B[\0X3S-*!0!(ERW&"4 8[H&8H88EH6'>4 $>HZF?A&NW>1GJY
MY-KZL8"+WF Y5G C*?#O0,!*2^*E=:PLA/79Y 4Y]1FV#CIH,?'*3I94LJ2C
M=TRZY&8*XUU!#H7@WUO9M#1Q3U\E7F-/;C6.K>R*(QJ'#; -QNAU+[FT6$J&
M'UZP4G[^5#+ T"!TM$$HL!?-UR@X^AC*;ZYS!>0FJ>X,?4[,7 &_!1A4Q]JZ
MHK(!EN3*.=P_\ZL)P:;YC*OQ2->)N:.M,C:TS!FR*ZP!+$[6["K/FM_8=!SX
M!/P4I.B 9B $_L*G3L4LS2^ [=]F?L.ENA.L/./2%ATHW'Q  6P)RX/HM$0E
M?"K%JH\BN-4HME;BTPV\%8HKY:C%>38YPEA=4O;2\/OOE;@#R'*$BAE,1\2<
M5Z_>6.SS&;<#]L^!Y.2Z=4ZNSLD]6$YNYW6C"W.N]C1&4AXAM#XXLK*D2:62
MMIL?L[:*E*2MJK@*K-C(VG!S&H^S*P%BOI0,)(-3C+ 4T(15QK&7DWVLBLOM
MD#/5MA<;-XMF<8R13(I]9L$H]N=.&(P2K$*T"DRUA5C>?%F1I0PSL[)V0'D!
M++U3[16MXE:,\*HJ35(GB^#B<&:I]K/AO([1PR<_8'W1Y^IZ3[>T_Z).:,6C
M1N$7G\:]4 6^C= F*S2C.7%/G TZN<+28 3MV3</3&2-4-2G;8Q?1/$EAU(,
MV8">I+^V?BBJXM%Y8A@ZYS-)YGRQ,NIILM6#49YQ+,PZX+;J/+!(.%7Y-SK^
M=='=A>"N+E]4V]W:T&>+OJE,"B!$X9R&(K$_NK]QV745E#<3/AOK*;<1-N?J
M]L52)-8N&@>T6?^Y-D:;$<&K2CWS@C+RE@H-3 ZSR+2:PF'E,M*+TS@$%P+P
M;JK$*#95Y'>!47%Q^"!M?&4%+==2JYP*YY#7E,"Z3B3SQ!0SBB@ #0^8!5><
M$_CF'9/6=?Z%5PY$9%CHYSBE4 4'*[TPCK1CK8UN7-(#&H_4-1_OU?L3)6'5
M9TY%B#7.&/=+2"05-XJ*I"^ AZL>7<UZ-,LL,ZP'.Y@BD4VQQC#&U*03Q=S$
MCU91LG>!(+85$-/ 2^)2[=[O^40L>N4FY[(VC A+%*70].32PMEB/?8[^Y'M
M"['+)UU1V;QX?<1=N#7BKKT@LO8>R/X*J14CK=8+J.M&':U.N+=*5>V!56S<
M6FO[7%=2A58UV4A3]'65 )'.5U!8B.1H$HP"NH_#DBVYD,5#RMY14LM4<2W(
M''!-0Y]B\N4J#-IXM[E0=#$3Z%[C>A. [A%(MW$0RJ*".8@NX_ 210$&0=&\
M@GVK<H_)E5!YW@PWJBYH8+C-"$25][%KD)O]%4F?EEN&M'5])5*Q4C@]"M\Q
M*.781+CXTI^V%Q5(2#IJJP!M)8QL.>< X@"8;@+V(]]7X6S0BAJ%/%V['5U7
M5HC^\H$1!*<)Z!DL %A5Q-TB W$Y6[E(:]LF5*SO@B'3WBS-T*A;>*-7KGYZ
M3VZC+297W@ZQUUFHJ 8C2>? 3\'NE1>RN+H!1'E=&;0I8%JBI>M1J2(VW?V5
M:DL3R+:0:2M&5JV19WT,OP&GRQ5E_E9F4G\:OUGDIG5!B"D7Y)<O.;S^^=.I
M\BWMU.K)FU?GSK^$I[*N.F"Y^G;#8%7FN+V&/0M %3M<>7<,?8Y3 0#'_V"9
M[YQCDU,R0XOK<*]TL'(UZ-HKX&-9AVC# $IEE%+*8FI7!2E3"UD&B:FT.Q!H
M%XF8IJP7?# !4RJ1"958MZ$)O_E<9D1,@R(<\<'Y(LY=+&UQ6RER6K[N]5:,
MQ5QF-&? L#"A:*-X*=EW:U.BJ!P13D?O!"C*.%+.5.M!N?8NB8?5L]&(;=%L
M\_($N[ "^I!M[S8UBVD)BW=3YS_V0]/8E^$1N\6 [LUF"#$+$AP0D6=_U_P'
M]1VX3C/2>4%*V'=GK=)UG55Y_E,2YS/5;=^ES>-2YH;5R/"@X0:0+K^(*$TE
MT52IE,+\@2N[7RE^!0+J-!:W=C,=:IL-*KIS'GB3?,EK(!MFE5I<J)@NK[7
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MARWU5=\XW3OE7:G<8['9-5_2B),K>8&)7^MA9?N\?&/N\1:=U_AR)8W"HPV
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M#6PD9S.PS!HA]X&>;"2G-2K92$Z++C:2LV%R[V.G@<=CS1QTW?Z@NTN&FWW
M'VO-;#A9V)A.&\IG8SHM(CS&F,Y?3IQ_@TCYKO6BM>L&U5OO_9%5HER['?^Q
MJR>]"XS/&C4?@U$3F/RN6S7OCVWNAW'I.#_+TTQ[R]OVG!_#.??:>V5'O$\Q
MS][TNV\_W)XH:+'!6@,;BN36&FB-0-8::!'AZ[L(;6(:3L5F6(''?IH._P>F
MG[/ ^=\YV_F,<&L[M+;#YK!):SNTML.=("9K4[I:>'CO93%(!=9X^,@.>L^L
MA_<JZ=G+WIH/+398\^%^F _O(<OEL9/$#AJ-[B=_Q2+"+B/"_L<2[I-!<!?H
MP9H6+<Y8TZ(U+7X;)[8EICVU7=F"CQ9==L(AWJ@KZ!T X5]!Y!Q\9*M%'/F'
MSF>VP C+YZWCENL\;SDOH[/=L)+>>N^/JE"DM6U:VZ:U;0JILC_>)>/F_?&U
M';1$O6.)-[\'1[0]P(<XP+L[F)L@>#9(OFHZ.&R\X8Z>]/X(9DW &6L4O(OX
M-M[UEDK?5B!HPN9LKK(]YT>6J[Q'EK5]N/RMC<YB@[71-0#);?IR@_QV#1<0
M;/JR182;,XU'F;Y\,L^C&</2VK\'WI?5H?,Z=W957]H%XK&&28LSUC!I#9-U
M,FMOUPV3NT!,^V'Z,C(J.A.++A9=;IZ)-=DK,^F]RJ^/'?FM4=1B@S6*[H]1
M=+<"%W>!)G;0%D81=,[.1#]:++A7+-C_$$IKX6R6F& MG!9GK(7S<5HX=S[T
M<A>(:3],5B*X;[MRJD66?4>6/0L"K9%=K=)FC9O6N&F-F]:X:2M.6JO6%7Y.
M&_!I$>%Q5)R\3RG1JDS6P&EQQAHXK8'3%IQL"C'MA\W*%IRTZ/)UZ')WB;91
MM\K; $777V)XZ=#YWWEL39S6Q&E-G-;$:4V<-G[3FK;6H&3C-RT6/*;XS?L3
M#ZVN9&V;%F>L;=/:-FWP9E.(:3^,539XTR++HP_>7!-<;6*Z-6Q:PZ8U;%K#
MIHW=M!8M&[MI$>$Z1-C_V$UKW6R0H&"MFQ9GK'7S<5HW;>2F-5C9R$V++C9R
M\Q8H,2W->2%>F\:A#S_^&D='+Q?+,%YQ[KP($NYE<9+^^&2Z&UK^K8&QS^W
M-VQV:UNVNOJ.VC&WA@$--&;N/M(_W''NAJ7)'NBC.-#]M!S^F2]X=.;\P:*S
M7=5!'EK&:L)VMV_+0+FCT]VBW&'UT[VV#6Y9AFO"=BU1-0TWFFF]L<AAD>.A
MD&,/['_'D;]R#OX,<N<MSZ.S0^=DCO]:56K7['LV.-$:]1Y?<")<.[L1:'9_
MO&H'P\-^R2..GM>./;H=/;I>9]]M<^^"R'D;6$7@D9CE; #>@PM03< 9&X!W
M_V)6$W9_;]=W$S;WT,)8$V!@#WC[(ENC#O'/_(*CA&9+#7ZK6]H:O2PV6*-7
M Y#\1CX+8-G]74K)O?5I.R4P/! 5[(;1YAW;H91<BPCWC0C[GY)[DL?1F?,B
MWE659A\$!&L(M#AC#8%[9@B\D>C9;FV]R+6EI3V)R+J!D/)K?&YS<RT&;0>#
M]BQ=]QU/SE>1\SE/(I[LA#JW#X1@+9\6&ZSELP%(WFGU>A;/K4FK_J[OC"UN
M6-S8H$F,]]WF>1R&CJ]JM#@L\AU^R;T\"\ZY$\]F@<?Q:_A_!W>QW%7%ZM9P
M>>R1C3<RV?3<07OL#OL=:[AY<-ZZ&T;0W4XYW@<\V5/VN]NFI]]9$L1YZO@L
M@VEG2;QP2A*JD\7.7A0?M(AP%T3H5A%AS4[Y)&/3D/_THQ^<WWT[K74V1=_
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MNV")[\SCT$?ZAAW!A4-DC3_>PF(@.(I)^S1RBC?9,H=Y&?"7GML9#]Q>K^<
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M$(V BTX!/G!M@>"L_P:>$GM?\&VA$Z>@^P*1H?X)MVN$XIE8)QZ%6#?,*JA
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MSML\=C<&55/2.H6TUT3/Z_>_.E[>'+\<&B^CM\W8#!6H??>H>1%CO2E')!4
M*K(%*8VNWF645<=)LP0X*' ZDW.B8PEUFU0)ENIQMQ2,<I/2("(I[&0>\)GS
M4O_Z7N;78F:8S 35F8F93/Q3^U/""7!FX:+%;#G81U#!F0"=7&$PQ6A*.$X,
MX;\2;C9$W;+U6T5T%:H8I7#R<Q[&2RT+4PXN?M)F@!+> 0&>)6Q!^?G(T_)0
M/JBEFT*VME*R1<2[6$@UNW=%!D0YF:*X)\B;BO:"4D)%"6WQ$43.=<9ND=0B
MZ=W,^%>AI9++#!YIE*=80U.IP6&J0X&I6C2QJ&I1]6M1M60#JX1?80F<"/-(
M$-O*^ @<$X3^;*7<"/KZ+PH)!+ I5JKF8!'5(NK-7/YKU[$HG*5+I8$"NH@"
M^*5(+ O0GF66ZMKKU*V^3=VRJ5LV=<NRV;LI^BA4"B,NL-75FE/"$$E+U[_D
ML*9)C1P,*L0J%F7$DD"621%V*<-8@$(#<>TPQK^PN-XU=C8K.EB<ME%5%N&:
M@G I#]'#*CVYAOE=F#ZQ6$?(SRC^-(_@X4(Q8OYYD.*G"#4N*LTA8Z^"B!BM
M*-,A)5OT5##!&#'@_UR7^\:"9U2Y4*<<EO)F*0G7,+E:KZY%:.O5O9U7]]=R
M7;K: M7UY=)N5]'NJWW =274=MP)?#O(U?J&"]:,M:#/ Q\$@E27(Y,%83RL
MU[WNX(77%;1,=[)4I=2"B\)JZ%XPJP?>?@O636OY].WXM.%7(%3C(J"K[& 0
M-"!,M0D_TA_-!\E])BN.Z9IBNO)QM"J*'D?%2U8NMNAYPU19F;&J:V\(["2>
M*GJ ;.:MTOQPIEKKH%(&8C"L#.X/+Q65I%E9YG6=+P"SD/MG\&?Z!9 X=451
MR4#\+ I,!BG'FOAH! ED-65VSH)0%RTNZ@/#Q+FU/%B$OS)]5L3);'+[%KG=
MA+*;LA"KYC8E0P@&7JKY.-.UB*57N)!&2 R4)6F*9\HR2J&(7M7G!&E+UGW7
M+3#,=E-X.WQZ>8*#R<*W"4ITKA[] FNA%Z7;L>Y3D!"Y:"?C,@E@<DM>EKQN
M9&>Y.JA"-&59"*6BD.G-OD@&2>C*.95:Y&N!%V81<Z!2CH*1'N&6@GX&>YE9
M=+?H;NW8%N&:@G!KXHM&MBHF2O2JX7%FV2_9<6&ZJAA*R.JMD+8DXVN9)P70
M4DP'=7S2T<>IZCB#K5K,LF(B!KEF/:KC6=6=21(8C%*M3F9MXY9(KDY;ENGO
M$GW-S/C:;#L#];'#S,4\#OD=[>>['[(TL"%+-F3I*T*6'KXCTXM<5WI]I5O_
M-+ =TV]4W?"$K6 BYTT:PH)3O._<BJ,COL!*H7[N!=BXSQ>[D[8*V?6DE"V'
MCY" &<8K%F8K5WV%A@"XN^<Q,+Y,Q0^7?J)VBHPZDJVT.0"_/8MCWYDQ,@W&
MHG.=,&9@7T?5Q4YFUU7ZRE)K)]UO363*J59KZ%,GB[9*;):M(:L#T1@(A_*V
MC=6;$PAKHM@$[$J(0S L"N*T:='8#KM!B3A5X(GDA9?]<U%HCR,BE&624RD!
MV77P@LJMZKD"$2C%A*7$"Q(O7V#;( ]]2V\RYX)1B\/S(,[3<&7:5^1,.D0V
MXMC-,<Y@['DP#3(E1)EWE^Q>*A$ &YQSK D+PM=9(AJ"JGVSB*Q!>A]D&$)S
MJJ<[13*U)3FJML7*@"YEAC6Z_KZ,SK 6B'2N+A9Q=,$!O[#]5IYDJ7!>+D"N
M0Y^=:'V.#=NI!2"UTI0-E4QKL;(*:*N5V +IY^I\X'=LU)=G\UB6 ,5?L&^P
M\'E/N>P<7'0[+!,5G$7DS/(0'252*  <5%1"\Y#IN$IXA+XR\;ZN ,!7-.P4
M0ONFEITMG7J,R(U-] @VR%V$:81_<7RV@+LTQ1Z1BM(OBC89Q>*Q_U^"KF/L
M/ 7[#X,%50C4S8TQV,7$6&031B-:PB ZTBO6()@ &G)NMQ[TNQIMV5"\+S5?
MK.G:*!@<+WE;8<T'P:'H_0C$!1(=E0TI-I'*:!M5)$FU?Y5)O*D\#Q5*@:;7
MBSCY0ALU1D'MBGB&>@_G51.+;K>4$HS>:SAG\;/Z75J#15T<$1TIV$[9<0T8
MJ9NMB.?4ZJ2W&=T= :>QS^70DA$5>AKV>Z0TD;I6EB+\X."\6)>1A4T5>F><
MFCS*]N75MXLK1E"L**XBZ_T0>,I]S^F3?JXI_1H_*R"_*$42O%='\T#" :P,
M:;_ $  =V5(%+=&M)2RCF6S9FGH)7_?$E=LKOI<Q"< +;]YR#[Z"Y_\%7Q]\
M!#X:1_ZA\YDM7.<5#X-+YP4\H!OR4>P)K&L5.9_SA)I54[A*D?N1TK5F=H(E
M/"_0G,9 0DO5%UBA)Q081=P1^"!>4? %=H>+*0"/ZZ?ALWB!VOJR) P$%M-=
M"3?DG,KK@M;#"@>[:,(E.E^(44QOB>SCI7K.$IFD2HJ\.>.7Z?[2=ZHW72D9
MKT_+)3X:;NRJJ$ZJ#N;8U!QP;07;E[<*H@@3'9EOT33P,U50 CX##URWX ()
ML,OX15R9O5;+-CQCLG7G]<T@:;\:.8WP26.9>%5..3P!!"8N6CC&XV4"6-%M
M=WNB!!D*%B#8P/*_JJ'B9]W:=4X%S+U S@/'"RSA1J=61U=Z1PK@&L#:UTYI
MSQ%W$,)B(5<_>WV;S>L(7#&%S83N$$5JJJZTNBL9%,L\R>BT34="/DLA-IH$
M"?)>C%T.1*IC,-O<4T$/![* #!4#;&#1ER1?4M.]!;$+TA>,7M5Q4HIG(*D.
M<0#8JF@O]HPN>1A>>&$#+'271UJT,1M$$YWE44J_PYWN/Q,2@.0\*;ZC6LY'
MU(#'\#?+@9[1Q4[KB/-,%[@%[?M<-%:?ID6H<+V01(R GLL4(28R8%$E:&C)
M9RTVKOA$O>'/N>S3C#"19P+[Q!@CN).>H1R!LP%S)(5%7%.;VG-7NJZ^#N,I
M;.T=2[YPN=(IE[JKW,LS'.?@/#@4$7?K^%%U;PN\6.?5<,#9$;PC))5:.?R&
M['Q+DD%G33+HCLJ"0,FN4[86HM" &Q3!+T_G@0\\F0RQXVZ[5SB/[D^&*:]T
M6IJD'(\KF.4+%;KSXY/IMA:V#L)KA:L:6]F&/>K3: [,K][:9TVX19@4<,X$
M6#GR:* PY">RV_4&,'1H)&>[>VGL,=W"1R2F1]NOG!EMH)ZPG:H%D)D9[ROU
MA3 RTS<E4W2[<*#(9]:-_UFB%J:V*MU"VKM2<=R([<M1ANW6:/B#"=.*+\8P
M[!KCHS-N!OBAH*8^'Z'[YZFPVX-B[%]K,C=<8/I1N)#B,,_XUJWGUW!2X<YH
MM0=7Y1300(7#[O:X9/I[*FZP#0>UT;]FCVY7CV[8Z@WLT>WDT5FJV]FCLU2W
MLT<'5#>R1[>31P=49QGF;AZ=I;K=/;I>JVW/[D'/CH( 972F%X?XY#^_FWQW
M$[7<"//4L=3+2P? %_B.BIS;?+9WANBX#J ;XP'K07P+4Y_S3IB?#HZUY?>%
M=$9]1G/RL7"S?"0WRZ$V#*Y!^>8&CR(<\>GWGL?Y;':?X+S*'%4/O1-L.Y)0
MO,D'$7X-^Z\6($\+*-Q1G6DZ.$0$0FF[FJ)&UU'4IJWW1JW^#NP=S;4?>+P,
MN?;\ 2&(_C08ESD/(G97<FC4AE_%"3P9(>*?(Q=X@_W)DZWA>J/V>I^(W:B-
M_FERJ_WDV2^"U NI22B@KO9RBI[D/V,]$L74W[(+R[D? >?^-6XR7]Z:T-R^
MD]2\;QS]2KE74<-T&YN_SIQI4<2BB$61+9BY]AU%'H(^MFA,^#6.CK8$C$>-
M"=>:#)N/"B\"W_DUSAPIBO,=-!7M"4/=<<"MX=8#05)<X#60?$#C\+U3\2N^
M8"'?'DNWN&AQ\6MQ\=U6,7'4?*/%MY8\'QD^/0\BEJPL1MVG!/NH4,H$QC+A
MY*C'T/S7F+B2;$, WAUD^L"2S'GS5.[=>8-) V8FR=Y9DFJLZTTU%%U'!93?
M<(/-;FW+]CCW[3B;9KK9YG$^L(W.'N<6C[,!AK:O/<^=,*'=^F3+E;YVT-[P
MT#=-$[9[%7;WJOOO_L,>]2,YZI)I;9.V--JV-[$)8/J&LDD3MKM]K&A;K-BZ
M)68OT>)Q&%;>/'5>\$5\!F"8!Y[S7!^N-;!8C=P>Y_X?Y]YJY-; LE?':0TL
M#9,KJ71YPD&(PEISW'?>Z-:M6."NE!WQ2YX$J1]0K=_'K*3O59K$+=V=-Y'"
M*1NNNQ[?L@>R^-O7SS__S_][-"+8[F:\-1ZMFT#[5UO>RP&[&Q5,>P_8>^ K
M"$;U8-KCXI0/WY@&")@_=?[Q9[Y0!>&9,Z,87EV>UQ6UFWV^1$M2I20Q5=>^
MJK)VZP:=ADSH-;5'UM#VR)('97MD[5:/K#>R91.H;I^Q\P<3K5@>KHBQ415^
MP59NJ6%$M')29#18/$(V"J(*[M0YBMH"4SGO(/UB]@>F]B; <D3"OM'/018I
M-[Z19<E#6;)<]L8^!S:(VJSJ>8GEP"/JXI1A+THJ=%[ 3O3."KRY,Z>>%"FV
M4DAU;RSNNZ(XN:^Z/XD6R!F6%Y U<M2S:B:S^8WL6;5I[I0:@J#$1778Y\$"
M'\&*Z(P>7B8!OA++[N*B#Y5HB$$ESV$VM5U:G.@K?G\ESV]WUV[O<F5.X/_S
MNU/>[TTYZWBG[=ZX=]KO3'NGXP'W3]N3SL"?CGL=WAU_)^A=O,&&+UXNEF&\
MXCP][?='[<Y _O[PM#QLO6@Y>G4-D2'^X,Z<87NY+,Z " &C.Y.QZW0'$T*X
M;G_L<+5DV:/[!?>HY;?3Z\"#[6Z;_ML1S[>[75=1(G#1<"6;2%'C+VJF(&IZ
M\PS;-"38IP[I*]<]Q%$\*6;$)@9G<0);)7I1O:@VK*3;<F _HI%== ;7-)%0
M'F8,^]U2^RH0@XXR@"8 GLUFU/(+>X[,08(B3@0$"%.V]KS\^&C4ZG9LE;I;
M)H4M&U%AL-OJ]^W1[>3135I#6PAY-X_.4MW.'IU0R.W1/=S1W=R&OND,KQ58
M[@ET=[";%D./[P3,>V5;C:]8:WKKRY[[2NB;-M?WOM9<WVVW>KL-K%])C0+-
MZ$[IIY+6]K@,LFHWOZ7XR7LGLGOF36L0NC.SVAHQ[C$2&I:@+1!K WR,5T'B
M(T\Y2SS1E/X%/^=AO$3;\-:HK^D V%J,G= A=[FNSH.*0KN!)W7RSIT!(!V3
M#0# K5)#.I/A7;EC0TYX2'.>Q(MEGI%/AX7.\R .XS/1./Y--$/7)NQF&PFQ
M]R^5/#03;#;>]KH[<8C[P-JOL_#<OP!^?=CY_8%MWR1&P28_<V\>"=YHY<5=
MDQ?OSCV'HUT]ZOUAJ$T W$[SV(9P%,%07R3Y&<5[HR=CM1.RR4-SS6:SR$%[
M)PYQ?_BA97[[)&">P-.X!2M>/D+QLC?<U:/>'W;:!,#M-(=M"$>1[/3=R;UP
M4DM+NR^I=CH6':RDVE@^V@3IY2IXO>813T!0/?87(+*FF4@(VE4!YI')JDTF
ME]U"G/UASTV@N%M=X/W)7LFJ/W_<"7GDH3EELW%R>QJ\95I6IGP\,J5@@:^"
MB$4>WU59X*%98Q.V>SL5?+RK1[T_'+0)@-MIIMH0CB(XZ)O/.R& /#2G;#A;
MM$&:5HIL+L-K@IAQ%0^T%LG'*4SV=O6H]X>1-@%P.\U;&\51GN<I/)ZFI@N=
M<H+>L>0+QVIW.R&G/#0GM:SCH3%@'Z!D5G!M9NOR&P2X[:_H*>;\C/4*=U4,
M>6@^V03A8<>8@A57MRVNEAEL#QBL'^=8<7,W.&RW/Z[PV'LN>F^ X^J#WJ<:
M]^_S!$LJ>R@;^WS)(S]UXHBJQ#*Q 2H]G5&Y9==9Q%EPSC+N8MGE0!1-3GB&
M?_Z5P\G. NX[2YZD<13QD,K%3GD8@-#M7&!]YQF63RI7H(T72Q# L;";^#M*
M13UFP/0O[(RGLC"SPZ/S((DCDMRI-C.//!B*'DEY.#OR"]&>)D[X61ZR)%S!
M7UZ2!YD3 4CA5L-2YC $4,O9W/'88IFG#KRK:MABY5G.SG(< =:+D6$ @FD>
MA#[]+N>A?<07D1S16<9QB,5XQ;!J@PJXM*.011%0F8NPF/-P:8"!JG.G&8Z?
MP5$FL*Z$ ["6+)L[%T$V!P@?^[#9B!>G@(\N<'$)7^ 14-5JK+I]QJ+@OT59
M:SQ!;TZG( 87)P0;D[.<Q2Q,6\[[#"ME!Q&<!E7:HQ+":G]PS/"/J/#MA;G/
M'7[)O5P>'(Z/.S/VG9SS58I%MSG5"L9SD6B#=8H-2(I?2H<O\.J")3XLZQC.
M!6L>YV$F2X2G,/D,RQNG I8,UG FHOC@N*<<JPTCIRM0]QI,I9\1AO0  [*D
M][TXX?!U))?O9)PMME4,_*Z4"U"11>"I=+/ =JI>CWAP L?!"#A8DCGP@B43
M9<W/61+$B/#ZH&(O $Q(X2P3)'?$TE10&$LT,HE)%GE$0PEX41WWB-X^PZ1'
MHDTX$8$?>,AXH )C !W0'^X"HHN9"9[&]PM87Q+A HPO+^+DRQ'5?83Y@^@_
M>5+Z><%]RC#27]&RYC$J^V=8S!JQ!RM6)[R E:B#_^'C"17 !PQ9L"]<5)0/
MIKD ('RKX3,%O)H!\Q!P :A@[6V-/EBEBEB0K%V?,F Y 9;-G\91GDKVY<&5
M3HB%5;IQH>NEN $R2\)76,]EL,@7#EM@YSAC.C@ G"*,O1+$1=N1#! -W\=_
M:=."*  L5'.?S@MV@(_@7H,HI\?I ==)YP"CHRE+"<ZX*21K1@2(CY5YMN0S
MLYRJ]F,U??D*X(EB7U5XX@@@H%QD\RKI-X6@C+N*L/^"FQSA+(Y]PD?JC, E
MJ<V#)7'GZEE2T7-Y!E$,=]4EX$H -Q87308(VY%P0@9B&C8M6.89!VS]-8[X
M>IGV0-"Z:%0!:"#> F*$);3,@O[MOL=FPW;[=-(=3T_[@VGWE+%![W0P\'QO
MTAYZ7=X'X<8LZ/_R$Y[]^PO@GKB=T]ZXWYM,Y$--J.K_LN70$AV]QH8@S#6%
M]P-5;@@8()"#A^P-GYLKGD*<,U:;4J<.4CNP;F!T1).(2\0LWF%Y-Z&FRFK\
M/> QJZ>WK:2_Y=8SVG[3+30@;(*#K]"JCD*VBO/LZ2RXY+Y9CU=U\!'B=ME^
M(A\;B]\J^M&=ME%1KNBT8;U7]%<;KZE'?_]^,AQ-GE775=&AUA2(.U$/#71E
MMQX.(IC"H:)C"C*B0DX# 3P /$R?X?=:$5E3L':_(]7(=J0RB-%VI+I11ZH%
M@$MMI=,:2,;TX*RU;3EK SBK4!6=+Q&I_+&3DU1;7.2@=^(O"]0807R,G,$/
M&V[TUF;&6T^^=+=JQM$,N0<.VC/U391J!*F #!U?D,HEU D VJ#OCCH#=]R;
M5&$!DFV:<V%7 5PF PA9!PJ9QRG$'7ZI%$N<;MSKNH-V>UU@DF."\@%J!BCN
MOC@I$L2OGV3.0Y*Q7P._SYR?X21?@3@':JOS]D-35)7G=?(C-C_C<#L!&R,M
MSF&>![ AO9AT% 0:]723QI#"8""5UT\O3UK.FXA,,7FFX!RIJN?JS*I(+W02
MIDA$VK ,[;@LY))R)9XMK#?2IN2K.71K.#GHG*5B_0@O8= B?5[9QH9MQX<K
MV30^* L?O@8B4.(%*5<MY>(E;ARF9XE0@$&=BLGZ)29 L]><K + ULB$H5ZD
MAY2QI"GX\)E,8@K_Y_$%*+&)2T2(2*^!*PG5*TJDJJ/?=%C%GL5!M'X,:N[L
M( .F[\%"G!^?!#_M>7.OP:1E^YW<UD%V)__8UEK5=%K]L3VZW3RZ86MBR6XW
MSZ[;FG3MT>WDT2'9#>W9[>39=6'Y]N@>\NAN&1IXG639'##=3UNC^Q'J&M^I
MZ!OV8.L-6^/>7K=]>J^L09^$(>&Y::QX3\:*.KO/UEJ57<UR[P=\UT>V7M7P
MQC*I?6!2.]?#[DYJX!XS,-%D<FO\Z&K-RZ+=K=2@/4:['_ZQ*U?@-NX'->T)
M[&F:!##-SSP\Y[A/G))%Z5'M"7S31$IQTS8]=>9*K'I1"D1YJ0-1WLM E*<(
MJFY_7=2]RRW;=(AM+=E(788-V.^M4I6WW'A17')-@,(W._5A,_;[L*>.]TP3
MH'!?5T^!,]NX1QH%E@\8J."\S>.#SN%.:%</SN0;1=MKR7HE-#>WLDPX&8XQ
M-J#3=4>3B=L=3K:9-GK?"LZM3]XI >-A%98]P)INK]7?)K[<MW;RC:^('R1L
MMFC;:_J=^HI%9ZLX.G,.7O$PN#QT7N0'W>U=(TW?_F-3'[[RLG%[[9X[Z8VW
M?=<T 5R[<OTT 5;W<"-M_T)J J!VZHYJ%'1^.7'^G5LU9O?5F'_\8S]5DFW;
MGA[%*>ZIHK#GRL'_P/1S%CC_.V>Q50D>BTJP1<;=A+U;/\*W8>]-V'OC.7ZC
M(/(.X/&O('(./K+5(H[\0^<S6UC1VXK>5O3>HU.THO<NBMXG\SR:,;3+_QYX
M7U:'SNOM&45L85@KRS=>EM\7K+%:P8/OO?&74:,@\A;K?1S\$L-+A\[_SN/=
M,,;O"[NPNH7%!ZNE-( --N)B:/SM>67R51P=Z<K/.GG!9B?LL?ZQ 0 V.V&O
M]8?[/_7]UR3V-COASWS!0:'X@VVE+:!U+>Q"4!]*PIWN5AM:65_$HSQVJQ;L
MHEIP'/DKY^#/('?>\CPZ.W1.YOBO<X 56+$O%G9:477U;;+!OFH#>^2->/#K
MH0G[M3Z$!M\)C8+(NR!RW@;WS>\;M>7'I0;LB!?@P=GVHSA%*Z3OHI#^9W[!
MD4OG>R:6[XOGKR$H]$@$_'W!&JLJ//C>&W\S-0HB)SE6GW@1[[*RL"_,PZH=
M%A^L M, IMB(:Z+I=^D[GIRO(N=SGD0\L4I,(SE(0]!H^[Y.Y#P[70MI7S!L
M%Q6>!\ PJQSMHG)T97SM<1A>VYP>^[,P!P]]N=7 V]V!TH;V/WNL)%T!CHT%
M_GINN]-WN]W1SO3*:#B6-%YU^@HLZ?9:XYUI;'%7_+AE5XM* Q "TTW[E)5A
MN@NZVE:%QS7H/)0T:16]75+T]@%R5O/;*<UO'R#W(*K@ W69V@*<]UR'_) $
MD1<L62A:?,[A6^PDM;^ZXEZ'Z:WMUFE$ ?,&*H-['>?76#1HGL[7F)S-IMMF
M=9,IAWG9$6"/%T<>[$K8%@]Z.^MI>_ ;I G[W:7^5$V E\W\N2M^W$<GJB9
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M7@['"F],5PX<38 +A5>Y$^6+*4^<>.:D&'F=.E,0#6:!%[ P7-$H]$Z:%^N
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M+@^=%R"3D>K1FXS<0;N]<>#7P$XRYV?8/"AI60[2]-L/)%&2 $'B=X8S% N
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M/ \(@FS!)!3KU[05.EX&$6'KVDX!FP)T%RUAE0*A<2:0O-@9P5@;5Q?L/P
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M05R9!A%F,XH4J>_;W2.0"XI7VL/Q>#*^C2I83[':WW\[2WSG6O6O7HGH=(7
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M=O=TR/GLM#^:3D\GW=[LM-?VV6C 1^W.E%?L!2=OI&J5QK.7ETN>9&A .P&
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MJ3("_<29Y1GYGZ.B1 @=LPYC*@6>4+1$.4*"6(F7)Z@NAR)**?(%S668[K(
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M$I4$#[<;FGH1-#105O@W-\RE!"9*N5&F65T#8ADRCY>T&"F079EO]P==]V0
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MLK5'PSZU/U:U$U3?R)7[(88YG;35SX2'%">8!4A9TPWOGZLPHL"4#F#S!F+
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M_?CB;V=7WL7YY=^J7%EYK@$)*246 88K(DX^D"8)XIZ@BQ.+G&@FZH"5LU?
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M!L0<EB2<\/Q>X,R4$4+J-9P3!?+!0%Z&>TWO0)-KH6#OL.:#\R[(V1]*A(=
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M?VUG4;$"Z:%:DG$39+Q6U&I0)%ZG8@X2@L%7W3ZKU!WW0=]F<X2EC&JS0F_
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M@"7'NF\T:!/9"ML_1Y]DKJLY3(?;^7HWR5QZ=!F ?K)(L:UT0!?(+)(K'"V
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MFX*0P9=E'%&Z5"PX@TKEKH)9G]Q)[3Y"U3R5(DO0'P#?EQ@F9.\43'">:$^
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M, 4L5.PN3X.2 -ISO/CBD7CUM![^?<&^BDZ70=-?E/5OR_EA^*&'.Y7.OMR
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MK=H"KG2KOX^ VY3--@R_6\CU'6+3P^'-5I,L"B.11C);=Z0YY]7; &&__YC
MG1H36&U4C0G\8$S@.9!++Z7=[/&D:S#+?40RK,$L:S#+&LRR!K/< TC&&LRR
M!K.LP2QK,,NJD/6Y:](J1M>7Z,EJUVB65?=DO0Q7_9;4C-'H^]4BG"0A>0W>
MK#)LY9BA^R!<!9Q^=K:\B8(2/]EC8I&C45V#4 &QYM<>^EJN?6OY>=O_?AY[
M"ZV&H@)$S,<4A$ZT$#-,J5 IL1]42NQ'IW/4I0RLV=-I^5I\78IT(D#$'7WX
M,I-WWG&PY&A>R_^1I(!?2X%:"GRS%/ANQ41;I,!Q$"2KF-J[UF+@<6*@ \I
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M0M++\/L*3FU$ &Z^%H IV*BGJ.7)_L5Z"B5GUH%/G9J4P!V R(.??.OG"G/
M8;C$A_.23>1OX'Z"0<X*!U*E=8YN&">7S84ZZ:5>PYF_WK?F1-[ ;Z';!5EZ
MUG6N![QJZ.2</OY)F!*^;\/)C]4?A?GD)7F:OHC\4W(;B"^<>:+\K< .?BB(
M#TQ[@W%_56*+3\'U<CX0@R=KLCAI3KBWR;R^%D3(V2?$CVO3]X"G+ABJ"'=;
M+0!]'4*38<&N=3L+Z&0M:=RC^H\>O;H^N11P*M"1 2'(><RWK?%D]\Y,5IW
M>S*;G>I$:OCXI8ONZ6/['MB@QP+A#&PH!*9MK1.O=*TN],+\\,30%J%W'NO
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M=F9KM3:3IU)(.5VFY#%^NAS#GES\VXN5WL>SEGQ<>M[N@-AUY[!2IT*E7VL
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M\*[E$]H WK=\.LX%RR*3E9D]CHXS1#<JU16F=P9M9@!;D1+P@B7-8$6,R9/
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M>OY3HH6SRDJI^PN:?E7?5GQI,M"1NL8VEIXB5:,FB!?HWQ4OY.)_S^+_*9'
M.\0_K!S<N=L.^LC8Y?"XMZ!X71Y \?]-L4 N_O<L_I_BY;]#_$VT;LRKRWAB
M<ZM*E;=-<^373"C^'^OG9R$B_.?/#N#]DN=W3V[Y!MS]Q Y98-R=W$#).E!O
M/%65Y?9QN>3DDI-+3BXYOU-R[B=K?-W;*KG?E^>,\ZQ!)EZU_.SA2M7:60L]
M>;9R3AQH.!NL_0GER6JY,Y56?,/A^<&UT\;8.Q('O.J[@*U!7_>3+,%/WZ@<
M!%9!5+?%\IBF2M&QQQ!E,59P)"G3\I7ZR!YKN:S?N:R_/T?\H;+>VC%+710F
M?83;"U0HUGLM_\!"6:> #O]*7.Q!D<MZ+NMOD?7W)X0_5-8UDF=5=;= ^+&E
M6I&QWO98?0!EG4YD_>(CWWM-_7[HK8\L!'DWZ=1G05[R^^;WF0JY%:OQ>Z.!
ML^I[S6XT6N&A';(88Z^I17>[8[;(:C* \_OX>" +,I)CXM,Q\7NCAC=@ C&C
M=K4VH&IV76%7#7-<K@N(">?W\7%#%F0DQ\2G8^+W1A=OP$2+\N(FOY5KO#YM
M,0/?7(\)*<'$6^.+_TZ*.G[,)J+,:1,M%WBPX;?OKNZ#Y#SUB9\[P2CV=B_X
M(Z?^S"E]NAB<VJ0D$D[Z+(_24B^H&FR)K+H'L*D%UPO!=&"M%+!D"PQG^JI3
MV*A^""NLA$L]T*'H)35255B&Q;!<U=4L0!2$X >P@&WP]?EZ%U:P<=0#W%_]
MKZN%,DAZ8?3/PACXEZF;/"E$OS6J65B[O_\'_/+P'<W151^JKN6+4 F'WWU0
M7,A_?90RNB@,9Q9AQ(,Z>N11K40\64?RZ__]/T_7\UV[EC3/\?QO#_6FGBST
M_'$L4;>F7IK[NFJ75 -\^IOJQ.HA."^<IK]BQ$.YW6^/-:L@:PKD5YK^K\+W
MWT(&I;B[5O>E)SP\*_>2HQOA-^(K27[_4:*&'W[F!592[L?78=V?G0['?C9J
MLE&AM_F&H5^IW[5/+P07_[XK_Z,6ECY4ZO\A"=Q%08:_!U@"VMIY)LSG'P%0
M)_5O 5PY:", 'A^E5GV+Y#YG\R7^J8E>5[0YA>DX0BLDB@"/GU)Q9:[BA+(@
M&!TCRP1A8,:7TU>OP\:?0/<U^7_@-/7(:+;*UOD>?W))FCWNI+1.2^.$GBAT
MFE56XJNB!'[M\CU)%&I<@^W5>;'9$QOLD&\(V5W=TQ44OB^A(-0*YT44FKW"
M>1F=*C\4SPT;"_Q ;DK3PK^J?*W)-:5_7]%V_;,50I4E# M2X[QG4YX=B@6^
M5P4KK/(<WZWPP]/?X&BQ  /DY%>TP/:J\#?8AUOA#W8@SK"C<<9 YW-2(35C
M 6"'SA750'5E3F"J2AB(3NOT63#5!P<,9V<AW_?#ACTN"V1))DA1K9C07T1>
MDM8;8T_R.GN$MV*I,B&L#O (!Y"4>$G*J%NRBQC\P(YF*F\OA6##C@<*IF O
M*>?5%BGMA^I2WE9-36ON#@>K;RI)@^+GE$V]-!9L=8,C7)5;^(M.>S0-(65Z
MION:YZYYKMV0HQ:R$_7:LC44X.?1U/>=E4D:HSU!RE1)]4A6#?=H,R%-+6K(
M$_%TL.L.92JNS7LE5))B*H:D*:XN:QPRZ2]&(2_.#;DQ;HYZG3UP:]/K;W19
MF;.<U1A1#YY4$[7.3B4A96K]CC\BD5VXM6QJ,K/"H+&=J!8+*-/KQX$ CJN6
M7+-5M:P[3-!K[B(X:'K]E=E(]F1LZ/(Z*1L>-9"G*SF&I*GU2]PNPI"NU)?K
M0WTQV2-(3;"3":3FVC_&+=$9>+ZML[XG3GKR%!TGHZ98)1(#IG44YRIO+1M:
MK6NX#J$.%"+-*F$MZ"A2DP(9TRC=FJXQE[1,)>D$\IR2W2OZ86'-:!E;;AN:
MJ?7VR!!2IB9*4KJ!5KR);1\ZW4.CH6GA9A0#RM0\*?ZPH^D.[?,145,G='G1
MV?"0,LU^==+CZZN-,)=+HWIGA/0WX\XL(4VM:3AOEQQ>MUJ\RJU:PZ"N+8\:
M"TE3BSK( WMK51&6+\6&U3QVE-FFE8R:6M5L.O:]?N.@RY;*!KJ)52HC!?(T
MS?Y#94[9Y9&^DZUF%Z^75[%8EV*%3#.UOQ =K4FX>[N]$$'$AM2KY!A2IL;<
M[L2>,><//5GEN2FR09?534)Y05+;AF#.5K.6+(I==SQ9'/?+Y0"2IB75<YG^
MVK(%N3Z7#Q79J6LN8D+2M/JI]32M(ZJ.+#!VX$0[=%G:)Z.F6+7U//) \K1E
MZS.Q1U=9?J);"6EJ64HP*[ONDBO9!U2/![4MN==6L4(IJ54==U@%ZZH2R7-&
MCZ%L*3#9J0DH4Y\WB!5>V]>!Z1K'QSIB:20V<R!EZNO5=14UZ@J-\>M&,V :
MC2:)"*923G]=4G2K;0Y:/9OSIWZC*MGHO HI4RQ=EO>]BLRL*43GM+H3FOJV
MZP^4<GKSQX-C299;"(Y0@^%B2/!CKK6+E7)Z137:GJWDI0$VO]];.Q;'K4B'
M5<KI%>'N?KD_3(^B+,:BQFH,[Y4F\.MI,?'D^B&,*HV>;%%]C M5M!TH"6EJ
M37:+]=>U/>'S(M&9@YA"G\=-.-.TF.@NKVXFWD%$VJH5.+5M?;):LPJ=9FG=
MK")$[-H\;TT74F5ZJ.I5?@ HTU*JD3U:'"TDGA/X_G!$U44RAI2IK]>/"E*A
M66HE8_O B_ICT[-&\.LIEE+4%HA3>>W)W YQ&MQDC#AC2)EBZ6ZA8>IL=J1Y
M<894T5[;T)<.I$RS5/8C9=F=80N>JK>%%O#3FP0;0]+4FN)=Z'CV0)K*F-@Z
M! >A3M0[R:BIJ88<)BYZ)8*UQYC.<XXUWSK 2#%IEDZW\T9G5_/:"#?#YB/]
M8 +9B@%E:LPNMS@B$DE12'T_87L+:2O2"*1,+5_UQGMVWXJZ]C:L34B[0=,T
M!BG3>]_KMW!&ZO<$6=A7@6+WX\84&T#2U/<'!X=:=9&JSEM:NT'&++WE). B
M(>E%^6BS-=5'#,)S@[@-;,NV&_1C2)IBJMAI,$M='QQL3- TJ3N,QYN(A:2I
MN1[EXW@DSZ9'&2/[X^EX,0DDX$VA2)I7)K TY4#;:_)A.Z=&F_6QVBLE$T@Q
MBR^U&Z[:J@J(VN^T@!Y:"[233" M++ZW'@AX@]CQHD32  )&K39(6)#F;&W+
MHA5@1-=(J5=2E^Q*$<5],H4T:RO8'EUT AGH$]OGZGIY.IJ4P!S0-&L'F\I:
M"8P%:^M.?U5;QKU6NQ=#TK1/IW 2UIWA,2]4R''3<?8]JYN,FIJL6/%(ARPW
M29F;"O,C$S.L9 X@:6JN[D*F#KM^%?RG3K%".]AZ%2290(JU[E+6M?'0'B'U
MMD,[J*<>6H$)2=.L96R'V!_,+5!"RJ9;%=6MM>R>:%.S%4 @7W$C86B++0+9
ME";+MF6<:%/3M>:E%;/8EBS9"J1YQ3)('K--F/Q-30$+8G2^4B0-&=?5'1$Z
M)1:U8DB:&G5_G-1JI",V97&WF[D,%=9&>$*:8D*\J_OK[IXB@!,:\%N$T)T:
M<)A0/#T!O&)51(=KL\AXA=N=8-.:;8"_CE[PEZ/9LDUY6SF0QQU4CC!\N#DN
M3$B:YA:OB8VZ+"_Y]7;D[%O[@4'1"6EJ6?-UI(L:MD3Y^F9HDBN>G*\-%I*F
MEF4UV7XKQ/L1HD?=^4)JX[L^GHR:WEO7FXP=.I0TNUWEIM:AM ">\XDVM3!%
M:851.>RN90RK#Z4QH=&$D; K+0?;YI0;M?>M%3!'PVF#\"AQ6 ;3)=*L5?S.
MCK&)CB"+LP@?]JMCNH\.(&EJ!BS5P-L\/@&>;C5LUM?3D=)MQY T-0&ORXX(
MFA^:<K3SY..Z5].P3C*!%&M'KFOC+<E#D<B-UHRP-!MM/"%-L;:VBU%NY[0G
M=ANISP]TGQ='4+PO^=BBNW";.R(:\'IC,^YVR/&6T9/)IED[<P_E]J&,R#SF
MLUM_*U1%G4IXD(;-:&5,VTUO![Y-]2=F60]I%W@:*)EF[<25EG-S?>3YP[#5
M:J&"Q@P'+"1-C;K9UR*DI;A#A!JQPZ-!M>OR(2%-PV8_:K3F3#R7ZTRIXY7Y
MU<3:QI TS80>[F]*M:"_0DH(-XZ,SG1-TB?:U):-#)HJ<R#2L$N#%7(<^DVU
M3R4+2S/!]-HEZB@O%\AAJ$RT/CE%)L!_1B^XNE/+106<J./(6.X<.J3)#Y=6
M0IH:%1LM\8DINQ,9>&; YS6/K$VSD#3%A,$HQKH>MFG8);'D[2-A8G1 5 I(
M+T1;DEZG)EWB*%,-I\>6^Y;20\V$-L4$?+H8+L>MYM;F5BNQ%E+SJF<E4T@S
MH=MH1(.U/Q9YK+*C5ML(]VI]L+(+'O=V/NFZG#PO\]MQI3U$*X0T"!+2M']8
M80.,V$8L?T#CUEZ/]FJE9T+2U&07],%LU$I,TZY[2E^0G'ZU,8PA:3HWTEOW
M6,VEJXB(*K%+MEMEQ$I(4ZRUI7U540Y!C\=T4CJ$B$0S$@M)T\"I#X[^HE(A
MILA![^]V;5:*%YL3;3H[HI:6T[HT(N1VHX1M,&\YK,V2A:59>[0J#-?;CQ<V
M1\L:8TVZ8G4.QKW@>:.1U/;K!Z9C8]OE-!@W")/:FY T-=M%J>7O:L?%"HEV
MTVZY1FN&M1E TM1DG;'=&BN'6ALIR8JLAJ5-RXZ24=-80,?!7+>T&5^/VK7Q
MS.BTVJMDKBG6+G8LIL@E>22/2V%[/3;#XZJ?C'H!NINXZJ"<HO,12M6:U<'2
MF;(GVM1LT87IM'U6V]CJ9#9WI[49$S)Q0IN:KJ)6VP/..^+ !1XO9X?N84-Z
M@/:"![ZL[BJNVM_7Y/4,1R;+#MK=,BPD3:=>2IUM8%1'&SEB]C6<;&]TX =#
MTC1KM1[5P9O, ;&J6(Q)ME,"2@V2IN8J#)=-O]6MM&S=Q893EVJ$6XB%"Y[]
M2C)V>[VQ:LKCO182G44?+<V34=.LM8)E;^!/]PR_]:PZOF!U_D@DDTVSEE65
M]6PKK[IVO;;76N:4&'NK$VUJNJMH3QL';+BR12Q0EIWYI$^:IH)=B ,8;M<-
M6]2ZBY3H;E_I;#TQB&)(FAIU36ABY'0:;7N\: FMME@!7O  DJ:84&HVIIWZ
M=LL#B$W(4K^VZ9/'9 (74J#2H3>D1N6Q+=B1B\U*S;FAL EMB@FM;GVSUR>D
M9&]UI4R$)+" L].XJ>G2G-^6R= F;9U=5P+1JBP/=3#="QY[2 [7>H.9+7E+
M(M9#4VL?)\<8DJ9&98@F7:VS1I^O$^%H3D[Q[HQD(6DZ;.&$@:TQ\YZ,&:NU
MX>E]S6HG$T@S856R,4;3!SS?#FO'S:K<.([)$VV*"3ZM4>VMB?01:MQA\&-S
M(*%N,ML+DJ!M&\Y,!JZT6EDOUXLJ/QAW .T%W[J\&$=UB>"'\MBU%NZZTMMV
MAR8D3><"=[-5V:XAC-UN5EKBQO*[@WXR:CILT6H3KK9N:?96Z!ZZE#!HP20'
M=BD9OL%GP^B [^M\?7=42[U&*!Z!$L<N9<.UM1V(('P>(UBISKB+V:X;H*=Q
MT_D+F^(GOBN:]OCHDG*=;<6B>AHWQ;">O>Y(?,Q[=MMO-(\C'-6W;<"%"[$
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M504'V,H2MOB5&SH!8 NP!78+L)4=;('= FR]AQ\$" .$72&*J*[-LPHV !>
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MC.]1D@OQ#!EM*=.P)VS1#25M0[RQ7NY*.P7#DO0(3K((AA&PY0I8#,L!  F
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M7D-YFZH<JOO5P9#Q/#=BV<-B6]!V,>7C<XD0!J> [<#VV_.L 70 .@ =@ Y
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MRK31<IU#73:K5'[$33="MY($5N(\-HVP*!K]=]XB$-PJ, PI$@N@8 &4 $H
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MC4O.3"8^]U><H\G^V279M$9I,CTI$K"PN &< $X )X 3P G@!' ". &< $X
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MT2JLFB[O1)]-<-7B8E*Q(V;&SMC9!:"#J:$UQKT9*@VF#.ZXG>.QOHN'GET
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M ]^;X/?M\1XJJ4Z_ *L_":O? F]/360\)S&@SG^^W20EPOT3<3:N=7RC356
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M9TD7/:L2I!I)YDCN!+FU:NJ9[Y";2:*FVXG[V)T]URU4OP=_.\)^R[A4:3K
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MYS!@63LS?*P-).6P#76$_9"8UJXG8*YU$YO'UMV-K&37\\5Y/;?L3,8?X F
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M2WLQP"/XWUAB.; U>#<6.(8R9+VZ\=N7"+,._%_5PKN%SR*2?<AGPPXN83O
MHEISA&S9<]#(,_"+ENR .M87=)O[>0P+Q G^4F,7@7^EK*6E8C 6!.NMX HB
M^ [P$:)#Q4&PU1F\CS[#@1XA+Y@A!>Z9OX$(IJ@UBGJP.^&R\6-(O/(SZ2K
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M)$JB1%*Q'-H:[D 6-R]+(@1,BI7@YRL3V:3<)FC)1OO1!+60T$J(!&"W:UJ
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M:EH(OUXHO_ZV@%19RX+S5$0G!"\4)"JL6B2[7@+ 0SX VFNT;/N./&XMEWZ
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MK!XW>8Y9M.XJ0OTA;_G.W@E8I98JDF-Y7^@0U6 F&F+OPR'M=P6(&#:HHVL
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MG228=!(_4]WNSFZW-@[N_'93@^'#_):;K*>E%6YE^$6W@<YMJMX5RY#?@(6
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M@]"__@.+HXC@%T$U$RH8XWJ6X^XJBCR6YKMJ(3CP_UWIG^/Z4V'AG]U/!TN
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M5S+SD#X]JQ@#%1 [+KV=#L@0?3MK8!R8&YW)C)AB:X2/6[##3^1GG&DR]C2
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M#PQ%#WJ2I[8BH!Q7/G/S+DX!"0\8]DZT+_9D&EM7="])=_<D; <Z', :V=X
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MZ2,3&<S+M [WZA( 'V""NS>=>^(V(K2;1!27W:4CA4$E "7(@#O?*;+0MGL
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M!-*TJ(OW1X;!0]8-86T/"FO[D\@9WB;2S4V>B)-]>IX;%-.MU':#E.7+D3-
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MS3?:N\.XV2*P/E/OI],'"K#U@H9#\0_6VN\QVH)&#+\Q@27J&D1V+[8(ARZ
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M44AP.($@U2'2%RQD'4E^?L'8>0IH,Z*K8J!U8Y\7L$)9N%9;( $J8P3)U)!
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MPX!/J\I;\(ESE.#O4'T7-7/AR>=JJWC4:S OOX5Q;N"0]@HN>Z@2[[JYW@2
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MN!\J1Z^(37^ &%$1!Z,BZ,!B\#F_4'X0_O3O\S_;7(2TD<T;SQZXOP?ZUW/
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M,"V[R:1/_9W )VJ,[&;U\=?VL_T[9<.M 3 FMYJI!KV.D;'B@,Y-\],2G5S
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M%=[7HIG\S>**_DCJ3)&XM^3JXW'@([8*[289&>3&$7+<(5M]\M;7UKYS<M>
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M,;<MY /#M\.%A^M\V4G _ZN685B^\SOP%(Z\X+/$+X[C$AUE D:> 1JJH*I
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MAP4^[@E$@ 4VS5;=8F5I)C:*(]PE1GQ#J:)J=BIF@9@%/LH"'[?1(\ "1J%
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MSH$I&X@@_DH,Y<!DWF+%!<K$1+2?0#$"UTD&JV= =B">@A6>:0/%&IL!+H?
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MC4>NS>:[:;R6G]'.,EO-B41#'_?HS'SC5I$<9R"-IY-I%D]RU&FOC;]N/?S
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MJT^R:3J9)D\['L:\^4<WT3^$-Y_7-46&-X6\1,W'&UQG<H,\Y]7KF=(R@CY
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MI00Q!*WYWJ!5$@$]KXS<!E883G>Y@@1-)TGLG#E!UVQ#4+$-$?&(3BP!7I8
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M!R%B#%2<EDMD"";L+\PD;6V,I7LZO2%S2U?6&= -+7-&K*A"P!8M[D]\(/)
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M+3(P,C(Q,C,Q>#(P9C P,BYJ<&>LNG=44]V[+1RD*54$I!.E*E5 0%HB*EU
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MR!5D E1")-"(R*;;&$W&TNTJ(_I+@**E>6]PA&0WAGEY7N "V2#X\UO.R-'
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M67O\6-@"J%O3U%@3.SDZ1Y,P(.S\\H6DAO1A[JD_:E</T0.UYQ^,P_3VOA"
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M:[3=RBT\?J30&KFS)K$>]\V_V&TK%]CU:]M$53K+OLB>2RCYW:/01YN/P)W
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MWY@[? !'@ =_P)&4TXW#G*B>NI08M.XT:4LSS7$C^^1<_MB>D?!V:E#%,P-
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M8IQ +_*GQ'N/Q(_R)]L0@:*^2--W?)S7*\="=(Y;B76T-X_-,"UZ E2FE=L
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M3L,_EAE4G39V\<7ZUS/C_G"N+HH%')?;R,^M\<\L!K-=:)N0=ET&T6P$T2H
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M<5(W)<1V-$0ZU@5![U]1H9'T$43A"<_3\H:K?GC9;9<OIARHJEH]N;$2!.7
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M#;K% ZEEZ8H]X..)%_<(,'"4OX7>V%+9-2#Z&E IIUT ^[CR)^1=S-!7NFN
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MJ.Z+7CH=CB!:$5]>A?,@"\ <%/4YVPP7Z^A9VQH]YJ"Q6V\>EXN7_L/$;1<
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MRM(L@";S$6"6'_H*DUZ 5A4QMQM]<CE:^S<0"_[;N"^V_.6)1&;!AS,UBVO
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MK"B0^.1_Y(Q0)""ZFEMTQ[55*M^'Z1A'E?]BI #_>7=K'FI@H[M-\>R7YM>
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M-6JI,,WS6J&).,RR>]=GQI7I@!%G4#'_L'N,)&<E9/N#3FF"Y;Q7#IG_6(R
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MA^JJVJ^STXKKSQNUYA4>J1%DQD [5QOY$!2*WLX@ C:H=#> A[:)E9<NU43
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M>Y1M+<0GQ>%9:RVS3*7Y=AG N#KO6'W:7M$P^ICR1Y$@#^96S)I[I540@3Z
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M^(A]]TN +1<;H\)F:F;):9-<@HF[K6;XS*/"P6'-++LV39H75^&2\^W_"/"
MG$X6M?#(],$@BM]_'Z8H :"H5L=)ZV;"TV>FMB^P'CJ?2B ?>^CO7&[@:+#D
M[%I&YZB.M%(B(+R.Y&/\LH:]<I,6'KYY'O=T2V4.G,=TAD+GW>KU_F&R?"?H
MS'@MRII@'?VUFQ<T*@1:):BLCC+@[BR#_1IN8]8V1:DX>(6F>7;CP=4)/-7\
M+< S/Q0E!KQCGONBER=8]*]0;.R*W2T+)VG UBV> R-<H9QG8$&VEOOY[I66
MM@!EC1^WZHYQ'!X2 9QK^?RE&.&F?A;HZ^=;9NSUD0S;(H_7E>4*?][ %(M^
MS[OO?VL',A?X6L]D9"7Q<.20AWSX<V)E[A6>M+'ZW\KX3]1N:I(]\J4/W8:)
M'R2U<PA>*T/3@$U>>;W!G#NG85D7$48G^^2$]L11C"I,L6#:-IJ6J<DFQQ,Q
MR[6H,N)03('%B['##R'#'F><?^*IZQW];Y\/U=]H1%S'@S'DF3$M;R#&-SG%
MQZM#!;S"#^</:"';_23P?C.* TG57T/CVO7:4>5V7&\F3RB41^46;IC%W)0"
M]7Z !NPL9AXA5KS+GIF5KQZ"UZ )+6F3QBUF=$]GM^4QVG;\0:W;86YR@T0
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M<?P#OLC GY-G3IXD(SMY]O3I4V<HSU)24IREH*"BIJ>EHJ:CIJ"@9:*E.\?
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MH5)=]!#^9Z2CA;_PW:)]2W+2,TC^Q=W*$//WLQHJ9729?9U9(O"Z/2DL5Z@
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M-Y7'5#'4L>0#[A%[D6'=*WA?!W\ZY<NZZ8%G+OQX,1I5@[@JD!H*"&5@G(@
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MIZMK8'B%ZDE[%8]+ GE\##K*=I;@7X G)PT1>"O7!M^G>D$$- KR$(5-GXG
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MOJF@RH.E\MTM!;#DVQ;3("TL7A[R5B4H0]B(P,AU+OR5P*KK*_(@)W$C(XC
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ME-^HPE=X3&S65F C%6L)"D;NGDHE 2C(&?)L#ME8S;&^)(!"+@F $@43^6M
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M]V'PEC@H\_U0G3R57?FA7ZI\H: VPK0K>YSGP,%^IBKLP:P>QV?KOB]:[=V
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MDF&IO>M\=:_A1I1F+29[T"L[9V/0"UBT2U <URL.VNQVJ2I_K]0F:!_[T#O
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MEHJ,Z..^\%]SR_IP(2+]'HAN+O6 98 $.(J?)\_@O=J6;OZ3B?__P*_.^HC
M*G!,\P[:MZQ@1*=CWD/[_MUG)OY&*L1=\"1G]H==;HN'>&I"<N9P5SU\UH--
M"!1<\<DI*,G-ZGQ\KROH'EQ7B=H-E:EUJ>T<("_D&@/MBU,H=&5.Z8J*SEX4
MP\PJ*I>CZ<P$\YBQU-K"PLB >Y\RXTQJT<\7^#&20PPT$9+[_70DV1$#)4D
M'7Q>RS^]\4 _E2A?6%]( J0EE.B1O38TWS$?LLQ3T/L;2V;JC]"0%K.K58-7
M:X'3AA*IM(:3[18C^XBOQ2D;<_;%[!X^\?IZ#SO><T,OWQ,;KGLT*!,KZW_-
M;@',A*="/R52#<H#28#&BYD>"4T;%5)F0+1@PNL*&:MD =6[:%%FZL")*]#.
M"9'DMT?6$L"M-3<@9[#;=/2:CV8V@$W/$;>%';+/^ELJCKKQ.CP' %SW"[:
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M-!Z0]>YED^8S+>(00<[G:PIUB"#?N8AD5^-Z"D^>;*P*"=]PX/.<[E4J:X_
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MJZ"L<(IQ<%$]2B5WP2W.Q*XBL>^*^EAW0^SK)J2GT7ZR&RMWD"T%7_<C*>;
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MHI5!ZE!317+A4PU9^](SC*^S)MJQIR25O0V/Y"\]CS@3/CX)@7,82?1*;9S
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M\3U:CI5*>HH+;CT;[B#- :)=BC<).U>M=UWJ5F$Z_62UL4T8M^+$2>]]2FW
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MO )RL"A<KN-\7?V3B%O,[7:"A;S/8EO%CE&#:JBIV2]*^_'+Q.GI:KX:<E'
M^&:@5W'G,F5&WDG/T'E6.C@]JVU\-1/)17.0RL_HC>#\N:,4]7*3?FE'*RMZ
M\.)W\A<DIRQ$FA"8^_5";B2#UK:] EMTN-+[L9]$T\V3[6+^92PZ(?4HP!LZ
M78W:MZ#(O1*E>,];N,AB<5.<KPSE]#+:NHJ6-]_\^L/F/GH_]V7J#P*!&PQL
M9%/0TLF&I4EZ;RU<1+[E&6?^6%AV>R;.GJ[ZIM_HB,ZAZBH9T276,;URD]M&
MPS)U[*ME!O_W:SHV\ C-2JQBR&?)PTONPT7+S\J3[.I'%B_-8.0SS@!PR#V-
M_;CA(SBOY[A2B^[5,B;R%[K7=QR?]5C8L[0Z")=)'[,1Y^<X]<'8S80Q,+R[
M&,?L8S<]N6\A)M=<UM92HA;+5BAX2Y=W?>*-(%2+?/FD2,R#H5*#$_PD1OPF
M9##-DWX;[1WN6B\QE0&K12+%)HZ9G)4RNHZNE*>,)$O,Y%\!4WRCSK'='UMW
MY>!Q??6U^[LE/O-Q].Z>"%::P:H7OPR\6 ZV/7Y.\.B)1!&]W.MW.04E0 #3
M,]MTID,89".$"W?F<Q%3?>Y\$O_^US7]L&MVCA\(W3'+,(D.YD,!UVXFA#K'
M&=)%X@?:X<Y3G%&U_/-84SC4HOMQ48W,<QSB8KQAQ:.:1XZ'X(EHX)D3O="M
M%MRLZ)@R];PGZ7,;;\(').0G*9\G>#Q?2'8/+LC/WU=B;Q-A6/.B,O10V<O+
M,"FKN[14:P=D'2U:78TPG)\&[DQ;\+<V<E;X<E=WERUYI?!86 L\L$?9Q(D>
MCBEZ$T?I4R @ A]?*W28)TV 1E]>/#<V+01=1&'/+SCHHELM36/;-Y\8]GST
M7-RX8+[8D?O5!PHJ*-\>K1..UC_!_^&;)B59V64V#1$Q45"&+,SCPB<<2?)C
M6*57R;*'"UN8NIF'G,0_,.'<+$G^E68GDN3[L2"PKEOE/Z'L+UV3O6*Y'UGZ
M1%Q\DN3VRG8V6>.\+VTOMJPZ#F.H\:K25XC DSF25J^C!>.JP-/#GG-[3"H(
M J!#!)J')C>,83OU#Q'@*=2;CX26>H0(F@B\PU$0^)(*$=WK)&TU18G$6X P
MGUX[$T(>@XG %U\*O;2Z<Y0(F,@RS>$YMZDW%>BVP9P$F[I?BWVYE6V]A-Q0
M6_CBJ(H0 4XHHD?[>W_@DF)H&PZUK@'\J9CVKW3O$L+!@_2-VT2 BG!R+RJ
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MB427K_3_9II]=Z<W?KLRX<?U4Y#+A>$?K__\T993O9EZ9JV5RZ(CP$K@L\:
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MJ0F4.ALH[K&"J85NWGWYN:#JZ+GN%[!;E%M9KBHWO1^)U?"UO(.TPPEFV!M
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MI<GGW0Z ] 8Y.4[+A))8<+8OX0L[Z>TP#O"MXTI- \_BQA<VSPO9_ORN]5Z
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M?9R3:I$8FI IQ>'AT7HT7:5YKG 7WAQRGL $ 67>FS8O2BX>*[-Z=EKA1-8
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M:A?>T?O3,3"/O8_,NV\_> _W5.=RS+OL1;8DOB@+]_+ 44O\^O!74,-)\TI
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M-?XQ8C\,E_2LVC O(C)9W<QMFM^VP6FR8#5C]Z6%PF+=DEM@F]!0K'!OG%;
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M\((7=? &$%+.B\I])^65-?">6G;$KIM*4<#MR@TJ8.IX;V=EK2TA8DT*ZJ;
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MWV9KW9)F7%L(XD5"-.&I*9LBGMP7V>4,1MIF?*8F;DRZ;1)Q& 5M+[[A?@5
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MCTC)?:0H]NK4GC.I:>ZJ:8D^'=V52&>.9)'SR"<--V2A5//?#?JGW9B:+O8
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M;5.XFNWD3^E]G XKP%=DO3KD3O0,DVQDZA\EBTE3IKJ/^&'&E?V_G;+XFA*
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MDZ*1*B!^#7-/X)-QAR3*6_X05G,,8KI(^B73:LN2;N=S--+]G:E@P;CG_!Y
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M+!Y+4-V&,@63N7U^'?YI [%WX/+K_[]](S;O,5VO05M]:WM#V"YT1%FLJGZ
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MKZ=';ZQ)3Q_ND1\N"Z&5 H8PP$)T]288VQ*8?G M3"\FD[L_^K/*;1T>:-@
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M6.XN5&?[7.Y2RN:4 $A9I]3K@>>D'W]_.HBFK!GR>,LYPL_?7K%8G)QGW!/
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MT?W@5(]2V$2,=>_2N6!+K&!A7!B2PY<6180=F>P5=N0,-&4#"3HX"8(FDL<
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M':&!X3ZKQYSA@%4U',!V^%60Z!L>M+23[1O3.(!''(T'*GE@&0Y0_C=%$M'
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M\SQ77:,;B0<F*G:EL" _?%L(.J*SY-#*J]B5T)KU$R,]7\8!>?' &)04">T
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M34G:Q<CQ#P#")U*--GOJZ Z^(@S[?L1_EIZ0TKX:4)#):(!,JM:7TY/VIJ6
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M*?W2]//9)9X82GZFNV3MW>)-G&$MX/FX]?5I@7EB2KX#+-JN.0[DZ>;TYLH
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M@I2C:5/U:/XH9@G4?"8;<_VC$,<),%$O$5X(S_+FF;WP0#5P'./GF>Z%5X.
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M#S4U/I2LFF<R#,#GI1QO9AJ,!'0&EF[=TE^Z_P7>KT>\\=KNWF=JS=X*6 6
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ME8M/U/].M%73\PCU,U*#)$,@<#+QOP!02P,$%     @ )#B<5AIF4C]M'0$
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M5%4$OKT 7^Z[ %WQ/G/L3C,-7XN*G//AF/1PT'/,T*0C@+Z]FEW7D2.M<?Z
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M*[Y4G*V33A0"KN<3>;)Z_VR8^YDCYS&AKG<DITA_57-B\AFRK'#@V\']2VQ
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M:"ES^ 1FWA,LS>W7KV:R:M,H2?$&!_?PM@AE(OGCL,@X,I5"QAC@6'V$)$I
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MK,]HS/CF?D/P8\$TU3%*+^4*ZU&-J/0GC<WZT:J#N\*4@>ZCOIE;4Y@V1>S
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M07'#L[I3&^QX)]R(2F7*%Z"\I1Q?*AT'Z@U+@Q'$S?ZRXMRSM.G4%<6=.:Q
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M'-1LXP-7W+[3[,W(4,W!,-:?\<&L8B=VWY?G)YJ@/KV7&2QV/6H/OZ9SY]3
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MVL'[0/_9X[SJON^<RZWGH(7B'D.Y15'T!3FSC]SX($,V\'ZL7)^:B@?*N4)
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MGG"<RJONO/3Y8SG6E)7WHL5L;XR!6J^*%B@@]]#5T\<V23VD@"GWJ/P=$$?
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M4"Y]8U8;OV D_]3@($SNK L'Z,K SD3'>EI2XE%:!>[SRL!K\9/LJ7[S!K@
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M&[M+R:JX!^&VGAW@.!7P1;K0RJQT5<0&\M_ M(UA'%;!:R5[7C2RE2^4TYJ
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MAKX2-];,_4C^W=?P:4DC&]:M)8 ::.?:E4L<!-1[K<^F%+FJE5OP"X6T?HK
MP*_$?RV<?QG:7(PI^=&U^$'4> $2'FB]U7T,BLJ^\K4E<MB4W/4ST?/RB\WR
MYL=2*[A6_SKH!9IR$<Q>8K1B9TOV&-1M5%9B=-5S[K5*@F(H[J(%/EOKJ* E
M1!(7FW@!(6DR*%L3S[7*;&?&JO?W2DNCZQVP,PM67?]:6\7;CX-6[S]?$BDJ
MIGYA>D?3 \[#RVAB41TH[ELN=?)VNDHP+_R5TO+,[TPI>$U8;0/@^GD5=65
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MG_3WO$<--+J=8[=";Y$Y2[WG[*4T"A];3-7Z,YS(4=D+SS!1U@:R;OH;B:%
M /73KRELX#=@Q5DO[7QG?ALJ#ZQ1NX%8;SCQ+QD:M;-5SWH&J5/>4Q*FTL%V
M+I:I7<*I[<T871)&&.^(1CZ?CY=2-@DXZ+VSOEYTZ1JUU]AW3__.4NVM"0@G
M3:)]#*4.Z/>2YW3X,O-<ZU4@;L:O$EY.A:D_>]$TQ1[9)C;,'ITQV_V9PN T
M@@["X:^JB-*0+=Y0)80%-1;H7) +MQXY, W-@P+;#\9,/\I,RYU,1<, 2TM/
MK ^/E[=]U:$RS6F,?@LI".5:;?*37TLR]G6G6!V#BK,-/A3+?_I7KL\T^[KZ
M$M!YJ(7NLIEG/P_8=&UWYD\L6Z>V$O1]^N=U!?L'7DF,Y_>0UW1$;]53'*PV
M*2Q/<U[PA^D=@Y[,>'_RIV+2D'*']LA[Y/H8#8="F@EY-NL%P3[YH+5&S<$#
MP5,WL?!I\Y+\_'@!ZC>:MTV"=C_E\0DM'#8=B$],J^>SC@P/2.[]W/C/D>$M
M&X-@KIIH1"5-?)B_,UMYJ.:<^#!&PZC:V%LI8;U"([:F\<\"N0(<(<J60]S#
M5C!AZU4Y9R!%UE_8E>Y&^# ]RH9UM$F@!L6XM821'L,UAW/L*TL=JO5E19V-
MG2/.\,R,ET_ 7D&DEB$HX1BT8-_N0;]&[@TGEB#%B^UM"2M5<R;?5LXTO_&]
MCC>S=%BY:WG"6#F!0]()F@B&+"!V@T7T3_#9V:9"UD8D029YOC?@.YLQ2/%[
MY:_N'+&:&7;KIN'+ [LA+X+5)=I;U9!NO^#,\3\MTP357W4L-FHZ$(NZV;F7
M^5&L#8F&P\@[KXJ--?MS9;-MWL)G?:7B'2Z<2CXG*+%7IG49\%T LP%S/:IM
M/-7#RB*JW6D<4VIS=@+60_<3?[%HF3=Z3P16!O>Y^P3_<BA$)Q[P]M'37?,G
MW82F]\8,466N0O3-F>B'&XV1IL$72BJ1?D,TWG+$Q]K@LJE,N);Q;13.T^E\
MQ"(T'<:8_F/MG;RMW%NP\Q87.PO"5WOH9LU2TY [*6:J6\PC.#CV5:"33HV4
M;'9L=DB9<>\<0XLN9LW^:DL8J:_W<V !A%NC_$TL\E5SY&U))M##3U,C7U;]
M]?T_TP('E97'DZE8LT'9'9@VVA>&/L<E[-OL'L/S:<EU8>4A0F?ADY84)143
MA8_<S9*%E9D'\]17Y>IP7&+$<BDF]?CD"-#$2ER#BKK;!<_H#WO0KC39&E_X
M>$U!^J?-GQUL0DAB@0^Z>H?B,L?MMR8H]*N;OSY(F[EDA5">/O<R/B!']N[/
MTZ\T[TC6JDI=2V+S-7^D5987(^U;_M_G^Y>Y A/<<>%]*%=$I!P/@+E'&>_4
MY.]22RA1J5@XFSW7S;?,EIU&=W$5_+M\X<!B1JQ&OUN@38!VD:+7\N]TAK 4
MUYS$*4?'&Q]H)LB(8]#I :!:9JR6U'Y^5?5YQG*\T:15TX]F+@;\G>_@" >I
M F7&#,MH\S(A2$#($K'OUG+&V<RBM-FQM"J;-#JUFSEGJ*:$OT#&W>]_/L&/
M9#KT MSF<-E*&>,0P'M!/3'ZUI='"+1M-?S -DY 99__ZEVF2YL@"A1EYK!V
M=Q"/5*\;=6]A(BXKCQLJ%]< 7+OO0&U>\3KS;&J+'_.1=P=WY_C74$(U.:B2
M_"\0?[&]^Z]3<7\M:.88 F"!;4K#!%]*&/LYLWG5Z1*H]#SX9[L<V)F=<&%3
MCK"XT*U:?]4=^2CX:CGI'NA^@):][[" =:\_CT3*JO<81D@A#OH45>Y?4/CY
M9_BGP^$RAW(=Z"GZ5#O[I;&V&ZOI:HFARL<@/GP9POOFCG KSYV$L7U'Y/FZ
M=TPLYR3%*T+V#&O,A (TEJ@(<GLT39!LT:4F%[/$+[21^L;;]BN\Q^"BE.;W
MB]P;=EKY"_%BAI2GJ<1?F9]%*TJ^)%MW'I'#96R67L/^35$CCO(W'8Z^KM>N
M\;G>;)'VJWOTYL[3)YZS1]H_RDL?4]V6E(,HN2GI%@Z[$A=CK'^3%YOA)#LF
MDU'W:4-8B*?(;_=S8.GKXOMC66ZU:J<U69&O#CT!&RP!$TW3#/$GHJ.%ZM_R
M]0>':&UW^NP;J'(>EDPQ73#5O-T7\M9D:A.MYF"*BZ+WMC-MT<_36(;\6*V0
MK6:N+]L:HU#'H*M_+JU+-H)8<FS'&\T88JQ/\^94KJ79"P]5UFKJ$>'N%>]^
MW*STXM4/&L"\.P;-Y[?S.) Q76?(T]SP]K&EQS=:D:EWW.F7+O3[_(EU>N)V
MXY9ONLZ:.FS"G_E<Y>?G$MQZW\39=*0$F?YAHBQZ"(>H6<E>9O(QJ$?N<V4R
M@8EP)N?7HB #U]+M29SM>#F]<XX7371$<M?4-:8$Y.>#)PJ92AZ>Q>Y;#-TN
M.N^KM^RW6*IMX@]6\X<*(')(3!LR3#'T2S0U2GQ_.'$M_VQH_@H!M?ST;@]J
M6%%^:9QQJ%WW"NA21\=.$7P/G,7K5#%M?3TO]%R01:^8$%*;9*=._4EVCBY'
MB2)2K =I=V#*Y7MI#\OTI;)5'GXW]C/#@HT.M>)"7!BW\2<$UP%&$>]MZL%$
MT5F!PG&2TCA%V),GMJ+.TJR][::8 $Z@)V2#*"V]H=IU8%)8< .//E/N/6U4
M=/G+!48Q%,S&I>!_^<XE<=14._-BBR2'-5#"G$4DVB1B,[K5>OKZLYP7[U$2
M2BN.MMP./5+$H/TI0@,T_%&1DH@#*;U'N-6Y9_8,!=Z;ZOM%;Y:3CJV"*C 7
M"DH'Z)DRK J0VI:./E4@GSB<Q.A3NG+\%<K-I\]E!SFNFYTGW+K-Y$'8R<H]
MH/LQQ)R=&8W(BY'ZOU .^G]XA'T17%.8^ I#XZ+8I>4PSMC7?D94+/S]<T,'
M_FCZDT61&6<&:)^9>B_]\0G]ZL$+TNXUDJDEQ V%A0?50QNDT8K?W.J]9[=K
MJ-_7H#8S'\T(3R-T?G*\?WK[3%4'.-ZD?DWONO (H-K1E!ZC)8X:/> KU. N
M05AT9YC;:I/@VGE)[AZY3)SGILG[ BO05Z+O,U'M63(2Y:S3)R/V&<4Q7;0A
M17(291_=%>-&A)M_:R'3&YT2QNIBOIS7&+/G+PHZNC;T.7O.I";F;W?Z>:[R
M.#5%D ):K3;!U34\4$OI&!3V!H%^,"9.+ENUYZ&8U@5,ZWB&$*TLC5G*VV_Z
M%)M_F-C5L*A%_=!B'#G)XR!R=D3IW;'Z@:FMY)DIW_N6*34YC^S;:[BS7;T-
MY H23ZH+%[MK5"@!/#]6Y/D\T-O16?F7+=Z34>V^"MFR^#8-UMTB2,DX)/%O
M!"G+"2+$>H:QSX,(Z$A[&06#<O>1/TK;BFR&Z\$6R[)2*HGF^\/,V>R';JZ!
M0;@..U-"U\_@M<+FVBO"+AGZEXP4O')38O:#J27D]ZI:5T?\?B5&C!.*8C2T
M"R9QN8@4B%61Y4N[QNW0_>?2>-/: ^48E<,,T'8\1+>]'F"6_>A7H54D&GTY
MZ2&?T[O[#"#_?A@1$RW*.B(.W"&GT[GPS&M-^%#WMA%EN/2#VG<S-W]#WO?*
M1_9Z0PL^Y'N*0):,.K(2,]#.F8F\2-6C9(?6]F'93/.O-=DAZB89*JK,?(:1
MJO:-O;?7[#T/SP(MB$Q["C)C+U+#G"EN-YQZI&\QKK08-O+:P/+2M&+$#J;^
M=<^EA^HY_1\2,]'/-ZX<@^Z3Y6(=1F[*[NRAN>8,W@8RWO\=J1/)\/J[9C2&
M@5+4&V)\@@IFZ4*8<*0#E?6"_E<R)=PH9=V[?]+<5YWS^VE*PNB!>$T(JB93
MOWWI[B;*#RD(\%,\B9X;=L3BVO,UL17@]>'I:3>5-$4>EY<^ORND65Y]R5A#
MNWM&C^LLH*.0BAB$?H_H%0!=6&[]OHXN.CP+J;7;W&?\?E9%SDQZL\6,AZF1
MMLRXV,Z\$I@M?819I)S.@,_4I>0#+X1A*@UO4_D,OV[R),6%OKZK\0*#FA25
MTQ(E/U!#5<S''H,$ )W'[)[%UU*%?_AR;QP-7BBZ/9, 6_:2UU-<NYNT'X7^
MC-0#+&"%;@=;$;OQ_C1]HOZ 3%HOHU):Q(=]XUN,?[N2DF'K5S1TR5"J]5#>
M< UD8\9&?_AR0HBRSX.2T,4;H3^>?9FW:'T17\/:G),#9M.PP-"T@.<+8.[E
M=M;=CVW"JX2N?(3;II36'&]U"3^7OMCL'8^PUC*JY)"&/A'_FO EV94_R+&F
M?B]=C2^E-,WJ<YW$AZ3./R^I>Y@BE2,7@GQ"N_6II<6"S;<D#$&Z=U:I80C)
M7(XP?M1(WJ%F7S[T,11IW1C2<N!(.YQF.[=;>4AE)\-<Y[@UM$L!=%<&+IPF
M)9I^)GZT\EM"O/(_;_%<C[+LW3VGP:W](=+K1G+@!GLI4(03$_%+9"4@Q,S"
M>ZQ-JTX?.$=O7$E9-RD2=>0RW-,6OQ2SOTTJPFI>.>S-:*VHQWI&IZEEM>[@
M@YV+'@Q97OMW08.U'B#_?J59MCOL.1;?MK2=&_BUYI'NZ?_X#:LCV[E+'$'A
M3^!*939G9>">/*?CQ*1.+?WC]8DY\RPOYKJ F6AD6@QH/Y9*!#07T/&B'$-^
MB<Q'J4IKKMG_CBH]-+Y-6?P%@7P33) AAT+(TT!H,4VGBE(49=TQN6Q=7-?&
M/<WS@F&_*\XW*>/(JK'>N%@B\M&'/V9QBG%AMV!) (R<C@6?=Z]EAK!:9@K(
M;9I,KSHZSUQ>1;V 93QN+.KS#2ODXI76JYX1B6%QRC(TMI-$_"^'#!@6T346
MV%9/$J8KQ+?K@.\SO,AN5;Y<1GG@19O]O"TR-_LQ)S"^Z(G%3#)WSTH#>)(8
MTTK38I9S*>#]9LM7[N/?ZK,"XHQW^M7&US9\F\!8#"N [LY(C%;:$!T;MAJY
MW=0:+R_1NJ^,-TM72KF]1G0=?^^H%=%^WG7O !JIU*QIYM<T\JPN0?KM0O^D
MQ!.&#\XC,1-Y,<MJ0W7_*5<JRG5_7>478J59F^MEQ';]8GQ@H.MSZ_R!Q1],
M(OKE,4C0%2SD!V%:M6Y+]:X$,@PE8Q;O2/Q[GZ9>CVQ<6Y;>I3:RPHC0R-HM
M(5?1&ZW#9B&!QM]KFV0[>MDUF9@P05T5<JX.B=R1"9>ORD:I'JHBP11PUS$H
MX@ =V6(>XHP.?/; R]CI]\\K= YC$ +S^ M/;?F+O/*$FO=/WCW2Y=7Y3[.7
M8P>#%P.N!W;."0-1]HV4[IS_K@:%&-7$G!N!' X87\QJ6#446=M1K_"=U22S
MO:7(85518A36G*F:LHHV=^%)U6=_?,Z))UD]CM)P?VZ?7&'2N:MU^[_KSVE"
ME"WL5#5FIO8C.:'>N:7<U\GDZ.$&;A?3=.8E8-%%" S;$=84-GP]Y4J-%H^Y
M\K<N=-,49E/ L_"#Y\/RT.-GN4W,NCQ/"SO_?VXL_]^;I)%B!LCZ?Q0SEE+L
MD_D?2( AX35?S%W?V;3_U]+(',E,C->^^8OQNP1I_@G(B*PJFICYSF <G%F\
MD!2Z8Z:M7!&S;TR2[(0RTIR/"I VL 63*S)ZS&!F&PW%'^)Z8[^'#01'0P4Z
M&#,>N!R4JD<OWJ4T-=WZ[GCG=+#H#KEC?/$8A)6+HTN3T>M'\"^NV9HFHM)H
M7N@RP:1S./-)>UOUVX21NKB0HR)!]VQI6$=[G5RW-S&1$<CIYB>#HV0T(-ZY
M0,*B,</IY&[TR,^?Z%'.L'.[2EVX9975NPNW.T5W]U=(<@3H@@LY,F6!=T1B
M6(.S?$VU8+>,]9Q]VT<'8?CK;X%ZJ]!AY=V68Q#'E_JCG/&>*B#'2#%+Q ,7
M[>$PY63Z>[^'2=V7)M[.<Q978JB@(VRPSLOC^.$32+//YX1@%A$AT?)08^),
MT"_+A-Z%]709UUO>/'/3DHT'%EWT<T?Y].N(8U!WVU6R'.WJCU)<*<)MD8ZS
M:"=3AKO92G'RGQ<M)[49FGQ87[5'(:4HZL: ^>%MPP)@RO1K_;AR,5OF16L7
M<[BXU,0P)[U9X(5O-BN#PZZG5__U/E0PS>ZH#'5CN4V+(AG5HEH\TQ=,9#9&
MV,]!R O0:Y@ "P6EA/95COF%BD"Z"/"#$D[RW& H!)P-1G:.0:PNE.4ZM=X"
MYV(KCX_,UQ6Z;G^7^.0[E-J%FQB"7+2<76V\+7C)Z5NYAF.>6\81-<JU9 I2
M-M&;8CN9'RYAL#_1'711:!]"G?A&Z9OK 8<_!* ]'"Z&ON7E'&]E?L>*X%UM
MT5RAO</V#@LE]&L(&#4::"Y%2'=G/(TO6='B'Z[<5?_U2U&5D,7WH!SV_>ZZ
M,,;HN<..P3NU3V9*H=J2$1>3@RPZVGG [FA1.RA-;9 &#O3^W%>&>*J).E@R
M&>@O4:J^U?'VA0C_I3\)'ZF8? WA,D3^0N+ZKT68?!\1RKW:Y#OU>X^C1O1Q
ML_>B^^T;[+8!7_BJUH2@L3N:'B1+I0UGR,BU-TD2 ?6&XM? +3S)8*%1PZ?W
M6<H%(??8M#%]8A$9#W(N;-9N18YG<]21)7L<<NV4$V-E7KI6U!I[IP7X2YZ9
MD,(^(S6S1[5I4G#8Q(FUSOJ]=BYWI:E6:\3X@ZDOM7])4R+$SP:AO[_Q"<Y,
MF#.+H;?.9GAP_^;<%.[W4E#L007H'CY'/O6</%AX6C^R44C1Q<23R*OVLRMY
MTWT>W\]M7P9[-RZUNJ]FBP&_7 \=:."A6DAT$+RWCB QK/Q;Z)6-+X?#HF3Z
M]-=EB)&VP];T6$ [B16,%3+I+2J9Z71X[M&\V-#P3B^I>-50F7@,J@7W)/(
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MMCYMH_YV@4M@3SLG?6"\!-6149A:C.H?G'2UX/-QXZOGEY_I<;?XG7"OK\:
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M$).<U'#=Y=9+VV0A6&LNJ,Z*TNK;70W@"$UH7*\O-\$A=R"XH3Z.ZQ,M6H5
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MWFO?Y#G0N)H+D+VSJ_EGS1/IT.'IF3U._H;'\P-]3BRO/@W<8*+(2U(7G;@
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M!;)WLD>HKJ%(0]S6R<<3PVJ*<)'8SH7H#WH_;+=>!0>H*CB0'(0N[3"<ZLX
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M9ZOGH0PF>2QC;&4;C"6RAY"$&#L]ELF^C1F,I9(L(VN8&4668:8LDYGA>OZ
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M1G\# ("54[$Z.VFOBR],&;#_^Y ^3Q8/X/TFF;J^5E1Z^USOF5=Q:@CTZY,
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MG V)A!6..)5=D6D*YF&Y,XQK\Q(V=5\K695XJI<H!,T?M_ @0N>:^]NQ.M2
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MKXED-</-#'H.PP2A33KH3W<<3JE;/\3F>EU2+;3Z\&E,SOMKDZDU\DD#4X&
ML:>U[P=19]*<@*)S?:4?9#KP;Y1#,W.Q_N9#>C/<1-P9V#OJP?Y[ZJ[3HT(S
M@LKG-A&E2PC*;-";J0Q5BM'$H3XUB5R<3DOKG0]+"89T0][XESF\UH<D%'YX
MRJ;:S+>B.3^3?#3LB.7%T 5(8W1CX%VX-V7%:FQKD*MLQ7L)"$ NM5*F_K^_
M^OJ_8=J.&*?&V7>VTYB:UV>ZNW@2D>7*6#788X#^EL#.XN9;+PU[(W&GF<1@
ME,#Z,<#MJ\:"B^F'1ZSB#>%LD!ZR.O4')I+D5D77AQ3VC\%(Z;ZS;]R^2C9F
M.*3\A2R']3[29Q^\8,<!9-Q@\C;158B1DP6M7[IKX>U^[WST<K_!Q:T5(FY0
M2X*&>R+<Z%&DG(:&UF, YU$^ZWUU((XA'4X\W!GR+BL4U"[0#+G1JY85Q[GI
MS*K&H[EGKT,"^&&!U]^ZL%TIN_[;S$(O:CMBKRS56*,^F%=KZ-?V]M+0/'<M
M)JK,F\SUV[V*K'>D:8/ODP!.4G;\MG9=0-/<D]:? Q>DZ_YL8MA^1Y^,\EP%
M0AR_!"14$W9'A6P(6UZGK?S\?+*&Y1B?SO+"8 4NQ6GNPD4)+5JA63QFISD%
MSD< ="[8&PF'Q'#]7)+L:.V8VJTUO!WIL'PZ[Z9BNE#$NZOQNS4D:FB"GU]D
M@$BF^V71SZX;LNUVS2C'BW\RIU.OL\WG/6]Q\;*P5CYA\"8,P>X,1)?HF,PV
M?N:J<(#EI&*+PL6ZEDUS15_RQ0QN1+\T_Z/_VKL4L8P_!O#07^_KCT*,")H*
M';2FR.X[63-7;IJ/0J8-E,KI2;96O+96S5.*+^/:9NP4LQKTW,R'_^OJ*E4E
MR5]%:?O'^.ZZ<CWYEUM^O1WFR8KX7RO/,K[*1/.,NVE=,Y3HXWUV;:J^*U.R
MN%OG3PS7]9)S(;;<ZV*+7RN_E%8Y09V=M!CA_E*.WH5?+2X#*[TMN*S%S:23
M3"_>P$MF6EXOX>GAZ#N42V">9-,HZ1%+AG% X5;HINB;*(CW]Z_I*OA#_\0#
MI>I9R(/6S\6^JTNRMIK' ,SL1M3H!;O33LL)P3&"A4&UL-"(K/88-976WJ9P
MOXW.RV*-[F6SL!P7:YC7F;IV&YDBT@OYW-A>1;/[F4[72[BXB3'\U[ A@Q,:
MM+JL^&BEG#$PU<"S D--3*GQ27OG A-Q%(LK3?>O;'=X);^A+?#6W@1@$DF$
M\FTX^;6APDK79[1$1K'B,#_[\N3#?[-BHW,?@[G7SZ?U2>1[Q^W==DYX9O86
MT,L_/#I\><($8(KE&Y]>ZF>K>)#LR[=I/MA%B3TL&1ZA_Q4Q]@RI3U;XJ1+B
MPF\S%2!Y#/C[28A/ME[4N4LGY1>M' ]>1U/0%8WMD2,>\KSX.Y7D^U,*(>SK
M=O-T1[,F[:%EJ^;8Y;>+;XCV:RC'E56F=UDLL(0.MZ"VYK=,["Y8*T\U!O&^
M51 4,;2Y$%)_XWK)J=3_-^ _GOM?4$L#!!0    ( "0XG%; +W $>KH  $3)
M   8    861A9RTR,#(R,3(S,7@R,&8P,#DN:G!GS+MW5%/1]R\8F@$ID=Z+
M%$&I(D4@)!3I(H+2FTHG%)$6('3I'104D"I-2J0CO1<5Z5U* DH32*A7$F#\
M_M9[;_Z8F;7FS9LU:_8]^Y][SKWK?-;9Y[,_^Y:K^:LUT U=31U-$ DI"$3R
M[P!=+8'4062DI/]I_XS\7Z.@I* @)Z>X#@9?HZ2Y3D-#?9V:FI:.X08M'3T=
M-?4-EAOTC$S,S,PT$%8V%B8V!B9FIO_<A(3LWS7D%%04%%1,M-2T3/_3=M4-
MHJ<D:293(B/A!Y'2DY#1DUSU@WC_S9."Y+\,]-^,A/3?'*^!*:FN4_\;T'@#
M1$I"1D9*3O:?6?_K#?[7#R*GIV"X>5?U&J/A<S"_%Y-T>%HAI8!:;0^ST01.
M\-Z+5Q%4UUE8V=@YA&X)B]R^(R,K)W]?05']@8:FEK:.[I.GQB:F9N86=O8.
MCD[.+J[>/KY^_LB P,C74=$QL7'QZ1EOWF9FO7N?753\L:2TK+SB4UU]0V-3
M<\N7UMZ^_H'!H>&1KY-3TS.S<_,+BQCL^L:OWYM;VSOXPZ/CD],SX._Y?W"1
M@,A(_KO]G^*B_X>+E)R<C!S\'UPDI/[_&4!/3G'S[C4&54/P<R]&?NEP2B:U
MM,+:'BJ!>T8XYA>O)JZS",I@A/#_@?9?R/[O 8OX?X3L?P#[WW$M@FC(2/XM
M'AD]" ZZ>%(4+P+Z7_%2G3N]B?L]AIIZC-T\#>>C>+8?X16A<PWYYU0%E"AY
M[ 5D4"[=VMFB([/>G2M:.+L7XZCA-:-CI *;1L8,G/.^?A&A[VU:.X'-4V4R
M"'Z96I4<>"=30'BQ$WH%BC $P:X!E2 (4+$?"#EWXO99Q3WN8MM:@>#*PAUG
M49PER*^B*3<T:!Z[UNDF>&QPZ79:0MX%X57&JDFN97:^'.]R&76<._TT&\(
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M5F:5"9FEVS1M8PT?XB'!\Q#0M*HTSA:3^M#6@GEUUNY7/8=])<%>ZZM1>;Q
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M;Z>+)=+?TTAI_9@9(=Z=D)"]\#_-GA*?KCH[[[/LUQXTKV+6A#.J4&%6DZ]
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M=J_9'\4??E Z59LF*N$BIGH6M9(@I]$?L'! NZH1L4MR6SJ@2#^]X!FGL((
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M>>1I&6#X">4)4&%7R9V;69JR\]#D7NJR&'XAT3L*RPV,$_H!8X.\"PD#//<
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M".1ES1(Y4ZQR#7:2VC-"'1(S*M95Q',FJ3-S2?/=&O*RSVMDZVK1#@&2[AK
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MO(N)/_>=.^I2$8.)1P6GTRJ,I;MRY?>6351:KN9; EO7M2')3_X2KU>F;IP
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M;*'77B @_.?IS%H9,W8"N).M6ZK+>.]:3)$&H$?SW<-A&GO9$T#''52I?,>
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MZL*.!7V;C"XD.3\@(?)=E8U=&]T+XWT9LJMKXG0Y#<0B5LT$:>R6[$!DU1-
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MQ"15!O^S"=E3:#,SW?EI3N1=66Y&W,O\,)QHF]8S<F8&--MA*YVPU[7$1GF
M7UV+IICF66VE2TR?@4AWS\<G1/J?]1,[:V&H?49]#I.U_1M/7J:^+7+5O(#/
MS,BUW%2W$RU.J="Y7JOSRE#NO( ^6D,JN@LYXXV!=]IS+D(1G9J,8XI&;AN/
MA7?IGO66'Z9>ZW[3L<LCG"$]\?"1WY.*LD>84 VVEO-2:C=*STEW ;P1Y8
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MNR< \5<F'9W)P9X+\K]N6A,]2%:4NE"8YM*>Y1?J^\GC="I7J"Y%^K13[Q.
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M^7OK941PB6"G_E6$!&(,*821<..<F.7$F$#8=!X]B:EZ:5_84JT[#3#'?3M
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MOB;8AK9WC:;EZ?NK+SF#KC]/)5NRD1H6%;.))@LYC8LZMX>A]T:,[P9"7\W
MQZ?7<]D_<;7F0/ZHDJ32L74!FW\"W0GEB3YZJ(Z)4J\*#X4_:JO,3T7:\1JB
MVGYH$7)JU1TTV?"PN[&V]20D>50^_?HET[6NN&+WM82P6_NY\H@TLEFO/^@Z
MT3^> *Q"N9?A]0,N![R1K8Y^V&X\H(+SZ"2WD["=CO0MU\5B@(; >%>U+O_T
MM5<Y3K_D/ETK$?99?R WCXNQ0(B04>"W0+DS /-VZ:)]L#%1IW5Q[2CH>,U&
M/U/5Z>CG7,B2R&OM%RUHRV$"R6Q39$'DCE5F<'.B4B]7L>WWHP?]/,W5T;H^
M/XZY1TK.D7F@N$.(_(7MJN3J^$)V>MI:/;JYU.QU09>G GHO[.X;=9_&YA?-
M2EO:WF\4\+#(?O:8^^&!8ML'Z/ 6DP(\1?ZTE,KK+DIGK:BZI=*NU=(4@L;/
M+CBGOJRB>=,;,&#V.$2NIQ9%!]/HFJM6;"#E6Y/\CB@*^TV9J^M@?%7JU$PL
MPN0YY^:S8R>LR#E<RKE*]'EWE(U&W*;OW.(7+<87U#>^V^9)ES86][S3T_[A
ME!G]:XQ8>P:HY=MZ2MPP(4WC(UY[H+CF6\9>*52]K.?CI*N?P.L!/EUBE!L[
M \Q_6I.*EN[A8NOT\Y&*SR-_F'(_W/LY''B1LN@FG=.YF\M5Z_8Y[O_1A(AG
MWK$>W&-&?HID\7I1]UZJKL+S:PU@MU$,B"+RX CZP5MPCI, BA+I*$8M:T[0
MO@@E%NYK9<'VQ+9EX,[%QA_0=:O0B=S*DNY[[D8#^1Z*O26(=BQ_;P)5N"$2
M7:SL<<QY$=C3;^R)6#C"OP'+'N<*QU$F3V,Q_+ CZJ5?X-X<$5.0_26YJ*^8
M.,).?_+B%:^.+<T>/>%#]+#W4P=9%7C!,+3;SD;F<^.O_VUM\?^%P:5%+C_1
MH0#),VH1F%O$.E1,3IO6E-K(K=UP)W_U+QNA?Y\XLI\!7+FBL(S;GIYPOOD9
MI<XCR^M_^KVA%Y6;SKU;\"7OK<S],AFZ+C3V!2XL*+VXS(//D7._M,I//:!)
MWGGRYUQ@FL:6 7CV(4<@;NOBB08,NQ@="[\X_\WW#,#E#F:!:_M!@B8J?>2;
MPBN,'D[)OWS&\<V^NY'>M1AL/?SB[2W'&#$&(#?)L7/<1BD>J.%:Z5[_"@V]
MW)Z6*ZL>+E3*'BW\6E^ZDRL4PTB^Z17,%4;1A.2QC7/Y2-S?-=$4T?B^^7/R
M2&WVD:Z8!F)(K.;I7,]<HAC[0?F&@I(Y$1&GF&KY=51"N\C8'' -^K?QB!]]
MG^QU H(#R8:?UVTL(UJN/R^P\G ]59?DN-ZXR)]<(&_U+#G,NP]]MS"72X3H
MNAE.#%Y8B?M,DHZ&,Q2N98[*.PA]V!.^W5N:*!"7=P;P9?4ZUWBG,T#XK Y)
M<AQ;1>9^@!FKFM;YN5 88W=C1U:\[#QQAPD>WI.A^X6X0AUPY 3)N@NJ9Q!0
M+)/KZ8+JC"B:N0MU )HZ]E<%[(";(W%K%'WB22=5GNB'BU0+4=;>X;*;8M.L
MD)!VZ@#0L- +/Z,9;]*2H0L'T[5PXB<B_9P6IKRVQ-CT#NT%%WVVJ^,!/&99
M],]U5W1D0[3G)\+V*UV[CBL;HE\-GVOG/,<+"P8JGG:+IO/2S7<W %7C<8!=
M+EK$]W.Z0@B0\X#Z"RA:]TR'&M'[ED:B=SB#_GIL/@7/7WD,VSLT(-\A:7>M
M=#E($16SRB!*#;^:G"1<H*W MH0\$G50;?/R0Z:/E+NG61A!BM6(;S 7#QEL
M-@95]6XP2^+@^FT)@-X1>,P'@+?>*JL_ U1/=#3KT-D/;E&XBZ;6! GZHOFN
MS+[O_KSH36?FZ+FAY32GMC[ZD"F97'YH2C;YMWM]B%>[5@@%;UIF;:.M&O>8
MX>2K^H30:!#(8P3QTY']WWYU8=@%SB^.K.M\4H>+]QX3I+*2LE__OM-V4N"+
M?OSY+7"B U63T8FB6Q<5Q0Q2%"#%LS#$N*V.LF^* <3*6;) ?[KW:OQ-39Q-
M%_;T'89]'7'3Z_(,7&=8<D+0^\W(A]=)BCZMGSG^I.,TY1SZ]0%ON(BHCB02
M+9=0-N\<]=(W*$=$4*Z\A!$GTI_1?S$5GT1/D286=\:W>FQTVL@+WC\>PTVI
M,47^DQ7;^'=*8J]O[5W=Q/_46IV'Y]=/__<M([?>23S^^6N0ID]ML?CP)_E*
M03@)W/DL/)R:*4/W>[6"BQ%VU'D&N*C*[X?E\#ALFDU5438,=#E9?,')S(1O
M ';W^.ARH9E/&\!+4Y2G^]%G (/*X.),3*M<&/DW<13^@NQ=1K9:ES:QG4&M
MW592<1GG.'JC,ES%E6Y<_1+-F[PH1GQP!OA[+6/ND"?C#*!G<YS3DG\80);'
MTK3P@*-[*OR2U->JX'M,:0EO;R:@'M2M0Y7+4LSH2HL?E9K6RBA:%?3)H*^,
M@B&X<"V'/&^G ))<9_V$_ZZJ<J?"O(4A$X-9'KUED1M(8IAB7FCK$03*AY2Y
M3\AAA)HU+:P*1/,^S(\[9_J:WPE3UBR;.,ZNSW#6F9GN\X)X1AD[OU]XI-LG
M<<P*:-!W645<&VDQ+<![9-I/6Q[[3;^P4GRFG7)7AU^4@/Y;KLOU^8L:ER@,
M:3PN.8Q6@T!"#.341T7QAIV53>\%'X.;6(3'WR553I+#[]6.UDZ5H,^=C77N
MM\@&B9C.JZ';S+ELH^; [H/\7XXV@)#+.+5@0> 8[M_##[7_/S7/^#\;?>*7
MJL8!X9,)$S_/ (+ FP5Z)_?A[&$ZLMW7,D-,?B9"G5C/ *N] OSM%,A:TUZ2
M,%P"=).<-V_&EVVRV=EYR0[[&U@YY[;W^?=1S>XB^DXF8,6QQ^9=\HF).X*A
MAG<<(YC1F;IN"N%H*MX9?_FP+;27GN2@OXC%LQ$DWR56)')2N_UN4:_T+O2;
M^WE4"N*KK^+;_#1?^(RW!A!P;3L7R,4$SLA%%".L"<Q*3GU0E_'@P\QD2/7L
M,OXVR^.L#U'TM)R0M!'DR^M;JLR;BA1G[U)[+EY#PD>O*BC31[D2@82WDP+B
M):LW;G;3:9Z<YUH)/A27<02_1E?P'4'WZY7H&/#7:WPWEDVCZ..U65/#O^T"
MRAP8R;](8H2N63ZB?GJC<]Y&LY^Q'^I2Y[/J&GU7GT/?&QV];H$"'S[M PBM
MRU,+-QO(<R7PV]3A:<_]I\.@]C\ATR;+7G.H3GZT1OSAD[$6#=&,,K)9CUP!
M&7L?.^KY?%11]0P P@<'-[;T*11%P^1SMZY$,<ER  )7DI!NR!@L%UQI$<FI
M7NY4"L-VVF ^>GE5JJ44!*1/>-)^O,;$NOC>>Q.RAJ-Q XD3CZ+^-) ,8Y$+
MUT=_?Z3^/I2H8RY ED]&A-$,<-GLBMPYO-LX01&JF(* %*%WNC.WO[J6>P3]
MKF9..@S@$+[9);2DR\AH#$S]%2(B[V)DK?VEQUO7CLRV8-@=8KC0T('E=>PG
MVJST""I484O[U!N$ZYO5/PX$B-.>6#;VWALEXN+5DG[WSF.BA05SL@L=*/HD
MB8G#&G?_G5+KU?24XG]F[WN'.3\K;Z,32OJ*+J%>H A%+T2'U8EQ3CLHUC!L
MYP<&;1(W&5S?]"@W:O9XYQPLCZ.^4O#@")?!?92 O96(DJW67*07PY= 50O-
M&4:6KF3A+U.][/J UX)FYS:=BPD=ET<=:R3'%N'=<"56ZT=-]'CS;E]^F89_
M+C]QAK:%M1!][.OK<BG/ARD"H-(*<K\9"914XL['5;Z&+BY$3\;K6IO65)E$
M2B@*E2PW091^[W4AY..[S$@:O>:PO#JH3FW72&VSD]-S=X&E[\E\;X93:*;-
M^ E?YT\S6[RJI%#%9"S!"1(DE025$/2KJ\HZM)9T2>A)L;_U_F_ADWT:O6MO
M@34+ 3$(*?A-L@XQNFN87#2PUXF/.+1YB1&@#N@;;?UY$[<!"OC(^,:GUV.8
M/$::Z\H1GFAY48_ED?=--#2:Q0=$U>IPU.FNQS:?*C^+[G<!.HF[+;=^7CD,
MT!!CH7#-8[>JL<1$N]_3(36;9P 2:0FT"<7UHTJ[W]A$;WXE?+3M:1+-(K'X
MHNAAU=N0C2DKU4*M.&#^)8,,2=*7Q:9+C*_U:7QPGG!K<%)+L#M!^YM3V,I3
MLJG.TM>[;^(&2%_I=*I-GY&1AQ&M7X?A//,0,-\T3+#W'K$(%>!38NUVR:-F
MNE\6_C7RJ7.BKH#$KD^HPU8NHM\L/_LFJNNV?S71AVP6;YH7*GMW+CB!@<YK
MXPGA]"/0>+Z/HE-&INLAKHI>^3J4.Z3&A!D!C;B7=%[X*Y+/65%5\.G"#$E7
M%(ZJ->LR1;8C^.+O-=4W3"C"K9IHQG9J/UZ)HOY^7SUPY3VC^3J3MT7+'=)B
M[QF _D I5E1LO,[$4<317?!I57&AHYV-0HZH>PM*43\I+"]&<R,T;G_*ZW>_
M^;<1^/73FD7(5K#EL-_!Q#8:?>U[=IMX7ZQ*3+[ /#OA*T:;PEW;B")P)7IM
MUBE=GO)HHK>QA2$-$RUVCM[\S7GUX ';NURG.KJ;!UP7*19D:Q+;0N$[[*(M
MF'M-5+PQ38W?($VDIFW-<W<S]L.>J($RPI.I%*T@5M<0YU?)>]*CA8POC-O5
M_HCHGH\!ROGHM':Q7'V8Y%]B]D\;=^,#FFN5</"7,:HTQ97\' A2G: $/E\8
M4<U X@7IUKZZ$_\1 'QSH?O9*!%Y:U^:9^,]]2=&?;!BIT5N 1W'O8KD0BMF
MKFS>7#NI$](/F)-0/])K>R+QR=E8 #@H/DNY6I5T&>9H/#8^:ZL7 A'I359.
M@QW):!L!PU3>05Z4N]=#BJUL\?E]U]H%>T0MY+="$[[JF+5:Y^K]?]S/Y/_*
M,'W)J?DY#J#'SU0*-C?[7_R6XNSW?P%02P,$%     @ )#B<5@Q)[FM5<@
MH7X  !@   !A9&%G+3(P,C(Q,C,Q>#(P9C Q,"YJ<&?$NP=8$U^_+3QTD"Z]
M*T5 !*0+TA1I(AT!:5'I1)JT (%0!*0+"BA=.M*D20L)'07IO4- $!!(D!(A
M))?_>\Y[[GO:=\^]YSS/MS/KF7DRD\G^S9[]VVNMV4.8):P"# ^U=+4 (F(
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MV#NFI_\Z8;<$3^U)#8QD+&1L!'B8S7)IL7Z243#7%<[EN403W\DC9I\R4/U
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M4NZR>2D<R,8[\^B1V3U=T/NNU(J#8&O/XC:BIS(C#]'Z"B=9,487^25H8$+
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MVL>?#'9^38LW9)FSQHF4&/U7WD?XSW$]GSX/Y@[^ZHZ@%PR0MX).!RBEP65
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M_188F/HTUBS=9:90C9VK>2M[IFK:\S5.K11;JH$8E],S:Y^H>>8B(;[XIDZ
MAN7.5B;P9V)=. %JX8Z^VWEVG)Q8A.YI8IT^M-5S=.<^BRZ\VR.O ?B)4"MR
M(>P^;-O >@TO>SJSKSCUVF8L#*6-1B #"NUV,HN/7S&RI8(A346"2G5A_0<
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MP79J4Z1H201G' 3TY9VX(A.@#S(3<L! Y.<"'Y^J1& YP5V)! UIQ"'5YQ/
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MY#J2QZ+O;XMMG!>AU]Z ?P-XAN'?$T00*T5K0 *+,+G"ZB> R&DEO^H)H*/
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M[*DA3+E20X"< 'X)1T7BEW#(R#'ZRS#_(/TG,?Z=,. 78>1_Y/D[)?&/%9X
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MACOZD:_? 6KN3D^!SR+/^F,7.PYM(FMDYD:8M.V +UKB24JK!C_4.E8IXZ:
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M#2<%1&\3P>?T\^J- .)5#^6/:;**VU47TWT%TPP[1,0G<DG!^ZJ))F0%=IT
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M^2]Y1$]IX]J[^7BQMS;&"6C^]'M3]FVABAPO9HJ1%>*K]-6TV8 BGK#G)B<
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MRO3+Q&Y[X1_ CID8W!4M?XO[EMBZ0;!)$0;T\7]^>@UH[5V5:E=VB!A0JD8
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M_+<?N]V5H9IV=>6MW"@'LD?],]<ZLSIMAZ[D"URS#%G>J"C[XC)<&%C DF'
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M?JO1<YTO A$6<$.95%SUS4F>-#SHTE!Z =%HR'P0VBY>CF;U5_V.?]?.I\W
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M(-A@Z498Z8\8NF$_)(_+V0-;LLE=U8\9*L79U]O6A.;[33+T!N/$5M>S.F/
MW 0DZI2HMMR-B]03V$8M+15LM/(F67Z49_U=?/C^YN*FH"<I4WO?05=U1172
M6>H&!MWTIMT2>G5%!QM?7^-BRUE7T]3TI2;MP>Q^V4-&_>48_;$ LFO&JG?Q
M,H"B'A".[N1TF[=)CVZ0\G^::/)FZ\R'E4_A:;PQQ^[3VG7[K'4ELK$G5$/+
MJN=%1$D;X&0@L#C[LQL_;TIOQE1DKC.J3/\C?P9.]4E;;$D.2E1&,>/QBR<1
MIYK>[^[.'"\GTWVE0KTH>=MK";MR >H_E@7BG9X)L# _]AI9(G=Z3/EMD"SC
M9-@9)1H&UT+K(EG<EAG'Y.\&KD!3/MNZOOOAS3^1VA=7%,DDF*-BNM:$6KK=
MU^IXYE==8NG6"M]N=-?=X'!QY(^+HX:\_>=? ^+TO%D/'P]J<, =&IGRK0#(
M67DT\>JH',JHI">,5M2N*7_S4T)\1']1C7-":8=PUQMS >*&/\.51%6JB2_K
MKB(I-RQ?$-+6>(*BY9$*XT:X]E*0^0*5EV&RB=?8S'2@8D\B!>#?>Y+!F(IB
MH-(?VU/G5/:HRJ3WFUBO_LAE4PV$FQ[*1"US8>N]M?(!J/:X8 9Y8^I+2?L0
M'5K2*PK4!3<^9=+"N.]LW[/>KYYU),$+$B2ZR9'V#X<VI\J7/B?$Y[L2^2:D
MZI=N]"P\GJA,^1$V,L(>PY6._QP#,OQ+8?L?1D [T.C7/? -Q)RM &XO@F"%
MS?$ ][US15R9A-L4N\ZD<7Q1MEW4'K_--Q$YF-)P3W;GFVBR%CMJI4%F()=O
M \F-$+39R)'$,32FH"C&,36M8X9@K5]_<AYRDIE:OWI9Y<DF"TIL==]EBK&C
MKH?$VF$3I%N.?[I<;;_Z)W=.9/\"-/Y\9)C ]^/;$&;;&IR(=!@E@6O@3$LJ
M5T3JGF7\?/>CRM72MO!X^NK$@^X"]])[O>^>TH<5)M#(T9^N]]NQPWV]RN&Z
M0")5O+SY=2PDWF>8\4=O(VVX?EM-FJYCMF-<_,A^0%LXQ_=W>;Y*F9?U(ROA
M]7Q45(?8,(;!"=9@%]V$8&G&=@[YH(ICHS]%.R1R6[#^6+032M:'@9@^-2#G
M6+M:1_O\<3ZQY5W.DU*^05^O3!,&BVUM%Z2OY9B3$D8^&)^$"*M?0V>7$+_E
MT$ZH"6MAQ*PL9"C+U=H\\N^>*MLT?KJ%MBK=.<8)O@X0(NT+H<EC]+^T;U%>
MV$&TCQK;9 <'\+7^HZ^5C0B8G9I=;JXP*\^H5O$)75+HR-.9\6MK'=#SI@$U
M,(R9)0ZV_0!#7);8I-@$,LBE_D\T7W;QVC="V50O[* K8S"V^EJF 2ZM!O6A
MX.W F.L/%AT:I<6%R:QC3 /H:2V 7_UQ >($,VI\EIV$'S=HWKP3II->X2ZM
MD+83-_.I_!4HYI1R><:H$RN2A/TLP^1FB8QY>>0;(._8V"=[X[OUDF1'D4$5
M;'N^(QG+]$;>@&;0+R,QQA?"^G'. FQL/MD?&L9IG\#4603RAM3/]/](#+G4
MPW9U3*;-+2FG8$GUQN\!/\5%3I-OIY.\'2 <[CR5[G0'1UV%)C['!N\V"'=4
MS,BZCGH=B\_W2)RR/[)HF#40=[X>*2B5<V\59X286J&11R9 2 DZJY6,:],3
M1I/]S3%6XSWL<\K:_NSDA\8+E3#;&KPD0:?I/(^USY:+V(_=3?5&\WBXX:TG
M?"7:_%H;WHH%666K>*O+C7Z4O4-6JGJ5,BCDO+*#$\R=2X_L>1Q)L,V^O2/A
MKE2GF/?.@V+(0')$EEBA@+RZWD&/F,^A!>I*YKY^7X0Y&T[*M\73]@P0E:QV
MC+62%88$J>G$1%VOQ3T[L+5[CA>'Z]:.OR1R\>0RY4::=DCRB]CXZ,H<9]Z7
M'AYJW*^IUVT+E_9J6FY&1MN1JQIB%8]=<;:IY=:S2UO31!E^ :S><C34V]?G
M9$]%NTPNB+;D1U+6SN_?AT-7P69;R ;_GAV!Z6DTDDUPT+]T<5,A?_G[FE-+
M6]-@-KVZH(BF-48B*8?D<]1Q-_ 4SE(,Y,NP!A</&K9D#(R/SW]'6VV^RK<9
M7X@UT9#Y$,[SOIJ;6S6.L(/9BT"( ":*?POR85:/HPQQE"G!I08^,_8/&H.^
M>=#]G/AV-3DS>Y'R+E:)/=<+?P6N3?Q5!WR4&LX^Z;,:MB1>@,Q^2?IN?[TQ
M:[5$3L?^=:I&2T=P5E%1AXKJSC H.-,!%]0S/]C+K7;--:/",O?-=(_' S>%
MD-IVV7+.:\R,J)K(<9*A[K5V_VXP/T("2-?"5L<Z X:NBF&J&@)R[D7;4@J5
M)?/?DM,5.?:N7+=IEJP9^GF[2Z05^08,*L3F_L6)]G8RGW\P*%NPTRI#OK"V
MUB7].J'MN)^!6C; ?!/:QV>2R7<1%($7> T@2 =K$"9]= &BWR!R8ONF-[W1
M4G+?[A(KG3G\NJXG^3UX%&$&[7<A<^BR:XKJ360!KABP )%;!E0:Y^7>A;T,
M!*,AYV2!V?TYAUX.$R'1)YXER10^G=1(EU+B#8(5SCFBHCZR<5RNDN?1M)3,
M+GV2M;7P[Y<HQ]!)KA@,EZA:GED,('@LA]N-\%]=8# ]Z#4+I(J$^WNC/V2(
M?BQN;OJ8_?W6+0_&"F,0KZ>^=\P)A(3 .PU7Q.O 'P$1OKZN(DEH&Y7'=0UA
M"M"[_'/62IZ:-_WIGV60:<Q%"<10L%%;_KNV.,TDTD(N0")!F,23O\C#VJMG
M3ATO+D!AB1>@;SG ^CD>?"X5&:(6CHTBQ+0JG@>H7X#RIQNV!7O ERYUY>C/
MOTSJ?[+@_Q4\'F-T(7$IYG[*>T7<)-Q'Z;(<^%?%\&]<SP/Q_GIB\_A:4P#-
M=4/=*\JK]#,A!G@/PIUXH06O\H]LS"03(MV"34NE[POXYH:M6+68H.[R/"=J
MD:*D*:+C'<+8)@+;@ZT<D?JZ*8(4?VZ1ZAL]?P\OH?'\U=6W/?L&O$$SS3#%
MXQJL:(*J;LE&H.-\IAMG;8 A3?VIP_W _;YG/J7Q;J_GLLSA,Q0Q1/:'7]O<
M#^[6EMO8/72*6$L2B./E2.I)_#D5-]./Q!K:L6]FS ."*-N"4EO7,Z=.;X7R
M2H/B!1UO+_;L>D>-?<V*V:#TM\[@KH M"8=IM>^Y1I%39*-"G@6\$M^N/4&R
MZC(0_*FK62Q8(C4$*:DV'B*\MNV8*XG*B.'<ND @7ZBUN1%WE!C5@ ^JO?\=
M^U#2**#E&F&#/>$O.+-('5=BU@P(HJ$)9Z(]$G,OVZ4XPRM>[7K4+T0VA^NU
MI^W8>W/^A(<]<[[#R]AN'SI[?BW<M+$E"1,#*_+!?T^68#D"X0SP<"?3M[>X
M3338Z!5)MA.:3ZK?#(1B]U9'!YA"O6#0[HR(D*DJC\J7\!<%[N_8IY;-D8%-
MGLGCC\/+[*E^PN2G"7QCK^J9%O;0Y]D#+67N,C)OZK=#O4NU*W"G*374H?=,
MGFX4@*W'.-2Z="?]'8WHJFZ%Q,4=#NUD7/^JLT!MTJ6B8\H0OMF/0&Z9=0@"
MQJCJA4?!BGW*50U5F[ES WRV1[U+,A\=%;^(@6QB!3WF04\*N/K](#6->R3P
M%].JG$&%5IL9$9?U_%_Y/@_6ISF[/>8)3^7*I/T6DW6<R:F^W<F3#*YY*"Q%
M^C^6U!5;7[79 F*"8D"6ELX9X4 $OQM&)5*,;-U@(87X $QZ 9H]^G19DND%
M7_T*8;6[0UQ\  ;!.'G#,5^9+D"/)#;^7"9CJK'_>9?E?PTCIQ".F,?C'&2J
MAY=<?WSPU+^$DO+RK<O%D(&YH>DZ-0B,H@?#"63^4&>T#,OFF?QP3T"-EO]-
M31^&^B_'HVR9NJ8/UFG=,U[]^+GU&+:AOU+Y6-FL7UF+P":\U^[K7F@#"S*H
M__5[4NV'2,7,7\/K![2GLPMQ'J>M,]-J]$ *"OG6<+$I\NB'E*O4HXIA9S$O
M[I<8M8_=%2BCVW-9=ZQ[Z>(\#+/G3Q'.>CJA&5VXT5A) AU*S[G/,BZ?A^'&
M=ZNYV7>40V,UVRMQ"/G]D[_G>&M8)QK26QUMEB,^7G\.[L]@C.P0G9!$:3W-
MZ$'_6F]T,E42ME"HH0+?/*HT>( GJ[S,.;>TFJMCX"QX X+-.($=FS*X?#.J
M9[XDO#VHU'RSTJ-P893A*':)DD7!(N8.?8E 8?IQ!I"-^<K:3U3"5I6M5M,#
M&AK3TG(>(H-]R0&OMR?N]RE_7'Y@KOMLA_\KC#O/3VT$?X>/:ZVHJSH=(8X8
M[U#"YA1A'<V!^],,/ .!:9G.R/)OI1J^]$R>^GB7-Q[IS_*29,0T93,VB-<)
M/KC$-Q<@%[NH' H#&CH(/1!KE#$)Q*SM*JE-ESD+]5^/U@>^-X/JXI@9E<>H
M.C$QLC' 7D]NHV8=IC.!=4/9MGPU&_(@O,\;%BS'9[OETA#;_R8U;4T1U$?C
MN2"@^L4V+P//S#MVW>5_.G(CL68'B%V "!_W$I#+7RY=\:S[YN?3]$M-'OP;
MA,G]1Y(;KU(FYK5?OP )5%V*LNT3Y$9#9<S0O_08\F\]WF#^'Q7T_PGRQ,T\
MBF'N:E5@Q@O-8T!FMPQX]QW;LK;54JY9[=R?>B4H^SG9V)V91)1,_COB>XX$
M#II Y+&"Y?;GB-3-V#TU2:,+TI4+K?!Z]TO)^$!V]9#KL"KB8:MTPU1*0T/G
M'VC?\,C$[YH6W 4(#8U68X,I0%E<U/@;9G8J-$;+Z#)'Z\YS**SW;&F\<V[>
M..G:XX>%HPU"=]HUT RT*_?<%W5=&1IFYLF_W JKTJ<<#T"WAQ_C<0/E*.0;
M6==YUS=6V^F:/>=9$G>:9&MZPEXKWB3SY UR:D;.51\/8D\B$1RN&9RQTB69
M%C5)E5(>/O%J.G\4AB@'?-7CCKBIWMVZ5VW*)3[U8\K-9_>TTC=H87_QC^][
M]_U'EN;'X/EJ]&@\@@%PFNE3XYHXS%R2%A4O52O4<;2_%R<025$W$HAN6PFS
M/(DAZ*W2\1D/F 8&)]3X/.Z1DCWI>?Y23B\KYU%.0'44Y&5G?%HGMZ3<TW$Y
MY!771N6GM7IR&5^3&B*?H$R$GNBCO9.&5J\>)LXAT?Y]N=1PJ0GX70=LB37N
M,<>.Y#LW4>-(:GCCRPKW-4_2]=UU;%5,BT]!R)OY1_[3NR/+E0MG#P:9LYT:
MW%9F-'9"7-W7/22.4V?JD5<W6^WZ[&C,X0KC595KF3NMU6^EEI;279Z\+1&Z
MHBW:Q+Z+X,+I)V&D!*2,-28K&SP4C+ZG^[V.=K!GI*:_<^=:#-9MK$P+;>FO
M)W]2R3CT-.Y8OC0_IFOLWR2-3A'DG80Z\];(O<H;Z"JS]A-D=XH![2?2$W^"
M&53YT"HV_EK8GWZ!E161+E44?14F;Z]E<0JV[-AFI7UNOA8>OFDJJVN4GS;P
M=-,XOU)?7$:*G(P]Z@)$K1FI:K\L<=6C&<=CP7!GR\I;<:YI;S_<SV9%@2IP
MJ7C/9N'U[<VG;@&--7@%PFT<92[2H120T6ZO[9S,M&AM2J,O;*J@=@^[?3)D
M3[.7,8WU[TXD@ZO]@OHD,L*,M7_5_UA]N-10E''#FO3F@ZP7 W?6Y>?J(K:\
M] XF[BS>OL=OADJ<LT)IA<O#CFQXNN;U4@F*-+Y0Y0*EQB3&/S<C[05X6N8_
MD.\_])O.92+<?8'&7X#8K385QH $XK2*1*6>,:L>O;,X#_A>H-F]*O"G8>40
MI39D%(*WX2N.?3%0_D,SCL5NQU^6$N\W2_@B3!5)HF8=:&K7FQC600-H-I6C
MF!CG7.P\GLTPO"QLST1LI=GK3WVC#=DQ[")M^^<L_X?Q&PY> RX6)B,DPR"U
M?YNG=X=%^2%J?N>E1!E@'67W%L'3FV>Y:>BB? &*KI"+7<!'N4K72&3C"JW\
M0DR0TZ^&1NF6VZO1B3OBZ&H&XJ\<<>S.:&(GB@H;F>I?;*4N 3P\H@N@WRCJ
MFWD6\8;S._V)JD]U 5&!P-H$C*CR-UTM/#/'KK^5\@5^LDCF!/5F/5AXVY.]
MI"7?1[ X3V^HCK5,:WI>2M"=GNA2/AS3*X.9NIM+<YZ\JORS,-+KP]*Q\@%D
M\(F-?G^4DSC>R5*A:H4CZT^S3$N%KLJ0 ;T&V*G1J-\U3/([[=6\WHMT(?X2
MD1\MGM(SM^/;[I\7=EP?1C-P#LRTYGQ886I @I< 29CO2U#./'D2*O*W-5G+
M8OO#C]ID#(-->>Z0FD+EQ/@&]S8#KJVKT+"&8;?1OJN=$4;CXAQKN[,##G2>
M*\H/+,5^B##ZK;*D&+F":_8W$<IU;6JRG>E=Q_Q"N?V-"%8%SXA$P]3LV8;1
M%5CXT-^:I.X[(Z \IMOG-9TN=C3N.4+8P5XZZ X$>"2WPK-1.[KF.EY913ZT
M_O+W2X<HVZB9\8Y%V]SHZLP+D ?V!Q;?]5'U M3C^VD]]PQ67<A9@G9A#/OU
M7SB/>=_+UA<WBOYK1Z%*X8V.KI^9*@B#/5/X]4C084UA\7?X^%=&S:?<#HF5
M\'/\BU%4O 'J[D@4FHG3'+#8+8Y!<S1'ER3;B3<QO_M$WX>]/9[O4=J8H/I"
MQZAW,HNO,*5AQ_UPY?X%Z.\ZWM *,9:1T.0!19T>&OP=RD_-<$]-_[EL_NP9
MO8-'T,L$'HFXK&/VTVV\#,")88HLGBG!<B12Y&17",D6=Z(SG1I-XOV9<=W-
M=<[^!22VYY?%T@^, 4^_.!"!@]I.VK^_,N\7VC@PI],M&)I&QDL*N?$]:PU=
MU: :U\D34QD96Z;3LNU?:+J[$N4XJ@2DXC5AH[VYG-7M$&><1$^:Y;.OS7&5
M Q\%&T(TGWSYN:#DMWA/(BE52:!C*OI+;/=A]?>]:'#=)>WE#.)F+!52BZ&U
M+9.B*;H'1]K\.AXH1\F?P]+JO3(KO;Q8!D29YBE_^^38ZU?6 Q;R\(=NS1$V
M\DZ50:<[R)33LRN&#]DG@^]%MD#8"=+8] 1I5#N.*4INZ=4:N6R_U%'M]Z$W
MOTM%\T;EIPU#-W4*3T0,XZ8*JQ(3?!(!T:7(7$RLC1NFS\MFLV;EO.PP?6(P
M5<CJ)$!T#=]\&F@V:<L"^*.J28J^ _[WO_SBV(C\^%)J^OIU[NZ7O@-Z/IE:
M>?GY;!BF"%[SEY0\U L%Y-7GOJJ9QQ\ @\]P+\ D>+52Q4*/4LHHR&=26B@Z
MZVO&T%67=*CFLYLT0T>4[1\O0/84V)EX2$,[&'VNSR/126L'&!C6XR@FFWX>
MC]\W&GMPRL/!N?Y\:"'K6=;,U*[9G3NCS477GSJ#3*,"]K5Z+T!SG -/8$&H
MW BX%\9#U! +#9'VJ'[I,\RIF\PMLQX"%JX23OI&0C/"3'^0D6AXGJAJ4>S*
M+XN%1A">YRT0U'#"1R/Y:8$C$<=M2P+N\<O0.<>5IBSL3QIN3([!C$K*W;*G
M!;STK(=Y_FH!.*J_4Z5N%R!&!!7@=-=MG+L#[#9O6^"EU/2Z*=:=V_0!Z(^N
M+_>F36[?7@2GK1KP$5O7SVS7[4H5?J12?EKY._YCE:F5V9L;23WOS'ES>KZ:
M/3NDPN8))/2$@@67$/V!V:,Q/'I1_<K!3;T?51U5/5^:Z4%WU&'F*O>D%3WV
M8W^OOUIE5#:;N68?7S">=ED#Y-CO#@0<EM""_GLU+%90!&(_4"2P(8F/3P8A
M>__:E)$_K/U>Y<GHOI;X;ZL&6:FYM&I#+F0;$.H+T']LSV3]LSUC6ZOZ+Z,6
M_V^C%OA?.G@M7D'2)72@_HY2L+/H-9B5*.J"I&T7]D<S!&Y8S5LEILD2:_V)
M7+^":B#G@:7](X]DS5[J%5:-RIPWR*G(L,"9)SUV"1JN*!PO;K%@N69_U^+6
M@VN,NHHOR48DUF3F1'N07+X&M&Z-.?1MC=CTJ ;=-QD8VZ^Q\(^T3V)]UD6K
MK/CN_3:KA4%77]7AGRPU)2 D>)8@.MG:8P1Y=]G8OU^R$,<:,][T8..5+]4^
MP$.L:"^$O%)> LJ@Y<MKMIO\6+J*OKWTFL-=Y8PS]MA()AI) 3>CK\?ZXF<K
M9OLNJ.-7E29F+Z ?#Q+[+]G&[VY NSA<O-DZTP^YNJ4CR5#N-I_??Y[S4Y$F
M[=;]'!A=SFW;&?PMX,9>;R?C7RGY%;(Y0-?R"]W+/7"*4'K04Z8[K8QT5V!"
M.1)SC6=Q$R'] 0VR1^6&Q_+RTR<SN\O3IWPL!5P&.:+9\*< S>H%*&YEKA.;
M.FN \-FY #GM[]I*9=:T[2;EA#6J\1!DQM38 "<9)N#5K[_US7^27T3_OL4W
M\GK0VWNZ=4LB:;IT\[.^0:I/1V16TMI:8TD/!&MXV!)Y >H>R9#T</VCSV/N
MHLL&E?6BW(UADM0R/F0_[/S;Y.#U''N[YYM_7C>J[:,485/28S+_3[2:4^]W
MSA'TU^A"X!M>Q07"LUOA.%/=\%:@SJ@,6K(<8*@DU7S[.CD'U:>=%)O$WES2
M!?@=;&5'A'-0J1L'5J5VM&R1>UWE0PT%/C2+R>VPW'YSLFNBMSI&JNG@- M;
M)#:=JE6G'"B6W^Y=\6]6Q?^A;A$"*:>,F=U$W("I<*E)CO7Z#!Z_AQ!,?-*9
M W"W;BYR/4MTVP_'B\*%7UNTDQ2\$A4Z]9@AGE66!4D%5Q)-S[73%>=DX=QX
M9[@BKCJN2E4%6J;[_ 9T'^K+QFRE;[9'\7K19V@I[KC:9((H +,S;8\9'^T+
M?+@T6?+2TVJE7[#ED)9'%%M-B=W[RX ]T<!%3-?X-%F.9/SYJ2R\:0QEW#-2
M<Z:;!4,?'>XQ$$? C*K"E7-;9Y"PPZ^*QO7(6W2ES%'Q-7$)P=MM5[Z($U$_
M7OWPOOJJ#O@;Z*)4_8$H27"8)O(0)ZY^XS3C[.#YU<'NIB823/_H"O>NQ^X
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MDI+1>T:@16)OH:#__^+L/>.:W);VX2 H2E7I-0HH2.\=@H4N390J1*43BH!
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M^Z?4A<.8YA)8U5 '+&A8G+>7?>I &D3SZQW.W-A-3E<^S@73)&^NNO@V9ZN
M.XTCO(,RU+3ZNNY1:-_0Y>AY;:AZ3?5ZFAK):2?G_=7@_)RFZ1H8U[&#8VKZ
M^;#T_#62V*^]0/>'P])CRB ,*EJ;?3!BI3E?*$D-M"Y)[OF\_L-1VH95@)_W
M1VWZ5]C<B(,YD<BXN=B)2HF[KJP&50S99L&J;BG\'3EC,\8$KSGP>><D0A)Z
M3QE4L9[>E5C8=.N=^Q>JX.3V^YX! Y2W9W,F$KY8*X[NTJH.&^!OO+%8:=!3
M,FP;^BZ+8IC(5]Y?6VQ(//=:0R);RLHDYM@0JF0U%,3I+#N#!MOCUR>+7ENC
M:-_R))DK#S8M'-JX>/?UEONYAYR9BI@S##8.NU53CQ=I&0FB1<D$FLSVNGUS
M2]JSNL,/NJ5W8O#X$2@2_)DROEG*#]<Q;(;/C@O S$2FF6X569JO;M_H_FYZ
M69=5LL'E E@NE_7+FH$:78S!22N1H:PB=I2;!=^R@G)=S-"06-$[!3!(L1PM
MA"X?1C])51&G5ZVK 4UDM#.W,@XHJQ<[9@OA+V24K0ZM]=]\EU]57EZMWR=T
M?Z.=Z4W^(CE#./+.I>\X\$9X"<&$_J51VRML!0CSV-+YN;[)5'"+G%'*>85#
MV65^A9]"WS9!LYG3-](Z@MAPN]/B@S592KJ#HKOO7<O,]7$6!L+;6F(B\]J,
M;&K);N BI5@J\KO5H?MSE_#NW4:B,1\(R5]\2!S#,E@%HDJ!\D$4)_[=C53X
MV_-JBG1TMSE1(T'G\44I>(8."X.H%TJ)OOEKM:6^$-FAIGR/Q-=^E)64[RE,
M^T@<)W&M-X@*3<W-N,CX:HZ ,WA/M4IB:K0\4=1FZ:^+[1E^3WG]4/@#M*]]
M#U&D2@.3_$R0P[5U!E$-+T)B])C[1)A]69W,;)L2)[R8Y;'I9%DUC$9J8?R,
MMOXCOFS;/X=#U\$L0;_0D7%$<KQ!QX$N?O@!CC)<V;PD R09*#FYVB@?#]!R
M>KLIQDN?YO.+HM;LB2TYUO#V1S%.:*<!CCZLINW*VI"TA4FBG<C)<.YDA_Q
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M4PCF&X+]!6B]!,%A29^+N931&HA/.8!B7N[-G958U8]B1*=-VKY@Z#0F],8
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M:3%;^ZJCJ41?U'Q+ /#:6O3)<1].M?)QBH8X*#5#_FKA8_V? F_%$!WST6E
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M>ZKKT(F"Y;W+WR(">;R<#M?%UA+#Z?'Q;8T/0YH'G<I<JW17(*X;EN*JM\F
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MTK"5J"%0'/*^(^L9JL:F&W;6.F8:DHH+$-.$F']O<.^!,$XEF"#*$,5?U\@
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M6+M:\O%$':W/J:FO#-10)$1&2OY\,$XUS?J58-&_1= ,\I=(H+3]D]K)(ZK
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MPEV9'-*\BB,$_>:9Q%BOKQ=IT<=Y@Z*49X^V Y-_?MGB$IAP_Q"[O^^TDY^
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M]_)CJ0/_<Z K@ID<6X@#MRN2]P!IX *KBD]8YTVQ?6GG2B\_?[N;Z%EA??E
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MJ,9WZN/3?UO+A<]P39HQT#FU)]B^@;OS-OLP=RY'.F/CP#$^B"B/"RMS[$G
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MC$=_XJB8Z[BDS]4W6LA:L X.0%K6M]CA:'=)YN]9&G] _!3/9=9BO3-^.Q;
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MPJO.,U$U/A\J.JR[?WU.??Z :&U=T,=O(08%KC%L5"J<"C&8/331Z@Y0O.]
MN,2SGMO@)Z[-&8/$D'0W\YSKQ@^)+)?:']9PTGO>-[+JUAF/IU-6=^E-9'],
M.;VK:*?]JPBHGSXN::'X:2BX9[SWA8?@KJ^#^V'U "RZ5PX<ZCB^;M1:.R&Z
MV%%:^SSB0_(,_>3YRVN3M!2+Z?I4Y?04]?*5J6,\]'X?S:J,C&2>_<:G^4'D
M@-_3U*@@H8]?UEE^%] 5]PC6JVY\'6Q^*)ZN\?'KS]?^$FVI4:'O2&)")=;2
M%#64*0!)47^-CQ*IJXMVJ,G*'G.,%V39]=V@]@'XH[?UK&UYJ:J\3@I?OAPF
M-[>W Y P5#U_]I]OC1*9;/$G/%CN\D%EX 6.$=CU(#AXE=-S"51CCL_7E\O<
M;%;[(!+JB1:3X9K:8GA&YI067BJQV31@*@RUZ;D5QOC7I8IA LO?KQ[0,X3:
M3WX@P@"KUF/A^F@]YLX&V^!?02AS''_EG4327X/^EB8EO(T#M?44X8"3<C!Z
M/89@=2<6!^GP.:YGCE#01C.KUTY.+SH-XL#0]<>_!>5521*TCLN7CQ/Q%AA@
MQ!E7N'3H@UW')NT<AX2M,]^E5!IM'K(7'*&/Y8U?Q02F=^.-L5 #,_E>:03]
MSJ$9Q B7V:%49F5-K_U&%!.B>ALH0]KV3)O/0R*]X;M$>@6VM6TD_ P9I\0C
M^04I_,HDNCAGROE7DA3-,+,OV8"5K,4I:H(9\4,S?#'5UYE]\X^.K/ZCP$<[
MQJ:28P301:0_FYV1OX0S'4$1F_HU/3Q"H&4\;8=28-;17";DO2O98FFY9YR2
MPZ'D1:P2F5C8M>_01XM?*[&ZZ_1?KU2B1]#"?9\U!%*34T?M-K:*]^9<9%8U
M4C[[L0A#O/CX]^>#4@>3CXR0HA?%37>_P'S;/(%O)KA_U,>A']?I0<_56EDH
M<C\G9K\VFA;S[P62/ ;B[ D"U\;^Z_7F(Q!OXX.ENC(0H4NL_Q=I[QT-9_2V
MC8[H44;O#$$07?0NH@<)"=$CB#(1G<$P>B]!D! M6J*+WCM!$)T19880?2;:
MQ(QQY/>^?YSUKN^L\WWG_+F?>?:>O9]][WU?U]KWOJ\;).@FJD"#SS0&,K)K
ML"WVFGYYX&M?+K7NLYVZW## 1=Z- 7-<;D=R]2BG,]$5B_"K/ M_ZYAJ;5XQ
M@ !%R\9GH"Y?B7C+-GH[H$^$UME@+V&Q:Q(HSLD\1"HAQ,Y@<6UO1O>XM/$V
M4O[((=V)DH#7UVW_N(.DP\IN:7\CL>$(8XK@)N<CG?F1=FA*J?PR/?B2.;9O
M.%-08]_)_=\U^D.+8A=_6_F97S]$G*:K^)N$SUWK]"4\/J#(6;8H@\T;(<P#
M=E3FO99T8/@@W+:(XY[3>ZN[RRN<!D0"7,N,IUHM!U]0*?U267;4RBJNK K"
MQ!'<,G3X;P4D_/ZNJBR8EQ966:[26R]A;)/RH6:S<UL#O[I'F,UI_5SQI&\+
MR''*;T=$6P;SI%8@*XQ=$\LM_!W>_$3X9U9/,!HBE[XM_K9W9H[?%YG8S[\K
M _Q6[MTYJ[7-/7^ X>2(_'XS,L!JXJY7A'%3X'D&EAY"/8OL23@+3B6&V'3R
MP\HLK'9S+%<<K:R'G>Z/_]HDA/AN<>0U%0\\&"GYK54)HH:0+%Q> Y#\35$!
M'ARSUJ,,,UI")NH_C<B<5K]QO.K.I=M7=)K_P"4;HJKU!!]SF3=4JUK=$;2Y
M!S;M!]51-<4F5WN<?3A5"5!/^+46PA:B)#'.NAKU3( BJ49%TA8+.O!":67@
M]<RCR7@_NKI&8LQH!NPL9%.!0N/EL>5J8-^?>4V[/CLJ.LB=E$80]1[;5TC9
M'_S"@JR2>\U!;3%7U.$ LC4U_!K0!$N$,A.?5?\<&-3S4H.'YSF&E&F> ,;S
MBE6+;W67HFL/;%#=FP.*T>71.')$ 1687MN$2G_%\+&] \[:8:US"E%[(/P)
M8Q2BB:>7/U5C@T^XF:S!SP=4'ZT6I'LMY!9+SR05?*FV%A-U$!I[M]ZP<)E[
MZ7&X6F;Q@'W0DF%!,K)NW$G*X"\/3X_^4:<"UAXG.\\=HR=S.JM\D&FH'BA&
M6C3%. PENXK!<V*,$:\B2S KO5ST:-+X:B:-P"_LC._''B6-!=2-]F>"HH.D
M0D?7B8M ;1@[1!CP0GIKR%>;\653'MX.96PFO3\2%(_KV?@ HU,#PX@PP@.)
M%?"]YIP59?1@G86U<#/+1@MI(4?.*14]<C':;_RY0!/Z;N:=1QUA6%^-'M'Y
MDYYAT)*<)MJ_WMEKXULCC-A*AT)'M"DOAJC&BB>%['#(KX<*]M(NQI81E1R=
MG0!E1?0P@)\PG9PEYLD\S$@?3-K))R!$593M^<"MZ(V>9UL^^<(XEMYPHK*"
MISN\I\7MEL43%'G^^5]ZH&T_M>10UA^=3TI^!RAVO6^?YW.I;IY,*LT,X'CK
M*5]+@ZG%,D%X!VU%,# _Q#$IQMEP1KKZA<V^V?"<MG@UM-E. $"S+DE*2IBP
MJ<H-ZU-[C=-"KG3T4%G_[F:;WEK^Y;( MZ<%M'Y[ ?S^?$=UWN==,7N)NZ6?
M/</NR(?UMG-/=%8*!+\XV[![WOJO.U[HE 0@+OKT&C!\I(:_UQFI>Y72347A
MLG"!,(_:RG6A7%_6BUC:.CG.F?986MQPW<()HMYRGI3JX!D_*8K[!JGL))T^
MC?X(9@ME<,:K;O[+*OD153Y<0(&I.#%OK%\0^9[C/K)<OJXH!G)1I@OD.&/<
M496X2@ZE67>16X"+#Z22[E[\>3A*M7-N">+YAHCCRKQI@^0:\"+1F!J3OK<Y
M?-[-CGX5)Z?IX2 3_Y[&J_E)0:M/6DN^TH*)MXG>:Q^C4MVY) >*H2,LR#F5
MY7<YT3Y; )Y$!R_=@WK_N^"49;8'):6&KA6-/9?#@/@< OI3R8Y.\6.IN'O&
M& ?Q\/53?67>_]YZFQ6-C:\!40-:UX#"X;QK0+@K7CIV6%%,G:TY?_ M@-GK
MC]XU(*BSV6[I8N.I&NSF^V3O__L.O3B'J_AN#DAL[ZP5A+X7SXA:C$\_FMQ>
M-#7@(8A_V9:B)S$F1?[0">="N.<B0!^AHY_54"WV,EGOF^'66U+C 50U\8LQ
MLM\N!"Z?$@#"XZ$J4)HZS"ZB2^GAO-@C)O_VTNZR\5\BB>+O]/XL&Q-QG-B6
MZFJ[$$ZX]SBGQJ"DE$,!J,$W*9PVTG&$PH1O-5;>:M3JIJB$A2B9A@V) O@9
M&A^3JFW:."G+(0Z-S=^^$J90J%G5Z!-F8^8.!2Q.7@-(\7>AQJUHXRCFD3^_
M%]G44J27SZBDJ*16/V4\2I=/]R)*,CXF?+AU=&9YR3ZB> ^3,9"3_^Y7A)W%
ME,M04#C?ZZAKP.;\26W?,0#Z+'M(];8'UZ[BF]Q2"+-!:_W7]KHN9JI*8[XG
M*]5]CX#\9GP>[TZR2^T+F'"&J)2&$/3*8):$JV+BE%>EH=0=*R7)J*F6"4*.
MSP+'OK4UI\9+]S5:_]2<V02;Y;Q2E_1@>\"<E#^BEJGIAZ6&J%YLSNPM*JI<
M W \#9#0YZ5>2/:AS":F#FJRP8[^P, -S@^'^> ?+Z^B0X%Z%[[N+U*QK'X@
MO)IU)9!]S3*?BC*72MOG\]61<X@^'':@A9J$$QM44FF:VN/,F=^47 /6V;4<
M< 97\9V@"HSBT7B_I;2B62M6.7'E0VG&*Q8Z*3WY.^U,5U%XVJ1-K06R<[18
M:<$5R/ :$,. >1B('USP.D8:ZEP#4LWR^_.J'::S@$#Y5GEA-=ZI4$+\$'AC
MMTD'W=64TBH@V(P>3#*181W]&PM=_)JZG(UH#-.%\CNU!;^?!$]" [%4. 4/
MLOT?D&#=!0<TX7-K*OD;6]6#A?O\DGMGM%M'<M4%*8.J7L6&<J:2NM!@LO46
M^-%TN^?[7Z0PZ=< *E]>.^F(!@?B"U]DW(\(*^L$%DI9KIQR,F%QX8\WBQZT
MI*'LCG2<ZQ0/<4#D2MX>=J=JD/@)%!WY7#U%@1\*\H]$@)4,_HKZA1C18I?%
M1%JT>":]ACE"O(/,+7OJ:OMO*4S+W+2S-'ZS@M"7IMC;4.[]J_@J&,+@/P\*
M*OLR.$B8&&U<^F><A4*P:BLNAMO-\;66BA\3CRG<&NH?4?_H\%0)D\FH@3 Z
MH(X^Y9@/&=-9ZHINN4H?>E:EZT4KL#M9ISY*.-JZBND&/B143:PJ%*C%\;6G
M@OYR=8[;7D5#A4+0;K^J&RM'H73=7'\V4G8&F;TSYSO_:&:Z&KS02O5X/9-)
M5IU<'AOU:<9,U1##6^*&Y\/4ER[]OD,RO^7Z2#B@]:%^)7U>Y[G,64P1:A]Y
MGLO1@Q9L:B>+W7%176)M*'@G*::BN"B$ZCDG63C$.;_ 2^4:=Z-FLK$/V6QP
M:*/>+\NQAE4*PY[SQQ/8VSB>5R TWX)7"IYO3@>_6 -!M,VON/S%%8A5:@(%
MS=^(CIZI:E]]*AA\BY'3;5H\C?/-LNH=O\V>.37FTZZ@\=CGMRO,R2X^X!H
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MP88,_[,_96R ^K0QXFAFI)LK>L)CXU [1#:$3BG9R&#D"6>#Z)24DE3HZ:E
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MOY-P64AK#,Y1LL&_/C ^9N<C!KSPV[<SY) _ ">AG0=R@720Q?Y0@=; +.Q
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MXRZ>IY3'PWJ]++>Z,]]ET+L/>PT'F>=;X.2;ZS%%59CI5VFU?C9BLP;IS-<
MLW@/OI0JLAV^L5XLP2/@>U4&.[=\+DQ3^1Z,1CHU+N=N:>U^P(_G-NMNXV+Q
M?-5\,2RJ8U_O/Z14=Q<KI!,^_ U(IU&D!/ZR92\*G6CW3]L,#O&^!@QQ\2P>
M5+TIZ9J5-C0Y^=XTN_T:MSN\S>M#_-.(H-8[?MZ! ++A\T@=7>40L[\'WBF
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M(AQG\WS'X44T[UJ7$D+@8%:M?URO<0ICK*R'! )S645,M;MIAHBLIL3*^,V
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MA?:VF.WR-7Q_DR7U2)C!J#?JIS'+A-6\FDL/\W,,[,%L=G^[8P]MDV'HYL"
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M[6.(OAM>#J%_TJPH7^?2";['0,DO9D'[WF?%L[ DA!C%/@0?2<2QRZS5(V%
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MSV_--?=3@^=+5$D/"BW84HBICMA:>&@QXQ!F7G$)$$E]KGL[!"P0FF].R!G
M.'5FFW1,J="/KN##\NV1$%^#YF1]^=6Z&I=1,U.A08XT;2&?K)=)@G/ ZG3#
M<>8155&L.: -X3Q3OSG.4R!:FYA:0Z'H;!_]2.5% OESY7=8%,V$5$T]:8Q@
MQW31D[L4CG_&Q:\HU?!!:$8Z>:[V\]O9""GXWMZ&MQSR-4'<QPD7W]7*?L@E
MJS_Q %<?[>6.E+J0?1IMU?=ISB*6/WKAL3Y/[H=WEP#Z/-K68TNCBQ)\C=]P
M5ZC^)4"W7'B!<8]Z>LBN$A%CTLULQU(+V4$>KC01(HO[1:7US>H:XV6.<T4^
MROY)[-48UCN3#]LX>_'N_]$#_O]M&#O=B4KRIM N!XCYZ+;S)Z*:QP[S;E;$
MF%OQ)2GZ(X<-T>L=8)+HQ8_#4AMQ3-H7_+,]\=ML8E*[ 7B/W:\:?NKZ]&*_
MH*M62%;DB++5X#EGCEYTNLM?H,%\M=TUHLMX32X[ :VLC3W9&5P>=+*NU7#Q
M^$&0\2VVZ .\5@-2_WZ1M5+Z\.Y:>.X3TN\%YE9<4>>7>"X-3$\ZKL>W6%_@
M6";%3^R>XSU8L#ECW^&PZS&(S@T=""_KGBH(H<AU6Q.Q#?WS36JA]_9CG94L
M@.+T(*BJR6YCJQ$8I4)%B,>TOF,="!)=C-^?],K!_)1@:M+EW55\J\]TXZ=\
M<:NG%]S,$AY9 V*P:9F;5@AH*NAT\SBNI],:AGPI.(#W#VD/-*S?*)#AG2=:
MX17;%X'+=2I">)EX3''%YQ@>\,3]&@:FK3N_VSA#7M3G,B@]*(2\6>Q*M^4?
M$SF\%=!LV3R-UW;=6O0KZX[X$/+RWQ7_JA. UOCAGA9:#ZH>%'!D7RJ;=LUP
M9Y_>@NHT)NCM&RLG])>;-M%/D_.5P((80X99J#4A \?S'&\;7V"U*9O#,U%8
M_S.93 :$OBE#$67N\?*YHCC7K6Z.ZQ-G1=:$*(P=C;/W-CHWIJ9%7-N[+#-U
ME^@]B]JCF+&(R%I/X'8K&1/;K:5Z*%;^)BG$Y9,NYZ@.%Y_);\=7[903X':>
M:S57.<CU*F>K<+I89I='70+>WXWOILE3"R@1+=6K;U>-=<#$=3CT4%)EO027
MA VKR$Q 67#L0UXT$'%S?$4:5*/4:K,NC"=YWI+J06-Z_TO/!XG0/*WNVX;N
MU$;>"HB_@$M CY3SRV62ND(N*6W 3GOZSR+.,#9AL5H6[IC,'*&-FOC<S4_5
M8["281*AI:T1F22\F:GZO_OG;4VI^Z;HQ<"&(R0?81\_W-EZ72I>]RA$U,0L
MUSBU?.>PG'MBSGI>SOC/]15O %]*&]*.5_K CGCGMOCU.8+ DWJ\_W"LJ+2N
MN.$QWP)]O2Q[W/#/O;_O$A)__1;(!!PB(Q=YB+)XWRX6-,47IV*7]./@T(I"
M#V0>?5G:R6TVOH0DUAL'*5O"HU OC*(=*P$,'O%<T-F5YK#P>"#Q\I&V<1%/
M.!+1NI23:1A9XP'N8D9SY78)UB(K.ZJW%A3&$G.V_5_S1G#K=.1X"V]< M"R
MO2IW"?ZX6=,IHO37;-\7=?5IFEH9KZ/)S6<2JBI)3+VJM_C>"2+>(N(O 4[E
ME#TP(%018X'T5V1M5AG1+W1-8^&G&M"U5X_;OG]6^OCC2(1:V9?6&>U.ED4J
M#R@+?U$Y[-L6I5FDM=4)>]Q"LF[NT)9YM/!FDJ  'M@%8B,*XFP6W[\9]Y >
M?,T1Y$^C_5Q]=$8+S^+"3$^JC"=7_<4ZGS+6/-P+J@'&-PO@O/2#H&K?@8R#
MV!(E!=+=FIJ0>-W[B!#E#M5?8MY?98#8(9J[$X>K%RE$=A4FW24+.^.&FK3#
MK;>NU3;5KC3!5H%HI7__O(8>^;8M%_B#;I%HG!<I#ZD&04\;6R?X4+]"!@8N
MC'V5!_]T 2SF#B  ^Q%PC 9^N%L8AU!-4<7+I"[G,D$BNVZHUTZ$M1T_LI W
M<_JW).#M//GLQ5)6W"$L@H<.JE'LNB"-:TW<]SO/]NT(]-90^?JFG%KVT3 P
MFSK*G)@8H<;6RU98)AK <2[R3IHGB>?86%H,M(L>:]F]BKC@=V']]1)S"T2W
M-#9F\URLS+?^C;=E*L,NOWG+0R[^/SJW"#X$?*MLML F*G:PDY.J?\S%VZCT
M,.=@7]^Z&??8ZD8.>=!PY]7,QV.&NVE"_>RH"6F+9A-H1F]1K.ZU@UZSON>/
M'@M]<N1;21V[\?=A\?++C3(@968 /BNP^-K$&&%S>"R!<?IK >!A6^$-/6:0
MQ/*(R;NV-FS:_RFC(W WJ!R<XDXCC]]?(.%MBYPN"YPUN.IM7P/REM6+Y<4'
M-69F!W,WZ2-^B@I[@ORU;Y0@B\4J5U#!KU'L%Y7P2*4@/,]37%(1#FQ-R,9R
MV(ALJ2]K-NB[B'HD%/BTQ(A0)2SY$5W"#W/;+@'QO,O\\66N/#,>^7.;EMT+
M\;Y>Z]^WUU27*"T85U^^*#GNHVALY890:A#B\_DSD#/E%PF!$C8BU%W Q[*T
MB>T[JM)K=E7E474?<9DT"L.8EOV. 47AC-?Q&JA4OHQ>:J<W3U=^V4_G"*==
M5#3[XH%M:'Z$/P9>-UYC-NE^KW4B\[6GU9]?YL3/^;,)=#-BAC^_2TZH"$#)
M<#P]TM7<4KCY-)3[G*[GB2 \_M>U<$H79;"<\N85/W MP6*Y&>MPPS'-BHXE
MSG6ST'@9@WB 4=1!_U(A):=]DO!PJXLR8S?8!U7KA5?QBK9E&!.Q7<,N/TMD
M7[-ZIWOM)!%E"^  K_%-IQ*?$2+QLC8$*UP BQ?+ANV]J:]N+6^7VS.]<XZ8
M[KXNKJS_3?W^Z[V87FDPR]=#KS@4 '*C)XQBG,A51GC3<=(90*[25U2C9KSH
M-'_0CTE)HKTY],PW<X\HB1F4[;0434LML.PLVISR*3,[3MM@D/O@9VK4=AVE
M,D:\(IZX1T0E0@@&&,=]KR;IQ+!ULA;$O&"AU5@='Y3&4_V)U_51:ING@CB7
MVR2*G BI12P=YY80]?!BZ05; >C4!;A/B9WU@S)9W]D_FRV!=+*/\SSR%]X)
MP]I!XR2):@WW'&F:IZ&P<4?D=[>U88+ _(1)V)]&JM[[OY.WV%/R2WX[RB9_
M4#M< 8^I?R?__W55[']2H "Z$I"DVXIB35[VN.-0.K>I \MMK<TC$+6+UAGI
MMPA4R?XN;<.]!NGC%!F)06CE^5M":7L8RRA463RA.02[>*U=]$_$K68!_AE/
MUH?]?0<Y@)7GE+SG5)#Q+M)#/"S6?KK9%"_09:3MPI8$XB2$*<NP)I$J'U=[
MV8\D=: *"968D%SV*TCDCW1^K=]B:-!0':UK=;L"GTIV[FO'%M:F(E>%=^HQ
MC*$G7.E627SK^_+#<[.Z%KQ)[OQ3Z].8.PE.#:^2)+M#K<Y5B6YC*#("\WY7
M8QGC0DR[OAO5$U'IN2Z&RF(N!09#U6O*)7O*2<!>.ZIFF&R[(15$O.,L,3N[
M2\)J9FOZ_NKN@KXS5OB^QEWCYTTOF7O4USDGSIPZ6[D()ICI:*E%ZDU;AM%]
M*:M"2IW/?=+?I[HX/;*0GY/W/+IQOBDYM4787,2X\R*M$D>%"XHGQ7J::"':
M4I&:I^E7>9K2QZC77L![.R9F9S@),"3,L'W\I?4GCC\U@$3U*Z67/:U6 +Z,
M^['0^\N+URQ(4IX#6IM *9[TWD?5=EU2?&=@67MTWW]U4LK*D',.TJUD73<B
MDCNS-7 S<N>4UX<Z\@'^)#& 1$D AA9;$C6:"9'<&;"@Y5@L:63\<"IE9]1*
M\V;TP\@L2<[K^M3^91:M;L7E**Z!TCF"Y0&(6;,"00V*FL+P?=AZ0F'>E>?Q
M]SE\,2D+V[08:<>\C^+K+;?8MN5.Z2#=']DW2/M:J-QO+>)NSZ#5=_\=%YLY
MG;?B&$M&5U@WBF&,""PBVHQ(N6E6CDGM\VPQ3]7U_WGB$Q]B#=#E.]ISVQ3"
MV<VX5/Z >@Y?W/'X+UD.SLO[7Z[?[P)WQKJ<6ISFMT95D]\\,7L.$2$7#L\[
M(&,;M-\.>U@Y4L[?A&K0M]()?VS "_@A,3%]#VL8JS5K8L"H$RMM$*:Y(-*Y
MH_-A_21%!IB6&RXZJO:CT:XSUG^@P=^+Q=5N%FQV<.M>9:Q2*4?@L"FB['V
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MBP6^SP1&<VC@:6,Q-Z4]GIHONJ%72QKCAAZ_+SG0%F%-8+C6&PQ8A;VZHI=
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M>21'-IT/E<2)QS0_R65J-L0*>QAB!O<3"M^IBU:D[-8Q3QUWL*XL1I3>.T5
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M4\5[[:8]+".O49'F,-=';;$JS ZPRE"2] YX\,Z/?C_!'L%35WMV,[.47_]
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M_RIA]N6I#Z^[-]^)_/(A.\N\L2X [&?(?S_K6AR^[N_M9Z6XF=@8V1_A$(>
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MH=$CIL>K4^A@=2R!L*) TO<G+GVASI'\$-<K)N@<C#ET6T7$2";>R.2,F7K
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M>:K)*Q/'V#3NBE28L\^*M=<(8\_]+O%DJOG7!.[)4"L$8Y]2MK YZ>++">]
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M_[STB24]@#U]1;B^O#Q6^1>:V2]:O-E?WKIOP>JM!W_C3CFGZ.5OG)4<CFU
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MI.<_)DE.4T-RTCG25IXI@'^4TW0!^_6J_U>*Z7\&\,_7?P%02P,$%     @
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M\6>]W'T7^3%5?P"=&_Q)'[V.:%HD&4^Z#+]&_)U\PO^*>IDK +TER/YQRW2
M_.SLX*+4O:FNE20R<Z&:*H4C*/3"O+ :*XR6S2G<'M^YJ%J)'E^:7^;2D6+>
M,GH$V&R +K$BQ%H0GL[]LKG"%E/^?JQ+<L]&ZTH_^-+3,ZTBQE:$:4-,#Z\
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M'0>.LT,ZUY2MBU!XHL -J]YW?(,/S(@N+$;7V,RP=I<68 '4!(]G23;):5<
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M])*?_WU/[_\D6,?(I=5SG']6L/OKACBNU3'FC!OG #<4EG=XM];J-_.+78L
M9.F+WZK[@T%_&PE+L^P&1,ZOPY)3EO*J5.D0ZWF'07JE,(>[MY=M2@2V#BE'
M0EVRUKSQUU]=(QJ\.<N]0 Z*:.Z* _GE+J'6HV-D0[IN 4TGL/,ICY96)R?2
MW@ _&H^13I_B5ZG,02-VMS@#D#^>H11IBP+. 0V=*23W+U!DEQ,S+@J5*.&@
MIL8M8MIN8EQX9<"!0IJ18L![Y6KAH\J0& E0$$C9E1]1!'?;!O&T/5^39UR
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M,,IF%QD:(IC]3M>OM96E6K_D%JVB/BME\GQ7I>O .: .T5LAC1'/1V<M\8:
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MC5?(XDJKW2+W "/4<%"#P/XQ&'D+^W1WV,V^?+ATV,NC6%-@/\7O155.?@J
MI3+9JG;9QR-Q!3"V,2[8B37->GN^!)'(KI*#3\2]JRSRO?-!G_4=[ W&!1L+
M?0&-&"0Q"<?]7/#X0A@##*-+//](V^5DKO:.XM5A*MZTXN3F6)@2(D)F&=R;
M6>"2$ER5@(S[&,'Y(<(-K\#!VK8*A!EW,ARHR'C??'ZE1YFB??3WKQ"I)G(O
MSWZ^:23.[<X&;6Y[&>,IXB/\(5YY<*'D:RDTN$].J>H@]\FRFIL(FBTH*/C&
M486%J=TBUUKB.0L8MRVZF3COU\UW/Z,?1*?+_:09,U..'*5SY8+7^)3-M1EP
MSSOY?I"ZY=_VZH=T=W] 7M<R$*473C!SK8%IS];E!+\(IO5HR-)J>""@B?NT
M%C8UL?-Q)G+VU^JN7@DBN$KI_VI(?3W;6%<IQ2Q/+;E?:VOC3D+.+K?AU,O:
MAA3-]]_#A==Y6<B&9:Z9^2H XX+94'C'HG[A]M2=EOC?*%J(@M7F^T 2:S-F
M$B7R!=U^C==T0+?@$9LS!W'L)^C? U4:A C>S_Y*=ABA-$K1@07"$Y7RV^?J
M=T*ZSTJ.%?_>E!X(H#SL!G/(QWMS:S9C+I#\BYDPZ\]_WKNS^ ["S.YG(_:Y
M3X.K] NA*LJA/>*BXA[CG1N7@+"E\R>T4Y^1>OHE]W]^?Y6Y 9-'Z8 9NAV#
M[=]ER*7V"4=HS3'\A!1K_'(B3,]"*@JW>-%WV.K5IPR>WOI/_[<PMIJ(OR"M
M59-1A)A9%3M 2PVX0.%E=C_\8R$>0IO@PSV-UYT)=\F/E-%Y43!]S"PZL>_7
M/K/9M/>^$NG"*8_O&FD\A/.5R5)M>B^]4LP%)1[L+]&)^=5K]F.)NUQ"3""Y
M%.))_26-_T%<T&@^(JX>R",Y>%.4Q'3W$N ";:/-QT<L::VP96Y.Z=@S2\Q^
MW,K&!"L1($B^^)*_(,"8S#[?%2$TTJG_D< =.('\/41%?L##,R8=P,MH]$Y
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M,!8B7GE3+\+E"EJKS1'J@?H#HPOIL]WLX\Z6P/EZ<?\YT4@Z;(_REH=PY&G
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MV7D'ARG+0O.@97R5&F@/G:M!+1.HX NTIU^-!4'J+CZI6 FWN=T9&&46:]7
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MPU--!81Z+9X2R[2&[ #A$?[<-3A:@X:VP3YPW6DBB1O_CZ"-U6V,]&%JD3U
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MS.4S>:XFW$N!3W72S_;<0QEC;>):K)9IA:4B7>@N 4>#O\C?I5ZDW"6?]]*
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MXA[1"B2GK<?,XH,)3_#\*'B[7P$^L(_M=*&X$NR<,B586.=4%,-!5ZUO^2C
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M'WN=G($QOD3,638::+6JJ)ZSV_<%<1]S/YDSE/M1T5ROL]$RK80,UI>PN7:
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MV<)DYS;CIPCO"61(4PM2Y"WII/2KY%M+FGI)%>/3*-PQ2&P,#B%Q,B/(3O[
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M9<W]!/S-_(<V_J>D$ E@T><]F>(02BBW*'^S9^5Q\^BQA-U2B?N<H2W;/?%
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M=GC[@[V3K" ^J&#"#R'73G:W+B4I3[GG)7U,2?C)P,0$ZE;-&UBX&;T*-?]
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M[SXGS3BFJ_9W\ '!$C=;CVDK,<FN'R6 56+@ T&&>*A=6OYZP=SY[WVMIC!
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MG4DVR6QO#^3\7[2]=50<S=HOV@0-$ @$=X=@">Z2$"RXRV )$&0" \'=@EN
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M?48'?58:>Z;N*)Q N:F@2HH(SX(>QVGM#8VJ*JZGQZM?!Q?H\>6(W2Y(19.
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M?;E9@-KJ&AA.!@(?Y5$JJ$V70<$^^(HQG8G/C[L39C'D1*:>M.JJXW!S&<O
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M$?J;8U#@=X*\\Y&(W*ZFO5%&D161^U6*6%"&#>72KX-*.7-2;<* M;*@).I
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M _Y9,[)"+Z_>*U;,=H@R.\YM6G#>&<"?[2^.F[ANH:T]HE\DFR6CB?3>>PD
MXB\VJG#]JM@?RN\\T,J8"68ZE%:]9X]]K:A[]+FZI3VW.<!I8&( 1M0>>2_,
MU,K7 X5+*J+[)#^_+F%L8B+*72>VG 6S@[W,NO7A72[TL+K35E#VD0D)Q47;
M(J%Q!&^AN'(.Y1*TB!!K[%^T:28BGJ%+%0TT04P;MY5SS@T(3*/J\\_?1)NS
M'9$P?L?)HE0[*M'(32G$#1Q<4Y9OQH]SR$U"B_<-5X",['103)!OR7B(?)JZ
MS]MPYM8")..KJM5A+R4!4+<;-"!/K'K2/%1-;1E?C)]"79R.$8$SEF0<FSBW
MM;MR>#OC$ER?<3U$1C"]9$D<?GP*S2V]B#_V4M2:50 %^/D:-EZ.NC:8=DL\
MF,"X$5ID;4*7X+MI.+59;=5BNRT!%R=;6BWQ/GJ7H'1OK1C@*K>K/&]2DAI-
MQF(#,?1"JS-MI6?ZP#?KP:6+:HD'QL(MNX(#;[@6%E2BG,;LY]CT;%<.[S]
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MV+R4!*!'ZU_E*OY. +]-_PM02P,$%     @ )#B<5LP\YY>!80  W7   !@
M  !A9&%G+3(P,C(Q,C,Q>#(P9C Q-2YJ<&?<O =4D]VV+OP"(M)%>HT*@H*
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MH*6AHZ,]0??'55._#:!^#YS@H#]S[JK624X3>X;SS[GD@N(_GQ*]4=K$?6\
M)R;_Z$4P(Q,/+Q^_P 5QB8N7)!44E915KJG>O*6MHZNG?]O4[+ZYQ0-+*X?'
MCD^<G%U</;V\7_K ?/U"7H>&A;^)B$Q(?)>4G/+^0VI6=DYN7G[!EZ_?R\HK
M*JM^5-<TM[2VM7?\[.P:'!H>&47_'L/,8N?F%Q:7EE=6\=L[NWO[!X3#HS_T
MH@'H:/[>_E(O#JI>M"=.T)U@^$,O&EJ?/S;@.$%_[NK),UHF#/;/.<_+!9WB
MNA'_N;2)453^'H[[T8L!)AXQA=D+^#]4^YMF_YYBP?\MS?ZW8O]'+PS 0D=#
M'3PZ#@ ,D$RS(B\"__^1):(!GJ%%A"6=SWOKM$NJPM E6 )YXYP37?#U1W(7
MZ3*SJMV8L?DA<),O'?G.9,F!/8-#.CDK#$3W<C30><XLX=FUDL_O)1/T@!?Z
M&]>9M9\7XS,:]?-M5UGG-$X]P-R1WI0Q^LR;PA6>)>_>Z.&Z)NWAME6$K:U*
MO5:<JW794Z<Q^S,_"_LSW6O9O]0C"HK>X9]$B0=C,*ZC;ME?RP3QJH< K9;:
M3C3MJ1)/,F]^2\:12)T&!0A101"^JK_:="ZXC"S>D])S+Y:(7<0XL@L-7'GL
MK7%*M.#+\O]4[T<M,D83**U-'IUK3V7AO7HM5B]G^)&YCM!I+7=6;[^7^2Y%
MEMJ^#MZL"SG97IZ-LP,=!:(A-T9L3_:VI5Y2O<^,/+WR4LXRMST;2C=E,&]]
M.?&BO'[TNE&@0]/,W9.A7";7Z?]*N'MA<5AP*!ST,KEFZ\UNO<@"VJ\EP$?H
M<O<J'4>;;B;<&!<>N4=CGT7(T!OQN)W"L^]3VBW.8%JAK_(9^DU#6=7O8M8K
MIHMY!I):G)U21<\SN]6$  W]3(8!F_1PO%.3G?BHM?X@W#+;U2IK2>EEU4#G
MQ0[(.R&TI>Y[7WKNVTM60^M;F=_3]Z<$.T?2+XJ]9?"&U%U?O;YE-%CA+_RR
M66I2=9-Y[9KG=^S4]>7?*BJB(3\5:-PC+V;2_J5<8F1BE "\Q5_Q1,X_)-3/
M^'^".S\CH&ZE6,I^>W"!J.,VE:;LI#GBV9K!H2X]L_:^>&^:P\5/?;MD-_9H
MX]P3R%V^Z$CUEI_+!44H=D*^#M[V<\V M[6&U6\A_J?YEF:@KXEW)6+J-,3K
M,.?74OVA3')/Z;OX.XATU[*+0WZ-9V5!WYM[O^H*?D*?+-?RG.Y+FQ,LKBU5
M]O7EP2V;D:)R?PNW*,7=M3,\N_1O%E\I%I3(#,T9OY(MR:JLQ.>%:+06G5')
M'G[TY*4&0%.M.*96Y-R[SFWVN%0%,%FD*R@Q-B!4S'SRM%&5R<!.\AQ8G/A2
M6H6*6/RYJG2RQ_N=;_A;$[/-O2AFYFYK@[2?9ZMKQ+18$NA]]?C5M.9G_$QR
MH3RJ&^]KAY!G&RHN_Q2O>JO*8QK&+_3XM%8F\SL3;8#KORG<2R"!!A[8S8Y
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M;W1Q8M*3LZ/PF@ *X&D86.58%<"YL>8U1+H,3SM6=K%RBG++J\3?KV_(SGM
M.+^H(>TQK%I<A<FS[:PE)9G$_V;:\V" I<VY5:U3:7H6)#R5+1Q95R-':C#T
M6YGU!BZ^+E%=4%W"U(>T991YM&0(K-0HAN7._AP=TGUE-=;A]%RZY*?*+['6
M+BOYH*2G(791^2O[F/NA]4D?&=U</ 3:6*Y&2YZ/IJ?[!I@3,?H^)*%/),C5
M1(L4Y=WRR._;_83:??-AN/?7P'$P7QXA*G>E!AR!F.4?&"DN_Y#Z0+UX\.G#
MCH_IGI"GZ.X,5M3"N0Q^Q/J] ?#N)>BJZG^:)&!/ [O49IRQ(CX@/)QB#1 U
MQHL*-HED(Z\>GXWJ%L2>/6V@S->T81>'>[F#51RNR2!*I$SQU&ESD!+)'$WB
M9CNUOZ8Z2!\=INK6]JL&U96QD]9-9"$4P9$","NW*GNHUP1\3(UZT.9>D-DI
MJL>O\_P5@W@YV!$9AIQACCM=!A>O)#CMY[[VJ$(+FAS;31)//U@?S^CPJ>!J
MX$6 U\B"Q.:\U2D(>N]0I ROIHLCU\\(O^AHNW>H*9PP%G-\V'[VO%#E@]/7
MYU()95B=*%!$G2C6 [1BI1#(A]/,]/)@'[?JX M%EN,#>-.>2T;;,YW)!C<;
M^:''IU1PFN%XB>::\#"B_B-%#<Z[<5TUY2XB5\_/"_'<X'O!<-,&'(9RG ZS
M.S-480LVQ(U+QWYQ?NJ^45(A6/A^_C4%8!MS?%A_DFDFMOV=5XHRU+H//>*R
M/!4*N84J20M 'XHNHF)5C=+RX,]J^]>EW=S4I1 !5 39\#?P,JMR6%*YNZII
M]S+SVEJ075JF>.TL*@HB^)0LM%(#G<I1XN79YV7H+#NVU@V;+-M,R.2,W"6!
M]I\2O+-@8 O<+TT1SA75TI.''C)Y/U(?_1C[\*D[YH?@LQ8^; U[.)B)J(C+
MOIUAC!L)L=)^?BD=Z[(I]B/=]VK,H(&H?&D[@T1D@?_7*51,^:XYL?+\[:.C
M0.% I]8,T-Y6G&IL(:Y9-D)$ %>9E(EHMGUTZTAC(J%GT?U01S#:8EEE66K1
M8SR*K(5@1JU[#5$Q3!1R)S;X;=N?USLA>Y'C:+*!#7B?+>HPE<3]CY]76HA.
M46D4H!8^L.--=7+Q^*!_1#?D1ZEE*B65(AM$4=_D$(L529"@3S]D#][[9?R!
M<[X2R_\EJ@Y1#1Q65C*!WR"8@J(\'+\1O-!HV8*N"\Z9RE_?N/&\%.;4M%\*
MOMX3P&MY=!!>WL>U8KJ2VA;:D)_?J]3MYLV7H"PR,SBZ4A)+ = KBXI0A:-"
MD!QYT$X<%UN,)(*'B?S%XU/P.W%6956#0WHU.V+)(SD@9_W[^B=!LL\O_.#C
MWKL/LWA33@%.DGMKVE^G,Q.LV;*1T"%]-Q:K\UHGOA:$CGV8%V4"UJ'06=D-
M!H;6R<#CFW6XAN)90_/Q7ZT"\3&M#=;T;Z5T6A^?J1-IO:_3JUZZ.;W@'X#>
M>_K!5M-I3+:/S+=!=,"+-D^S/PHVYH2%&/4G>%:*(IZ5>FB.J8^.IGW!0)5.
M0Q[8M/DZJ3*>3V=@B\W_?.*9MB][.S+LY5%)K@]VDJ&YQB*FSM_#85_*4-:Z
MCF-<[$YKV<-@K@P;SR'%>=3WZ5;_N##P]R^J/J_K=.?83R^G]DR&?9DMEA2#
M1DEERRN\;66FOY(W6QYR\/RVR';2@159B0)(U2>^%*H?5RP;PJ$.5]">7TC9
MB/G%/TH\QZ=604=&4BNI!' K1+ "&06N4&Y\K^@1VB!#\*M,0?<FPI)/S1DD
M/%QP^-V3H+8T;#'UC]F!\-Q /?A3"I!0C9T^/M5- 3Y;K/FN0!) @N#Y$E@5
MN9D:XB[?1X<1/NQ4]^%F5Y\KF&C[,731!P91@"9-\'S"*@78YT*0Z*$[VZCK
M%& F [2M[XTX9@*3@RMZ(#,:\$+2@I_\JNK%K+JAC;^[4/9PA ODM<#2!CL^
MVSRDL4%DZ.D6\7)E]U>HQ5';2*)=UT!*K%@LBY.KIGK[2BUM0R0II4)8[F!F
M,>[DA\_LK+E1^HZ:J67\KTW;%QZWAJ?0!ZG%22C&S/6-@6_A^^+V(+QQW(3\
M&\,5*J)5U7&ZP]$<JF>;B9G>\SM;YH',Y&Z,<B/IKJTS60*O]-F]5/U1B]GP
MG=&9ZLZ G(#U@X.LE%HVB]R]0PJ0LK=J=I"34Q-(=9OCF+\G=PX]9ZN(.?)S
MLJ1(*PERJ'2 +D0&3AVE=V%PJJ\N-;A%Y3.YR(+E_VQ!(]W\]+B%R<!EHA.N
M!WX?^\FB65-X9S/=T$"+I<KE2MPIY:]EDD(?YS"U[&-.]W ZGY]C.6;9WY O
MX-<D6_:3\/2_OD?9[VQ<JN<5K.[5H/>;JL=FL%O!D#JXQ3S11+/AN51KO840
MOZ1H6@IPE4^(8Z]X7$U*C3J<CZN"::?].[5M2,]O:0P3-SD/4K=+7?\^,A\0
M[K*']$09JB9#QE1-8@+D5)D.T_:Q%. MI'GK6%B! I!.H8=$,S/I_U_LK;2Y
MFPEH;'O&# ($4VY1'GBM*<8;:#N1\%67_>V;CI<!/OC=[*^VC=M]X\9M/)H"
MN.2P@Y?F=IZVZF]=?="R3RMS3R>;Q9\ZKVM3P-_4YS=-2E6(8W45X#K:3\S%
M:'N>V%D96%5*K,-/ZB 3S]=RUCY73Y\WCVMG98*\Z?FLFPE#:H6LEU7_&-K3
M-JB%CCR6Y,Z:D-,Z%[2N[0-FWW6#M) %@CLLTXR25\_<1WPO#NRCS7_(*<%E
M.J"/6CO2TO"]I^(1@: IJ;.>B_+@AT';,'$A<+WDL&;?#1/Q2"S+_,D8PD^Q
MF<CE!E;XV<% )H)6N:&<?]JANXQC0\.PA[7708J<\.#MI>'TEEP?K[OU(XXD
M**(/<C=P'WFT<N@,[SG6H0"=/>1>JNUR#(-W/UH,*?[G>0Q:D7]B]9#BI7_U
M'G:"6*?>)7!+^)?6 6WN9=!%[B,&"G""2F<3# JIAS:A@ATWLJ^+1 WM@N&(
MS@LC%&#](@4X8D(K(E[M;2,/DI;["I:S(G>,*YG^MK2T*(Z709-WY/6-C9QC
MA33M(-J93_DD2PW!H:D\XR0EA9)U>!1^>HX],KR=G8.H68HWG [?$[Z]9/1]
M<,/M,TWFT*\GT!XMFV!-VZ(/RU>D)L&.<5RNZ=($+7O_KZ[RT LR$L'C9C\,
MO]M=3^".-6U<>+4VU6"4H8/>E)#KSB'WGS$HSW^/3EZH3"],_Z&9M,^^O@+5
M2&GND6/<(.JZ+MN<@M];17^5;WQ4YS!8GE=\,F./%(C,+9;W2:W:R]\[D)6O
MQS.\49AF<JY*;2@-.)F69]GN^*/FQ[/X]I O8FCP'"**S$B YC^8)A2V"4#"
MU[=0<QBW&PN/+'_T=:?76;P/G!"A&R0Z'JL3&M;,E#G%$_/Z?.B_&W4R_^*=
M=^$2TASZR?#*MPCR)IVQ'H^*50>.=*/+W1@LAM35Q 9^NRH]6I@W-SMYM^@Z
MYFJPWZC%=/=V&>*SF]64S_%0),G8:H0,AJOT*VCP6@[#7;*M7/Q&V3[Y2&/>
M;(8?O#T0(4G5A3EOVNL_\DZ^Q"6G*A3&\)GA!_)-( <!@\8>1"@:^K?M"WC1
M$!DO7VWET"Z\[-F5:'!*@Z,RI..IA<M,[73,VK$F4<(CG(<,JGXR8+JQU&IX
M%FX/_Y2&^+V6X3J*41[?=O];!08>/>ZJC[#6)E<>^B8W_$MJ%0]>+U:.DR!5
M-EQ5;H5Y%:A3=SK5&\OO]:A]NFM2O%G9,[T:62EY^W_.E_]8-*U)/RR:18UQ
M\T>](4A8(J3\6'LD-#WD2QI#I-B='JDN=B;>G15KT/?ZJC O" >A5F=P0UT_
MWQ77XN1Y66#_ZT&G8M'7'I;^,LY7QN]SO+MV+"E %4]B9L^LK>3^6IMR("^>
MV7>4YV1S&S*O3M_T3/-9NP=N2Z)YEZC.U+LR_JLE+*I5&KN&Y"9\UW++6Z4]
M,%8Z\^ F+>@\>UF5Y)7U,;"_>*2:\1&YQF-IGKNA8X_D/=[]Z^A)]1R>H<7!
M&"W;6_7X<KF2]W )2TMW^<7:]WJ3O'2)5D<EZ34E:=Z/M[MI)W0&^!^^2+@H
MRF\NS%X/M\B%,>L.-# 2/7$!Z57064.YI=;@1E>K0H6"/&,QT-6(;EX)?HE"
ML\G)W/J2>O>452L#G?WZC-PT$GN^NL:Q%E$1;Q=5"!4 QRIHZ!H,FO:@ZH+Q
M FJ.Z[9E0;8,08'G"%#LDS>*<<Q0<[_%5)MV]\OS;-SA]S6:]A7Q?:T!#E;]
M1"T7W%(KVL^H(GMLS>_"7GNVPY/*@K.^EK?D"U3:%V[(CW.O'(&)8DI@/DWE
M-MP^J\HJ]&0ZKL4GJ?S8/FYQNNKS>)7&D7G\;:OB"L@+0_++/5OWQ^-6&KN(
M #01M,WY%["$[(/$'62 2A01H=UX\>[FEV01"O"ZIF-IP.XF^$/MPO'$(]2-
M<*U[=\O_G,4Y'#GVH_I$:#BY:0 A#\FJ^,<.6Q5$--X3<>"1JNF>%2DUJ'GE
MG^%J)S0 =$R/Z'R..#YI3!S]7HB3KZ(G[[";[MI%7D2*D?Y+]2.IM@:UP-XC
MIPYC$;AF+9[MDV,1S$D+NE3WK4[ZN#U9952N5F_9[ #I4J*,!84H;G$5OYL2
MP:=_GA4<O]$:D#XE&.4?/1>1':]_UB&F*#^QQ^#V2L4WM*V1E#8IIH&)X//@
M^XC7='BJ8=YG1\D^C^>@#S7*IF];%E>EQM8ZRS=,Y]C#MC:**V)$6\BR0QAM
MW6&O#^GM7O>>/6@2WU-9:\T(]>N!&.Y*E&!"N4ST_KL)I'^BF$=3?A;SX>U]
MAU+ITA3@6S3JB-M[MD$<ONE)5/'[:$CE#$';09!,!,XX[E"L!D4*!5$ +2LB
M\5^S/Q8$=H@D!?"UBSZ*I=YZA>.'?R=<,R@,M'W4CW>#UT4YAFA:Y,Q3J?HI
MVD\[1UFNZ?$1/'D[(.^IQ!G]Q5G?3AL9!L7=C/7L+ZLU54W%2G.FU?4-;_I4
M2FN&R_8CBD_$S)<M)=R>2^QY)G(9GQ?WE>A&",TD:N$#\L/*Z\&&55$WO]5&
MGL#J'70&""5<FE@]O,Y YV$$':  CEO<JU-7"5IY$->#<+.D"ZE3K'JMYY6_
MB2;%/LH$E"\R!$5><C%$9JP<K"#2=O0*BX8. WF/*XB\A;N(,S"/._C D("L
M-7,35]7[NX;T/3ESER1%F.*7H<F$$)Q\(XIKO7P-PDGPFS:-,A:4-CJ(P-H\
MS'S\<%R/3^JCP.9R[F.U=$_L]-CX;$>L0@^OT2C\@KVG8[;.N6]!=+>^Z5P]
M+OT6_;FQZV/(A$6FE=5->RAK1;D^?=U%T=B+:->LH%? .O"EX&NM>/?-A;Y_
M(T&?<R6K.D/(]<!/.[<68[ @7WUB@T%49*\#T0PMH@!]2^2;$%PFNT5673:9
MT]:)C !O"U" 4! N=0V\0^7?;]'$BW0CRTBY02*D<,)5:4#?IUKD>I&2K"CX
M]B[F+RT'1P'B--D((?YSR!,$Y.QF6K:KSY$RYGQUE&7UU7.1]X'01A5W533S
M#(2%&#C8( ]-OSH"EYXAS*+O]7;-6[N^<*^J?-5P2C#01]-!*..Z*M->7Q1"
M<".0VQ6C^+KF,29JJL731R'^9T'E*$['3E]0PQ]@*+8G]T'*3^;CP];N#^U1
M *8,QM7*T4I,;AWMNDW1OH4@\0,CDU+5YF_N#B%/;0W2I-L1!6@!=_R2=$-:
M(QI)8'91C,XS^=%J_XQ0,F?=H#=)+H"VRPT,>9EH5I6@T?ER';@\<] H=&QA
MJBV>..%24;IXQ+N^@IMK23\]4G?58=9 <4#1@T"N?%_7/B>LK%;J$,WBV:[2
MYD%4(T!F$:$"4BN:W(/G!Y_FO.TYGRU?5^)75IOP*Z!3<7C@OD^UDC4U#)^
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MW9KBX:,/#8/R^TX['U&=Z<_DIVHNI\C%M>36'@:L;?>W56U6>R#S,R8VCCZ
M*]%!7@@><I_=E?H1-\S*[B<9[.JHO.BIT;LHJ>\A8:(%?3<MSQM<!#N#&1LJ
M<;E1,!'CLK0LVF=F/='X []CBWZKQ=!\0IIN[6 %]**WL-*F/&M;<3-#K)G&
M_:!55L\I5<+-F;Z(5-OT3]@,UM_0E^:/%>N431YKMVM"M&*O#G&'2XU.(KH,
M]HBLUC7ZNZ@E'M1N1BL!M>^0W#S%_$']%D[\@T20>]J=8TL:U@Q,GH2[OYL4
MX5&]<=-+L& )V&GZ-07 E7CL,O/8<FM.J6LQ_UP_!9%XH@K_Y+EAMX'="M:D
MQ2\D)SIAV1E7_')+WM'^;M/X,>Z>"7!?7_Y!%_O1PND$!Z9)Z$I[Z4V!U[>T
MJ* 'T/PVG\ H3DV')!Z3MEI^]4QVIQUAI(REP84@;G)7/VQS>A]#:,W@V/2J
M_>/AO&;Y[.0471T]%NN<L:8E#4_(4XN_*,?&*O\)&@K[_XP:?S-_F674-F\9
M!2@I)*Z-%;9[00Z9J=,??9_LO?Z7BR9I=C(VH#,;HECZI==PI=3*XFP8ZGX"
M=LBX9O"A963C !9QS3I.RETNX'EDW+XQCI025J<_5ZQ\?T0QQ@++FFAMY6H*
MO7)9;"SK6P74^YY%I^BOLWN]ZVA_?-JL9M6<F\%U/.]K^(UT ?R3L$%F:%H4
M0I/Q4?PS_,\/0D)L6C_;=''06?':F4G/5A%)?,J;;+QRU%YY\!0T"HHH&V_R
M8-N2N3@DAGO\0O^:V(#QY.(A.;EJ;><P26,-CIJ9WMV%R!J.*"Q7!"BMMK]8
M8VUUXWS_,1O083LU#_(C&%OB&C[-; 6C>,IC9":LG'GL5+\=F_E'T X;/WTB
M8RSFUODH8 ?B;PXBGIT2.>8I=2+%/';S#GLR;'^E9/Q[=T5T".&[RF)"G>,O
M5*&^(D(:?*8D5?^ )$ RCB&K]SA*=$1]V9A_17@AM<7VR79.]"=#;T"ZO9"/
M4</(2JHQ4<P'Q->@@FA&)1K;WKV9GR/[DK&"-QW2@_((J/6<SO7;#Z7&K2("
MN-CL63?Y9BO;_/ ](5*9\0.:6#@%@(N@!BN(C+BU%@A+N58.S%J[O']W8_$F
M?98;RU(AYW"&YWU![1='J(;IX"KBU3,VO>2H30H@/XO T$[/[5KU-8\2XKUG
M]>O4* "C=ZR%CJYE7<^T[-0&Y//-3.0'U%^4.F[^PWHFE"K* W(H_8P"_%:5
M783NFO]31SX[/EW&@[RQH]LS3.6ANNWT_Y %:GCVS_'.Z/W DR]G4%/VJX%1
M ]K<\QF9?_FK#/^1P,>.#:%3LOUD12*?)LM0UJBWOE$1VR=ON-O#I%M7MGM^
M7O"G54,/>K>YVLGA'F=PE$\R[:\9)[;Q[ _:8!@M6=X67M%E,I;L"(K-2T*J
MC!\-Q#VF ,6[*H;,[2CA3>]"O@KCL"E0V9"=HW7:FPJ\:)M(X!/FL@0&UP.F
MBU\;DL4Q$]0@^_]+"/0"P>-%'?PS1#F\3E)NM:'.CE$Z']-'X?77-!F!2:/W
M V[>K1PLRJNK^R1=;']OV_!<<U9L3FI$VVT9V2_/$J/?I=Q<9 ^#5(0WL]/!
M90;KE(M<3\.<S >?CO9NM?CP%*4P2I:,:O%!TIXSG'"Z5C*WK]6_Y85X7:S8
M^TDISJ5@U<(O-/:3ZE-_?Q<Q:8$DL@C;\W'%-8:6(Y%"=:M$ETIETYIP@[P@
M_C?JP8+\Q0\!/CK@9?''M!?OJA!+GA>X$J)?0A;LG?_7 RKL_]:BXU<JTQ$0
M_"R5N-FR;R,UD5J$) H@PI.QUT\!)'=6_Y8DJ<VB #_M^L@UR!WD$R3_ &)>
MUHFZO<4ANNQ?*VF64^=&) :\K&O'H8Q[UV9OK+BXQ<F9+E?/*69KBZ>9W]1]
M&]@#YMFC %$-IU0SWJB#O;,GQ7;:Q9.X1=]?WC[+1",AR467/H-&HEL;5$DY
MFJ+.F*EZB3!O]I/.(L)5>'[<IY)X!&= Y:7W)1X9+">5KYU3FHG51]H3..9
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M7@DKD;<5KU2[I7#]])?)@G#5)?\B9Z3T8IL;WT"]2A'3O8UL],'Z;7>AR]=
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MS4,][0:9_:WZ.P*8$]![CHQ62<*I-E?2V#+ E%L&186#<.KS#(]?K$T\UPH
M%2)EW=9,\:\6@[3YX2.AS\B4/ML6[I<8Y">\8&@VW956X:/?YZ(UE7$A3NF/
ME!FM58_DM/6K2!A-*M][VR 9JH Z_Z%'&W7M.C5,1ZFA[TZ/Q;UBP\.)<4\X
ML^=>?)X5\;>C=4D#R(28GK[?(.1\)L0C'74^:D(GOM[K)W$'D]7.W5=N0,XJ
M*_'QXT\STD+Z3N\+L^UHO[V&7TY]'8*K6)RBQ(U#ZSA%[8_JCU+]^)B/.K\,
MO=_0*+WOTI_Y7<OPE(I8J_#/REBYLPC[S.V.2OB5)1:QPY"+53*X&W%&IPN
M3'93@EJQVM^5/GQF_,@&W,M^FZ$\T(?D7!XH?X+P\B_+1789:ZR:3GJPT[JE
M ;U]'L$1(CIW_UN)I*S>H*4[ZSLF%FP?_R9!HP=JH[$.Y@HR>"#E##APZ3P
MF340V+2_4>]EWCS0CL5IQ(I&+]86$/DSV#O_QV:B@B=-_//0/0AQ'1Q:",&V
MKR!$#FFX7E:I?N%$B^:O%E:Z)9E:=TJ^?+,L<5.;@8USIZ\RS6V98:7(@":R
M3[$[X5/V 5^M]A>6(T?-5=7%C,M=\#1!NGV[@C$37^9-$"'$4I^+WJS&DYL7
MCAQA'"<+-;D+[)&\A:+4GWS8"@C;I=F\HEB"Y+RA$_,/I K-P$P[O6*KI!Z2
M::+*B(7I3W[MUK7MDXDH]2-MDX@A5X<<7'F@2\12:+C.I3*_-JPH6XLA2QZG
MM"I ^JOF?"G?XG5H0S9)"R=.E3U+ $VC+.BXQO%CE?V^P401+Z>"ZDR3CPD+
MO0=]&?U_*CW\_!-N*^\EXB/O+2ZY^ZKM ]#<;L/_?%<WWW]1L9H"":&0BOE$
MZ2#*5OEM"2] -M9TN(]\-AU6N,9'>"!_8AI:SYNR*C, 6YQ!<$1(=^6*UTX/
M#7 QN78):F63,SN)%S#7$5N*U<0-#FQ-:JL!D0_[@&,_<49L<[%;"=,M*(&J
MYYAZ%';N'[KQ=<2+W\7M54@3\3%Z!^<U&\&0:R9*Z/E8"S + =%H8/C&VZGB
M1?_5RE2OF,D7CT^9R>G/3K=;SL,\(CRLF$\9:Q/6+6#^$4.D++>MK5%/)>9-
M[-6&N(Z;V<?.CNZL/<(.3/'>EKE&_YXRH9<4['ND_8KC=QNW$>5&Z^J?_O!2
MWS_+\1>T<I/'][3M4WNN_G8==$\MMC;MEV7G,GZ:N2#QJZ9T<(SS"] ?HH+>
M946%3CZ&$:U)G$IX-7S/C<SQ(+%GA_:K=R 5!]\=U8O8?R<@7*?)CQ\9V!R:
M#>DWTBEPG,NHD='?2U9\=&=C_%,S6@^P<;L]%7;T25C29U(\WGAUM,94/3^L
M.QK^6HR[@3<[!KW%^42<DJ'7<=LOP8#YI;?^Y>_7XCS06$"L@FMXH#)?=DFK
MN>5FJ177Y!=LHXN8AGP[_\]J;'C* ^*44Q3GUV_=%A;\ET-0T-7_CI["&DQ"
M>,SW5'IW:T9U8$/56'5:L.[)\_=Z:UM:'>]'[BBL.F*=9C"\H(;[^HD'\L0E
M\.NIMF>.WX-- X="H6Q=ZU;P-D2/R.+"FFH)I=JS#SD?K;8@/]'EM@@HN@5]
MDH0*I+^R(3+$2H/?CQ?B=#7\0UBO%9,/RT!?JJZ5^HW(M,H6Q7#YO2_ENW86
MC7D;I&<ZNS6%--0'?BNOBQJ.4<6&3V7>0S6$L-:-1XW-W(3>].H%DN[4FQ0L
MA.*E0\+3LL;&B-N+2%7S9SJ_GLNGM%5JS (/X28BEB!60R^LH9HI")'6G>.F
M9*N>O[HY8++?4UL8,OX^>NWUZ_7W21*;Z:2-,PB1N0KRM=:)>919<.$"8_>-
M],WTQNQKD1O31O4>=3:C#ADCJ_V(2\%+3G5P*VMFJ)\KU*.O[\*3MFZE768'
M;KL_$"C6?6J9VO;L_*+R73Z-XB]*Y?P$\P9F$0,^ 6L<@[>N>H4?1H+=^G!D
M#4_E8$)%5 =&W>%&2/FIZ;.3>DW#:%)X=R1;CXH1]#PY'Y*2@[2VJJWQM1N:
MH*X4//OA:'H@[N!K</U8EU9904$I<PWMP#8GC_DQ3^':7]&7(A:OTG TG,(5
M_*>$T)CJ+^6?;L3V3.9ND\2IG!N(),SN.QM[E.OIW[B'^J*6KXX8O[KP^J="
M="#"&*7.Q%!+A3=?]&H2)$>L%%Y22_4G2&VR R?J3-ZZG$*HRR@_5>YH?/UA
M.C!Y U5Z93-@C:W##-IZ<S<+&LSQ!:CBZ08AKW2>;&(2@?&YB5CFO+F5$MJO
M?/N]\VASF-"E7<5&VB<JSC<^3[FA,0-)@8'K3S-@FQ^9\%PD[@*>%!324^65
ME#:L=2#X&.T.WX##[C+,;;_$;!A]]D$./K&91GV[,>(KRZ6WNKL'SVS=&1G%
M:I^ WH#]F,B%!5NZA@$6_"Z>!_I201XLZ*,D$1U2/KS%Q:^OC BT?03O'W9$
M(-W;0LGZR9E+\'!Y>TU1V2^[Z*CVF4,!IF#+7RL@MCMV MXJUW7&S/$(O2 ]
MT2M"Z^?7D.PIOZ0=\RTH[-L26[_M#<!N-EC<I9"*MO(&IS-/2>H^T_2^ *KY
M_'7NZ,8J#T0+I8ZA,?O8QD-$JLJG:CH''W?GL.N^'_J:JY6Q@1T<QQV/=2RW
M44'%R>4S:S[+5NQV+>6\:4PKKN=?J\-[18(*_K'CBPZSB'5VCBA<-2*Z9]ZP
M.[[>)$QX[$A:#CDQOD^*U7=,,T<;N=CM/4_8S[;J(6@C]3M;Q@]^"EM?S.JL
MOG)4T^XHF?&E*"WX3Q.% 9TP5[[>']F'_M/+-/C!247/*,T98,DDB4<73^CO
MV8H-7T/0 !S9X@ 01BSEZLUQC8"0WY[E3 'H%!/F"W+F#A-Y(.P(EK5-F33?
M!!P:FSO* U&&>"#98C.0LV$K%[SMV\WA^#%PB/X7!.R=;U;'DRQ4BR?J;=;U
M:$X>[*A2S&(F0(*@BG]KW47C_WT)N%\\]LQK'DA,H4@"X*4<5 Y\#L*6F.1:
M:.-XH.OFP&TY$&%_HVY<!KE\I [B.#P/F@?@9!=T^)_-GI]P28&=OO38-GM3
MI59U+[@F[L"AYW'=B@GQG<^T71.CPZ;R1K>B)B_%-ALPUR;FT8;S!N2"J!\C
M.C'CGF4J'R\8$2F:Y[1WM5V<RO;'2RTC*H*KB[SH<(L4&ZNYTI:/&(_VXG2#
MHQXS$$7H<H#$P; VC68C&.LR\K@1@N[0,3LA]IRLS@Q?8=TXBA//DU%/Y\)?
M92>#7SY>&R(TT'&)0=9RGCT+!,@ +3CBA$O<\OLIL)Q[5*3&+8B'C-0,86:0
M@\# 3LIHA[Q:Q3P:ST9,W0$L\^X8J5F,!,&(:455H15DU_D'D4+%*[EF:26C
M1C;%S9;4'>2H&KW1>:>"PII")V_]DP6#::-61A+G \H>GW@/SN6/>5<KD/<1
MZO%W5;E_?XD.^J\T6^T=XX':\RG+!JNXME)G[KGM6 [J=VTYDY-6QP.E6!!'
M_:8124YX=LP&>'L+$+.F>B./%E#?@ZM@V+DK0"0_;3W ]4&&X=P+6C@.QIK=
MBO:#SX.7-(#H2Y.XQ"+NC1I_R [:+<@*1'4;<@Z0L+.0VW_9?\%!(+D^, ]U
MBMXZ3L2Y1J1>KO[L(73MY8L'[]Z=OJW\ +1X#2L*U?2$2%4NUF5)6T6G?T<<
M7OZ^R1\Y,<9X<G#_S9M[S4N%G4=RC+7018G_Z2;8LU(;.EL"P%PAZ7.O3N05
MW'<H ,YA8;=G*!WU5X+^J?#_4CJIK_U_44F)G2S=B9!":B!Z_WQZ"&O[(;M7
M.?7,U6Q]F\MG;@Y-2PH6*/=#=ULS53&/I20Q3=9Y]X[_4@%4 8(9&@N$?<ZC
ME[@2CVDB;+VI-:YG95MO.LA\9'4K<5ZB11=@?.P=H3D+&4/DF!9R=$:DLTWC
MN8K##]=$9J=@62'$?5R%>804"ER"=':"&Z+S9-)I$K[([P%E11\U0"8;4OV]
M+FN_5KH&-HZ:V"8\UC?_7NNQU#G1Y>Y(_\*,89R8;(,>H'=]"ZV6O1CN[:3W
MK9<'*KY?+)7R\N-;$.C"U_?$*"+X??U5UD7V'\P4?BS&)Z]2L,!$.I?OCXK1
MH$]I4C6-0HEU!(WYA;.@N>/FSD18^WE*A"ZK3LI7LYXH:H> D6K67"#EK=^<
M[M$7V6:#^73C9RY)JF>EYX@WO:X^ *L=*OQC/"3OS_"9]Y=8RMZ&L.%I.J8%
M<+>"8Q9OR)Z9[WN&S0Q&GHT?E[V8F[)\:^3I)PD2F9#T)F5QC4)8BO#C^'AL
MY?MG%C4O%D,EK7^.J;88; =_[2<TBM4<9YD->-REZ*8K!?[Z:NSSG<"'[B:<
M8*IEWGY!V7=H"*5S^W&1I36X^<[:Z=EO8=&/6^.G4I_YC*L5A7Z;'@2\[MOW
M-5?"E=H(Q]A"I'H,0[B)>Y).3)9KS!R*]0J\B>.\/+AP2;[5X.89[3W#,,/I
MWWNFOC"RIH+WDYDE;9D9<2CXQ"V\<XJXA:^\F^7GB0ONR3M6]S1K6[Y>_MH5
M(6=FZ># Q1.RJM2W*=N_7_Q,^M O6\<XS> 8&FUNV@V,L,1S$4=FK2MZG^U_
M?."+N*FXLD).<F#V8.BF,M-:IVDERI+TQ&4$L0C_Z'U$CK)!=TX_3)99_['7
M)/D'+F>/R+'SYKD%[RZ3(@8)<.(LQ]O*(I^ B2'J])<WLQV8")E6N8/[R*XF
MZXQ"[^KM%S<?PU[<N+-T6@FT3?(WDTQ/H, ZV8\V0K<P".2_->\\R@H42V4%
M(!]N'+6CT+(E\"SA;XVFZI;C?]I%G! L.[,9W%?O/H&((>Z;98:6#2/1SCR0
M_(+]?&;,1O$GO">J1_[=SA/"_(U2Z_ 63)2"*+,R/:K54-GP>?K+5=71WL[]
M,*2 G1C8_[7L7/UQ:H1J8Z9H=F+NL$G!O(-_7$YE]:5BV>3/MN!@GUZ]7YT
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M_</^O7?N  8PAO3[L<_E(T+6Y2X%;E%_K3:L"9(3]U(3O'"(?%QORAR" 4K
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ME%PP=C[VF9/C)?\;H[[T^Z.#9T.;>L]:,( 4S1Q_4SJ7\1]U-G^KH]VK+>X
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MKEK@?F=GNZ_QDT&\+:Z8.+4>$V)O*-F>?CIT]FA@^6R0;91? *]* GW< #Y
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MJ)1)_ '4.*O]1=660%@*'$V/FQPL%CPM">W10EY&(*B2D7DVV%'Q-.T=7MH
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M,Q0"MGZ>&?<=!A!.6I:91#U2/XA3#"SH4 O+X_Y2'<CSY7QD!1,8;QF>Y;*
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M@XK8IFQG;8O$'*BI]:(LRV4MC'7E;Z3N%G-]??3P,"/2:=N X"1H$@(_<^I
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M!F:ECQ&N^LUT)=<9Y!H42G2Z>2YZ7HU(==?4:KS]5)L]MAF+ 3Y#L_)';F.
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M'+A*[844-Z,?<>)\_52?C::I*@:GOA/H:0L4KKEA1#MV>]S9DG?]N2ZS&'D
M@;'3 _H*=8.F*$EUE\4"V_0Q%B?6:]Z#J@<L?N+AW-V011OK^<,]4#UO$0Q
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M&6I=#%5\)GK2!5/\EQPZW_^NU-R33?_(;MS]X%")NZU74NKB1ITPN6K[7;*
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M++;EE=R^WQ%8 <&;%$H(S-'=.(F<[A56^Z*D6@(<+6_J"W[GDH@(W;D9:V7
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M/45E$MYA!I?%O 31>*:E)\!PYW.2_LDNTRZA7#.S&Y'8HM\'\%:F<!0F5U,
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M?!VX_;8=06U_?5]#:#_HOC))*K="T_QFG?&S'Z$)<5S?O?T$(*ZLXGQ.93J
M>^$\=/<"NL+6CJQL!D)[KG_KU ;JO9/(S_TSS[%6LI8FVMXNC<QKE?]'G][Y
MET)D^40>M^?G>F4>F_RO>_T_P97?G_X&4$L#!!0    ( "0XG%8D^GMR8D,
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M4!#A6.)LX.&P ;@4.'@4.)A>@ 6K)P'.7S;@_]UP<+$ZWB DNDE,@NU0=QO
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MNFZRB^K#::S?3A+3<HBM<2+^F/87R_Z_&1;R/V79WPS[NUTP@!0/![MX>!2
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M5\%3U7+8Q,@Z BH%_^+JB/;)0S^U4[R\"D<5YV@K7_==*LZ<\/8CW%#O[#"
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MEK4@^::%?H(F*)CU;Y9;LB-8.F%G31LD"PO,$DX'^?/U#T/'J?&PV-1L0'(
M?C(MQ%\N),ZHI54Z3RI1J2.3-[YJ6W)?VII0BD'J"[DL4GJM[5GWT6[XL^K4
MF2=5$4>2K_KWKQ<OHTY6ZKC/__S&KHVF$:?&V>R@EQ,H]<EY7IGVI"IU5RJ7
M=__&(O,\FM_0K7N%8"_H+L+6*",L2Z"M,G*FJ>>M&A.NMM]90_D/'W>MQIDZ
MV:+],E>H1\WPZQ+1=Z<<"0!3DE)IFR.NT-^_HP=E,?F[57MMQ,Q58LXL?>K
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M.1EFB&]583G':]N(A5UXBO6+=#N7",X?_7ALLC=,A)_<*NW-5FQ&SF_TPS%
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M6OYK:3TQ=4")75=.2[/SCX(=XWB98BF?F5D)VPULMP[I?,2S?%3!RB**<CG
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M? >@E9/ZIW1#97#-\K,E^>_+=T]>V[-_K6QTX7L8ZK]=O3[([-=O<IO6)AN
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M<F>31G2PT?:H8S;Y-M':^5V;S!;B+Z?FFX:$MTO0:0PLOJ/KN&07_JZXKV'
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MA2YDRP5+L_Z\# ][*>_^'9X<")P"U\6#%!F$PLDSH[WCRQYWU#3JK/)%W<[
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MS?> V>-'.ZK=6W/;+V>%/DK$3WQ6^A '8SF@)?O)^7//*=WPF?0@\E?+_AV
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M_]>[_G\09XK(BY!8\I&"5R8>1X8JUV?7]TP.QHC !@2V)1L>F_#-B.Z5-%-
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M$'/?TU'29.9/-:=JGR VN\-K#C#XJ*"]PW=!V<;RQ*C>/A;3IQ!(G:+9ZX!
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M"!\1$A*3D#\F)B$C(21\_.0Q&04E%145$2DUS1-*&G)**LI_.L'"N6^#BT>
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MD73(%P=#C1H+GSL/'H>/GWD:'3T!^\R4<DP;OMR")F^4",3^SE@1[:NSL_0
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ML_F:WM+G*;KC#WCR0B]]9RZ5 \,RN6VJ=2D_]EG%GV.M_W$!J9G'X#CTDXD
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MGOC/TQ5]M)&5G(P.T-D96!"<>+^A,;_H-!G_:OGWR5@9Z85-XC)J[<F?R3N
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M>CO<R:_JC9];\>'#8NF43 :?RD8>Y$ [N06=5KIG3G[NBB?PM7/F B367N_
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M  7Y#/A0OL\,<O\5,>C7*X %> J2DEV9F&VBR[.O>(8VF$L3MJTJAI=;$_D
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M//8^(<27,66SG7L")MJQM-,?;PR./.NV="5;PBKN(M623^,_HK/5DOBXE.V
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M=-H&9;:D,\1$S5(:I ]:\J'"3M.F!S4%?0R[>M?GV<&4IX+17]],>BETBM,
M6]5X6#0QC?5>*FS*"MMJ"GT=3TXL4$_M(80BHQH]"<NT.S-*3;RLZUR\PY4)
M='O]ZN +V,?:&'E_*0?F&]J?SOR/!'-$>.B?Y&:Z#/PKZZL+H.F4X6^=Q7@@
M8(] K]._A57PO4Q32E^7\]\OU1EZXA^:*$%($P<-((*:+YL=W!$W4N<L3)M
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M)X)HP9WZF;Q[#>3> B+,*+'&VD@/RLW .#B]<AYF=BAU^TU]2[-%(N=WCWN
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M<JAMEB%U]#4>#=R^:M+Y;,$K;)D]AIW!N2S@ 8["M1&KB_;!CCK?$ZZ-R5+
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MLT='14!=BA?,-VUYQZ4_-IG02#&;4?#VYB\SDQ8I/2>S4I>F?F%<_-_J-5:
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MXUJ%BZ6(-Q)W<W/C>75TQ$NMH?SS1B"W50&_B)^<\H=Q2_? GA^,,23#I&1
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M2V)JNS.0:Q%\"<#K[ZA-O)IHEOW1[U2URR5#F4C7_#G-9(7'$[R>2RQZVRH
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M8FKW$A4!B$5D(K,+!N"/G0K[N=:H0]$B JU[NVT8=CQ-3W;U[TL G51;]+E
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M>,T!>]4'SPKF G_L+CK5N'*>2+LQQ.,R\!OA.67Y@CH_6;]%T"W3:YI#3$P
MBBSA%+O(15Y<'EXI>!!X:_2=XE&9"TOBXO;G8?=1*FEZO3,_WC6^^P"YU5@
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M1L+D85WX)> -C LJE:&7 TYS>O[XMJ!P]IL!RMB_V>2NBT*FD4MVHW=C3O=
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MCJTW7)!0J$#%0&,B#AO9"4A=*+?)>:F5>9.+GCJ/(#MD,40R9N? _(?Y^F?
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M>'ZV]_"/0H3;>!G7.!S?4XB.C?B\U''CG9639*-T]$C7_.K2#(:;V@YKQB)
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M 7%&3%$_X]_C#*'[U(NA+G>!;T&3NYOPM@C!F#D)/2>%@QSI[_HL[3(^2JQ
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M5V]0;F29GTGU0H]L/^M\ZV9<=^G;">%&V%25PL8[0P"%CL6&]+4'$YDWTXL
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MWDQ/R<Y,U8A.6U_])Y_X*"*CS^)G9I2=K6.S6F.A0C6@(R^EKP@W^WUF4+:
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M'DNA.3RW^NM:3.M*ULLX'-R;3]%65E2<K_H_^('$9<@8#7"3H'8<2R>6(B+
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M!0MGXDK-M_#S24U7CG;*K'<0D7X-%G1^LV8\O>^%$*R@,O2;6WE]^,B+$%=
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M9YG!O^7+>\SDGL?VFXE!:34Q<6$J7(5-U*I&K$O[=7%L6GN\== "TOCOZN8
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MZ_!J3W0IA<D 4_RM!!O0DEM,M_^Q/XN72R!=K5GQOXN;90KT.-PXL^'6U/M
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M:XZ_5EG6XBQ(+MEP@"GE>W:,RB)I^M7/,+>#7.:W,RV5'9YWPK7X%MI>J?)
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M>".HR<[B3]C _9VS^K"3<?1DP1!N_:,O?X= HRY#YN-M?56V*D"#NI&UOC&
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M=V7KIC4/K$9];"%9S?=3OHL?8<U(\$&)A4DS'FW':5-P]QO7OE+[:?DM8<C
M:*3GK0&[;(T@?\NF3V9>C6)/!:0OW[%?]R4YBFK_DC\'?:G?B(X-=AM4T*/)
MF=NI.WNJHX5_]W)U).#QK6%]X2]8]DMCN#LVG:,*F@NS 6*"US2DWM;FE;CS
MU;V?MX*2L$OT"&_?2&9P)CF<=%E$N(,1^7@$ZNHC?PO*:K'C?L3T2ONOOP-=
MPK9I([0+$>*E4U&!$0M^6+>*F"DOS5F(-7LT:(7Y*OOT57XHT)S-XQH@@+UQ
M_R/G].=E5_KC^%O'B/9KP!_Q'$Q0QF-L@H<-PEMDW +QWJ[ 9-R;5BLN+0F0
MV2B[6LAP%D7-JY==%$0&(,L!4*F:)>-$H8!KP,CFS4^ 8U6]!G2/<49S$!#=
MO+#Y][>FT\.[#;O[GA>W5)LG9RV]_"(HK,H.Z?_",LQ<+H4>WF=?IF*$!5P#
MU,>;=3Z>3ZD'14IX:LV])-5P( 9<L$XU8UN6V7YQ\&,R0R/DOUC+Y]X+>(2(
M'9D>P-->I?G>MK7@0TY(@=AMD5SCZR)K=G4FW\CB"%SZA=?#MN2-B!I.UN4P
MM%T]KPRX4W<]P%X<NZN9L[$KYYT++L"Q&ETO_H;F6U6V2+BSH.Q='C$RE8Z&
MS/#,VE _.%W6_&">?>VBP*01.4-T5.@&[^I#["R]AV+J,939=T@%T*Q6/&.^
MG2$YIB@#H>ZJ?2.?>_?>_*:<#=]+X<8FM$P;;"].,AW<X:4^;P6I9QIY<<^2
MHBSFTOB1@,I7[ISSLDN>^)FH>=3\AT8E$##Y==(H4@6V>18VDLI)8;K-<6LT
M=PGB4V8_72@9&"7?SD3"1==/X3V9.=.T?.B'I(<U'IJ,-^OZ($2Z<U0M1?/!
M9UH<=SN]GVV&>Y+_VI(GVW)M)823!)#>$&!-.9F]QVNMH6/R+2Y#HG?<W+)D
MWRGEOZW%:Q?S]ZX,-3"FVZ#*PWS9,?QQ>1JC?][V>T.IS?P(M?KYWP;XY3#?
MLRG5SR_Z4O.Q^J?X1K"9VF8A1PN3-U^VDLP;;-/*/N/V=W"*8W:88$-#I7]^
MP(3,PN-?*:09S6<;U6[EX:G$D;8)TED,J[]V[[TY(S+3%<[PUWL,1/QNCJL>
M#C&!M. S;TY)6"IG:+6(+H/4W<>S%[/JWUSYS#,?/(^GE-A]#E=!FVK55T\H
M2J$0E##HVZK/.L19T$*U^R3,]Q/7.@E(B9Q-,K)V+FRZ#JEV4ET6KP'VIK.\
MZE.VY6:J#Q^V>IJSW=:Z,&#5[(XF>=-(S1;^4/$7<A3"GT53JU-0%8UAZEGY
MC:>0W6BNQD*7,TK/BLNIL0F=&5Q390MK#1/Y$RO1"VDQ#%8=?H\ >>9B*[[E
M9[)P0PSY,XQA2";5S,FE3M,E+'Y!ED7A'A0N%-W[<WL0X.6>@_'NO' [^<D6
M[LA5]T"TO#3K\>P<TV6VMI%0B^8XCY2'$38Z=[N?P%3WJMS;:4/V8?74V[S/
M?MK+]P  WO@G#&LB>7#QGR&7+T:5N;<N.$/<:$M]<DSM&;OYN0#NOX8;9 "W
M>ESVC41<RP-FV>>9\*P8F=!FJ:(V[9BS?@/_-#NBQX^;$H543[Y3J7&R- LP
MQD/+I8K-%<"*4(@72G#5E?>QI-6:#+L"QO C=CK;CI@*J\73@.[RT/L[%6\?
MQN!(AQS+70DQ2'2@9C:Z;PU&OV'^ 5Y =,JW7/5^G68-QN<X'@\,GX<K_)3'
MQ'QE+O;2J$*/Z[:8-BUQ;K/N_6P_ T/W==_,ZD&8] LDHKZ)&J_'C$@\80U=
MM0?] >TVJ@>9E >[_NUB8L(LW/YRM3 0Q[ FZ/!)U3$G!IE%G]9[#3!E6#-B
MK6N?*S6OD9-:HO IS1!D+BNFS:FVO#,0\*3$J%;=S1EGA::U499"7P.F+U]2
MX87\V6L8!K9::7&"*"5U!]=R6COYQ%6"?JB=#WTE-;$V60F08?S_[/F _[9>
M'$V[[[E\&]_Z3BF#"NW6)5GA#%V=4E1U?BA];*9I#;E=?5?QW(C62I-"[_O#
M@S^RA&/%,(%5L1"XS[(V#I2W<]_5%*1HT3(/(4H"4L+74I@_2K^X%SC6W'36
MAG[94JJ++N_VXD_Q+!,(P+V%EH*V4S]!&U+G^F$+V6;1 TW^<TLU3DB:,45K
M!+JI=Y&Y'LU?\6,1I]N"X2^V/PZBV;830N3TNKL<*>9_9^GU(O8&=@!G7=HY
M6=W26L0ZZSPB$;<KEWA9@X-J2YWM!PP=[R^2I+#PL(76N"PRR5W5*GH<+O]K
MA KNP3/ [V-(NI?"IN1[PYOE4"H$6XV:?B+-]UTV!AS*?C1I&\[/];$YWB&@
M^N;D\:$)X7\-H)(<#LZL:8UUC9:^!A@B:Z&D=BXI;J4:.C.!4H-M;?%/M2Q(
MV.5'2"9=^XR+UMP&!6:Y58Y&$8=9+Y)L9S0/F0*H%NF#X)NHS+G\MD:FJ.1.
M><.8"E2+>NZ1]-;4UA)RWJ"+L+)*5LC%/V( H[F_^QW&;>J*H?)7M,M6:OL8
M[$;.G/7XUGG$0<(W*R/!%:H_SZ\!G2IL#HHPO'A%!AO$NN9-I>F;-UQ-TFUS
MC;@%\,0UP+9\QD7[*D?L1*%4ITM&7G4L.U[2U'8,^$A.7WO>&U*>K2,<_-S9
MP[FN^;31-S0=;E3UR<X%I+Y^;,. *I]+B>UL.J3!>J\<1K!R5K% W'2?]QF]
M'')N6--4$86MMC)TP:FNJO#"N \3->8*VFC^1!1Y$\S2><V<3:OTR-@Q\>NW
MP"B PO0$@DJ9WA9/A'V;!V.T>VT^5I+UJ&YN]6E5X:=KP.-/\IECC9QW80J=
M%G0-&1!.C;&3E(^O*I6BJYV2 6L$!A33*E-.>D$KK#(>H[5GQZQY85]RY%[^
M_KT[7'A4'MKZ0?@PK)7FL-D%8V*N+%A#&CPP2QEFUK/O]^A8?-CQZ>DI ;+M
MY[A(M8CR;#^P+F9LC,@X.X!A-N[[LI#_"%FM0"C>2V!#,%Z'+897;UA%RLFH
MV[#KJ"A6/=N<5KYP-%CX2!CD,E2F8KL4*BT_>)#HL:K$O8COJP72CT/^S/3(
MT 1H.E$Q_()=GHUB(<NPT@QV8VR,MO6?4=NVYY8 JR;:)[VJ[?SU2FQG-"/O
ML7$%NR;(JJO"+"#ON&:^?Z7ND/;?S*MXET-SSB@52R")??&'5#/J.UQOU* ^
MSCQ":P'L9-0:<K]/H'H6'H<F6[$BS;_SY-X^?=Q4<W BC%U:#2G%Q+8W(B.7
M0<0[TZR^>98/]6&1QM> <)\O-(^7?Y7,UQ(??-W>LN?\L[LL&HJ>77HSD6D\
M#E<OU^IG3AJ\P^ALJ?#DW1VQ:5D6@%O9'GZHD0G'C=[^#/9JU*8@O0?AS^%Y
MPO)(XYU(W4<#>+IX6ZD=GC:6#NS!VAI6X\G= OM0IS[BR%NI&YZ0?+]R\Z%S
M1J"_X=[DW[QB>9Z J*)>FK?'+Q5<GU\E_YW?BXVNUG([&64SJ#5_]CE[#C'8
MQ$*^71_COBE;B--$M4ATU(X""Q>[K>^5\43]>FG>0D\)O(<6'@2V>R;U;#[1
MA5"%BDK1%#3',\E'Q 56 YO*5LZ'N:P,#[$&D2O[)OW&Z+-2R=G@VI.CFMT^
M1Y25<\A<PI?W_K]V?RF!7X\K<0*G'$XAC]DNA0O*2M:!XJ+<3K_Z=ZB>#]X@
M:O0)E%Y'T<0B__;>9[^WEHK[2LR4.]Z/EB^F,U7:1$0O-9M"7TV=JM1:> [+
M_6SQ]GYWQ"A@=:LV^#9R>W?(*[7&&9T!I=UQ9[*X/SE)G/GA86E/,&_2B_F
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M!?OID,1=F.-9&>,,D,9)@AM1-]\G KD&D%8TE@]3A;@]+?V#C)PG)7*SS#\
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M)S6EN#Q#WKHNQ5N43J@CU9SI2"ZXR9EQA3/H0LH!M>/,W\W \!3OMP_9>_A
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MFH_HV[_Q&_Z_"Z)T? (FCA]5'USK2KOCPVD_=M3 @O;I?4GTK6A_2 W@PV-
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MF]KGO5<"HWR:M"?A)#XN#TSW4PUI6R)%.?P3BLBTNDQL<<?6*XWE8#.'S+G
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MV'S<JB!V1P;%Y@=MV9;$V6]X<GT61? @JSC^U6;AH5FX 7+0.>[K8A96#/?
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MBD0_9"DGVZ,$\/54Z<B31P 08#?KO =9!,,=(!S.(Q;1?-LY#O.R2W!6#'8
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M[?JQ.[U14CZ88P@QR-]3_KK7)A$/O-W6'=(5Q32.GP'16\-+10A3.F8M5Y5
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M>S=&>_B]M,T7"YEFR:(GI-V=$N_?B#BGXEJ]C/=\,7&>W^=LTW>%'[61VL7
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M;^!0]-_U+VNP#[<"L\. V2RG7Y\EAVL/W@R4/RU>3O^9,R/9U)91FG<[J-,
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M&$#R E38<5KD37S4JTJ$?<]L\]C;0LS<DE5E'D.$>9JP6?#7M\]3] VNMT"
MQ[GG2<V7[SD# :)_3Q[JXLE?Y_8CKK&:\8O7N%>5BV1U[$Q,)@L&>M1N^;I4
M[M1(:\\[72QQ9WL4)7M(ZP8Z%X=S['@Q<7J-S$W(BD+*8L]5*/!G:?&0AR/B
MN4",IF@P>JFT*="79_;12EY$",MDJV#^%B;Z-1GJ'>S\# Y7+M +;QA,_=SB
M4*ROK9Q=2CC"90STC$>%2,ZTJHAGG(%B:Q-5*O=^;^G\E74AY+>+1FK4.%L6
M289LW *4%&S/9H7<P2_'V2PYQCN%.\N687AX1Y1]6N[8P3BIPERH6O^Q8$*/
M69#0<S1MA )Q!WD86J+W9,@UI.B,#(01\:('XUGU0J6@SP<M>9_-OBE.AV;]
M8<+'.T=CBEQ'?!G]P ZN) I)BUU\83Y39XFH^*WKW]P2*VQ\*TS!\.W8#V$3
MF$^G_X?+]1B9".HDF2>KCR(U01=XPW@;2\LV#.:45N&)(;>W(<QB2'BA*X:]
M"-MFQWUC][DN"ZO/O!A6V$Y_BU7!2(M&'?7QO^^3YT%!-XKPK"!!-7!@C*\J
M_[8IEVK1AX:HT.K"^M8&<T=Y :_M=7-M06?NFM3IHB V8EO)UE$]VI\#C;>V
MXM%@2/O<^OY?#(GM -J3G R]0C9;74[D8YG=)4MBVW2[Y=C],_6G1L3;OC3&
M%IV!=/YB;A7P$#.\,<C/\T*-[[QGOYC5.7#J\$_7?"O2;4OU 4+0 D+/^YL/
M?^MU 'BWCC#=:WM5%@4Q=\L*O-Y0Y,+A1SSVCWE)5QB'.0.]#"JBL'Y#3NQ7
M[]JSZ<-UL%CE2!C7X+NFZZ!L&NP>OW?*JJ[L"S$,)51_6DSO1W2N34@/ME.>
MNZ=_SQPR!*GS 0@R/ITGZ"U5E% X\BP[UZ3P)TF\5;7R@-Y8<6J#_[]VUAW"
M@'P*%!#*5A[R"=7D=5M(Q/#/2NSZ7BK[[BSG/6^IO6G-)(?K_43Z"N)4J;*>
MW2TE1%L"77B8/B$K;G?W=\M<26MB4>WPO!Z#<:NKHJ?0:\>'OX*/N:BE5\=W
M=SZ0U0'H*H3AW"=S(5.'HV8/L]'#^"V"YMIPS[K'\+LLOH+L320]'M9MP?&J
M5ES:$%\2_1/UO)84Y+IQ.AK9.G1%UO3Y7T-#U&N'E;3$3. /SC:JV3FR+I36
M?+.Y/CJH8FXKZSAQ=#)]1%J_ZH]W?W1F#_N"/@TMK<QXXC)7ZPO\\BJ\!PQ^
MXJH((U];NH'^.'6]HRDC=V\QXVVW0 K3C4<'DG=%BJA4PI!">%4%_+]*K(TC
MH8#H.J7L44I6S%.?4%9Y=CD6%Q1L9F1LSQKJ4JN];I:\;O!..&M=F2?(K&9;
M<30IVD6XHR5J[(K?GYK!JE*1>IT=&^92LBL!G44R0RAUREOH)WJLH*Y@MJ7G
M;&#2>@$*=1'R!_ITVM]JPR[\B;UHP,E*=UA[KM'G=$,#_&^Z8=T''H?\+4Y*
M_RI.;\AL)#/@P!)-IL=9[O!>A$;;W"8X'D6N-"0*<Q#U6-,&J)/6ZX=^R(AI
M7Y1;8YC];B;O;=YYH+_#JGU)NJG[$Z^.#,7!ST32'5<TM'8_IA7NG8\(-*"W
M 0+G']9/APQP2BX4%BT92#A-9JQZK<U6@L\)XQ__8.,4^P];W]_C(!EN+UT@
M+"B*1,DNT[MFVO>8!1[-'ZX*E0;)&+&Q5UU=5$/>#A!!/3B"1]@RI>,&NI,O
M(OH55$=.FHJ[D!,O2/6^(S?&%1A3U4;@^*PND -"J8?,%+K&\8_,PTAW3D<4
MX=WP:/E <+R,+7@G.Q8-_XEK/;?&=P'.SK$^6RGW4N2(FZ*+AQY!!I/H:\%!
M<,<-N<'1WL_A\Q,.";-#N>"3,F5G'!0C?\I$4S]%']_K?^S[(T:\.(DXHA>I
M$_>GQ.D[]E2C5H)<2W7NZ'JAW85XZ E]^__!*B\([QG(.9%VH(.NU1H[?AD!
M/Q?(IM*MJ7GSQ7=T'YD?G!?O]EO;3R@7<$P/Y,$/LG%%R[RU:[9J6?%W(/L)
M^'M!AZI==->MT2M?G&S H.0*T#, MI+W6B;TTB:1H_W<W/H6*_ZZHR=!=* -
M*G<KG[N9GD:_@:[K.'=%R.GK?Y)%:_(*I$\BAD\"&"50=;<+-$[(!H.[)RWG
M55$?,7J>E_-%QHA FM;8(%Y?D9WMM_J6&D2%;'KRYO<X!QD&F%>X'(.CRU^.
M7W:;7MQ&%P\KG,Y0S5??BGS<@\5[+?BC3.*Q$A&<ZJJ7\:>AN_^2? ^27L@D
ML8,."2G1+;#92G?G*J[S^%@X^] IHG?P2>NTD+/WQ:J.X3LZG94-Q! @(8^%
M3-G<2.!+Q068;KL(-T]6%-;'7LP5="ET\O52C B*HX&?@]'_G=T ISR2U)9<
M:*U?QVI K02X(^IVJ[QSX;RK7;=T_?IMX30=O^>8#E'^<6/ K&5;,;$^W>7(
M+'W P_/-HM@8LYD(E1 !W>X$%)$TW?EX@66.:'Z"<Z2R*#;V>>W<GB^CSW
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M]ZS,9CNK8TYRLRJX^.JU)WNIKT#WM5OF^9&CZ0,6.R\[PD-XIU4%@/A^&L&
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MNYX"GC.^SFEZUM;K =;?V3YU-C!!G^;*0/@FN-Y*4/^#Z5E,$N>D&-52[<=
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M9&5;+W;\I$",B8-47O^>H!G0:_>*64R<S_S;ANC'5OX3\?0%@",UJS&Z%'N
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M;9XT:ELU#AQ?BD3:YP-#U\+MAOU%/6TLZOOB5G_N]1!_[>6R>X@R6SG0QH]
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MOI+EF_Q6W]*:W!,L*WP@#.^2SZDO$&09O.4F-?41>9A]4MI2)^DG*3F:!L,
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MRL<&^DM9W"='?B-Y$C:OD-RF%$G1 77/52EK9F)S^[=GG5H5N_;:M22OTS"
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M(;3;\\E\9H05W;-$G"0P20SR\3T"G1[?&*=!<#*ZR)FE9?GU'UJ8-Z@'G!)
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M^1&H=J([?BO&+H<QFA+<@N*SGU3,4P\=G_^F/U -V<S.F1RPS:+, -EHW@<
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M32P1;%#L<&;<0E[ALBN8?TMWQ5?SZQ"/KYW;0_ZG4GY%8]YYDRR4,#QWURF
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M\N3<(GBW)1$U*T4\X\]_!WJM[88@>?:J]UYI=K+^]DE)4V=YF8636CI?A^*
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M2P8_;6!/4'%4XW(%XP<!@2SOF>BOWGJ4/.^=\"]EAL1'5$,(M)&12"*/WH"
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M#^!)880X?*@/>Q2C'AYJ8.HVAE-;ZF: -4B+12#\I#P+9,JI2B=E-" "3&3
M*L>@8'O^G[@LADKF;[)BG_[*&+NT/C8SJJM94WZ3XD5N=#H%Q,#P.3 N7UWM
MGROH5"M6U@QV?L2ZB&MMB :8](#0GTC5(G:)V+#/P?=NDSW%VG8^_X+_^-23
MQ=&#FHT<[)](8/;<;9 7D KP".#NA]%M@?C\#47FM@/<R.A%^D#-7-XGEK=U
M=Q%^S&E]@1X)IX"M48_<"OPI0 RJFQNWT_]IFX2F(RJ.)#\H'BUV\PUN\='<
M=S/#95K]^VW@6G_.H-ODY M-:#O/ ,PT"_UF45G?DQFP^^V#W^]<0RI$U3VI
MNXFI/4K3*4EE#_S^%,!&$X6OC9)R)NH;"-6MC./DV/VU(\OV.H5/SG/FXVM8
M]U_7OI+VP*69;:XHC]P-H95%E9-*0P&X6O\86<V%R) 9NII>\M7Q6\[@/?!N
MD:7 ?=D)C9^04X HE1U)U+2)F]9==8I02%BH?ESS4JS'3'?WJ6;TZ,((]'<J
MUM1^FAI.G+M!6*M8!O*[(4"$DS\NT>X;+3Y9E!N$"W594GZO=?/66A; O8UW
M(V8,A=OK",P)3&G>I6X0)]V/NLZNP=G>CO?8Z;^_G$I5ISLD7?1_JCJCC0*2
MTRE.U&MD&_P<DI-<!$ZWG'Q\1>?;!USJBZZ]#/M/Z_,SJ)2' W\4\-QSXA0/
MXGH/)WNG@#@#T;!HF?W%PTD-BQ.V#NNC;PI>ESC,L$7E!CX7#LJ20#[<= @#
M(B@6 :J$WEAR($J^FKB?(I ^(ELH;<3&78ZRN-YZ397LM![7"X[*%R@AHTKA
MC39C!^Z>UNTSZJ2)'ZFJK1-/<.!,'2=!!R'I> /HP>4.RZLS.XR6O2;+N71[
M"8#]I41,/7=WZLOCJH:<%3%?]VMK.(:BH6_9CVXIUJFUR-D+'5[^BGA!>425
M)T,^EU0W5X)=_1/D,M<4Y==<G[T%W/GW)49G8,_#B1*T?:91]+$VW=O*3/!$
M!T)I,?^ZQU2=@;[;[8<FW^?Z!X0>ZL@6E-/DX#<=R=T5U$L$K@S<L(TE0=W0
ML:+"*ISU+L\-Y@P_B<VVM($"[QD7DQ)8Q2;IJ*$*O8C7R-24%'(48@;>] @G
M(DG1!%"G5 .,?\G=A3W&&_SMEU5@O<">VC_?X,^'&AO9X9]F7:7,"N\"'!P$
M 5Q1:-N3MK*I0S"S.:Y="2AZM26F[OM;LNV4=]3O@:ZY^?4,V[ 4U>NI%L2L
MG0!"$>ZP-#GH"SS]B4O[IR67^JK*1H:YO+=?C?4NYE4ED#B!#K4S=156M[L>
MM7QK>?TX]I&.DXD00P3?OZ(JA"$Y9MGG4\MD&_WG)3=X'.Z/H4CLS,W(VYE9
MD7X*5YA7/0+S,HZ..I!L2W#)Y='HYV)F=,BRS:>N(W0CHE<&2NF(WBO*,6CV
M37YL:H*2?U55M6@_\->?TI9GUP>_]U5>IV^N5G8YJ:;QDJ%=+J:O=_6-U+%*
M51=M_ *A#P) NY/4'YWG_P .%Q(Z3[[5BQE' /M+9[62_7KWLF/_=@9OZ@_M
M+YM>T7_U," -? U*$R,VI%. <,^.X^KH%3]VI^QQO"KSJR=O[?.E_CU=5'K6
MVJ28:F?&_1/$3DZW)*:\?% %$9 +*P7?J)V;EY P2[K&,OR :DDNPRV]:@%,
M48T->OBM)%X;5WULO*:6UREINU3R,&)$^'%]$8*/$)X:7T=^7O5XSC)6)$>0
MB8>?/;D@^*@ZA%0VC5+'Q*%@WL#$3]#^?>PIH/.-U%%F$7-N%56V3'2,L9!B
M1U4$QSE&Z(A+.8XI[1H.PB[/?9^P, SX??522-8H =_.WA&A-XZ6A#^;<?N9
MA_NCI,5 <:C+W#_'Q>(SSP2,1_VH $6#+M3M16,XE>O=N7M:@G,+MX]J1]2U
MKT\[+MY!M&9>M]ECW4YY@6I%/M*F>@,[W65I%\M1Z]-8R"S006+A)/_%/F(>
M*3[_.-+@6\*5 C:7O$)8">3OHON\*03")B2=Y\V6]GG+7)_NGB&0B([!/\YX
MGOQPR.'"&U&LFU2K8:MY[].S_O3I'$63:@Y8H4DY.?=3,O[R51W%29)?$AY2
M<)_F1O$BX1K%,Q/&'3%5XY.BUA>3URP/UQK*+/*T=+XX/GW[^BCK??'ASKT(
M&:)'.DY,NE[,^TZ<58V3&78-1Y+POO^%]4B*[A 5CQ9#>!+S*O!@.@^CE4&-
M<-.>KE, Q=/HO7)&2?S/[YK,JJ\DO$-<>H'\^G<B>,F--C-!0[G>/9FA>?%'
MUZRN"C0PZ:#N6ES_KD+'O-NH,%WG'#(_C"_R2QV+]Q_WXBJ3-S&VE+9;1',0
M^WM@\2Z(_\[^V'FO0"O"@)SP+47^&5,SIT'X(Y^IZ+QBP#PWJ@KB@^'5?[ "
MQ(K_M:PC%A\'YT+Q<G[2=6'QG@U0[4F_%'78QX'A-_!-BZW]^EV-A)1L8$!T
M-FN'!F=K)D!<>]/V=L!%SVJ%]W\,;Y\"HA(1CN+<9!5]$$1FP;0G7<32OUN*
MC7[@UU$7BLHRXT1AI]X%\M"8(0H!3Z6GGB/)6>[GGBTI'W^+J$C]CC8Y03_G
M%B77XCU*\')M6I^-EH>YL'K:&JP"%S1=E276B_3NAS,&@0G6PY+]AMQ$RYEK
MY-!_""&\WDWYK:N8%AX3Z[Z1,&KW/NKN>.I4.KHUCP,Z"3\2,71UI;$>:V7_
MTZ*Q21*-]<^:Y0.]%XL&=CT\B8]^/;TE;Y1EV',_0N/0,JDSW%J7J_Y?^BF
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MV'JKR+Y+ED3I-DO9%SN> E="1+UJ/JXLMO\;4^DLC9\*#7 ),QT<\/SCN6.
M<G4./2@I%K6=-L$9\WXH8/R4KNY]5JJVCX39 4_-A@&*O+8\C&?O.7&?B_[7
M[4O_GUZQF6\."K@30;[M%GTTR9,*-#]5E[#4HPCK"+5N+@&[+0Q_^L;L'?_;
MG+/SX N0&:V*,"5K$"WPRMTP(!A,M<VY,2Y)9$H+]SZ7>V.-^6F>!1?3G[\[
MT2,*=2=E2&_,ZT4]\M(R+'Z)XW")&R*<'W=5R4\32AB2KWF?<N/31V)>4_6%
M4\!#F]?BEPFHGA-8+^C\CG*$/+RE2_&:F(5UK&N8@H+/ OC['16R7Y,4%YUZ
M7Y"+T\XI0'2?W&HU;2B\C95]K6[ XQ[!*5U]Z0/*SU/"S&$LP]&CR>!E=;[+
M21-5LL1B&:5@A9E\2)1YJ?7:P\*VZB3?2]1UZ+MN^L=2YJ?0(9#WZ*^A7G$6
M<G6>*M$Q9WE!UC2]6TM8K"\.-Y7;UA=>6/+6G$FTR=9Y/?F7$$KS)!K-"KVX
MA12L7Q"GZ0VHUX;@@*PVE:[JF8. #TO2(IFITD9B?1"ZP[(_HY0[PQ33WL!P
MYFCE T[>3E*BXNVPIK*4W^Q^;#=$^TY(:>.U&!\P=H2R[%BB;DY8<2/R9WC#
M2*T[+JR%L8M7FD>&=SX(>KYA#L6!'J%F7?N!;(8JY*Q^0REQ,<).:9D7R0@W
MRBH4T2]5^%+K:C7 ]I<4W81VM1TI[^1UA 35B]R)-PBSG-37^>P3NIBI3K;K
M\0@S3%CF&/)_G?$8YC&K?X?9@&*->#X=(4V]0Y8M@X=9$%<]+DSOK$XQ4R5#
MV/V4*EH8GYN-X'[(9G'VL?9!J\GL%%]XRE$O1C N!:%3Y0SW[)KAL<[24C$I
MNQUUY9O?NORS<1TAC[;TX5#EV/^F*5S8P&+^_ U2/(SN)JQU;<W<97FT\&Q_
M+MXH[O<&MVPPE\*K?)(I.2YH!95,@E5N1...>N++LFT6!DG;8='BOV)5DPM6
M/XJ;MI_3/6LQ@8VQ^2M( 4BV>,GRL%/7=O6]H?""A04WXVM+??%NY2PVF;TF
MUWTW,-X@[#SM9TO29BF9'3RNKAYE0EO ./"CKAE.Q[!LA:V7N1#S9_=(.L2C
M[OR+FW^WCP6Z8^K'JV3JK<#F=3D4D\/LRZ]EG/V2DB+[RSM1Q4BOU!CA_$Y0
MU+%I]&'YCO\A.W/3"YEO"[]5WCH&)'>()Z?D?A;"9<ONV*PDG@+F;,#D0%#,
M83-"F2])M?N<$9??^R:FPR4=E;2)CQ2G' 3@I"%(.6:1:U*QS0:GS <]EB>/
M4*R;B$^^^=<W7'/SBU49>=89]K(#%41D[H#%8V$[,0*]0'9?K# <9C>!&S_,
M,3"1X^SJ%/$WO'LWN3])E!!*=$NIHHB2,78G'S20L1ALBV5HU7JBU\Q**Y/=
MN:Z9&WYQJR,$.C'5O .63;1<Q.*Q<B05C(((V\1H*//?(WMYIH,G*ZLO)^A)
M1SQ-6%5/8F(%.'TC%ZVD1..045G BVL7%^ 1!NJ^]UU+'\$3H@#,&.TUM!$Y
MFL)"'C94A!?UT 0G$.SX=H6>Y(M#?OCM%]1AP_LO7>QGCR97],+62\(]\=SG
MR%&PLWZ<D.@#_J5YC(40L7U9TY;'D/N 1RJ'^R,L]$* !,"_/3QJIP9?@9K-
MZD%K$]8C-=KY-Q\FUYT82S6VQ4J]X6GDLG]S;IG)EI4Q)OANQ#1:=AS-?9;7
M8,(7?8L*J&X)^E$]1*+!?E;XHEJKYM0]=I[(9Z:^^TOG(KH]M&O(8&*<R22L
MCIMK="4Q*';HUD^&O3)(=9D>S?_IK]4K>^2[1&:2!?GG?R=,.*2F]_1%\)PW
MN\9L'@05+HB\F_"_+/^:H>>*2'&R?7K:J"]3J$S5*8#Q/*$]KFN/&=X'9(<Z
M=?>$OFNY 0GN]%@3^=PY_U[4T S@.=WT"_-D--XNXB=-A+!-O4;4R$S\[+,3
M:!@CW6;RQ\R-&Q0<^+N,B)0OQ(%_:?5E"[Q$\VW80K/9Y^$6?3SPA#6S6T.B
M8S4,IH)R;Q;[4S[.E%.]R9>(>LXG10@YHAJ.5E$X6Y*7=VQ\4ETKFH2(2P_[
MYL<LE:(7F, 0"MNAIQCY8&HQ43L:[1XC?QV;VEM2NOHM)SJ@B<U+NY_H^U<\
MV%>XY[QMIVEB"-/Q8@+P-4*,>/'&3RP9PO,>^SS6\LM\D3?C'>KP/"!<80()
M144*C_8CF>"A(,ZM8*QI@KY!>7<%9 )\:Y3>'$AH\G@:#AVBBE 4J7>(8J>
M'HP0PF*Z3B%5!%[1#<-1+-S%M5PMS :>J-4(R<J2C0J\;4X!#(<YMK!9DO(%
M>-1ZS_C2%L!]WHV<MSU\+\)]T0\C^^06T#\#CZQ3WBD/(5K<_-9 B(M#6!7[
M7"!_F;")[CMO_GO.7=>2H8:G[)+99EX]R;L3%=OHP4KFPV'HH7G&"WVYQ3(Y
MSTB_DVP?W'[;#%A>'T=KU9_$HM4@6!XX_T2?N(A-G*;X9:MG75BSQQ3[R-O
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M<(%(5F"CB>$ R$>,HLV/^MDR[8PNZYG<S??;>G7+SV.J6_>TIO8>W[5!"1A
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MS0CJK]DR5:25S/-26GJ@]5/HAO)LS.9R@VU8?= +\=NH68C"A%+1P+?7'"*
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MW;4\P/"-VY(IN.HD"G^12R#'MB?6E\U;+1<.3\P7MG_Z^<[7OYO(QIM>BE/
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M(C"<4//?#R]77H1F@X=Q&>B79QJ=N[2@> G[6C@'_#F">N7B@\7?#(JWYY>
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M]D7U^5-HC,<^6;I_;QE7+5N'?$/>"M;@7'7ZJ"&EP-(EU<AROB_I(1--=#B
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M09YI]1J0N:D*S50FSQM,5J#>\B7*A/8@WD"K/E\"7BQ3;@$E@"+X.?0O;K[
M 7_R\A<9^RB7TCZ=4?5%Y_:0TZ ;\[V=I!U<YG-5:7:Y&S-NUTDBK$0O=-1&
MVK97_",J@P7P65=)9?0+3_G?GX[BS/^>JS2![_+%E&=?K^NLX^C7)MQSWEFB
M'A.BA]^!^ZW!_Z[OD0?=*G+Q._--M[0<^-;+'?',J(NTF.UG9Z!8>U(_:'DT
M8P>)<XH(G@&JC1V!H@**(_<J?P84'@GD1+SP6R Y!H1:([M!,=R@A#:V(HU"
M*Y7>.<M^3T7GS_)-ZFK1-'O[=;JZ?TFM+'J52>('.3W7=9V*+3;77[*/=\E\
MC[F&F"A]\!@V.S9NG%Z^9:O++5@HSK^I:YDI'-SNZ^50:&7@XN&Q9_]TO(M3
M\M-B9" DROD2P$=P^PKM,&#4P:Z9>=H]2X4?_5:U>N756JSV^'0H8A$H-D"0
M2CK7PN?J+*C5N!]FP:-G-20L'^,ZWC4Z(AQ"JF-TPSA#WP<:?VXXSJ'/YRO+
MQ"'CZY;)G&NV C)_=+LS[;WUGGOF+]R\LY1D\4$R'N9>!)74:)KRU9E9HDI+
M-K@3*,HW>%3%AW4*KS>(M^%']&?=C<D;?Q%T9A/#_Y]H>\^X)K^N332 "%*5
MW@."]&(!Z0F@=)$F!*D*(DUZ"Q"Z5.D(*$CO-?0.H084 >D"4D(1Z0DU0@B3
M_S/GS/,[<]YS9N8W\WY87_(AV7O?:UWKNG;66C>/TCB=AGRJ-@I(B#\6G#KM
MA\Z7+N@_R<U7$NJIW$0+FF35 7M,VW2 "@ '0!YBGME?8[(K#F])N?MK(5F=
M-HUIANC%*X <!<;J1DVP@Q4;R34 5 =I ST8A/J&J>/>M,337LD-J@$=<W(K
M;GDI3J;'BB35U4@+L9#M&FTV'?/V]O"=5;[0(P76DQH !FW^<%%.=2KZE9F;
M$/*X& X9$*D<=A"0N>VN)BS+;#V]R3 9\'&C65R7!XIT-QBAV745S7&3W39,
MNQEG9!+>>P*<MWN:884):ENGK<,.O9C;$ACK:!R:W\<T\>AIKM*.3[9"@]_0
MLMC?P<KI4L$T6R9/@90?6D5K7+U>^S MO+VAVE1$L@D ..U2Z8=N/_,%>3==
M)55)$?AS)BTS-/9XH%L(0Y6DZ[NF*ZHL^5#)T\5Y AJGYAFBJ%O] KVUM[B^
MOCY.Z01ZA,UP78M_U'<T\CC+F2LV?8Y.?FCS(//5D#OE_FB@2.Q]0<I<6>U+
M,$X]8]W+$@2FDQP7%J0.(U! =&*Y:]UGZ;^6=I_/&W#0JN*KSWA^,]C+:9RS
M*T;[68IV&W+X$">9\<AT\<W;95:JW X#N302@50K_5?^^HUZS*!7F(R]M!JG
MBXR8QBX)Y(3]"BT. I5HZKKE]>-84VC^=W3ITI%H!!$OAV="TSQ^&DQ3TZF-
M)C.>DI1_VS;MU>L:_-HQ_-Y&<_(;(_U?2:5<I_L$#.-%UHO/LC*0_[5:$^BQ
MXL0YS^&DUT;EAY*@07UC8ZROT&=-^91_\MJ0SVKB=JA"<A[>,G>W6,KHZ;+
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MU-6I[%OCM_!]]'0Q\WPG0=#X3@3+J*92M$OH_2_^"6E'I?NN&)*!1_<(?+4
M*[LVSHD--FB(KVFRHEFY5X-<PE>;A"FSL$J=!M1L#FFAX8NR,#VP72([[<T/
MS1BRGZ'O7]J-S7?ZY8,7YCLXM[U)-A'S]*CEU'S<N\G#0BSG.H+*_*Z,CMU
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M01^Q.)X'"4\3_8*=+Q+G*J7MQ9 K%0'RC"(V?G>[K_%EB$E]0P [=_4/;!U
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MV+%'.@8L Y,O2SY_3J8EBO4F4=S=$Q-1^?!T<K]*]*Z9F9G7G2=4=I1L1"&
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M\2>#[7';:YK*8O.:^6IQM3\;7.^-([.+>XL=TL\>NU<W-75J,^BK_[.<PA\
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MU<XAJE5!>\T>?I)]*S]]3K>Q_HCII;7>G2+K[\\?_#"2)83/TO/U?N9EAFO
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MO]1V;4%)(%"4U2S42LM'OC;,1U@^L]U,\9F:#U)S+3<UI95:%"0M$=%%<')
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M4!)BB>"(XV!Q MB46#B46#=] /OM=>)A_:T!_]*PL&^O$9^ \ X1\>T!]10
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M3:/4I.-UWG@[;P#X>3I@S,@B8[$=1 3S1+9U4DAQ(72L]"\=!^)PZ5*&P)_
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M%=A!@S=P3U78K_E CSIL[J =G[3/'.^Y4_N]7EM[:*1F&4M%>V?S<O4XY))
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M;Y%)6_;/5GO<M">NR@$M'WM<4+"EV4K6NVO^ELE7WH9(93=&<YW3IQ&V(X5
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MJLQKK_K&0/U>W]DDR8JSIT/<VME9_JH!!;0LD.0'8[0\_WD(XS^3#UMIT8"
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MQ]?_&>IH<@/ S8./<539P)><L4&W^/P:8%\0BR5;DS"%M[PS*LI!M,6<JM\
M*1!TP U@FW\#C&>T!X4HLM^2"E_8L8*NJ75=/-JFEV5.TV+G/7F$DM@4;[O&
M1CHF98W4D?TW6>/N[8CL=P^N*XJ'8PB0A^!/#.M)E3_HDOU^:1*NA\=2CAA>
MI2L&%T,WNY)Y,#ZH6R"J\S$X)S+E+YFIT5<TWB&HF] 4</YOIZ@-U:0^BUH
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MZTSRYT.$XA 12?5911;+\N -0!C4TAJQ:2<-<%U&E,&DFA\@+WMM[PM??2$
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M@$PIOL3.2[H#?+\@C79M.[D9DM@#(^Z.#XMDE##SWDN9B@/6>K(]"8 R'P%
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M#/$7<")WYJ$7-E0OQ=H:9%1*7X%,WZ^7^]I$T=)WD1LNBIV+RB2?L(&\+B,
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M)O7_[(,5K#OWA@^H;S^YJ\B4"^@J\%.2^ZG1_#!HXZDAAM =<\EHS9 +-L1
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MT&?"9BDX=RL0GP[?SEQM!J'BBKZ7>/3-0KZ((D$RY=[C;+6Z0I-"!B7#\M\
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MOV[^*N3G%[Z?K3E=L&#DBV\[!J^<1P;I0)9W6[E,PC<TF:Y3[<])V"C!6[<
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M+=N"1>3<B%M3I5FR'QYL'O1^Y2"Y!3BWONAD)X_HN@7\\5[4;P^B40\QY6V
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M>R'7E=W*S[@83^ZT('MN 0C'=@?_,V%E]2D1]I<H=MGL:.DIQM5&Q589[:F
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ME%[NXK]Y'9I)1BV)RYVJ3+7XO:YK )EX9K%.278&P05#UFJE/(QR-S]QK&(
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MK9*;5E8##8WH8*%+D:GX1WZRJ(71GUXL(T*=:B[;N^ES-?JA%.UAW1VM8M<
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MPHC7R.-"S[GSOSKP\,L["B0,A V+O0:POJW?D;!"U4Z[UP];Z63M;H;8^,9
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M<!MTL)DW^9]S[CWGWO-N?>]5O:IOS_14]>Y?+^O5W6M-[XV<0:X )*J**HH
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M,0+NZ#QNO2,0=T)@EL/'D  ^<0<2.'N\TPJ_W[HNRT#X_PA!]G^#Z/H+887
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M63/$_),@I/]0X1]$"_Z21.F-@C,2.(8T<R$!N60D<#2/!& H^T*/R^^PS9%
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M(B\ZA3O4C[N>E#6Q69]=2"03F8!G0>NF89\Y!JY?!+VM3;%A3+1B^/GC2JM
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MWV%Y>MHZY\=LQ S>1CV,_Q:W206J%0D5>C69 ^.)*5[UN?$:(C%8GI6,E7#
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MQD/AW0*1QA$YJU+7+^;Q&/XW[-J&EYU/(I"]X-#G1WLX4ZN/%US\%=ENUUX
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MG\8;ZJ?O:+3.GG'&-C&3_BA/Y3"0LLO[:L(731+[1X:Y#;&GR:59S@MI5L]
M3Q;:\2]^2>']O;[#>XN13<3 7Z!BSDO%+5TR(16H:+,4"_@-#A+N7IH")*SZ
M7,K)$ZKS<)JZZ+QRK,-\=R]#\"VAOTU!+2I$-;L-0'XW;B;/V;9^NF W9HO[
M1]=0SJMXS3U5HC-4;8'6J<>L->/>,3\%A59CB]B4B"8Q2B.)Z)Z[>7KCF#2X
M.^+^@T*>/6*=B BO5K^+$*+C!%-R_M(J3.<=G_%&J>*GU@VKO+Y1+79JQE6!
MVYO*BIS0A07/V^(.<\>J$4A M(WMG_@.W$8<<K_0N<1 ">D1(2PMF=82_,BY
MIB-!"JBZ?:,BQX%T5[+!_KJNZB*9W&!6YN85BF>"$'!5D)L.*K3L'@)<].'7
MZNP0^-+RW6^ 1 '%C9M]T0\X!GXF,X2B1M9YD$^M+=>/V%OH<-2OO.&1-4.T
M:OO7>OR9'UQC?,E\-PMSG3U-MVE7+S0:1*[<1$$K]%O%[SV!S:E&);K]F"KY
M9'!^>)AD+%*4'[$ZA2VN-U%D"[H;[!SWO4!(IV[VTK2BZ-^?U#FJ2)FOO#GD
M.I'IPRT=IX4(:^TA8O]2(>57Y-,4GI]PS]GFCMP2$M[>OSO2WR+A7M@5'/]-
M3N\\%SO1>&OL=.<<*2G1QOC8'&>F7M=+<V((M.I!ZG2$(BK/[[?-&DVQTG5$
M:)]7UXAG7 ;:DQ$$J7Q> CA]5MOA2MK?*52?6&5!!^N"S4UC<V\,HPW>+]@-
M1AI0\*BM3V=@BGJ7I9+O1L41;&XF!L8 Z]Y;<[6F^5K\-244DJIR/PB"XUH)
MDURSTL_=G/S;;Y:38:&O!9GCTKM^S%H)1\JL>UP2Q )6_'>.,8M>GUEG=5U;
M'&)W8<G2E,::KW6)SH"8D^;0Y8&8WLHXHE_ #RTB\3W6_)I"1="X)BM785^W
M*NY%D$_;%,?H4>^ OKF#NMZZ@<?_#2PG+]=_QV]6M"5LMA>4N\J*A?03\<*)
M]^Q$2<?;M*ZS=?ZV0A&;I2O+C_O:\%A3;'Q=#"&&3E,YQ>8!.C5'RC!P00!+
M'+IKQZ DGZJ,+WCO]LN0<]8# VUT6RBC!6$^MAA(56:B!PG+7\QOO^96KYU.
MGA>HX6FX>@$$@#66;1O3!0; ,-]>2NZ4%JU,6V*!GS@RM/CQ6J2V^[$HT> 2
M X$UGP(7"ZBP0Y$3R%U2EX9$\(QXW)4?-2#XK(WT+@>WG;F>A&A39C\^IY-0
M7?)+%$*@;LKZNQE;VO2OS2,9)-K$[=4H*%/N!D+ D&+2SJ("0R\WGI+P/&1S
M2(+<%=\DP+U$I4?W'=K-CP#>?$/N;<M^II(/(M3>XW[\FEY%D.&&%\"B)AP\
MYN[VB^@!J[-EVE!_K(Z4_5WMU2^3S$VLKH938-E,S\Y\STG%JT"6;*^-KT!W
MK6H;B\QBG',J:)F\9566(%QV_/]M*.;Z#7@6F*U(@&Z$IXK,F*HYV)DAFU#
MFZ)UXHM0^6R"EF5/MWSIW).L/%/_YGGWVDA_Q\9X?@$@Z$5WS6I/DD]EU=.@
M(+E^K$C[ED!DDN U0ZYY0!QQ"YP'9Q\@YGQINX#C00D,:&:^_Z1:KQEC>N"R
MC\G4#'H"08FGN'(3N%FJV<FS_>ZXSAUX$^C,/O@??.P^8!OT^9%@OZV;59O*
M*34M07A,]-_&?>ZO>#2,)$@FZ= <PL,#J7E3$>[^#VM4LS-=N8N,.\](Q^VT
MB?3(@[4<#%MSONI[^\00>]D3<!F^I@ZE"F-_HOII#=X9BK3&>=?QD.OU(D6T
MMVTZKTIWL>WX(\OHUZHF]6X3G5(4U")G-XGN)6YW@;J(M?J</RUAC\[Z!&LW
M+'@&RQY3#OSD\T+"*[_3KGB-=497INZWZY<=[3\=L&0J<UG2"Z1K)! 7LF>K
MW7!!SB_=N7[RI7^9I6_4[;)N99_K"-V2]CWC*3%<^-G\:2U*>M7!&JC6:O$!
MK<?C!9!LO>%=2-FC<\"E_6[M3!!962\1%ICWS06>M$MBES2M4NFEJ(.8QP1
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MQ0"T90[KR(2EJN[ ,])%H:J#N_\3D))A2".I[WCLHQA%;*=;CK+D"^"UYA=
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M+JE05G/TCE7=-0S;P+,7IM-?TM_0D; 6:K2E.I=97N([]/0%WS"</K7!V%\
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ME=Q@FVBOQG/]@<!(.5;,CT,QYB@"+VI/GP!6Y%;P[+(:_:.%A5O%\59AY2?
M*W@XR2;HLDE;C<O,2PR7LG#+4Z1BH@/#?PA4A/@TS H>R;5U0J1]@;_065R5
M<7D;!;(YWFBTX0RF"S>57D?:$K%&7E8^08+=W<E\>CZP0O-G)A;HP@WX0^,'
M7-YI6@</-3D8:$25T60ZL>#W7%<BM*H-M)=UP/WK<C7^H_-[QPL8B:P]QT$W
M)-W'GMTL^ 2U*YEP?8.T8X5\;5LJ_'0@P6&='MB+N^;].@A,OW[-?/0&E>5;
M#YKI_C>4C2M"EY%K[LD/5?6#Q+V"%45Q:?D'-BUO_R8I_B)VKMVJ^+&\5CN3
MCNI.A?=0<$]=IKU875 F7F*KE<;5G:HB>Y.M.^!V77Y&[WP2JRL[O',=N*2?
MB.4<@ <$5>!$/(/+*PCVJO4(V&WEE^!4MVUMGZ>3(X!Q<N6C+Y3K O_H1&^=
MX"'5_AZ]<N70D!(>UU X^FCN'1C%3W[RH^%XP03=0NB5S;;BR)!:7/ML-O_#
MMTUX9^2]BCM[U-5K$9S>,]/E:@A6(69=M 9&T#MC ZYZ*^JP%^^G VR57ZQ(
MCFQBV4Y(M/FTE=)%C/D4<79Y74NPR":<B%DLEWCP_@0H6B#NKG_"!L*$K2SR
M;(I%'&R*LLDS$ESL<QM32>VWP/?],14=#NHFZ%T&A<%2:K.=IG]PG@^.$NM'
MVCE5H2.?$0_:M\.L_<7I(7@#7_9Q ^J4O'8+YI\ IFO4>O.:NT:$A_"#2</5
M/\LV1P1"]MO-S4W-W]!66H)\3&(NL7NFOUE[#-VIWK.!HDO1HJN6?;SHOQ80
MS9QZX;LWN<5X>:6$5I=J\%'\V$H7EH(?B4=T=Y#!V2('>G6EVZKUK+\HVZU_
MT7G7?$XZ?C6.UX5B3(7-,BSL<T?+%FU6##(D[ICE4<;;7ZZ:+S/!;,+5LTO<
MO27_3L)5]NF+Y*<*$VU\DKA71X_D_A.>K#"CKG4RN-1EXVTVI(8]LA"D)<?W
MN0GB5LMEAN+;I5U*"5^.)U-[7 2^ECI-L;+8%. 1JE(Z9-$#'U>R4231M8-H
M1\TX3V-G?PP.)^BJ/<X88:&D#F<SA^MEE(7]JB>Z;L*7<SFN'C:1BJF/[.;K
MC<*@+,%*T*<W^G$64>6.@VW8M6F@PW;) C9N](QCP,0_U O6QAL_$XF'B+W:
M+8)I'8M '5' (3VM1<4UX(E<PV<OZ;4">+&WC/F#JFQ%J_)5X2D#@_56%< &
M\?JZ$6;T]5*!U4R[[7D3J6)]>@0I,#;0LAT$?S;1\C@/EFGI![#&P#.WL:<"
MK,\BE&U8A\&I OERJ2_/JQPH2SS^0-Y)>GWS/U5.Y^C9=@#S[.C>'%-"3WSD
M9BY;?#4JL437=,S#H,&*?SM\?JO7Y7PX\RNL?LT(F.\HNZ,\6.X,=9O ,42T
MJ7?43K&E^N$+M>EYF=5^H5<-X]W4KZQ$]P<;*8F)[(DO7)X16%][5R?Y8!<4
MKTN_;VIM\IL:CLA#FZY9 &[@O-3V%81YI$#'. +R#F"1*C'686VIS(&,](E@
M@);X?UO?[W]JN 8!Z/VR!Q#='6&TK0QV*KGJAW#TW,?^N??35EP OA$JOH];
M""49W2.'CY]*3[T7,GR)888E&R7P EL%$L&:R-,K!><WIP^C&1Y[D_<E42C>
M[O]-F.,_<(,\']*!$=7C5#:**#%<P197)EKAW!P%&SD ]['AFM5K;P#G'W]8
M;P,T&^OJ:2LZA8Z<&31X+VU3YM*6V1S%7"_@G8-O,_.73Z66!+#9BIC%FZ!9
MH*.W32)D_1'WG4)+PXHV<5Z PSG&><RNN*A<U%TUA6&$+J,3=4*=?X/%7$L1
M;]3D9^9%>A<<Q7B5+N0F0EBS,84ARXR:G\9XOFFR'_B&%5*%%C2?S,*.G' D
MCO:+3H^BL3&#_1MD<[>4B6:^,U+-?-][6U.,?[=T._&G1>EI(Z9E7KH1E_#N
M][;EQ&!5W-VT$EU.<0(BABK& VE&- +\WA)LP6F/,9(Q8A*K]W$O20K?!MH)
MIJL,Z(HK6FYC?J&_0E)2:8:/<;AW;<Q5O&9H:Y:=O!]U[C/=S?=4*Q!,I_<!
M'G=M)%6 L_U<-EDGM:L7S_G9?!Y?=#2*GV-SZBMW4Z,SA F_L7(HQ[=)&TN*
MVWL"5!G\)AG@22X:*[MT8RS'W1:7(E#/^C]=$_XC*<W9';#;W5=<Z#2O">*%
M]0M[Z./9V&71VC%HP\]GD_AK@[WFYJ:?QSUG0OCB*24!YB62;#E=W_+9 VH#
M[1/ L>Y?*C!(_3GG=>D#VMIQ +/BP.2CQM^+)P"ZQZ\G@/@OA2< LL6_S&L!
M4+:%9Z\I?OT?#?[?8^H^RK0^ZO[!VW>/ZFV_(#M&.6A]MS#@.?EL)XS7Z)$Y
M://!DS[ WE;B\<]_#.!C1/,\R4L/DCVG>Y;-)\ R/02A1U8-;*,VNGGIC+5Y
MXOD8HIOVB#KR!.C3]!M;FWOHRMZU<;!TJ/N\L_A(OYM<-%HYA5^:'0E!GFX4
M)OF$Z)$<Y[S>!UZ:SO-Z'42Y"$D?PENT5%]9T./*.)_I?&<]]8]E^I ;Z+S
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M33W4SIF]A5JED>F=F9BGI+NX_YKB8>N2H'S DSZG2O[[LD"1B!3HY(\9>\5
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M:-F]C)<4@>:>F!J9F- E?TE24/JV^Q^\HONF=*IOB0:VBJ1RE,0W'D')L=-
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MB=?635_ADQ9'?+DP%(D.0^+%W#OJ\X+=E'C)U%C]S685;"C2$/S1V#C-[F@
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M_6"UM6' EK3?H,EDGJOS8"Y_(,E(LW PZL-4=.L4&M^Z?U)J_-(#T9<L0K<
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M,_7\_E7>SOF@7]]X+A?)V!YJJ)V^L5-U+_+:8RLAL/?/5O9-I0"\LA="@?
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M%9$4M+('KU[V-++KA>=F5I 5#!CC6+M(;QF^W(H.],)8#];#/Z@91].B?0:
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M/F;)X?B>.9\H 9,Y)RCH_Q)4 F!LB7#!W@D<L,@N,__CMVE%&ZU:B(VO(_D
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ML:\B@R\9,/0#JB_EY+*X[SSF)?G]P4HR],P\4R_SENY''R'_S-]:VO2GD\E
M55_W0G#I)DGY9H9QY>=J?20JYP$B7N'NPI61-\FT%XGC7L4[GG5C2=Z*5&,@
MZ%KXH4XF/JPRTM$NF0-S[5,HCID2.KX2/<:6%KN@16("^!:"F6P:9D(\V_HA
M.]'1W"Q!P2D!NM#C$:=(#ZCD^6.FXO1Q#]HJ(&ZH!M4R,0)87, 8[<@E.^;/
M?*Z*SUIERFU3G)97;:$ALZ-DYP69NW)N+\8>/OC TNR8^];L8&F]1;SDHNN)
M)%:GOE6$/[&;O9(A87A.M.A/7"^I.?)[G0D&*HJ)ABK8.<("'+K5(^!)R5?0
M;(C,ET,,J2,BNZV);K_:OLEDG+MB2W3V*EE;,2(;E=4_-5[[>MC$)'1]H-U?
M7$1I;NMPZC]6,W+^/;KAV\F2<[JYV-9\6N6WDU+@7/:8.W#P.EJZ.Y-F\K?Z
M[/$#0_/<6=7QE$+2%&JJ(*]OF/->@+=N^H/V5+F;*K5M/8E.AUEM2/^(;_I
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MUYSF6IM,#,->X L1.9\,=M<Y[I=H13) [SRD_DS::JJ3O56DD_N2@]'X:[*
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MCO?&Q',F#<RQK:LXT#G8+>I\?+V]X]-B3CF83@6^^';_LBD"I)"^B1'IL$,
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M$YV6^_TIH9'C! 81'<\Z/>27:K]I]O].L8#_3YK]4[%_Z;4 P$1\!'<>XA.
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M$9P'W5$X;>0__J3DZ:U5RM;K+2APY'Q^EBUE.= C7PRJ*WM.>!*5OA>Z:=U
M*9V0A=X*73&/\-P.]/B4O'+XV==4ESSF>^<HRZ2*;'4$M9RP,WILMI%R@ZA#
M/TD>W,6N1D-SUL@:N$4+.$H">^9_\>5(TJ9U1<F/+!1UOV46+-MN++1#:C$S
M)N$&14\-Z"*=^?!/@*0F\@_\\CE %64LU8I]:(VS6-T^U=P5V:N[L$5S158<
M>G>#XXM]\"^TAN=HMTU "]J9QO$5A9#77YAPNARDQ!VI3Q''&I=&]K<,-X?.
MC<#&XOFDT-=VPZP[2'<:SF]7<6[T7]/\<A^ECO@25K( VQQE6^FD0IR)V\[H
MT@F S\C@*YS_C-!:$'&TN"2TV%+7&ZG$"N'_#:V%[") 3,>1ZY/EY%WSW7"P
M+BO,,[M.$[P_,;!\NBG:/4!K@)WH)%B/P5M*GARJ^0"8_>543YA&+E^<R?Q(
M'BI;ZP[]]B]LSKL?J!KU[;=+OS?[F0];78$SUK_QD@.."!#^C9A&Z+L",_.-
M)X?J;#M"=]MPGSU9PI;VM#8@+4A_Y@XG0:SK"S0IR_YX2+!MQ>1S9+A#(?I1
M*?(17JY:BP636JX]N4B7M%%,<,3^+2?]@GN>\P6"R!U2_DJX@J SW"6$I_>G
MIW5=";-':.9))S*<C,^%&R1D?/G>E@POH,QH2G83S1X!GE BA5YG.MU59%SN
MT\I6$_?F(3[^9D2_[@/GJ;_4ZJ0R;NC4@V?;]:]W_F(_P:3-=^.?Y:! P\]$
M6B1P#O2$[+B&BMO/"[\3+,L/A]44E]3N>Y672F_I9H^>_N"XYO^HP.\ZIC\/
M+W>4O=THU0W/_-YCR@U0/-K,IS6_PM:L2V@AZCOJ*12 0^E?FRJ/J5N+#/$7
MXJ'U-XZ?R/GJ#/D&/)\-IW$>%<;MRSX 'A?XP,37*85O3VK ]PO?!I/N/3:'
M80^ HU^E54CT,ZM\0A-KY^@'?4UG42'8Y / 5 LQQ@(@W+#UY@^ZFO3G<%^'
MSO!V!DFNG_ 6Q&1',#08]B[[GE70;X?:"U+LA6_JUGQ]XPGX,M(R-%\^1\5M
MM[((&W58I1"&E[L8HWR9FH;W95HRGZ70#Z0IS$E% \"]"8V+Z8V?I;A!Y&Y_
M,2"?8F3U4$RU^:-$F0637V1UHG+%X?,OLHK,<<L^^"KD_OO05]]QG*OE$)'*
MF_W[FC\:"@IG/=%7P57U>B5PM@HOJ_!"EP2CZ<&!GC=0L8]=_M55M[>_")?U
M X L+]*$(ROH21^#HTO+HWKN:]W[ZV!X4S&5!YT2H3'@[NX5^1*B]W/&[ZS;
M9WFU;5.0>$P7'GS.7@C$9"R.Q,B"GSW@!=2YPFL#N:T@?1U+?YO3<-!VY*K4
MBS=%!C(10-4J_>'/)(\DB0J7%V8ERTY_RI?S)8>$I!=<U>6?MB;..^ONI$%Z
M'&/A&S9(,2SWO'33'LD,E3 =^+GUL>/V@M&"AYAQQ:S=\B5ME:B#[.EN-+*Y
M<<-<SN9IP=&F<QG3N50A2\+%V1UV8AA3651<,$3Z-D$1$=A4] #8*SILID"V
M;V=Z ,06K]E=\U+=$5*XO<XJ-SOMGKHTH\#94(.W[/>+N#EA++3?F'+" '^5
MDH.:,:M"W1'KJEI(WW" T2L3S(C--!\FA!G"\XXNQ85 96BH!W ]TEBR^K0R
M^N)F+=:&9L<MD26<1&;>Q78-X4!B-PI'^Y)8C,>=?>-X9U;\B;:L \*2, VJ
M31?.)0Q[2<;XGCJ9M@W@>J$1I^D[DXE1)_]\]7TM)+BN-^A,IYNBQQ6$3+++
M2J/DW5ZFYD>Y-%L9*FZN&)K!.LUF75M),+^LIQL>_9RK6CH.]><E_31@<";^
MRW>G""74'&5]1HCX528\?H/O2:&5/;Y$;=\@#-G9FI)%=8$R$/1G,=]B419C
M(P-#=0/##KWE-W'P%J!B8_H3%W=\FATU"_=@NX*85T84Z_B&@W1I)A?D,"54
MH*3W^GK'@ED/:6@G\/'MZ^F+,>S]>M]G5F_J&U+NUY%L6%=T:,7CYZT=6P&*
M2%%U!R @F3=^8?FYKGO(@L#1#M^Y7/6K<"93%6+#1K.E(;YB1CJ'EQ0CA+ND
MJV"<4UAWK+9T,32*A9F]O,)V7=:F$!,B<=]4M;UEW4]]#M9!W0 %:2A/66.W
M6;)?HJTG+G"DLM< B^DV'W= 7^,J6@(.][(<F;(0POXEV&Z2D=+A+KNXB[1<
M+S&KWFIK=#6LZMXV@K^/B5KEE&%1F=W2IQQ/F+68D$4(GM\? LNN[D_JK7S]
M,)AR_#!8NL18;JTAT=W1%%#N5_)DKQL#>X5J]NMKY)P$W%49UFF#=?& S9S1
MVH>V8L+N9ET=-E.W!F5:%J3W25:$*X56&/*LKI !&*W]HJ"Z .7\CI_H\[!S
M/8VK**A3]L&UD-X#((P-;&=3$(*>&XON%[E-\HEHOM86/"8J-//#(&H%J6TR
M=]H00M%:/ZDK9YYM_&7 -.+CF[.KDR'_N+-3P2SLGV'GY097(5"/;/W]V89V
MIMHH&ZEY.]89/%GD'M9.Q&PUZLA^"D?A6;?^CL_W]%"5-5&OWI_J2066VNHQ
MA:G]46<>QK%N2RB]"WE,G:,*OO&/#J8UPK5O+4&L'>L(]W/UXVS1X0R*S]3/
MG#^0A X;)G\*_>*)EQ7EM-"<#=G\'HGD6/G)T'PG;BBHC"M3M&F#&O\ZTZ7]
MV/-7G'@L7X.1U[#XY.:.6V4Q.4S8(K];>72XLF,_8]S:Z_<#BJB#*WO&,/7=
MOT(]*2QGY0TY7YNC+Q$S&27W\2-3@T?MG<( ^WO_EH]P*:HXSJVN3_30I%,N
M=C4>!W!9];72P^3W?5FAXANKY+WY*SKB(2E7PB,,IKU=@W:-8,-'BXW(@K1^
M\Z),B M%E5A0-]C;_@T?KS>3+N6"SBV1QC)"ES6+GU<$RE$ZDY,WX2WK5SRN
M+";A=D.6RJ:[+%\J;8NJ WSWG$EA9O8/M5I#L@W#"6Z2MR(LE<]775I( 1="
M+*,B=I#=;DHLJ*@'A%JW/G\=6CYKCM6<X%7P$9V4VAZ-M0=;FL(R*G_S 4"Q
MUXXJ1M=ZNA-/H*GH(YKF%ONT9A[Q;<F1!DYL-KK2"P5[28!G.>'V/0+T,@L:
MVDGY>,;EQZ+\4PT(4;)%$9:@B85(I3B&7_T*0=,<257<]YW:S,U^OYE*-6]9
M&\Z:ZE3EI %9.I051F:>3VHR,<K^ZO,M%N0;?L('+.&AFT\#=R>MZWA AC#D
M(]<S[5'C+X^CQ<5>%6BPG@0&D1COJ]GZBKAC3[VNFJ6#\&9-G1@UI: C#&A-
M+N';+R(<(X@6NKY<C#)';,]I;%&,:,=J;YI<"S5HX+:TP$S\-'1@HN7F0;<M
MM<IM;+T<.2<PXNJW]?'W1/HWR;K8@*?7#D=81UUBW>ENOSBN\YN)"[FOWBQY
M6@??Z'LOJG0M;82YRFO?$D2_2.C:%*3#Q#@J%[?0XY>?K=N"&-:<UJ?F0CW[
M]=JB=K0R?@XK?CD4D2,B5%UW8^&DXWO9"_#2(_RNY>UQ2IF?,U*RZ!Z[H"-0
MF3-%?..("E,-*R>GX6KY\<V9&ED0$ZU2^-0,+.ZTH7DQR%[&4XI6*6+JLVXX
MJ?>NX$T#MKI,:+P3K<T#0+W7GGNP%^"#*NE1&2P.IW(A][P)M!.W.J;.8U:B
M9XFRS["0<*K-4"257O%C[:_4W])"S+HRA*<K6'DH/O"2-;)]:(_E"9'LP0LP
M^D*DA-&(%( ^RH18F=/:TK5:JQAT*XOSB9URPT=H468V5>*<@VU+Q<&1+[*J
M8JF*=?%51%6?_2/"F<KPT,^W].SE:_ME+DVZM?8D'TU"A]47#K:PAE0#T/HD
MB+.P4\).,T,-R%IU-CE(H;LR39,\.EX<J ??]J]K.D7 =!.M-%()!)7($K#6
M70JKDNJ[/%]R2\[7] UA;#NRM<4NC?.&J5BF^(2Q'\Z<U9&>@!;\1+G"SL(-
M%C+73;<;%F@@D;FOMSKM=3N%_ GZK=^G];V(<%^]=NJD::Z'EJ_S0AZ; Q<3
M5Q?"!>OX-AWNH-'#G+9]J]QF(S7"50M^0D,LH:>*?6/(M]+3]%6GLVTHY2YX
MLG0QK\G]LF1%&D:W ;BWQI7U+,GP138Z&P5U&[VG!0DFSN(X^NV)+EBOW%1\
MG .Y6"W#7$O2V'<8&1L('AU.:Z#"R9[!NVH=>6'UEMK)6Q4>&8.W7#PYS+J<
M,O/?^W2L;$8?&ZYIQ-Z*W)4?MRIOX* L' HII.9:-*\DE1SP\^> !VIAY#OB
M&TH8WTCH-BDO'EW4$<:L9Q)9Z+^HXD^1!"V _1&!\9#=Y\2X%!+4 6BT@2F@
MW\M+T]@G;F(1VA*!E"L47$X\BQ_-V^Z'Q,<K"1,@?@@6Q>VSDD^3-UM\)W7.
M?;V# @^ 1#/82CS@<&=US2JW66HT0V$_A$Z\Y: ;!%I)/MV]?].&<]^:<Z\*
M&]?X#I)H'5^=WZ5Q@HU= GOO095MW.N@V\\I5'<>DK>EBE7G@JN0=FDY20)U
M,XDN:-8#H'?ZE!^6$GT?%M62O\<2]%<&U$*!;"4>0IE9*K 'Q*N$=ES-!1,H
M:U'X2Q(H/?JSJ-4)>]A>''ZE-I'-BXPA??DV0.H1-:Z#NGD6#C5(W$R/HU<[
MNGO$ZWTR-40CB/099;YA"*<#7D%_L#]=_(=1= $1$%7N_0!ZSO)^'\<3C\04
M_JN6?0=96S=TCFZ4\U2W47PG0P#ZIBC+WD\FQ-UTEBO]&9[,@%7,UL=4GUD7
M@*B61$DCWM9I;.,!*@SC >^RK3<%!<H,D'W[?W8$W6IE6\EO' HNOIOE;=,Q
MLCCFIY"003^7D3X^3TL[OB"\1"9X=,:S^NVXP2L/.BE\0K&P<J#/,/YLXF.S
MD Y-KC3G%[G:MYZ!D;GFQ,3?-]ICID5HG5Q.CQ6Q)5TP=.M3KW!JA3A?>I>G
MU@>FN?4!20^8LG#23.X2> 7%S8#(WMP/@*#$8?GU'S_DHL$<56+SL^BM(^T&
MR0F,!6[DJLV51Y%F)=#H/M+X)&V':@B/#B\6\<*/*Y:&<T3TO.B1FX]J9&]B
MP((WT33MGW/\Q#0@!D=J158K%*?Y$91""94\HMS*DY*SA=;7.FO-NLBHPUBP
MJEJ$GEA4WID]JNIS<^ 35I&W/RLRBW0> !_GM%8T5^9$.MIKB</<R881N(^&
MY@X$*WW^'60%EPFGH0WZ$FRE7'0D44QA0\GJ#P#-N9N:Q;BH7]2'QB6N5WM+
MSK[:PPKE RZ8<UNG] % "7RG?@<@4)8$>##VX00T1_>LDGN+@LKKO.3%.# L
M&95>R%M/U@VR-)@;=IN!4)K$(U:K9PLA++WWM+,78P3:^XCZDS:U/XK8G:\R
MS4,^T%1S#32.OG#$\L&1!'B#-@SF7VN!+FU\P=Z*'S L4Q*3@-NI))J]5R]0
MEFX"A>_<^]OX)>YB."[D%6P^>"O;_FR<=<%20('AWSQCGS+N&S(99)E^0;MO
M(*?\DI)LC6J^_/;1YAC:(5_SEIN0JW^67,Y=BH[QKL*DC(F%6TC7F<QB+62E
M13$*B%71SG;+!'D:6':)YMPP VX?MMT-SG\2(#$Z_B.NO]QM6@DUW.H! +@4
M=6@G$+_:3N-8^^P]SVU^S/X <-HVQ'H ,%8*M[%\;KP+8ZW@B7ZR'ZI<H\>M
MV?)TL""/.[\M> #UC@:$=QSRJM]AP?6JUT<<KFS+AL'<KM;,L0LZVZT3><<"
MWX(NO^.!IY>\2/3']4 [K:<GFQGHE'4+4*HK.P/D6Q60B-I=KG&QUH%&OZH,
M>YE6A?6Q%H)X D=R[3-$6&K+Q[;Z_\"%X++3ZK+><D*PK[Q_U4#T;>&'$-ET
M4^3BB!]Y-;,ZF2RUTQ@ ,N)^N7O44K3@'KX1L8#289R_1RD\&9D^FLR65L/#
M+T5+TGR.V1J+P^*?AFVU9\F$^+T<'FB/H^O=774R<7LFM-S%#-#T>[%*F5,8
M^T^,X,60UF'\F# FWW?0,RIS;17;_*32_&S5@K0@W7DAQ8(]=D5G/O',*.FZ
MD"VD3XK .+@R'T[$&3<> %WIW)OBW>D&G3^'8[LMBOI0%]A.Z4(D#0=I=B-*
M ?:>%V5-K<B;6"K?^7U)9T1D"Q5,IQBF4JXH1"<*.9Y$R-(DH^F:.3R.R%C3
MR%=^225HGEEM,QKGL59< .(!*RQ*G]YEAEZ2D8%Y\\+ ;'GGSU(X5G#87_9D
MIKJ3XW(]W_6':\6FT=U!^ $2U;#18H<;7#O-2CF^W_[2G=T,+_C&Y'F+] ^_
MK"=C[V5_HH0!3B.YKSXVGQ9V,7GCKU<2B@;VEDI[-@>#"Q=2CXK%+FM)#(=R
M1*1(-%\ UB)2SBI);@$0<?]:172HF^Q$[0. 9'&^NSSO>K+?S82(;)]K'-7O
MW>;S8S1J[$=PRE'#])U1( LG5001)K"DN!&)WZ=!1 H, 1=.7LQQB#QS0]2O
MR.3]0K-<7H#']#YKDSU"6CDPY><[3  3 (,)D!/V[Y)U)@ /AIO2#>!1>JFW
M)"2I1T_G'D^4:W2J3XBW/FR?(>5<WB2&FTJ([QS 1=%/#D!#31F# (\^^&R@
MM3K8V6Q<R(A(K/V@0NNF!^>.\- LQ5U])A8X)ZEV)^[LY[UD(WATSDI5=7?!
MJ2O_ $"7++7$A>8J0*0R=@9O\V)G9X6-"4IW3&=FN1S1J!OJ]+_=);J$\TQ<
M0W.&/*R][=PVF<GGA&[*A08* ")C\3C<)TY3^3XD\"P)SKGO_[G:'8DOVZ)G
MV=^+9TY)"7+NG4))I;X?M]K7-B7FMB?XTGB,HZQG<%2USH'G[J75%M?CBU8[
M4:'PV=B(M]'.-M]-SJ&*[:VN5/"K@&$^$T='V<[*O*H4 (*?&+#A+HF=36P%
M HUBC/&V@!\\(T-[(C2)&38N%WH#(O-CJ8V :>1Z/X,:4'5E8NCN*Z_4W?7N
M9+N4Z"X1S!58;'.]4!OLBO!#D=UH*6%"'!0COB6<%D'?Q/F<,K)3;N'S-,)N
MLPVWTQI25S'G79X?GGZ+N8N8<E:.>L4\<R%!8-;'Q[VXZ/X>'OBS!SS]ZN@.
M+#(UG.<*;X\[E5 <^E@.,9@0MTSO0NM<QNUX)C;)$*^B,??U*? H^!23CAQO
M,FQ%5C?W&QJ**Q9PYKD6<(@B95WJ[T<IF>'5Z+OVC?R.3VWW]M%JRYWZ22KQ
MF/5&>V".G\CJFF)7>&:0&$K<R]9IFTLM,N66=M@;7![JFRF>K\^UFO06G3+L
M66B_=R#5*08+@<(,NE*64\SUJ3M\E"^6I2;2YG4;[S;?[!TV:9[7A:*V>=X1
M/%J_%J^)['D $)S<:K%7?2C6/E!:Y%U.S"]\:M+2@$F30:2%D'T3C:Q#\:E"
MNJNCFJAT'7:".2;^F:=T:Z*V7$?^Q8_\%FF'J_EWJ<G:[U\T]:UL-E86%F7A
M\$-Q3CU\T=VE=KNO?H8O[X,]Z$?**_9)68CG<)8D=[A?O)2@QN\[TLB#5Z-?
M%8EPQ%NRSFL,U7(\/[_W7-;V@*W\XYEI7%08W+X^A_D59AORWUI/%:H0M=F@
ML?.@HS'Q+W2;QS?)9+ZUC^B//G(@Z&9'9K,4&O^(:>"Z/\D6';@L\!9Z ,1P
MOWX 5#)U)+ M>.@C-BFROFY06-P.66YX<C'F[3GYVQ*.WY=<D'; J5?F[]1+
ME8+Q\4;TS?,,%'B14'X 3"B#G(4PUD7@_]*K?%\]MA3_^5SH..DX.O]OY"L<
M3MND#94E"0#_3? (3"[*4I=]GFT0G&/[0@0(4B[G(]\\EV$5Y!VK1T5IM-)P
M\*X2+E+:U9WDH>IY*DW'Q73Q6#D:3Z]"S,2N9%8W.K!7/=:4RN#M^;+GYV//
MF&X5H,G>.L0*%<%<2M18?%-[UG,[_P2= 71_>&KESV7+B!#-4R&>KNH0%UXS
MG;QF,:@O1)F"+4G8M9]!UUAE&.4]U]&\+#T.TBFTM+=D;F?F/L@[$ZL[>%^)
MT6+KP?OM/!=BK9?C)R5:5!$8_X^Z]'V2G521X-"![+.)YBSF*XB-3#79<0/$
MK*. Q?>;<\A'B%1=,OO\J\Z@! >,T]6#,>\'P--UG>G?],</XY:Y67#HK&2$
M4/6D V4AY3LQ5EAU>\'E5]IY'+MOJWTV&_E05IIH"4?T6YGHF2^%F,;3/02Z
MLP^1JR0$*%BZ:\<BFI?NG_%ALE:LPM3E:$WMR%A_8$0D5^M&"4/"FN%;U0G<
MBHB\G3V-I*C#J7KLS?F5_2Y ?K[/Z5;@UBI*,)%2H^96V.Z:(O:'PQ,+'2^7
MDX85+W9[9GZGL#,OCJ?0DMW^&G=O/8L @:/W%[)76ERO^?@> &47)]%=!5"K
MS1'C/HVG6$X.)D0+6K0I:.5Y4@!.C-=)U+OD$>I5?5/QTX3'Q^W@8=/ 8F+!
M^K)8H&]_\<X7/JOAHW8FQ>(E:,[HZ/B2@875CO;WRCCG(/MNRAOB"@T5Z')1
M]SH)KQQ9*G.%<4O @KM9?0*=7U,W2Y\NKD854J R:U>0VLGJZ5+C-O2SL./5
MK2MLS)4M#/%C:Y(F-+G$7(@OO6BI5;Y0K\5V>G)4D9VP_T?[B^TDQH!Y:D^-
MW#TX[YBRL9TU-\67JFPG6B8S@Q56L!1DT*1K"4@>=*AD%%#F,S$/FH^\9<II
MCC+\3S7H_Y<$V*.7A9\0:&D1*8UP1TU$G%\6Q'EA,5SQ[E5HW.-'N=?0 3L>
M +.E?/<\-3%^R928UR+1DZ6Q<EDW6N,3RCIZDF[$L21$JJ+3._E%='\F2"Q?
MH7$82^[<&I%@L&U"^1*Q73[GRTT*BDXRZ>(1Y\MA[[>F!DB']+V?%6O$I/)D
M&OK$MPO$0_RHW/U%T!VS::-)7?EZ%K_XGN1D;(Y/^9(_  :2LA\ H'B#H72G
M:.C+"LYM_[OT!P K<.8!4'I/9:=HJ1@J?L9@GGFY_?2L%$;%#?^0;,NY5EE2
MHKWP7XBA]#MB=#C[L/QK8 W\?5[].V (,OW/;NU/@LI9SLD?BS^%2!C'8KQ2
M?RO["#_OJ["F8<RA+NS;[FSK.ZDXLX[@ZZQ/'Y,02H6GMNFKA=5D]5Z*@%(%
M*<MH9\+.-F\MD+I%+8.2JHIW).(6TK&Z!@<$"?$*U1^G*%N0]BG%57^,S;@A
M(;0</9.3#8JAJ!">M59P=)JJTXELL^BR$<YY+L'[T2U%JC8EGMH^UG_H :"L
M7;?KZL9A1S.(CWO@E'+,\^.RHP$/&^>5*)8/$6E'K;I7)D=8-XQ97_@IW$E@
M@5?PCAJ3XIF>MWQ98A1$J4Q8WVP8J]OL!T7T=0?&2AD; V@((E;'/[^ER&N(
MX)KD.!ALBP#$YAZKL'+]K=MY O+<%"@CL\/0UG8/N]:,W'V:Y) CES2$V^&&
M6&<WX:_,Q*Q55_56@;]FZ?S\-%SB*8/#57PSS&*:R/1KJ"S.2F?_LB@H7RMZ
M/2J41'.8B^R9TU6GB8G8RZ0*<*:^PY1H:</W7/.+"I>@K/H (<KG+2MV)X*J
MIWH!T P]%Q%(D9PMFU:@=X:F(**M$&Q&E'^](C-/^RYCY5 I!)$NEGAR,W)L
M^N)Z<[+%6KG64^U./^'DQYWHP-4EFZWM:D@_CLMIMW3C=/E)_X+-L5$]GS^X
M@#/IE=.YH://?G-'5SF^OI;ZD:Y(K"QFI4 27E7XL6G5 %6YFR8!+C;W0OZZ
M><L*R_M$ANJZO M!HE/"O"0<;OU56=K<7'QQ9$W#BB5CRC3UX_!\[;UZOBN^
M&+0L?SZ:*'MD?3,E6;H(=0D(19[VK9 .MT^!YG 88*#W33HF]_LXY9;J2R^.
M9)&9YZ5V-O(E3#DM[_X\5__/8B$L);NO9GNIHX.$X^2$B>&.HH&!LZO,W/<X
M16' @N\H/%Y5_5I9+\O=5$OIPD00=<]2.V\Z83P@S$I GWO$>P0B?M4.Q( V
MGTA/U&JZ$+-NOQ@3'8Y(_>JSYN?I/%B^KYQNX=BI>PYIO.4SD%?M^9$@BE.P
M5TD'E86]<0=NQ-T%<+(GEQ4M69OMVA\KAV**-L,TRCS\JOT\>+D+GSMNI]3P
M=V]8&!67U)KD/YW!R0ECX<[[3RW5+V&FZ#$?[L= D>6IZX,NZE/?!<"3MB*/
M:K*$T]'U]=MM UQH@=P-Y6,CXWIRV^,'P)WE[KOY"ZI(R=CPV911P*C5> 2!
ML_2KR,2@%;OB_DWI-!S/PAV8\JZG>B*6O Z%NH^0 =?*^\@E%]0#EM;3!\#G
M[%DE6ISG6SC)HCZ]'F[IBB%@<+Z6D5$U\X"A%?/D>U Q.[]H3EC7:<<GD$Y=
M]VT#^C4(M-)@-691^-%H)B",*8_Z%XQ6&&SHE/FBS>KMUM1'VJ35-@?I6S\^
M/@Q,N.IU(1R^E6F",0;4>;3/U@NS+;=/GGH<4E&\ _9>9*$N?UE!:#2<:!1R
M??VJ1;G#;4;ZPSY8'NKR *#1#WT Z"L#G[ML)HN@V^\H\KNFMPP__B9^_!,,
MSGQKUIUY@W<A_O,L_$;M+CIY] $0>29DR923M2=@0  <5#D5_V,NE3VN\1OZ
M^:+^DR\Y_D(_K=L7%W=:_:^A"<#>!T!]CS933K7P_XHSC)2$K+9Z]\%.1.IH
M[0UVY>R/&N_SR'&MQM_NBM6%;F 1+S$W!GU4$C.]A]N5=*-G<E?WAU,'NL[\
MCT0=[LB8JI1=%]@Y @$J:G%%E&0GW26%I&/&\WI7PR&N/ UV/321MRKWR4<;
M='>)H21>E3>.3UHZ5+1)&>J'OQ>/-90[+E2DLTYNQHQ93H^79?#I@I95"]%5
M:A-#HS)9FI<N#DF0("$4O7":=<@O\RD_!['/2IG@F"+8UTP[S6(V_D.UV42?
MK>I4XG:J2]?6!6]=EMY=RKYJ&ET:U;X69U2"[9-:9O(TD"3#)MU$K_YS!XOT
MKF\?>MFD;>]-F)8'4/(JL[1S=USA>/>5_#X:$-WKN7F7(3 _B3E<8^OQHOPZ
M#NJP".(=UQ#/+8%S8HT*@:@9K5B OB!Z\K?R^RI@$/9**TCB)3*!\K\).7\O
M#IX!U+5K08<$Z3U/(UL#+?&>51+4OF&%$>+2U^**,I=D^[)K"^*OGUUFSJ=]
MV11PAI1!XU37YN.D..4<[L.P3%W[F?JS@*J$'\L&IQ8E"TE:-XEVQ_&SC]F5
M/<U7YZ(I[@NJ]K81STY:"CD8].&Y!QXC_F_)]P^Q_LH2/=MN"Y'*=RB'1FU7
MTL^);!*?<ZG3HU*(<AK(/DE9]Y8[S>GNX2]WC1.-[$X;,%8:V@6AMOFZ]7FP
M"PMUJ10&N&TG+.E4QUZ>B=YFDDBC:K\OG]&^:HL$(KG[+G8OJ"HMO+.E=3DG
M?>](GN8HBEKG'+2&OZ]Y3WRZY4LR%3O*O)V.+\[3SYBI* '6(;Q*]J$J76=^
M?V5)).M8Z-P:=WC@?KD+?CZDNP3RNA;$DNN[]SFZTJ9,=JM87JP?S$"HTNE9
M.XOD_M+2]NJ8MI'P%-A7B6DI1@H-+RG(_LBJ?R;5&O;DQ5=K1T5L "JJ8.7$
M6E@; 4Y6)3L4?*H_M3'K5Y3/5I>JTCQZ%(5:P@]CO*C,_KY!1%F^72,F_8EK
M\*.[@C:07 ^4Z7)^.S9V^'@QG>N*K$4XM*$I.+"?53Z@3(CT#@=*!J'P97#'
MZ%;U9CM(;&B66)#L4QP_!9)".7I7<5HEUWS4REQ\&#9F7RK,(R1*DZR58J-5
ME@&-#; .A!C]71ZG'GJP&;>WG5/+2J&_S"+JSQ8?:K,>5"F65%54V7!_KUG&
M)^2N)5E4>^)\866\Y\F4TVYXY_S?_%E:8L">:LS;?3?]WK?P6R5=RF4%?:R6
M+)<@J\PU[]RMU/3M5YNCZ?-G*P\ B<E&4:@H2W,0SPY?0'W>"+L4-S0E:"2#
M.R5$J\N,5VL7M5#[4&9QO%GSY\15L')@@,^A^*BUSX'5P,A*:7QJC<R[\GVH
M$KKH(:]>_!8I,.. LSE*HF"D35@EZ6U;U 95:V',7/3;RQ$.Y7"UJK =_'B'
MJ?%KPG4YQZ7MTF]0GTHRN7-3UH[FS..?<-P_!-%[:NC^R$Z;N105"V.J%/G^
M&[%,@48Z6M^2E;YC+ZQBMAVY2M7TWJ?=+"F$4%GN6Z5!@UF_N+]6BV7FR';Q
M_Q0GKP=B.2$^7HD'Z \8?$]BU=MF5!A+I@%_O%M]+XR__P[JR+GVZQ< HWO5
MPUF.-9V<=V4*&;+<]ELW/CIWE0:>BJ$&9_1[P,O-I_>!VC[1R<._@/9.X=<C
M#Z/_]LB#0;-80A<T]_YMH7_'TC3P0M5E&3N@+K,;1W$FS5G\L\:M <SZU:^'
M);[_+TZ>9[HL)PDPM,J@T&D=0<&SW:S1> HL.%G&ZC%YLMA8J<+['O:NH2/:
MNBK Z\6!..E&:6AKTWX+]WAVF#.(;F9BPTT,CX/!^+ETKKVDG/%ZC.U:DT%6
MY:MI$1815&>L7<9""/#RD*0\A7'Q>35_KKV5T-<E$^-!CM8+BVX<<4^.+;40
M-C^F 4(76N(LR0%1L3JA-UX:L;GE\PO;63%,C!G/IYGC:BF=OA?0>6R2B 4T
M\$0R)TKPY-KE@$R?VRH,K%6J2>JE$OVHIM,_ /"R42NUH3!;+>A0HJQ+$J@@
M9DXLZ_1Z;@2::]*1G*E^;C\T'A;8 KI!*@*:[DB55EA QK W>%QY2%U?P+$B
MI8XGT:FB30*=^WK(OTTB_BR$F:56ZLVL-%:#L6AR2"OS?8IO6[?\^[4A!I]6
MA&S4A=M(CE(80GQ-++C3O(S:C3]Q-PM28FN&1:^X;<L+\[?5BI*C8+LO#*6I
MIWO'@(G.62$LN2CJ)$B4:,4L<5!3^FYWL7XP?3BRL!O0341#$_LE+]C005RW
M:ZK'<3&=T1:D(<BB<J5&KW!=\TU9DG#!Z._'^Z_2_TE&RH/"XD()B<.,O(1P
M6BC*WX_G,EB%F/B6^>*_=AIP&<S\\3DM#1DI!7 636;@4]G#+W"32$U+%:J]
M8]K(*L7MK]#6:A5>7+!['35RDU(R:<,+5HEF?2\4.^X=A^<AGO[FW-!KVE%N
M:C([5E\*RSI&A\A[$_S.XM.)6N2 2N (;\5CKPE#-H_[,N;.,:>4W)V-/)B4
M O/<XW &G:+B]:_=- -!I0AHU&NS]G&@E'2&,:=>.6V4W5:HL2;I2C3RJ*^W
MC<->=[DE*.&6??8V74'NJ35=MR,"\!/PLG2&I;<86[8Q;5+]@R2!^AMD)^ 3
M6@MOBI(<:1\6WI9'E%]A[)J;>3;S;2QY%78;]#7Z4&%U?QO&=@NV9<FZV@T2
MNLWCTLQFG[U'H.^5_K;^>,RD'@-?=R1@'1MB[>T78_"V[U>&PMN^PI7"I#6=
M>,Y:2>=;XN5_C9L$_SY+6OW'+ D5_;?.\%_<R%4(8]W[G[,DJM]F2?_KL:6"
M09J>X.6 (A*Z"\+!S'!]W*=B$B P8LAB6OW2G4-88Y<*5&W04<[595J5+VGV
M^I1U=JK?X;'//(WA$/")BJJUTN_#)R3_Z?%'DCP#)?;R0O#&BNY1G PQ93R@
M]CW1X^F-N.'WGN.(15GD$R]1'H&5?]B1=V.';=[EH^3E^,V-^&",JL00K7AT
MTGQQ=QTF!P-[2Q7"QN:[JPIK,\^YRNLS;6QEH^A1IZ,LQ^$;:<M:O[8YAH<B
MYV_\XS[2D0ZBT !HLA#)][M!H<AA#=EU@YA=]-HE(HJ$?9]D^ A1:(SD[0[2
MY"2/ 7_F*K\F@]:L3H6=52ZPGZOY7TS8B7RSJ"BKW*Y2,JAW .N,YQU.JT[5
M#9<HSG<.@42G[->VC&?CR4%]0OSA=2,(:K']:LV?BD?'>.+%>A51VD#K27U%
MK8I"%LUE%F9%#4\&@FZ<J/JSKRJ6I/34@W3CF@7WC=:5S]I(#GG>HZ(D\6[K
M@C&8\E90/0W9"+5]WDY.;W@5&8K%RCR]2;$F;8L<[.&O/Z>2V587SR[>B00[
M-IE:S=6_%'TIKKU;%XVPM[!\H*>G13LL_@FOI3W+I<)/IK!-(TFEQC]LT 73
M6IC'CW2G9_T46N0E\H8@MRU%WF!'3W"ZD&7*1OS9:3=%'CKI\Q*F!80(0]62
M>7+CT[)TC9X%V^3"$2]></-B3Y,9%X)H*,7@1KL7!"?<Q>?5S@YL)#V6>O)K
MT ;5<\Y!:D[E+\(NE>FC3G-;H\'/G=-E9[RK9/.A;:)/5H,[1=ZG[;)K=NK5
M^_ 0DVK?Y':)UYV$3!ZLRG4$*N-N,5ZE'33^K"ZFP_%.^2G4=X\EM4(6;D%D
M3O]RGX8\!#6;\')EM.P#B7I@N.65CTAT9G9DU\92(FE.)GL*D7E.V'^9>DH\
MDU)\^W(M8C<,H%WIYD.8YFM23><05=9/^+I'Z$B;+=N5;%N$#K@BOJYOYE.\
M9!EWT\!5&UI]H4;97><QEV9B?W^@898;W"F'?R)*X^JYVZ/C]=B1E2U3I<FX
M#E<@A/-X=!EUG"K?'&ITJ-7Z:;#T]0=;!5*>J@S9$+1=UJ$F<0E]*WB_*B2)
M=Q(S2H!M->ML&C6EV%"'ERLB@[ONSTO,*O]._B;Q4ZLK4099@N0!+(7@/0K2
MVGM0D<>'_S&4@0N^?]Q+Y(_06&"-N<;D \"52#Q?JVVZG&?1K+&E*6QV&45;
M:XF&Z9HQ;-M;;B.=7^_4MI0OU34I1LH[T;VS[R@JR#^C34I256WKR^QN?*L?
M4[^(F@5=MUN^*_%/-8\"P&:;UX2T\9(68Y_'_D*IR'8J(\+7,TSR--( Z<=Q
MZCP5;Z<2K7<O<L=8EGS5-$81JPI$NRXH+(_$WN]F^)CC?_&\3Y#_B)1V'_\
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MMS1!\\]%?0NN=OH M ">MU[%Q]+9E>_NBFI3?^ $*$FT, COK1@6^A6*^+I
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M;"/3&__LOV7LOZL_@L5TZ,+XX4AB^>?)([FV_[T<Y)XO=.GA=CK'>/*X4O
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M/VZ&=C+04JQW.2*MNTP2([>6.Z=S&Y/JI:*]JX=:F52XO\96NS\2=6)?7GN
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MR4>OW1"8WS(-L"'#Z_![403Y.:X!2%8CP6Y&%>4Y@<*/[9/W8_O\,L_ \:E
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M95\,HLQO+<H^<BM-OC5^<!&M#7V <M"QYZH9-K=[Z4$CZRQT^=7Q>_!7NJD
MKL7[$ )4<I<)KO1\DRK(4S_&7+?;ZZQM\CJNC)0M+'B(_P@OP"5JJ13#C'XL
M/K6=+.0#W6(*?1^G[ >WH%(B+_GP\6XW.5=L%6V;]TE ^:++IN* )H*X74/N
M<I$#4UKW*TE6;RQP7_W*DN8D7.GMF\)2ZJS%N+L.-9OFU-9GNJ9/O/OCA^P=
M*0(5,GQ>>'KM%VE<-OV\6EX8VWAQA7J4NJ58-F-:4WODT[R?MO*HFUW*$H/0
MWJ'HD<,U])C@RP<R)'G1.2R6KQC7)4B.3 3Z*K$ R,S$5W>D4=ZS<<8AQ?2)
M0=GGJI2I978YG^2@');@@;L4Y-Y:@._9SU^!,!Q8N )9V58@ATR0:^)@M>$@
M9RX@]&\=;;J:FR.!MVA1H89^(Q(#.I*4QD28X+H Z&=D3F!Y[]"1?^;!B'#E
M6:=G55UT5J)U8K95SL. +\J4^1PENHHQIL8H:_@ E>G&]05C3;$-?<%35Z'9
M'H1Z497I\UJA;I"H9 *H)>,">YWJ\,?:FOK&&R^/DDU"OHX/SUZN[1EL#&%8
M(>CIIEL84F1(PI -.SI)OEBNB=,HS-=LFJ 1JP^9QB]XRC[317MI?=?_(DI6
M:UC"\<: 9OPX*^.[RJGLQHR!RKGCEZ[T\[3'9C/:N9[N'6A[I.-$H#^#5[!I
M.3 WW4)X*RK$UEUQ(70'0XMG_GTQ+-B=5<R4N5CL15;*N;O&HS/WMEZAX?,I
M$Y5GG6%/WU/>'HJ$AX4-/WJ7!4N'"^OM:+D4S&GRO@V^Y"GQ,@X/+#*WGNN5
MT2DO8H;823+9\;CLM= N5<]G9JA9/FI"KJUM_5WRO':6L#AJA8:98)4W5Z,(
M;0^AG']R Q9ZD,JJ JEP2W#V\Y/;%NH0[^'L""8D>K >&.^:H,@V5X*60$R$
MFQKZ*6M$:+C[*%E#!.\B-5R ?NHT$BLB;6\Y,&)9&='9UWBD.U\QHW1D=V$^
MV^5Y:7?WETBN*/K,%3*DN;%(=^QE8S7YZ/%(*W<^R<@T8=,9R&^[]+VQOH_R
M%GK/YVO[_4+NC4'LG&DW/$SHNCYDVH_7T.,/[$X_3#&LJ_F^>NT[?B$'\#!Z
M2FCCQB!Q^0:&<$B"DGJ;:3?Z4]Q62IUJT_O9+TM6D55WNZRR"6* W(26>L%Y
MT=A.;8>K$]959S2SYQ\?D+@VV"8W/!8?F.OS<CS>%5J*)<_:OM$==E#7*#51
M'YJN$O+UXR97#=F7%;%=OE9UF57O[X:^^F=*7MEM1^57AR529XHB25GO?C%:
M2WRX7\)+]79E,>W+7266ZSM\C)O/?!D0N;GC'US(J]!"^7/G]?L28R4=GI<?
ML?:G.XWTL%BSN)6$MK=->Z1]-+,?5+LQ_: Q7AWJ*E#] #WYV.K+;XOXP&[$
M_J[X4FR4NY^'([>;/ _:WG-H\W1&Q765@UBK2_UK# 71/4)^35OVF,0&1&2'
MH:$_.W(BS-8C:4%QC/!*^6_<C06<-/PTWKMS$80.7K:+"R&^;"F/3.X7[UR9
M?NS?[<!3X"Y!M5Y@-*_7-*#;Y55,+@V'A1U$9E ],#'1HIW^?I(2Z5=NO2XU
M]XX1$K>[O-KI-JI#3/[!EQ;A&<:L+N6MWU.O"JG(:FI*WY*5BWK,E3AY=;N'
M<;W8G8DMV!8^HU9=;FS F[C&83]O7==OFFRE^'GS/46+033MCS>!\%8LJF#H
M5-L.\!EA[[E +<H!"W"=M4..*'Z\4V15"_GWR(OB*>N/BO&?/8E!F0%QC#WA
M/J4\CT[AQ22K6"A"M3LF!BRJ#Y FZ&M#/"GW0OG0][,:/G->N*_K1\V5T$*W
M;;T$"U)#]S,16YQ>4L)QT$%B0Y7G&8AJ.1R[40X-Q +!ZF!4/1C^U(L7$T9.
M@ 6(XB!(-[RQH0=Y:*%80BPP",^$+ Y38H1C4:9L%[' AW8<5FW- :'- '?W
M;O0#Y"+*%K%NCN1]PQO?-I43P2-#R7M+?\<H(AESI3L(LO%L$(RPQX%8>B,V
M!:1(^\ K!8HQM&R^5_O-*_71#3,-/ 5$JSWPL(%1%NJ#3 IKTXE#V"7T8\3C
M9/<"!Y/BXOY@'Q<?6TN&USQU,>JTZO?("F-%6X#EQ'X7(Q@11NP)S>;EJ?G/
MD"5*JBUSKK%/!]N:)U>NQ,Q/3<)GG&CYR=P$-1@/655"\Q8;8)?M_*^-H5_D
M_/C [Z/]_N9D]7@QIH_C-V7.IW*K47:S[Z.LY5UC+>$B+Z<?/).'QNQ:PJK'
MG-PC_93<9YP5&/>D+[:EA["(XT>1K$<]U!'E/?_T-&7:(57DTE:RP5&]Z9.:
MD/4@GD#..@>'5T=)O3=N2!.$=A.G;$I2QE978T3#;E8..4%KMD4WG,7ZF,3N
MCB_Y84R?6Y/X(^1= P.TGA_[$Z/D72Z@15']7\8%YJY5AB>1>\\ZA:R*__:9
MZYL]X]N:!PD/.H,^@>B^N5<A,0EYK=RC3LD>\WR52?.F;BHZ\:9RW.U4.53E
M%WII1(<#I"%V&9$UL(L8'A0_' K-'G02A*XT50=<=JXCM/HMCS\WGDO8^*T;
M09R+V6Y>N"D<$P:?N2AIFL&T[7^USJ8\16/Y7EJ4HRC?HJ-1DB2W/Y*=PNC]
MF BUF:\$$AQU8$$SCQJY+3U][_*,$LW6T;RRVG52=C>NO1[ _=10Z .*'LX;
MYF;**MS=C51V^/B$6'\X$$G>P"JF9RK@G$XCQIK\A?WC.#O A[_[;5<+_Y9"
M.US^]NF2K,!94;[)&DET@_&=UP]N:3B_#5HL8+G.^=%K:!1LSRJWI6-B7\]]
ME!6OG6<J_J*L96LB^WJB 5@L,/HK)<NRC,S7>D1>FVQPG9R]-0$S:2^QJ$/2
M8D_-W?('LI??-X@5S,TP !0"H7["X^U+-//VYO(CGP2+/U17E8ZR(VVR.5II
M+6\.. N2=58T*)@6EG+NO8_'VP-1R-FX%GH5=?G3-WG4U2(.1SED\[HVV=/%
MD*'=!GHE=7OXQWW>Y"^D@WR5%C,HGV XQ_<:K>'C8^XS;U)<KA1<5%^.EE)A
MX*YKF=4X=)VAFX"T32*TSRF8B#'D[%A@:8/ZS^TT-\-K6(#4NA5\(&,'0DD$
M8X'([)_VER*KV4_T\Q#\LR&O;R_EE')Q/&EZPLDM[?:(?HT%X:U0TVO#C\B/
M6EOYU?L /^:_H:2).U7+X.IKI&<2ODI< 43)O#P!:CDH2LRM6$HL,*FP\ /-
MF""E AV6H)1;3"I;SI5-@8N)D"G+X ?.00K7O,0HB39$/R_M7N0R)76W<;P+
M*%%#B=>+H;]DZ"H%)II?]>5UR7>X$9)4!(^T+:NH';&)XBI[BV[:@S+[=@+$
M@^NTR0L5T)"]R@P.YFB3=@/,$%,9\D(QDBG2S-KYK<U#I1,%K5R/W44^NA'<
M)O_;@<8"(66+&:<L$I1HIK\40FDH&AA$WXXGW=4V?;TR JE@T_62+G\1R?O6
M""K2I#1P=\:E4X$R@(T9TS%Z4/3Y4.ON@L[HB.&[O6_B['5FL!MB(3-ID7$R
MNRU+]:"?\P']7&&!]@84.?R=1%$O,[AZDV/=T.SI@+6,H68BOY)9:[*3X5Z<
M&N]X$<KBR!^!BU120+-'1-*APO'":GV[CQNW:LR:MIC. A^O4,]ZU(3&'RX%
MEH\9"#XOZW;Q304VI$6XX(2W7W3>J&]K7@>TX4LDW_.TTBF9Y6=TXU[M\-6P
MZ!(WV=29R%Z'8K:5.5,M6S[569ULHA[V @/V6/_1/^X5W>"=/KCQ09&CU-+Z
M_;JRFO*Z,O7TS7LGKI_7?A,LI%A$%^&+1NS),2]6(D+CGEH8C+D?.\-\BA^$
MKS\C KCXH_ V?MMZ_H3RUR&L0O_M$/8,*9#9IX.B!8O=A?3/B 2JFR)5XA])
M#?5\?1#@\2)5FF:&=)EW)*(("URB5Z8/6K'8*EPV2#:9YKGCEZ7>X8@&>=HQ
MT W^B95Q#;2S +>TMK$5G$[KJVI.4WCSF7N0S:\1NB;VN4I5W9=*E:1E^V[L
MD=\(44:.BDBXG)9[_N;E\!WWR#2E1PT!%Z96@_2MK^K="]73UM-8J\_XX]61
MEX/F&W&S #3A G[*]\Y(*V.$4[;/KY'6/3=0S :)RBR52\8&>(N\<A(6<1?2
M-J@;YY8Z<]>6XDKG#CG.*IELHVY(J+OK,Z'VQRO#,6/G,US@7CB;G\F6I&E/
MFK"(9[AUG>-PMF_=3,,:0RMQDT4IBMK:&IX[N(+D?74HP/Z11E*@HVX.SZQ9
M64"M*HY2MR% DT8@^^=A&_K9=R89A-R7OVI(SO3CECU-NTV6?<;4C?NUSW=>
MQY,V7)Y=!.3%S</^1/%[H=:9<7)C(-CBL%T/A[7N'Y!L6DB@CCN]><-A3P9P
MGJ:8NC(*3W2>F&(ZW5EFQ.D9I^\*;%K^QS\N\75%?#\*0XBT:D<L,!Q\8]CR
M3+D_MQY.WG$I166U[3,H*?N979;-]C?S:"Q #D<88D(COZ%Y#T$8M4S;05K#
M 2R F ==@&S8->/6&$07"ZQX@^&-"I=PV0WY88&7&-R8]1R0G.)'G& !#'/[
M(O2<G'X!I;T%1L>JH:7#6BU.F41@B(Q1R E;@$+ IP4:+_^!3A/6O=?Y*NO&
MYK<&OZ07^LF?Q;J8<_X<0/9/YA39XA2H-Z01IFF/A^7OGC+;E#NTF-.G7#@K
M^UP6"M^B4#I8RQMMIO("&]:E^!03C1OSQ#!D?..[1OU5,T"Q+8YD.>([)<J9
M,@AV(&$!@8/SL<"^/.B7[(!9U.LSN4E4P>Z"1O#M:HNJSSZ>COFM<I&NXOD6
MTE\C[%;4  \9^4[[34@%+-AZI)AS[,#!S.F(9!A<9782\RRVB=;9PS%_P=-5
ME*VJ!]+NY4N'F_FL,RQP\1RWE%]O%I]YHZG5[CG3S0M4>Q0,2E+=O;'X@F50
MO KE@M!K;[N^)538;E,X-SL_]R GW73GUGMT#_74&Y9GZ@0<U<2ML1=*7O,D
M8P&2<^CD([O)-LTXN>HYIN"&J_?V:5D(!@U3?O6(*P:A")0 ;F^J'&,NG\9B
M <Y!SE&H BU*[WOGH%?! 3,ODH6:)'O4F/)=P/6&NI.RR?>O)\<62% W9MJ"
M=1*9!YI'2TSV]U=*1@2C=R?Q H@SH>R_VASZ90%19O)!,[# K\OE[\1(L'%)
M8!T+_(GY^7-+[0;XWR,O%B*8(7 UJ"V#U9<*F1Z8Y3!Q7%_](4_C0E7MH#NA
MV&]=1"8 \9+#%BATZ_,B)87 -0,F7R"4@?W$*C"-^Q_ >L@LZ+T$%)%'T3P)
M2UI,W>;#*S:>%:..XU[OWJQJ&!"RL*D\@R"^@(C &XE>TEB T ,+H%6\JVCQ
M5L&_B$'_78K_)'Z#^EGQ7TF\F_ZNHHKGV35?1DUC(U]^Q+.K%)1'K# 62)UY
MG8XY%NC.6=@#K2J"!/U[816>;1DTOLPCSH<6H1BZ46?S,UW5VOIA]M=3!D<V
M.D8ESV@!>8!N"U>4?O9@^^MWS[(QC,J+W><T&4188#$&!^M>Y>)6K0Y*% O<
MRFN%H3AQ+'=)8"P_4^T-%FCG\V7  EGW%Q?0U#._GU'\64*WA:/>_TV:=,->
MG(L3@0I,\P_,4-JMTZ#0DA+._8^IMTMCIG+N!%=%X+V.HY O*L\*N/2A9(/)
M.4(BLEC L+1F]& F1W3 WI,A_MJ]0P/]5K8NZ) BFSX6(,M&6&/"#8-A"#7G
MOYQ6)/OP%PGD+Q+#(MV_*/ZM^'^?H@[$!A0,0#[S(YPQ)+L_#D_NBTR='3U#
MW2]90&N8*<.[0Z & YW25\:7EM4#T6]?ZE)%)L*5N!:]4T[[?OVZ*8$4&/Y&
M@0PR]"_V?A$</N&C_I_<>']6L06EO4C?[HRW+;HUSX*@#Y,0TKM^7T1B5XR!
M6T>5A*R04G+AWS[9;"2B'P&87).FU%6%;_'A2<5"^I/MCM$;L_(JS&'YF00_
M[D_+8X$;_Z0!_/[@AUIT^ZANK7<$\/O][(7OV<\.:9W8L@+(?]S_R<3V5]_'
MZJ@%!%+Y.M&,[K(+9L5]<R8L'WH=F0U%BU"&O8]%'8[Z8($R5L#[F6X,%D@3
M'OIV,DS$L 6^8=8^JH-7Z8-Q<V3#R7$6?S@"_O) #;;^(RB<)^#W^[@7#>%B
MPL6J2/3C_H^7X6+"A:J#[T@\\3UW\Z_J0K2I_V2I4@^GD> =LQ3 JL+.'A5C
M;_</_?Y_O@AD>=CYF'*_8(MT 760>MZ.SB?HQ@*/1$ZNFEB<OY0$GXND-Z4W
M6A_=Q/4J.ERMFE3&[8KAD^VIC3_C $\\0DS>H=_7$KI5[]GY#<]^?/KE:_N4
M5TVF1==?Z>G%B7_@92XGV5&$@NI1NTM:H-L52+>$S^ZL&%C^)FCJJEHBR_5/
M06+9C+-,\IT5/5PZQ*,S8<6,#/T.JV<0%B_,"LKGSLBA;)K>]PYSEF"+MUF9
M2;,GKU]\IE D??,FA+@^9F7"!?XMW-/$IB3:>9G<TJU.Z$[6EAK0U!YJ]:I3
M">"R85)=) C0Y@F0?_^^V"MC!T=GKX(B8$<R#W =^:W#C!B37'"<JA+=$J1"
M&_W2GQ^7/]P55Q0M,RF=_LSXYO1D'DA^/W[E?\TKM@W#ABKSK1GP4T@H4';(
M"[>Z8_HI50U/L8<Y?)UW/$ AD(QD&[< !-;\E)><PR4@KQ"^LIBQ^KJ(;;VR
MR#.SH/,L&9N0]'OD-8Q<SUQ:)*\D+L/"F=!6^\/P5*VAJHL')R7=204"RC)D
MW]?CFS5:N@W8*O$.]M2*O<#=924."[3-S"A]+:1' UR _-Y\T^PIV9"*1/H#
MRS>/U6>M>8<;,@B],-UF$U A8?=[3.^_FK *$!]3Y_=?[")[>_7MHSB21<.K
M2*TPM(1M&X6:EB:N744 GFAQ@SP<I*]9"L.0[<!.:&)1CXNU,9'.G91HQBG(
M/K?/PQ6]0>)P2+OD$\B!J3\?9+&_%P>L^' M[\DH;H2KT3HX\I&&@XX<AM6X
MIL"-*Z]C!3CNX8CZ@&-LLB*86[B&681;<5DS2&4<#_:P0(>;SZ@ 7LE_Z-J1
M%F_) M%GDG%^92$"A!(OQP&UVV!X2A7X5 A&"T;8VN!07^)NI<Y_+K[""LR7
MA+DG5VI&?*U1[[A7\]V#/$:?UG0P,P=EE+N\)SL7F-O(I*3Y.Q9U?S4&=<P*
MD-/\)6.UGY-MJHX D"(_90SZ.=FC:3Z"#MA/&;_Y.5F!&;M_?'RE*Q0"7R2A
M41/^5R#A"5M)!M]LX>I92;.FXL[O-2[5%R6TR+XEBQ%59/SC&5+3/__@[DSI
M((IRUBDK3^V@W\U+962?+[U03_9\RRAA]<1Y,'K6K<\ =IYU>.9X4TN*G&EZ
MZ_CN*,_(-W.)N-R. CF7ER]M^;_&OWB?U,*PF:#(A$-J/SFEW)DHB#TI_A>G
MFVQ,R#OI'*/"$236(Q.DSDGG.QTL<@&V>[8!+OT7!R2'18'G=@3=L$<+5-ML
M/"BACV;;]57C-?G%G5\I_;R_C-RF>7Q?\![>>[S!2T?\B&^3H[$HW7'0(1;
MM9%<2O/E?^SO/"CAK+(E0&HAB=K_"KRR@<^N0CY?&L8".U=QT[CI>[ASN PJ
MIT?'%8M@VI@R,,D#Y@/_AE%#$-)SB0MR$<.\C1%*:M.Z*\\S5J*5(T8R_0!"
M8MTRT 1XX'CX%7 E9>?<[2_S>PM'7F,K-;71-CC&#N<="5U]2"(CM/$$@C+/
M8/CQ:RCNL6A^B04,/XYM9S5#L$#()C(6$SUAA&-0V5HXQ)O_=T2,!Q?HON-@
MA(AV%.3 J;X;0\>$ UQT:C\+%-D:BKVN=)LA#<*@ _+#YG9K^D]?JQ/:?KT9
M6_?,=3_^QOA]6"N,W'1;!')D_TA9;L+^T?[C^6NK6O%?"F(8DSE+B#2 RRG?
M?XDU]I?@Y<7;%BY):!-K<DV[U)^I35UX2=,G_7:\NF5%A4WM$L6-%828%YUF
M!Q8@0$LN%9'?&-\4MK[B\IDDGM&CL8#W=.RY4C\F)XKE@*.6\D\X<^B>%RM'
M62\Z:G=()WG6>/LG.CU.(K]!+3AO$N/Q@5.&M<*"%].Y4 4);N;TO8G,"#W0
ME'?RV74UJ1O/3-)D+^U\:AU%E'B,SN-7O>X=<7"V$ VB=R?5*"X!V[*:&/$H
ML[R:YQMY]D65Y&P,#JX0:8]]95%A4+8LI';G/*/*83O:X^ S 8C&_HNCD&O=
M0Q!8QNK%D<5MX SAEOL[@?;VM<8"V>[C8$3^" 15"/Y9\%=.3)_7!3Z5-L,]
M=RD:APPCLG^1_#,G_Q\RB0!?\A_""#2@/L!Q!<VK 7XW>[' O7;=Q[0W^O'X
MKO:;AK>.+Q-.)IIUV+/B$ )K/LX1&2R^?DC*;F_MP)UFD'(VRD&?Z9F?'S2D
M(Z<+Y+)?WG2>3["9(K!^C@6J>-'?42I8 "*IC<B&[&I@ 3D,-62A3Q_-]_L"
MQV"!Z03,"S0'%H"EY*%T84<Y6" =0@+[ME: H<7[=NX0J?TRY3)O!&?=V?U#
MV*L5F@4E%V']9PS,U_$>//3<$NB3QHQF?!^ TY^CQ\!MT7_K,9/RIG90.INI
M,8'D3DKP@TX/2<,,:0U!S6H>\BC?HC@BT<\]DGF6B!G5X4I9,X[IWZQ+(Q;G
M--C0YUDW9R)ONWRWJ0.'Y;XP^/=CW$P"77(SD^Z*1Z6#*B,WN>*=N7._"@A&
MT,T*B\<#K"X;%WPOG!F8^WH,0IZ"+]F9LR'-EF>>5- C5G! ,["Y*Q[N1,\#
M3K4C_F8;<=K]-V,D(';6#JGTR/MD?UH\GXAXLJP[<GP>OZ5<B.L UV?NRO1D
M4GZ0$)!-DU4MKVYL]+NYQZ?+4Q\'C,@0N,8!!+R\@8;;OT\""+W_;TP"]1]/
M ME?EMW?OF[A3 \R 'YI<?S]'F[1 7]'12 #R=MI$6M!YKY @BMJEM:(M775
M\:I7;@7@,C;T+.^[C'>^7T48OBF"='35*52$\'_^DMKE7!R?^#1 :Z9I V\R
M6"(6[:/+*>>,*6R]2/R=;A_62AFZ<%E!R%<0<1Q9@@%[C=RM&WMXICP]/64?
M*A-N)57@8.72[:H(,MO[G6,8#BP@^D%4N!JSA/;$ @$W#'$]?@C7X^%(2DR,
M2#<$19 +V1<B4 C\"S6"9L#@[Q6NXOI_)^H;%@#<H!@5'!AK7P*=LUC@2!""
M^#:N=9H IT!IMZZY;0$:Q,;>C J2U$3ECL@9DNF\M7SY*6F&@SITUBCT-YTY
M8LE.+- NXXO##-F1R 4,L&F!CL0!A[ .\*D,C!4++%(DXCIO)5Z9YYD\Q&&!
MU59W/,F"6G%<]<L:LU]I6_6'(/R0<-F:YCVU^>5<MWK*MA,W(5+#JE@]?4C)
M$S&++<]P1JUYR]Y/RKS.##H:7&3'):2_1@O^):5,BI*9Q2)CM'981_5T5JLE
M;99[E7I/G!7A2^4&F?UF+53W/#@\]2BA$ID[T+I I8TX-DE609J]X=D;-K**
M49;J-^$H^:1@TR_3KU@B^Z<<4E[& D'F9F@UI$CP8;%MQ_1A1_KET"5-,_$[
M7APJ]C5)Z6:M!*"WB2S+[!-S#;B)2'4#3<EVL=&/)&@/*RB@)NZ6J]J:^OB!
M;]^[$*/1/=40KV7WZ] J@A3_0_,.^!'\A9M:@"%_9IH.*/["57W/?S$%^M7?
M(/&@[.^,EN[[\:_&0%/M2[CFE_I3\!'HQ\B:75/D0!M&;*+2SE_((4$YSV+6
M."?>9"K4/495\2Y[ESIK?J;OI_,4'-GB^C_YV5K^O]+>0N^@8XP\S__'WGO'
M-;5VZZ)!%%!Z[T6*J#01$*G!0A.1W@54:@A56H! *-*;@(""%*77"-)!>A&0
M%IJ$&KK4A!IJ;EAK[7WVM]8Z=W_G[KOWV>=W[Q_SCXS,S'=FC'<\XQESOF.\
M.( S#G ;@,$!)DC/5?3Q//@EN08.H+8"MX$SG;UM6@P&P0ZH\$QYK]'[P/O_
M22?<H5,BX'P8&@<X"]K$7T9[;$N \L^=<.\V:,$54=&73G02R8H<:%6XS;]=
M)PSF6)SSDU@V,&<7A@-M3@;"C*T3+WM'I]5_ZX^#"5!RVTYE?ZGGXKW[179A
M>*Q>A .KM-WI^HOA&1KVLNLU?U-P^N,DS2S1-Y:==[#\_&]%S<SSSP>09Z7!
M&)&V.HJL7&,LK(//YFMU/2.-W,>-3]8>4C)!FSK^$)X9?^E)6,1Q:=!"+#G6
MM4-:+YL:&R/)XE&0.R76[D@M^9Y76;/G2:!> -<",?VG3U#SRC&_6^L<9."K
M#NHYF;4537&AR3Z55?UX#OJ\5SGC\%L1K1;6:%Z#%IOP:+PR]>R>5(/4Y3S5
M87N$#B5R1HPS0SPZY+KN1^[\]7AUZQGHI8;R;VBEVD_/D<:05*4ZD#MIZ@='
MOH@MJ0>,HH5),IY)O"XM7<\UB?IC,1K/,8UIQ>MFS&6(D-"7[A)I#2DEO>V'
MB,>3EB]Z[G6F!F@^FU>1)1@7T,9.%C_ T.RV*4!<U6+(&=@-GZ]YEG[Z, D*
M<YB;PP&H^.43";"T)2 .$@PLT*UH4WJ]37JQFG829EN<[AZ05OWDO::^+IE1
M\E9<35!ZQ2.TVO.A!K?COA2(CUX9!V?5X$+E".JM10_7T9LK+X-BZX#21"!E
M3,_N(VR> XJ2]I?^L7M5%I@0=-S74'RPO*6@,6'YG=6HJNS14%D,Q17-43\)
M2*C:V"E/K@9QZ 8.4&W=&%ZZ56JEDDE%Q)//+$B;JW1UVV0<!R#)P;PS/DN.
M]&N#Y:U5,8PM(GFZ>'64:\)I@9Z@%[I!<16NSP=.;P[0&)I"Y=[;I3B%S;:N
M>_ G&T6W)W=:N9--ZOF_8*)Q?OW@5PI@?X#8;MQ[+,#)"VK/F_+P9_+3=[U.
MW"'7C9BB=@22T+".55F3A6U:R'/0CI%:+K>ZC>NM'O-V58,XX(0R@<8WNXG5
M&>X*M/KT._5LX[6M<E++JHC'%=7$6U&^"S'/((M[]&VQ 8PLE!$-M/.<Y ,.
M-OF@6WR-!0>UI7PFO5Z,AV'^9=>>9MR_OR:MR3T0(B^\7G?8QDF-35*7?!9X
M\O1;767$M%7<9Q?2S:F^J$#O.<)8;S@(TZ0UVN!;@-7O'%<Q-5=7\^)\\JT.
M(KQ]W?W*2O45YR$X3Z/*8HG:9R@OAC*TH@36IG^(=.\*E3!5 @^YWWEKVAS_
M!<1#0M0I14Q>X[[(I@NDE;]F9TZS9 +&YTQ.W/W' B4\AH;9ZFI/]";C:"E(
MV3@\;[8LL@ \/F$HY_FJV]6<2)6SL*[]]>496F^ZW>4?N_3D4X<]=7S1O.@L
M[6KH:5[A5_L97!=<]2GS5[6F,22$G'"CBC'&R?)N888$SZW0R:;$[W.T*7L"
M^(S!;MR<63R#@:_O_;#@7D'%2K4[3&YBVAS"LP1PZ)1;]Z\Y2]]OPCYQ'V P
M7/.V3IO/'8LIRC%7=N*Y$IYEN%A5LVHFJ;<"8NI7Y@Y(&^^@C!S#PS(<"J3O
MS.";KOH$>6LZU>E<=>>K VW3B4P$?$%UGC*L+C<1$]G&01G8TZ]&;MP_OZ96
MP-Y>=F38$TQ(++6FTO7M%39K+GN6VOY4$ZHMN-PPXJ"8D_QS2UA;QHTTKL;2
M408]T?72:&R65-:',ER6>)XT6NWAB 20\I<.:-RDHQWLL?4)VNS\!%W+M<*;
M_HYDW1T'"$M)NAC3C"JD!Z'&KM\SOZ66YTG3M62QI/?'F"S*G:2F&O/+.7.A
M9?&SWRL8&>J"JK>VIE5HE8)&[V:?^191'**:HO9%.+$^'=72,1%.;M/R.Z-S
M*KE7&YUJ*W8\2HE<NU=RK&>AEQJK8,1@;Z'IG(S(BLCMRAG3 :'>EM?QEL^5
M"NJ7*"C97 +&_.6Z+D5IWW@8M;_]+),R0UX0]@]-7T/_KNDK8.\BL["&']W"
M =B!&S;F9U25>P2_S('G?>8[.N?2L)_]3<?7;0E76?Z%RSW9<4(RSI=^0@^W
M?5'_K/K*W736+IYU@OZ1<>>#5%M>JX@5IV\FF-A.4@ETME-F9=]628$M8JU*
MS;),K(LDUOG=4:@U07-+OP93)N6S?A"XLX$/,T]J*M)2Y7W*N TK5@13CYC=
M1-QRO/&PS6[K2BBQB^)U#:(2_DTAE*NLGU5C%OW'L6&S1] A_GB,(G]2U_:6
M3I,_R;*_G&/$#M%9CMM+688"U#:5AJ_<PH3BY7L8>B\&X!WZM]^IW\&=GU$2
MT_-F5,!#E%+SS!Z!"J92\RUJXL>8")^;9#6VU-V9>,7$]F:Z>> )8+_N:<22
M'P^DZ9P:2&1F=V]GL@.RROU5TJ%<3 ;#,>]CD[!![B7(6:%WMM*B3FP48)_1
M81Q3Q!F:>R[@XX-88D=3W@8($GE=,/J[<B!PO^"^20;EZ2.$..D <V_!\QDC
M-=%A$4%JRV1',<'7RBR%^;+TK_PJ5_=^JQPV&,BH[#I%;)^P">)CK<&@^^[*
MI@L.(%Y_WD4*7!PAV*,Y&U)3:7+3'OQS(1J19%33HM98TWH/[(QA= D'*(.?
MIBK[-ZVWX6ULMT_)#/N>50(;?X>/S$)%O3B A?G1O5@"V'CH^8\1@DWQ#W#>
MLT^5T8Y.Y'B*#T1%ICT<,*V/+K6H'19*]^*A?CFJHNG,ZTR5H3Z:F@-U<F*%
MF+<DU9DV\.ACA(+;XTG'W-4\ @ ?F&ZP^BUW$EQ^;4LXZ8T8[Y6_C ]0$!Y4
M5X"07R^H\'IU6<0&ZP>KVA^[XC[O<8#>._>Y:OF.YBPD?II"_<8W)<"UYFUQ
MI=&OW&G]X,N1D8\K.7G$ #J'M4?>%L0)"AR;BI ;)9CZ+FGUJC0QK,E3!F35
M)QOP2T^)K4%,?TS[^\%ZJVL+LD2;,8GF:F>?&C3@DS>2<R&._=L=9<KN@E5%
M+E4S+R]O7B7I[]$5U?9DV_S^79Q@CT&1F1X%JZ@<[=L.D&4%)KA>Z1@($^1)
M02+0G3_@]5"S5W<NLUF44@A0MAU7MV>$&"<EHR:XRQO,J=?&=T!OUZ6CQD5R
M)KK*XF\D/F*F8,+4;,Y9SOO+QV6OFP.!FU?RU[PI$F#"D5;N6=@4Q)D]0FK1
MZ#J$1ZCJ%3"X6;;T6KK4NG*PO,0Z(]+Q0Q[6O'7PN7 &Z*7$699I,'6;=,@-
M*5YG/T6I*T&.7#'D -\KJG'KYG*0Z@6G*$=YNEE(U\.JH9**WJ+'*9V@&R#A
MZZ[.<>\@Q\">B:EL!UDJ[['9+A'Z=6F-X(:KULFQ+SF:2I @9/HGNTXQ-N&8
M'X73FO6W<UTSWON_5@3XZ-N64FPW>]N$+HPX5DRFKM,@+;^DWH=;D3A?I2E,
MZFF$1;V&+,<&:JL50EG06>;J0E-??\4=(:94!GC?P/G>?XSW5>T#>'Z@LY'
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MO9[!OV6Q/D)_VNLP^\\4=HPR@$*6%G4:A -PG?C-[G6#/9T/3_,);+.GY'"
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M"=ZUU1>=*DUT$A-?A^775'ZM_.BOM!DXK]0L\W"1",ETW'0JV)M!?@K$,$9
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M9G)T14S_X93*HQ7?+IQ23OLZ.:*WT/3'CTSJ8"\^ZV=,.V\XOVM>V:1%)8=
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M*&_UL"HY'G1L?*=295^MY@.$9]GMG0P.T-R=26%R\.C([\JO%T$9F^0:U6?
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MI0T/7H(].0I<F_KBU9^MZ<HT'O!X/:%L49)YE=!F3B(KBA+85-I]6ED?X?N
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M_?:1 ^(HMH:#6G>Q8&#4[1W!3GIM'EC^[KC$B<RM2N9/8Z>F(!2V1(3P+&E
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MDLC7[]7ESXKCH^&UR9;02WJNR_<HZ0A^L73"&2)SGYOU2/+>-'_AKKU(0<?
M9;G'S/U5EG$!S,D*,5$8VVPSSJVTHM__5M)V\SU/)I3J:C<@:H&[@><).KG=
MI(2G&89^AS56?RTGH-XTY,XN!Q<RS7GW1@U\RGSOWNI@"/-4KG4SEX%HWBD_
M9C\Z+X!!@R@25,$$E5F>?I _R6!5R?L\ZZL4CRV_7>>E\K(IP]-,YGV$J2)O
MN5(YCRJ'9.:+)RNYRG;1$@)&K^[FM&M0O:H?4S#@R>_WCL NM"&OC$?RUTA;
ME2#6$AZ43F!]S-12I5 ?MJQ!EQ.ZZ?KN(ZD*:\,]0EI6X.HXP#43[7%+O"OR
MMQ5%WW#"J@@Y54:R/]*KJN-XKH]H[R^$+VT>Q2D-U;8NO7NA23RB 7-B:>V3
M??*5JHQF[NK55<9Q^=$,.#9]N*VS1^I0U=WW?E5%56QRRL.KS0.?0UYI*&0?
MP)/=!@+/A:N']WQY#-&^,V6H @<G>]:G%:.;FZGJ0C#>P>YZ&/7[%-'W,7NB
M_G3C7_ D7;6N'/L)W666.'"@^*9:/_FI87D'[U@'=USXAJ%]]S97IM)R),:[
MUWSDJ8?TLRR77'(ETYMK96$IEVO"XKB<.;WSK01JX/P_ WU>PIRJ/=,XINMW
M&]SVCWW&!Q*@ OAHC;(VAF2T>=-O!TGXE&AUA1F3_DQ5'1-\8+7+YR_U8^G2
MYHL(5"/FMD#*H!\K9+L-8;O4<*FN9JC"P>;9G8%\XS GJQ3,C:IFD0S!0AR
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MA\C).+4$I5'%WAI*[5*3&ZIN@.J7VGE>0)U<GNHO/^V-AF_&ML5A2X H*.G
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M/Z-HV4"\!R'I<N^!)AL#37 @LG/##[":B$GT2-B^';!;^'EF3K#']W?*"\[
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MX\GI"_/X*G2Z-T+YZ3:=-^IS@@1CHC'TM1%8X*(U0M/=.:DQW/:Y7Q0S)6=
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M"H'?.?*)!1WQF<+D[>$P'';Z!ZM(X\NZ[I31OR?D7CPZ_B]02P,$%     @
M)#B<5BY>%DX(!0  8!<  !@   !A9&%G+3(P,C(Q,C,Q>&5X,3-D,2YH=&WM
M6&UOVS80_BN<BZT.8+T[F2,[!E(GQ0*T3= Z&/:1%D\648K4*#J.^^MWI"3;
MR=JM"]8TZQK$MG0\DG>\YQX>.?G!\\YE064&C/PR?_V*,)6M2I"&9!JH0>F:
MFX+,555125Z#UEP(\D)SM@1"COUHZ(?^\9'G32<XU*SMHV1*AD$\"N(P3D@4
MIM%Q&O],3E^3_O5\=N"TSRYG\]^NSIM9KZY?O+J8D9X7!+\FLR XFY\U#3A\
M1.::RIH;KB0507#^ID=ZA3%5&@3K]=I?)[[2RV#^-BA,*8:!4*H&GQG6FTZL
M!+^!LNFD!$-)5E!=@SGI7<]?>B/4,-P(F$Z"[K?172BVF4X8OR&UV0@XZ954
M+[GTC*K2)*S,&'L&V'Q/Y]9;<V:*- K#'\<598S+I2<@-^FA/QKM1)HOBZU,
M-:ZE&@0U_ ;LV'NC9@*H3A?*%./[$WRL9]7URY4T7DY++C;I\SDOH29O8$W>
MJI+*YX-&@K\U:)X_'SOMFG\ '!K=,W!K/"KX$@>WMC8"+ADB(TV.4*-9D!25
MB?U$<?-@35C<,6$-SMF%$@P;SV\+ON"HG_C1)%C@*E9?P.8,S03]4!MGH W/
M>4;MXI+%AI@"R)7F,N,5%>3\%K*576YRF:,6Z,?V(QY^GA]7*UVO**:R4>0=
M9,Z;X_"(J-QY]([J!950>Y>W C;D-#.V)0[#^$LX]'G8N9 D4U*VQCKJL::>
M2KG"E7\+E=+.RE-&ER"!7,C,)WVK\M.S41R'XYDJD:@V[BT:'R 3D9=*E^B6
M]Y+D2KOA-IA1!- @1LX@@W(!FB31 )7BF-":Y%QTQ.<6"N.M,=/0:2H9QA])
M1"+]X5PEKVMK*?Y;38;L1PK0@";N6]48WADU(!<#<@486=*_ OZAX ?DU4H-
MR*S@D/\97UW 6M\&)', Q8=J+\+1B%S[[_R9OXUUE!R& ^L/9:JRM%P]%! #
M;*>N6[DA[Z5:X_HL(748,70A@"R49J!/>F$/K1.B);KM>UW1K'W''AH_K(/6
MC74FHZ*%O ,+TNQX77 #GNT(*<ZH*8H<]SD(M1.D;1K\.T!M21ZYUJ@RM; <
M[_%^,U4_.G!N!X;M>_'5[)ECX-J\R%=";#!_RDI8K&[QJ^'W%==@=_7:1G2'
MCS[%#-$D.NRS@RT*=FC?(KV%0G2<#,<V!W8K$-A@!@X#_S\HQ$\/"EPBR97-
MSH5,:BB7F/B\H:<.)Y1K!$JEH;:0&-AFBE4==L.YD6>QH4*,U /7*^<2ZT,K
MQP&9JS@<#Z+62C2(4A5H-V=]CZO\3R#%UC<NR"<]6Q[U.NRT2]5 R,N4$+2J
M(>T>]E?%AKYH]CM;%UEGT9N[55>X@T=;<UG)7@GU=Q!LUKOM<8@==EO7E\1=
M-Z9MW%K&:ZR<!#>;M. ,-U-4L#M*F(PG@56<?@R,?^7/D7]T^,@>G2'$TG]J
MYS#QD^$C&WI:X4&'Q"-;$R3W0/R-(@:3#"D6,S+N?5N^?<M!>YII_F+ST"1O
MF;_;YZI;4BO!&7D6NK_'=2.H@X_4Z=^!]?6 ]8:6#]X_6FC9>NDKX^H[IIX2
MIN;VYN\_491\ZGZ@7VTOIV#;J)K&@T]4X,WMY5,!B#.F^2[T]A1 L_=+K5:2
MV9. TFF7K'M7HG<;VO. /1T)//AX[7N7WOM7L:UD_R;V_AUO19?@+330]Q[-
M,6-3>J,X:^,_&OGQCE0:6>BNA9N[8W<9/?T#4$L#!!0    ( "0XG%;]%:Y\
M$ 4  .(5   8    861A9RTR,#(R,3(S,7AE>#$S9#(N:'1M[9A];]LV$(>_
MRLU%5P>P7NUTCNP82)T$"]:D0>)@V)^T2%E$*5*CZ#C:I]^1DAPW:_82K&F&
M-8C?R"-Y1S[\\<3I=YYW(G,B4T;AQ\7Y>Z J71=,&D@U(P9+-]SDL%!E222<
M,ZVY$/!.<[IB  =^-/)#_^"MY\VFV-6\;:-D J,@'@=Q& \A"I/H((G'<'0.
M_9O%?,]9'W^8+WZY/&E&O;QY]_YL#CTO"'X>SH/@>''<5&#W$2PTD14W7$DB
M@N#DH@>]W)@R"8+-9N-OAK[2JV!Q%>2F$*- *%4QGQK:FTUM";XS0F?3@AD"
M:4YTQ<QA[V9QZHW1PG CV&P:=)^-[5+1>C:E_!8J4PMVV"N(7G'I&54FP[ T
M$VP98/4#FSMOPZG)DR@,7T]*0BF7*T^PS"3[_GA\7Z3Y*M^6J2:T1#-!#+]E
MMN^=7E/!B$Z6RN23AP-\KF79M<N4-%Y&"B[JY,V"%ZR""[:!*U40^6;0E.!G
MQ33/WDR<=<5_8]@UAF?8G?&(X"OLW/K:%'!)D8QD^!8MF@E)T!CL*XJ;+]:%
MY2<N;)@+=JD$Q<J3NYPO.=H/_7@:+'$6RR_@<XIN,OU4'^=,&Y[QE-C)A64-
M)F=PJ;E,>4D$G'*)^X7CMP\96C']4N.X7.MJ37 K&P77+'71'(1O064NHFNB
MET2RROMP)U@-1ZFQ-7$8?I&%^7OLG$E(E92MLTYZK*M'4JYQOJ]8J;3S\HB2
M%9,,SF3J0]^:?/]J',?A9*X*%*K:_8HF>ZA$<*IT@6%YIY I[;JK<4<!0X<H
M'+.4%4NF81@-T"B.@520<=$)GYLHEJXU[C0,FD@*)W<H(A+E#\<J>%593_'?
M6E)4/\B99NCBKE>-XYU3 S@;P#G*Z4]<0O^*U(62= \6I!C /.<L^R-BW9JU
MX0T@=8SBEW)GD:,QW/C7_MS?+G<TW \'-B1"56F5N7PJ$P.L)ZY94<-'J38X
M12N6.$P,60H&2Z4ITX>]L(?>"=%JW?9W59*T_8TM-+YH1]>M#28EHJ7>\8)*
M.]GDW##/-F0)CJ@)%CGY<Q2U R3M3OAW6&UU'N76J"*Q9$YVI+\9JA_MN; #
M0W>C^&K^+'#AVJV1K86H<0L5I;"X;A'6[-<UU\P>[)5=T7L^^@0WB89HOX\(
M=A3< [^%O44A.AB.)G8;W,] 8!<S< S\_U"(7QX*7*+.%<WAA6)J")>X\7FC
M4!TGA&L$I=2LLD@,;#7!Q Z;X=BH.UA1(B/5P+7*MGJ$'5*7=#@I1*NU:(A2
M)=-NS.J!5OF/D&)3'+?(ASV;(?4Z=MJI:A#R4B4$*2N6=%]V9\4N?=X<>38U
MLL%B-)\F7N$]'FW:Y8XD.Y0G2*W6)B%KHR9=7A6]GOP5E,T*M"WV0W\X?+US
MI'U)&+L^;>76.5YA1B6XJ9.<4SQDT<">-.%P,@VLX>QSA/Y92"/_8/^9(SI&
M[I)_[.?(_R%Z9D>/2GP  GR6L4\V#\C^!LWS1O2N?BHRK;AT4EK>0:4$I_ J
M='_/&T90!9_/!K_A]57QNB#%DS6I!<P>S%^9KF]DO3RR%O:N*8'_PGGWV/-H
MO]S>A]PGAS8E)&FJUM*@5Y@'.MN]1Q+ YO[LI0#CG&G><[U-0DGZ<:4Q'FH3
M4:63;@OO7,I]6M&FHS8Y%YAW>^WO;M/O7@:V);MW@0]O&4NR8MY2,_+1(QEF
MY@FY59RV.(S'?CS:2DU3%KJ+R>;VTEV'SGX'4$L#!!0    ( "0XG%9]'^PH
MC 8  /H<   8    861A9RTR,#(R,3(S,7AE>#$U9#$N:'1MY5EM;]LV$/XK
M-Q=K4\!ZM9TZ<AH@=9*N6]L%B8MM'VF)EMA0I$92<;Q?OR,E.[+7%461IED6
MP+9"'>_UN>.1//S!\TY%041*,_AI]NXM9#*M2RH,I(H2@Z-+9@J8R:HB MY1
MI1CG\$JQ+*< !WXT]$/_8-_SC@Z1U;2=(T4"PR >!W$8#R *D^@@B0_@^!WL
M?9A-GSOJDU^GLS_.3QNIYQ]>O7TSA9X7!+\-ID%P,CMI7B#["&:*",T,DX+P
M(#A]WX->84R5!,%RN?27 U^J/)A=!(4I^3#@4FKJ9R;K'1W:$?RF)#LZ+*DA
MD!9$:6I>]C[,SKPQ4AAF.#TZ#-:_#>U<9JNCPXQ=@S8K3E_V2J)R)CPCJV00
M5F:",P-\O4-SXRU99HHD"L,?)Q7),B9RC].%24;^>'P[I%A>;,9D8UJB*">&
M75/+^S.2.Q*0L%J3+:0PWH*4C*^29S-64@WOZ1(N9$G$LWXS@K^:*K9X-G'4
MFOU%D1'R-/3&>(2S'+6PJDT:H0F^ _N)XN;!2IQO25Q29\I<\@Q?GMX4;,Z0
M?N1'A\$<?51]PD\IIT3A%%-,=EWV*5_<N8DIPINJCHU6BB7?$N2>$V9P3CKY
MA*V'K,Q!J_1ECV0D]Q#I<10/HAMZ$XTRM";R/U9Y#PA'L+U6I"I8VEL+R)BN
M.%DE3' FJ#?G,KV:% W[T=@?;<(<AP,_'K5XLTHT+KU_EUPSC9'ES*R2@F49
M%4CP],D8]9O<NV*#87#6QY*TI H&?9@63!"8(J$B',XY26D?7KR GQD1>2U1
M)LGZ\(JRCYAZ6(S",!ZUL[Z3,Y<%,]33%6J:5(IZ2X0'TLP2V!OO>U'X'$;C
M\,"I"@!GN\,X_O\$PVYM0K''%2Y($(_!KC1W*/6!&+^EQDPFC]S"SRXNQUAF
MJ:#P1J3^9G%YO+X88HU[53-N&P:81L,^O)<^Q-'X6PG\'045-5P:1:GIPV7]
M5R%K]'96:Z.8+:U$77TKX8VT?E.T=0WG2EXS82MY'(VB;Y?:YU16G-J(1B\F
M&A2MZCDN^" 7=[Y"/$20[1$-IJ!@I<7AY+/Y-Y4E[@%6-O4<>31Y_LB]<X)]
M*EPRI?N/S]#.LOH1$YPM5MN:_48AE4+;G:"1#B.*+JBBF)/:CLA:P8*I$FJ1
M81]F">S6"6N(7J/IC:$E#'SXA:ZPC"RD*HEM[EVRQ9.!?^+#!=-7<$92(Y5N
M005$9%L<AGYW-NXMG; 6C2VSH7_LPT],(Y^58W!"KRF7E=O)8B[OS+!BF(#N
MBK(I <="U%CL+F@EE;'2SE#TTR?1?CB)0^\,4!/';F7!0=%X*RREY9RJAFH0
M]6TW$L/>EV;6ELAN?O4!6\6TP#TX;KKG%!W.USMRR_N2IK7"#1-&Q-I\>H.[
M6Y$[2TNFM?76%^MP>3KM2@8;)VO-5H/EQ"QJA4S5+CRP6DN%!C11FJ]N\;(.
M@*Y+A)C5%@<L?F3%!!+KN\-0?QW=>P#0+DZCT$=$9>TYQ2>T18)3'V;DICOX
MCF"O[5;7BZD%HBRI)4%A0C/TBJ/5'=!:3;8QRL0F0W.TH(V -LC9JJ]ASW8.
M@\' BT>C>!0^7Z,:+KVQ,^.68'\X'._?$IQYZ'LL!81KN1MP!*-M36[1>#IM
M/,7TAI13@^8!L0 %VIX.M/.WC/#OL;0]W*+[1D#.KJU7=8UIWWH1JP"%3(*0
MQCI.44PNDI76DP4Q]J5#C0U$BX\40Y];)&,\*JJTS;%E(?5M36>VU_FS9@KK
M29-]6$P:6-JL?['&?*?$'*<N$Z*# 6ZZL0C>)FV':%.#;JFQ<T6U*+$&$8T=
MG45#Z2JGX],BM^8-U*%2LJQY[@X2G;E.T/\#(%MJ_($U4L."8%P7->>K1]B%
M/'@U.H0QOOU"K>QAI\/7RYX]_;7'S&3.Z9KI7"I$M)=*SDFE:;)^Z*JUC]+:
M$T%[2(IY:S!OMP^5K;[;1\K_/" V"C_9QJM4&982WJ)_+HV193MCA!-:S9KQ
M)*IN0$O.,G@2NK^NHUK!:Z=]@T $.L#]H,@-[@GA*2FK";R6(D\+*O+F9-ED
M=V&<L=<+%5'6O_=JX-< WMD<N*A^363M-<)W#NMGV]!_C_?\Z&MB_A^*9^!J
MQ/J^Y*&HYY1IO@NU*6 DO<J5Q(79%C&IDC60.E<[VR_:4F9KJ+OR:/]?0Z][
M2=:.=._(=N_ *MRW>7-%R95'%MA@)N1:LJP-^WCLQ\,-X)NQT%V@-+=Z[IKP
MZ&]02P,$%     @ )#B<5JCG>P+I!@  <2(  !@   !A9&%G+3(P,C(Q,C,Q
M>&5X,35D,BYH=&WM6GMSXC80_RK;W+27I/C)(P32S!!"'KU++@/<7?NGL 56
M(TNN+(?0R8?ORC8$:)K+]1C:Z20S("*MM+]=[:YV+1]]9UD]$1$1T! NAE?O
M(91!%E.A(5"4:.R=,AW!4"8)$7!%E6*<PXEBX80"'-I>S7;MPX9E'1_A4MUR
MCA0MJ#E^T_%=OPJ>V_(.6U4?.E>P^W'8W<NI3S]TA[_>] JN-Q]/WE]V8<=R
MG,_5KN.<#D^+ 5S>@Z$B(F6:24&XX_2N=V GTCII.<YT.K6G55NJB3/L.Y&.
M><WA4J;4#G6X<WQD>O";DO#X**::0! 1E5+]T\['X9G51 K--*?'1\Z\+6A'
M,IP='X7L#E(]X_2GG9BH"1.6EDFKZB:ZC3,='%ZCN;>F+-11RW/=[]L)"4,F
M)A:G8]VJV\WF8Y=BDVC1)PO16HIRHMD=-6L_PWF) Q(F<[*Q%-H:DYCQ6>OM
MD,4TA6LZA;Z,B7A;*7JP3:EBX[?MG#IE?U!<"-?4]%Y;A+,)HC#0V@73%HZ!
M^7A^\<-P'*UPG-)<E)'D(0[V[B,V8DA?M_TC9X0Z2I[04\ I43A%1^UUE3VE
MBXV+&*!Y4[4N8\VN/PII)J^PS1="@O8=2U%$SO2L%;$PI +)?WC3]-UJ^\@Q
MI(70FP']]]O@-Z&3H"^"\; 5N"%+$TYF+28X$]0:<1G<SHWFT+?-&KGUYE@_
M9 KZ=-R"Z\[@U'EWX70:]5K=NO#]6N-@@X(L:?^W+-5L/%N2[4M6U0G)A H*
MER*P%U:U'5RULPJ<9(P;KX6N5ZO M;3!]YI;Q/ +\HXR&&A%J:[ (/LCDADJ
M(T1BQ0B'&Z)NMXBG %"!GQD1DS2#&R7O&!X@%=1+W4-KW!*4=9>XH3+A]*^N
M.V?>,<I"5A>4WU'- F+8XL%BE;P+/_8.YGZ<@J))-N(L #F&;L0$^;=$.\6
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M[CY%O!=LZ:@WQ76%LBKPS:MA&+P;:5!8U;.")R#G,,ZY8#_%B:F$3[DLX=S
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MDT:635O1*0QNG"'LV'0=19$3[NV%>_YN _F==6=.!#O-FOW!8+B_^\L.ZEQ
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MX:*4GC/&(3(4O:7S1]7(B-HN'%4,0=':I+ &KGMT'X:YQ97(?? [DWXLA([
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M*8Q;B?RXXC#5(RP-F?U"DA7<@M(Z;WP_"<I5R_=\)U9FR$L37Q"(*1%B^I2
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MYS)<4O]M L>$.HT-932ZD0V#NU\/'PC''8[Z) !KK]#RQO)HTV7C61W/&17
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M/E'@)4,B&?Z+R"#I2196F!YV?USCB6T9(9%[&'^OGD>PZ$M;.* J3T3JYF;
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M=?ILB& V%8&Z'.!&8GS3N)N]-<*<V@HQSX'[Y0EB#T G$[P,*<[PP[W +2G
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M^0]02P$"% ,4    "  D.)Q6!U9NF4\:  !1'@$ $0              @ $
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M-2YJ<&=02P$"% ,4    "  D.)Q6'09&'G4V  !_/P  &
M@ &5R@H 861A9RTR,#(R,3(S,7@R,&8P,#8N:G!G4$L! A0#%     @ )#B<
M5MK %,#,7@  6FD  !@              ( !0 $+ &%D86<M,C R,C$R,S%X
M,C!F,# W+FIP9U!+ 0(4 Q0    ( "0XG%8:9E(_;1T! .\T 0 8
M      "  4)@"P!A9&%G+3(P,C(Q,C,Q>#(P9C P."YJ<&=02P$"% ,4
M"  D.)Q6P"]P!'JZ  !$R0  &               @ 'E?0P 861A9RTR,#(R
M,3(S,7@R,&8P,#DN:G!G4$L! A0#%     @ )#B<5@Q)[FM5<@  H7X  !@
M             ( !E3@- &%D86<M,C R,C$R,S%X,C!F,#$P+FIP9U!+ 0(4
M Q0    ( "0XG%:4K*\I]Y(  )J>   8              "  2"K#0!A9&%G
M+3(P,C(Q,C,Q>#(P9C Q,2YJ<&=02P$"% ,4    "  D.)Q6[T&%?30> 0"N
M* $ &               @ %-/@X 861A9RTR,#(R,3(S,7@R,&8P,3(N:G!G
M4$L! A0#%     @ )#B<5LNICSKHM   $;X  !@              ( !MUP/
M &%D86<M,C R,C$R,S%X,C!F,#$S+FIP9U!+ 0(4 Q0    ( "0XG%81F\SN
M@XT  -&=   8              "  =41$ !A9&%G+3(P,C(Q,C,Q>#(P9C Q
M-"YJ<&=02P$"% ,4    "  D.)Q6S#SGEX%A  #=<   &
M@ &.GQ  861A9RTR,#(R,3(S,7@R,&8P,34N:G!G4$L! A0#%     @ )#B<
M5KEJ@3-'4@  MEH  !@              ( !10$1 &%D86<M,C R,C$R,S%X
M,C!F,#$V+FIP9U!+ 0(4 Q0    ( "0XG%8D^GMR8D,  .=0   8
M      "  <)3$0!A9&%G+3(P,C(Q,C,Q>#(P9C Q-RYJ<&=02P$"% ,4
M"  D.)Q62?S!M^=2  #'50  &               @ %:EQ$ 861A9RTR,#(R
M,3(S,7@R,&8P,3@N:G!G4$L! A0#%     @ )#B<5C$T8X?V60$ #&0! !@
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M,RYJ<&=02P$"% ,4    "  D.)Q6-"62*1B!  #VA0  &
M@ '*)!8 861A9RTR,#(R,3(S,7@R,&8P,C0N:G!G4$L! A0#%     @ )#B<
M5@.EUFSB%0$ 4!\! !@              ( !&*86 &%D86<M,C R,C$R,S%X
M,C!F,#(U+FIP9U!+ 0(4 Q0    ( "0XG%9QRJ\<]X8  *&3   8
M      "  3"\%P!A9&%G+3(P,C(Q,C,Q>#(P9C R-BYJ<&=02P$"% ,4
M"  D.)Q6TZ OB-Z3  ! P@  &               @ %=0Q@ 861A9RTR,#(R
M,3(S,7@R,&8P,CDN:G!G4$L! A0#%     @ )#B<5NH:MZ%D"   MS   !@
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M,2YH=&U02P$"% ,4    "  D.)Q6J.=[ ND&  !Q(@  &
M@ %G^A@ 861A9RTR,#(R,3(S,7AE>#$U9#(N:'1M4$L! A0#%     @ )#B<
M5D4<#6A%!0  &Q$  !@              ( !A@$9 &%D86<M,C R,C$R,S%X
M97@Q-60S+FAT;5!+ 0(4 Q0    ( "0XG%;1RH'Z/P,  &L'   8
M      "  0$'&0!A9&%G+3(P,C(Q,C,Q>&5X,35D-"YH=&U02P$"% ,4
M"  D.)Q6H)XTZ$0(  "4*P  &               @ %V"AD 861A9RTR,#(R
M,3(S,7AE>#$U9#4N:'1M4$L! A0#%     @ )#B<5F H"HK_:@   IL" !<
M             ( !\!(9 &%D86<M,C R,C$R,S%X97@R9#4N:'1M4$L! A0#
M%     @ )#B<5NB,\;H<!   LBT  !<              ( !)'X9 &%D86<M
H,C R,C$R,S%X97@X9#$N:'1M4$L%!@     K "L J@L  '6"&0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
